<SEC-DOCUMENT>0001628280-18-013539.txt : 20181105
<SEC-HEADER>0001628280-18-013539.hdr.sgml : 20181105
<ACCEPTANCE-DATETIME>20181105073207
ACCESSION NUMBER:		0001628280-18-013539
CONFORMED SUBMISSION TYPE:	10-12G
PUBLIC DOCUMENT COUNT:		33
FILED AS OF DATE:		20181105
DATE AS OF CHANGE:		20181105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL ORGANIC CHEMICALS [2860]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-12G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55264
		FILM NUMBER:		181158752

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-12G
<SEQUENCE>1
<FILENAME>dyadicform10.htm
<DESCRIPTION>10-12G
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0CBE7E4C6D4706F1DC8020875C1F6565"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As Filed with the Securities and Exchange Commission on </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">November&#160;5, 2018</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GENERAL FORM FOR REGISTRATION OF SECURITIES</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">45-0486747</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">140 Intracoastal Pointe Drive, Suite 404</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Jupiter, Florida 33477</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices) (Zip Code)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(561) 743-8333</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Copies to:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark A. Emalfarb, CEO</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dyadic International, Inc.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140 Intracoastal Pointe Drive, Suite 404</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jupiter, Florida 33477</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kimberly C. Petillo-D&#233;cossard</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cahill Gordon &amp; Reindel LLP</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80 Pine Street</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, NY 10005</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(212) 701-3265</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities to be registered pursuant to Section 12(b) of the Act: None</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities to be registered pursuant to Section 12(g) of the Act:</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.875%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock, par value $0.001 per share</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Title of class)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">or an emerging growth company</font><font style="font-family:inherit;font-size:10pt;">. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">emerging growth company</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:inherit;font-size:10pt;">in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:19%;"></td><td style="width:18%;"></td><td style="width:27%;"></td><td style="width:18%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large Accelerated Filer </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated Filer </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Accelerated Filer </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller Reporting Company </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging Growth Company </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s20813FF2CA5B0F5E599A20875C3D1401"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:82%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PART I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC62A87BBEB9157C4708520875C6F3D95"><font style="font-family:inherit;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC62A87BBEB9157C4708520875C6F3D95">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 1A.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC037782C3C53B57B192120875C97FBBC"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC037782C3C53B57B192120875C97FBBC">10</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s54C15C36EE57C3FA95C920875CC9A313"><font style="font-family:inherit;font-size:10pt;">Financial Information</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s54C15C36EE57C3FA95C920875CC9A313">28</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0C959501E4D1CF37CF5820875D235F54"><font style="font-family:inherit;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0C959501E4D1CF37CF5820875D235F54">35</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1388905FF13C6560142520875D23FB64"><font style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1388905FF13C6560142520875D23FB64">36</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 5.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s16423DFD7638A97F989A20875D37A3FF"><font style="font-family:inherit;font-size:10pt;">Directors and Executive Officers</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s16423DFD7638A97F989A20875D37A3FF">38</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s19A64CCD599EBBDB40A820875D69D53B"><font style="font-family:inherit;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s19A64CCD599EBBDB40A820875D69D53B">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 7.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s43EEE94C926BE47D4F1720875D91DAB7"><font style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s43EEE94C926BE47D4F1720875D91DAB7">48</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 8.</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s807B07E07868C24C855820875DC31194"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s807B07E07868C24C855820875DC31194">51</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 9.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB346839E968AA982407920875DE198B8"><font style="font-family:inherit;font-size:10pt;">Market Price of and Dividends on the Registrant&#8217;s Common Equity and Related Stockholder Matters</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB346839E968AA982407920875DE198B8">53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 10.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCEC70D5025C38F2B8C8F20875E090376"><font style="font-family:inherit;font-size:10pt;">Recent Sales of Unregistered Securities</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCEC70D5025C38F2B8C8F20875E090376">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 11.</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5FF90E642C2722C61D9A20875E31EB9A"><font style="font-family:inherit;font-size:10pt;">Description of Registrant&#8217;s Securities to be Registered</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5FF90E642C2722C61D9A20875E31EB9A">58</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 12.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE629EB5FA2EDE176E2F720875E634092"><font style="font-family:inherit;font-size:10pt;">Indemnification of Directors and Officers</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE629EB5FA2EDE176E2F720875E634092">59</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 13.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s231D95AA90DBFA05724920875E8BC61D"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5C1F551D487D0035DCF120875EDBDF4B">61</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 14.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s24e67c6e2a5e4f43a5cf440cf943275f"><font style="font-family:inherit;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s24e67c6e2a5e4f43a5cf440cf943275f">102</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 15.</font></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7A193ABF94D668839BBE2087624BCF99"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7A193ABF94D668839BBE2087624BCF99">103</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INFORMATION REQUIRED IN REGISTRATION STATEMENT</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPLANATORY NOTE</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">You should rely only on the information contained in this General Form for Registration of Securities on Form 10 (the &#8220;Registration Statement&#8221;) or to which we have referred you. We have not authorized anyone to provide you with information that is different. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On the date of effectiveness of this Registration Statement we will become subject to the requirements of Regulation 13(a) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and will be required to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and will be required to comply with all other obligations of the Exchange Act applicable to issuers filing registration statements pursuant to Section 12(g) of the Exchange Act. Our periodic and current report will be available on the website, www.dyadic.com, free of charge, as soon as reasonably practicable after such materials are filed with or furnished to the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As used in this Registration Statement, unless the context otherwise requires the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Dyadic&#8221; and the &#8220;Company&#8221; refer to Dyadic International, Inc., a Delaware corporation, and its subsidiaries.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Information (other than historical facts) set forth in this Registration Statement contains forward-looking statements within the meaning of the Federal Securities Laws, which involve a number of risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Forward-looking statements generally can be identified by use of the words &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;will,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; potential&#8221; or &#8220;continue&#8221; and other similar terms or variations of them or similar terminology. Such forward-looking statements are included under Item 1. &#8220;Business&#8221; and Item 2. &#8220;Financial Information - Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. Dyadic cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Dyadic&#8217;s control. These factors include, but are not limited to, our ability to implement our strategic initiatives, our ability to execute and achieve our research and development objectives, our ability to obtain new license agreements, our dependence on our licensees for research and development funding, milestones and royalties for the products and/or processes that utilize licensed rights, our ability to maintain uninterrupted access </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to research facilities under contract and at a competitive cost structure, our ability to hire and maintain, as well as our reliance on qualified employees and professionals, economic, political and market conditions and price fluctuations, government and industry regulation, U.S. and global competition, upgrade financial staffing, implement and monitor internal controls, and comply with financial reporting requirements, and other factors. We caution you that the foregoing list of important factors is not exclusive. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Before investing in our common stock, investors should be aware that the occurrence of the events described under the caption &#8220;Risk Factors&#8221; and elsewhere in this Registration Statement could have a material adverse effect on our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this Registration Statement to conform these statements to actual results or to changes in our expectations.</font></div><div><a name="sC62A87BBEB9157C4708520875C6F3D95"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Business</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Myceliophthora thermophila</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (&#8220;DuPont&#8221;), the industrial biosciences business of DuPont (NYSE: DD) for $75.0 million (the &#8220;DuPont Transaction&#8221;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines (such as virus-like particles (VLPs) and antigens), monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, as well as other therapeutic enzymes and proteins. Additionally, in early 2018, we began to conduct certain funded research activities to further understand if, or how the C1 technology can be applied for use in developing and manufacturing metabolites.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Technology</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company believes that the C1 cell line is unique in its growth and production capabilities compared to traditional filamentous fungal cells, and the C1 gene expression platform has the potential to be used in the discovery, development and manufacturing of biologic medicines and vaccines, given its anticipated competitive advantages compared to other leading pharmaceutical expression systems, such as CHO (&#8220;Chinese Hamster Ovary&#8221;) cells. Specifically, the C1 cell line has:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A unique morphology&#160;which translates into better growth conditions and very high secreted protein yield and has been used in industrial production for 20 years at up to 500,000-liter scale.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Several significant potential operational advantages include:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High productivity and low cost synthetic media for the upstream fermentation steps</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potential for greater protein yield for certain downstream processing steps due to the higher purity of secreted proteins</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No virus-like particles or virus carryover from production cells which eliminates two purification steps typical for CHO production; low pH viral inactivation and virus nano filtration&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wide pH and temperature operating conditions which has the potential to translate into more reliable and robust production processes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter production cycle times than CHO which translates into the following savings:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reduction of nearly 10-14 days vs CHO for the process of seed flask to fermenter</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ferm</font><font style="font-family:inherit;font-size:10pt;color:#000000;">entation cycle time of 5-7 days which is 1/2 to 1/3rd the typical fermentation production time of CHO</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">C1&#8217;s characteristics lead the Company to believe that the C1 technology has the potential to become an alternative gene expression platform to CHO, E.coli, yeast, insect cells, and other organisms currently in use for developing and manufacturing protein-based biologics because of C1&#8217;s potential speed of development and low production costs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Industry and Market</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our research collaborations and ongoing discussions with leading pharmaceutical and biotech companies continue to support the Company&#8217;s belief that the biopharmaceutical market is an attractive opportunity to apply the C1 technology. The Company is focused on penetrating the biologics market in the following segments:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recombinant vaccines market</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New innovative biologic therapeutics</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biosimilars / Biobetters non-Glycosylated protein market</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biosimilars / Biobetters Glycosylated protein</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;market </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The use of biologic medicines, such as antibodies, is growing significantly. However, biologic medicines are very expensive for both patients and health care systems, and the Company believes that such high cost is in part the result of the following bottlenecks in the development and manufacture of biologic medicines:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low yielding gene expression systems currently used by the biopharmaceutical industry</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expensive media in the case of CHO cell lines</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long production time in the case of CHO cell lines</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Previous underfunded development efforts for a more efficient next generation gene expression system</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The biopharmaceutical industry&#8217;s reluctance to utilize certain advances to develop next generation gene expression systems for bio-manufacturing, such as application of cutting-edge metabolic and glyco-engineering tools to generate more productive microorganisms</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company believes that the biopharmaceutical industry needs a next generation expression platform that is safe, reliable, productive and cost effective to produce more affordable biologic medicines in larger volumes using smaller fermentation vessels. The Company also believes that by further engineering our C1 technology it will have the potential to be an alternative to CHO and other expression systems for certain biologic vaccines and drugs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Business Development Efforts</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company continues to attempt to raise the commercial, scientific and technical profile of its C1 technology through the following targeted business development efforts:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regularly attending and making presentations at various biopharmaceutical and industry conferences;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Business development meetings with pharmaceutical companies and industry thought leaders around the world;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific meetings with interested parties within academia, industry and governmental agencies in Europe, North America, Asia, Israel and elsewhere;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Updated Company&#8217;s website, media interviews and renewed marketing presentation materials.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In order to develop C1 into a leading next generation protein expression and production platform for use in speeding up the development and lowering the cost of manufacturing bio-pharmaceuticals, the Company strategically determined to utilize a portion of the proceeds from the DuPont Transaction in combination with additional funding sought from industry and government programs to generate sufficient research data to demonstrate C1&#8217;s potential operational benefits and reduced capital requirements in developing and manufacturing biologic vaccines and drugs. Since the closing of the DuPont Transaction in December 2015, the Company has achieved the following in its business development initiatives:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retained two new board members who previously worked at Merck and Pfizer and have strong scientific background and extensive business experience in the biopharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Entered into four funded feasibility and expression projects with top tier pharmaceutical companies, including Sa</font><font style="font-family:inherit;font-size:10pt;color:#000000;">nofi-Aventis Deutschland GmbH</font><font style="font-family:inherit;font-size:10pt;">&#32;and Mitsubishi Tanabe Pharma;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Two funded proof of concept research collaborations with two different biotechnology companies to test the feasibility of producing an important active moiety and seven different molecular biology enzymes respectively;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Signed a research and development collaboration with The Israel Institute for Biological Research (&#8220;IIBR&#8221;) and having ongoing discussions with other governmental agencies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Entered into a funded research and development collaboration to evaluate the potential to produce an animal health protein;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hired several experienced consultants with relationships within the biopharmaceutical industry and governmental agencies to expand the C1 network and reach out to potential research and business partners.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Potential Opportunity to Use C1 in Drug Discovery and Early Development Process</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">While our focus has been and remains on developing stable C1 cell lines for use in speeding up the development and manufacturing of biologics at lower cost, we have identified a new area where C1 may add value based on our discussions with various pharmaceutical and biotech companies. This new area is the biologics drug discovery and early development process, which requires sufficient levels of protein to be expressed as quickly as possible in order to identify new drug candidates within a limited time. Currently, HEK 293 cells (human embryonic kidney cells) are commonly used for this application.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since C1 cells have the capability to express and produce comparable and even larger quantities of protein than HEK 293 cells, we believe that C1 has the potential to help overcome certain protein expression challenges in the biologics drug discovery and development stages. To capitalize on this opportunity, we will need to spend additional resources to modify our C1 technology for this application.  We are in discussions with interested third parties, including our existing collaborators, to determine our next steps and potential funding.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company believes that the unique attributes of C1, together with our platform research and development programs, has the potential to create attractive research, licensing, partnering/collaboration and other revenue and funding opportunities in the animal and human biopharmaceutical industries. The funded research projects mentioned above and others that we are actively seeking may help defray some of our research expenses, as we continue to develop and demonstrate the potential of our C1 technology. The Company will continue seeking research collaboration opportunities and partners to potentially commercialize C1-based products.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Research Partners and Contract Research Organizations (CROs)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">After the closing of DuPont Transaction, we initially conducted our research and development work on C1 at DuPont&#8217;s research center in Wageningen, The Netherlands, Dyadic&#8217;s former C1 research and development center that was acquired by DuPont in the DuPont Transaction on December 31, 2015 (&#8220;DuPont Research Center&#8221;). On September 30, 2017, the Company </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">concluded the research services provided by DuPont, and successfully transitioned the C1 platform research programs to the following two contract research organizations:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">(1) Research and Development Agreement with Our Prime CRO, VTT Technical Research Centre of Finland, Ltd</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In September 2016, the Company entered into a multi-year research and development agreement with VTT Technical Research Centre of Finland, Ltd, a third-party Contract Research Organization, (the &#8220;Prime CRO&#8221;) to begin to further modify and improve the Company&#8217;s C1 technology to be a safe and efficient expression system for use in speeding up development and lowering the cost of manufacturing pharmaceutical products and processes. Our Prime CRO is one of the leading research and technology organizations in Europe, and it has conducted research and development on fungi and other microorganisms for more than three decades. We believe that our Prime CRO has the required skills&#160;and experience&#160;in fungal strain development to help us further develop our C1 technology and achieve our goal and objectives.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">(2) Collaboration Agreement with BDI</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On June 30, 2017, the Company entered into a strategic Research Services Agreement (the &#8220;RSA&#8221;) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (&#8220;BDI Pharma&#8221;), and a Service Framework Agreement (the &#8220;SFA&#8221;, and together with the RSA,  the &#8220;R&amp;D Agreements&#8221;), with VLP The Vaccines Company, S.L.U. (&#8220;VLPbio&#8221;), both of which companies are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (&#8220;BDI Holdings&#8221; and together with BDI Pharma and VLPbio, &#8220;BDI&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The R&amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic&#8217;s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team&#8217;s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic&#8217;s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All the data and any products developed from the funded research projects will be owned by Dyadic. We anticipate that BDI will conduct gene expression work and cGMP media development coupled with fermentation optimization work, with a goal of improving the C1 technology&#8217;s production process for manufacturing vaccines, antibodies, enzymes and other therapeutic proteins.  Additionally, BDI is conducting research and development on our behalf to express and produce a variety of C1-based biologic products to demonstrate C1&#8217;s capabilities and to identify potential animal and human pharmaceutical products which may be out licensed to third parties for commercialization. Those proteins include mAbs, Fc-Fusion, Bi-specific antibodies, Fabs, VLP and others that may be used for human and animal health applications.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Upon closing of the BDI transaction, the Company paid EUR &#8364;1 million in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR &#8364;936,000 over two years in the conduct of the research and development project under the RSA, and approximately 60% of the amount has been spent as of September 2018. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI&#8217;s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR &#8364;1 million for a 50% share and EUR &#8364;8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI the first EUR &#8364;1.5 million of the net income from Dyadic&#8217;s commercialization, if any, of the selected product. We anticipate that we will need to provide additional funding together with other third parties to continue the further development and commercialization of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1 million in contract research services specified by Dyadic over two years since the closing of the BDI transaction. Other shareholders of BDI include the founders of BDI and Inveready, an independent Spanish venture capital firm specializing in biotechnology.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Research and Development (&#8220;R&amp;D&#8221;) Programs</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s current research and development activities are focused on the following biopharmaceutical programs:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">(1) Internal Research Programs</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">C1 Production Host Improvement Programs</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has contracted our Prime CRO to further improve the C1 technology to become an even more robust, versatile and efficient therapeutic protein production platform which may be used to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers. This includes: (i) improving the genome sequence-accuracy for the application of system biology tools, (ii) improving the C1 genetic tools, (iii) further reducing the background protease(s) levels by identifying and deleting certain protease genes and/or modifying C1 fermentation processes, (iv) developing C1 strains where one or more specific integration sites are being used to increase productivity and to what we expect will help with future regulatory approvals, and (v) modify the glycosylation pathway of C1 cells in order for C1 to express certain mAbs and other proteins with mammalian like glycosylation structures.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have made improvements to our C1 technology platform through our collaborations with the Prime CRO, and the data generated up to date confirms our belief that C1 has the potential to be used to speed up the development and lower the production costs of certain biologics.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data demonstrating C1&#8217;s capability to express a variety of types of vaccines and therapeutic proteins including monoclonal antibodies (mAbs), Fab antibody fragments, Fc-Fusion proteins, and difficult-to-express genes such as virus-like particles (VLPs), Bi-Specific antibodies, and antigens, at a higher productivity level than other gene expression platforms.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data demonstrating that the binding kinetics of mAbs produced from C1 are virtually indistinguishable from the binding kinetics of reference mAbs which were produced in CHO cells.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generated C1 strains that have lower background protease activity, while remaining healthy and viable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Created a C1 protease expression library to quickly identify and eliminate protease genes to improve protein stability and productivity.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed and used a variety of novel genetic elements, molecular tools that can be used in biologics drug development and manufacturing.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Improved C1 fed batch fermentation process with low cost defined media, as compared to the expensive, complex growth media being used with CHO. Continue optimizing both the media and the fermentation process to further increase mAb and other protein yields and productivity.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Glycosylated Therapeutic Programs</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s longer-term objective, which will require substantially more time and additional capital is to apply the C1 technology for the large therapeutic glycoprotein market. We believe that the rapid advances being made in genomics and synthetic biology, make the C1 fungal cell line a promising candidate to further engineer glycosylation pathways: (i) to produce therapeutic proteins having human like glycoforms structures such as G0, G1, G2, G0F, G1F and G2F and (ii) to create potentially improved immunogenicity in the case of vaccines.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The initial steps to develop C1 strains that produce mAbs with mammalian-like glycosylation are progressing well at the Prime CRO, and we are actively working on additional steps. The remaining work according to the research plan is anticipated to last through year end 2020 with a goal of reaching G1F and G2F glycan structures. Based on research results we had to date, the Company believes that our C1 technology has the potential to become a useful platform for the development and production of therapeutic glycoproteins with human-like or potentially even superior glycan structures. We believe that, if successful, the glycoengineering of C1 cells may help to position the C1 technology to be an important production platform for developing and manufacturing glycosylated antibodies and other glycoproteins.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Although we have made good progress working with our Prime CRO since September 2016, there remains additional work and data needed to develop our C1 technology into a potentially safe and efficient expression system for use in speeding up the development and lowering the cost of animal and human biologic vaccines and drugs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">(2) Biologic Vaccines Programs - ZAPI</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We continue our participation in the ZAPI vaccination program. ZAPI (www.zapi-imi.eu) is a research and development project funded as part of IMI EU program (Zoonoses Anticipation and Preparedness Initiative (ZAPI project; IMI Grant Agreement n&#176;115760)), with the assistance and partial financial support of IMI and the European Commission, and in-kind contributions from EFPIA partners. This project aims to develop a suitable platform for the rapid development and production of vaccines and protocols to fast-track registration of product developed to combat epidemic Zoonotic diseases that have the potential to affect human and animal populations. If the C1 antigens are used within the ZAPI project, there will be additional performance and safety data which we would expect to help us in our efforts to apply the C1 expression system for use in developing and manufacturing vaccines across the broader animal and human health industries.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s C1 expressed antigens were tested in a very small mice study within the ZAPI project and the data indicated that the C1 technology produced antigen generated an immune response in mice that protected the mice and showed no negative effects on the health of the mice. We anticipate that more immunogenicity and safety testing will be conducted within the ZAPI project in the months and years ahead.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our current efforts are focused on demonstrating C1&#8217;s ability to express antigens at target levels set by the ZAPI consortium. For now, we have been asked to focus on expressing a specific antigen against the Schmallenberg virus (SBV), and the data obtained so far has indicated promising expression levels of this antigen which we anticipate will be transferred to other groups within ZAPI who may carry out additional animal trials, and if successful, C1 may eventually be validated as the preferred production host for the production of ZAPI&#8217;s antigens.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">(3) Israel Institute for Biological Research (IIBR)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the first quarter of 2018, we entered into a research and development collaboration with the Israel Institute for Biological Research (&#8220;IIBR&#8221;) to further advance our C1 expression platform for the development and manufacture of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies (biologics)</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">,</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;to combat emerging diseases and threats.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This project provides us with an opportunity to work with a renowned organization, aiming to integrate our C1 gene expression platform into an end to end product development and manufacturing capability to produce biologics, and if possible, to get some of these biologics through the regulatory approval process.&#160;All of the collaboration work is to be performed at IIBR&#8217;s laboratories using their in-house resources.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">(4) Monoclonal antibodies (mAbs), Fc-Fusion, and Fab</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has a number of internally and externally funded research programs to express different types of therapeutic proteins including monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, and Fc-Fusion proteins using our C1 technology. So far, we have been able to demonstrate C1&#8217;s ability to express an IgG mAb at 9 grams per liter (g/l) in 90 hours which equates to 2.4 grams per liter per day (g/l/d), a Fab antibody fragment at 2.6 g/l/d, a Fc-Fusion protein at 1.35 g/l/d as well as other proteins at various expression levels. The Company believes that such results are promising and show greater productivity potential of C1 compared to the average expression yields of CHO cells which is the predominant production system used to manufacture glycosylated mAbs-derived biopharmaceutical drugs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In December 2016 and May 2017, the Company entered into two funded feasibility and expression research projects with two of the world&#8217;s largest pharmaceutical companies, respectively. The first project was successfully completed in the last quarter of 2017, and the second one was successfully completed in the second quarter of 2018. We believe that the data generated to date from these collaborations, and otherwise, continues to demonstrate the potential of the C1 technology to produce high levels of glycosylated mAbs and other therapeutic proteins faster, with higher productivity and at a much lower cost than that can be achieved using CHO cells.  However, in order to potentially commercialize or capitalize on C1&#8217;s potential in producing glycoproteins, we will need to complete the glycoengineering of C1 to be able to demonstrate a variety of biological and analytical data related to performance, stability and safety.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">(5) Mitsubishi Tanabe Program</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the first quarter of 2018, we entered into a collaboration with Mitsubishi Tanabe Pharma Corp. to express two of its therapeutic compounds using our C1 production platform. This research and development program is aiming to help Mitsubishi Tanabe overcome specific gene expression challenges and to further demonstrate the potential of C1 to become a platform for manufacturing protein-based biologics because of its speed of development and low production costs.  If this challenging gene </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">expression program is successful, we expect this project to generate additional data and to increase the diversity of the types of proteins that our C1 platform can potentially produce at higher yields and with lower cost.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">(6) Sanofi-Aventis Program</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In September 2018, we entered into a </font><font style="font-family:inherit;font-size:10pt;color:#000000;">funded proof of concept research collaboration with Sanofi-Aventis Deutschland GmbH, a company of the Sanofi group, one of the World&#8217;s top tier biopharmaceutical companies. This research collaboration is to use our C1 platform to express multiple types of therapeutic compounds, aiming to overcome specific gene expression challenges and to further demonstrate the potential of C1 to become a platform of choice for manufacturing protein-based vaccine and biologic drugs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">(7) Potential Commercialization Program at BDI</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under our collaboration program with BDI, we have begun to evaluate a Virus Like Particle (VLP) and a basket of therapeutic proteins that are commonly used to produce animal and human biopharmaceutical vaccines and drugs, either glycosylated or non-glycosylated proteins (including mAbs, Fabs, and bi-specific mAbs, etc.) to determine which, if any, of these proteins might be potential candidates for future commercialization.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We were able to demonstrate that C1 is capable of expressing certain types of antibodies at various yield levels as well as the ability to express other therapeutic proteins, which are difficult-to-express by other cell lines. In particular:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Secreted Virus Like Particle (VLP) monomers was expressed by C1 and appears to have been properly assembled to form a 60-mers protein structure. Transmission Electronic Microscopy (TEM) analysis confirmed the correct structure of the VLP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our first and initial attempt to express Blinatumomab, a bi-specific drug, was successful as the initial unoptimized expression level was 0.6 g/l (0.12 g/l/d). Blinatumomab is a new type of treatment for leukemia, developed by Amgen, with a rapidly growing market. The initial expression level of Blinatumomab is a start in generating data that we believe will help us to demonstrate the potential of C1 to be used as a production host for expressing more complex and difficult to express drugs such as bi-specific antibodies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have reached the expression level of the antibody fragment Certolizumab using C1 as high as 12.0 g/l in 112 hours (2.6 g/l/d). Certolizumab is a constituting part of Cimzia Pegol, which is a recombinant, humanized and pegylated Fab antibody fragment. We are continuing the development work on increasing the productivity of Certolizumab to a higher level. In addition, we expect to conduct a variety of comparability and quality analytics with the C1 expressed Certolizumab together with our partnership with BDI and other third parties.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">(8) Other Market Opportunities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In January 2018, the Company entered into a funded proof of concept research collaboration with an integrated, global biotech company to use metabolic modeling, synthetic biology and genome engineering techniques to demonstrate the benefits of using C1 as a primary metabolite-producing host organism. We believe that the knowledge and data generated in this program is expected to enhance our understanding of C1&#8217;s metabolic characteristics and help us in advancing our ongoing C1 biologic vaccine and drug research and development programs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In June 2018, the Company entered into another funded proof of concept research collaboration to test the feasibility of using C1 technology to produce seven different molecular biology enzymes as pharmaceutical products&#160;which are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid&#160;as a therapeutic or diagnostic agent.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">November&#160;5, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, we had 6 employees located in the United States, and 2 key consultants located in Europe. None of our employees are represented by a labor union, and we consider our employee relations to be good.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Facilities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,400. The lease expires on June 30, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">2019, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies approximately 258 square feet with annual rentals and common area maintenance charges of approximately $4,700. The lease expires on January 31, 2019, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Founded in 1979 by Mark A. Emalfarb, our Chief Executive Officer, Dyadic has focused on the development of C1 expression platform since 1992, refining and optimizing the C1 technology to become an industry leading gene expression and protein production system.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Currently, Dyadic is a global biotechnology company with operations in the United States and The Netherlands. Dyadic was incorporated in Delaware in September 2002. Our principal corporate offices are located at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477; telephone number (561) 743-8333; website </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">www.dyadic.com.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Reports filed with the OTC Markets Group are available through the &#8220;Investors&#8221; section of the Dyadic website. Following the effective date of this registration statement, we also intend to make available our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after electronically filing such material with, or furnishing it to the Securities and Exchange Commission (SEC). Once filed with the SEC, such documents may be read and/or copied at the SEC&#8217;s Public Reference Room at 100 F Street N.E., Washington, D.C. 20549, on official business days between the hours of 10 a.m. and 3 p.m. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that electronically file with the SEC at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">www.sec.gov.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We also make available through the &#8220;Investors - Corporate Governance&#8221; section of our website the charters of each of the committees of our Board of Directors, and codes of conducts and ethics for our directors, officers, and employees. Such materials are also available in print upon the written request of any stockholder to Dyadic International, 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477, Attention: Investor Relations.</font></div><div><a name="sC037782C3C53B57B192120875C97FBBC"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the following material risks, together with the other matters described in this Registration Statement and in our financial statements and the related notes thereto in evaluating our current business and future performance. We cannot assure you that any of the events discussed in the risk factors below will not occur. If we are not able to successfully address any of the following risks or difficulties, we could experience significant changes in our business, operations and financial performance. In such circumstances, the trading price of our common stock could decline, and in some cases, such declines could be significant and you could lose part or all of your investment. In addition to the risks described below, other unforeseeable risks and uncertainties or factors that we currently believe are immaterial may also adversely affect our operating results, and there may be other risks that may arise in the future. Certain statements contained in this Registration Statement (including certain statements used in the discussion of our risk factors) constitute forward-looking statements. Please refer to the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; appearing on page 1 of this Registration Statement for important limitations and guidelines regarding reliance on forward-looking statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business and Industry</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not succeed in implementing our new business strategy.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the December 31, 2015 sale of substantially all of the assets of our industrial technology business to DuPont&#8217;s Industrial Biosciences business for $75 million in cash (the &#8220;DuPont Transaction&#8221;), DuPont obtained certain rights to utilize the C1 technology for development and production of pharmaceutical products, for which it will make royalty payments to Dyadic upon commercialization. At the same time, Dyadic retained the co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, with Dyadic currently having exclusive ability to enter into sub-license agreements in that field (subject to the terms of the license and certain exceptions). We cannot predict whether DuPont intends to or will pursue the use of the C1 technology to develop or manufacture pharmaceutical products or whether or when we might receive royalties </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">from DuPont. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents owned or licensed in by DuPont. Consequently, our business has changed dramatically as compared to the past as we no longer have any product revenue related to our enzyme business. We have begun to apply the C1 technology in the biopharmaceutical market, which is relatively new to us. This change in our business makes it difficult to evaluate our current business and to predict our future operating results or financial performance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As we attempt to adapt the C1 technology for use in the biopharmaceutical market, our business is subject to the execution, integration, and research and development risks that early-stage companies customarily face with new technologies, products and markets. These risks relate to, among other things, our ability to successfully further develop the C1 technology, products and processes, assemble and maintain adequate production and research and development (&#8220;R&amp;D&#8221;) capabilities, comply with regulatory requirements, construct effective channels of distribution and manage growth. We have encountered and will continue to encounter risks and difficulties frequently experienced by early stage companies in expanding and upgrading our intellectual property, regulatory, marketing, sales and R&amp;D capabilities, improving our accounting and financial reporting and internal controls infrastructure, and adapting to the rapidly evolving industries in which we operate.  Additionally, we are subject to competition from much larger companies with more resources than us. Also, the market for developing and manufacturing pharmaceutical proteins produced from a filamentous fungus, such as the C1 fungus, is a market that is not yet established and is subject to a high level of regulatory hurdles from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and other governmental bodies and there is a risk that such technologies will not be adopted by the pharmaceutical industry or governmental agencies and therefore not succeed and/or not grow at the rates projected or at all.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have not yet commercialized any products for the biopharmaceutical market, and we may never be able to do so. Other than certain members of our board of directors, we currently have neither qualified personnel with experience or expertise in research and development of biopharmaceutical products nor personnel with regulatory, manufacturing, marketing, sales and licensing experience in these areas.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We do not know when or if we and/or our current and/or future collaborators and licensees will complete any of our or their product development efforts, obtain regulatory approval for any product candidates incorporating our technologies or successfully commercialize any approved products. Even if we and/or our licensees and collaborators are successful in developing products that are approved for marketing, we and they will still require that these products gain regulatory approval and market acceptance. The biopharmaceutical industry is a high risk industry in that even if we are successful at expressing certain proteins, these proteins may fail to be advanced or approved for use or sale for many reasons including their characteristics, stability, glycosylation structures, containments, purity, performance, safety and regulatory reasons.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve certain technology, product and/or commercial milestones, access fees and royalties, launch products and/or processes, or achieve profitability. In addition, our expenses could increase if we are required by the FDA or other domestic and foreign regulatory authorities to perform studies or trials in addition to those currently expected, or if there are delays in completing additional safety studies such as toxicology and pathogenicity studies, clinical trials, preclinical studies, animal or human studies or the development of any of our or our collaborators&#8217; product candidates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As a result of the evolving nature of our business, our operating history in past periods will not provide a reliable basis to evaluate our current business or predict our future performance. Any assessments of our current business or predictions regarding our future success or viability are likely not as accurate as they could be if we had a longer operating history in our new line of business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have a history of net losses, and we may not achieve or maintain profitability.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, we have an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$27.4 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Prior to the DuPont Transaction, our revenues were derived from licensing, licensing milestones and a very small amount of royalties from the licensing of the C1 expression system to third parties mainly within the industrial biotechnology markets, the operation of our industrial enzyme business and the collection of R&amp;D fees from third parties. Our profitability has strongly relied on, and will be even more reliant going forward on, third party industry and government research funding, licensing partnerships and other forms of collaborations. We believe that it is likely that if we do not sign license agreements or other forms of collaborations, we will incur losses because of our planned levels of R&amp;D and additional general and administrative expenditures that we believe is necessary to operate our business and further develop the C1 technology for use in the pharmaceutical business. The amount of our future net losses will depend, in part, on the rate of increase in our expenses along with other potential cost of unforeseen circumstances, our ability to generate research funding, government grants, receipt of access fees, milestones, royalty and other payments, and whether we are able to generate revenues by entering into license agreements or other forms of collaborations, launch new products and/or processes </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">from future licensees or collaborators, and our ability to raise additional capital. The net losses we anticipate incurring over the next several years will have an adverse effect on our stockholders&#8217; equity and working capital.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The R&amp;D efforts needed to enhance the C1 technology for use in developing and manufacturing biopharmaceuticals will require significant funding and increased staffing; therefore, we expect near-term operating and research expenses to continue, and maybe even accelerate, as we further develop our research and business plans, and our goals and objectives. Consequently, we will require significant additional revenue to achieve profitability. We cannot provide assurance that we will be able to generate any revenues from our focus and efforts as we intend to apply the C1 technology into the biopharmaceutical industry. If we fail to enter into new license agreements or other forms of collaborations, or generate revenues and profit from additional research projects and government grants, the market price of our common stock will likely decrease. Further regulatory complications, competition from other technologies, or delays in the adoption of the C1 technology by the biopharmaceutical industry may force us to reduce our staffing and research and development efforts, which may further affect our ability to generate cash flow.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on collaborations with third parties and if we fail to maintain or successfully manage existing, or enter into new, strategic collaborations, we may not be able to develop and commercialize many of our technologies and products and achieve profitability. We have a small number of research collaborations, and the nonperformance or loss of any collaboration could have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our R&amp;D revenue is generated from a relatively small number of research collaborations. These collaborations could be delayed or be discontinued, as they have in the past, at any time with little advance notice. We expect it to take a period of time before we will be successful, if at all, in obtaining additional research funding from industry and/or governmental sources. Therefore, for the time being, most of the research funding to further technology and product development will be incurred directly by the Company without any expense reimbursement from existing or new licensees and collaborators. If these research collaborations are lost or do not perform as expected, it could have a material adverse effect on our business, financial condition and operating results.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our ability to enter into, maintain and manage collaborations in our target market is fundamental to the success of our business. We currently rely on, and expect to continue to rely on, our current and future partners, in part, for research and development, manufacturing and distribution, sales and marketing services, and application and regulatory know how. In addition, we intend to enter into additional collaborations to conduct research, develop, produce, market, license and sell our technologies and products and processes we anticipate developing. However, we may not be successful in entering into collaborative arrangements with third parties. Any failure to enter into such arrangements on favorable terms could delay or hinder our ability to develop and commercialize our technologies, products and processes and could increase our costs of research and development and commercialization.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited or no control over the resources that any collaborator or licensee may devote to our programs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any of our current or future collaborators or licensees may, breach or terminate their agreements with us or otherwise fail to perform and conduct their required activities successfully and in a timely manner. Our collaborators or licensees may elect not to develop products arising out of our collaborative or license arrangements or may choose not to devote sufficient resources to the development, manufacture, market or sale of these products. If any of these events occur, we or our collaborators or licensees may not develop our technologies or commercialize our or their products.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reductions in collaborators&#8217; R&amp;D budgets may affect our businesses.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Fluctuations in the R&amp;D budgets of government agencies, our customers, licensees, collaborators and research partners could have a significant impact on the interest in and demand for our technology. Private R&amp;D budgets fluctuate due to changes in available resources, consolidation in the pharmaceutical and other industries, spending priorities and institutional budgetary policies. Governmental agencies, which we periodically receive research funding from, also experience fluctuations in their R&amp;D budgets, which may negatively impact our ability to receive funding from such agencies. Our businesses could be seriously damaged by significant decreases in life sciences and/or pharmaceutical R&amp;D expenditures by government agencies and existing and potential partners.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We heavily rely on contracts with third-party contract research organizations (&#8220;CROs&#8221;) to conduct our research and development, which may not be available to the Company on commercially reasonable terms or at all.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As a result of the DuPont Transaction, we no longer own a research and development laboratory and we became dependent upon the performance and research capacity of a number of third-party contract research organizations to conduct our research and development projects, which include services and programs in connection with the modification and enhancement of the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Company&#8217;s C1 expression platform and to support our business development efforts for C1&#8217;s use in biopharmaceutical applications. The licensing and service arrangements with these third party CROs are not guaranteed to be renewed or continued on reasonable terms, if at all. The Company may be unable to maintain or expand its access to third party CROs to conduct our research projects. Failure to maintain and expand access to certain third party CROs could have a material adverse impact on the Company&#8217;s research projects, financial condition and operating results.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are heavily dependent upon the availability and performance of third-party research organizations. If we require research capacity and/or capabilities and are unable to obtain it in sufficient quantity, and quality we may not be able to offer our technologies or products for license, or sale, or we may be required to make substantial capital investments to build out that capacity or to contract with other research organizations on terms that may be less favorable than our current arrangements. In addition, if we contract with other research organizations, we may experience delays of several months in qualifying them or in starting up research programs at these facilities, which could harm our relationships with our licensees, collaborators or customers and we may be required to make a capital investment in connection with these arrangements. This could have a material adverse effect on our business, revenues or operating results.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Additionally, if we were unsuccessful in retaining a contract research organization with the requisite experience and skills we require and were required to build our own research facility, it could take a year or longer before such owned research facility is able to be brought online to carry out the necessary technology and product development efforts of the Company. Any funding and resources we utilize to acquire or build internal research capabilities could be at the expense of other potentially more profitable opportunities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Conflicts with our CROs, collaborators and/or licensees could harm our business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">An important part of our strategy includes involvement in proprietary research programs. We may pursue opportunities in the pharmaceutical field that could conflict with those of our collaborators and licensees. Moreover, disagreements with DuPont, our current and/or future CROs, collaborators or licensees could develop over rights to our intellectual property, over further licensing of our technologies to other parties in certain pharmaceutical fields, or over other reasons. Any conflict with DuPont, our current and/or future CROs, collaborators or licensees could reduce our ability to obtain future collaboration agreements and negatively impact our relationship with existing collaborators or licensees, which could reduce our revenues and profits.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Some of our current and/or future CROs, collaborators and/or licensees could also become competitors in the future. Our current and/or future CROs, collaborators and/or licensees could develop competing technologies or products, preclude us from entering into collaborations or license agreements with their customers, could fail to obtain timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of their technology and products and processes. Any of these developments could harm our technology development and value, product development efforts, revenue, profits and overall business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If issues arise with our current and/or future CROs, collaborators and/or licensees, we will need to either commercialize products resulting from our proprietary programs directly or by licensing to other companies, which could cause us to lose revenue or incur losses. Similarly, we may lose revenue or incur losses if we are unable to license our technology to new licensees on commercially reasonable terms, or are unable to develop the capability to market and sell products and processes on our own.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on our collaborators and other third parties to deliver timely and accurate information in order to accurately report our financial results as required by law.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We need to receive timely, accurate and complete information from a number of third parties in order to accurately and timely report our financial results. We rely on third parties to provide us with complete and accurate information regarding research developments and data, revenues, expenses and payments owed to or by us on a timely basis. We will need to establish the proper controls related to obtaining and reporting information from our CROs, licensees and collaborators related to research results and other data, when milestones are earned, if any, when royalties are earned, if any, as well as other types of potential revenues and expenses. If the information that we receive is not accurate, our consolidated financial statements may be materially incorrect and may require restatement. Although we may have contractual rights to receive information, such provisions may not ensure that we receive information that is accurate or timely. As a result, we may have difficulty in completing accurate and timely financial disclosures, which could have a material adverse effect on our business, financial condition and results of operations and the market price of our common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;If our competitors develop technologies and products more quickly and market more effectively than our product candidates, our commercial opportunity will be reduced or eliminated. Because of the competition and safety risks in the biopharmaceutical industry, any product candidates are subject to extensive regulation, which are costly and time consuming.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any biopharmaceutical products we or our current or collaborators or licensees develop through the C1 expression system will compete in highly competitive and regulated markets. Many of the organizations competing with us in the market for such products have more capital resources, larger R&amp;D and marketing staff, facilities and capabilities, and greater experience in research and development, regulatory approval, manufacturing and commercialization of technology and products. Accordingly, our competitors may be able to develop technologies and products more rapidly. If a competitor develops superior technology or products, or more cost-effective alternatives to our and our collaborators&#8217; or licensees&#8217; technologies, products or processes, it could have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Customers may prefer existing or future technologies over the C1 expression system. Well-known and highly competitive biotechnology companies offer comparable or alternative technologies for the same products and services as our biopharmaceutical business. We anticipate that we, and our current or future collaborators and licensees will continue to encounter increased competition as new companies enter these markets and as the development of biological processes and products evolve.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pharmaceutical companies are usually more focused on the qualitative and safety aspects of the products rather than on the actual cost or potential cost savings of producing such safe pharmaceutical products. It is expected to be a very difficult task, and it is expected to take a very long time to get the biopharmaceutical industry to adopt a new expression system, including the C1 expression system. Even if the C1 technology delivers on its promise of expressing high volumes of low-cost proteins with the proper qualitative properties without negative side effects, it is still expected to take a very long time to obtain adoption of the C1 expression system by both the pharmaceutical industry and governmental regulatory agencies.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We could fail to manage our growth, which would impair our business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We will need to take the following steps, among others, to manage our growth.  If we fail to achieve one or more of these, it could have a material adverse effect on our business, financial condition and results of operations.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance our cash burn with technology and product development, advancement and value creation of such technologies and products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maintain and gain additional CROs, or other technology collaborators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maintain and gain additional strategic partners and technology licensees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File, maintain and defend our intellectual property and protect our proprietary information and trade secrets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Develop technology, products and processes that do not infringe on the intellectual property of third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recruit and hire the required employees necessary to maintain and grow our business and to advance our technologies and products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Achieve technical success in our and our licensees&#8217; or collaborators&#8217; research and product development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Implement and oversee our operational and financial control systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operate successful recruiting and training programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Access manufacturing capacity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Access additional growth capital;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recruit and maintain consultants, board members and scientific advisory board members;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manage scientific risks and uncertainties that may arise during our R&amp;D and regulatory programs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Limit litigation risks and uncertainties.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our revenue growth depends in part on market and regulatory acceptance of the C1 technology to develop and manufacture animal and/or human biopharmaceutical products.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The success of our biopharmaceutical business will depend on our ability to develop, register, and introduce similar, new and improved technologies and products in a timely manner, at significantly lower manufacturing costs that address the evolving requirements of the pharmaceutical industry and potential customers. There is no assurance that the C1 technology or any product expressed from C1 will perform the same or better, save our customers money relative to existing gene expression technologies or those of our competitors, provide our customers with other benefits, obtain governmental safety and regulatory approvals, be registered or will gain market acceptance. If we fail to develop similar, new and better performing technologies, products and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">processes at significantly lower manufacturing costs, make fermentation yield improvements on our existing production processes, generate the necessary safety and regulatory data or gain registration and market acceptance of the C1 technology and C1 expressed products or processes, we could fail to recoup our R&amp;D investment and fail to capitalize on potential opportunities or gain market share from our competitors. Any failure, for technological, quality, safety, regulatory, or other reasons, to develop and launch improved technologies and new products, could negatively impact our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The dynamic and conservative nature of the biopharmaceutical industry, the unpredictable nature of the product development process and the time and cost of new technology adoption in the biopharmaceutical industry may affect our ability to meet the requirements of the marketplace or achieve market and/or regulatory acceptance. Some factors affecting market and regulatory acceptance of our technologies and products include:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Availability, quality, performance and price of competitive products and processes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Functionality and cost of similar, new and existing technologies and products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Timing of product introduction, performance and pricing compared to our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientists&#8217;, customers&#8217; and regulatory agencies&#8217; opinions of our technology and products&#8217; utility and our ability to effectively incorporate their feedback into future technology development or product offerings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The status of C1 and other expression technologies including CHO, E.coli, other microbial, algae, plant and other expression systems as to safety, quality, purity and expression levels, capital expenditure intensity, operating costs, and continually changing governmental and industry regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The impact of our, DuPont&#8217;s and our collaborators&#8217; intellectual property, and that of our competitors</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competition with and against much larger companies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory hurdles, timing, costs and receipt of approvals.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The expenses or losses associated with unsuccessful technology and product development activities or lack of market acceptance of our new technologies and products could seriously harm our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We must continually offer new products and technologies.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The biopharmaceutical industry is characterized by rapid technological change, and the area of gene and protein research and platform development is a rapidly-evolving field.&#160; Our future success will depend on our ability to maintain a competitive position with respect to technological advances in terms of product and process quality, stability, safety, productivity and cost.&#160; Rapid technological development by others could cause our products and technologies to become obsolete and it could have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Potential future regulations limiting our ability to sell genetically engineered products could harm our business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We, our current and future collaborators and licensees expect to develop biologic products using genetically engineered microorganisms (GMOs). Products derived from GMOs may in some instances be subject to bans or additional regulation by federal, state, local and foreign government agencies. These agencies may not allow us or our collaborators and licensees to produce and market products derived from GMOs in a timely manner or under technically or commercially feasible conditions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Compliance with FDA, Environmental Protection Agency (EPA) and EU regulations could result in expenses, delays or other impediments to our product development programs or the commercialization of resulting products. The FDA currently applies the same regulatory standards to products made through genetic engineering as those applied to products developed through traditional methodologies. Regardless of GMO status, a product may be subject to lengthy FDA reviews and unfavorable FDA determinations due to safety concerns or changes in the FDA&#8217;s regulatory policy. The EPA regulates biologically-derived enzyme-related chemical substances not within the FDA&#8217;s jurisdiction. An unfavorable EPA ruling could delay commercialization or require modification of the production process or product in question, resulting in higher manufacturing costs, thereby making the product uneconomical. The EU and other countries also have regulations regarding the development, production and marketing of products from GMOs, which may be as or more restrictive than U.S. regulations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Further, we, DuPont, our current and future collaborators and licensees are subject to regulations in the other countries in which we operate outside of the U.S. and EU, which may have different rules and regulations depending on the jurisdiction. Different countries have different rules regarding which products qualify as GMO. If any of these countries expand the definition of GMO and increase the regulatory burden on GMO products, our business could be harmed.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Other changes in regulatory requirements, laws and policies, or evolving interpretations of existing regulatory requirements, laws and policies, may result in increased compliance costs, delays, capital expenditures and other financial obligations that could adversely affect our business or financial results.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public views on ethical and social issues may limit use of our technologies.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our success will depend in part upon our ability, our current and future collaborators&#8217; or licensees&#8217; ability, to develop pharmaceutical products discovered, developed and manufactured through the C1 expression system. Governmental authorities could, for social, ethical or other purposes, limit the use of genetic processes or prohibit the practice of using a modified C1 organism to produce biologic vaccines, drugs and other biologic products. Concerns about the C1 expression system, and particularly about the expression of genes from C1 for pharmaceutical purposes, could adversely affect their market acceptance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The commercial success of our current and future collaborations and our licensees&#8217; potential products will depend in part on public acceptance of the use of genetically engineered products including enzymes, vaccines, drugs and other protein products produced in this manner. Claims that genetically engineered products are unsafe for consumption or pose a danger to the environment, animals or humans may influence public attitudes. Our and our licensees&#8217; genetically engineered products may not gain public acceptance. Negative public reaction to GMOs and products could result in increased government regulation of genetic research and resulting products, including stricter labeling laws or other regulations, and could cause a decrease in the demand for our products. If we and/or our collaborators are not able to overcome the ethical, legal, and social concerns relating to genetic engineering, some or all of our products and processes may not gain public acceptance. Any of the considerations below could result in expenses, delays, or other impediments to our and our licensees&#8217; programs or the public acceptance and commercialization of products and processes dependent on our technologies and could have a material adverse effect on our business, financial condition and results of operations:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">public attitudes about the safety and environmental hazards of, and ethical concerns over, genetic research and genetically engineered products and processes, which could influence public acceptance of our and our licensees&#8217; technologies, products and processes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">public attitudes regarding, and potential changes to laws governing, ownership of genetic material which could harm our intellectual property rights with respect to our genetic material and discourage collaborative partners or licensees from supporting, developing, or commercializing our products, processes and technologies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">government regulations are changing rapidly, which likely will result in greater government regulation of genetic research and derivative technologies and products derived from such technologies, making approvals of such technologies and the products derived from such technologies to be delayed, more expensive with added risks.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by environmental, health and safety laws, regulations and liabilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We and our CROs are subject to various federal, state and local environmental laws and regulations relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials, and the health and safety of our employees. These laws, regulations and permits can often require expensive pollution control equipment or operational changes to limit actual or potential impacts to the environment. A violation of these laws and regulations or permit conditions can result in substantial fines, criminal sanctions, permit revocations and/or facility shutdowns.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, new laws, new interpretations of existing laws, increased government enforcement of environmental laws, or other developments could require us or our contract research organizations to make additional significant expenditures. Present and future environmental laws and regulations and interpretations thereof, more vigorous enforcement of policies and discovery of currently unknown conditions may require substantial expenditures that could have a material adverse effect on our results of operations and financial position. Additionally, any such developments may have a negative impact on our contract manufacturers, which could harm our business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may fail to commercialize the C1 expression system for the expression of therapeutic proteins, antibodies and vaccines.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have not yet developed any C1-based biopharmaceutical products, conducted the necessary safety, efficacy, cost and regulatory studies, or completed the commercialization of any therapeutic proteins, antibodies and vaccines.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To date, drug companies have developed and commercialized only a small number of gene-based products in comparison to the total number of drug molecules available in the marketplace. Our biopharmaceutical business should be evaluated as having the same risks as those inherent to early-stage biotechnology companies because the application of the C1 expression system for the expression of pre-clinical and clinical quantities of therapeutic proteins, antibodies and vaccines is still in early development.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Successful development of the C1 expression system for biopharmaceutical purposes will require significant research, development and capital investment, including testing, to prove its safety, efficacy and cost-effectiveness. In general, our experience has been that each step in the process has been longer and costlier than originally projected, and we anticipate that this is likely to remain the case with respect to the continuing development efforts of our biopharmaceutical business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have no experience submitting applications to the FDA or similar regulatory authorities, and could be subject to lengthy and/or unfavorable regulatory proceedings.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">While we anticipate that many of our current and future collaborators or licensees have experience submitting application to the FDA or other applicable regulatory authorities, we have no such experience. Neither we nor any collaborator or licensee has yet submitted any application with the FDA or any other regulatory authority for any product candidate generated through the use of the C1 expression system as it relates to the development and manufacture of pharmaceutical products. The FDA may not have substantial experience with technology similar to ours, which could result in delays or regulatory action against us. We, our current and future collaborators and licensees, may not be able to able to obtain regulatory approval for our products, which would harm our business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The C1 expression system has been tested for use in the manufacturing of an enzyme in the production of wine, beer and fruit juices, and has generated promising safety and toxicity data for that enzyme. The C1 expression system could produce vaccines, antibodies, or therapeutic products and enzymes that have safety, toxicity, pathogenicity, immunogenicity and other issues associated with them. The C1 expression system may be subject to lengthy regulatory reviews and unfavorable regulatory determinations if it raises safety questions which cannot be satisfactorily answered or if results from studies do not meet regulatory requirements. An unfavorable regulatory ruling could be difficult to resolve and could delay or possibly prevent a product from being commercialized, or even the use of the C1 technology to produce future products which would have a material adverse effect on our growth and prospects. Additionally, future products produced by us or our current and future collaborators or licensees using the C1 expression system may not be approved by the FDA or other regulatory agencies in the U.S. or worldwide. There is no assurance that safety, toxicity, pathogenicity, immunogenicity and other issues will not arise in current or future product development and manufacturing programs due to media, fermentation, inherent properties or genetic changes in the C1 strain and fermentation process.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If these therapeutic protein products, antibodies or vaccines are not approved by regulators, we or our current and future customers or collaborators and licensees will not be able to commercialize them, and we may not receive research funding, upfront license fees, milestone and royalty payments which are based upon the successful advancement of these products through the drug development and approval process. Even after investing significant time and expense, any regulatory approval may also impose limitations on the uses for which we can market a product, and any marketed product and its manufacturer are subject to continual review. Discovery of previously unknown problems with a product or manufacturer may result in new restrictions on the product, manufacturer and manufacturing facility, including withdrawal of the product from the market. In certain countries, regulatory agencies also set or approve prices, which may result in low or unprofitable margins and would have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Alternative technologies may not require microbial or other cell produced proteins.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research is being conducted with cell or gene based therapies and other technologies that offer a possible alternative to producing proteins as they are today based on microbial, organic matter containing Carbon, Hydrogen, and Oxygen or other organisms, that may allow genes to be directly inserted into cells that can be implanted into animals and humans directly, displacing the need for the existing methods used for development of biologic vaccines and drugs. If they are successful, these new methods may supplant or greatly reduce the need for microorganisms, Carbon, Hydrogen, and Oxygen or other organisms to produce these proteins externally as the injected cells in animals and human may be able to do so internally.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Business Risks That We Face</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may need substantial additional capital in the future to fund our business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our future capital requirements may be substantial, particularly as we continue to further develop, engineer and optimize the C1 expression system and our other proprietary technologies, products and processes for licensing for research and development, and commercialization of potential animal and human pharmaceutical products.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our need for additional capital, if any, will depend on many factors, including (i) the technical and financial success of our efforts to enter the biopharmaceutical industry, (ii) the progress and scope of our collaborative and independent R&amp;D projects and other ongoing and future potential projects, (iii) the receipt of future upfront fees, potential milestones, royalties and other </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">payments from future licensees or other types of collaborations if any, (iv) our ability to obtain payments from other potential pharmaceutical business customers through research funding, milestones, license agreements and other forms of collaborative agreements, (v) the extent to which we can obtain licensees, or other types of collaborative partnerships for the research, development and commercialization of proteins in the biopharmaceutical industry, (vi) the effect of any acquisitions of other technologies and/or businesses that we may make in the future, and (vii) the filing, prosecution, enforcement and defense of patent claims and/or infringements by us, and our collaborators.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We currently have very little leverage and if our capital resources are insufficient to meet our capital requirements, we will have to raise additional funds to continue the development of our technologies and complete the development and commercialization of products, if any, resulting from our technologies. If acquisition of additional funds is not possible or if we engage in future equity financings, dilution to our existing stockholders may result. If we raise debt financing, we may be subject to restrictive covenants that limit our ability to conduct our business. We may not be able to raise funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research or development programs or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, sell certain assets of the company which will limit future opportunities, or grant licenses on terms that are not favorable to us. Without sufficient funding or revenue, we may have to curtail, cease, or dispose of, one or more of our operations and would have a material adverse effect on our business, financial condition, and future prospects.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in global economic and financial markets may have a negative effect on our business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our business is subject to a variety of market forces including, but not limited to, domestic and international economic, political and social conditions. Many of these forces are beyond our control. Any change in market conditions that negatively impacts our operations or the demand of our current or prospective customers could adversely affect our business operations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, changes in the global financial, pharmaceutical and biotech markets may make it difficult to accurately forecast operating results. These changes have had, and may continue to have, a negative effect on our business, results of operations, financial condition and liquidity. In the event of a downturn in global economic activity, current or potential customers may go out of business, may be unable to fund purchases or determine to reduce purchases, all of which could lead to reduced demand for our products, reduced gross margins, and increased customer payment delays or defaults. Further, suppliers may not be able to supply us with needed raw materials on a timely basis, may increase prices or go out of business, which could result in our inability to meet consumer demand or affect our gross margins. We are also limited in our ability to reduce costs to offset the results of a prolonged or severe economic downturn given certain fixed costs associated with our operations and difficulties if we overstrained our resources. The timing and nature of a sustained recovery in the credit and financial markets remains uncertain, and there can be no assurance that market conditions will significantly improve in the near future or that our results will not continue to be materially and adversely affected.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we lose key personnel, including key management or board members, or are unable to attract and retain additional personnel, it could delay our technology and product development programs, harm our R&amp;D efforts, and we may be unable to pursue research funding, licenses and other forms of collaborations or develop our own products.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our planned activities will require retention and ongoing recruiting of additional expertise in specific areas applicable to our industries, technologies and products being developed. These activities will not only require the development of additional expertise by existing management personnel, but also the addition of new research and scientific, regulatory, licensing, sales, marketing, management, accounting and finance and other personnel. The inability to acquire or develop this expertise or the loss of principal members of our management, broad of directors, consultants, accounting and finance, sales, and scientific staff could impair the growth, if any, of our business. Competition for experienced personnel from numerous companies, academic institutions and other research facilities may limit our ability to attract and retain qualified management, directors, consultants, and scientific personnel on acceptable terms. Failure to attract and retain qualified personnel would inhibit our ability to maintain and pursue collaborations and develop our products and core technologies.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Personnel changes may disrupt our operations. Hiring and training new personnel will entail costs and may divert our resources and attention from revenue-generating efforts. In addition, we periodically engage consultants to assist us in our business and operations, these consultants operate as independent contractors, and we, therefore, do not have as much control over their activities as we do over the activities of our employees. Our directors and consultants may be affiliated with or employed by other parties, and some may have consulting or other advisory arrangements with other entities that may conflict or compete with their obligations to us. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inability to protect our intellectual property could harm our ability to compete.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our success will depend in part on our ability to obtain patents and on our and DuPont&#8217;s (as part of the DuPont Transaction, patents were assigned to DuPont) and our current and future collaborators&#8217; and licensees&#8217; ability to maintain adequate protection of our and their intellectual property. If we, DuPont, or our current and future collaborators and licensees do not adequately protect our intellectual property, competitors may be able to practice our technologies and erode our competitive advantage. The laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting their proprietary rights in these foreign countries.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">However, the patent positions of biotechnology companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our, and in certain instances the C1 patents assigned to DuPont, and our current and future collaborators and licensees proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We intend, from time to time, to apply for patents covering both our technologies and our products, while at other times, we only maintain such knowledge as trade secrets without applying for patents, as we deem appropriate. However, existing and future patent applications may be challenged and are not guaranteed to result in the issuing of patents. Even if a patent is obtained, it may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Others, including DuPont and our current and future collaborators and licensees, may independently develop similar or alternative technologies or design around our, DuPont&#8217;s or our current and future collaborators&#8217; and licensees&#8217; patented technologies. In addition, DuPont, our current and future collaborators, licenses, or other third parties may challenge or invalidate our patents, or our patents may fail to provide us with any competitive advantages. If any third party is able to gain intellectual property protections for technology similar to our own, they may be successful in blocking us and our licensees from using C1 technology and/or commercializing products derived from the C1 technology.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The United States Leahy-Smith America Invents Act, enacted in September 2011, brought significant changes to the U.S. patent system, which include a change to a &#8220;first to file&#8221; system from a &#8220;first to invent&#8221; system and changes to the procedures for challenging issued patents and disputing patent applications during the examination process, among other things. The effects of these changes on our patent portfolio and business have yet to be determined, as the final substantive provisions of the America Invents Act took effect on March 16, 2013. The United States Patent and Trademark Office (the &#8220;USPTO&#8221;), only recently finalized the rules relating to these changes and the courts have yet to address the new provisions. These changes could increase the costs and uncertainties surrounding the prosecution of our patent applications and the enforcement or defense of our patent rights. Additional uncertainty may result from legal precedent handed down by the United States Court of Appeals for the Federal Circuit and United States Supreme Court as they determine legal issues concerning the scope and construction of patent claims and inconsistent interpretation of patent laws by the lower courts. Accordingly, we cannot ensure that any of our pending patent applications will result in issued patents, or even if issued, predict the breadth of the claims upheld in our and other companies&#8217; patents. Given that the degree of future protection for our proprietary rights is uncertain, we cannot ensure that we were the first to invent the inventions covered by our pending patent applications, or that we were the first to file patent applications for these inventions or the patents we have obtained.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, Dyadic will continue to review its existing and potential patent positions and rights. Based on our analysis if and when the commercial opportunities and patent enforceability are questionable, we may abandon certain patents in some countries. There is a risk that we will abandon potentially valuable patents.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and resources and could prevent us and our collaborators from commercializing our or their technologies and products or negatively impact our stock price.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our commercial success depends in part on neither infringing patents and proprietary rights of third parties, nor breaching any licenses that we have entered into with regard to our technologies and products. Others have filed, and in the future are likely to file, patent applications covering genes or gene fragments, genetic elements, screening, gene expression and fermentation processes and other intellectual property that we may wish to utilize with the C1 expression system or products and systems that are similar to those developed with its use. If these patent applications result in issued patents and we wish to use the claimed technology, we may need to obtain a license from the appropriate third party.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Third parties may assert that we and/or our current and future collaborators and licensees are employing their proprietary technology without authorization. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes these patents. We could incur substantial costs and diversion of management and technical personnel in defending ourselves against any of these claims or enforcing our patents and other intellectual property rights. Parties making claims against us may be able to obtain injunctive or other equitable relief, which could effectively block our ability to further develop, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">commercialize and sell products, and could result in the award of substantial damages against us. If a claim of infringement against us is successful, we may be required to pay damages and obtain one or more licenses from third parties. In the event that we are unable to obtain these licenses at a reasonable cost, we and/or current and future collaborators and licensees could encounter delays in product commercialization while we attempt to develop alternative methods or products. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing available products.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, unauthorized parties may attempt to steal, copy or otherwise obtain and use our C1 microbial strains, genetic elements, development and manufacturing processes, other technology or products. Monitoring unauthorized use of our intellectual property is difficult, and we cannot be certain that the steps we have taken will prevent unauthorized use of our technologies, particularly in certain foreign countries where the local laws may not protect our proprietary rights as fully as in the United States. Moreover, third parties could practice our inventions in territories where we do not have patent protection. Such third parties may then try to import into the United States or other territories products, or information leading to potentially competing products, made using our inventions in countries where we do not have patent protection for those inventions. If competitors are able to use our technologies, our ability and our current and future collaborators&#8217; and licensees&#8217; ability to compete effectively could be harmed. Moreover, others may independently develop and obtain patents for technologies that are similar to or superior to our technologies. If that happens, we may need to license these technologies, and we may not be able to obtain licenses on reasonable terms, if at all, which could harm our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We rely in part on trade secret protection to protect our confidential and proprietary information and processes. However, trade secrets are difficult to protect. We have taken measures to protect our trade secrets and proprietary information, but these measures may not be effective. We require employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. Nevertheless, our proprietary information may be disclosed, third parties could reverse engineer our biocatalysts and others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be sued for product liability.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We or our current and future collaborators and licenses may be held liable if any product we or they develop, or any product which is made with the use or incorporation of, any of our technologies, causes injury or is found otherwise unsuitable or unsafe during product testing, manufacturing, marketing or sale. These claims could be brought by various parties, including other companies who purchase products from our current and future collaborators and licenses or by end users of the products.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">While we maintain product liability insurance, it may not fully cover all of our potential liabilities and our liability could in some cases exceed our total assets, which would have a material adverse effect on our business, results of operations, financial condition and cash flows, or cause us to go out of business. Further, insurance coverage is expensive and may be difficult to obtain, and may not be available to us or to our collaborators and licensees in the future on acceptable terms, or at all. Inability to obtain sufficient insurance coverage at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products developed by us, or our collaborators and licensees.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign currency fluctuations could adversely affect our results.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the conduct of our business, in certain instances, we are required to receive payments or pay our obligations in currencies other than U.S. dollars. Especially since a large portion of our research and development is done in the EU and our CROs and certain consultants request payments in Euros. As a result, we are exposed to changes in currency exchange rates with respect to our business transactions denominated in non-US dollars.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Fluctuations in currency exchange rates have in the past and may in the future negatively affect our revenue, expenses and our financial position and results of operations as expressed in U.S. dollars. Our management monitors foreign currency exposures and may in the ordinary course of business enter into foreign currency forward contracts or options contracts related to specific foreign currency transactions or anticipated cash flows. We do not hedge, and have no current plans to hedge in the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">future, the translation of financial statements of consolidated subsidiaries whose local books and records are maintained in foreign currency.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) to offset future taxable income may be subject to certain limitations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In general, under Section 382 of the Internal Revenue Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its NOLs, to offset future taxable income. If the Internal Revenue Service challenges our analysis that our existing NOLs are not subject to limitations arising from previous ownership changes, our ability to utilize NOLs could be limited by Section 382 of the Internal Revenue Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Internal Revenue Code. Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may make acquisitions, investments and strategic alliances that may use significant resources, result in disruptions to our business or distractions of our management, may not proceed as planned, and could expose us to unforeseen liabilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may seek to expend our business through the acquisition of, investment in and strategic alliances with companies, technologies, products, and services. If we are able to identify suitable acquisition, investment or strategic alliance targets, we may be unable to negotiate successfully their acquisition at a price or on terms and conditions acceptable to us.  Acquisition, investments and strategic alliances involve a number of risks, including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the potential adverse effect on our cash position as a result of all or a portion of an acquisition, investment or strategic alliance purchase price being paid in cash;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the potential issuance of securities that would dilute our stockholders&#8217; percentage ownership;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated costs and liabilities, including the potential to incur restructuring and other related expenses, including significant transaction costs that may be incurred regardless of whether a potential strategic alliance, acquisition or investment is completed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability to effectively and quickly assimilate the operations, technologies, products and services or products of the acquired company or business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability to integrate acquired personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability to oversee, retain and motivate key employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability to retain customers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">minimizing the diversion of management&#8217;s attention from other business concerns; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential loss of invested capital.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We cannot assure you that, following an acquisition, investment or strategic alliance, we will achieve expected research and development results, anticipated synergies, revenues, specific net income or loss levels that justify such transaction or that the transaction will result in increased earnings, or reduced losses, for the combined company in any future period. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses or to provide funding for such business, which would result in dilution for stockholders or the incurrence of indebtedness and may not be available on terms which would otherwise be acceptable to us. We may not be able to oversee such investment(s) nor operate acquired businesses profitably or otherwise implement our growth strategy successfully.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations, and could result in a material disruption of our research activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and delays in our research efforts and financial reporting compliance, as well as significant increase in costs to recover or reproduce the data.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Stock Repurchase Program</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our stock repurchase program may be extended, suspended or discontinued at any time, which could cause the price of our common stock to be volatile or to decrease.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 16, 2016, the Board of Directors authorized a one-year stock repurchase program, under which the Company was authorized to repurchase up to $15 million of its outstanding common stock (the &#8220;2016 Stock Repurchase Program&#8221;). The 2016 Stock Repurchase Program ended on February 15, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On August 16, 2017, the Board of Directors authorized a new one-year stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding common stock (the &#8220;2017 Stock Repurchase Program&#8221;).</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;On August 6, 2018, the Board of Directors authorized an extension of this stock repurchase program through August 15, 2019. Please refer to our consolidated financial statements note under &#8220;Shareholders</font><font style="font-family:inherit;font-size:10pt;">&#8217;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Equity - Share Repurchases and Buybacks&#8221; for share repurchases and buyback information and activities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the 2017 Stock Repurchase Program, the Company is authorized to repurchase shares in open-market purchases in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The extent to which the Company repurchases its shares, and the timing of such repurchases, is dependent upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by the Company&#8217;s management. The repurchase program may be extended, suspended or discontinued at any time. The Company expects to finance the program from its existing cash resources. All repurchased shares are held in treasury.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;However, the board may decide to retire these shares in the future.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to the Stock Repurchase Programs above, our Board of Directors may, on a case by case basis, authorize the repurchase of the Company&#8217;s shares in privately negotiated transactions, if such transaction is in the best interest of the Company and its shareholders.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company may in the future determine to initiate a new repurchase program depending upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by the Company&#8217;s Board of Directors and management.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The price of our shares of common stock is likely to be volatile, and you could lose all or part of your investment.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The trading price of our common stock has been, and is likely to continue to be, volatile. Biotechnology company stocks generally tend to experience extreme price fluctuations. The valuations of many biotechnology companies without consistent product sales and earnings are extraordinarily high based on conventional valuation standards such as price-to-earnings and price-to-sales ratios. These trading prices and valuations may not be sustained. Factors that may result in fluctuations in our stock price include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the public&#8217;s perception of the prospects of biotechnology companies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Broad market and industry factors including market fluctuations or political and economic conditions such as war, recession or changes in interest and currency rates.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Announcements of new technological innovations, patents&#160;or new products or processes by us, DuPont or our current or future collaborators, licensees and competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Announcements by us, DuPont or our collaborators and licensees relating to our relationships or either of our relationships with other third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Coverage of, or changes in financial estimates by us or securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conditions or trends in the biotechnology industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the market valuations of other biotechnology companies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Limitations or expanded uses in the areas within the biopharmaceutical or other industries into which we can apply our technologies and products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Actual or anticipated changes in our growth rate relative to our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developments in domestic and international governmental policy or regulations;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Announcements by us, DuPont, our current and future collaborators and licenses, or our competitors of significant acquisitions, divestures, strategic partnerships, license agreements, joint ventures or capital commitments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The position of our cash, cash equivalents and marketable securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any changes in our debt position;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developments in patent or other proprietary rights held by us, DuPont or by others;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Negative effects related to the stock or business performance of DuPont, our current and future collaborators and licensees, or the abandonment of projects using our technology by our collaborators and/or licensees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific risks inherent to emerging technologies such as the C1 expression system;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Set-backs, and/or failures, and or delays in our or our current and future collaborators&#8217; and licensees&#8217; R&amp;D and commercialization programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delays or failure to receive regulatory approvals by us, DuPont and/or our current and future collaborators and licensees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss or expiration of our or DuPont&#8217;s intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lawsuits initiated by or against us, DuPont, or our current and future collaborators and licensees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Period-to-period fluctuations in our operating results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future royalties from product sales, if any, by DuPont, our current or future strategic partners, collaborators or licensees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future royalties may be owed to DuPont by us, our collaborators, licenses, or sub-licensees under certain circumstances related to our DuPont Pharma License;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of our common stock or other securities in the open market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock buy-back programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock splits and reverse stock split;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Decisions made by the board related to potential registration of Dyadic&#8217;s stock under the Securities Act of 1933, and/or up listing to another stock exchange.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Volatile stock prices can lead to securities class action litigation. In 2007, a stockholder filed a securities class action suit against us, which we settled on July 27, 2010. If we were to become party to another securities class action suit, we could incur substantial legal fees and our management&#8217;s attention and resources could be diverted from operating our business to responding to litigation.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our quarterly and annual operating results may be volatile.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our quarterly and annual operating results have fluctuated in the past and are likely to do so in the future. These fluctuations could cause our stock price to vary significantly or decline. Some of the factors that could impact our operating results include:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expiration of or cancellations of our research contracts with current and future collaborators and/or licensees, which may not be renewed or replaced;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Setbacks or failures in our and our current and future collaborators and licensees research, development and commercialization efforts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Setbacks, or delays in our research and development efforts to develop and produce biologics.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Setbacks, or delays in our research and development efforts to re-engineer the C1 technology for its application and use in developing and producing biologics.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The speed, and success rate of our discovery and research and development efforts leading to potential licenses, or other forms of collaborations, access fees, milestones and royalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The timing and willingness of current and future collaborators and licensees to utilize C1 to develop and commercialize their products which would result in potential upfront fees, milestones and royalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and industry specific economic conditions, which may affect our current and future collaborators&#8217; and licensees&#8217; R&amp;D expenditures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The adoption and acceptance of the C1 expression system by biopharmaceutical companies and regulatory agencies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The addition or loss of one or more of the collaborative partners, grants, research funding, or licensees we are working with to further develop and commercialize our technologies and products in the pharmaceutical industry;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to file, maintain and defend our intellectual property and to protect our proprietary information and trade secrets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to develop technology, products and processes that do not infringe on the intellectual property of third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The improvement and advances made by our competitors to CHO, E.coli, yeast, inset cells, plant and other expression systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The introduction by our competitors of new discovery and expression technologies competitive with the C1technology;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to enter into new research projects, grants, licenses or other forms of collaborations and generate revenue from such parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific risk associated with emerging technologies such as the C1 expression system;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Failure to bring on the necessary research, CDMO and manufacturing capacity if required;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertainty regarding the timing of research funding, grants or upfront license fees for new C1 expression system collaborations, license agreements or expanded license agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delays or failure to receive upfront fees, milestones and royalties and other payments.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A large portion of our expenses are relatively fixed, including expenses for personnel. Accordingly, if revenues do not grow as anticipated due to the expiration of research contracts or government research grants, the failure to obtain new contracts, licensees or other forms of collaborations or other factors, we may not be able to correspondingly reduce our operating expenses. Failure to achieve anticipated levels of revenue could, therefore, significantly harm our operating results for a particular fiscal period or for even prolonged periods of time.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Due to the possibility of fluctuations in our revenues and expenses, we believe that quarter-to-quarter comparisons of our operating results are not necessarily a good indication of our future performance. Our operating results in some quarters, or even in some years may not meet the expectations of stock market analysts and investors, potentially causing our stock price to possibly decline.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not expect to pay cash dividends in the future.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have never paid cash dividends on our stock and do not anticipate paying any dividends for the foreseeable future. The payment of dividends on our shares, if ever, will depend on our earnings, financial condition and other business and economic factors deemed relevant for consideration by our board of directors. If we do not pay dividends, our stock may be less valuable because a return on investment will only occur if and to the extent that our stock price appreciates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our anti-takeover defense provisions may deter potential acquirers and depress our stock price.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Certain provisions of our certificate of incorporation, bylaws and Delaware law, as well as certain agreements we have with our executives, could make it substantially more difficult for a third party to acquire control of us. These provisions include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue preferred stock with rights senior to those of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a classified board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Action by written consent by stockholders is not permitted;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors has the exclusive right to fill vacancies and set the number of directors cumulative voting by our stockholders is not allowed; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We require advance notice for nomination of directors by our stockholders and for stockholder proposals.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">These provisions may discourage certain types of transactions involving an actual or potential change in control. These provisions may also limit our stockholders&#8217; ability to approve transactions that they may deem to be in their best interests and discourage transactions in which our stockholders might otherwise receive a premium for their shares over the current market price.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of ownership among our existing officers, directors and principal stockholders may prevent other stockholders from influencing significant corporate decisions and depress our stock price.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our executive officers, directors and principal stockholders (5% stockholders) together control approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">45.6%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of our </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26,713,486</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of outstanding common stock as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our Founder and Chief Executive Officer Mark Emalfarb, through the Mark A. Emalfarb Trust under agreement dated October 1, 1987, as amended (the &#8220;MAE Trust&#8221;) of which he is the trustee and beneficiary, owned approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">15.4%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of our outstanding common stock as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Further, the Francisco Trust U/A/D February 28, 1996 (the &#8220;Francisco Trust&#8221;), whose beneficiaries are the descendants and spouse of Mr. Emalfarb, owned approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">14.1%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of our outstanding common stock as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. We have historically been partially controlled, managed and partially funded by Mr. Emalfarb, and affiliates of Mr. Emalfarb. Collectively, Mr. Emalfarb and stockholders affiliated with Mr. Emalfarb controlled approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">29.5%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of our outstanding common stock as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Mr. Emalfarb may be able to control or significantly influence all matters requiring approval by our shareholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of Mr. Emalfarb may not always coincide with the interests of other shareholders, and he may take actions that advance his personal interests and are contrary to the desires of our other shareholders.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If our existing officers, directors and principal stockholders act together, they will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. In addition, this concentration of ownership may delay or prevent a change in control and might affect the market price of our shares, even when a change may be in the best interests of all stockholders. Certain of our principal stockholders may elect to increase their holdings of our common stock, which may have the impact of delaying or preventing a change of control. Moreover, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders, and, accordingly, they could cause us to enter into transactions or agreements, which we would not otherwise consider.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not commence the publication of research or reports about our business, or publish negative reports about our business, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us or our business. We have no control over these analysts. If one or more analysts release a negative report, or release a positive report and subsequently downgrade or change that report, potentially causing our stock price would likely decline. Additionally, if one or more of these analysts cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future issuances of shares of our common stock may negatively affect our stock price.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The sale of additional shares of our common stock, or the perception that such sales could occur, could harm the prevailing market price of shares of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, there were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26,713,486</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of our common stock outstanding. Approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">45.6%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of these outstanding common shares are beneficially owned or controlled by our executive officers, directors and principal stockholders. Shares held by our affiliates and certain of our directors, officers and employees are &#8220;restricted securities&#8221; as defined by Rule 144 (&#8220;Rule 144&#8221;) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and subject to certain restrictions on resale. Restricted securities may be sold in the public market only if they are registered under the Securities Act or are sold pursuant to an exemption from registration such as Rule 144.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our common stock has a relatively small public float. As a result, sales of substantial amounts of shares of our common stock, or even the potential for such sales, may materially and adversely affect prevailing market prices for our common stock. In addition, any adverse effect on the market price of our common stock could make it difficult for us to raise additional capital through sales of equity securities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We incur significant costs as a listing company on the OTCQX U.S. Premier marketplace, and those costs will increase if, as and when we decide to register our shares with the Securities and Exchange Commission (&#8220;SEC&#8221;) and operate as a public company, and our management will be required to devote substantial time to compliance initiatives.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As a company quoted on the OTCQX U.S. Premier marketplace, we incur significant legal, accounting and other expenses that we did not incur previously. The OTCQX Alternative Reporting Standards impose various requirements on companies that require our management and other personnel to devote a substantial amount of time to compliance initiatives. These costs will further increase if we become a fully reporting company under the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may in the future seek to list our common stock on the NASDAQ Stock Market or another U.S. or foreign stock exchange. However, we do not currently meet the listing standards for any national securities exchange. During the period that our common stock is quoted on the OTCQX U.S. Premier or any other over-the-counter system, an investor may find it more difficult to dispose of shares or obtain accurate quotations as to the market value of our common stock than would be the case if and when we list on the NASDAQ Stock Market or another U.S. or foreign stock exchange.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, if we fail to meet the criteria set forth in certain SEC regulations, various requirements would be imposed by law on broker-dealers who sell our securities to persons other than established customers and accredited investors. Consequently, such regulations may deter broker-dealers from recommending or selling our common stock, which may further affect its liquidity. This would also make it more difficult for us to raise additional capital.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may not be able to meet the initial listing standards of any stock exchange, correctly predict the timing of such listing or, if listed, maintain such a listing.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will incur significant costs as a result of operating as a listed full reporting public company, and our management will be required to devote substantial time to compliance initiatives.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Exchange Act, the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as related rules implemented by the SEC, impose various requirements on public companies that require our management and other personnel to devote a substantial amount of time to compliance initiatives.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, the Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls over financial reporting and disclosure controls and procedures.  In particular, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to evaluate the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act.  Our compliance with Section 404 requires that we incur substantial accounting expense and expend significant management time on compliance-related issues. Moreover, if we are not able to maintain compliance with the requirements of Section 404, our stock price could decline, and we could face sanctions or investigation or investigations or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the SEC does not declare this Registration Statement effective or otherwise delays the effectiveness of this Registration Statement, the Company may be negatively affected and stockholders may not be able to sell shares in the amounts or at the times they might otherwise to.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Although the Company is undertaking the steps it believes are necessary to permit the SEC to declare this Registration Statement effective, it is possible that the SEC may, by application of its policies or procedures, delay the effectiveness of the Registration Statement or make it impractical for the Company to respond to the SEC in a manner that permits it to declare the Registration Statement effective.  If the Registration Statement is not declared effective, the Company may be negatively affected and stockholders will need to rely on exemptions from the registration requirements of the Securities Act, such as Rule 144.  Such exemptions typically limit the amount of share that can be sold, require that shares be sold in certain types of transactions, require certain holding periods and limit the number of times that shares can be sold.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because we will become a reporting company under the Exchange Act by means other than a traditional underwritten initial public offering, we may not be able to attract the attention of research analysts at major brokerage firms.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Because we will not become a reporting company by conducting an underwritten initial public offering, or IPO, of our common stock, and because we will not be listed on a national securities exchange upon the effective date of this registration statement, security analysts of brokerage firms may not provide coverage of our company. In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we were to become a public reporting </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">company by means of an IPO because they may be less familiar with our company as a result of more limited coverage by analysts and the media. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to the Potential Reverse Stock Split and Potential Listing on the NASDAQ or another National Stock Market</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The potential Reverse Stock Split, if effected, would provide additional authorized shares for issuance by our Board of Directors, which could be used to frustrate any change in control or takeover transaction or have adverse consequences to our shareholders.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In April 2018, our Board of Directors approved for submission to a vote of our shareholders the grant of authority to the Board of Directors to amend our Certificate of Incorporation to effect the Reverse Stock Split. At our annual shareholders meeting on June 6, 2018, our shareholders approved the proposal. If the Board of Directors effects the Reverse Stock Split, we would have additional authorized shares of common stock that the Board of Directors could issue in the future without shareholders&#8217; approval. Such additional shares could be issued, among other purposes, in financing transactions or to resist or frustrate a third-party transaction that is favored by a majority of the independent shareholders. This could have an anti-takeover effect, in that additional shares could be issued, within the limits imposed by applicable law, in one or more transactions that could make a change in control or takeover of us more difficult.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A large number of available shares of common stock could have adverse consequences, including but not limited to, our current shareholders could be potentially diluted by future issuances of shares of common stock for capital raising purposes, to acquire additional assets, for equity compensation of officers and directors and for other corporate purposes.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Board of Directors has not yet effected the potential Reverse Stock Split and even if effected, the Reverse Stock Split may not increase the price of our common stock and have other adverse consequences on the price of our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our Board of Directors has not yet effected the potential Reverse Stock Split. As part of the shareholder approval of the Reverse Stock Split, the Board of Directors reserved the right to abandon the Reverse Stock Split proposal without further action by our shareholders at any time before the effectiveness of the filing of the amended Certificate of Incorporation with the Delaware Secretary of State or delay (for up to 24 months after the annual meeting on June 6, 2018), if it determines, in its sole discretion, that such action is in the best interests of the Company and its shareholders. If the Board of Directors abandons or further delays the Reverse Stock Split, the trading price of our common stock may be negatively affected. We cannot assure you, when or whether at all, the Board of Directors will effect the Reverse Stock Split.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If the Board of Directors effects the Reverse Stock Split, we expect that the Reverse Stock Split would increase the market price of our common stock. However, the effect of the Reverse Stock Split of our common stock upon the market price of our common stock cannot be predicted with certainty, and the results of reverse stock splits by companies in similar circumstances have been varied. The Reverse Stock Split could also be viewed negatively by the market and other factors, such as those described above, and therefore, may adversely affect the market price of the shares of our common stock. Consequently, the market price per post-Reverse Stock Split share may not increase in proportion to the reduction of the number of shares of our common stock outstanding before the implementation of the Reverse Stock Split. Accordingly, the total market capitalization of our shares of common stock after the Reverse Stock Split may be lower than the total market capitalization before the Reverse Stock Split.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The potential Reverse Stock Split could decrease the liquidity of our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If effected, the Reverse Stock Split could adversely affect the liquidity of our common stock given the dramatic reduction in the number of shares that will be outstanding after the Reverse Stock Split. In addition, the Reverse Stock Split could increase the number of shareholders who own odd lots (less than 100 shares) of our common stock, creating the potential for such shareholders to experience an increase in the cost of selling their shares and greater difficulty effecting such sales.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even after the potential Reverse Stock Split, the trading price of our common stock may not be high enough to attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors or the Nasdaq or another national stock exchange that the company may seek to become listed on. Consequently, the trading liquidity of our common stock may not improve.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Even if the Board of Directors effects the Reverse Stock Split, there can be no assurance that the Reverse Stock Split would result in a share price that will attract new investors, including institutional investors, or that the share price will satisfy the investing requirements of those investors or the Nasdaq or another national stock exchange that the company may seek to become listed on. Further, other factors, such as our financial results, market conditions and the market perception of our business, may adversely affect the interest of new investors in the shares of our common stock. As a result, the trading liquidity of our common stock may not necessarily improve, our share price may decline, and you may lose all or part of your investment.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Investing in our common stock involves a high degree of risk. We cannot assure you that any of the events discussed in the risk factors will not occur. If we are not able to successfully address any of the risks or difficulties, we could experience a material adverse effect on our business, operations and financial performance. In such circumstances, the trading price of our common stock could decline, and in some cases, such declines could be significant, and you could lose part or all of your investment. In addition to the risks, other unforeseeable risks and uncertainties that we currently believe are immaterial or unknown to us may also adversely affect our business, operating results or financial performance.</font></div><div><a name="s54C15C36EE57C3FA95C920875CC9A313"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Financial Information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Financial Information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table provides selected historical consolidated financial data as of and for the periods shown. The data as of and for the fiscal years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2016</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;have been derived from our audited consolidated financial statements for those dates and periods. The data as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;have been derived from the condensed consolidated financial statements for those periods and dates. The selected financial data below should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our Consolidated Financial Statements and related notes provided in Item 13 of this Form 10 registration statement.&#160; Our historical results are not necessarily indicative of the results that may be expected in the future.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Selected financial data for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">June 30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;and for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">December 31, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">758,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">592,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total costs and expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,391,587</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,099,290</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,885,302</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,548,133</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,045,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,770,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,126,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,955,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,639,929</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">746,834</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,135,819</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,608,739</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,377,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,163,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,606,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,031,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-average number of shares</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,109,756</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,159,363</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,917,961</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,538,444</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,109,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,220,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,917,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,538,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss (income) per common share</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,581,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,516,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,615,774</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,627,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investment securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,031,502</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,389,065</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">922,648</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,066,643</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">568,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,769,982</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,473,957</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,744,159</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,700,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,242,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">768,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,010,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,242,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">768,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,010,237</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,303,536</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,231,194</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,975,264</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,690,183</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this registration statement.&#160; The discussion may contain forward-looking statements based on current expectations that involve risks and uncertainties.&#160; For additional information on our use of forward-looking statements, please see the &#8220;CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS&#8221; section on page 1 of this Registration Statement. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Risk Factors&#8221; or in other parts of this registration statement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Description of Business</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Myceliophthora thermophila</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (&#8220;DuPont&#8221;), the industrial biosciences business of DuPont (NYSE: DD) for $75.0 million (the &#8220;DuPont Transaction&#8221;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines (such as virus-like particles (VLPs) and antigens), monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, FC-Fusion proteins, biosimilars and/or biobetters, as well as other therapeutic enzymes and proteins. Additionally, in early 2018, we began to conduct certain funded research activities to further understand if, or how the C1 technology can be applied for use in developing and manufacturing metabolites.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2018 (Unaudited) Compared to </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Months Ended June 30, 2017 (Unaudited)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue, Cost of Revenue, and Provision for Contract Losses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes the Company&#8217;s revenue, cost of research and development revenue and provision for contract losses for the six months ended June 30, 2018 and 2017:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of research and development revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275,925</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321,322</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for contract losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The changes in revenue and cost of research and development revenue reflected different research collaborations completed in 2017 and new research collaborations started in 2018. The provision for contract losses recorded in 2017 was associated with the Company&#8217;s extended involvement in the ZAPI program and another research collaboration completed in 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expenses for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,178,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$739,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the same period a year ago. The increase of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$439,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;primarily reflects the costs of additional internal research activities with third-party contract research organizations and personnel related costs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expenses - related party, for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, increased to approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$733,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the same period a year ago. The increase reflects the research and development costs related to the Company&#8217;s R&amp;D Agreements with BDI, which started in July 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">General and administrative expenses for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, decreased </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26.8%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;to approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2,215,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,024,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the same period a year ago. The decrease primarily reflects reductions in legal and litigation costs of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$699,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, share-based compensation expenses related to stock options granted in 2018 of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$146,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and other cost reductions of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$29,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, offset by increases in business development costs of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$54,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and separation costs (including stock option modification costs), net of compensation cost reduction, associated with our former CFO of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$11,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Exchange Gain</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Foreign currency exchange gain for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$206,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the same period a year ago. The change reflects the reduction in cash balance carried in Euro and the currency fluctuation of the Euro in comparison to the U.S. dollar.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Income</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Interest income for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, increased </font><font style="font-family:inherit;font-size:10pt;color:#000000;">65.0%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;to approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$406,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$246,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the same period a year ago. The increase in interest income reflects the higher yield on the Company&#8217;s investment grade securities, which are classified as held-to-maturity.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Compared to the Year Ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue, Cost of Revenue, and Provision for Contract Losses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">758,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">592,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of research and development revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680,197</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">516,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for contract losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The increases in research and development revenue, and the cost of research and development revenue reflected the activities of ZAPI and two confidential biopharmaceutical research collaborations that began in December 2016 and June 2017, respectively. The provision for contract losses principally reflected the increase in the total estimated research costs due to the Company&#8217;s extended involvement in the ZAPI program and one of the aforementioned biopharmaceutical research collaborations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and developments costs are expensed as incurred and primarily include salary and benefit costs, third-party contract research organizations service and supply costs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expenses for the year ended December&#160;31, 2017, increased to $1,765,000 compared to $886,000 for the year ended December&#160;31, 2016. The increase principally reflects the costs associated with ongoing and new research projects with third-party contract research organizations. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expenses - related party, for the year ended December&#160;31, 2017, increased to $438,000 compared to $0 for the year ended December&#160;31, 2016. The increase reflects the research and development costs related to the Company&#8217;s R&amp;D Agreements with BDI.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">General and administrative expenses for the year ended December 31, 2017 increased to $5,030,000 compared to $4,562,000 for the year ended December 31, 2016. The change principally reflects increase in new employment agreements for executives of $312,000, business development costs of $228,000, financial reporting costs of $93,000, and other of $8,000, offset by a reduction in legal and litigation costs of $118,000 and board compensation costs of $55,000.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Exchange Gain or Loss</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s foreign currency exchange gain, for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was $</font><font style="font-family:inherit;font-size:10pt;color:#000000;">249,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to a loss of $</font><font style="font-family:inherit;font-size:10pt;color:#000000;">147,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2016</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The change represents the strengthening of Euro in comparison to U.S. dollar.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Settlement of Litigation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On April 14, 2017, the Company received from Greenberg Traurig, LLP, and Greenberg Traurig, P.A. (collectively, &#8220;Greenberg Traurig&#8221;) a settlement in the amount of $4,500,000, net of legal fees and expenses. The Company made a payment of $141,777 to Mark A. Emalfarb to satisfy a prior related contractual obligation regarding his portion of the settlement. The Company recorded a net amount of $4,358,223 after related expenses, in the first quarter of 2017. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On April 19, 2016, the Company received $2.1 million, in connection with the Company&#8217;s settlement with Bilzin Sumberg Baena Price &amp; Axelrod LLP, in related professional liability litigation. The Company recorded this amount in the Company&#8217;s consolidated statement of operations, net of legal fees and expenses, for the year ended December 31, 2016. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Income</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Interest income for the year ended December 31, 2017 increased to $566,000 compared to $485,000, for the year ended December 31, 2016. The increase in interest income reflects returns earned on the Company&#8217;s investment grade debt securities, which are classified as held-to-maturity.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company had net operating loss (&#8220;NOL&#8221;) carryforwards available in 2017 that will begin to expire in 2035.  As of December 31, 2017, and 2016, the Company had NOLs in the amount of approximately $2.9 million and $8.2 million, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For the year ended December 31, 2017, the Company&#8217;s current income tax benefit of $66,694 consisted of differences between our estimated tax provisions and the actual amounts incurred of $167,784 offset by AMT taxes of $101,090. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Deferred tax assets as of December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2016</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively. Due to the Company&#8217;s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2016</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our primary source of cash has been the cash received from the DuPont Transaction in December 2015, investment income, and funding from our research collaboration agreements. In 2017, the Company&#8217;s liquidity was further improved with the receipt of a litigation settlement of approximately $4.4 million, net of legal fees and other payments, and the release of escrowed funds from the DuPont Transaction of approximately $7.4 million. The Company completed its 2016 Stock Repurchase Program in February 2017. On August 16, 2017, the Board of Directors authorized the 2017 Stock Repurchase Program, under which the Company may repurchase up to $5 million of its outstanding common stock. On August 6, 2018, the Board of Directors authorized an extension of the 2017 Stock Repurchase Program through August 15, 2019. The Company expects to finance the 2017 Stock Repurchase Program from its existing cash on hand. As of June 30, 2018, the Company has repurchased a total of 13,012,929&#160;shares of its common stock at weighted average price of $1.53 for an aggregate purchase price of $19,885,308.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our ability to achieve profitability depends on a number of factors, including our scientific results and our ability to continue to obtain funded research and development collaborations from industry and government programs, as well as sublicense agreements.  We may continue to incur substantial operating losses even if we begin to generate revenues from research and development and licensing. Our primary future cash needs are expected to be for general operating activities including additional costs and expenses related to our becoming an SEC reporting company and a potential uplisting to a national exchange, and our business development and research and development expenses. We believe our existing cash position and investments in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for the next twelve months.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, cash and cash equivalents were approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The carrying value of investment grade securities, including accrued interest at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$42.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to $43.3 million at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At December 31, 2017, cash, cash equivalents and restricted cash were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$14.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at December 31, 2016. The carrying value of investment grade securities, including accrued interest as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$43.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$43.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at December 31, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash flows:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,377,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,163,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,606,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,031,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186,295</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,046,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,556,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(374,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,684,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,222,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,120,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of exchange rate changes on cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,989</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,698</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,920</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net decrease in cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,567,528</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,274,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,467,868</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,708,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows from Operating Activities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash used in operating activities for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;resulted from </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of net loss, offset by share-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, amortization of premium on held-to-maturity securities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and changes in operating assets and liabilities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash provided by operating activities for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;resulted from </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of net income, share-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, amortization of premium on held-to-maturity security of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and changes in operating assets and liabilities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, offset by upfront collaboration payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, foreign currency exchange gain of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and amortization of contract losses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash used in operating activities for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was principally attributable to a net loss of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, BDI research and development activities of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, foreign currency exchange gain of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, amortization of contract losses of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, partially offset by stock based compensation expense of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, changes in operating assets and liabilities of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and net amortization of premium on held-to-maturity securities of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows from Investing Activities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash provided by investing activities for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the same period a year ago. Cash flows provided by investing activities in 2018 and 2017 were primarily related to net proceeds from maturities of investment grade securities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash provided by investing activities for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was primarily related to proceeds from maturities, net of purchases of investment grade debt securities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows from Financing Activities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash used in financing activities for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the same period a year ago. Cash flows used in financing activities in 2018 and 2017 were primarily related to repurchases of common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash used in financing activities for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was primarily attributable to the repurchase of common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures about Market Risk</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The primary objective of our investment activities is to preserve principal while maximizing our income from investments and minimizing our market risk. We currently invest in government money market funds and investment-grade corporate debt in accordance with our investment policy, which we may change from time to time. The securities in which we invest have market risk. This means that a change in prevailing interest rates, and/or credit risk, may cause the fair value of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the prevailing interest rate later rises, the fair value of our investment will probably decline. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, our portfolio of financial instruments consists of cash equivalents, short-term and long-term interest-bearing securities, including government money market funds and corporate bonds. The average duration of all of our held-to-maturity investments held as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, was less than 12 months.  Due to the short-term nature of these financial instruments, we believe there is minimal exposure to interest rate risk, and/or credit risk, arising from our portfolio of financial instruments.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;In general, we conduct the majority of our business in U.S. dollars and the euro, both considered to be among the most stable currencies in the world.&#160; We do not hedge currency risks of non-U.S.-dollar-denominated transactions with currency forward contracts or swaps. Gains and losses on these non-U.S.-currency transactions are generally offset by corresponding losses and gains through natural hedges. Substantially all of our revenue and operating expenditures are transacted in U.S. dollars and the euro. For further information, see &#8220;Risk Factors&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">on Item 1A of this Form 10. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We do not have any off-balance sheet arrangements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Critical Accounting Policies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The preparation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third party collaborations and government grants. The Company may generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services, milestone payments, and royalties.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the input methods, revenue will be recognized on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company adopted the following practical expedients and exemptions: We generally expense sales commissions when incurred because the amortization period would be one year or less. We do not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Provision for Contract Losses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company assesses the profitability of our collaboration agreements to provide research services to our contracted business partners and identifies those contracts where current operating results or forecasts indicate probable future losses. If the anticipated contract cost exceeds the anticipated contract revenue, a provision for the entire estimated loss on the contract is recorded and then accreted into the statement of operations over the remaining term of the contract. The provision for contract losses is based on judgment and estimates, including revenues and costs, where applicable, the consideration of our business partners&#8217; reimbursement, and when such loss is deemed probable to occur and is reasonable to estimate.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In order to properly record services that have been rendered but not yet billed to the Company, we review open contracts and purchase orders, communicate with our personnel and we estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly or quarterly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of accrued research and development expenses include amounts owed to contract research organizations, to service providers in connection with commercialization and development activities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have granted stock options and restricted stock to employees, directors and consultants. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model considers volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options and restricted stock and applied a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144. We also used the weighted-average vesting period and contractual term of the option as the best estimate of the expected life of a new option (except for our CEO which is 5 years). The Company performs a review on assumptions used in the Black-Scholes option-pricing model on an annual basis. During the Company&#8217;s annual review of its volatility assumption in 2018, the Company determined that it would be appropriate to use the Company&#8217;s historical volatilities since 2016, as the DuPont Transaction resulted in significant changes in the Company&#8217;s business and capital structure. The change in assumption is effective January 1, 2018 and only impacts new options granted in 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. These estimates are neither predictive nor indicative of the future performance of our stock. As a result, if other assumptions had been used, our recorded share-based compensation expense could have been materially different from that reported. In addition, because some of the options and restricted stock issued to employees, consultants and other third-parties </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">vest upon the achievement of certain milestones, the total ultimate expense of share-based compensation is uncertain.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with board member and employee terminations, the Company may modify certain terms to outstanding share-based awards. We have recorded charges related to these modifications based on the estimated fair value of the share-based options immediately prior to and immediately after the modification occurs, with any incremental value being charged to expense. We have used the Black-Scholes pricing model in this valuation process, and this requires management to use various assumptions and estimates. Future modifications to share-based compensation transactions may result in significant expenses being recorded in our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Income Taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, &#8220;Income Taxes&#8221;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#8217;s financial statements or tax returns.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date.  A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In determining taxable income for the Company&#8217;s consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements.  ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return.  For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#8220;unrecognized benefits.&#8221; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents a company&#8217;s potential future obligation to the taxing authority for a tax position that was not recognized because of applying the provision of ASC 740. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">The Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;) was enacted on December 22, 2017 and is effective January 1, 2018. The new legislation includes, among other things a reduction of the U.S. corporate income tax rate from 35% to 21%, and a change to alternative minimum taxes. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of June 30, 2018, the Company did not record any provisional estimate related to the changes in the alternative minimum tax. The staff of the SEC recognized the complexity of determining the impact of the TCJA, and on December&#160;22, 2017 issued guidance in Staff Accounting Bulletin 118 (&#8220;SAB 118&#8221;). SAB 118 allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. The Company will continue to analyze the TCJA and related accounting guidance and interpretations in order to finalize any impact within the measurement period. We currently anticipate recording any resulting adjustments by the end of 2018.</font></div><div><a name="s0C959501E4D1CF37CF5820875D235F54"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Properties</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,450. The lease expires on June 30, 2019, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies approximately 258 square feet with annual rentals and common area maintenance charges of approximately $4,700. The lease expires on January 31, 2019, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that our current and anticipated facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space is available to accommodate any expansion of our operations, but such space may not be available in the same building, if and when such space is needed.</font></div><div><a name="s1388905FF13C6560142520875D23FB64"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Security Ownership of Certain Beneficial Owners and Management</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table sets forth certain information regarding the beneficial ownership of our common stock as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;(except as noted below), by:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">each person known by us to be the beneficial owner of more than 5% of the outstanding shares of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">each of our directors, named executive officers; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all of our directors and executive officers as a group.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The amounts and percentages of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a &#8220;beneficial owner&#8221; of a security if that person has or shares voting power, which includes the power to vote or direct the voting of a security, or investment power, which includes the power to dispose of or to direct the disposition of a security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 60 days of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Securities that can be so acquired are deemed to be outstanding for purposes of computing such person&#8217;s ownership percentage, but not for purposes of computing any other person&#8217;s percentage. Under these rules, more than one person may be deemed a beneficial owner of the same securities and a person may be deemed to be a beneficial owner of securities as to which such person has no economic interest. Except as otherwise indicated in these footnotes, each of the beneficial owners listed has, to our knowledge, sole voting and investment power with respect to the indicated shares of common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, the Company has </font><font style="font-family:inherit;font-size:10pt;color:#000000;">38,966,988</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of common stock issued and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26,713,486</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of common stock outstanding with the remaining </font><font style="font-family:inherit;font-size:10pt;color:#000000;">12,253,502</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares held in treasury.  The beneficial ownership table below includes those shares of common stock underlying options that are currently exercisable or exercisable within sixty (60) days of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, but excludes those shares issued or repurchased subsequent to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Name and Address of Beneficial Owner</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Common Shares Held</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable within 60 Days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Common Share Equivalents Beneficially Owned</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Percentage of Common Share Equivalents Beneficially Owned (%) </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Five Percent Shareholders:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark A. Emalfarb </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,116,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,686,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.2%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Francisco Trust U/A/D February 28, 1996 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,773,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,773,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.1%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bandera Master Fund L.P. </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,490,271</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,490,271</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.3%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pinnacle Family Office Investments, L.P. </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Named Executive Officers and Directors:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark A. Emalfarb </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,116,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,686,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.2%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael P. Tarnok</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jack L. Kaye</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,625</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Seth J, Herbst, M.D.</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arindam Bose, Ph.D</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Barry C. Buckland, Ph.D</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ping W. Rawson</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,473</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,973</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ronen Tchelet, Ph.D</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew S. Jones</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All current executive officers and directors as a group</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,397,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,394,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,821,971</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.7%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9 persons)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">* Less than 1%</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Except as otherwise noted, the address for each shareholder is c/o Dyadic International, Inc., 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Based on </font><font style="font-family:inherit;font-size:8pt;">26,713,486</font><font style="font-family:inherit;font-size:8pt;">&#32;shares of common stock outstanding as of </font><font style="font-family:inherit;font-size:8pt;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:8pt;">. Shares of common stock subject to options that are currently exercisable or exercisable within 60 days are deemed outstanding for purposes of computing the percentage of the person holding such options, but are not deemed outstanding for purposes of computing the percentage of any other person.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Includes 4,116,987 shares held by Mark A. Emalfarb beneficially through the MAE Trust, of which Mr. Emalfarb is the sole beneficiary and serves as sole trustee.  In addition, Mr. Emalfarb holds </font><font style="font-family:inherit;font-size:8pt;">570,000</font><font style="font-family:inherit;font-size:8pt;">&#32;shares of common stock underlying options that are presently exercisable. Based on the information available to us, the address of the MAE Trust is 193 Spyglass Court, Jupiter, 33477.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The trustee of the Francisco Trust is Adam Morgan, and the beneficiaries thereof are the spouse and descendants of Mark A. Emalfarb. The address of the Francisco Trust is 3128 San Michele Drive, Palm Beach Gardens, Florida 33418. Mr. Emalfarb disclaims beneficial ownership of such shares.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Based on the information available to us, the address is c/o Bandera Master Fund L.P., 50 Broad Street #1820, New York, NY 10004.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Based on the information available to us, the address is c/o Pinnacle Family Office Investments, L.P., 5910 North Central Expressway, Suite 1475, Dallas, TX&#160;75206.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><a name="s16423DFD7638A97F989A20875D37A3FF"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5. Directors and Executive Officers</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table provides information regarding our executive officers and directors as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">November&#160;5, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Age</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Position(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Director Since</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark A. Emalfarb </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Chief Executive Officer, Director</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2004</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ping W. Rawson </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Accounting Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ronen Tchelet, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President of Research and Business Development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew S. Jones</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managing Director of Business Development and Licensing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael P. Tarnok </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)(3)(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman, Director</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jack L. Kaye </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Seth J. Herbst, MD </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(3)(4)(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2008</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arindam Bose, Ph.D. </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Barry C. Buckland, Ph.D. </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(4)(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Member of the Board of Directors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Member of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Member of the Compensation Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Member of the Nominating Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Member of the Science and Technology Committee.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Thomas L. Dubinski, former Vice President and Chief Financial Officer, left the Company for medical reasons, which was announced on March 15, 2018. Ping W. Rawson, the Company&#8217;s Director of Financial Reporting since June 2016, was promoted to Chief Accounting Officer on March 14, 2018 and currently serves as the Company&#8217;s principal financial officer and assumed responsibility for finance, tax and treasury.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive Officers</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mark A. Emalfarb, President, Chief Executive Officer and Director</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Mark A. Emalfarb is the founder of Dyadic, and currently serves as the Chief Executive Officer and a member of the Board of Directors of the Company. He has been a member of Dyadic&#8217;s board of directors and has previously served as its Chairman from October 2004 until April 2007 and from June 2008 until January 2015. Since founding the predecessor to Dyadic in 1979, Mr. Emalfarb has served as a Director, President and Chief Executive Officer for substantially all of that time and has successfully led and managed the evolution of Dyadic from its origins as a pioneer and leader in providing ingredients used in the stone-washing of blue jeans to the discovery, development, manufacturing and commercialization of specialty enzymes used in various industrial applications and the development of an integrated technology platform based on Dyadic&#8217;s patented and proprietary C1 fungal microorganism. Mr. Emalfarb is an inventor of over 25 U.S. and foreign biotechnology patents and patent applications resulting from discoveries related to the patented and proprietary C1 fungus, and has been the architect behind its formation of several strategic research and development, manufacturing and marketing relationships with U.S. and international partners. Mr. Emalfarb earned his B.A. degree from the University of Iowa in 1977.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ping W. Rawson, Chief Accounting Officer</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Ping W. Rawson was appointed as our Chief Accounting Officer in March 2018. She currently serves as the Company&#8217;s principal financial officer, and is responsible for all aspects of finance, tax and treasury. Prior to joining Dyadic in June 2016 as our Director of Financial Reporting, Ms. Rawson served as a technical accounting management position for ADT security services, where she led accounting and financial reporting workstream for acquisition, integration and restructuring.  Prior to that, Ms. Rawson was an accounting research principal for NextEra Energy, Inc. (Florida Power &amp; Light Company), where she was responsible for accounting research and new standards implementation. Previously, Ms. Rawson was a manager at Deloitte in New York City, where she was a subject matter specialist for derivatives, financial instruments and valuation, providing audit, SEC reporting, and capital markets consulting services to large banking and multinational public companies in the financial service industry.  Ms. Rawson holds both a M.B.A. in Finance, and a M.S. in Accounting from the State University of New York at Buffalo, and a B.S. in Economics from Guangdong University of Foreign Studies in China. She is a certified public accountant in the state of New York.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ronen Tchelet, Ph.D., Vice President of Research and Business Development</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Ronen Tchelet, Ph.D. joined Dyadic in May 2014, and has been our Vice President of Research and Business Development since January 2016. Since&#160;joining&#160;Dyadic,&#160;Dr. Tchelet&#160;has been&#160;a key contributor to Dyadic&#8217;s transformation into&#160;a pharmaceutical biotech company. Prior to joining Dyadic, Dr. Tchelet was the founder and Managing Director of Codexis Laboratories Hungary kft. (&#8220;CLH&#8221;) and a Vice President of Codexis Inc. from 2007 through 2014. While&#160;at CLH, Dr. Tchelet&#160;established a state-of-the-art laboratory for strain engineering and all aspects of fermentation&#160;including process optimization and scale&#160;up. During this time period,&#160;Dr. Tchelet&#160;also led a collaboration that successfully developed&#160;C1 technology&#160;for the Biofuel and the Bio-Industrial enzymes applications. Dr. Tchelet&#8217;s&#160;experience in the pharmaceutical industry includes prior employment at TEVA Pharmaceutical Industries LTD (&#8220;TEVA&#8221;), API Division during the late 2000&#8217;s&#160;to 2006. While at&#160;TEVA, he served as a Chief Technology Officer of Biotechnology and head of TEVA&#8217;s Biotechnology Research and Development fermentation plant in Hungary.&#160;Also during the period of 2000 through 2005,&#160;Dr. Tchelet was the Director of Quality Assurance&#160;for&#160;TEVA&#8217;s flag ship innovative drug, COPAXONE&#174;. Throughout his career, Dr. Tchelet has led several&#160;Biotechnology projects&#160;that have encompassed all aspects of&#160;research and&#160;development, operations management, and manufacturing&#160;of API&#8217;s and biologics.&#160;Dr. Tchelet received his Ph.D. in Molecular Microbiology and Biotechnology from Tel Aviv University in 1993 and did his postdoctoral work as an EERO fellow at the Institute of Environmental Science and Technology (EAWAG) in Switzerland.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Matthew S. Jones, Managing Director of Business Development and Licensing</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Matthew S. Jones joined Dyadic in May 2016, and serves as our Managing Director of Business Development and Licensing to lead Dyadic&#8217;s strategic partnerships, licensing and commercial opportunities within and across the biopharmaceutical industry. A veteran of the life sciences industry with two decades of commercial deal making and leadership experience, Mr. Jones has developed and implemented strategies which have delivered revenue growth, organically and through acquisitions, for a diverse range of life science businesses both in Europe and the US.&#160;&#160;Prior to joining Dyadic, Mr. Jones served as Chief Commercial Officer for Concept Life Sciences from its formation until 2016. Prior to that, Mr. Jones was Vice President of Global Sales &amp; Business Development at Lonza Biologics, where he implemented new income-generating revenue streams and captured enterprise synergies in manufacturing, research and client/vendor relationships.&#160;&#160;From 2009 to 2012, Mr. Jones served as Executive Vice President of Business Development &amp; Marketing at Ricerca Biosciences LLC,&#160;responsible for strategic partnerships, royalty and asset license optimization and marketing effectiveness and where Mr. Jones supported the Bain Ventures trade sale of the business toward WiL research. From 2003 to 2009, Mr. Jones was Senior Vice President of Business Development at MDS Pharma Services Inc., where he was responsible for global biopharmaceutical and clinical commercial growth strategies. Earlier in his career, Mr. Jones also held senior level leadership roles within the biopharmaceutical industry with Alkermes, Inc. and GlaxoSmithKline plc. Mr. Jones is a graduate of Warwick University&#160;and London Business School.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Employee Directors</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Michael P. Tarnok, Chairman, Director</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Michael P. Tarnok </font><font style="font-family:inherit;font-size:10pt;color:#000000;">joined Dyadic&#8217;s board of directors on June 12, 2014 and has served on the Company&#8217;s audit, nominating and compensation committees, and on January 12, 2015 Mr. Tarnok was appointed Dyadic&#8217;s Chairman of the Board of Directors. Mr. Tarnok is also currently a board member of Global Health Council, and Ionetix, Inc. In addition, Mr. Tarnok&#8217;s prior board service includes Keryx Biopharmaceuticals, Inc., where he also served as Chairman of the Board. Mr. Tarnok is a seasoned finance and operational executive with extensive pharmaceutical industry experience in a wide range of functional areas. He spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director-US Manufacturing and from 2000 to 2007 served as a Senior Vice President in Pfizer&#8217;s US Pharmaceutical Division. In this position, Mr. Tarnok managed multiple responsibilities for the division including, finance, access contracting, trade management, information technology, Sarbanes-Oxley compliance and the Greenstone generics division. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America. Mr. Tarnok earned an M.B.A. in Marketing from New York University and a B.S. in Accounting from St. John&#8217;s University.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Jack Kaye, Director</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Jack L. Kaye joined Dyadic&#8217;s board of directors in May 2015 and currently serves as chairman of the Company&#8217;s audit committee. He also serves on the Company&#8217;s compensation committee. Mr. Kaye is currently the Chairman of the audit committee and a member of the compensation committee and special transaction pricing committee of uniQure B.V. where he has served since May 2016. Mr. Kaye&#8217;s prior board service includes Keryx Biopharmaceuticals Inc., a position he has held from 2006 to May 2016 where he served as Chairman of the audit committee and he was also a member of their nominating and governance committee.&#160; He also served on the boards of Tongli Pharmaceuticals (USA) Inc. and Balboa Biosciences, Inc., where he served as Chairman of both audit committees. In the past, Mr. Kaye was selected to participate on several dissident board slates which included the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Astellas, Inc./OSI, Roche Pharmaceuticals, Inc./Illumina and the Horizon, Inc./Depomed hostile M&amp;A transactions. Mr. Kaye was a partner at Deloitte LLP from 1978 until May 2006, when he retired. At Deloitte, Mr. Kaye was responsible for serving a diverse client base of public and private, global and domestic companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/ Sarbanes-Oxley issues. In addition, he has served as Deloitte&#8217;s Tristate liaison with the banking and finance community and assisted clients with numerous merger and acquisition transactions. Mr. Kaye served as Partner-in-Charge of Deloitte&#8217;s Tri-State Core Client practice, a position he held for more than twenty years. He earned a B.B.A. from Baruch College and is a Certified Public Accountant.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Seth J. Herbst, MD, Director</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Seth J. Herbst, MD has been on Dyadic&#8217;s board of directors since June 2008 and is a board certified obstetrician/gynecologist who is also board certified in advanced laparoscopic and minimally invasive gynecologic surgery.&#160; Dr. Herbst is the founder and President of the Institute for Women&#8217;s Health and Body in May of 1997, an OB/GYN practice with multiple locations in Palm Beach County, Florida.&#160; He is the co-founder of Visions Clinical Research since 1999, which performs medical and surgical clinical trials throughout the United States.&#160; Dr. Herbst is also a consultant for multiple medical device companies in the United States and a member of medical advisory boards for these and other companies.&#160; He received his B.S. degree from American University in 1978 and his medical degree from Universidad del Noreste School of Medicine in Tampico, Mexico in 1983.&#160; Dr. Herbst completed his OB/GYN residency and was Chief Resident at Long Island College Hospital in Brooklyn, New York.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Arindam Bose, Ph.D., Director</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Arindam Bose, Ph.D. joined Dyadic&#8217;s board of directors on August 15, 2016 and serves on the Company&#8217;s audit and science and technology committees. Dr. Bose retired from Pfizer Worldwide Research &amp; Development in 2016 after 34 years in leadership roles in bioprocess development and clinical manufacturing.&#160;Dr. Bose&#8217;s final position at Pfizer was Vice-President, Biotherapeutics Pharmaceutical Sciences External Affairs and Biosimilar Strategy with responsibility for external sourcing, competitive intelligence and external influencing as well as for executing the technical development plan for Pfizer&#8217;s entry into biosimilars. He is widely recognized as a Key Thought Leader in the biopharmaceutical industry. Dr. Bose has served as the Chair of the Biologics and Biotechnology Leadership Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), the chief advocacy arm of the US pharmaceutical industry. His outstanding accomplishments and service to the profession have been recognized by his election as &#8220;Fellow&#8221; of 3 leading professional organizations: American Chemical Society, American Institute of Chemical Engineers and American Institute for Medical and Biological Engineering. Dr. Bose was elected to the US National Academy of Engineering in February 2017 for innovative research in biologics manufacturing. He received a Ph.D. in chemical engineering from Purdue University, a M.S. from the University of Michigan, Ann Arbor and a B. Tech from the Indian Institute of Technology, Kanpur.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Barry C. Buckland, Ph.D., Director</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Barry Buckland, Ph.D. joined Dyadic&#8217;s board of directors in January 2018. Dr. Buckland retired from Merck Research Laboratories in 2009 after 28 years of contributions to the Bioprocess R&amp;D group including more than 12 years as leader in the position of Vice President. Since leaving the Merck Research Laboratories, Dr. Buckland has headed up his own consulting company (BiologicB, LLC). He also is President of Engineering Conferences International (ECI), a not for profit organization which organizes prestigious conferences with an engineering focus. Dr. Buckland has chaired successful conference such as Microbial Engineering I and Vaccine Technology Conferences I to IV.  He is also a visiting professor at University College London in the Biochemical Engineering Department and is the author or co-author of more than 70 publications. His previous Board experience includes Enumeral Biomedical and Mucosis. Dr. Buckland was a Senior Advisor to Protein Sciences until they were purchased by Sanofi in 2017. Dr. Buckland became Executive Director of NIIMBL (National Institute for Innovation for Manufacturing Biopharmaceuticals) in 2017. Dr. Buckland was elected to the USA National Academy of Engineering in 1997.  In 2008, Dr. Buckland was awarded the ACS Marvin Johnson award for Biotechnology. In 2009, Dr. Buckland was awarded the Discoverers Award by the Pharmaceutical Research and Manufacturers of America (PhRMA) for his role in the discovery and development of GARDASIL, an effective vaccine against HPV. He was one of three recipients.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Involvement in Certain&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">None of our directors or executive officers have been convicted in any criminal proceeding during the past 10 years and none of them have been parties to any judicial or administrative proceeding during the past 10 years that resulted in a judgment, decree or final order enjoining them from future violations of, or prohibiting activities subject to, federal or state securities laws or a finding of any violation of federal or state securities laws or commodities laws. Similarly, no bankruptcy petitions have been </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">filed by or against any business or property of any of our directors or officers, nor has any bankruptcy petition been filed against a partnership or business association in which these persons were general partners, directors or executive officers.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Relationships</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There are no family relationships between or among any of our directors or executive officers.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There are no arrangements or understandings between any two or more of our directors or executive officers, and there is no arrangement, plan or understanding as to whether non-management stockholders will exercise their voting rights to continue to elect the current board of directors. There are also no arrangements, agreements or understandings between non-management stockholders that may directly or indirectly participate in or influence the management of our affairs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Board of Directors and Committees</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Board is responsible for directing and overseeing the business and affairs of the Company. The Board represents the Company&#8217;s shareholders and its primary purpose is to build long-term shareholder value. The Board meets on a regularly scheduled basis during the year to review significant developments affecting the Company and to act on matters that, in accordance with good corporate governance, require Board approval. It also holds annual meetings and acts by unanimous written consent when an important matter requires Board action between scheduled meetings.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have a classified board of directors currently fixed at six members. The board has four committees: Audit, Compensation, Nominating, and Science and Technology. Currently, Mr. Michael P. Tarnok serves as Chairman of the Board of Directors. Mr. Jack Kaye serves as Chairman of the Audit Committee, Mr. Michael Tarnok serves as Chairman of the Compensation Committee, Dr. Seth Herbst serves as Chairman of the Nominating Committee, and Dr. Arindam Bose serves as Chairman of the Science and Technology Committee.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Audit Committee. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">The Audit Committee has oversight responsibility for quality and integrity of our consolidated financial statements. A copy of the Charter of the Audit Committee is available on our website, located at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">www.Dyadic.com</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The committee meets privately with members of our independent registered public accounting firm, has the sole authority to retain and dismiss the independent registered public accounting firm and reviews its performance and independence from management. The independent registered public accounting firm has unrestricted access and reports directly to the committee. The primary functions of the Audit Committee are to oversee (i) the audit of our consolidated financial statements and (ii) our internal financial and accounting processes.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The SEC, NYSE and NASDAQ have established rules and regulations regarding the composition of audit committees and the qualifications of audit committee members. Although we are not required to comply with SEC, NYSE and NASDAQ rules, our Board of Directors has examined the composition of our Audit Committee and the qualifications of our Audit Committee members in light of the current rules and regulations governing audit committees. Based upon this examination, our Board of Directors has determined that each member of our Audit Committee is independent and is otherwise qualified to be a member of our Audit Committee in accordance with the rules of the SEC, NYSE and NASDAQ.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Additionally, the SEC requires that at least one member of the audit committee have a heightened level of financial and accounting sophistication. Such a person is known as the audit committee financial expert under the SEC&#8217;s rules. Although we are not required to comply with SEC, NYSE and NASDAQ rules, our Board of Directors has determined that Mr. Kaye is an audit committee financial expert, as the SEC defines that term, and is an independent member of our Board of Directors and our Audit Committee. Please see Mr. Kaye&#8217;s biography included in this Form 10 for a description of his relevant experience.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Compensation Committee. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">The duties and responsibilities of the Compensation Committee are set forth in the Charter of the Compensation Committee. A copy of the Charter of the Compensation Committee is available on our website, located at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">www.Dyadic.com</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. As discussed in its charter, among other things, the duties and responsibilities of the Compensation Committee include evaluating the performance of the Chief Executive Officer, Chief Financial Officer and other key personnel of the Company, including, but not limited to, our incentive and equity-based plans. The Compensation Committee evaluates the performance of the Chief Executive Officer, Chief Financial Officer and other key personnel of the Company on an annual basis and reviews and approves on an annual basis all compensation programs and awards relating to such officers and key personnel. The Compensation Committee applies discretion in the determination of individual executive compensation packages to ensure compliance with the Company&#8217;s compensation philosophy. The Chief Executive Officer makes recommendations to the Compensation Committee with respect to the compensation packages for officers other than himself.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Nominating Committee.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The Nominating Committee&#8217;s functions include: establishing criteria for the selection of new directors to serve on the board of directors; identifying individuals believed to be qualified as candidates to serve on the board of directors; recommending for selection by the board of directors the candidates for all directorships to be filled by the board of directors or by the shareholders at an annual or special meeting; reviewing the board of directors&#8217; committee structure and recommending to the board of directors the directors to serve on the committees of the board; recommending members of the board of directors to serve as the respective chairs of the committees of the board of directors; developing and recommending to the board of directors, for its approval, an annual self-evaluation process of the board of directors and its committees and, based on those results, making recommendations to the board of directors regarding those board processes; and performing any other activities consistent with the committee&#8217;s charter, our bylaws and applicable law as the committee or the board of directors deems appropriate. A copy of the Charter of the Nominating Committee is available on our website, located at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">www.Dyadic.com</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Nominating Committee does not currently have any formal minimum qualification requirements that must be met by a nominee to serve as a member of the board of directors. The Nominating Committee will take into account all factors it considers appropriate, which may include experience, accomplishments, education, understanding of the business and the industries in which we operate, specific skills, general business acumen and the highest personal and professional integrity. The Nominating Committee generally seeks individuals with broad experience at the policy-making level in business, or with particular industry expertise. While we do not have a formal diversity policy for board membership, we look for potential candidates that help ensure that the board of directors has the benefit of a wide range of attributes. We believe that all of our directors should be committed to enhancing shareholder value and should have sufficient time to carry out their duties and to provide insight and practical wisdom based on experience. Each director must also represent the interests of all shareholders.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Nominating Committee currently has no fixed process for identifying new nominees for election as a director, thereby retaining the flexibility to adapt its process to the circumstances. The Nominating Committee has the ability, if it deems it necessary or appropriate, to retain the services of an independent search firm to identify new director candidates. The Nominating Committee has determined that it will consider any potential candidate proposed by a member of our board or senior management. Any director candidate so proposed will be personally interviewed by at least one member of the Nominating Committee and our Chief Executive Officer and their assessment of his or her qualifications will be provided to the full Nominating Committee.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our policy and procedures regarding director candidates recommended by shareholders are contained in the Nominating Committee&#8217;s charter. The Nominating Committee may consider for inclusion in its nominations for new directors any candidates recommended by shareholders, but must consider any candidate for director recommended by (i) any shareholder beneficially owning more than 5% of our outstanding common stock for at least one year as of the date the recommendation was made or (ii)&#160;a group of shareholders that beneficially owned, in the aggregate, more than 5% of our outstanding common stock, with each of the shares used to calculate that ownership held for at least one year as of the date the recommendation was made. The Nominating Committee will consider the candidate based on the same criteria established for selection of director nominees generally. The Nominating Committee reserves the right to reject any candidate in its discretion, including, without limitation, rejection of a candidate who has a special interest agenda other than the best interests of the Company and the shareholders, generally.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Science and Technology Committee. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">The responsibility of Science and Technology Committee is to periodically examine management&#8217;s strategic direction and investments in the Company&#8217;s biopharmaceutical research and development and technology initiatives.  The duties and responsibilities of the Science and Technology Committee are set forth in the Charter of the Science and Technology Committee. A copy of the Charter of the Science and Technology Committee is available on our website located at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">www.Dyadic.com</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. As discussed in its charter, among other things, the duties and responsibilities of the Science and Technology Committee are following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Review, evaluate and report to the Board regarding the performance of the Vice-President, Research and Development (and, his or her team), the contract research organizations being considered or working on behalf of the Company in achieving the strategic goals and objectives and the quality and direction of the Company&#8217;s biopharmaceutical research and development programs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identify and discuss significant emerging science and technology issues and trends.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Review the Company&#8217;s approaches to acquiring and maintaining a range of distinct technology positions (including but not limited to contracts, grants, collaborative efforts, alliances and capital investments).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluate the soundness/risks associated with the technologies in which the Company is investing its research and development efforts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Periodically review the Company&#8217;s overall patent strategies.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Independence of Directors</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are not currently listed on any national securities exchange that has a requirement that any members of the board of directors be independent. However, in evaluating the independence of its members and the composition of the committees of the board of directors, the board utilizes the definition of independence as that term is defined by the rules promulgated by the NYSE and NASDAQ, as applicable, and as the term is defined by the SEC for audit committee members. We believe that Drs. Herbst, Bose and Buckland, as well as Messrs. Kaye and Tarnok qualify as independent directors, as that term is defined by NYSE and NASDAQ rules and as defined by the SEC rules for audit committee membership.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Code of Conduct and Ethics</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have adopted a Code of Conduct and Ethics, or the Code, which applies to all of our directors and employees, including our principal executive officer and principal financial officer. The Code includes guidelines dealing with the ethical handling of conflicts of interest, compliance with federal and state laws, financial reporting, and our proprietary information. The Code also contains procedures for dealing with and reporting violations of the Code. We have posted our Code of Conduct and Ethics on our website, located at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">www.Dyadic.com</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div><a name="s19A64CCD599EBBDB40A820875D69D53B"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6. Executive Compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Philosophy and Objectives</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The philosophy underlying our executive compensation program is to provide an attractive, flexible and market-based total compensation program tied to performance and aligned with the interests of our shareholders. Our objective is to recruit and retain the caliber of executive officers and other key employees necessary to deliver sustained high performance to our shareholders, customers, and communities where we have a strong presence. Our executive compensation program is an important component of these overall human resources policies. Equally important, we view compensation practices as a means for communicating our goals and standards of conduct and performance and for motivating and rewarding employees in relation to their achievements.&#160; The organization&#8217;s executive compensation program is designed to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Encourage the attraction and retention of high-caliber executives.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provide a competitive total compensation package, including benefits.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reinforce the goals of the organization by supporting teamwork and collaboration.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ensure that pay is perceived to be fair and equitable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Be flexible to potentially reward individual accomplishments as well as organizational success.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ensure that the program is easy to explain, understand, and administer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance the needs of the both the Company and employees to be competitive with the limits of available financial resources.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ensure that the program complies with state and federal legislation.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From time to time, the Company will consult with a compensation specialist to determine whether its overall compensation practices and policies are appropriate for the specific market conditions for the Company and the industries in which it operates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary Compensation Table</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes the compensation paid or accrued to our &#8220;named executive officers&#8221; (as defined by the SEC&#8217;s disclosure requirements) during the fiscal year 2017:</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Name and Principal Position</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Salary ($) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Stock Awards ($) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Option Awards ($)</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Nonequity incentive plan compensation ($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Nonqualifed deferred compensation earnings ($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">All other payments ($) </font><font style="font-family:inherit;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Total ($)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Mark A. Emalfarb (*)  </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">382,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">244,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">655,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,281,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">President, CEO and Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Thomas L. Dubinski </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">230,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">121,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">123,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">475,774</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">Former VP and CFO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Ronen Tchelet, Ph.D. </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">200,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">81,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">288,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">VP of Research and Business Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew S. Jones </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">256,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">65,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">321,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">Managing Dir. of Bus. Dev and Licensing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(*)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Mr. Emalfarb also serves on the Board of Director, for which he receives no direct, indirect or incremental compensation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The Option Awards amount represented stock options granted on January 3, 2017 in connection with the annual share-based compensation rewards, vesting upon grant or one year anniversary in accordance with their individual employment agreement or consulting agreement.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The Option Awards amount represented the grant date fair market value of each option granted in 2017, computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be recognized by the named executive officers. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our consolidated financial statements.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other payments paid to Mr. Emalfarb included $141,777 for a litigation settlement payment, $12,891 for car allowance, $55,362 for Company&#8217;s contribution to the 401(k) retirement plan, and $444,996 for installment payments relating to his prior employment agreement. Other compensation paid to Mr. Dubinski included </font><font style="font-family:inherit;font-size:8pt;">$11,437</font><font style="font-family:inherit;font-size:8pt;">&#32;for Company&#8217;s contribution to the 401(k) retirement plan and $112,500 for installment payments relating to his prior employment agreement. Other compensation paid to Mr. Tchelet included </font><font style="font-family:inherit;font-size:8pt;">$6,073</font><font style="font-family:inherit;font-size:8pt;">&#32;for sales commission earned in 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Prior to March 22, 2018, Mr. Dubinski served as the Company&#8217;s Chief Financial Officer. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The amounts represent the compensation for services of Mr. Tchelet for the year ended </font><font style="font-family:inherit;font-size:8pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8pt;">, in accordance with  the Sky Blue Biotech Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The amounts represent the compensation for services of Mr. Jones for the year ended </font><font style="font-family:inherit;font-size:8pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:8pt;">, in accordance with the Jones Consultant Agreement. </font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employment Agreements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mark A. Emalfarb</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On June 21, 2016, the Company entered into a new employment agreement (the &#8220;Emalfarb Agreement&#8221;) with Mr. Emalfarb. The Emalfarb Agreement has an initial term of three years and automatic renewals of two years at the end of each term, unless either party provides a notice of nonrenewal, and provides that Mr. Emalfarb be employed as our President and Chief Executive Officer and that we will cause Mr. Emalfarb to be elected as a member of the Board. The material terms of the Emalfarb Agreement are summarized below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Base Salary and Bonus</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Mr. Emalfarb will receive an annual base salary of $375,000 and he may be eligible for an annual bonus award, with the timing and amount of any such bonus determined in the sole discretion of the Compensation Committee of the Board.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Performance Stock Options. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Mr. Emalfarb will have the opportunity to be awarded three (3) annual stock option grants, each such annual option incentive stock option grant will be to purchase up to three hundred thousand (300,000) shares of common stock (the &#8220;Maximum Option Bonus&#8221;) based on performance achievements in 2016, 2017 and 2018. Performance incentives for the six-month period January-June 2019 will be agreed to by the Board and Mr. Emalfarb based solely on the Compensation Committee&#8217;s evaluation of Mr. Emalfarb&#8217;s performance during that time period. The stock option grant(s), if granted by the Compensation Committee, will have a five-year term and shall vest on the grant date. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Upon the execution of the Emalfarb Agreement, Mr. Emalfarb received a stock option grant to purchase 100,000 shares of common stock (the &#8220;First Option&#8221;), with an exercise price equal to $1.67. On January 3, 2017, Mr. Emalfarb received a stock option grant to purchase 150,000 shares of common stock (the &#8220;Second Option&#8221;), with an exercise price equal to $1.63 per share. The First Option and Second Option together represent 83.3% of the 2016 Maximum Option Bonus. On January 2, 2018, Mr. Emalfarb received a stock option grant to purchase 270,000 shares of common stock for his 2017 performance, representing 90% of the 2017 Maximum Option Bonus. All options granted to Mr. Emalfarb vest immediately and have a five-year term from the date of grant. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stock Exchange Stock Option</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In addition, Mr. Emalfarb received a stock option grant to purchase up to four hundred thousand (400,000) shares of common stock at an exercise price of $1.67, equal to the closing price of Dyadic common stock on June 21, 2016. The stock option shall vest and become exercisable only if the Company&#8217;s shares of common stock commence trading on the Nasdaq Capital Markets or other stock exchange approved by the Board. The Stock Exchange stock option grant has a five-year term.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Licensing/Collaboration Transaction Stock Options. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">A stock option to purchase up to six hundred thousand (600,000) shares of common stock shall be proportionally awarded, vest and become exercisable when each of three (3) Bona Fide Licensing / Collaboration Transactions are entered into with the Company. A Bona Fide transaction is defined as a license, joint venture or other collaboration for a specific biological with the intent to commercialize and/or a license agreement that generates a cumulative five million dollars in non-refundable cash, or when either the vaccine or biologics pharmaceutical business categories are sold.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Severance Terms. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Mr. Emalfarb will be eligible for severance benefits comparable to other executives at his level. In addition, if Mr. Emalfarb&#8217;s employment is terminated by the Company without cause, by Mr. Emalfarb for good reason, or due to Mr. Emalfarb&#8217;s death or disability, then the Company shall fulfill its obligations as for annual base salary through the effective date of termination and he will be entitled to receive his accrued but unpaid vacation through the date thereof plus, in the sole discretion of the Compensation Committee, the 2016, 2017, 2018 Maximum Option Bonus and performance incentive for the period January through June 21, 2019 may be awarded. In addition, all of Mr. Emalfarb&#8217;s unvested Stock Exchange Stock Options and Licensing/Collaboration Transaction Stock Options will vest immediately in the event milestones for which the options would have been awarded are achieved within one year from the date of termination or upon a change of control.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Change of Control</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In the sole discretion of the Compensation Committee, Mr. Emalfarb may be awarded an additional bonus on or before the occurrence of a change of control.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Side Letter</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In connection with the execution of the Emalfarb Agreement, the Company and Mr. Emalfarb entered into a separate agreement (the &#8220;Side Letter&#8221;) under which the Company agreed to pay Mr. Emalfarb in monthly installments over the initial term of the Emalfarb Agreement, $1,335,000, equal to the amount of the severance payments that would have been payable under his previous employment agreement if Mr. Emalfarb resigned for &#8220;good reason&#8221; in connection with a change in control.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Thomas L. Dubinski</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On May 1, 2016, the Company entered into a new employment agreement (the &#8220;Dubinski Agreement&#8221;) with Mr. Dubinski. The Dubinski Agreement had a two-year term. The material terms of Dubinski Agreement are summarized below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Base Salary and Bonus</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Mr. Dubinski was entitled to an annual base salary of $225,000 and he was eligible for an annual bonus award, with the timing and amount of any such bonus determined in the sole discretion of the Compensation Committee of the Board.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Performance Stock Options. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Mr. Dubinski was provided the opportunity to be awarded two (2) annual stock option grants (the &#8220;2016 and 2017 Maximum Option Bonus&#8221;). Each such annual option incentive stock option grant was to purchase up to one hundred sixty thousand (160,000) shares of common stock based on performance achievements in 2016 and 2017. The Compensation Committee of the Board established the performance criteria based on the Company&#8217;s business and strategic plans.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Upon the execution of Dubinski Agreement, he received a stock option grant to purchase 53,333 shares of common stock (the &#8220;First Option&#8221;) with an exercise price equal to $1.69. On January 3, 2017, Mr. Dubinski received a stock option grant to purchase 74,667 shares of common stock (the &#8220;Second Option&#8221;) with an exercise price equal to $1.63 per share. The First Option and Second Option together represent 80% of the 2016 Maximum Option Bonus. On January 2, 2018, Mr. Dubinski received a stock option grant to purchase 112,000 shares of common stock for his 2017 performance, representing 70% of the 2017 Maximum Option Bonus. All options granted to Mr. Dubinski vest immediately and has a ten-year term from the date of grant. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stock Exchange Stock Option</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Upon the execution of Dubinski&#8217;s Agreement, Mr. Dubinski received a stock option grant to purchase up to 250,000 shares of common stock at an exercise price equal to the closing price of Dyadic common stock on May 2, 2016. The stock option would have vested and become exercisable if the Company&#8217;s shares of common stock commence trading on the Nasdaq Capital Markets or other stock exchange approved by the Board. The Stock Exchange stock option grant had a five-year term.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Severance Terms. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Mr. Dubinski was eligible for severance benefits comparable to other executives at his level. In addition, if Mr. Dubinski&#8217;s employment was terminated by the Company without cause he would be entitled to annual base salary through the effective date of termination and accrued but unpaid vacation through the date thereof plus, in the discretion of the Compensation </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Committee, the 2016 and 2017 Maximum Option Bonus and, for six (6) months following the date of termination, an amount per month equal to one-twelfth (1/12) of Mr. Dubinski Annual Base Salary. In addition, Mr. Dubinski was able to continue to participate in the Company&#8217;s health, insurance and disability plans for a six-month period following termination. If Mr. Dubinski&#8217;s employment was terminated by Mr. Dubinski for good reason he would be entitled to annual base salary through the effective date of termination and accrued but unpaid vacation through the date thereof plus, in the discretion of the Compensation Committee, the 2016 and 2017 Maximum Option Bonus.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Change of Control</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In the sole discretion of the Compensation Committee, Mr. Dubinski may be awarded an additional bonus on or before the occurrence of a change of control.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Installment Payments. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the execution of the Dubinski Agreement, the Company agreed to pay Mr. Dubinski, in monthly installments over the initial term of the Dubinski Agreement, $200,000, equal to the amount of the severance payments that would have been payable under his previous employment agreement if Mr. Dubinski resigned for &#8220;good reason&#8221; in connection with a change in control. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Thomas L. Dubinski went on medical leave on March 15, 2018, and will not return to the Company. In connection with Mr. Dubinski&#8217;s separation, the Company agreed to pay Mr. Dubinski a lump sum equal to the remaining salary and installment payments due for the initial term of the Dubinski Agreement, plus the cost of health care continuation coverage for a period of twelve months, and to permit Mr. Dubinski to exercise his vested, outstanding stock options through June 30, 2019, subject to his general release of claims. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ronen Tchelet, Ph.D.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We entered into a consulting agreement with Sky Blue Biotech kft, dated January 1, 2016 (the &#8220;Sky Blue Biotech Agreement&#8221;), to engage Mr. Tchelet to serve as our Vice President of Research and Business Development.  The engagement term of the Sky Blue Biotech Agreement is one year and will renew annually on the anniversary date of the agreement, unless the Company or Mr. Tchelet provides notice of non-renewal any time after the one year anniversary date with not less than 90 days&#8217; notice. Mr. Tchelet is subject to an annual performance evaluation and adjustment of his base consulting fees, in the sole discretion of the Company. Mr. Tchelet&#8217;s will be paid at the rate of &#8364;180,000 per annum in 2018 and he is also eligible for a discretionary annual target bonus of up to 40% of his base contract amount if specific performance targets are met. During the engagement period, Mr. Tchelet shall be entitled to reimbursement of all business travel, entertainment and other business expenses reasonably incurred in the performance of his duties for the Company.  Additionally, if the Company enters into a licensing agreement or research and development agreement sourced and developed by Mr. Tchelet during the engagement period, Mr. Tchelet shall receive the following: (i) a commission of up to 1% of the up-front licensing revenue and (ii) a commission of up to 2.5% of the research and development revenue. Commissions will be paid quarterly within 30 days of the Company&#8217;s receipt of payment.  On January 19, 2016, the Company granted Mr. Tchelet a stock option to purchase 200,000 shares of the Company&#8217;s common stock at $1.57 per share. The stock option was granted for a ten-year term and vests in four equal annual installments. On January 3, 2017, the Company granted Mr. Tchelet a stock option to purchase 50,000 shares of the Company&#8217;s common stock at $1.63 per share. On January 2, 2018, the Company granted Mr. Tchelet a stock option to purchase 60,000 shares of the Company&#8217;s common stock at $1.39 per share. The stock options granted in 2017 and 2018 have a ten-year term and vest in one year.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Mr. Tchelet is subject to certain restrictive covenants, including Company ownership of Mr. Tchelet&#8217;s work product which shall remain the sole and exclusive property of the Company, non-disclosure for five years following the date of execution of the agreement or for three years following the termination of agreement whichever is last to occur, and non-solicitation for five years following the termination of the Sky Blue Biotech Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Matthew S. Jones</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We entered into a consulting agreement with Novaro Ltd. dated March 31, 2017 (the &#8220;Jones Consultant Agreement&#8221;) to engage Mr. Jones as our Managing Director Business Development and Licensing. The engagement term of the Jones Consultant Agreement is one year and will renew annually on the anniversary date of the agreement, unless the Company or Novaro Ltd. provides notice of non-renewal any time after the first annual anniversary date with then not less than 90 days&#8217; notice.&#160;Mr. Jones is subject to an annual performance evaluation and adjustment of his base consulting fees, in the sole discretion of the Company. Mr. Jones will be paid &#163;203,528 per annum in 2018 for the consulting services provided and he is eligible for a discretionary annual target bonus of up to 40% of the base contract value if specific performance targets are met as specified in the Jones Consultant Agreement. During the engagement period, Mr. Jones shall be entitled to reimbursement of all business travel, entertainment and other business expenses reasonably incurred in the performance of his duties on behalf of the Company. On January 3, 2017, the Company granted Mr. Jones a stock option to purchase 40,000 shares of the Company&#8217;s common stock at </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.63 per share. On January 2, 2018, the Company granted Mr. Jones a stock option to purchase 50,000 shares of the Company&#8217;s common stock at $1.39 per share. The stock options granted in 2017 and 2018 have a ten-year term and vest in one year.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Mr. Jones is subject to certain restrictive covenants, including Company ownership of Mr. Jones&#8217; work product which shall remain the sole and exclusive property of the Company, non-disclosure for five years following the date of execution of the agreement or for three years following the termination of agreement whichever is last to occur, and non-solicitation for five years following the termination of agreement.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding Equity Awards at Fiscal Year-End</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes the outstanding equity award holdings held by our &#8220;named executive officers&#8221; (as defined by the SEC&#8217;s disclosure requirements) at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:15%;"></td><td style="width:3%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option Awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Awards</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercised</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercised</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incentive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Awards:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercised</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unearned</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">or Units</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">That</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Have</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Not</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Market<br>Value<br>of<br>Shares<br>or<br>Units<br>of<br>Stock<br>That<br>Have<br>Not</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incentive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Awards:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unearned</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Units or</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rights</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">That</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Have Not</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incentive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Plan</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Awards:</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Market</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">or Payout</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unearned</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Units or</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rights</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">That</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Have Not</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unexercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Vested</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Vested<br>($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Vested</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Vested</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Mark A. Emalfarb</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4/13/2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.67</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6/20/2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6/20/2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">150,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/3/2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Thomas L. Dubinski</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">200,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7/31/2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">250,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5/1/2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">53,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5/1/2026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">74,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/3/2027</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Ronen Tchelet, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4/30/2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">150,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/18/2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/3/2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Matthew S. Jones</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1/3/2027</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Represent stock options issued in connection with the contingent compensation incentives discussed in their respective employment agreements, and will only vest upon the achievement of the performance milestones specified in the employment agreements. In the event that the performance milestones are not achieved, the option grants relating to any unattained milestones will be automatically canceled. Mr. Dubinski&#8217;s grant of 250,000 options was canceled in March 2018 due to the termination of his employment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The expiration date of Mr. Dubinski&#8217;s vested outstanding stock options were modified to June 30, 2019 upon the termination of his employment in March 2018.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pension Benefits</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 1, 2009, the Company instituted a 401(k) defined contribution plan (the &#8220;401(k) Plan&#8221;) under which participants may elect to defer up to 100% of their compensation up to a maximum amount determined annually pursuant to Internal Revenue Service regulations. Employee contributions may begin 90 days after the date of hire and are immediately vested.&#160; The 401(k) Plan provides a safe harbor basic match contribution for all eligible employees who make salary deferrals. The match contribution is equal to 100% of the employee&#8217;s salary deferral up to 4% of such employee&#8217;s annual deferred compensation.&#160; This match contribution is credited to the employee&#8217;s account and is 100% vested.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director Compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table sets forth the total compensation for our non-employee directors for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fees earned or paid in cash </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock awards ($) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options awards</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-equity incentive plan compensation ($) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nonqualifed deferred compensation earnings ($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">All other compensation ($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total ($)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Michael P. Tarnok</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">72,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">81,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">153,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Jack L. Kaye</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">69,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">81,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">151,100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Seth J. Herbst, MD</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">81,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">141,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Arindam Bose, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">60,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">153,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">213,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stephen J. Warner </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">81,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">106,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effective January 1, 2016, directors who are also employees or officers of the Company or any of its subsidiaries do not receive any separate compensation as a director. Non-employee directors receive an annual retainer for board service of $60,000, paid in equal monthly installments. A director serving as Chairman of the Board shall also receive an additional annual retainer of $12,000, paid in equal monthly installments. An independent director who serves as Chair of the Company&#8217;s Audit Committee shall also receive an additional annual retainer of $9,600, paid in equal monthly installments. The annual stock option award for non-employee directors is 50,000 options. Newly appointed directors are issued 30,000 stock options in the first year. In August 2017, the Board granted additional 50,000 shares of stock options to Mr. Bose for his special contribution to the Company&#8217;s business. All options granted to directors vest 25% upon grant and the remaining 75% will vest annually in equal installments over four years. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The Stock Option Awards represented the grant date fair market value of each option granted in 2017, computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be recognized by the named directors. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our consolidated financial statements. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Mr. Warner resigned from the Board of Directors of the Company on June 1, 2017. The Board of Directors approved an amendment to his previously granted equity awards by providing acceleration of the vesting dates and extension of the exercise period through May 31, 2020. The incremental cost of such modification was $41,550, which was excluded from the table above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Mr. Buckland was appointed to Dyadic&#8217;s Board of Directors in January 2018, and no fees were paid to him in 2017. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(5) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Options to purchase 155,000 shares (Mr. Tarnok), 130,000 shares (Mr. Kaye), 280,000 shares (Mr. Herbst), 130,000 shares (Mr. Bose), and 200,000 shares (Mr. Warner) were outstanding at December 31, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="s43EEE94C926BE47D4F1720875D91DAB7"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7. Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a description of transactions since January 1, 2016 or related transactions to which we have been a party, in which the amount involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two years, and in which any of our executive officers, directors or holders of more than 5% of our common stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest, other than compensation, termination and change in control arrangements, which are described above under &#8220;Executive Compensation.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2010 Convertible Notes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On August 23, 2010, the Company completed a private placement of $4,000,000 aggregate principal of convertible subordinated secured promissory notes (the &#8220;2010 Notes&#8221;) with ten investors, some of whom are related parties.&#160; Mark A. Emalfarb, our founder and Chief Executive Officer, was issued an aggregate amount of $1,000,000 of 2010 Notes. Michael J. Faby, our former Chief Financial Officer was issued an aggregate amount of $100,000 of 2010 Notes. Lisa Joy Emalfarb, the sister in law of our founder and Chief Executive Officer, was issued an aggregate amount of $100,000 of 2010 Notes. Univest Management, Inc. wholly owned by Frank P. Gerardi, our former Director, was issued an aggregate amount of $100,000 of the 2010 Notes.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The 2010 Notes paid interest quarterly at 8% per annum and were convertible at the holder&#8217;s option into unregistered shares of the Company&#8217;s common stock at a price of $1.82 per share, which represents 120% of the average closing price of the Company&#8217;s common stock for the 30-day period preceding August 23, 2010. The Company would not effect any conversion of the 2010 Notes, to the extent that after giving effect to such conversion, any holder would beneficially own in excess of 4.9% of the Company&#8217;s outstanding common stock (the &#8220;Beneficial Ownership Limitation&#8221;). The Beneficial Ownership Limitation may be waived by the holder upon not less than 61 days prior notice.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 14, 2014, the Company extended the maturity date of the 2010 Notes to January 1, 2016.  In conjunction with the extension of the 2010 Convertible Debt, the share conversion price was reduced from $1.82 to $1.48. The extended Convertible Debt also included a warrant provision in the event Dyadic elected to call the Convertible Debt early, in whole or in part, after March 31, 2015 and prior to the January 1, 2016 maturity date.  Had the Convertible Debt holder(s), upon such call notice, elect not to convert their notes into common shares, Dyadic would pay the Convertible Debt holders&#8217; their then current </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">outstanding Convertible Debt balance, and issue warrants to purchase common stock equal to 25% of the redeemed Convertible Debt balance at $1.48per common share. If such warrants were issued, the warrants would have a three year term.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 31, 2015, in connection with the DuPont Transaction, all of outstanding 2010 Notes were either repaid or converted into shares of Dyadic&#8217;s commons stock. A total of $3,268,000 in convertible debt and $65,897 in accrued interest was exchanged for 2,252,33 shares of Dyadic&#8217;s common stock and 563,160 warrants with a $1.48 per share strike price with a December 31, 2016 expiration date.  A total of $550,000 in debt and $11,090 in accrued interest was repaid in cash and 94,780 warrants with a $1.48 per share strike price with a December 31, 2016 expiration date was issued to convertible debt holders who elected not to convert. Among them, the following are related parties:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of $1,000,000 in convertible debt and $20,164 in accrued interest owned by Mark A. Emalfarb, our founder and Chief Executive Officer, was exchanged for 689,300 shares of Dyadic&#8217;s common stock and 172,325 warrants with a $1.48 per share strike price with a December 31, 2016 expiration date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of $100,000 in debt and $2,016 in accrued interest owned by Michael J. Faby, our former Chief Financial Officer, was repaid in cash and an additional 17,233 warrants with a $1.48 per share strike price with a December 31, 2016 expiration date was issued as he elected not to convert.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;A total of $100,000 in debt and $2,016 in accrued interest owned by Lisa Joy Emalfarb, the sister in law of our founder and Chief Executive Officer, was repaid in cash and an additional 17,233 warrants with a $1.48 per share strike price with a December 31, 2016 expiration date was issued as she elected not to convert.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of $100,000 in convertible debt and $2,016 in accrued interest owned by Univest Management, Inc. wholly owned by Frank P. Gerardi, our former Director, was exchanged for 68,930 shares of Dyadic&#8217;s common stock and 17,233 warrants with a $1.48 per share strike price with a December 31, 2016 expiration date.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2011 Convertible Notes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In October 2011, the Company completed a private placement of $3,000,000 aggregate principal of convertible subordinated secured promissory notes (the &#8220;2011 Notes&#8221;) with five investors, some of whom are related parties. The Francisco Trust, under agreement dated February 28, 1996, as amended (the &#8220;Francisco Trust&#8221;), a trust administered at that time by Morley Alperstein, the former father-in-law of Mark A. Emalfarb, our founder and chief executive officer, and the beneficiaries thereof are the spouse and descendants of Mark A. Emalfarb, was issued an aggregate amount of $500,000 of 2011 Notes. Michael J. Faby, our former Chief Financial Officer was issued an aggregate amount of $50,000 of 2011 Notes. Univest Management, Inc., wholly owned by Frank P. Gerardi, our former Director, was issued an aggregate amount of $50,000 of 2011 Notes.&#160; </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The 2011 Notes paid interest quarterly at 8% per annum and were convertible at the holder&#8217;s option into unregistered shares of the Company&#8217;s common stock at a price equal to the lesser of $1.28 per share. The Company agreed not affect any conversion of the 2011 Notes, to the extent that after giving effect to such conversion, any holder would beneficially own in excess of 4.9% of the Company&#8217;s outstanding common stock. The Beneficial Ownership Limitation may be waived by the holder upon not less than 61 days prior notice. On October 7, 2013, the Company extended the maturity date of the 2011 Notes to January 1, 2015. The amendment includes a provision that allows the Company to prepay all or part of the outstanding principal, without penalty, any time after March 31, 2014.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 14, 2014, the Company extended the maturity date of the 2011 Notes to January 1, 2016. The extended Convertible Debt also included a warrant provision in the event Dyadic elected to call the Convertible Debt early, in whole or in part, after March 31, 2015 and prior to the January 1, 2016 maturity date.  Had the Convertible Debt holder(s), upon such call notice, elect not to convert their notes into common shares, Dyadic would pay the Convertible Debt holders&#8217; their current outstanding Convertible Debt balance, and issue warrants to purchase common stock equal to 25% of the redeemed Convertible Debt balance at $1.48per common share. The $1.48 was the market closing price of Dyadic&#8217;s stock on the date of the transaction. If such warrants were issued, the warrants would have a three year term.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On April 13, 2015, $50,000 of the 2011 Notes owned by Michael J. Faby, our former Chief Financial Officer, was repaid together with accrued interest.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 31, 2015, in connection with the DuPont Transaction, all of the outstanding 2011 Notes were either repaid or converted into shares of Dyadic&#8217;s commons stock. A total of $2,842,787 in convertible debt and $54,079 in accrued interest was exchanged for 2,263,177 shares of Dyadic&#8217;s common stock and 489,336 warrants with a $1.48 per share strike price with a December 31, 2016 expiration date.  Among them, the following are related parties:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of $500,000 in convertible debt and $10,082 in accrued interest owned by the Francisco Trust, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">a trust administered at that time by Morley Alperstein, the former father-in-law of Mark A. Emalfarb, our founder and chief executive officer, </font><font style="font-family:inherit;font-size:10pt;">and the beneficiaries thereof are the spouse and descendants of Mark A. Emalfarb, was exchanged for 398,502 shares of Dyadic&#8217;s common stock and 86,163 warrants with a $1.48 per share strike price with a December 31, 2016 expiration date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of $50,000 in convertible debt and $1,008 in accrued interest owned by Univest Management, Inc. wholly owned by Frank P. Gerardi, our former Director, was exchanged for 39,850 shares of Dyadic&#8217;s com</font><font style="font-family:inherit;font-size:10pt;color:#000000;">mon stock and 8,616 warrants with a $1.48 per share strike price with a December 31, 2016 expiration date.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrant Exercise</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,147,273</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;warrants with an exercise price of $1.48 per share were exercised, resulting in an aggregate issuance of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">121,312</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of our common stock.  Of which, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">17,233</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;warrants were cash exercised with a net proceed to the Company of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$25,505</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,130,040</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;warrants were net (cashless) settled in shares of common stock based on the difference between the exercise price and the volume weighted average market price on the exercise date, resulting in an issuance of 104,079 shares of common stock.  In 2016, there were an additional 2,500 shares of common stock issued in connection with warrants exercised in 2015.  Among them, the following are related parties:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of 172,325 warrants owned by Mark A. Emalfarb, our founder and Chief Executive Officer, was net (cashless) exercised, resulting in 16,015 shares of Dyadic&#8217;s common stock.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of 86,163 warrants owned by the Francisco Trust, a trust administered by Adam Morgan, and the beneficiaries thereof are the spouse and descendants of Mark A. Emalfarb, our Chief Executive Officer, was net (cashless) exercised, resulting in 8,008 shares of Dyadic&#8217;s common stock.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of 17,233 warrants owned by Michael J. Faby, our former Chief Financial Officer, was net (cashless) exercised, resulting in 1,602 shares of Dyadic&#8217;s common stock.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of 17,233 warrants owned by Lisa Joy Emalfarb, the sister in law of our founder and Chief Executive Officer, was net (cashless) exercised, resulting in 1,864 shares of Dyadic&#8217;s common stock.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of 25,849 warrants owned by Univest Management, Inc. wholly owned by Frank P. Gerardi, our former Director, was net (cashless) exercised, resulting in 2,094 shares of Dyadic&#8217;s common stock.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of 326,175 warrants owned by Pinnacle Family Office Investments, L.P., was net (cashless) exercised, resulting in 30,314 shares of Dyadic&#8217;s common stock.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest in Litigation Proceeds</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In consideration for the October 22, 2013 dismissal of arbitration proceedings initiated by our founder and Chief Executive Officer Mark A. Emalfarb against the Company, the Company agreed to reimburse Mr. Emalfarb approximately $313,000 for past expenses incurred.&#160; In addition to this reimbursement, Mr. Emalfarb was entitled to receive 5% of the proceeds to the Company net of legal expenses up to $25 million and 8% of any net proceeds in excess of $25 million, but in any case, the maximum amount payable was $6 million of the net proceeds, if any, received by the Company related to the professional liability lawsuit against the Company&#8217;s former outside legal counsel discussed under &#8220;Item 8. Legal Proceedings&#8212;Professional Liability Lawsuit.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On March 1, 2017, Dyadic and Greenberg Traurig settled before the case went to the jury. On April 14, 2017, the Company received from Greenberg Traurig, LLP, and Greenberg Traurig, P.A. (collectively, &#8220;Greenberg Traurig&#8221;) a settlement in the amount of $4,500,000, net of legal fees and expenses. The Company made a payment of $141,777 to Mark A. Emalfarb to satisfy this above contractual obligation regarding his portion of the settlement. The Company recorded a net amount of $4,358,223 after related expenses, in the first quarter of 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Privately Negotiated Share Buyback Transaction</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 11, 2017, the Company entered into a Securities Purchase Agreement with Pinnacle Family Office Investments L.P (&#8220;Pinnacle&#8221;), which owned more than 5% of the Company&#8217;s common stock at that time, to repurchase an aggregate of 2,363,590&#160;shares of its common stock at $1.54 per share for an aggregate purchase price of $3,639,929.  Upon repurchase, the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">shares are treated by Dyadic as treasury stock. The repurchase of shares from Pinnacle was in addition to Dyadic&#8217;s 2016 Stock Repurchase Program.  All share buyback transactions are fully disclosed in our consolidated financial statements footnote entitled &#8220;Shareholders&#8217; Equity&#8221;.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options Granted to Executive Officers and Directors</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have granted stock options and restricted stock to our executive officers and directors, as more fully described in the section above entitled &#8220;Executive Compensation&#8221;.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Indemnification Agreements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have entered, and intend to continue to enter, into separate indemnification agreements with each of our directors and executive officers.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Related Party Transactions Policy</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our written audit committee charter requires that our board of directors review and approve, if the duty is not delegated to a comparable body of the board of directors, all related party transactions in accordance with the regulations of the SEC.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Director</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:normal;">&#32;Independence</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our common stock is not listed on any national securities exchange (or quoted on any inter-dealer quotation service) that imposes independent standards on our board of directors or any committee thereof. However, in evaluating the independence of its members and the composition of the committees of the board of directors, the board utilizes the definition of &#8220;independence&#8221; as that term is defined by the rules promulgated by the SEC. We believe that Drs. Bose, Herbst and Buckland, as well as Messrs. Kaye and Tarnok qualify as &#8220;independent&#8221; directors, as that term is defined by SEC rules.</font></div><div><a name="s807B07E07868C24C855820875DC31194"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8. Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are involved in various claims, legal actions and regulatory proceedings arising from time to time in the ordinary course of business. Other than the matters set forth below, in the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on our combined financial position, results of operations or cash flows. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These provisions are reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. While the Company believes that it has valid defenses with respect to the legal matters pending against it, protracted litigation and/or an unfavorable resolution of one or more of such proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#8217;s consolidated financial position, cash flows or results of operations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Professional Liability Lawsuit</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On March 26, 2009, the Company filed a complaint in the Circuit Court of the 15</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Judicial Circuit in and for Palm Beach County, Florida against Ernst &amp; Young LLP and Ernst &amp; Young-Hong Kong, L.P., alleging professional negligence/malpractice, breach of fiduciary duty and constructive fraud in connection with the accounting, advisory, auditing, consulting, financial and transactional services they provided to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On April 14, 2009, the Company amended the complaint (the &#8220;Amended Complaint&#8221;) by naming as additional defendants the Company&#8217;s former outside legal counsel consisting of the law firms of Greenberg Traurig, LLP, Greenberg Traurig, P.A. (collectively, &#8220;Greenberg Traurig&#8221;), Jenkens &amp; Gilchrist, P.C. (&#8220;Jenkens &amp; Gilchrist&#8221;) and Bilzin Sumberg Baena Price &amp; Axelrod LLP (&#8220;Bilzin Sumberg&#8221;) as well as attorney Robert I. Schwimmer who previously represented the Company while an attorney at Jenkens &amp; Gilchrist and later at Greenberg Traurig. Jenkens &amp; Gilchrist went out of business in 2007 and is in the process of winding up its business and affairs. The Company also named as defendants the law firm of Moscowitz &amp; Moscowitz, P.A. and its attorneys Norman A. Moscowitz and Jane W. Moscowitz (collectively, the &#8220;Moscowitz Defendants&#8221;) who conducted the investigation and authored the investigative report requested by the Company&#8217;s Audit Committee following the discovery of alleged improprieties at the Company&#8217;s Asian subsidiaries. The claims against the Company&#8217;s former outside legal counsel are for breach of fiduciary duty and professional negligence. In addition to these claims, the Amended Complaint contains a claim of civil conspiracy against Ernst &amp; Young LLP, Greenberg Traurig and Mr. Schwimmer. The claims against Ernst &amp; Young LLP and Ernst &amp; Young-Hong Kong, L.P. were subsequently stayed in the Circuit Court action and submitted to binding arbitration. A final hearing before the arbitration tribunal was completed on May 27, 2011.&#160;On February 29, 2012, the arbitration tribunal issued a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Final Award which found no auditor negligence, denied the Company any recovery against Ernst &amp; Young LLP and Ernst &amp; Young Hong Kong L.P., and further provided that each party shall bear its own attorneys&#8217; fees and costs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 11, 2011, defendants Jenkens &amp; Gilchrist, Bilzin Sumberg and the Moscowitz Defendants filed a counterclaim in the Circuit Court against the Company and a Third Party Complaint against its President and Chief Executive Officer, Mark Emalfarb, individually, for abuse of process.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The counter claim and Third Party Complaint filed by Jenkens &amp; Gilchrist and Bilzin Sumberg also included claims for common law indemnity against the Company and Mr. Emalfarb.&#160;In addition, Jenkens &amp; Gilchrist made a claim against the Company for breach of the implied covenant of good faith and fair dealing.&#160;On July 18, 2011, the Moscowitz Defendants filed a motion for summary judgment which the Circuit Court denied in its entirety.&#160;On September 9, 2011, Jenkens &amp; Gilchrist and Bilzin Sumberg amended their counterclaim and Third Party Complaint which dropped their claims for abuse of process but retained their claims for common law indemnity against the Company and Mr. Emalfarb.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Bilzin Sumberg also added claims against the Company and Mr. Emalfarb for breach of its retainer agreements and for declaratory relief.&#160;Also on September 9, 2011, the Moscowitz Defendants dropped their claims for abuse of process against the Company and Mr. Emalfarb.&#160;On December 8, 2011, the Circuit Court dismissed without prejudice all counterclaims against the Company and all third party claims against Mr. Emalfarb.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 18, 2012, the Company filed a Second Amended Complaint which expanded and amplified the Company&#8217;s prior allegations of negligent acts and omissions by the defendants in the Circuit Court proceedings.&#160;All of the defendants have filed and served their answers and affirmative defenses.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On August 8, 2012, the Company, Jenkens &amp; Gilchrist and Mr. Schwimmer entered into a Settlement Agreement and General Releases (the &#8220;J&amp;G Settlement Agreement&#8221;) whereby Jenkens &amp; Gilchrist paid the Company $525,000 for the mutual release and discharge of (1) all causes of action between the Company and Jenkens &amp; Gilchrist, and (2) causes of action between the Company and Mr. Schwimmer including, but not limited to, those in the professional liability lawsuit, but only those which occurred while Mr. Schwimmer served as an attorney at Jenkens &amp; Gilchrist and not while he served as an attorney at Greenberg Traurig or any other time. Such amount was included in other income in the consolidated statement of operations for the year ended December 31, 2012. Pursuant to the J&amp;G Settlement Agreement, the Company, Jenkens &amp; Gilchrist and Mr. Schwimmer have filed a Stipulation of Settlement with the Court to enforce the terms of the J&amp;G Settlement Agreement including, but not limited to, the dismissal of Counts I and II of the Second Amended Complaint against Jenkens &amp; Gilchrist and Mr. Schwimmer with prejudice.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 24, 2013, each of the remaining defendants served their amended affirmative defenses to the Second Amended Complaint. On February 11, 2013, the Company served its reply to such amended affirmative defenses.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company and the defendants in the Circuit Court proceedings are continuing to engage in written discovery, oral depositions and motion practice.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On November 26, 2013, the Court entered a Case Management Order.&#160;Pursuant to the Order, all pretrial motions and other litigation activities were to have been concluded by the end of 2014.&#160;The Court ordered mediation was held on November 10</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and 11</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th,</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;2014.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 31, 2015, the Company reached a settlement with one of the three remaining defendant law firms in its ongoing professional liability litigation. On August 12, 2015 the Company received full payment in the amount of $2,170,000, which is net of fees and expenses. The settlement amount was reported in the Company&#8217;s consolidated statement of operations, in other income, for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 29, 2015, the Court removed the professional liability litigation from the Court&#8217;s eight week trial docket which commenced on October 26, 2015. Instead, the Court, in an effort to promote settlement, ordered the parties to non-binding arbitration with an initial hearing to occur before December 16, 2015. The parties were scheduled to appear before the Court on November 13, 2015 for hearings on various pre-trial motions. At that time, the Court was expected to address when the professional liability litigation will be set for trial in 2016. The parties also voluntarily agreed to again attend mediation on November 18, 2015.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The parties attended both mediation and non-binding arbitration. No resolution was reached. Pretrial motion practice is now substantially completed.&#160;On March 3, 2016, the Court issued an Order setting a six week jury trial commencing January 6, 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On April 5, 2016, the Company reached a settlement with one of the two remaining defendant law firms, Bilzin Sumberg Baena Price &amp; Axelrod LLP, in its ongoing professional liability litigation.&#160;On April 19, 2016, the Company received full payment in the amount of $2,100,000, which is net of legal fees and expenses.&#160;The settlement amount was reported in the Company&#8217;s consolidated statement of operations, in other income, for the quarter ended June 30, 2016.&#160;The trial with the remaining defendant law firm Greenberg Traurig, LLP, Greenberg Traurig, P.A. (collectively, &#8220;Greenberg Traurig&#8221;) and the estate of Robert I Schwimmer remains set for January 6, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 8, 2016, the Court heard oral argument on Greenberg Traurig&#8217;s Renewed Motion for Summary Judgment as to its judgmental immunity affirmative defense.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 28, 2016, the Company stipulated to the release of the estate of Robert Schwimmer as a defendant. This was a procedural decision as Greenberg Traurig remains liable for the negligent conduct of deceased Greenberg Traurig lawyer, Robert Schwimmer.&#160; </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On August 17, 2016, the Court denied Greenberg Traurig&#8217;s Renewed Motion for Summary Judgment as to its judgmental immunity affirmative defense.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 17, 2016, Greenberg Traurig filed a Motion to Continue the Trial. On October 18, 2016, Greenberg Traurig filed a motion to bifurcate the liability and damages determination by the jury into separate trials.&#160; On October 27, 2016, the Court heard oral argument on both motions.&#160; Both motions were denied.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Trial commenced against Greenberg Traurig in this continuing professional liability litigation on January 6, 2017 and continued for eight weeks thereafter. On March 1, 2017, Dyadic and Greenberg Traurig settled before the case went to the jury, and reached a confidential settlement. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">On April 14, 2017, the Company received the full settlement payment in the amount of $4,500,000, net of legal fees and expenses. Per the settlement agreement dated October 22, 2013 between Mark A. Emalfarb ("MAE"), and Dyadic, whereby Dyadic agreed to pay MAE 5% of any net company proceeds in connection with the litigation up to $25 million, and 8% of any net company proceeds in excess of $25 million; provided, that the maximum amount payable under the agreement be limited to $6 million.  In the second quarter of 2017, the Company made a payment of $141,777 to MAE to satisfy this prior contractual obligation.&#160;The net litigation settlement gain of $4,358,223 was reported in the Company&#8217;s consolidated statement of operations, in other income, in the first quarter of 2017.&#160;</font></div><div><a name="sB346839E968AA982407920875DE198B8"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9. Market Price of and Dividends on the Registrant&#8217;s Common Equity and Related Stockholder Matters</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our common stock is quoted under the symbol &#8220;DYAI&#8221; on the OTCQX U.S. Premier operated by OTC Markets Group.&#160; There is no assurance that our common stock will continue to be traded on the OTC or that any liquidity for our stockholder exists.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Price</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table shows the high and low closing bid quotations for our common stock as reported by the OTC Markets Group for the periods indicated. These quotations reflect inter-dealer prices, without retail markup, markdown or commissions.&#160; Trading on the OTC markets is limited and the prices quoted by brokers are not a reliable indication of the value of our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year ended December 31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter (through November 2, 2018)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year ended December 31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.58</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.53</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year ended December 31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.85</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Holders</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, there were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">69</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;holders of record of our issued and outstanding common stock.&#160; There are greater than </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,970</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;beneficial holders owning at least 100 shares of the Company&#8217;s common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">While there are no restrictions on the payment of dividends, we have not declared or paid any cash dividends on shares of Dyadic common stock in the last two fiscal years, and we presently have no intention of paying any cash dividend in the foreseeable future. The Company&#8217;s current policy is to retain earnings, if any, to finance the expansion of its business. The future payment of dividends will depend on the results of operations, financial condition, capital expenditure plans and other factors that we deem relevant and will be at the sole discretion of the board of directors.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Compensation Plan Information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes information about our equity compensation plans as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Plan Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Securities</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">to be Issued Upon</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding Options,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Warrants and Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options, Warrants</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">and Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Securities Remaining</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Available for Future Issuance</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Under Equity Compensation</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Plans (Excluding Securities</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Reflected in Column</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation plans approved by security holders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,712,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,006,711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><a name="sCEC70D5025C38F2B8C8F20875E090376"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 10. Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Option Awards</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the last three fiscal years since January 1, 2016, the Company has granted stock options to purchase 2,933,390 shares of its common stock, to employees, directors and consultants at a weighted average price of $1.56 per share under its 2006 Stock Option Plan and 2011 Equity Incentive Plan (the &#8220;Stock Plans&#8221;). The issuances of these securities were exempt from registration in reliance on Rule 701 of the Securities Act, pursuant to compensatory plans approved by the Company&#8217;s board of directors and stockholder.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table reflects the total issuances of 300,538 shares of our common stock during the last three fiscal years since January 1, 2016 upon the exercise of options granted pursuant to our Stock Plans. Of which, 264,288 shares of common stock were issued as a result of net (cashless) settlement of 800,000 stock options based on the difference between the exercise price and the volume weighted average market price on the exercise date. We received $5,938 in total exercise price proceeds paid upon their exercise of 36,250 stock options. During the same period, 153,732 shares of our common stock were issued to employees, officers and directors of the Company.&#160;All shares were issued in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act, as the shares were issued in transactions not involving any public offering or distribution, or in reliance on Rule 701 of the Securities Act, pursuant to compensatory plans approved by the Company&#8217;s board of directors and stockholder.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Shares Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;Total Exercise Price Paid </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/6/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/8/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.93</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/8/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/8/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/8/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/11/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/12/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/12/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,754</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/15/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/20/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,879</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/27/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/27/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,286</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2/10/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2/18/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,569</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2/22/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2/24/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,299</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2/24/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,311</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/30/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,540</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/30/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/30/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/1/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/1/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,182</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/1/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/1/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,496</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/4/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/7/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,798</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/12/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/12/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,206</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5/23/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8/19/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,972</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/24/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/24/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.55</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/31/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1,438</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8/22/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4,500</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Note:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Options were net (cashless) settled in shares of common stock based on the difference between the exercise price and the volume weighted average market price on the exercise date. Therefore, no cash was received from the option exercise.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Unit Awards</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;During the last three fiscal years since January 1, 2016, the Company granted 247,550 restricted stock units to employees, officers and directors of the Company at a weighted average price of $1.48 per share under its Stock Plans. The RSUs represent the right to be issued on a future date shares of our common stock for vested RSUs. The issuances of these securities were exempt from registration in reliance on Rule 701 of the Securities Act, pursuant to compensatory plans approved by the Company&#8217;s board of directors and stockholder.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table reflects issuances of 316,550 shares of our common stock during the last three fiscal years since January 1, 2016 upon the vesting of restricted stock units pursuant to our Stock Plans. All shares of common stock were issued to key employees, officers and directors of the Company.&#160; All shares were issued in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act, as the shares were issued in transactions not involving any public offering or distribution.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Shares Issued</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/4/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/8/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,697</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/19/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,094</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/28/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6/5/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Prior to 2015, the Company issued convertible notes to raise capital to finance its operations. On December 31, 2015, in connection with the DuPont Transaction, the Company issued warrants to purchase 1,147,273 shares of our common stock with a $1.48 per share strike price to exchange the outstanding convertible notes and accrued interest. All warrants were issued in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act, as the shares were issued in transactions not involving any public offering or distribution.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">No warrants to purchase our common or preferred shares have been issued since January 1, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table reflects issuances of our common stock during the last three fiscal years since January 1, 2016 upon the exercise of warrants. In total, 123,812 shares of our common stock were issued upon the exercise of 1,149,773 warrants. All of such shares were issued in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act, as the shares were issued in transactions not involving any public offering or distribution.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date of Issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Shares Issued Pursuant to Warrants Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;Total Exercise Price Paid </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/7/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$375</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/3/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/23/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/5/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$25,505</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/15/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/19/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,094</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/27/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/30/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,055</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Note:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Warrants were net (cashless) settled in shares of common stock based on the difference between the exercise price and the volume weighted average market price on the exercise date. Therefore, no cash was received from the warrant exercise.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sale of Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 19, 2016, the Company&#8217;s Chairman of Board of Director Michael P. Tarnok purchased a total of 64,516 shares of common stock at $1.55 per share, the market closing price. The aggregate amount paid was pursuant to a securities purchase agreement and the certificate evidencing the shares issued contains a legend stating that the shares have not been registered under the Securities Act and are subject to restrictions on transferability and sale pursuant to the Securities Act.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to these issuances of common stock, the total number of shares outstanding was affected, from time to time, by repurchase of shares by the Company pursuant to its stock repurchase program as described in Note 7 to our Consolidated Financial Statements included in the 2017 Annual Report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><a name="s5FF90E642C2722C61D9A20875E31EB9A"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 11. Description of Registrant&#8217;s Securities to Be Registered</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our authorized capital stock currently consists of 100,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.0001 per share, the rights and preferences of which may be established from time to time by our board of directors.&#160; As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">October&#160;12, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, the Company has </font><font style="font-family:inherit;font-size:10pt;color:#000000;">38,966,988</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of our common stock issued and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26,713,486</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of common stock outstanding with the remaining </font><font style="font-family:inherit;font-size:10pt;color:#000000;">12,253,502</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares held in treasury.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The description of our securities contained herein is a summary only and may be exclusive of certain information that may be important to you.&#160; For more complete information, you should read our Certificate of Incorporation and its restatements, together with our corporate bylaws which have been filed with the SEC as exhibits to this registration statement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Holders of our Common Stock are entitled to receive ratably, from funds legally available for the payment thereof, dividends when and as declared by resolution of the board of directors, subject to any preferential dividend rights which may be granted to holders of any preferred stock authorized and issued by the board of directors. Holders of our common stock do not have cumulative voting rights and are entitled to one vote per share on all matters to be voted upon by stockholders. Our common stock is not entitled to preemptive rights and is not subject to redemption, including sinking fund provisions, or conversion. Upon our liquidation, dissolution or winding up, the assets, if any, legally available for distribution to stockholders are distributable ratably among the holders of our common stock after payment of all classes or series of our preferred stock. All outstanding shares of our common stock are validly issued, fully-paid and non-assessable. The rights, preferences and privileges of holders of our common stock are subject to the preferential rights of all classes or series of preferred stock that we may issue in the future.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our Restated Certificate of Incorporation permits us to issue up to 5,000,000 shares of preferred stock, par value $0.0001 per share. The preferred stock may be issued in any number of series as determined by the board of directors. The board of directors may by resolution fix the designation and number of shares of any such series of preferred stock and may determine, alter or revoke the rights, preferences, privileges and restrictions pertaining to any wholly unissued series and the board of directors may increase or decrease the number of shares of any such series (but not below the number of shares of that series then outstanding).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have no preferred stock issued or outstanding.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transfer Agent and Registrar</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The transfer agent and registrar for the Company&#8217;s common stock is Continental Stock Transfer &amp; Trust Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Anti-Takeover Effects of Certificate of Incorporation and Bylaws</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Certain provisions in our Restated Certificate of Incorporation and our bylaws could have the effect of impeding or discouraging the acquisition of control of us by means of a merger, tender offer, proxy contest or otherwise, including a transaction in which our stockholders would receive a premium over the market price for their shares, and thereby protects the continuity of our management. Specifically, our Restated Certificate of Incorporation or bylaws contain the following provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors is composed of three classes of directors who serve staggered three-year terms so that only one-third of the directors are eligible for election at any annual meeting of stockholders, and cumulative voting in the election of directors is specifically denied.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any action permitted to be taken by our stockholders is required to be effected at a duly called annual or special meeting of stockholders and cannot be effected by a written consent.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our stockholders will not be permitted to call a special meeting of stockholders, and the only business matters permitted to be conducted at any annual or special meeting of stockholders will be business matters properly brought before that meeting in accordance with specified procedures.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specific procedures are established for stockholder nominations for directors and stockholder proposals of business to be considered at an annual or special meeting of stockholders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors establishes the number of directors, and vacancies on our board of directors must be filled by a majority approval of the remaining directors, and directors may not be removed by stockholder action without cause.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors is empowered to adopt, amend or repeal our bylaws, while our stockholders may adopt, amend or repeal our bylaws only upon an affirmative vote of the holders of at least two-thirds of the voting power of all then outstanding shares of stock entitled to vote.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors has the power to designate and establish new classes of preferred stock having terms that the board of directors determines to be advisable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to extraordinary matters that are brought to our stockholders for a vote, including the sale of all or substantially all of our assets, a merger, a consolidation, the conversion of us into another type of entity or the amendment of our Restated Certificate of Incorporation, unless that matter is affirmatively recommended by our board of directors, its approval will require the affirmative vote of the holders of at least two-thirds of the voting power of all then outstanding shares of stock entitled to vote.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The foregoing provisions of our Restated Certificate of Incorporation and bylaws and other provisions pertaining to the limitation of liability and indemnification of directors may be amended or repealed only with the affirmative vote of the holders of at least two-thirds of the voting power of all then outstanding shares of stock entitled to vote.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, if in the due exercise of its fiduciary obligations, the board of directors were to determine that a takeover proposal was not in our best interest, shares of common stock or preferred stock could be issued by the board of directors without stockholder approval in one or more transactions that might prevent or render more difficult or costly the completion of the takeover by:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">diluting the voting or other rights of the proposed acquirer or insurgent stockholder group;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">putting a substantial voting block in institutional or other hands that might undertake to support the incumbent board of directors; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">effecting an acquisition that might complicate or preclude the takeover.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The effect of all of the foregoing provisions may be to delay or prevent a tender offer or takeover attempt that a stockholder may determine to be in his or her best interest, including attempts that might result in a premium over the market price for the shares held by the stockholders.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware Anti-Takeover Law</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are not currently subject to the provisions of Section 203 of the Delaware General Corporation Law concerning corporate takeovers.&#160; If we become listed on a national stock exchange or have a class of voting stock held by more than 2000 record holders, we will be governed by the provisions of Section 203 of the General Corporation Law of Delaware. In general, such law prohibits a Delaware public corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless it is approved in a prescribed manner.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As a result of Section 203 of the General Corporation Law of Delaware, potential acquirers may be discouraged from attempting to effect acquisition transactions with us, thereby possibly depriving holders of our securities of certain opportunities to sell or otherwise dispose of such securities at above-market prices pursuant to such transactions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reports to Stockholders</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We intend to comply with the periodic reporting requirements of the Securities Exchange Act of 1934. We plan to furnish our stockholders with an annual report for each fiscal year beginning for the fiscal year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;containing financial statements audited by our independent registered public accounting firm. The SEC maintains an Internet site at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The public may also read and copy any materials we file with the SEC at the SEC&#8217;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 (call 1-800-SEC-0330 for information).</font></div><div><a name="sE629EB5FA2EDE176E2F720875E634092"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 12. Indemnification of Directors and Officers</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our certificate of incorporation eliminates the personal liability of our directors for monetary damages arising from a breach of their fiduciary duty as directors to the fullest extent permitted by Delaware law. This limitation does not affect the availability of equitable remedies, such as injunctive relief or rescission. Our certificate of incorporation and bylaws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law, including in circumstances in which indemnification is otherwise discretionary under Delaware law.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under Delaware law, we may indemnify our directors or officers or other persons who were, are or are threatened to be made a party to an action, suit or proceeding because the person is or was our director, officer, employee or agent, against expenses, including attorneys&#8217; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by them in connection with the action, suit or proceeding if the person:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#8217;s conduct was unlawful.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If the person is found liable to the corporation, no indemnification shall be made unless the court in which the action was brought determines that the person is fairly and reasonably entitled, under the circumstances and despite the adjudication of liability, to indemnity for an amount of expenses that the court deems proper.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. See Exhibit 10.10 for a copy of Director and Officer Indemnification Agreement. </font></div><div><a name="s231D95AA90DBFA05724920875E8BC61D"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 13. Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Condensed consolidated financial statements for three and six months ended June 30, 2018 and 2017</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Consolidated financial statements for years ended December 31, 2017 and 2016</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><a name="s5C1F551D487D0035DCF120875EDBDF4B"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div><div><a name="sa2d01ebfdb354d1ba2277b6be2818965"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Audited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,218,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investment securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,111,207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,898,754</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">489,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,128</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,029</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of prepaid research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,015,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,741</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,608</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,581,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,615,774</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investment securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,031,502</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">922,648</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current portion of prepaid research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,449</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,492</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,769,982</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,744,159</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,450</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,959</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred research and development obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,675</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">768,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies (See Note 4)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $.0001 par value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized shares - 5,000,000; none issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $.001 par value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized shares - 100,000,000; issued shares - 38,936,988 and 38,936,988, outstanding shares - 28,060,811 and 28,327,811 as of June 30, 2018 and December 31, 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,256,578</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,913,557</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Treasury stock, shares held at cost - 10,876,177 and 10,609,177 shares, as of June 30, 2018 and December 31, 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,000,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,625,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,991,286</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,351,357</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,303,536</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,975,264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities and stockholders</font><font style="font-family:inherit;font-size:10pt;">&#8217;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,769,982</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,744,159</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><a name="sad84e3ded8154a4b91f6f51e1a1d18e0"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,286</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,402</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,616</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Costs and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs of research and development revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for contract losses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,175</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,715</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">601,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,178,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">739,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development - related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,849</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">733,398</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">921,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,233,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,214,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,024,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency exchange gain, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,198</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(178,277</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,358</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(206,113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,977,508</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,685,243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,391,587</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,099,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,816,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,477,841</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,045,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,770,361</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement of litigation, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,358,223</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">246,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219,585</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,236</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,604,652</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Loss) income before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,596,637</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,347,605</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,639,929</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">834,291</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,901</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,457</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net (loss) income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,596,637</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,349,506</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,639,929</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">746,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income per common share</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average common shares outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,060,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,707,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,109,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,159,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,060,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,707,289</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,109,756</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,220,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited consolidated financial statements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><a name="s017faeccc70d4f3aafc820a6f0ae7e13"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:20%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Treasury Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">paid-in capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">&#160;Total</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,936,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10,609,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(16,625,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">93,913,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(27,351,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49,975,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">343,021</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">343,021</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repurchases of common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(267,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(374,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(374,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,639,929</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,639,929</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,936,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,937</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10,876,177</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(17,000,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">94,256,578</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(30,991,286</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">46,303,536</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these unaudited consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><a name="sd28b30d8a6474240a2e9386a73fc81ad"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOW</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,639,929</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">746,834</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Stock-based compensation expense </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,021</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479,046</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Amortization of premium on held-to-maturity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Provision for contract losses </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(140,165</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Foreign currency exchange gain, net </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,358</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(206,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Changes in operating assets and liabilities: </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Interest receivable </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Accounts receivable </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,121</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510,316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Prepaid research and development </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,124,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Prepaid expenses and other current assets </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,973</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,667</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Accounts payable </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(275,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Accrued expenses </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,491</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206,258</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Deferred research and development obligations </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(122,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Income taxes payable </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(102,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash (used in) provided by operating activities </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,377,014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,163,344</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of held-to-maturity securities, including premium</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,320,705</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,581,018</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from maturities of investment securities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,507,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,628,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash provided by investing activities </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186,295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,046,982</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repurchases of common stock  </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(374,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,686,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash used in financing activities </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(374,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,684,869</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of exchange rate changes on cash </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,989</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,698</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net decrease in cash, cash equivalents and restricted cash </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,567,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,274,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786,348</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,254,216</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, cash equivalents and restricted cash at end of period </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,218,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,979,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for (refund received from) income taxes </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(163,735</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these unaudited consolidated financial statements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><a name="s441b7a5ca9ec4be8a43cdf293879a7b6"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to the Consolidated Financial Statements (Unaudited)</font></div><div><a name="s10620eb189544aee9578480713f0bdf3"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 1:&#160;&#160;&#160;&#160;Organization and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, the Netherlands and third-party lab-collaborations in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Myceliophthora thermophila</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 31, 2015, the Company sold its industrial technology business to DuPont&#8217;s (NYSE: DD) industrial biosciences business for $75.0 million (the &#8220;DuPont Transaction&#8221;). As part of the DuPont Transaction, DuPont granted back Dyadic co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, with the exclusive ability to enter into sub-license agreements. DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines (such as virus-like particles (VLPs) and antigens), monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, as well as other therapeutic enzymes and proteins. Additionally, in early 2018, we began to conduct certain funded research activities to further understand if, or how the C1 technology can be applied for use in developing and manufacturing metabolites.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intra-entity transactions and balances have been eliminated in consolidation. The Company has reclassified certain 2017 amounts previously reported to conform to the 2018 consolidated financial statement presentation.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying unaudited interim consolidated financial statements for the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial reporting.&#160;Accordingly, certain information and footnote disclosures normally included in annual consolidated financial statements have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments (consisting of only normal recurring adjustments and the elimination of intra-entity accounts) considered necessary for a fair presentation of all periods presented.&#160;The results of the Company&#8217;s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes included in our Annual Report for the year ended December&#160;31, 2017, which was posted to the OTC Markets website on March&#160;27, 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For both the three months ended June&#160;30, 2018 and 2017, the Company&#8217;s revenue was generated from two and three customers respectively. For both the six months ended June&#160;30, 2018 and 2017, the Company&#8217;s revenue was generated from three customers. At June&#160;30, 2018, and December&#160;31, 2017, the Company&#8217;s account receivable was from one customer and three customers, respectively. The loss of business from one or a combination of the Company&#8217;s customers could adversely affect its revenues.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For the three and six months ended June&#160;30, 2018, all of the Company revenue and accounts receivable were from United States customers. For the three and six months ended June 30, 2017, there was one European customer that accounted for approximately 37.9% and 35.9% of total revenue, respectively and 100% of total accounts receivable.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment Securities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Investment securities are classified as held-to-maturity, available-for-sale, or trading. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#8217;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security.  When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s investments in money market funds have been classified and accounted for as available-for-sale securities, and presented as cash equivalents on the consolidated balance sheet. As of June&#160;30, 2018 and December&#160;31, 2017, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of June&#160;30, 2018 and December&#160;31, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date.  Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve months. There was no allowance for doubtful accounts as of June&#160;30, 2018 and December 31, 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes billed and unbilled receivables as of June&#160;30, 2018 and December 31, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Audited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Billed receivable </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,128</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,554</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,128</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Prepaid Expenses and Other Current Assets</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Prepaid expenses and other current assets consist of the following:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Audited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses - various</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,204</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,741</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,608</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Accounts Payable</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts payable consist of the following:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Audited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,404</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,865</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,769</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Accrued Expenses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;color:#000000;">Accrued expenses consist of the following:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Audited)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee wages and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,450</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,959</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Provision for Contract Losses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company assesses the profitability of our collaboration agreements to provide research services to our contracted business partners and identifies those contracts where current operating results or forecasts indicate probable future losses. If the anticipated contract cost exceeds the anticipated contract revenue, a provision for the entire estimated loss on the contract is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">recorded and then accreted into the statement of operations over the remaining term of the contract. The provision for contract losses is based on judgment and estimates, and costs and when such loss is deemed probable to occur and is reasonable to estimate.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Costs</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. R&amp;D costs are related to the Company&#8217;s internally funded pharmaceutical programs and other governmental and commercial projects.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs during the three and six months ended June&#160;30, 2018 and 2017 were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br>June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outside contracted services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481,335</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,351</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">950,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">504,239</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contracted services - related party</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">733,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Personnel related costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,558</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,975</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,548</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,412</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facilities, overhead and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,643</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">942,048</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,911,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">739,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;) was enacted on December 22, 2017 and is effective January 1, 2018. The new legislation includes, among other things a reduction of the U.S. corporate income tax rate from 35% to 21%, and a change to alternative minimum taxes.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of June 30, 2018, the Company did not record any provisional estimate related to changes to alternative minimum taxes. The staff of the SEC recognized the complexity of determining the impact of the TCJA, and on December&#160;22, 2017 issued guidance in Staff Accounting Bulletin 118 (&#8220;SAB 118&#8221;). SAB 118 allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. The Company will continue to analyze the TCJA and related accounting guidance and interpretations in order to finalize any impact within the measurement period. We currently anticipate finalizing and recording any resulting adjustments by the end of 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For the three and six months ended June 30, 2018, the Company did not record any current income tax provisions. There were no unrecognized tax benefits as of June 30, 2018 and December 31, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Deferred tax assets as of June 30, 2018 and December 31, 2017 were approximately $6.0 million and $3.9 million, respectively. Due to the Company&#8217;s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of June 30, 2018 and December 31, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Net Loss (Income) Per Share</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Basic net loss (income) per share is computed by dividing net loss (income) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss (income) per share adjusts the weighted average number of common shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock and convertible debt, were exercised or converted into common stock, calculated by applying the treasury stock method.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For the three months ended June&#160;30, 2018 and 2017, the effect of the potential exercise of options to purchase 3,441,890 and 2,476,890 shares of common stock were excluded from the computation of diluted net loss (income) per share, respectively, as their effect would have been anti-dilutive.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For the six months ended June&#160;30, 2018 and 2017, the effect of the potential exercise of options to purchase 3,441,890 and 2,366,890 shares of common stock were excluded from the computation of diluted net loss (income) per share, respectively, as their effect would have been anti-dilutive.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Recent Accounting Pronouncements Not Adopted as of June&#160;30, 2018</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019 and early application is permitted. The Company does not expect the standard to have a material impact on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company is currently evaluating the impact, if any, of this newly issued guidance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The amendments will be effective for the Company beginning in the first quarter of 2019. The Company is still evaluating the impact, if any, of this guidance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from the Tax Cuts and Jobs Act that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company is currently evaluating the impact, if any, of this newly issued guidance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The Company adopted this ASU effective January 1, 2018. The impact of adopting of this ASU on our consolidated financial statements was not material.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope and Modification Accounting. An entity may change the terms or conditions of a share-based payment award for many different reasons, and the nature and effect of the change can vary significantly. Modification is currently defined as &#8220;a change in any of the terms or conditions of a share-based payment award.&#8221; The amendments in this ASU provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in accordance with Topic 718. The Company adopted this ASU effective January 1, 2018. The impact of adopting of this ASU on our consolidated financial statements was not material.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 1, 2018, we adopted Accounting Standards Codification, or ASC, Topic 606, &#8220;Revenue from Contracts with Customers&#8221;, and all related amendments, using the full retrospective transition method. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Topic 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most prior revenue recognition guidance. This new standard requires an entity to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">recognize revenue for the transfer of promised goods or services to a customer in an amount that reflects the consideration that the entity expects to receive and consistent with the delivery of the performance obligation described in the underlying contract with the customer.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have determined that the impact of adopting this new standard is not material to our revenue recognition model, and therefore, no adjustment was made to our previously reported consolidated financial statements. As a result of the adoption of Topic 606, the Company&#8217;s accounting policy for revenue recognition is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third party collaborations and government grants. The Company may generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.  We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the input methods, revenue will be recognized on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company adopted the following practical expedients and exemptions: We generally expense sales commissions when incurred because the amortization period would be one year or less. We do not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In November 2016, the FASB issued ASU 2016-18, &#8220;Statement of Cash Flows (Topic 230): Restricted Cash,&#8221; which modifies the presentation of the statement of cash flows and requires reconciliation of the overall change in the total of cash, cash equivalents, restricted cash and restricted cash equivalents. As a result, the statement of cash flows will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents. The ASU is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company early adopted this ASU effective July 1, 2017. The adoption of this ASU impacted the Company&#8217;s presentation of its statement of cash flows, but did not have a material impact on the Company&#8217;s consolidated balance sheet or consolidated statement of operations. Accordingly, the Company has retrospectively adjusted the presentation of its consolidated statement of cash flows for all periods presented.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,&#8221; which made eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The ASU further clarified how the predominance principle should be applied to cash receipts and payments relating to more than one class of cash flows. The Company adopted this ASU effective January 1, 2018. In accordance with this ASU, the Company retrospectively adjusted the presentation of its consolidated statement of cash flows for all periods presented by reclassifying the cash outflows of premium on held-to-maturity securities from operating cash flows to investing cash flows.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes, by financial statement line item, the adjusted presentation upon the adoption of ASU 2016-18 and ASU 2016-15, in the Company&#8217;s condensed consolidated statement of cash flows as of June 30, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Filed <br>June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted<br> June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of premium on held-to-maturity securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511,343</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">701,326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,163,344</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase of held-to-maturity securities, including premiums</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,119,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(462,018</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,581,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,703</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,506,297</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(459,315</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,046,982</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net decrease in cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,277,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,274,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,364,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,254,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,611,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,367,562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,979,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s4c6052b0c31d429a9a2edeffc623d167"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 2: Cash, Cash Equivalents, and Investments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following tables show the Company&#8217;s cash, money market funds, and short-term and long-term investment securities by major security type as of June&#160;30, 2018 and December&#160;31, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018 (Unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Holding Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Holding Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357,603</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357,603</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money Market Funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,861,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,861,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,218,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,218,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-Term Investment Securities </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Bonds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,011,019</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,188</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,111,207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Investment Securities </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Bonds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,027,230</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,031,502</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,257,069</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,361,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017 (Audited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Holding Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Holding Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">838,110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">838,110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money Market Funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,948,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,948,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786,348</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786,348</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-Term Investment Securities </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Bonds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,811,273</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(87,481</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,898,754</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Investment Securities </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Bonds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911,698</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">922,648</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,509,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98,431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,607,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Definition of the three-level fair value hierarchy:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Level 2 - Other inputs that are directly or indirectly observable in the markets</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Level 3 - Inputs that are generally unobservable </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The premium paid to purchase held-to-maturity investment securities was $26,014 and $361,469 for the three months ended June&#160;30, 2018 and 2017, respectively.  The premium paid to purchase held-to-maturity investment securities was $313,705 and $462,018 for the six months ended June&#160;30, 2018 and 2017, respectively. The premium paid to purchase held-to-maturity investment securities was $915,084 for the year ended December 31, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company&#8217;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment&#8217;s cost basis. As of June&#160;30, 2018, the Company does not consider any of its investments to be other-than-temporarily impaired.</font></div><div><a name="se9d9202fc8f74acd9f31a076501c193a"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 3:&#160;&#160;&#160;&#160;Research and Collaboration Agreement</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On June 30, 2017, the Company entered into a strategic Research Services Agreement (the &#8220;RSA&#8221;) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (&#8220;BDI Pharma&#8221;), and a Service Framework Agreement (the &#8220;SFA&#8221;, and together with the RSA,  the &#8220;R&amp;D Agreements&#8221;), with VLP The Vaccines Company, S.L.U. (&#8220;VLPbio&#8221;), both of which companies are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (&#8220;BDI Holdings&#8221; and together with BDI Pharma and VLPbio, &#8220;BDI&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The R&amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic&#8217;s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team&#8217;s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic&#8217;s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All the data and any products developed from the funded research projects will be owned by Dyadic.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Upon closing of the BDI transaction, the Company paid EUR &#8364;1 million in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR &#8364;936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI&#8217;s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR &#8364;1 million for a 50% share and EUR &#8364;8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR &#8364;1.5 million of the net income from Dyadic&#8217;s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1 million in contract research services specified by Dyadic over the next two years.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has concluded that BDI is not a Variable Interest Entity (&#8220;VIE&#8221;), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest.  Additionally, Dyadic is not the primary beneficiary of BDI, because Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company&#8217;s consolidated financial results.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component.  As the fair value of BDI equity interest was considered immaterial, the initial payment of approximately USD $1.1 million (EUR &#8364;1.0 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment and the remaining USD $1 million commitment to be paid by Dyadic under the SFA will be expensed as the related research services are performed by BDI. As of June&#160;30, 2018, there were three collaboration projects in progress under the SFA for a total of approximately EUR &#8364;0.7 million.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At June&#160;30, 2018, the prepaid research and development collaboration payment of approximately USD $0.7 million is included in our consolidated balance sheet and has been allocated between the current and noncurrent positions based on whether it is expected to be used over the next 12-month period or beyond. For the three and six months ended June&#160;30, 2018, the research and development expenses related to the BDI R&amp;D Agreements were recorded in research and development - related party in our consolidated statements of operations in the amount of approximately $0.3 million and $0.7 million, respectively.</font></div><div><a name="sa044ee775c4e4fcaa5594d5f830aa405"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 4:&#160;&#160;&#160;&#160;Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Jupiter, Florida Headquarters</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,400. The lease expires on June 30, 2019, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">The Netherlands Office</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies approximately 900 square feet with annual rentals and common area maintenance charges of approximately $4,700. The lease expires on January 31, 2019, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employment Agreements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with Ping Rawson&#8217;s appointment as the Company&#8217;s Chief Accounting Officer, the Company&#8217;s Board of Directors approved compensation for Ms. Rawson as follows: Ms. Rawson will be entitled to an annual base salary of $210,000 and she is eligible for a discretionary annual performance bonus up to 100,000 stock options priced at the grant date. In addition, the Company granted Ms. Rawson a sign-on award of 50,000 stock options that will vest annually in equal installments over four years, and a conditional award of 50,000 stock options that will vest upon the Company&#8217;s becoming an SEC reporting entity. Such options will automatically vest, if for any reason the Board determines not to pursue SEC registration or in the event of a change of control. Ms. Rawson will be eligible for six months of severance benefits, if her services are no longer required due to a change of control or any reason other than for cause. Such severance benefits will increase to twelve months, one year from the effective date of the agreement or upon the Company becoming an SEC reporting entity, whichever occurs first.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Obligations</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of June&#160;30, 2018, there have been no material changes to the Company&#8217;s purchase obligations outside the ordinary course of business as compared to December&#160;31, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On March 1, 2017, Dyadic and the Company&#8217;s former outside legal counsel consisting of the law firms of Greenberg Traurig, LLP, and Greenberg Traurig, P.A. reached a confidential settlement regarding its professional liability litigation before the case went to the jury. On April 14, 2017, the Company received the full settlement payment in the amount of $4.5 million, net </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">of legal fees and expenses. In connection with a settlement agreement dated October 22, 2013 between Mark A. Emalfarb (&#8220;MAE&#8221;), and Dyadic, Dyadic agreed to pay MAE 5% of any net settlement proceeds up to $25 million, and 8% in excess of $25 million provided that the maximum amount payable under the agreement be limited to $6 million. In the second quarter of 2017, the Company made a payment of $141,777 to MAE to satisfy this prior contractual obligation. The net litigation settlement gain of $4,358,223 was reported in the Company&#8217;s consolidated statement of operations, in other income, in the first quarter of 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions are reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a case. Litigation is inherently unpredictable and costly. Any litigations, claims or investigations against the Company could have a material adverse effect on the Company&#8217;s consolidated financial position, cash flows or results of operations.</font></div><div><a name="s6cb8199762b44817a6e88be46a508269"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 5:&#160;&#160;&#160;&#160;Share-Based Compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Equity Plans</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) was adopted by the Company&#8217;s Board of Directors on April 28, 2011, and approved by the Company&#8217;s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company&#8217;s 2006 Stock Option Plan (the &#8220;2006 Plan&#8221;). Since the effective date of the 2011 Plan, all future equity awards have been made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company&#8217;s common stock have been reserved for issuance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of June&#160;30, 2018, the Company had 3,441,890 stock options outstanding and an additional 1,277,211 shares of common stock available for grant under the 2011 Plan. As of December 31, 2017, the Company had 2,712,390 stock options outstanding and an additional 2,006,711 shares of common stock available for grant under the 2011 Plan.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Options are granted to purchase common stock at prices that are equal to the fair value of the common shares on the date the option is granted.  Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company&#8217;s 2011 Plan is no more than ten years except for options granted to the CEO, which is five years.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Risk-free interest rate</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Expected dividend yield</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Expected stock price volatility.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The expected stock price volatility was calculated based on the Company&#8217;s own volatility since the DuPont Transaction. During the Company&#8217;s annual review of its volatility assumption in 2018, the Company determined that it would be appropriate to use the Company&#8217;s historical volatilities since 2016, as the DuPont Transaction had significant changes in the Company&#8217;s business and capital structure. The change in assumption is effective January 1, 2018 and only has impact on new options granted in 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Expected life of option.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company determined to use the weighted-average vesting period and contractual term of the option as the best estimate of the expected life of a new option (except for the CEO which is 5 years).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Discount for lack of marketability.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The Company applies a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The assumptions used in the Black-Scholes option pricing model for stock options granted during the six months ended June&#160;30, 2018 are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:79%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-Free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.24% - 2.65%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life of option</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 - 6.25 years</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount for lack of marketability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes the stock option activity for the six months ended June&#160;30, 2018:</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,712,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">979,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,441,890</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,840</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,148,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Represents the following stock options granted:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Annual share-based compensation awards on January 2, 2018, including: (a) 492,000 stock options with an exercise price of $1.39 granted to executives and key personnel, vesting upon grant or one year anniversary, (b) 250,000 stock options with an exercise price of $1.39 granted to Board of Directors, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 87,500 stock options with an exercise price of $1.39 granted to employees, vesting annually in equal installments over four years. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">One-time awards on March 18, 2018, including: (a) 50,000 stock options with an exercise price of $1.44 granted to key personnel, vesting upon one year anniversary, (b) a sign-on award of 50,000 stock options and a conditional award of 50,000 stock options with an exercise price of $1.44 to the newly appointed Chief Accounting Officer. The sign-on options will vest annually in equal installments over four years, and the conditional award will vest once certain conditions are met.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Represents the cancellation of performance-based stock options granted to the Company&#8217;s former Chief Financial Officer, who separated from the Company on March 22, 2018. In addition, the Compensation Committee approved an extension of the exercise period of his vested stock options to June 30, 2019. The incremental cost of such modification, which approximated $39,000, was recognized immediately. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Expenses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We recognize all share-based payments to employees and our board of directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company&#8217;s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Total non-cash stock option compensation expense was allocated among the following expense categories:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended<br>June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,529</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,322</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,883</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,396</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,871</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,021</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479,046</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><a name="s9e9c041b28de4b4d9ab24363f00d48e5"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 6:&#160;&#160;&#160;&#160;Shareholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share Repurchases and Buybacks</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:none;">Privately Negotiated Share Buyback Transactions</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 11, 2017, the Company entered into a Securities Purchase Agreement with Pinnacle Family Office Investments L.P. (&#8220;Pinnacle&#8221;) to repurchase an aggregate of 2,363,590 shares of its common stock at $1.54 per share for an aggregate purchase price of $3,639,929.  Upon repurchase, the shares were treated by Dyadic as treasury stock. The repurchase of shares from Pinnacle was in addition to Dyadic&#8217;s 2016 Stock Repurchase Program discussed below.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:none;">Stock Repurchase Programs</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 16, 2016, the Board of Directors authorized a one-year stock repurchase program, under which the Company was authorized to repurchase up to $15 million of its outstanding common stock (the &#8220;2016 Stock Repurchase Program&#8221;). The 2016 Stock Repurchase Program ended on February 15, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On August 16, 2017, the Board of Directors authorized a new one-year stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding common stock (the &#8220;2017 Stock Repurchase Program&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the 2017 Stock Repurchase Program, the Company is authorized to repurchase shares in open-market purchases in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The extent to which the Company repurchases its shares, and the timing of such repurchases, is dependent upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by the Company&#8217;s management. The repurchase program may be extended, suspended or discontinued at any time. The Company expects to finance the program from its existing cash resources. All repurchased shares are held in treasury.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes the Company&#8217;s stock repurchase activities:</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Number of Shares Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Average Price Paid per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Number of Treasury Shares Purchased as Part of Publicly Announced Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Privately Negotiated Transactions:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 12, 2016 - Abengoa repurchased and retired shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,136,752</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,884,615</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,363,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,639,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,363,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016 Stock Repurchase Program </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January through December 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,548,473</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,401,906</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,548,473</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,598,094</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">867,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,384,021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">867,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,214,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">662,356</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,551,717</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017 Stock Repurchase Program:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September through December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">537,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,462,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,231,339</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,231,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,087,519</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total open market and privately negotiated purchases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,012,929</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,885,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,876,177</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The 2016 Stock Repurchase Program ended on February 15, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of June&#160;30, 2018, there were 10,876,177 shares of common stock held in treasury, at a cost of approximately $17.0&#160;million, representing the purchase price on the date the shares were surrendered to the Company. As of December&#160;31, 2017, there were 10,609,177 shares held in treasury, at a cost of approximately $16.6 million.</font></div><div><a name="se0c59f3f3dbf462cba4f2dfb54b85539"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 7:&#160;&#160;&#160;&#160;Subsequent Events  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has reviewed subsequent events through August&#160;9, 2018, the date these unaudited consolidated financial statements were available to be issued. Except as discussed in these quarterly financial statements and below, management is not aware of any material events that have occurred after the balance sheet date that would require adjustment to, or disclosure in the unaudited consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On August 6, 2018, the Company&#8217;s Board of Directors authorized an extension of the Company&#8217;s existing stock repurchase program through August 15, 2019. Under the existing stock repurchase program, Dyadic may repurchase up to $5 million of the Company&#8217;s common stock in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The extent to which Dyadic repurchases its stock, and the timing of such repurchases, will depend upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by Dyadic&#8217;s management. The repurchase program may be extended, suspended or discontinued at any time. Since August 2017, the Company has repurchased approximately $0.9 million of its common stock under this program, leaving it with additional authorization of up to approximately $4.1 million under the program as a result of this extension. The Company expects to finance the program from existing cash resources.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><a name="sf1e5b87613ec45e99ded88a0ea912653"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><a name="s7ad01a841aec4c3ca1346f731bff8219"></a></div><div style="line-height:120%;padding-bottom:16px;"><img src="auditreport2018001.jpg" alt="auditreport2018001.jpg" style="height:883px;width:682px;"></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><a name="s44c57dcb0e814e2a9511cc49c840e047"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Escrowed funds from sale of assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,364,859</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investment securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,898,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,050,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">489,841</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493,154</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of prepaid research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,015,194</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,615,774</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,627,924</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investment securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">922,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,066,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current portion of prepaid research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,744,159</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,700,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,261</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279,057</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,959</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for contract losses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred research and development obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">768,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,010,237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitment and contingencies (See Note 5)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $.0001 par value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized shares - 5,000,000; none issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $.001 par value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized shares - 100,000,000; issued shares - 38,936,988 and 38,930,738, outstanding shares - 28,327,811 and 32,382,265, as of December 31, 2017 and 2016, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,913,557</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,257,472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Treasury stock, shares held at cost - 10,609,177 and 6,548,473 shares, as of December 31, 2017 and 2016, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,625,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,401,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,351,357</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,204,314</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,975,264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,690,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,744,159</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,700,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these audited consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><a name="s75cd758f78214a9ea539f53972fd0cae"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">758,420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">592,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Costs and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs of research and development revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680,197</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">516,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for contract losses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,765,474</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">885,602</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development - related party</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,030,354</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,562,115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency exchange (gain) loss, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(249,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,338</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,885,302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,548,133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,126,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,955,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other income:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement of litigation, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,358,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">566,146</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">484,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,924,369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,584,581</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,202,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,370,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Benefit) provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,135,819</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,608,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted-average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,917,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,538,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these audited consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><a name="s6286a68b59ea44618047f31f2dcac0b5"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="34"></td></tr><tr><td style="width:15%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Treasury Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional paid-in capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Stock</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">subscriptions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Stock to be issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;Total </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,298,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">92,157,374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(40,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">350,553</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,713,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">73,794,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,774</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">624,711</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">624,808</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Vesting of restricted stocks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">219,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">349,959</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(350,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">123,812</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25,757</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(375</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25,505</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">264,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Sale of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">64,516</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">99,935</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repayment of stock subscriptions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at Repurchases of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,136,752</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,136</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6,548,473</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10,401,906</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,882,479</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(13,286,521</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,608,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,608,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,930,738</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,931</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6,548,473</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10,401,906</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">93,257,472</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(25,204,314</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">57,690,183</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">643,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">643,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repurchases of common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,060,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6,223,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6,223,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cumulative effect of change in accounting principle</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,224</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,224</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,135,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,135,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,936,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,937</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10,609,177</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(16,625,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">93,913,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(27,351,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49,975,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these audited consolidated financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><a name="sab22c9474c964d37b467687e2872ef80"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,135,819</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,608,739</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643,430</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624,808</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Amortization of premium on held-to-maturity securities, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(560,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Provision for contract losses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216,324</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Foreign currency exchange gain, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(249,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Interest receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(493,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333,020</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(513,466</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Prepaid research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,167,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,726</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">254,268</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,434</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(339,740</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(242,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,722,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Deferred research and development obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(122,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Income taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,606,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,031,713</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Purchases of held-to-maturity investment securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,548,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54,095,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Proceeds from maturities of investment securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,651,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,539,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,556,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Repurchases of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,223,967</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,286,521</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Proceeds from exercise of options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Proceeds from issuance of stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Proceeds from repayment of stock subscriptions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Proceeds from exercise of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,222,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,120,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of exchange rate changes on cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,920</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net decrease in cash, cash equivalents and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,467,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,708,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,254,216</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,962,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, cash equivalents and restricted cash at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,254,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">909</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for (received from) income taxes (refund)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(163,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-cash items</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vesting of restricted stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock for warrants previously issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these audited consolidated financial statements </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><a name="s810dd1cd3f7a4bc3955881ebedd12de0"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to the Consolidated Financial Statements</font></div><div><a name="s397d3940007246f0b7f79e53ac033560"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 1:&#160;&#160;&#160;&#160;Organization and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States and the Netherlands. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Myceliophthora thermophila</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 31, 2015, the Company sold its industrial technology business to DuPont&#8217;s (NYSE: DD) industrial biosciences business for $75.0 million (the &#8220;DuPont Transaction&#8221;). The DuPont Transaction included $8.0 million of the purchase price held in escrow for 18 months to ensure Dyadic&#8217;s obligations with respect to certain indemnity claims and working capital adjustments. The escrow amount of approximately $7.4 million was net of contractual working capital adjustments agreed to by the parties and interest earned to the release date, as previously reported. The Company received the escrowed funds on July 6, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">When held in the escrow account, the Company&#8217;s escrowed funds from sale of assets were considered restricted cash, which includes cash and cash equivalents that are legally or contractually restricted as to withdrawal or usage. Effective July 1, 2017, we early adopted ASU 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash, which requires that restricted cash be included with cash and cash equivalents when reconciling the beginning and end of period total amounts shown on the statement of cash flows. As required by this ASU, we applied this change retrospectively to our consolidated statement of cash flows for the year ended December 31, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">DuPont granted Dyadic co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, with the exclusive ability to enter into sub-license agreements. DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, as well as other therapeutic proteins.  In early 2018, we began to conduct certain funded research activities to further understand if, or how the C1 technology can be applied for use in developing and manufacturing metabolites.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.  All significant intra-entity transactions and balances have been eliminated in consolidation. The Company has reclassified certain 2016 amounts previously reported to conform to the 2017 consolidated financial statement presentation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions, and has not experienced any losses in such accounts.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s revenues and accounts receivable were generated from two collaboration partners and one foreign government grant in 2017 and 2016. The loss of business from one or a combination of the Company&#8217;s significant customers could adversely affect its operations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company conducts operations in The Netherlands through its foreign subsidiary, and generates a portion of its revenues from customers that are located outside of the United States. There was one European customer that accounted for approximately 22.7% of total revenue and approximately 14.9% of total accounts receivable for 2017. There were two European customers that accounted for approximately 99.5% of total revenue and approximately 78.7% of total accounts receivable for 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment Securities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Investment securities are classified as held-to-maturity, available-for-sale, or trading. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#8217;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, the statement of cash flows reflects an investing outflow for the face value of the debt, with the premium reflected as an operating outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s investments in money market funds have been classified and accounted for as available-for-sale securities, and presented as cash equivalents on the consolidated balance sheet. As of December&#160;31, 2017 and 2016, all our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of December&#160;31, 2017 and 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company classifies its investment securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Investment securities with maturities of 12 months or less are classified as short-term, and investment securities with maturities greater than 12 months are classified as long-term, from the applicable reporting date.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts receivable consist billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract costs and contract revenue (or amounts reimbursable under contracts) over billings to date.  Such amounts become billable according to the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing accounts receivable. Substantially all of our accounts receivable were current and unbilled amounts that will be billed and collected over the next twelve months. There was no allowance for doubtful accounts as of December 31, 2017 and 2016.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarized the billed and unbilled receivables recorded in accounts receivable for the years ended December 31, 2017 and 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Billed receivable </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,554</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">463,213</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588,213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Prepaid Expenses and Other Current Assets</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Prepaid expenses and other current assets consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses - general</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,313</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid value added taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,608</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,289</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Accounts Payable</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts payable consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,865</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,930</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Accrued Expenses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;color:#000000;">Accrued expenses consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee wages and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,329</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,959</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Revenue is recognized when (1) persuasive evidence of an arrangement exists; (2) services have been rendered or product has been delivered; (3) price to the customer is fixed and determinable; and (4) collection of the underlying receivable is reasonably assured.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since the sale of our industrial technology business to DuPont on December 31, 2015, the Company has devoted substantial resources to the research and development of its C1 technology for use in the pharmaceutical industry and enhancement of our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">intellectual property portfolio. We have no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third party collaborations and government grants. The Company may generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company recognizes revenue from research funding under collaboration agreements when earned on a &#8220;proportional performance&#8221; basis as research hours are incurred. The Company typically&#160;performs services as specified in each respective agreement on a best efforts basis, and revenue is recognized over the respective contract periods as the services are performed. The Company initially defers revenue for any amounts billed and payments received in advance of related services performed. The Company then recognizes revenue pursuant to the related pattern of performance, based on total labor hours incurred relative to total labor hours estimated under the contract. Contract accounting requires judgment relative to assessing risks, estimating the revenue and costs and making assumptions for the length of time to complete the contract. Any changes to these assumptions and estimates could result in further adjustments in the future. Changes in estimated revenues, cost of revenues and the related effect on operating income are recognized in the current period using a cumulative catch-up adjustment to reflect the cumulative effect of the changes on current and prior periods based on a contact&#8217;s proportional performance completed.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Provision for Contract Losses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company assesses the profitability of our collaboration agreements to provide research services to our contracted business partners and identifies those contracts where current operating results or forecasts indicate probable future losses. If the anticipated contract cost exceeds the anticipated contract revenue, a provision for the entire estimated loss on the contract is recorded and then accreted into the statement of operations over the remaining term of the contract. The provision for contract losses is based on judgment and estimates, including revenues and costs and when such loss is deemed probable to occur and is reasonable to estimate.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with two collaboration agreements, provisions for loss of $220,715 and $436,916 were established for the years ended December 31, 2017 and 2016, respectively. As of December 31, 2017 and 2016, the remaining contract losses on the balance sheet were $0 and $216,324, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Costs</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. The R&amp;D costs are related to the Company&#8217;s internally funded R&amp;D pharmaceutical programs and other governmental and commercial projects.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expenses consist of personnel-related costs, facilities, research-related overhead, services from contract research organizations, and other external costs. Research and development costs incurred by type of cost during the years ended December 31, 2017 and 2016 were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outside contracted services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,299,072</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outside contracted services - related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Personnel related costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facilities, overhead and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,568</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,203,095</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">885,602</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Transaction Gain or Loss</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s foreign subsidiary uses the U.S. dollar as its functional currency, and it initially measures foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and nonmonetary assets and liabilities are converted at historical rates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation Settlement</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On March 1, 2017, the Company and Greenberg Traurig, LLP, and Greenberg Traurig, P.A. (collectively, &#8220;Greenberg Traurig&#8221;) reached a settlement before the case went to the jury. On April 14, 2017, the Company received the full settlement </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">payment in the amount of $4,500,000, net of legal fees and expenses. In connection with a settlement agreement dated October 22, 2013 between Mark A. Emalfarb (&#8220;MAE&#8221;), and Dyadic, Dyadic agreed to pay MAE 5% of any net settlement proceeds up to $25 million, and 8% in excess of $25 million provided that the maximum amount payable under the agreement be limited to $6 million. In the second quarter of 2017, the Company made a payment of $141,777 to MAE to satisfy this prior contractual obligation. The net litigation settlement gain of $4,358,223 was reported in the Company&#8217;s consolidated statement of operations, in other income, in the first quarter of 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On April 19, 2016, the Company received $2.1 million, in connection with the Company&#8217;s settlement with Bilzin Sumberg Baena Price &amp; Axelrod LLP, in related professional liability litigation. The Company recorded such amount in the Company&#8217;s consolidated statement of operations, net of legal fees and expenses, for the year ended December 31, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:72px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-72px;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Assets and liabilities on the audited consolidated balance sheets are measured at carrying values, which approximate fair values due to the short term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third party broker service for disclosure purposes.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, &#8220;Income Taxes&#8221;.  Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#8217;s financial statements or tax returns.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date.  A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In determining taxable income for the Company&#8217;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements.  ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return.  For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#8220;unrecognized benefits.&#8221; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#8217;s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provision of ASC 740.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company classifies accrued interest and penalties related to its tax positions as a component of income tax expense. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for the years before 2014.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#8217; equity but are excluded from net income (loss) under U.S. GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We recognize all share-based payments to employees and our board of directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock and convertible debt, were exercised or converted into common stock, calculated by applying the treasury stock method. Potentially dilutive securities whose effect would have been anti-dilutive are excluded from the calculation of diluted loss per share.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For the year ended December&#160;31, 2017, 2,712,390 shares of stock options were excluded from the computation of diluted loss per share, as the effect would have been anti-dilutive.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For the year ended December&#160;31, 2016, a total of 3,258,666 shares of potentially dilutive securities were excluded from the computation of diluted loss per share, which included 2,158,083 stock options and 1,147,276 warrants for the period prior to actual exercise as of December&#160;31, 2016, as the effect would have been anti-dilutive.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016-01 will be effective for the Company beginning in the first quarter of 2018. The Company will adopt this new accounting guidance as required, and it is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company is currently evaluating the impact, if any, of the adoption of this newly issued guidance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU 2016-08, Revenue from Contracts with Customers (Topic 606) - Principal versus Agent Considerations (Reporting Revenue Gross versus Net); ASU 2016-10, Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing; and ASU 2016-12, Revenue from Contracts with Customer (Topic 606) - Narrow-Scope Improvement and Practical Expedients. The </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Company must adopt ASU 2016-08, ASU 2016-10, and ASU 2016-12 together with ASU 2014-09 (collectively, the &#8220;new revenue standards.&#8221;)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company will adopt the new revenue standards on January 1, 2018, using the full retrospective transition method. The Company does not expect the adoption of the new revenue standards to have a material impact on its consolidated financial position or result of operations. The Company&#8217;s first quarter 2018 report include with the new required disclosures.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019 and early application is permitted. The Company does not expect the standard to have a material impact on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The amendments will be effective for interim and annual reporting periods beginning after December 15, 2018 (effective January 1, 2019 for the Company). The Company is still evaluating the impact, if any, of the adoption of this guidance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,&#8221; which made eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The ASU further clarified how the predominance principle should be applied to cash receipts and payments relating to more than one class of cash flows. The ASU is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company will adopt this new accounting guidance on January 1, 2018, and the Company&#8217;s consolidated statements of cash flows will be revised retrospectively for each period presented.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope and Modification Accounting. An entity may change the terms or conditions of a share-based payment award for many different reasons, and the nature and effect of the change can vary significantly. Modification is currently defined as &#8220;a change in any of the terms or conditions of a share-based payment award.&#8221; The amendments in this ASU provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in accordance with Topic 718. The amendments will be effective for interim and annual reporting periods beginning after December 15, 2017. This pronouncement is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Recent Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. The guidance simplifies several aspects of the accounting for employee share-based payment transactions including allowing excess tax benefits or tax deficiencies to be recognized as income tax benefits or expenses in the Statements of Operations rather than in Additional Paid in Capital (APIC). Also, excess tax benefits no longer represent a financing cash inflow on the Statement of Cash Flows and instead will be included as an operating activity. Under this guidance, excess tax benefits and tax deficiencies will be excluded from the calculation of diluted earnings per share, whereas under current accounting guidance, these amounts must be estimated and included in the calculation. In addition, this simplifies the accounting for forfeitures and changes the statutory tax withholding requirements for share-based payments.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company adopted ASU 2016-09 in the first quarter of 2017 that began January 1, 2017. We have elected to account for forfeitures as they occur, rather than estimate expected forfeitures over the course of a vesting period. Because of the adoption of ASU 2016-09, we recognized the net cumulative effect of this change as an $11,224 increase to additional paid-in-capital, and an $11,224 increase to accumulative deficit as of January 1, 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In November 2016, the FASB issued ASU 2016-18, &#8220;Statement of Cash Flows (Topic 230): Restricted Cash,&#8221; which modifies the presentation of the statement of cash flows and requires reconciliation to the overall change in the total of cash, cash equivalents, restricted cash and restricted cash equivalents. As a result, the statement of cash flows will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents. The ASU is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2017. The ASU is to be applied retrospectively for each period presented.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company early adopted ASU 2016-18 in the third quarter of 2017. The adoption of this ASU impacted the Company&#8217;s presentation of its statement of cash flows, however, it did not have a material impact on the Company&#8217;s consolidated balance sheet or consolidated statement of operations. Accordingly, the Company has retrospectively adjusted the presentation of its consolidated statement of cash flows for all periods presented. The following table summarizes, by financial statement line item, the adjusted presentation in the Company&#8217;s consolidated statement of cash flows as of December 31, 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Filed December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,677</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,035,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,677</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,031,713</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (decrease) increase in cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,711,781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,708,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,601,138</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,361,182</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,962,320</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,364,859</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,254,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="se65369ac8e374b8dad341c1563b6ce6e"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 2:&#160;&#160;&#160;&#160;Cash, Cash Equivalent, and Investments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company&#8217;s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of December&#160;31, 2017, and 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Holding Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Holding Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">838,110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">838,110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money Market Funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,948,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,948,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786,348</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786,348</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-Term Investment Securities </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Bonds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,811,273</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(87,481</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,898,754</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Investment Securities </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Bonds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911,698</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">922,648</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,509,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98,431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,607,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Holding Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Holding Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,501,160</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,501,160</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money Market Funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,388,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,388,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889,357</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889,357</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-Term Investment Securities </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Bonds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,983,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">708</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(67,426</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,050,052</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Investment Securities </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Bonds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,058,240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,403</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,066,643</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,930,931</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">708</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75,829</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,006,052</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">See Note 1 - Significant accounting policy for the definition of the three-level fair value hierarchy</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Short-term investment securities will mature within 12 months or less, from the applicable reporting date </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Long-term investment securities will mature between 12 and 18 months, from the applicable reporting date</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The premiums paid to purchase held-to-maturity investment securities were $915,084 and $1,553,375 for the years ended December&#160;31, 2017 and 2016, respectively</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company&#8217;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment&#8217;s cost basis. As of December&#160;31, 2017, the Company does not consider any of its investments to be other-than-temporarily impaired.</font></div><div><a name="s8a0caaef268647bcbd58515d142e1486"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 3:&#160;&#160;&#160;&#160;Research and Collaboration Agreement</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On June 30, 2017, the Company entered into a strategic Research Services Agreement (the &#8220;RSA&#8221;) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (&#8220;BDI Pharma&#8221;), and a Service Framework Agreement (the &#8220;SFA&#8221;, and together with the RSA,  the &#8220;R&amp;D Agreements&#8221;), with VLP The Vaccines Company, S.L.U. (&#8220;VLPbio&#8221;), both companies are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (&#8220;BDI Holdings&#8221; and together with BDI Pharma and VLPbio, &#8220;BDI&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The R&amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic&#8217;s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team&#8217;s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic&#8217;s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All the data and any products developed from the funded research projects will be owned by Dyadic.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Upon closing of the BDI transaction, the Company paid EUR &#8364;1 million in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR &#8364;936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI&#8217;s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR &#8364;1 million for a 50% share and EUR &#8364;8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR &#8364;1.5 million of the net income from Dyadic&#8217;s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1 million in contract research services specified by Dyadic over two years since the closing of the BDI transaction.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has concluded that BDI is not a Variable Interest Entity (&#8220;VIE&#8221;), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest.  Additionally, Dyadic is not the primary beneficiary of BDI. Specifically, Dyadic does not have the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company&#8217;s consolidated financial results.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component.  As the fair value of BDI equity interest was considered immaterial, the initial payment of approximately USD $1.1 million (EUR &#8364;1.0 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment and the remaining USD $1 million commitment to be paid by Dyadic under the SFA will be expensed as the related research services are performed by BDI. As of December&#160;31, 2017, there were three collaboration projects in progress under the SFA for a total of approximately EUR &#8364;0.6 million.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At December&#160;31, 2017, the prepaid research and development collaboration payment of approximately USD $1.2 million is included in our consolidated balance sheet and has been allocated between the current and noncurrent based on whether it is expected to be used over the next 12-month period or beyond. For the year ended December&#160;31, 2017, research and development expenses related to BDI were recorded as research and development - related party in our consolidated statements of operations in the amount of approximately USD $0.4 million.</font></div><div><a name="s622af20794b645b188ac7a8e789654cf"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 4:&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The significant components of loss before income taxes are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,096,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,920,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105,574</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,450,310</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total loss before provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,202,513</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,370,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The significant components of our (benefit) provision for income tax for the years ended December 31, 2017 and 2016 are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current and deferred tax (benefit) expense</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,694</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,073</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For the year ended December 31, 2017, the Company&#8217;s current income tax benefit of $66,694 consisted of differences between our estimated tax provisions and the actual amounts incurred of $167,784 offset by AMT taxes of $101,090.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The income tax provision differs from the expense amount that would result from applying the federal statutory rates to income before income taxes due to deferred income tax resulting from permanent differences, state taxes and a change in the deferred tax valuation allowance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;) was enacted on December 22, 2017 and is effective January 1, 2018. The new legislation contains several key provisions, including a reduction of the U.S. corporate income tax rate from 35% to 21%, and a change to alternative minimum taxes. We are required to remeasure all our U.S. deferred tax assets as of December 22, 2017 and record the impact of such remeasurement in our 2017 financial statements. For the year ended December 31, 2017, we recorded a decrease to deferred tax assets of $0.4 million and increase in valuation allowance of the same amount, all of which reflects the estimated impact associated with the remeasurement of our U.S. deferred tax asset at the lower U.S. federal corporate income tax rate.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December 31, 2017, the Company did not record any provisional estimate related to changes to alternative minimum taxes.&#160; The staff of the SEC recognized the complexity of determining the impact of the TCJA, and on December&#160;22, 2017 issued </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">guidance in Staff Accounting Bulletin 118 (&#8220;SAB 118&#8221;). SAB 118 has provided guidance which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. The Company will continue to analyze the TCJA and related accounting guidance and interpretations in order to finalize any impacts within the measurement period. We currently anticipate finalizing and recording any resulting adjustments by the end of fiscal year 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The reconciliation between the statutory tax rates and the Company&#8217;s actual effective tax rate is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax at U.S. statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.45</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.57</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-deductible items</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48.87</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">True-up adjustment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.66</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10.78</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in tax rates</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMT adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The significant components of the Company&#8217;s net deferred income tax assets are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain/Loss on disposals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Escrowed funds in connection with the sale of assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,568,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOL carryforward</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,088,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,445,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMT credit carryforward</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,005,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,063,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General business credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,656,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,656,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax asset, net of deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,891,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,606,200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,891,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,606,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.  Based on management&#8217;s evaluation, the net deferred tax asset was offset by a full valuation allowance as of December 31, 2017 and 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company had net operating loss (&#8220;NOL&#8221;) carryforwards available in 2017 that will begin to expire in 2035.  As of December 31, 2017, and 2016, the Company had NOLs in the amount of approximately $2.9 million and $8.2 million, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December 31, 2017 and 2016, no liability for unrecognized tax benefits was required to be reported.  The Company does not expect any significant changes in its unrecognized tax benefits in the next year.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On March 30, 2017, the Company received a letter from the United States Internal Revenue Service (the &#8220;IRS&#8221;) informing the Company that its 2015 federal tax return was selected for examination. During the period of May to September 2017, the Company had several meetings with the IRS agent and provided the IRS with all requested information.  On October 17, 2017, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the Company received the final closing letter from the IRS, informing the Company that its review of our tax filing for 2015 was complete, and no changes were required. </font></div><div><a name="se2f94e57685240edba08d8a477bbd1bb"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 5:&#160;&#160;&#160;&#160;Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Jupiter, Florida Headquarters</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,400. The lease expires on June 30, 2018, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">The Netherlands Office</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company maintains a small satellite office in Wageningen, The Netherlands. The Company occupies approximately 900 square feet with annual rentals and common area maintenance charges of approximately $4,700. The lease expires on January 31, 2019.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Obligations</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table provides a schedule of commitments related to agreements to purchase certain services in the ordinary course of business, as of December&#160;31, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,825,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207,031</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,032,840</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The purchase obligations in the table above primarily related to our contracts with the Company&#8217;s contract research organizations to provide certain research services.  The contracts set forth the Company&#8217;s minimum purchase requirements that are subject to adjustments based on certain performance conditions.  Most contracts expire in 2018 except one which expires in March 2019.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Professional Liability Lawsuit</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On March 26, 2009, the Company filed a complaint in the Circuit Court of the 15</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Judicial Circuit in and for Palm Beach County, Florida against Ernst &amp; Young LLP and Ernst &amp; Young-Hong Kong, L.P., alleging professional negligence/malpractice, breach of fiduciary duty and constructive fraud in connection with the accounting, advisory, auditing, consulting, financial and transactional services they provided to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On April 14, 2009, the Company amended the complaint (the &#8220;Amended Complaint&#8221;) by naming as additional defendants the Company&#8217;s former outside legal counsel consisting of the law firms of Greenberg Traurig, LLP, Greenberg Traurig, P.A. (collectively, &#8220;Greenberg Traurig&#8221;), Jenkens &amp; Gilchrist, P.C. (&#8220;Jenkens &amp; Gilchrist&#8221;) and Bilzin Sumberg Baena Price &amp; Axelrod LLP (&#8220;Bilzin Sumberg&#8221;) as well as attorney Robert I. Schwimmer who previously represented the Company while an attorney at Jenkens &amp; Gilchrist and later at Greenberg Traurig. Jenkens &amp; Gilchrist went out of business in 2007 and is in the process of winding up its business and affairs. The Company also named as defendants the law firm of Moscowitz &amp; Moscowitz, P.A. and its attorneys Norman A. Moscowitz and Jane W. Moscowitz (collectively, the &#8220;Moscowitz Defendants&#8221;) who conducted the investigation and authored the investigative report requested by the Company&#8217;s Audit Committee following the discovery of alleged improprieties at the Company&#8217;s Asian subsidiaries. The claims against the Company&#8217;s former outside legal counsel are for breach of fiduciary duty and professional negligence. In addition to these claims, the Amended Complaint contains a claim of civil conspiracy against Ernst &amp; Young LLP, Greenberg Traurig and Mr. Schwimmer. The claims against Ernst &amp; Young LLP and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Ernst &amp; Young-Hong Kong, L.P. were subsequently stayed in the Circuit Court action and submitted to binding arbitration. A final hearing before the arbitration tribunal was completed on May 27, 2011.&#160;On February 29, 2012, the arbitration tribunal issued a Final Award which found no auditor negligence, denied the Company any recovery against Ernst &amp; Young LLP and Ernst &amp; Young Hong Kong L.P., and further provided that each party shall bear its own attorneys&#8217; fees and costs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 11, 2011, defendants Jenkens &amp; Gilchrist, Bilzin Sumberg and the Moscowitz Defendants filed a counterclaim in the Circuit Court against the Company and a Third Party Complaint against its President and Chief Executive Officer, Mark Emalfarb, individually, for abuse of process.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The counter claim and Third Party Complaint filed by Jenkens &amp; Gilchrist and Bilzin Sumberg also included claims for common law indemnity against the Company and Mr. Emalfarb.&#160;In addition, Jenkens &amp; Gilchrist made a claim against the Company for breach of the implied covenant of good faith and fair dealing.&#160;On July 18, 2011, the Moscowitz Defendants filed a motion for summary judgment which the Circuit Court denied in its entirety.&#160;On September 9, 2011, Jenkens &amp; Gilchrist and Bilzin Sumberg amended their counterclaim and Third Party Complaint which dropped their claims for abuse of process but retained their claims for common law indemnity against the Company and Mr. Emalfarb.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Bilzin Sumberg also added claims against the Company and Mr. Emalfarb for breach of its retainer agreements and for declaratory relief.&#160;Also on September 9, 2011, the Moscowitz Defendants dropped their claims for abuse of process against the Company and Mr. Emalfarb.&#160;On December 8, 2011, the Circuit Court dismissed without prejudice all counterclaims against the Company and all third party claims against Mr. Emalfarb.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 18, 2012, the Company filed a Second Amended Complaint which expanded and amplified the Company&#8217;s prior allegations of negligent acts and omissions by the defendants in the Circuit Court proceedings.&#160;All of the defendants have filed and served their answers and affirmative defenses.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On August 8, 2012, the Company, Jenkens &amp; Gilchrist and Mr. Schwimmer entered into a Settlement Agreement and General Releases (the &#8220;J&amp;G Settlement Agreement&#8221;) whereby Jenkens &amp; Gilchrist paid the Company $525,000 for the mutual release and discharge of (1) all causes of action between the Company and Jenkens &amp; Gilchrist, and (2) causes of action between the Company and Mr. Schwimmer including, but not limited to, those in the professional liability lawsuit, but only those which occurred while Mr. Schwimmer served as an attorney at Jenkens &amp; Gilchrist and not while he served as an attorney at Greenberg Traurig or any other time. Such amount was included in other income in the consolidated statement of operations for the year ended December 31, 2012. Pursuant to the J&amp;G Settlement Agreement, the Company, Jenkens &amp; Gilchrist and Mr. Schwimmer have filed a Stipulation of Settlement with the Court to enforce the terms of the J&amp;G Settlement Agreement including, but not limited to, the dismissal of Counts I and II of the Second Amended Complaint against Jenkens &amp; Gilchrist and Mr. Schwimmer with prejudice.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 24, 2013, each of the remaining defendants served their amended affirmative defenses to the Second Amended Complaint. On February 11, 2013, the Company served its reply to such amended affirmative defenses.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company and the defendants in the Circuit Court proceedings are continuing to engage in written discovery, oral depositions and motion practice.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On November 26, 2013, the Court entered a Case Management Order.&#160;Pursuant to the Order, all pretrial motions and other litigation activities were to have been concluded by the end of 2014.&#160;The Court ordered mediation was held on November 10</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and 11</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th,</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;2014.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 31, 2015, the Company reached a settlement with one of the three remaining defendant law firms in its ongoing professional liability litigation. On August 12, 2015 the Company received full payment in the amount of $2,170,000, which is net of fees and expenses. The settlement amount was reported in the Company&#8217;s consolidated statement of operations, in other income, for the year ended December&#160;31, 2015.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 29, 2015, the Court removed the professional liability litigation from the Court&#8217;s eight week trial docket which commenced on October 26, 2015. Instead, the Court, in an effort to promote settlement, ordered the parties to non-binding arbitration with an initial hearing to occur before December 16, 2015. The parties were scheduled to appear before the Court on November 13, 2015 for hearings on various pre-trial motions. At that time, the Court was expected to address when the professional liability litigation will be set for trial in 2016. The parties also voluntarily agreed to again attend mediation on November 18, 2015.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The parties attended both mediation and non-binding arbitration. No resolution was reached. Pretrial motion practice is now substantially completed.&#160;On March 3, 2016, the Court issued an Order setting a six week jury trial commencing January 6, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On April 5, 2016, the Company reached a settlement with one of the two remaining defendant law firms, Bilzin Sumberg Baena Price &amp; Axelrod LLP, in its ongoing professional liability litigation.&#160;On April 19, 2016, the Company received full payment in the amount of $2,100,000, which is net of legal fees and expenses.&#160;The settlement amount was reported in the Company&#8217;s consolidated statement of operations, in other income, for the quarter ended June 30, 2016.&#160;The trial with the remaining defendant law firm Greenberg Traurig, LLP, Greenberg Traurig, P.A. (collectively, &#8220;Greenberg Traurig&#8221;) and the estate of Robert I Schwimmer remains set for January 6, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 8, 2016, the Court heard oral argument on Greenberg Traurig&#8217;s Renewed Motion for Summary Judgment as to its judgmental immunity affirmative defense.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 28, 2016, the Company stipulated to the release of the estate of Robert Schwimmer as a defendant. This was a procedural decision as Greenberg Traurig remains liable for the negligent conduct of deceased Greenberg Traurig lawyer, Robert Schwimmer.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On August 17, 2016, the Court denied Greenberg Traurig&#8217;s Renewed Motion for Summary Judgment as to its judgmental immunity affirmative defense.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 17, 2016, Greenberg Traurig filed a Motion to Continue the Trial. On October 18, 2016, Greenberg Traurig filed a motion to bifurcate the liability and damages determination by the jury into separate trials.&#160; On October 27, 2016, the Court heard oral argument on both motions.&#160; Both motions were denied.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Trial commenced against Greenberg Traurig in this continuing professional liability litigation on January 6, 2017 and continued for eight weeks thereafter. On March 1, 2017, Dyadic and Greenberg Traurig settled before the case went to the jury, and reached a confidential settlement. On April 14, 2017, the Company received the full settlement payment in the amount of $4,500,000, net of legal fees and expenses. Per the settlement agreement dated October 22, 2013 between Mark A. Emalfarb (&#8220;MAE&#8221;), and Dyadic, whereby Dyadic agreed to pay MAE 5% of any net company proceeds up to $25 million, and 8% of any net company proceeds in excess of $25 million; provided, that the maximum amount payable under the agreement be limited to $6 million.  In the second quarter of 2017, the Company made a payment of $141,777 to MAE to satisfy this prior contractual obligation.&#160;The net litigation settlement gain of $4,358,223 was reported in the Company&#8217;s consolidated statement of operations, in other income, in the first quarter of 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to the matters noted above, from time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions are reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. While the Company believes that it has valid defenses with respect to the legal matters pending against it, protracted litigation and/or an unfavorable resolution of one or more of such proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#8217;s consolidated financial position, cash flows or results of operations.</font></div><div><a name="s7fcfc81d58c74f47befefeabb33953af"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 6:&#160;&#160;&#160;&#160;Share-Based Compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Equity Plans</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) was adopted by the Company&#8217;s Board of Directors on April 28, 2011, and approved by the Company&#8217;s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company&#8217;s 2006 Stock Option Plan (the &#8220;2006 Plan&#8221;). Since the effective date of the 2011 Plan, all future equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company&#8217;s common stock have been initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December&#160;31, 2017, there were 2,712,390 stock options outstanding and 2,006,711 shares of common stock were available for grant under the Company&#8217;s Equity Compensation Plans.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December&#160;31, 2016, there were 2,158,083 stock options outstanding and 2,567,268 shares of common stock were available for grant under the Company&#8217;s Equity Compensation Plans.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Options are granted to purchase common stock at prices that are equal to the fair value of the common shares on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company&#8217;s 2011 Plan is no more than ten years except for options granted to the CEO, which is five years.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. The Company has elected to account for forfeitures as they occur, upon the adoption of ASU 2016-09 beginning on January 1, 2017 (See Note 1 Recently Adopted Accounting Pronouncement). Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Risk-free interest rate.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Expected dividend yield.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Expected stock price volatility.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The expected stock price volatility was historically calculated based on the Company&#8217;s own volatility. During the Company&#8217;s annual review of its volatility assumption in 2017, the Company determined that it would be appropriate to use historical volatilities of peer companies adjusted for term and leverage as the best estimate of the Company&#8217;s expected stock price volatility, given the significant changes in the Company&#8217;s business and capital structure after the DuPont Transaction. The change in assumption is effective January 1, 2017 and only has impact on new options granted in 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Expected life of option. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. During the Company&#8217;s annual review of its expected life of option assumption in 2017, the Company determined that it would be appropriate to use the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option (except for the CEO which remains 5 years), given the reduction in force and employee pool changes after the DuPont Transaction. The change in assumption is effective January 1, 2017, and only has an impact on new options granted in 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Discount for lack of marketability.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The Company applies a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The assumptions used in the Black-Scholes option pricing model for stock options granted for years ended December 31, 2017 and 2016 are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:67%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.87% - 2.15%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.18% - 2.24%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.24% - 71.43%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.01% - 77.50%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 - 6.25 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 - 10 Years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount for lack of marketability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.72%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes the stock option activities for years ended December 31, 2017 and 2016:</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,711,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,293,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.67</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(800,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,896,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,158,083</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">660,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,250</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,712,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.62</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,090</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,461,503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,090</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Represents stock options granted on January 3, 2017 in connection with routine annual share-based compensation awards, including (a) 339,667 stock options with an exercise price of $1.63 granted to executives and key personnel, vesting upon grant or one year anniversary, (b) 250,000 stock options with an exercise price of $1.63 granted to Board of Directors, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 20,890 stock options with an exercise price of $1.63 granted to employees, vesting annually in equal installments over four years, as well as 50,000 stock options granted to a board member during the third quarter of 2017 with an exercise price of $1.43, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In April 2017, the Compensation Committee and the Board of Directors approved the amendment to equity awards previously granted to a board member who resigned on June 1, 2017. The amendment provided for (1) acceleration of the vesting dates, and (2) extension of the exercise period. At the time of such modification, the incremental cost of this change was recognized immediately and the amount was immaterial.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The weighted average grant-date fair market value of stock options granted for the years ended December&#160;31, 2017 and 2016 was $0.82 and $1.24 respectively, based on the Black-Scholes option pricing model. The intrinsic value of options exercised for the years ended December&#160;31, 2017 and 2016 was $7,313 and $431,397, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December&#160;31, 2017, total unrecognized compensation cost related to non-vested stock options granted under the Company&#8217;s share option plan was approximately $211,012, which is expected to be recognized over a weighted average period of 2.63 years. The Company will adjust unrecognized compensation cost for actual forfeitures as they occur.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Restricted stock is granted subject to certain restrictions. Vesting conditions are determined at the time of grant under the plan. The fair market value of restricted stock is generally determined based on the closing market price of the stock on the grant date.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For the year ended December&#160;31, 2017, there were no restricted stock granted. For the year ended December 31, 2016, there were 100,300 shares granted to our board of directors with a weighted average grant-date fair value of $1.53 per share. As of December&#160;31, 2017, and 2016, there was no unrecognized compensation cost related to non-vested restricted stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Expenses</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company recognized non-cash share-based compensation expense for its share-based awards in its statement of operations, and these charges had no impact on the Company&#8217;s reported cash flows.  Total non-cash share-based compensation expense was included among the following expense categories:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132,751</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,598</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624,808</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes the Company&#8217;s non-cash share-based compensation expense by award type for the years ended December&#160;31, 2017, and 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense - stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense - restricted stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,420</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624,808</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sed1bf255bdff48b49a6a662c493146df"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 7:&#160;&#160;&#160;&#160;Shareholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issuances of Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The shares of common stock issued for the years ended December&#160;31, 2017 and 2016 are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Issue Price per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Issue Price per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted shares and compensation </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">316,550</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.58</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sale of common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of warrants </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,812</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769,166</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">During the year ended December&#160;31, 2016, 1,147,273 warrants with an exercise price of $1.48 per share were exercised, resulting in an aggregate issuance of 121,312 shares of our common stock. An additional 2,500 shares of common stock were issued in connection with warrants exercised in 2015. As of December&#160;31, 2017 and 2016, there were no warrants outstanding.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share Repurchases and Buybacks</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Privately Negotiated Share Buyback Transactions</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 12, 2016, the Company repurchased and retired an aggregate of 2,136,752 shares of its common stock at $1.35 per share for an aggregate purchase price of $2,884,615 pursuant to a Securities Purchase Agreement entered into with Abengoa Bioenergy New Technologies, LLC (&#8220;ABNT&#8221;). The $1.35 per share price is equal to the average conversion price that Dyadic convertible debt holders received upon conversion of debt as of December&#160;31, 2015. These shares repurchased from ABNT were treated as effective retirements, and therefore reduced reported shares issued and outstanding by the number of shares repurchased. The Company recorded the excess of the purchase price over the par value of the common stock in the accumulated deficit in compliance with US GAAP.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 11, 2017, the Company entered into a Securities Purchase Agreement with Pinnacle Family Office Investments L.P (&#8220;Pinnacle&#8221;) to repurchase an aggregate of 2,363,590 shares of its common stock at $1.54 per share for an aggregate purchase price of $3,639,929.  Upon repurchase, the shares are treated by Dyadic as treasury stock.  Subsequent to the repurchase, Pinnacle continued to own approximately 2.1 million common shares of Dyadic.  The repurchase of shares from Pinnacle was in addition to Dyadic&#8217;s 2016 Stock Repurchase Program discussed below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Stock Repurchase Programs</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 16, 2016, the Board of Directors authorized a one-year stock repurchase program, under which the Company was authorized to repurchase up to $15 million of its outstanding common stock (the &#8220;2016 Stock Repurchase Program&#8221;). The 2016 Stock Repurchase Program ended on February 15, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On August 16, 2017, the Board of Directors authorized a new one-year stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding common stock (the &#8220;2017 Stock Repurchase Program&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the 2017 Stock Repurchase Program, the Company is authorized to repurchase shares in open-market purchases in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The extent to which the Company repurchases its shares, and the timing of such repurchases, is dependent upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by the Company&#8217;s management. The repurchase program may be extended, suspended or discontinued at any time. The Company expects to finance the program from its existing cash resources. All repurchased shares are held in treasury.</font></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s stock repurchase activities:</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of Shares Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Average Repurchase Price per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Number of Treasury Shares Purchased as Part of Publicly Announced Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Privately Negotiated Transactions:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 12, 2016 - ABNT repurchased and retired shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,136,752</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,884,615</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,363,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,639,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,363,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016 Stock Repurchase Program </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January through December 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,548,473</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,401,906</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,548,473</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,598,094</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">867,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,384,021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">867,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,214,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">662,356</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,551,717</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017 Stock Repurchase Program:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,990,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,840</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,959,290</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,824,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,607</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,816</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,607</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,462,339</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total open market and privately negotiated purchases</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,745,929</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,510,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,609,177</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The 2016 Stock Repurchase Program ended on February 15, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Treasury Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December&#160;31, 2017, 10,609,177 shares of common stock are being held in treasury, at a cost of approximately $16.6 million, representing the purchase price on the date the shares were surrendered to the Company. As of December&#160;31, 2016, there were 6,548,473 shares held in treasury, at a cost of approximately $10.4 million.</font></div><div><a name="s17c3727305d141299677429a7522c9e5"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 8:&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through March&#160;27, 2018, the date the consolidated financial statements were available to be issued. Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Subsequent to December&#160;31, 2017, the Company repurchased, pursuant to the terms of its 2017 Stock Repurchase Program, 267,000 additional shares at a weighted average price of $1.40 per share through March&#160;27, 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Grant</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 2, 2018, the Company granted to executives and key personnel 492,000 stock options with an exercise price of $1.39.  The options vest upon grant or one year anniversary.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 2, 2018, the Company granted to Board of Directors 200,000 stock options with an exercise price of $1.39.  The options vest 25% upon grant and the remaining 75% will vest annually in equal installments over four years.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 2, 2018, the Company granted to non-executive employees and consultants 87,500 stock options with an exercise price of $1.39.  The options will vest annually in equal installments over four years for employees, and upon one year anniversary for consultants.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On March 19, 2018, the Company granted to one key personnel a one-time award of 50,000 stock options with an exercise price of $1.44.  The options will vest upon one year anniversary. In addition, the Company granted to the newly appointed Chief Accounting Officer a sign-on award of 50,000 stock options and a conditional award of 50,000 stock options with an exercise price of $1.44. The sign-on options will vest annually in equal installments over four years, and the conditional award will vest once certain conditions are met.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Board Member</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 3, 2018, the Company appointed Barry Buckland, Ph.D., to its Board of Directors, and granted 50,000 stock options with an exercise of $1.39. The options vest 25% upon grant and the remaining 75% will vest annually in equal installments over four years.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Departure of Chief Financial Officer and Appointment of Chief Accounting Officer</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s Chief Financial Officer, Thomas L. Dubinski, will not be returning from his previously announced medical leave of absence. Ping W. Rawson, the Company&#8217;s Director of Financial Reporting since June 2016, was promoted to Chief Accounting Officer on March 14, 2018 and will serve as the Company&#8217;s principal financial officer and assume responsibility for finance, tax and treasury.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></div><hr style="page-break-after:always"><div><a name="s24e67c6e2a5e4f43a5cf440cf943275f"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 14. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There have been no changes in and/or disagreements with Mayer Hoffman McCann P.C., our independent registered public accountants, on accounting and financial disclosure matters.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></div><hr style="page-break-after:always"><div><a name="s7A193ABF94D668839BBE2087624BCF99"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 15.&#160;Financial Statement and Exhibits</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Financial Statement</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statement attached to this Registration Statement are listed under </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Item 13. Financial Statements and Supplementary Data.&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Exhibits</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Exhibit</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit21form10.htm"><font style="font-family:inherit;font-size:10pt;">Investment Shareholders Agreement with respect to Biotechnology Developments for Industry, S.L, and VLP The Vaccines Company, S.L.U.  dated June 30, 2017</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31form10.htm"><font style="font-family:inherit;font-size:10pt;">Restated Certificate of Incorporation dated November 1, 2004</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit32form10.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws dated June 25, 2014</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit41form10.htm"><font style="font-family:inherit;font-size:10pt;">Specimen Stock Certificate Evidencing Shares of Common Stock</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit101form10.htm"><font style="font-family:inherit;font-size:10pt;">Dyadic International, Inc. 2006 Stock Option Plan</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit102form10.htm"><font style="font-family:inherit;font-size:10pt;">Dyadic International, Inc. 2011 Equity Incentive Plan</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit103form10.htm"><font style="font-family:inherit;font-size:10pt;">Form of Restricted Stock Unit Agreement Pursuant to the Dyadic International, Inc. 2011 Equity Incentive Plan</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit104form10.htm"><font style="font-family:inherit;font-size:10pt;">Form of Stock Option Agreement Pursuant to the Dyadic International, Inc. 2011 Equity Incentive Plan</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit105form10.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated June 16, 2016, and First Amendment dated January 23, 2017, by and between Dyadic International, Inc. and Mark A. Emalfarb</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit106form10.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated May 1, 2016, by and between Dyadic International, Inc. and Thomas L. Dubinski</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit107form10.htm"><font style="font-family:inherit;font-size:10pt;">Consulting Agreement, dated January 1, 2016, by and between Dyadic Netherlands B.V. and Sky Blue Biotech kft on behalf of Ronen Tchelet</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit108form10.htm"><font style="font-family:inherit;font-size:10pt;">Consulting Agreement, dated March 13, 2017, by and between Dyadic International, Inc. and Novaro Ltd. on behalf of Matthew Jones</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit109form10.htm"><font style="font-family:inherit;font-size:10pt;">Compensation Letter, dated March 26, 2018, by and between Dyadic International, Inc. and Ping W. Rawson</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1010form10.htm"><font style="font-family:inherit;font-size:10pt;">Form of Director and Officer Indemnification Agreement</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1011form10.htm"><font style="font-family:inherit;font-size:10pt;">Intracoastal Pointe Office Building Lease Agreement by and between Dyadic International, Inc. and Quentin Partners Co. dated December 30, 2010 and Renewal of Lease dated June 8, 2018</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1012form10.htm"><font style="font-family:inherit;font-size:10pt;">Pharma License Agreement with Danisco US, Inc. dated December 31, 2015</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13</font><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1013form10.htm"><font style="font-family:inherit;font-size:10pt;">Commission Contract with VTT Technical Research Centre of Finland Ltd dated September 2, 2016</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14</font><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1014form10.htm"><font style="font-family:inherit;font-size:10pt;">Research Services Agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. dated June 30, 2017</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15</font><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1015form10.htm"><font style="font-family:inherit;font-size:10pt;">Service Framework Agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.  dated June 30, 2017</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1016form10.htm"><font style="font-family:inherit;font-size:10pt;">Feasibility Study Agreement with Sanofi-Aventis Deutschland GmbH dated September 7, 2018</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.17&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit1017form10.htm"><font style="font-family:inherit;font-size:10pt;">License Agreement with VTT Technical Research Centre of Finland Ltd dated July 17, 2017</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit211form10.htm"><font style="font-family:inherit;font-size:10pt;">Subsidiaries of the Registrant</font></a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">This filing excludes schedules and similar attachments pursuant to Item 601(b)(2) of Regulation S-K.&#160; A copy of any omitted schedule will be furnished supplementary to the SEC upon request; provided, however, that the parties may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any document so furnished.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">**</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Identifies each management contract or compensatory plan or arrangement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">&#8224;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Portions of the exhibits have been omitted pursuant to a request for confidential treatment.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on </font><font style="font-family:inherit;font-size:10pt;color:#000000;">November&#160;5, 2018</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:50.9765625%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dyadic International, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark A. Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark A. Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ping W. Rawson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ping W. Rawson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Accounting Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>exhibit21form10.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="se2864f4c21c449a3aa4b2f5934dffc15"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit  2.1</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVESTMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">with respect to</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biotechnology for Industry, S.L. </font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">and</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP The Vaccines Company, S.L.U. </font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">executed by</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Creux An&#225;lisis Estrat&#233;gicos, S.L.</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Carlos Bl&#225;zquez Escudero</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Ricardo Arjona Antol&#237;n</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ms. Ana G&#243;mez Rodr&#237;guez</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Luis Hilario Guerra Trueba</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Floema Biotec, S.L.</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Jorge Hern&#225;ndez Esteban</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Yahia El-Amrani</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">and</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC</font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVEREADY INNVIERTE BIOTECH II, S.C.R., S.A. </font></div><div style="line-height:180%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Madrid, on June 30 2017</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="s91f0b346f37049a283a4e37cd9eb4830"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:87%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DEFINITIONS AND INTERPRETATION.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PURPOSE OF THE AGREEMENT; CLOSING.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXECUTION OF THE INVESTMENT ROUNDS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI PHARMACEUTICALS&#8217; CAPITAL INCREASE AND USE OF PROCEEDS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC&#8217;S PREFERRED CONDITIONS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SHAREHOLDERS AGREEMENTS OF THE COMPANY AND OF VLP.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SERVICE FRAMEWORK AGREEMENT; RESEARCH SERVICES AGREEMENT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CLOSING CONDITIONS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CLOSING. ACTIONS ON THE CLOSING DATE. CLOSING DELIVERIES.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">COVENANTS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">11.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXISTING SHAREHOLDERS&#8217; WARRANTIES.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">12.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXISTING SHAREHOLDERS SPECIFIC INDEMNITIES OBLIGATIONS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LIMITATION OF LIABILITY.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">14.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVESTORS&#8217; WARRANTIES.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">15.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TERM.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TERMINATION.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFIDENTIALITY.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">18.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXPENSES AND TAXES.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ASSIGNMENT.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMENDMENT.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">21.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOTICES.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:87%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">22.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SUCCESSORS AND ASSIGNS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">23.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SEVERABILITY.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">24.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SUPREMACY.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">25.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ENTIRE AGREEMENT; COUNTERPARTS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FURTHER ACTIONS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">27.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NON-WAIVER.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">28.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PUBLICITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">29.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">APPLICABLE LAW AND ARBITRATION.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:180%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s0239D5F00181D80D6161D4DC19692C5A"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVESTMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REGARDING</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BIOTECHONOLOGY DEVELOPMENTS FOR INDUSTRY, S.L.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AND</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP THE VACCINES COMPANY, S.L.U.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In Madrid, on June 30, 2017</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OF THE ONE PART </font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Creux An&#225;lisis Estrat&#233;gicos, S.L.</font><font style="font-family:inherit;font-size:11pt;">,</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">a Spanish limited liability company, with registered office in calle &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca, holder of Spanish tax identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, represented by Mr. Emilio Guti&#233;rrez G&#243;mez, of legal age, a Spanish national, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in force, and domiciled for this purposes in calle &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca. He acts in his capacity of Sole Director of the mentioned company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at calle &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca, acting in his own name and behalf.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Carlos Bl&#225;zquez Escudero</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, represented by Mr. Pablo Guti&#233;rrez G&#243;mez, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purposes at calle &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca. He acts in the name and on behalf of Mr. Carlos Bl&#225;zquez Escudero on virtue of  special powers of attorney granted on his favour..</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Ricardo Arjona Antol&#237;n</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; - Sevilla, acting in his own name and behalf.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ms. Ana G&#243;mez Rodr&#237;guez</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at calle &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca, acting in her own name and behalf.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Luis Hilario Guerra Trueba</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Valladolid, represented by Mr. Emilio Guti&#233;rrez G&#243;mez, of legal age, a Spanish national, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in force, and domiciled for this purposes in calle &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca. He acts in his capacity of Attorney of Mr. Guerra Trueba.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Floema Biotec, S.L.</font><font style="font-family:inherit;font-size:11pt;">, a Spanish limited liability company, with registered office in calle Gran V&#237;a 6, 5&#186; izquierda, holder of Spanish tax identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, represented by Mr. Antonio de Leyva Tejada, of legal age, a Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in force, and domiciled for this purposes at calle &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 28036, Madrid. He acts in the name and on behalf of the entity Floema Biotec, S.L. on virtue of a special power of attorney (proxy) granted on his favour.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Jorge Hern&#225;ndez Esteban</font><font style="font-family:inherit;font-size:11pt;">,</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at calle &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Madrid, acting in his own name and behalf.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Yahia El-Amrani</font><font style="font-family:inherit;font-size:11pt;">,</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">of legal age, with Moroccan nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Madrid, represented by Mr. Emilio Guti&#233;rrez G&#243;mez, of legal age, a Spanish national, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in force, and domiciled for this purposes in calle &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca. He acts in his capacity of Attorney of Mr. El-Amrani.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Hereinafter the persons and companies identified in items (1) through (9) will be jointly referred to as the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Existing Shareholders</font><font style="font-family:inherit;font-size:11pt;">&#8221;.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OF ANOTHER PART</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(10)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC</font><font style="font-family:inherit;font-size:11pt;">, a US company incorporated and existing under the laws of Florida, USA, and duly registered with the Trade Registry of the State of Florida, USA with company registration number 45-0486747, having its corporate domicile at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477, USA (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:11pt;">&#8221;), represented by Mr. Antonio Ca&#241;adas Bouwen, of legal age, with Spanish nationality, with ID number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in force, and domiciled for this purposes in Madrid &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. He acts in his capacity of Special Attorney of Dyadic.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(11)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#1f497d;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVEREADY INNVIERTE BIOTECH II, S.C.R., S.A.</font><font style="font-family:inherit;font-size:11pt;">,</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">a Spanish company, with registered office in calle Cavallers, 50, 08034 Barcelona, holder of Spanish tax identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Inveready</font><font style="font-family:inherit;font-size:11pt;">&#8221;), represented by Mr. Roger Piqu&#233; Pijuan, of legal age, a Spanish national, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in force, and domiciled for this purposes in &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. He acts in his capacity of general attorney of Inveready.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Hereinafter the companies identified in items (10) and (11) will be jointly referred to as the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Investors</font><font style="font-family:inherit;font-size:11pt;">&#8221;.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AND OF ANOTHER PART</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(12)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biotechnology Developments For Industry, S.L.</font><font style="font-family:inherit;font-size:11pt;">, a Spanish limited liability company, with registered office in Avenida Francisco Valles, 8, 47151, Boecillo (Valladolid), holder of Spanish tax identification number B47729934 (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Holding</font><font style="font-family:inherit;font-size:11pt;">&#8221; or the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:11pt;">&#8221;), represented by Mr. Pablo Guti&#233;rrez G&#243;mez, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in force, and domiciled for this purposes in &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Boecillo. He acts in his capacity of Chief Executive Officer of BDI Holding.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(13)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP The Vaccines Company, S.L.U.</font><font style="font-family:inherit;font-size:11pt;">, a Spanish limited liability company, with registered office in &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca, Spain, holder of Spanish tax identification number B37515111 (</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;VLP&#8221;</font><font style="font-family:inherit;font-size:11pt;">), represented by Mr. Emilio Guti&#233;rrez G&#243;mez, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at calle &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca. He acts in his capacity of legal representative of Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. which is the sole director of VLP.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Existing Shareholders and the Investors shall be jointly referred to as the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders</font><font style="font-family:inherit;font-size:11pt;">&#8221; and each one of them, individually, as a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholder</font><font style="font-family:inherit;font-size:11pt;">&#8221;. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Finally, the Shareholders, BDI Holding and VLP shall be jointly referred to as the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:11pt;">&#8221; and each one of them as a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Parties mutually acknowledge their legal capacity to execute this agreement (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and, accordingly,</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WHEREAS</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company is a Spanish limited liability company, with its registered office at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, incorporated by virtue of the public deed granted by the Public Notary from Madrid, Mr. Jorge Prades L&#243;pez, on 22 September 2014, under number 789 of his public records, registered in the Commercial Registry of Valladolid under volume 1477, sheet 91, page VA-27242, and with tax identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">II.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company is the sole shareholder of the entities listed in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule I</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">(the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Subsidiaries</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and carries out its Business, directly and indirectly, through its Subsidiaries. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">III.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VLP is a Spanish limited liability company, with its registered office at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca, Spain, incorporated by virtue of the public deed granted by the Public Notary from Madrid, Mr. Antonio Moren&#233;s Giles who was substituting Mr. Andr&#233;s de la Fuente O&#8217;Connor, on March 16 2012, under number 435 of his public records, registered in the Commercial Registry of Salamanca under volume 426, sheet 219, page SA-14239, and with tax identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">IV.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">At the Agreement Date, (i) the Existing Shareholders hold the entire share capital of the Company  as set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule II</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">and (ii) the Company holds the entire share capital of VLP as set out in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule I</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">V.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Prior to the execution of this Agreement, the Investors and their advisors have carried out a Due Diligence (as defined below) of BDI Group, and a digital device containing the information provided for these purposes to the Investors through an online virtual data room established by BDI Group and hosted by iDeals is  delivered to the Investors on the Agreement Date and which shall be deposited jointly by the Parties with the Public Notary on the Closing Date by means of a notarial affidavit of deposit (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">acta notarial de dep&#243;sito</font><font style="font-family:inherit;font-size:11pt;">&#8221;), which includes a letter issued by iDeals, whereby such entity confirms that all of the contents of the digital device reflect the content of the virtual data room as of June 6 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VI.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">That in the context of (i) the Due Diligence review of the BDI Group on legal and labor made until April 7</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;2017, and on financial, IP and tax aspects made until June 6 2017 conducted by the Investors and their advisors, to the Investors&#8217; entire satisfaction with full access to the information regarding such companies in the mentioned areas in order to determine the advantages and disadvantages of carrying out the Investment (as this term is defined below) (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Due Diligence</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and (ii) subject to the Covenants and Closing Conditions set forth herein, the Investors are interested in, on Closing Date:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:36px;text-indent:-36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">investing in the Company and in VLP through an increase of capital of each of BDI Holding and VLP (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Investment Rounds</font><font style="font-family:inherit;font-size:11pt;">&#8221;);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">entering into a shareholders agreement with the Existing Shareholders for the Company in the form attached to this Agreement as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit A1</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">(the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Holding</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;) that will regulate the relationships among the Investors and the Existing Shareholders, in their capacity as shareholders of the Company, the relationships of such shareholders with the Company, the system of governance and management of the Company and the transfers of shares in the Company and several other commitments of the Shareholders related to the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">entering into a shareholders agreement with the Company for VLP in the form attached to this Agreement as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit A2</font><font style="font-family:inherit;font-size:11pt;">&#32;(the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;) that will regulate the relationships among the Investors and the Company, in their capacity as shareholders of VLP, </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:72px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">the relationships of such shareholders with VLP, the system of governance and management of VLP and the transfers of shares in VLP and several other commitments of the shareholders related to VLP; and</font></div><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">iv.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">entering into certain ancillary commitments and/or agreements as specified in this Agreement, among others, the Service Framework Agreement and the Research Services Agreement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VII.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Existing Shareholders, the Company and VLP are interested in formalizing on the Agreement Date the terms and conditions that shall govern (i) their mutual obligations with regard to the final structure of the Investment Rounds and the commitments of the Parties in this respect and (ii) their relations as shareholders of the Company or VLP (as applicable) upon the Closing Date, and the Investors are interested in making such Investment Rounds, subject to the compliance with the covenants set forth  in Clause 10 of this Agreement, the Closing Conditions set forth in Clause 8 of this Agreement and on the basis of the representations given and the warranties made and pursuant to the terms and conditions contained herein.</font></div></td></tr></table><div><a name="sAED15B14D71F0A54C169D4DC198CB958"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Now therefore, in consideration of the foregoing, the Parties agree to enter into this Agreement, which shall be governed by the following: </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CLAUSES</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DEFINITIONS AND INTERPRETATION.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:11pt;">. In the Agreement the following terms shall have the meanings specified below:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Affiliate</font><font style="font-family:inherit;font-size:11pt;">&#8221; means any entity directly or indirectly controlled by, controlling, or under common control with, a Party to this Agreement, but only for so long as such control shall continue. For purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, &#8220;controlled by&#8221;, &#8220;controlling&#8221; and &#8220;under common control with&#8221;) means possession, direct or indirect, of  (a) the power to direct or cause direction of the management and policies of an entity (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221; means this agreement, together with its Exhibits and its Schedules.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Agreement Date</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the date on which the Agreement is executed, as appears first above written.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Anti-Bribery Laws</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8221; </font><font style="font-family:inherit;font-size:11pt;">means:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the Spanish Criminal Code; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any other Applicable Law, rule or regulation of similar purpose and scope in any jurisdiction applicable to the BDI Group, including without limitation the Foreign Corrupt Practices Act of the United States and the United Kingdom Bribery Act of 2010, as both may be amended from time to time.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Applicable Law&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means, with respect to any Person, any law, regulation, rule, judgment, order, decree, award, Governmental Approval, grant, license, agreement, guideline, policy, requirement, or other governmental restriction or any similar form of decision of, or determination by, or any interpretation or administration of any of the foregoing by, any Governmental Authority, then in force and applicable to such Person or its subsidiaries or their respective assets.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Holding</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Recital 12.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;BDI Holding Shareholders Agreements&#8221; </font><font style="font-family:inherit;font-size:11pt;">means the shareholders agreement substantially in the form attached as Exhibit A1.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Group</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the Company and the Subsidiaries.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;BDI Pharmaceuticals&#8221; </font><font style="font-family:inherit;font-size:11pt;">means Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;BDI Pharmaceuticals&#8217; Capital Increase&#8221; </font><font style="font-family:inherit;font-size:11pt;">shall have the meaning set forth in Clause 4.2.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;BDI Pharmceutical&#8217;s Capital Increase Deed&#8221; </font><font style="font-family:inherit;font-size:11pt;">shall have the meaning set forth in Clause 4.2.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Pharmaceuticals&#8217; Project A Account</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the BDI Pharmaceuticals&#8217; bank account n&#186; IBAN: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (Banco de Santander) into which BDI Holding shall transfer EUR 934,000.- resulting from the Dyadic&#8217;s Cash-In Component. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Pharmaceuticals&#8217; Account</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the BDI Pharmaceuticals&#8217; bank account n&#186; IBAN &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (Bankinter) into which BDI Holding shall transfer the remaining EUR 216,000 resulting from the Inveready&#8217;s Company Cash-in Component.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Business</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the corporate activity or business ordinarily carried out by BDI Group consisting of the investigation, development and innovation of technical and scientific activities, such as biotechnology and other with technology basis.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Business Day</font><font style="font-family:inherit;font-size:11pt;">&#8221; means any day except Saturdays, Sundays or public holidays or days in which banks are not open in Madrid, Spain or Jupiter, Florida.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Bylaws of BDI Holding</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the bylaws of the Company. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Bylaws of VLP</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the bylaws of VLP.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Capital Increases</font><font style="font-family:inherit;font-size:11pt;">&#8221; means, collectively, the BDI Pharmaceuticals&#8217; Capital Increase in</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">,</font><font style="font-family:inherit;font-size:11pt;">&#32;VLP&#8217;s Capital Increase and the Company&#8217;s Capital Increase.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Capital Increase Deeds</font><font style="font-family:inherit;font-size:11pt;">&#8221; means, collectively, the Company&#8217;s Capital Increase Deed, BDI Pharmaceuticals&#8217; Capital Increase Deed and VLP Capital Increase Deed.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Closing</font><font style="font-family:inherit;font-size:11pt;">&#8221; means closing formalization of this Agreement by virtue of the execution of the Capital Increases and all the transactions contemplated by this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Closing Conditions</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 8.1.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Closing Date</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 9.1.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Closing Deliveries</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 9.4</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Recital 12.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company&#8217;s Accounts</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the Company&#8217;s following bank accounts where Dyadic and Inveready shall transfer their respective portions of the Cash-In Component:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:60px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic&#8217;s Company Cash-In Component shall be transferred to Company&#8217;s bank account n&#186; IBAN: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (Banco de Santander); and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:60px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inveready&#8217;s Company Cash-In Component shall be transferred to Company&#8217;s bank account n&#186; IBAN:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (Bankinter).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Companies Acts</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8221; </font><font style="font-family:inherit;font-size:11pt;">means the Spanish Companies Act 1/2010 dated July 2nd (&#8220;Real Decreto Legislativo 1/2010, de 2 de julio, por el que se aprueba el texto refundido de la Ley de Sociedades de Capital&#8221;) and includes any enactment passed after that Act which may, by reason of that or any other enactment, be cited together with that Act as &#8220;the Companies Acts&#8221;.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company&#8217;s Capital Increase</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 3.1.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company&#8217;s Capital Increase Deed</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 3.1.3.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company&#8217;s Capital Increase Shares</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the Shares newly issued by the virtue of the Company&#8217;s Capital Increase.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company Cash-In Component</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the aggregate of the Investors&#8217; cash (EUR) contributions necessary for the Company&#8217;s Capital Increase. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company&#8217;s Shares</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the shares in which the share capital of the Company is divided after the Company&#8217;s Capital Increase.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company&#8217;s VLP Cash-In Component</font><font style="font-family:inherit;font-size:11pt;">&#8221; has the meaning set forth in Clause 3.2.2. (ii).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Confidential Information&#8221;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">shall have the meaning set forth in Clause 17 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Covenants</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the covenants agreed by the Parties as set forth in Clause 10 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Data Protection Legislation</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the LOPD and any regulations made thereunder and the Data Protection Directive 95/46/EC in the territory in which the BDI Group is incorporated or in which the Business operates as the case may be.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Data Room&#8221; </font><font style="font-family:inherit;font-size:11pt;">means the contents of the electronic data room via iDeals containing (i) documents and information relating to the legal and labour areas of the BDI Group uploaded until April 7</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;2017, (ii) documents and information relating to the IP, finance and tax areas of the BDI Group uploaded until June 6 2017, and (iii) the information memoranda and presentations provided by the Company before the date of this Agreement contained on pendrive delivered to the Investors on the Agreement Date and that will further be deposited before the Public Notary on Closing Date.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Disclosed Information&#8221; </font><font style="font-family:inherit;font-size:11pt;">or</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;&#8220;Disclosed</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8221; </font><font style="font-family:inherit;font-size:11pt;">means true and correct information disclosed to the Investors in the Data Room with sufficient detail to enable the Investors to identify the nature and scope of the matters, facts or circumstances disclosed and the nature of their consequences. Any documents and information relating to the legal and labour areas of the BDI Group uploaded after April 7</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;2017 and any documents and information relating to the IP, finance and tax areas of the BDI Group uploaded after June 6 2017 shall not be considered as Disclosed in the Data Room.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 17.1.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Domain Names</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning given in Section 13.3 of Schedule IV</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Due Diligence&#8221; </font><font style="font-family:inherit;font-size:11pt;">shall have the meaning given in Whereas VI.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Recital 10.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dyadic&#8217;s Company Cash-In Component</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 3.1.2. (ii). </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Dyadic&#8217;s Nominee&#8221; </font><font style="font-family:inherit;font-size:11pt;">shall have the meaning set forth in Clause 5.1.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dyadic&#8217;s VLP Cash-In Component</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 3.2.2. (ii).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Encumbrance</font><font style="font-family:inherit;font-size:11pt;">&#8221; means any interest or equity of any person (including any right to acquire, option or right of pre-emption or conversion) or any mortgage, charge (whether fixed or floating), pledge, lien, assignment, hypothecation, security interest, right of retention of title or any other form of security interest or obligation (including any conditional obligations to create any of the same).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Existing Shareholders</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Recital 9.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Financial Statements</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning given in section 6.1 of Schedule IV.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Financial Projections</font><font style="font-family:inherit;font-size:11pt;">&#8221; means those projections included in the file 1.9.1. of the Data Room.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Indebtedness&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means all borrowings and indebtedness (including by way of acceptance credits, discounting or similar facilities, finance leases, loan stocks, bonds, debentures, notes, debt or inventory financing, or sale and finance leaseback arrangements, overdrafts, or other similar arrangements the purpose of which is to borrow money), together with any interest accrued on such amounts, owed to any banking, financial, acceptance, credit, lending or other similar institution or organisation or any institutional investor or any other person.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Indemnification Claim</font><font style="font-family:inherit;font-size:11pt;">&#8221; means any claim of (i) any breach or inaccuracy of any of the Warranties set forth in Section 11 of the Agreement and Schedule V attached thereto as well as (ii) the Specific Indemnities set forth in Clause 12, and (iii) any breach or inaccuracy of the Covenants or obligations of the Existing Shareholders, the Company or VLP under this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Inveready</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Recital 11. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Inveready&#8217;s Company Cash-In Component</font><font style="font-family:inherit;font-size:11pt;">&#8221; has the meaning set forth in Clause 3.2.1. (ii). </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Inveready&#8217;s VLP Cash-In Component</font><font style="font-family:inherit;font-size:11pt;">&#8221; has the meaning set forth in Clause 3.2.2. (ii).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Investment Rounds</font><font style="font-family:inherit;font-size:11pt;">&#8221; has the meaning set forth in Clause 3.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Investors&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;shall have the meaning set forth in Recital 11.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;IP Rights&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;shall have the meaning given in section 13.1 of Schedule IV</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Last Accounts</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the balance sheet of the BDI Group as at the Last Accounts Date and the profit and loss account of the BDI Group made up to the Last Accounts Date and (in each case) the directors&#8217; reports and notes thereon (true copies of which are included in the Data Room).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Last Accounts Date</font><font style="font-family:inherit;font-size:11pt;">&#8221; means 31 December 2016.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Law&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means any state, provincial, local or foreign statute, law, ordinance, regulation, rule, code, order or other requirement or rule of law.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Liability Distribution Percentages</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the percentages set forth in Schedule III.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Long Stop Date&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;has the meaning set forth in Clause 8.4.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LOPD</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the Protection of Personal Data Act 15/1999 of December 13th (&#8220;Ley Org&#225;nica 15/1999 de Protecci&#243;n de Datos&#8221;).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Loss&#8221;</font><font style="font-family:inherit;font-size:11pt;">&#32;means any actual (as opposite to contingent) losses, claims, demands, actions, damages, penalties, fines, obligations and liabilities (including reasonably incurred costs and expenses)</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">together with any VAT thereon, other than loss of profits and indirect damages, as a direct consequence of any breach of the Warranties or any breach of any other obligations established in the Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Management Accounts</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8221; </font><font style="font-family:inherit;font-size:11pt;">means the balance sheet and profit and loss account of the BDI Group for the period from the Last Accounts Date until the Management Accounts Date (true copies of which are included in the Data Room).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Management Accounts Date</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8221; </font><font style="font-family:inherit;font-size:11pt;">means 30 April 2017.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Material Adverse Effect&#8221; </font><font style="font-family:inherit;font-size:11pt;">means, with respect to BDI Group, the effect of any circumstance, change, development or event that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">decreases the net equity, turn over or EBIT, of the BDI Group by more than five per cent (5%) as set forth in the Management Accounts; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">prevents or materially impedes, interferes with, hinders or substantially delays the consummation of the Transaction contemplated by this Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Material Contract</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8221; </font><font style="font-family:inherit;font-size:11pt;">means any contract, arrangement or obligation to which the BDI Group are a party and which is:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">with a significant customer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">with a significant supplier; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">material to the continued operations and business of the BDI Group; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">outside the ordinary course of its business.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Notary</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the Spanish Notary designated by the Company to authorize the Capital Increase Deeds.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Option Notice</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning given in Clause 5.2.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Out Licenses</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning given in Clause 13.6 of Schedule IV.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:11pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Recital 13.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Person/s</font><font style="font-family:inherit;font-size:11pt;">&#8221; means any individual, corporation, business trust, joint venture, association, company, limited liability entity, firm, partnership, or other entity or governmental body, including their heirs, successors and assignees.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PGC</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8221; </font><font style="font-family:inherit;font-size:11pt;">means the General Accounting Plan (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">RD1514/2007, de 16 de noviembre, por el que se aprueba el Plan General de Contabilidad</font><font style="font-family:inherit;font-size:11pt;">.&#8221;) of generally accepted accounting practices, principles and standards in compliance with all Applicable Laws in Spain.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Preferred Option</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 5.1. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Project A</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the C1 project (including the research license to be granted by Dyadic for the use of C1 within Project A) set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 17.1.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Research Services Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the separate agreement to be entered into by Dyadic, on the one hand, and BDI Pharmaceuticals, on the other hand, on the Closing Date and in the agreed form attached to this Agreement as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit C</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Services Framework Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the separate agreement to be entered into by Dyadic, on the one hand, and BDI Pharmaceuticals, on the other hand, on the Closing Date and in the agreed form attached to this Agreement as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit B</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Recital 13.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders Agreements</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the BDI Holding Shareholders Agreement and the VLP Shareholders Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Specific Indemnities</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the specific indemnities set out in Clause 12 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Spanish Law&#8221; </font><font style="font-family:inherit;font-size:11pt;">means any law, regulation, rule, order and/or decree, then in force and applicable in Spain.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Subsidiaries</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the companies described in Schedule I to this Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Tax</font><font style="font-family:inherit;font-size:11pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Taxes</font><font style="font-family:inherit;font-size:11pt;">&#8221; means all forms of tax, charge, duty, impost, tariff, withholding, deduction, rate, levy and governmental charge (whether national or local) in the nature of tax whenever created, enacted or imposed, and whether of Spain or elsewhere, and any amount payable to any Tax Authority or any other person as a result of any enactment relating to tax, together with all related fines, penalties, interest, costs, charges and surcharges.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Tax Authority</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#8221; </font><font style="font-family:inherit;font-size:11pt;">means any statutory or governmental authority or body (whether in Spain or elsewhere) involved in the collection or administration of Tax.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Transaction</font><font style="font-family:inherit;font-size:11pt;">&#8221; and &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Transaction Documents</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 2.1.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;Use of Proceeds&#8221; </font><font style="font-family:inherit;font-size:11pt;">shall have the meaning set forth in Clause 4.1.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Recital 13.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP&#8217;s Accounts</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the VLP&#8217;s following bank accounts where Dyadic, Inveready and the Company shall transfer their respective investment within the share capital of VLP according to Clause 3.2.2:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:61px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic&#8217;s VLP Cash-In Component shall be transferred to VLP&#8217;s bank account n&#186; IBAN: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (Banco de Santander); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:61px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inveready&#8217;s VLP Cash-In Component shall be transferred to VLP&#8217;s bank account n&#186; IBAN: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (Bankinter); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:61px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company&#8217;s VLP Cash-In Component shall be transferred to VLP&#8217;s bank account n&#186; IBAN:  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Bankinter).</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP&#8217;s Capital Increase</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall have the meaning set forth in Clause 3.2. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP&#8217;s Capital Increase Deed</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the Spanish notarial deed which shall be used to formalize the VLP&#8217;s Capital Increase.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP&#8217;s Capital Increase Shares</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the shares newly issued by the virtue of the VLP&#8217;s Capital Increase.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;VLP Shareholders Agreement&#8221; </font><font style="font-family:inherit;font-size:11pt;">means the shareholders agreement substantially in the form attached to this Agreement as Exhibit A2.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Warranties</font><font style="font-family:inherit;font-size:11pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Warranty</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the warranties set forth in Schedule IV.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Interpretation</font><font style="font-family:inherit;font-size:11pt;">:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the Agreement, unless indicated otherwise:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reference to the Agreement must be deemed to be made to the Agreement, its Exhibits and its Schedules.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reference to &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Clause</font><font style="font-family:inherit;font-size:11pt;">&#8221;, &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Exhibit</font><font style="font-family:inherit;font-size:11pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Schedule</font><font style="font-family:inherit;font-size:11pt;">&#8221; must be deemed to be made to a Clause of, Exhibit to or Schedule to the Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Exhibits and Schedules: The Exhibits and Schedules to this Agreement are incorporated into and form an integral part of this Agreement.  If an Exhibit is a form of agreement, such agreement, when executed and delivered by the corresponding Parties at Closing Date shall constitute a document independent of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Wherever the terms &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">includes</font><font style="font-family:inherit;font-size:11pt;">&#8221;, &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">included</font><font style="font-family:inherit;font-size:11pt;">&#8221;, &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">include</font><font style="font-family:inherit;font-size:11pt;">&#8221; and &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">including</font><font style="font-family:inherit;font-size:11pt;">&#8221; are used, they shall be deemed to be followed by the expression &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">without limitation</font><font style="font-family:inherit;font-size:11pt;">&#8221;. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reference to one gender includes the other, and words in the singular shall include the plural, and vice versa. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If an obligation is qualified or formulated by reference to the use of &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">best endeavors</font><font style="font-family:inherit;font-size:11pt;">&#8221;, &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">best efforts</font><font style="font-family:inherit;font-size:11pt;">&#8221; or another similar expression, it refers to the endeavors that a Person with the firm intention to achieve an outcome would use in similar circumstances to ensure the achievement of such outcome as soon as possible, taking into account, among other factors: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the price, financial interest and other terms of the obligation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the degree of risk normally entailed by the achievement of the expected outcome; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the ability of an unrelated Person to exert an influence on the performance of the obligation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">that in no event shall any Party having committed to use best efforts be obliged to perform any payment or furnish any sort of financial guarantee to a third party in the context of the achievement of the outcome to which such Party had committed to use its best efforts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reference to &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">days</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall be deemed to be made to &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">calendar days</font><font style="font-family:inherit;font-size:11pt;">&#8221;. Any periods expressed in days shall start to be counted from the day immediately following that on which the counting starts. If the last day of a period is not a Business Day, the period in question shall be deemed </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:72px;padding-bottom:13px;padding-top:13px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">to have been automatically extended until the first following Business Day. Periods expressed in months shall be counted from date to date unless in the last month of the period such date does not exist, in which case the period shall end on the first Business Day of the immediately following month.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reference to &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">from</font><font style="font-family:inherit;font-size:11pt;">&#8221;, &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">as from</font><font style="font-family:inherit;font-size:11pt;">&#8221;, &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">as of</font><font style="font-family:inherit;font-size:11pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">through</font><font style="font-family:inherit;font-size:11pt;">&#8221; a given date shall be understood to include such date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The headings used in the Agreement are included for reference only and shall not form part of the Agreement for any other purpose or affect the interpretation of any of its clauses.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Terms appearing in Spanish shall have the meanings ascribed to them in Spanish legislation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(xi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">References to </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8220;&#8364;&#8221;,</font><font style="font-family:inherit;font-size:11pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">EUR</font><font style="font-family:inherit;font-size:11pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Euro</font><font style="font-family:inherit;font-size:11pt;">&#8221; are references to the lawful currency from time to time of the Eurozone.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(xii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If any Warranty is qualified by the expression &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">to the Existing Shareholder&#8217;s, the Company&#8217;s, or VLP&#8217;s knowledge or &#8220;to the Company&#8217;s knowledge&#8221; </font><font style="font-family:inherit;font-size:11pt;">&#32;or words to such effect, such expression shall mean that the Company has made due and careful inquiry into the subject matter of that Warranty (including inquiries, where applicable, of the directors, officers, managers, senior employees, agents and advisers of the members of the BDI Group) and gives, to the best of their current knowledge, the corresponding Warranty, in their belief that said Warranty is true and accurate, acting in compliance with the principles of contractual good faith and the proper care of a dedicated professional, taking into account the history of the Company in the normal and ordinary course of its business, it being understood that it shall be used for the sole purposes of avoiding potential claims regarding fraud or willful misconduct against the Company in case of misrepresentation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PURPOSE OF THE AGREEMENT; CLOSING.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The purpose of this Agreement is to set out the framework of binding rules that the Parties shall abide by in relation to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the execution of the Investment Rounds, including the Capital Increases, as described in Clause 3 below;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the execution of BDI Pharmaceuticals&#8217; Capital Increase as described in Clause 4 below;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">execution of the BDI Holding Shareholders Agreement that will regulate the relations of the Existing Shareholders and the Investors after the Closing Date as direct Shareholders of the Company in connection with, amongst other: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the governance and administration of the Company, and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the transfer of shares of the Company, for the purposes of providing a stable shareholding structure and facilitating the management of the Company with the objective of maximizing value for the Shareholders; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">certain other commitments of the Shareholders related to the Company.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">execution of the VLP Shareholders Agreement that will regulate the relations of the Company and the Investors after the Closing Date as direct shareholders of VLP in connection with, amongst other: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the governance and administration of VLP, and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the transfer of shares of VLP, for the purposes of providing with a stable shareholding structure and facilitating the management of VLP with the objective of maximizing value for the Shareholders; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">certain other commitments of the Shareholders related to the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">execution of the Services Framework Agreement between Dyadic International, Inc  and BDI Pharmaceuticals in the form of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:11pt;">; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">execution of the Research Services Agreement between Dyadic International, Inc and BDI Pharmaceuticals in form of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit C</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement, the Capital Increases Deeds, the Shareholders Agreements, the Services Framework Agreement, the Research Services Agreement and the completion of all the other actions set forth in this Agreement shall be jointly referred to as the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Transaction Documents</font><font style="font-family:inherit;font-size:11pt;">&#8221;, being the whole transaction established in this Agreement referred to as the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Transaction</font><font style="font-family:inherit;font-size:11pt;">&#8221;.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Parties further agree that after the Closing Date they shall exercise their rights as Shareholders of the Company, of BDI Pharmaceuticals and of VLP in a way that ensures performance of and compliance with the Agreement. Without prejudice to the generality of the foregoing, after the Closing Date the Parties undertake promptly to pass, or to cause their appointees in the relevant corporate bodies of the Company and any of the Subsidiaries of the BDI Group to promptly pass, any resolution or take any action necessary or convenient to implement fully and abide by the provisions of this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXECUTION OF THE INVESTMENT ROUNDS. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Investment Round in the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:1px;"><font style="font-family:inherit;font-size:12pt;">3.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Existing Shareholders irrevocably undertake to hold a General Shareholders Meeting (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Junta General de socios con car&#225;cter universal</font><font style="font-family:inherit;font-size:11pt;">&#8221;) on the Agreement Date with the aim to conduct and approve the Company&#8217;s Capital Increase. The Existing Shareholders shall adopt the following decisions:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)&#160;&#160;&#160;&#160;To approve the capital increase within the share capital of the Company for a total amount of EUR 1,434,000.-. Said Capital Increase shall be made through the issuance of 16,440,249 newly issued shares (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">participaciones sociales</font><font style="font-family:inherit;font-size:11pt;">&#8221;) in the Company, of ONE CENT OF EURO (&#8364;0,01) of face value each, numbered from 49,985,001 to 66,425,249 (both inclusive) and with the same economic and voting rights assigned to all the current shares of the Company (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company&#8217;s Capital Increase Shares</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">). The subscription of the Capital Increase Shares of the Company by the Investors is set forth in Clause 3.2.1(ii) hereunder.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)&#160;&#160;&#160;&#160;Said Company&#8217;s Capital Increase shall be unanimously approved by all the Existing Shareholders. Consequently, the issuance to the Investors of the newly issued shares payable in cash will be conditional on the Investors making their cash payment of their respective Cash-in Component by means of wire transfers from the Investors to be received in the Company&#8217;s bank account on Closing Date. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii)&#160;&#160;&#160;&#160;The Existing Shareholders hereby irrevocably agree to take the actions set forth in this Clause 3.1 to enable the Company to issue the Company&#8217;s Capital Increase Shares to the Investors. Consequently, the Existing Shareholders and, if necessary, the Company, will expressly and irrevocably waive any and all rights of first refusal, pre-emptive rights, notices, consents or other rights such Existing Shareholders and/or the Company may have under any agreement or arrangement in connection with the Company&#8217;s Capital Increase. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iv)&#160;&#160;&#160;&#160;The decisions adopted by the Existing Shareholders in the General Shareholders Meeting shall be reflected in the corresponding minutes substantially in the form attached hereto as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit D1</font><font style="font-family:inherit;font-size:11pt;">&#32;which will include (i) the Company&#8217;s Capital Increase approval according to the terms described in this Clause 3.1, (ii) the waiver of all rights of first refusal, pre-emptive rights, notices, consents or other rights that the Existing Shareholders and, if applicable, the Company may have in relation to the Company&#8217;s Capital Increase, (iii) the amendment of the Bylaws of BDI Holding pursuant to the Company&#8217;s Capital Increase and (iv) any other resolution to be adopted by the Existing Shareholders according to Spanish Law in order to implement the Company&#8217;s Capital Increase. The Existing Shareholders undertake to sign and approve the content of said minutes.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Investors shall on the Closing Date:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i) execute the wire transfers in due time so that the cash payments will be received in the Company&#8217;s Accounts on the Closing Date  and will provide reasonable evidence to the Existing Shareholders and to the the Secretary of the Board of the Company, Ms. Ana G&#243;mez Rodriguez, that the Investment Round of the Company has been effectively made; and</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii) subscribe for all the Company&#8217;s Capital Increase Shares in the Company&#8217;s Capital Increase as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:84px;"><font style="font-family:Wingdings;font-size:6pt;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic shall subscribe for 10,707,750 shares of the Capital Increase Shares by virtue of a cash contribution amounting to 934,000 Euros (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dyadic&#8217;s Company Cash-In Component</font><font style="font-family:inherit;font-size:11pt;">&#8221;). The price per share shall be composed by a nominal value of 0,01 Euros per share (for a total amount of 107,077.50 Euros)plus a share premium of 0,077 Euros per share (for a total amount of 826,922.50 Euros); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:84px;"><font style="font-family:Wingdings;font-size:6pt;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inveready shall subscribe for 5,732,499 shares of the Capital Increase Shares by virtue of the cash contribution amounting to 500,000.- Euros (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Inveready&#8217;s Company Cash-In Component</font><font style="font-family:inherit;font-size:11pt;">&#8221;). The price per share shall be composed by a nominal value of 0,01 Euros per share (for a total amount of 57,324.99 Euros) plus a share premium of 0,077 Euros per share (for a total amount of 442,675.01 Euros).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The subscription of the Company&#8217;s Capital Increase Shares shall be effected by means of the notarization of a capital increase deed (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company&#8217;s Capital Increase Deed</font><font style="font-family:inherit;font-size:11pt;">&#8221;) in compliance with all the required formalities under Spanish Law, including the registration of the Company&#8217;s Capital Increase Deed in the Commercial Registry by the Company immediately following the Closing. For such purposes, the Secretary of the Board of the Company, Ms. Ana G&#243;mez Rodriguez, shall issue and sign the corresponding Certificate of the decisions made in the General Shareholders Meeting, which shall be approved and signed by her and by the Chairman of the Board, Mr. Pablo Guti&#233;rrez G&#243;mez. This Certificate shall further be passed into public deed in the presence of the Spanish Public Notary by such Director of the Company and, subsequently, the Company shall file such public deed with the Commercial Registry of Valladolid.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.1.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Company, through its Secretary, Ms. Ana G&#243;mez Rodriguez shall on the Closing Date: </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i) Register the Investors as the titleholders of the Company&#8217;s Capital Increase Shares in the Company&#8217;s Shares Registry Book (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Libro Registro de Socios</font><font style="font-family:inherit;font-size:11pt;">&#8221;); and</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii) Deliver to each Investor a certificate certifying that the Investors&#8217; ownership of the Company&#8217;s Capital Increase Shares subscribed by each Investor as a result of the Company&#8217;s Capital Increase have been registered in the Company&#8217;s Shares Registry Book (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Libro Registro de Socios</font><font style="font-family:inherit;font-size:11pt;">&#8221;).</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.1.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">After the completion of the Company&#8217;s Capital Increase, the share capital of the Company shall be distributed as follows:</font></div></td></tr></table><div style="line-height:120%;padding-left:36px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.23076923076923%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:29%;"></td><td style="width:13%;"></td><td style="width:16%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">N&#186; (inclusive)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Creux An&#225;lisis Estrat&#233;gicos, S.L.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17.65%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11,721,379</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[1 - 7,331,502]; </font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[32,500,001 &#8211; 34,946, 362];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[41,985,001 &#8211; 43,033,003];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[46,485,001 &#8211; 47,380,512]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.56%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5,024,443</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[15,979,178 &#8211; 19,023,353];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[34,946,363 &#8211; 36,054,945];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[44,237,333 &#8211; 44,682,429];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[48,558,414 &#8211; 48,985,000]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Carlos Bl&#225;zquez Escudero</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,34%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4,212,731</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[10,302,463 &#8211; 13,273,422];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[32,000,001 &#8211; 32,500,000];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[43,467,805 &#8211; 43,839,825];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[47,799,092 &#8211; 48,168,841]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Ricardo Arjona Antol&#237;n</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.39%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4,910,077</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[7,331,503 &#8211; 10,302,462];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[36,054,946 &#8211; 37,140,682];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[43,033,004 &#8211; 43,467,804];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[47,380,513 &#8211; 47,799,091]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ms. Ana G&#243;mez Rodr&#237;guez</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.77%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4,495,819</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[13,273,423 &#8211; 15,979,177];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[37,140,683 &#8211; 38,143,667];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[43,839,826 &#8211; 44,237,332];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[48,168,842 &#8211; 48,558,413]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2,781,290</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[19,023,354 &#8211; 19,342,466];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[38,143,668 &#8211; 38,401,948];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[44,682,430 &#8211; 45,886,325];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[48,985,001 &#8211; 49,985,000]</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Floema Biotec, S.L.</font></div></td><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16.04 %</font></div></td><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10,654,955</font></div></td><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[19,342,467 &#8211; 27,342,466];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[38,401,949 &#8211; 41,056,903]</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:36px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.23076923076923%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:29%;"></td><td style="width:13%;"></td><td style="width:16%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:middle;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders</font></div></td><td style="vertical-align:middle;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">%</font></div></td><td style="vertical-align:middle;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:middle;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">N&#186; (inclusive)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Jorge Hern&#225;ndez Esteban</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.66%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3,757,607</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[27,342,467 &#8211; 29,808,219];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[41,056,904 -41,985,000];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[45,886,326 &#8211; 46,250,082]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2,426,699</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[29,808,220 &#8211; 32,000,000];</font></div><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[46,250,083 &#8211; 46,485,000]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16.12%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10,707,750</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[49,985,001 &#8211; 60,692,750]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#1f497d;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVEREADY INNVIERTE BIOTECH II, S.C.R., S.A.</font><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8.63%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5,732,499</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[60,692,751 &#8211; 66,425,249]</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TOTAL</font></div></td><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">100 %</font></div></td><td style="vertical-align:top;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">66,425,249</font></div></td><td style="vertical-align:top;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[1 - 66,425,249]</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Investment Round in VLP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Company, as sole shareholder of VLP, irrevocably undertakes to adopt the following corporate resolutions on the Agreement Date with the aim to conduct and approve VLP&#8217;s Capital Increase. The Company shall therefore adopt the following decisions:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)&#160;&#160;&#160;&#160;To approve the capital increase within the share capital of VLP for a total amount of EUR 700,000.-. Said capital increase shall be made through the issuance of 786,154 newly issued shares (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">participaciones sociales</font><font style="font-family:inherit;font-size:11pt;">&#8221;) in VLP, of TEN CENTS OF EURO (&#8364;0.10) of face value each, numbered 1,460,001 to 2,246,154 (both inclusive) and with the same economic and voting rights assigned to all the current shares of VLP (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Capital Increase Shares</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">). </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)&#160;&#160;&#160;&#160;Said VLP&#8217;s Capital Increase shall be approved by the Company. Consequently, the issuance to the Investors and the Company of the newly issued shares payable in cash will be conditional on the Investors and the Company making their payments of their respective cash by means of wire transfers from the Investors and the Company to be received in VLP&#8217;s Accounts on Closing Date. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii)&#160;&#160;&#160;&#160;The Company hereby irrevocably agree to take the actions set forth in this Clause 3.2 to enable VLP to issue the VLP&#8217;s Capital Increase Shares to the Investors and the Company. Consequently, the Company and, if necessary, VLP will expressly and irrevocably waive any and all rights of first refusal, pre-emptive rights, notices, consents or other rights the Company and/or the VLP may have under any agreement or arrangement in connection with VLP&#8217;s Capital Increase. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iv)&#160;&#160;&#160;&#160;The decisions adopted by the Company shall be reflected in the corresponding minutes substantially in the form attached hereto as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit D2</font><font style="font-family:inherit;font-size:11pt;">&#32;which will include (i) VLP&#8217;s Capital Increase approval according to the terms described in this Clause 3.2, (ii) the waiver of all rights of first refusal, pre-emptive rights, notices, consents or other rights that the Company and, if applicable, VLP may have in relation to the VLP&#8217;s Capital Increase, (iii) the amendment of the by-laws of VLP pursuant to the VLP&#8217;s Capital Increase and (iv) any other resolution to be adopted by the Company according to Spanish Law in order to implement VLP&#8217;s Capital Increase. The Company undertakes to sign and approve the content of said minutes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Company and the Investors shall on the Closing Date:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i) execute the wire transfers in due time so that the cash payments will be received in VLP&#8217;s Accounts on Closing Date and will provide reasonable evidence to the sole director of VLP, BDI Pharmaceuticals, duly represented by Mr. Emilio Guti&#233;rrez G&#243;mez, that the Investment Round of VLP has been effectively made. For the sake of clarity, the obligation of the Company to execute its wire transfer shall be subject to receipt from Inveready of the Inveready&#8217;s Company Cash-In Component; and</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii) subscribe for all the VLP&#8217;s Capital Increase Shares in VLP&#8217;s Capital Increase as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:Wingdings;font-size:6pt;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company shall subscribe for 318,954 shares of the VLP&#8217;s Capital Increase Shares by virtue of a cash contribution amounting to 284,000.- Euros (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company&#8217;s VLP Cash-in Component</font><font style="font-family:inherit;font-size:11pt;">&#8221;). The price per share shall be composed by a nominal value of 0.10 Euros per share (for a total amount of 31,895.40 Euros) plus a share premium of 0.79 Euros per share (for a total amount of 252,104.60 Euros); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:Wingdings;font-size:6pt;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic shall subscribe for 74,123  shares of the VLP&#8217;s Capital Increase Shares by virtue of a cash contribution amounting to 66,000.- Euros (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dyadic&#8217;s VLP Cash-in Component)</font><font style="font-family:inherit;font-size:11pt;">. The price per share shall be composed by a nominal value of 0.10 Euros per share (for a total amount of 7,412.30 Euros) plus a share premium of 0.79 Euros per share (for a total amount of 58,587.70 Euros); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:Wingdings;font-size:6pt;">n</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inveready shall subscribe for 393,077 shares of the VLP&#8217;s Capital Increase Shares by virtue of the cash contribution amounting to 350,000.- Euros (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Inveready&#8217;s VLP Cash-in Component)</font><font style="font-family:inherit;font-size:11pt;">. The price per share shall be composed by a nominal value of 0.10 Euros per share (for a total amount of 39,307.70 Euros) plus a share premium of 0.79 Euros per share (for a total amount of 310,692.30 Euros).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.2.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The subscription of the VLP&#8217;s Capital Increase Shares shall be effected by means of the notarization of a capital increase deed (the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8220;VLP&#8217;s Capital Increase Deed</font><font style="font-family:inherit;font-size:11pt;">&#8221;) in compliance with all the required formalities under Spanish law, including the registration of the VLP&#8217;s Capital Increase Deed in the Commercial Registry by VLP immediately following the Closing. For such purposes, the sole director of VLP, BDI Pharmaceuticals, duly represented by Mr. Emilio Guti&#233;rrez G&#243;mez, shall issue and sign the corresponding Certificate of the decisions made by the Company, which shall be approved and signed by him. This Certificate shall further be passed into public deed in the presence of the Spanish Public Notary by such Director of the Company (duly represented) and, subsequently, VLP shall file such public deed with the Commercial Registry of Salamanca.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.2.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">VLP, through its sole director, BDI Pharmaceuticals, duly represented by Mr. Emilio Guti&#233;rrez G&#243;mez, shall on the Closing Date: </font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i) Register the Investors and the Company as the titleholders of the VLP&#8217;s Capital Increase Shares in the VLP&#8217;s Shares Registry Book (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Libro Registro de Socios</font><font style="font-family:inherit;font-size:11pt;">&#8221;); and</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii) Deliver to each Investor and to the Company a certificate certifying that the Investors&#8217; and Company&#8217;s ownership over the VLP&#8217;s Capital Increase Shares subscribed by each Investor and the Company as a result of VLP&#8217;s Capital Increase have been registered in VLP&#8217;s Shares Registry Book (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Libro Registro de Socios</font><font style="font-family:inherit;font-size:11pt;">&#8221;).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.2.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">After the completion of VLP&#8217;s Capital Increase, the share capital of VLP shall be distributed as follows:</font></div></td></tr></table><div style="line-height:120%;padding-left:36px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.23076923076923%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:35%;"></td><td style="width:16%;"></td><td style="width:19%;"></td><td style="width:30%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">N&#186; (inclusive)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Biotechnology Developments for Industry, S.L.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">79.20%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1,778,954</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[1 &#8211; 1,778,954]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.30%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">74,123</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[1,778,955 &#8211; 1,853,077]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">INVEREADY INNVIERTE BIOTECH II, S.C.R., S.A.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17.50%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">393,077</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[1,853078 &#8211; 2,246,154]</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TOTAL</font></div></td><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">100 %</font></div></td><td style="vertical-align:top;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2,246,154</font></div></td><td style="vertical-align:top;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[1 &#8211; 2,246,154]</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI PHARMACEUTICALS&#8217; CAPITAL INCREASE AND USE OF PROCEEDS. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">EUR 1,150,000 resulting from the Company Cash-In Component received by BDI Holding by virtue of the Company&#8217;s Capital Increase shall be used (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Use of Proceeds</font><font style="font-family:inherit;font-size:11pt;">&#8221;) (i) for the development of Project A to be carried out by BDI Pharmaceuticals in accordance with the terms and provisions of the Research Services Agreement (EUR 934,000) and (ii) to finance the working capital of BDI Pharmaceuticals (EUR 216,000).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">In order to allocate EUR 1,150,000 resulting from the Company Cash-In Component in accordance with the Use of Proceeds as set forth in Clause 4.1 above, on the Closing Date, BDI Holding, as sole shareholder of BDI Pharmaceuticals, subject to receipt of the Dyadic&#8217;s Company Cash-In Component and Inveready&#8217;s Company Cash-In Component, shall effect a cash capital increase (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">aumento de capital dinerario</font><font style="font-family:inherit;font-size:11pt;">&#8221;) in BDI Pharmaceuticals by virtue of which BDI Pharmaceuticals increases its share capital in an aggregate amount  equal to EUR 1,150,000 (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Pharmaceuticals&#8217; Capital Increase</font><font style="font-family:inherit;font-size:11pt;">&#8221;). For such purposes, BDI Holding shall execute two wire transfers so that the cash payment corresponding to BDI Pharmaceuticals&#8217; Capital Increase will be made on Closing Date and will provide reasonable evidence to the Shareholders that the transfers have been effectively made. The subscription of all the newly issued shares of BDI Pharmaceuticals&#8217; Capital Increase shall be made by BDI Holding and effected by means of the notarization of a capital increase deed (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Pharmaceuticals&#8217; Capital Increase Deed</font><font style="font-family:inherit;font-size:11pt;">&#8221;) in compliance with all necessary acts to fulfill the required formalities under Spanish law, including the registration of the BDI Pharmaceuticals&#8217; Capital Increase Deed in the Commercial Registry.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">At such time as the BDI Pharmaceuticals&#8217; Capital Increase (i.e. EUR 1,150,000) is transferred and available to BDI Pharmaceuticals, the amount equal to EUR 934,000 transferred into a separate bank account of BDI Pharmaceuticals (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Pharmaceuticals&#8217; Project A Account</font><font style="font-family:inherit;font-size:11pt;">&#8221;), shall be used exclusively by BDI Pharmaceuticals for Project A under and in accordance with the terms and conditions set forth in the Research Services Agreement, keeping the other EUR 216,000 in BDI Pharmaceuticals&#8217; Account</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">to finance the working capital of BDI Pharmaceuticals. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVESTORS&#8217; PREFERRED CONDITIONS. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">After the Closing Date and within a period not exceeding five (5) years from such date, Dyadic (or any director, shareholder or other nominee of Dyadic designated by Dyadic in its sole discretion &#8211;jointly in this section 5 defined as &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dyadic&#8217;s Nominee</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and Inveready will have the option to invest in BDI Holding up to an additional 1,000,000 Euros and 500,000 Euros &#8211; respectively - (as &#8220;cash in&#8221; to be materialized through an increase of capital in BDI Holding) as follows:</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The pre-money valuation of BDI Holding will be at least thirty-three percent (33%) greater than the immediately preceding capital increase post-money valuation of BDI Holding (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Preferred Option</font><font style="font-family:inherit;font-size:11pt;">&#8221;); unless it is resolved pursuant to a General Shareholders Meeting that a capital increase in BDI Holding will be effected within the four (4) months following receipt of Dyadic&#8217;s (or Dyadic&#8217;s Nominee) Option Notice or Inveready&#8217;s Option Notice (as defined below), in which case Dyadic (or Dyadic&#8217;s Nominee) and Inveready will only have the right to invest in such capital increase at a discount of twenty percent (20%) of the capital raise valuation pertaining to such capital increase.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In connection with execution of the Preferred Option by Dyadic (or Dyadic&#8217;s Nominee) and Inveready, the Existing Shareholders and, if necessary, the Company, expressly and irrevocably undertake to waive any and all rights of first refusal, pre-emptive rights, notices, consents or other rights such shareholders and/or the Company may have under any agreement or arrangement in connection with the execution of the Preferred Option.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">In order to exercise the Preferred Option, at any time between the Closing Date and the date that is the fifth (5</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">) anniversary of such date, Dyadic (or Dyadic&#8217;s Nominee) and/or Inveready shall send a written notice to BDI Holding stating (i) its intention to exercise its Preferred Option and (ii) the amount that Dyadic (or Dyadic&#8217;s Nominee) and/or Inveready are willing to invest in the Company (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Option Notice</font><font style="font-family:inherit;font-size:11pt;">&#8221;).  In the thirty (30) day period commencing on the date that is one hundred twenty (120) days following the Company&#8217;s receipt of the Option Notice, all its Shareholders shall unanimously approve a capital increase in the Company pursuant to which the Company shall issue to Dyadic (or Dyadic&#8217;s Nominee) and/or Inveready the corresponding number of shares (with the same voting and economic rights as the other outstanding shares of the Company) at a value equal to thirty-three percent (33%) greater than the immediately preceding capital increase post-money valuation of the Company; provided, however, that if a capital increase has been duly approved pursuant to a General Shareholders Meeting of the Company within the four (4) months following receipt of Dyadic&#8217;s (or Dyadic&#8217;s Nominee) Option Notice or Inveready&#8217;s Option Notice, the provisions of Clause 5.1 shall apply and the Preferred Option shall cease to be enforceable). All shareholders of the Company (including Dyadic and Inveready) and the Company shall have expressly waive any and all rights of first refusal, pre-emptive rights, notices, consents or other rights such shareholders and/or the Company may have under any agreement or arrangement, with respect to the shares so subscribed for by Dyadic (or Dyadic&#8217;s Nominee) and/or Inveready.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Not later than the date that is fifteen (15) Business Days following the unanimous resolution to increase the capital of the Company adopted at the General Shareholders Meeting derived from the exercise of the Preferred Option, Dyadic or its nominee and/or Inveready shall subscribe and pay for the newly issued shares through a wire transfer of cash or other immediately available funds to the Company&#8217;s Accounts of the total amount of the cash contribution applicable to such capital increase. In the event that Dyadic or Dyadic&#8217;s Nominee and/or Inveready does not pay-in its capital for the newly issued shares within such fifteen (15) Business Day period, the increase of capital shall be considered as cancelled and Dyadic or Dyadic&#8217;s Nominee and/or Inveready will have no further rights to exercise the Preferred Option. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SHAREHOLDERS AGREEMENTS OF THE COMPANY AND OF VLP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Shareholders and the Company undertake to execute and enter into a BDI Holding Shareholders Agreement in the form attached to this Agreement as Exhibit A1.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Investors, the Company and VLP undertake to execute and enter into a VLP Shareholders Agreement in the form attached to this Agreement as Exhibit A2.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On Closing Date:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i) the BDI Holding Shareholders Agreement shall be entered into among all of the Shareholders and the Company by private means and further passed into public deed (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Escritura P&#250;blica</font><font style="font-family:inherit;font-size:11pt;">&#8221;) before the Notary; and</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii) VLP Shareholders Agreement shall be entered into among the Company, the Investors and VLP by private means and further passed into public deed (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Escritura P&#250;blica</font><font style="font-family:inherit;font-size:11pt;">&#8221;) before the Notary.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Shareholders further undertake to amend the existing Bylaws of BDI Holding and to adopt the necessary corporate decisions within the Company in order to comply with the terms and conditions agreed in the executed BDI Holding Shareholders Agreement and on terms reasonably acceptable to the Investors, to the extent permitted by the relevant Commercial Registry. For such purposes, the Shareholders will hold on the Closing Date a General Shareholders Meeting (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Junta General de socios con car&#225;cter universal</font><font style="font-family:inherit;font-size:11pt;">&#8221;) with the aim to adopt the amended Bylaws of BDI Holding and, if necessary, to pass said amended Bylaws of BDI Holding into public deed and file them at the corresponding Commercial Registry.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company and the Investors further undertake to amend the existing Bylaws of VLP and to adopt the necessary corporate decisions within VLP in order to comply with the terms and conditions agreed in the executed VLP Shareholders Agreement and on terms reasonably acceptable to the Investors, to the extent permitted by the relevant Commercial Registry. For such purposes, the Company and the Investors will hold on the Closing Date a General Shareholders Meeting (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Junta General de socios con car&#225;cter universal</font><font style="font-family:inherit;font-size:11pt;">&#8221;) with the aim to adopt the amended Bylaws of VLP and, if necessary, to pass said amended Bylaws of VLP into public deed and file them at the corresponding Commercial Registry.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">From and after the Closing Date:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i) the relationships between the Shareholders, as shareholders of the Company, shall be exclusively governed by the terms and conditions of the BDI Holding Shareholders Agreement and the Bylaws of BDI Holding  (as amended pursuant to the General Shareholders Meeting set forth in Clause 6.4).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii) the relationships between the Investors and the Company, as shareholders of VLP, shall be exclusively governed by the terms and conditions of the VLP Shareholders Agreement (as amended pursuant to the General Shareholders Meeting set forth in Clause 6.5).</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Parties acknowledge and agree that the provisions of Shareholders Agreements shall prevail over the Bylaws of BDI Holding and the Bylaws of VLP (as in force from time to time). Therefore, in the event that any of the provisions in Shareholders Agreements is not fully incorporated in the Bylaws of BDI Holding and the Bylaws of VLP and an inconsistency arises, the Shareholders Agreements shall prevail among the Parties and, upon request of any shareholder, the Parties shall exercise all powers and rights available to them, in order to give effect to the provisions of Shareholders Agreements and to procure the amendment of the Bylaws of BDI Holding and the Bylaws of VLP to conform to the Shareholders Agreements to the fullest possible extent.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SERVICE FRAMEWORK AGREEMENT; RESEARCH SERVICES AGREEMENT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic shall cause Dyadic International Inc. and the Company shall cause BDI Pharmaceuticals to execute and enter into (i) a Service Framework Agreement substantially in the form attached to this Agreement as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit B </font><font style="font-family:inherit;font-size:11pt;">and (ii) a Research Services Agreement substantially in the form attached to this Agreement as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit C.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">7.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On Closing Date, the Service Framework Agreement and the Research Services Agreement shall be entered into between Dyadic International Inc. and BDI Pharmaceuticals by private means.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CLOSING CONDITIONS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">General Conditions</font><font style="font-family:inherit;font-size:11pt;">: The obligations of the Parties to effect the Closing shall be subject to the following conditions, unless waived in writing by all of the Parties (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Closing</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Conditions</font><font style="font-family:inherit;font-size:11pt;">&#8221;):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Existing Shareholders shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Hold a General Shareholders Meeting (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Junta General de socios con car&#225;cter universal&#8221;)</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Company on the Agreement Date for the purpose of conducting and approving the Company&#8217;s Capital Increase as mentioned in Clause 3.1.1 above;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company shall: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">File of the 2015 and 2016 annual accounts of the Company at the corresponding Trade Registry.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Cause BDI Pharmaceuticals to file the 2015 and 2016 annual accounts of BDI Pharmaceuticals at the corresponding Trade Registry.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">File at the corresponding Trade Registry the Public Deed dated January 31, 2017 granted before the public notary of Valladolid, Mr. Javier G&#243;mez Mart&#237;nez (n&#186; 399 of his protocol), by means of which the share capital of the Company was increased by &#8364;80,000.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Implement the agreed 2016 incentive plan whereby Mr. Pablo Guti&#233;rrez as Chief Executive Officer and Mrs. Ana G&#243;mez as Chief Technical Officer of the Company would share their 2016 bonus of up to 6% of the share capital within the Company with the following &#8220;key shareholders&#8221;: Mr. Ricardo Arjona; Mr. Emilio Guti&#233;rrez and Mr. Luis Hilario. Said implementation shall be made through the granting of options over shares between the Existing Shareholders and includes passing the Company&#8217;s decision into Public Deed and file it at the Registry Book of Shares of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">e.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Adopt the necessary corporate decisions as sole shareholder of VLP and BDI Pharmaceuticals for the purpose of approving the 2016 annual accounts of both companies and file them at the corresponding Trade Registry(ies).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">f.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Adopt the necessary corporate decisions as sole shareholder of VLP on the Agreement Date for the purpose of conducting and approving VLP&#8217;s Capital Increase as mentioned in Clause 3.2.1 above;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">g.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Execute the wire transfers to VLP&#8217;s Account as stated in Clause 3.2.2;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">h.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Adopt the necessary corporate decisions as sole shareholder of BDI Pharmaceuticals on the Agreement Date for the purpose of conducting and approving BDI Pharmaceuticals&#8217; Capital Increase as mentioned in Clause 4.2. above;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Execute the wire transfer to BDI Pharmaceuticals&#8217; Account as stated in Clause 4.2.;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">j.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Cause BDI Pharmaceuticals to deposit an amount equal to EUR 934,000 into BDI Pharmaceuticals&#8217; Project A Account&#8221; as stated in Clause 4.3.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VLP shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">File of the 2016 annual accounts of VLP at the corresponding Trade Registry.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Notify BANKIA, S.A. about the investment of the Investors in the Company and in VLP and receive the corresponding consent of BANKIA, S.A. for such investment, saving the change of ownership clause resulting from the loan agreement n&#186; 15.876.357/60 dated May 20</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;2015. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic shall on Closing Date and subject to the fulfillment of Closing Conditions 8.1(i)(a), 8.1(ii) (not including letter &#8220;g.&#8221; of such provision which shall be fulfilled together with the other wire transfers on Closing Date mentioned in this Agreement (Clauses 8.1(ii)g and 8.1(v)): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Cause Dyadic International Inc to execute and enter into the Service Framework Agreement and the Research Services Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Cause Dyadic&#8217;s Company Cash-In Component to be effectively transferred and received in the Company&#8217;s Account;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Cause Dyadic&#8217;s VLP Cash-In Component to be effectively transferred and received in VLP&#8217;s Account.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inveready shall on the Closing Date and subject to the fulfillment of Closing Conditions 8.1(i)(a) and 8.1(ii) (not including letter &#8220;g.&#8221; of such provision which shall be fulfilled together with the other wire transfers on Closing Date mentioned in this Agreement (Clauses 8.1(ii)g and 8.1(iv)): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Cause Inveready&#8217;s Company Cash-In Component to be effectively transferred and received in the Company&#8217;s Account.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Cause Inveready&#8217;s VLP Cash-In Component to be effectively transferred and received in VLP&#8217;s Account.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Specific Conditions to the execution of the Transaction Documents on Closing Date by the Investors</font><font style="font-family:inherit;font-size:11pt;">: The obligation of the Investors to enter into the Transaction Documents (other than this Investment Agreement) shall be subject to the following conditions, except to the extent waived in writing by the Investors, that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Since the date of execution of this Agreement and through the Closing:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">no Material Adverse Event shall have occurred or be continuing,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">nor there has been any breach of the Covenants set forth in Clause 10,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the Warranties set forth in Clauses 11 and 14 and Schedule IV shall be true and correct in all material respects at the date when made and at the Closing Date. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Specific Conditions for the execution of the Transaction Documents on Closing Date by the Parties</font><font style="font-family:inherit;font-size:11pt;">: The Parties shall have received the documents referred to in Section 9.4 of this Agreement.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Date of fulfilment of the Closing Conditions</font><font style="font-family:inherit;font-size:11pt;">. All the Closing Conditions (except for the Closing Conditions 8.1(ii).g, 8.1.(iv) and 8.1.(v) which shall be fulfilled on Closing Date) must be fulfilled within ten (10) Business Days from the Agreement Date or on such other date as may be agreed upon in writing by all the Parties (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Long Stop Date</font><font style="font-family:inherit;font-size:11pt;">&#8221;). The Long Stop Date may under no circumstances exceed in any case June 30</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Completion</font><font style="font-family:inherit;font-size:11pt;">. This Agreement will become effective on the Agreement Date. Once the Closing Conditions have been fulfilled or waived, the Capital Increases shall be completed on the Closing Date before the Notary according to the provisions of Clause 3 together with all the other agreements. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Proceedings at Closing Date</font><font style="font-family:inherit;font-size:11pt;">: All proceedings to be taken and all documents to be executed and delivered by the Parties at the Closing shall be deemed to have been taken and executed simultaneously and no proceedings shall be deemed taken nor any documents executed or delivered until all have been taken, executed and delivered.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CLOSING. ACTIONS ON THE CLOSING DATE. CLOSING DELIVERIES.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Closing Date will be the date set by the Company within ten (10) Business Days from the date of fulfilment or waiver of the Closing Conditions, except for the Closing Conditions 8.1(ii).g, 8.1.(iv) and 8.1.(v) which shall be fulfilled on Closing Date (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Closing Date</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:11pt;">).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Party that first becomes aware of the fulfilment of any Closing Condition will notify BDI Holding of that fulfilment. Once the last pending Closing Condition (except for the Closing Conditions 8.1(ii).g, 8.1.(iv) and 8.1.(v) which shall be fulfilled on Closing Date) has been fulfilled or waived, BDI Holding will give the Parties notice of the Closing Date at least five (5) Business Days in advance.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Closing will be carried out before the Notary at the time designated by BDI Holding.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">On the Closing Date, in one and the same act (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#8220;en unidad de acto&#8221;</font><font style="font-family:inherit;font-size:11pt;">), the Parties shall execute the following actions related to the Transaction Documents:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Execute the Certificate of the Minutes described in Clause 3.1.1 (iv) above and pass the same into public deed before the Public Notary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.3.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Execute the Certificate of the Minutes described in Clause 3.2.1 (iv) above and pass the same into public deed before the Public Notary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.3.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Execute BDI Pharmaceuticals&#8217; Capital Increase Deed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.3.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Execute the Minutes and Certificate of the Minutes approving the change of the governing body of the Company (accepting the resignation of the current Company&#8217;s directors and appointing the new directors) and any amendments of the Bylaws of BDI Holding as per this Agreement; pass such Certificate of the Minutes into public deed before the Public Notary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.3.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Execute the Minutes and Certificate of the Minutes approving the change of the governing body of VLP (accepting the resignation of the current Company&#8217;s director and appointing the new directors) and any amendments of the Bylaws of VLP as per this Agreement; pass such Certificate of the Minutes into public deed before the Public Notary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.3.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">&#32;Execute the Minutes and Certificate of the Minutes approving the change of the governing body of BDI Pharmaceuticals (accepting the resignation of the current director and appointing new directors) </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:36px;padding-bottom:13px;padding-top:13px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">and any amendments of the Bylaws of BDI Pharmaceuticals; pass such Certificate of the Minutes into public deed before the Public Notary;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.3.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Execute the Shareholders Agreements substantially in the form attached to this Agreement as Exhibit A1 and A2 and pass such agreements into public deeds.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.3.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Execute the Service Framework Agreement between Dyadic International Inc. and BDI Pharmaceuticals substantially in the form attached to this Agreement as Exhibit B.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.3.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Execute the Research Services Agreement between Dyadic International Inc. and BDI Pharmaceuticals substantially in the form attached to this Agreement as Exhibit C. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Simultaneously or prior to the Closing Date, the following actions shall be performed and the following items shall be delivered duly executed by the Parties (where appropriate) (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Closing Deliveries</font><font style="font-family:inherit;font-size:11pt;">&#8221;):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By all the Parties: Delivery by the Parties of the corresponding Powers of Attorney to execute the Agreement; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By the Company and VLP:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery of the Minutes approving (i) the Company&#8217;s Capital Increase according to the terms described in Clause 3.1.1 (iv) above, (ii) the waiver of all rights of first refusal, pre-emptive rights, notices, consents or other rights the Existing Shareholders and, if applicable, the Company may have in relation to the Company&#8217;s Capital Increase, (iii) the amendment of the Bylaws of BDI Holding pursuant to this Company&#8217;s Capital Increase, and (iv) any other resolution to be adopted by the Existing Shareholders according to Spanish Law in order to implement the Company&#8217;s Capital Increase;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery of the Minutes approving (i) VLP&#8217;s Capital Increase according to the terms described in Clause 3.2.1 (iv) above (ii) the waiver of all rights of first refusal, pre-emptive rights, notices, consents or other rights that the Company and, if applicable, VLP may have in relation to the VLP&#8217;s Capital Increase, (iii) the amendment of the by-laws of VLP pursuant to the VLP&#8217;s Capital Increase and (iv) any other resolution to be adopted by the Company according to Spanish Law in order to implement VLP&#8217;s Capital Increase;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery of the Minutes approving (i) BDI Pharmaceuticals&#8217; Capital Increase according to the terms described in Clause 4.2 above, (ii) the amendment of the by-laws of BDI Pharmaceuticals pursuant to the BDI Pharmaceuticals&#8217; Capital Increase and (iii) any other resolution to be adopted by BDI Pharmaceuticals according to Spanish Law in order to implement BDI Pharmaceuticals&#8217; Capital Increase;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery by BDI Holding of the original bank certificates proving that Dyadic&#8217;s Company Cash-in Component and Inveready&#8217;s Company Cash-in Component have been transferred to the Company&#8217;s Accounts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">e.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery by VLP of the original bank certificates proving that Dyadic&#8217;s VLP Cash-in Component, the Company&#8217;s VLP Cash-in Component  and Inveready&#8217;s VLP Cash-in Component have been transferred to the VLP&#8217;s Accounts;  </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">f.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">A bank document to be issued by BDI Pharmaceuticals&#8217; bank evidencing that the Company has duly transferred the cash payment corresponding to BDI Pharmaceuticals&#8217; Capital Increase in BDI Pharmaceuticals&#8217; bank accounts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">g.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Evidence that the Company has deposited (i) an amount equal to EUR 934,000 into BDI Pharmaceuticals&#8217; Project A Account.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">h.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Registration of the Company&#8217;s Capital Increase on the share registry book of the Company by way of an entry made by the secretary of its Board of Directors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Registration of BDI Pharmaceuticals&#8217; Capital Increase Deed on the share registry book of BDI Pharmaceuticals by way of an entry made by the secretary of its Board of Directors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">j.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Registration of VLP&#8217;s Capital Increase Deed on the share registry book of VLP by way of an entry made by its sole director;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">k.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery by BDI Holding of the written resignation of the current Directors of the Company and of BDI Pharmaceuticals effective upon the Closing Date;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">l.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery by VLP of the written resignation of the current sole Director of VLP effective upon the Closing Date;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">m.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Labour and Tax Certificate: The Company shall provide the Investors with certificates from the Spanish Social Security and Tax Authorities in relation to BDI Group evidencing i) the absence of outstanding obligations and payments to the Social Security Authority and ii) the absence of any tax debt, sanctions and liabilities towards the Spanish Tax Authorities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:84px;"><font style="font-family:inherit;font-size:12pt;">n.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery by BDI Pharmaceuticals of a written statement from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, S.A. stating that (i) it undertakes to continue with the lease agreement entered into BDI Pharmaceuticals &#8211;as lessee- with Verbia Nanotechnology S.L. &#8211;as lessor- in relation to the industrial premises located in Boecillo (Calle Louis Proust 13, plot ZT-3.1.3, 47151 Boecillo (Valladolid) after the enforcement of the mortgage of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, S.A. and (ii) it accepts the sublease agreement entered into by BDI Pharmaceuticals and VLP on March 15</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;2016.</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:38px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:11pt;">By the Shareholders:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:104px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:76px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery by the corresponding Shareholder of the written acceptance letter of the Directors appointed by it for the Company, BDI Pharmaceuticals and VLP effective upon the Closing Date;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:74px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:38px;"><font style="font-family:inherit;font-size:11pt;">(iv)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-1.3333333333333333px;"><font style="font-family:inherit;font-size:11pt;">By Dyadic:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:104px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:76px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery by Dyadic to the Notary of its Spanish Tax Identification Number;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:104px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:76px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery by Dyadic to the Notary of the Foreign Identification Numbers of the Directors appointed by it;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:104px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:76px;"><font style="font-family:inherit;font-size:12pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Delivery by Dyadic to the Notary of the corresponding D-1A form to communicate the foreign investment to the Spanish General Directorate for Trade and Investment. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The abovementioned actions shall be undertaken simultaneously on the Closing Date, as part of a single transaction (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">unidad de acto</font><font style="font-family:inherit;font-size:11pt;">&#8221;). Consequently, none of the foregoing actions shall be held to have been completed until such time as each and every one of the other actions is completed.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">COVENANTS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Access and Information: Between the date hereof and the Closing Date, subject to Spanish Law and as reasonably necessary to preserve attorney client privilege:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Existing Shareholders and the Company shall, and shall cause the BDI Group to authorize and permit the Investors to have reasonable access, upon reasonable notice and in such manner as will not unreasonably interfere with the conduct of the Business or the other businesses of BDI Group to (a) properties, assets, facilities, premises, books and records, contracts and other documents and data relating to the Business as the Investors may from time to time reasonably request and (b) the other members of senior management and employees of the Business.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Existing Shareholders and the Company shall, and shall cause BDI Group to furnish the Investors with such financial, trading, operating and other data and information relating to the Business as the Investors may reasonably request and provided that such request that does not impose on the Company or the Existing Shareholders any unreasonable burden. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">iii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Existing Shareholders and the Company shall promptly notify the Investors of any material breach of Clause 10.2 below and of any material matters affecting or that would reasonably be expected to affect the Business, the Transactions contemplated by this Agreement or the Closing.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No information or notice provided to the Investors pursuant to this Clause 10.1 shall operate as a waiver of or otherwise affect any representation, warranty or agreement given or made by the Existing Shareholders or the Company in this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Conduct of Business: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">During the period from the date hereof until the Closing Date, the Existing Shareholders and the Company shall, and shall cause the BDI Group to conduct the Business in the ordinary course consistent with past practice and (without limiting the generality of the foregoing) to use commercially reasonable efforts to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">maintain and preserve intact the Business organizations and relationships with third parties and to keep available the services of the Business employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">maintain and preserve intact in a manner consistent with past practices (A) all material assets, structures, equipment and other tangible personal and real property of or required in the operation of the Business in their present repair, order and condition, except for ordinary wear and tear, (B) the business operations, franchise and goodwill of the Business, (C) the insurance coverage applicable to the Business (or equivalent replacement coverage), (D) all permits required for the conduct of the Business as conducted as of the date hereof or for the ownership and use of the assets of the Business, and (E) all accounting and other records in the ordinary and usual course;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">continue to collect accounts receivable in a manner consistent with past practices, without discounts; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">perform all material obligations of the Business and continue capital expenditures in accordance with current capital expenditure programs in a manner consistent with past practices.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">ii.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Without limiting the generality of the foregoing, from the date hereof until the Closing Date, with respect to the Business, the Existing Shareholders shall not and shall ensure that the BDI Group does not, without the prior written consent (which shall not be unreasonably withheld, conditioned or delayed) of the Investors unless it is within the ordinary course of  business, or derived from or in connection with what is expressly provided for in this Agreement:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">sell, lease, assign, license, transfer or otherwise dispose of any assets, rights or properties (or portions thereof) of the BDI Group;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">mortgage, pledge or subject any material assets or properties of the BDI Group to any additional lien;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">make, grant or promise any material bonus or any material increase to the compensation of any Business employees, officer or director, or make, grant, promise, or defer payment of, or make any other material change in employment terms for any employee, officer or director of the BDI Group;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">engage any new member of the managing bodies in the BDI Group or to decide on any material change in the workforce of the BDI Group;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">e.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">create, incur, assume or guarantee any Indebtedness for borrowed money or any Indebtedness outside of the ordinary course of business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">f.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">make or change any material tax election, file any material amended tax return, enter into any material tax closing agreement, settle any material tax claim or assessment relating to the Business, surrender any material right to claim a refund of material taxes, consent to any material extension or waiver of the limitation period applicable to any material tax claim or assessment relating to the Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">g.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">change the fiscal year end of any of the BDI Group or change any annual accounting period of any of the BDI Group, or, except  as may be required by a change in Law, adopt or change any accounting method used as of the date of this Agreement  or by any company of the BDI Group;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">h.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(A) acquire or agree to acquire by merging or consolidating with, or by purchasing a substantial portion of the assets of any Person or division thereof (other than inventory in the ordinary course of business) or otherwise acquire or license any assets or properties (other than inventory in the ordinary course of business) that are material, individually or in the aggregate to the BDI Group  taken as a whole or to the Business, (B) effect any recapitalization, reclassification or like change in its capitalization or (C) make any loan, advance or capital contribution to, or acquire any equity interests or securities convertible or exchangeable into equity interests in, or otherwise make any investment in any Person;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">amend or authorize the amendment of the bylaws (or similar organizational documents) of the BDI Group;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">j.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">pay, discharge, settle or satisfy any claims, liabilities or obligations (absolute, accrued, asserted or unasserted, contingent or otherwise), other than the payment, discharge, settlement or satisfaction of any of the following (i) in the ordinary course of business or (ii) if the amount involved is less than EUR 10.000 in the aggregate; or defer payment of any accounts payable other than in the ordinary course of business, or give any discount, accommodation or other concession other than in the ordinary course of business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">k.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">declare or pay, or set aside funds for the payment of, any dividends on or make any other distributions in stock or property in respect of any of the equity interests; split, combine or reclassify any of its capital stock (or other equity interests) or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock (or other equity interests); change any rights, preferences, privileges or restrictions on any of its outstanding equity interests; adopt or carry out any plan of liquidation or dissolution; or repurchase, redeem, or otherwise acquire, directly or indirectly, any shares of stock or other equity interests;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">l.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(A) commence a lawsuit other than (1) for the routine collection of bills or any other trade receivables, (2) in such cases where the Existing Shareholders or the Company in good faith determines that failure to commence suit would result in the material impairment of a valuable aspect of the Business (provided that the Existing Shareholders or the Company obtain the Investors approval and consent prior to the filing of such a suit), or (3) in connection with the enforcement or breach of the terms of this Agreement, or (B) settle or agree to settle any pending or threatened lawsuit or proceeding or material dispute; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">m.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">enter into any oral or written agreement, contract, commitment, arrangement or understanding to do any of the foregoing.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">n.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Conduct any activities on behalf of any member of the BDI Group, Dyadic or any third party that, directly or indirectly, incorporate or use (whether alone or in combination with any other intellectual property of the BDI Group or any third party) any component of the C1 Technology (as such term is defined in the Research Services Agreement) or any derivatives or modifications thereof, except as expressly permitted by and in accordance with the terms and provisions of the Research License Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Efforts; No Inconsistent Actions.: Subject to the terms and conditions hereof, the Existing Shareholders, the Company and the Investors shall cooperate and use commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to consummate and make effective this Transaction and to cause the conditions to each other&#8217;s obligation to close the transaction as set forth in Clauses 3 to 7 to be satisfied.  The Existing Shareholders, the Company and the Investors shall cooperate with each other to the extent reasonable in connection with the foregoing.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notification of Certain Matters.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each Party shall give prompt notice to the other of (i) the occurrence, or failure to occur, of any event or the existence of any condition that has caused or could reasonably be expected to cause any of its representations or warranties contained in this Agreement to be untrue or inaccurate in any material </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">respect at any time after the date hereof, up to and including the Closing Date, that reasonably could be expected to prevent the Closing from occurring and (ii) any failure on its part to comply with or satisfy, in any material respect, any covenant, condition or agreement to be complied with or satisfied by it under this Agreement, which failure reasonably could be expected to prevent the Closing from occurring.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">10.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Exclusivity. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Until the earlier of the Closing and such time as this Agreement is terminated in accordance with Clause 16, neither the Company nor the Existing Shareholders will directly or indirectly enter into or knowingly solicit, initiate, encourage, facilitate or continue any inquiries or negotiation, discussion, contract, agreement, instrument, arrangement or understanding with any party (whether or not binding), or any merger, recapitalization or similar transaction, with respect to the sale of the BDI Group&#8217;s shares, the assets of the BDI Group or any or all of the Business.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Existing Shareholders shall immediately cease and cause to be terminated, all existing discussions or negotiations with any Persons conducted heretofore with respect to an inquiry, proposal or offer from any Person (other than the Investors) relating to the direct or indirect disposition, whether by sale, merger or otherwise, of all or any portion of the Business or the Company&#8217;s shares owned by the Existing Shareholders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Existing Shareholders agree that the rights and remedies for non-compliance with this Clause 10.6 shall include the right to seek the specific enforcement of such provision, it being acknowledged and agreed that any such breach or threatened breach shall cause irreparable injury to the Investors and that money damages would not provide an adequate remedy to the Investors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXISTING SHAREHOLDERS&#8217; WARRANTIES.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">11.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company and the Existing Shareholders jointly and severally, except as otherwise provided herein, represent and warrant to the Investors that each of the warranties of the Company and each Existing Shareholder set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule IV</font><font style="font-family:inherit;font-size:11pt;">&#32;attached to this Agreement (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Warranties</font><font style="font-family:inherit;font-size:11pt;">&#8221;) (i) are true, exact, complete and accurate and not misleading as at the Agreement Date  and (ii) gives the right to the Investors to be indemnified in accordance with the terms and conditions of this Agreement for Losses in the event that any of the  Warranties is proved to be false or misleading or is otherwise breached according to the Company and Existing Shareholders&#8217; indemnification obligations stated in the Schedule V attached to this Agreement. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company and the Existing Shareholders will jointly and severally, except as otherwise provided herein, ratify at Closing Date sections 11.1(i) and (ii) above.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;text-indent:-36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11.2 Each Warranty shall be construed as a separate and independent warranty and, except where expressly stated, shall not be limited or restricted by reference to or inference from the terms of any other Warranty or any other provision of this Agreement and the Investors shall have a separate claim and right of action in respect of each and every breach of Warranty.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">11.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The rights and remedies of the Investors in respect of any breach of the Warranties shall not be limited or, in any other way, restricted or affected by:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the execution of the Transaction Documents on Closing Date; or</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">either Investor failing to exercise or delaying the exercise of any right or remedy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">11.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company and the Existing Shareholders&#8217; indemnification obligations are set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule V</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXISTING SHAREHOLDERS SPECIFIC INDEMNITIES OBLIGATIONS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">12.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition to the rights and remedies in paragraph 1 of Schedule V, the Existing Shareholders shall fully indemnify and hold harmless on demand on a continuing basis the Investors, the Company and/or any BDI Group, from and against any and all Losses suffered or incurred by the Investor, the Company and/or any BDI Group relating to, arising out of or resulting from specific indemnities listed in this Clause 12 (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Specific Indemnities</font><font style="font-family:inherit;font-size:11pt;">&#8221;).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">a</font><font style="font-family:inherit;font-size:12pt;">ny breach by BDI Pharmaceuticals and/or VLP caused before the Closing Date of the labour and social security regulations regarding the temporary recruitment for specific projects or services with temporary employees, which may imply severance payments, fines and the return of social security deductions, in connection with the current temporary contracts and the previous temporary contracts entered into; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(ii) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any breach by BDI Pharmaceuticals and/or VLP caused before the Closing Date in connection with the minimum salaries stated by the applicable Collective Bargaining Agreements for each professional category, which may imply monetary claims, social security contributions and associated fines.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">12.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Limitations of liability established in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Schedule VI</font><font style="font-family:inherit;font-size:11pt;">&#32;shall not apply to the Specific Indemnities set forth in Clause 12.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LIMITATION OF LIABILITY.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Subject to clause 13.2, the limitations contained in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Schedule VI</font><font style="font-family:inherit;font-size:11pt;">&#32;shall apply to (i) any breach or inaccuracy of any of the Warranties set forth in Section 11 of the Agreement and Schedule IV attached thereto as well as (ii) any breach or inaccuracy of the Covenants, agreements or obligations of the Existing Shareholders, the Company or VLP under this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">13.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notwithstanding any other provisions of this Agreement, none of the limitations contained in this Agreement, </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Schedule VI</font><font style="font-family:inherit;font-size:11pt;">&#32;or any statutory limitation shall apply in relation to (i) the Specific Indemnities, (ii) any claim relating to the warranties of Section 1 (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Authority and Capacity</font><font style="font-family:inherit;font-size:11pt;">) and 2 (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Title of Shares in the Company and VLP</font><font style="font-family:inherit;font-size:11pt;">) listed in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Schedule IV</font><font style="font-family:inherit;font-size:11pt;">&#32;and (iii) the liability of the Existing Shareholders to any claim where the fact, matter or circumstance giving rise to such claim arises as a result of fraud (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">dolo</font><font style="font-family:inherit;font-size:11pt;">&#8221; o &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">culpa grave</font><font style="font-family:inherit;font-size:11pt;">&#8221;), fraudulent misrepresentation, deliberate misstatement or wilful concealment on the part of any of the Existing Shareholders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVESTORS&#8217; WARRANTIES.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Investors represent and warrant to the Company and to the Existing Shareholders that each of the warranties of such Investor set out in this Clause 14 (i) is true, correct, complete, accurate and not misleading as of the date hereof and on Closing Date; and (ii) gives the right to the Company and the Existing Shareholders to be indemnified in accordance with the terms and conditions of this Agreement for Losses in the event that any of the mentioned warranties is proved to be false or misleading or is otherwise breached. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic is a corporation duly organized and validly existing under the laws of the State of Florida, USA. This Investor has the corporate power and authority to enter into the Transaction Documents to which it is a party, to consummate the transactions contemplated by such Transaction Documents and to carry out its obligations thereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic is not insolvent or the subject of any proceedings for its administration, safeguard or liquidation or any other insolvency, bankruptcy, receivership proceedings applicable under the laws of any jurisdiction and no facts exist that would result in any such event occurring. This Investor is not the subject of any voluntary or judicial reorganization proceedings, or in liquidation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The execution of this Agreement by Dyadic&#8217;s signatory and the consummation of the Transaction contemplated herein have been duly authorized by Dyadic&#8217;s board of directors and by all necessary consents, actions and proceedings of such Investor required by Applicable Laws. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement has been duly executed by Dyadic and constitutes its legal and binding obligation, enforceable against it in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors rights generally. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic has the financial resources required to close the transactions contemplated by this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No Conflict: The execution, delivery and performance of this Agreement and of the Transaction Documents to which Dyadic is a party and the consummation of the transactions contemplated by hereby and thereby, do not and will not (i) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under any agreement to which Dyadic is a party is bound, or (ii) result in a violation of any Law to which Dyadic is subject.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inveready.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inveready is duly organized and validly existing under the laws of Spain. This Investor has the corporate power and authority to enter into this Agreement and to carry out its obligations hereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inveready is not insolvent or the subject of any proceedings for its administration, safeguard or liquidation or any other insolvency, bankruptcy, receivership proceedings applicable under the laws of any jurisdiction and no facts exist that would result in any such event occurring. This Investor is not the subject of any voluntary or judicial reorganization proceedings, or in liquidation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The execution of this Agreement by Inveready&#8217;s signatory and the consummation of the Transaction contemplated herein have been duly authorized by Inveready&#8217;s board of directors and by all necessary consents, actions and proceedings of such Investor required by Applicable Laws. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement has been duly executed by Inveready and constitutes its legal and binding obligation, enforceable against it in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors rights generally.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inveready has the financial resources required to close the transactions contemplated by this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No Conflict: The execution, delivery and performance of this Agreement and of the Transaction Documents to which Inveready is a party and the consummation of the transactions contemplated by hereby and thereby, do not and will not (i) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under any agreement to which Inveready is a party is bound, or (ii) result in a violation of any Law to which Inveready is subject.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TERM.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Unless the Agreement shall have expired on the Long Stop Date in accordance with Clause 8.2 above, this Agreement shall remain in full force and effect as long as each of the Parties continue holding Shares in the Company, and as long as expressly stated herein for those obligations for which the Agreement expressly foresees a longer term.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TERMINATION.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">16.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Termination of Agreement: Notwithstanding anything herein to the contrary, this Agreement may be terminated:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">at any time prior to the Closing Date by mutual written consent of all of the Parties; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">by either the Company and all of the Existing Shareholders, on the one hand, or either of the Investors, on the other hand, by written notice to the other Parties, if the Closing has not taken place on or before the Long Stop Date, or such later date as the Parties may agree to in writing (not exceeding under any circumstances June 30</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;2017 as set forth in Clause 8.4 above). In this case and if derived from the non-fulfillment of any of the Closing Conditions, each of the Parties shall have the right to claim for any damages to the Party who failed to perform the Closing Conditions in breach of its obligations under this Agreement subject to the terms and conditions of this Agreement; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">by either the Company and all the Existing Shareholders, on the one hand, or either of the Investors on the other hand, by written notice to the other Parties, if the Closing Conditions have not been fulfilled or waived by any of the Parties before the Long Stop Date, or such later date as all the Parties may agree to in writing. In this case, each of the Parties shall have the right to claim for any damages to the Party who failed to perform the Closing Conditions in breach of its obligations under this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">16.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Effect of Termination: In the event of termination by any Party or Parties pursuant to this Clause 16, written notice thereof shall promptly be given to the other Parties and the transactions contemplated by this Agreement shall be terminated without further action by any Party. If the transactions contemplated by this Agreement are terminated as provided herein:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company and the Existing Shareholders, on the one hand, and the Investors, on the other hand, shall return to the other all documents and other materials received from the other Parties (including all copies or reproductions thereof in whatever form or medium, including electronic copies, or materials developed from any such documents or other materials) relating to the Transaction, whether obtained before or after the date hereof; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If this Agreement is terminated as provided in this Clause 16, this Agreement shall become null and void and of no further force or effect (except as otherwise provided in this Clause 16); provided, that the provisions of Clauses regarding &#8220;Definitions and interpretation rules&#8221;, &#8220;Closing Conditions&#8221;, &#8220;Confidentiality&#8221;, &#8220;Expenses and taxes&#8221;, &#8220;Notices&#8221;, and &#8220;Applicable Law and Jurisdiction&#8221;) shall survive any termination hereof.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Nothing in this Clause 16 shall be deemed to release, or limit the Liabilities of, any Party from any Liability for any intentional breach by such Party of any representation, warranty or covenant (including the requirement to consummate the Closing if all of the Closing Conditions set forth in Clause 8 have been satisfied) contained in this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFIDENTIALITY.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Definition</font><font style="font-family:inherit;font-size:11pt;">.  &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:11pt;">&#8221; means any information disclosed by one Party (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;) to the other (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;), whether oral, written, visual, electromagnetic, electronic or in any other form, and whether contained in memoranda, summaries, notes, analyses, compilations, studies or other documents, and whether the same have been prepared by the Disclosing Party or the Receiving Party: (i) which, if in written, graphic, machine-readable or other tangible form is marked as &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Confidential</font><font style="font-family:inherit;font-size:11pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Proprietary</font><font style="font-family:inherit;font-size:11pt;">,&#8221; or which, if disclosed orally or by demonstration, is identified at the time of initial disclosure as confidential and is summarized in writing and similarly marked and delivered to the Receiving Party within thirty (30) Days after initial disclosure; and (ii) which includes but is not necessarily limited to (A) technical data or information, including proprietary host organisms and their strains, plasmids/vectors, DNA sequences, genetic elements, genomic information and annotated genomic information, gene expression tools and protocols, fungal high throughput screening, enzymes and other proteins and their applications, research and manufacturing protocols and practices, formulae, charts, analyses, reports, patent applications, trade secrets, ideas, methods, processes, know-how, computer programs, products, equipment, raw materials, designs, data sheets, schematics, configurations, specifications, techniques, drawings, and the like, whether or not relating to experimental data, projects, products, processes, research practices and the like, (B) past, present and future business, financial and commercial data or information, prices and pricing methods, marketing and customer information, financial forecasts and projections, and other data or information relating to strategies, plans, budgets, sales and the like; and (C) any other data or information delivered by the Disclosing Party to the Receiving Party or which the Receiving Party has acquired from the Disclosing Party by way of the former&#8217;s inspection or observation during visits to the research laboratory, manufacturing plan or other type of facility of the latter Party. The Parties expressly acknowledge and agree that all information of a proprietary and/or confidential nature furnished by the Disclosing Party to the Receiving Party in furtherance of the Disclosing Party&#8217;s obligations under this Agreement shall be deemed Confidential Information.</font><font style="font-family:inherit;font-size:12pt;">&#32;Notwithstanding anything to the contrary contained herein, any failure by the Disclosing Party to mark, identify or confirm the Confidential Information shall not relieve Receiving Party of its obligations under this Agreement where Receiving Party knows or has reason to know that the information disclosed to it is Confidential Information.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Confidential Information Exclusions</font><font style="font-family:inherit;font-size:11pt;">.  Confidential Information will exclude information the Receiving Party can demonstrate is: (i) now or hereafter, through no unauthorized act or failure to act on Receiving Party&#8217;s part, in the public domain; (ii) known to the Receiving Party from a source other than the Disclosing Party (including former employees of the Disclosing Party) without an obligation of confidentiality at the time Receiving Party receives the same from the Disclosing Party, as evidenced by contemporaneous written records; (iii) furnished to others by the Disclosing Party without restriction </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:36px;padding-bottom:13px;padding-top:13px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">on disclosure; or (iv) independently developed by the Receiving Party without use of the Disclosing Party&#8217;s Confidential Information, as evidenced by contemporaneous written records.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Confidentiality Obligation</font><font style="font-family:inherit;font-size:11pt;">.  For a period commencing on this date and ending on the tenth (10th) anniversary after the termination of the Agreement, the Receiving Party shall treat as confidential all of the Disclosing Party&#8217;s Confidential Information and shall not use such Confidential Information for any purpose whatsoever other than for the purposes set forth herein, except as expressly otherwise permitted under this Agreement. Without limiting the foregoing, the Receiving Party shall use the same degree of care and means that it utilizes to protect its own information of a similar nature, but in any event not less than reasonable care and means, to prevent the unauthorized use or the disclosure of such Confidential Information to Third Parties. The Confidential Information may be disclosed only to employees or contractors of the Receiving Party with a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">need to know</font><font style="font-family:inherit;font-size:11pt;">&#8221; who are instructed and agree not to disclose the Confidential Information and not to use the Confidential Information for any purpose, except as set forth herein; provided, however, in the case of BDI Group, the term &#8220;employees or contractors of a Receiving Party&#8221; shall include employees of each of those of BDI Group and any contract research organizations with whom BDI Group has written agreements pursuant to which such contract research organization is performing or will perform work under a project and is bound by an obligation of confidence to BDI Group that makes such contract research organization liable for any breach by its employees of those confidentiality obligations to BDI Group. The Receiving Party shall have appropriate written agreements with any such employees or contract research organizations sufficient to comply with the provisions of this Agreement. A Receiving Party may not alter, decompile, disassemble, reverse engineer, or otherwise modify any Confidential Information received hereunder and the mingling of the Confidential Information with information of the Receiving Party shall not affect the confidential nature or ownership of the same as stated hereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Permitted Disclosures of Confidential Information by BDI Group.  </font><font style="font-family:inherit;font-size:11pt;">Nothing in this Agreement shall prevent the Receiving Party from disclosing Confidential Information to the extent the Receiving Party is legally compelled to do so by any governmental investigative or judicial agency pursuant to proceedings over which such agency has jurisdiction; provided, however, that prior to any such disclosure and to the extent permitted by law, the Receiving Party shall (i) assert the confidential nature of the Confidential Information to the agency; (ii) immediately notify the Disclosing Party in writing of the agency&#8217;s order or request to disclose; and (iii) cooperate fully with the Disclosing Party in protecting against any such disclosure and/or obtaining a protective order narrowing the scope of the compelled disclosure and protecting its confidentiality.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXPENSES AND TAXES.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">18.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Parties will be responsible for the expenses and taxes derived from negotiating, formalising and executing this Agreement, as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Costs incurred in formalizing the Capital Increase Deed before the Notary shall be paid by the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Costs incurred in formalizing BDI Pharmaceuticals&#8217; Capital Increase Deed before the Notary shall be paid by BDI Pharmaceuticals.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Fees for advisors and other professionals will be paid by the Party that contracted the services in each case.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Taxes resulting from formalizing and executing this Agreement and the transactions envisaged in it will be borne, in each case, in accordance with Applicable Law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Up to EUR 20,000 to be paid by VLP to Inveready for the cost related to the services provided by its advisors in the Transaction, cost which shall be duly evidenced to VLP in an open book basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">18.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Parties further agree that Inveready shall have the right to charge VLP an aggregate yearly amount of EUR 18,000 in the concept of portfolio management fees, being such amount to be paid by VLP on a monthly basis.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the event VLP was in an insolvency proceeding (&#8220;concurso de acreedores&#8221;), BDI Holding will pay Inveready an annual fee of EUR 12,000, while Inveready remains on the Board of Directors of BDI, instead of paying the EUR 18,000 referred to in the paragraph above. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ASSIGNMENT. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">19.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Subject to Clause 19.2, none of the Parties to this Agreement may assign its rights and obligations hereunder to any third Person, without the prior written consent of the other Parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">19.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic shall be entitled to assign its rights under this Agreement and/or any other transaction document to any member of Dyadic&#8217;s Affiliates, with the Existing Shareholders&#8217; prior written consent provided that Dyadic remains jointly and severally liable with the assignee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AMENDMENT. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">20.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Except as otherwise specifically provided herein, neither this Agreement nor any term hereof may be amended or otherwise modified other than by an instrument in writing (i) signed by the Parties to this Agreement and (ii) expressly purporting to amend or otherwise modify this Agreement. No provision of this Agreement may be waived, discharged or terminated other than by an instrument in writing signed by the Party against which the enforcement of such waiver, discharge or termination is sought.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOTICES. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">21.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Unless otherwise expressly set out in the Agreement, all notices, consents, requests, instructions, approvals and other communications provided for herein shall be in writing and shall be deemed validly given (i) upon personal delivery, or (ii) three Business Days after being sent by recognized express courier service that maintains records of receipt. In all cases and without prejudice of the notice requirements set out before, as a further requirement any notices shall be also sent via email at the email addresses provided in this Clause.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">It is hereby understood that notice shall be deemed as received when sent to the addresses indicated below for each of the Parties:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">For the Existing Shareholders</font><font style="font-family:inherit;font-size:11pt;">:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Creux An&#225;lisis Estrat&#233;gicos, S.L.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn.: Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca (Espa&#241;a).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca (Espa&#241;a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Carlos Bl&#225;zquez Escudero</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: calle Pradillo Ventorro 3, 2&#186;, Salamanca (Espa&#241;a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Ricardo Arjona Antol&#237;n</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Sevilla (Espa&#241;a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ms. Ana G&#243;mez Rodr&#237;guez</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca (Espa&#241;a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Luis Hilario Guerra Trueba</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Valladolid (Espa&#241;a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Floema Biotec, S.L.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn.: Mr. Jos&#233; Pellicer Espa&#241;a</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Madrid (Espa&#241;a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Jorge Hern&#225;ndez Esteban</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Madrid (Espa&#241;a).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Yahia El-Amrani Bentahar</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Madrid (Espa&#241;a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:37px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:152px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-152px;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">For the Investors</font><font style="font-family:inherit;font-size:11pt;">:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn.: Mark A. Emalfarb, CEO</font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: 140 Intracoastal Pointe Drive, Suite 404</font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Jupiter, Florida 33477</font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.:  561-743-8333</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: memalfarb@dyadic.com</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:85px;text-indent:-19px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">With copy to: Laura Nemeth, Squire Patton Boggs</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:85px;text-indent:-19px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Email: laura.nemeth@squirepb.com</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVEREADY INNVIERTE BIOTECH II, S.C.R., S.A.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn.: Roger Piqu&#233; Pijuan</font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:37px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;padding-left:152px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-152px;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">For the Company</font><font style="font-family:inherit;font-size:11pt;">:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biotechonology Developments for Industry, S.L.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn.: Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: avenida Francisco Vall&#233;s 8, 47151, Boecillo &#8211; Valladolid (Espa&#241;a).</font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:14px;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iv) </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">For VLP:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:85px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:66px;"><font style="font-family:inherit;font-size:11pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VLP The Vaccines Company, S.L.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn.: Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca</font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In order for any change to the above addresses or persons for the notice purposes to be binding upon the Parties, the relevant party must notify it accordingly with at least ten (10) days in advance following the terms included under this Clause 21.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SUCCESSORS AND ASSIGNS. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">22.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement shall inure to the benefit of, and shall be binding upon, the Parties, and their respective successors, permitted assigns and their heirs and legal representatives.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SEVERABILITY. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">23.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Every term and provision of this Agreement is intended to be severable. If any term or provision hereof is illegal or invalid for any reason whatsoever, such term or provision will be enforced to the maximum extent permitted by law and, in any event, such illegality or invalidity shall not affect the validity of the remainder of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SUPREMACY. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each Party acknowledges that this Agreement includes provisions that may deviate from the provisions in the Bylaws and agrees that, among the Parties to this Agreement, the terms and conditions of this Agreement shall prevail and each Party agrees to take all such necessary or appropriate actions, including by voting and or waiving any rights under the Bylaws, in order to give full effect to the terms and conditions set forth in this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ENTIRE AGREEMENT; COUNTERPARTS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">25.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement (including its Schedules and Exhibits) constitutes the full and entire understanding and agreement of the Parties and supersedes any and all prior agreements, arrangements and understandings relating to the subject matters hereof. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">25.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement may be executed in one or more counterparts, including by facsimile, all of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FURTHER ACTIONS. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Each Party shall execute and deliver such other agreements and documents, and take such other actions, as may reasonably be requested to give effect to the provisions of this Agreement, in each case as are not inconsistent with the terms and provisions of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NON-WAIVER. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">No provision of this Agreement shall be deemed to have been waived unless such waiver is given in writing, and shall be deemed limited to that expressly provided for in such waiver.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PUBLICITY</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Publicity; Use of Name. Dyadic may issue any press releases or make any other public statement with respect to the transactions contemplated hereby without the prior consent of BDI Group and notwithstanding the existence of any confidentiality or non-disclosure obligations that Dyadic may have, which, for the avoidance of doubt, may include the filing of this Agreement and/or a summaries thereof with the U.S. Securities and Exchange Commission by Dyadic as required by U.S. federal securities law (such requirement to be determined by Dyadic in its sole discretion) and industry and investor conferences and presentations. BDI Group may not issue any press releases or make any other public statement with respect to the transactions contemplated hereby without the prior written consent </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:36px;padding-bottom:13px;padding-top:13px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">of Dyadic, which may be withheld in Dyadic&#8217; sole discretion. The Parties may (i) disclose the terms of this Agreement to such Party&#8217;s auditors, attorneys, bankers or investment bankers as necessary for their rendition of services to such Party; and (ii) disclose the terms of this Agreement to bona fide prospective investors, merger partners, strategic partners, or acquirors and their respective professional advisors, in connection with the negotiation, entry into and/or performance of a business transaction between such parties, including the conduct of due diligence involved in such transaction, provided, however, that such parties are subject to obligations of confidentiality and non-use at least as restrictive as those set forth in Clause 17.  During the term of this Agreement and for a reasonable time thereafter, Dyadic may use BDI Group and its Affiliates name and logo in a press release, marketing material and/or advertisement disclosing the existence of this Agreement.  Except for disclosures permitted pursuant to this Clause 28.1, neither Party will use the other&#8217;s name for advertising or external publicity purposes without its consent, except that Dyadicmay include in its promotional materials references to and quotations from publications of results of the projects. In addition, in the event there is a third party beneficiary to projects contracted by Dyadic to BDI Pharmaceuticals under the Services Framework Agreement whose direct beneficiary will be a third party introduced by Dyadic and whose aim, planning and budgets shall be agreed in writing by Dyadic and BDI Pharmaceuticals, such third party may issue press releases or make any other public statement with respect to such project or the results yielded thereunder without the prior written consent of BDI Pharmaceuticals.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic will provide BDI Group and Inveready with a copy of the draft of the relevant press release, and will give to BDI Group and Inveready 24 hours in order to provide Dyadic with any suggested edits and changes.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Inveready may issue press releases or make other public statements with respect to the transactions contemplated hereby only with the prior consent of Dyadic which shall be given in its absolute and entire discretion.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dyadic retains all publicity rights in connection with the application(s) of C1 Technology. For clarity, neither Inveready nor BDI can issue a press release or public statement in connection with any research related to Dyadic projects, including but not limited to Project A.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the event that Dyadic did not respond to Inveready within 48 hours, Inveready may issue the information unrelated to the C1 Technology and Dyadic projects including but not limited to Project A that it sent to Dyadic.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">APPLICABLE LAW AND ARBITRATION.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Agreement shall be governed by, and interpreted under, the laws of Spain, without application of rules on conflicts of laws. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">All disputes between the Parties shall be resolved by this Clause 29.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any Party shall give the other party written notice of any dispute under this or in connection with this Agreement. The Parties shall attempt to resolve such dispute promptly by negotiation among the Parties and their advisors and executive officers of the BDI Group, Dyadic and/or Inveready, as applicable, who have authority to settle the dispute.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Within ten (10) Business Days after delivery of the notice, the party(ies) receiving the notice shall submit to the other a written response. The notice and response shall include: (A) a statement of each party&#8217;s position and a summary of arguments supporting that position; an (B) in the case of any member of the BDI Group, Dyadic and/or Inveready, the name and title executive officer of such Party who </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">will represent such Party and, in the case of any Party, the name and title of any other person who will accompany such Party during the negotiations. Within thirty (30) days after delivery of the disputing Party&#8217;s notice, Parties shall meet at a mutually acceptable time and place, and thereafter as often as they deem reasonably necessary, to attempt to resolve the dispute. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">If such dispute has not been resolved by the Parties in accordance with Clause 29.2 within forty-five (45) days after the disputing Party&#8217;s request notice, or if the Parties fail to meet within thirty (30) days after such request notice, then each of the Parties agree to submit all disputes, controversies or claims that may arise between them that directly or indirectly relate to this Agreement, including issues concerning the existence, validity, effectiveness, interpretation, compliance or termination hereof, to be resolved by arbitration at the Madrid Chambers of Commerce and Industry in accordance with the rules regulating such body, which rules are deemed to be incorporated by reference into this Clause.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The arbitration proceedings shall be carried out before the Court of Arbitration of the Madrid Chambers of Commerce and Industry and subject to the regulations of said Court, whenever not referred to herein. The seat or legal place of the arbitration shall be Madrid.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The arbitration shall be resolved by a tribunal of one arbitrator appointed in accordance with the rules of the Court of Arbitration of the Madrid Chambers of Commerce and Industry. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The Parties hereby undertake to voluntarily comply with the arbitral award issued, as soon as it becomes final.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">The arbitration language shall be Spanish. To the extent that any supporting or accompanying documents of the relevant claim or answer to the claim are originally drafted in Spanish, such documents shall be translated into English. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><a name="s711bf3fd00a14ce9a5064966e383fd76"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF, </font><font style="font-family:inherit;font-size:11pt;">the Parties have executed the Agreement in one counterpart to be raised into public, in the place and on the date first above written.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:47%;"></td><td style="width:6%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On behalf of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Creux An&#225;lisis Estrat&#233;gicos, S.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #00000a;"><div style="padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Ricardo Arjona Antol&#237;n</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Pablo Guti&#233;rrez G&#243;mez</font></div><div style="padding-bottom:13px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On behalf of</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;Mr. Carlos Bl&#225;zquez Escudero</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #00000a;"><div style="padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Ricardo Arjona Antol&#237;n</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Ana G&#243;mez Rodr&#237;guez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #00000a;"><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ms. Ana G&#243;mez Rodr&#237;guez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On behalf of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Luis Hilario Guerra Trueba</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/</font><font style="font-family:inherit;font-size:11pt;">&#160;Antonio De Leyva Tejadaon</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Jorge Hern&#225;ndez Esteban</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Antonio De Leyva Tejadaon behalf of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Floema Biotec, S.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #00000a;"><div style="padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Jorge Hern&#225;ndez Esteban</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #00000a;"><div style="text-align:justify;padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="text-align:justify;padding-left:12px;text-indent:-12px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On behalf of</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;Mr. Yahia El-Amrani</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Pablo Guti&#233;rrez G&#243;mez</font></div><div style="padding-bottom:13px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">on behalf of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biotechnology Developments for Industry, S.L.</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Antonio Ca&#241;adas Bouwen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Roger Piqu&#233; Pijuan </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Antonio Ca&#241;adas Bouwen</font></div><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On behalf of Dyadic International (USA), Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Roger Piqu&#233; Pijuan </font></div><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On behalf of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVEREADY INNVIERTE BIOTECH II, S.C.R., S.A.</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="padding-bottom:13px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">on behalf of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP The Vaccines Company, S.L.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:144%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><a name="sec41cf7d19e9412cb1f1a02c3fbf196b"></a></div><div></div><div><br></div><div style="line-height:144%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule I</font></div><div style="line-height:144%;padding-bottom:13px;padding-top:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Subsidiaries</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:60%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Spanish Tax Identification Number so called (NIF/CIF): B-86206695</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date and place of incorporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">27 April 2011 in Madrid (Spain)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Registered address</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C/ L&#243;pez de Hoyos 35, 1&#186;, Madrid (Spain)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VLP The Vaccines Company, S.L.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VLP The Vaccines Company, S.L.U</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Spanish Tax Identification Number so called (NIF/CIF): B-37515111</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date and place of incorporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16 March 2012 in Madrid (Spain)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Registered address</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C/ Vel&#225;zquez 4, 5&#186;, 37005 Salamanca (Spain)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><a name="s658dbd66e4ef438683fbd729046e912c"></a></div><div></div><div><br></div><div style="line-height:144%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule II</font><font style="font-family:inherit;font-size:11pt;">Existing Shareholders of BDI Holding</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:29%;"></td><td style="width:12%;"></td><td style="width:19%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">N&#186; (inclusive)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Creux An&#225;lisis Estrat&#233;gicos, S.L.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23.45%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11,721,379</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[1 - 7,331,502]; [32,500,001 &#8211; 34,946, 362];</font></div><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[41,985,001 &#8211; 43,033,003]; [46,485,001 &#8211; 47,380,512]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10.05%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5,024,443</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[15,979,178 &#8211; 19,023,353]; [34,946,363 &#8211; 36,054,945]; [44,237,333 &#8211; 44,682,429]; [48,558,414 &#8211; 48,985,000]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Carlos Bl&#225;zquez Escudero</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8.43%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4,212,731</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[10,302,463 &#8211; 13,273,422]; [32,000,001 &#8211; 32,500,000]; [43,467,805 &#8211; 43,839,825]; [47,799,092 &#8211; 48,168,841]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Ricardo Arjona Antol&#237;n</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.82%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4,910,077</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[7,331,503 &#8211; 10,302,462]; [36,054,946 &#8211; 37,140,682]; [43,033,004 &#8211; 43,467,804]; [47,380,513 &#8211; 47,799,091]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ms. Ana G&#243;mez Rodr&#237;guez</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8.995%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4,495,819</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[13,273,423 &#8211; 15,979,177]; [37,140,683 &#8211; 38,143,667]; [43,839,826 &#8211; 44,237,332]; [48,168,842 &#8211; 48,558,413]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Luis Hilario Guerra Trueba</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.565%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2,781,290</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[19,023,354 &#8211; 19,342,466]; [38,143,668 &#8211; 38,401,948]; [44,682,430 &#8211; 45,886,325]; [48,985,001 &#8211; 49,985,000]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Floema Biotec, S.L.</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">21.32%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10,654,955</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[19,342,467 &#8211; 27,342,466]; [38,401,949 &#8211; 41,056,903]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Jorge Hern&#225;ndez Esteban</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.52%</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3,757,607</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #ffffff;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[27,342,467 &#8211; 29,808,219]; [41,056,904 -41,985,000]; [45,886,326 &#8211; 46,250,082]</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Yahia El-Amrani</font></div></td><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.85%</font></div></td><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2,426,699</font></div></td><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[29,808,220 &#8211; 32,000,000]; [46,250,083 &#8211; 46,485,000]</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:29%;"></td><td style="width:12%;"></td><td style="width:19%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:middle;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders</font></div></td><td style="vertical-align:middle;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">%</font></div></td><td style="vertical-align:middle;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:middle;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;"><div style="text-align:center;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">N&#186; (inclusive)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TOTAL</font></div></td><td style="vertical-align:middle;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">100%</font></div></td><td style="vertical-align:top;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">49,985,000</font></div></td><td style="vertical-align:top;background-color:#f2f2f2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:center;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[1 &#8211; 46,485,000]</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><a name="s0ed4512249004b46a0553929b8f67266"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Schedule III</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Liability Distribution Percentages </font></div><div style="line-height:120%;padding-left:4px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.57264957264957%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Liability Distribution Percentages </font></div><div style="padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Ricardo Arjona Antol&#237;n</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.82%</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ms. Ana G&#243;mez Rodr&#237;guez</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8.995%</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Luis Hilario Guerra Trueba</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.565%</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Creux An&#225;lisis Estrat&#233;gicos, S.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23.45%</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Jorge Hern&#225;ndez Esteban</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.52%</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Yahia El-Amrani</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.85%</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10.05%</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Carlos Bl&#225;zquez Escudero</font></div><div style="padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8.43%</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Floema Biotec, S.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">21.32%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">100%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><a name="s16b221395fb34c3e87a87ca17d972533"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule IV</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Company and Existing Shareholders&#8217; Warranties</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Capitalized terms used but not defined herein shall have the meanings set forth in the </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Investment Agreement</font><font style="font-family:inherit;font-size:11pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AUTHORITY AND CAPACITY</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company, with respect to the Company and VLP, and each Existing Shareholder, with respect to such Shareholder, the Company and VLP, each hereby represent and warrant to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Such Existing Shareholder, the Company, and VLP has full power and authority to enter into, deliver and perform this Agreement and the other Transaction Documents to which such Existing Shareholder or the Company or VLP is a party.  The Agreement and the other Transaction Documents, when executed, will constitute, valid and binding obligations of such Existing Shareholder, the Company, and/or VLP (where applicable, in accordance with the parties of the relevant agreement) and are enforceable against such Existing Shareholder, the Company and/or VLP (where applicable, in accordance with the parties of the relevant agreement) in accordance with their respective terms. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The execution and delivery of, and the performance by such Existing Shareholder, the Company and/or VLP of their respective obligations under this Agreement and the other Transaction Documents to which such Existing Shareholder, the Company, or VLP is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not (i) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under any agreement to which such Existing Shareholder, the Company or VLP is bound, or (ii) result in a violation of any Law to which such Existing Shareholder, the Company or VLP is subject or (iii) will not result in a breach of any order, judgment or decree of any court or governmental agency or Encumbrance to which any of the Existing Shareholders, the Company or VLP is a party or by which any of the Existing Shareholders, the Company or VLP or any of their respective assets is bound.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">None of such Existing Shareholder, the Company, or VLP is involved in any court or administrative or arbitration proceedings of any kind and no such proceedings are pending or threatened against or such Existing Shareholder, Company or VLP that challenge or seek to prevent or otherwise delay the transactions contemplated by this Agreement or any other Transaction Document. To such Existing Shareholder`s, the Company&#8217;s, or VLP&#8217;s knowledge no event has occurred or circumstances exist that may give rise to or serve as the basis for any such proceedings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">None of the Company, BDI Pharmaceuticals, VLP, or such Existing Shareholder has at any time:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">been the subject of a bankruptcy order;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">had a bankruptcy petition filed against it/him/her and, as well, that none are to be known to be pending in future action;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">entered into an individual voluntary arrangement whatsoever, a deed of arrangement or into any other composition or arrangement of any kind with its/his/her creditors in satisfaction of its/his/her debts; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:46px;"><font style="font-family:inherit;font-size:11pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">had any execution, sequestration or other process levied or applied for or any diligence done or attempted to be done in respect of the whole or any part of any of its/his/her property or assets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No receiver (including any administrative receiver) has been appointed in respect of all or any part of any of the property, assets or undertakings of the Company, BDI Pharmaceuticals, VLP, or such Existing Shareholder</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TITLE OF SHARES IN THE COMPANY.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each Existing Shareholder, with respect to the shares in the Company owned by such Existing Shareholder, and the Company, represent and warrant to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Such Existing Shareholder is the legal and beneficial owner of such Existing Shareholder&#8217;s shares in the Company (notwithstanding any applicable provisions under Spanish law in relation to the marriage community property regime).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All the shares in the Company issued to the Existing Shareholders have been validly issued, are fully paid and constitute the entire issued and to be issued share capital of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as expressly set forth in the Transaction Documents and save to the call options granted on the Closing Date by some of the Existing Shareholders, there is no Encumbrance on, over or affecting any of such Existing Shareholder&#8217;s shares in the Company and there is no agreement or arrangement to give or create any such Encumbrance. No claim has been made by any person seeking to claim any such Encumbrance. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as expressly set forth in the Transaction Documents and save to the call options granted on the Closing Date by some of the Existing Shareholders, there are no formal agreements or arrangements in force which provide for the present or future allotment, issue, transfer, redemption or repayment of, or grant to any person of the right (whether conditional or otherwise) to require the allotment, issue, transfer, redemption or repayment of, any share or loan capital of the Company (including any option or right of pre-emption or conversion). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No shares in the capital of the Company have been issued, and no transfer of any such shares has been registered, except in accordance with Spanish law and the bylaws of the Company.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company, with respect to the shares in the Company that will be owned by the Investors as a result of the Investment Round in the Company as stated in clause 3.1 of the Investment Agreement, represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Investors will be the legal and beneficial owners upon Closing of such shares that will be validly issued upon the full cash payment that will be received in the Company&#8217;s Account on the Closing Date. Said shares will be subscribed by the Investors with no Encumbrance on, over or affecting any of such shares in the Company, except for those expressly set forth in the Transaction Documents.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">THE COMPANY&#8217;S SUBSIDIARIES AND OTHER INTERESTS.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company is the legal and beneficial owner of all of the shares</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">in the Subsidiaries (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Subsidiaries&#8217; Shares</font><font style="font-family:inherit;font-size:11pt;">&#8221;) as set forth on Schedule I of the Investment Agreement.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Subsidiaries&#8217; Shares have all been validly issued, are fully paid and constitute the entire issued and to be issued share capital of the mentioned companies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as expressly set forth in the Transaction Documents, there is no Encumbrance on, over or affecting any of the Subsidiaries&#8217; Shares and there is no agreement or arrangement to give or create any such Encumbrance.  No claim has been made by any person seeking to claim any such Encumbrance</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as expressly set forth in the Transaction Documents, there are no formal agreements or arrangements in force which provide for the present or future allotment, issue, transfer, redemption or repayment of, or grant to any person of the right (whether conditional or otherwise) to require the allotment, issue, transfer, redemption or repayment of, any share or loan capital of either Subsidiary (including any option or right of pre-emption or conversion).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No shares in the capital of the Subsidiaries have been issued, and no transfer of any such shares has been registered, except in accordance with Spanish law and the bylaws of each of the Subsidiaries.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except for the Company&#8217;s ownership of the Subsidiaries, no member of the BDI Group owns or has any interest of any nature in any shares or other equity interest, debentures or other securities of corporate body, partnership, limited liability company or any other person, whether organized in Spain or elsewhere.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company, with respect to the shares in BDI Pharmaceuticals that will be owned by the Company as a result of BDI Pharmaceuticals&#8217; Capital Increase as stated in clause 4 of the Investment Agreement, represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">It will be the legal and beneficial owner upon Closing of such shares that will be validly issued upon the Company making the deposit of the cash payment into a separate bank account of BDI Pharmaceuticals on the Closing Date. Said shares will be subscribed by the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company with no Encumbrance on, over or affecting any of such shares in BDI Pharmaceuticals, except for those expressly set forth in the Transaction Documents.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company, with respect to the shares in VLP that will be owned by the Company and the Investors as a result of the Investment Round in VLP as stated in clause 3.2 of the Investment Agreement, represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Investors and the Company will be the legal and beneficial owners of such shares upon Closing that will be validly issued upon the full cash payment that will be received in VLP&#8217;s Account on the Closing Date. Said shares will be subscribed by the Investors and the Company with no Encumbrance on, over or affecting any of such shares in VLP, except for those expressly set forth in the Transaction Documents.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CORPORATE MATTERS</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrants to the Investors that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each member of the BDI Group is empowered and duly qualified to carry on with business in Spain and in all other jurisdictions in which they now carry on Business and have at all times carried on Business and conducted their affairs in all material respects in accordance with their respective bylaws and any other documents to which each such member is a party.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Due compliance has been made with the Companies Acts (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Ley de Sociedades de Capital</font><font style="font-family:inherit;font-size:11pt;">), and all other legal requirements in connection with the formation of each member of the BDI Group, the allotment or issue of any of such member&#8217;s shares, debentures and other securities and the payment of dividends. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All resolutions and documents required by the Companies Acts (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Ley de Sociedades de Capital</font><font style="font-family:inherit;font-size:11pt;">) or any other legislation to be filed with the competent Commercial Registry in Spain, or any other competent authority in any relevant jurisdiction, in respect of the BDI Group have been duly filed and were true, accurate and correct when filed.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All documents of title relating to the assets of the BDI Group, an executed copy of all agreements to which any member of the BDI Group is a party and an original executed copy of every document or instrument creating or evidencing an Encumbrance over any of their assets, property or undertaking, are in their possession or under their control.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The nominative shares&#8217; book and the minutes&#8217; book of each member of the BDI Group and BDi Pharmaceuticals&#8217;s and VLP&#8217;s mandatory corporate books regarding its agreements with its sole shareholder (the Company), are in the BDI Group&#8217;s possession or under their control, are current and have been maintained in accordance with all Applicable Laws and comprise a complete and accurate record of all information required to be recorded in them. No member of the BDI Group has received any notice that any information contained in any of such statutory books is incorrect or should be rectified. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No one is entitled to receive from any member of the BDI Group any bonus, finder&#8217;s fee, brokerage or other commission or payment in connection with the execution of the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Investment Agreement or any of the other Transaction Documents, except for the payment of expenses and taxes set forth in the Investment Agreement.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No director of any of the member of the BDI Group is now or has at any time been subject to any disqualification (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">inhabilitaci&#243;n</font><font style="font-family:inherit;font-size:11pt;">) order based on Applicable Law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group is unable to pay its debts within the meaning of Spanish Bankruptcy Act (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Ley 22/2003, de 9 de julio, Concursal</font><font style="font-family:inherit;font-size:11pt;">&#8221;). No member of the BDI Group has stopped paying its debts as they fall due. No order has been made or petition presented or meeting convened for the purpose of considering a resolution for the winding up of any member of the BDI Group, nor has any such resolution been approved. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ACCOUNTS </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Last Accounts were prepared in accordance with the historical cost convention. The bases and policies of accounting adopted for the purposes of preparing the Last Accounts are the same as those adopted in preparing the accounts of BDI Group in respect of the preceding three accounting periods.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Last Accounts of BDI Group:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">have been prepared in accordance with PGC consistently applied for the preceding three accounting periods and give the value of the assets and liabilities and state of affairs of the members of the BDI Group as at the Last Accounts Date and of its profits or losses for the financial period ended on that date; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">comply with all applicable requirements of the Companies Acts and other Spanish Law and have been filed and deposited in accordance with the requirements of all Spanish Law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Management Accounts of each member of the BDI Group: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">have been prepared in accordance with accounting policies consistent with those used in preparing the Last Accounts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">state the value of the assets and liabilities and state of affairs of such member of the BDI Group as at the Management Accounts Date; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">fairly present the profits or losses of such member for each period to which they relate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(d) &#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">have accounted for all tax accruals of such member of the BDI Group outstanding as at the Management Accounts Date;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">has accounted for the corporate income tax (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Impuesto de Sociedades</font><font style="font-family:inherit;font-size:11pt;">) provision (including deferred tax) to be assessed on each of the members of the BDI Group </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:93px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">or for which it may be accountable in respect of the period ended on the Management Accounts Date; and</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">are not affected by any extraordinary, exceptional or non-recurring item, transactions of a nature not usually undertaken, or by any change in the basis of accounting, by charges, releases or credits relating to the period ended on the Management Accounts Date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All the accounts, books, ledgers, financial and other records, of whatsoever kind, of the each of the members of the BDI Group are in their possession or under their control, are current and have been maintained in accordance with all Spanish Law and PGC on a proper and consistent basis and comprise complete and accurate records of all information required to be recorded therein. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All the accounting records and systems (including computerised accounting systems) of the BDI Group are recorded, stored, maintained or operated or otherwise held by the accounting firm of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FINANCE </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The financial statements issued since the incorporation date of each member of the BDI Group and, consequently, the financial information of each member of the BDI Group Disclosed in the Data Room (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;Financial Statements&#8221;</font><font style="font-family:inherit;font-size:11pt;">) have been prepared in accordance with the PGC applied on a consistent basis. Such Financial Statements (including balance sheets, profit and loss and cash-flow statements) are complete and present a true and fair view in all material respects of the assets, liabilities, financial position, results of operations, profits and losses, changes in shareholders&#8217; equity and cash flows of the BDI Group. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each member of the BDI Group has no material liabilities or obligations, due or accrued except as reflected in the Financial Statements. The financial information provided to the Investors during the due diligence process has not been construed with the aim to mislead the Investors and has been prepared in good faith.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Since the Last Accounts Date, no member of the BDI Group has made or agreed to make any capital expenditure or incurred or agreed to incur any capital commitments nor has any member of the BDI Group</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">disposed of or realised any capital assets or any interest therein except within the ordinary course of business. The Financial Statements have not been affected by any (i) extraordinary item and/or</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;">(ii) item affecting comparability, (iii) revaluation, reclassification or appreciation of any asset or property, (iv) capital gain, (v) overpriced sale or other revenue, (vi) under-priced expenditure, or (vii) cancellation of depreciation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Since the Last Accounts Date, no dividend or other distribution has been or is treated as having been declared, made or paid by any member of the BDI Group.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All dividends or distributions declared, made or paid by the BDI Group have been declared, made or paid in accordance with each member of the BDI Group&#8217;s bylaws and the applicable provisions of the Companies Acts and in accordance with any agreements or arrangements between any member of the BDI Group and any third party regulating the payment of dividends and distributions.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group has loaned any money which has not been repaid to such member except for those loans or credits lent to other companies of BDI Group as listed in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 6.5</font><font style="font-family:inherit;font-size:11pt;">, nor has any member of the BDI Group made any loan or quasi-loan contrary to Applicable </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">There are no liabilities outstanding on the part of any member of the BDI Group that should be reflected in the Last Accounts in accordance with the PGC, other than those liabilities included in the Last Accounts or those that have been incurred in the ordinary and proper course of trading since the Last Accounts Date.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group has borrowings other than those set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 6.7</font><font style="font-family:inherit;font-size:11pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:11pt;">attached hereto, is in default of any of its obligations thereunder, and no event has occurred that, with the passage of time or the giving of notice, would constitute a default thereunder. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Since the Last Accounts Date, no member of the BDI Group has repaid or become liable to repay any borrowings in advance of the stated maturity thereof.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 6.9</font><font style="font-family:inherit;font-size:11pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:11pt;">attached hereto or set forth in the Transaction Documents:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No filings are necessary to be made or monies paid to comply with the conditions to Closing and Closing Deliveries set forth in Sections 8 and 9 of the Investment Agreement, respectfully.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No Encumbrance, guarantee, indemnity or other similar security arrangement has been given or entered into by any member of the BDI Group or any third party in respect of borrowings or other obligations of the BDI Group (including the Existing Shareholders or any of their Affiliates, nor has any such person agreed to do so.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group have given or entered into, or agreed to give or enter into, any guarantee, indemnity or other similar security arrangement in respect of the borrowings or other indebtedness of, or the default in the performance of any obligation by, any other person.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No enforcement proceeding has been initiated in respect of any Encumbrance over any of the assets of the BDI Group, whether by virtue of the stated maturity date of the Indebtedness having been reached or otherwise.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">e.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group has received notice (whether formal or informal) from any lenders of money to it, requiring repayment or notifying of the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">enforcement of any Encumbrance or other security the creditor may hold over any of their assets and there are no circumstances which could give rise to any such notice.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">f.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group has received any subsidy or financial assistance from any governmental department, authority or agency.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">g.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group has paid any management fee or other compensation (including bonuses) to any Existing Shareholder or their Affiliates, (except for customary salary payments) outside the ordinary course of business nor any other extraordinary payment been made or become payable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">h.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">There has been no change in accounting methods, principles or practices.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Since the incorporation date  up until the date of signature of the Investment Agreement, the Business of the BDI Group has been conducted in the ordinary, regular and usual course of business consistent with past practices, including, but not limited to: (i) the payment of accounts payable when due without entering into arrangements having the purpose of postponing the due dates thereof as compared to the ordinary course of business; and (iii) without postponing any investments or purchases as compared to the ordinary course of business.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TRADING</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Since the Management Accounts Date:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Business of the BDI Group has been carried on in the ordinary and normal course of business so as to maintain the same as a going concern and without any material alteration in the nature, scope or manner of such business.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Without limiting the generality of the foregoing, no member of the BDI Group has (i) acquired any business, line of business or person by merger or consolidation, purchase of material assets or equity interests, in a single transaction or a series of related transactions, or entered into any contract, letter of intent or similar arrangement (whether or not enforceable) with respect to the foregoing; (ii) disposed of or agreed to dispose of any material assets essential to the BDI Group&#8217;s core business otherwise than in the normal course of its business; or (iii) entered into any agreement, transaction, obligation, commitment, understanding, arrangement or liability that is not entirely on an arm&#8217;s-length basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">There has been no Material Adverse Effect in the turnover or the financial or trading position of the BDI Group and no fact, event or matter has occurred which will give rise to any such change.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The members of the BDI Group are not a party to or subject to any agreement, transaction, obligation, commitment, understanding, arrangement or liability that:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:46px;"><font style="font-family:inherit;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">is outside the ordinary and normal course of the BDI Group&#8217;s Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">is not of an entirely arm&#8217;s length nature; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">is a restrictive trading or other agreement or arrangement pursuant to which any part of the BDI Group&#8217;s Business is carried on or which in any way restricts its freedom to carry on the whole or any part of its Business in any part of the world in such manner as it thinks fit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group has entered into any guarantee or agreement for indemnity or for suretyship in respect of any debt, liability or obligation of any third party (including the Existing Shareholders and/or any of their connected persons or associates).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group has agreed to become, a member of any joint venture, consortium, partnership or other unincorporated association, or a party to any agreement or arrangement for sharing commissions, or other income, all of the foregoing except for those entered into by the BDI Group in their ordinary course of business, except those set forth in Schedule 7.4. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">There is no outstanding agreement or arrangement allowing any third party to act or trade as agent of any of the members of the BDI Group.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 7.6</font><font style="font-family:inherit;font-size:11pt;">&#32;attached hereto, there is not now outstanding and there has not at any time during the three years prior to the Closing Date been entered into any contract or arrangement between any member of the BDI Group, on the one hand, and the Existing Shareholders or any of their Affiliates, on the other hand. The BDI Group does not depend upon the use of any assets owned by, or facilities or services provided by, any Existing Shareholder or any of their Affiliates.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except for the licenses granted pursuant to the terms of the Transaction Documents that will be granted on Closing, the BDI Group has all material licences, permissions, authorisations and consents necessary to carry on its Business as currently conducted and as proposed to be conducted; all such licences, permissions, authorisations and consents are in full force and effect; BDI is not in default thereof; and no event has occurred or is continuing, that, with the passage of time or giving of notice, would constitute a default thereunder. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ANTI CORRUPTION</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company and each of the Existing Shareholder hereby represent and warrant to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group nor any Existing Shareholder is, or has ever been, engaged in any activity, practice or conduct which would constitute an offence under the Anti-Bribery Laws.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group nor any Existing Shareholder is, or has ever been, the subject of any investigation, inquiry or enforcement proceedings by any governmental, </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">administrative or regulatory body or any customer regarding any matter which would constitute an offence or alleged offence under the Anti-Bribery Laws, and no such investigation, inquiry or proceedings have been threatened in writing or are pending</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group or any Existing Shareholder is aware of any facts or circumstances that may result in an investigation, inquiry or enforcement proceeding</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:11pt;">and the Company shall operate in compliance with all Anti-Bribery Law</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SANCTIONS.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company and each of the Existing Shareholder hereby represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group is, or has ever, directly or indirectly through a third party, engaged in any activity: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">with individuals and/or entities designated on any of the European Union, United Nations and/or United States government restricted or denied parties lists or other similar lists (including without limitation the Specially Designated Nationals and Blocked Persons lists) of other countries with jurisdiction over this transaction; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">subject to sanctions or trade requirements imposed by the European Union, its member states, the United Nations and/or the United States of America, including without limitation the comprehensive sanctions restricting commerce with Cuba, Iran, North Korea, Crimea&#160;- Region of Ukraine, Sudan or Syria or any other country subject to selective sanction or other trade restrictions.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group nor any Existing Shareholder is aware of any facts or circumstances that may result in an investigation, inquiry or enforcement proceeding related to the alleged violation of any sanctions or export/import laws and regulations by the Company or any member of the BDI Group or any of its respective officers, consultants, agents or employees, and the Company shall operate in compliance with all sanctions and export/import laws and regulations.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">COMPETITION AND TRADE.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group has committed or omitted to do any act or thing which could give rise to any material fine or penalty; nor has they been notified of any investigation, inspection or procedure that could result in the imposition of a fine or penalty, deriving from any agreement, practice or arrangement which contravenes anti-trust, anti-monopoly, anti-cartel legislation, fair trading, consumer protection or similar legislation or regulations in any applicable jurisdiction in which the BDI Group carries out its Business. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group is, or has ever been, the subject of any investigation by the Spanish Competition Authority, the European Commission or any other anti-trust </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">regulatory body, nor has any member of the BDI Group contravened any undertakings given to any such body.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group exceeds, and the BDI Group as a consolidated group does not exceed, the market share or turnover thresholds set out under Spanish and/or European Competition Law and under any other Applicable Law where the BDI Group carries on its Business. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MATERIAL ASSETS. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">11.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The members of the BDI Group are the legal and beneficial owners of and have good and marketable title to all material assets used in the course of their Business, free and clear of all Encumbrances, except for those set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 11.1</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11pt;">&#32;There is no dispute, directly or indirectly, between any of the members of the BDI Group and any other person relating to any of the assets to the BDI Group.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">11.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The assets owned by the BDI Group, together with the services and facilities to which the BDI Group have a contractual right to use, comprise all the assets, services and facilities necessary for the carrying on of the Business of the BDI Group as now carried on and as proposed to be carried on. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">11.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All the tangible assets of the BDI Group are in good working order and repair, ordinary wear and tear excepted.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INSURANCE</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrants to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">12.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The insurance policies contracted by the BDI Group provide customary coverage against accident, damage, injury, third party loss, and other risks normally insured against by persons carrying on the same type of business as that carried on by the BDI Group in similar market conditions.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">12.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All policies of insurance effect by or for the benefit of any member of the BDI Group are listed in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 12.2</font><font style="font-family:inherit;font-size:11pt;">&#32;thereto and are currently in full force and effect and to the Company&#8217;s knowledge nothing has been done or omitted to be done which is likely to make any such policy of insurance void or voidable or which is likely to result in an increase in premium.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">12.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No claim is outstanding or may be made under any such policies and no circumstances exist that are likely to give rise to such a claim. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INTELLECTUAL PROPERTY RIGHTS</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrants to the Investors that:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group owns all right, title and interest in and to, or possesses adequate rights or licenses to use, patents, patent rights, copyrights, inventions, licenses, governmental authorizations, discoveries, formulas, technical assistance, trade secrets, knowhow and other intellectual property rights (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">IP Rights</font><font style="font-family:inherit;font-size:11pt;">&#8221;) necessary to conduct the Business as now conducted. The IP Rights are free from any Encumbrances and are valid, subsisting and enforceable, except for those patent applications that are still under prosecution as set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 13.1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">None of the BDI Group owns registered or unregistered trademarks, trade names, service marks, service mark registrations, service names, copyrights, trademarks or brand names</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">nor has applied for the registrations of copyrights, trademarks or brand names.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">None of the BDI Group IP Rights have expired, terminated, or are expected to expire or terminate, within three (3) years from the date of the Investment Agreement.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The domain names listed in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 13.3</font><font style="font-family:inherit;font-size:11pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:11pt;">thereto are all the internet domain names owned or used by the BDI Group (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Domain Names&#8221;</font><font style="font-family:inherit;font-size:11pt;">). The members of the BDI Group are the sole registered proprietors of the Domain Names.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">To the Company&#8217;s knowledge, none of the members of the BDI Group have made any alleged or suspected infringement on or misappropriation, as of the date of the Investment Agreement or in the six (6) years preceding such date, of the intellectual property rights of others or the infringement on or misappropriation by others, as of the date of the Investment Agreement or in the six (6) years preceding such date, of the BDI Group&#8217;s IP Rights.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">To the Company&#8217;s knowledge</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">, t</font><font style="font-family:inherit;font-size:11pt;">he BDI Group does not have any notice, written or verbal as of the date of the Investment Agreement or in the six (6) years proceeding such date that related to the infringement or misappropriation by the BDI Group of the IP Rights of others. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">None of the IP Rights or Domain Names are subject to any pending proceedings for opposition, cancellation, revocation, rectification, licence of right or relating to title or any similar proceedings anywhere in the world.  The Existing Shareholders are not aware of any material circumstances which might result in the cancellation or revocation of the Domain Names or IP Rights.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All intellectual property licenses granted by any member of the BDI Group to any third party (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Out Licenses</font><font style="font-family:inherit;font-size:11pt;">&#8221;) are listed in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 13.6</font><font style="font-family:inherit;font-size:11pt;">&#32;thereto and are valid and binding and in full force and effect.  No party to any Out License is in default of the terms thereof and, to the Company&#8217;s knowledge, no fact or situation exists that would, with the giving or notice or passage of time, constitute a default under any Out License. All Out Licenses have, where required, been duly recorded or registered.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Other than pursuant to the Out Licences, no member of the BDI Group has granted and or is obligated to grant any license, sub-license, Encumbrance or assignment in respect of any of the BDI Group&#8217;s IP Rights.  </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All licenses or other material rights or permission to use any third party intellectual property used by the BDI Group in the operation of the Business have been obtained by the BDI Group and all license fees, royalties and any other amounts (if any) due and payable under such license agreements have been paid, except for those payment obligations of certain royalties to CSIC as set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 13.8</font><font style="font-family:inherit;font-size:11pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No activities have been conducted on behalf of any member of the BDI Group, Dyadic or any third party that, directly or indirectly, incorporate or use (whether alone or in combination with any other intellectual property of the BDI Group or any third party) any component of the C1 Technology (as such term is defined in the Research Services Agreement) or any derivatives or modifications thereof, except as expressly permitted by and in accordance with the terms and provisions of the Research License Agreement </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Whether in the carrying on of its Business or otherwise, no member of the BDI Group has breached any obligations of confidentiality or non-disclosure owed to any third party or as engaged in any act of unfair competition.  To the Company&#8217;s knowledge, no third party has breached any obligations of confidentiality or non-disclosure owed to any member of the BDI Group or engaged in any act of unfair competition with respect to any member of the BDI Group.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">None of the Existing Shareholders nor any member of the BDI Group have, except subject to a confidentiality agreement, disclosed or permitted, agreed to, undertaken or arranged the disclosure of any confidential information of the BDI Group to any third parties, unless required by law, to any public administrative body, or in the framework of any bid or in light of reaching a possible investment agreement in the BDI Group. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">To the Company&#8217;s knowledge, no employee of the BDI Group is obligated under any contract (including licenses, covenants or legal commitments of any nature) or any agreement, or subject to any judgment, decree or order of any court or administrative agency, that would interfere with the use of his or her best efforts to promote the interests of the BDI Group in the operation of the Business as conducted on the date of the Investment Agreement.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title and ownership of any and all rights with respect to any inventions of the BDI Group&#8217;s employees during their employment with the BDI Group vests in the BDI Group. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13.14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All inventors named in patent applications or in issued patents have entered into agreements with the BDI Group assigning to the BDI Group all of the inventors&#8217; right, title and interest in and to such patent application(s) and patents describing and claiming their invention(s).  All persons involved in the conception, making, development and work related to the BDI Group&#8217;s IP Rights have entered into agreements with the BDI Group assigning to the BDI Group, to the extend deemed necessary or appropriate by the BDI Group all of such persons&#8217; right, title and interest in and to the BDI Group&#8217;s IP Rights.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MATERIAL CONTRACTS </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrant to the Investors that:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">14.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accurate and complete copies of all contracts or other agreements to which any member of the BDI Group is a party and which are material to the Business (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Material Contracts</font><font style="font-family:inherit;font-size:11pt;">&#8221;) have been Disclosed in the Data Room and all such Material Contracts are legal, valid, binding and enforceable, except insofar as enforcement may be limited by bankruptcy, insolvency, or other Laws affecting generally the enforceability of creditors&#8217; rights and by limitations on the availability of equitable remedies.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">14.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No member of the BDI Group is in breach or default and no fact or event has occurred which with the notice or the passage of time, would constitute a breach or default by any member of the BDI Group under any Material Contract, or permit termination, modification, or acceleration under the Material Contract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">14.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">To the Company&#8217;s knowledge, no party with whom any member of the BDI Group have entered into any Material Contract has given notice to terminate or rescind or has sought to repudiate or disclaim or materially change the terms of any such Material Contract in connection with the Investment of the Investors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">14.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No Material Contract to which any member of the BDI Group is a party is the subject of any dispute or claim and to the Company&#8217;s knowledge there are no facts, matters or circumstances which could give rise to any dispute or claim.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DATA PROTECTION</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:28px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrant to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">15.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group complies with (and established the procedures necessary to ensure compliance with) all relevant requirements of the Data Protection Legislation in Spain and in all other jurisdictions in which the BDI Group has carried on the Business.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">15.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group has not:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">received an order, warrant, notice or allegation from either the information commissioner or other relevant body or a data subject alleging non-compliance with the Data Protection Legislation in Spain, and in any of the other jurisdictions in which the BDI Group has carried on the Business and there are no circumstances which may give rise to any such order, warrant, notice or allegation whether in Spain or elsewhere;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">received a claim for compensation and no individual will have the right to claim compensation under the LOPD for loss or unauthorised disclosure of data whether in Spain or elsewhere.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LITIGATION AND DISPUTES </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrant to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as Disclosed in the Data Room, neither the BDI Group nor any person for whose acts or defaults the BDI Group may be vicariously liable have been involved in any legal </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">or administrative or arbitration proceedings (whether as claimant or defendant or otherwise) and no such proceedings are pending or, to the Company&#8217;s knowledge,  threatened, and, to the Company&#8217;s knowledge, there are no facts, matters or circumstances which are likely to give rise to any such proceedings. There is no unfulfilled or unsatisfied judgment or court order outstanding against any member of the BDI Group.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No governmental or official investigation or inquiry concerning the BDI Group or their Business or any of its directors, officers or employees is in progress or pending or, to the Company&#8217;s knowledge, threatened, and to the Company&#8217;s knowledge, there are no facts, matters or circumstances that are likely to give rise to any such investigation or inquiry. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as expressly set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 16.3</font><font style="font-family:inherit;font-size:11pt;">, there is no dispute with any government or any agency or body acting on behalf of such government or any other body or authority in Spain or elsewhere in relation to the Business of the BDI Group and, to the Company&#8217;s knowledge, there are no facts, matters or circumstances that are likely to give rise to any such dispute.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group is not party to any undertaking or assurance given to any court or government or governmental agency or regulatory body which is still in force except for those set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 16.4</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group and its respective officers, agents and employees and any other person acting on behalf of the BDI Group (during the course of their duties in relation to the BDI Group) have conducted and are conducting its Business in all material respects in accordance with Spanish law or the law of any jurisdictions in which it carries on the Business. The BDI Group has not received any notice of any violation of any Applicable Laws and, to the Company&#8217;s knowledge, there are no investigations or inquiries in existence or pending in respect of the BDI Group or its Business and the Company has no knowledge of any fact or matter which could lead to such investigations or enquiries in any jurisdictions in which it carries on the Business. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group are not in breach of any order, decree or judgment of any court or any   governmental or regulatory authority.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EMPLOYMENT.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrant to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A list of all the directors, officers and employees of the BDI Group together with full particulars (including annual gross salary, length of service and job position) has been Disclosed in the Data Room.  Such information is true, materially complete and accurate and not misleading on the Closing Date. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">None of the agents/contractors who have a contractual relationship with the members of the BDI Group are registered as employees of the BDI Group and none of them are entitled to any payments (including but not limited to any severance payment/goodwill compensation or any other indemnification as a consequence of the termination of the contractual relationship, damages, any pending remuneration or benefits, any social </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">security contributions) on Closing Date. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as expressly set forth in the Transaction Documents, no change has been made in the rate of remuneration, emoluments, pension benefits or other terms of employment, of any director, officer or key employee in relation to the information provided in the Data Room as established in section 17.1 above. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The salaries and all other benefits (including incentive plans, holiday pay and overtime pay) of all directors, officers and employees (and former directors, officers and employees) have been paid up in full on Closing Date, except for the accrual of the extra pays effective in  June and December, as well as the holidays accrued according to Spanish law as set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 17.4</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All social security contributions arising or in respect of any period on or before the Closing Date have been paid in full by all the members of the BDI Group and they are therefore under no liability to pay any penalty, fine, surcharge or interest in connection with any social security contribution. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each person (national or foreign) employed, hired or engaged by the BDI Group has valid and subsisting permission to live and work full time in Spain in the role in which they are employed, hired or engaged.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In relation to each of its employees and workers and so far as relevant in relation to each of its former employees and workers, the BDI Group have complied in all material respects with all employment and social security statutes, regulations, codes of conduct, collective agreements, terms and conditions of employment, common law, orders and awards relevant to their conditions of service or to the relations between them and their employees and workers (or former employees and workers, as the case may be) or any recognised trade union.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17.8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">There are no court or other proceedings between the BDI Group on the one hand and any director, officer, employee or consultant or former director, officer, employee or consultant on the other hand nor are any such proceedings pending or threatened and there are no facts, matters or circumstances which could give rise to any such proceedings. No employee is subject to a current disciplinary warning or procedure and there are no unresolved grievances. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PENSIONS</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrant to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">18.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group has not prior to Closing Date paid, provided or contributed towards, and the BDI Group has not promised or proposed nor are under any obligation, liability or commitment however established and whether or not legally enforceable to pay, provide or contribute towards, any benefits under a pension scheme or any other pension arrangements for or in respect of any present or past officer or employee (or any spouse, child or dependant of any of them) of the BDI Group or of any predecessor of the  Business.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REAL PROPERTIES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrant to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group does not own any real property (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">inmuebles</font><font style="font-family:inherit;font-size:11pt;">).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The information related to all real property leased or sub-leased by the BDI Group (the industrial premises located in Boecillo (Calle Louis Proust 13, plot ZT-3.1.3, 47151 Boecillo (Valladolid, Spain), together with copies of the corresponding contracts have been Disclosed in the Data Room. All such information is true, complete, accurate and not misleading in any material respects whatsoever.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group has paid the rent and all other sums payable under the lease or licenses (i.e. real estate property tax -IBI-, ford rates, garbage rates) and have observed and performed the covenants on the part of the tenant and the conditions contained in the lease or sub-lease or licenses under which the property is held and no notices have been served by the landlord in respect of the any lease, sub-lease or licence. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group have not received written notice of any dispute, claim, complaint or demand of any kind affecting the property and there are no facts, matters or circumstances which might reasonably be expected to give rise to any such dispute, claim, complaint or demand of any kind.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 19.5</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">,</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;">the BDI Group represents that they have the necessary facilities, lab equipment and personnel to timely and efficiently perform and render the services under the Research Services Agreement and the Services Framework Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group represents and warrants that the actual enforcement procedure started by LIBERBANK, S.A. over the industrial premises mentioned in 19.2 above will not affect the execution of the services under the Research Services Agreement and the Service Framework Agreement</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TAX </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company hereby represents and warrant to the Investors that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group has complied in all material respects in respect with all tax obligations and have made the relevant payment when due. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In accordance with PGC and consistently with their own accounting practices, procedures and rules, applied on a uniform and consistent basis in recent financial years, whether in Spain or elsewhere, the BDI Group have recorded sufficient provisions and reserves for the payment of taxes that have become chargeable but the voluntary period for assessment and payment of which has not yet expired.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a) Tax returns required to be filed by or on behalf of the BDI Group have been filed in a timely manner (within any applicable extension periods validly obtained) and all such Tax returns are true, correct and complete in all respects; (b) all Taxes or amounts required </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">to be withheld or paid by or on behalf of the BDI Group has been timely withheld or paid in full; (c) the BDI Group has not granted any extension or waiver of the statute of limitations applicable to any Tax return, which period (after giving effect to any such extension or waiver) has not yet expired; (e) there are no special arrangements with any Tax Authority regarding the Taxes of the BDI Group and there are no requests for rulings pending with any Tax Authority regarding the BDI Group; (f) the BDI Group is not a party to any written agreement or arrangement that could result in an obligation to pay any amounts of or in respect of Tax of any other person; and (g) there are no Encumbrances for Taxes on any of the assets of the BDI Group. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group has maintained all records and all other information in relation to Taxes which it was required to maintain and prepared and retained all such documentation as is necessary or reasonable to defend the tax-deductible character of the costs borne by it and the reasonability of other tax attributes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as set forth in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule 20.5</font><font style="font-family:inherit;font-size:11pt;">, the BDI Group has not been subject within the past four (4) years been subject to, nor is currently subject to, any audits, investigations, disputes, claims or other proceedings with respect to Tax matters involving the BDI Group or any of its employees, directors, managers or consultants, and there is no basis for such audits, investigations, disputes, claims or proceedings (it being understood that the Tax authorities may start conducting such activities at any time, at its sole criteria) in accordance with all Applicable Laws. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group has duly reported in its non-resident income tax (&#8220;NRIT&#8221;) annual returns the payments made to non-residents entities and individuals for the services rendered.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group has not entered into, is not, has not been a party to, or has not otherwise been involved in any scheme or arrangement that (i) was entered into solely or wholly or mainly with a view to avoiding, reducing, postponing or extinguishing any actual or potential liability for Tax; or (ii) was designed for the purpose of unlawfully avoiding Taxes, and the BDI Group have not unlawfully invoked an exemption or reduction of Tax.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In respect of every transaction or series of transactions in respect of which the BDI Group is subject to any transfer pricing rules, (i) each such transactions have been carried out at arm&#8217;s length prices, (ii)  provision between the BDI Group and any other person is real, has provided a benefit to the recipient and</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">is not susceptible to adjustment by any Tax Authority and (iii) the BDI Group has prepared and retained all such documentation as is necessary or reasonable to identify the terms of the transactions, justify the actual rendering of the services</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">and the methodology used in arriving at arm&#8217;s length terms for such transactions.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group has not acquired property for proceeds greater than the fair market value thereof from, or disposed of property for proceeds less than the fair market value thereof to, or received or performed services for other than the fair market value from or to, or paid or received interest or any other amount other than at a fair market value rate to or from any Existing Shareholders or a related individual of any of the Existing Shareholders or other person with whom it does not deal at arm&#8217;s length within the meaning of </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:46px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Applicable Laws.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group has timely complied with all legally required reporting obligations in respect of commissions, fees, rebates, salaries, benefits in kind, commercial discounts by means of credit notes through the relevant forms. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All goods, services or other inputs for which the BDI Group has claimed any credit, deduction or similar with respect to any value added tax or similar tax have been or are to be used for the purposes of the Business and a valid credit, deduction or similar is available to the extent claimed.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Taxes deducted by the BDI Group from payments or benefits in kind granted to any person have been properly deducted and accounted for and timely paid to the relevant authorities in accordance with Spanish Law or normal provisions have been made for payments or granting of benefits in kind not yet due.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Neither the entering into the Investment Agreement or the other Transaction Documents, nor the Closing, will cause the BDI Group to incur or sustain any liability to taxation that would not otherwise have arisen or affect the value of any asset for the purposes of ascertaining any present or future liability of the BDI Group to taxation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All losses and reliefs shown in the Last Accounts or in the Tax returns or computations are valid and properly claimed and are available to offset taxable profits of the BDI Group and there are no circumstances in existence, which might cause the disallowance in whole or part of any such losses, tax credits or reliefs. All claims for relief, allowances or repayment of Taxes and all elections, options and the like that have, will or may affect the liability of the BDI Group for Tax have been duly, timely and properly made and remain valid.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20.15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The BDI Group has not benefited from or granted any abnormal or benevolent advantages or secret commissions; as such concepts are interpreted as at the Closing Date in accordance with the applicable Spanish Law.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><a name="s996c85b4a02e423185d64fbc21e4d174"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule V</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Company and Existing Shareholders&#8217; Indemnification Obligation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">1.&#160;&#160;&#160;&#160;INDEMNIFICATION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.1&#160;&#160;&#160;&#160;Subject to the provisions of the Agreement, on and after the Closing Date, each of the Existing Shareholders and the Company shall indemnify and hold harmless the Investors from and against any and all Losses suffered by such Investors relating to, arising out of or resulting from (i) any breach or inaccuracy of any of the Warranties set forth in Section 11 of the Agreement and Schedule V attached thereto as well as (ii) the Specific Indemnities set forth in Clause 12 and (iii) any breach or inaccuracy of the Covenants or obligations of the Existing Shareholders, the Company or VLP under this Agreement. It is hereby expressly agreed by the Parties that the Company and the Existing Shareholders shall be joint and severally liable, being the Existing Shareholders&#8217; liability divided in accordance to the Liability Distribution Percentages as established in Schedule III.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.2&#160;&#160;&#160;&#160;Notice of Indemnification Claim (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Indemnification Claim</font><font style="font-family:inherit;font-size:11pt;">&#8221;): No Indemnification Claim may be made by either of the Investors to the Existing Shareholders or Company in respect of a Loss unless and until the written notice of such Indemnification Claim has been delivered to the Company and the Existing Shareholder, which notice shall specifically state in reasonable detail:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)&#160;&#160;&#160;&#160;the  Warranty(ies), Specific Indemnities, Covenants or obligations for which the breach is alleged;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)&#160;&#160;&#160;&#160;the reason that the Investor is alleging said breach; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii)&#160;&#160;&#160;&#160;the nature and  amount of the Loss (if known).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.3&#160;&#160;&#160;&#160;Double Indemnification Claims: Nothing in this Agreement is intended to require or permit the payment by the Existing Shareholders or the Company of duplicative, in whole or in part, indemnity payments hereunder and/or under the Transaction Documents to the Investors. If the Existing Shareholders or the Company pay an indemnity to the Investors in connection with Losses and the Investors subsequently recover(s) all or part of the amount of such indemnity from a third party, the Investors shall as promptly as possible repay to the Existing Shareholders or the Company the amount so recovered (up to the amount of the indemnity previously received).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.4&#160;&#160;&#160;&#160;Remedial Action: If the Company or any Existing Shareholder breaches its Warranties, Specific Indemnities, Covenants or obligations under this Agreement, and such breach is capable of being remedied, the breaching party shall be afforded a period of thirty (30) days to cure such breach.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">2.&#160;&#160;&#160;&#160;CONDUCT OF INDEMNIFICATION CLAIMS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.1&#160;&#160;&#160;&#160;Indemnification Claim Notice: If any of the Investors becomes aware of any matter that may give rise to a Indemnification Claim against any of the Existing Shareholder or the Company, notice of that fact shall be given to said Existing Shareholder or the Company in accordance with Clause 1.2 of this Schedule V and no later than thirty (30) days after the Investor becomes aware of the circumstances giving rise to such Indemnification Claim; provided, however, that any failure to give such timely notice shall not affect the rights of the Investor hereunder except to the extent of the Loss suffered by the Existing Shareholder or the Company as a result of such failure. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.2&#160;&#160;&#160;&#160;Third-Party Indemnification Claim: If the Indemnification Claim in question results from or arise in connection with a claim by or liability to a third party:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">(i)&#160;&#160;&#160;&#160;subject to having served notice on the Investor within thirty (30) days from the receipt of the Investor&#8217;s notice of Indemnification Claim referred to in paragraph 2.1 that they desire to conduct the defence of a third-party claim, the Existing Shareholders and the Company shall be entitled to conduct and/or control at their own expense the defence of such third-party claim (including, without limitation, by making or causing the Company and/or the relevant </font><font style="font-family:inherit;font-size:12pt;">BDI</font><font style="font-family:inherit;font-size:11pt;">&#32;Group to make counterclaims or other claims against said third party; provided that such counterclaims or claims are related to the underlying claim) it being agreed that this shall not prevent any of the Investors from being indemnified by the Existing Shareholders and the Company under paragraph 1.1.  In such case, no admission of liability (whether express or implied) shall be made by or on behalf of the Investor (including the Company or </font><font style="font-family:inherit;font-size:12pt;">its Subsidiaries</font><font style="font-family:inherit;font-size:11pt;">);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)&#160;&#160;&#160;&#160;if the Existing Shareholders and the Company do not notify the Investor within a reasonable time, which shall in any event be within thirty (30) days, from the receipt of Investor&#8217;s notice of a Indemnification Claim referred to in paragraph 2.1 that the Existing Shareholders and the Company desire to conduct the defence of a third-party claim, the Investor shall conduct the defence of the third-party claim in good faith; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii)&#160;&#160;&#160;&#160;any Party who undertakes the defence of a third-party claim shall give to the other Parties the opportunity to comment and be associated in the defence, shall take into account any reasonable comments, shall keep such other Parties informed of the development of the underlying claim and shall promptly communicate or give to the other Parties access to all notices, communications and filings (including court papers).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iv) A failure by an Investor to comply with its obligations under paragraph 2.2 shall not affect the rights of such Investor except to the extent of the Loss suffered by the Existing Shareholders and the Company as a result of such failure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">3.&#160;&#160;&#160;&#160;PAYMENTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.1&#160;&#160;&#160;&#160;Payment of Indemnification Claim: The Existing Shareholders and the Company shall not be required to make any payment until the amount in respect of which the Indemnification Claim has been made is due and payable. If the indemnification of the Loss or its amount is disputed by a Party, no payment or set-off shall be required to be made by the Existing Shareholders and the Company until such dispute has been finally settled by mutual agreement between the Parties or an enforceable decision has been rendered in accordance with Section 29 of the Investment Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.2. At the option the Investors, any Loss that any of the Existing Shareholders shall pay to the Investors may be settled in cash or in shares held by the relevant Existing Shareholder in the Company subject to the quantitative limitations set forth in clause 4.4 of Schedule VI. If paid in shares, the number of shares will be calculated by dividing the value of the Loss by the price per each of the Company&#8217;s shares paid in by the Investors in the Company&#8217;s Capital Increase. Each of the Parties hereby irrevocably waives any pre-emption rights that they may have so as to enable the transfer of any shares in the capital of the Company contemplated by this clause 3.2. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.3&#160;&#160;&#160;&#160;Return of Recovered Amounts from Third Parties: If any indemnity paid by an Existing Shareholders and/or the Company, pursuant to Section 3.1 above, in discharge of any Indemnification Claim under this Agreement and an Investor, the Company or any BDI Group subsequently recovers (whether by payment, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">discount, credit, relief or otherwise) from a third party an amount in respect of the same Loss, the Investor shall within ninety (90) days pay on behalf of itself (including the Company or the BDI Group), as the case may be, to the Existing Shareholders and/or the Company, in accordance with the Liability Percentage, an amount equal to the sum recovered from said third party after deduction of all costs and expenses of recovery and (if any) any resulting increase in insurance premiums.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.5 &#160;&#160;&#160;&#160;If, as a consequence of any indemnity paid by the Existing Shareholders and the Company, the Investor and/or the BDI Group are compelled to make any tax payment, the Existing Shareholders and the Company shall pay to such Investor or the BDI Group (as applicable) such additional amounts are necessary to ensure receipt by the Investor and/or the BDI Group of the full amount which they would have received but for the tax obligation.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><a name="s4200e4eb14034e0ea876fd0529f29964"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule VI</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Limitation of Liability </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">1&#160;&#160;&#160;&#160;TIME LIMITS FOR BRINGING INDEMNIFICATION CLAIMS.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company and the Existing Shareholders shall not be liable for any Losses unless and until the Company and the Existing Shareholders have received from the Investors written notice in accordance to Schedule V on or before:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i) in respect of an Indemnification Claim (other than a claim under the Specific Indemnities, Warranties 17, 18 and 20), twenty-four (24) months from the Closing Date; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii) in respect of an Indemnification Claim in relation only to the Warranties 17, 18 and 20, the expiry of the statute of limitations established under the Spanish Law.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any Indemnification Claim shall (if not previously satisfied, withdrawn or settled) be deemed to have been withdrawn and waived by the Investors unless legal and/or administrative proceedings in respect of such Indemnification Claim have been commenced within one year after the notification of such Indemnification Claim to the Company and the Existing Shareholders pursuant to paragraph 1.1.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">2&#160;&#160;&#160;&#160;ACTS OF THE INVESTOR.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Existing Shareholders and the Company shall not be liable (or such liability shall be reduced) in respect of any Indemnification Claim to the extent that such Indemnification Claim arises or is increased as a result of any breach by the Investors of any of its obligations under this Agreement or any of the Transaction Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">3&#160;&#160;&#160;&#160;GENERAL LIMITATIONS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Existing Shareholders and the Company shall not be liable (or such liability shall be reduced in the case of paragraph (c) below) in respect of any Indemnification Claim:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)&#160;&#160;&#160;&#160;that arises as a result of, or would not have arisen but for, or a liability is increased as a result of, legislation not in force at the Closing Date or any change in legislation, case law or doctrine issued by administrative public bodies, with retrospective effect after the Closing Date;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;(b)&#160;&#160;&#160;&#160;in cases where the obligation to indemnify is related to any information, circumstances or events that have been Disclosed in the Data Room, except those covered by the Specific Indemnity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)&#160;&#160;&#160;&#160;in cases where a provision has been recorded in the Financial Statements  or in the Financial Projections of the BDI Group to cover any damages; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)&#160;&#160;&#160;&#160;in the event that the liability in question does not materialize as actual (as opposite to contingent) damage suffered by the Investors.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">4&#160;&#160;&#160;&#160;QUANTITATIVE LIMITATIONS</font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.1&#160;&#160;&#160;&#160;The Existing Shareholders and/or the Company shall not be liable in respect of any Losses unless the aggregate liability for all Indemnification Claims exceeds &#8364;25,000, in which case the Existing Shareholders and/or the Company shall be liable for the entire amount and not merely the excess.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.2&#160;&#160;&#160;&#160;In calculating liability for Indemnification Claims for the purposes of clause 4.1 above, any Indemnification Claim which is less than &#8364;2,500 (excluding interest, costs and expenses) shall be disregarded.  For these purposes, a number of Indemnification Claims arising out of the same or similar subject matter, facts, events or circumstances shall be aggregated and form a single Indemnification Claim</font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.3&#160;&#160;&#160;&#160;If the amount indicated in 4.1 above is exceeded, the Investors shall set off the amount of the corresponding Indemnification Claim from (i) any provisions recorded in the Financial Projections of the BDI Group to cover any contingencies; and (ii) then, if there are indemnifications still outstanding, from any amounts recovered from the Spanish Tax Authorities in connection with the outstanding proceedings related  to VAT claims followed against the Spanish Tax Authorities. </font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.4&#160;&#160;&#160;&#160;The maximum limit on the direct or indirect aggregate liability of the Existing Shareholders shall be, at the entire and absolute discretion of the Investors, (i) four hundred thousand euros (&#8364;400,000) if paid in cash by the Existing Shareholders or (ii) one million five hundred thousand Euros (&#8364;1,500,000) if the Investors decide the Existing Shareholders to settle the Indemnification Claim totally in shares in accordance with Clause 3.2 of Schedule V above. Accordingly, the maximum limit of the liability of each of the Existing Shareholders shall be calculated by applying the proportions set forth in the Liability Distribution Percentages (as established in Schedule III) to the foregoing amounts.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">5&#160;&#160;&#160;&#160;EXCEPTIONS TO THE LIMITATION OF LIABILITY</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">As mentioned in Clause 13.2 of this Agreement,</font><font style="font-family:inherit;font-size:11pt;">&#32;the limitations of liability contained in this Agreement, </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Schedule VI</font><font style="font-family:inherit;font-size:11pt;">&#32;or any statutory limitation shall not apply in relation to:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i) the Specific Indemnities,</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii) any claim relating to the warranties of Section 1 (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Authority and Capacity</font><font style="font-family:inherit;font-size:11pt;">) and 2 (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Title of Shares in the Company and VLP</font><font style="font-family:inherit;font-size:11pt;">) listed in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule IV</font><font style="font-family:inherit;font-size:11pt;">&#32;and</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii) the liability of the Existing Shareholders to any claim where the fact, matter or circumstance giving rise to such claim arises as a result of fraud (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">dolo</font><font style="font-family:inherit;font-size:11pt;">&#8221;), fraudulent misrepresentation, deliberate misstatement or wilful concealment on the part of any of the Existing Shareholders.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><a name="s8ab8b7cf786c43aba232fee57b4a255e"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT A1</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">BDI Holding Shareholders Agreement</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SHAREHOLDERS AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">with respect to</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biotechnology Developments for Industry, S.L.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">executed by</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Creux An</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#225;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">lisis Estrat</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#233;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">gicos, S.L.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Emilio Guti</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#233;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">rrez G</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#243;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">mez </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Carlos Bl</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#225;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">zquez Escudero </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Ricardo Arjona Antol</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#237;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">n </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ms. Ana G&#243;mez Rodr</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#237;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">guez</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Luis Hilario Guerra Trueba</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Floema Biotec, S.L.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Jorge Hern</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#225;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ndez Esteban</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Yahia El-Amrani Bentahar</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVEREADY INNVIERTE BIOTECH II, S.C.R., S.A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Madrid, on 30 June 2017</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><a name="sa0ad00cd9f2c4f5aafe9d189e4be7131"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:90%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">DEFINITIONS AND INTERPRETATION.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">PURPOSE OF THE AGREEMENT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">BUSINESS OF THE COMPANY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">BOARD OF DIRECTORS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#353936;">GENERAL SHAREHOLDERS</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#525456;">' </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#353936;">MEETING.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">CONFLICT OF INTEREST</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">MANAGING DIRECTOR ("CEO").</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">INFORMATION RIGHTS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">DIVIDEND POLICY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">ACCOUNTING AND FINANCIAL REPORTING</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">OBLIGATIONS OF EACH PARTY.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">PRE-EMPTIVE RIGHTS FOR CAPITAL INCREASE.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">LOCK-IN PERIOD AND FUTURE TRANSFERS OF SHARES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">DRAG-ALONG RIGHT.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">TAG-ALONG RIGHT.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">NATURE OF THIS AGREEMENT AND BYLAWS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">TERM</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">TERMINATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">MINIMUM COMMITMENT TERM FOR THE KEY EMPLOYEES.</font></div><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">NON COMPETE, NON-SOLICITATION AND EXCLUSIVITY.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">CONFIDENTIALITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">INDEMNITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">NOTICES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">ASSIGNMENT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">GOVERNING LAW AND JURISDICTION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353936;font-weight:bold;">41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><a name="s49e5aa2459d14682b1a74cbca05a0ce1"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SHAREHOLDERS AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REGARDING</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BIOTECHONOLOGY DEVELOPMENTS FOR INDUSTRY, S.L.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In Madrid, on 30 June 2017</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OF THE ONE PART</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Creux: An&#225;lisis Estrat&#233;gicos, S.L.</font><font style="font-family:inherit;font-size:11pt;">, a Spanish limited liability company, with registered office in &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca, holder of Spanish tax identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, represented by Mr. Emilio Guti&#233;rrez G&#243;mez, of legal age, a Spanish national, holding taxpayer identification number 70.882.858-D, in force, and domiciled for this purposes in &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca. He acts in his capacity of Sole Director of the mentioned company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca, acting in his own name and behalf.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Carlos Bl&#225;zquez Escudero</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca, represented by Mr. Pablo Guti&#233;rrez G&#243;mez, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purposes at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca. He acts in the name and on behalf of Mr. Carlos Bl&#225;zquez Escudero on virtue of special powers of attorney granted on his favour.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Ricardo Arjona Antol&#237;n</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, acting in his own name and behalf.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ms. Ana G&#243;mcz Rodr&#237;guez</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, acting in her own name and behalf.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Luis Hilario Guerra Trueba</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, represented by Mr. Emilio Guti&#233;rrez G&#243;mez, by virtue of a special power of attorney granted in his favour.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Floema Biotec, S.L.</font><font style="font-family:inherit;font-size:11pt;">, a Spanish limited liability company, with registered office in &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, holder of Spanish tax identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, represented by Mr. Antonio de Leyva Tejada, of legal age, a Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in force, and domiciled for this purposes at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. He acts in the name and on behalf of the entity Floema Biotec, S.L. on virtue of a special power of attorney (proxy) granted on his favour.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Jorge Hern&#225;ndez Esteban</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, acting in his own name and behalf.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Mr. Yahia El-Amrani Bentahar</font><font style="font-family:inherit;font-size:11pt;">, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and domiciled for this purpose at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, represented by Mr. Emilio Guti&#233;rrez G&#243;mez, by virtue of a special power of attorney granted in his favour.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(10)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC</font><font style="font-family:inherit;font-size:11pt;">, a US company incorporated and existing under the laws of Florida, USA, and duly registered with the Trade Registry of the State of Florida, USA with company </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:36px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">registration number 45-0486747, having its corporate domicile at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477, USA ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:11pt;">"), represented by Mr. Antonio Ca&#241;adas Bouwen, of legal age, a Spanish national, with taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in force, and domiciled for this purposes &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. He acts in his capacity of special attorney of Dyadic; and</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(11)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVEREADY INNVIERTE BIOTECH II, S.C.R.</font><font style="font-family:inherit;font-size:11pt;">,</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;S.A.</font><font style="font-family:inherit;font-size:11pt;">, a Spanish company, with registered office in calle Cavallers, 50, 08034 Barcelona, holder of Spanish tax identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Inveready</font><font style="font-family:inherit;font-size:11pt;">"), represented by Mr. Roger Piqu&#233; Pijuan, of legal age, a Spanish national, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in force, and domiciled for this purposes in &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 08034 Barcelona. He acts in his capacity of general attorney of Inveready.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Hereinafter the persons and companies identified in items (1) through (9) will be jointly referred to as the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Initial Shareholders</font><font style="font-family:inherit;font-size:11pt;">".</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Hereinafter the persons and companies identified in items (1) through (11) will be jointly referred to as the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders</font><font style="font-family:inherit;font-size:11pt;">".</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AND OF ANOTHER PART</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(12)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biotechnology Developments For Industry, S.L.</font><font style="font-family:inherit;font-size:11pt;">, a Spanish limited liability company, with registered office in Avenida Francisco Valles, 8, 47151, Boecillo (Valladolid), holder of Spanish tax identification number B47729934 ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Holding</font><font style="font-family:inherit;font-size:11pt;">" or the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:11pt;">"), represented by Mr. Pablo Guti&#233;rrez G&#243;mez, of legal age, with Spanish nationality, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in force, and domiciled for this purposes in Louis Proust 13, Boecillo. He acts in his capacity of Chief Executive Officer of BDI Holding.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Finally, the Shareholders and the Company shall be jointly referred to as the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:11pt;">" and each one of them as a "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:11pt;">''.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the capacity in which they act, the Parties reciprocally recognize each other to have the necessary and sufficient legal capacity and powers of representation to enter into this </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders Agreement</font><font style="font-family:inherit;font-size:11pt;">&#32;(hereinafter this "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Agreement&#8221;</font><font style="font-family:inherit;font-size:11pt;">)</font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">and for this purpose, they state the following</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WHEREAS</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company is a Spanish limited liability company, with registered office at Avenida Francisco Vall&#233;s 8, 47151, Boecillo (Valladolid), incorporated by virtue of the public deed granted by the Public Notary from Madrid, Mr. Jorge Prades L&#243;pez., on 22 September 2014, under number 789 of his public records, registered in the Commercial Registry of Valladolid under volume 1477, sheet 91, page VA-27242, and with tax identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The By-Laws of the Company before entering into this Agreement are attached hereto as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule I</font><font style="font-family:inherit;font-size:11pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">II.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company is the sole shareholder of the entities listed in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule II</font><font style="font-family:inherit;font-size:11pt;">&#32;and carries out its Business, directly and indirectly, through its Subsidiaries.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">III.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On the Effective Date, an investment agreement was entered into by the Shareholders and the Company pursuant to which Dyadic and Inveready will invest an aggregate amount of &#8364;1,434,000 in the Company by means of a capital increase in the Company ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Capital Increase</font><font style="font-family:inherit;font-size:11pt;">"), subject to the waiver or fulfillment of the closing conditions and covenants established in the Investment Agreement.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">IV.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On the Effective Date, and pursuant to the terms of the Investment Agreement, Dyadic and Inveready entered into the share capital of the Company through a capital injection of EUR 1,434,000 with the unanimous approval of all the Initial Shareholders. After the mentioned capital increase, the Shareholders hold the entire share capital of the Company as set out in </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule III</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">V.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Parties have decided to enter into this Shareholders Agreement in order to regulate (i) the relationships among the Shareholders, (ii) the relationships between the Shareholders and the Company, (iii) the system of governance and management of the Company and (iv) the transfers of shares in the Company and certain other commitments of the Shareholders related to the Company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">THE PARTIES</font><font style="font-family:inherit;font-size:11pt;">&#32;agree as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DEFINITIONS AND INTERPRETATION.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:11pt;">. In the Agreement the following terms shall have the meanings specified below:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Accounting Principles</font><font style="font-family:inherit;font-size:11pt;">" means the Spanish generally accepted accounting principles as laid down in the Spanish General Accounting Plan ("Plan General Contable").</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Affiliate</font><font style="font-family:inherit;font-size:11pt;">" means any entity directly or indirectly controlled by, controlling, or under common control with, a party to this Agreement, but only for so long as such control shall continue. For purposes of this definition, "control" (including, with correlative meanings, "controlled by", "controlling" and "under common control with") means possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies of art entity (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Applicable Law</font><font style="font-family:inherit;font-size:11pt;">" means, with respect to any Person, any law, regulation, rule, judgment, order, decree, award, Governmental Approval, grant, license, agreement, guideline, policy, requirement, or other governmental restriction or any similar form of decision of, or determination by, or any interpretation or administration of any of the foregoing by, any Governmental Authority, then in force and applicable to such Person or its subsidiaries or their respective assets.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Auditors</font><font style="font-family:inherit;font-size:11pt;">" means the auditor(s) of the Company as may be appointed from time to time by General Shareholders Meeting.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Audited Financial Statements</font><font style="font-family:inherit;font-size:11pt;">" means the audited balance sheet and profit and loss account of the Company (as well as further financial statements required by the Applicable Law for the annual accounts) for the financial period ended on and as at December 31, including the reports and notes annexed to them, prepared in accordance with the Accounting Principles and audited by the Auditors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Holding</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Recital 12.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Group</font><font style="font-family:inherit;font-size:11pt;">" means the Company and the Subsidiaries.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI Pharmaceuticals</font><font style="font-family:inherit;font-size:11pt;">" means Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Board Meeting</font><font style="font-family:inherit;font-size:11pt;">'' shall have the meaning ascribed to it in Clause 4.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Board of Directors</font><font style="font-family:inherit;font-size:11pt;">" or "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Board</font><font style="font-family:inherit;font-size:11pt;">" means the Board of Directors of the Company as set forth in Clause 4.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Board Reserved Matters</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 4.12.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Business</font><font style="font-family:inherit;font-size:11pt;">" means the corporate activity or business ordinarily carried out by BDI Group consisting of [to be included].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Business Day</font><font style="font-family:inherit;font-size:11pt;">" means any day except Saturdays, Sundays or public holidays or days in which banks are not open in Madrid, Spain or Jupiter, Florida.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Bylaws</font><font style="font-family:inherit;font-size:11pt;">" means the bylaws of the Company, as amended according to the terms and conditions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Capital Increase</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Whereas III.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Call Options</font><font style="font-family:inherit;font-size:11pt;">" mean the call option agreements in the form attached as Schedule VI which have been entered into between some of the Existing Shareholders and raised into public deed on the Effective Date;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CEO</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 7.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CEO Management Contract</font><font style="font-family:inherit;font-size:11pt;">" means the separate agreement to be entered into by the Company, on the one hand, and the Chief Executive Officer (CEO) on the other hand, on the Effective Date and in the agreed form attached to this Agreement as </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Schedule IV</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Chairman</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 4.6. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Recital 12.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Competitor</font><font style="font-family:inherit;font-size:11pt;">" shall mean any Person or entity (other than Dyadic or any of its Affiliates or any of Dyadic's directors or employees) who provides genetic modifications, and/or fermentation media and process development related to any fungal strains that have the taxonomy of either (i) </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Myceliopthora</font><font style="font-family:inherit;font-size:11pt;">, (ii) </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Corynascus</font><font style="font-family:inherit;font-size:11pt;">&#32;or (iii) </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Sporotrichium</font><font style="font-family:inherit;font-size:11pt;">&#32;and/ or any strains derived, generated, adapted and or otherwise therefrom.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 21.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Deed of Adherence</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 14.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Directors</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 4.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 21.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Disinvestment</font><font style="font-family:inherit;font-size:11pt;">" means the sale or disposal in any other manner by the Shareholders of all of their shareholding interest in the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Drag Along Right</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 15.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Recital 10.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:11pt;">" means the date of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Extraordinary Board Meetings</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 4.7.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Financial Year</font><font style="font-family:inherit;font-size:11pt;">" means each financial year of the Company starting on January, 1st and ending on December, 31st of each year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Free Cash Flow</font><font style="font-family:inherit;font-size:11pt;">" means, for a given Financial Year, the cash generated by the Company's operations and (subject to the provisions of applicable laws and this Agreement) available for distribution to Shareholders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">General Shareholders' Meeting</font><font style="font-family:inherit;font-size:11pt;">" means a shareholders' meeting of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Governmental Authority</font><font style="font-family:inherit;font-size:11pt;">" means any government or political subdivision thereof, including without limitation, any governmental department, commission, board, bureau, agency, regulatory authority, judicial or administrative body, having jurisdiction over the matter or matters in question.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Initial Shareholders</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Recital 11.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Inveready</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Recital 11.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Investment Agreement</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Whereas III.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Key Employees</font><font style="font-family:inherit;font-size:11pt;">" mean Mr. Emilio Guti&#233;rrez G&#243;mez, Ms. Ana G&#243;mez Rodr&#237;guez and Mr. Pablo Guti&#233;rrez G&#243;mez.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Lock-In Period</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 14.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Minimum Commitment Term</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 20.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Notary</font><font style="font-family:inherit;font-size:11pt;">" means the Spanish Notary designated by the Company to authorize the Capital Increase Deed and the Public Deed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Notice</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Cause 24.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Offer</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Cause 16.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Offered Shares</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 16. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Offer Notice</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 16.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Offerer</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 16.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ordinary Board Meetings</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 4.7.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:11pt;">" or "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Recital 12.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Person/s</font><font style="font-family:inherit;font-size:11pt;">" means any individual, corporation, business trust, joint venture, association, company, limited liability entity, firm, partnership, or other entity or governmental body, including their heirs, successors and assignees.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Public Deed</font><font style="font-family:inherit;font-size:11pt;">" means the deed notarizing this Agreement to be executed by the Parties on the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 21.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Sale</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 15.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Sale Request</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 16.2.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Secretary</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 4.6.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shares</font><font style="font-family:inherit;font-size:11pt;">" means the shares in which the share capital of the Company is divided after the Capital Increase.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Recital 11.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Shareholders Reserved Matters</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 5.6.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Spanish Companies Acts</font><font style="font-family:inherit;font-size:11pt;">" means the Spanish Companies Act 1/2010 dated July 2nd (&#8220;Real Decreto Legislativo 1/2010, de 2 de julio, por el que se aprueba el texto refundido de la Ley de Sociedades de Capital") and includes any enactment passed after that Act which may, by reason of that or any other enactment, be cited together with that Act as "the Companies Acts".</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Spanish Law</font><font style="font-family:inherit;font-size:11pt;">" means any law, regulation, rule, order and/or decree, then in force and applicable in Spain.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Subsidiaries</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Whereas II.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Tag Along Right</font><font style="font-family:inherit;font-size:11pt;">" shall have the meaning set forth in Clause 16.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Transfer</font><font style="font-family:inherit;font-size:11pt;">" shall mean, with respect to any share or any interest in any share, a direct or indirect transfer or disposition in any form, including a promise to sell, option, sale, assignment, conveyance, pledge, mortgage, encumbrance, securitization, any purported severance or alienation of any beneficial interest (including the creation of any derivative or synthetic interest) or the act of so doing, as the context requires.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Interpretation</font><font style="font-family:inherit;font-size:11pt;">:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the Agreement, unless indicated otherwise:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reference to the Agreement must be deemed to be made to the Agreement and its Schedules.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reference to "Clause" or "Schedule" must be deemed to be made to a Clause of, or Schedule to the Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Schedules: The Schedules to this Agreement are incorporated into and form an integral part of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Wherever the terms "includes", "included", "include" and "including" are used, they shall be deemed to be followed by the expression "without limitation".</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reference to one gender includes the other, and words in the singular shall include the plural, and vice versa.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If an obligation is qualified or formulated by reference to the use of "best endeavors", "best efforts" or another similar expression, it refers to the endeavors that a Person with the firm intention to achieve an outcome would use in similar circumstances to ensure the achievement of such outcome as soon as possible, taking into account, among other factors:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the price, financial interest and other terms of the obligation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the degree of risk normally entailed by the achievement of the expected outcome;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the ability of an unrelated Person to exert an influence on the performance of the obligation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">that in no event shall any Party having committed to use best efforts be obliged to perform any payment or furnish any sort of financial guarantee to a third party in the context of the achievement of the outcome to which such Party had committed to use its best efforts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reference to "days" shall be deemed to be made to "calendar days''. Any periods expressed in days shall start to be counted from the day immediately following that on which the counting starts. If the last day of a period is not a Business Day, the period in question shall be deemed to have been automatically extended until the first following Business Day. Periods expressed in months shall be counted from date to date unless in the last month of the period such date does not exist, in which case the period shall end on the first Business Day of the immediately following month.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any reference to "from", "as from", "as of" or "through" a given date shall be understood to include such date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The headings used in the Agreement are included for reference only and shall not form part of the Agreement for any other purpose or affect the interpretation of any of its clauses.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Terms appearing in Spanish shall have the meanings ascribed to them in Spanish legislation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(xi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">References to "&#8364;" or "Euro" are references to the lawful currency from time to time of the Eurozone.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PURPOSE OF THE AGREEMENT.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The purpose of this Agreement is to establish the terms of th collaboration between the Shareholders in order to regulate:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the governance and administration of the Company, and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the transfer of shares of the Company, for the purposes of providing with a stable shareholding structure and facilitating the management of the Company with the objective of maximizing value for the Shareholders; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">several other commitments of the Shareholders related to the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the event that any conflict or discrepancy arises between the Bylaws and this Agreement, the provisions of this Agreement shall prevail. Therefore, in the event that any of the provisions in this Agreement are not fully incorporated in Bylaws and an inconsistency arises, this Agreement shall prevail among the Shareholders and, upon request of any Shareholder, the Parties shall exercise all powers and rights available to them, in order to give effect to the provisions of this Agreement and to procure the amendment of the Bylaws to conform to this Agreement to the fullest possible extent,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BUSINESS OF THE COMP ANY</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company and its Subsidiaries shall be primarily engaged in the Business and any future business as may be approved by the Shareholders from time to time in accordance with the terms of this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BOARD OF DIRECTORS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company shall be governed by a Board of Directors which shall be subject to the provisions set forth in this Clause 4.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Powers and responsibilities of the Board</font><font style="font-family:inherit;font-size:11pt;">: Except with respect to those matters expressly reserved to the General Shareholders Meeting by the Spanish Companies Acts, the Bylaws or this Agreement, the Board shall have the following duties:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">to propose the annual business plan for conducting the Company's business for approval by a General Shareholders Meeting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">to manage and instruct the CEO in relation with the management of all aspects of the Company's operations including but not limited to the organization of proper financial records;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">to close the Company's books at the end of each year, and prepare the list of inventory, the balance sheet, profit and loss statement, the statement of changes in the net equity, the cash flow statement (if any) and a report of the Company's operations as required by Spanish Companies Acts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">to cause all reports and documents to be filed with the proper government agencies in Spain; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any other duties as may be set forth in the Bylaws or as may be determined by the General Shareholders Meeting, to the extent required by the Spanish Companies Acts.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The day-to-day running and the overall direction and supervision of the Business shall be the responsibility of the Board of Directors, directly or indirectly through the CEO and any other managers, expressly acting under the principles, guidelines and instructions received from the Board and the principles set out in this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Composition of the Board</font><font style="font-family:inherit;font-size:11pt;">. The Company shall, unless subsequently agreed otherwise in writing by the General Shareholders Meeting pursuant to the majorities set forth in Clause 5.6, be governed by a Board composed of five (5) members (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Directors</font><font style="font-family:inherit;font-size:11pt;">") that shall be appointed as follows:</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:36px;text-indent:-36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333935;">(i)&#160;&#160;&#160;&#160;Dyadic shall nominate two Directors for their appointment;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333935;">(ii)&#160;&#160;&#160;&#160;Inveready shall nominate one Director for their appointment; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333935;">(iii)&#160;&#160;&#160;&#160;The Initial Shareholders (by simple majority) shall nominate two Directors for their appointment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333935;">However, the Shareholders shall not be entitled to appoint as Director a Person who is already a (i) member of the board of any Competitor of BDI Group or (ii) a member of the management team of any Competitor of BDI Group, unless the prior approval of all the members </font><font style="font-family:inherit;font-size:11pt;color:#333935;font-style:italic;">of </font><font style="font-family:inherit;font-size:11pt;color:#333935;">the Board is previously obtained in written.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#333935;">4</font><font style="font-family:inherit;font-size:11pt;color:#505050;">.</font><font style="font-family:inherit;font-size:11pt;color:#333935;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333935;">With effect from the Effective Date:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333935;">(i)&#160;&#160;&#160;&#160;The Dyadic Directors shall be: (a) </font><font style="font-family:inherit;font-size:11pt;color:#333935;font-weight:bold;">Mr. Mark Aaron Emalfarb</font><font style="font-family:inherit;font-size:11pt;color:#333935;">, of legal age, of United States of America nationality, divorced, with professional domicile at C/0 Dyadic International, USA, Inc. 140 Intracoastal Pointe Drive, Suite# 404, Jupiter, Florida 33477 USA and provided with passport of his nationality number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in force; and (b) </font><font style="font-family:inherit;font-size:11pt;color:#333935;font-weight:bold;">Mr. Dr. Ronen Tchelet</font><font style="font-family:inherit;font-size:11pt;color:#333935;">, of legal age, of Israeli nationality, married, with professional domicile at Tel Aviv University, Tel Aviv, Israel and provided with passport of his nationality number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#534233;">&#32;in </font><font style="font-family:inherit;font-size:11pt;color:#333935;">force;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333935;">(ii)&#160;&#160;&#160;&#160;The Inveready Director shall be: </font><font style="font-family:inherit;font-size:11pt;color:#333935;font-weight:bold;">Inveready Asset Management, S.G.E.I.C., S.A.</font><font style="font-family:inherit;font-size:11pt;color:#333935;">, Spanish company, with registered office in &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Barcelona, holder of Spanish tax identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, represented by </font><font style="font-family:inherit;font-size:11pt;color:#333935;font-weight:bold;">Mr. Roger Piqu&#233; Pijuan</font><font style="font-family:inherit;font-size:11pt;color:#333935;">, of legal age, a Spanish national, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#534233;">&#32;in </font><font style="font-family:inherit;font-size:11pt;color:#333935;">force, and domiciled for this purposes in &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 08034 Barcelona;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(iii)&#160;&#160;&#160;&#160;The Initial Shareholders Directors shall be: (a) </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Mr. Pablo Guti&#233;rrez G&#243;mez</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">, </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">of legal age, of Spanish nationality, single, with professional domicile at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Valladolid, and provided with Spanish Identification Number (D</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">N.L) n&#176; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in force; and (b) </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Mr. Ricardo Arjona Antolin</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">, of legal age, of Spanish nationality, married, with professional domicile at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Valladolid and provided with Spanish Identification Number (D.N.I.) n&#176; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in force.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">4</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;text-decoration:underline;">Appointments and Removal of Directors</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">. Th</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">e Directors shall be appointed at a General Shareholders Meeting in accordance with the provisions of this Agreement. The Shareholders undertake to vote for the appointment or dismissal of the Directors nominated by the Shareholder who is entitled to make the corresponding appointment or dismissal, pursuant to Clause 4.3 above.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The Dire</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">tors shall be appointed at the General Shareholders Meeting for an indefinite period of time</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">. </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Each Shareholder who has the right to designate a Director shall also have the right to remove (or cause to be removed) or replace at any time and for any reason (including death, resignation, inability to act or dismissal) such Director from its office and designate (or cause to be designated) an alternative Director in his/her place.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Ea</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">h Shareholder undertakes to the other </font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">S</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">hareholders that it shall take all practicable steps, directly or indirectly, including the exercise of voting rights in the General Shareholders' Meeting, to effect th</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">appointments and removals of any Director designated by the entitled Shareholder</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">4.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;text-decoration:underline;">Positions in the Board</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">. The Board shall appoint a chairman (the "</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Chairman</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">") and a Secretary (the "</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Secretary</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">") to the Board as follow:</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(i)&#160;&#160;&#160;&#160;The p</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">rson holding the position of Chairman of the Board shall be proposed for appointment or dismissal by the Initial Shareholders, provided that the Initial Shareholders remain with the majority (more than 50%) of the sharehold</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">r</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">s</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">hip in the Company. In case th</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Initial Shareholders have less than 50% shareholdership in the Company, the Board shall be entitled to appoint a new Chairman of the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">In addition to any specific responsibilities impos</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">d by Spanish Companies Acts, the Chairman shall:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(a)&#160;&#160;&#160;&#160;convene General Shareholders Meetings;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(b)&#160;&#160;&#160;&#160;convene ordinary and extraordinary meetings of the Board;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(c)&#160;&#160;&#160;&#160;chair the meetings of the Board and the General Shareholders Meetings in accordance with the Spanish Companies Acts;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(d)&#160;&#160;&#160;&#160;sign the minutes of the Board M</font><font style="font-family:inherit;font-size:11pt;color:#5e5f62;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">etings upon their approval in </font><font style="font-family:inherit;font-size:11pt;color:#363636;">accordance with the Spanish Companies Acts; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(e)&#160;&#160;&#160;&#160;sign the minutes of the General Shareholders Meetings upon their approval in accordance with the Spanish Companies Acts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The Chairman of the Board shall not have a casting vote within the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(ii)&#160;&#160;&#160;&#160;The Secretary may be a person who is not a Director of the Company, in which case such non-director Secretary will not be considered in determining the presence of the quorums required for a Board Meeting to be validly held and such non-director Secretary shall not have a right to vote in the said Board. The person holding the position of Secretary of the Board shall</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">. </font><font style="font-family:inherit;font-size:11pt;color:#363636;">be proposed for appointment or dismissal by Dyadic, however the latter shall consider all candidates submitted by the CFO.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">In addition to any specific responsibilities imposed by the Spanish Companies Acts, the Secretary shall:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(a)&#160;&#160;&#160;&#160;attend, as</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">Secretary of these meetings, all meetings of the "Board and all General Shareholders Meetings and record all the proceedings of such meetings in a book of minutes to be in custody for such purposes;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(b)&#160;&#160;&#160;&#160;sign the minutes of the Board Meetings upon their approval in accordance with the Spanish Companies Acts;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(c)&#160;&#160;&#160;&#160;sign the minutes of the General Shareholders Meetings upon their approval in accordance with the Spanish Companies Acts; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(d)&#160;&#160;&#160;&#160;perform such other duties and have such other powers as the Board may from time to time determine according to the Spanish Companies Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(iii)&#160;&#160;&#160;&#160;The offices of Chairman and Secretary to the Board shall be initially held by </font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Mr. Ricardo Arjona Antolin</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;and </font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Mr. Borja Diaz-Guerra Heredero</font><font style="font-family:inherit;font-size:11pt;color:#363636;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">4.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Meetings of the Board</font><font style="font-family:inherit;font-size:11pt;color:#363636;">. Each of the Shareholders shall cause each of its designated Directors to adopt and comply with the following rules in relation to the meetings of</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">the Board:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The Board will meet at least 4 times per Financial Year and at least once every calendar quarter ("</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Ordinary Board Meetings</font><font style="font-family:inherit;font-size:11pt;color:#363636;">'') and whenever called by the Chairman, at the Chairman's own initiative or upon petition of any Director ("</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Extraordinary Board Meetings</font><font style="font-family:inherit;font-size:11pt;color:#363636;">") indicating the items on the agenda to be discussed. In the latter case, the Extraordinary Board Meeting shall be held within the next twenty (20) days following the date of request of the said Director.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The Board will be called by written notice not less than 15 days in advance </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">of the meeting date, which notice shall be served on all the Directors at th</font><font style="font-family:inherit;font-size:11pt;color:#626162;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">address notified from time to time by each Director to the Chairman and Secretary.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">The summons shall be effected (a) by any means as may be required by the Spanish Companies Acts and (b) by means of a notice sent by letter, fax, e-mail or any other written or electronic means with </font><font style="font-family:inherit;font-size:11pt;color:#626162;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">onfirmation of receipt at the address designated by su</font><font style="font-family:inherit;font-size:11pt;color:#626162;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">h Director for su</font><font style="font-family:inherit;font-size:11pt;color:#626162;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">h purposes. The notice shall state: (a) date, place and hour of the meeting, (b) the agenda to be discussed together with the relevant supporting materials for discussion at such meeting in English language, (c) the name of the person or persons who have summoned the meeting, as well as (d) confirmation of date, place and hour of a rescheduled Board Meeting in accordance with Clause 4.10.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">Any Director attending a meeting shall have the right to propose additional topics for discussion at any meeting which were not originally includ</font><font style="font-family:inherit;font-size:11pt;color:#626162;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">d in the agenda for that meeting and no unanimity or majority shall be required for the inclusion of any such additional topics.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">All Board meetings shall be conducted in English.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">4.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;text-decoration:underline;">Universal Board Meetings</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">. In the case of a </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-style:italic;">"Universal Board Meeting" </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(i.e. a meeting where all the Directors are present or represented by proxy and unanimously agree to hold a Board Meeting), none of the formalities and requirements related to the prior notice set forth in Clause 4.7 shall apply.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">A resolution in writing </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-style:italic;">("por escrito y sin sesi&#243;n") </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">signed by all the Directors of the Board shall be as valid and binding as if it had been passed at a duly convened meeting of the Board, provided that all Directors are notified in advance of the resolutions being adopted in such manner and do not oppose such system.. These resolutions shall also be recorded in minutes.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">4.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;text-decoration:underline;">Venue</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">. The meetings may be conducted physically at the registered office of the Company or such other place as the Board may from time to time determine within the territory of Spain or by electronic means (videoconference or conference call).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">4.10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;text-decoration:underline;">Attendance and Quorum</font><font style="font-family:inherit;font-size:11pt;color:#626162;">. </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">A Director may attend in person or by proxy. Such proxy may be granted to another Director, a copy of which shall be delivered to the Chairman and the Secretary of the Board at the commencement of th</font><font style="font-family:inherit;font-size:11pt;color:#626162;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">meeting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">Directors may participate in and vot</font><font style="font-family:inherit;font-size:11pt;color:#626162;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">at Board Meetings by means of a conference telephone or video conference or any communication equipment</font><font style="font-family:inherit;font-size:11pt;color:#626162;">, </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">provided that all Directors have the requir</font><font style="font-family:inherit;font-size:11pt;color:#626162;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">d te</font><font style="font-family:inherit;font-size:11pt;color:#626162;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">hnical equipment and all persons participating in the meeting can identify each other, which shall be expressly noted in the minutes of the relevant meeting and the certificate of such minutes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">In such case, the meeting of the Board shall be deemed a single meeting held in the registered office of the Company. Any Director so participating in a meeting shall be deemed to be present in person and shall count for quorum purposes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">For such purposes, the Shareholders undertake to hold a General Shareholders Meeting with the purposes to amend the Bylaws setting forth the following provision (in Spanish):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">"Board Directors' meetings could be held simultaneously in several halls as long as it is guaranteed by audio-visual or telephonic methods, the interactivity and intercommunication between them, so they are held in real time and therefore, in a sole act</font><font style="font-family:inherit;font-size:11pt;color:#575757;font-style:italic;">. </font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">In this case it will be stated in the call the connexion system and if necessary, the places where the technical methods are available in order to assist and participate in the meeting". </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The Persons invited to attend a meeting of the Board of Directors shall be subject to the confidentiality provisions applicable to directors under the Spanish Companies Law and, furthermore, to the confidentiality provisions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Each Shareholder acknowledges and agrees that the Board shall only be deemed to be validly constituted and entitled to pass any resolutions, if at least 4 Directors are present (whether in person or by proxy), and each Shareholder hereby covenants to the other Shareholders to ensure that the Directors nominated by it pursuant to Clause 4.3 abstain from participating in Board Meetings and from voting any resolutions if the Board is not validly constituted in accordance with this Clause.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">If within one hour of the time appointed for holding a Board Meeting, a quorum as specified above is not present, the meeting shall be adjourned for 14 days and reconvened at the same time of day and place and if at such rescheduled meeting a quorum as per the above is not present within 30 minutes of the time appointed for the meeting, a valid quorum shall be deemed constituted if at least 3 Directors are present. However no resolution shall be passed at such meeting on any matter other than the matters specifically set forth in the notice to the Directors, and no additional matter shall be taken up at such adjourned meeting.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">4.11</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Ordinary Vote Requirements</font><font style="font-family:inherit;font-size:11pt;color:#363636;">. Unless this Agreement, the Bylaws or Spanish Companies Acts require a greater majority, resolutions not addressing Board Reserved Matters will be passed by a simple majority of the attending Directors, provided that quorum requirements set forth in Clause 4.10 are met.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">4.12</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Board Reserved Matters</font><font style="font-family:inherit;font-size:11pt;color:#363636;">. Unless this Agreement expressly states differently, any decision by the Board of Directors (i) shall be reserved to the competence of the Board as a collective body, (ii) shall not be delegated to any one or more Board members or executive committees or managing directors and it shall be approved by the majority of the Board members.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">However, in addition to the requirements indi</font><font style="font-family:inherit;font-size:11pt;color:#5a5b5e;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">ated in the previous paragraph, the Board of Directors shall not take, and shall cause the Company not to take, any of the following resolutions that are qualified as Board reserved matters (the "</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Board Reserved Matters</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">") and, therefor</font><font style="font-family:inherit;font-size:11pt;color:#717177;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">, can only be adopted by the affirmative vote of four (4) Directors:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(i)&#160;&#160;&#160;&#160;change in the registered office location;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(ii)&#160;&#160;&#160;&#160;any specific capital expenditure (whether through acquisition or lease) which would result in obligations for the Company, individually or in aggregate, regarding such specific capital </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">expenditure of more than 250,000 Euros per transaction, or 500,000 Euros cumulatively over a period of 1 year;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(iii)&#160;&#160;&#160;&#160;sale or transfer to a third Person of any individual asset of the Company with a market value, at the time of its sale or transfer, exceeding 300,000 Euros;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(iv)&#160;&#160;&#160;&#160;appointment, dismissal, determination of the remuneration and benefits or any other action in relation with the CEO and/or of the Key Employ</font><font style="font-family:inherit;font-size:11pt;color:#5a5b5e;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">es within any of the companies of the BDI Group;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(v)&#160;&#160;&#160;&#160;any negotiation and subscription of loans or credit facilities for a value of more than 500,000 Euros;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(vi)&#160;&#160;&#160;&#160;transfer or disposal, by any means, directly or indirectly, of any share in the corporate </font><font style="font-family:inherit;font-size:11pt;color:#5a5b5e;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">apital of any of the Subsidiaries or of any interest in them</font><font style="font-family:inherit;font-size:11pt;color:#5a5b5e;">, </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">unless said transfers or disposals are due to a restructuring process of th</font><font style="font-family:inherit;font-size:11pt;color:#5a5b5e;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">BDI Group related to tax efficient intra</font><font style="font-family:inherit;font-size:11pt;color:#868991;">-</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">group schemes; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(vii)&#160;&#160;&#160;&#160;exercising the vote in the General Shareholders Meeting and management bodies of the Subsidiaries in respect of Shareholders Reserved Matt</font><font style="font-family:inherit;font-size:11pt;color:#5a5b5e;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">rs or 'Board Reserved Matters,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">However, in addition to the requirements indicated in the Board Reserved Matters, the Board of Directors shall not take, and shall cause the Company not to take, any of the resolutions indicated in section 4.12</font><font style="font-family:inherit;font-size:11pt;color:#5a5b5e;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(iii) with the affirmative vote of the Directors appointed by Dyadic and Inveready.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The Board R</font><font style="font-family:inherit;font-size:11pt;color:#5a5b5e;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">served Matters are also meant to apply to BDI Pharmaceuticals, so that if a decision as to any of these matters is to be made at BDI Pharmaceuticals, the matter will be first resolved by the Board of Directors of the Company pursuant to this and the Company will then, acting as shareholder of BDI Pharmaceuticals, act in accordance with the resolution adopted at the Board of Directors of the Company.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">4.13</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;text-decoration:underline;">Other Meetings of the Directors</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">. In addition to the Ordinary or Extraordinary Board Meetings, the Directors of the Board may hold more frequent informal meetings to monitor and support the operation of the Business and to direct the </font><font style="font-family:inherit;font-size:11pt;color:#373737;">management of the Company. Such informal meetings of the Directors shall not be qualified as Board Meetings as provided for under the Spanish Companies Acts and, therefore, during these meetings, no corporate resolutions shall be passed by the Directors. The terms and conditions set forth in this Agreement for the calling of Board Meetings shall apply </font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">mutatis muiandi </font><font style="font-family:inherit;font-size:11pt;color:#373737;">to those other meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">4.14</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Directors' compensation</font><font style="font-family:inherit;font-size:11pt;color:#373737;">. The Directors will receive no compensation for their position as members of the Board, unless otherwise agreed at a General Shareholders Meeting. Consequently, the Shareholder who appointed the corresponding Director shall bear the corresponding Director's costs and expenses incurred in attending Board Meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">4.15</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Disclosure of Information</font><font style="font-family:inherit;font-size:11pt;color:#373737;">. Each Director shall be entitled to disclose any information relating to the Company and its affairs and financial position to the Shareholder who appointed such Director.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">4.16</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Conduct of Directors</font><font style="font-family:inherit;font-size:11pt;color:#373737;">. Each Shareholder covenants that, unless so requested by the Shareholder nominating a Director, it will not carry out or cause to be carried out any act whereby such Director will be removed from office, other than for reasons of fraud, wilful misconduct or gross negligence. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;color:#373737;">For the avoidance of doubt, each Shareholder may appoint and remove their Directors at their own discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Each Shareholder shall, so far as such Shareholder is lawfully able, ensure that Directors nominated by such Shareholder:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(i)&#160;&#160;&#160;&#160;is not wilfully or unreasonably fail to attend a Board meeting in order to prevent any resolution to be adopted; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(ii)&#160;&#160;&#160;&#160;carry out such Director's duties in accordance with the principles, terms, conditions and obligations set out in this Agreement, the Bylaws and the Spanish Companies Acts. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">4.17</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Governing body of BDI Pharmaceuticals</font><font style="font-family:inherit;font-size:11pt;color:#373737;">: BDI Pharmaceuticals shall be administered by a Board of Directors, the composition and functioning of which shall be equivalent to that of the Board of Directors pursuant to Cause 4. The provisions of this Clause 4 shall also apply </font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">"mutatis muiandi" </font><font style="font-family:inherit;font-size:11pt;color:#373737;">to BDI Pharmaceuticals and,</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5a;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">thus, any decision in respect of any matter which may constitute a Board Reserved Matter must be agreed and passed in accordance with the provisions set out in this Clause.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">5&#160;&#160;&#160;&#160;GENERAL SHAREHOLDERS' MEETING</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The General Shareholders' Meeting of the Company will be held at least once a year within the 6 months after the end of each Financial Year for the purposes: (i) </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">of d</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">i</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">s</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">ussing and approving the annual accounts, (ii) application of the year results, (iii) approval of the composition of the Board, as well as (iv) resolving any other matters that may be compulsory under the Spanish Companies Acts or otherwise validly resolved in the General Shareholders Meeting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The Shareholders may attend general shareholders meetings of the Company (i) in person; (ii) by videoconferen</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">e or by telephone, provided that the persons taking part in the meeting can h</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">ar each other and each attendee recognizes the identity of the other attendees; (iii) or represented by another person, even if such person is not a Shareholder, provided that su</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">h person is duly empowered by the Shareholder through a duly granted proxy. The attorney must present evidence satisfactory to the Chairman, assi</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">s</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">ted by the Secretary, of his/her authority to act for and on behalf of the relevant Shareholder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">5.2&#160;&#160;&#160;&#160;Summon of the General Shareholders' Meetings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(i)&#160;&#160;&#160;&#160;A General Shareholders' Meeting may be summoned by the Chairman of the Board at the Chairman's own initiative or pursuant to the written request of Shareholders representing at least 5% of the Company's share capital, indicating the items on the agenda to be discussed. In the latter case, the General Shareholders' M</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">eting shall be held within 45 days following the date of request of such </font><font style="font-family:inherit;font-size:11pt;color:#57585a;">S</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">hareholders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(ii)&#160;&#160;&#160;&#160;The summons shall be effected (a) by any means as may be required by the Spanish Companies Acts and (b) by m</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">ans of a notice sent by letter, fax, e</font><font style="font-family:inherit;font-size:11pt;color:#71787c;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">mail or any other written or electroni</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">c </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">m</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">ans that may ensure the reception of the notice by all Shareholders at the address designated by such shareholder for this purpose. The notice shall state: (a) date, (b) place and (c) hour of the meeting, (d) the agenda to be discussed together with the relevant supporting materials, (e) the name of the person or persons who have summoned the General Shareholders' Meeting, as </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">well as (f) confirmation of date, place and hour of a rescheduled General Shareholders' Meeting in accordanc</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">with Clause 5</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">4.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(iii)&#160;&#160;&#160;&#160;A notice summoning a General Shareholders</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">' </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Meeting must be delivered to the Shareholders at least 30 days b</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">fore the date of such meeting (unless a longer term is compulsory under Spanish Companies Acts).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(iv)&#160;&#160;&#160;&#160;In the case of a </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-style:italic;">"Universal Shareholders' Meeting" </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(i.e</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">. </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">a meeting where all the shareholders are present or represented by proxy and unanimously resolv</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">to hold a General Shareholders Meeting), none of the formalities and requirements set out in this Clause 5.2 shall apply</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Venue of the General Shareholders' Meetings</font><font style="font-family:inherit;font-size:11pt;color:#373737;">: The General Shareholders' Meeting shall take place at the Company's registered office or elsewhere as the Chairman may reasonably determine within the territory of Spain.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">5.4&#160;&#160;&#160;&#160;The following rules apply to the quorum of the General Shareholders' Meetings:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">No business shall be discussed at any General Shareholders&#8217; Meeting unless a sufficient quorum is present.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Each Shareholder acknowledges and agrees that the Shareholders</font><font style="font-family:inherit;font-size:11pt;color:#929292;">' </font><font style="font-family:inherit;font-size:11pt;color:#373737;">Meetings shall be deemed to be validly constituted if at least 82% of the share capital of the Company is present or duly represented (unless a higher quorum is compulsory under Spanish Companies Acts).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">A Shareholder may be represented in a Shareholders' Meeting by its legal representative, including any director, officer or by written proxy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">If within one hour of the time appointed for holding a Shareholders' Meeting, a quorum as specified above is not present, the meeting shall be adjourned for 14 days and reconvened at the same time of day and place. If at such rescheduled meeting a quorum is not present within 30 minutes after the time appointed for the meeting, the Shareholders present shall constitute a valid quorum without the requirement set forth in</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">Clause 5.4(ii) above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">5.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Adoption of Resolutions</font><font style="font-family:inherit;font-size:11pt;color:#373737;">: </font><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Ordinary Vote Requirements</font><font style="font-family:inherit;font-size:11pt;color:#373737;">. Each Share shall entitle the right to cast one (1) vote at the General Shareholders' Meeting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Unless this Agreement, the Bylaws and/ or the Spanish Companies Acts require a greater majority, resolutions not addressing any of the Shareholders Reserved Matters (as defined in Clause 7.6) shall be passed by affirmative vote of Shareholders representing a simple majority of the share capital of the Company, that is, over 50% of</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">the share capital.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">5.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Adoption of Resolutions</font><font style="font-family:inherit;font-size:11pt;color:#373737;">: </font><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Shareholders Reserved Matters</font><font style="font-family:inherit;font-size:11pt;color:#373737;">. Notwithstanding the above, the following matters shall only be adopted with the favorable vote of Shareholders representing 82% per cent of the share capital of the Company and shall be deemed as reserved matters (the "Shareholders Reserved Matters&#8221;):</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(i)&#160;&#160;&#160;&#160;Increase or reduction of the share capital of the Company; merger, dissolution, liquidation or the global assignment of assets and liabilities (unless a mandatory rule requires these transactions); the abolition of the </font><font style="font-family:inherit;font-size:11pt;color:#404441;">preferential assumption or subscription rights and the exclusion of shareholders;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404441;">(ii)&#160;&#160;&#160;&#160;Change in the registered office location;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404441;">(iii)&#160;&#160;&#160;&#160;Creation or modification of special classes of shares or quotes with or without preferential rights;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404441;">(iv)&#160;&#160;&#160;&#160;Amendment of the structure of the Board of the Company and th</font><font style="font-family:inherit;font-size:11pt;color:#686a70;">e </font><font style="font-family:inherit;font-size:11pt;color:#404441;">remuneration of the Directors, except when made in accordance with this Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404441;">(v)&#160;&#160;&#160;&#160;Establishment or change of the dividend policy of the Company and declaration of dividend other than in. accordance with Clause 9 hereof and any other distribution, payment or disbursement of any kind or nature to the Shareholders (as shareholders) which is not applied in similar terms (pari passu) to all of them;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404441;">(vi)&#160;&#160;&#160;&#160;Authorization of a Disinvestment other than in accordanc</font><font style="font-family:inherit;font-size:11pt;color:#686a70;">e </font><font style="font-family:inherit;font-size:11pt;color:#404441;">with th</font><font style="font-family:inherit;font-size:11pt;color:#585a58;">e </font><font style="font-family:inherit;font-size:11pt;color:#404441;">transfer of shares provisions in this Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404441;">(vii)&#160;&#160;&#160;&#160;Granting any power of attorney or authorization or similar authority to any person or entity to carry out, any action which is a Shareholders Reserved Matters.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404441;">5</font><font style="font-family:inherit;font-size:11pt;color:#585a58;">.</font><font style="font-family:inherit;font-size:11pt;color:#404441;">7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404441;text-decoration:underline;">General Shareholders' Meeting of BDI Pharmaceuticals</font><font style="font-family:inherit;font-size:11pt;color:#404441;">. The Company shall exercise its voting rights in any Subsidiaries in a manner consistent with the purpose of this Agreement and the governance principles and rules for adopting resolutions set forth herein. In this sense, the provisions of this Clause shall also apply </font><font style="font-family:inherit;font-size:11pt;color:#404441;font-style:italic;">"mutatis mutundi" </font><font style="font-family:inherit;font-size:11pt;color:#404441;">to BDI Pharmaceuticals and thus, any decision in respect of any matter whi</font><font style="font-family:inherit;font-size:11pt;color:#686a70;">c</font><font style="font-family:inherit;font-size:11pt;color:#404441;">h may constitute a Shareholders Reserved Matter in BDI Pharmaceuticals shall be previously approved by the Board of Directors of the Company with the affirmative vote of at least four (4) Directors, as provided in Clause 4.12.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404441;font-weight:bold;">6&#160;&#160;&#160;&#160;CONFLICT OF INTEREST</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404441;">6.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404441;">In the event that a resolution must be adopted on an agreement that has been or is to be signed between the Company or BDI Pharmaceuticals or VLP</font><font style="font-family:inherit;font-size:11pt;color:#686a70;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#404441;">and (i) any Shareholder or a Director, (ii) a related person (as per the definition of "related person" in article 231 of the Spanish Companies Law) or a company from. the relevant Shareholder or Director's group (as per the definition of "group" in article 42 of the Commercial Code), the Shareholder or Director (as the case may be) in question shall not have voting rights on any resolution that </font><font style="font-family:inherit;font-size:11pt;color:#363636;">is taken by the General Shareholders Meeting or the Board of Directors on such matter.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">7&#160;&#160;&#160;&#160;MANAGING DIRECTOR ("CEO").</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">7.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The CEO will have general responsibility for the management of the Company in compliance with Spanish Companies Acts and the powers granted to the CEO by the Board of Director of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">7.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The CEO will carry out his duties in accordance with (i) this Agreement, (ii) the overall directions from the Company's Board and Shareholders' Meeting, as the case may be, (iii) his management contract with the Company (iv) the Bylaws and (v) the powers granted to the CEO by the Company for such purposes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">7.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The CEO shall be empowered to undertake any management actions or decisions which are not considered as Shareholders Reserved Matters and/ or Board Reserved Matters, as per this Agreement or are not delegable according to Spanish Companies Acts.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">7.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The Parties agree that Mr. Pablo Guti&#233;rrez G&#243;mez will initially be appointed at the Effective Date as the CEO of the Company. The terms and conditions, including remuneration of the CEO, will be those included in the management contract attached in Schedule IV to this Agreement (the "CEO Management Contract")</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">8&#160;&#160;&#160;&#160;INFORMATION RIGHTS.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">8.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Each Shareholder shall have ful1 access to the books and records of the Company and of the companies of BDI Group. The Company shall permit in reasonable terms access to the Companies' premises and to internal and external personnel (i.e. consulting firms, auditors, etc.) representing such Shareholder upon prior request with time enough in advance (which must include a list of the information required to be reviewed) to allow the Company to prepare any required report or their respective financial statements, all in accordance with customary practices in the industry.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">9&#160;&#160;&#160;&#160;DIVIDEND POLICY</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">9.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">To the extent permitted by the Spanish Companies Acts, and unless otherwise agreed by the Shareholders as a Shareholders Reserved Matter pursuant to Clause 5.6, the Parties agree that until Financial Year 2020 no dividend shall be distributed by the Shareholders in BDI Holding, and for the Financial Year 2020 onwards, the Parties agree that the Company will distribute and declare an annual dividend equivalent to at least 50% of the net profits of the Company, provided that (i) the Company shall not declare, pay or make any dividend or other distribution in excess of 80% of the Company's Free Cash-Flow in any </font><font style="font-family:inherit;font-size:11pt;color:#393d3a;">Financial Year, and (ii) there is sufficient </font><font style="font-family:inherit;font-size:11pt;color:#63666c;">c</font><font style="font-family:inherit;font-size:11pt;color:#393d3a;">ash available in the Company to proceed with such distribution. To th</font><font style="font-family:inherit;font-size:11pt;color:#63666c;">e </font><font style="font-family:inherit;font-size:11pt;color:#393d3a;">extent permitted by law, th</font><font style="font-family:inherit;font-size:11pt;color:#63666c;">e </font><font style="font-family:inherit;font-size:11pt;color:#393d3a;">Shareholders expressly undertake n</font><font style="font-family:inherit;font-size:11pt;color:#63666c;">o</font><font style="font-family:inherit;font-size:11pt;color:#393d3a;">t to invoke the application of Article </font><font style="font-family:inherit;font-size:11pt;color:#63666c;">3</font><font style="font-family:inherit;font-size:11pt;color:#393d3a;">48 bis of the Spanish Companies Act in o</font><font style="font-family:inherit;font-size:11pt;color:#63666c;">r</font><font style="font-family:inherit;font-size:11pt;color:#393d3a;">der to comply with this provision</font><font style="font-family:inherit;font-size:11pt;color:#828389;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;font-weight:bold;">10&#160;&#160;&#160;&#160;ACCOUNTING AND FINANCIAL REPORTING</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">10.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">The fiscal year of the Company shall be January 1st to December 31st each year ("Financial Year") and all the books and record of the Company shall be closed at the end of each interim calendar quarter of March 31st, June 30th and September 30th and at the year</font><font style="font-family:inherit;font-size:11pt;color:#828389;">-</font><font style="font-family:inherit;font-size:11pt;color:#393d3a;">end at December 31st every year.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">10.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">The Parties hereby undertake to appoint an Auditor that will be in ch</font><font style="font-family:inherit;font-size:11pt;color:#63666c;">ar</font><font style="font-family:inherit;font-size:11pt;color:#393d3a;">ge of auditing the annual financial statements and footnotes of the Company each Financial Year. The General Shareholders Meeting shall appoint the Auditor of the Company even if, according to the Spanish Companies Acts, the appointment of auditors is not mandatory.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">10.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">The Parties shall ensure that the quarterly Interim Financial Statements and the Audited Annual Financial Statements will be prepared by the Company and provided to the Board of Directors and Investors within 30 days after each interim quarter and 45 days after each year</font><font style="font-family:inherit;font-size:11pt;color:#828389;">-</font><font style="font-family:inherit;font-size:11pt;color:#393d3a;">end. The Audit Committee of the BDI Holding's Board of Directors will approve the quarterly interim Financial Statements and the Audited Financial Statements, within the timeframes above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">10.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">The Parties shall ensure that the accounting records of the Company shall be prepared in accordance with Spanish generally acceptable Accounting Principles. The books and records and Financial Statements of the Company shall be kept in Euros.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">10.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">The Company will assist Investors by providing financial information and documentation necessary to comply with US financial reporting disclosures, including but not limited to Variable Interest Entity ("VIE") in a timely manner.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">10.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">All records and supporting documents, including but not limited to accounting books and records, invoices, cash books, inventory records, bank accounts and receipts shall be kept at the head office of the Company for the term required by the Applicable Law.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;font-weight:bold;">11&#160;&#160;&#160;&#160;REPRESENTATIONS AND WARRANTIES</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">11.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">As of the Effective Date each of Dyadic, Inveready, Creux Analisis Estrategicos, S.L. and Floema Biotec, S.L. represent and warrant to the other Parties that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393d3a;">It is a duly organized corporation existing in good standing under the Applicable Law of the jurisdiction indicated in the preamble hereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">It has the corporate power, legal capacity and authority to enter :into and perform the obligations contemplated herein, and to execute any other agreement, document, instrument or certificate contemplated by this Agreement or to be executed in connection with the completion of the transactions contemplated by this Agreement. This Agreement and any other agreement, document, instrument or certificate contemplated by this Agreement or to be executed in connection with the completion of the transactions contemplated by this Agreement, when executed, will constitute legal, valid and binding obligations of such Party, enforceable against such Party in accordance with their respective terms;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The execution and performance of this Agreement do not contravene or conflict with any provisions of their Applicable Law or of its bylaws or of any instruments or contracts binding it;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The execution and performance of this Agreement have been validly authorized by all necessary corporate action and that this Agreement is valid, binding and enforceable against such Party;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">It is not aware of any matter or fact likely to prohibit or restrain its ability to enter into or perform obligations under this Agreement or any other agreement, document, instrument or certificate contemplated by this Agreement or complete the transactions contemplated hereunder and thereunder; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">It is not subject to bankruptcy, insolvency or similar proceedings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">11.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">As of</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">the Effective Date, each of the remaining Shareholders not identified in clause 10.1 above, represents and warrants to the other Parties that: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">It has the power, legal capacity and authority to enter into and perform the obligations contemplated herein, and to execute any other agreement, document, instrument or certificate contemplated by this Agreement or to be executed in connection with. the completion of the transactions contemplated by this Agreement This Agreement and any other agreement, document, instrument or certificate contemplated by this Agreement or to be executed in connection with the completion of the transactions contemplated by this Agreement, when </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;color:#363636;">executed, will constitute legal, valid and binding obligations of</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">such Party, enforceable against such Party in accordance with their respective terms;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The execution and performance of this Agreement do not contravene or conflict with any provisions of laws or of any instruments or contracts binding on it;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">This Agreement is valid, binding and enforceable against such Party; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">He/She is not aware of any matter or fact likely to prohibit or restrain its ability to enter into or perform obligations under this Agreement or any other agreement, document, instrument or certificate contemplated by this Agreement or complete the transactions contemplated hereunder and thereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">11.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Each of the Shareholders acknowledges that the other Shareholders in entering into this Agreement have relied on the warranties mentioned in this Section, and vice versa.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">12&#160;&#160;&#160;&#160;OBLIGATIONS OF EACH PARTY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">12.1&#160;&#160;&#160;&#160;Each Party shall undertake:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">To perform and observe any terms, conditions and provisions as provided in this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">To take all</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">necessary steps to give full effect to the provisions of this Agreement, including, without limitation, by way of executing all such documents and doing all such acts and things as</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">may reasonably be required to give effect to the provisions of this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">To cause any person representing that Party at a General Shareholders Meeting and each Director nominated by such Party to act in accordance with and give effect to the provisions of this Agreement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">To ensure that the Company will act and comply with the terms and conditions of this Agreement throughout the term of this Agreement, as well as any resolution adopted by the Board of Directors and/ or the General Shareholders Meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">13</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">PRE-EMPTIVE RIGHTS FOR CAPITAL INCREASE.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">13.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Each Shareholder shall have the right to subscribe for all or any part of its pro rata share of newly issued shares that the Company may, from time to time, propose to sell or issue in accordance with the Bylaws and Spanish Companies Acts.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">14&#160;&#160;&#160;&#160;LOCK-IN PERIOD AND FUTURE TRANSFERS OF SHARE</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">S</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">14.1&#160;&#160;&#160;&#160;General Terms</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The Parties may only transfer their Shares in compliance with the terms of Clauses 14, 15 and 16 herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">14.2&#160;&#160;&#160;&#160;Lock-in</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Except as otherwise provided in this Agreement, the Initial Shareholders shall not be entitled to make any Transfer of any of its Shares in whole or in part until a year after (i) the Investors hold less than 10% of the total Shares of the Company, (ii) the Investors have transferred all their shares in the Company or (iii) 5 years, whichever happens first Additionally, the Parties agree that no Investors shall be entitled to make any Transfer of any of in. Shares in whole or in part at any time prior to 30 June 2019 (the "</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Lock-In Period</font><font style="font-family:inherit;font-size:11pt;color:#373737;">").</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">14.3&#160;&#160;&#160;&#160;After the Lock-In Period:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">None of the Shareholders shall make any Transfer of any of its Shares in whole or in part to any person who is</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">not a party to this</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">Agreement without first obtaining from the transferee the execution of a Deed of Adherence substantially in the form attached hereto as Schedule V and as long as such Shareholder has duly complied with the provisions for the transfer of Shares included in the Bylaws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">None of the Shareholders shall be entitled to transfer or offer to transfer such Shareholder's Shares to any Person to which any of the following </font><font style="font-family:inherit;font-size:11pt;color:#373737;">standards is applicable:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Such Person is, directly or indirectly, a Competitor of the Company, including a Person who is a partner, shareholder member, employee, </font><font style="font-family:inherit;font-size:11pt;color:#373737;">agent, trustee or consultant to a Competitor; provided however that if such Person owns solely for investment less than 5 % of any class of securities of any Competitor traded on any [national] securities exchange, then such Person shall not be barred under this Clause as an indirect Competitor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Such Person or any of</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">its Affiliates is declared by the relevant courts to be engaged in criminal activities or is declared to be Controlled by Person(s) engaged in criminal activities, and vice versa; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Such Person or any of its Affiliates is considered in the relevant business community to be disreputable, unethical, or dishonest.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">14.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The Deed of Adherence shall be in favour of the Company and the Parties to this Agreement and shall be delivered to the Company at its registered office.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">14.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">As an exception to the provisions included in Clauses 14.2 and 14.3 above, any Shareholder shall be entitled to freely transfer its Shares, in whole or in part, at any time without applying any pre-emptive right of the other Shareholders, as long as the Transfer is</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">a mortis causa transf</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">r to the inheritor or legatee of any of the Shareholders that are individuals; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">a Transfer to an Affiliate, director or employee of a Shareholder, as long as:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">the relevant Affiliate shall execute a Deed of Adherence to this Agreement, substantially in the form attached hereto as Schedule V, simultaneous with such Transfer before a Spanish public notary, which costs shall be borne by the said relevant Affiliate;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">such Affiliate: (w) is not insolvent or unable to pay its debts within the meaning of the Spanish Insolvency Act (Lei; </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;font-style:italic;">22/2003, de 9 de Julio, Concursal) </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">(or under the insolvency laws of any applicable jurisdiction or has stopped paying debts as the fall due); (x) no order has been made, petition presented or resolution passed for its insolvency declaration; (y) no insolvency administrator (or similar agent or receiver under the insolvency laws of any applicable jurisdiction) has been appointed by an offi</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">c</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">ial rec</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">iver in respect of the said Affiliate or all or any of its assets and no steps hav</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">been taken to initiate any such appointment and no individual voluntary arrangement has been proposed; nor (</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">z</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">) has become subje</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">c</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">t to any analogous proceedings (including any liquidation process), appointments or arrangements under the laws of any applicable jurisdiction;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">a Transfer derived from the ex</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">r</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">c</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">ise of any of the Call Options</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">. </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">In such cases, the transferee of such Shares shall have agreed, in a signed writing, to be bound by the terms and conditions of this Agreement in relation with such Shares acquired</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">14.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">Any Transfer by the Parties in contravention of this Agreement shall be null and void </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;font-style:italic;">ab initio </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">and shall not bind or be re</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">c</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">ognized by the Company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;font-weight:bold;">15&#160;&#160;&#160;&#160;DRAG-ALONG RIGHT.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">15.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">If the General Shareholders Meeting resolves to proceed with a Disinvestment (considered as a Shareholder Reserved Matt</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">r) by way of s</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">lling to a third Person all the Shares of the Company (the "Sale")</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">, </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">then the Shareholders that vote favorably for such Disinvestment shall have the right (th</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">"Drag-Along </font><font style="font-family:inherit;font-size:11pt;color:#363636;">Right") to force the other Shareholders to sell to such third Person all the Shares owned by any of</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">them, all in accordance with the following provisions and as long as the price to be paid by the third Person for all the Shares of the Company is equal or higher than the greater of the following amounts: (i) 15,000,000 Euros (under a cash free/ debt free basis); or (ii) 10 times the consolidated sales of BDI Group in the last Financial Year (under a cash free/ debt free basis).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">15.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">In order that the Shareholders through the General Shareholders Meeting may resolve to initiate a Disinvestment, a General Shareholders Meeting must be called as set forth in this Agreement and the notice for such meeting shall additionally set forth (i) the identity of the third Person acquiring the Shares and (ii) all other material terms and conditions of the Sale (particularly those related to the date of the Sale, the price, the terms of payment of the price, the representations and warranties and the related indemnity obligations).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">15.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Upon resolution by General Shareholders Meeting to proceed with the Disinvestment, at request of any of the Shareholders, all the other Shareholders shall be obliged to sell all of their Shares in the Company to the third Person in the same date and at the price per Share and at the same terms and conditions included in the notice mentioned above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">15.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">In case of a Disinvestment, the Transfer of all the Shares shall not be subject to the application of the pre-emptive right ("</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">derecho de adquisici&#243;n preferente") </font><font style="font-family:inherit;font-size:11pt;color:#363636;">included in the Company's Bylaws in favour of any Shareholders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">15.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The Parties agree to include in the Bylaws, as an accessory obligation </font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">("prestaci&#243;n accesoria&#8221;) </font><font style="font-family:inherit;font-size:11pt;color:#363636;">to any holder of Shares of the Company, the obligation to comply with the provisions of Clause 15 in respect of this Drag Along Right.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">16</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">TAG-ALONG RIGHT.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">16.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Without prejudice to the pre-emption right over any Transfer of Shares as established in the Bylaws and in case that neither any Shareholder nor the Company exercise such right, if any of the Shareholders decides to Transfer any of its Shares then such Shareholder shall obtain from a good faith third Person (the "</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Offeror</font><font style="font-family:inherit;font-size:11pt;color:#494949;">'</font><font style="font-family:inherit;font-size:11pt;color:#363636;">') a written offer (the "</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Offer</font><font style="font-family:inherit;font-size:11pt;color:#363636;">") to purchase any such Shares from such Shareholder (the "</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Offered Shares</font><font style="font-family:inherit;font-size:11pt;color:#363636;">"), which Offer shall include the purchase of Shares held by each of the other Shareholders pro rata to their respective shareholding interests over the total share capital of the Company. In this sense, such Shareholder shall send an offer notice (the "</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Offer Notice</font><font style="font-family:inherit;font-size:11pt;color:#363636;">") to the other Shareholders, which shall set forth the identity of the Offeror and all other material terms and conditions of the Offer (particularly those related to the price, the terms of payment of the price, the representations and warranties and the related indemnity obligations).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">16.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">The other Shareholders shall have fifteen (15) Business Days from the dale of the delivery of the Offer Notice by the transferring Shareholder to send a written notice to such Shareholder exercising its Tag Along Right and indicating its election to include its Shares in the sale proposed by the transferring Shareholder on the same terms and conditions (the "</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;font-weight:bold;">Sale Request</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">").</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">16.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Within 90 days from the receipt of the Sale Request, th.e transferring Shareholder shall be able to sell its Shares to the Offeror at a purchase price, and subject to terms and conditions, no more favorable to the Offerer than those that were set forth in the Offer Notice, in which case the Shareholders that may have exercised the Offer shall have the obligation to join such sale and sell to the Offerer such exercising Shareholder's Shares pro rata to the percentage that the Shares that the transferring Shareholder transfers represent over the total Shares held by such Shareholder, at the same purchase price per Share and, subject to the same terms and conditions as those actually applicable to the sale of Shares by transferring Shareholder to the Offeror, including the terms of payment of the price, the representations and warranties and the related indemnity obligations (if any) in favor of the third Person, which shall be provided and assumed by the Shareholders pro rata to the Shares sold by each of them over the total number of Shares sold by the Shareholders and with no joint and several liability.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">16.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">If none of the Shareholders elect to exercise their Tag-Along Right, the transferring Shareholder may, within 90 days from the delivery of the Offer Notice, sell such Offered Shares to the Offeror at a purchase price, and on terms and conditions, no more favorable to the transferring Shareholder than those that were set forth in the Offer Notice. Upon the consummation of the sale to the Offerer, the transferring Shareholder shall promptly notify the remaining Shareholders as to the circumstances thereof, including the date of the sale, the identity of the purchaser, the Shares sold and the price and other key terms and conditions of such sale.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">16.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">If the Transfer by the transferring Shareholder is not consummated within 90 days after the dale on which the transferring Shareholder receives the Sale Request pursuant to the previous paragraphs of this Clause, or absent such Sale Request within 90 days after the date of expiration of the term for delivery of the Sale Request, then the transferring Shareholder shall not be permitted to sell or Transfer the Offered Shares without again complying with the requir</font><font style="font-family:inherit;font-size:11pt;color:#626566;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">ments of this Clause.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">16.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">The Board of Directors may, at its absolute discretion, refuse to register any share transfer, without giving any reason thereof, if the process of such transfer is not carried out in accordance with the provisions of this Agreement or the Bylaws. In the case that the Board of Directors refuses to register any share transfer, it shall give written notice notifying the transferor and the transferee of such refusal </font><font style="font-family:inherit;font-size:11pt;color:#363636;">within 24 hours from the date of the Company's receipt of request for the registration of such share transfer.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">17&#160;&#160;&#160;&#160;NATURE OF THIS AGREEMENT AND BYLAWS.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">17.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">On the Effective Date, a General Shareholders' Meeting of the Company shall be held and all the Parties shall unanimously approve, amongst other resolutions, the amendments to the Company's Bylaws required to reflect the provisions of this Agreement. After the Effective Date, the Bylaws of the Company shall be interpreted at all times in accordance with the provisions of this Agreement The bylaws of the Company and BDI Pharmaceuticals shall be interpreted at all times in accordance with the provisions of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">17.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Notwithstanding the above, it is acknowledged that certain articles of the</font><font style="font-family:inherit;font-size:11pt;color:#737373;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">Bylaws as amended to adapt to the provisions of the Agreement may not be</font><font style="font-family:inherit;font-size:11pt;color:#737373;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">admissible for registration with the Commercial Registry. As stated in Clause 2.2, the Parties agree that the provisions of this Agreement shall prevail between the Parties, and between the Shareholders and the Company (to the extent legally permitted), as a shareholders' agreement, including, particularly, where a relevant article of the Bylaws differs from the terms of this Agreement. If this Agreement is subsequently amended in whole or in part in any manner that shall affect the Bylaws, the Parties shall promptly proceed to adopt any resolutions that may be necessary to amend the Bylaws and have them filed with the Commercial Registry so that they reflect the provisions of this Agreement at all times, to the extent legally possible.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">18&#160;&#160;&#160;&#160;TERM</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">This Agreement shall become effective upon the Effective Date and continue to be in full force and effect unless terminated in accordance with the provisions of Clause 19.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">19&#160;&#160;&#160;&#160;TERMINATION</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">19.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">This Agreement shall be automatically terminated in any of the following events and the Parties shall not be liable for such termination for whatsoever reason:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">when a Shareholder ceases to hold any Shares through the Transfer of Shares in accordance with the terms of this Agreement, this Agreement shall terminate in respect of such Shareholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">when all of the Parties agree in writing to terminate this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">upon the dissolution and winding-up of the Company under the Spanish Companies Acts</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5b;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">19.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">In the event of the breach of the Agreement by any of the Parties ("Party in Breach"), one or several of the other Parties shall provide written notice of such breach to the Party in Breach. If the Party in Breach does not remedy the breach within a period of thirty (30) days after the date of the notice, the other Party or Parties may terminate the Agreement with the termination effect pursuant to the terms set forth in Clause 19.3 hereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">19.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">Effect of termination.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">Termination of this Agreement shall be without prejudice to any right or obligation of either Party accrued before termination of the Agreen1ent.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">Clauses 1 (Definitions), 19.3 (Effect of termination),  20  (N</font><font style="font-family:inherit;font-size:11pt;color:#5d5e5f;">o</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">n</font><font style="font-family:inherit;font-size:11pt;color:#78777b;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">Competition and Non-Solicitation), 21 (Confidentiality), 22 (Indemnity), 23 (Notices), 25 (General) and 26 </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(Governing Law and Jurisdiction) shall remain in full force after the termination of this Agreement</font><font style="font-family:inherit;font-size:11pt;color:#5d5e5f;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">20</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">MINIMUM COMMITMENT TERM FOR THE KEY EMPLOYEES. NON COMPETE, NON-SOLICITATION AND EXCLUSIVITY.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">20</font><font style="font-family:inherit;font-size:11pt;color:#5d5e5f;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">Minimum commitment term (the "Minimum Commitment Term") of the Key Employees. Each of the Key Employees undertake to work and/ or provide his/her services in the sole benefit of the Company or the companies of the BDI Group (as applicable) as set forth in their corresponding employment or services agreements from the Effective Date and until the earlier of th</font><font style="font-family:inherit;font-size:11pt;color:#5d5e5f;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">following dates with a minimum of three years (the "Initial Term"):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">12 months additional to the date when Inveready' s Shares in the BDI Group are less than 10%; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">12 months additional to the date after when Inveready have transferred all its Shares; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">Four and a half years from the execution of this Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">The Parties further agree that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">If in breach of the provisions included in Clause 20.1. before, any of the Key Employees terminates his/ her agreement by virtue of which he/ she works and/ or provides his/her services to any of the companies of the BDI Group, he/ she shall indemnify the Company with Shares hold by such Key Employee in accordance with the following:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">With the totality of the Shares hold by such Key Employee if the termination by the Key Employee takes place within the first three (3) years from the Effective Date. The transfer of the Shares to the Company shall be made with a payment of &#8364;1 by the Company..</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">If the termination by the Key Employee takes place after the end of the third year from the Effective Date, with an amount of Shares proportional to the moment when the Key Employee terminates his/her agreement, taking into account that the indemnification with 100% of the Shares would apply if the termination takes place on the first day of the third year and a indemnification with 0% of the Shares would apply if the termination takes place on the last day of the Initial Period. Of the remaining shares of the Key Employee, the Company will have a call option in order to acquire those shares at market value.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">The Parties expressly agree that the mentioned indemnification is an adequate penalty to compensate the breach of the Initial Term, so each of the Parties expressly waives the right to</font><font style="font-family:inherit;font-size:11pt;color:#353535;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#353535;">bring any action to claim any further damage or loss caused as well as any loss of profit. The Parties expressly state for the record the essential nature of the foregoing provisions as Investors make their investment acquiring part of the Shares of the Company by virtue of the personal and professional qualities of the Key Employees and the obligations assumed in said provision.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">The Key Employee shall be completely released from the Minimum Commitment Term if the corresponding company of the BDI Group is in material breach of its </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;color:#353535;">contractual obligations of their corresponding agreements. In addition, in the following cases the corresponding Key Employee will be entitled to early terminate the Agreement without paying any indemnification as long as the Board of Directors of the Company authorizes it by simple majority (authorization that shall not be unreasonably withheld) in the following cases:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;color:#353535;">-</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">If the relevant company within the BDI Group where he/ she works or provides his/her services is in material breach of its contractual obligations under such agreements. Examples of material breach, but not limited to, will be the following:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">-</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">If such company substantially modifies the contra</font><font style="font-family:inherit;font-size:11pt;color:#626669;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">tual conditions, or breaches any material term: or</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">If such company breaches any of its payment obligati</font><font style="font-family:inherit;font-size:11pt;color:#626669;">o</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">n</font><font style="font-family:inherit;font-size:11pt;color:#626669;">s </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">for a longer period of two months; or</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">-</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">If such company requires the Key Employee to relocate his/her principal place of work; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">-</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">If such company materially diminishes the Key Employee's duties or responsibilities in a manner which is inconsistent with the provisions of his/her agreement or with his/her status in the BDI Group; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">-</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">If such company reduces the Key Employee's compensation or salary.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:144px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">-</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">If the Key Employee has to terminate his/her agreement due to material personal reasons such as, but not limited to, a disease or from a disease incompatible with the performance of his/her duties, or the necessity of moving to any other location due to take care of a sick family member.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">20.2&#160;&#160;&#160;&#160;Non-competition and non</font><font style="font-family:inherit;font-size:11pt;color:#75787c;">-</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">solicitation.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Definitions:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">For the purposes of this Clause 20</font><font style="font-family:inherit;font-size:11pt;color:#535754;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">2:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Cessation Date</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">": The date when the Key Employee ceases to work or provide his/her services to the relevant company of BDI Group.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Restricted Period</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">"</font><font style="font-family:inherit;font-size:11pt;color:#535754;">: </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The period from the Effective Date and until the termination of the Initial </font><font style="font-family:inherit;font-size:11pt;color:#535754;">T</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">erm (as defined in Clause 20.1</font><font style="font-family:inherit;font-size:11pt;color:#535754;">. </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">before);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Competitive Services</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">": genetic modifications, and/or fermentation media and process development related to any fungal strains that have the taxonomy of either (i) Myceliopthora, (ii) Corynascus or (iii) Sporotrichium and/ or any strains derived, generated, adapted and or otherwise therefrom</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Restrictive covenants.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Each of the Key Employees covenants that he/ she shall not, directly or indirectly, except with the prior written consent of the Company to take any of the following actions:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Non-competition: for the Restricted Period be employed, concerned., interested, assist in or be otherwise engaged in the supply of any services to any other companies (except for companies of BDI Group) which are considered Competitive Services;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Non-solicitation of customers: for the Restricted Period with, canvass, solicit or approach, or cause to be canvassed, solicited or approached, for orders in respect of any goods or services provided or dealt in by the Company or entice or endeavour to entice away from the Company any person who at the Cessation Date, or within 90 days prior to that date, is or was a client or customer of the Company or was in the habit of dealing with the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Non-solicitation of suppliers: for the Restricted Period interfere or seek to interfere, or take any action which may interfere with the continuance of supplies of goods or services from any suppliers who have been supplying components, materials, goods or services to the Company at any time during 180 days prior to the Cessation Date;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Non-solicitation of employees: for the Restricted Period, employ, solicit or entice, or endeavour to employ, solicit or entice away from the Company any of the officers or employees of the Company or of any Subsidiary.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">The restriction set out in paragraph (d) above shall not prohibit the relevant Key Employee from employing any officer or employee who has responded to a bona fide recruitment advertisement not specifically targeted at that person.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">No use of trading names: at any time after the Cessation Date, use in a trade or business name, or trade or service mark or carry on a business under a title containing the words &#8220;BDI&#8221;  or any other word or words similar to, or capable of confusion with, them; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">No assistance: assist any other person to do any of the above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">The Parties agree that if, during the Initial Term a Key Employee is in breach of the provisions included in Clause 20.2.(ii) before, such Key Employee shall indemnify the Company with all the Shares hold by such Key Employee. Such Shares shall be then transfer to the Company with a payment of &#8364;1 by the Company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">The Parties expressly agree that the mentioned indemnification is an adequate penalty to compensate the breach of the Key Employee, so each of the Parties expressly waives the right to bring any action to claim any further damage or loss caused as well as any loss of profit.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">20.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">Exclusivity. Each of the Key Employees undertakes to work and/ or provide his/her services as set forth in their corresponding employment or services agreements on an exclusive basis in the benefit of the relevant company of the BDI Group. </font><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;font-weight:bold;">The Key Employees shall not perform any other professional activity or render any services unrelated to the interest of the Company and the BDI Group</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">Notwithstanding the foregoing, each of the Key Employees currently assumes the positions included in </font><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;font-weight:bold;">Schedule 20.3 </font><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">&#32;(the "</font><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;font-weight:bold;">Permitted Positions</font><font style="font-family:inherit;font-size:11pt;color:#3a3e3a;">"), and the Parties agree that the Permitted Positions do not (and will not) constitute a breach the undertakings contained in this Clause. being each of the Key Employees as a result entitled to remain in the Permitted Positions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The Parties agree that if, during the initial Term a Key Employee is in breach of the provisions of this Clause, such Key Employee shall indemnify the Company with all the Shares hold by such Key Employee. Such Shares shall be then transfer to the Company with a payment of &#8364;1 by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">The Parties expressly agree that the mentioned indemnification is an adequate penalty to compensate the breach of the Key Employee, so each of the Parties expressly waives the right to bring any action to claim any further damage or loss caused as well as any loss of profit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Each of the Key Employees shall be completely released from the exclusivity obligations set forth in this Clause if the corresponding company of the BDI Group breaches any of its payment obligations under the corresponding agreement with the Key Employee for a longer period of two months.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">21&#160;&#160;&#160;&#160;CONFIDENTIALITY</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">21.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Definition. "</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:11pt;color:#363636;">" means any information disclosed by one Party (the "</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:11pt;color:#363636;">") to the other (the "</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:11pt;color:#363636;">"), whether oral, written, visual, electromagnetic, electronic or in any other form, and whether contained in memoranda, summaries, notes, analyses, compilations, studies or other documents, and whether the same have been prepared by the Disclosing Party or the Receiving Party: (i) which, if in written, graphic, machine-readable or other tangible form is marked as "Confidential" or "Proprietary," or which, if disclosed orally or by demonstration, </font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">is </font><font style="font-family:inherit;font-size:11pt;color:#363636;">identified at the time of initial disclosure as confidential and is summarized in writing and similarly marked and delivered to the Receiving Party within thirty (30) Days after initial disclosure; and (ii) which includes but is not necessarily limited to (A) technical data or information, including proprietary host organisms and their strains, plasmids/vectors, DNA sequences, gene expression, fungal high throughput screening, enzymes and their applications, research and manufacturing protocols and practices, formulae, charts, analyses, reports, patent applications, trade secrets, ideas, methods, processes, know-how, computer programs, products, equipment, raw materials, designs, data sheets, schematics, configurations, specifications, techniques, drawings, and the like, whether or not relating to experimental data, projects, products, processes, research practices and the like, (B) past, present and future business, financial and commercial data or information, prices and. pricing methods, marketing and customer information, financial forecasts and projections, and other data or information relating to strategics, plans, budgets, </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">sales and the like; and (C) any other data or inf</font><font style="font-family:inherit;font-size:11pt;color:#575757;">o</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">rmation delivered b</font><font style="font-family:inherit;font-size:11pt;color:#575757;">y t</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">h</font><font style="font-family:inherit;font-size:11pt;color:#575757;">e </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">Disclosing Party to the Receiving Party or which the Receiving Party has acquired from the Disclosing Party by way of the former's inspection or observation during visits to the research laboratory, manufacturing plan or other type of facility of the latter Party. The Parties expressly acknowledge and agre</font><font style="font-family:inherit;font-size:11pt;color:#575757;">e </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">that all information of a proprietary and/ or confidential nature furnished by the Disclosing Party to the Receiving Party in furtherance of the Disclosing Party's obligations under this Agreement shall be deemed Confidential Information.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">21.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">Confidential Information Exclusions. Confidential Information will exclude information the Receiving Party can demonstrate is: (i) now or hereafter, through no unauthorized act or failure to act on Receiving Party's part, in the public domain; (ii) known to the Receiving Party from a source other than the Disclosing Party (including former employees of the Disclosing Party) without an obligation of confidentiality at the time Receiving Party receives the same from the Disclosing Party, </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">as evidenced by contemporaneous written records; (iii) furnished to others by the Disclosing Party without restriction on disclosure; or (iv) independently developed by the Receiving Party without use of the Disclosing Party's Confidential Information, as evidenced by contemporaneous written records. Nothing in this Agreement shall prevent the Receiving Party from disclosing Confidential Information to the extent the Receiving Party is legally compelled to do so by any governmental investigative</font><font style="font-family:inherit;font-size:11pt;color:#575757;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">or judicial agency pursuant to proceedings over which such agency has jurisdiction; provided</font><font style="font-family:inherit;font-size:11pt;color:#575757;">, </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">however, that prior to any such disclosure, the Receiving Party shall (a) assert the confidential nature of the Confidential Information to the </font><font style="font-family:inherit;font-size:11pt;color:#575757;">a</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">gency; (b) immediately notify the Disclosing Party in writing of th</font><font style="font-family:inherit;font-size:11pt;color:#575757;">e </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">agency's order or request to disclose; and (c) cooperate fully with the Disclosing Party in prot</font><font style="font-family:inherit;font-size:11pt;color:#575757;">e</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">cting against any such disclosure and/ or obtaining a protectiv</font><font style="font-family:inherit;font-size:11pt;color:#575757;">e </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">order narrowing the scope of the compelled disclosure and protecting its confidentiality.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">21.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3b413d;">Confidentiality Obligation</font><font style="font-family:inherit;font-size:11pt;color:#575757;">. </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">For a period commencing on this date and ending on the tenth (10th) anniversary after the termination of the Agre</font><font style="font-family:inherit;font-size:11pt;color:#575757;">e</font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">ment</font><font style="font-family:inherit;font-size:11pt;color:#575757;">, </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">th</font><font style="font-family:inherit;font-size:11pt;color:#575757;">e </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">Receiving Party shall treat as confidential all of the Disclosing Party's Confidential Information and shall not use such Confidential Information for any purpose whatsoever other than for the purposes set forth herein, except as expressly otherwise permitted under this Agreement. Without limiting th</font><font style="font-family:inherit;font-size:11pt;color:#696a71;">e </font><font style="font-family:inherit;font-size:11pt;color:#3b413d;">foregoing, the Receiving Party shall use the same degree of care and means that it utilizes to protect its own information of a similar nature, but in any event not less than reasonable care and means, to prevent the unauthorized use or th</font><font style="font-family:inherit;font-size:11pt;color:#696a71;">e </font><font style="font-family:inherit;font-size:11pt;color:#363636;">disclosure of such Confidential Information to third parties. The Confidential Information may be disclosed only to employees or contractors of the Receiving Party with a "need to know" who are instructed and agree not to disclose the Confidential Information and not to use the Confidential Information for any purpose, except as set forth herein; provided, however, in the case of BDI Group, the term "employees or contractors of a Receiving Party" shall include employees of each of those of BDI Group and any contract research organizations with whom BDI Group has written agreements pursuant to which such contract research organization is performing or will perform work under a project and is bound by an obligation of confidence to BDI Group that makes such contract research organization liable for any breach by its employees of those confidentiality obligations to BDI Group. The Receiving Party shall have appropriate written agreements with any such employees or contract research organizations sufficient to comply with the provisions of this Agreement. A Receiving Party may not alter, decompile, disassemble, reverse engineer, or otherwise modify any Confidential Information received hereunder and the mingling of the Confidential Information with information of the Receiving Party shall not affect the confidential nature or ownership of the same as stated hereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">21.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">No Confidential Information of Other Persons.  Each Party represents and warrants to the other that it has not used and shall not use in the course of its performance hereunder, and shall not disclose to the other, any confidential information of any other Person, unless it is expressly authorized in writing by such Person to do so.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">22&#160;&#160;&#160;&#160;INDEMNITY</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">22.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Save to the specific remedies set forth in Clauses 20, each Party (the "Defaulting Party") agrees to indemnify and hold harmless the other Parties from and against (and pay the full amount of) any and all direct losses, liabilities, actions, damages or injuries, claims, demands, judgments, costs, expenses, suits or proceedings including appeals, which are incurred by the other Party (the "Non-Defaulting Party"), arising out of:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">any breach of a representation or warranty made in this Agreement by the Defaulting Party;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">any breach of other obligations in this Agreement by the Defaulting Party; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">any fraud, willful misconduct or breach of Spanish Law by the Defaulting Party in the context of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">22</font><font style="font-family:inherit;font-size:11pt;color:#686a6d;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">The indemnity set forth under this Clause shall not limit any other right, which the Non</font><font style="font-family:inherit;font-size:11pt;color:#7c7e86;">-</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Defaulting Party may have under this Agreement or under Spanish Law.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;font-weight:bold;">23&#160;&#160;&#160;&#160;NOTICES</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#575a5b;">23</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Unless otherwise expressly set out in the Agreement, all notices, consents, requests, instructions, approvals and other communications provided for herein shall be in writing and shall be deemed validly given (i) upon personal d</font><font style="font-family:inherit;font-size:11pt;color:#575a5b;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">livery, or (ii) three Business Days after being sent by recognized express courier s</font><font style="font-family:inherit;font-size:11pt;color:#575a5b;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">rvice that maintains records of receipt. In all cases and without prejudice of the notice requirements set out before, as a further requirement any notices shall be also sent via email at the email addresses provided in this Clause.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">It is hereby understood that notice shall be deemed as received when sent to th</font><font style="font-family:inherit;font-size:11pt;color:#575a5b;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">addresses indicated below for each of the Parties:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;font-weight:bold;">Creux Analisis Bstrategicos, S.L.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Attn.</font><font style="font-family:inherit;font-size:11pt;color:#575a5b;">: </font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Mr. Emilio</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Guti&#233;rrez G&#243;mez</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca (Espana). </font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Tel</font><font style="font-family:inherit;font-size:11pt;color:#7c7e86;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">E</font><font style="font-family:inherit;font-size:11pt;color:#7c7e86;">-</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca (Espana).</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Tel</font><font style="font-family:inherit;font-size:11pt;color:#575a5b;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">E-Miail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;font-weight:bold;">Mr. Carlos Blaziqtrez Escudero</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Salamanca (Espana). </font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">E</font><font style="font-family:inherit;font-size:11pt;color:#686a6d;">-</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;font-weight:bold;">Mr. Ricardo Arjona Antolin</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, S</font><font style="font-family:inherit;font-size:11pt;color:#575a5b;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">villa (Espana)</font><font style="font-family:inherit;font-size:11pt;color:#575a5b;">.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;font-weight:bold;">Ms. Ana G&#243;mez Rodrigue</font><font style="font-family:inherit;font-size:11pt;color:#575a5b;font-weight:bold;">z</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, S</font><font style="font-family:inherit;font-size:11pt;color:#575a5b;">a</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">lamanca (Espana). </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Mr. Luis Hilario Guerra Trueba</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Valladolid (Espana).</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Floema Biotec, S.L.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Attn.: Mr. Jose Pellicer Espana</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Madrid (Espana).</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Mr. Jorge Hernandez Esteban</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 28055 Madrid (Espana).</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Mr. Yahia El-Amrani Bentahar</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 28055, Madrid (Espana). </font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Attn.: Mark A. Emalfarb, CEO</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Address: 140 Intracoastal Pointe Drive, Suite 404</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Jupiter, Florida 33477</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Tel.: 561-743-8333</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">E-Mail: memalfarb@dyadic.com</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">With copy to: Laura Nemeth, Squire Patton Boggs</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Email: laura.nemeth@squirepb.com</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">INVEREADY INNVIERTE BIOTECH II, S.C.R., S.A.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Attn.: Roger Pique Pijuan</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;color:#363636;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Biotechonology Developments for Industry, S.L.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Attn.: Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Boecillo - Valladolid</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(Espana).</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#5d5d5e;">23.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">In order for any </font><font style="font-family:inherit;font-size:11pt;color:#5d5d5e;">c</font><font style="font-family:inherit;font-size:11pt;color:#414141;">hange to the above addr</font><font style="font-family:inherit;font-size:11pt;color:#5d5d5e;">e</font><font style="font-family:inherit;font-size:11pt;color:#414141;">sses or persons for the noti</font><font style="font-family:inherit;font-size:11pt;color:#5d5d5e;">ce </font><font style="font-family:inherit;font-size:11pt;color:#414141;">purpos</font><font style="font-family:inherit;font-size:11pt;color:#5d5d5e;">e</font><font style="font-family:inherit;font-size:11pt;color:#414141;">s to be binding upon the Parties, th</font><font style="font-family:inherit;font-size:11pt;color:#5d5d5e;">e </font><font style="font-family:inherit;font-size:11pt;color:#414141;">relevant party must notify it ac</font><font style="font-family:inherit;font-size:11pt;color:#5d5d5e;">c</font><font style="font-family:inherit;font-size:11pt;color:#414141;">ordingly with at least Ten (10) days in advance following the terms included under this Clause 23.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;font-weight:bold;">24&#160;&#160;&#160;&#160;ASSIGNMENT</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#414141;">24.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">Subject to Clause 24</font><font style="font-family:inherit;font-size:11pt;color:#5d5d5e;">.</font><font style="font-family:inherit;font-size:11pt;color:#414141;">2, neither Party may assign this Agreement, in whole or in part, without the other Parties' written consent except for the case where the Transfer of Shares shall take place pursuant to the provisions of Clause 14.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#414141;">24.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">Any Shareholder shall be entitled to assign its rights under this Agreement to any of its Affiliates as long as such assignment is derived from a Transfer of Shares which complies with the terms and conditions of this Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;font-weight:bold;">25&#160;&#160;&#160;&#160;GENERAL</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">25.1&#160;&#160;&#160;&#160;Transferability; Derogation arid Binding Effect</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">Except as otherwise provided herein, this Agreement shall be binding upon and inure to the benefit of the Company, and the Shareholders, and their respective heirs, executors, administrators, legal representatives, successors and assigns, subject to the restrictions on Transfer set forth in this Agreement in Clause 14.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">Each Shareholder hereby binds its heirs, executors, administrators, legal representatives, successors and assigns to perform and fulfil the terms of this Agreement as fully and comple</font><font style="font-family:inherit;font-size:11pt;color:#5d5d5e;">t</font><font style="font-family:inherit;font-size:11pt;color:#414141;">ely as if they were personally present to do so. To the extent permitted by this Agreement, whether or not any express assignment has been made, the provisions of this Agreement are also for the benefit of, and enforceable by, any transferee of securities of the Company by a Shareholder; provided (a) that, as a condition to any such Transfer, such Shareholder's transferee shall have agreed, in a signed writing, to be bound by the terms and conditions of this Agreement, as if such transferee were art original signatory hereto, and (b) that any transferor hereunder shall not be released from any liabilities by the Company or any other Shareholder</font><font style="font-family:inherit;font-size:11pt;color:#5d5d5e;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">25.2&#160;&#160;&#160;&#160;Waiver</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">No waiver by each Party of its right to enforce any provision of this Agreement shall constitute a waiver of such Party's right to enforce such provisions thereafter or to enforce any other provisions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">25.3&#160;&#160;&#160;&#160;Entire Agreement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">This Agreement and all of the attachments hereto contain the entire and final agreement of the Parties with respect to the subject matters of this Agreement and superseded any and all prior agreements, written or oral, with respect to the subject matter of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">25.4&#160;&#160;&#160;&#160;Severability</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction is ineffective as to that jurisdiction to the extent of the prohibition or unenforceability, and does not invalidate the remaining provisions of this Agreement nor affect the validity or enforceability of that provision in any other jurisdiction</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">25.5&#160;&#160;&#160;&#160;Amendment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">No provisions of this Agreement shall be altered, amended or modified in any way except by an instrument in writing executed by the Parties and passed into Public Deed before a Spanish Notary.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">25.6&#160;&#160;&#160;&#160;Costs</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Each Party must bear its own costs arising out of the negotiation, preparation and execution of this Agreement The Notary costs for passing this Agreement into Public Deed shall be borne by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">26&#160;&#160;&#160;&#160;GOVERNING LAW AND JURISDICTION</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">26.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The Agreement shall be governed by, and interpreted under, the laws of Spain, without application of rules on conflicts of laws.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">26</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">.</font><font style="font-family:inherit;font-size:11pt;color:#373737;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The Parties hereby agree to submit all disputes, controversies or claims that may arise between them that directly or indirectly relate to this Agreement, including issues concerning the existence, validity, effectiveness, interpretation, compliance or termination hereof, to be resolved by arbitration at law of the Arbitration Court of the Madrid Chambers of Commerce in accordance with the rules regulating such body, which rules are deemed to be incorporated by reference into this Clause.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">26.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The arbitration proceedings shall be carried out before the Court of Arbitration of</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">the Madrid Chambers of Commerce and subject to the regulations of said Court, whenever not referred to herein. The seat or legal place of the arbitration shall be Madrid.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">26.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The arbitration shall be resolved by 1 sole arbitrator selected in accordance with the rules of the Court of Arbitration of the Madrid Chambers of Commerce.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404541;">26.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404541;">The Parties and BDI Holding hereby undertake to voluntarily comply with the arbitral award issued, as soon as it becomes final.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404541;">26.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404541;">The term for an award to be issued shall be 6 months as of the dale of acceptance by the Arbitrator</font><font style="font-family:inherit;font-size:11pt;color:#636568;">.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404541;">26.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404541;">The arbitration language shall be Spanish, provided, however, that to the extent that any supporting or accompanying documents of the relevant claim or answer to the claim are originally drafted in English, there shall be no obligation to translate such documents into Spanish.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">IN WITNESS WHEREOF,</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">&#32;the Parties have executed the Agreement in one counterpart to be raised into public, in the place and on the date first above written.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Emilio Guti&#233;rrez G&#243;mez<br>On behalf of Creux Analisis<br>Estrategicos, S.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Ricardo Arjona Antol&#237;n</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">Mr. Pablo Guti&#233;rrez G&#243;mez<br>On behalf of Mr. Carlos Bl&#225;zquez<br>Escudero</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">Mr. Ricardo Arjona Antolin</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Ana G&#243;mez Rodr&#237;guez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">Ms. Ana G&#243;mez Rodriguez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">Mr. Emilio Guti&#233;rrez G&#243;mez on <br>behalf of Mr. Luis Hilario Guerra Trueba</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/</font><font style="font-family:inherit;font-size:11pt;">&#160;Antonio De Leyva Tejadaon</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Jorge Hern&#225;ndez Esteban</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">Mr. Antonio  De Leyva Tejadaon<br>behalf of Floema Biotec, S.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">Mr</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;font-style:italic;">. </font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">Jorge Hernandez Esteban</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Emilio Guti&#233;rrez G&#243;mez on behalf of <br>Yahia EI-Amrani Bentahar<br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Pablo Guti&#233;rrez G&#243;mez <br>on behalf of Biotechnology <br>Developments for Industry, S.L.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Antonio Ca&#241;adas Bouwen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Roger Piqu&#233; Pijuan </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Antonio Canadas Bouwen<br>on behalf of Dyadic International<br>(USA), Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Roger Pique Pijuan <br>On behalf of INVEREADY <br>INNVIERTE BIOTECH II, S.C.R., S.A.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><a name="s7048df0461c9451abc541fa1c4d2f62e"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">SCHEDULE I</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">BYLAWS OF THE COMPANY</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit1014schedule1.jpg" alt="exhibit1014schedule1.jpg" style="height:141px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#333733;font-weight:bold;">Informacion Mercantil interactiva d</font><font style="font-family:inherit;font-size:8pt;color:#707078;font-weight:bold;">e </font><font style="font-family:inherit;font-size:8pt;color:#333733;font-weight:bold;">los Registros Merc</font><font style="font-family:inherit;font-size:8pt;color:#4b4f4d;font-weight:bold;">an</font><font style="font-family:inherit;font-size:8pt;color:#333733;font-weight:bold;">t</font><font style="font-family:inherit;font-size:8pt;color:#4b4f4d;font-weight:bold;">illes </font><font style="font-family:inherit;font-size:8pt;color:#333733;font-weight:bold;">de</font><font style="font-family:inherit;font-size:8pt;color:#4b4f4d;font-weight:bold;">&#32;Es</font><font style="font-family:inherit;font-size:8pt;color:#333733;font-weight:bold;">p</font><font style="font-family:inherit;font-size:8pt;color:#4b4f4d;font-weight:bold;">an</font><font style="font-family:inherit;font-size:8pt;color:#333733;font-weight:bold;">a</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;color:#333733;font-weight:bold;">REGISTRO MERCANTIL DE VALLADOLID</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333733;">Expedida el dia</font><font style="font-family:inherit;font-size:11pt;color:#a4a4a7;">: </font><font style="font-family:inherit;font-size:11pt;">06</font><font style="font-family:inherit;font-size:11pt;color:#333733;">/06/2017 a las 09</font><font style="font-family:inherit;font-size:11pt;color:#4b4f4d;">:</font><font style="font-family:inherit;font-size:11pt;color:#333733;">45 horas</font><font style="font-family:inherit;font-size:11pt;color:#838387;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#333733;font-weight:bold;">ESTATUTOS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">DATOS GENERALES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:82.90598290598291%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:27%;"></td><td style="width:10%;"></td><td style="width:63%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Denominaci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#353535;">n</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">BIOTECHOLOGY DEVELOPMENTS FOR INDUSTRY SL</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">lnicio de Operaciones:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">22/09/2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Domicilio Social</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">AVDA FRANCISCO VALLES 8</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">BOECILLO47151-VALLADOLID</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Duraci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#353535;">n</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">lndefinida</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">C</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">.</font><font style="font-family:inherit;font-size:11pt;color:#353535;">I.F.:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">B47729934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Datos Registraies:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Hoja VA-27242</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Tomo 1477</font></div><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Folio 91</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#333733;">Objeto Social:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333733;font-weight:bold;">La tenencia de participaciones y acciones de otras sociedades en porcentaje superior al cinco por ciento (5%), con animo de gestionarlas y sin incidir en actividades de las reservadas por la Ley de Mercado de Valores y legislaci&#243;n concordante para sociedades especiales, etc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#333733;">C.N.A.E.:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333733;font-weight:bold;">6420-Actividades de las sociedades holding</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#333733;">Estructura del &#243;rgano:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333733;font-weight:bold;">Consejo de administraci&#243;n</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#333733;">&#218;ltimo dep&#243;sito contable</font><font style="font-family:inherit;font-size:11pt;color:#838387;">:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333733;font-weight:bold;">2015</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">ASIENTOS</font><font style="font-family:inherit;font-size:11pt;color:#5e5e5e;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#333333;">DE PRESENTACION VIGENTES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Diario de documentos (Datos actualizados el 06/06/2017 , a las 09:00 horas) </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">Diarlo/Asiento:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">No tiene asientos de presentaci&#243;n vigentes</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Diario de cuentas (Datos actualizados el 06/06/2017 , a las 09:00 horas) </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">Dlario/Asiento:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">143/1051</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Este documento, tras haber sido retirado por el interesado, ha sido ingresado de nuevo en el Registro con fecha 02/06/2017</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">El documento contiene los siguientes actos:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">-</font><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Dep&#243;sito de cuentas</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Diario de libros (Datos actualizados el 06/06/2017, a las 09:00 horas)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">Diario/Asiento:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">No tiene asientos de presentaci&#243;n vigentes</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#5f6368;">SITUACIONES ESPECIALES</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#323635;font-weight:bold;">No existen situaciones especiales</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;font-weight:bold;">ESTATUTOS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">ESTATUTOS SOCIALES DE LA SOCIDAD &#8220;BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY, S.L.&#8221;,- CAPITULO I. DENOMINACI&#211;N, OBJETO, DURACI&#211;N Y DOMICILIO.-ART&#205;TITULO 1.- La Sociedad se denomina &#8220;BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY, S.L.&#8221; y se regir&#225; por los presentes Estatutos a no ser que la ley aplicable establezca regulaci&#243;n distinta para casos especiales, en cuy caso habr&#225; que cumplir los requisitos que la ley disponga. En Cuanto no estuviera previsto en estos Estatutos, se regir&#225; por la vigente Ley de sociedades de Capital (la &#8220;Ley) y las dem&#225;s disposiciones legales aplicables. ART&#205;CULO 2.- La Sociedad tiene por objeto la tenencia de participaciones y acciones de otras sociedades en porcentaje superior al cinco por ciento (5%), con &#225;nimo de gestionarlas y sin incidir en actividades de las reservadas por la Let de Mercado de Valores y legisaci&#243;n concordante para sociedades especiales, as&#237; como la prestaci&#243;n de servicios de administraci&#243;n, consultor&#237;a, financieros, contables, de gersti&#243;n y de cualesquiera otros necesarios, a entidades o sciedades participadeas. El c&#243;diga de Clasificati&#243;n Nacional de Actividades Econ&#243;micas 2009 (&#8220;CNAE&#8221;) correspondiente a dicha actividad se corresponde con la 64.20 &#8220;Actidades de las sociedades holding&#8221;. Quedan excluidas del objeto social todas aquellas actividades para cuyo ejercicio la Let exija requisitos especiales o de capital minimo que no queden cumlidos por esta Sociedad. Si las disposiciones legales exigiesen para el ejercio de algunas actividades comprendidas en el ojeto social alg&#250;n titulo profesional o authorizaci&#243;n administrativa o inscupci&#243;n en Registros P&#250;blicos, dichas actividades no podr&#225;n iniciarse antes de que se hayan cumplido los requisitos administrativos exigidos y, si fuera preceptivo, deber&#225;n realiarse por medio de persona que ostente la necesaria titularidad profesional. ART&#205;CULO 3.- La Sociedad tiene duraci&#243;n indefinida y dar&#225; comienzo a sus operaciones sociales el dia de la fecha del otorgamiento de la correspondiente escritura de constitusi&#243;n. ART&#205;CULO 4.- La sociedad tiene su domicillo en la calle Avda. Francisco Vall&#233;s 8, 47151 Boecilio (Valladolid). Previo acuerdo de la Junta General, el domicilio social podr&#225; ser trasladado a cualquier otro punto del territorio nacional. El &#211;rgano de Administraci&#243;n podr&#225; decidir el traslado del domicilio dentro del mismo t&#233;rmino municipal, as&#237; como la creaci&#243;n, supresion o traslado de Sucursales, Agencies, Delegaciones u oficinas en cualquier lugar del territotio nacional o extranjero. CAP&#205;TULO II. CAPITAL SOCIAL Y PARTICIPACIONES.- ART&#205;CULO 5.- El capital social es de cuatrocientos noventa y nueve mil ochocientos cincuenta eros, y est&#225; dividido en 49.985.000 participaciones sociales, n&#250;meros uno -1- al cuarenta y nueve millones novecientos ochenta y cinco mil -49.985.00-, ambos inclusive, de un c&#233;ntimo de uro -0,01 euro- de valor nominal cada una de ellas, indivisibles y acumulabales, que no tendr&#225;n el car&#225;cter de valores, n&#297; estar&#227;na representadas por medio de t&#237;tulos o de anotaciones en cuenta, ni se denominar&#225;n acciones. ART&#205;CULO 6.- La transmisi&#243;n de participaciones sociales se formalizar&#225; en documento p&#250;blico en los t&#233;rminos establecidos en al art. 106 de la Ley. La Sociedad llevar&#225; un Libro Registro de Socios, en el que se har&#225; constar la titularldad originarla y las sucesivas transmisiones de las participaciones sociales y la constituci&#243;n de derechos reales u otros grav&#225;menes sobre las mismas, haci&#233;ndose constar en cada anotaci&#243;n la identidad y domicilio del titular del dominio o del derecho o gravamen constituido. El socio o las titulates de derechos o grav&#225;menes tendr&#225;n registrados a su nombre, pero estos certificados no sustituir&#225;n al documento p&#250;blico de adquisici&#243;n originaria o derivativa. ART&#205;CULO 7.- La transmisi&#243;n voluntaria de participaciones sociales a sociedades pertenecientes al mismo grupo que la transmitente ser&#225; libre. En los dem&#225;s casos, la transmisi&#243;n voluntaria estar&#225; sometida a las siguientes reglas: a) El socio que se proponga trandmitir todas sus participaciones o participaciones sociales o parte de ellas, deber&#225; comunicarlo por conducto notarial al &#211;rgano de Administraci&#243;n, hacieno constar el n&#250;mero y caracteristicas de las participaciones que pretende transmitir, la identidad del adquirente y el precio y dem&#225;s codiciones de la transmisi&#243;n. b) La transmisi&#243;n quedar&#225; sometida al consentimiento de la Sociedad, que se expresar&#225; mediante acuerdo de la Junta General, previa inclus&#243;n del asunto en el orden del dia, adoptadp por la mayoris ordinaria establecida en estos Estatutos. c) La Sociedad s&#243;lo podr&#225; denegar el consentimiento si comunica al transmitente, por conducto notarial, la identidad de uno o varios socios o terceros qu adquieran la totalidad de las participaciones que se pretenda transmitir. No ser&#225; necesaria ninguna comunicaci&#243;n al trandmitente si acud&#237;o a la Junta General donde se </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">adptaron dichos acurrdos. Los socios concurrentes a la Junta General tendr&#225;n preferencia para la adquisici&#243;n, y si fueren varios los interesados en adquirir, se distibuir&#225;n entre todos ellos a prorrata de su participaci&#243;n en al capital social. Cuando no sea posible comunicar ta identidad de uno o varios socios o terceros adquirentes de la totalidad de las participaciones, la Junta General podr&#225; acordar que sea la propia Sociedad la qu adquiera las participaciones que ning&#250;n socio o tercero aceptado por la Junta quiera adquirir, conforme a lo establecido en al articulo 140 de la Ley. d) El precio de las participaciones, la forma de pagoy las dem&#225;s condiciones de la operaci&#243;n, ser&#225;n las comunicadas a la Sociedad por el socio transmitente. En caso de que existiere aplazamiento de pago, ser&#225; requisito que una entidad de cr&#233;dito garantice el pago del precio aplazado. e) Cuando el precio notificado se considere excesivo por acuerdo ordinario de la Junta General o cuando se trate de transmisi&#243;ngratuita u onerose por t&#237;tulo distinto del de compraventa, el precio de adquisci&#243;n ser&#225; fijado de com&#250;n acuerdo por las partes y, en su defecto, ser&#225; el valor razanbale de las participaciones, entendi&#233;ndose por tal el que determine un Auditor de Cuentas distinto del auditor de cuentas de la Sociedad, designado a tal efecto por los administradores de &#233;sta. Si el &#8220;valor razonable&#8221; as&#237; fijando no fuere aceptado por quien pretenda la trandmisi&#243;n, podr&#225; desistir de ella y ser&#225; de su cargo la retribuci&#243;n del auditor. En los dem&#225;s casos, dicha retribuci&#243;n ser&#225; de cuenta de la Sociedad. f) En los casos de aportaci&#243;n de las participaciones sociales a sociedad an&#243;nima o comanditaria por acciones, se entender&#225; por valor real el que resulte del informe elaborado por el experto independiente nombrado por el Registrador Mercantil. g) El documento p&#250;blico de trandmisi&#243;n deber&#225; otorgrase en el plazo de un mes a contar desde la comunicaci&#243;n por la Sociedad del adquirente o adquirentes. h) El socio podr&#225; transmitir las participaciones en las condiciones comunicadas a la Sociedad cuando hayan transcurrido tres (3) meses desde que hubiere puesto en conocimiento de &#233;sta su prop&#243;sito de transmitir sin que la Sociedad le hubiere comunicado la identidad del adquirente o adquirentes de todas las participaciones ofrecidas, y dentro del plazo de seis (6) meses a contar desde la fecha de comuncacni&#243;n inicial a la Sociedad. Transcurrido este plazo de seis (6) meses sin que se haya producido la transmisi&#243;n, precisar&#225; cumplie de nuevo todos los requisitos indicados. i) Los anteriores tr&#225;mites no ser&#225;n necesarios cuando la Junta General de la Sociedad, celebrada con car&#225;cter universal, apruebe por unanimidad la transmisi&#243;n pretendida por un socio. ART&#205;CULO 8.- Las transmisiones forzosas se ajustar&#225;n a lo establecido en el articulo 109 de la Ley. La adquisici&#243;n de alguna participaci&#243;n social por sucesi&#243;n hereditaria confiere al heredero o legatario la condici&#243;n de socio. En los surpuestos de copropiedad, usufructo, prenda o embargo de participaciones, es estar&#225; a lo dispuesto en los art&#237;culos 126 a 133 de la Ley. ART&#205;CULO 9.- Las transmisiones de participaciones sociales que no se ajusten a lo determinado en los art&#237;culos anteriores no producir&#225;n efecto alguno frente a la Sociedad. CAP&#205;TULO III. &#211;RGANOS SOCIALES.- ART&#205;CULO 10.- Son &#211;rganos Sociales: LA JUNTA GENERAL y el &#211;RGANO DE ADMINISTRACI&#211;N. A) LA JUNTA GENERAL:- ART&#205;CULO 11.- Los socios, reunidos en Junta General, dcidir&#225;n por las mayor&#237;as establecidas en el art&#237;culo 15 de estos Estatuos, en los asuntos propios de la competencia de la Junta, que ser&#225;n los siguientes: a) La censura de la gesti&#243;n social, la approbaci&#243;n de las cuentas anuales y la aplicaci&#243;n del resultado. b) El combramiento y separaci&#243;n de los administradores, liquidadores y, en su caso, de los de ellos. c) La authorizaci&#243;n a los administradores para el ejercicio, por cuenta propia o ajena, del mismo, an&#225;logo o complementario g&#233;nero de actividad que constituya el objeto social. d) La modificaci&#243;n de los Estatutos Sociales. e) El aumento y reducci&#243;n de capital. f) La supresi&#243;n o limitaci&#243;n del derencho de asunci&#243;n preferente. g) La transformaci&#243;n, fusi&#243;n, escisi&#243;n o la cesi&#243;n global de activo y pasivo y el traslado de domicilio al extranjero de la Sociedad. h) La disoluci&#243;n de la Sociedad. i) La aprobaci&#243;n del balance final de liquidaci&#243;n. j) Cualesquiera otros asuntos que expresamente determine la Ley olos Estatutos. Todos los socios, incluso los disidentes y los ausentes, quedan sometidos a los acuerdos de la Junta General. ART&#205;CULO 12.- La Junta General ser&#225; convocada por los administradores y, en su caso, por los liquidadores y, en los casos a que se refleran los art&#237;culos 170 y 171 de la Ley, en la forma all establecida. La Junta General Ordinaria ser&#225; convocada por los administradores para su celebraci&#243;n dentro de los seis primeros meses de cada ejercicio anterior y resolver sobre la aplicaci&#243;n del resultado. Tambi&#233;n podr&#225;n convocar Junta General Extraordinaria siempre que lo crean oportuno para los intereses sociales y necesariamente cuando lo sliciten, mediante requerimiento notarial, uno o varios socios que representen, al </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">menos, el cinco por ciento (5%) del capital social, expresando en la slicitud los asuntos a trater en la Junta y debiendo ser convacada la Junta para su celebraci&#243;n dento de los dos meses siguientes a la fecha en que se hubiere recibldo el requiremento. ART&#205;CULO 13.- La Junta General ser&#225; convocada por comunicaci&#243;n individual y escrita, remitida (i) correo certificado a cada uno de los socios al domicilio designado al efecto o que conste en la documentaci&#243;n de la Sociedad; o (ii) por correo electr&#243;nico designado al efecto o que conste en la documentaci&#243;n de la Sociedad siendo precisa la confirmaci&#243;n de lectura de dicho correo electr&#243;nico por parte del socio. En la convoatoria se expersar&#225; el nombre de la Sociedad, el lugar, la fecha y hora de la reuni&#243;n y el orden del d&#237;a en el que figurar&#225;n los asuntos a tratar, as&#237; como la identidad de la persona o personas que realicen ta comunicaci&#243;n. Entre la convocatoria y la fecha prevista para la reuni&#243;n deber&#225; existir un plazo de, al menos, quince (15) dias, que se computar&#225;n a partir de la fecha en que se hubiere remitido el anuncio al &#250;ltimo de los socios. La Junta podr&#225; celebrarse fuera del t&#233;rmino municipal donde la Sociedad teenga su domicilio. La Junta General quedar&#225; v&#225;lidamente constituida para tratar cualquier asunto, sin necesidad de previa convocatoria, siempre que est&#233; presente o representado la totalidad de capital social y los concurrentes acepten por unanimidad la celebraci&#243;n de la reuni&#243;n y el orden del d&#237;a de la misma. ART&#205;CULO 14.- Todos los socios , cualquiera que sea el n&#250;mero de sus participaciones, tienen derecho de asistencia a las Juntas, y podr&#225;n hacerse representar por otra persona, aunque no sea socio. La representaci&#243;n deber&#225; conferirse por escrito y, cuando no consteen documento p&#250;blico, deber&#225; realizarse con car&#225;cter especial para cada Junta. ART&#205;CULO 15.- Cada oarticipaci&#243;n da derecho a un voto. En caso de existir Consejo de Administraci&#243;n, su Presidente y Secretario lo ser&#225;n de la Junta. En caso de no existir Consejo de Administraci&#243;n, ser&#225;n Presidente y Secretario de la Junta cualesquiera de los administradores de la sociedad y, s&#237; s&#243;lo existe uno, &#233;ste ser&#225; el Secretario y de Presidente actuar&#225; el socio que resulte elegido por los socios concurrentes al comienzo de la reuni&#243;n. En cualquier caso, podr&#225;n ser sustituidos por las personas que la Junta designe. El Presidente dirigir&#225; las discusuines y resolver&#225; las cuestiones de procedimiento que pudleran surgir. Antes de entrar en el orden del d&#237;a, se formar&#225; la lista de asistentes, expresando el car&#225;cter en que concurren y el n&#250;mero de participaciones propias y ajenas que posean o representen. Corresponder&#225; al Presidente de la Junta dirgir y ordenar los debates, fijar el orden de las intervenciones, as&#237; como las propuestas de resoluci&#243;n. Los acuerdos se adoptar&#225;n por mavor&#237;a de los votos v&#225;lidamente emitidos, siempre que representen al menos un terico de los votos correspondientas a las participaciones sociales en que se divida el capital social. Por excepci&#243;n a lo dispuesto en el p&#225;rrafo anterior, para optar por cualquiera de las formas de administaci&#243;n fijada en estos Estatutos, aumentar o reducir el capital social o aprobar cualquier otra modificaci&#243;n estatutaria, y para acordar la disoluci&#243;n de la Sociedad de acuerdo al articulo 368 de la Ley, el voto favorable deber&#225; representar m&#225;s de la mitad de los votos correspondientes a las participaciones en que se divida el capital social. Asimismo, la autorizaci&#243;n a los administradores para que se dediquen, por cuenta propia o ajena, al mismo, an&#225;logo o complementario g&#233;nero de actividad que constituya el objeto social; la supresi&#243;n o la limitaci&#243;n del derecho de preferencia en los aumentos de capital; la transformaci&#243;n, la fusi&#243;n, la escisi&#243;n, la cesi&#243;n global de activo y pasivo y el traslado del domicilio al extranjero de la Sociedad, y la exclusi&#243;n de socios requerir&#225;n el voto favorable de, al menos, dos tercios de los votos correspondientes a las participaciones en que se divida el capital social. Para la obtenci&#243;n de las mayor&#237;as no se computar&#225;n los votos en blanco. Quedan a salvo los supuestos en que la Ley exija acuerdos un&#225;nimes o mayor&#237;as distintas. ART&#205;CULO 16.- </font><font style="font-family:inherit;font-size:11pt;color:#414141;">La asistencia a la Junta podr</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">&#32;rea</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">l</font><font style="font-family:inherit;font-size:11pt;color:#414141;">izarse bien acudiendo al lugar en que vaya a realizarse la reuni</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">n, bien a otros lugares conectados con aqu</font><font style="font-family:inherit;font-size:11pt;">&#233;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">l par sistemas de videoconferencias que permitan el reconocimiento e identificaci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">n de los asistentes, la permanente comunicaci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">n entre los concurrentes, independientemente del lugar en que se encuentren, as</font><font style="font-family:inherit;font-size:11pt;">&#237;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">&#32;como la intervenci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">n y emisi</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">n del voto en tiempo real</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">La convocatoria indicar</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">&#32;la posibilidad de asistencia mediante videoconferencia, especificando </font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">l</font><font style="font-family:inherit;font-size:11pt;color:#414141;">a forma en que podr</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">&#32;efectuarse. ART&#205;CULO 17</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">.</font><font style="font-family:inherit;font-size:11pt;color:#414141;">- Los acuerdos sociales deber&#225;n constar en acta que deber&#225; ser aprobada por la propia Junta al final de la reuni&#243;n o, en su defecto, y dentro del plaza de quince (15) dias, por el Presidente de la Junta y dos socios interventores, uno en representaci&#243;n de la mayor&#237;a y otro por la minor&#237;a</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">Deber&#225; asimismo prepararse una lista de asistentes, que podr&#225; incluirse al comienzo del acta, adjuntarse a la misma coma anexo firmado por el Presidente y Secretario de la Junta o incorporarse </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">a soporte inform&#225;tico</font><font style="font-family:inherit;font-size:11pt;color:#7b7b7e;">, </font><font style="font-family:inherit;font-size:11pt;color:#414141;">con las requisitos previstos en la legislaci&#243;n aplicable</font><font style="font-family:inherit;font-size:11pt;color:#959495;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">B) </font><font style="font-family:inherit;font-size:11pt;">&#211;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">RGANO DE ADMINISTRACI</font><font style="font-family:inherit;font-size:11pt;">&#211;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">N</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">:-</font><font style="font-family:inherit;font-size:11pt;color:#414141;">&#32;ART</font><font style="font-family:inherit;font-size:11pt;">&#205;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">CULO 18.- La administraci&#243;n de la Sociedad se podr&#225; confiar a</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">: </font><font style="font-family:inherit;font-size:11pt;color:#414141;">a) un administrador &#250;nico, b) un m</font><font style="font-family:inherit;font-size:11pt;">&#237;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">nimo de dos (2) y m&#225;ximo de diez (10) administradores que act&#250;en solidariamente</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">, </font><font style="font-family:inherit;font-size:11pt;color:#414141;">c) dos administradores que act&#250;en mancomunadamente, o d) un Consejo de Administraci&#243;n</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">En la escritura de constituci&#243;n de la Sociedad se determinar&#225; el modo en que originariamente se organiza la administraci&#243;n</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">En lo sucesivo la Junta General, con el voto favorable representativo de m&#225;s de la mitad de los votos correspondientes a las part</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">i</font><font style="font-family:inherit;font-size:11pt;color:#414141;">cipaciones en que se divide el capital social, podr&#225; optar por otro sistema o modo de administraci&#243;n de los se&#241;alados, sin necesidad de modificar los Estatutos, y en virtud de acuerdo que deber&#225; elevarse a escritura p</font><font style="font-family:inherit;font-size:11pt;">&#250;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">blica e inscribirse en el Registro Mercantil</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">ART</font><font style="font-family:inherit;font-size:11pt;">&#205;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">CULO 19</font><font style="font-family:inherit;font-size:11pt;color:#7b7b7e;">.</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">- </font><font style="font-family:inherit;font-size:11pt;color:#414141;">Para ser administrador no es necesario ser socio de la Sociedad</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">Su nombramiento y separaci&#243;n </font><font style="font-family:inherit;font-size:11pt;color:#7b7b7e;">-</font><font style="font-family:inherit;font-size:11pt;color:#414141;">que podr&#225; ser acordada en cualquier momenta- compete a la Junta General, con las mayor</font><font style="font-family:inherit;font-size:11pt;">&#237;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">as ordinarias. La duraci&#243;n del cargo ser&#225; por plazo indefinido. El cargo de administrador ser&#225; gratuito</font><font style="font-family:inherit;font-size:11pt;color:#7b7b7e;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">Dicho r&#233;gimen se establece sin perjuicio de otras remuneraciones que puedan proceder por el desempe&#241;o en la propia Sociedad de otras funciones o trabajos adicionales a los de Administrador</font><font style="font-family:inherit;font-size:11pt;color:#7b7b7e;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">En el caso de que el cargo de administrador recaiga en un miembro del equipo d</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">i</font><font style="font-family:inherit;font-size:11pt;color:#414141;">rectivo </font><font style="font-family:inherit;font-size:11pt;color:#6d8b83;">-</font><font style="font-family:inherit;font-size:11pt;color:#414141;">o empleado de la Sociedad, cualqu</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">i</font><font style="font-family:inherit;font-size:11pt;color:#414141;">era que sea su categor&#237;a o funci&#243;n-</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">, </font><font style="font-family:inherit;font-size:11pt;color:#414141;">ambas relaciones se mantendr&#225;n con independencia en cuanto a sus cometidos, origen y fin de las mismas, retribuci&#243;n, y cualesquiera otras consideraciones, sin que sea posible identificarlas o subsumirlas unas en otras. No podr&#225;n ser nombrados administradores quienes se hallen comprendidos en alguna causa de incapacidad o incompatibilidad legal o prohibici&#243;n para ejercer el cargo, especialmente las determinadas por la Ley 5/2006 de 10 de abr</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">i</font><font style="font-family:inherit;font-size:11pt;color:#414141;">l y otras espe</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">c</font><font style="font-family:inherit;font-size:11pt;color:#414141;">&#237;ficas de las Comunidades Aut&#243;nomas o cualquier otra establecida por la normativa aplicable</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">A&#250;n cuando la administraci&#243;n de la Sociedad no recaiga en &#243;rgano colegiado, los Administradores podr&#225;n dejar constanc</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">i</font><font style="font-family:inherit;font-size:11pt;color:#414141;">a en Acta de las decisiones que adopten a su entera d</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">i</font><font style="font-family:inherit;font-size:11pt;color:#414141;">screci&#243;n</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">Dichas Actas ser&#225;n transcritas en el Libro de Actas de la Sociedad</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">ART</font><font style="font-family:inherit;font-size:11pt;">&#205;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">CULO 20</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">.</font><font style="font-family:inherit;font-size:11pt;color:#414141;">- Cuando la administraci&#243;n recaiga en un Consejo de Administraci&#243;n, se observar&#225;n las reglas siguientes</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">: </font><font style="font-family:inherit;font-size:11pt;color:#414141;">a) El n&#250;mero de consejeros no podr&#225; ser inferior a tres (3) ni superior a doce (12). b) El Consejo de Administraci&#243;n ser&#225; convocado por su Presidente o el que haga sus veces</font><font style="font-family:inherit;font-size:11pt;color:#7b7b7e;">. </font><font style="font-family:inherit;font-size:11pt;color:#414141;">Los Consejeros que constituyan al menos un tercio de los miembros del consejo podr&#225;n convocar&#237;o, indicando el orden del d&#237;a, para su celebraci&#243;n, en la localidad donde radique el domicilio social, si previa petici&#243;n al Presi</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">d</font><font style="font-family:inherit;font-size:11pt;color:#414141;">ente o q</font><font style="font-family:inherit;font-size:11pt;color:#5a5a5b;">uie</font><font style="font-family:inherit;font-size:11pt;color:#414141;">n </font><font style="font-family:inherit;font-size:11pt;color:#363636;">hiciera sus veces, &#233;ste sin causa justificada no hubiera hecho la convocatoria en el plazo de un mes. La convocatoria se har&#225; siempre por carta, telegrama, fax o correo electr&#243;nico al domicllio o direcci&#243;n de correo electr&#243;nico de cada uno de los miembros del Consejo de Administraci&#243;n que conste en los archivos de la Sociedad, con una antelaci&#243;n minima de cinco (5) d&#237;as a la fecha de la reuni&#243;n</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">. </font><font style="font-family:inherit;font-size:11pt;color:#363636;">c) El Consejo quedar&#225; v&#225;lidamente constituido cuando concurran a la reuni&#243;n, presentes o representados, siempre por otro consejero, la mayoria de los vocales que lo integran. La representaci&#243;n se conferir&#225; mediante carta dirigida al Presidente o al Vicepresidente, en su caso. Ser&#225; v&#225;lida la reuni&#243;n sin necesidad de previa convocatoria cuando estando reunidos todos los miembros del Consejo</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">decidan, por unanimidad, celebrar sesi&#243;n. Corresponder&#225; al Presidente o a quien haga sus veces dirigir y ordenar los debates, fijar el orden de las intervenciones, as&#237; como las propuestas de resoluci&#243;n. En ausencia del Presidente y/o Secretario, o quienes hicieran sus veces, actuar&#225;n como Presidente y/o Secretario de la reuni&#243;n el o los designados por los Consejeros asistentes por mayor&#237;a. d) Los acuerdos se adoptar&#225;n por mayor&#237;a absoluta de los consejeros concurrentes o representados en la reuni&#243;n. e) Los acuerdos se consignar&#225;n en acta, que ser&#225; aprobada por el propio &#243;rgano al final de la reuni&#243;n o en la siguiente, y que ser&#225; firmada por el Secretario de la sesi&#243;n, con el visto bueno de quien hubiera actuado como Presidente. f) Cuando la Junta General de Socios no lo hiciera, el Consejo nombrar&#225; de su seno un Presidente y, en su caso, uno o m&#225;s Vicepresidentes. Tambi&#233;n designar&#225; un Secretario y, en su caso, uno o m&#225;s Vicesecretarios, que podr&#225;n ser no consejeros. Tarnbi&#233;n, con el voto favorable de las dos terceras partes de los componentes del Consejo, podr&#225; delegar alguna o todas sus facultades de administraci&#243;n y representaci&#243;n -salvo las indelegables conforme a la Ley- en favor de una Comisi&#243;n Ejecutiva o de uno o varios Consejeros Delegados, designando a los administradores que hayan de ocupar tales cargos y el r&#233;gimen de su actuaci&#243;n</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">. </font><font style="font-family:inherit;font-size:11pt;color:#363636;">g) Los acuerdos del Consejo podr&#225;n adoptarse por escrito y sin sesi&#243;n con el voto favorable de la mayor&#237;a seq&#250;n se indica en el </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">p&#225;rrafo d), siempre que todos los miembros del Consejo hayan sido notificados con antelaci&#243;n de los acuerdos que se pretenda adoptar de esa forma y ninguno de ellos se oponga a este procedimiento. Estos acuerdos se her&#225;n constar en acta</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">. </font><font style="font-family:inherit;font-size:11pt;color:#363636;">h) Ser&#225;n v&#225;lidos los acuerdos del Consejo de Administraci&#243;n celebrados por videoconferencia o por conferencia telef&#243;nica m&#250;ltiple, siempre que ninguno de los miembros del Consejo se oponga a este procedimiento, dispongan de los medios necesarios para ello y se reconozcan rec&#237;procamente, lo cual deber&#225; expresarse en el acta del Consejo y en la certificaci&#243;n de los acuerdos que se expida. En tal caso, la sesi&#243;n del Consejo se considerar&#225; &#250;nica y celebrada en el lugar del domicilio social. ART&#205;CULO 21.- La representaci&#243;n de la Sociedad, enjuicio y fuera de &#233;l, corresponde a los administradores en la forma determinada en el Art&#237;culo 233 de la Ley y</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">de conformidad con la forma de administraci&#243;n elegida por la Junta General en cada momento. La representaci&#243;n se extender&#225; a todos los actos comprendidos en el objeto social delimitado en el Art&#237;culo 2 de estos Estatutos. Cualquier limitaci&#243;n de las facultades representativas de los administradores, aunque se halle inscrita en el Registro Mercantil, ser&#225; ineficaz frente a terceros. La Sociedad quedar&#225; obligada frente a terceros que hayan obrado de buena fe y sin culpa grave, aunque se desprenda de estos Estatutos inscritos en el Registro que el acto no est&#225; comprendido dentro del objeto social. CAP</font><font style="font-family:inherit;font-size:10pt;">&#205;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">TULO IV. EJERCICIO SOCIAL</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">.- </font><font style="font-family:inherit;font-size:11pt;color:#363636;">ART</font><font style="font-family:inherit;font-size:10pt;">&#205;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">CULO 22</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">.</font><font style="font-family:inherit;font-size:11pt;color:#363636;">- El ejercicio social comenzar</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;el 1 de enero de cada afta y</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">finailzar</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;el d</font><font style="font-family:inherit;font-size:11pt;">&#237;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">a 31 de dic</font><font style="font-family:inherit;font-size:11pt;">&#237;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">embre del mismo a</font><font style="font-family:inherit;font-size:11pt;">&#241;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">o. Los administradores est</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">n obligados a formular en el plazo m</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">ximo de tres (3) meses contados a partir del cierre del ejercicio social, las cuentas anuales, el informe de gesti</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">n en su caso y la propuesta de aplicaci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">n del resultado. Las cuentas comprender</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">n el balance, la cuenta de p&#233;rdidas y gananc&#236;as, un estado que refleje los cambios en el patrimonio neto del ejercicio, un estado de flujos de efectivo, en su caso, y la memoria</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">. </font><font style="font-family:inherit;font-size:11pt;color:#363636;">Estos documentos, que forman una unidad, deber</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">n ser redactados con claridad y mostrar la imagen fiel del patrimonio, de la situaci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">n financiera y de los resultados de la Soc&#237;edad, de acuerdo con lo establecido en el C</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">digo de Comercio y en las Leyes</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">. </font><font style="font-family:inherit;font-size:11pt;color:#363636;">CAP</font><font style="font-family:inherit;font-size:11pt;">&#205;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">TULO V. DISOLUCI</font><font style="font-family:inherit;font-size:11pt;">&#211;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">N Y LIQUIDACl</font><font style="font-family:inherit;font-size:11pt;">&#211;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">N.- ART&#205;CULO </font><font style="font-family:inherit;font-size:11pt;color:#454848;">23</font><font style="font-family:inherit;font-size:11pt;color:#a1a0a6;">.</font><font style="font-family:inherit;font-size:11pt;color:#454848;">- La disoluc</font><font style="font-family:inherit;font-size:11pt;color:#77757c;">i&#243;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">n y l</font><font style="font-family:inherit;font-size:11pt;color:#5b5e61;">i</font><font style="font-family:inherit;font-size:11pt;color:#454848;">qu</font><font style="font-family:inherit;font-size:11pt;color:#5b5e61;">i</font><font style="font-family:inherit;font-size:11pt;color:#454848;">daci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">n de la Sociedad se regir&#225; por las normas del Titulo X de la Ley. La Junta General de Socios designar&#225; un liquidador &#250;nico cuyo poder de representaci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">n se extender</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">&#32;a todas aquellas operaciones necesarias para la l</font><font style="font-family:inherit;font-size:11pt;color:#5b5e61;">i</font><font style="font-family:inherit;font-size:11pt;color:#454848;">quidaci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">n de la Sociedad</font><font style="font-family:inherit;font-size:11pt;color:#77757c;">. </font><font style="font-family:inherit;font-size:11pt;color:#454848;">DISPOSICI&#211;N FINAL</font><font style="font-family:inherit;font-size:11pt;color:#77757c;">.</font><font style="font-family:inherit;font-size:11pt;color:#454848;">- Toda controversia o conflicto de naturaleza societaria entre las socios, entre las socios y los administradores y entre cualesquiera de los anteriores y la sociedad, incluidas las cuestiones relativas a la interpretaci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">n de los Estatutos, ser</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">n resueltas definitivamente mediante arbitraje de Derecho, administrado por la Corte de Arbitraje de Madrid de la C</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">mara de Comercio e lndustria, de acuerdo con su Reglamento de Arbitraje vigente a la fecha de presentaci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">n de la solicitud de arbitraje</font><font style="font-family:inherit;font-size:11pt;color:#a1a0a6;">. </font><font style="font-family:inherit;font-size:11pt;color:#454848;">El tribunal arb</font><font style="font-family:inherit;font-size:11pt;color:#5b5e61;">i</font><font style="font-family:inherit;font-size:11pt;color:#454848;">tral que se designe a tal efecto estar</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">&#32;compuesto por un </font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">rbitro y el idioma del arbitraje ser</font><font style="font-family:inherit;font-size:11pt;">&#225;</font><font style="font-family:inherit;font-size:11pt;color:#454848;">&#32;el espa&#241;ol</font><font style="font-family:inherit;font-size:11pt;color:#a1a0a6;">. </font><font style="font-family:inherit;font-size:11pt;color:#454848;">La sede del arbitraje ser&#225; Madrid.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><a name="s9fcdbf7bb04d4d60b5549403b3505dfa"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">SCHEDULE 2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">Subsidiaries</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">Biotechnology Developments for </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">Industry in Pharmaceuticals, S.L</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">U.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:83.33333333333334%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:42%;"></td><td style="width:58%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company name</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Biotechnology Developments for Industry in </font></div><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pharmaceuticals, S.L.U.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company number</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Spanish Tax Identification Number so called<br>(NIF / CIF): B-86206695</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date and place of incorporation</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">27 April 2011 in Madrid (Spain)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Registered address</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C/ L&#243;pez de Hoyos 35, 1&#176;, Madrid, (Spain)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">VLP The Vaccines Company, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">S.L</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">U.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:83.33333333333334%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:42%;"></td><td style="width:58%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company name</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VLP The Vaccines Company, S.L.U.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Company number</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Spanish Tax Identification Number so called<br>(NIF / CIF): B-37515111</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date and place of incorporation</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16 March 2012 in Madrid (Spain)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Registered address</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C/ Vel&#225;zquez 4, 5&#176;, 37005 Salamanca (Spain)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><a name="s659b3278e4db4ee49e63d9631b7febe2"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">SCHEDULE III</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">Shareholders of the Company</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.74358974358975%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:22%;"></td><td style="width:17%;"></td><td style="width:24%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#ededee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">Shareholders</font></div></td><td style="vertical-align:bottom;background-color:#ededee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#ededee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;background-color:#ededee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">N&#176; (inclusive)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Creux Analiais Estrategicos, S. L.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.65%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,721,379</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[l - 7,331,502]; [32,500,001 -</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;34,946, 362];</font></div><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[41,985,001&#160;-&#160;43,033,003]; [46,485,001&#160;-&#160;47,380,512]</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Emilio <br>Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.56%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,024,442</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[15,979,178 - 19,023,353]; [34,,946,363 - 36,054,945]; [44,237,333 - 44,682,429]; [48,558,414 - 48,985,000]</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Carlos </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bl&#225;zquez Escudero</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.34%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,212,731</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[10,302,463 - 13,273,422]; [32,000,001 - 32,500,000]; [43,467,805 - 43,839,825]; [47,799,092 - 48,168,841]</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Ricardo <br>Arjona Antol&#237;n</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.39%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,910,077</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[7,331,503 -10,302,462]; [36,054,946 - 37, 140,682];[43,033,004 - 43,467,804];[47,380,513 - 47,799,091]</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Ana G&#243;mez Rodriguez</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.77%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,495,819</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[13,273,423 - 15,979,177];[37,140,683 - 38,143,667];[43,839,826 - 44,237,332];[48,168,842 - 48,558,413]</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Luis Hilario Guerra Trueba</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.19%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,781,29</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[19,023,354 - 19,342,466];[38,143,668 - 38,401,948];[44,682,430 - 45,886,325]; [48,985,001 - 49,985,000]</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Floerna Bio tee, S. L.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.04%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,654,955</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[19,342,467 - 27,342,466]; [38,401,949, - 41,056,903]</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr.Jorge </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hernandez Esteban</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.66%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,757,607</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[27,342,467 - 29,808,219]; [41,056,904 - 41,985,000]; [45,886,326 - 46,250,082]</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Yahia El- </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amrani</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.65%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,426,699</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[29,808,220 - 32,000,000];</font></div><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[46,250,083 - 46,485,000]</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DYADIC INTERNATIONAL (USA), INC.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.12%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,707,750</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[49,985,001 - 60,692,750]</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INVEREADY INNVIERTE BIOTECHII, S.C.R., S.A.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.63%</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,732,499</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[60,692,751 - 66,425,249</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.74358974358975%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:22%;"></td><td style="width:17%;"></td><td style="width:24%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#ededee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">Shareholders</font></div></td><td style="vertical-align:bottom;background-color:#ededee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#ededee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;background-color:#ededee;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">N&#176; (inclusive)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;font-weight:bold;">TOTAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">66,416,423</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">1&#160;-&#160;66,425</font><font style="font-family:inherit;font-size:11pt;color:#585858;">,</font><font style="font-family:inherit;font-size:11pt;color:#414141;">249</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><a name="sbe3e794277994178827d8caf6bb62e78"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373b3a;font-weight:bold;">S</font><font style="font-family:inherit;font-size:11pt;color:#4c4c50;font-weight:bold;">C</font><font style="font-family:inherit;font-size:11pt;color:#373b3a;font-weight:bold;">HEDUL</font><font style="font-family:inherit;font-size:11pt;color:#4c4c50;font-weight:bold;">E </font><font style="font-family:inherit;font-size:11pt;color:#373b3a;font-weight:bold;">IV</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#5e5e5e;font-weight:bold;">C</font><font style="font-family:inherit;font-size:11pt;color:#4c4c50;font-weight:bold;">E</font><font style="font-family:inherit;font-size:11pt;color:#373b3a;font-weight:bold;">O Management Contract</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><a name="s5beaafc3527947888a6597c6e295b138"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT A2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">VLP Shareholders Agreement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373937;font-weight:bold;">SHAREHOLDERS AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#464848;">wi</font><font style="font-family:inherit;font-size:11pt;color:#373937;">th </font><font style="font-family:inherit;font-size:11pt;color:#464848;">r</font><font style="font-family:inherit;font-size:11pt;color:#373937;">espect to</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373937;font-weight:bold;">VLP The Vaccines Company, S</font><font style="font-family:inherit;font-size:11pt;color:#545b62;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11pt;color:#373937;font-weight:bold;">L.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373937;">executed by</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373937;">Biotechnology Developments for Industry, S.L. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373937;">DYADIC INTERNATIONAL (USA)</font><font style="font-family:inherit;font-size:11pt;color:#464848;">, </font><font style="font-family:inherit;font-size:11pt;color:#373937;">INC</font><font style="font-family:inherit;font-size:11pt;color:#464848;">; </font><font style="font-family:inherit;font-size:11pt;color:#373937;">and </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373937;">INVEREADY INNVIERTE BIOTECH II</font><font style="font-family:inherit;font-size:11pt;color:#464848;">, </font><font style="font-family:inherit;font-size:11pt;color:#373937;">S</font><font style="font-family:inherit;font-size:11pt;color:#464848;">.</font><font style="font-family:inherit;font-size:11pt;color:#373937;">C.R., S.A.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#464848;">Madrid, on 30 June 2017</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s9650b719d3df473d8475e06f4846ad46"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;text-decoration:underline;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:79%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DEFINITIONS AND INTERPERTATION.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s734cd0725b49449ea10fcccda5182c88">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PURPOSE OF THE AGREEMENT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sf67508d06212461ab96504c61ea0beea">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BUSINESS OF THE COMPANY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sccf2e445266c43bd87a02508289f3bfd">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BOARD OF DIRECTORS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s4a33a6deaf464197816dc3a9e35a821c">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GENERAL SHAREHOLDERS&#8217; MEETING.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sa11735d746174cb1956757db575f3ce0">14</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFLICT OF INTEREST</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sdad24ca060aa47be9181ea1576789367">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MANAGEMENT OF THE COMPANY.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sd963b760503542d296cc22210319698e">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INFORMATION RIGHTS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s5cd29b538fdb4ac680893c7bb03f7611">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DIVIDEND POLICY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sd8d1b8c4c6e74730ac5e84c5bafe68f9">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ACCOUNTING AND FINANCIAL REPORTING</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sb75e280fc6254be2921fccf2eb18c52f">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s6d5fbce6a41e49a5b67e2a22c2974a32">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OBLIGATIONS OF EACH PARTY.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s4050cc8cd4b3427b928931b8b366fbad">18</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PRE-EMPTIVE RIGHTS FOR CAPITAL INCREASE.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s74beb68dc18e4a949a10786ec57b9606">18</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LOCK-IN PERIOD AND FUTURE TRANSFERS OF SHARES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s268f013a04cd43d0ab2b30c48ff11c7c">19</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DRAG-ALONG RIGHT.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#scb61f6b9cc734e18a46005d5ba26b0a1">20</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TAG-ALONG RIGHT.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sf6ad613735d44cd4afb321002dfb872b">21</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NATURE OF THIS AGREEMENT AND BYLAWS.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s36651cfd0bb44728b2b9357b4c828548">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TERM</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s79b96838db9243d3a8ca423c01c32339">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TERMINATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sbe95d9f3c8f247b883953b87d42675af">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONFIDENTIALITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#scdde92ff95a943aeb759e4115cd5b0d0">24</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INDEMNITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s8c1851e7a13a419897616a41ebc22be7">25</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOTICES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#scabacdad2f964977b4f03134c14bab7e">25</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ASSIGNMENT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sf9544a1abe28433c8cd8eda194d0ab0a">26</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GENERAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sea5b79da9a7e441db81c309ee72e511a">27</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GOVERNING LAW AND JURISDICTION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s392221a51b3a43719cb04b8087443cbb">28</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="se25c6ec3f9884c97ab92fd7bbd9ed99a"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">SHAREHOLDES  AGREEMENT</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">REGARDING</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">VLP The Vaccines Company, S.L.U.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;">In Madrid, on 30 June, 2017</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">OF THE ONE PART</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC,</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">&#32;a US company incorporated and existing under the laws of Florida, USA, and duly registered with the  Trade Registry of the State of Florida, USA with company registration number 45</font><font style="font-family:inherit;font-size:11pt;color:#5e5e5f;">-</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">0486747, having its corporate domicile at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477, USA ("</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">"), represented by Mr. Antonio Ca&#241;adas Bouwen, of legal age, a Spanish national, with tax identification number 33,514,340-M, in force, and domiciled for this purposes in Madrid (28006) Plaqza Marqu&#233;s de Salamanca 3 and 4 - 7</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">&#32;floor. He acts in his capacity of special attorney of Dyadic.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">INVEREADY INNVIERTE BIOTECI</font><font style="font-family:inherit;font-size:11pt;color:#929299;font-weight:bold;">-</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">1 II, S.C.R.,</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">S.A.</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">, a Spanish company, with registered office in calle Cavallers, 50, 08034 Barcelona, holder of Spanish tax identification number A</font><font style="font-family:inherit;font-size:11pt;color:#787983;">-</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">65888232 ("</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">Inveready</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">"), represented by Mr. Roger Piqu&#233; Pijuan, of legal age, a Spanish national, holding taxpayer identification number 38853387</font><font style="font-family:inherit;font-size:11pt;color:#787983;">-</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">Q in force, and domiciled for this purposes in calle Cavaliers, 50, 08034 Barcelona. H</font><font style="font-family:inherit;font-size:11pt;color:#5e5e5f;">e </font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">acts in his capacity of general attorney of Inveready.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">Biotechnology Developments For Industry, S.L.</font><font style="font-family:inherit;font-size:11pt;color:#787983;font-weight:bold;">,</font><font style="font-family:inherit;font-size:11pt;color:#787983;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">a Spanish limited liability company, with registered office in Avenida Francisco Valles, 8, 47151, Boecillo (Valladolid)</font><font style="font-family:inherit;font-size:11pt;color:#5e5e5f;">, </font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">holder of Spanish tax identification number B47729934 ("</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">BDI Holding</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;">"), represented by Mr. Pablo Gutierrez G6mez., of legal age, with Spanish nationality, holding taxpayer identification number (70.868.817 K), in force, and domiciled for this purposes in Louis Proust 13, Boecillo. He acts in his capacity of Chief Executive Officer of BDI Holding.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;">Hereinafter the persons and companies identified in items (1) and (2) will be jointly referred to as the </font><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">"Investors".</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;">Hereinafter the persons and companies identified in items (1) through (3) will be jointly referred to as the </font><font style="font-family:inherit;font-size:11pt;color:#5e5e5f;font-weight:bold;">&#8220;Shar</font><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">eholders"</font><font style="font-family:inherit;font-size:11pt;color:#5e5e5f;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">AND OF ANOTHER PART</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">VLP The Vaccines  Company, S.L.U.,</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;a Spanish limited liability company, with registered office in Calle Velazquez, 4-5&#176;, 37005, Salamanca, Spain, holder of Spanish tax identification number B37515111 (</font><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"VLP"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;or the </font><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Company''</font><font style="font-family:inherit;font-size:11pt;color:#393939;">), represented by Emilio Gutierrez Gomez, of legal age, with Spanish nationality, holding taxpayer identification number 70.882.858-D and domiciled for this purpose  at calle Velazquez 4, 5&#176; A, Salamanca. He acts in his capacity of legal representative of Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. which is the sole director of VLP.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">Finally, the Shareholders and the Company shall be jointly referred to as the </font><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Parties"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;and each one of them as a </font><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">''Party".</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:3px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">In the capacity in which they act, the Parties reciprocally recognize each other to have the necessary and sufficient legal capacity and powers of representation to enter into this </font><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">Shareholders Agreement</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;(hereinafter this </font><font style="font-family:inherit;font-size:11pt;color:#393939;font-style:italic;font-weight:bold;">&#8220;Agreement&#8221;</font><font style="font-family:inherit;font-size:11pt;color:#393939;">) and for this purpose, they state the following</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">WHEREAS</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">The Company is is a Spanish limited liability company, with its registered office at Calle Vel&#225;zquez, 4, 5&#176; A, 37005, Salamanca, Spain, incorporated by virtue of the public deed granted by the Public Notary from Madrid, Mr. Antonio Moren&#233;s Giles who was substituting Mr. Andr&#233;s de la Fuente O'Connor, on March 16</font><font style="font-family:inherit;font-size:11pt;color:#393939;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;color:#393939;">, 2012, under number 435 of his public records, registered in the Commercial Registry of Salamanca under volume 426, sheet 219, page SA-14239, and with tax identification number B37515111.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">The By-Laws of the Company before entering into this Agreement are attached hereto as </font><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;text-decoration:underline;">Schedule I</font><font style="font-family:inherit;font-size:11pt;color:#393939;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">II.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">On the Effective Date, an investment agreement was entered into by all the shareholders </font><font style="font-family:inherit;font-size:11pt;color:#393939;font-style:italic;">of </font><font style="font-family:inherit;font-size:11pt;color:#393939;">BDI Holding (including the Investors), BDI Holding and the Company (</font><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Investment Agreement"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">) pursuant to which, among other agreements, BDI Holding, Dyadic and Inveready will invest in VLP for an aggregate amount of EUR 700,000.- by means of a capital increase in VLP ("</font><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">Capital Increase</font><font style="font-family:inherit;font-size:11pt;color:#393939;">"), subject to the waiver or fulfillment of the Closing Conditions and Covenants established in sections 8 and 10 of the Investment Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">III.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">On the Effective Date, and pursuant to the terms of the Investment Agreement BDI Holding, Dyadic and Inveready entered into the share capital of the Company through a capital injection of EUR 700,000 (the </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Capital Injection"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">) </font><font style="font-family:inherit;font-size:11pt;color:#7e7e80;">- </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">with the corporate approval of BDI Holding (former sole shareholder). After the mentioned capital increase, the Shareholders of VLP hold the entire share capital of the Company as set out in </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;text-decoration:underline;">Schedule II</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">IV.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The Parties have decided to enter into this Shareholders Agreement in order to regulate (i) the relationships among the Shareholders, (ii) the relationships between. the Shareholders and the Company, (iii) the system of governance and management of the Company and (iv) the transfers of shares in the Company and certain other commitments of the Shareholders related to the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">THE PARTIES</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;agree as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><a name="s734cd0725b49449ea10fcccda5182c88"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">DEFINITIONS AND INTERPRETATION</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">. In the Agreement the following terms shall have the meanings specified below:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Accounting</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Principles"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;means the Spanish generally accepted accounting principles as laid down in the Spanish General Accounting Plan (</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Plan General Contable"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">)</font><font style="font-family:inherit;font-size:11pt;color:#5d5e5e;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Affiliate"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;means any entity directly or indirectly controlled by, controlling, or under common control with, a party to this Agreement, but only for so long as such control shall continue. for purposes of this definition, "control" (including, with correlativ</font><font style="font-family:inherit;font-size:11pt;color:#5d5e5e;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">meanings, "controlled by", "controlling" and "under common control with") means possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies of an entity (whether through ownership of s</font><font style="font-family:inherit;font-size:11pt;color:#5d5e5e;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">curities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voling securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Applicable Law"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;means, with respect to any Person, any law, regulation, rule, judgment, order, decree, award</font><font style="font-family:inherit;font-size:11pt;color:#5d5e5e;">, </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Governmental Approval, grant, license, agreement, guideline, policy, requirement, or other governmental restriction or any similar form of decision of, or determination by, or any interpretation or administration of any of the foregoing by, any Governmental Authority, then in force and applicable to such Person or its subsidiaries or their respective assets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">&#8220;Auditors&#8221;</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;means the auditor(s) of the Company as may be appointed from time to time by General Shareholders Meeting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Audited Financial Statements"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;means the audited balance sheet and profit and loss account of the Company (as well as further financial statements required by the Applicable Law for the annual accounts) for the financial period ended on and as at December 31, including the reports and notes annexed to them, prepared in accordance with the Accounting Principles and audited by the Auditors.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:2px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"BDI Holding"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;shall have the meaning set forth in Recital 3</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"BDI Group"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;means BDI Holding and the Subsidiaries.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"BDI Pharmaceuticals"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;means Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Board Meeting''</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;shall have the meaning ascribed to it in Clause 4.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Board of Directors"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;or "</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Board</font><font style="font-family:inherit;font-size:11pt;color:#363636;">" means the Board of Directors of the Company as set forth in Cause 4.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Board Reserved Matters"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;shall have the meaning set forth in Clause 4.12.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Business"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;means the corporate activity or business ordinarily carried out by BDI Group consisting of [to be included].</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Business Day"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;means any day except Saturdays, Sundays or public holidays or days in which banks are not open in Madrid, Spain or Jupiter, Florida.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Bylaws"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;means the bylaws of the</font><font style="font-family:inherit;font-size:11pt;color:#525252;">.</font><font style="font-family:inherit;font-size:11pt;color:#363636;">Company, as amended according to the terms and conditions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Capital Increase"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;shall have the meaning set forth in Whereas III.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Capital Injection"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;shall have the meaning set forth in Whereas IV</font><font style="font-family:inherit;font-size:11pt;color:#363636;font-style:italic;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:50px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Chairman"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;shall have the meaning set forth in Clause 4.6.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:50px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Company"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;shall have the meaning set forth in Recital 4.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:1px;text-align:justify;padding-left:50px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">"Competitor"</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;shall mean any Person or entity (other than Dyadic or any of its Affiliates or any of Dyadic's directors or employees) who provides genetic </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">modifications, and/ or fermentation media and process development related to any fungal strains that have the taxonomy of either (i) </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-style:italic;">Mycelioptlum1, </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">(ii) </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-style:italic;">Carfnascus </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">or (iii) </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-style:italic;">Sporotrichiunt </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">and/ or any strains derived, generated, adapted and or otherwise therefrom.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"Confidential Information" </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">shall have the meaning set forth i.11. Clause 21. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">Deed of Adherence</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">" shall have the meaning set forth in Clause 14.3. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">Directors</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">" shall have the meaning set forth in </font><font style="font-family:inherit;font-size:11pt;color:#5e5e61;">C</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">lause 4.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"Disclosing Party"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">&#32;shall have the meaning set forth in Clause 21.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"Disinvestment"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">&#32;means the sale or disposal in any other manner by the Shareholders of all of their shareholding Interest in the Company. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">Drag-Along Right</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">" shall have the meaning set forth in Clause 15.1.(c). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;">"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">" shall have the meaning s</font><font style="font-family:inherit;font-size:11pt;color:#5e5e61;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">t forth in Recital 1.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"Effective Date"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">&#32;means the date of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"Extraordinary Board Meetings"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">&#32;shall have the meaning set forth in Clause 4.</font><font style="font-family:inherit;font-size:11pt;color:#5e5e61;">7</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"Exercising Party"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">&#32;shall have the meaning set forth in Clause 15.2.(a).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"Financial Year"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">&#32;means each financial year of the Company starting on January, 1st and ending on December, 31st of each year.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"Free Cash-Flow"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">&#32;means, for a given Financial Year, the cash generat</font><font style="font-family:inherit;font-size:11pt;color:#5e5e61;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">d by the Company's operations and (subject to the provisions of applicable laws and this Agreement) available for distribution to Shareholders.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"General Shareholders' Meeting"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">&#32;means a shareholders' meeting of th</font><font style="font-family:inherit;font-size:11pt;color:#5e5e61;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"Governmental Authority"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">&#32;means any government or political subdivision thereof, including without limitation, any governmental department, corn.mission, board, bureau, agency, regulatory authority, judicial or administrati</font><font style="font-family:inherit;font-size:11pt;color:#5e5e61;">ve </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">body, having jurisdiction over the matter or matters in question.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413e;font-weight:bold;">"Intellectual Property"</font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">&#32;means all registered and unregistered trademarks, trade names, servi</font><font style="font-family:inherit;font-size:11pt;color:#5e5e61;">ce </font><font style="font-family:inherit;font-size:11pt;color:#3d413e;">marks, service mark registrations, service names, patents, patent </font><font style="font-family:inherit;font-size:11pt;color:#393939;">rights., copyrights, inventions, licenses, approvals, governmental authorizations, applications for registrations of copyrights and trademarks, brand names, discoveries, formulas, technical assistance, trade secrets, knowhow and other intellectual property rights necessary to conduct the Business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Inveready"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;shall have the meaning set forth in Recital 2.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Inveready Drag-Along Right"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;shall have the meaning set forth in Gause15.1.(a).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Investment Agreement"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;shall have the meaning set forth in Whereas II.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Investment Bank'</font><font style="font-family:inherit;font-size:11pt;color:#393939;">' shall have the meaning set forth in Clause 15.1.(c).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Investors"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;shall have the meaning set forth in Recital 3.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Key Employees"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;means Mr. Emilio Guti&#233;rrez G&#243;mez and Ms. Ana G&#243;mez Rodr&#237;guez.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Lock-In Period"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;shall have the meaning set forth in Clause 14.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Notary"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;means the Spanish Notary designated by BDI Holding to authorize the Capital Increase Deed and the Public Deed.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Notice"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;shall have the meaning set forth in Clause 23. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">"</font><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">Offer</font><font style="font-family:inherit;font-size:11pt;color:#393939;">" shall have the meaning set forth in Clause 16.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Offered Shares"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;shall have the meaning set forth in Clause 16.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Offer Notice"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;shall have the meaning set forth in Clause 16.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Offeror"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;shall have the meaning set forth in Clause 16.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Ordinary Board Meetings"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;shall have the meaning set forth in Clause 4.7. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Party"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;or </font><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Parties" </font><font style="font-family:inherit;font-size:11pt;color:#393939;">shall have the meaning set forth in Recital 4.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Person/s"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;means any individual, corporation, business trust, joint venture, association, company, limited liability entity, firm, partnership, or other entity or governmental body, including their heirs, successors and assignees.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">"Public Deed"</font><font style="font-family:inherit;font-size:11pt;color:#393939;">&#32;means the deed notarizing this Agreement to be executed by the Parties on the Effective Date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#57585a;font-weight:bold;">"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Receiving Party"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;shall have the meaning set forth in Claus</font><font style="font-family:inherit;font-size:11pt;color:#777880;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">21. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Sale Request"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;shall have the meaning set forth in Clause 16.2. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Sale Notice"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;shall have the meaning set forth in Clause 15.2</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(a).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Secretary"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;shall have the meaning set forth in Clause 4.6.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Shares"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;means the shares in which the share capital of the Company is divided after the Capital Increase.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Shareholders"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;shall have the meaning set forth in Recital 3.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Shareholders' Drag-Along Right"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;shall have the meaning set forth in Clause 15.1.(b).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Shareholders Reserved Matters"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;shall have the meaning set forth in Clause 5.6. "Spanish Companies Acts" means the Spanish Companies Act 1/2010 dated July 2nd ("Real Decreto Legislativo 1/2010, de 2 de julio, por el que se aprueba el texto refundido de la Ley de Sociedades de Capital") and includes any enactment passed after that Act which may, by reason of that or any other enactment, be cited together with that Act as "the Companies Acts".</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Spanish Law"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;means any law, regulation, rule, order and/or decree, then in force and applicable in Spain.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Subsidiaries"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;means VLP and BDI Pharmaceuticals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Tag Along Right"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;shall have the meaning set forth in Clause 16</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">"Transfer"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;shall mean, with respect to any share or any interest in any share, a direct or indirect transfer or disposition in any form, including a pron-use to sell, option, sale, assignment,conveyance, pledge, mortgage, encumbrance, securitization, any purported severance or alienation of any beneficial interest (in</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">luding the creation of any derivativ</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">or synthetic interest) or the act of s</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">o </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">doing, as the context requires.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#57585a;font-weight:bold;">"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">VLP</font><font style="font-family:inherit;font-size:11pt;color:#57585a;font-weight:bold;">"</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">&#32;s</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">hall have the meaning set forth in R</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">cital 4</font><font style="font-family:inherit;font-size:11pt;color:#777880;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#57585a;">1</font><font style="font-family:inherit;font-size:11pt;color:#777880;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;text-decoration:underline;">Interpretation</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">In the Agreement, unless indicated oth</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">rwis</font><font style="font-family:inherit;font-size:11pt;color:#57585a;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">Any reference to the Agreement must be deemed to be made to the Agreement and its Schedules.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">Any reference to "Clause" or "Schedule" must be deemed to be made to a Clause of, or Schedule to the Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">Schedules: The Schedules to this Agreement are incorporated into and form an integral part of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">Wherever the terms "includes", "included'', "include" and "including" are used, they shall be deemed to be followed by the expression "without limitation".</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">Any reference to one gender includes the other, and words in the singular shall include the plural, and vice versa.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">If an obligation is qualified or formulated by reference to the use of "best endeavors", "best efforts" or another similar expression, it refers to the endeavors that a Person with the firm intention to achieve an outcome would use in similar circumstances to ensure the achievement of such outcome as soon as possible, taking into account, among other factors:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">the price, financial interest and other terms of the obligation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">the degree of risk normally entailed by the achievement of the expected outcome;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">the ability of an unrelated Person to exert an influence on the performance of the obligation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">that in no event shall any Party having committed to use best efforts be obliged to perform any payment or furnish any sort of financial guarantee to a third party in the context of the achievement of the outcome to which such Party had committed to use its best efforts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">Any reference to </font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-style:italic;">&#8220;</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">days" shall be deemed to be made to "calendar days". Any periods expressed in days shall start to be counted from the day immediately following that on which the counting starts. If the last day of a period is not a Business Day, the period in question shall be deemed to have been automatically extended until the first following Business Day. Periods expressed in months shall be counted from date to date unless in the last month of the period such date does not exist, in which case the </font><font style="font-family:inherit;font-size:11pt;color:#404040;">period shall end on the first Business Day of the immediately following month.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">Any ref</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5b;">e</font><font style="font-family:inherit;font-size:11pt;color:#404040;">rence to "from", "as from", "as of" or "through" a given date shall be understood to include such date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">The headings used in the Agreement are included for reference only and shall not form part of the Agreement for any other purpose or affect th</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5b;">e </font><font style="font-family:inherit;font-size:11pt;color:#404040;">interpretation of any of its clauses</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5b;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">Terms appearing in Spanish shall have the meanings ascribed to them in Spanish legislation.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(xi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">References to"&#8364;" or "Euro" are references to the lawful currency from time to time of the Eurozone.</font></div></td></tr></table><div><a name="sf67508d06212461ab96504c61ea0beea"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404040;font-weight:bold;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;font-weight:bold;">PURPOSE OF THE AGREEMENT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#5b5a5b;">2</font><font style="font-family:inherit;font-size:11pt;color:#404040;">.1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">Th</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5b;">e </font><font style="font-family:inherit;font-size:11pt;color:#404040;">purpos</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5b;">e </font><font style="font-family:inherit;font-size:11pt;color:#404040;">of this Agreement is to establish the terms of the collaboration between the Shareholders in order to regulate:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">the governance and administration of the Company, and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">the transfer of shares of the Company, for the purposes of providing with a stable shareholding structure and facilitating the management of the Company with the objective of maximizing value for the Shareholders; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">several other commitments of the Shareholders related to the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">In the event that any conflict or discrepancy arises between the Bylaws and this Agreement, the provisions of this Agreement shall prevail. Therefore, in the event that any of the provisions in this Agreement are not folly incorporated in Bylaws and an inconsistency arises, this Agreement shall prevail among the Shareholders and, upon request of any Shareholder, the Parties shall exercise all powers and lights available to them, in order to give effect to the provisions of this Agreement and to procure the amendment of the Bylaws to conform to this Agreement to the fullest possible extent.</font></div></td></tr></table><div><a name="sccf2e445266c43bd87a02508289f3bfd"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404040;font-weight:bold;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;font-weight:bold;">BUSINESS OF THE COMPANY</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">The Company shall be primarily engaged in the Business and any future business as may be approved by the Shareholders from time to time in accordance with the terms of this Agreement.</font></div><div><a name="s4a33a6deaf464197816dc3a9e35a821c"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">4&#160;&#160;&#160;&#160;BOARD OF DIRECTORS</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">4</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">.</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">The Company shall be governed by a Board of Directors which shall be subject to the provisions set forth in this Clause 4.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">4</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">.</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;text-decoration:underline;">Powers and responsibilities of the Board</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">: Except with respect to those matters expressly reserved to the General Shareholders Meeting by the Spanish Companies Acts, the Bylaws or this Agreement, the Board shall have the following duties:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">to propose the annual business plan for conducting the Company's business for approval by a General Shareholders Meeting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">to manage and instruct the managers and attorneys of the Company in relation with the management of</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">all aspects of the Company's operations including but not limited to the organization of proper financial records:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">to close the Company's books at the end of each year, and prepare the list of inventory, the balance sheet, profit and loss statement, the statement of changes in the net equity, the cash flow statement (if any) and a report of the Company's operations as required by the Spanish Companies Acts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">to cause all reports and documents to be filed with the proper government agencies in Spain; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">any other duties as may be set forth in the Bylaws or as may be determined by the General Shareholders Meeting, to the extent required by the Spanish Companies Acts.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">The day-to-day running and the overall direction and supervision of the Business shall be the responsibility of the Board of Directors, directly or indirectly through the CEO and any other managers, expressly acting under the principles, guidelines and instructions received from the Board and the principles set out in this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">4.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;text-decoration:underline;">Composition of the Board</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">. The Company shall, unless subsequently agreed otherwise in writing by the General Shareholders Meeting pursuant to the majorities set forth in Clause 5.6, be governed by a Board composed of three (3) members (th</font><font style="font-family:inherit;font-size:11pt;color:#5a5a58;">e </font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">"</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;font-weight:bold;">Directors</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">") that shall be appointed as follows:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">(i)&#160;&#160;&#160;&#160;Inveready shall nominate one Director for his appointment; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">(ii)&#160;&#160;&#160;&#160;BDI Holding shall nominate two Directors for their appointment;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">However, the Shareholders shall not be entitled to appoint as Director a Person who is already a (i) member of the board of any Competitor of BDI Group or (ii) a member of the management team of any Competitor of BDI Group, unless the prior approval of all the members of the Board is previously obtained in written.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">4.4&#160;&#160;&#160;&#160;With effect from the Effective Date:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">(i)&#160;&#160;&#160;&#160;The Inveready Director shall be: </font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;font-weight:bold;">Inveready Asset Management, S.G.E.I.C., S.A.</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">, Spanish company, with registered office in calle Cavallers, 50, 08034 Barcelona, holder of Spanish tax identification number A-65696007, represented by Mr. Roger Piqu&#233; Pijuan, of legal age, a Spanish national, holding taxpayer identification number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in force, and domiciled for this purposes in &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. He acts in his capacity of general attorn</font><font style="font-family:inherit;font-size:11pt;color:#5a5a58;">e</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">y of Inveready.;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">(ii)&#160;&#160;&#160;&#160;The BDI Holding Directors shall be</font><font style="font-family:inherit;font-size:11pt;color:#5a5a58;">: </font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">(a) </font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;font-weight:bold;">Mr. Pablo Gutierrez G&#243;mez</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">, of legal age, of Spanish nationality, single, with professional domicile at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Valladolid, and provided with Spanish Identification Number (D.N.I.) n&#176; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, both in force; and (b) </font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;font-weight:bold;">Mr. Ricardo Arjona Antolin</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">, of legal age, of Spanish nationality, married, with professional domicile at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, Valladolid and provided with Spanish Identification Number (D</font><font style="font-family:inherit;font-size:11pt;color:#5a5a58;">.</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">N.I.) n&#176; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#5e412f;">, b</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">oth in force.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">4.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;text-decoration:underline;">Appointments and Removal of Directors.</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">&#32;The Directors shall be appointed at a General Shareholders Meeting in accordance with the provisions of this Agreement, The Shareholders undertake to vote for the appointment or dismissal of the Directors nominated by the Sharehold</font><font style="font-family:inherit;font-size:11pt;color:#5a5a58;">e</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">r who is entitled to make the corresponding appointment or dismissal, pursuant to Clause 4.3 above.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">The Directors shall be appointed at the General Shareholders Meeting for an indefinite period of time. Each Shareholder who has the right to designate a Director shall also have the right to remove (or </font><font style="font-family:inherit;font-size:11pt;color:#5a5a58;">c</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">au</font><font style="font-family:inherit;font-size:11pt;color:#5a5a58;">s</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">e to be removed) or replace at any time and for any reason (including d</font><font style="font-family:inherit;font-size:11pt;color:#5a5a58;">e</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">ath, r</font><font style="font-family:inherit;font-size:11pt;color:#5a5a58;">e</font><font style="font-family:inherit;font-size:11pt;color:#3e3e3e;">signation, inability to act or </font><font style="font-family:inherit;font-size:11pt;color:#373737;">dismissal) such Director from its office and designate (or cause to be designated) an alternative Director in his/her place.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Each Shareholder undertakes to the other Shareholders that it shall take all practicable steps, directly or indirectly, including the exercise of voting rights in the General Shareholders' Meeting, to effect the appointments and removals of any Director designated by the entitled Shareholder.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">4.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Positions in the Board</font><font style="font-family:inherit;font-size:11pt;color:#373737;">. The Board shall appoint a chairman (the "</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Chairman</font><font style="font-family:inherit;font-size:11pt;color:#373737;">") and a Secretary (the "</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Secretary</font><font style="font-family:inherit;font-size:11pt;color:#373737;">") to the Board as follow:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The person holding the position of Chairman of the Board shall be proposed for appointment or dismissal by BDI Holding. In addition to any specific responsibilities imposed by the Spanish Companies Acts, the Chairman shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">convene General Shareholders Meetings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">convene ordinary and extraordinary meetings of the Board;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">chair the meetings of the Board and the General Shareholders Meetings in accordance with the Spanish Companies Acts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">sign the minutes of the Board Meetings upon their approval in accordance with the Spanish Companies Acts; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">sign the minutes of the General Shareholders Meetings upon their approval in accordance with the Spanish Companies Acts.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The Chairman of the Board shall not have a casting vote within the Board.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">BDI Holding, will be entitled to nominate the Secretary of the Board of the Company, who may also</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">be a person who is not a Director of the Company, in which case such non-director Secretary will not be considered in determining the presence of the quorums required for a Board Meeting to be validly held and such non-director Secretary shall not have a right to vote in the said Board. The replacement of the Secretary office shall be made by BDI Holding Directors' decision</font><font style="font-family:inherit;font-size:11pt;color:#535353;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">In addition to any specific responsibilities imposed by the Spanish Companies Acts, the Secretary shall:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">attend, as Secretary of these meetings, all meetings of the Board and all General Shareholders Meetings and record all the proceedings of such meetings in a book of minutes to be in custody for such purposes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">sign the minutes of the Board Meetings upon their approval in accordance with the Spanish Companies Acts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">sign the minutes of the General Shareholders Meetings upon their approval in accordance with the Spanish Companies Acts; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">perform such other duties and have such other powers as the Board may from tune to time determine according to the Spanish Companies Act.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(iii)&#160;&#160;&#160;&#160;The offices of Chairman and Secretary to the Board shall be initially held by </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Mr. Ricardo Arjona Antol&#237;n</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;and </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Mr. Borja D&#237;az-Guerra Heredero</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">, respectively.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">4</font><font style="font-family:inherit;font-size:11pt;color:#626266;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;text-decoration:underline;">Meetings of the Board.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">&#32;Each of the Shareholders shall cause each of its designated Directors to adopt and comply with the following rules in relation to the meetings of the Board:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(i) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The Board will meet at least 4 times per Financial Year and at least once every calendar quarter ("</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Ordinary Board Meetings</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">") and whenever called by the Chairman, at the Chairman's own initiative or upon petition of any Director ("</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Extraordinary Board Meetings</font><font style="font-family:inherit;font-size:11pt;color:#626266;">"</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">) indicating the items on the agenda to be discussed. In the latter case, the Extraordinary Board Meeting shall be held within the next twenty (20) days following the date of request of the said Director.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The Board will be called by written notice not less than 15 days In advance of the meeting date, which notice shall be served on all the Directors at the address notified from time to tim</font><font style="font-family:inherit;font-size:11pt;color:#626266;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">by each Director to the Chairman and Secretary.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The summons shall be effected (a) by any means as may be required by Spanish Companies Acts and (b) by means of a notice sent by letter, fax, e</font><font style="font-family:inherit;font-size:11pt;color:#7c7c83;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">mail or any other written or electronic means with confirmation of receipt at the address designated by such Director for such purposes. The notice shall state: (a) date, place and hour of the meeting, (b) the agenda to be discussed together with the relevant supporting materials for discussion at such meeting in English language, (c) the name of the person or persons who have summoned the meeting, as well as (d) confirmation of date, place and hour of a rescheduled Board Meeting in accordance with Clause 4.10.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Any Director attending a meeting shall have the right to propose additional topics for discussion at any meeting which were not originally included in the agenda for that meeting and no unanimity or majority shall be required for the inclusion of any such additional topics</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(v)&#160;&#160;&#160;&#160;All Board meetings shall be conducted in English.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">4.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Universal Board Meetings</font><font style="font-family:inherit;font-size:11pt;color:#373737;">. In the case of a </font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">"Universal Board Meeting" </font><font style="font-family:inherit;font-size:11pt;color:#373737;">(i.e. a meeting where all the Directors are present or represented by proxy and unanimously agree to hold a Board Meeting), none of the formalities and requirements related to the prior notice set forth in Clause 4.7 shall apply.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">A</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">resolution in writing ("</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">por</font><font style="font-family:inherit;font-size:11pt;color:#373737;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">escrito y sin sesi&#243;n") </font><font style="font-family:inherit;font-size:11pt;color:#373737;">signed by all the Directors of the Board shall be as valid and binding as if it had been passed at a duly convened meeting of the Board, provided that all Directors are notified in advance of the resolutions being adopted in such manner and do not oppose such system. These resolutions shall also be recorded in minutes.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">4.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Venue</font><font style="font-family:inherit;font-size:11pt;color:#373737;">. The meetings may be conducted physically at the registered office of the Company or such other place as the Board may from time to time determine within the territory of Spain or by electronic means (videoconference or conference call).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">4</font><font style="font-family:inherit;font-size:11pt;color:#616161;">.</font><font style="font-family:inherit;font-size:11pt;color:#373737;">10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Attendance and Quorum</font><font style="font-family:inherit;font-size:11pt;color:#373737;">. A Director may attend in person or by proxy. Such proxy may be granted to another Director, a copy of which shall be delivered to the Chairman and the Secretary of the Board at the commencement of the meeting</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Directors may participate in and vote at Board Meetings by means of a conference telephone or video conference or any communication equipment, provided that all Directors have the required technical equipment and all persons participating in the meeting can identify each other, which shall be expressly noted in the minutes of the relevant meeting and the certificate of such minutes. In such case, the meeting of the Board shall be deemed a single meeting held in the registered office of the Company. Any Director so participating in a meeting shall be deemed to be present in person and shall count for quorum purposes.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">For such purposes, the Shareholders undertake to hold a General Shareholders Meeting with the purposes to amend the Bylaws setting forth the following provision (in Spanish):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">"Board Directors' meetings could be held simultaneously in several halls as long as it is guaranteed </font><font style="font-family:inherit;font-size:11pt;color:#414141;font-style:italic;">by aud</font><font style="font-family:inherit;font-size:11pt;color:#58585b;font-style:italic;">i</font><font style="font-family:inherit;font-size:11pt;color:#414141;font-style:italic;">o</font><font style="font-family:inherit;font-size:11pt;color:#58585b;font-style:italic;">-</font><font style="font-family:inherit;font-size:11pt;color:#414141;font-style:italic;">visual or telephonic  methods, the interactivity and intercommunication b</font><font style="font-family:inherit;font-size:11pt;color:#58585b;font-style:italic;">e</font><font style="font-family:inherit;font-size:11pt;color:#414141;font-style:italic;">tween them</font><font style="font-family:inherit;font-size:11pt;color:#69696e;font-style:italic;">, </font><font style="font-family:inherit;font-size:11pt;color:#414141;font-style:italic;">so they are held in real time and therefore, in a sole act. In this case if will be stated in the </font><font style="font-family:inherit;font-size:11pt;color:#bdbdc3;font-style:italic;">'</font><font style="font-family:inherit;font-size:11pt;color:#414141;font-style:italic;">cali the connexion system and if necessary, the places where the technical methods are a</font><font style="font-family:inherit;font-size:11pt;color:#69696e;font-style:italic;">v</font><font style="font-family:inherit;font-size:11pt;color:#414141;font-style:italic;">ailable in order to assist and participate in the meeting".</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">The Persons invited to attend a meeting of the Board of Directors shall be subject to the  confidentiality provisions applicable to  directors under the  Spanish Companies Law and,  furthermore,  to the confidentiality provisions of  this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">Each Shareholder acknowledges and agrees that the Board shall only be deemed to  be  validly constituted and entitled  to  pass any resolutions, if at least  3 Directors are present (whether in person or by proxy), and each Shareholder hereby covenants to the other Shareholders  to ensure  that the Directors nominated by it pursuant to Clause 4.3  abstain from participating in Board Meetings and from voting any resolutions if the Board is not validly constituted in accordance with this Clause.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">If within one hour of the time appointed for holding a Board Meeting, a quorum as specified above is not present, the meeting shall be adjourned for 14 days and reconvened at the same time of day and place and if at such rescheduled meeting a quorum as per the above is not present within 30 minutes of the time appointed for the meeting, a valid quorum. shall be deemed constituted if at least 2 Directors are present.  However no resolution shall be passed at such meeting on any matter other than the matters specifically set forth in the notice to the Directors, and no additional matter shall be taken up at such adjourned meeting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#414141;">4.11</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;text-decoration:underline;">Ordinar</font><font style="font-family:inherit;font-size:11pt;color:#58585b;text-decoration:underline;">y</font><font style="font-family:inherit;font-size:11pt;color:#58585b;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#414141;text-decoration:underline;">Vote Requirements</font><font style="font-family:inherit;font-size:11pt;color:#414141;">. Unless this Agreement, the Bylaws or the Spanish Companies Acts require a greater majority, resolutions not addressing Board Reserved Matters will be passed by a simple majority of the attending Directors, provided that quorum requirements set forth in Clause 4</font><font style="font-family:inherit;font-size:11pt;color:#58585b;">.</font><font style="font-family:inherit;font-size:11pt;color:#414141;">10 are met.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#414141;">4.12</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;text-decoration:underline;">Board Reserved Matters</font><font style="font-family:inherit;font-size:11pt;color:#414141;">. Unless this Agreement expressly states differently, any decision by the Board of Directors (i) shall be reserved to the competence of the Board as a collective body, (ii) shall not be delegated to any one or more Board members  or executive committees  or managing directors  and it shall be approved by the majority of the Board members.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#414141;">However, in addition to the requirements indicated in the previous paragraph, the Board  of Directors  shall not take, and shall cause the Company and its </font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">Affiliates not to take, any of the following resolutions that are qualified as Board reserved matters (the "</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-weight:bold;">Board Reserved Matters</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">") and,  therefore, can only be adopted by the affirmative vote of three (3) Directors:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(i)&#160;&#160;&#160;&#160;change in the registered office location;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(ii)&#160;&#160;&#160;&#160;any specific capital expenditure (whether through acquisition or lease) which would result in obligations for the Company, individually or in aggregate, regarding such specific capital expenditure of more than 250,000 Euros per transaction, or 500,000 Euros cumulatively over a period of</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">1 year;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(iii)&#160;&#160;&#160;&#160;sale or transfer to a third Person of any individual asset of the Company with a market value, at the time of Its sale or transfer exceeding 300,000 Euros;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(iv)&#160;&#160;&#160;&#160;appointment, dismissal,  determination of the remuneration and benefits, and any other actions related to the Key Employees;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(v)&#160;&#160;&#160;&#160;any negotiation and subscription of loans, or credit facilities or guarantees for a value of</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">more than 100,000 Euros;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(vi)&#160;&#160;&#160;&#160;approval of the annual budget of the Company and its modifications; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(vii)&#160;&#160;&#160;&#160;incorporation and sale or other transfer disposition of any subsidiaries; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(viii)&#160;&#160;&#160;&#160;recruiting any employee with an annual cost exceeding&#8364; 65,000;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(ix)&#160;&#160;&#160;&#160;Execution of loans or guarantees in favor of the Shareholders, Directors or employees of the Company or Affiliates exceeding &#8364; 5,000 &#8364;, unless they are executed in the ordinary course of business;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(x)&#160;&#160;&#160;&#160;Granting of any security over the assets of the Company, except for the guarantees to be granted in the ordinary course of business of the Company;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(xi)&#160;&#160;&#160;&#160;Disposal by any means of any Intellectual Property of the Company;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(xii)&#160;&#160;&#160;&#160;starting insolvency proceedings  or taking steps aimed at a shareholders&#8217; voluntary winding-up or which might lead to the winding-up of Company, except if such approval of resolutions  results  from  the application  of a mandatory legal provision;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">(xiii)&#160;&#160;&#160;&#160;transfer or disposal, by any means, directly or indirectly, of any share in the corporate </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">&#183;</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">capital of any of the Affiliates of VLP, if any, or of</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3a3a3a;">any interest in them; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(xiv)&#160;&#160;&#160;&#160;exercising the vote in the General Shareholders Meeting and management bodies of the Affiliates in respect of Shareholders Reserved Matters or Board Reserved Matters.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(xv)&#160;&#160;&#160;&#160;Signing  agreements  or  contracts  with  related  parties,  including administrators, partners and directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(xvi)&#160;&#160;&#160;&#160;Investments that exceed SEVENTY FIVE THOUSAND euros (&#8364; 75,000) not included  in  the  annual  budget.  Expenses,  transactions,  loans,  and  any commercial operation for amounts over &#8364; 75,000.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">4.13</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;text-decoration:underline;">Other Meetings of the Directors</font><font style="font-family:inherit;font-size:11pt;color:#404040;">. In addition to the Ordinary or Extraordinary Board Meetings, the Directors of the  Board may hold more frequent Informal meetings to monitor and support the operation of the Business and to direct the management of the Company. Such informal meetings of the Directors shall not be qualified as Board Meetings as provided for under the Spanish Companies Acts and, therefore, during these meetings, no corporate resolutions shall be passed by the Directors. The terms and conditions set forth in this Agreement for the calling of Board Meetings shall apply </font><font style="font-family:inherit;font-size:11pt;color:#404040;font-style:italic;">muiatis muiandi </font><font style="font-family:inherit;font-size:11pt;color:#404040;">to those other meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">4.14</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;text-decoration:underline;">Directors' compensation</font><font style="font-family:inherit;font-size:11pt;color:#404040;">. The Directors will receive no compensation for their position as  members  of the Board,  unless otherwise agreed at a  General Shareholders Meeting. Consequently, the Shareholder who appointed the corresponding  Director shall bear  the </font><font style="font-family:inherit;font-size:11pt;color:#626368;">c</font><font style="font-family:inherit;font-size:11pt;color:#404040;">orr</font><font style="font-family:inherit;font-size:11pt;color:#626368;">e</font><font style="font-family:inherit;font-size:11pt;color:#404040;">sponding  Director's costs and expenses incurred in attending Board Meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">4.15</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;text-decoration:underline;">Disclosure  of Information</font><font style="font-family:inherit;font-size:11pt;color:#404040;">.  Each Director shall be entitled  to disclose any information relating to the Company and its affairs and financial position to the Shareholder who appointed such Director.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">4.16</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;text-decoration:underline;">Conduct of Directors</font><font style="font-family:inherit;font-size:11pt;color:#404040;">. Each Shareholder covenants that, unless so requested by the Shareholder nominating a Director, it will not carry out or cause to be carded out any act whereby such Director will be removed from office other than for reasons of fraud, wilful misconduct or gross negligence. For the avoidance of doubt, the corresponding Shareholder may appoint and remove their Directors at their own discretion.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">The corresponding Shareholder shall, so far as such Shareholder is lawfully able, ensure that Directors nominated by such Shareholder (if applicable):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(i)&#160;&#160;&#160;&#160;Is not wilfully or unreasonably fail to attend a Board meeting in order to prevent any resolution to be adopted; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">(ii)&#160;&#160;&#160;&#160;carry out such Director's duties in accordance with the principles, terms, conditions and obligations set out in this Agreement, the Bylaws and the Spanish Companies Acts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><a name="sa11735d746174cb1956757db575f3ce0"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">GENERAL SHAREHOLDERS' MEETING.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">The General Shareholders' Meeting of the Company will be held at least once a year within the 6 months after the end of each Financial Year for the purposes: (i) of discussing and approving the annual accounts, (ii) application of the year results, (iii) approval of the composition of the Board, as well as (iv) resolving any other matters that may be compulsory under the Spanish Companies Acts or otherwise validly resolved in the General Shareholders Meeting.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">The Shareholders may attend general shareholders meetings of the Company (i) in person; (ii) by videoconference or by telephone, provided that the persons taking part in the meeting can hear each other and each attendee recognizes the identity of the other attendees; (iii) or represented by another person, even if such person is not a Shareholder, provided that such person is duly empowered by the Shareholder through a duly granted proxy. The attorney must present evidence satisfactory to the Chairman, assisted by the Secretary, of his/her authority to act for and on behalf of the relevant Shareholder.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">Summon of the General Shareholders' Meetings:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">A General Shareholders&#8217;  Meeting may be summoned by the Chairman of the Board at the Chairman's own initiative or pursuant to the written request of Shareholders representing at least 3% of the Company's share capital indicating the items on  the  agenda  to be  discussed.  In the  latter case,  the  General Shareholders&#8217;  Meeting shall be held within 45 days following the date of</font><font style="font-family:inherit;font-size:11pt;color:#393939;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#393939;">request of the such Shareholders.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">The summons shall be effected (a) by any means as may be required by Spanish Companies Acts and (b) by means of a notice sent by letter, fax, e-mail or any other written or electronic means that may ensure the reception of the notice by all Shareholders  at the address  designated by such shareholder for this purpose. The notice shall state: (a) date, (b) place and (c) hour of the meeting, (d) the agenda to be discussed together with the relevant supporting materials, (e) the  name  of the  person  or  persons  who  have  summoned the  General Shareholders' Meeting, as well as (f) confirmation of date, place and hour of a rescheduled General Shareholders' Meeting in accordance with Clause 5.4.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">A notice summoning a General Shareholders' Meeting must be delivered to the Shareholders at least 30 days before the date of such meeting (unless a longer term is compulsory under the Spanish Companies Act)</font><font style="font-family:inherit;font-size:11pt;color:#5d5e61;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">In the case of a </font><font style="font-family:inherit;font-size:11pt;color:#3d423e;font-style:italic;">"Universal Shareholders' Meeting" </font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">(i.e. a meeting where all the shareholders are present or represented by proxy and unanimously resolve t</font><font style="font-family:inherit;font-size:11pt;color:#5d5e61;">o </font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">hold a General Shareholders Meeting), none of the formalities and requirements set out in this Clause 5.2 shall apply.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;text-decoration:underline;">Venue of the General Shareholders' Meetings</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">: The General Shareholders' Meeting shall take place at the Company's registered office or elsewhere as the Chairman may reasonably determine within the territory of Spain.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">5.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">The following rules apply to the quorum of the General Shareholders' Meetings:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">No business shall be discussed at any General Shareholders' Meeting unless a sufficient quorum is present.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Each  Shareholder  acknowledges  and  agrees that  the Shareholders</font><font style="font-family:inherit;font-size:11pt;color:#747980;">' </font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Meetings shall be deemed to be validly constituted if at least 66%  of th</font><font style="font-family:inherit;font-size:11pt;color:#5d5e61;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">share capital of  the Company is present or duly represented (unless a higher quorum is compulsory under the Spanish Companies Acts).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">A Shareholder may be represented in a Shareholders' Meeting by its legal representative, including any director, officer or by written proxy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">If within one hour of the time appointed for holding a Shareholders</font><font style="font-family:inherit;font-size:11pt;color:#747980;">' </font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Meeting, a quorum as specified above is not present, the meeting shall be adjourned for 14 days and reconvened at the same time of day and place. If at such rescheduled meeting a quorum is not present within 30 minutes after the lune appointed for the meeting, the Shareholders present shall constitute a valid quorum without the requirement set forth in Clause 5.4(ii) above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">5.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;text-decoration:underline;">Adoption of Resolutions</font><font style="font-family:inherit;font-size:11pt;color:#5d5e61;">: </font><font style="font-family:inherit;font-size:11pt;color:#3d423e;text-decoration:underline;">Ordinary Vote Requirements</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">. Each Share shall entitle the right to cast one (1) vote at the General Shareholders' Meeting.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d423e;">Unless this Agreement, the Bylaws and/ or the Spanish Companies Acts require a greater majority, resolutions not addressing any of the Shareholders Reserved Matters (as  defined in Clause  5.6) shall be passed  by affirmative  vote  of Shareholders- representing a </font><font style="font-family:inherit;font-size:11pt;color:#bebdc1;">'</font><font style="font-family:inherit;font-size:11pt;color:#3d423e;">simple majority of the share capital of the Company, that is, over 50% of the share capital.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">5.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Adoption of Resolutions</font><font style="font-family:inherit;font-size:11pt;color:#373737;">: </font><font style="font-family:inherit;font-size:11pt;color:#373737;text-decoration:underline;">Shareholders Reserved Matters</font><font style="font-family:inherit;font-size:11pt;color:#373737;">. Notwithstanding the above, the following matters shall only be adopted with the favorable vote of Shareholders representing 85% per</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">cent of the share capital of the Company and shall be deemed as reserved matters (the "</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Shareholders Reserved Matters</font><font style="font-family:inherit;font-size:11pt;color:#373737;">"):</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Increase  or  reduction of the  share capital of  the  Company, merger, dissolution, liquidation or the global assignment of assets and liabilities (unless a mandatory rule requires these transactions); substantially modify the  corporate purpose of the  Company: issuance of bonds or debt convertible into  shares; the abolition of the preferential assumption or subscription rights and the exclusion of shareholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Change in the registered office location;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Creation or modification of special classes of shares  or quotes with or without preferential rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Amendment of the structure of the  Board  of the  Company and the remuneration of the Directors, except when made in accordance with this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Establishment or change  of the dividend policy  of the Company and declaration of dividend other than in accordance with. Clause 9 hereof and any other distribution, payment or disbursement of any kind or nature to the Shareholders (as shareholders) which is not applied in similar terms (pari passu) to all of them;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Appointment of the Auditors of the Company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Authorization of a Disinvestment  other  than  in accordance  with the transfer of shares provisions in this Agreement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Granting any power of attorney or authorization or similar authority to any person or entity to carry out any action which is a Shareholders Reserved Matters.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Material changes in bylaws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Material modification of the corporate purpose of the Company.</font></div></td></tr></table><div><a name="sdad24ca060aa47be9181ea1576789367"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">CONFLICT OF INTEREST</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">6.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">In the event that a resolution must be adopted on an agreement that has been or is to be signed between the Company and (i) any Shareholder or a Director, (ii) a </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">related person (as per the definition of "related person" in article 231 of th</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5d;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Spanish Companies Law) or a company from the relevant Shareholder or Director's group (as per the definition of "group" in article 42 of the Commercial Code), the Shareholder or Director (as the case may be) in question shall not have voting rights on any resolution that is taken by the General Shareholders Meeting or the Board of Directors on such matter.</font></div></td></tr></table><div><a name="sd963b760503542d296cc22210319698e"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">MANAGEMENTOFTHECOMPANY.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">7.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">On the Effective Date, the  Board of Directors will approve to grant general powers for the management of the day to</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">day business affairs of the Company to the Key Employees.</font></div></td></tr></table><div><a name="s5cd29b538fdb4ac680893c7bb03f7611"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">INFORMATION RIGHTS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">8.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Each Shareholder shall have full access to the books and records of the Company. The Company  shall permit in reasonable terms access to  the Companies</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5d;">' </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">premises and to internal and external personnel (i.e. consulting firms, auditors, etc.) representing such Shareholder upon their prior request with time enough .in advance (which must include a list of the information required to be reviewed) to allow the Company to prepar</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5d;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">an</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5d;">y </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">required report or their respective financial statements, all in accordance with customary practices in the industry.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><a name="sd8d1b8c4c6e74730ac5e84c5bafe68f9"></a></div><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">DIVIDEND POLICY</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">9.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">To the extent permitted by the </font><font style="font-family:inherit;font-size:11pt;color:#5b5a5d;">S</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">panish Companies Acts, and unless otherwise agreed by the Shareholders as a Shareholders Reserved Matter pursuant to Clause 5.6, the Parties agree that until Financial Year 2020 no dividend shall be distributed by the Shareholders in the Company, and for the Financial Year 2020 onwards the Parties agree that the Company will distribute and declare an annual dividend equivalent to at l</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5d;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">ast 50% of the net profits of the Company, provided that (i) the Company shall not declare, pay or make any dividend or other distribution in. excess of 80% of the Company's Free Cash-Flow in any Financial Year, and (ii) there is sufficient cash available in the Company' to proceed with such distribution. To the extent permitted by law, the Shareholders expressly undertake not to invoke the appli</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5d;">c</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">ation of Article 348 bis of the Spanish Companies Act in order to comply with this pro</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5d;">v</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">ision.</font></div></td></tr></table><div><a name="sb75e280fc6254be2921fccf2eb18c52f"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">ACCOUNTING AND FINANCIAL REPORTING</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">10.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The fiscal year of the Company shall be January 1st to December 31st each year ("</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;font-weight:bold;">Financial Year</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">") and all the books and r</font><font style="font-family:inherit;font-size:11pt;color:#5b5a5d;">ec</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">ord of the Company shall be closed </font><font style="font-family:inherit;font-size:11pt;color:#393939;">at the end of</font><font style="font-family:inherit;font-size:11pt;color:#393939;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#393939;">each interim calendar quarter of</font><font style="font-family:inherit;font-size:11pt;color:#393939;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#393939;">March 31st, June 30th and September 30th and at the year-end at December 31st every year.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">10.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">The Parties hereby undertake to appoint an Auditor that will be in charge of auditing the annual financial statements and footnotes of the Company each Financial Year. The General Shareholders Meeting shall appoint the Auditor of the Company even if, according to the Spanish Companies Acts, the appointment of auditors is not mandatory.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">10.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">The Parties shall ensure that quarterly Interim Financial Statements and the Audited Annual Financial Statements will be prepared by the Company and</font><font style="font-family:inherit;font-size:11pt;color:#666666;">. </font><font style="font-family:inherit;font-size:11pt;color:#393939;">provided to the Board of Directors and Investors within 30 days after each interim quarter and 45 days after each year-end, The Audit Committee of the VLP' s Board of Directors will approve the quarterly interim Financial Statements and the Audited Financial Statements, within the timeframes above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">10.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">The Parties shall ensure that the accounting records of the Company shall be prepared in accordance with Spanish generally acceptable Accounting Principles. The books and records and Financial Statements of the Company shall be kept in Euros.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">10.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">The Company will assist Investors by providing financial information and documentation necessary to comply with US financial reporting disclosures, including but not limited to Variable Interest Entity ("VIE") in a timely manner.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">10.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">All records and supporting documents, including but not limited to accounting books and records, invoices, cash books, inventory records, bank accounts and receipts shall be kept at the head office of the Company for the term required by the Applicable Law.</font></div></td></tr></table><div><a name="s6d5fbce6a41e49a5b67e2a22c2974a32"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">11</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">11.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">As of the Effective Date each of Dyadic, Inveready and BDI Holding represent and warrant to the other Parties that</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">It is a duly organized corporation existing in good standing under the Applicable Law of the jurisdiction indicated in the preamble hereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">It has the corporate power, legal capacity and authority to enter into and perform the obligations contemplated herein, and to execute any other agreement, document, instrument </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-top:12px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;color:#393939;">or certificate contemplated by this </font><font style="font-family:inherit;font-size:11pt;color:#404040;">Agreement or to be executed in connection with the completion of the transactions contemplated by this Agreement. This Agreement and any other agreement, document, instrument or certificate contemplated by this Agreement or to be executed in</font><font style="font-family:inherit;font-size:11pt;color:#404040;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#404040;">connection with the completion of the transactions contemplated by this Agreement, when executed, will constitute legal, valid and binding obligations of such Party, enforceable against such Party in accordance with their respective terms;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">The execution and performance of this Agreement do not contravene or conflict with any provisions of their Applicable Law or of its bylaws or of any instruments or contracts binding it;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">The execution and performance of this Agreement have been validly authorized by all necessary corporate action and that this Agreement is valid, binding and enforceable against such Party;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">It is not aware of any matter or fact likely to prohibit or restrain its ability to enter into or perform obligations under this Agreement or any other agreement, document, instrument or certificate contemplated by this Agreement or complete the transactions contemplated hereunder and thereunder; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">It is not subject to bankruptcy, insolvency or similar proceedings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">11.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;font-weight:bold;">Each of the Shareholders acknowledges that the other Shareholders in entering into this Agreement have relied on the warranties mentioned in this Section, and vice versa.</font></div></td></tr></table><div><a name="s4050cc8cd4b3427b928931b8b366fbad"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404040;font-weight:bold;">12</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;font-weight:bold;">OBLIGATIONS OF EACH PARTY.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">12.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">Each Party shall undertake:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">To perform and observe any terms, conditions and provisions as provided in this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">To take all necessary steps to give full effect to the provisions of this Agreement, including, without limitation, by way of executing all such documents and doing all such acts and things as may reasonably be required to give effect to the provisions of this Agreement:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#404040;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">To cause any person representing that Party at a General Shareholders Meeting and each Director nominated by such Party </font><font style="font-family:inherit;font-size:11pt;color:#5b5a5d;">t</font><font style="font-family:inherit;font-size:11pt;color:#404040;">o act in accordance with and give effect to the provisions of this Agreement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">To ensure that the Company will act and comply with the terms and conditions of this Agreement throughout the term of this Agreement, as well as any resolution adopted by the Board of Directors and/ or the General Shareholders Meeting.</font></div></td></tr></table><div><a name="s74beb68dc18e4a949a10786ec57b9606"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">13</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;font-weight:bold;">PRE-EMPTIVE RIGHTS FOR CAPITAL INCREASE.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#393939;">13.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#393939;">Each Shareholder shall have the right to subscribe for all or any part of its pro rata share of newly issued shares that the Company may, from time to time, propose to issue in accordance with the Bylaws and the Spanish Companies Acts.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><a name="s268f013a04cd43d0ab2b30c48ff11c7c"></a></div><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">14</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LOCK-IN PERIOD AND FUTURE TRANSFERS OF SHARES</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">General Terms</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Parties may only transfer their Shares in compliance with the terms of Clauses 14, 15 and 16 herein.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Lock-in</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as otherwise provided in this Agreement, BDI Holding shall not be entitled to make any Transfer of any of its Shares in whole or in part until a year after (i) the Investors hold less than 10% of the total Shares of the Company, (ii) the Investors have transferred all their shares in the Company or (iii) 5 years, whichever happens first (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Lock-In Period</font><font style="font-family:inherit;font-size:11pt;">").</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">After the Lock-In Period:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">none of the Shareholders shall make any Transfer of any of its Shares in whole or in part to any person who is not a party to this Agreement without first obtaining from the transferee the execution of a Deed of Adherence substantially in the form attached hereto as Schedule III and as long as such Shareholder has duly complied with the provisions for the transfer of Shares included in the Bylaws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">None of the Shareholders shall be entitled to transfer or offer to transfer such Shareholder's Shares to any Person to which any of the following standards is applicable:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Such Person is, directly and indirectly, a Competitor of the Company, including a Person who is a partner, shareholder member, employee, agent, trustee or consultant to a Competitor; provided however that if such Person owns solely for investment less than 5% of any class of securities of any Competitor traded on any [national] securities exchange, then such Person shall not be barred under this Clause as an indirect Competitor;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Such Person or any of its Affiliates is declared by the relevant courts to be engaged in criminal activities or is declared to be Controlled by Person(s) engaged in criminal activities, and vice versa; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Such Person or any of its Affiliates is considered in the relevant business community to be disreputable, unethical, or dishonest.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">11.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Deed of Adherence shall be in favour of the Company and the Parties to this Agreement and shall be delivered to the Company at its registered office.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As an exception to the provisions included in Clauses 14.2 and 14.3 above, any Shareholder shall be entitled to freely transfer its Shares, in whole or in part, at any time without applying any pre-emptive right of the other Shareholders, as long as the Transfer is a Transfer to an Affiliate, director or employee of a Shareholder and:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the relevant Affiliate shall execute a Deed of Adherence to this Agreement, substantially in the form attached hereto as Schedule III, simultaneous with such Transfer before a Spanish public notary, which costs shall be borne by the said relevant Affiliate;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">such Affiliate: (w) is not insolvent or unable to pay its debts within the meaning of the Spanish Insolvency Act (</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Ley 22/2003, de 9 de Julio, Concursal</font><font style="font-family:inherit;font-size:11pt;">) (or under the insolvency laws of any applicable jurisdiction or has stopped paying debts as the fall due); (x) no order has been made, petition presented or resolution passed for its insolvency declaration; (y) no insolvency administrator (or similar agent or receiver under the insolvency laws of any applicable jurisdiction) has been appointed by an official receiver in respect of the said Affiliate or all or any of its assets and no steps have been taken to initiate any such appointment and no individual voluntary arrangement has been proposed; nor (z) has become subject to any analogous proceedings (including any liquidation process), appointments or arrangements under the laws of any applicable jurisdiction;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">14.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any Transfer by the Parties in contravention of this Agreement shall be null and void </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">ab initio</font><font style="font-family:inherit;font-size:11pt;">&#32;and shall not bind or be recognized by the Company.</font></div></td></tr></table><div><a name="scb61f6b9cc734e18a46005d5ba26b0a1"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3a403b;font-weight:bold;">15&#160;&#160;&#160;&#160;DRAG-ALONG RIGHTS.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">15.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The Parties expressly agree as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">If after 24 months from the Effective Date, a third Person offers to purchase 100% of the Shares, then Inveready shall have the right ("</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Inveready Drag Along Right</font><font style="font-family:inherit;font-size:11pt;color:#373737;">") to force all the other Shareholders to sell and they shall be obliged to sell to such third Person the Shares owned by them, subject to the fulfillment of the following requirement (if applicable).</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">If the Inveready Drag Along Right is exercised by Inveready before 36 months from the Effective Date, the Inveready Drag Along Right shall only be binding upon the other Shareholders if the price to be paid by the third Person for all the Shares of the Company is</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">equal or higher than 8,000,000 Euros (under a cash free/debt free basis).</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">For offers by a third Person on or after 36 months from the Effective Date, the Inveready Drag Along Right will have no price restriction.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">If a third Person offers to purchase 100% of the Shares, then any of the Shareholders shall have the right ("</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Shareholders' Drag-Along Right</font><font style="font-family:inherit;font-size:11pt;color:#373737;">") to force all the oilier Shareholders to sell and they shall be obliged to sell to such third Person the Shares owned by them, as long as the price to be paid by the third Person for all the Shares of the Company is</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">equal or higher than 20,000,000 Euros (under a cash free/</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">.</font><font style="font-family:inherit;font-size:11pt;color:#373737;">debt free basis); or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">If Shareholders representing at least 50,1 % of the share capital of the Company adopts the decision to proceed with a Disinvestment by way of offering through an investment bank (the </font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">"Investment Bank"</font><font style="font-family:inherit;font-size:11pt;color:#373737;">) all the Shares of the Company, then the Shareholders that vote favourably for such Disinvestment shall have the right (the </font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">"Drag-Along Right"</font><font style="font-family:inherit;font-size:11pt;color:#373737;">) to carry out such Disinvestment and to force the other Shareholders to sell to any third Person identify by the Investment Bank all the Shares owned by</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">any of them. To these effects, all Shareholders will be obligated to sell their shares and no right of first refusal shall be in place.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">15.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The Parties expressly agree that the exercise of the Inveready' s Drag Along Right, the Shareholders' Drag Along Right or the Drag Along Right</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:11pt;color:#373737;">shall be carried out as follows</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The Party or Parties exercising any of the foregoing rights (the "</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Exercising Party</font><font style="font-family:inherit;font-size:11pt;color:#373737;">") shall notify all the other Shareholders in writing of its/</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#373737;">their election to sell its Shares (the "Sale </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-top:12px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Notice") and shall include in t:he Sale Notice a statement of its intention to exercise such right The Sale Notice shall set </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">forth the id</font><font style="font-family:inherit;font-size:11pt;color:#5e6266;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">ntity of the third Person and all other material terms and conditions of the Sale (particularly those related to the price, the terms of payment of th</font><font style="font-family:inherit;font-size:11pt;color:#5e6266;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">price, the representations and warranties and the related indemnity obligations), and the sale shall occur on the same terms and conditions applicable to the sale of the Exercising Party's Shares to the third Person;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">Upon exercise by the Exercising Party of its right, all the other Shareholders shall be obliged to sell all their Shares in the Company to the third Person included in the Sale Notice, simultaneously to the transfer to the third Person of the Shares held by the Exercising Party, at the same price, pro rata and on the same other terms and conditions as may have been agreed to by the Exercising Party and the third Person for the Sale, including the terms of payment of the price, the representations and warranties and the related indemnity obligations (if any) in favor of the third Person, which shall be provided and assumed by the Shareholders pro rata to the Shares sold by each of them over the total number of Shares sold by them and with no joint and several liability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">15.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">In case of exercise of the Inveready's Drag Along Right, the Shareholders' Drag Along Right or the Drag Along Right, the Transfer of all the Shares shall not be subject to the application of the pre-emptive right ("</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;font-style:italic;font-weight:bold;">derecho </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;font-weight:bold;">de </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;font-style:italic;font-weight:bold;">adquisicion preferente</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;font-style:italic;">") </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">included in the Company's Bylaws in favour of the other Shareholders, except for in the case of exercise by Inveready of the Inveready's Drag Along Right if the price to be paid by the third Person for all the Shares of the Company is lower than 8,000,000 Euros (under a cash free/ debt .free basis), in which case the pre-emptive right included in the Company's Bylaws shall apply so the others Shareholders having the right to purchase the Inveready's Shares under the terms and conditions includ</font><font style="font-family:inherit;font-size:11pt;color:#5e6266;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">d therein.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">15.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">Liquidation Preference: In th</font><font style="font-family:inherit;font-size:11pt;color:#5e6266;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">case of a liquidation event (merger, acquisition, divestment, spin out, sale of the Company, Initial Public Offering, or dissolving of the Company, reduction of the share capital with return of contributions), or distribution of dividends, the distribution will be as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d3d3d;">In the first place, Investors and BDI Holding (for the amount invested) will be entitled to receive the amounts in cash provided to the Company to subscribe their shares. As well as the Preferential Dividends (in accordance with clause 15.5) accrued and not paid up to the date of the mentioned distribution.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The remaining will be distributed among all Shareholders pro-rata in proportion to their shares in the Company</font><font style="font-family:inherit;font-size:11pt;color:#464646;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">15.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Preferential Div</font><font style="font-family:inherit;font-size:11pt;color:#464646;">i</font><font style="font-family:inherit;font-size:11pt;color:#373737;">dends: The Investors and BDI Holding (for the amount invested in the Company) will have the right to preferentially receive a yearly dividend of 8% on the capital invested by them in the Company</font><font style="font-family:inherit;font-size:11pt;color:#464646;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">15.6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The Parties expressly agree that the actions mentioned in provisions 15</font><font style="font-family:inherit;font-size:11pt;color:#464646;">.</font><font style="font-family:inherit;font-size:11pt;color:#373737;">4</font><font style="font-family:inherit;font-size:11pt;color:#464646;">. </font><font style="font-family:inherit;font-size:11pt;color:#373737;">and 15.5 above shall be carried out ensuring the optimization of any legal, tax and accounting impact for the Parties.</font></div></td></tr></table><div><a name="sf6ad613735d44cd4afb321002dfb872b"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">16</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">TAG-ALONG RIGHT.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">16.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Without prejudice to the pre</font><font style="font-family:inherit;font-size:11pt;color:#464646;">-</font><font style="font-family:inherit;font-size:11pt;color:#373737;">emption right over any Transfer of Shares as established in the Bylaws and in case that ne</font><font style="font-family:inherit;font-size:11pt;color:#464646;">i</font><font style="font-family:inherit;font-size:11pt;color:#373737;">ther any Shareholder nor the Company exercise such right, if any of the Shareholders decides to Transfer any of its Shares then such Shareholder shall obtain from a good faith third Person (the "</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Offerer</font><font style="font-family:inherit;font-size:11pt;color:#373737;">") a written offer (the "</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Offer</font><font style="font-family:inherit;font-size:11pt;color:#373737;">") to purchase any such Shares from such Shareholder (the "</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Offered Shares</font><font style="font-family:inherit;font-size:11pt;color:#373737;">"), which Offer shall include the purchase of Shares held by </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;color:#373737;">each of the other Shareholders pro rata to their respective shareholding interests over the total share capital of the Company</font><font style="font-family:inherit;font-size:11pt;color:#464646;">. </font><font style="font-family:inherit;font-size:11pt;color:#373737;">In this sense</font><font style="font-family:inherit;font-size:11pt;color:#464646;">, </font><font style="font-family:inherit;font-size:11pt;color:#373737;">such Shareholder shall send an offer notice (the "</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Offer Notice</font><font style="font-family:inherit;font-size:11pt;color:#373737;">") to the other Shareholders, which shall set forth the identity of the Offeror and all other material terms and conditions of the Offer (particularly those related to the price, the terms of payment of the price/ the representations and warranties and the related indemnity obligations).</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">16.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">The Investors shall have fifteen (15) Business Days from the date of the delivery of the Offer Notice by the transferring Shareholder to send a written notice to such Shareholder exercising its Tag Along Right and indicating its election to include its Shares in the sale proposed by the transferring Shareholder on the same terms and conditions (the "</font><font style="font-family:inherit;font-size:11pt;color:#373737;font-weight:bold;">Sale Request</font><font style="font-family:inherit;font-size:11pt;color:#373737;">")</font><font style="font-family:inherit;font-size:11pt;color:#464646;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#373737;">16.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373737;">Within 90 days from the receipt of the Sale Request, the transferring Shareholder shall be able to sell </font><font style="font-family:inherit;font-size:11pt;color:#464646;">i</font><font style="font-family:inherit;font-size:11pt;color:#373737;">ts Shares to the Offerer at a purchase price/ and sub</font><font style="font-family:inherit;font-size:11pt;color:#464646;">j</font><font style="font-family:inherit;font-size:11pt;color:#373737;">ect to terms and conditions, no more favorable to the Offerer than those that were set forth in the Offer Notice, in which case the Shareholders that may have exercised its Tag Along Right shall have the obligation to join such sale and sell to the </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Offeror such exercising Shareholder's Shares pro rata to the percentage that the Shares that th</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">transferring Shareholder transfers represent over the total Shares held by such Shareholder, at the same purchase price per Share and, subject to the same terms and conditions as those actually applicable to the sale of Shares by transferring Shareholder to the Offeror, including the terms of payment of the price, the representations and warranties and the related indemnity obligations (if any) in favor of the third Person, which shall be provided and assumed by the Sharehold</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">rs pro rata to the Shares sold by each of them over the total number of Shares sold by the Shareholders and with no joint and several liability</font><font style="font-family:inherit;font-size:11pt;color:#6e6d74;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">As an exception to the foregoing, in case that the Offered Shares represent more than 50.1% of the total share capital of the Company, the Parties expressly agree that the Investors that may have exercised their Tag Along Right shall have the preferential right to sell the totality of their shares in the Company to the third Person, so the remaining Shares to be transferred by the other exercising Shareholders shall be transferred by each of the exercising Shareholders on a pro rata basis ov</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">r the total Shares held by each of such Shareholders in the Company.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">16</font><font style="font-family:inherit;font-size:11pt;color:#6e6d74;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">If none of the Investors elect to exercise their Tag-Along Right, the transferring Shareholder 1nay, within 90 days from the delivery of the Offer Notice</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">, </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">sell such Offered Shares to the Offeror at a purchase price, and on terms and conditions, no more favorable to the transferring Shareholder than those that w</font><font style="font-family:inherit;font-size:11pt;color:#6e6d74;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">re s</font><font style="font-family:inherit;font-size:11pt;color:#6e6d74;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">t forth in the Offer Notice. Upon the consummation of the sale to the Offeror, the transferring Shareholder shall promptly notify the remaining Shareholders as to the circumstances thereof, including the date of the sale, the identity of the purchaser, the Shares sold arid the price and other key terms and conditions of such sale.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">16.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">If the Transfer by the transferring Shareholder is not consummated within 90 days after the date on which the transferring Shareholder receives the Sale Request pursuant to the previous paragraphs of this Clause, or absent such Sal</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e </font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">Request within 90 days after the date of expiration of the term for delivery of the Sale Request, then the transferring Shareholder shall not be permitted to sell or Transfer the Offered Shares without again complying with the requirements of this Clause.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">16</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">.</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#3d413d;">The Board of Directors may, at its absolute discr</font><font style="font-family:inherit;font-size:11pt;color:#5b5b5d;">e</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">tion, refuse to register any share transfer, without-giving any</font><font style="font-family:inherit;font-size:11pt;color:#a3a3a6;">-</font><font style="font-family:inherit;font-size:11pt;color:#3d413d;">reason thereof, if the-process of such transfer is not carried out in accordance with the provisions of this Agreement or the Bylaws. In </font><font style="font-family:inherit;font-size:11pt;color:#363636;">the case that the Board of Directors refuses to register any share transfer, it shall give written notice notifying the transferor and the transferee of such refusal within 24 hours from the date of the Company's receipt of request for the registration of such share transfer.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><a name="s36651cfd0bb44728b2b9357b4c828548"></a></div><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">17</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NATURE OF THIS AGREEMENT AND BYLAWS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">17.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On the Effective Date, a General Shareholders' Meeting of the Company shall be held and all the Parties shall unanimously approve, amongst other resolutions, the amendments to the Company's Bylaws required to reflect the provisions of this Agreement. After the Effective Date, the Bylaws of the Company shall be interpreted at all times in accordance with the provisions of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">17.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notwithstanding the above, it is acknowledged that certain articles of the Bylaws as amended to adapt to the provisions of the Agreement may not be admissible for registration with the Commercial Registry. As stated in Clause 2.2, the Parties agree that the provisions of this Agreement shall prevail between the Parties, and between the Shareholders and the Company (to the extent legally permitted), as a shareholders' agreement, including, particularly, where a relevant article of the Bylaws differs from the terms of this Agreement. If this Agreement is subsequently amended in whole or in part many manner that shall affect the Bylaws, the Parties shall promptly proceed to adopt any resolutions that may be necessary to amend the Bylaws and have them filed with the Commercial Registry so that they reflect the provisions of this Agreement at all times, to the extent legally possible.</font></div></td></tr></table><div><a name="s79b96838db9243d3a8ca423c01c32339"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">18</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TERM</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement shall become effective upon the Effective Date and continue to be in full force and effect unless terminated in accordance with the provisions of Clause 19.</font></div><div><a name="sbe95d9f3c8f247b883953b87d42675af"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">19</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TERMINATION</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement shall be automatically terminated in any of the following events and the Parties shall not be liable for such termination for whatsoever reason:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">when a Shareholder ceases to hold any Shares through the Transfer of Shares in accordance with the terms of this Agreement, this Agreement shall terminate in respect of such Shareholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">when all of the Parties agree in writing to terminate this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">upon the dissolution and winding-up of the Company under the Spanish Companies Acts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the event of the breach of the Agreement by any of the Parties ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Party in Breach</font><font style="font-family:inherit;font-size:11pt;">"), one or several of the other Parties shall provide written notice of such breach to the Party in Breach. If the Party in Breach does not remedy the breach within a period of thirty (30) days after the date of the notice, the other Party or Parties may terminate the Agreement with the termination effect pursuant to the terms set forth in Clause 19.3 hereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">19.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Effect of termination.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Termination of this Agreement shall be without prejudice to any right or obligation of either Party accrued before termination of the Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Clauses 1 (Definitions), 19.3 (Effect of termination), 20 (Non Competition and Non-Solicitation), 21 (Confidentiality), 22 (Indemnity), 23 (Notices), 25 (General) and 26 (Governing Law and Jurisdiction) shall remain in full force after the termination of this Agreement.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><a name="scdde92ff95a943aeb759e4115cd5b0d0"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">20&#160;&#160;&#160;&#160;CONFIDENTIALITY</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">20.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Definition. "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:11pt;">" means any information disclosed by one Party (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:11pt;">") to the other (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:11pt;">''), whether oral, written, visual, electromagnetic, electronic or in any other form, and whether contained in memoranda, summaries, notes, analyses, compilations, studies or other documents, and whether the same have been prepared by the Disclosing Party or the Receiving Party: (i) which, if in written, graphic, machine-readable or other tangible form is marked as "Confidential" or "Proprietary," or which, if disclosed orally or by demonstration, is identified at the time of initial disclosure as confidential and is summarized in writing and similarly marked and delivered to the Receiving Party within thirty (30) Days after initial disclosure; and (ii) which includes but is not necessarily limited to (A) technical data or information, including proprietary host organisms and their strains, plasmids/vectors, DNA sequences, gene expression, fungal high throughput screening, enzymes arid their applications, research and manufacturing protocols and practices, formulae, charts, analyses, reports, patent applications, trade secrets, ideas, methods, processes, know-how, computer programs, products, equipment, raw materials, designs, data sheets, schematics, configurations, specifications, techniques, drawings, and the like, whether or not relating to experimental data, projects, products, processes, research practices and the like, (B) past, present and future business, financial and commercial data or information, prices and pricing methods, marketing and customer information, financial forecasts and projections, and other data or information relating to strategies, plans, budgets, sales and the like; and (C) any other data or information delivered by the Disclosing Party to the Receiving Party or which the Receiving Party has acquired from the Disclosing Party by way of the former's inspection or observation during visits to the research laboratory, manufacturing plan or other    (type of facility of the latter Party. The Parties expressly acknowledge and agree that all information of a proprietary and/ or confidential nature furnished by the Disclosing Party to the Receiving Party in furtherance of the Disclosing Party's obligations under this Agreement shall be deemed Confidential Information.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">20.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Confidential Information Exclusions.  Confidential Information will exclude information the Receiving Party can demonstrate is: (i) now or hereafter, through no unauthorized act or failure to act on Receiving Party's part, in the public domain; (ii) known to the Receiving Party from a source other than the Disclosing Party (including former employees of the Disclosing Party) without an obligation of confidentiality at the time Receiving Party receives the same from the Disclosing Party, as evidenced by contemporaneous written records; (iii) furnished to others by the Disclosing Party without restriction on disclosure; or (iv) independently developed by the Receiving Party without use of the Disclosing Party's Confidential Information, as evidenced by contemporaneous written records. Nothing in this Agreement shall prevent the Receiving Party from disclosing Confidential Information to the extent the Receiving Party is legally compelled to do so by any governmental investigative or judicial agency pursuant to proceedings over which such agency has jurisdiction; provided, however, that prior to any such disclosure, the Receiving Party shall (a) assert the confidential nature of the Confidential Information to the agency; (b) immediately notify the Disclosing Party in writing of the agency's order or request to disclose; and (c) cooperate fully with the Disclosing Party in protecting against any such disclosure and/ or obtaining a protective order narrowing the scope of the compelled disclosure and protecting its confidentiality.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">20.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Confidentially Obligation. For a period commencing on this date and ending on the tenth (10th) anniversary after the termination of the Agreement, the Receiving Party shall treat as confidential all of the Disclosing' Party's Confidential Information and shall not use such Confidential Information for any purpose whatsoever other than. for the purposes set forth herein, except as expressly otherwise permitted under this Agreement. Without limiting the foregoing, the Receiving Party shall use the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:11pt;">same degree of care and means that it utilizes to protect its own Information of a similar nature, but in any event not less than reasonable care and means, to prevent the unauthorized use or the disclosure of such Confidential Information to third parties. The Confidential Information may be disclosed only to employees or contractors of the Receiving Party with a "need to know" who arc instructed and agree not to disclose the Confidential Information and not to use the Confidential Information for any purpose, except as set forth herein; provided, however, in the case of BDI Group, the term "employees or contractors of a Receiving Party" shall include employees of each of those of BDI Group and any contract research organizations with whom BDI Group has written agreements pursuant to which such contract research organization is performing or will perform work under a project and is bound by an obligation of confidence to BDI Group that makes such contract research organization liable for any breach by Its employees of those confidentiality obligations to BDI Group. The Receiving Party shall have appropriate written agreements with any such employees or contract research organizations sufficient to comply with the provisions of this Agreement. A Receiving Party may not alter, decompile, disassemble, reverse engineer, or otherwise modify any Confidential Information received hereunder and the mingling of the Confidential Information with information of the Receiving Party shall not affect the confidential nature or ownership of the same as stated hereunder.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">20.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No Confidential Information of Other Persons.  Each Party represents and warrants to the other that it has not used and shall not use in the course of its performance hereunder, and shall not disclose to the other, any confidential information of any other Person, unless it is expressly authorized in writing by such Person to do so.</font></div></td></tr></table><div><a name="s8c1851e7a13a419897616a41ebc22be7"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">21</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INDEMNITY</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">21.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each Party (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Defaulting Party</font><font style="font-family:inherit;font-size:11pt;">") agrees to indemnify and hold harmless the other Parties from and against (and pay the full amount of) any and all direct losses, liabilities, actions, damages or injuries, claims, demands, judgments, costs, expenses, suits or proceedings including appeals, which are incurred by the other Party (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Non-Defaulting Party</font><font style="font-family:inherit;font-size:11pt;">"), arising out of:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)&#160;&#160;&#160;&#160;any breach of a representation or warranty made in this Agreement by the Defaulting Party;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)&#160;&#160;&#160;&#160;any breach of other obligations in this Agreement by the Defaulting Party; and</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">any fraud, willful misconduct or breach of Spanish Law by the Defaulting Party in the context of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">21.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The indemnity set forth under this Clause shall not limit any other right, which the Non-Defaulting Party may have under this Agreement or under Spanish Law.</font></div></td></tr></table><div><a name="scabacdad2f964977b4f03134c14bab7e"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">22</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOTICES</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">22.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Unless otherwise expressly set out in the Agreement, all notices, consents, requests, instructions, approvals and other communications provided for herein shall be in writing and shall be deemed validly given (i) upon personal delivery, or (ii) three Business Days after being sent by recognized express courier service that maintains records of receipt. In all cases and without prejudice of the notice requirements set out before, as a further requirement any notices shall be also sent via email at the email addresses provided in this Clause.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">It is hereby understood that notice shall be deemed as received when sent to the addresses indicated below for each of the Parties:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn.: Mark A. Emalfarb, CEO</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: 140 Intracoastal Pointe Drive, Suite 404</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Jupiter, Florida 33477</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: 561-743-8333</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: memalfarb@dyadic.com</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">With copy to: Laura Nemeth, Squire Patton Boggs</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Email: laura.nemeth@squirepb.com</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVEREADY INNVIERTE BIOTECH II, S.C.R., S.A.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn.: Roger Pique Pijuan</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Biotechnology Developments for Industry, S.L.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn.: Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: avenida Francisco Vall&#233;s 8, 47151, Boecillo - Valladolid (Espa&#241;a).</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VLP The Vaccines Company, S.L.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attn.: Mr. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address: Calle Vel&#225;zquez, 4-5&#176;, 37005, Salamanca</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Tel.: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">E-Mail: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">22.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In order for any change to the above addresses or persons for the notice purposes to be binding upon the Parties, the relevant party must notify it accordingly with at least ten (10) days in advance following the terms included under this Clause 23.</font></div></td></tr></table><div><a name="sf9544a1abe28433c8cd8eda194d0ab0a"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">23</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ASSIGNMENT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">23.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Subject to Clause 24.2, neither Party may assign this Agreement, in whole or in part, without the other Parties' written consent except for the case where the transfer of Shares shall take place pursuant to the provisions of Clause 14.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">23.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any Shareholder shall be entitled to assign its rights under this Agreement to any of its Affiliates, as long as such assignment is derived from a Transfer of Shares which complies with the terms and conditions of this Agreement.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><a name="sea5b79da9a7e441db81c309ee72e511a"></a></div><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">24</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GENERAL</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">24.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Transferability; Derogation and Binding Effect</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as otherwise provided herein, this Agreement shall be binding upon and inure to the benefit of the Company, and the Shareholders, and their respective heirs, executors, administrators, legal representatives, successors and assigns, subject to the restrictions on Transfer set forth in this Agreement in Clause 14.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each Shareholder hereby binds its heirs, executors, administrators, legal representatives, successors and assigns to perform and fulfil the terms of this Agreement as fully and completely as if they were personally present to do so. To the extent permitted by this Agreement, whether or not any express assignment has been made, the provisions of this Agreement are also for the benefit of, and enforceable by, any transferee of securities of the Company by a Shareholder; provided (a) that, as a condition to any such Transfer, such Shareholder's transferee shall have agreed, in a signed writing, to be bound by the terms and conditions of this Agreement, as if such transferee were an original signatory hereto, and (b) that any transferor hereunder shall not be released from any liabilities by the Company or any other Shareholder.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">24.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Waiver</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No waiver by each Party of its right to enforce any provision of this Agreement shall constitute a waiver of such Party's right to enforce such provisions thereafter or to enforce any other provisions of this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">24.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Entire Agreement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement and all of the attachments hereto contain the entire and final agreement of the Parties with respect to the subject matters of this Agreement and superseded any and all prior agreements, written or oral, with respect to the subject matter of this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">24.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Severability</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction is ineffective as to that jurisdiction to the extent of the prohibition or unenforceability, and does not invalidate the remaining provisions of this Agreement nor affect the validity or enforceability of that provision in any other jurisdiction.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">24.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Amendment</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No provisions of this Agreement shall be altered, amended or modified in any way except by an instrument in writing executed by the Parties and passed into Public Deed before a Spanish Notary.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">24.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Costs</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each Patty must bear its own costs arising out of the negotiation, preparation and execution of this Agreement. The Notary costs for passing this Agreement into Public Deed shall be borne by the Company.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><a name="s392221a51b3a43719cb04b8087443cbb"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">25&#160;&#160;&#160;&#160;GOVERNING LAW AND JURISDICTION</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Agreement shall be governed by, and interpreted under, the laws of Spain, without application of rules on conflicts of laws.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Parties hereby agree to submit all disputes, controversies or claims that may arise between them that directly or indirectly relate to this Agreement, including issues concerning the existence, validity, effectiveness, interpretation, compliance or termination hereof, to be resolved by arbitration at law of the Arbitration Court of the Madrid Chambers of Commerce in accordance with the rules regulating such body, which rules are deemed to be incorporated by reference into this Clause.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The arbitration proceedings shall be carried out before the Court of Arbitration of the Madrid Chambers of Commerce and subject to the regulations of said Court, whenever not referred to herein. The seat or legal place of the arbitration shall be Madrid.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The arbitration shall be resolved by 1 sole arbitrator selected in accordance with the rules of the Court of Arbitration of the Madrid Chambers of Commerce.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Parties hereby undertake to voluntarily comply with the arbitral award issued, as soon as it becomes final.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The term for an award to be issued shall be 6 months as of the date of acceptance by the Arbitrator.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">25.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The arbitration language shall be Spanish, provided, however, that to the extent that any supporting or accompanying documents of the relevant claim or answer to the claim are originally drafted in English, there shall be no obligation to translate such documents into Spanish.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="s451c658c6a014cbbb40183b58fad99dc"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:93px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Parties have executed the Agreement in one counterpart to be raised into public, in the place and on the date first above written.</font></div><div style="line-height:120%;padding-bottom:93px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:50.427350427350426%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Antonio Ca&#241;adas Bouwen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Antonio Ca&#241;adas Bouwen</font></div><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">on behalf of </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:93px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:88.46153846153845%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Pablo Gutierrez G&#243;mez on behalf of Biotechonology Developments for Industry, S.L.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:93px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:88.46153846153845%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Roger Piqu&#233; Pijuan </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Roger Piqu&#233; Pijuan on behalf of INVEREADY INNVIERTE BIOTECH II, S.C.R., S.A.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:88.46153846153845%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Emilio Guti&#233;rrez G&#243;mez on behalf of VLP The Vaccines Company, S.L.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><a name="s96f054e4236e4f29a244f346364c8341"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373b3a;font-weight:bold;">SCHEDUL</font><font style="font-family:inherit;font-size:11pt;color:#494c4c;font-weight:bold;">E </font><font style="font-family:inherit;font-size:11pt;color:#373b3a;font-weight:bold;">I </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#373b3a;font-weight:bold;">BYLAWS OF THE COMPANY</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;"><img src="exhibit1014schedule1.jpg" alt="exhibit1014schedule1.jpg" style="height:141px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Informaci&#243;n Mercantil interactiva de los Registros Mercantiles de Espa&#241;a</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;color:#353535;font-weight:bold;">REGISTRO MERCANTIL DE SALAMANCA</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#353535;">Expedida el d&#237;a: 21/02/2017 a las 12</font><font style="font-family:inherit;font-size:10pt;color:#4c4c4c;">:</font><font style="font-family:inherit;font-size:10pt;color:#353535;">43 horas.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;color:#353535;font-weight:bold;">ESTATUTOS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">DATOS GENERALES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:69.87179487179486%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:43%;"></td><td style="width:57%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Denominaci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#353535;">n</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">VLP THE VACCINES COMPANY SL</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">lnicio de Operaciones:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">16/03/2012</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Domicilio Social</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">C</font><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;font-style:italic;">/</font><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">VELAZQUEZ 4 5&#176; A</font></div><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">SALAMANCA37005-SALAMANCA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Duraci</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#353535;">n</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">lndefinida</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">C</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">.</font><font style="font-family:inherit;font-size:11pt;color:#353535;">I.F.:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">B37515111</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Datos Registraies:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Hoja SA-14239</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Tomo 426</font></div><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Folio 219</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">Objeto Social:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVESTIGACI&#211;N, DESARROLLO E INNOVACI&#211;N., ACTIVIDADES CIENTIFICAS Y T&#201;CNICAS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Estructura del </font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#353535;">rgano</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Administrador &#250;nfco</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Unipersonalidad:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">La sociedad de esta hoja es unipersonal, siendo su socio &#250;nico BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY SL, con N.I.F: B4729934</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#353535;">&#218;ltimo dep</font><font style="font-family:inherit;font-size:11pt;">&#243;</font><font style="font-family:inherit;font-size:11pt;color:#353535;">sito contable:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">2015</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">ASIENTOS DE PRESENTACION VIGENTES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;font-weight:bold;">No existen asientos de presentaci&#243;n vigentes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;">SITUACIONES ESPECIALES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#404040;font-weight:bold;">No existen situaciones especiales</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESTATUTOS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESTATUTOS: TITULO I. DISPOSICIONES GENERALES. Art&#237;culo 1&#176;.- R&#233;gimen. La presente sociedad VLP THE VACCINES COMPANY, S.L., se regir&#225; por los presentes Estatutos, por el Real Decreto Legislativo 1/2010, de 2 de julio y por las dem&#225;s disposiciones legales que le sean aplicables. Art&#237;culo 2&#176;- Objeto. La compa&#241;&#237;a tiene por objeto de su actividad: Desarrollo de vacunas innovadoras, basadas en plataforma VLP. Actividades de l+D en Biotecnolog&#237;a. Servicios t&#233;cnicos. Servicios tecnol&#243;gicos. Servicios de asesoramiento tecnol&#243;gico. Desarrollo de f&#225;rmacos. Las actividades enumeradas podr&#225;n tambi&#233;n ser desarrolladas por la sociedad, total o parcialmente, de modo indirecto, mediante la participaci&#243;n en otras sociedades. Si las disposiciones legales exigiesen para alguna de las actividades de la sociedad alguna autorizaci&#243;n administrativa, dichas actividades deber&#225;n realizarse por medio de persona que ostente dicha titularidad profesional y, en su caso, no podr&#225;n iniciarse antes de que se hayan cumplido los requisitos administrativos exigidos. Quedan excluidas todas aquellas actividades para cuyo ejercicio la ley exija requisitos especiales que no queden cumplidos por esta sociedad. Art&#237;culo 3&#176;.- Duraci&#243;n. Su duraci&#243;n ser&#225; indefinida, y dar&#225; comienzo a sus operaciones el d&#237;a 16 de Marzo de 2.012. Si la ley exigere para el inicio de alguna de las operaciones enumeradas en el art&#237;culo anterior la obtenci&#243;n de licencia administrativa, la inscripci&#243;n en un registro p&#250;blico, o cualquier otro requisito, no podr&#225; la sociedad iniciar la citada actividad espec&#237;fica hasta que el requisito exigido quede cumplido conforme a la ley. Art&#237;culo 4&#176;.- Domicllio. Su domicllio social queda fijado en Salamanca, calle Vel&#225;zquez, n&#250;mero 4, 5&#176;A. Podr&#225; el &#243;rgano de administraci&#243;n de la sociedad establecer, suprimir o trasladar cuantas sucursales, agencias o delegaciones tenga por conveniente. TITULO II. DEL CAPITAL Y PARTICIPACIONES SOCIALES. Art&#237;culo 5&#176;.- Capital social y participaciones sociales. El capital socia queda fijado en la cifra de CIENTO CUARENTA Y SEIS MIL EUROS, totalmente desemboisados y est&#225; dividido en 1,460.000 participaciones sociales, de diez c&#233;ntimos de valor nominal, cada una, numeradas correlativamente del 1 al 1,460.00, ambos inclusive, que no podr&#225;n estar representada por media de t&#237;tulos, ni de anotaciones en cuenta, ni denominarse acciones. Art&#237;culo 6&#176;.- Libro Registro. La sociedad llevar&#225; un libro de registro de socios, en el que se har&#225;n constar la titularidad originaria y las sucesivas transmisiones, voluntarias a forzosas, de las participaciones sociales, as&#237; como la constituci&#243;n de derechos reales y otros grav&#225;menes sobre las mismas; en cada anotaci&#243;n se indicar&#225; la identidad y domicilio del titular de la participaci&#243;n o del derecho o gravamen constituido sabre aquellas. Cualquier socio podr&#225; examinar este libro cuya llevanza y custodia corresponde al &#243;rgano de administraci&#243;n. Los socios y las titulares de grav&#225;menes o derechos reales sobre las participaciones saciales tienen derecho a obtener certificaci&#243;n de las participaciones o titularidades registradas a su nombre. Los datos personales de las socios podr&#225;n modificarse a su instancia, no surtiendo entre tanto efectos frente a la sociedad. Art&#237;culo 7&#176;.-Transmisi&#243;n de participaciones. I) Transmisi&#243;n intervivos: 1) Si ser&#225; libre la transmisi&#243;n de participaciones entre socios, en favor del c&#243;nyuge, ascendientes o descendientes del socio o de sociedades pertenecientes al mismo grupo (art. 42, 1 C. Comercio) de la transmitente. 2) En los dem&#225;s casos el socio que se proponga transmitir participaciones deber&#225; comunicarlo por escrito al &#243;rgano de administraci&#243;n de la sociedad, quien lo notificar&#225; del mismo mode a los socios en el plazo de siete d&#237;as. Los socios podr&#225;n optar a la compra en el plazo de las siete d&#237;as siguientes a la recepci&#243;n de la comunicaci&#243;n; si optaren varios, las participaciones se distribuir&#225;n entre ellos a prorrata de las que ya tengan. Si ning&#250;n socio ejercita el derecho de tanteo, podr&#225; la sociedad a trav&#233;s de su &#243;rgano de administraci&#243;n presentar en el plazo de los 10 d&#237;as siguientes uno o varios terceros para adquirir las participaciones ofertadas. En su defecto, en el plaza de 20 d&#237;as siguientes podr&#225; la Junta General acordar que sea la propia sociedad la que adquiera las participaciones conforme a lo establecido en el art&#237;culo 140 del Real Decreto Legislativo 1/2010. -Si transcurridos los plazos citados el socio transmitente no recibe por conducto notarial aceptaci&#243;n de su oferta quedar&#225; libre para transmitir sus part&#237;cipaciones en la forma notificada y en el plazo de los dos meses siguientes a la conclusi&#243;n del &#250;ltimo plazo indicado. II) Transmis&#237;on forzosa. En caso de remate o adjudicaci&#243;n de participaciones sociales, como consecuencia de cualquier procedimiento de apremio, los socios y en su defecto la socidad podr&#225;n subgrogarse en lugar del rematante o del acreedor adjudicatario, mientras el remate o la Adjudicaci&#243;n no sea firme, en la forma prevista en el art. 10 9 del Real Decreto Legislativo 1/2010; si la subrogada es la sociedad, debar&#225; amortizar las participaciones adquiridas en la forma y plazos previstos en el art. 140 del Real Decreto Legislativo 1/2010.III) Transmisi&#243;n mortis causa. En caso de transmisi&#243;n mortis causa de participaciones sociales, si el heredero o legatario que las detentare no fuere el c&#243;nyuge, ascendientes o los decendientes del fallecido podr&#225;n los dem&#225;s socios adquirirlas en el plazo de 15 d&#237;as desde la comunicac&#243;n a la sociedad de la adquisici&#243;n hereditaria, o, en defecto de los socios, de la propia sociedad, previo acuerdo de la Junta General, en el plazo de los 20 d&#237;as siguientes, pagando a los titulares el valor convenido o en su defecto el valor razonable al del fallecimiento, es decir el fijado por el auditor, en la forma prevista en el art. 110 del Real Descreto Legislativo 1/2010. IV) Normas generales. 1) Si se emitieren participac&#237;ones con prestaciones assesorias, se aplicar&#225;n las reglas especiales dictadas para esta clase de participac&#237;ones. Las reglas transcritas se aplicar&#225;n, de igual </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">modo aunque con las necesaria adataci&#243;n y en los plazos fijados en el art. 305 del Real Decreto Legislativo 1/2010, a las transmisiones de derechos de preferencia en caso de creaci&#243;n de nuevas participaciones La transmisi&#243;n de  participaciones se formalizar&#225; conforme a la ley, su adquisici&#243;n por cualquier t&#237;tulo deber&#225; ser comunicada prescrito a la sociedad para su Inscripci&#243;n en el Libro Registro de socios. Sin cumplir este requisito no podr&#225; el socio pretender el ejercicio de los derechos que le correspondan en las sociedad. Las transmisiones de participaciones sociales que no se ajusten a estas reglas no producir&#225;n efecto alguno frente a la sociedad. La sociedad no podr&#225; adquirir sus propias participaciones salvo en los casos previstos en el art. 40 de la ley. Art&#237;culo 8&#176;. Cotitularidad. En caso de cotitularidad de paricipaciones o de derechos s obre ellas, los cotitulares habr&#225;n de comunicar a la socidedad la persona designada por todos ellos para el ejercicio de los derechos, pero del cumplimiento de las obligaciones frente a la sociedad responder&#225;n solidariamente todos los cotitulares. Art&#237;culo 9&#176;.-Usufructo y prenda. En caso de usufracto y prenda de participaciones sociales, el derecho de voto corresponder&#225; al titular de las participaciones, TITULO III. DE LOS ORGANOS SOCIALES. Secci&#243;n Primera. De la Junta General. Art&#237;culo 10&#176;.-&#211;rganos. La sociedad ser&#225; regida por la Junta General de socios, y adminstrada y representada por el &#243;rgano de administracti&#243;n designado por &#233;sta.  Art&#237;culo 11&#176;.- Mayor&#237;a. La voluntad de los socios expresada por mayor&#237;a regir&#225; la vida de la sociedad. Todos los socios, incluso los disidentes y los ausentes, quedan sometidos a los acuerdos de la Junta General, sin perjuicio del derecho de separaci&#243;n del socio cuadno legalmente proceda. Se entender&#225; que hay mayor&#237;a cuando vote a favor del acuerdo un n&#250;mero de socios que represente m&#225;s de la mitad del capital social, salvo para los casos en los que la ley establece imperativamente un qu&#243;rum inferior. No obstante para aumentar o redcuir el capital social, prorrogar, transformar, o suprimir el derecho de preferencia en los aumentos de capital, excluir socios, suprimir la prohibici&#243;n de comptencia de los administradores, modificar en caulquier forma los Estatutos Sociales para la que no se exija mayor&#237;a cualificada, y en los dem&#225;s casos en que as&#237; lo exija a la ley, ser&#225; necesario que voten a favor del acuerdo un n&#250;mero de socios que representen al menos las dos terceras partes del capital social, sin peerjuicio de lo indicado a continuacti&#243;n. Asimlsmo, los acuerdos relat&#237;vos a la modificaci&#243;n de la composici&#243;n de los &#243;rganos de gobierno, fusi&#243;n, escisi&#243;n o cesi&#243;n global de activos o pasivos, as&#237; como la disoluci&#243;n de la sociedad (salvo que dicho acuerdo sea adoptado por requisto legal), ser&#225;n adoptados con, al menos, el voto favorable del 86% del capital social. Para decidir el ejercicio de la acci&#243;n de responsabilidad de los administradores y adoptar el acuerdo de disoluci&#243;n en los casos previstos en las letras a) a g) del art&#237;culo 363.1 y en el previsto en el art&#237;culo 363.2 del Real Decreto Legislativo 1/2010, bastar&#225; una mayor&#237;a de votes v&#225;lidos que representen al menos un tercio del capital social. Art&#237;culo 12&#176;.- Convocatoria. La mayor&#237;a habr&#225; de formarse necesariamente en Junta General convocada al efecto por el &#243;rgano de administraci&#243;n (o de liquidaci&#243;n en su case). La convocatoria de la Junta se har&#225; por carta certificada, telegrama o telefax individual a todos las socios al domicilio par estos designado al efecto o en su defecto al que conste en el libro de registro de socios. Entre la remisi&#243;n del &#250;ltimo anuncio y la fecha prevista para la celebraci&#243;n de la Junta deber&#225; existir un plazo de al menos quince d&#237;as, salvo en los de fusi&#243;n o escisi&#243;n en que la relaci&#243;n jabera ser coma m&#237;nimo de un mes y en aquellos otros en que la ley exija un plazo distinto. La convocatoria expresar&#225; el nombre de la sociedad, la fecha, hora y Jugar de reuni&#243;n, la persona que realiza la comunicaci&#243;n, as&#237; como el orden del d&#237;a, expres&#225;ndose con la debida claridad los asuntos sobre los que hayan de deliberar y las dem&#225;s menciones que exija la ley seg&#250;n los temas a tratar; si omitiere el lugar de reuni&#243;n se entender&#225; que se convoca para celebrarse en el domicilio social. A los socios que residan en el extranjero la convocatoria les ser&#225; enviada al domicilio en Espa&#241;a que obligatoriamente deber&#225;n haber hecho constar en el Libro-Registro. El &#243;rgano de admlnistraci&#243;n est&#225; obligado a convocar la Junta General para su celebraci&#243;n dentro de los seis primeros meses de cada ejercicio a fin de censurar la gesti&#243;n social, aprobar en su caso las cuentas del ejercicio anterior y resolver sobre la aplicaci&#243;n del resultado; s&#237; no lo hiciere. cualquier socio podr&#225; solicitar su convocatoria al Juez de Primera lnstancia del Domicilio social. Sin embargo, la Junta quedar&#225; v&#225;lidamente constituida tratar cualquier asunto, sin necesidad de para previa convocatoria, siempre que est&#233; presente o presentado la totalidad del capital social y las concurrentes acepten por unanimidad la celebraci&#243;n de la reuni&#243;n y el orden del d&#237;a de la misma. La Junta Universal podr&#225; reunirse en cualquier lugar del territorio nacional o del extranjero. Art&#237;culo 14&#176;.- Derecho de asistencia. Todos las socios tienen derecho a asistir a la Junta General. El socio podr&#225; hacerse representar por medio de otro socio, su c&#243;nyuge, ascendientes, descendientes o persona que ostente poder general en documento p&#250;blico para administrar todo el patrimonio del representado en territorio general. Si la representaci&#243;n no consta en documento p&#250;blico, deber&#225; ser especial para cada Junta y en todo caso constar&#225; par escrito. Art&#237;culo 15&#176; .- Actuar&#225;n coma Presidente y Secretario de la Junta General los del Consejo de Administraci&#243;n y en su defecto las designados, al comienzo de la sesi&#243;n, por los socios concurrentes. Las deliberaciones las dirigir&#225; el Presidente; cada punto del orden del d&#237;a ser&#225; objeto de votaci&#243;n por separado. Los acuerdos sociales deber&#225;n constar en acta que incluir&#225; necesariamente la lista de asistentes y deber&#225; ser aprobada por la propia Junta al final de la reuni&#243;n, o, en su defecto, y dentro del plazo de quince d&#237;as, per el Presidente de la Junta General y dos socios lnterventores, uno en representaci&#243;n de la mayor&#237;a y otro de la minor&#237;a. Secci&#243;n Segunda. Del </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#243;rgano de Administraci&#243;n. Art&#237;culo 16&#176;.- La sociedad ser&#225; administrada y representada, seg&#250;n decida la Junta General, por un Administrador &#250;nico, dos o m&#225;s administradores solidarios o mancomunados hasta un m&#225;ximo de cinco, o por un Consejo de Administraci&#243;n integrado par un n&#250;mero de miembros no inferior a tres ni superior a doce, todos los cuales podr&#225;n no ser socios, pudiendo serlo tanto las personas fisicas como las personas jur&#237;dicas. Se consigna expresamente la prohibici&#243;n de que ocupen y ejerzan cargos en la sociedad personas incompatibles conforme a las disposiciones estatales y auton&#243;micas vigentes.  Art&#237;culo 17&#176;.- Si el &#243;rgano de administraci&#243;n fuese un Consejo, el n&#250;mero exacto de sus miembros ser&#225; fijado por la Junta General. El Consejo de Administraci&#243;n se reunir&#225;, a instancia del Presidente o del que haga sus veces, cuando lo requiera el inter&#233;s s social o lo solicite cualquiera de sus miembros; la convocatoria se har&#225; por escrito individual (carta, telegrama o telefax) a todos los consejeros; se entender&#225; v&#225;lidarnente constituido cuando concurran a la reuni&#243;n la mitad m&#225;s uno de sus componentes, pudiendo cualquier consejero conferir su representaci&#243;n a otro consejero; las deliberaciones se efectuar&#225;n por puntos separados y ser&#225;n moderadas por el Presidente; para adoptar acuerdos, que tarnbi&#233;n se votar&#225;n por separado, ser&#225; preciso el voto favorable de la mayor&#237;a absoluta de los concurrentes a la sesi&#243;n, salvo para la delegaci&#243;n permanente de facultades en una Com&#237;si&#243;n Ejecutiva o en u no o varios Consejeros Delegados y par a la designaci&#243;n de los administradores que hayan de ocupar tales cargos, en qua ser&#225; preciso el voto favorable de las dos terceras partes de los miembros del Consejo. Si podr&#225; no los elegir ha designado la Junta, el Consejo a su propio Presidente y Vicepresidente, a su Secretario y Vicesecretario que podr&#225;n no ser consejeros, y a uno o varios Consejeros Delegados de entre los miembros del Consejo, con los requisites legales. Las discusiones y acuerdos del Consejo se har&#225;n constar en acta que ser&#225; firmada por el Presidente y el Secretario o por quienes los hubleren sustituido. Las certificaciones de las acuerdos sar&#225;n expedidas por las personas designadas en el art. 109 y siguientes del RRM. Su fonnalizaci&#243;n en documento p&#250;blico podr&#225; ser realizada par las personas se&#241;aladas en el art&#237;culo 108 del citado Reglamento y edem&#225;s por cualquier componente del Consejo, con cargo vigente e inscrito, sin necesidad de delegaci&#243;n expresa. Art&#237;culo 17&#176;.- bis. Las reuniones del Consejo de Administraci&#243;n, si lo hubiere, se convocar&#225;n con 24 horas de antelaci&#243;n, pero si el convocante estimare que los asuntos a tratar son de mayor urgencia, bastar&#225; una antelaci&#243;n de seis horas. Art&#237;culo 18&#176;.- Duraci&#243;n. Los Administradores ejercer&#225;n su cargo por tiempo indefinido, pero podr&#225;n ser separados de su cargo en cualquier momento aunque la separaci&#243;n no figure en el orden del d&#237;a. Art&#237;culo 19&#176;.- Representaci&#243;n. Al &#243;rgano de administraci&#243;n designado por la Junta corresponde al de forma Individual si es Administrador &#218;nico o (Administrador Solidario; b) de forman mancomunada si hay varios Administradores Mancomunados, debiendo actuar conjuntamente todos ellos; y el de forma colegiada si hay Consejo de Administraci&#243;n, el poder de representaci&#243;n de la Sociedad, en juicio y fuera de &#233;l, con el &#225;mbito necesario establecido en el art. 234 del Real Decreto Legislativo 1/2010; queda incluso facultado en la forma m&#225;s amplia para dirigir, administrar, disponer de los blenes y representar a la Sociedad, pudiendo celebrar toda suerte de actos y contratos de adrnintstraci&#243;n, ordinaila extraordinaria, y de disposici&#243;n o de riguroso dominio sobre toda clase de bienes muebles, lnmuebles, valores, dinero, efectos de cornerclo o establecimientos mercantiles. Esta representaci&#243;n organlca se extenders. consecuentemente, al &#225;mbito mercantil, comercial y bancario y alcanzar&#225; incluso a las actos para los que suele exigirse menci&#243;n explicita, siendo bastante para gravar, hipotecar, transigir, endeudarse, decidir la participaci&#243;n en otras sociedades, recurrir en casaci&#243;n o amparo, prestar confesi&#243;n en juicio, absolver posiciones e garantizar negocios ajenos, percibir cantidades del Tesoro P&#250;blico o de cualquier otra dependencia p&#250;blica, sin m&#225;s limitaciones que las establecidas en la ley. Podr&#225; el &#243;rgano de administraci&#243;n, aunque le fuere delegado, otorgar y revocar poderes generales o especiales con las facultades que detalle, incluida la de sustituir o subapoderar total o parcialmente conforme a la ley. En ning&#250;n caso podr&#225;n ser objeto de Delegaci&#243;n las facultades que la ley no autoriza a delegar. Si los Estatutos o los acuerdos de la Junta estableciesen limitaciones al ejercicio del poder de representaci&#243;n, las limitaciones establecidas tendr&#225;n un alcance meramente lnterno. Art&#237;culo 20&#176;.- Retribuci&#243;n. El cargo de Administrador es gratuito. No obstante si alguno de los administradores prestase a la sociedad servicios por cargos para los que hubiere sido nombrado o por trabajos profesionales o de cualquier otra &#237;ndole que en misma realice, la remuneraci&#243;n que por este concepto reciba lo ser&#225; en funci&#243;n del trabajo que desarrolle con arreglo a la legislaci&#243;n mercantil o laboral ordinaria. Art&#237;culo 21&#176;.-Prohibici&#243;n de cornpetencia, Los administradores no podr&#225;n dedicarse par cuenta propia o ajena al mismo, an&#225;logo o complementario genera de actividad que constituya el objeto social, salvo autorizaci&#243;n expresa de la Junta General. Art&#237;culo 22&#176;.- Libro de actas. La Sociedad llevar&#225; un libro o libras de actas en los qua constaran, al menos, todos los acuerdos tomados per las &#243;rganos colegiados de sociedad, con expresi&#243;n de los datos relativos a la convocatoria y a la constituci&#243;n si &#243;rgano, un resumen de los asuntos debatidos, las intervenciones&#183;de las que se haya solicitado constancia; los&#183;aeuerdos adoptados y los resultados de&#183; las votaciones. Cualquier socio y las personas que hubleren asistido a la Junta General en representaci&#243;n de las socios no asistentes, podr&#225;n obtener en cualquier memento certificaci&#243;n de</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">los acuerdos y de las actas de las juntas generales. Art&#237;culo 23&#176;.- Ejercicio econ&#243;mico. El ejercicio econ&#243;mico de la sociedad finalizar&#225; el 31 de Diciembre de cada a&#241;o. Art&#237;culo 24&#176;.- Cuentas anuales. En el plazo m&#225;xirno de tres meses contados a partir del cierre de cada ejercicio social, el &#243;rgano de administraci&#243;n deber&#225; formular el balance con la cuenta de p&#233;rdidas y ganancias, la memoria y la propuesta de aplicaci&#243;n del resultado. A partir de la convocatoria de la Junta a celebrar antes del BO de Junio de cada a&#241;o y a cuya aprobaci&#243;n deben ser sometidos, cualquier socio podr&#225; obtener gratuitamente de la sociedad estos documentos y el informe de las auditores en su caso; en la convocatoria de la Junta se reccrdar&#225; este derecho. Tambi&#233;n podr&#225;n los socios que representen al menos el 5% del capital social examinar la Contabilidad en el domicilio social en uni&#243;n de experto contable. Art&#237;culo 25&#176;.- Aplicaci&#243;n de resultados. La Junta resolver&#225; sobre la aplicaci&#243;n del resultado, con estricta observancia de las disposiciones legales sobre reservas, previsiones o amortizaciones. Los beneficios liquidos se distribuir&#225;n entre los socios en proporci&#243;n a su participaci&#243;n en el capital social. TITULO IV. DISOLUCION Y LIQUIDACION. Art&#237;culo 26&#176;. Disoluci&#243;n. La Sociedad se disolver&#225; por cualquiera de las causas enumeradas en la ley, y una vez acordada, se abre el periodo de liquidaci&#243;n, que realizar&#225; el &#243;rgano de administraci&#243;n si la Junta general no designa otros liquidadores. Art&#237;culo 27&#176;.- lnventario y Balance inicial. Los liquidadores formular&#225;n un inventario y un balance de la sociedad con referencia al d&#237;a en que se hubiere acordado la disoluci&#243;n, en el plazo de tres meses a contar desde la apertura del per&#237;odo de liquidaci&#243;n. Art&#237;culo 28&#176;.- Balance final. Concluidas las operaciones liquidatorias, las liquidadores omitir&#225;n a la aprobaci&#243;n&#183;de la Junta General balance final, un informe sobre dichas operaciones y un proyecto de reparto entre los socios de activo resultante. La cuota liquidatoria ser&#225; proporciona la participaci&#243;n de cada socio en el capital social, no podr&#225; ser satisfecha sin el previo page a las acreedores del importe de sus cr&#233;ditos o si consignarlo en una entidad de cr&#233;dito del territorio municipal del domicilio social. Art&#237;culo 29&#176;.- A la escritura p&#250;blica de extinci&#243;n de la sociedad se incorporar&#225; el balance final de liquidaci&#243;n y la relaci&#243;n de los socios en la que conste su identidad, y el valor de la cuota de liquidaci&#243;n que les hubiere correspondido a cada uno.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><a name="sf88136caf36a4c61a39a1300bb813eb0"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders of the Company</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:49%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dyadic International (USA), Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,30%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,123</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[1,778,955 -</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,853,077]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INVEREADY INNVIERTE</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BIOTECH II, S.C.R., S.A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393,077</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[1,853078 - 2,246,154]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biotechnology Developments for Industry, S. L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,20%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,778,954</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[1 -1,778,954]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TOTAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,246,154</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[1 - 2,246,154]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><a name="se0a8b3c5d77c47bab4f46832e7868e13"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE III </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ADHERENCE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THIS AGREEMENT</font><font style="font-family:inherit;font-size:10pt;">&#32;is made on [&#9679;].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BETWEEN:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#9679;], a corporation organized and existing under the laws of [&#9679;], having its principal place of business at [&#9679;] (the New Shareholder);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#9679;], a corporation organized and existing under the laws of [&#9679;], having its principal place of business at[&#9679;]; (the Original Shareholder) and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#9679;], a corporation organised and existing under the laws of [&#9679;], having its principle place of business at [&#9679;] ([&#9679;])</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#9679;], a corporation organised and existing under the laws of [&#9679;], having its principle place of business at [&#9679;]([&#9679;])</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#9679;], a corporation organised and existing under the  laws of [&#9679;], having its principle place of business at [&#9679;], ([&#9679;])</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#9679;], [&#9679;] and [&#9679;] shall be jointly referred as the (the Continuing Shareholders). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Original Shareholder and the Continuing Shareholders are parties to the Shareholders Agreement in relation to VLP The Vaccines Company, S.L. dated _________________ 2017 (the "</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders Agreement</font><font style="font-family:inherit;font-size:10pt;">").</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Original Shareholder proposes to sell and transfer and the New Shareholder proposes to purchase [&#9679;] shares of [&#9679;] par value each in the share capital of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">VLP The Vaccines Company, S.L.</font><font style="font-family:inherit;font-size:10pt;">&#32;(the "</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:10pt;">") from the Original Shareholder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(C)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Agreement is made in compliance with Clause ____ of the Shareholders Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IT IS AGREED</font><font style="font-family:inherit;font-size:10pt;">&#32;as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The New Shareholder confirms that it has been supplied with a copy of the Shareholders Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The New Shareholder undertakes to the Continuing Shareholders to be bound by the Shareholders Agreement and any other agreement where the original Shareholder is a party thereto in all respects as if the New Shareholder were a party to the Shareholders Agreement and any other agreement and named in it as a Shareholder or party and to observe and perform all the provisions and obligations of the Shareholders Agreement and any other agreement applicable to or binding on a Shareholder under the Shareholders  Agreement or any other agreement insofar as it falls to be observed or performed on or after the date of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Continuing Shareholders undertakes to the New Shareholder to observe and perform all provisions and obligations of the Shareholders Agreement applicable to or binding on a Shareholder under the Shareholders Agreement and acknowledge that the New Shareholder shall be entitled to the rights and benefits of the Shareholders Agreement as if the New Shareholder were named in the Shareholders Agreement in place of the Original Shareholder with effect from the date of this Agreement.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Agreement is made for the benefit of: (a) the parties to the Shareholders Agreement, and (b) every other person who after the date of the Shareholders Agreement (and whether before or after the execution of this Agreement) assumes any rights or obligations under the Shareholders Agreement or adheres to it.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The address, facsimile number and contact person of the New Shareholder for the purposes of clause 23 of the Shareholders Agreement is as follows:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[Name]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[Address] </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fax:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[&#9679;]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">marked for the attention of :&#160;&#160;[&#9679;]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Agreement is governed by and shall be construed in accordance with Spanish law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:inherit;font-size:10pt;">, the Parties have caused this Agreement to be executed by  (their duly authorized representatives, as of the day and year first above mentioned.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:40.81196581196581%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:17%;"></td><td style="width:83%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><a name="s8c6affb826c64c6c80b21f7d629980cb"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT B</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Service Framework Agreement </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Efiled as Exhibit 10.15 to Dyadic International, Inc&#8217;s Form 10</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><a name="s5b91186be47942988e6855475b9b13de"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT C</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Research Services Agreement </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Efiled as Exhibit 10.14 to Dyadic International, Inc&#8217;s Form 10</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><a name="sc5288128462745aeaefe588b4aff19ec"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">EXHIBIT D1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Minutes of the General Shareholders Meeting of the Company </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">ACTA DE LA JUNTA GENERAL EXTRAORDINARIA Y UNIVERSAL DA LA SOCIEDAD BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY, S.L.</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">En Madrid, a las 9:00 a.m., el d&#237;a 30 de junio de 2017, reunidos en la calle Velazquez 12, Planta Baja, 28001, Madrid, presentes o debidamente representados, todos los socios de la sociedad </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY, S.L.</font><font style="font-family:inherit;font-size:10pt;">, con C.I.F. n&#250;mero B47729934 (la "</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sociedad</font><font style="font-family:inherit;font-size:10pt;">"), que representan la totalidad de su capital social, acuerdan por unanimidad la celebraci&#243;n de la Junta General Extraordinaria y Universal de socios de la Sociedad, al amparo de lo previsto en el art&#237;culo 178 de la Ley de Sociedades de Capital.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Antes de la aprobaci&#243;n de los acuerdos incluidos en el orden del d&#237;a, se procede a la elaboraci&#243;n de la lista de asistentes, resultando estar presentes:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La sociedad </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Creux An&#225;lisis Estrat&#233;glcos, S.L.</font><font style="font-family:inherit;font-size:10pt;">, representada en este acto por D. Emilio Guti&#233;rrez G&#243;mez, titular de 11.721.379 participaciones representativas del 23,45% del capital social.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Emilio Guti&#233;rrez G&#243;mez</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Emilio Guti&#233;rrez G&#243;mez</font><font style="font-family:inherit;font-size:10pt;">, titular de 5.024.443 participaciones represenrativas del 10,05% del capital social.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D. Emilio Guti&#233;rrez G&#243;mez asiste a su vez en calidad de Consejero del Consejo de Administraci&#243;n de la Socicdad.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Carlos Bl&#225;zquez Escudero</font><font style="font-family:inherit;font-size:10pt;">, representado en este acto por D. Pablo Guti&#233;rrez G&#243;mez, titular de 4.212.731 participaciones representativas del 8,43% del capital social. D. Pablo Guti&#233;rrez G&#243;mez representa a D. Carlos Bl&#225;zquez Escudero en virtud de poder especial (proxy) otorgado a su favor.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Ricardo Arjona Antolin</font><font style="font-family:inherit;font-size:10pt;">, titular de 4.910.077 participaciones representativas del 9,82% del capital social.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Ricardo Arjona Antol&#237;n</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Ricardo Arjona Antolin</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D. Ricardo Arjona Antolfn asistc a su vez en calidad de Consejero del Conscjo de Administraci&#243;n de la Sociedad.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D&#241;a. Ana G&#243;mez Rodr&#237;guez</font><font style="font-family:inherit;font-size:10pt;">, titular de 4.495.819 participaciones rcpresentativas del 8,995% del capital social.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Ana G&#243;mez Rodr&#237;guez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D&#241;a. Ana G&#243;mez Rodr&#237;guez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D&#241;a. Ana G&#243;mez Rodr&#237;guez asiste a su vez en calidad de Secretario y Consejero del Consejo de Adrninistracion de la Sociedad.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Luis Hilario Guerra Trueba</font><font style="font-family:inherit;font-size:10pt;">, representado en este acto por D. Emi1io Guti&#233;rrez G&#243;mez, titular de 2.781.290 participaciones representativas del 5,565% del capital social. D. Emilio Guti&#233;rrez G&#243;mez representa a D. Luis Hilario Trueba en virtud de poder especial (proxy) otorgado en su favor.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La sociedad </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Floema Biotec, S.L.</font><font style="font-family:inherit;font-size:10pt;">, representada en este acto por D. Antonio de Leyva Tejada, titular de 10.654.955 participaciones representativas del 21,32% del capital social. D. Anlonio de Leyva Tejada representa a la sociedad Floema Biolec, S.I.. en virtud del poder especial (proxy) otorgado a su favor.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/</font><font style="font-family:inherit;font-size:11pt;">&#160;Antonio De Leyva Tejadaon</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Antonio de Leyva Tejada</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Jorge Hern&#225;ndez Esteban</font><font style="font-family:inherit;font-size:10pt;">, titular de 3.757.607 participaciones representativas del 7,52 % del capital social.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Jorge Hern&#225;ndez Esteban</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Jorge Hernandez Esteban</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Yahia El-Amrani Bentahar</font><font style="font-family:inherit;font-size:10pt;">, representado en este acto par D. Emilio Guti&#233;rrez G&#243;mez, titular de 2.426.699 participaciones representativas del 4,85% del capital social. D. Emilio Guti&#233;rrez G&#243;mez representa a D. Yahia El Arnrani Bentahar en virtud de poder especial (proxy) olorgado en su favor.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Pablo Guti&#233;rrez G&#243;mez</font><font style="font-family:inherit;font-size:10pt;">, asiste en su calidad de Presidente y Consejero del Consejo de Administraci&#243;n de la Sociedad.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asimismo, asisten las siguientes entidades, debidamente representadas, a los efectos del Acuerdo Segundo a aprobar en la presente Junta:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La sociedad </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dyadic International (USA)</font><font style="font-family:inherit;font-size:10pt;">, Inc., representada en este acto por D. Antonio Cafiadas Bouwen, en su condici&#243;n de apoderado especial de la misma,</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Antonio Ca&#241;adas Bouwen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Antonio Ca&#324;adas Bouwen</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La sociedad </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inveready Innvierte Biotech II, S.C.R., S.A.</font><font style="font-family:inherit;font-size:10pt;">, representada en este acto por D. Roger Piqu&#233; Pijuan, en su condici&#243;n de apoderado general de la misma.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Roger Piqu&#233; Pijuan </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Roger Piqu&#233; Pijuan</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estando presentes, por tanto, todos los socios que representan la totalidad del capital social, se decide, por unanimidad, la celebraci&#243;n de la Junta General Extraordinaria y Universal, para tratar y deliberar, previa aceptaci&#243;n tambien por unanimidad, el siguiente</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ORDEN DEL D&#205;A</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">PRIMERO</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- ACLARACI&#211;N DE LA ASIGNACI&#211;N DE LAS PARTICIPACIONES A LOS SOCIOS DE LA SOCIEDAD EN LAS AMPLIACIONES DE CAPITAL ELEVADAS A P&#218;BLICO EN VIRTUD DE LA ESCRITURA PUBLICA OTORGADA ANTE EL NOTARIO DE VALLADOUD D. JAVIER G&#211;MEZ MART&#205;NEZ, EL DIA 31 DE ENERO DE 2017, BAJO EL NUMERO 399 DE SU PROTOCOLO.</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">SEGUNDO</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- AUMENTO DEL CAPITAL SOCIAL DE LA SOCIEDAD Y CORRESPONDIENTE MODIFICACI&#211;N ESTATUTARIA.</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">TERCERO</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- DELEGACI&#211;N DE FACULTADES.</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">CUARTO</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- REDACCI&#211;N, LECTURA Y APROBACI&#211;N DEL ACTA DE LA JUNTA.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Por acuerdo un&#225;nime de los socios de la Sociedad, se designa como Presidente de la Junta a D. Pablo Guti&#233;rrez G&#243;mez, y como Secretario de la misma a D&#324;a, Ana G&#243;mez Rodr&#237;guez.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La Junta dispensa al consejero auscnte, D. Jos&#233; Pellicer Espa&#324;a, de su deber de asistencia a la reuni&#243;n de la Junta General de Socios establecido en el articulo 180 de la Ley de Sociedades de Capital.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">El Presidente declara Ia Junta v&#225;lidamente constituida para deliberar y adoptar acuerdos, por concurrir a ella, personalmente o debidamente representados, todos los socios de la Socicdad que rcpresentan el 100% del capital social, tras lo cual se pasa, sin m&#225;s dilaci&#243;n, a la deliberaci&#243;n de los puntos integrantes del Orden del Dia, adopt&#225;ndosc los siguientes acuerdos por unanimidad:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">ACUERDOS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">PRIMERO.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- ACLARACI&#211;N DE LA ASIGNACI&#211;N DE LAS PARTICIPACIONES A LOS SOCIOS DE LA SOCIEDAD EN LAS AMPLIACIONES DE CAPITAL ELEVADAS A P&#218;BLICO EN VIRTUD DE LA ESCRITURA PUBLICA OTORGADA ANTE EI. NOTARIO DEV ALLADOLID, D. JAVIER G&#211;MEZ MART&#205;NEZ, EL D&#205;A 31 DE ENERO DE 2017, BAJO EL N&#218;MERO 399 DE SU PROTOCOLO.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La Junta acuerda por unanimidad aclarar y dejar constancia de la asignaci&#243;n de las participaciones sociales creadas en virtudd de las ampliaciones de capital social de la Sociedad formalizadas en Escritura P&#250;blica otorgada ante el Notario de Valladolid D. Javier G&#243;mez Mart&#237;nez, el d&#237;a 31 de encro de 2017, bajo el n&#250;rmcro 399 de su protocolo (Ia "</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Escritura</font><font style="font-family:inherit;font-size:10pt;">"), hacienda constar que la asignaci&#243;n de las participaciones sociales creadas en las referidas ampliaciones de capital fue la indicada a continuaci&#243;n:</font></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A la sociedad </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Creux An&#225;lisis Estrat&#233;gtcos, S.L.,</font><font style="font-family:inherit;font-size:10pt;">&#32;se le asignaron 1.943.515 participaciones sociales, numeradas del 41.985.001 al 43.033.003 y del 46.485.001 al 47.380.512, todas inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Ricardo Arjona Antol&#237;n</font><font style="font-family:inherit;font-size:10pt;">, se le asignaron 853.380 participaciones sociales, numeradas del 43.033.004 al 43.467.804 y del 47.380.513 al 47.799.091, todas inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Carlos Bl&#225;zquez Escudero</font><font style="font-family:inherit;font-size:10pt;">, se le asignaron 741.771 participaciones sociales, numeradas del 43.467.805 al 43.839.825 y del 47.799.092 al 48.168.841, todas inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;A </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D&#324;a. Ana G&#243;mez Rodr&#237;guez</font><font style="font-family:inherit;font-size:10pt;">, se le asignaron 787.079 participaciones sociales, nwneradas del 43.839.826 al 44.237.332 y del 48.168.842 al 48.558.413, todas inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Emilio Guti&#233;rrez G&#243;mez</font><font style="font-family:inherit;font-size:10pt;">, se le asignaron 871.684 participaciones sociales, numeradas del 44.237.333 al 44.682.429 y del 48.558.414 al 48.985.000, todas inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Luis Hilario Guerra</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Trueba</font><font style="font-family:inherit;font-size:10pt;">, se le asignaron 2.203.896 participaciones sociales, numeradas del 44.682.430 al 45.886.325 y del 48.985.001 al 49.985.000, todas inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Jorge Hernandez Esteban</font><font style="font-family:inherit;font-size:10pt;">, se le asignaron 363.757 participaciones sodales, numeradas del 45.886.326 al 46.250.082, ambas inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D. Yahia ElAmrani Bentahar</font><font style="font-family:inherit;font-size:10pt;">, se le asignaron 234.918 participaciones sociales, numeradas del 46.250.083 al 46.485.000, ambas inclusive.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adicionalmente, la Junta acuerda por unanimidad dejar constancia de que en la Escritura, por un error tipogr&#225;fico, se dej&#243; constancia de que el desembolso realizado por el socio D. Luis Hilario Guerra Trueba en la prirnera ampliaci&#243;n de capital ascendi&#243; a 12.042,00 Euros, cuando en realidad ascendio a 12.038,96 Euros conforme se indica en el certificado bancario adjunto a la citada Escritura.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Las anteriores aclaraciones en ning&#250;n caso modifican las cifras conespondientes a las ampliaciones de capital suscritas en virtud de la Escritura, ni el n&#250;mero de participaciones suscritas por cada uno de los socios en las citadas ampliaciones.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">SEGUNDO</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- AUMENTO DEL CAPITAL SOCIAL DE LA SOOEDAD Y CORRESPONDIENTE MODIFICACI&#211;N ESTATUTARIA.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La Junta acuerda por unanimidad aumentar el capital social en la cifra de </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CIENTO SESENTA Y CUATRO MIL CUATROCIENTOS DOS EUROS CON CUARENTA Y NUEVE C&#201;NTIMOS (164.402,49 &#8364;), </font><font style="font-family:inherit;font-size:10pt;">es decir, hasta la nueva cifra de</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;SEISCIENTOS SESENTA Y CUATRO MIL DOSCIENTOS CINCUENTA Y DOS EUROS CON CUARENTA Y NUEVE C&#201;NTIMOS (664.252,49 &#8364;)</font><font style="font-family:inherit;font-size:10pt;">, mediante la creaci&#243;n de</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;DIECIS&#201;IS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MILLONES CUATROCIBNTAS CUARENTA MIL DOSCIENTAS CUARENTA Y NUEVE (16.440.249)</font><font style="font-family:inherit;font-size:10pt;">&#32;nuevas participaciones de </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UN C&#201;NTIMO (0,01 &#8364;)</font><font style="font-family:inherit;font-size:10pt;">&#32;de valor nominal cada una de ellas, numeradas del 49.985.001 al 66.425.249, ambas inclusive. Las nuevas participaciones se crean con una prima de asuncion total de </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UN MILL&#211;N DOSCIENTOS SESENTA Y NUEVE MIL QUINIENTOS NOVENTA Y SIETE EUROS CON CINCUENTA Y UN C&#201;NTIMOS</font><font style="font-family:inherit;font-size:10pt;">&#32;(1.269.597,51 &#8364;), es decir, de aproximadamente 0,077 &#8364; por parti.cipaci&#243;n.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Las nuevas participaciones tendr&#225;n los mismos derechos politicos y econ&#243;micos que las restantes participaciones de la Sociedad actualmente en circulaci&#243;n.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adicionalmente, en este mismo acto, todos los socios de la Sociedad, es decir </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Creux An&#225;lisis Estrategicos, S.L., D. Emilio Guti&#233;rrez G&#243;mez, D. Carlos Bl&#225;zquez Escudero, D. Ricardo Arjona Antolin, D&#324;a. Ana G&#243;mez Rodr&#237;guez, D. Luis Hilario Guerra Trueba, Floema Biotec, S.L., D. Jorge Hernandez Esteban y D. Yahia El-Amrani Bcntahar</font><font style="font-family:inherit;font-size:10pt;">, presentes en la Junta o a trav&#233;s de sus representantes, renuncian totalmente a su derecho de asunci&#243;n preferente sabre las nuevas participaciones creadas con motivo del presenle aumento de capital de la Sociedad. Asirrusmo, la Junta acucrda por unanimidad que las entidades </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dyadic International (USA), Inc. e Invercady Innvierte Biotech II, S.C.R., S.A.</font><font style="font-family:inherit;font-size:10pt;">, presentes en la Junta y debidamente representadas a trav&#233;s de sus representantes legales, suscriban las nuevas participaciones sociales creadas, quienes lo aceptan expresamente y </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">asumen las nuevas participaciones, en la forma y en los t&#233;rminos y condicioncs establecidos en el presence acuerdo a probado por unanimidad por la Junta.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A los efectos del articulo 198.4.1&#176; del Reglamento del Registro Mercantil, se hace constar que la asunci&#243;n de las nuevas participaciones, mediante su desembolso integro por su valor nominal total asi coma la prima correspondiente, deber&#225; llevarse a cabo mediante aportaci&#243;n dineraria como sigue:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La sociedad </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dyadic International (USA), Inc.,</font><font style="font-family:inherit;font-size:10pt;">&#32;con n&#250;mero de idenlificaci&#243;n (EIN) 65-0645993, de nacionalidad estadounidense, con dorrricilio social en calle 140 Iritracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477-USA, representada en este acto por D. Antonio Ca&#324;adas Bouwen en su calidad de apoderado especial de la misma, presente en la Junta, asume </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.707.750</font><font style="font-family:inherit;font-size:10pt;">&#32;nuevas participaciones sociales, numeros </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">49.985.001</font><font style="font-family:inherit;font-size:10pt;">&#32;al </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">60.692.750</font><font style="font-family:inherit;font-size:10pt;">, ambos inclusive, cuyo desembolso total realizara mediante aportaci&#243;n dineraria, a traves del ingreso de su valor nominal total, es decir, </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CIENTO SIETE MIL SETENTA Y SIETE EUROS CON CINCUENTA C&#201;NTIMOS (107.077,50 &#8364;)</font><font style="font-family:inherit;font-size:10pt;">, as&#237; como la prima total correspondiente, es decir, </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OCHOCIENTOS VEINTISEIS MIL NOVECIENTOS VEINTID&#211;S EUROS CON CINCUENTA C&#201;NTIMOS (826.922,50&#8364;)</font><font style="font-family:inherit;font-size:10pt;">&#32;(haciendo un total de 934.000 &#8364;), en la cuenta n&#176; ES43-0049-0133-1120-1069-4591 que la Sociedad mantiene abierta en el Banco Santander, S.A.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Una vez realizado el desembolso, se har&#225; constar la titularidad de las nuevas participaciones socialcs a favor de Dyadic International (USA), Inc.en el Libra Registro de Socios de la Sociedad.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La sociedad </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inveready lnnvierte Biotech II, S.C.R., S.A.,</font><font style="font-family:inherit;font-size:10pt;">&#32;con N.I.F. n&#250;mero A-65888232, de nacionalidad espa&#241;ola, con domicilio social en calle Cavallers, 50,08034 Barcelona, representada en este acto por D. Roger Piqu&#233; Pijuan en su calidad de apoderado de la misma, presente en la Junta, asume </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.732.499</font><font style="font-family:inherit;font-size:10pt;">&#32;nuevas participaciones socialcs, n&#250;meros </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">60.692.751</font><font style="font-family:inherit;font-size:10pt;">&#32;al </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">66.425.249</font><font style="font-family:inherit;font-size:10pt;">, ambos inclusive, cuyo desembolso total realizar&#225; mediante aportaci&#243;n dincraria, a trav&#233;s del ingreso de su valor nominal total, es decir, </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CINCUENTA Y SIETE MIL TRESCIENTOS VEINTICUATRO EUROS CON NOVENTA Y NUEVE C&#201;NTIMOS (57.324,99 &#8364;),</font><font style="font-family:inherit;font-size:10pt;">&#32;as&#237; como la prima total correspondiente, es decir, </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CUATROCIENTOS CUARENTA Y DOS MIL SEISCIENTOS SETENTA Y CINCO EUROS CON UN C&#201;NTIMO (442.675,01 &#8364;)</font><font style="font-family:inherit;font-size:10pt;">&#32;(haciendo un total de 500.000 &#8364;), en la cuenta n&#176; ES48-0128-0209-1801..0001-2303 que la Sociedad mantiene abierta en Bankinter, S.A.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Una vez realizado el desembolso, se har&#225; constar la titularidad de las nuevas participaciones sociales a favor de Inveready Innvierte Biotech II, S.C.R., S.A., en el Libro Registro de Socios de la Sociedad.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La Junta acuerda por unanimidad la asunci&#243;n de las anteriores participaciones por las entidades </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dyadic International (USA), Inc. e Inveready Innvierte Biotech II, S.C.R.,. S.A.</font><font style="font-family:inherit;font-size:10pt;">&#32;y en la forma anteriormente mendonada. Asimismo, la Junta acuerda por unanimidad que el aurnento de capital acordado deber&#225; ser desembolsado en metalico por las entidades </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dyadic International (USA), Inc. e Inveready Innvierte Biotech II, S.C.R., S.A.</font><font style="font-family:inherit;font-size:10pt;">, mediante ingreso del 100% del valor nominal de las nuevas participaciones que cada uno de ellos ha suscrito y de su correspondiente prime, es decir, por el importe total de </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UN MILL&#211;N CUATROCIFNI'OS TREINTA Y CUATRO MIL EUROS (1.434.000 &#8364;)</font><font style="font-family:inherit;font-size:10pt;">, en las cuentas bancarias antes resenadas, y antes del final del d&#237;a de hoy (i.e. 30 de junio de 2017), lo que deber&#225; acreditarse con los correspondientes certificados bancarios.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No obstante lo anterior, la Junta acuerda por unanimidad que si por cualquier motive no se desembolsase por las dos entidades arriba referidas el valor nominal y la prima de asunci&#243;n correspondiente a la totalidad de las nuevas participaciones sociales creadas, la ampliaci&#243;n de capital del presente acuerdo quedara sin efecto, lo cual es expresamente aceptado por las entidades Dyadic International (USA), Inc. e Inveready Innvierte Biotech</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II, S.C.R., S.A.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Como consecuencia de lo anterior, y condicionado al efectivo desembolso del valor nominal total de las participaciones y de su correspondiente prima objeto del presente aumento de capital, Ia Junta acuerda por unanimidad modificar el Art&#237;culo 5&#176; de los Estatutos Sociales de la Sociedad, el cual quedar&#225; con la siguiente nueva redacci&#243;n:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">"</font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">ART&#205;CULO 5.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">- El capital social es de </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">SEISCIENTOS SESENTA Y CUATRO MIL DOSCIENTOS CINCUENTA Y DOS EUROS CON CUARENTA Y NUEVE C&#201;NTIMOS (664.252,49 &#8364;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;y est&#225; dividido en 66.425.249 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">PARTICIPACIONES SOCIALES</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, n&#250;meros </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">UNO (1) al SESENTA Y SEIS MILLONES CUATROCIENTOS VEINTICINCO MIL, DOSCIENTAS CUARENTA Y NUEVE</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;(66.425.249), ambos inclusive, de </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">UN C&#201;NTIMO</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;(0,01 &#8364;) de valor nominal cada una de ellas, indivisibles y acumulables, que no tendr&#225;n el car&#225;cter de valores, ni estart&#225;n representadas por medio de tiiulos o de anotaciones en cuenta, ni se denominar&#225;m acciones."</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">TERCERO</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.- DELEGACI&#211;N DE FACULTADES.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">La Junta decide facultar a los Consejeros de la Sociedad para que, cualquicra de ellos, pueda, en su caso, clevar a p&#250;blico las decisioncs adopladas, facult&#225;ndoles especialmente en todo lo necesario y convenienle para su ejecuci&#243;n, desarrollo y curnplimiento, para firmar cuantos documentos pubhcos o privados, incluidos los de indole fiscal, sean precisos o convenientes parn su mejor ejccuci&#243;n hasta llegar a su inscripci&#243;n en el Registro Mercantil, pudiendo otorgar incluso escriluras de ratificaci&#243;n, subsanaci&#243;n y/o aclaraci&#243;n a la vista de las sugerencias verbales y/o la calificacion escrita del Rcgistrador Mercantil.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">CUARTO.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- REDACCI&#211;N, LECTURA Y APROBACI&#211;N DEL ACTA DE LA JUNTA.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No hacienda uso de la palabra en el turno de ruegos y preguntas ninguno de las asistentes y no formaliz&#225;ndose ulteriores cucstiones, el Secrctario procedi&#243; a la redacci&#243;n y lectura de la prcscnte Acta quc. fue aprobada uriarumernente par los asistentes y firrnada a continuaci6n por el Presidente y el Secrelario de la Junta.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:20%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EL PRESIDENTE DE LA JUNTA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EL SECRETARIO DE LA JUNTA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Ana G&#243;mez Rodr&#237;guez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D. Pablo Guit&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D&#324;a Ana G&#243;mez Rodr&#237;quez</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="s4c0a11e1b19142298945bab8a54f0a22"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MINUTES OF THE GENERAL SHAREHOLDER'S MEETING OF THE COMPANY BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY, S.L.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Madrid, at 9:00 a.m., on 30 June 2017, at Velazquez 12, Planta Baja, 28001, Madrid, being present or duly represented all the shareholders of the company BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY, S.L. (the "</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:10pt;">''), with C.I.F. number B47729934, as recorded in the list of attendees set out in the minutes, representing 100% of the Company's share capital, they have agreed on an unanimous vote to hold an Extraordinary and Universal General Shareholders Meeting in accordance with Section 178 of the Spanish Companies Act.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before discussing the points included in the Agenda, the list of attendees of the meeting, which is as follows, is drawn up:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Creux An&#225;lisis Estrat&#233;gicos, S.L.,</font><font style="font-family:inherit;font-size:10pt;">&#32;duly represented by Mr. Emilio Guti&#233;rrez G&#243;mez, holder of 11,721,379 shares, which represents 23.45% of the share capital.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font><font style="font-family:inherit;font-size:10pt;">, holder of 5,024,443 shares, which represents 10.05% of the share capital.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Emilio Gutierrez G&#243;mez also attends to this meeting as Director of the Board of Directors of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Carlos Bl&#225;zquez Escudero</font><font style="font-family:inherit;font-size:10pt;">, duly represented by Mr. Pablo Gutierrez G&#243;mez, holder of 4,212,731 shares, which represents 8.43% of the share capital. Mr. Pablo Gutierrez G&#243;mez acts in the name and on behalf of Mr. Carlos Bl&#225;zquez Escudero by virtue of a special power of attorney (proxy) granted in his favor.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Carlos Bl&#225;zquez Escudero</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Carlos Bl&#225;zquez Escudero</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Ricardo Arjona Antol&#237;n</font><font style="font-family:inherit;font-size:10pt;">, holder of 41910,077 shares, which represents 9.82% of the share capital.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Ricardo Arjona Antol&#237;n</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Ricardo Arjona Antol&#237;n</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Ricardo Arjona Antolin also attends to this meeting as Director of the Board of Directors of lhe Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ms. Ana G&#243;mez Rodr&#237;guez</font><font style="font-family:inherit;font-size:10pt;">, holder of 4,495,819 shares, which represents 8.995% of the share capital.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Ana G&#243;mez Rodr&#237;guez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ms. Ana G&#243;mez Rodr&#237;guez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Ana G&#243;mez Rodr&#237;guez also attends to this meeting as Secretary and Director of the Board of Directors of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Luis Hilario Guerra Trueba</font><font style="font-family:inherit;font-size:10pt;">, duly represented by Mr. Emilio Gutierrez G&#243;mez, holder of 2,781,290 shares, which represents 5.565% of the share capital. Mr. Emilio Guti&#233;rrez G&#243;mez acts in the name and on behalf of Mr. Luis Hilario Guerra Trueba on virtue of a special power of attorney (proxy) granted on his favor.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Floema Biotec, S.L.</font><font style="font-family:inherit;font-size:10pt;">, duly represented by Mr. Antonio de Leyva Tejada, holder of 10,654,955 shares, which represents 21.32% of the share capital. Mr. Antonio de Leyva Tejada acts in the name and on behalf of the entity Floema Biotec, S.L. by virtue of a special power of attorney (proxy) granted on his favor.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/</font><font style="font-family:inherit;font-size:11pt;">&#160;Antonio De Leyva Tejadaon</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Antonio de Leyva Tejada</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Jorge Hernandez Esteban</font><font style="font-family:inherit;font-size:10pt;">, holder of 3,757,607 shares, which represents 7.52% of the share capital.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Jorge Hern&#225;ndez Esteban</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Jorge Hernandez Esteban</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Yahia El-Amrani Bentahar</font><font style="font-family:inherit;font-size:10pt;">, duly represented by Mr. Emilio Guti&#233;rrez G&#243;mez, holder of 2,426,699 shares, which represents 4.85% of the share capital. Mr. Emilio Guti&#233;rrez G&#243;mez acts in the name and on behalf of Mr. Yahia El-Amrani Benlahar on virtue of a special power of attorney (proxy) granted on his favor</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Pablo Guti&#233;rrez G&#243;mez</font><font style="font-family:inherit;font-size:10pt;">, attends in his condition of Chairman and Director of the Board of Directors of the Company.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, the following entities attend to this meeting, duly represented, for the purpose of the Second Resolution to be approved at the meeting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dyadic International (USA), Inc.</font><font style="font-family:inherit;font-size:10pt;">, duly represented by Mr. Antonio Ca&#324;adas Bouwen, in his condition of special attorney.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Antonio Ca&#241;adas Bouwen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Antonio Ca&#241;adas Bouwen</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inveready Innvierte Biotech II, S.C.R., S.A.</font><font style="font-family:inherit;font-size:10pt;">, duly represented by Mr. Roger Piqu&#233; Pijuan, in his condition of general attorney.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:29.561671763506624%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Roger Piqu&#233; Pijuan </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Roger Piqu&#233; Pijuan</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thus, being present all the shareholders of the Company, representing 100% of the Company's share capital, the attendees approve unanimously to hold the Extraordinary and Universal General Shareholders Meeting to discuss and deliberate the following Agenda:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AGENDA</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">FIRST</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- CLARIFICATION OF THE ALLOCATION TO THE SHAREHOLDERS OF THE SHARES CREATED BY THE INCREASES OF CAPITAL FORMALIZAED BY VIRTUE OF THE PUBLIC DEED GRANTED BEFORE THE PUBLIC NOTARY OF VALLADOLID, MR. JAVIER G&#211;MEZ MART&#205;NEZ, ON 31 JANUARY 2017, UNDER NUMBER 399 OF HIS PUBLIC RECORDS.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">SECOND</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- SHARE CAPITAL INCREASE OF THE COMPANY AND AMENDMENT OF THE COMPANY'S BY-LAWS.</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">THIRD</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- DELEGATION OF FACULTIES.</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">FOURTH</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">- DRAFTING, READING AND APPROVAL OF THE MINUTES OF THE GENERAL SHAREHOLDERS MEETING.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The shareholders unanimously appointed Mr. Pablo Gutierrez G&#243;mez and Ms. Ana G&#243;mez Rodr&#237;guez as Chairman and Secretary to the General Meeting, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The General Shareholder's Meeting exempts the non-present member of the Board of Directors, Mr. Jos&#233; Pellicer Espa&#241;a, from his duty to attend the General Meeting in accordance with Article 180 of the Spanish Comparucs Act.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The session is declared open by the Chairman, who declares the meeting with sufficient quorum to adopt valid resolutions, being present or duly represented all the shareholders of the Company representing 100% of the Company's share capital, and proceed to discuss the resolutions proposed in the Agenda, which were then unanimously approved by the attending shareholders as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RESOLUTIONS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">FIRST</font><font style="font-family:inherit;font-size:10pt;">.- CLARIFICATION OF THE ALLOCATION TO THE SHAREHOLDERS OF THE SHARES CREATED BY THE INCREASES OF CAPITAL FORMALIZAED BY VIRTUE OF THE PUBLIC DEED GRANTED BEFORE THE PUBLIC NOTARY OF VALLADOLID, MR. JAVIER G&#211;MEZ MART&#204;NEZ, ON 31 JANUARY 2017, UNDER NUMBER 399 OF HIS PUBLIC RECORDS.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The General Shareholders Meeting unanimously approves to clarify and put on record that the allocation of the new shares created by virtue of the Company's share capital increases formalized by virtue of the Public Deed granted before the Public Notary of Valladolid, Mr. Javier G&#243;mez Mart&#236;nez, on 31 January 2017, under number 399 of his records (the "</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Public Deed</font><font style="font-family:inherit;font-size:10pt;">") was the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Creux An&#225;lisis Estrat&#233;gtcos, S.L.</font><font style="font-family:inherit;font-size:10pt;">&#32;subscribed 1,943,515 shares, .numbered from 41,985,001 to 43,033,003 and from 46,485,001 to 47,380,512, all of them inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Ricardo Arjona Antolin</font><font style="font-family:inherit;font-size:10pt;">&#32;subscribed 853,380 shares, numbered from 43,033,004 to 43,467,804 and from 47,380,513 to 47,799,091, all of them inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Carlos Bl&#225;zquez Escudero</font><font style="font-family:inherit;font-size:10pt;">&#32;subscribed 741,771 shares, numbered from 43,467,805 to 43,839,825 and from 47,799,092 to 48,168,841, all of them inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ms. Ana G&#243;mez Rodr&#237;guez</font><font style="font-family:inherit;font-size:10pt;">&#32;subscribed 787,079 shares, numbered from 43,839,826 to 44,237,332 and from 48,168,842 to 48,558,413, all of them inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Emilio Guti&#233;rrez G&#243;mez </font><font style="font-family:inherit;font-size:10pt;">subscribed 871,684 shares, numbered from 44,237,333 to 44,682,429 and from 48,558,414 to 48,985,000, all of them inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Luis Hilario Guerra Trueba</font><font style="font-family:inherit;font-size:10pt;">&#32;subscribed 2,203,896 shares, numbered from 44,682,430 to 45,886,325 and from 48,985,001 to 49,985,000, all of them inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Jorge Hern&#225;ndez Esteban</font><font style="font-family:inherit;font-size:10pt;">&#32;subscribed 363,757 shares, numbered from 45,886,326 to 46,250,082, both inclusive.</font></div></td></tr></table><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Yahia El-Amrani Bentahar</font><font style="font-family:inherit;font-size:10pt;">&#32;subscribed 234.918 shares, numbered from 46,250,083 to 46,485,000, both inclusive.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the General Shareholders Meeting unanimously approves to state that in the Public Deed, because of a typographical error, it was stated that the disbursement executed by the shareholder Mr. Luis Hilario Guerra Trueba in the first share capital increase amounted to a total amount of &#8364; 12,042.00 instead of the correct amount of &#8364; 12,038.96 as it is indicated in the banking certificate attached to the referred Public Deed.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing clarifications, in any case neither amend the figures related to the subscribed share capital increases by virtue of the Public Deed, nor the number of the shares subscribed by each of the shareholders in such. share capital increases.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">SECOND</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.- SHARE CAPITAL INCREASE OF THE COMPANY AND AMENDMENT OF THE COMPANY'S BY-LAWS.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The General Shareholders Meeting unanimously approves to increase the share capital of the Company in the amount of &#8364; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">164,402.49</font><font style="font-family:inherit;font-size:10pt;">, that is, to the amount of &#8364; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">664,252.49</font><font style="font-family:inherit;font-size:10pt;">&#32;by creating </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,440,249</font><font style="font-family:inherit;font-size:10pt;">&#32;new shares, each with a par value of &#8364; 0,01, numbered consecutively from 49,985,001 to 66,425,249, both inclusive. The new shares are created with a total share premium amounting to &#8364; 1,269,597.51 that is, &#8364; 0,077 per share.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new shares will have the same economic and political rights that the existing shares of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, in this act, all the shareholders of the Company, that is,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Creux An&#225;lisis Estrat&#233;giccs, S.L., Mr. Emilio Guti&#233;rrez G&#243;mez, Mr. Carlos Bl&#225;zquez Escudero, Mr. Ricardo Arjona Antol&#237;n, Ms. Ana G&#243;mez Rodr&#237;guez, Mr. Luis Hilario Guerra Trueba, Floema Biotec, S.L., Mr. Jorge Hern&#225;ndez Esteban and Mr. Yahia Bl-Amrani Bentahar,</font><font style="font-family:inherit;font-size:10pt;">&#32;all of them present at this Meeting or duly represented by their legal representatives, totally resign to their pre-emptive right over the new shares created by virtue of the capital increase of the Company. Furthermore, the General Meeting unanimously approves that the entities </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dyadic International (USA), Inc. and lnveready Innvierte Biotcch II, S.C.R., S.A.,</font><font style="font-family:inherit;font-size:10pt;">&#32;present at this Meeting and duly represented by their legal representatives, subscribe the new shares created, and they expressly accept and subscribe the new shares in the manner and under the terms and conditions established in this resolution unanimously approved by the General Shareholders Meeting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Article 198.4.1&#176; of the Commercial Registry Regulations, it is established that the subscription of the new shares through their total disbursement of their par value and the corresponding share premium shall be carried out by cash contribution as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The entity </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dyadic Intenational (USA), Inc.,</font><font style="font-family:inherit;font-size:10pt;">&#32;with company identification number (EIN) 65-0645993, of American nationality, with its registered office at calle 140 Intrecoastal Pointe Drive, Suite 404, Jupiter, Florida 33477-USA, duly represented by Mr. Antonio Ca&#241;adas Bouwen in his capacity of special attorney, present at this Meeting, subscribes 10,707,750 new shares, numbered from 49,985,001 to 60,692,750, both inclusive, and the disbursement of such shares shall be made through cash contribution of their total par value, that is, Euros 107,077.50, and of the corresponding total share premium, that is,&#8364; 826,922.50 (amounting to a total sum of &#8364; 934,000), into the bank account number ES43-0049-0133-1120-1069-4591 of the Company at Banco Santander, S.A.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once the disbursement has been made, the ownership of the newly created shares will be registered in the Shareholders Registry Book of the Company in favour of Dyadic International (USA), Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The entity </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inveready Irmvierte Biotech II, S.C.R., S.A.,</font><font style="font-family:inherit;font-size:10pt;">&#32;with N.I.F. number A-65888232, of Spanish nationality, with its registered office at calle Cavallers, SO, 08034 Barcelona, duly represented by Mr. Roger Piqu&#233; Pijuan, in his capacity as general attorney, present at this Meeting, subscribes 5,732,449 new shares, numbered 60,692,751 to 66,425,249 both inclusive, and the disbursement of such shares shall be made through cash contribution of their total par value, that is, Euros 57,324.99 and of the corresponding total share premium, that is, &#8364; 442,675.01 (amounting to the total sum of&#8364; 500,000), into the bank account number ES48-0128-0209-1801-0001-2303 of the Company at Bankinter, S.A</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once the disbursement has been made, the ownership of the newly created shares will be registered in the Shareholders Registry Book of the Company in favour of lnveready Inrrvierte Biotech II, S.C.R., S.A.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The General Shareholders Meeting unanimously approves the subscription of the abovementioned shares by the entities Dyadic International (USA), Inc. and Inveready Innvierte Biotech II, S.C.R., S.A. in the manner mentioned before. Furthermore, the General Shareholders Meeting unanimously approves that the capital increase agreed shall be paid up in cash by the entities Dyadic International (USA), Inc. and Inveready Innvierte Biotech II, S.C.R, S.A., through the transfer of the 100% of the par value of the new shares subscribed by each of them and their corresponding share premium, that is, the total amount of &#8364; 1,434,000, into the before mentioned bank accounts and before the end of this date (i.e. 30 June 2017), which shall be accredited with the corresponding banking certificates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing, the General Shareholders Meeting unanimously approves that, if for any reason the par value of the total of the newly created shares and the corresponding share premium is not disbursed by the two abovementioned entities, the approved share capital increase shall not have effects, condition which is expressly accepted by the entities Dyadic International (USA), Inc. and Inveready Innvierte Biotech II, S.C.R., S.A.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By virtue of the foregoing and subject to the total disbursement of the par value and share premium of the newly created shares, the General Shareholders Meeting unanimously approves to amend Article 5 of the Bylaws, which shall be read as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">"</font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">ARTICLE 5</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.- The share capital is </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EUR 664,252.49</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, and it is divided into </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">66,425,24:9 SHARES</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, numbered from 1 to 66,425,2491 both inclusive, of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EUR 0,01</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, par value each, indivisible and cumulative, not to be deemed securities nor represented in certificates or book entries and not to be called shares".</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">THIRD</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.- DELEGATION OF FACULTIE</font><font style="font-family:inherit;font-size:10pt;">S.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The General Shareholders Meeting unanimously approves to expressly empower the Directors of the Company, so that any of them, indistinctly, may formalise the decisions hereby adopted, especially empowering them to do everything which is necessary and convenient for their execution and performance, to sign whatever public or private documents, including tax documents, as may be necessary or convenient, and to undertake whatever actions as are suitable for their performance, until they are registered with the Commercial Registry. They are also empowered to execute public deeds of ratification, substitution and/ or clarification in the light of the verbal suggestions and/ or written opinions of the Commercial Registry.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">FOURTH</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.- DRAFTING, READING AND APPROVAL OF THE MINUTES OF THE GENERAL SHAREHOLDERS MEETING.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">And there being no further matters to be dealt, the session is adjourned so that the minutes can be drawn up and they were then read by the Secretary, being unanimously approved by all the attendees, and signed by the Secretary with the approval of the Chairman.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:47%;"></td><td style="width:6%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE CHAIRMAN OF THE MEETING</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE SECRETARY OF THE MEETING</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ </font><font style="font-family:inherit;font-size:11pt;">Ana G&#243;mez Rodr&#237;guez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Pablo Guti&#233;rrez G&#243;mez</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Ana G&#243;mez Rodr&#237;guez</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s5A702CFE8E76380F66DAD4DC1E1BD6B0"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT D2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Minutes of the Sole Shareholder of VLP</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">ACTA DE CONSIGNACI&#211;N DE LAS DECISIONES DEL SOCIO &#218;NICO DE LA SOCIEDAD VLP THE VACCINES COMPANY, S.L.U.</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">En Madrid, a las 9:30 a.m., el dia 30 de junio de 2017, en la calle Vel&#225;zquez 12, Planta Baja, 28001, Madrid, el socio &#250;nico de la sociedad </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">VLP THE VACCINES COMPANY, S.L.U.</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">&#32;(la "</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">Sociedad</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">"), la entidad BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY, S.L. (el "</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">Socio &#218;nico</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">"), que representa la totalidad del capital social, por medio de su rcpresentante legal </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">D. Pablo Guti&#233;rrez G&#243;mcz</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">, en calidad de consejero delegado del Socio &#218;nico.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">Asimismo, asisten las siguienles entidades, debidamente representadas, a las efectos de la primera decisi&#243;n a adoptar en la presente Junta:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">La sociedad </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">Dyadic International (USA), Inc.</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">, representada en este acto por D. Antonio Ca&#241;adas Bouwen, en su condici&#243;n de apoderado especial de la misma.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:24px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Antonio Ca&#241;adas Bouwen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">D. Antonio Ca&#241;adas Bouwen</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">La sociedad </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">Inveready Innvicrte Biotcch II, S.C.R., S.A.</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">, representada </font><font style="font-family:inherit;font-size:10pt;color:#545b5b;">e</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">n este acto por D. Roger Piqu&#233; Pijuan, en su condici&#243;n de apoderado general de la misma.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:24px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Roger Piqu&#233; Pijuan </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">D. Roger Piqu&#233; Pijuan</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">En virtud de lo ant</font><font style="font-family:inherit;font-size:10pt;color:#545b5b;">e</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">rior, el Socio &#218;nico decide adoptar, al amparo del art&#237;culo 15 de la Ley de Sociedades de Capital, las siguientes</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">DECISIONES</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;text-decoration:underline;">PRIMERA</font><font style="font-family:inherit;font-size:10pt;color:#545b5b;font-weight:bold;">.</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">- AUMENTO DEL CAPITAL SOCIAL DE LA SOCIEDAD Y CORRESPONDIENTE MODIFICACI&#211;N ESTATUTARIA.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">El Socio &#218;nico decide aumentar el capital social de la Sociedad en la cifra de </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">SETENTA Y OCHO MIL SEISCIENTOS QUINCE EUROS CON CUARENTA C&#201;NTIMOS (78.615,40 &#8364;)</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">, es decir, hasta la nueva cifra de </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">DOSCIENTOS VEINTICUATRO MIL SEISCIENTOS QUINCE EUROS CON CUARENTA C&#201;NTIMOS (224.615,40 Euros)</font><font style="font-family:inherit;font-size:10pt;color:#545b5b;">, </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">mediante la creaci&#243;n de </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">SETECIENTAS OCHENTA Y SEIS MIL CIENTO CINCUENTA Y CUATRO (786.154) </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">nuevas participaciones de </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">DIEZ C&#201;NTIMOS (0,10 &#8364;)</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">&#32;de valor nominal cada una de ellas, numeradas del 1.460.001 al 2.246.154, ambos inclusive. Las nuevas participaciones se crean con una prima de asunci&#243;n total de </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;font-weight:bold;">SEISCIENTOS VEINTI&#218;N MIL TRESCIENTOS OCHENTA Y CUATRO CON SESENTA C&#201;NTIMOS (621.384,60 &#8364;)</font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">, es decir, aproximadamente 0,79 &#8364; por participaci&#243;n.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:3px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#363636;">Las nuevas participaciones tendr&#225;n los mismos derechos pol&#237;ticos y econ&#243;micos que las restantes parlicipaciones de la Sociedad actualmente en circulaci&#243;n.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#363636;">Asimismo, en este mismo acto, el Socio </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">&#218;</font><font style="font-family:inherit;font-size:10pt;color:#363636;">nico de la Sociedad, Biotechnology Developments for Industry, S.L., de nacionalidad espa&#241;ola, con domicilio social en avenida Francisco Vall&#233;s 8, 47151, Boecillo (Valladolid), con C.I</font><font style="font-family:inherit;font-size:10pt;color:#4d4d4d;">.</font><font style="font-family:inherit;font-size:10pt;color:#363636;">F. n&#250;mero B-47729934, constituida por tiempo indefinido mediante escritura de constituci&#243;n otorgada ante el Notario de Madrid D. Jorge Prades L&#243;pez, el dia 22 de septiembre 2014, bajo el n&#250;mero 789 de orden de su protocolo e inscrita en el Registro Mercantil de Valladolid al Torno 1477, Folio 91, Hoja VA-27242 y representada en este acto por D. Pablo Guti&#233;rrez G&#243;mez en su calidad de consejero delegado de la rnisma, presente en la Junta, manifiesta su deseo de ejercitar parcialrnente su derecho de asunci&#243;n preferente sobre las nuevas participaciones creadas en el aumento de capital de </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#363636;">la Sociedad, mediante la asunci&#243;n de TRESCIENTAS DIECIOCHO MIL NOVECIENTAS CINCUENTA Y CUATRO (318.954) nuevas participaciones sociales, ruimeros 1.460.001 a 1.778.954, ambos inclusive, cuyo desembolso total se realizar&#225; mediante aportaci&#243;n dineraria, a trav&#233;s de ingreso de su valor nominal total, es decir TREINTA Y UN MIL OCHOCIENTOS NOVENTA Y CINCO EUROS CON CUARENTA C&#201;NTIMOS (31.895,40 &#8364;), as&#237; como la prima de asunci&#243;n total correspondiente, es decir, DOSCIENTOS CINCUENTA Y DOS MIL CIENTO CUATRO EUROS CON SESENTA C&#201;NTIMOS (252.104,60 &#8364;) (haciendo un total de 284.000 &#8364;), en la cuenta n&#176; F.506-0128-0209-1605-0000-1193 que la Sociedad mantiene abierta en Bankinter, S.A. Adicionalmente, el Socio </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">&#218;</font><font style="font-family:inherit;font-size:10pt;color:#363636;">nico, renuncia a su derecho de asunci&#243;n preferente sobre las restantes nuevas participaciones sociales que le pudieran corresponder, creadas con motivo del aumento de capital de la Sociedad. Asimismo, el Socio </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">&#218;</font><font style="font-family:inherit;font-size:10pt;color:#363636;">nico decide que las entidades </font><font style="font-family:inherit;font-size:10pt;color:#363636;font-weight:bold;">Dyadic International (USA), Inc. e Inveready Innvierte Biotech II, S.C.R., S.A.</font><font style="font-family:inherit;font-size:10pt;color:#363636;">, presentes en la Junta y debidamente representadas a trav&#233;s de sus representantes legales, suscriban las restantes nuevas participaciones sociales creadas, quienes lo aceptan expresamente y asumen las nuevas participaciones, en la forma y en los t&#233;rminos y condiciones establecidos en el presente acuerdo decidido por el Socio </font><font style="font-family:inherit;font-size:10pt;color:#3d3d3d;">&#218;</font><font style="font-family:inherit;font-size:10pt;color:#363636;">nico. </font></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#363636;">Una vez realizado el desembolso, se har&#225; constar la titularidad de las nuevas participaciones sociales a favor de BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY, S.L. en el Libra Registro de Socios de la Sociedad.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#363636;">A los efectos del articulo 198.4.1 &#176; del Reglamento del Registro Mercantil, se hace constar que la asunci&#243;n de las restantes nuevas participaciones, mediante su desembolso &#237;ntegro por su valor nominal total as&#237; coma la prima correspondiente, se lleva a cabo mediante aportaci&#243;n dineraria coma sigue:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;color:#363636;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#363636;">La sociedad </font><font style="font-family:inherit;font-size:10pt;color:#363636;font-weight:bold;">Dyadic International (USA), Inc.</font><font style="font-family:inherit;font-size:10pt;color:#363636;">, con n&#250;mero de identificaci&#243;n (EIN)65</font><font style="font-family:inherit;font-size:10pt;color:#919191;">-</font><font style="font-family:inherit;font-size:10pt;color:#363636;">0645993, de nacionalidad estadounidense, con domicilio social en calle 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477-USA, representada en este acto par D. Antonio Ca&#241;adas Bouwen en su calidad de apoderado especial de la misma, presente en la Junta, asume SETENTA Y CUATRO MIL CIENTO </font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">VEINTITR&#201;S (74.123) nuevas participacioncs sociales, nurncros 1.778.955 a l1.853.077, ambos inclusive, cuyo desembolso total realizar&#225; mediante aportaci&#243;n dineraria, a trav&#233;s del ingreso de su valor nominal total, es decir, SIETE MIL CUATROCIENTOS DOCE EUROS CON TREINTA C&#201;NTIMOS (7.412,30 &#8364;),asi coma la prima total corresporidiertte, es declr, CINCUENTA Y OCHO MIL QUlNIENTOS OCHENTA Y SIETE EUROS CON SETENTA C&#201;NTIMOS (58.587,70 &#8364;) (hacienda un total de 66.000 &#8364;), en la cuenta n&#176; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; que la Sociedad mantiene abierta en el Banco Santander, S.A.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3a403b;">Una vez realizado el deserobolso, se hara coristar la titularidad de las nuevas participaciones socialos a favor de Dyadi</font><font style="font-family:inherit;font-size:10pt;color:#525353;">c </font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">Int</font><font style="font-family:inherit;font-size:10pt;color:#525353;">e</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">rnational (USA), Inc. en cl Libra Registro de Socios de la Sociedad.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;color:#3a403b;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3a403b;">La sociedad </font><font style="font-family:inherit;font-size:10pt;color:#3a403b;font-weight:bold;">Inveready Innvierte Biotech II, S.C.R., S.A.</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">, con N.I.F. rrumero A-65888232, de nadonalidad espariola, con domi</font><font style="font-family:inherit;font-size:10pt;color:#525353;">c</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">ilio social en ca1le Cavaliers, 50,08034 Barcelona, representada en este acto par D. Roger Pique Pijuan en su calidad de apodcrado general de la misma, presente en la Junta, asume TRESCIENTAS NOVENTA Y TRES MIL SETENTA Y SIETE (393.077) nuevas participacioncs sodales, rurmeros 1.853.078 al 2.246.154, ambos inclusive, cuyo desembolso total realizara mediante aportaci&#243;n dineraria, a traves del ingreso de su valor nominal total, es decir, TREINTA Y NUEVE MIL TRESCIENTOS SIETE EUROS CON SETENTA C&#201;NTIMOS (39.307,70 &#8364;), asf coma la prima total correspondiente, es decir, TRFSCIENTOS DIEZ MIL SEISCIENTOS NOVENTA Y DOS EUROS CON TREINT A C&#201;NTIMOS (310.692,30 &#8364;) (hacienda un total de 350.000 &#8364;), en la cuenta n&#176; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; que la Sociedad mantiene abierta en Bankinter, S.A.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3a403b;">Una vez realizado el desembolso, se har&#225; constar la titularidad de las nuevas participaciones sociales a favor de Inveready Innvierte Biotech II, S.C</font><font style="font-family:inherit;font-size:10pt;color:#525353;">.</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">R</font><font style="font-family:inherit;font-size:10pt;color:#525353;">.</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">, S.A</font><font style="font-family:inherit;font-size:10pt;color:#525353;">.</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">, en el Libro Registro de Socios de la Sociedad.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3a403b;">El Socio &#218;nico decide que se lleve a cabo la asunci&#243;n de las anteriores participaciones y sus respectivas primas por las entidades Biotechnology Developments for Industry S.L., Dyadi</font><font style="font-family:inherit;font-size:10pt;color:#525353;">c </font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">lntemational (USA), Inc</font><font style="font-family:inherit;font-size:10pt;color:#525353;">. </font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">e In.veready Innvierte Biotech TI, S.C.R., S.A en la forma an.terionnente mencionada</font><font style="font-family:inherit;font-size:10pt;color:#525353;">. </font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">Asimisrno, el Socio &#218;nico decide que el aumento de capital acordado debera ser desembolsado en metalico por las entidades Biotechnology Developments for Industry S</font><font style="font-family:inherit;font-size:10pt;color:#525353;">.</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">L., Dyadic International (USA), In</font><font style="font-family:inherit;font-size:10pt;color:#525353;">c</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">. </font><font style="font-family:inherit;font-size:10pt;color:#525353;">e </font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">Inveready Innvierte Biotcch U, S</font><font style="font-family:inherit;font-size:10pt;color:#525353;">.</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">C.R., S.A, mediante ingreso del 100</font><font style="font-family:inherit;font-size:10pt;color:#525353;">% </font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">del valor nominal de las nuevas participaciones que cada uno de ellos ha suscrito y de sus respectivas </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3a403b;">primas, es decir, par el importe total de SETECIENTOS MIL EUROS (700.000 &#8364;), en las cuentas bancarias antes resefiadas y an</font><font style="font-family:inherit;font-size:10pt;color:#525353;">t</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">es del final del dia de hoy (i.e</font><font style="font-family:inherit;font-size:10pt;color:#525353;">. </font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">30 de junio de 2017), lo que se acredi</font><font style="font-family:inherit;font-size:10pt;color:#525353;">t</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">ara con las correspondientes </font><font style="font-family:inherit;font-size:10pt;color:#525353;">ce</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">rtificad</font><font style="font-family:inherit;font-size:10pt;color:#525353;">o</font><font style="font-family:inherit;font-size:10pt;color:#3a403b;">s bancarios.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3a403b;">No obstante lo anterior, el Socio Unico decide que si por cualquier motivo no se desembolsase par las tres entidades arriba referidas el valor nominal y la prima d</font><font style="font-family:inherit;font-size:10pt;color:#525353;">e asunci&#243;n </font><font style="font-family:inherit;font-size:10pt;color:#333333;">correspondiente a la totalidad de las nuevas participaciones sociales creadas, la ampliaci&#243;n de capital del presente acuerdo quedara sin efecto, lo cual es expresamente aceptado por las entidades Biotechnology Develompents for Industry, S.L., Dyadic International (USA), Inc. e Inveready Innvierte Biotech II, S.C.R., S.A.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Como consecuencia de lo anterior, y condicionado al efectivo desembolso del valor nominal total de las participaciones y de sus respectivas primas, objeto del presente aumento de capital, el Socio &#218;nico decide modificar el articulo 5&#176; de los estatutos sociales de Ia Sociedad, el cual quedar&#225; con la siguiente nueva redaci&#243;n:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-style:italic;">"</font><font style="font-family:inherit;font-size:10pt;color:#333333;font-style:italic;text-decoration:underline;">Articulo 5&#176;</font><font style="font-family:inherit;font-size:10pt;color:#333333;font-style:italic;">.- Capital social y participaciones sociales. El capital social. queda fijado en la cifra de DOSCIENTOS VEINTICUATRO MIL SEISCIENTOS QUINCE EUROS CON CUARENTA CENTIMOS (224.615,40 Euros), totalmente desembolsados y esta dividido en </font><font style="font-family:inherit;font-size:10pt;color:#333333;">DOS </font><font style="font-family:inherit;font-size:10pt;color:#333333;font-style:italic;">MILLONES DOSCIENTAS CUARENTA Y SEIS MIL CIENTO CINCUENTA Y CUATR (2.246.154) participaciones sociales, de DIEZ CENTIMOS (0,10 Euros) de valor nominal, cada una, numeradas correlativamente del 1 al 2.246</font><font style="font-family:inherit;font-size:10pt;color:#464646;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;color:#333333;font-style:italic;">154, ambos inclusive, que no podran esiar represeniadas por media de titulos, ni de anotaciones en cuenia, ni denominarse acciones",</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">SEGUNDA</font><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">.- DELEGACI&#211;N DE FACULTADES.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">El Socio Unico decide facultar a cualquiera de los miembros del &#243;rgano de administracicn de la Sociedad para que, cualquiera de ellos, pueda, en su caso, elevar a publico las decisiones adoptadas, facultandoles especialmente en todo lo necesarlo y conveniente para su ejecuci&#243;n, desarrollo y cumplimiento, para firmar cuantos documentos publicos o privados, incluidos los de indole fiscal, sean precises o convenientes para su mejor ejecuci&#243;n hasta llegar a su inscripcion en el Registro Mercantil, pudiendo otorgar incluso escrituras de ratificaci&#243;n, subsanaci&#243;n y/o aclaraci&#243;n a la vista de las sugerendas verbales y/o la calificaci&#243;n escrita del Registrador Mercantil.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Lo que se consigna en el presente acta, de conformidad con lo previsto en el arnticulo 15 LSC y el articulo 97.2 del Reglamento del Registro Mercantil, siendo dicha acta leida y firmada en prueba de conformidad por el representante del Socio Unico, en el lugar y la fecha citados en el encabezamiento.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">El Socio Unico</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:38.034188034188034%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">Biotechnology Developments for<br>Industry, S.L.</font><font style="font-family:inherit;font-size:10pt;color:#333333;">, a trav&#233;s de su representante<br>D. Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><a name="s2344f8593d704f31bb03febd826ae50f"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">MINUTES OF THE DECISIONS OF THE SOLE SHAREHOLDER OF THE COMPANY VLP THE VACCINES COMPANY, S.L.U.</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;">In Madrid, at 9:30 a.m., on 30 June 2017, al calle Vel&#225;zquez 12, Planta Baja, 28001, the sole shareholder of the company </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">VLP THE VACCINES COMPANY, S.L.U.</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">&#32;(the "</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">"), the company </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY, S.L</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5f;font-weight:bold;">.</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5f;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">(the "</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">Sole Shareholder</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">"), representing the entire share capital, duly represented by its representative Mr. Pablo Gutierrez G6mez in his capacity as Managing Director of the Sole Shareholder.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;">Furthermore, the following entities attend, duly represented, for the purpose of the first decision to be approved at the Meeting.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;">The entity </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">Dyadic International (USA), Inc.</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">, duly represented by Mr. Antonio Ca&#241;adas Bouwen, in his condition of Managrng Director.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Antonio Ca&#241;adas Bouwen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">D. Antonio Ca&#241;adas Bouwen</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;">The entity </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">Inveready Innvierte Biotech II, S.C.R., S.A.</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">, duly represented by Mr</font><font style="font-family:inherit;font-size:10pt;color:#868790;">. </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">Roger Piqu&#233; Pijuan, in his condition of general attorney.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.982905982905983%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Roger Piqu&#233; Pijuan </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">D. Roger Piqu&#233; Pijuan</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;">Pursuant to the abovementioned, th</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5f;">e </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">Sole Sharehold</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5f;">e</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">r adopts, according to article 15 of the Spanish Companies Act, the following</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">DECISIONS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;text-decoration:underline;">FIRST</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">.- SHARE CAPITAL INCREASE OF THE COMPANY AND AMENDMENT OF THE COMPANY'S BY-LAWS.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;">The Sole Shareholder decides to increase the share capital of the Company in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">EUR 78,615.40</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">&#32;that is, to the amount of </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">EUR 224,615.40</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">&#32;by issuing </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">786,154</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">&#32;new shares, each with a par value of EUR 0.10, numbered consecutively from 1,460,001 to 2,246,154</font><font style="font-family:inherit;font-size:10pt;color:#5b5b5f;">, </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">both inclusive. The new shares are created with. a total share premium amounting to </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">EUR 621,384.60</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">, that is, </font><font style="font-family:inherit;font-size:10pt;color:#373d3a;font-weight:bold;">EUR 0.79</font><font style="font-family:inherit;font-size:10pt;color:#373d3a;">&#32;per share.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373d3a;">The new shares will have the same economic and political rights that the existing shares of the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Furthermore, in this act, the Sole Shareholder of the Company, the company Biotechnology Developments for Industry, S.L., of Spanish nationality, with C.I.F. number B-47729934, and with registered office at avenida Francisco Valles 8, 47151, Boecillo (Valladolid), incorporated for an indefinite term by the Public Deed granted before the Notary from Madrid Mr. Jorge Prades L&#243;pez, on 22 September 2014, under number 789 of his records, and duly registered at the Commercial Registry of Valladolid, on Volume 1477, Sheet 91, Page VA-27242 and duly represented in this act by Mr. Pablo Guti&#233;rrez G&#243;rnez in his capacity as Managing Director, present at this Meeting, represents his will to partially exercise his pre-emptive subscription right over the new shares issued by the capital increase, by the subscription of 318,954 new shares, numbered from 1,460,001 to 1,778,954, both inclusive, and the disbursement of such shares shall be made through cash contribution of their total par value, that is, EUR 31,895.40, and of the corresponding total share premium, that is, EUR 252,104.60 (amounting to the total sum of EUR 284,000), into the bank account number ES06-0128-0209-1605-0000-1193of the Company at Bankinter, S.A. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Additionally, the Sole Shareholder resigns to his pre-emptive right over the remaining new shares created by virtue of the capital increase of the Company. Furthermore, the Sole Shareholder decides that the entities </font><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">Dyadic International (USA), Inc.</font><font style="font-family:inherit;font-size:10pt;color:#333333;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">Inveready Innvierte Biotech II, S.C.R.L S.A.</font><font style="font-family:inherit;font-size:10pt;color:#333333;">, present at this Meeting and duly represented by their legal representatives, subscribe the remaining new shares created, and they expressly accept and subscribe the new shares in the manner and under the terms and conditions established in this resolution.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Once the disbursement has been made, the ownership of the newly created shares will be registered in the Shareholders Registry Book of the Company in favour of Biotechnology Developments for Industry, S.L.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Pursuant to the Article 198.4.1&#176; of the Commercial Registry Regulations, it establishes that the subscription of the remaining new shares, by the total disbursement of its par value as well as its relevant share premium, it is performed by the following cash contribution as follows:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;color:#333333;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">The entity </font><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">Dyadic International (USA), Inc.</font><font style="font-family:inherit;font-size:10pt;color:#333333;">, with company identification number (EIN) 65-0645993, of American nationality, with its registered office at calle 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477-USA, duly represented by Mr. Antonio Ca&#241;adas in his capacity as Special Attorney, present at this Meeting, subscribes 74,123 new shares, numbered from 1,778,955 to 1,853,077, both inclusive, and the disbursement of such shares shall be made through cash contribution of their total par value, that is, EUR 7,412.30, and of the corresponding total share premium, that is, EUR 58,587.70 (amounting to a total sum of EUR 66,000), into the bank account number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of the Company at Banco Santander, S.A.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#404040;">Once the disbursement has been made, the own</font><font style="font-family:inherit;font-size:10pt;color:#66666a;">e</font><font style="font-family:inherit;font-size:10pt;color:#404040;">rship of the newly created shares will be registered in the Shareholders Registry Book of the Company in favour of Dyadic International (USA), Inc.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;color:#404040;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#404040;">The entity</font><font style="font-family:inherit;font-size:10pt;color:#404040;font-weight:bold;">&#32;Inveready Innvicrte Biotech II, S.C.R., S.A.,</font><font style="font-family:inherit;font-size:10pt;color:#404040;">&#32;with N.I.F. number A</font><font style="font-family:inherit;font-size:10pt;color:#7c7b83;">-</font><font style="font-family:inherit;font-size:10pt;color:#404040;">65888232, of Spanish nationality, with its register</font><font style="font-family:inherit;font-size:10pt;color:#66666a;">e</font><font style="font-family:inherit;font-size:10pt;color:#404040;">d office at calle Cavallers, 50,08034 Barcelona, duly represented by Mr. Roger Piqu&#233; Pijuan, in his capacity as general attorney, present at this Meeting, subscribes, 393,077 new shares, numbered from 1,853,078 to 2,246,154, both inclusive, and the disbursement of such shares shall be made through cash contribution of their total par value, that is, EUR 39,307.70, and of the corresponding total share premium, that is, EUR 310,692.30 (amounting to the total sum of EUR 350,000), into the bank account number &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of the Company at Bankinter, S.A.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#404040;">Once the disbursement has been made, the own</font><font style="font-family:inherit;font-size:10pt;color:#66666a;">e</font><font style="font-family:inherit;font-size:10pt;color:#404040;">rship of the newly created shares will be registered in the Shareholders Registry Book of the Company in favour of Inveready Innvierte Biotcch IT, S.C.R., S.A.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#404040;">The Sole Shareholder decides the subscription of the abovementioned shares and of the corresponding share premium by the entities Biotechnology Developments for Industry, S.L., Dyadic International (USA), Inc. and Inveready Innvierte Biotech II, S.C.R., S.A. in the mariner mentioned before. Furthermore, U1e Sole Shareholder decides that the capital increase agreed shall be paid up in cash by the entities Biotechnology Developments for Industry, S.L., Dyadic International (USA), Inc. and Inveready Innvierte Biotech II, S.C.R., S.A., through the transfer of the 100% of the par value of the new shares subscribed by each of them and their corresponding share premium, that is, the total amount of &#8364; 700,000, into the above mentioned bank accounts and before the end of this date (i.e. 30 June 2017), which will be accredited with the corresponding ban.king certificates.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#404040;">Notwithstanding the foregoing, the Sole Shareholder decides that, if for any reason the par value of the total of the newly created shares and the corresponding share premium were not disbursed by the three abovementioned entities, the approved share capital increase would not have effects, condition which is expressly accepted by the entities Biotechnology Developments for Industry, S.L., Dyadic International (USA), Jnc, and Inveready Innvierte Biotech II, S.C.R., S.A.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#404040;">By virtue of the foregoing and subject to the total disbursement of the par value and the corresponding share premium of the newly created shares, the Sole Shareholder decides to approve to amend Article 5" of the Bylaws, which shall be read as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#404040;font-style:italic;">"</font><font style="font-family:inherit;font-size:10pt;color:#404040;font-style:italic;text-decoration:underline;">Article 5</font><font style="font-family:inherit;font-size:10pt;color:#404040;font-style:italic;">.- Share Capital and shares. The share capital is </font><font style="font-family:inherit;font-size:10pt;color:#404040;font-style:italic;font-weight:bold;">EUR 224,615.40</font><font style="font-family:inherit;font-size:10pt;color:#404040;font-style:italic;">, fully paid up and it is divided into </font><font style="font-family:inherit;font-size:10pt;color:#404040;font-style:italic;font-weight:bold;">2,246,154 shares</font><font style="font-family:inherit;font-size:10pt;color:#404040;font-style:italic;">, of </font><font style="font-family:inherit;font-size:10pt;color:#404040;font-style:italic;font-weight:bold;">EUR 0.10</font><font style="font-family:inherit;font-size:10pt;color:#404040;font-style:italic;">&#32;par value each, numbered consecutively from 1 to 2,246,154, both inclusive, not to be deemed securities nor represented in certificates or book entries and not to be called shares."</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">SECOND</font><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">.- DELEGATION OF FACULTIES.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">The Sole Shareholder decides to expressly empower any of the members of the governing body of the Company, so that any of them, indistinctly, may formalise the decisions hereby adopted, especially empowering them to do everything which is necessary and convenient for their execution and performance, to sign whatever public or private documents, including tax documents, as may be necessary or convenient, and to undertake whatever actions as are suitable for their performance, until they are registered with the Commercial Registry. They are also empowered to execute public deeds of ratification, substitution and/ or clarification in the light of the verbal suggestions and/ or written opinions of the Commercial Registry.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">The precedent is herein recorded pursuant to article 15 of the Spanish Companies Act and to article 97.2 of the Commercial Registry Regulations. These minutes, after being read, are signed in prove of acceptance by the legal representative of the Sole Shareholder, in the place and on the date set forth above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">The Sole Shareholder</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:47.43589743589743%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Pablo Guti&#233;rrez G&#243;mez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">BIOTECHNOLOGY DEVELOPMENTS FOR</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">INDUSTRY, S.L. </font><font style="font-family:inherit;font-size:10pt;color:#333333;">hereby represented by Mr. Pablo</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Guti&#233;rrez G&#243;mez</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:3px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:3px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#525354;">ARAN</font><font style="font-family:inherit;font-size:10pt;color:#626365;">C</font><font style="font-family:inherit;font-size:10pt;color:#525354;">EL NOTARIAL</font><font style="font-family:inherit;font-size:10pt;color:#949699;">. </font><font style="font-family:inherit;font-size:10pt;color:#525354;">DERECHOS DEVENGAO</font><font style="font-family:inherit;font-size:10pt;color:#626365;">O</font><font style="font-family:inherit;font-size:10pt;color:#525354;">S</font><font style="font-family:inherit;font-size:10pt;color:#a7a7ab;">. </font><font style="font-family:inherit;font-size:10pt;color:#525354;">A</font><font style="font-family:inherit;font-size:10pt;color:#626365;">ranc</font><font style="font-family:inherit;font-size:10pt;color:#525354;">e</font><font style="font-family:inherit;font-size:10pt;color:#626365;">l </font><font style="font-family:inherit;font-size:10pt;color:#525354;">a</font><font style="font-family:inherit;font-size:10pt;color:#626365;">p</font><font style="font-family:inherit;font-size:10pt;color:#787b82;">l</font><font style="font-family:inherit;font-size:10pt;color:#626365;">ica</font><font style="font-family:inherit;font-size:10pt;color:#525354;">b</font><font style="font-family:inherit;font-size:10pt;color:#626365;">l</font><font style="font-family:inherit;font-size:10pt;color:#525354;">e</font><font style="font-family:inherit;font-size:10pt;color:#787b82;">, </font><font style="font-family:inherit;font-size:10pt;color:#626365;">n</font><font style="font-family:inherit;font-size:10pt;color:#525354;">um</font><font style="font-family:inherit;font-size:10pt;color:#626365;">e</font><font style="font-family:inherit;font-size:10pt;color:#525354;">ros</font><font style="font-family:inherit;font-size:10pt;color:#a7a7ab;">: </font><font style="font-family:inherit;font-size:10pt;color:#525354;">2</font><font style="font-family:inherit;font-size:10pt;color:#787b82;">, </font><font style="font-family:inherit;font-size:10pt;color:#525354;">4</font></div><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#525354;">C</font><font style="font-family:inherit;font-size:10pt;color:#626365;">onc</font><font style="font-family:inherit;font-size:10pt;color:#525354;">ep</font><font style="font-family:inherit;font-size:10pt;color:#626365;">lo(</font><font style="font-family:inherit;font-size:10pt;color:#525354;">s</font><font style="font-family:inherit;font-size:10pt;color:#626365;">)</font><font style="font-family:inherit;font-size:10pt;color:#949699;">: </font><font style="font-family:inherit;font-size:10pt;color:#525354;">CUMPLIMIENTO DE CONDICIONES Y A</font><font style="font-family:inherit;font-size:10pt;color:#626365;">C</font><font style="font-family:inherit;font-size:10pt;color:#525354;">U</font><font style="font-family:inherit;font-size:10pt;color:#626365;">E</font><font style="font-family:inherit;font-size:10pt;color:#525354;">RDO DE INVERSION</font></div><div style="padding-top:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#525354;">Ba</font><font style="font-family:inherit;font-size:10pt;color:#626365;">s</font><font style="font-family:inherit;font-size:10pt;color:#525354;">e</font><font style="font-family:inherit;font-size:10pt;color:#626365;">(</font><font style="font-family:inherit;font-size:10pt;color:#525354;">s</font><font style="font-family:inherit;font-size:10pt;color:#626365;">)</font><font style="font-family:inherit;font-size:10pt;color:#949699;">: </font><font style="font-family:inherit;font-size:10pt;color:#525354;">VALOR</font><font style="font-family:inherit;font-size:10pt;color:#626365;">(</font><font style="font-family:inherit;font-size:10pt;color:#525354;">ES</font><font style="font-family:inherit;font-size:10pt;color:#626365;">) </font><font style="font-family:inherit;font-size:10pt;color:#525354;">DE</font><font style="font-family:inherit;font-size:10pt;color:#626365;">C</font><font style="font-family:inherit;font-size:10pt;color:#525354;">LARADO</font><font style="font-family:inherit;font-size:10pt;color:#626365;">(</font><font style="font-family:inherit;font-size:10pt;color:#525354;">S</font><font style="font-family:inherit;font-size:10pt;color:#626365;">)</font><font style="font-family:inherit;font-size:10pt;color:#525354;">TOTAL</font><font style="font-family:inherit;font-size:10pt;color:#a7a7ab;">: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8364;</font><font style="font-family:inherit;font-size:10pt;color:#525354;">&#160;</font><font style="font-family:inherit;font-size:10pt;color:#626365;">(</font><font style="font-family:inherit;font-size:10pt;color:#525354;">lmp</font><font style="font-family:inherit;font-size:10pt;color:#626365;">u</font><font style="font-family:inherit;font-size:10pt;color:#525354;">estos e</font><font style="font-family:inherit;font-size:10pt;color:#626365;">xcl</font><font style="font-family:inherit;font-size:10pt;color:#525354;">u</font><font style="font-family:inherit;font-size:10pt;color:#626365;">ido</font><font style="font-family:inherit;font-size:10pt;color:#525354;">s</font><font style="font-family:inherit;font-size:10pt;color:#626365;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">ES COPIA DE SU ORIGINAL que, bajo el n&#250;mero de orden al princi pio </font><font style="font-family:inherit;font-size:10pt;color:#525354;">i</font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">ndi</font><font style="font-family:inherit;font-size:10pt;color:#525354;">c</font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">ado</font><font style="font-family:inherit;font-size:10pt;color:#626365;">, </font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">obra en el protocolo general de instrumentos p&#250;blicos de </font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;font-weight:bold;">DON IGNACIO MART&#205;NEZ</font><font style="font-family:inherit;font-size:10pt;color:#525354;font-weight:bold;">-</font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;font-weight:bold;">GIL VICH, </font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">donde queda anotada. Y para LOS COMPARECIENTES, seg&#250;n intervienen, la expido, yo, </font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;font-weight:bold;">JOS&#201; LUIS MART&#205;NEZ-GIL VICH, </font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">como sust</font><font style="font-family:inherit;font-size:10pt;color:#525354;">i</font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">tuto por imposibilidad accidental d</font><font style="font-family:inherit;font-size:10pt;color:#525354;">e </font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">mi compa&#241;ero de residencia, en doscientos veintidos folios de papel de uso exclusivo para documentos notariales, n&#250;meros: el del presente y los doscientos veintiun anteriores en orden ascendente correlativo de la misma serie. En Madrid</font><font style="font-family:inherit;font-size:10pt;color:#525354;">, </font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">a tres de julio de dos mil diec</font><font style="font-family:inherit;font-size:10pt;color:#525354;">i</font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">sie</font><font style="font-family:inherit;font-size:10pt;color:#525354;">t</font><font style="font-family:inherit;font-size:10pt;color:#3a3a3a;">e; DOY FE</font><font style="font-family:inherit;font-size:10pt;color:#525354;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;"><img src="stamp3.jpg" alt="stamp3.jpg" style="height:258px;width:186px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>exhibit31form10.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBBA1319C69B27C0BD6C44342C47E564B"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 3.1</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:82%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="ex31imagea01.jpg" alt="ex31imagea01.jpg" style="height:133px;width:353px;"></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PAGE 1</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS ON FILE OF "DYADIC INTERNATIONAL, INC." AS RECEIVED AND FILED IN THIS OFFICE.</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED:</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATE OF INCORPORATION, FILED THE TWENTY-THIRD DAY OF SEPTEMBER, A.D. 2002, AT 9 O'CLOCK A.M.</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESTATED CERTIFICATE, CHANGING ITS NAME FROM "CCP WORLDWIDE, INC." TO "DYADIC INTERNATIONAL, INC.", FILED THE FIRST DAY OF NOVEMBER, A.D. 2004, AT 7:46 O'CLOCK P.M.</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESTATED CERTIFICATE, FILED THE THIRD DAY OF NOVEMBER, A.D. 2004, AT 1:17 O'CLOCK P.M.</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AND I DO HEREBY FURTHER CERTIFY THAT THE AFORESAID CERTIFICATES ARE THE ONLY CERTIFICATES ON RECORD OF THE AFORESAID CORPORATION.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:82%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:122px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="a31image2.jpg" alt="a31image2.jpg" style="height:114px;width:439px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:122px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s999DAD784FE6C71256914342C50570C6"></a></div><div></div><div><br></div><div style="line-height:125%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">RESTATED CERTIFICATE OF INCORPORATION </font></div><div style="line-height:125%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">OF</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:140%;padding-top:1px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:130%;text-align:justify;text-indent:48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#030303;"></font><font style="font-family:inherit;font-size:10pt;color:#030303;">Dyadic International, Inc. (the "Corporation"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "GCL"), hereby certifies as follows:</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:128%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">First: The name of the Corporation is Dyadic International, Inc. A Certificate of Incorporation of the Corporation was originally filed by the Corporation with the Secretary of State of Delaware on September 23, 2002</font><font style="font-family:inherit;font-size:10pt;color:#202020;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">and an Amended and Restated Certificate of Incorporation was filed with the Secretary of State of Delaware on November l, 2004. The Corporation was originally incorporated under the name CCP Worldwide, Inc.</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:128%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">Second: This Restated Certificate of Incorporation restates and integrates, but does not farther amend, the provisions of the Certificate of Incorporation of the Corporation as originally filed and heretofore amended or supplemented</font><font style="font-family:inherit;font-size:10pt;color:#202020;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">and there is no discrepancy between those provisions and the provisions of this Restated Certificate of Incorporation. This Restated Certificate of Incorporation was duly adopted in accordance with the provisions of Section 245 of the GCL, and was approved by unanimous written consent of the directors of the Corporation without a vote of the stockholders.</font></div><div style="line-height:110%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:131%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">Third: The text of the Certificate of Incorporation of the Corporation is hereby restated and superseded to read in its entirety as fol1ows:</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE I</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">NAME OF CORPORATION</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#030303;"></font><font style="font-family:inherit;font-size:10pt;color:#030303;">The name of this corporation (the "Corporation") is Dyadic International</font><font style="font-family:inherit;font-size:10pt;color:#202020;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">Inc</font><font style="font-family:inherit;font-size:10pt;color:#202020;">.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE II</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">REGISTERED OFFICE</font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:131%;text-align:justify;text-indent:48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#030303;"></font><font style="font-family:inherit;font-size:10pt;color:#030303;">The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware is 2711 Centerville Road, Suite 400, City of Wilmington 19808, County of New Castle; and the name of the registered agent of the Corporation in the State of Delaware at such address is Corporation Service Company.</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE III</font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">PURPOSE</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:128%;text-align:justify;text-indent:48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#030303;"></font><font style="font-family:inherit;font-size:10pt;color:#030303;">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the "GCL").</font></div><div style="line-height:128%;text-align:justify;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">State of Delaware</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Secretary of State</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Division of Corporations</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Delivered 01:17PM 11/03/2004</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">FILED 01:17 PM 11/03/2004</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">SRV 040792475 - 3571891 FILE</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:129%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE IV </font></div><div style="line-height:129%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">AUTHORIZED STOCK</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:129%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">The total number of shares of all classes of stock which the Corporation shall have authority to issue shall be one hundred five million (105,000,000) shares, of which one hundred million (100,000,000) shares shall be common stock, par value $0.001 per share (the "Common Stock"), and five million (5,000,000) shares shall be preferred stock, par value $0.0001 per share (the "Preferred Stock"). All of the shares of Common Stock shall be of one class.</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:126%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">The shares of Preferred Stock shall be undesignated Preferred Stock and may be issued from time to time in one or more series pursuant to a resolution or resolutions providing for such issuance and duly adopted by the Board of Directors of the Corporation, authority to do so being hereby expressly vested in the Corporation's Board of Directors</font><font style="font-family:inherit;font-size:10pt;color:#191919;">. </font><font style="font-family:inherit;font-size:10pt;color:#030303;">The Board of Directors is further authorized to determine or alter the rights, preferences, privileges and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock and to fix the number of shares of any series of Preferred Stock and the designation of any such series of Preferred Stock. The Board of Directors of the Corporation, within the limits and restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number of shares constituting any series, may increase or decrease (but not below the number of shares in any such series when outstanding) the number of shares of any series subsequent to the issuance of shares of that series.</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:129%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">The authority of the Board of Directors of the Corporation with respect to each such class or series of Preferred Stock shall include, without limitation of the foregoing, the right to determine and fix:</font></div><div style="line-height:110%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(a)&#160;&#160;&#160;&#160;the distinctive designation of such class or series and the number of shares to constitute such class or series;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(b)&#160;&#160;&#160;&#160;the rate at which dividends on the shares of such class or series shall be declared and paid or set aside for payment, whether dividends at the rate so determined shall be cumulative or accruing, and whether the shares of such class or series shall be entitled to any participating or other dividends in addition to dividends at the rate so determined</font><font style="font-family:inherit;font-size:10pt;color:#191919;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">and if so, on what terms;</font></div><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(c)&#160;&#160;&#160;&#160;the right or obligation, if any, of the Corporation to redeem shares of the particular class or series of Preferred Stock and, if redeemable, the price, terms and manner of such redemption;</font></div><div style="line-height:110%;padding-top:1px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:124%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(d)&#160;&#160;&#160;&#160;the special and relative rights and preferences, if any, and the amount or amounts per share, which the shares of such class or series of Preferred Stock shall be entitled to receive upon any voluntary or involuntary liquidation, dissolution or winding up of the Corporation;</font></div><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(e)&#160;&#160;&#160;&#160;the terms and conditions, if any, upon which shares of such class or series shall be convertible into</font><font style="font-family:inherit;font-size:10pt;color:#191919;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">or exchangeable for, shares of capital stock of any other class or series, inc1uding the price or prices or the rate or rates of conversion or exchange and the terms of adjustment, </font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">i</font><font style="font-family:inherit;font-size:10pt;color:#030303;">f any;</font></div><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(f)&#160;&#160;&#160;&#160;the obligation, if any, of the Corporation to retire, redeem or purchase shares of such class or series pursuant to a sinking fund or fund of a similar nature or otherwise, and the terms and conditions of such obligations;</font></div><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:126%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(g)&#160;&#160;&#160;&#160;voting rights, if any, on the issuance of additional shares of such class or series or any shares of any other class or series of Preferred Stock;</font></div><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:127%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(h)&#160;&#160;&#160;&#160;limitations, if any, on the issuance of additional shares of such class or series or any shares of any other class or series of Preferred Stock; and</font></div><div style="line-height:110%;padding-top:1px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">2</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:128%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(i)&#160;&#160;&#160;&#160;such other preferences, powers, qualifications, special or relative rights and privileges thereof as the Board of Directors of the Corporation, acting in accordance with this Certificate of Incorporation, may deem advisable and are not inconsistent with the law and the provisions of this Certificate of Incorporation</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">.</font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE IV</font></div><div style="line-height:130%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">[Omitted as permitted by GCL]</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE V </font></div><div style="line-height:130%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ELECTION OF DIRECTORS</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:126%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">A</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#030303;">The business and affairs of the Corporation shall be managed by or under the direction of a Board of Directors</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:126%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">B.&#160;&#160;&#160;&#160;The election of directors of the Corporation need not be by written ballot unless otherwise required by the Bylaws of the Corporation.</font></div><div style="line-height:110%;padding-top:1px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:127%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">C.&#160;&#160;&#160;&#160;Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the Board of Directors shall be divided into three classes designated as Class I</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">Class II and Class III</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">respectively. Promptly following the effectiveness of this Section C, directors shall be assigned to each class in accordance with a resolution or resolutions adopted by the Board of Directors. Each class shall consist, as nearly as possible, of one-third of the total number of directors constituting the entire Board of Directors. The term of office of the Class I directors shall expire at the annual meeting of stockholders to be held in 2005, and, at that meeting, Class I directors shall be elected for a full term of three years. At the annual meeting of stockholders to be held in 2006, the term of office of the Class II directors shall expire, and Class II directors shall be elected for a full term of three years</font><font style="font-family:inherit;font-size:10pt;color:#1c1c1c;">. </font><font style="font-family:inherit;font-size:10pt;color:#030303;">At the annual meeting of stockholders to be held in 2007, the term of office of the Class III directors shall expire, and Class m directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. If the number of directors is changed, an increase or decrease shall be apportioned among the classes so as to maintain the number of directors in each class as nearly equal as possible, and any additional director of any class elected to fill a vacancy resulting from an increase in such class shall hold office for a term that shall coincide with the remaining term of that class, but in no case shall a decrease in the number of directors remove or shorten the term of any incumbent director.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:129%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">D.&#160;&#160;&#160;&#160;Notwithstanding the foregoing provisions of this section, each director shall serve until his successor is duly elected and qualified or until his death, resignation or removal.</font></div><div style="line-height:110%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:128%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">E.&#160;&#160;&#160;&#160;No stockholder shall be entitled to cumulate votes in the election of directors. Directo</font><font style="font-family:inherit;font-size:10pt;color:#191919;">r</font><font style="font-family:inherit;font-size:10pt;color:#030303;">s may only be removed for cause</font><font style="font-family:inherit;font-size:10pt;color:#191919;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">as provided in Section 141(k)(1) of the GCL.</font></div><div style="line-height:100%;padding-top:1px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:129%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">F.&#160;&#160;&#160;&#160;Subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, except as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director's successor shall have been elected and qualified.</font></div><div style="line-height:110%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:129%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">G.&#160;&#160;&#160;&#160;If at the time of filling any vacancy or any newly created directorship, the directors then in office shall constitute Jess than a majority of the whole board (as constituted immediately prior to any such increase)</font><font style="font-family:inherit;font-size:10pt;color:#191919;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">the Delaware Court of Chancery may, upon application of any stockholder or stockholders holding at least ten percent (10%) of the total number of the shares at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace the directors chosen by the directors then in offices as aforesaid, which election shall be governed by Section 211 of the GCL</font><font style="font-family:inherit;font-size:10pt;color:#191919;">.</font></div><div style="line-height:100%;padding-top:1px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">H.&#160;&#160;&#160;&#160;Notwithstanding the foregoing, whenever the holders of any one or more series of Preferred Stock issued by the Corporation shall have the right, voting separately by series, to elect directors at an annual or special meeting of stockholders, the election, term of office, filling of vacancies and other features of such directorships shall be governed by the terms of the series of Preferred Stock applicable thereto, and such directors so elected shall not be divided into classes pursuant to this Article VI unless expressly provided by such terms</font><font style="font-family:inherit;font-size:10pt;color:#191919;">.</font></div><div style="line-height:130%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE VI</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">BYLAWS</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">Subject to paragraph (h) of Section 11.01 of the Bylaws, the Bylaws may be altered or amended or new Bylaws adopted by the affirmative vote of at least sixty-six. and two-thirds percent (66-2/3%) of the voting power of an of the then outstanding shares of the voting stock of the corporation entitled to vote. The Board of Di</font><font style="font-family:inherit;font-size:10pt;color:#161616;">r</font><font style="font-family:inherit;font-size:10pt;color:#030303;">ectors shall also have the power to adopt</font><font style="font-family:inherit;font-size:10pt;color:#161616;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">amend, or repeal Bylaws.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE VII</font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">NUMBER OF DIRECTORS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">The number of directors that constitutes the entire Board of Directors of the Corporation shall be fixed exclusively by one or more resolutions adopted by the Board of Directors.</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:131%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE VIII </font></div><div style="line-height:131%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">MEETINGS OF STOCKHOLDERS</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:128%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">A.&#160;&#160;&#160;&#160;Meetings of stockholders of the Corporation may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide</font><font style="font-family:inherit;font-size:10pt;color:#161616;">. </font><font style="font-family:inherit;font-size:10pt;color:#030303;">The books of the Corporation may be kept (subject to any provisions of applicable statutes) outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors of the Corporation.</font></div><div style="line-height:110%;padding-top:1px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:126%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">B</font><font style="font-family:inherit;font-size:10pt;color:#161616;">.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#030303;">No action shall be taken by the stockholders of the Corporation except at an annual or special meeting of stockholders called in accordance with the Bylaws.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:119%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">C.&#160;&#160;&#160;&#160;Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:125%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">D.&#160;&#160;&#160;&#160;Special meetings of the stockholders of the Corporation may only be called, for any purpose or purposes, by (i) the Chairman of the Board of Directors, (ii) the Chief Executive Officer, or (iii) the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption).</font></div><div style="line-height:110%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:124%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">E</font><font style="font-family:inherit;font-size:10pt;color:#161616;">.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#030303;">Notwithstanding any other provisions of this Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:124%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">particular class or series of the voting stock of the Corporation required by Jaw, this Certificate of Incorporation or the terms of any series of Preferred Stock, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of the voting stock, voting together as a single class, shall be required to approve any of the following actions if such action is not affirmatively recommended by the Board of Directors:</font></div><div style="line-height:124%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:127%;padding-top:2px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(1)&#160;&#160;&#160;&#160;the merger or consolidation of the Corporation with any other corporation or entity;</font></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(2)&#160;&#160;&#160;&#160;the sale, conveyance or other disposition of all or substantially all of the assets of the Corporation; or</font></div><div style="line-height:100%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(3)&#160;&#160;&#160;&#160;the conversion of the Corporation into another type of corporation or entity.</font></div><div style="line-height:110%;padding-top:1px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE IX</font></div><div style="line-height:119%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">LIMITATION ON LIABILITY OF DIRECTORS; </font></div><div style="line-height:119%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">INDEMNIFICATION OF DIRECTORS AND OFFICERS; </font></div><div style="line-height:119%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">PERSONAL LIABILITY OF DIRECTORS</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:127%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">The Corporation shall indemnify each of the Corporation's directors and officers in each and every situation where, under Section 145 of the GCL, as amended from time to time ("Section 145"), the Corporation is permitted or empowered to make such indemnification. The Corporation may, in the sole discretion of the Board of Directors of the Corporation, indemnify any other person who may be indemnified pursuant to Section 145 to the extent that the Board of Directors deems advisable, as permitted by Section 145.</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:128%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">No director shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director</font><font style="font-family:inherit;font-size:10pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">provided, however, that the foregoing shall not eliminate or limit the liability of a director of the Corporation (i) for any breach of the director's duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law. (iii) under Section 174 of the GCL, or (iv) for any transaction from which the director derived an improper personal benefit. If the GCL is subsequently amended to further eliminate or limit the liability of a director, then a director of the Corporation, in addition to the circumstances in which a director is not personally liable as set forth in the preceding sentence, shall not be liable to the fullest extent permitted by the amended GCL</font><font style="font-family:inherit;font-size:10pt;color:#1d1d1d;">. </font><font style="font-family:inherit;font-size:10pt;color:#030303;">For purposes of this Article X, "fiduciary duty as a director" shall include any fiduciary duty arising out of service at the Corporation's request as a director of another corporation, partnership, joint venture or other enterprise, and "personal liability to the Corporation or its stockholders" shall include any liability to such other corporation, partnership, joint venture, trust or other enterprise and any liability to the Corporation in its capacity as a security holder, joint venturer, partner, beneficiary, creditor or investor of or in any such other corporation, partnership, joint venture, trust or other enterprise.</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">Neither any amendment nor repeal of this Article X nor the adoption of any provision of this Certificate of Incorporation inconsistent with this Article X shall eliminate or reduce the effect of this Article X in respect of any matter occurring, or any cause of action, suit or claim that</font><font style="font-family:inherit;font-size:10pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">but for this Article X, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.</font></div><div style="line-height:100%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE X</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">COMPROMISE OR ARRANGEMENT</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;text-align:justify;text-indent:48px;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;color:#030303;"></font><font style="font-family:inherit;font-size:10pt;color:#030303;">Whenever a compromise or arrangement is proposed between this Corporation and its creditors or any class of them and/or between this Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this Corporation or on the application of any receiver or receivers appointed for this Corporation under Section 291 of the GCL or on the application of trustees in dissolution or of any receiver or receivers appointed for this Corporation under Section 279 of the GCL, order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this Corporation as consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made</font><font style="font-family:inherit;font-size:10pt;color:#191919;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders of this Corporation as the case may be, and also on this Corporation.</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">ARTICLE XI </font></div><div style="line-height:123%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">AMENDMENT OF PROVISIONS OF </font></div><div style="line-height:123%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#030303;font-weight:bold;">CERTIFICATE OF INCORPORATION</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:124%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">A.&#160;&#160;&#160;&#160;The corporation reserves the right at any time, and from time to time, to amend</font><font style="font-family:inherit;font-size:10pt;color:#191919;">, </font><font style="font-family:inherit;font-size:10pt;color:#030303;">alter, change or repeal any provisions contained in this Certificate of Incorporation, and other provisions authorized by the State of Delaware at the time in force may be added or inserted, in the manner now or hereafter prescribed by statute, except as provided in paragraph B</font><font style="font-family:inherit;font-size:10pt;color:#191919;">. </font><font style="font-family:inherit;font-size:10pt;color:#030303;">of this Article XII, and all rights conferred upon stockholde</font><font style="font-family:inherit;font-size:10pt;color:#191919;">r</font><font style="font-family:inherit;font-size:10pt;color:#030303;">s herein are granted subject to this</font><font style="font-family:inherit;font-size:10pt;color:#030303;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#030303;">reservation.</font></div><div style="line-height:110%;padding-top:1px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:124%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">B.&#160;&#160;&#160;&#160;Notwithstanding any other provisions of this Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the voting stock of the Corporation required by law, this Certificate of Incorporation or the terms of any series of Preferred Stock, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of the voting stock, voting together as a single class, shall be required to alter, amend or repeal</font><font style="font-family:inherit;font-size:10pt;color:#191919;">:</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(1)&#160;&#160;&#160;&#160;Article VI, VII, VIII, IX or XII of this Certificate of Incorporation, or</font></div><div style="line-height:110%;padding-top:1px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:128%;padding-top:1px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#030303;">(2)&#160;&#160;&#160;&#160;any other Article of this Certificate of Incorporation if such alteration, amendment or repeal is not affirmatively recommended by the Board of Directors</font><font style="font-family:inherit;font-size:10pt;color:#191919;">.</font></div><div style="line-height:128%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">6</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div><a name="s6F33318228F41589467F4342C70EA842"></a></div><div><div style="line-height:100%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#020202;">JENKENS  &amp; GILCHRIST</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#020202;">Nov  3 2004  12:04    P.02</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#020202;">In Witness Whereof, the undersigned bu caused this Restated Certificate of Incorporation to be duly executed on behalf of the Corporation on November 1, 2004.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:44.65811965811966%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DYADIC INTERNATIONAL, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark A. Emalfarb</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: Mark A. Emalfarb</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title : President</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">7</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div><a name="sAFDBECD3EDB959A0DBE14342C71A1D18"></a></div><div></div><div><br></div><div style="line-height:226%;padding-top:2px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:82%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="ex31imagea01.jpg" alt="ex31imagea01.jpg" style="height:133px;width:353px;"></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PAGE 1</font></div></td></tr></table></div></div><div style="line-height:226%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:232%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY "DYADIC INTERNATIONAL, INC." IS DULY INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE AND IS IN GOOD STANDING AND HAS A LEGAL CORPORATE EXISTENCE SO FAR AS THE RECORDS OF THIS OFFICE SHOW, AS OF THE NINTH DAY OF NOVEMBER, A.D. 2004.</font></div><div style="line-height:232%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">AND I DO HEREBY FURTHER CERTIFY THAT THE FRANCHISE TAXES HAVE BEEN PAID TO DATE. </font></div><div style="line-height:232%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">AND I DO HEREBY FURTHER CERTIFY THAT THE ANNUAL REPORTS HAVE BEEN FILED TO DATE.</font></div><div style="line-height:232%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">AND I DO HEREBY FURTHER CERTIFY THAT THE SAID "DYADIC INTERNATIONAL, INC." WAS INCORPORATED ON THE TWENTY-THIRD DAY OF SEPTEMBER, A.D. 2002.</font></div><div style="line-height:232%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:232%;padding-bottom:12px;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:232%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:82%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:122px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="a31image3.jpg" alt="a31image3.jpg" style="height:114px;width:428px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:122px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>4
<FILENAME>exhibit32form10.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD3E4C222474E07D85342434B74329148"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 3.2</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:140%;padding-top:1px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;font-weight:bold;">AMENDED AND RESTATED BYLAWS </font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;font-weight:bold;">OF</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;font-weight:bold;">(A DELAWARE CORPORATION) </font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;font-weight:bold;">EFFECTIVE AS OF JUNE 25, 2014</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:225%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:225%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:225%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:225%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:225%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:225%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:225%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:225%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:225%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:225%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sEDA4C7888C6CBE52F22B434B74627306"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:130%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:130%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:130%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:6%;"></td><td style="width:16%;"></td><td style="width:6%;"></td><td style="width:65%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;font-weight:bold;">Page</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">ARTICLE I</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">OFFICES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 1.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Registered Office</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 1.02</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Other Offices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">ARTICLE II</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">STOCKHOLDERS' MEETINGS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Place of Meetings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.02</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Annual Meetings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.03</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Special Meetings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.04</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Notice of Meetings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.05</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Quorum</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.06</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Adjournment and Notice of Adjourned Meetings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.07</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Voting Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.08</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Joint Owners of Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.09</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">List of Stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.10</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Action Without Meeting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.11</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Organization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 2.12</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Supermajority Vote Requirement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">ARTICLE III</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">DIRECTORS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 3</font><font style="font-family:inherit;font-size:11.5pt;color:#505050;">.</font><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 3</font><font style="font-family:inherit;font-size:11.5pt;color:#505050;">.</font><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">02</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Powers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Section 3.03</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Classes of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Section 3.04</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Vacancies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Section 3.05</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Resignation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Section 3.06</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Removal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Section 3.07</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Meetings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Section 3.08</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Quorum and Voting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Section 3.09</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Action Without Meeting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Section 3.10</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Fees and Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Section 3.11</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Co</font><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">mmittees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Section 3.12</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Organization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">ARTICLE IV</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">OFFICERS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 4.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Officers Designated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 4.02</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Tenure and Duties of Officers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 4.03</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Delegation of Authority</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 4.04</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Resignations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 4.05</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Removal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">i</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div><div style="line-height:130%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:130%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:130%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;font-weight:bold;">(Continued)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:130%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:6%;"></td><td style="width:16%;"></td><td style="width:6%;"></td><td style="width:65%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;font-weight:bold;">Page</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:120px;text-indent:-118px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">ARTICLE V</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE CORPORATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 5.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Execution of Corporate Instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 5.02</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Voting of Securities Owned by the Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">ARTICLE VI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">SHARES OF STOCK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 6.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Form and Execution of Certificates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 6.02</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Lost Certificates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 6.03</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Transfers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 6.04</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Fixing Record Dates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 6.05</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Registered Stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">ARTICLE VII</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">OTHER SECURITIES OF THE CORPORATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 7.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Execution of Other Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">ARTICLE VIII</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">DIVIDENDS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 8.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Declaration of Dividends</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Section 8.02</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">Dividend Reserve</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">ARTICLE IX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">FISCAL YEAR</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Section 9.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">ARTICLE X</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">INDEMNIFICATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Section l0.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Indemnification of Directors, Officers, Employees and Other Agents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">ARTICLE XI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">NOTICES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Section 11.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Notices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">ARTICLE XII</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">AMENDMENTS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Section 12.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Amendments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">ARTICLE XIII</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">LOANS TO OFFICERS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Section 13.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#3b3b3b;">Loans to Officers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">ARTICLE XI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">FORUM</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Section 14.01</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Forum</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:right;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#3b3b3b;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">ii</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div><a name="s2E0920920CB1146008AF434B752AB9A9"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">BYLAWS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">OF</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">(A DELAWARE CORPORATION)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">ARTICLE I </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">OFFICES</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Section 1.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Registered Office</font><font style="font-family:inherit;font-size:11pt;color:#363636;">. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Section 1.02&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Other Offices</font><font style="font-family:inherit;font-size:11pt;color:#363636;">. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the corporation may require.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">ARTICLE II </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">STOCKHOLDERS' MEETINGS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Section 2.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Place of Meetings</font><font style="font-family:inherit;font-size:11pt;color:#363636;">. Meetings of the stockholders of the corporation shall be held at such place, either within or without the State of Delaware, as may be designated from time to time by the Board of Directors, or, if not so designated, then at the office of the corporation required to be maintained pursuant to </font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Section 1.02</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Section 2.02&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Annual Meetings</font><font style="font-family:inherit;font-size:11pt;color:#363636;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(a)&#160;&#160;&#160;&#160;The annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as may lawfully come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations of persons for election to the Board of Directors of the corporation shall be, and the proposal of business to be considered by the stockholders may be, made at an annual meeting of stockholders pursuant to the corporation's notice of meeting of stockholders (i) by or at the direction of the Board of Directors; or (ii) by any stockholder of the corporation who was a stockholder of record at the time of giving of notice provided for in the following paragraph, who is entitled to vote at the meeting and who complied with the notice procedures set forth in this </font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Section 2.02</font><font style="font-family:inherit;font-size:11pt;color:#363636;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(b)&#160;&#160;&#160;&#160;At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting</font><font style="font-family:inherit;font-size:11pt;color:#484848;">. </font><font style="font-family:inherit;font-size:11pt;color:#363636;">For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (iii) of </font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Section 2.02(a)</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;of these Bylaws, (i) the stockholder must have given timely notice thereof in writing to the Secretary of the corporation, (ii) such other business must be a proper matter for stockholder action under the Delaware General Corporation Law ("DGCL"), (iii) if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">has provided the corporation with a Solicitation Notice (as defined in this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2.02(b)</font><font style="font-family:inherit;font-size:11pt;color:#353535;">), such stockholder or beneficial owner must, in the case of a proposal, have delivered a proxy statement and form of proxy to holders of at least the percentage of the corporation's voting shares required under applicable law to carry any such proposal, or, in the case of a nomination or nominations, have delivered a proxy statement and form of proxy to holders of a percentage of the corporation's voting shares reasonably believed by such stockholder or beneficial owner to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder, and must, in either case, have included in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">such materials the Solicitation Notice, and (iv) if no Solicitation Notice relating thereto has been timely provided pursuant to this section, the stockholder or beneficial owner proposing such business or nomination must not have solicited a number of proxies sufficient to have required the delivery of such a Solicitation Notice under this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2.02</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. To be timely, a stockholder's notice shall be delivered to the Secretary at the principal executive offices of the corporation not later than the close of business on the ninetieth (90th) day nor earlier than the close of business on the one hundred twentieth (120th) day prior to the first anniversary of the preceding year's annual meeting; provided, however, that in the event that the date of the annual meeting is advanced more than thirty (30) days prior to or delayed by more than thirty (30) days after the anniversary of the preceding year's annual meeting, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the one hundred twentieth (120th) day prior to such annual meeting and not later than the close of business on the later of the ninetieth (90th) day prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made. In no event shall the public announcement of an adjournment of an annual meeting commence a new time period for the giving of a stockholder's notice as described above. Such stockholder's notice shall set forth: (A) as to each person whom the stockholder proposed to nominate for election or reelection as a director all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the "1934 Act") and Rule 14a-11 thereunder (including such person's written consent to being named in the proxy statement as a nominee and to serving as a director if elected); (B) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made; and (C) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (i) the name and address of such stockholder, as they appear on the corporation's books, and of such beneficial owner, (ii) the class and number of shares of the corporation which are owned beneficially and of record by such stockholder and such beneficial owner, and (iii) whether either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of, in the case of the proposal, at least the percentage of the corporation's voting shares required under applicable law to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the corporation's voting shares to elect such nominee or nominees (an affirmative statement of such intent, a "Solicitation Notice").</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(c)&#160;&#160;&#160;&#160;Notwithstanding anything in the second sentence of </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2.02(b)</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;of these Bylaws to the contrary, in the event that the number of directors to be elected to the Board of Directors of the corporation is increased and there is no public announcement naming all of the nominees for director or specifying the size of the increased Board of Directors made by the corporation at least one hundred (100) days prior to the first anniversary of the preceding year's annual meeting, a stockholder's notice required by this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2.02</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary at the principal executive offices of the corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the corporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(d)&#160;&#160;&#160;&#160;Only such persons who are nominated in accordance with the procedures set forth in this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2.02</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;shall be eligible to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2.02</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. Except as otherwise provided by law, the Chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any proposed nomination or business is not in compliance with these Bylaws, to declare </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">that such defective proposal or nomination shall not be presented for stockholder action at the meeting and shall be disregarded.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(e)&#160;&#160;&#160;&#160;Notwithstanding the foregoing provisions of this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2.02</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy prepared by the corporation for a stockholder's meeting, stockholders must provide notice as required by the regulations promulgated under the 1934 Act. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation's proxy statement pursuant to Rule 14a-8 under the 1934 Act or the disclosure obligations of the corporation arising under Regulation 14A under the 1934 Act, including without limitation those arising under Item 7 of Schedule 14A.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(f)&#160;&#160;&#160;&#160;For purposes of this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:11pt;color:#484848;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">02</font><font style="font-family:inherit;font-size:11pt;color:#353535;">, "public announcement" shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the 1934 Act.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 2.03&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Special Meetings</font><font style="font-family:inherit;font-size:11pt;color:#353535;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(a)&#160;&#160;&#160;&#160;Special meetings of the stockholders of the corporation may only be called, for any purpose or purposes, by (i) the Chairman of the Board of Directors, (ii) the Chief Executive Officer, or (iii) the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(b)&#160;&#160;&#160;&#160;The Board of Directors shall determine the time and place of each special meeting. Upon determination of the time and place of the meeting, the Chairman of the Board</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">Chief Executive Officer, President or Secretary shall cause notice to be given to the stockholders entitled to vote, in accordance with the provisions of </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2.04</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;of these Bylaws. No business may be transacted at a special meeting except for the business specified in the notice of the meeting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(c)&#160;&#160;&#160;&#160;In the event a special meeting of stockholders is called for the purpose of electing one or more directors to the Board of Directors, nominations of persons for election to the Board of Directors may be made (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the corporation who is a stockholder of record at the time of giving notice provided for in these Bylaws who shall be entitled to vote at the meeting and who complies with the notice procedures set forth in the next sentence. Any such stockholder may nominate a person or persons (as the case may be), for election to such position(s) as specified in the corporation's notice of meeting, by giving the notice required by </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:11pt;color:#464646;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">02(b)</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;of these Bylaws to the Secretary at the principal executive offices of the corporation except that such notice will be deemed to be timely received by the corporation only if it is received by the Secretary not later than the close of business on the tenth (10th) day following the earlier of (i) the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting, or (ii) the mailing by the corporation to stockholders of the notice for the meeting. In no event shall the public announcement of an adjournment of a special meeting commence a new time period for the giving of a stockholder's notice as described above.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 2.04&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Notice of Meetings</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. Except as otherwise provided by law or the Certificate of Incorporation, written notice of each meeting of stockholders shall be given not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, date and hour and purpose or purposes of the meeting. Notice of the time, place and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, either before or after such meeting, and will be waived by any stockholder by his attendance thereat in person or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened</font><font style="font-family:inherit;font-size:11pt;color:#464646;">. </font><font style="font-family:inherit;font-size:11pt;color:#353535;">Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 2.05 </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Quorum</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. At all meetings of stockholders, except where otherwise provided by statute or by the Certificate of Incorporation, or by these Bylaws, the presence, in person or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time</font><font style="font-family:inherit;font-size:11pt;color:#464646;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting</font><font style="font-family:inherit;font-size:11pt;color:#464646;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors</font><font style="font-family:inherit;font-size:11pt;color:#464646;">. </font><font style="font-family:inherit;font-size:11pt;color:#353535;">Where a separate vote by a class or classes or series is required, except where otherwise provided by statute or by the Certificate of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter and, except where otherwise provided by statute or by the Certificate of lncorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of the votes cast by the holders of shares of such class or classes or series shall be the act of such class or classes or series.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 2.06&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Adjournment and Notice of Adjourned Meetings</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority of the shares casting votes. When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 2.07&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Voting Rights</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 2.09</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;of these Bylaws</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">shall be entitled to vote at any meeting of stockholders. Every person entitled to vote shall have the right to do so either in person or by an agent or agents authorized by a proxy granted in accordance with Delaware law.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">An agent so appointed need not be a stockholder. No proxy shall be voted after three (3) years from its date of creation unless the proxy provides for a longer period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 2.08&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Joint Owners of Stock</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">. </font><font style="font-family:inherit;font-size:11pt;color:#353535;">If shares or other securities having voting power stand of record in the names of two (2) or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two (2) or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(a)&#160;&#160;&#160;&#160;if only one (1) votes, his act binds all;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(b)&#160;&#160;&#160;&#160;if more than one (1) votes, the act of the majority so voting binds all; or (c) if more than one (1) votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the DGCL, </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 217(b)</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of subsection;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(c)&#160;&#160;&#160;&#160;shall be a majority or even-split in interest.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 2.09&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">List of Stockholders</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. The Secretary shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten ( 10) days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not specified, at the place where the meeting is to be held. The list shall be produced and kept at the time and place of meeting during the whole time thereof and may be inspected by any stockholder who is present.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 2.10&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Action Without Meeting</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. No action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with these Bylaws, and no action shall be taken by the stockholders by written consent.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 2.11&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Organization</font><font style="font-family:inherit;font-size:11pt;color:#353535;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(a)&#160;&#160;&#160;&#160;At every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the President, or, if the President is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairman. The Secretary</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">or, in his absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(b)&#160;&#160;&#160;&#160;The Board of Directors of the corporation shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly authorized and constituted proxies and such other persons as the chairman shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 2.12&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Supermajority Vote Requirement</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. Notwithstanding any other provisions of these Bylaws or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the voting stock of the corporation required by law, the Certificate of Incorporation or the terms of any series of Preferred Stock, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of the voting stock, voting together as a single class, shall be required to approve any of the following actions if such action is not affirmatively recommended by the Board of Directors:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(a)&#160;&#160;&#160;&#160;the merger or consolidation of the corporation with any other corporation or entity;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(b)&#160;&#160;&#160;&#160;the sale, conveyance or other disposition of all or substantially all of the assets of the corporation;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(c)&#160;&#160;&#160;&#160;the conversion of the corporation into another type of corporation or entity; or</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(d)&#160;&#160;&#160;&#160;the amendment, repeal or amendment of any provision of the Certificate of Incorporation (except that as to Articles VI, VII, VIII, IX and XII of the Certificate of Incorporation, such affirmative stockholder vote shall be required regardless of whether the Board of Directors does or does not affirmatively recommend the action).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">ARTICLE Ill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">DIRECTORS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Section 3.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Number</font><font style="font-family:inherit;font-size:11pt;color:#363636;">. The authorized number of directors of the corporation shall be fixed in accordance with the Certificate of Incorporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">Directors need not be stockholders unless so required by the Certificate of Incorporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Section 3.02&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Powers</font><font style="font-family:inherit;font-size:11pt;color:#363636;">. The powers of the corporation shall be exercised, its business conducted and its property controlled by the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Section 3.03&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Classes of Directors</font><font style="font-family:inherit;font-size:11pt;color:#363636;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:54px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(a)&#160;&#160;&#160;&#160;Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the Board of Directors shall be divided into three classes designated as Class I, Class II and Class III, respectively. Promptly following the effectiveness of this Section 3.03, directors shall be assigned to each class in accordance with a resolution or resolutions adopted by the Board of Directors. Each class shall consist, as nearly as possible, of one-third (1/3) of the total number of directors constituting the entire Board of Directors. The term of office of the Class I directors shall expire at the annual meeting of stockholders to be held in 2017, and, at that meeting, Class I directors shall be elected for a full term of three years. At the annual meeting of stockholders to be held in 2015, the term of office of the Class II directors shall expire, and Class II directors shall be elected for a full term of three years. At the annual meeting of stockholders to be held in 2016, the term of office of the Class III directors shall expire, and Class III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three (3) years to succeed the directors of the class whose terms expire at such annual meeting. If the number of directors is changed, an increase or decrease shall be apportioned among the classes so as to maintain the number of directors in each class as nearly equal as possible, and any additional director of any class </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">elected to fill a vacancy resulting from an increase in such class, but in no case shall a decrease in the number of directors remove or shorten the term of any incumbent director.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:54px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(b)&#160;&#160;&#160;&#160;In the event that the corporation is unable to have a classified Board of Directors under applicable law, </font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Section 3.03(a)</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;of these Bylaws shall not apply and all directors shall be elected at each annual meeting of stockholders to hold office until the next annual meeting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:54px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(c)&#160;&#160;&#160;&#160;Notwithstanding the foregoing provisions of this section, each director shall serve until his successor is duly elected and qualified or until his death, resignation or removal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:54px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(d)&#160;&#160;&#160;&#160;No stockholder shall be entitled to cumulate votes in the election of directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:54px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(e)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, whenever the holders of any one or more series of Preferred Stock issued by the corporation shall have the right, voting separately by series</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:11pt;color:#363636;">to elect directors at an annual or special meeting of stockholders, the election, term of office, filling of vacancies and other features of such directorships shall be governed by the terms of the series of Preferred Stock applicable thereto, and such directors so elected shall not be divided into classes pursuant to this </font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Section 3.03</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;unless expressly provided by such terms.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Section 3.04&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Vacancies</font><font style="font-family:inherit;font-size:11pt;color:#363636;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(a)&#160;&#160;&#160;&#160;Unless otherwise provided in the Certificate of lncorporation, any vacancies on the Board of Directors resulting from death</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:11pt;color:#363636;">resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, except as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director's successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this </font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Section 3</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">04</font><font style="font-family:inherit;font-size:11pt;color:#363636;">&#32;in the case of the death, removal or resignation of any director.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;">(b)&#160;&#160;&#160;&#160;If at the time of filling any vacancy or any newly created directorship, the directors then in office shall constitute less than a majority of the whole board (as constituted immediately prior to any such increase), the Delaware Court of Chancery may, upon application of any stockholder or stockholders holding at least ten percent (10%) of the total number of the shares at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace the directors chosen by the directors then in offices as aforesaid, which election shall be governed by Section 211 of the DGCL</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#363636;font-weight:bold;">Section 3.05&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#363636;text-decoration:underline;">Resignation</font><font style="font-family:inherit;font-size:11pt;color:#363636;">. Any director may resign at any time by delivering his written resignation to the Secretary, such resignation to specify whether it will be effective at a particular time, upon receipt by the Secretary or at the pleasure of the Board of Directors</font><font style="font-family:inherit;font-size:11pt;color:#4b4b4b;">. </font><font style="font-family:inherit;font-size:11pt;color:#363636;">If no such specification is made, it shall be deemed effective at the pleasure of the Board of Directors. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each Director so chosen shall hold office for the </font><font style="font-family:inherit;font-size:11pt;color:#353535;">unexpired portion of the term of the Director whose place shall be vacated and until his successor shall have been duly elected and qualified.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 3</font><font style="font-family:inherit;font-size:11pt;color:#484848;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">06&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Removal</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. Directors may only be removed for cause, as provided in Section 141(k)(l) of the DGCL.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 3.07&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Meetings</font><font style="font-family:inherit;font-size:11pt;color:#353535;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(a)&#160;&#160;&#160;&#160;Regular Meetings. Unless otherwise restricted by the Certificate oflncorporation, regular meetings of the Board of Directors may be held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors and publicized among all directors. No formal notice shall be required for regular meetings of the Board of Directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(b)&#160;&#160;&#160;&#160;Special Meetings</font><font style="font-family:inherit;font-size:11pt;color:#484848;">. </font><font style="font-family:inherit;font-size:11pt;color:#353535;">Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors may be held at any time and place within or without the State of Delaware whenever called by the Chairman of the Board</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">the President or any two of the directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(c)&#160;&#160;&#160;&#160;Telephone Meetings. Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(d)&#160;&#160;&#160;&#160;Notice of Meetings. Notice of the time and place of all special meetings of the Board of Directors shall be orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">facsimile, telegraph or telex, or by electronic mail or other electronic means, during normal business hours, at least twenty-four (24) hours before the date and time of the meeting, or sent in writing to each director by first class mail, charges prepaid, at least three (3) days before the date of the meeting. Notice of any meeting may be waived in writing at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(e)&#160;&#160;&#160;&#160;Waiver of Notice. The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though had at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present shall sign a written waiver of notice. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting</font><font style="font-family:inherit;font-size:11pt;color:#484848;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 3.08&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Quorum and Voting</font><font style="font-family:inherit;font-size:11pt;color:#484848;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(a)&#160;&#160;&#160;&#160;Unless the Certificate of lncorporation requires a greater number and except with respect to indemnification questions arising under </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 10</font><font style="font-family:inherit;font-size:11pt;color:#484848;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">01</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;hereof, for which a quorum shall be one-third of the total number of directors fixed from time to time in accordance with the Certificate of Incorporation, a quorum of the Board of Directors shall consist of a majority of the total number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation; provided, however, at any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(b)&#160;&#160;&#160;&#160;At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 3.09&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Action Without Meeting</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in writing, and such writing or writings are filed with the minutes of proceedings of the Board of Directors or committee.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 3.10&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Fees and Compensation</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 3.11&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Committees</font><font style="font-family:inherit;font-size:11pt;color:#353535;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(a)&#160;&#160;&#160;&#160;Executive Committee. The Board of Directors may appoint an Executive Committee to consist of one (1) or more members of the Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to (i) approving or adopting, or recommending to the stockholders, any action or matter expressly required by the DGCL to be submitted to stockholders for approval, or (ii) adopting, amending or repealing any bylaw of the corporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(b)&#160;&#160;&#160;&#160;Other Committees. The Board of Directors may, from time to time, appoint such other committees as may be permitted by law. Such other committees appointed by the Board of Directors shall consist of one (1) or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(c)&#160;&#160;&#160;&#160;Term. Each member of a committee of the Board of Directors shall serve a term on the committee coexistent with such member's term on the Board of Directors. The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock and the provisions of subsections (a) or (b) of this Bylaw, may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee</font><font style="font-family:inherit;font-size:11pt;color:#505050;">. </font><font style="font-family:inherit;font-size:11pt;color:#333333;">The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(d)&#160;&#160;&#160;&#160;Meetings. Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this </font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Section 3.11</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#32;shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called by any director who is a member of such committee, upon written notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of written notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such special </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. A majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Section 3.12&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Organization</font><font style="font-family:inherit;font-size:11pt;color:#333333;">. At every meeting of the directors, the Chairman of the Board of Directors</font><font style="font-family:inherit;font-size:11pt;color:#505050;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">or, if a Chairman has not been appointed or is absent, the President (if a director), or if the President is absent, the most senior Vice President (if a director), or, in the absence of any such person, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his absence, any Assistant Secretary directed to do so by the President, shall act as secretary of the meeting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333630;font-weight:bold;">ARTICLE IV </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333630;font-weight:bold;">OFFICERS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333630;font-weight:bold;">Section 4.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333630;text-decoration:underline;">Officers Designated</font><font style="font-family:inherit;font-size:11pt;color:#333630;">. The officers of the corporation shall include, if and when designated by the Board of Directors, the Chairman of the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer, the Treasurer and the Controller, all of whom shall be elected at the annual organizational meeting of the Board of Directors. The Board of Directors may also appoint one or more Assistant Secretaries, Assistant Treasurers, Assistant Controllers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333630;font-weight:bold;">Section 4.02&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333630;text-decoration:underline;">Tenure and Duties of Officers</font><font style="font-family:inherit;font-size:11pt;color:#333630;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333630;">(a)&#160;&#160;&#160;&#160;General. All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333630;">(b)&#160;&#160;&#160;&#160;Duties of Chairman of the Board of Directors. The Chairman of the Board of Directors, when present, shall preside at all meetings of the stockholders and the Board of Directors. The Chairman of the Board of Directors shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. If there is no Chief Executive Officer or President, then the Chairman of the Board of Directors shall also serve as the Chief Executive Officer of the corporation and shall have the powers and duties prescribed in paragraph (c) of this </font><font style="font-family:inherit;font-size:11pt;color:#333630;text-decoration:underline;">Section 4.02</font><font style="font-family:inherit;font-size:11pt;color:#333630;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333630;">(c)&#160;&#160;&#160;&#160;Duties of Chief Executive Officer. If the corporation has a Chief Executive Officer, the Chief Executive Officer shall be the chief executive officer of the corporation and shall have all of the authority, powers and duties provided for or reserved to the President in paragraph (d) of this </font><font style="font-family:inherit;font-size:11pt;color:#333630;text-decoration:underline;">Section 4.02</font><font style="font-family:inherit;font-size:11pt;color:#333630;">&#32;in lieu of the President, and the President shall be the Chief Operating Officer of the corporation charged with the duty and power to manage the operations of the business of the corporation but subject to the overall direction of the Chief Executive Officer and the Board of Directors. In the absence or disability of the Chief Executive Officer, or in the event of his inability or refusal to act, the President shall perform the duties and have the authority and exercise the powers of the Chief Executive Officer.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333630;">(d)&#160;&#160;&#160;&#160;Duties of President. The President shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors or the Chief Executive Officer has been appointed and is present. Unless some other person has been elected Chief Executive Officer of the corporation, the President shall be the </font><font style="font-family:inherit;font-size:11pt;color:#353535;">chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation. The President shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(e)&#160;&#160;&#160;&#160;Duties of Chief Operating Officer. Unless the Board of Directors appoints a Chief Operating Officer that is separate from the President, the President shall be the Chief Operating Officer of the Corporation charged with the duty and power to manage the operations of the business of the Corporation but subject to the overall direction of the Chief Executive Officer and the Board of Directors. If the Board of Directors appoints a Chief Operating Officer that is separate from the President, the Board of Directors shall determine the relative duties and powers of the President and the Chief Operating Officer, and each will be subject to the overall direction of the Chief Executive Officer and the Board of Directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(f)&#160;&#160;&#160;&#160;Duties of Vice Presidents. The Vice Presidents may assume and perform the duties of the President in the absence or disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or, in his absence or disability, the President, shall designate from time to time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(g)&#160;&#160;&#160;&#160;Duties of Secretary. The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring notice. The Secretary shall perform all other duties given him in these Bylaws and other duties commonly incident to his office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. The Chief Executive Officer or, in his absence or disability, the President may direct any Assistant Secretary to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or, in his absence or disability, the President, shall designate from time to time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(h)&#160;&#160;&#160;&#160;Duties of Chief Financial Officer. The Chief Financial Officer shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the Chief Executive Officer, or, in his absence or disability, the President. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or, in his absence or disability, the President, shall designate from time to time</font><font style="font-family:inherit;font-size:11pt;color:#525252;">. </font><font style="font-family:inherit;font-size:11pt;color:#353535;">The Chief Executive Officer, or, in his absence or disability, the President, may direct the Treasurer or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the </font><font style="font-family:inherit;font-size:11pt;color:#303030;">Chief Financial Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">Directors or the Chief Executive Officer, or, in his absence or disability, the President, shall designate from time to time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">Section 4.03&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#303030;text-decoration:underline;">Delegation of Authority</font><font style="font-family:inherit;font-size:11pt;color:#303030;">. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">Section 4.04&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#303030;text-decoration:underline;">Resignations</font><font style="font-family:inherit;font-size:11pt;color:#303030;">. Any officer may resign at any time by giving written notice to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">Section 4.05&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#303030;text-decoration:underline;">Removal</font><font style="font-family:inherit;font-size:11pt;color:#303030;">. Any officer may be removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or superior officers upon whom such power of removal may have been conferred by the Board of Directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">ARTICLEV</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE CORPORATION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">Section 5.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#303030;text-decoration:underline;">Execution of Corporate Instruments</font><font style="font-family:inherit;font-size:11pt;color:#303030;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">(a)&#160;&#160;&#160;&#160;The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name without limitation, or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">(b)&#160;&#160;&#160;&#160;All checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">(c)&#160;&#160;&#160;&#160;Unless authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 5.02&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Voting of Securities Owned by the Corporation</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. All stock and other securities of other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer, the President, or any Vice President.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">ARTICLE VI </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">SHARES OF STOCK</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 6.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Form and Execution of Certificates</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. The shares of the corporation shall be represented by certificates, provided that the Board of Directors of the corporation may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">shares. Certificates for the shares of stock of the corporation shall be in such form as is consistent with the Certificate of lncorporation and applicable law. Every holder of stock in the corporation represented by certificates shall be entitled to have a certificate signed by or in the name of the corporation by the Chairman of the Board of Directors, or the President or any Vice President and by the Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. Each certificate shall state upon the face or back thereof, in full or in summary, all of the powers, designations, preferences, and rights, and the limitations or restrictions of the shares authorized to be issued or shall, except as otherwise required by law, set forth on the face or back a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional, or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated stock, the corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to this section or otherwise required by law or with respect to this section a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise expressly provided by law, the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 6.02&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Direct Registration</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. Notwithstanding any other provision in these Bylaws, the corporation may adopt a system of issuance, recordation and transfer of shares of the corporation by electronic or other means not involving any issuance of certificates, including provisions for notice to purchasers in substitution for any required statements on certificates, and as may be required by applicable corporate securities laws, which system has been approved by the Securities and Exchange Commission. Any system so adopted shall not become effective as </font><font style="font-family:inherit;font-size:11pt;color:#333333;">to issued and outstanding certificated securities until the certificates therefor have been surrendered to the corporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Section 6.03&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Lost Certificates</font><font style="font-family:inherit;font-size:11pt;color:#333333;">. A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed</font><font style="font-family:inherit;font-size:11pt;color:#454545;">. </font><font style="font-family:inherit;font-size:11pt;color:#333333;">The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost</font><font style="font-family:inherit;font-size:11pt;color:#454545;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">stolen, or destroyed certificate or certificates, or his legal representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have been lost, stolen</font><font style="font-family:inherit;font-size:11pt;color:#454545;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">or destroyed.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Section 6.04&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Transfers</font><font style="font-family:inherit;font-size:11pt;color:#333333;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(a)&#160;&#160;&#160;&#160;Transfers of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by attorney duly authorized, and upon the surrender of a properly endorsed certificate or certificates for a like number of shares</font><font style="font-family:inherit;font-size:11pt;color:#454545;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(b)&#160;&#160;&#160;&#160;The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the corporation to restrict the transfer of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Section 6.05&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Fixing Record Dates</font><font style="font-family:inherit;font-size:11pt;color:#333333;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(a)&#160;&#160;&#160;&#160;In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable law, not be more than sixty (60) nor less than ten (10) days before the date of such meeting</font><font style="font-family:inherit;font-size:11pt;color:#454545;">. </font><font style="font-family:inherit;font-size:11pt;color:#333333;">If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(b)&#160;&#160;&#160;&#160;In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change</font><font style="font-family:inherit;font-size:11pt;color:#454545;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60) days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Section 6.06</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Registered Stockholders</font><font style="font-family:inherit;font-size:11pt;color:#333333;">. The corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware</font><font style="font-family:inherit;font-size:11pt;color:#494949;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">ARTICLE VII</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">OTHER SECURITIES OF THE CORPORATION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Section 7.01</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Execution of Other Securities</font><font style="font-family:inherit;font-size:11pt;color:#333333;">. All bonds, debentures and other corporate securities of the corporation</font><font style="font-family:inherit;font-size:11pt;color:#494949;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">other than stock certificates (covered in </font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Section 6.01</font><font style="font-family:inherit;font-size:11pt;color:#333333;">), may be signed by the Chairman of the Board of Directors, the President or any Vice President, or such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an Assistant Treasurer; provided, however, that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person</font><font style="font-family:inherit;font-size:11pt;color:#494949;">. </font><font style="font-family:inherit;font-size:11pt;color:#333333;">In case any officer who shall have signed or attested any bond</font><font style="font-family:inherit;font-size:11pt;color:#494949;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">debenture or other corporate security, or whose facsimile signature shall appear thereon or on any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">ARTICLE VIII </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">DIVIDENDS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Section 8.01</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Declaration of Dividends</font><font style="font-family:inherit;font-size:11pt;color:#333333;">. Dividends upon the capital stock of the corporation, subject to the provisions of the Certificate of lncorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 8.02&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Dividend Reserve</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">ARTICLE IX </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">FISCAL YEAR</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 9.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Fiscal Year</font><font style="font-family:inherit;font-size:11pt;color:#353535;">. The fiscal year of the corporation shall be fixed by resolution of the Board of Directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">ARTICLE X </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">INDEMNIFICATION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 10.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Indemnification of Directors, Officers, Employees and Other Agents</font><font style="font-family:inherit;font-size:11pt;color:#353535;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(a)&#160;&#160;&#160;&#160;Directors and Officers. The corporation shall indemnify its directors and officers to the fullest extent not prohibited by the DGCL or any other applicable law; provided, however, that the corporation may modify the extent of such indemnification by individual contracts with its directors and officers; and, provided, further, that the corporation shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by the Board of Directors of the corporation, (iii) such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested in the corporation under the DGCL or any other applicable law or (iv) such indemnification is required to be made under </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">subsection (d)</font><font style="font-family:inherit;font-size:11pt;color:#353535;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(b)&#160;&#160;&#160;&#160;Employees and Other Agents. The corporation shall have power to indemnify its employees and other agents as set forth in the DGCL or any other applicable law</font><font style="font-family:inherit;font-size:11pt;color:#484848;">. </font><font style="font-family:inherit;font-size:11pt;color:#353535;">The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any such person to such officers or other persons as the Board of Directors shall determine, to the extent not prohibited by the DGCL.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(c)&#160;&#160;&#160;&#160;Expenses. The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or officer, of the corporation, or is or was serving at the request of the corporation as a director or executive officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director or officer in connection with such proceeding upon receipt of an undertaking by or on behalf of such person to repay said amounts </font><font style="font-family:inherit;font-size:11pt;color:#333333;">if it should be determined ultimately that such person is not entitled to be indemnified under this </font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Section 10.01</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#32;or otherwise.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph (e) of this </font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Section 10.01</font><font style="font-family:inherit;font-size:11pt;color:#333333;">, no advance shall be made by the corporation to an officer of the corporation (except by reason of the fact that such officer is or was a director of the corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative</font><font style="font-family:inherit;font-size:11pt;color:#454545;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">if a determination is reasonably and promptly made (i) by the Board of Directors by a majority vote of a quorum consisting of directors who were not parties to the proceeding, or (ii) if such quorum is not obtainable, or, even if obtainable, a quorum of disinterested directors so directs, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(d)&#160;&#160;&#160;&#160;Enforcement. Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and officers under this Bylaw shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the corporation and the director or officer. Any right to indemnification or advances granted by this </font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Section 10.01</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#32;to a director or officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i) the claim for indemnification or advances is denied, in whole or in part, or (ii) no disposition of such claim is made within ninety (90) days of request therefor. The claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting his claim. In connection with any claim for indemnification, the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount claimed. In connection with any claim by an officer of the corporation (except in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such executive officer is or was a director of the corporation) for advances, the corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation, or with respect to any criminal action or proceeding that such person acted without reasonable cause to believe that his conduct was lawful. Neither the failure of the corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any suit brought by a director or officer to enforce a right to indemnification or to an advancement of expenses hereunder, the burden of proving that the director or officer is not entitled to be indemnified</font><font style="font-family:inherit;font-size:11pt;color:#454545;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">or to such advancement of expenses, under this </font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Section 10.01</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#32;or otherwise shall be on the corporation.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(e)&#160;&#160;&#160;&#160;Non-Exclusivity of Rights. The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the Delaware General Corporation Law, or by any other applicable law.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(f)&#160;&#160;&#160;&#160;Survival of Rights. The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director, officer, employee or other agent and shall inure to the benefit of the heirs, executors and administrators of such a person.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(g)&#160;&#160;&#160;&#160;Insurance. To the fullest extent permitted by the DGCL or any other applicable law, the corporation, upon approval by the Board of Directors</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 10.01</font><font style="font-family:inherit;font-size:11pt;color:#353535;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(h)&#160;&#160;&#160;&#160;Amendments. Any repeal or modification of this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 10.01</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;shall only be prospective and shall not affect the rights under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the corporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(i)&#160;&#160;&#160;&#160;Saving Clause. If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the corporation shall nevertheless indemnify each director and officer to the full extent not prohibited by any applicable portion of this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 10.01</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;that shall not have been invalidated, or by any other applicable law. If this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 10.01</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and officer to the full extent under any other applicable law.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(j)&#160;&#160;&#160;&#160;Certain Definitions. For the purposes of this Bylaw, the following definitions shall apply:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(i)&#160;&#160;&#160;&#160;The term "proceeding" shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(ii)&#160;&#160;&#160;&#160;The term "expenses" shall be broadly construed and shall include, without limitation, court costs, attorneys' fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(iii)&#160;&#160;&#160;&#160;The term "corporation" shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership</font><font style="font-family:inherit;font-size:11pt;color:#494949;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">joint venture, trust or other enterprise, shall stand in the same position under the provisions of this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 10</font><font style="font-family:inherit;font-size:11pt;color:#494949;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">01</font><font style="font-family:inherit;font-size:11pt;color:#353535;">&#32;with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued</font><font style="font-family:inherit;font-size:11pt;color:#494949;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(iv)&#160;&#160;&#160;&#160;References to a "director," "executive officer," "officer</font><font style="font-family:inherit;font-size:11pt;color:#494949;">,</font><font style="font-family:inherit;font-size:11pt;color:#353535;">" "employee," or "agent" of the corporation shall include, without limitation, situations where such person is serving at the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">request of the corporation as, respectively</font><font style="font-family:inherit;font-size:11pt;color:#494949;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">a director, executive officer, officer, employee, trustee or agent of another corporation, partnership</font><font style="font-family:inherit;font-size:11pt;color:#494949;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">joint venture, trust or other enterprise.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(v)&#160;&#160;&#160;&#160;References to "other enterprises" shall include employee benefit plans; references to "fines" shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to "serving at the request of the corporation" shall include any service as a director</font><font style="font-family:inherit;font-size:11pt;color:#494949;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner "not opposed to the best interests of the corporation" as referred to in this </font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Section 10.01</font><font style="font-family:inherit;font-size:11pt;color:#353535;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">ARTICLE XI </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">NOTICES</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;font-weight:bold;">Section 11.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#353535;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:11pt;color:#494949;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(a)&#160;&#160;&#160;&#160;Notice to Stockholders. Whenever, under any provisions of these Bylaws, notice is required to be given to any stockholder, it shall be given in writing, timely and duly deposited in the United States mail, postage prepaid, and addressed to his last known post office address as shown by the stock record of the corporation or its transfer agent.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(b)&#160;&#160;&#160;&#160;Notice to Directors. Any notice required to be given to any director may be given by the method stated in subsection (a), or by overnight delivery service, facsimile</font><font style="font-family:inherit;font-size:11pt;color:#494949;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">telex or telegram, except that such notice other than one which is delivered personally shall be sent to such address as such director shall have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#353535;">(c)&#160;&#160;&#160;&#160;Affidavit of Mailing. An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected</font><font style="font-family:inherit;font-size:11pt;color:#494949;">, </font><font style="font-family:inherit;font-size:11pt;color:#353535;">specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(d)&#160;&#160;&#160;&#160;Time Notices Deemed Given. All notices given by mail or by overnight delivery service, as above provided, shall be deemed to have been given as at the time of mailing, and all notices given by facsimile, telex or telegram shall be deemed to have been given as of the sending time recorded at time of transmission.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(e)&#160;&#160;&#160;&#160;Methods of Notice. It shall not be necessary that the same method of giving notice be employed in respect of all directors, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(f)&#160;&#160;&#160;&#160;Failure to Receive Notice. The period or limitation of time within which any stockholder may exercise any option or right</font><font style="font-family:inherit;font-size:11pt;color:#454545;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">or enjoy any privilege or benefit, or be required to act, or within which any director may exercise any power or right, or enjoy any privilege, pursuant to any notice sent him in the manner above provided, shall not be affected or extended in any manner by the failure of such stockholder or such director to receive such notice.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(g)&#160;&#160;&#160;&#160;Notice to Person With Whom Communication Is Unlawful. Whenever notice is required to be given, under any provision of law or of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person</font><font style="font-family:inherit;font-size:11pt;color:#454545;">. </font><font style="font-family:inherit;font-size:11pt;color:#333333;">Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given</font><font style="font-family:inherit;font-size:11pt;color:#454545;">. </font><font style="font-family:inherit;font-size:11pt;color:#333333;">In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state</font><font style="font-family:inherit;font-size:11pt;color:#454545;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(h)&#160;&#160;&#160;&#160;Notice to Person With Undeliverable Address. Whenever notice is required to be given, under any provision of law or the Certificate of Incorporation or Bylaws of the corporation, to any stockholder to whom (i) notice of two consecutive annual meetings, and all notices of meetings or of the taking of action by written consent without a meeting to such person during the period between such two consecutive annual meetings, or (ii) all, and at least two</font><font style="font-family:inherit;font-size:11pt;color:#454545;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">payments (if sent by first class mail) of dividends or interest on securities during a twelve&#8226; month period, have been mailed addressed to such person at his address as shown on the records of the corporation and have been returned undeliverable</font><font style="font-family:inherit;font-size:11pt;color:#454545;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">the giving of such notice to such person shall not be required. Any action or meeting which shall be taken or held without notice to such person shall have the same force and effect as if such notice had been duly given. If any such person shall deliver to the corporation a written notice setting forth his then current address, the requirement that notice be given to such person shall be reinstated. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate need not state that notice was not given to persons to whom notice was not required to be given pursuant to this paragraph.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">(i)&#160;&#160;&#160;&#160;Notice by Electronic Transmission. Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders may be given by electronic mail or other electronic transmission, in the manner provided in Section 232 of the DGCL.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">ARTICLE XII </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">AMENDMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Section 12.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Amendments</font><font style="font-family:inherit;font-size:11pt;color:#333333;">. Subject to paragraph (h) of </font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Section 10.01</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#32;of the Bylaws, the Bylaws may be repealed, altered or amended or new Bylaws adopted by the affirmative vote of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of the voting stock of the corporation entitled to vote. The Board of Directors shall also have the power to adopt, amend, or repeal Bylaws.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">ARTICLE XIII </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">LOANS TO OFFICERS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Section 13.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Loans to Officers</font><font style="font-family:inherit;font-size:11pt;color:#333333;">. The corporation may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who is a Director of the corporation or its subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in such manner as the Board of Directors shall approve</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">including, without limitation, a pledge of shares of stock of the corporation. Nothing in these Bylaws shall be deemed to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;">deny</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#333333;">limit or restrict the powers of guaranty or warranty of the corporation at common law or under any statute.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">ARTICLE XIV </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">FORUM</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#333333;font-weight:bold;">Section 14.01&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#333333;text-decoration:underline;">Fourm</font><font style="font-family:inherit;font-size:11pt;color:#333333;">. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (A) any derivative action or proceeding brought on behalf of the Corporation, (B) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer, employee or agent of the Corporation to the Corporation or the Corporation's stockholders, (C) any action or proceeding asserting a claim against the Corporation arising pursuant to any provision of the Delaware General Corporation Law or the Corporation</font><font style="font-family:inherit;font-size:11pt;color:#484848;">'</font><font style="font-family:inherit;font-size:11pt;color:#333333;">s Certificate of Incorporation or these Bylaws, or (D) any action or proceeding asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><a name="sCB7304F8589F702B8E05434B7A462BB1"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:50px;width:66px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:64px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f322c;font-weight:bold;">CERTIFICATE OF ADOPTION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f322c;font-weight:bold;">OF AMENDED AND RESTATED BYLAWS </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f322c;font-weight:bold;">OF</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f322c;font-weight:bold;">DYADIC INTERNATIONAL, INC. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f322c;font-weight:bold;text-decoration:underline;">CERTIFICATE BY SECRETARY OF ADOPTION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#2f322c;">The undersigned hereby certifies that the undersigned is the duly elected, qualified, and acting Secretary of Dyadic International, Inc</font><font style="font-family:inherit;font-size:11.5pt;color:#464844;">.</font><font style="font-family:inherit;font-size:11.5pt;color:#616161;">, </font><font style="font-family:inherit;font-size:11.5pt;color:#2f322c;">a Delaware corporation, and that the foregoing Amended and Restated Bylaws were adopted as the Bylaws of the corporation pursuant to resolutions at a duly noticed and called meeting of the Board of Directors on June 25</font><font style="font-family:inherit;font-size:11.5pt;color:#616161;">, </font><font style="font-family:inherit;font-size:11.5pt;color:#2f322c;">2014 at which a quorum was present.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#2f322c;">Executed on June 25, 2014.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:48.504273504273506%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Michael J. Faby</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael J. Faby, Secretary</font></div></td></tr></table></div></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>5
<FILENAME>exhibit41form10.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sa4c6d90f3c724c97be505e11ac2ee180"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 4.1</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="dyadicspecimen2018103111001.jpg" alt="dyadicspecimen2018103111001.jpg" style="height:883px;width:682px;"></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;"><img src="dyadicspecimen2018103111002.jpg" alt="dyadicspecimen2018103111002.jpg" style="height:883px;width:682px;"></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>exhibit101form10.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s92973E675B03A7BDFE3544B72B215FC1"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2006 STOCK OPTION PLAN</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purpose of the Dyadic International, Inc. 2006 Stock Option Plan (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Plan</font><font style="font-family:inherit;font-size:10pt;">&#8221;) is to provide (i) designated Employees of DYADIC INTERNATIONAL, INC. (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and its subsidiaries, (ii) Key Advisors who perform consulting or advisory services for the Company or its Subsidiaries and (iii) Non-Employee Directors who serve on the Board of Directors of the Company (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Board</font><font style="font-family:inherit;font-size:10pt;">&#8221;) with the opportunity to receive grants of incentive stock options and nonqualified stock options. The Company believes that the Plan will encourage the participants to contribute materially to the growth of the Company, thereby benefiting the Company&#8217;s stockholders, and will align the economic interests of the participants with those of the stockholders. A Glossary of defined terms used in this Plan is set forth in Section 18 hereof.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Administration</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Committee</font><font style="font-family:inherit;font-size:10pt;">. The Plan shall be administered by the Compensation Committee of the Board, a majority of whose members are &#8220;outside directors&#8221; as defined under section 162(m) of the Code and related Treasury regulations, and &#8220;non-employee directors&#8221; as defined under Rule 16b-3 under the Exchange Act (the &#8220;Committee&#8221;). However, the Board may ratify or approve any grants as it deems appropriate.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Committee Authority</font><font style="font-family:inherit;font-size:10pt;">. The Committee shall have the sole authority to (i) determine the individuals to whom grants shall be made under the Plan, (ii) determine the type, size and terms of the Grants to be made to each such individual, (iii) determine the time when the Grants will be made and the duration of any applicable exercise or restriction period, including the criteria for exercisability and the acceleration of exercisability, (iv) amend the terms of any previously issued grant, and (v) deal with any other matters arising under the Plan. In the event the Committee determines section 409A of the Code may be applicable to an Option granted hereunder, the Plan shall prohibit the acceleration of the time or schedule of payment of compensation hereunder, except to the extent permitted under section 409A of the Code and the applicable Treasury regulations thereunder.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Committee Determinations</font><font style="font-family:inherit;font-size:10pt;">. The Committee shall have full power and authority to administer and interpret the Plan, to make factual determinations and to adopt or amend such rules, regulations, agreements and instruments for implementing the Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. The Committee&#8217;s interpretations of the Plan and all determinations made by the Committee pursuant to the powers vested in it hereunder shall be conclusive and binding on all persons having any interest in the Plan or in any awards granted hereunder. All powers of the Committee shall be executed in its sole discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives of the Plan and need not be uniform as to similarly situated individuals.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Grants</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grants of Options under the Plan may consist of Incentive Stock Options as described in Section 5 or Nonqualified Stock Options as described in Section 5. All Grants shall be subject to the terms and conditions set forth herein and to such other terms and conditions consistent with this Plan as the Committee deems appropriate and as are specified in a Grant Instrument or amendment thereto. The Committee shall approve the form and provisions of each Grant Instrument. Grants under a particular Section of the Plan need not be uniform as among the grantees.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Shares Subject to the Plan</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Shares Authorized</font><font style="font-family:inherit;font-size:10pt;">. Subject to adjustment as described below, the aggregate number of shares of Company Stock that may be issued or transferred under the Plan is 4,700,000 shares. The maximum aggregate number of shares of Company Stock that shall be subject to Grants made under the Plan to any individual during any calendar year shall be 1,200,000 shares, subject to adjustment as described below. The shares may be authorized but unissued </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">shares of Company Stock or reacquired shares of Company Stock, including shares purchased by the Company on the open market for purposes of the Plan. If and to the extent Options granted under the Plan terminate, expire, or are canceled, forfeited, exchanged or surrendered without having been exercised, the shares subject to such Grants shall again be available for purposes of the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Adjustments</font><font style="font-family:inherit;font-size:10pt;">. If there is any change in the number or kind of shares of Company Stock outstanding (i) by reason of a stock dividend, spinoff, recapitalization, stock split, or combination or exchange of shares, (ii) by reason of a merger, reorganization or consolidation in which the Company is the surviving corporation, (iii) by reason of a reclassification or change in par value, or (iv) by reason of any other extraordinary or unusual event affecting the outstanding Company Stock as a class without the Company&#8217;s receipt of consideration, or if the value of outstanding shares of Company Stock is substantially reduced as a result of a spinoff or the Company&#8217;s payment of an extraordinary dividend or distribution, the maximum number of shares of Company Stock available for Grants, then in that event (A) the maximum number of shares of Company Stock that any individual participating in the Plan may be granted in any year, (B) the number of shares covered by outstanding Grants, (C) the kind of shares issued under the Plan, and (D) the price per share or the applicable market value of such Grants may be appropriately adjusted by the Committee to reflect any increase or decrease in the number of, or change in the kind or value of, issued shares of Company Stock to preclude, to the extent practicable, the enlargement or dilution of rights and benefits under such Grants; provided, however, that any fractional shares resulting from such adjustment shall be eliminated. Any adjustments determined by the Committee shall be final, binding and conclusive.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Eligibility for Participation</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Eligible Persons</font><font style="font-family:inherit;font-size:10pt;">. All Employees of the Company and its Subsidiaries, including Employees who are officers or members of the Board, and Non-Employee Directors shall be eligible to participate in the Plan. Key Advisors who perform services for the Company or any of its Subsidiaries shall be eligible to participate in the Plan if (i) they render bona fide services to the Company or its Subsidiaries, (ii) the services are not in connection with the offer and sale of securities in a capital-raising transaction and (iii) such Key Advisors do not directly or indirectly promote or maintain a market for the Company&#8217;s securities.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Selection of Grantees</font><font style="font-family:inherit;font-size:10pt;">. The Committee shall select the Employees, Non-Employee Directors and Key Advisors to receive Grants and shall determine the number of shares of Company Stock subject to a particular Grant in such manner as the Committee determines. Employees, Key Advisors and Non-Employee Directors who receive Grants under this Plan shall hereinafter be referred to as &#8220;Grantees.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Granting of Options</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Number of Shares</font><font style="font-family:inherit;font-size:10pt;">. The Committee shall determine the number of shares of Company Stock that will be subject to each Grant of Options to Employees, Non-Employee Directors and Key Advisors.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Type of Option and Price</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;The Committee may grant Incentive Stock Options that are intended to qualify as &#8220;Incentive Stock Options&#8221; within the meaning of section 422 of the Code or Nonqualified Stock Options that are not intended so to qualify or any combination of Incentive Stock Options and Nonqualified Stock Options, all in accordance with the terms and conditions set forth in this Plan. Incentive Stock Options may be granted only to Employees. Nonqualified Stock Options may be granted to Employees, Non-Employee Directors and Key Advisors.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;The purchase price (the &#8220;Exercise Price&#8221;) of Company Stock subject to an Option shall be determined by the Committee and shall be equal to or greater than the Fair Market Value (as defined below) of a share of Company Stock on the date the Option is granted; provided, however, that an Incentive Stock </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option shall not be granted to an Employee who, at the time of grant, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any parent or subsidiary of the Company, unless the Exercise Price per share is not less than one hundred ten percent (110%) of the Fair Market Value of Company Stock on the date of grant.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;While the Company Stock is publicly traded, the Fair Market Value per share shall be determined as follows: (x) if the principal trading market for the Company Stock is a national securities exchange or the Nasdaq National Market, the last reported sale price thereof on the relevant date or (if there were no trades on that date) the latest preceding date upon which a sale was reported. or (y) if the Company Stock is not principally traded on such exchange or market, the mean between the last reported &#8220;bid&#8221; and &#8220;asked&#8221; prices of Company Stock on the relevant date, as reported on Nasdaq or, if not so reported, as reported by the National Daily Quotation Bureau, Inc. or as reported in a customary financial reporting service, as applicable and as the Committee determines. If the Company Stock ever ceases to be publicly traded or, if publicly traded, is not subject to reported transactions or &#8220;bid&#8221; or &#8220;asked&#8221; quotations as set forth above, the Fair Market Value per share shall be as determined by the Committee.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Option Term</font><font style="font-family:inherit;font-size:10pt;">. The Committee shall determine the term of each Option. The term of any Option shall not exceed ten (10) years from the date of grant. However, an Incentive Stock Option that is granted to an Employee who, at the time, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, or any parent or subsidiary of the Company, may not have a term that exceeds five years from the date of grant.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercisability of Options</font><font style="font-family:inherit;font-size:10pt;">. Options shall become exercisable in accordance with such terms and conditions, consistent with the Plan, as may be determined by the Committee and specified in the Grant Instrument. The Committee may waive or accelerate the satisfaction of an exercise term or condition of any or all outstanding Options at any time for any reason.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Termination of Employment, Disability or Death</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Except as provided below, an Option may only be exercised while the Grantee is employed by, or providing service to, the Company as an Employee, Key Advisor or member of the Board. In the event that a Grantee ceases to be employed by the Company (in the case of an Employee), serve on the Board (in the case of a Non-Employee Director) or provide service to, the Company (in the case of a Key Advisor) for any reason other than Disability, death, or termination for Cause, any Option which is otherwise exercisable by the Grantee shall terminate unless exercised within 90 days after the date on which the Grantee ceases to be employed by, serve on the Board of, or provide service to, the Company, as applicable, or within such other period of time as may be specified by the Committee, but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee any of the Grantee&#8217;s Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Company shall terminate as of such date.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;In the event the Grantee ceases to be employed by the Company (in the case of Employees), serve on the Board (in the case of a Non-Employee Director) or provide service to the Company (in the case of a Key Advisor) on account of a termination for Cause by the Company, any Option held by that Grantee shall terminate as of the date such Grantee ceases to be employed by, serve on the Board or provide service to, the Company, as applicable. In addition, notwithstanding any other provisions of this Section 5, if the Committee determines that the Grantee has engaged in conduct that constitutes Cause at any time while the Grantee is employed by, serving on the Board or providing service to, as applicable, the Company or after the Grantee&#8217;s termination of employment, Board membership or service, as applicable, any Option held by that Grantee shall immediately terminate and that Grantee shall automatically forfeit all shares underlying any exercised portion of an Option for which the Company has not yet delivered the share certificates, upon refund by the Company of the Exercise Price paid by that Grantee for such shares. Upon any exercise of an </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option, the Company may withhold delivery of share certificates pending resolution of an inquiry that could lead to a finding resulting in a forfeiture.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;In the event the Grantee ceases to be employed by, serve on the Board or provide service to, the Company, as applicable, because the Grantee is Disabled, any Option which is otherwise exercisable by that Grantee shall terminate unless exercised within one year after the date on which that Grantee ceases to be employed by, be on the Board or provide service to, the Company, as applicable (or within such other period of time as may be specified by the Committee), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee, any of a Grantee&#8217;s Options which are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, serve on the Board or provide service to, the Company, as applicable, shall terminate as of such date.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;If the Grantee dies while employed by, serving on the Board or providing service to, the Company, as applicable, or within 90 days after the date on which the Grantee ceases to be employed, serve on the Board or provide service on account of a termination specified in Section 5(e)(i) above (or within such other period of time as may be specified by the Committee), any Option that is otherwise exercisable by that Grantee shall terminate unless exercised within one year after the date on which that Grantee ceases to be employed by, serve on the Board or provide service to, the Company, as applicable (or within such other period of time as may be specified by the Committee), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Committee, any of the Grantee&#8217;s Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Company shall terminate as of such date.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercise of Options</font><font style="font-family:inherit;font-size:10pt;">. A Grantee may exercise an Option that has become exercisable, in whole or in part, by delivering a notice of exercise to the Company with payment of the Exercise Price. The Grantee shall pay the Exercise Price for an Option as specified by the Committee (w) in cash, (x) with the approval of the Committee, by delivering shares of Company Stock owned by the Grantee (including Company Stock acquired in connection with the exercise of an Option, subject to such restrictions as the Committee deems appropriate) and having a Fair Market Value on the date of exercise equal to the Exercise Price or by attestation (on a form prescribed by the Committee) to ownership of shares of Company Stock having a Fair Market Value on the date of exercise equal to the Exercise Price, (y) pay through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, or (z) by such other method as the Committee may approve. The Committee may authorize loans by the Company to Grantees in connection with the exercise of an Option, upon such terms and conditions as the Committee, in its sole discretion, deems appropriate. Shares of Company Stock used to exercise an Option shall have been held by the Grantee for the requisite period of time to avoid adverse accounting consequences to the Company with respect to the Option. The Grantee shall pay the Exercise Price and the amount of any withholding tax due at the time of exercise.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Limits on Incentive Stock Options</font><font style="font-family:inherit;font-size:10pt;">. Each Incentive Stock Option shall provide that, if the aggregate Fair Market Value of the stock on the date of the grant with respect to which Incentive Stock Options are exercisable for the first time by a Grantee during any calendar year, under the Plan or any other stock option plan of the Company or a parent or subsidiary, exceeds $100,000, then the Option, as to the excess, shall be treated as a Nonqualified Stock Option. An Incentive Stock Option shall not be granted to any person who is not an Employee of the Company or a parent or subsidiary (within the meaning of section 424(f) of the Code).</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Withholding of Taxes</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Required Withholding</font><font style="font-family:inherit;font-size:10pt;">. All Grants under the Plan shall be subject to any applicable federal (including FICA), state and local tax withholding requirements. The Company shall have the right to deduct from other wages paid to the Grantee, any federal, state or local taxes required by law to be withheld with respect to such Grants or any exercise thereof. In the case of Options paid in Company Stock, the Company may require that the Grantee or other person receiving or exercising Grants pay to the Company the amount of any federal, state or local taxes that the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company is required to withhold with respect to such Grants, or the Company may deduct from other wages paid by the Company the amount of any withholding taxes due with respect to such Grants.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Election to Withhold Shares</font><font style="font-family:inherit;font-size:10pt;">. If the Committee so permits, a Grantee may elect to satisfy the Company&#8217;s income tax withholding obligation with respect to Options paid in Company Stock by having shares withheld up to an amount that does not exceed the Grantee&#8217;s minimum applicable withholding tax rate for federal (including FICA), state and local tax liabilities. The election must be in a form and manner prescribed by the Committee and may be subject to the prior approval of the Committee.</font></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Transfer of Grants</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Nontransferability of Grants</font><font style="font-family:inherit;font-size:10pt;">. Except as provided below, only the Grantee may exercise rights under a Grant during the Grantee&#8217;s lifetime. A Grantee may not transfer those rights except by will or by the laws of descent and distribution or, with respect to Grants other than Incentive Stock Options, if permitted in any specific case by the Committee, pursuant to a domestic relations order. When a Grantee dies, such Grantee&#8217;s Successor Grantee may exercise such rights, provided that any such Successor Grantee must furnish proof satisfactory to the Company of his or her right to receive the Grant under the Grantee&#8217;s will or under the applicable laws of descent and distribution.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transfer of Nonqualified Stock Options</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding the foregoing, the Committee may provide, in a Grant Instrument, that a Grantee may transfer Nonqualified Stock Options to immediate family members, or one or more trusts or other entities for the benefit of or owned by immediate family members, consistent with the applicable securities laws, according to such terms as the Committee may determine; provided that the Grantee receives no consideration for the transfer of an Option and the transferred Option shall continue to be subject to the same terms and conditions as were applicable to the Option immediately before the transfer.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Consequences of a Change of Control</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Assumption of Grants</font><font style="font-family:inherit;font-size:10pt;">. Upon the occurrence of a Change of Control in which the Company is not the surviving corporation (or survives only as a subsidiary of another corporation), unless the Committee determines otherwise, all outstanding Options that are not exercised shall be assumed by, or replaced with comparable options or rights by the surviving corporation (or a parent of the surviving corporation), and other outstanding Grants shall be converted to similar grants of the surviving corporation (or a parent of the surviving corporation).</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Alternatives</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding the foregoing, in the event of a Change in Control, the Committee may, but shall not be obligated to, take any of the following actions with respect to any or all outstanding Grants: the Committee may (i) determine that outstanding Options shall automatically accelerate and become fully exercisable, (ii) require that Grantees surrender their outstanding Options in exchange for a payment by the Company, in cash or Company Stock as determined by the Committee, in an amount equal to the amount by which the then Fair Market Value of the shares of Company Stock subject to the Grantee&#8217;s unexercised Options exceeds the Exercise Price of the Options or (iii) after giving Grantees an opportunity exercise their outstanding Options, terminate any or all unexercised Options at such time as the Committee deems appropriate. Such surrender, termination or settlement shall take place as of the date of the Change of Control or such other date as the Committee may specify. The Committee shall have no obligation to take any of the foregoing actions, and, in the absence of any such actions, outstanding Grants shall continue in effect according to their terms (subject to any assumption pursuant to Subsection (a)).</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Requirements for Issuance or Transfer of Shares</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Limitations on Issuance or Transfer of Shares</font><font style="font-family:inherit;font-size:10pt;">. No Company Stock shall be issued or transferred in connection with any Grant hereunder unless and until all legal requirements applicable to the issuance or transfer of such Company Stock have been complied with to the satisfaction of the Committee. The Committee shall have the right to condition any Grant made to any Grantee hereunder on such Grantee&#8217;s undertaking in writing to comply with </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">such restrictions on his or her subsequent disposition of such shares of Company Stock as the Committee shall deem necessary or advisable, and certificates representing such shares maybe legended to reflect any such restrictions. Certificates representing shares of Company Stock issued or transferred under the Plan will be subject to such stop-transfer orders and other restrictions as may be required by applicable laws, regulations and interpretations, including any requirement that a legend be placed thereon.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Lock-Up Period</font><font style="font-family:inherit;font-size:10pt;">. If so requested by the Company or any representative of the underwriters (the &#8220;Managing Underwriter&#8221;) in connection with any underwritten offering of securities of that Company under the Securities Act a Grantee (including any successors or assigns) shall not sell or otherwise transfer any shares or other securities of the Company during the 30-day period preceding and the 180-day period following the effective date of a registration statement of the Company filed under the Securities Act for such underwriting (or such shorter period as may be requested by the Managing Underwriter and agreed to by the Company) (the &#8220;Market Standoff Period&#8221;). The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such Market Standoff Period. Certificates representing Company stock issued upon exercise of Options or otherwise pursuant to the Plan shall bear such legend regarding the lock-up period obligations as counsel to the Company shall determine.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amendment and Termination of the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Amendment</font><font style="font-family:inherit;font-size:10pt;">. The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not amend the Plan without stockholder approval if (i) such approval is required in order for Incentive Stock Options granted or to be granted under the Plan to meet the requirements of section 422 of the Code, (ii) such approval is required in order to exempt compensation under the Plan from the deduction limit under section 162(m) of the Code, or (iii) such approval is required by applicable stock exchange requirements. When amending or terminating the Plan, no Board action shall cause the application of the requirements, the twenty percent (20%) penalty or immediate tax recognition under section 409A of the Code.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Termination of Plan</font><font style="font-family:inherit;font-size:10pt;">. The Plan shall terminate on the day immediately preceding the tenth anniversary of its effective date, unless the Plan is terminated earlier by the Board or is extended by the Board with the approval of the stockholders.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Termination and Amendment of Outstanding Grants</font><font style="font-family:inherit;font-size:10pt;">. A termination or amendment of the Plan that occurs after a Grant is made shall not materially impair the rights of a Grantee unless the Grantee consents or unless the Committee acts under Section 16(b) hereunder. The termination of the Plan shall not impair the power and authority of the Committee with respect to an outstanding Grant. Whether or not the Plan has terminated, an outstanding Grant may be terminated or amended under Section 16(b) hereunder or may be amended by agreement of the Company and the Grantee consistent with the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Governing Document</font><font style="font-family:inherit;font-size:10pt;">. The Plan shall be the controlling document. No other statements, representations, explanatory materials or examples, oral or written, may amend the Plan in any manner. The Plan shall be binding upon and enforceable against the Company and its successors and assigns.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Funding the Plan</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Plan shall be unfunded. The Company shall not be required to establish any special or separate fund or to make any other segregation of assets to assure the payment of any Grants under this Plan. In no event shall interest be paid or accrued on any Grant, including unpaid installments of Grants.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Rights of Participants</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nothing in this Plan shall entitle any Employee, Key Advisor, Non-Employee Director or other person to any claim or right to be granted a Grant under this Plan. Neither this Plan nor any action taken hereunder shall be construed as giving any individual any rights to be retained by or in the employ of the Company or any other employment rights.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">No Fractional Shares</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No fractional shares of Company Stock shall be issued or delivered pursuant to the Plan or any Grant. The Committee shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Heading</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section headings are for reference only. In the event of a conflict between a title and the content of a Section, the content of the Section shall control.</font></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Effective Date of the Plan</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to approval by the Company&#8217;s stockholders, the Plan shall be effective on April 19, 2006, the date of the adoption of this Plan by the Board of Directors of the Company.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Grants in Connection with Corporate Transactions and Otherwise</font><font style="font-family:inherit;font-size:10pt;">. Nothing contained in this Plan shall be construed to (i) limit the right of the Committee to make Grants under this Plan in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business or assets of any corporation, firm or association, including Grants to employees thereof who become Employees of the Company, or for other proper corporate purposes, or (ii) limit the right of the Company to grant stock options or make other awards outside of this Plan. Without limiting the foregoing, the Committee may make a Grant to an employee of another corporation who becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation involving the Company or any of its Subsidiaries in substitution for a stock option or stock award grant made by such corporation. The terms and conditions of the substitute grants may vary from the terms and conditions required by the Plan and from those of the substituted stock incentives. The Committee shall prescribe the provisions of the substitute grants.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Compliance with Law</font><font style="font-family:inherit;font-size:10pt;">. The Plan, the exercise of Options and the obligations of the Company to issue or transfer shares of Company Stock under Grants shall be subject to all applicable laws and to approvals by any governmental or regulatory agency as may be required. With respect to Grantees subject to section 16 of the Exchange Act, it is the intent of the Company that the Plan and all transactions under the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In addition, it is the intent of the Company that the Plan and applicable Grants under the Plan comply with the applicable provisions of section 162(m), section 409A and section 422 of the Code. To the extent that any legal requirement of section 16 of the Exchange Act, or section 162(m), section 409A and section 422 of the Code as set forth in the Plan ceases to be required under section 16 of the Exchange Act, or section 162(m), section 409A and section 422 of the Code, that Plan provision shall cease to apply. The Committee may revoke any Grant if it is contrary to law or modify a Grant to bring it into compliance with any valid and mandatory government regulation. The Committee may also adopt rules regarding the withholding of taxes on payments to Grantees. The Committee may, in its sole discretion, agree to limit its authority under this Section.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Savings Provision</font><font style="font-family:inherit;font-size:10pt;">. In the event any provision of this Plan shall be deemed to cause the application of the twenty percent (20%) penalty or immediate tax recognition under section 409A of the Code, the provision that causes either the application of the penalty or immediate tax recognition shall become null and void, and the Plan shall be construed and enforced as if the provision causing the negative tax consequences had never been contained herein.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:10pt;">. The validity, construction, interpretation and effect of the Plan and Grant Instruments issued under the Plan shall be governed and construed by and determined in accordance with the laws of Florida, without giving effect to the conflict of laws provisions thereof.</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Glossary</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following terms shall have the meaning assigned them below</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Board</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the Board of Directors of the Company.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cause</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean, except to the extent specified otherwise by the Committee, a finding by the Committee that the Grantee (i) has breached his or her employment or service contract with the Company, in the case of Employees or Key Advisors, or breached his fiduciary duties to the Company or otherwise been removed from the Board by the action of the Board, in the case of a Non-Employee Director, (ii) has engaged in disloyalty to the Company, including, without limitation, fraud, embezzlement, theft, commission of a felony or proven dishonesty in the course of his or her employment or service, (iii) has disclosed trade secrets or confidential information of the Company to persons not entitled to receive such information or (iv) has engaged in such other behavior detrimental to the interests of the Company as the Committee determines.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change of Control</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the occurrence of any of the following events:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Any &#8220;person&#8221; (defined to have the meaning in this definition of Change of Control as is assigned that term in sections 13(d) and 14(d) of the Exchange Act) other than an &#8220;Excluded Stockholder&#8221; (as defined herein) becomes a &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the voting power of the then outstanding securities of the Company; provided that a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the stockholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the transaction, shares entitling such stockholders to more than fifty percent (50%) of all votes to which all stockholders of the parent corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); the term &#8220;Excluded Stockholder&#8221; meaning, for purposes of this definition of Change of Control, any person who is the beneficial owner, directly or indirectly of more than twenty percent (20%) of the voting power of the then outstanding securities of the Company;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;The stockholders of the Company approve (or, if stockholder approval is not required, the Board approves) an agreement providing for (i) the merger or consolidation of the Company with another corporation where the stockholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to more than fifty percent (50%) of all votes to which all stockholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote), (ii) the liquidation or dissolution of the Company; or (iii) the sale or other disposition of assets equal to or greater than forty percent (40%) of the total gross fair market value of all assets of the Company immediately prior to such sale or disposition; or</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;Any person other than an Excluded Person has commenced a tender offer or exchange offer for thirty percent (30%) or more of the voting power of the then outstanding stock of the Company.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Code</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the Internal Revenue Code of 1986, as amended. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Committee</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the Compensation Committee of the Board. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean Dyadic International, Inc., a Delaware corporation. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Company Stock</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean shares of common stock of the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disability</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean a Grantee&#8217;s becoming disabled within the meaning of section 22(e)(3) of the Code.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employees</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean all employees of the Company and its Subsidiaries, including Employees who are officers or members of the Board.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exchange Act</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exercise Price</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the purchase price of Company Stock subject to an Option under a Grant.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Grantee&#8221; shall mean Key Advisors and Non-Employee Directors who receive Grants under this Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Grants</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean awards of Options made by the Committee under the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Grant Instruments</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the written instrument evidencing the Committee&#8217;s Grant of an Option to a Participant, or an amendment thereto.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Incentive Stock Options</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean Options qualifying as such within the meaning of section 422 of the Code.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Key Advisors</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean consultants and advisors who perform services for the Company or any of its</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsidiaries.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Managing Underwriter</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning assigned that term in Section 9(b) of the Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Market Standoff Period</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall have the meaning assigned that term in Section 9(b) of the Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Employee Directors</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean members of the Board who are not Employees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Qualifying Options</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean Options that do not qualify as Incentive Stock Options.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Options</font><font style="font-family:inherit;font-size:10pt;">&#8221; means Incentive Stock Options and Non-Qualifying Options, without distinction. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Plan</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the Dyadic International, Inc. 2006 Stock Option Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Act</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Subsidiary</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean any corporation or other legal entity of which the Company owns, directly or indirectly, 50% or more of the stock or other equity interests, the holders of which are generally entitled to vote for the election of the board of directors or other governing body of such corporation or other legal entity.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Successor Grantee</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the personal representative or other person entitled to succeed to the rights of a Grantee following his or her death.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>7
<FILENAME>exhibit102form10.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD72FAD8B079F5B740E91488FF57ADC1F"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.2</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">2011 EQUITY INCENTIVE AWARD PLAN</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE l.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">PURPOSE</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">The purpose of the Dyadic International, Inc. 2011 Equity Incentive Award Plan (the "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Plan</font><font style="font-family:inherit;font-size:9.5pt;">") is to promote the success and enhance the value of Dyadic International, Inc. (the "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:9.5pt;">") by linking the personal interests of the members of the Board, Employees, and Consultants to those of Company stockholders and by providing such individuals with an incentive for outstanding performance to generate superior returns to Company stockholders. The Plan is further intended to provide flexibility to the Company in its ability to motivate, attract, and retain the services of members of the Board, Employees, and Consultants upon whose judgment, interest, and special effort the successful conduct of the Company's operation is largely dependent.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 2.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">DEFINITIONS AND CONSTRUCTION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. The singular pronoun shall include the plural where the context so indicates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.1 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Administrator</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the entity that conducts the general administration of the Plan as provided in Article 13. With reference to the duties of the Committee under the Plan which have been delegated to one or more persons pursuant to Section 13.6, or as to which the Board has assumed, the term "Administrator" shall refer to such person(s) unless the Committee or the Board has revoked such delegation or the Board has terminated the assumption of such duties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.2 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Award</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean an Option, a Restricted Stock award, a Restricted Stock Unit award, a Performance Award, a Dividend Equivalents award, a Deferred Stock award, a Stock Payment award or a Stock Appreciation Right, which may be awarded or granted under the Plan (collectively, "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Awards</font><font style="font-family:inherit;font-size:9.5pt;">").</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.3 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Award Agreement</font><font style="font-family:inherit;font-size:9.5pt;">'' shall mean any written notice, agreement, terms and conditions, contract or other instrument or document evidencing an Award, including through electronic medium, which shall contain such terms and conditions with respect to an Award as the Administrator shall determine consistent with the Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.4 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the Board of Directors of the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.5 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Change in Control</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean and includes each of the following:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission) whereby any "person" or related "group" of"persons" (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its parents or subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a "person" that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company's securities outstanding immediately after such acquisition; or</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new director(s) (other than a director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in Section 2.5(a or Section 2.5(c)) whose election by the Board or nomination for election by the Company's stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(c) The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company's assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(i) Which results in the Company's voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company's assets or otherwise succeeds to the business of the Company (the Company or such person, the "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Successor Entity</font><font style="font-family:inherit;font-size:9.5pt;">")) </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">directly or indirectly, at least a majority of the combined voting power of the Successor Entity's outstanding voting securities immediately after the transaction, and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(ii) After which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; </font><font style="font-family:inherit;font-size:9.5pt;font-style:italic;">provided, however, </font><font style="font-family:inherit;font-size:9.5pt;">that no person or group shall be treated for purposes of this Section 2.5(c)(ii) as beneficially owning 50% or more of combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction; or</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(d) The Company's stockholders approve a liquidation or dissolution of the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">In addition, if a Change in Control constitutes a payment event with respect to any Award which provides for the deferral of compensation and is subject to Section 409A of the Code, the transaction or event described in subsection (a), (b), (c) or (d) with respect to such Award must also constitute a "change in control event," as defined in Treasury Regulation &#167;l .409A-3(i)(5) to the extent required by Section 409A.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">The Committee shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control of the Company has occurred pursuant to the above definition</font><font style="font-family:inherit;font-size:9.5pt;color:#232323;">, </font><font style="font-family:inherit;font-size:9.5pt;">and the date of the occurrence of such Change in Control and any incidental matters relating thereto.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.6 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the Internal Revenue Code of 1986, as amended from time to time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.7 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Committee</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the Compensation Committee of the Board, or another committee or subcommittee of the Board, appointed as provided in Section 13.1.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.8 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Common Stock</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the common stock of the Company, par value $0.001 per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.9 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean Dyadic International, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.10 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Consultant</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean any consultant or adviser engaged to provide services to the Company or any Subsidiary that qualifies as a consultant under the applicable rules of the Securities and Exchange Commission for registration of shares on a Form S-8 Registration Statement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.11 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Covered Employee</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean any Employee who is</font><font style="font-family:inherit;font-size:9.5pt;color:#232323;">, </font><font style="font-family:inherit;font-size:9.5pt;">or could be, a "covered employee" within the meaning of Section 162(m) of the Code.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.12 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Deferred Stock</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean a right to receive Common Stock awarded under Section 9.4.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.13 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Director</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean a member of the Board, as constituted from time to time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.14 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Dividend Equivalent</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean a right to receive the equivalent value (in cash or Common Stock) of dividends paid on Common Stock, awarded under Section 9.2.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.15 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">DRO</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean a domestic relations order as defined by the Code or Title I of the Employee Retirement Income Security Act of 1974, as amended from time to time, or the rules thereunder.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.16 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the date the Plan is approved by the Board, subject to approval of the Plan by the Company's stockholders.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.17 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Eligible</font><font style="font-family:inherit;font-size:9.5pt;">&#32;</font><font style="font-family:inherit;font-size:9.5pt;">Individual" shall mean any person who is an Employee, a Consultant or a Non-Employee Director, as determined by the Committee.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.18 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Employee</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean any officer or other employee (as determined in accordance with Section 340l(c) of the Code and the Treasury Regulations thereunder) of the Company or of any Subsidiary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.19 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Equity Restructuring</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off, rights offering or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of shares of Common Stock (or other securities of the Company) or the share price of Common Stock (or other securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.20 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Exchange Act</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.21 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Fair Market Value</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean, as of any given date</font><font style="font-family:inherit;font-size:9.5pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:9.5pt;">the value of a share of Common Stock determined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) If the Common Stock is listed on any established stock exchange (such as the New York Stock Exchange, the NASDAQ Global Market and the NASDAQ Global Select Market) or national market system, its Fair Market Value shall be the closing sales price for a share of Common Stock as quoted on such exchange or system for such date or, if there is no closing sales </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">price for a share of Common Stock on the date in question, the closing sales price for a share of Common Stock on the last preceding date for which such quotation exists, as reported in </font><font style="font-family:inherit;font-size:9.5pt;font-style:italic;">The Wall Street Journal </font><font style="font-family:inherit;font-size:9.5pt;">or such other source as the Administrator deems reliable;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) If the Common Stock is not listed on an established stock exchange or national market system, but the Common Stock is regularly quoted by a recognized securities dealer</font><font style="font-family:inherit;font-size:9.5pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:9.5pt;">its Fair Market Value shall be the mean of the high bid and low asked prices for such date or, if there are no high bid and low asked prices for a share of Common Stock on such date, the high bid and low asked prices for a share of Common Stock on the last preceding date for which such information exists, as reported in </font><font style="font-family:inherit;font-size:9.5pt;font-style:italic;">The Wall Street Journal </font><font style="font-family:inherit;font-size:9.5pt;">or such other source as the Administrator deems reliable; or</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(c) If the Common Stock is neither listed on an established stock exchange or a national market system nor regularly quoted by a recognized securities dealer, its Fair Market Value shall be established by the Administrator in good faith.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.22 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Greater Than 10% Stockholder</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean an individual then owning (within the meaning of Section 424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or any subsidiary corporation (as defined in Section 424(f) of the Code) or parent corporation thereof (as defined in Section 424(e) of the Code).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.23 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Holder</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean a person who has been granted an Award.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.24 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Incentive Stock Option</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean an Option that is intended to qualify as an incentive stock option and conforms to the applicable provisions of Section 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.25 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Non-Employee Director</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean a Director of the Company who is not an Employee.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.26 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Non-Qualified Stock Option</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean an Option that is not an Incentive Stock Option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.27 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean a right to purchase shares of Common Stock at a specified exercise price, granted under Article 6. An Option shall be either a Non-Qualified Stock Option or an Incentive Stock Option; provided, however, that Options granted to Non-Employee Directors and Consultants shall be Non-Qualified Stock Options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.28 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Performance Award</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean a cash bonus award, stock bonus award, performance award or incentive award that is paid in cash, Common Stock or a combination of both, awarded under Section 9.1.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.29 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Performance-Based Compensation</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean any compensation that is intended to qualify as "performance-based compensation" as described in Section 162(m)(4)(C) of the Code.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.30 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Performance Criteria</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the criteria (and adjustments) that the Committee selects for an Award for purposes of establishing the Performance Goal or Performance Goals for a Performance Period, determined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) The Performance Criteria that shall be used to establish Performance Goals are limited to the following: (i) net earnings (either before or after one or more of the following: (A) interest, (B) taxes, (C) depreciation and (D) amortization), (ii) gross or net sales or revenue, (iii) net income (either before or after taxes), (iv) operating earnings or profit</font><font style="font-family:inherit;font-size:9.5pt;color:#191919;">, </font><font style="font-family:inherit;font-size:9.5pt;">(v) cash flow (including, but not limited to, operating cash flow and free cash flow), (vi) return on assets, (vii) return on capital, (viii) return on stockholders' equity</font><font style="font-family:inherit;font-size:9.5pt;color:#191919;">, </font><font style="font-family:inherit;font-size:9.5pt;">(ix) return on sales, (x) gross or net profit or operating margin, (xi) costs, (xii) funds from operations, (xiii) expenses</font><font style="font-family:inherit;font-size:9.5pt;color:#191919;">, </font><font style="font-family:inherit;font-size:9.5pt;">(xiv) working capital, (xv) earnings per share, (xvi) price per share of Common Stock, (xvii) regulatory body approval for commercialization of a product, (xviii) implementation or completion of critical projects and (xix) market share, any of which may be measured either in absolute terms for the Company or any operating unit of the Company or as compared to any incremental increase or decrease or as compared to results of a peer group or to market performance indicators or indices.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) The Administrator may, in its sole discretion, provide that one or more objectively determinable adjustments shall be made to one or more of the Performance Goals. Such adjustments may include one or more of the following: (i) items related to a change in accounting principle; (ii) items relating to financing activities; (iii) expenses for restrncturing or productivity initiatives; (iv) other non-operating items; (v) items related to acquisitions; (vi) items attributable to the business operations of any entity acquired by the Company during the Performance Period; (vii) items related to the disposal of a business or segment of a business; (viii) items related to discontinued operations that do not qualify as a segment of a business under United States generally accepted accounting principles ("</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">GAAP</font><font style="font-family:inherit;font-size:9.5pt;">"); (ix) items attributable to any stock dividend, stock split, combination or exchange of shares occurring during the Performance Period; or (x) any other items of significant income or expense which are determined to be appropriate adjustments; (xi) items relating to unusual or extraordinary corporate transactions, events or developments, (xii) items related to amortization of acquired intangible assets; (xiii) items that are outside the scope of the Company's core, on-going business activities; or (xiv) items relating to any other unusual or nonrecurring events or changes in applicable laws, accounting principles or business conditions. For all Awards intended to qualify as Performance-Based Compensation, such determinations shall be made within the time prescribed by, and otherwise in compliance with, Section 162(m) of the Code.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.31 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Performance Goals</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean, for a Performance Period, one or more goals established in writing by the Administrator for the Performance Period based upon one or more Performance Criteria. Depending on the Performance Criteria </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">used to establish such Performance Goals, the Performance Goals may be expressed in terms of overall Company performance or the performance of a division, business unit, or an individual.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.32 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Performance Period</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean one or more periods of time, which may be of varying and overlapping durations, as the Administrator may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Holder's right to, and the payment of, a Performance Award.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.33 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Plan</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean this Dyadic International, Inc. 2011 Equity Incentive Award Plan, as it may be amended or restated from time to time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.34 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Prior Plan</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the Dyadic International, Inc. 2006 Stock Option Plan, as such plan may be amended from time to time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.35 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Public Trading Date</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the first date upon which Common Stock is listed (or approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer quotation system.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.36 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Restricted Stock</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean Common Stock awarded under Article 8 that is subject to certain restrictions and may be subject to risk of forfeiture or repurchase.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.37 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Restricted Stock Units</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the right to receive Common Stock awarded under Section 9.5.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.38 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Securities Act</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.39 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Stock Appreciation Right</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean a stock appreciation right granted under Article I 0.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.40 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Stock Payment</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean (a) a payment in the form of shares of Common Stock, or (b) an option or other right to purchase shares of Common Stock, as part of a bonus, deferred compensation or other arrangement, awarded under Section 9.3.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.41 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Subsidiary</font><font style="font-family:inherit;font-size:9.5pt;">" means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing more than fifty percent (50%) of the total combined voting power of all classes of securities or interests in one of the other entities in such chain.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.42 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Substitute Award</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean an Award granted under the Plan upon the assumption of, or in substitution for, outstanding equity awards previously granted by a company or other entity in connection with a corporate transaction, such as a merger</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">, </font><font style="font-family:inherit;font-size:9.5pt;">combination, consolidation or acquisition of property or stock; provided, however, that in no event shall the term "Substitute Award" be construed to refer to an award made in connection with the cancellation and repricing of an Option or Stock Appreciation Right.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">2.43 "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Termination of Service</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) As to a Consultant, the time when the engagement of a Holder as a Consultant to the Company or a Subsidiary is terminated for any reason, with or without cause</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">, </font><font style="font-family:inherit;font-size:9.5pt;">including, without limitation, by resignation, discharge, death or retirement, but excluding terminations where the Consultant simultaneously commences or remains in employment or service with the Company or any Subsidiary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) As to a Non-Employee Director, the time when a Holder who is a Non-Employee Director ceases to be a Director for any reason, including, without limitation, a termination by resignation</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">, </font><font style="font-family:inherit;font-size:9.5pt;">failure to be elected, death or retirement, but excluding terminations where the Holder simultaneously commences or remains in employment or service with the Company or any Subsidiary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(c) As to an Employee, the time when the employee-employer relationship between a Holder and the Company or any Subsidiary is terminated for any reason, including, without limitation, a termination by resignation, discharge, death, disability or retirement; but excluding terminations where the Holder simultaneously commences or remains in employment or service with the Company or any Subsidiary,</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">The Administrator, in its sole discretion, shall determine the effect of all matters and questions relating to a Termination of Service, including, without limitation, the question of whether a Termination of Service resulted from a discharge for cause and all questions of whether particular leaves of absence constitute a Termination of Service; </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;">, </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:9.5pt;">, that, with respect to Incentive Stock Options, unless the Administrator otherwise provides in the terms of the Award Agreement or otherwise, a leave of absence</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">, </font><font style="font-family:inherit;font-size:9.5pt;">change in status from an employee to an independent contractor or other change in the employee-employer relationship shall constitute a Termination of Service only if, and to the extent that, such leave of absence, change in status or other change intenupts employment for the purposes of Section 422(a)(2) of the Code and the then applicable regulations and revenue rulings under said Section. For purposes of the Plan, a Holder's employee-employer relationship or consultancy relations shall be deemed </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">to be terminated in the event that the Subsidiary employing or contracting with such Holder ceases to remain a Subsidiary following any merger, sale of stock or other corporate transaction or event (including, without limitation, a spin-off).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 3.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">SHARES SUBJECT TO THE PLAN</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">3.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Number of Shares</font><font style="font-family:inherit;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) Subject to Section 14.2 and Section 3.l(b) the aggregate number of shares of Stock which may be issued or transferred pursuant to Awards under the Plan is the sum of (i) 3,000,000 shares, (ii) any shares of Stock which as of the Effective Date are available for issuance under the Prior Plan, or are subject to awards under the Prior Plan which are forfeited or lapse unexercised and which following the Effective Date are not issued under the Prior Plan; and (iii) an annual increase on the first day of each year beginning in 2012 and ending in 2021, equal to 1,500,000 shares or such smaller number of shares of Stock as determined by the Board.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) To the extent that an Award terminates, expires, or lapses for any reason, or an Award is settled in cash without the delivery of shares to the Holder, then any shares of Common Stock subject to the Award shall again be available for the grant of an Award pursuant to the Plan. Any shares of Common Stock tendered or withheld to satisfy the grant or exercise price or tax withholding obligation pursuant to any Award shall again be available for the grant of an Award pursuant to the Plan. Any shares of Common Stock repurchased by the Company prior to vesting so that such shares are returned to the Company will again be available for Awards. To the extent permitted by applicable law or any exchange rule, shares of Common Stock issued in assumption of, or in substitution for, any outstanding awards of any entity acquired in any form of combination by the Company or any Subsidiary shall not be counted against shares of Common Stock available for grant pursuant to the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards shall not be counted against the shares available for issuance under the Plan. Notwithstanding the provisions of this Section 3.l(b), no shares of Common Stock may again be optioned, granted or awarded if such action would cause an Incentive Stock Option to fail to qualify as an incentive stock option under Section 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">3.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Stock Distributed</font><font style="font-family:inherit;font-size:9.5pt;">. Any Common Stock distributed pursuant to an Award may consist, in whole or in part, of authorized and unissued Common Stock, treasury Common Stock or Common Stock purchased on the open market.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 4.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">GRANTING OF AWARDS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">4.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Participation</font><font style="font-family:inherit;font-size:9.5pt;">. The Administrator may, from time to time</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">, </font><font style="font-family:inherit;font-size:9.5pt;">select from among all Eligible Individuals, those to whom an Award shall be granted and shall determine the nature and amount of each Award, which shall not be inconsistent with the requirements of the Plan. Except as provided in Article 12 regarding the automatic grant of options to Non-Employee Directors, no Eligible Individual shall have any right to be granted an Award pursuant to the Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">4.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Award Agreement</font><font style="font-family:inherit;font-size:9.5pt;">. Each Award shall be evidenced by an Award Agreement. Award Agreements evidencing Awards intended to qualify as Performance-Based Compensation shall contain such terms and conditions as may be necessary to meet the applicable provisions of Section 162(m) of the Code. Award Agreements evidencing Incentive Stock Options shall contain such terms and conditions as may be necessary to meet the applicable provisions of Section 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">4.3 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Limitations Applicable to Section 16 Persons</font><font style="font-family:inherit;font-size:9.5pt;">. Notwithstanding any other provision of the Plan, the Plan, and any Award granted or awarded to any individual who is then subject to Section 16 of the Exchange Act, shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including Rule 16b-3 of the Exchange Act and any amendments thereto) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, the Plan and Awards granted or awarded hereunder shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">4.4 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">At-Will Employment</font><font style="font-family:inherit;font-size:9.5pt;">. Nothing in the Plan or in any Award Agreement hereunder shall confer upon any Holder any right to continue in the employ of, or as a Director or Consultant for, the Company or any Subsidiary, or shall interfere with or restrict in any way the rights of the Company and any Subsidiary, which rights are hereby expressly reserved, to discharge any Holder at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Holder and the Company or any Subsidiary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">4.5 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Foreign Holders</font><font style="font-family:inherit;font-size:9.5pt;">. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries operate or have Employees, Non-Employee Directors or Consultants, or in order to comply with the requirements of any foreign stock exchange, the Administrator, in its sole discretion, shall have the power and authority to: (a) determine which Subsidiaries shall be covered by the Plan; (b) determine which Eligible Individuals outside the United States are eligible to participate in the Plan; (c) modify the terms and conditions of any Award granted to Eligible Individuals outside the United States to comply with applicable foreign laws or listing requirements of any such foreign stock </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">exchange; (d) establish subplans and modify exercise procedures and other terms and procedures, to the extent such actions may be necessary or advisable (any such subplans and/or modifications shall be attached to the Plan as appendices); </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;">, </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:9.5pt;">, that no such subplans and/or modifications shall increase the share limitations contained in Sections 3.1; and (e) take any action, before or after an Award is made, that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals or listing requirements of any such foreign stock exchange. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act</font><font style="font-family:inherit;font-size:9.5pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:9.5pt;">the Securities Act or any other securities law or governing statute or any other applicable law.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">4.6 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Stand-Alone and Tandem Awards</font><font style="font-family:inherit;font-size:9.5pt;">. Awards granted pursuant to the Plan may, in the sole discretion of the Administrator, be granted either alone, in addition to, or in tandem with, any other Award granted pursuant to the Plan. Awards granted in addition to or in tandem with other Awards may be granted either at the same time as or at a different time from the grant of such other Awards.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 5.</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">PROVISIONS APPLICABLE TO AWARDS INTENDED TO QUALIFY AS </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">PERFORMANCE-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">5.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Purpose</font><font style="font-family:inherit;font-size:9.5pt;">. The Committee</font><font style="font-family:inherit;font-size:9.5pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:9.5pt;">in its sole discretion, may determine whether an Award is to qualify as Performance-Based Compensation. If the Committee, in its sole discretion, decides to grant such an Award to an Eligible Individual that is intended to qualify as Performance-Based Compensation, then the provisions of this Article 5 shall control over any contrary provision contained in the Plan. The Administrator may in its sole discretion grant Awards to other Eligible Individuals that are based on Performance Criteria or Performance Goals but that do not satisfy the requirements of this Article 5 and that are not intended to qualify as Performance-Based Compensation. Unless otherwise specified by the Administrator at the time of grant, the Performance Criteria with respect to an Award intended to be Performance-Based Compensation payable to a Covered Employee shall be determined on the basis of GAAP.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">5.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Applicability</font><font style="font-family:inherit;font-size:9.5pt;">. The grant of an Award to an Eligible Individual for a particular Performance Period shall not require the grant of an Award to such Individual in any subsequent Performance Period and the grant of an Award to any one Eligible Individual shall not require the grant of an Award to any other Eligible Individual in such period or in any other period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">5.3 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Types of Awards</font><font style="font-family:inherit;font-size:9.5pt;">. Notwithstanding anything in the Plan to the contrary, the Committee may grant any Award to an Eligible Individual intended to qualify as Performance-Based Compensation, including, without limitation, Restricted Stock the restrictions with respect to which lapse upon the attainment of specified Performance Goals, and any performance or incentive Awards described in Article 9 that vest or become exercisable or payable upon the attainment of one or more specified Performance Goals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">5.4 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Procedures with Respect to Performance-Based Awards</font><font style="font-family:inherit;font-size:9.5pt;">. To the extent necessary to comply with the requirements of Section 162(m)(4)(C) of the Code, with respect to any Award granted under Articles 8 or 9 to one or more Eligible Individuals and which is intended to qualify as Performance-Based Compensation, no later than 90 days following the commencement of any Performance Period or any designated fiscal period or period of service (or such earlier time as may be required under Section 162(m) of the Code), the Committee shall, in writing, (a) designate one or more Holders, (b) select the Performance Criteria applicable to the Performance Period, (c) establish the Performance Goals, and amounts of such Awards, as applicable, which may be earned for such Performance Period based on the Performance Criteria, and (d) specify the relationship between Performance Criteria and the Performance Goals and the amounts of such Awards, as applicable, to be earned by each Covered Employee for such Performance Period. Following the completion of each Performance Period, the Committee shall certify in writing whether and the extent to which the applicable Performance Goals have been achieved for such Performance Period. In determining the amount earned under such Awards, the Committee shall have the right to reduce or eliminate (but not to increase) the amount payable at a given level of performance to take into account additional factors that the Committee may deem relevant to the assessment of individual or corporate performance for the Performance Period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">5.5 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Payment of Performance-Based Awards</font><font style="font-family:inherit;font-size:9.5pt;">. Unless otherwise provided in the applicable Award Agreement and only to the extent otherwise permitted by Section 162(m)(4)(C) of the Code, as to an Award that is intended to qualify as Performance-Based Compensation, the Holder must be employed by the Company or a Subsidiary throughout the Performance Period. Furthermore, a Holder shall be eligible to receive payment pursuant to such Awards for a Performance Period only if and to the extent the Performance Goals for such period are achieved.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">5.6 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Additional Limitations</font><font style="font-family:inherit;font-size:9.5pt;">. Notwithstanding any other provision of the Plan, any Award which is granted to an Eligible Individual and is intended to qualify as Performance-Based Compensation shall be subject to any additional limitations set forth in Section 162(m) of the Code or any regulations or rulings issued thereunder that are requirements for qualification as Performance-Based Compensation, and the Plan and the Award Agreement shall be deemed amended to the extent necessary to conform to such requirements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 6.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">GRANTING OF OPTIONS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">6.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Granting of Options to Eligible Individuals</font><font style="font-family:inherit;font-size:9.5pt;">. The Administrator is authorized to grant Options to Eligible Individuals from time to time, in its sole discretion, on such terms and conditions as it may determine which shall not be inconsistent with the Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">6.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Qualification of lncentive Stock Options</font><font style="font-family:inherit;font-size:9.5pt;">. No Incentive Stock Option shall be granted to any person who is not an Employee of the Company or any subsidiary corporation of the Company (as defined in Section 424(f) of the Code). No person who qualifies as a Greater Than 10% Stockholder may be granted an Incentive Stock Option unless such Incentive Stock Option conforms to the applicable provisions of Section 422 of the Code. Any Incentive Stock Option granted under the Plan may be modified by the Administrator, with the consent of the Holder, to disqualify such Option from treatment as an "incentive stock option" under Section 422 of the Code. To the extent that the aggregate fair market value of stock with respect to which "incentive stock options" (within the meaning of Section 422 of the Code, but without regard to Section 422(d) of the Code) are exercisable for the first time by a Holder during any calendar year under the Plan, and all other plans of the Company and any Subsidiary or parent corporation thereof (as defined in Section 424(e) of the Code), exceeds $100,000, the Options shall be treated as Non-Qualified Stock Options to the extent required by Section 422 of the Code. The rule set forth in the preceding sentence shall be applied by taking Options and other "incentive stock options" into account in the order in which they were granted and the fair market value of stock shall be determined as of the time the respective options were granted.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">6.3 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Option Exercise Price</font><font style="font-family:inherit;font-size:9.5pt;">. The exercise price per share of Common Stock subject to each Option shall be set by the Administrator, but shall not be less than 100% of the Fair Market Value of a share of Common Stock on the date the Option is granted (or, as to Incentive Stock Options, on the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code), unless otherwise determined by the Administrator. In addition, in the case of incentive Stock Options granted to a Greater Than 10% Stockholder, such price shall not be less than 110% of the Fair Market Value of a share of Common Stock on the date the Option is granted (or the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">6.4 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Option Term</font><font style="font-family:inherit;font-size:9.5pt;">. The term of each Option shall be set by the Administrator in its sole discretion; provided, however, that the term shall not be more than ten (10) years from the date the Option is granted, or five (5) years from the date an Incentive Stock Option is granted to a Greater Than 10% Stockholder. The Administrator shall determine the time period, including the time period following a Termination of Service, during which the Holder has the right to exercise the vested Options, which time period may not extend beyond the term of the Option term. Except as limited by the requirements of Section 409A or Section 422 of the Code and regulations and rulings thereunder, the Administrator may extend the term of any outstanding Option, and may extend the time period during which vested Options may be exercised, in connection with any Termination of Service of the Holder, and may amend any other term or condition of such Option relating to such a Termination of Service.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">6.5 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Option Vesting</font><font style="font-family:inherit;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) The Administrator shall determine the period during which a Holder shall vest in an Option and have the right to exercise such Option in whole or in part. Such vesting may be based on service with the Company or any Subsidiary, any of the Performance Criteria, or any other criteria selected by the Administrator. At any time after grant of an Option</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">, </font><font style="font-family:inherit;font-size:9.5pt;">the Administrator may, in its sole discretion and subject to whatever terms and conditions it selects, accelerate the period during which an Option vests.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) No portion of an Option which is unexercisable at a Holder's Termination of Service shall thereafter become exercisable, except as may be otherwise provided by the Administrator either in the Award Agreement or by action of the Administrator following the grant of the Option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">6.6 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Substitute Awards</font><font style="font-family:inherit;font-size:9.5pt;">. Notwithstanding the foregoing provisions of this Article 6 to the contrary, in the case of an Option that is a Substitute Award, the price per share of the shares subject to such Option may be less than the Fair Market Value per share on the date of grant, </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;">, that the excess of: (a) the aggregate Fair Market Value (as of the date such Substitute Award is granted) of the shares subject to the Substitute Award, over (b) the aggregate exercise price thereof does not exceed the excess of: (x) the aggregate fair market value (as of the time immediately preceding the transaction giving rise to the Substitute Award, such fair market value to be determined by the Administrator) of the shares of the predecessor entity that were subject to the grant assumed or substituted for by the Company, over (y) the aggregate exercise price of such shares.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">6.7 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Substitution of Stock Appreciation Rights</font><font style="font-family:inherit;font-size:9.5pt;">. The Administrator may provide in the Award Agreement evidencing the grant of an Option that the Administrator, in its sole discretion, shall have the right to substitute a Stock Appreciation Right for such Option at any time prior to or upon exercise of such Option; </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;">, that such Stock Appreciation Right shall be exercisable with respect to the same number of shares of Common Stock for which such substituted Option would have been exercisable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 7.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">EXERCISE OF OPTIONS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">7.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Partial Exercise</font><font style="font-family:inherit;font-size:9.5pt;">. An exercisable Option may be exercised in whole or in part. However, an Option shall not be exercisable with respect to fractional shares and the Administrator may require that, by the terms of the Option, a partial exercise must be with respect to a minimum number of shares.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">7.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Manner of Exercise</font><font style="font-family:inherit;font-size:9.5pt;">. All or a portion of an exercisable Option shall be deemed exercised upon delivery of all of the following to the Secretary of the Company, or such other person or entity designated by the Administrator, or his, her or its office, as applicable:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) A written notice complying with the applicable rules established by the Administrator stating that the Option, or a portion thereof, is exercised. The notice shall be signed by the Holder or other person then entitled to exercise the Option or such portion of the Option;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) Such representations and documents as the Administrator, in its sole discretion, deems necessary or advisable to effect compliance with all applicable provisions of the Securities Act and any other federal</font><font style="font-family:inherit;font-size:9.5pt;color:#232323;">, </font><font style="font-family:inherit;font-size:9.5pt;">state or foreign securities laws or regulations. The Administrator may, in its sole discretion, also take whatever additional actions it deems appropriate to effect such compliance including, without limitation</font><font style="font-family:inherit;font-size:9.5pt;color:#232323;">, </font><font style="font-family:inherit;font-size:9.5pt;">placing legends on share certificates and issuing stop-transfer notices to agents and registrars;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(c) In the event that the Option shall be exercised pursuant to Section 11.3 by any person or persons other than the Holder, appropriate proof of the right of such person or persons to exercise the Option; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(d) Full payment of the exercise price and applicable withholding taxes to the Secretary of the Company for the shares with respect to which the Option, or portion thereof, is exercised, in a manner permitted by Section 11.1 and 11.2.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">7.3 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Notification Regarding Disposition</font><font style="font-family:inherit;font-size:9.5pt;">. The Holder shall give the Company prompt notice of any disposition of shares of Common Stock acquired by exercise of an Incentive Stock Option which occurs within (a) two years from the date of granting (including the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code) such Option to such Holder, or (b) one year after the transfer of such shares to such Holder.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLES. 8</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">AWARD OF RESTRICTED STOCK</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">8.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Award of Restricted Stock</font><font style="font-family:inherit;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) The Administrator is authorized to grant Restricted Stock to Eligible Individuals, and shall determine the terms and conditions, including the restrictions applicable to each award of Restricted Stock, which terms and conditions shall not be inconsistent with the Plan, and may impose such conditions on the issuance of such Restricted Stock as it deems appropriate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) The Administrator shall establish the purchase price, if any, and form of payment for Restricted Stock; provided, however, that such purchase price shall be no less than the par value of the Common Stock to be purchased, unless otherwise permitted by applicable state law. In all cases, legal consideration shall be required for each issuance of Restricted Stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">8.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Rights as Stockholders</font><font style="font-family:inherit;font-size:9.5pt;">. Subject to Section 8.4, upon issuance of Restricted Stock, the Holder shall have, unless otherwise provided by the Administrator, all the rights of a stockholder with respect to said shares, subject to the restrictions in his or her Award Agreement, including the right to receive all dividends and other distributions paid or made with respect to the shares; </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;">, </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:9.5pt;">, that, in the sole discretion of the Administrator, any extraordinary distributions with respect to the Common Stock shall be subject to the restrictions set forth in Section 8.3.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">8.3 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Restrictions</font><font style="font-family:inherit;font-size:9.5pt;">. All shares of Restricted Stock (including any shares received by Holders thereof with respect to shares of Restricted Stock as a result of stock dividends, stock splits or any other form of recapitalization) shall, in the terms of each individual Award Agreement, be subject to such restrictions and vesting requirements as the Administrator shall provide. Such restrictions may include, without limitation, restrictions concerning voting rights and transferability and such restrictions may lapse separately or in combination at such times and pursuant to such circumstances or based on such criteria as selected by the Administrator, including, without limitation, criteria based on the Holder's duration of employment, directorship or consultancy with the Company</font><font style="font-family:inherit;font-size:9.5pt;color:#212121;">, </font><font style="font-family:inherit;font-size:9.5pt;">the Performance Criteria, Company performance, individual performance or other criteria selected by the Administrator. By action taken after the Restricted Stock is issued, the Administrator may, on such terms and conditions as it may determine to be appropriate, accelerate the vesting of such Restricted Stock by removing any or all of the restrictions imposed by the terms of the Award Agreement. Restricted Stock may not be sold or encumbered until all restrictions are terminated or expire.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">8.4 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Repurchase or Forfeiture of Restricted Stock</font><font style="font-family:inherit;font-size:9.5pt;">. If no price was paid by the Holder for the Restricted Stock, upon a Termination of Service the Holder's rights in unvested Restricted Stock then subject to restrictions shall lapse, and such Restricted Stock shall be surrendered to the Company and cancelled without consideration. If a price was paid by the Holder for the Restricted Stock, upon a Termination of Service the Company shall have the right to repurchase from the Holder the unvested Restricted Stock then subject to restrictions at a cash price per share equal to the price paid by the Holder for such Restricted Stock or such other amount as may be specified in the Award Agreement. The Administrator in its sole discretion may provide that in the event of certain events, including a Change in Control, the Holder's death, retirement or disability or any other specified Termination of Service or any other event, the Holder's rights in unvested Restricted Stock shall not lapse, such Restricted Stock shall vest and, if applicable, the Company shall not have a right of repurchase.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">8.5 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Certificates for Restricted Stock</font><font style="font-family:inherit;font-size:9.5pt;">. Restricted Stock granted pursuant to the Plan may be evidenced in such manner as the Administrator shall determine. Certificates or book entries evidencing shares of Restricted Stock must include an appropriate legend referring to the terms, conditions, and restrictions applicable to such Restricted Stock, and the Company may, in its sole discretion, retain physical possession of any stock certificate until such time as all applicable restrictions lapse.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">8.6 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Section 83(b) Election</font><font style="font-family:inherit;font-size:9.5pt;">. If a Holder makes an election under Section 83(b) of the Code to be taxed with respect to the Restricted Stock as of the date of transfer of the Restricted Stock rather than as of the date or dates upon which the Holder would otherwise be taxable under Section 83(a) of the Code, the Holder shall be required to deliver a copy of such election to the Company promptly after filing such election with the Internal Revenue Service</font><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 9.</font></div><div style="line-height:120%;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">AWARD OF PERFORMANCE AWARDS, DIVIDEND EQUIVALENTS, DEFERRED </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">STOCK, STOCK PAYMENTS, RESTRICTED STOCK UNITS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">9.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Performance Awards</font><font style="font-family:inherit;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) The Administrator is authorized to grant Performance Awards to any Eligible Individual and to determine whether such Performance Awards shall be Performance-Based Compensation. The value of Performance Awards may be linked to any one or more of the Performance Criteria or other specific criteria determined by the Administrator, in each case on a specified date or dates or over any period or periods determined by the Administrator. In making such determinations, the Administrator shall consider (among such other factors as it deems relevant in light of the specific type of Award) the contributions, responsibilities and other compensation of the particular Eligible Individual. Performance Awards may be paid in cash, shares of Common Stock, or both, as determined by the Administrator.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) Without limiting Section 9.l(a), the Administrator may grant Performance Awards to any Eligible Individual in the form of a cash bonus payable upon the attainment of objective Performance Goals, or such other criteria, whether or not objective, which are established by the Administrator, in each case on a specified date or dates or over any period or periods determined by the Administrator. Any such bonuses paid to a Holder which are intended to be Performance-Based Compensation shall be based upon objectively determinable bonus formulas established in accordance with the provisions of Article </font><font style="font-family:inherit;font-size:9.5pt;font-style:italic;">5.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">9.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Dividend Equivalents</font><font style="font-family:inherit;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) Dividend Equivalents may be granted by the Administrator based on dividends declared on the Common Stock, to be credited as of dividend payment dates during the period between the date an Award is granted to a Holder and the date such Award vests, is exercised, is distributed or expires, as determined by the Administrator. Such Dividend Equivalents shall be converted to cash or additional shares of Common Stock by such formula and at such time and subject to such limitations as may be determined by the Administrator.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) Notwithstanding the foregoing, no Dividend Equivalents shall be payable with respect to Options or Stock Appreciation Rights, unless otherwise determined by the Administrator.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">9.3 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Stock Payments</font><font style="font-family:inherit;font-size:9.5pt;">. The Administrator is authorized to make Stock Payments to any Eligible Individual. The number or value of shares of any Stock Payment shall be determined by the Administrator and may be based upon one or more Performance Criteria or any other specific criteria, including service to the Company or any Subsidiary, determined by the Administrator. Stock Payments may, but are not required to be made in lieu of base salary, bonus, fees or other cash compensation otherwise payable to such Eligible Individual.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">9.4 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Deferred Stock</font><font style="font-family:inherit;font-size:9.5pt;">. The Administrator is authorized to grant Deferred Stock to any Eligible Individual. The number of shares of Deferred Stock shall be determined by the Administrator and may be based on one or more Performance Criteria or other specific criteria, including service to the Company or any Subsidiary, as the Administrator determines</font><font style="font-family:inherit;font-size:9.5pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:9.5pt;">in each case on a specified date or dates or over any period or periods determined by the Administrator. Common Stock underlying a Deferred Stock award will not be issued until the Deferred Stock award has vested, pursuant to a vesting schedule or other conditions or criteria set by the Administrator. Unless otherwise provided by the Administrator, a Holder of Deferred Stock shall have no rights as a Company </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">stockholder with respect to such Deferred Stock until such time as the Award has vested and the Common Stock underlying the Award has been issued to the Holder.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">9.5 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Restricted Stock Units</font><font style="font-family:inherit;font-size:9.5pt;">. The Administrator is authorized to grant Restricted Stock Units to any Eligible Individual. The number and terms and conditions of Restricted Stock Units shall be determined by the Administrator. The Administrator shall specify the date or dates on which the Restricted Stock Units shall become fully vested and nonforfeitable</font><font style="font-family:inherit;font-size:9.5pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:9.5pt;">and may specify such conditions to vesting as it deems appropriate, including conditions based on one or more Performance Criteria or other specific criteria, including service to the Company or any Subsidiary, in each case on a specified date or dates or over any period or periods, as the Administrator determines. The Administrator shall specify, or permit the Holder to elect, the conditions and dates upon which the shares of Common Stock underlying the Restricted Stock Units which shall be issued. On the distribution dates, the Company shall issue to the Holder one unrestricted, fully transferable share of Common Stock for each vested and nonforfeitable Restricted Stock Unit.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">9.6 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:9.5pt;">. The term of a Performance Award, Dividend Equivalent award, Deferred Stock award, Stock Payment award and/or Restricted Stock Unit award shall be set by the Administrator in its sole discretion.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">9.7 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Exercise or Purchase Price</font><font style="font-family:inherit;font-size:9.5pt;">. The Administrator may establish the exercise or purchase price of a Performance Award, shares of Deferred Stock, shares distributed as a Stock Payment award or shares distributed pursuant to a Restricted Stock Unit award; </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;">, </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:9.5pt;">, that value of the consideration shall not be less than the par value of a share of Common Stock, unless otherwise permitted by applicable law.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">9.8 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Exercise upon Termination of Service</font><font style="font-family:inherit;font-size:9.5pt;">. A Performance Award, Dividend Equivalent award, Deferred Stock award, Stock Payment award and/or Restricted Stock Unit award is exercisable or distributable only while the Holder is an Employee, Director or Consultant, as applicable. The Administrator, however, in its sole discretion may provide that the Performance Award, Dividend Equivalent award, Deferred Stock award, Stock Payment award and/or Restricted Stock Unit award may be exercised or distributed subsequent to a Termination of Service in certain events, including a Change in Control, the Holder's death, retirement or disability or any other specified Termination of Service.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 10.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">AWARD OF STOCK APPRECIATION RIGHTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">10.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Grant of Stock Appreciation Rights</font><font style="font-family:inherit;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) The Administrator is authorized to grant Stock Appreciation Rights to Eligible Individuals from time to time, in its sole discretion, on such terms and conditions as it may determine consistent with the Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) A Stock Appreciation Right shall entitle the Holder (or other person entitled to exercise the Stock Appreciation Right pursuant to the Plan) to exercise all or a specified portion of the Stock Appreciation Right (to the extent then exercisable pursuant to its terms) and to receive from the Company an amount determined by multiplying the difference obtained by subtracting the exercise price per share of the Stock Appreciation Right from the per share Fair Market Value on the date of exercise of the Stock Appreciation Right by the number of shares of Common Stock with respect to which the Stock Appreciation Right shall have been exercised, subject to any limitations the Administrator may impose. Except as described in (c) below, the exercise price per share of Common Stock subject to each Stock Appreciation Right shall be set by the Administrator, but shall not be less than 1 00% of the Fair Market Value on the date the Stock Appreciation Right is granted, unless determined otherwise by the Administrator.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(c) Notwithstanding the foregoing provisions of Section I 0.1 (b) to the contrary, in the case of an Stock Appreciation Right that is a Substitute Award, the price per share of the shares subject to such Stock Appreciation Right may be less than the Fair Market Value per share on the date of grant, </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;">, that the excess of: (a) the aggregate Fair Market Value (as of the date such Substitute Award is granted) of the shares subject to the Substitute Award, over (b) the aggregate exercise price thereof does not exceed the excess of: (x) the aggregate fair market value (as of the time immediately preceding the transaction giving rise to the Substitute Award, such fair market value to be determined by the Administrator) of the shares of the predecessor entity that were subject to the grant assumed or substituted for by the Company, over (y) the aggregate exercise price of such shares.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">10.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Stock Appreciation Right Vesting</font><font style="font-family:inherit;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) The Administrator shall determine the period during which a Holder shall vest in a Stock Appreciation Right and have the right to exercise such Stock Appreciation Right in whole or in part. Such vesting may be based on service with the Company or any Subsidiary, or any other criteria selected by the Administrator. At any time after grant of a Stock Appreciation Right, the Administrator may, in its sole discretion and subject to whatever terms and conditions it selects, accelerate the period during which a Stock Appreciation Right vests.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) No portion of a Stock Appreciation Right which is unexercisable at Termination of Service shall thereafter become exercisable, except as may be otherwise provided by the Administrator either in the Award Agreement or by action of the Administrator following the grant of the Stock Appreciation Right.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">10.3 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Manner of Exercise</font><font style="font-family:inherit;font-size:9.5pt;">. All or a portion of an exercisable Stock Appreciation Right shall be deemed exercised upon delivery of all of the following to the Secretary of the Company, or such other person or entity designated by the Administrator, or his, her or its office</font><font style="font-family:inherit;font-size:9.5pt;color:#161616;">, </font><font style="font-family:inherit;font-size:9.5pt;">as applicable:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) A written notice complying with the applicable mies established by the Administrator stating that the Stock Appreciation Right, or a portion thereof, is exercised. The notice shall be signed by the Holder or other person then entitled to exercise the Stock Appreciation Right or such portion of the Stock Appreciation Right;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) Such representations and documents as the Administrator, in its sole discretion, deems necessary or advisable to effect compliance with all applicable provisions of the Securities Act and any other federal, state or foreign securities laws or regulations. The Administrator may, in its sole discretion, also take whatever additional actions it deems appropriate to effect such compliance; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(c) In the event that the Stock Appreciation Right shall be exercised pursuant to this Section 10.3 by any person or persons other than the Holder, appropriate proof of the right of such person or persons to exercise the Stock Appreciation Right.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">10.4 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Payment</font><font style="font-family:inherit;font-size:9.5pt;">. Payment of the amount determined under Section 10.l(b) above shall be in cash, shares of Common Stock (based on its Fair Market Value as of the date the Stock Appreciation Right is exercised), or a combination of both, as determined by the Administrator.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 11.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ADDITIONAL TERMS OF AWARDS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">11.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Payment</font><font style="font-family:inherit;font-size:9.5pt;">. The Administrator shall determine the methods by which payments by any Holder with respect to any Awards granted under the Plan shall be made, including, without limitation: (a) cash or check, (b) shares of Common Stock (including, in the case of payment of the exercise price of an Award, shares of Common Stock issuable pursuant to the exercise of the Award) or shares of Common Stock held for such period of time as may be required by the Administrator in order to avoid adverse accounting consequences, in each case, having a Fair Market Value on the date of delivery equal to the aggregate payments required, (c) delivery of a notice that the Holder has placed a market sell order with a broker with respect to shares of Common Stock then issuable upon exercise or vesting of an Award, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the aggregate payments required, </font><font style="font-family:inherit;font-size:9.5pt;font-style:italic;">provided, </font><font style="font-family:inherit;font-size:9.5pt;">that payment of such proceeds is then made to the Company upon settlement of such sale, or (d) other form of legal consideration acceptable to the Administrator. The Administrator shall also determine the methods by which shares of Common Stock shall be delivered or deemed to be delivered to Holders. Notwithstanding any other provision of the Plan to the contrary, no Holder who is a Director or an "executive officer" of the Company within the meaning of Section 13(k) of the Exchange Act shall be permitted to make payment with respect to any Awards granted under the Plan, or continue any extension of credit with respect to such payment with a loan from the Company or a loan arranged by the Company in violation of Section 13(k) of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">11.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Tax Withholding</font><font style="font-family:inherit;font-size:9.5pt;">. The Company or any Subsidiary shall have the authority and the right to deduct or withhold, or require a Holder to remit to the Company, an amount sufficient to satisfy federal, state, local and foreign taxes (including the Holder's FICA or employment tax obligation) required by law to be withheld with respect to any taxable event concerning a Holder arising as a result of the Plan. The Administrator may in its sole discretion and in satisfaction of the foregoing requirement withhold, or allow a Holder to elect to have the Company withhold shares of Common Stock otherwise issuable under an Award (or allow the surrender of shares of Common Stock). Unless determined otherwise by the Administrator, the number of shares of Common Stock which may be so withheld or surrendered shall be limited to the number of shares which have a Fair Market Value on the date of withholding or repurchase no greater than the aggregate amount of such liabilities based on the minimum statutory withholding rates for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such supplemental taxable income. The Administrator shall determine the fair market value of the Common Stock, consistent with applicable provisions of the Code, for tax withholding obligations due in connection with a broker&#8226; assisted cashless Option or Stock Appreciation Right exercise involving the sale of shares to pay the Option or Stock Appreciation Right exercise price or any tax withholding obligation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">11.3 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Transferability of Awards</font><font style="font-family:inherit;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) Except as otherwise provided in Section 11.3(b):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(i) No Award under the Plan may be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution or, subject to the consent of the Administrator, pursuant to a DRO, unless and until such Award has been exercised, or the shares underlying such Award have been issued, and all restrictions applicable to such shares have lapsed;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(ii) No Award or interest or right therein shall be liable for the debts, contracts or engagements of the Holder or his successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, hypothecation, encumbrance</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">, </font><font style="font-family:inherit;font-size:9.5pt;">assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(iii) During the lifetime of the Holder, only the Holder may exercise an Award (or any portion thereof) granted to him under the Plan, unless it has been disposed of pursuant to a DRO; after the death of the Holder, any exercisable portion of an Award may, prior to the time when such portion becomes unexercisable under the Plan or the applicable Award Agreement, be exercised by his personal representative or by any person empowered to do so under the deceased Holder's will or under the then applicable laws of descent and distribution.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) Notwithstanding Section l l.3(a), the Administrator, in its sole discretion, may determine to permit a Holder to transfer an Award other than an Incentive Stock Option to any one or more Permitted Transferees (as defined below), subject to the following terms and conditions: (i) an Award transferred to a Permitted Transferee shall not be assignable or transferable by the Permitted Transferee other than by will or the laws of descent and distribution; (ii) an Award transferred to a Permitted Transferee shall continue to be subject to all the terms and conditions of the Award as applicable to the original Holder (other than the ability to further transfer the Award)</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">; </font><font style="font-family:inherit;font-size:9.5pt;">and (iii) the Holder and the Permitted Transferee shall execute any and all documents requested by the Administrator, including, without limitation documents to (A) confirm the status of the transferee as a Permitted Transferee, (B) satisfy any requirements for an exemption for the transfer under applicable federal</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">, </font><font style="font-family:inherit;font-size:9.5pt;">state and foreign securities laws and (C) evidence the transfer. For purposes of this Section I l.3(b), "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Permitted Transferee</font><font style="font-family:inherit;font-size:9.5pt;">" shall mean, with respect to a Holder, any "family member" of the Holder</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">, </font><font style="font-family:inherit;font-size:9.5pt;">as defined under the instructions to use of the Form S-8 Registration Statement under the Securities Act, or any other transferee specifically approved by the Administrator after taking into account any state, federal</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">, </font><font style="font-family:inherit;font-size:9.5pt;">local or foreign tax and securities laws applicable to transferable Awards.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(c) Notwithstanding Section Il.3(a), a Holder may, in the manner determined by the Administrator, designate a beneficiary to exercise the rights of the Holder and to receive any distribution with respect to any Award upon the Holder's death. A beneficiary, legal guardian, legal representative, or other person claiming any rights pursuant to the Plan is subject to all terms and conditions of the Plan and any Award Agreement applicable to the Holder, except to the extent the Plan and Award Agreement otherwise provide, and to any additional restrictions deemed necessary or appropriate by the Administrator. If the Holder is married or a domestic partner in a domestic partnership qualified under applicable law and resides in a community property state, a designation of a person other than the Holder</font><font style="font-family:inherit;font-size:9.5pt;color:#181818;">'</font><font style="font-family:inherit;font-size:9.5pt;">s spouse or domestic partner, as applicable, as his or her beneficiary with respect to more than 50% of the Holder's interest in the Award shall not be effective without the prior written consent of the Holder's spouse or domestic partner. If no beneficiary has been designated or survives the Holder, payment shall be made to the person entitled thereto pursuant to the Holder's will or the laws of descent and distribution. Subject to the foregoing, a beneficiary designation may be changed or revoked by a Holder at any time provided the change or revocation is filed with the Administrator prior to the Holder's death.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">11.4 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Conditions to Issuance of Shares</font><font style="font-family:inherit;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any certificates or make any book entries evidencing shares of Common Stock pursuant to the exercise of any Award, unless and until the Board has determined, with advice of counsel, that the issuance of such shares is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Common Stock are listed or traded, and the shares of Common Stock are covered by an effective registration statement or applicable exemption from registration. In addition to the terms and conditions provided herein</font><font style="font-family:inherit;font-size:9.5pt;color:#232323;">, </font><font style="font-family:inherit;font-size:9.5pt;">the Board may require that a Holder make such reasonable covenants, agreements, and representations as the Board</font><font style="font-family:inherit;font-size:9.5pt;color:#232323;">, </font><font style="font-family:inherit;font-size:9.5pt;">in its discretion, deems advisable in order to comply with any such laws, regulations, or requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) All Common Stock certificates delivered pursuant to the Plan and all shares issued pursuant to book entry procedures are subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state, or foreign securities or other laws, rules and regulations and the rules of any securities exchange or automated quotation system on which the Common Stock is listed, quoted, or traded. The Administrator may place legends on any Common Stock certificate or book entry to reference restrictions applicable to the Common Stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(c) The Administrator shall have the right to require any Holder to comply with any timing or other restrictions with respect to the settlement, distribution or exercise of any Award, including a window-period limitation, as may be imposed in the sole discretion of the Administrator.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(d) No fractional shares of Common Stock shall be issued and the Administrator shall determine, in its sole discretion, whether cash shall be given in lieu of fractional shares or whether such fractional shares shall be eliminated by rounding down.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(e) Notwithstanding any other provision of the Plan, unless otherwise determined by the Administrator or required by any applicable law, rule or regulation, the Company shall not deliver to any Holder certificates evidencing shares of Common </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Stock issued in connection with any Award and instead such shares of Common Stock shall be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">11.5 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Forfeiture Provisions</font><font style="font-family:inherit;font-size:9.5pt;">. Pursuant to its general authority to determine the terms and conditions applicable to Awards under the Plan, the Administrator shall have the right to provide, in the terms of Awards made under the Plan, or to require a Holder to agree by separate written instrument, that: (a)(i) any proceeds, gains or other economic benefit actually or constructively received by the Holder upon any receipt or exercise of the Award, or upon the receipt or resale of any Common Stock underlying the Award, must be paid to the Company, and (ii) the Award shall terminate and any unexercised portion of the Award (whether or not vested) shall be forfeited, if (b)(i) a Termination of Service occurs prior to a specified date, or within a specified time period following receipt or exercise of the Award, or (ii) the Holder at any time, or during a specified time period, engages in any activity in competition with the Company, or which is inimical, contrary or harmful to the interests of the Company, as further defined by the Administrator or (iii) the Holder incurs a Termination of Service for "cause" (as such term is defined in the sole discretion of the Administrator, or as set forth in a written agreement relating to such Award between the Company and the Holder).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">11.6 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Repricing</font><font style="font-family:inherit;font-size:9.5pt;">. Subject to Section 14.2, the Administrator shall have the authority, without the approval of the stockholders of the Company, to amend any outstanding award, in whole or in part, to increase or reduce the price per share or to cancel and replace an Award, in whole or in part, with the grant of an Award having a price per share that is less than, greater than or equal to the price per share of the original Award.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 12.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">NON-EMPLOYEE DIRECTOR AWARDS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">12.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Non-Employee Director Awards</font><font style="font-family:inherit;font-size:9.5pt;">. The Board may grant Awards to Non-Employee Directors, subject to the limitations of the Plan, pursuant to a written non-discretionary formula established by the Committee, or any successor committee thereto carrying out its responsibilities on the date of grant of any such Award (the "</font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Non-Employee Director Equity Compensation Policy</font><font style="font-family:inherit;font-size:9.5pt;">"). The Non-Employee Director Equity Compensation Policy shall set forth the type of Award(s) to be granted to Non-Employee Directors, the number of shares of Common Stock to be subject to Non-Employee Director Awards, the conditions on which such Awards shall be granted, become exercisable and/or payable and expire, and such other terms and conditions as the Committee (or such other successor committee as described above) shall determine in its discretion.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 13.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ADMINISTRATION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">13.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Administrator</font><font style="font-family:inherit;font-size:9.5pt;">. The Compensation Committee (or another committee or a subcommittee of the Board assuming the functions of the Committee under the Plan) shall administer the Plan (except as otherwise permitted herein) and shall consist solely of two or more Non-Employee Directors appointed by and holding office at the pleasure of the Board, each of whom is intended to qualify as both a "non-employee director" as defined by Rule 16b-3 of the Exchange Act or any successor rule, an "outside director" for purposes of Section 162(m) of the Code and an "independent director" under the rules of the NASDAQ Stock Market (or other principal securities market on which shares of Common Stock are traded); </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:9.5pt;">, that any action taken by the Committee shall be valid and effective, whether or not members of the Committee at the time of such action are later determined not to have satisfied the requirements for membership set forth in this Section 13.l or otherwise provided in any charter of the Committee. Except as may otherwise be provided in any charter of the Committee, appointment of Committee members shall be effective upon acceptance of appointment. Committee members may resign at any time by delivering written notice to the Board. Vacancies in the Committee may only be filled by the Board. Notwithstanding the foregoing, (a) the full Board, acting by a majority of its members in office, shall conduct the general administration of the Plan with respect to Awards granted to Non-Employee Directors and (b) the Board or Committee may delegate its authority hereunder to the extent permitted by Section 13.6.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">13.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Duties and Powers of Committee</font><font style="font-family:inherit;font-size:9.5pt;">. It shall be the duty of the Committee to conduct the general administration of the Plan in accordance with its provisions. The Committee shall have the power to interpret the Plan and the Award Agreement, and to adopt such rules for the administration, interpretation and application of the Plan as are not inconsistent therewith, to interpret, amend or revoke any such rules and to amend any Award Agreement provided that the rights or obligations of the holder of the Award that is the subject of any such Award Agreement are not affected adversely by such amendment, unless the consent of the Holder is obtained or such amendment is otherwise permitted under Section 14.10. Any such grant or award under the Plan need not be the same with respect to each holder. Any such interpretations and rules with respect to Incentive Stock Options shall be consistent with the provisions of Section 422 of the Code. In its sole discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Committee under the Plan except with respect to matters which under Rule 16b-3 under the Exchange Act or any successor rule, or Section 162(m) of the Code, or any regulations or rules issued thereunder, are required to be determined in the sole discretion of the Committee.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">13.3 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Action by the Committee</font><font style="font-family:inherit;font-size:9.5pt;">. Unless otherwise established by the Board or in any charter of the Committee</font><font style="font-family:inherit;font-size:9.5pt;color:#232323;">, </font><font style="font-family:inherit;font-size:9.5pt;">a majority of the Committee shall constitute a quorum and the acts of a majority of the members present at any meeting at which a quorum is present, and acts approved in writing by all members of the Committee in lieu of a meeting, shall be deemed the acts of the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Committee. Each member of the Committee is entitled to, in good faith, rely or act upon any report or other information furnished to that member by any officer or other employee of the Company or any Subsidiary, the Company's independent certified public accountants, or any executive compensation consultant or other professional retained by the Company to assist in the administration of the Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">13.4 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Authority of Administrator</font><font style="font-family:inherit;font-size:9.5pt;">. Subject to any specific designation in the Plan, the Administrator has the exclusive power, authority and sole discretion to:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) Designate Eligible Individuals to receive Awards;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) Determine the type or types of Awards to be granted to each Holder;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(c) Determine the number of Awards to be granted and the number of shares of Common Stock to which an Award will relate;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(d) Determine the terms and conditions of any Award granted pursuant to the Plan, including, but not limited to, the exercise price, grant price, or purchase price, any reload provision, any restrictions or limitations on the Award, any schedule for vesting, lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations or waivers thereof, and any provisions related to non-competition and recapture of gain on an Award, based in each case on such considerations as the Administrator in its sole discretion determines;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(e) Determine whether, to what extent, and pursuant to what circumstances an Award may be settled in, or the exercise price of an Award may be paid in cash, Common Stock, other Awards, or other property, or an Award may be canceled, forfeited, or surrendered;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(f) Prescribe the form of each Award Agreement, which need not be identical for each Holder; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(g) Decide all other matters that must be determined in connection with an Award;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(h) Establish, adopt, or revise any rules and regulations as it may deem necessary or advisable to administer the Plan;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(i) Interpret the terms of, and any matter arising pursuant to, the Plan or any Award Agreement; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(j) Make all other decisions and determinations that may be required pursuant to the Plan or as the Administrator deems necessary or advisable to administer the Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">13.5 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Decisions Binding</font><font style="font-family:inherit;font-size:9.5pt;">. The Administrator's interpretation of the Plan, any Awards granted pursuant to the Plan, any Award Agreement and all decisions and determinations by the Administrator with respect to the Plan are final</font><font style="font-family:inherit;font-size:9.5pt;color:#1c1c1c;">, </font><font style="font-family:inherit;font-size:9.5pt;">binding, and conclusive on all parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">13.6 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Delegation of Authority</font><font style="font-family:inherit;font-size:9.5pt;">. To the extent permitted by applicable law, the Board or Committee may from time to time delegate to a committee of one or more members of the Board or one or more officers of the Company the authority to grant or amend Awards; </font><font style="font-family:inherit;font-size:9.5pt;font-style:italic;">provided, however, </font><font style="font-family:inherit;font-size:9.5pt;">that in no event shall an officer be delegated the authority to grant awards to, or amend awards held by, the following individuals: (a) individuals who are subject to Section 16 of the Exchange Act, (b) Covered Employees, or (c) officers of the Company (or Directors) to whom authority to grant or amend Awards has been delegated hereunder. Any delegation hereunder shall be subject to the restrictions and limits that the Board or Committee specifies at the time of such delegation, and the Board may at any time rescind the authority so delegated or appoint a new delegatee. At all times, the delegatee appointed under this Section 13.6 shall serve in such capacity at the pleasure of the Board and the Committee.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">ARTICLE 14.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;font-weight:bold;">MISCELLANEOUS PROVISIONS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.1 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Amendment, Suspension or Termination of the Plan</font><font style="font-family:inherit;font-size:9.5pt;">. Except as otherwise provided in this Section 14.1, the Plan may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Board. However, without approval of the Company's stockholders given within twelve (12) months before or after the action by the Administrator, no action of the Administrator may, except as provided in Section 14.2, increase the limits imposed in Section 3.1 on the maximum number of shares which may be issued under the Plan. Except as provided in Section 14.10, no amendment, suspension or termination of the Plan shall, without the consent of the Holder, impair any rights or obligations under any Award theretofore granted or awarded, unless the Award itself otherwise expressly so provides. No Awards may be granted or awarded during any period of suspension or after termination of the Plan, and in no event may any A ward be granted under the Plan after the tenth (10</font><font style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:inherit;font-size:9.5pt;">) anniversary of the Effective Date.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.2 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Changes in Common Stock or Assets of the Company, Acquisition or Liquidation of the Company and Other Corporate Events</font><font style="font-family:inherit;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(a) In the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of the Company's stock or the share price of the Company's stock other than an Equity Restructuring, the Administrator may make equitable adjustments, if any, to reflect such change with respect to (i) the aggregate number and kind of shares that may be issued under the Plan (including, but not limited to, adjustments of the limitations in Section 3.1 on the maximum number and kind of shares which may be issued under the Plan); (ii) the number and kind of shares of Common Stock (or other securities or property) subject to outstanding Awards; (iii) the terms and conditions of any outstanding Awards (including, without limitation, any applicable performance targets or criteria with respect thereto)</font><font style="font-family:inherit;font-size:9.5pt;color:#1c1c1c;">; </font><font style="font-family:inherit;font-size:9.5pt;">and (iv) the grant or exercise price per share for any outstanding Awards under the Plan. Any adjustment affecting an Award intended as Performance-Based Compensation shall be made consistent with the requirements of Section 162(m) of the Code.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(b) In the event of any transaction or event described in Section 14.2(a) or any unusual or nonrecurring transactions or events affecting the Company, any affiliate of the Company, or the financial statements of the Company or any affiliate, or of changes in applicable laws, regulations or accounting principles, the Administrator, in its sole discretion, and on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event and either automatically or upon the Holder's request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any Award under the Plan, to facilitate such transactions or events or to give effect to such changes in laws, regulations or principles.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(i) To provide for either (A) termination of any such Award in exchange for an amount of cash, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Holder's rights (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction or event described in this Section 14.2 the Administrator determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Holder's rights, then such Award may be terminated by the Company without payment) or (B) the replacement of such Award with other rights or property selected by the Administrator in its sole discretion having an aggregate value not exceeding the amount that could have been attained upon the exercise of such Award or realization of the Holder's rights had such Award been currently exercisable or payable or fully vested;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(ii) To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by similar options</font><font style="font-family:inherit;font-size:9.5pt;color:#202020;">, </font><font style="font-family:inherit;font-size:9.5pt;">rights or awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(iii) To make adjustments in the number and type of shares of the Company's stock (or other securities or property) subject to outstanding Awards, and in the number and kind of outstanding Restricted Stock or Deferred Stock and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards and Awards which may be granted in the future;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(iv) To provide that such Award shall be exercisable or payable or fully vested with respect to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the applicable Award Agreement; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(v) To provide that the Award cannot vest, be exercised or become payable after such event.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(c) In connection with the occurrence of any Equity Restructuring, and notwithstanding anything to the contrary in Sections 14.2(a) and 14.2(b):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(i) The number and type of securities subject to each outstanding Award and/or the exercise price or grant price thereof, if applicable, shall be equitably adjusted. The adjustments provided under this Section 14.2(c) shall be nondiscretionary and shall be final and binding on the affected Holder and the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:96px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(ii) The Administrator shall make such equitable adjustments, if any, as the Administrator in its discretion may deem appropriate to reflect such Equity Restructuring with respect to the aggregate number and kind of shares that may be issued under the Plan (including, but not limited to, adjustments of the limitations in Section 3.1 on the maximum number and kind of shares which may be issued under the Plan).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(d) Notwithstanding any other provision of the Plan, but subject to Section 14.2(e), in the event of a Change in Control, each outstanding Award shall be assumed or an equivalent Award substituted by the successor corporation or a parent or subsidiary of the successor corporation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(e) In the event that the successor corporation in a Change in Control refuses to assume or substitute for an Award upon a Change in Control, such Award shall become fully vested and, if applicable, exercisable and all forfeiture restrictions on </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">such Award shall lapse, in each case, as of immediately prior to the consummation of such Change in Control. If an Award is exercisable in lieu of assumption or substitution in the event of a Change in Control, the Administrator shall notify the Holder that the Award shall be fully exercisable for a period of fifteen (15) days from the date of such notice, contingent upon the occurrence of the Change in Control, and the Award shall terminate upon the expiration of such period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(f) The Administrator may, in its sole discretion, include such further provisions and limitations in any Award, agreement or certificate</font><font style="font-family:inherit;font-size:9.5pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:9.5pt;">as it may deem equitable and in the best interests of the Company that are not inconsistent with the provisions of the Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(g) With respect to Awards which are granted to Covered Employees and are intended to qualify as Performance-Based Compensation, no adjustment or action described in this Section 14.2 or in any other provision of the Plan shall be authorized to the extent that such adjustment or action would cause such Award to fail to so qualify as Performance-Based Compensation</font><font style="font-family:inherit;font-size:9.5pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:9.5pt;">unless the Administrator determines that the Award should not so qualify. No adjustment or action described in this Section 14.2 or in any other provision of the Plan shall be authorized to the extent that such adjustment or action would cause the Plan to violate Section 422(b)(l) of the Code. Furthermore, no such adjustment or action shall be authorized to the extent such adjustment or action would result in short-swing profits liability under Section 16 or violate the exemptive conditions of Rule 16b-3 unless the Administrator determines that the Award is not to comply with such exemptive conditions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(h) The existence of the Plan, the Award Agreement and the Awards granted hereunder shall not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company's capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, warrants or rights to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(i) No action shall be taken under this Section 14.2 which shall cause an Award to fail to comply with Section 409A of the Code or the Treasury Regulations thereunder, to the extent applicable to such Award.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:72px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">(j) In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock including any Equity Restructuring, for reasons of administrative convenience</font><font style="font-family:inherit;font-size:9.5pt;color:#1d1d1d;">, </font><font style="font-family:inherit;font-size:9.5pt;">the Company in its sole discretion may refuse to permit the exercise of any Award during a period of up to thirty (30) days prior to the consummation of any such transaction.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.3 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Approval of Plan by Stockholders</font><font style="font-family:inherit;font-size:9.5pt;">. The Plan will be submitted for the approval of the Company's stockholders within twelve (12) months of the date of the Board's initial adoption of the Plan. Awards may be granted or awarded prior to such stockholder approval, provided that such Awards shall not be exercisable, shall not vest and the restrictions thereon shall not lapse and no shares of Common Stock shall be issued pursuant thereto prior to the time when the Plan is approved by the stockholders, and provided further that if such approval has not been obtained at the end of said twelve (12) month period, all Awards previously granted or awarded under the Plan shall thereupon be canceled and become null and void.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.4 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">No Stockholders Rights</font><font style="font-family:inherit;font-size:9.5pt;">. Except as otherwise provided herein, a Holder shall have none of the rights of a stockholder with respect to shares of Common Stock covered by any Award until the Holder becomes the record owner of such shares of Common Stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.5 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Paperless Administration</font><font style="font-family:inherit;font-size:9.5pt;">. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response, then the paperless documentation, granting or exercise of Awards by a Holder may be permitted through the use of such an automated system.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.6 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Effect of Plan upon Other Compensation Plans</font><font style="font-family:inherit;font-size:9.5pt;">. The adoption of the Plan shall not affect any other compensation or incentive plans in effect for the Company or any Subsidiary, Nothing in the Plan shall be construed to limit the right of the Company or any Subsidiary: (a) to establish any other forms of incentives or compensation for Employees, Directors or Consultants of the Company or any Subsidiary, or (b) to grant or assume options or other rights or awards otherwise than under the Plan in connection with any proper corporate purpose including without limitation, the grant or assumption of options in connection with the acquisition by purchase, lease, merger, consolidation or otherwise, of the business, stock or assets of any corporation, partnership, limited liability company, firm or association.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.7 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Compliance with Laws</font><font style="font-family:inherit;font-size:9.5pt;">. The Plan, the granting and vesting of Awards under the Plan and the issuance and delivery of shares of Common Stock and the payment of money under the Plan or under Awards granted or awarded hereunder are subject to compliance with all applicable federal, state, local and foreign laws, rules and regulations (including but not limited to state, federal and foreign securities law and margin requirements) and to such approvals by any listing, regulatory or governmental authority as may, in the opinion of counsel for the Company, be necessary or advisable in connection therewith. Any securities </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">delivered under the Plan shall be subject to such restrictions, and the person acquiring such securities shall, if requested by the Company, provide such assurances and representations to the Company as the Company may deem necessary or desirable to assure compliance with all applicable legal requirements. To the extent permitted by applicable law, the Plan and Awards granted or awarded hereunder shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.8 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Titles and Headings, References to Sections of the Code or Exchange Act</font><font style="font-family:inherit;font-size:9.5pt;">. The titles and headings of the Sections in the Plan are for convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control. References to sections of the Code or the Exchange Act shall include any amendment or successor thereto.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.9 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:9.5pt;">. The Plan and any agreements hereunder shall be administered, interpreted and enforced under the internal laws of the State of Delaware without regard to conflicts of laws thereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.10 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Section 409A</font><font style="font-family:inherit;font-size:9.5pt;">. To the extent that the Administrator determines that any Award granted under the Plan is subject to Section 409A of the Code, the Award Agreement evidencing such Award shall incorporate the terms and conditions required by Section 409A of the Code. To the extent applicable, the Plan and Award Agreements shall be interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date. Notwithstanding any provision of the Plan to the contrary, in the event that following the Effective Date the Administrator determines that any Award may be subject to Section 409A of the Code and related Department of Treasury guidance (including such Department of Treasury guidance as may be issued after the Effective Date), the Administrator may adopt such amendments to the Plan and the applicable Award Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Administrator determines are necessary or appropriate to (a) exempt the Award from Section 409A of the Code and/or preserve the intended tax treatment of the benefits provided with respect to the Award, or (b) comply with the requirements of Section 409A of the Code and related Department of Treasury guidance and thereby avoid the application of any penalty taxes under such Section.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.11 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">No Rights to Awards</font><font style="font-family:inherit;font-size:9.5pt;">. No Eligible Individual or other person shall have any claim to be granted any Award pursuant to the Plan, and neither the Company nor the Administrator is obligated to treat Eligible Individuals, Holders or any other persons uniformly.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.12 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Unfunded Status of Awards</font><font style="font-family:inherit;font-size:9.5pt;">. The Plan is intended to be an "unfunded" plan for incentive compensation. With respect to any payments not yet made to a Holder pursuant to an Award, nothing contained in the Plan or any Award Agreement shall give the Holder any rights that are greater than those of a general creditor of the Company or any Subsidiary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.13 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Indemnification</font><font style="font-family:inherit;font-size:9.5pt;">. To the extent allowable pursuant to applicable law, each member of the Committee or of the Board shall be indemnified and held harmless by the Company from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by such member in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action or failure to act pursuant to the Plan and against and from any and all amounts paid by him or her in satisfaction of judgment in such action, suit, or proceeding against him or her; </font><font style="font-family:inherit;font-size:9.5pt;font-style:italic;">provided </font><font style="font-family:inherit;font-size:9.5pt;">he or she gives the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled pursuant to the Company's Certificate of Incorporation or Bylaws, as a matter of law, or otherwise</font><font style="font-family:inherit;font-size:9.5pt;color:#242424;">, </font><font style="font-family:inherit;font-size:9.5pt;">or any power that the Company may have to indemnify them or hold them harmless.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.14 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Relationship to other Benefits</font><font style="font-family:inherit;font-size:9.5pt;">. No payment pursuant to the Plan shall be taken into acconnt in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except to the extent otherwise expressly provided in writing in such other plan or an agreement thereunder.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">14.15 </font><font style="font-family:inherit;font-size:9.5pt;text-decoration:underline;">Expenses</font><font style="font-family:inherit;font-size:9.5pt;">. The expenses of administering the Plan shall be borne by the Company and its Subsidiaries.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">* * * * *</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">I hereby certify that the foregoing Plan was duly adopted by the Board of Directors of Dyadic International, Inc. on April 28, 2011.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">* * * * *</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">I hereby certify that the foregoing Plan was approved by the stockholders of Dyadic International, Inc. on June 15, 2011.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Executed on this 15" day of June, 2011.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:34.69387755102041%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Adam J. Morgan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Secretary</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>8
<FILENAME>exhibit103form10.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6BE827CE594302D0CFD149A0018132B9"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.3</font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RESTRICTED STOCK AGREEMENT</font></div><div style="line-height:130%;padding-top:1px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">RESTRICTED STOCK AGREEMENT made this ___________ day of ___________ by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the &#8220;Company&#8221;), ___________ (&#8220;Stockholder&#8221;).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Recitals:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A.&#160;&#160;&#160;&#160;The Company&#8217;s 2011 Equity Incentive Award Plan (the &#8220;Plan&#8221;) is designed to promote and increase the personal interest of Company employees in the success of the Company by providing incentives and rewards to such employees.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;text-indent:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">B.&#160;&#160;&#160;&#160;The Company has agreed to issue ___________(___________) shares of common stock (the &#8220;Restricted Shares&#8221;) to Stockholder, an executive employee of the Company, in consideration for services rendered and to be rendered by Stockholder pursuant to the provisions of that certain Employment Agreement dated ___________ (the &#8220;Employment Agreement&#8221;), a copy of which is attached hereto.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;text-indent:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C.&#160;&#160;&#160;&#160;Stockholder wishes to acquire the Restricted Shares for such consideration and under such terms.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NOW THEREFORE, in consideration of the premises, and the mutual covenants and agreements set forth below, the parties hereby agree as follows:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Issuance</font><font style="font-family:inherit;font-size:11pt;">. The Company hereby issues the Restricted Shares to Stockholder in consideration for services rendered and to be rendered by Stockholder as an executive employee pursuant to the Employment Agreement.  In addition to restrictions on transfers of such securities imposed thereon by the federal securities laws and regulations, the Company hereby imposes, pursuant to the Plan certain additional burdens on the Restricted Shares as set forth hereinbelow, including, without limitation, a risk of forfeiture in certain circumstances arising from Stockholder&#8217;s ongoing employment status.</font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Transfer of Stock; Investment Intent</font><font style="font-family:inherit;font-size:11pt;">. Stockholder represents and warrants that all of the Restricted Shares are being acquired for investment and not with a view to, or with any present intention of, selling or otherwise distributing the Restricted Shares. Stockholder further represents that Stockholder is capable of evaluating the merits and risks of an investment in the Restricted Shares, has made such an evaluation and is able to bear the economic risk of an investment in the Restricted Shares indefinitely.  Except as otherwise provided in this Agreement, Stockholder shall not sell, transfer, assign, convey, pledge, encumber or in any manner dispose of the Restricted Shares, either voluntarily or involuntarily.  All stock certificates evidencing the Restricted Shares shall be imprinted with a legend n substantially the following form:</font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:60%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">THE TRANSFER OR ENCUMBRANCE OF THE SHARES OF STOCK REPRESENTED BY THE WITHIN CERTIFICATE IS RESTRICTED UNDER THE TERMS OF A RESTRICTED STOCK AGREEMENT  DATED  SEPTEMBER ___________,  2013,  A  COPY  OF WHICH IS ON FILE IN THE PRINCIPAL OFFICE OF THE COMPANY.</font></div><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">THE  SHARES  REPRESENTED  BY  THIS  CERTIFICATE  HAVE NOT  BEEN  REGISTERED  UNDER  THE  SECURITIES  ACT  OF 1933, AS AMENDED (THE &#8220;ACT&#8221;).  THESE SHARES HAVE BEEN ACQUIRED FOR  INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE MORTGAGED, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SHARES UNDER THE ACT OR AN OPINION OF COUNSEL FOR THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Risk of Forfeiture</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a.&#160;&#160;&#160;&#160;Upon termination of Stockholder&#8217;s employment with the Company at any time before ___________the Company shall have an immediate and automatic option, without any action having to be taken on the part of Stockholder to activate the option, to repurchase from Stockholder at the par value per share (the &#8220;Purchase Price&#8221;) that number of the Restricted Shares as is set forth opposite the following applicable periods:</font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Date on Which Termination Occurs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Vested Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Shares Subject to Option</font></div></td></tr></table></div></div><div style="line-height:140%;padding-top:1px;text-align:left;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Termination of employment shall mean cessation of the employment relation between the Company and Stockholder as a result of Stockholder&#8217;s death, disability, Resignation Without Good Reason (as defined in the Employment Agreement), retirement or Termination by the Company for Cause (as defined in the Employment Agreement).  (For purposes of this Agreement, all references to &#8220;Stockholder&#8221; shall be deemed to include Stockholder&#8217;s estate wherever applicable.)</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the event of Termination by the Company Without Cause or Resignation for Good Reason (as defined in the Employment Agreement), none of the Restricted Shares shall be subject to the above option, provided, however, that Stockholder&#8217;s continuous status as an employee has not terminated prior to such Termination by the Company Without Cause or Resignation for Good Reason.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">b.&#160;&#160;&#160;&#160;Following a Change of Control, none of the Restricted Shares shall be subject to the above option.  A &#8220;Change of Control&#8221; means either (i) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation any reorganization, merger or consolidation or stock transfer, but excluding any such transaction effected primarily for the purpose of changing the domicile of the Company), unless the Company&#8217;s stockholders of record immediately prior to such transaction or series of related transactions hold, immediately after </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">2</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">such transaction or series of related transactions, at least thirty-five percent (35%) of the voting power of the surviving or acquiring entity, or (ii)  a sale of all or substantially all of the assets of the Company.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;text-indent:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">c.&#160;&#160;&#160;&#160;Upon the occurrences of the following events, the Company shall have an immediate and automatic option, without any action having to be taken on the part of Stockholder to activate the option, to purchase from Stockholder or his transferee, at the price set forth in Section 4, all of the Restricted Shares subject to the option applicable to the timetable in subsection a above:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)&#160;&#160;&#160;&#160;An Event of Bankruptcy with respect to Stockholder defined as follows: (A) an adjudication or order for relief by a state or federal court that such person is bankrupt or insolvent or is subject to Chapter 11 or any reorganization proceeding; or (B) filing by such person of a voluntary petition in any state or federal court to be adjudicated a bankrupt or to subject such person to Chapter 11 or any reorganization proceeding; or (C) the filing by a third party of an involuntary petition in any state or federal court to have such person adjudicated bankrupt or insolvent, or for an order for relief, or to subject such  person to the provisions of Chapter 11 or any reorganization proceeding or to obtain the appointment of a receiver which is not dismissed within one hundred-twenty (120) days of the date of the filing; or (D) the making by such person of a general assignment for the benefit of creditors;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)&#160;&#160;&#160;&#160;An order or adjudication by any court that the spouse of Stockholder has acquired any right in the Restricted Shares as a result of equitable distribution rights under any applicable law or statute; or</font></div><div style="line-height:120%;padding-top:1px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii)&#160;&#160;&#160;&#160;Any other event which adversely and involuntarily affects Stockholder&#8217;s rights in the Restricted Shares so that Stockholder would be required to transfer the Restricted Shares to a third party, and which is not otherwise provided for in this Agreement.</font></div><div style="line-height:100%;text-align:left;text-indent:48px;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Purchase Price</font><font style="font-family:inherit;font-size:11pt;">.  If the Company exercises its purchase rights under Section 3, the price per share shall be the fair market value of the Restricted Shares on the date of the event giving rise to the transfer. The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) shall establish the fair market value, and shall not take into account the impact on the valuation of any restrictions on the Restricted Shares other than restrictions which by their terms will never lapse.</font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exercise of Company&#8217;s Options</font><font style="font-family:inherit;font-size:11pt;">. The Company may exercise its options pursuant to Section 3 by giving Stockholder notice of its election within sixty (60) days of the later of the date on which Stockholder&#8217;s employment under the Employment Agreement is terminated or another triggering event described in Section 3 occurs. The notice shall include a closing date, which date shall be within thirty (30) days of the date the notice is given.  The closing shall be at the principal office of the Company. Voting rights on the Restricted Shares subject to the option shall be vested in the Company as of the date the Company gives notice of its election to exercise the option.  At its election, the Company shall pay the full amount for the Restricted Shares by check at the closing.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">At the closing, Stockholder&#8217;s legal representative (as the case may be) shall deliver to the Company the stock certificate evidencing the Restricted Shares to be redeemed, properly endorsed in blank with all transfer and excise taxes paid and, in the event of death, Stockholder&#8217;s legal representative shall also deliver copies of letters testamentary or authority to act on behalf of the estate and a release or tax letter from appropriate tax authorities stating that the Restricted Shares transferred are not subject to taxes. Stockholder, or Stockholder&#8217;s representative if Stockholder is deceased, shall warrant that the Restricted Shares transferred are free and clear of all liens, encumbrances and claims.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Payment of Taxes and Section 83(b) Election</font><font style="font-family:inherit;font-size:11pt;">.  Stockholder agrees that concurrently with the execution of this Agreement Stockholder will execute an election under Section 83(b) of the Internal Revenue Code to be taxed currently on Stockholder&#8217;s compensation related to receipt of the Restricted Shares, which compensation is calculated to be the difference between the price Stockholder paid for the Restricted Shares and the amount which the Company has determined to be the fair market value of the Restricted Shares. The Company shall determine the amount of federal and state withholding due with respect to Stockholder&#8217;s compensation in the form of the Restricted Shares, and such amount shall be withheld from Stockholder&#8217;s next paycheck.  Stockholder agrees to pay the Company the amount of withholding due with respect to the Restricted Shares within five (5) days of the date the Company gives Stockholder notice of the amount due, time being of the essence.  No stock certificates shall be delivered on behalf of Stockholder until the payment of the withholding due is made.  If the payment is not made within five (5) days of the date that the Company gives notice to Stockholder of the amount due, time being of the essence, the Company may arrange for withholding of all amounts due from Stockholder&#8217;s pay until Stockholder&#8217;s obligation is satisfied.</font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Specific Performance</font><font style="font-family:inherit;font-size:11pt;">.  Because of the unique character of the Restricted Shares, the parties to this Agreement agree that the Company and its stockholders will be irreparably damaged in the event that this Agreement is not specifically enforced.  Should any dispute arise concerning the sale or transfer of the Restricted Shares, an injunction may be issued restraining any sale or transfer pending the determination of such controversy.  In the event of any controversy concerning the right of the Company to purchase or of Stockholder to sell any of the Shares, such right or obligation shall be enforceable in a court of equity by a decree of specific performance.  Such remedy shall, however, be in addition to any other remedies which the parties may have.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Stockholder agrees that in the event of any violation of this Agreement, an action may be commenced by the Company for any such preliminary and permanent injunctive relief and other equitable relief in any court of competent jurisdiction in the State of Florida or in any other court of competent jurisdiction. Stockholder hereby waives any objections on the grounds of improper jurisdiction or venue to the commencement of an action in the State of Florida and agrees that effective service of process may be made upon Stockholder by mail under the notice provisions contained in Section 9.2.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Contract of Employment</font><font style="font-family:inherit;font-size:11pt;">.  Nothing contained in this Agreement shall be deemed to require the Company to continue Stockholder&#8217;s employment with the Company.  From time to time, the Company may distribute employee manuals or handbooks, and officers or the Board may make written or</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">oral statements relating to the Company&#8217;s policies and procedures.  Such manuals, handbooks and statements are intended only for the general guidance of employees.  No policies, procedures or statements of any nature by or on behalf of the Company (whether written or oral, and whether or not contained in any formal employee manual or handbook) shall be construed to modify this Agreement.</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Binding Effect</font><font style="font-family:inherit;font-size:11pt;">. This Agreement shall be binding, not only upon the parties to this Agreement, but also on their heirs, executors, administrators, personal representatives, successors, assigns (including any transferee of a party to this Agreement), and the parties agree, for themselves and their successors, assigns and representatives to execute any instrument which may be necessary legally to give effect to the terms and conditions of this Agreement.</font></div><div style="line-height:110%;text-align:left;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:11pt;">.  All notices, requests and amendments under this Agreement, shall be in writing, and notices shall be deemed to have been given when personally delivered or the next business day after being sent by overnight courier service addressed as follows (i) if to the Company:  140 Intracoastal Pointe Dr. #404, Jupiter, FL 33477, Attention President, or at such other address as the Company shall designate by notice; or (ii) if to Stockholder: to Stockholder&#8217;s address appearing below, or at such other address as Stockholder shall designate by notice.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:11pt;">.  The invalidity or unenforeceability of any particular provision of this Agreement shall not affect the other provisions hereof, and this Agreement shall be construed in all respects as if such invalid or unenforceable provisions were omitted.</font></div><div style="line-height:110%;text-align:left;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.4&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Governing Law; Jurisdiction</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement shall be governed by the internal laws of Florida. The parties hereby consent to the exclusive jurisdiction of the courts of Palm Beach County, Florida for purposes of adjudicating any issue hereunder.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.5&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment</font><font style="font-family:inherit;font-size:11pt;">.  Neither this Agreement nor any of the terms and conditions set forth in this Agreement may be altered or amended verbally, and any such alteration or amendment shall only be effective when reduced to writing and signed by each of the parties.</font></div><div style="line-height:110%;text-align:left;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.6&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Stock Splits, etc.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;In the event that, as the result of a stock split or stock dividend or combination of shares or any other change, or exchange for other securities, by reclassification, reorganization, merger, consolidation, recapitalization or otherwise, Stockholder shall, as the owner of the Restricted Shares subject to restrictions hereunder, be entitled to new or additional or different shares of stock or securities, the certificate or certificates for, or other evidences of, such new or additional or different shares or securities, shall also be imprinted with a legend as provided in Section 1, and all provisions of this Agreement relating to restrictions and lapse of restrictions shall be applicable to such new or additional or different shares or securities to the extent applicable to the shares with respect to which they were distributed, and such new or additional or different shares or securities shall be deemed to be &#8220;Restricted Shares&#8221; for all purposes hereof; provided, however that if Stockholder shall receive rights, warrants or fractional interests in respect of any such Restricted Shares, such rights or warrants may be held, exercised, sold or otherwise disposed of, and such fractional interests may be settled, by Stockholder free and clear of the restrictions set forth in this Agreement.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.7&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Entire Agreement; Rights and Interest</font><font style="font-family:inherit;font-size:11pt;">. This Agreement constitutes the entire agreement of the parties with respect to the matters covered hereby, and supersedes any previous agreements, whether written or oral.  Each party hereby stipulates and acknowledges that there are no other understandings, expectations or agreements, either written or oral, respecting Stockholder&#8217;s rights and entitlements as a stockholder of the Company, including, without limitation, any understandings, expectations, or agreements regarding any employment, compensation or other benefits, governance of the Company or the payment of dividends, except as expressly set forth in the Employment Agreement.  Further, no such understandings, expectations or agreements which may hereafter arise shall be enforceable unless the same shall be reduced to a writing signed by the parties to be changed.</font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the parties to this Agreement have executed this Agreement effective the date and year first above written.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:42.73504273504273%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">DYADIC INTERNATIONAL, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:42.73504273504273%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:25%;"></td><td style="width:75%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Address:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">- </font><font style="font-family:inherit;font-size:10pt;">6</font><font style="font-family:inherit;font-size:10pt;">&#32;-</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>9
<FILENAME>exhibit104form10.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6E8B96A3116EF60A3432AFA846AED4F3"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.4</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2011 EQUITY INCENTIVE AWARD PLAN</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK OPTION GRANT NOTICE</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dyadic International, Inc., a Delaware corporation, (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;), pursuant to its 2011 Equity Incentive Award Plan, as amended from time to time (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Plan</font><font style="font-family:inherit;font-size:10pt;">&#8221;), hereby grants to the Holder listed below (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Participant</font><font style="font-family:inherit;font-size:10pt;">&#8221;), an option to purchase the number of shares of the Company&#8217;s common stock, par value $0.001 (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Stock</font><font style="font-family:inherit;font-size:10pt;">&#8221;), set forth below (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:10pt;">&#8221;). This Option is subject to all of the terms and conditions set forth herein and in the Stock Option Agreement attached hereto as </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Stock Option Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and the Plan, each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Stock Option Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Participant Name: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Participant ID: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Plan Name: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Award Number:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares Granted: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Award Type:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Award Date: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Award Price: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vesting Schedule: &#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expiration Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By signing the Stock Option Grant Notice below and the Stock Option Agreement attached hereto as </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">, Participant agrees to be bound by the terms and conditions of the Plan, the Stock Option Agreement and this Grant Notice. Participant has reviewed the Stock Option Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and the Stock Option Agreement and fully understands all provisions of this Grant Notice, the Stock Option Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Stock Option Agreement. </font></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:48.07692307692308%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:24%;"></td><td style="width:76%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL,&#160;INC.:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Print Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Participant:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Print Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK OPTION AGREEMENT</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Stock Option Grant Notice (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Grant Notice</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to which this Stock Option Agreement (this &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;) is attached, Dyadic International, Inc., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;), has granted to Participant an Option under the Company&#8217;s 2011 Equity Incentive Award Plan, as amended from time to time (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Plan</font><font style="font-family:inherit;font-size:10pt;">&#8221;), to purchase the number of shares of Stock indicated in the Grant Notice. </font></div><div style="line-height:120%;padding-top:20px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARTICLE 1. </font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GENERAL </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Defined Terms</font><font style="font-family:inherit;font-size:10pt;">. Wherever the following terms are used in this Agreement they shall have the meanings specified below, unless the context clearly indicates otherwise. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Grant Notice. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Incorporation of Terms of Plan</font><font style="font-family:inherit;font-size:10pt;">. The Option is subject to the terms and conditions of the Plan which are incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control. </font></div><div style="line-height:120%;padding-top:20px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARTICLE 2. </font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GRANT OF OPTION </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Grant of Option</font><font style="font-family:inherit;font-size:10pt;">. In consideration of Participant&#8217;s past and/or continued employment with or service to the Company or a Subsidiary and for other good and valuable consideration, effective as of the Grant Date set forth in the Grant Notice (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Grant Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), the Company grants to Participant the Option to purchase any part or all of an aggregate of the number of shares of Stock set forth in the Grant Notice, upon the terms and conditions set forth in the Plan and this Agreement, subject to adjustments as provided in Section&#160;14.2 of the Plan. Unless designated as a Nonstatutory Stock Option in the Grant Notice, the Option shall be an Incentive Stock Option to the maximum extent permitted by law. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercise Price</font><font style="font-family:inherit;font-size:10pt;">. The exercise price of the shares of Stock subject to the Option shall be as set forth in the Grant Notice, without commission or other charge; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:10pt;">, that the price per share of the shares of Stock subject to the Option shall not be less than 100% of the Fair Market Value of a share of Stock on the Grant Date. Notwithstanding the foregoing, if this Option is designated as an Incentive Stock Option and Participant owns (within the meaning of Section&#160;424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or any &#8220;subsidiary corporation&#8221; of the Company or any &#8220;parent corporation&#8221; of the Company (each within the meaning of Section&#160;424 of the Code), the price per share of the shares of Stock subject to the Option shall not be less than 110% of the Fair Market Value of a share of Stock on the Grant Date. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Consideration to the Company</font><font style="font-family:inherit;font-size:10pt;">. In consideration of the grant of the Option by the Company, Participant agrees to render faithful and efficient services to the Company or any Subsidiary. Nothing in the Plan or this Agreement shall confer upon Participant any right to continue in the employ or service of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARTICLE 3. </font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PERIOD OF EXERCISABILITY </font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Commencement of Exercisability</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Subject to Sections 3.2, 3.3, 5.10 and 5.16 hereof, the Option shall become vested and exercisable in such amounts and at such times as are set forth in the Grant Notice. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) No portion of the Option which has not become vested and exercisable at the date of Participant&#8217;s Termination of Service shall thereafter become vested and exercisable, except as may be otherwise provided by the Administrator or as set forth in a written agreement between the Company and Participant. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Notwithstanding Sections 3.1(a) hereof and the Grant Notice, but subject to Section&#160;3.1(b) hereof, pursuant to Section&#160;14.2 of the Plan, the Option shall become fully vested and exercisable with respect to all shares of Stock covered thereby in the event of a Change in Control, in connection with which the successor corporation does not assume the Option or substitute an equivalent right for the Option. Should the successor corporation assume the Option or substitute an equivalent right, then no such acceleration shall apply. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Duration of Exercisability</font><font style="font-family:inherit;font-size:10pt;">. The installments provided for in the vesting schedule set forth in the Grant Notice are cumulative. Each such installment which becomes vested and exercisable pursuant to the vesting schedule set forth in the Grant Notice shall remain vested and exercisable until it becomes unexercisable under Section&#160;3.3 hereof. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expiration of Option</font><font style="font-family:inherit;font-size:10pt;">. The Option may not be exercised to any extent by anyone after the first to occur of the following events: </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) The Expiration Date set forth in the Grant Notice, which shall in no event be more than ten (10)&#160;years from the Grant Date; </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) If this Option is designated as an Incentive Stock Option and Participant owned (within the meaning of Section&#160;424(d) of the Code), at the time the Option was granted, more than 10% of the total combined voting power of all classes of stock of the Company or any &#8220;subsidiary corporation&#8221; of the Company or any &#8220;parent corporation&#8221; of the Company (each within the meaning of Section&#160;424 of the Code), the expiration of five (5)&#160;years from the Grant Date; </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) The expiration of three (3)&#160;months from the date of Participant&#8217;s Termination of Service, unless such termination occurs by reason of Participant&#8217;s death or disability; or </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) The expiration of one (1)&#160;year from the date of Participant&#8217;s Termination of Service by reason of Participant&#8217;s death or disability. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Special Tax Consequences</font><font style="font-family:inherit;font-size:10pt;">. Participant acknowledges that, to the extent that the aggregate Fair Market Value (determined as of the time the Option is granted) of all shares of Stock with respect to which Incentive Stock Options, including the Option (if applicable), are exercisable for the first time by Participant in any calendar year exceeds $100,000, the Option and such other options shall be Nonstatutory Stock Options to the extent necessary to comply with the limitations imposed by Section&#160;422(d) of the Code. Participant further acknowledges that the rule set forth in the preceding sentence shall be applied by taking the Option and other &#8220;incentive stock options&#8221; into account in the order in which they were granted, as determined under Section&#160;422(d) of the Code and the Treasury Regulations thereunder. Participant also acknowledges that an Incentive Stock Option exercised more than three (3)&#160;months after Participant&#8217;s Termination of Employment, other than by reason of death or disability, will be taxed as a Nonstatutory Stock Option. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.5 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tax Indemnity</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) The Participant agrees to indemnify and keep indemnified the Company, any Subsidiary and his/her employing company, if different, from and against any liability for or obligation to pay any Tax Liability (a &#8220;Tax Liability&#8221; being any liability for income tax, withholding tax and any other employment related taxes or social security contributions in any jurisdiction) that is attributable to (1)&#160;the grant or exercise of, or any benefit derived by the Participant </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">from, the Option, (2)&#160;the acquisition by the Participant of the Stock on exercise of the Option, or (3)&#160;the disposal of any Stock. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) The Option cannot be exercised until the Participant has made such arrangements as the Company may require for the satisfaction of any Tax Liability that may arise in connection with the exercise of the Option and/or the acquisition of the Stock by the Participant. The Company shall not be required to issue, allot or transfer Stock until the Employee has satisfied this obligation. </font></div><div style="line-height:120%;padding-top:20px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARTICLE 4. </font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXERCISE OF OPTION</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Person Eligible to Exercise</font><font style="font-family:inherit;font-size:10pt;">. During the lifetime of Participant, only Participant may exercise the Option or any portion thereof. After the death of Participant, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section&#160;3.3 hereof, be exercised by Participant&#8217;s personal representative or by any person empowered to do so under the deceased Participant&#8217;s will or under the then applicable laws of descent and distribution. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Partial Exercise</font><font style="font-family:inherit;font-size:10pt;">. Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised in whole or in part at any time prior to the time when the Option or portion thereof becomes unexercisable under Section&#160;3.3 hereof. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Manner of Exercise</font><font style="font-family:inherit;font-size:10pt;">. The Option, or any exercisable portion thereof, may be exercised solely by delivery to the Secretary of the Company (or any third party administrator or other person or entity designated by the Company), during regular business hours, of all of the following prior to the time when the Option or such portion thereof becomes unexercisable under Section&#160;3.3 hereof: </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) An exercise notice in a form specified by the Administrator, stating that the Option or portion thereof is thereby exercised, such notice complying with all applicable rules established by the Administrator; </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) The receipt by the Company of full payment for the shares of Stock with respect to which the Option or portion thereof is exercised, including payment of any applicable withholding tax, which shall be made by deduction from other compensation payable to Participant or in such other form of consideration permitted under Section&#160;4.4 hereof that is acceptable to the Company; </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Any other written representations as may be required in the Administrator&#8217;s reasonable discretion to evidence compliance with the Securities Act or any other applicable law, rule or regulation; and </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) In the event the Option or portion thereof shall be exercised pursuant to Section&#160;4.1 hereof by any person or persons other than Participant, appropriate proof of the right of such person or persons to exercise the Option. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding any of the foregoing, the Company shall have the right to specify all conditions of the manner of exercise, which conditions may vary by country and which may be subject to change from time to time. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Method of Payment</font><font style="font-family:inherit;font-size:10pt;">. Payment of the exercise price shall be by any of the following, or a combination thereof, at the election of Participant: </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Cash or check; </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) With the consent of the Administrator, surrender of shares of Stock (including, without limitation, shares of Stock otherwise issuable upon exercise of the Option) held for such period of time as may be required by the Administrator in order to avoid adverse accounting consequences and having a Fair Market Value on the date of delivery equal to the aggregate exercise price of the Option or exercised portion thereof; or </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Other property acceptable to the Administrator (including, without limitation, through the delivery of a notice that Participant has placed a market sell order with a broker with respect to shares of Stock then issuable upon exercise of the Option, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the Option exercise price; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:10pt;">&#32;that payment of such proceeds is then made to </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Company at such time as may be required by the Company, but in any event not later than the settlement of such sale). </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Conditions to Issuance of Stock</font><font style="font-family:inherit;font-size:10pt;">. The shares of Stock deliverable upon the exercise of the Option, or any portion thereof, may be either previously authorized but unissued shares of Stock or issued shares of Stock which have then been reacquired by the Company. Such shares of Stock shall be fully paid and nonassessable. The Company shall not be required to issue or deliver any shares of Stock purchased upon the exercise of the Option or portion thereof prior to fulfillment of all of the following conditions: </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) The admission of such shares of Stock to listing on all stock exchanges on which such Stock is then listed; </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) The completion of any registration or other qualification of such shares of Stock under any state or federal law or under rulings or regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable; </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) The obtaining of any approval or other clearance from any state or federal governmental agency which the Administrator shall, in its absolute discretion, determine to be necessary or advisable; </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) The receipt by the Company of full payment for such shares of Stock, including payment of any applicable withholding tax, which may be in one or more of the forms of consideration permitted under Section&#160;4.4 hereof; and </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e) The lapse of such reasonable period of time following the exercise of the Option as the Administrator may from time to time establish for reasons of administrative convenience. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Rights as Stockholder</font><font style="font-family:inherit;font-size:10pt;">. The holder of the Option shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of any shares of Stock purchasable upon the exercise of any part of the Option unless and until such shares of Stock shall have been issued by the Company and held of record by such holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). No adjustment will be made for a dividend or other right for which the record date is prior to the date the shares of Stock are issued, except as provided in Section&#160;14.2 of the Plan. </font></div><div style="line-height:120%;padding-top:20px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARTICLE 5. </font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER PROVISIONS </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.1 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Administration</font><font style="font-family:inherit;font-size:10pt;">. The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules. All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon Participant, the Company and all other interested persons. No member of the Committee or the Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the Option. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Whole Shares</font><font style="font-family:inherit;font-size:10pt;">. The Option may only be exercised for whole shares of Stock. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Option Not Transferable</font><font style="font-family:inherit;font-size:10pt;">. Subject to Section&#160;4.1 hereof, the Option may not be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution, unless and until the shares of Stock underlying the Option have been issued, and all restrictions applicable to such shares of Stock have lapsed. Neither the Option nor any interest or right therein shall be liable for the debts, contracts or engagements of Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Binding Agreement</font><font style="font-family:inherit;font-size:10pt;">. Subject to the limitation on the transferability of the Option contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Adjustments Upon Specified Events</font><font style="font-family:inherit;font-size:10pt;">. The Administrator may accelerate the vesting of the Option in such circumstances as it, in its sole discretion, may determine. In addition, upon the occurrence of certain events relating to the Stock contemplated by Section&#160;14.2 of the Plan (including, without limitation, an extraordinary cash dividend on such Stock), the Administrator shall make such adjustments the Administrator deems appropriate in the number of shares of Stock subject to the Option, the exercise price of the Option and the kind of securities that may be issued upon exercise of the Option. Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and Section&#160;14.2 of the Plan. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:10pt;">. Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company at the Company&#8217;s principal office, and any notice to be given to Participant shall be addressed to Participant at Participant&#8217;s last address reflected on the Company&#8217;s records. By a notice given pursuant to this Section&#160;5.6, either party may hereafter designate a different address for notices to be given to that party. Any notice which is required to be given to Participant shall, if Participant is then deceased, be given to the person entitled to exercise his or her Option pursuant to Section&#160;4.1 hereof by written notice under this Section&#160;5.6. Any notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Titles</font><font style="font-family:inherit;font-size:10pt;">. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:10pt;">. The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.9 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Conformity to Securities Laws</font><font style="font-family:inherit;font-size:10pt;">. Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, and state securities laws and regulations. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Option is granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.10 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Amendments, Suspension and Termination</font><font style="font-family:inherit;font-size:10pt;">. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;provided</font><font style="font-family:inherit;font-size:10pt;">&#32;that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the Option in any material way without the prior written consent of Participant. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.11 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:10pt;">. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in Section&#160;5.3 hereof, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.12 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notification of Disposition</font><font style="font-family:inherit;font-size:10pt;">. If this Option is designated as an Incentive Stock Option, Participant shall give prompt notice to the Company of any disposition or other transfer of any shares of Stock acquired under this Agreement if such disposition or transfer is made (a)&#160;within two (2)&#160;years from the Grant Date with respect to such shares of Stock or (b)&#160;within one (1)&#160;year after the transfer of such shares of Stock to Participant. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.13 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Limitations Applicable to Section&#160;16 Persons</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Option and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.14 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Not a Contract of Employment</font><font style="font-family:inherit;font-size:10pt;">. Nothing in this Agreement or in the Plan shall confer upon the Participant any right to continue to serve as an employee or other service provider of the Company or any of its Subsidiaries. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.15 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:10pt;">. The Plan, the Grant Notice and this Agreement (including all Exhibits thereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.16 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section&#160;409A</font><font style="font-family:inherit;font-size:10pt;">. This Option is not intended to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section&#160;409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 409A</font><font style="font-family:inherit;font-size:10pt;">&#8221;). However, notwithstanding any other provision of the Plan, the Grant Notice or this Agreement, if at any time the Administrator determines that the Option (or any portion thereof) may be subject to Section&#160;409A, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Participant or any other person for failure to do so) to adopt such amendments to the Plan, the Grant Notice or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate either for the Option to be exempt from the application of Section&#160;409A or to comply with the requirements of Section&#160;409A. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.17 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Limitation on Participant&#8217;s Rights</font><font style="font-family:inherit;font-size:10pt;">. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Stock as a general unsecured creditor with respect to options, as and when exercised pursuant to the terms hereof.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:inherit;font-size:10pt;">, the Company has caused a duly authorized officer to execute this Agreement, and Participant has executed this Agreement, effective as of the Grant Date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THE COMPANY:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:48.07692307692308%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:24%;"></td><td style="width:76%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL,&#160;INC.:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Print Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Participant:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Print Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>10
<FILENAME>exhibit105form10.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCB5804E6E7DB394E128143F02A0D4172"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 10.5</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">EMP</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">L</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">OYMENT AGREEMEN</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">T</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">EM</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">P</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">L</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">O</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">Y</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">ME</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">N</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">T A</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">GR</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">EEM</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">EN</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">T </font><font style="font-family:Arial;font-size:10pt;color:#303030;">(</font><font style="font-family:Arial;font-size:10pt;color:#414141;">"</font><font style="font-family:Arial;font-size:10pt;color:#303030;">Agreemen</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">") made </font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">his 16th day o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">f J</font><font style="font-family:Arial;font-size:10pt;color:#303030;">une</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">2016 by and be</font><font style="font-family:Arial;font-size:10pt;color:#414141;">tw</font><font style="font-family:Arial;font-size:10pt;color:#303030;">een </font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">D</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">Y</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">ADIC IN</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">TER</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">N</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">AT</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">I</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">O</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">N</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">A</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">L</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">, I</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">N</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">C</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">., </font><font style="font-family:Arial;font-size:10pt;color:#303030;">a De</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">awa</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e co</font><font style="font-family:Arial;font-size:10pt;color:#414141;">rp</font><font style="font-family:Arial;font-size:10pt;color:#303030;">oration (</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he </font><font style="font-family:Arial;font-size:10pt;color:#414141;">"</font><font style="font-family:Arial;font-size:10pt;color:#303030;">Company</font><font style="font-family:Arial;font-size:10pt;color:#414141;">"</font><font style="font-family:Arial;font-size:10pt;color:#303030;">)</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">and </font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">MA</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">R</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">K A. EMAL</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">F</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">A</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">RB</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">a </font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">esident of </font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he State of Florida (the "Executi</font><font style="font-family:Arial;font-size:10pt;color:#414141;">v</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#414141;">")</font><font style="font-family:Arial;font-size:10pt;color:#303030;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">Recital</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">The Board of Di</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ectors of the Company (the "Board</font><font style="font-family:Arial;font-size:10pt;color:#414141;">"</font><font style="font-family:Arial;font-size:10pt;color:#303030;">) has determined that it is in the best interests of the Company and its stockho</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ders to continue to employ the E</font><font style="font-family:Arial;font-size:10pt;color:#414141;">x</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ecut</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ve as Presiden</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t </font><font style="font-family:Arial;font-size:10pt;color:#303030;">an</font><font style="font-family:Arial;font-size:10pt;color:#414141;">d C</font><font style="font-family:Arial;font-size:10pt;color:#303030;">hief Ex</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ec</font><font style="font-family:Arial;font-size:10pt;color:#303030;">utive Offi</font><font style="font-family:Arial;font-size:10pt;color:#414141;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">and </font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he Executive des</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">res to conti</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ue </font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o serve </font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n tha</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t </font><font style="font-family:Arial;font-size:10pt;color:#303030;">capacity</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">on the te</font><font style="font-family:Arial;font-size:10pt;color:#414141;">rm</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">nd </font><font style="font-family:Arial;font-size:10pt;color:#303030;">co</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">d</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">tions set forth </font><font style="font-family:Arial;font-size:10pt;color:#414141;">h</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ere</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n</font><font style="font-family:Arial;font-size:10pt;color:#414141;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">N</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">OW, THEREFORE, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">it is hereby agreed as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#414141;">1</font><font style="font-family:Arial;font-size:10pt;color:#303030;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">Emp</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;text-decoration:underline;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">oyme</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;text-decoration:underline;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">t Period</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">The Company shall cont</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nue to employ the Executive, and </font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he E</font><font style="font-family:Arial;font-size:10pt;color:#414141;">x</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ecu</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ive shall cont</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n</font><font style="font-family:Arial;font-size:10pt;color:#414141;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e to serve the Company</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">on the </font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#414141;">rm</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s and cond</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ons se</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t f</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ort</font><font style="font-family:Arial;font-size:10pt;color:#414141;">h in thi</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s </font><font style="font-family:Arial;font-size:10pt;color:#414141;">Agr</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">me</font><font style="font-family:Arial;font-size:10pt;color:#414141;">nt</font><font style="font-family:Arial;font-size:10pt;color:#303030;">, for the pe</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ri</font><font style="font-family:Arial;font-size:10pt;color:#303030;">od beginning o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the date hereof (</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he "Commencemen</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Da</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#414141;">") </font><font style="font-family:Arial;font-size:10pt;color:#303030;">and endin</font><font style="font-family:Arial;font-size:10pt;color:#414141;">g </font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n th</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e third (3r</font><font style="font-family:Arial;font-size:10pt;color:#414141;">d</font><font style="font-family:Arial;font-size:10pt;color:#303030;">) anniversary of the Commencement Da</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e (the "Initial Term</font><font style="font-family:Arial;font-size:10pt;color:#414141;">") w</font><font style="font-family:Arial;font-size:10pt;color:#303030;">hich per</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">od shall </font><font style="font-family:Arial;font-size:10pt;color:#414141;">aut</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">matic</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ally renew continuously for additional periods of two (2) years (each</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">a "Renewal Term") unless one party gives written notice of termination to the othe</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">at least sixty (60) days prior to the end of the then current term except as otherwise specifically provided below (the In</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">tial Term and the Renewa</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Term(s), if any, shall hereinafter collec</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">i</font><font style="font-family:Arial;font-size:10pt;color:#414141;">v</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ely be re</font><font style="font-family:Arial;font-size:10pt;color:#414141;">f</font><font style="font-family:Arial;font-size:10pt;color:#303030;">er</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ed to as</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">t</font><font style="font-family:Arial;font-size:10pt;color:#414141;">h</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e </font><font style="font-family:Arial;font-size:10pt;color:#414141;">"</font><font style="font-family:Arial;font-size:10pt;color:#303030;">Em</font><font style="font-family:Arial;font-size:10pt;color:#414141;">p</font><font style="font-family:Arial;font-size:10pt;color:#303030;">loyment Period</font><font style="font-family:Arial;font-size:10pt;color:#414141;">").</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">Pos</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;text-decoration:underline;">it</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">ion a</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;text-decoration:underline;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">d</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;text-decoration:underline;">D</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">u</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;text-decoration:underline;">ti</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">es</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">During the Emp</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">oymen</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Per</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">od</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">th</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">E</font><font style="font-family:Arial;font-size:10pt;color:#414141;">x</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ecu</font><font style="font-family:Arial;font-size:10pt;color:#414141;">tiv</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e s</font><font style="font-family:Arial;font-size:10pt;color:#414141;">h</font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ll </font><font style="font-family:Arial;font-size:10pt;color:#303030;">con</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">i</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">u</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">to be employed as the President and Chief Executive Officer of the Company, and the Company shall cause the Executive </font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o be elected as a member of the Board</font><font style="font-family:Arial;font-size:10pt;color:#0d0d0d;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">During the Employment Period, the Executive shall have authority to make operating decisions, plan the strategic direction of the Company</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">and hire</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">promote</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">and terminate the emp</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">oyment of pe</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">son</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">el</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">subjec</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t </font><font style="font-family:Arial;font-size:10pt;color:#303030;">to the direc</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ion o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">f </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the Boa</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">d. During the Emp</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">oyment Period</font><font style="font-family:Arial;font-size:10pt;color:#5f5f5e;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the Executive sha</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ll </font><font style="font-family:Arial;font-size:10pt;color:#303030;">have such </font><font style="font-family:Arial;font-size:10pt;color:#414141;">re</font><font style="font-family:Arial;font-size:10pt;color:#303030;">asona</font><font style="font-family:Arial;font-size:10pt;color:#414141;">bl</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">d cu</font><font style="font-family:Arial;font-size:10pt;color:#414141;">st</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">m</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ary po</font><font style="font-family:Arial;font-size:10pt;color:#414141;">w</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s as are </font><font style="font-family:Arial;font-size:10pt;color:#414141;">g</font><font style="font-family:Arial;font-size:10pt;color:#303030;">enerally assoc</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ated wi</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">h t</font><font style="font-family:Arial;font-size:10pt;color:#414141;">h</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e positions of P</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">esident a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">d Chie</font><font style="font-family:Arial;font-size:10pt;color:#414141;">f </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Exec</font><font style="font-family:Arial;font-size:10pt;color:#414141;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">tive Offic</font><font style="font-family:Arial;font-size:10pt;color:#414141;">er. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">During the Employment Period, the Executive shall devote his principal attention and time to the business and affairs of the Company and use his reasonable efforts to carry out suc</font><font style="font-family:Arial;font-size:10pt;color:#414141;">h </font><font style="font-family:Arial;font-size:10pt;color:#303030;">responsibilities faithful</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y and efficiently. It shall not be considered a vio</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ation of the foregoing for </font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he Exec</font><font style="font-family:Arial;font-size:10pt;color:#414141;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">tive to serve on co</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">pora</font><font style="font-family:Arial;font-size:10pt;color:#414141;">te</font><font style="font-family:Arial;font-size:10pt;color:#303030;">, civ</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ic </font><font style="font-family:Arial;font-size:10pt;color:#303030;">or charitable b</font><font style="font-family:Arial;font-size:10pt;color:#414141;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ds of d</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ir</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ectors or committees </font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">hereof </font><font style="font-family:Arial;font-size:10pt;color:#414141;">(</font><font style="font-family:Arial;font-size:10pt;color:#303030;">excl</font><font style="font-family:Arial;font-size:10pt;color:#414141;">udi</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ng thos</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">whic</font><font style="font-family:Arial;font-size:10pt;color:#414141;">h w</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ld create a confl</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ct of </font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nteres</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">) and manage his perso</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l </font><font style="font-family:Arial;font-size:10pt;color:#303030;">investments, so </font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ong as s</font><font style="font-family:Arial;font-size:10pt;color:#414141;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ch ac</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ti</font><font style="font-family:Arial;font-size:10pt;color:#303030;">vit</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">es do not </font><font style="font-family:Arial;font-size:10pt;color:#414141;">m</font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ia</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ll</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y </font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">erfere wi</font><font style="font-family:Arial;font-size:10pt;color:#414141;">th </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the </font><font style="font-family:Arial;font-size:10pt;color:#414141;">p</font><font style="font-family:Arial;font-size:10pt;color:#303030;">erfo</font><font style="font-family:Arial;font-size:10pt;color:#414141;">rm</font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ce o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">f t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he E</font><font style="font-family:Arial;font-size:10pt;color:#414141;">x</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ecu</font><font style="font-family:Arial;font-size:10pt;color:#414141;">tiv</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#414141;">'</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s respo</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">sibi</font><font style="font-family:Arial;font-size:10pt;color:#414141;">li</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#414141;">s </font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">s an </font><font style="font-family:Arial;font-size:10pt;color:#303030;">emp</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">oyee of the Company in accordance with this Agreemen</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">3</font><font style="font-family:Arial;font-size:10pt;color:#0d0d0d;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;text-decoration:underline;">C</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">ompensat</font><font style="font-family:Arial;font-size:10pt;color:#414141;font-weight:bold;text-decoration:underline;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">on</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#414141;">(</font><font style="font-family:Arial;font-size:10pt;color:#303030;">a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#303030;text-decoration:underline;">Base Salary</font><font style="font-family:Arial;font-size:10pt;color:#303030;">. During the Employm</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nt Per</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">od</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he E</font><font style="font-family:Arial;font-size:10pt;color:#414141;">x</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ecu</font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">i</font><font style="font-family:Arial;font-size:10pt;color:#414141;">v</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e s</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ha</font><font style="font-family:Arial;font-size:10pt;color:#303030;">l</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ecei</font><font style="font-family:Arial;font-size:10pt;color:#414141;">v</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e an </font><font style="font-family:Arial;font-size:10pt;color:#414141;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">u</font><font style="font-family:Arial;font-size:10pt;color:#414141;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">l base salary (</font><font style="font-family:Arial;font-size:10pt;color:#414141;">th</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e </font><font style="font-family:Arial;font-size:10pt;color:#414141;">"</font><font style="font-family:Arial;font-size:10pt;color:#303030;">Annual Base Salary") of three h</font><font style="font-family:Arial;font-size:10pt;color:#414141;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ndred seventy five thousand dollars </font><font style="font-family:Arial;font-size:10pt;color:#414141;">($</font><font style="font-family:Arial;font-size:10pt;color:#303030;">3</font><font style="font-family:Arial;font-size:10pt;color:#414141;">7</font><font style="font-family:Arial;font-size:10pt;color:#303030;">5</font><font style="font-family:Arial;font-size:10pt;color:#414141;">,</font><font style="font-family:Arial;font-size:10pt;color:#303030;">000</font><font style="font-family:Arial;font-size:10pt;color:#414141;">), </font><font style="font-family:Arial;font-size:10pt;color:#303030;">payab</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e in ac</font><font style="font-family:Arial;font-size:10pt;color:#414141;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">orda</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ce </font><font style="font-family:Arial;font-size:10pt;color:#414141;">w</font><font style="font-family:Arial;font-size:10pt;color:#303030;">it</font><font style="font-family:Arial;font-size:10pt;color:#414141;">h </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the reg</font><font style="font-family:Arial;font-size:10pt;color:#414141;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">lar payro</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">l p</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">act</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ces o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">f </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the Co</font><font style="font-family:Arial;font-size:10pt;color:#414141;">mpany. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Dur</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ing </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the E</font><font style="font-family:Arial;font-size:10pt;color:#414141;">m</font><font style="font-family:Arial;font-size:10pt;color:#303030;">p</font><font style="font-family:Arial;font-size:10pt;color:#414141;">loyment </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Period, the Annual Base Salary may be reviewed by the Board for possible increases.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#303030;text-decoration:underline;">Annual Bonus</font><font style="font-family:Arial;font-size:10pt;color:#303030;">. In addition to the Annual Base Salary, the Company may a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">w</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ard the E</font><font style="font-family:Arial;font-size:10pt;color:#414141;">x</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ecut</font><font style="font-family:Arial;font-size:10pt;color:#414141;">iv</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e an a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nua</font><font style="font-family:Arial;font-size:10pt;color:#414141;">l </font><font style="font-family:Arial;font-size:10pt;color:#303030;">bo</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">us</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">with the timing a</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">d amount o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">f </font><font style="font-family:Arial;font-size:10pt;color:#303030;">any s</font><font style="font-family:Arial;font-size:10pt;color:#414141;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ch bo</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">us deter</font><font style="font-family:Arial;font-size:10pt;color:#414141;">m</font><font style="font-family:Arial;font-size:10pt;color:#303030;">i</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#414141;">d </font><font style="font-family:Arial;font-size:10pt;color:#303030;">in </font><font style="font-family:Arial;font-size:10pt;color:#414141;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he s</font><font style="font-family:Arial;font-size:10pt;color:#414141;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">l</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e di</font><font style="font-family:Arial;font-size:10pt;color:#303030;">scret</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n </font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#414141;">f th</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e Compensation Comm</font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ttee of the Boa</font><font style="font-family:Arial;font-size:10pt;color:#414141;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">d </font><font style="font-family:Arial;font-size:10pt;color:#414141;">(</font><font style="font-family:Arial;font-size:10pt;color:#303030;">the "Co</font><font style="font-family:Arial;font-size:10pt;color:#414141;">m</font><font style="font-family:Arial;font-size:10pt;color:#303030;">pe</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">satio</font><font style="font-family:Arial;font-size:10pt;color:#414141;">n </font><font style="font-family:Arial;font-size:10pt;color:#303030;">C</font><font style="font-family:Arial;font-size:10pt;color:#414141;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">m</font><font style="font-family:Arial;font-size:10pt;color:#414141;">m</font><font style="font-family:Arial;font-size:10pt;color:#303030;">i</font><font style="font-family:Arial;font-size:10pt;color:#414141;">tt</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ee</font><font style="font-family:Arial;font-size:10pt;color:#414141;">").</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#414141;">(</font><font style="font-family:Arial;font-size:10pt;color:#303030;">c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#303030;text-decoration:underline;">Performance Stock Options</font><font style="font-family:Arial;font-size:10pt;color:#0d0d0d;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">The Executive shall have the opportunity to be awarded three (3) annual incentive stock options</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">each such annual </font><font style="font-family:Arial;font-size:10pt;color:#414141;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ncentive stock option will be to purchase </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">u</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">p to t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">hree h</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">nd</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ed thousand (300,000) sha</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">es o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">f c</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ommon s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">toc</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">k </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">(</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">the </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">"M</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">x</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">imum Option Bo</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">u</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s") b</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ase</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">d </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">on performan</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">c</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e achievements in 2016</font><font style="font-family:Arial;font-size:10pt;color:#545457;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">20</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">1</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">7 and 20</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">1</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">8 as prov</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ded belo</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">w:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:54px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">(</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">For 20</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">1</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">6, the Board has approved an aggregate grant to the Execu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ive of options to purchase up to three hundred thousand (300,000) shares, and will gran</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">upon the mutual execution hereof a first option to the Executive to purchase one hund</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ed thousand (100</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">,</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">00</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">0</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">) sha</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">es of the above </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">eferenc</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">e</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">d </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">h</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ee hundred thousa</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">d </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">(</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">300</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">,</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">000) sha</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">x</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ercise price equal to the price of t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">C</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">omp</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">a</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ny</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">'</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">s pub</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ic</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">y-</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">raded s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">es on </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">Ju</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ne </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">3, 2</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">0</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">1</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">6</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">w</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ic</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">shall </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">est </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">mmed</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ate</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">y</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">. I</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">n </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">D</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ecem</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">b</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">er </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">2</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">016 the Co</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">m</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">pensa</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ion Comm</font><font style="font-family:Arial;font-size:10pt;color:#545457;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">tte</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e w</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ill </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">asses</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">the achievement of the 2016 performance objectives that have been established and agreed </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">pon between the Company and the Executive and then g</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ant a second option to purchase up to two hundred thousand (200,000) shares or a portion thereof, w</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ich opt</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">on shall be p</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">iced at an exer</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">c</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e price equal to the p</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ri</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ce o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">f t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">he C</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">o</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">mpany's public</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">y-</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">tr</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">d</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ed share</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">on </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">the fi</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">rst b</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">siness da</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">y </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">f </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">2017</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">and shall vest on January 2</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">, 2</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">017.</font></div><div style="line-height:120%;text-align:left;padding-left:54px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">(</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ii</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">On the first business day of each of 2018 and 2019, the Company shall gran</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">the Executive an option to purchase up to three hundred thousand (300</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">,</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">000) shares based on the Compensation Comm</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ttee's evaluation of the Executive</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">'</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">s prior year performance o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">bj</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ectives es</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">abl</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">she</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">d </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">and agreed upon by </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">he Com</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">p</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">any and </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">he E</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">x</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ecut</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ive</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">. In </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">e</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ch case</font><font style="font-family:Arial;font-size:10pt;color:#545457;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">p</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">on s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">l be </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">pri</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ced at an exercise price equal to the pri</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">c</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e of th</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">e </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">Com</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">p</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ny</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">'</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s publ</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ic</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ly</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">tr</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">aded s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ha</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">res on the first </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">bu</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">n</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">e</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">day of each of 2</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">01</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">8 and 2019</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">respec</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ti</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">vel</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">y, and shall </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">vest on the gran</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">Pe</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">rf</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">rm</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ance </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ncentives for the t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">me period running from January 2019 through May 2019 will be ag</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">eed </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">by t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">he Boar</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">d </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">and the Execu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">. S</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ho</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ul</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">d the Employmen</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">Per</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">io</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">d </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">erm</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">na</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">te </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">th</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">e en</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">d </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">of </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">the </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">Initi</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">al Te</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">m </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">f</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">or an</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">y </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">her </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">eason </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">han Ca</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">se (a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s de</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">fined </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">in </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">Sec</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">. 5(</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">b</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">)), p</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">erfo</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">manc</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">e </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">tock </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">pti</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">cen</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ives fo</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">he </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ime period </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">J</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">anuary 2019 throug</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">Ma</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">y </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">20</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">1</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">9 </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">w</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ill be b</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">a</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">se</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">d s</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">olely on t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e Compe</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">sat</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">on Committee's evaluation of the Executive's performance during this period and will be awa</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ded</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">pr</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ced and will vest on the first business day of 20</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">1</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">9</font><font style="font-family:Arial;font-size:10pt;color:#0b0b0b;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;text-decoration:underline;">St</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;text-decoration:underline;">oc</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;text-decoration:underline;">k Ex</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;text-decoration:underline;">chan</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;text-decoration:underline;">g</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;text-decoration:underline;">e S</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;text-decoration:underline;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;text-decoration:underline;">ock Option</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">. U</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">po</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">the e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">x</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ecution o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">f </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">th</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">s </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">Ag</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">reemen</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t, th</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e E</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">x</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">cu</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ive </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">all be </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">g</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ra</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ted a five </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">(</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">5</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">) </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">year </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">toc</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">k </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">option to purchase fo</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ur </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">h</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">un</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">dred t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">hou</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">san</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">d (4</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">0</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">0,00</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">0</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">) </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">shares </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">of </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e Compan</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">y's </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">common s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">c</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">k at a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">exe</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">c</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">se price equa</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">to t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e J</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ne 3</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">20</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">1</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">6 publ</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">cl</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">y</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">-tra</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">d</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">d price</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">, which option grant shall vest and become exercisable if the Company's shares of common stock commence trad</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ng on the Nasdaq Capital Market or other stock e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">x</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">change appro</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ed by the Board. </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">I</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">n the event that </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">here is a Change of Control or sa</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e of the Company (as defined in Sec. 5(d) below</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">), </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">or in </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">he even</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">of passage o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">f </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a forma</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">B</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">o</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">rd r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">esol</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n d</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ete</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">rm</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">in</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">in</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">g no</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">pu</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">rs</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ch </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">an u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">p-listi</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ng, t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">his option sha</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">l automaticall</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">y v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">es</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">and </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">b</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">x</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">erc</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">sab</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">suc</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">me</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">(</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;text-decoration:underline;">Licensing/Collaboration Transaction Stock Options</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">. </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">Upon the execution of this </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">A</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">greement, </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">he Company sha</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">l cause the Compensation Committee to authorize for the Executive stock options that are each exercisable for not </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ess than five (5) years from their effective dates to </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">p</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">u</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ch</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">a</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">se up to six hundred </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">housan</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">d </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">(600</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">,00</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">0) shares of the C</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">o</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">m</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">pa</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">n</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">y</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">'s common st</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ock w</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">h</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ic</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">h </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">h</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">all b</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">w</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">arded </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">he E</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">x</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ecu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e and exe</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">rci</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">sable as </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">f</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ollows.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">F</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">purposes of th</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">s Agreement a Bona Fide transaction is defined as a </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">icense, joint venture or </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">o</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ther collaboration for development of a specific biologic with the i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">tent to commercialize and/or a </font><font style="font-family:Arial;font-size:10pt;color:#545457;">l</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">cense ag</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">eemen</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">that generates a cumulative five million dollars ($5,000</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">,</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">000) in non-</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">efundable cash, o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">r w</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">he</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">n </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">eit</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">er t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">accine </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">o</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">r biologic pha</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">rm</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ace</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">cal busines</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">s </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">ca</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">egory </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">s s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ol</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">d.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">(</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">a </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">fi</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">rs</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">opt</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">on f</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">o</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">r two hundred </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">th</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">sand (</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">2</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">00</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">,</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">000</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">) </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">shares a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t a</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">n </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">exe</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">r</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ci</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">se </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">pr</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">ce </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">equal </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">o t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">e </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">J</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">une 3</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">2016 publicly</font><font style="font-family:Arial;font-size:10pt;color:#0b0b0b;">-</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">traded price of the common stock (</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3d;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2f;">he "First Option") will be </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">awarded and vest when the Company shall have entered into a Bona Fide licensing agreement or other form of collaboration with Sanofi or another biotech/pharmaceutical company approved by the Board providing for the Company's grant of a license or other form of collaboration to such party to the Company's C1 technology for use in developing or manufacturing vaccines, antibodies or other biologics (the "First License/Collaboration");</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(ii)&#160;&#160;&#160;&#160;a second option for two hundred thousand (200,000) shares at an exercise price equal to the June 3, 2016 publicly-traded price of the common stock (the "Second Option") will be awarded and vest when the Company shall have entered into a second such Bona Fide licensing agreement or other form of collaboration with Sanofi or another biotech/pharmaceutical company approved by the Board providing for the Company's grant of a license or other form of collaboration to such party to the Company's C1 technology for use in developing or manufacturing vaccines, anti-bodies or other biologics (the "Second License/Collaboration");</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(iii)&#160;&#160;&#160;&#160;on the date when the Company shall have entered into a second such Bona Fide licensing agreement or other form of collaboration with another biotech/pharmaceutical company as approved by the Board providing for the Company's grant of a license or other form of collaboration to such party to the Company's C1 technology for use in developing or manufacturing vaccines, antibodies or other biologics (the "Third License/Collaboration), a third option will be awarded to the Executive, exercisable for five (5) years, to purchase an additional two hundred thousand (200,000) shares of the Company's common stock at an exercise price equal to the price of the Company's publicly-traded shares on the date the Second License/Collaboration Agreement is executed by both parties. This option award will vest when the Company shall have entered into a Third License/Collaboration agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(iv)&#160;&#160;&#160;&#160;All awarded options will vest upon Change of Control as defined in Sec. 5(d) below.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Other Benefits</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. During the Employment Period</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">the Executive shall be entitled to participate in all benefit plans, practices, policies and programs provided by the Company (including without limitation, vacation, medical, prescription</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">dental, disability, retirement, salary continuance</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">employee life insurance, group life insurance, and accidental death and travel accident insurance plans and programs) that are commensurate with the Executive's position as chief executive officer and that are not less favorable than benefits provided to other executives of the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Vacation</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. In respect of each twelve (12) month period falling within the Employment Period, the Executive shall be entitled to an aggregate of six (6) weeks of vacation, which sha</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">l</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">l be deemed vested and earned by the Executive in advance at the rate of three (3) weeks per each six (6) month period of the Employment Period, with no entitlement to acceleration of the aggregate in the event of a Change of Control or sale of the Company (as defined in Sec. 5(d) below). For each twelve (12) month period a total of three (3) weeks' vacation may be carried forward with no more than six (6) weeks carried forward at any point in time.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Expenses</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. During the Employment Period, the Executive shall receive reimbursement for all reasonable expenses incurred by the Executive in carrying out the Executive's duties under this Agreement, provided that the Executive complies with the generally applicable policies and procedures of the Company for submission of expense reports, receipts or similar documentation of such expenses. The Company shall pay directly, or reimburse the Executive for, automobile expenses in amounts similar to the payments provided to him in 2015.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">4.</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;text-decoration:underline;">Covenants of Execu</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;font-weight:bold;text-decoration:underline;">ti</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;text-decoration:underline;">ve</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">Proprietary Rights</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">(</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">i)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">Ownership of Intel</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">l</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">ectual Property</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">. The Executive hereby exp</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">essly agrees that a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">l </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">esearch</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">biological mater</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">als, discoveries, inventions and innovations (whether or not </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">educed to practice or documented)</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">improvements, developme</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ts</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">methods, designs</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">analyses, drawings</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">reports and a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ll </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">imi</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">l</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">a</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">r or </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ated i</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">f</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">orm</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">io</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n (</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">w</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">et</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">er p</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">at</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">en</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">b</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">le or no</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">, a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">d whe</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">he</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">or no</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">red</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">uce</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">d </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">to writing), </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">t</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ade </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">se</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">crets </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">(b</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">eing </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">in</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">f</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">o</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">rmatio</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ab</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">o</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ut the b</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">u</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">in</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">es</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">s o</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">f </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">he Company wh</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">c</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s co</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">si</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ed by </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">Com</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">pa</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ny t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o be confiden</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ti</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">al and is </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">pr</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">oprietary to </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e Co</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">mp</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ny) </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">and confidentia</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l inform</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ti</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">on</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">copy</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ri</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">g</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ht</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">bl</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e works, and similar and related information (in whatever form or medium)</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">which (x) either (A) relate to the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Company's actual or anticipated business, research and developmen</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">x</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">isting or fu</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ure pr</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">o</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">duc</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s or services or (B) result from any work performed by the Executive for the Company and </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">(</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">y) a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e co</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">cei</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">v</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d, d</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">v</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">p</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ed</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">made </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">or </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">con</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">trib</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">uted to </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">n whole or </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">n part </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">b</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">y </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e E</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">x</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ecu</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ive </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ur</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ng </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e E</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">mpl</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ym</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">nt </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Per</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">od </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">('W</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">rk </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Product") shall be and remain the so</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e and excl</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">u</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ve </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">pr</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ope</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">rty </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">f </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">t</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e Co</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">mp</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ny</font><font style="font-family:Arial;font-size:10pt;color:#0a0a0a;">. </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">The </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Exe</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">c</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">uti</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">v</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">s</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">hall co</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">mm</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">unicate prom</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">p</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">tl</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">y </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">and fully all Work </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">P</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ro</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">uct to </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e Compa</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ny</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(i</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">Work Made for Hire</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">. The Executive ac</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">k</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">nowledges tha</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">, unless othe</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">rw</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ise agreed </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">n </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">w</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">riting by the Company, al</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Work Product eligible for any form of copyright protection made or contributed to in whole or in part by the Executive w</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">thin the scope of the Executive</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">'</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s employment </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">b</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">y </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e Co</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">pany </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">durin</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">g </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e E</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ployme</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">t Period s</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">all be deemed a "</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">w</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ork </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ad</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">e f</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r hir</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">" und</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">th</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">e </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">c</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">opy</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ri</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">g</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ht la</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ws </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">d sh</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">a</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ll be o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">w</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ned exclusivel</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">y </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">by the C</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">o</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">mpan</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">y.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">(</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">Assignment of Proprietary Rights</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">. The E</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">x</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ecutive hereby assigns, t</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ansfe</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">rs </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">and conv</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">e</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ys to the Company, and s</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">all assign</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">transfe</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">and convey to the Company, all right, ti</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">le an</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">interes</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">n and to all inventions, ideas</font><font style="font-family:Arial;font-size:10pt;color:#505050;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">improvements, des</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">gns</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">p</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ocesses</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">tradema</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">rk</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">service marks, t</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ad</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">e </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">na</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">es</font><font style="font-family:Arial;font-size:10pt;color:#505050;">, </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ra</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">de </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">e</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">crets</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">r</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ad</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">r</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">e</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ss</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">da</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ta, dis</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">coveries a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">nd </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">he</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r pr</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">pr</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ie</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ry </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">asse</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">d </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">p</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">r</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">opriet</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ry r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">igh</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ts </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">in </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">a</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">nd o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">f the </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Wo</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">rk </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Produc</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e "Prop</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ri</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">etary Rig</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ts</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">"</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">) </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">f</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">C</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">mp</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ny'</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">x</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">clus</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">iv</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ownership </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">d use, to</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">g</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">et</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">er </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">with </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">all </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">rig</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">hts </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o s</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">u</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">d </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">re</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">cove</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r f</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">or </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">p</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">as</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t a</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">nd fu</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">tur</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">infring</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">eme</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">t or </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">isa</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">pp</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">r</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">opri</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ti</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">hereof</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">which sha</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ll </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">enjoy exclusive ownership and use, together with all rig</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ts to s</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">u</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e and reco</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">v</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">for past and future infringement or misappropriation thereof</font><font style="font-family:Arial;font-size:10pt;color:#0a0a0a;">.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">(</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">i</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">v</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">Fu</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">rth</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">er</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">I</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">nstru</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">en</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">s</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">. At the r</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">e</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">q</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">u</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">es</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">f </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">the C</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">om</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">pa</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ny</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">, at a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ll t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">imes </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">du</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">rin</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">g the </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">E</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ploy</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ent Pe</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">io</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">an</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">the</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">eaft</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">e</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">r</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">th</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">e </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Executive </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">wi</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">l</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l pr</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ptl</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">y </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">nd fully a</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ss</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">st </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e C</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">om</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">p</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">an</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">y i</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n eff</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">cting </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">t</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">p</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">u</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">rp</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ose of </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">he forego</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">n</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">g </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">assignme</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">t</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">i</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ncl</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ud</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">in</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">g </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">but n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t limit</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ed </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">fu</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">rt</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ct</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">f </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">x</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ec</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">uting </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ny </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">and all documents necessary to secure for the Co</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">pany such Proprietary Rights and other rig</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ts to all </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">W</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ork Product and al</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">confidential information related thereto</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">providing cooperation and giving testi</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">m</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ony</font><font style="font-family:Arial;font-size:10pt;color:#505050;">.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">v)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">I</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">na</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">pp</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">licab</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">ili</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">ty o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">f</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">Sec. 4(a) in Certa</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">n C</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">rcumstances</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">. </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">The Com</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">pa</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">n</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">y </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">xpressly </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ac</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">kn</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">owle</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ges and ag</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ees that, and the E</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">x</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ecu</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ive is hereby </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">a</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">d</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">vi</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">se</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">this S</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">e</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">c. 4</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">(</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a) d</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">o</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">es </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">not apply t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o any i</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ve</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">tion </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">f</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">or </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">w</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">hic</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o eq</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ui</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">pmen</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">supp</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ies</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, f</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ac</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">li</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ies or </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">tr</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">se</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">cre</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t info</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">rmatio</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">of </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">Co</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">mpany was used and which </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">w</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">as developed entirely on the Executive's own time, unless (A) the </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">in</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">vention </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">es to the business of the Company or to the Company's actual or demonst</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ably anticipated research o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">development or (B) the invention results from any work perfo</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">med b</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">y t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">he E</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">x</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ecutive </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">f</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r th</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e Compan</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">y.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">(</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">O</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">wn</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">e</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">rsh</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">ip and Cove</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">an</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">t t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">o Retu</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;text-decoration:underline;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">n Documents</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">. </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">T</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">h</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e E</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">x</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ecu</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">tiv</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e ag</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ees </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">h</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">at </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">ll W</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">rk </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">P</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">oduct and a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">l docume</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ts or other tangible materials (whether orig</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">nals</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">copies o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">abstracts)</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#505050;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">nclud</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ng w</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">it</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">hout limitation</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">price lists, quotation guides, ou</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">standing quotations</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">books</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">records, ma</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">uals, files</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">sales </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">l</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">iteratu</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">e, tra</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ning materials</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">customer records, correspondence, compute</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">disks or </font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">p</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">rint-out documen</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s, contracts</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">r</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">ders</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">messages, phone an</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">d </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">address l</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">i</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">sts</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">invoices a</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">n</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">d receipts, and all o</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">b</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">jec</font><font style="font-family:Arial;font-size:10pt;color:#3a3a3a;">t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">s </font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ss</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#212121;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">iated therewith</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">which in </font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny way relat</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o the bus</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ne</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s or affairs of the </font><font style="font-family:Arial;font-size:10pt;color:#212121;">C</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ompany, e</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ther fu</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">shed to </font><font style="font-family:Arial;font-size:10pt;color:#444445;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he Executive by the Compa</font><font style="font-family:Arial;font-size:10pt;color:#444445;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y o</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">prepared, compiled or otherwise acqu</font><font style="font-family:Arial;font-size:10pt;color:#444445;">ir</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ed by </font><font style="font-family:Arial;font-size:10pt;color:#444445;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he E</font><font style="font-family:Arial;font-size:10pt;color:#444445;">x</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#444445;">cut</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#444445;">v</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e du</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">in</font><font style="font-family:Arial;font-size:10pt;color:#444445;">g </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the Emp</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">oyment Pe</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">iod</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">shall be the so</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e and exclus</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ve property of the Compa</font><font style="font-family:Arial;font-size:10pt;color:#444445;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y. </font><font style="font-family:Arial;font-size:10pt;color:#444445;">T</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he Executi</font><font style="font-family:Arial;font-size:10pt;color:#444445;">v</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e sha</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">l no</font><font style="font-family:Arial;font-size:10pt;color:#444445;">t </font><font style="font-family:Arial;font-size:10pt;color:#303030;">use</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">copy o</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">duplicate any of the afo</font><font style="font-family:Arial;font-size:10pt;color:#212121;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ementioned documents or ob</font><font style="font-family:Arial;font-size:10pt;color:#444445;">j</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ects</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">nor </font><font style="font-family:Arial;font-size:10pt;color:#444445;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">emove them from </font><font style="font-family:Arial;font-size:10pt;color:#444445;">th</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e f</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ac</font><font style="font-family:Arial;font-size:10pt;color:#303030;">il</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ie</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s of the </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Co</font><font style="font-family:Arial;font-size:10pt;color:#303030;">m</font><font style="font-family:Arial;font-size:10pt;color:#212121;">pa</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny, n</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r u</font><font style="font-family:Arial;font-size:10pt;color:#212121;">se </font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#212121;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y </font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nforma</font><font style="font-family:Arial;font-size:10pt;color:#212121;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ion con</font><font style="font-family:Arial;font-size:10pt;color:#212121;">cern</font><font style="font-family:Arial;font-size:10pt;color:#303030;">in</font><font style="font-family:Arial;font-size:10pt;color:#212121;">g </font><font style="font-family:Arial;font-size:10pt;color:#303030;">th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">m exce</font><font style="font-family:Arial;font-size:10pt;color:#212121;">p</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t for the benefit </font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">f the Company, eith</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r during th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e E</font><font style="font-family:Arial;font-size:10pt;color:#303030;">mpl</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">yment </font><font style="font-family:Arial;font-size:10pt;color:#212121;">P</font><font style="font-family:Arial;font-size:10pt;color:#303030;">eriod </font><font style="font-family:Arial;font-size:10pt;color:#212121;">or </font><font style="font-family:Arial;font-size:10pt;color:#303030;">thereafter. Th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e E</font><font style="font-family:Arial;font-size:10pt;color:#303030;">x</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">cutive ag</font><font style="font-family:Arial;font-size:10pt;color:#212121;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ees that he will deliver all of the a</font><font style="font-family:Arial;font-size:10pt;color:#212121;">fo</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rementioned docum</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nts and </font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">bj</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">cts th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t may b</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">in his po</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ss</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ss</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ion to th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Company </font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">term</font><font style="font-family:Arial;font-size:10pt;color:#444445;">in</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ation of his employment with the Company, or at any other time upon the Company</font><font style="font-family:Arial;font-size:10pt;color:#444445;">'</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s req</font><font style="font-family:Arial;font-size:10pt;color:#444445;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">est, </font><font style="font-family:Arial;font-size:10pt;color:#444445;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">og</font><font style="font-family:Arial;font-size:10pt;color:#6c6c6c;">&#8226; </font><font style="font-family:Arial;font-size:10pt;color:#303030;">ether with h</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s written certification of comp</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">iance with the provisions o</font><font style="font-family:Arial;font-size:10pt;color:#444445;">f </font><font style="font-family:Arial;font-size:10pt;color:#303030;">this Sec</font><font style="font-family:Arial;font-size:10pt;color:#444445;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">4(b).</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#303030;text-decoration:underline;">No</font><font style="font-family:Arial;font-size:10pt;color:#212121;text-decoration:underline;">n-Di</font><font style="font-family:Arial;font-size:10pt;color:#303030;text-decoration:underline;">scl</font><font style="font-family:Arial;font-size:10pt;color:#212121;text-decoration:underline;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;text-decoration:underline;">s</font><font style="font-family:Arial;font-size:10pt;color:#212121;text-decoration:underline;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;text-decoration:underline;">re Covenant</font><font style="font-family:Arial;font-size:10pt;color:#212121;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">T</font><font style="font-family:Arial;font-size:10pt;color:#212121;">he </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Executive sh</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">l</font><font style="font-family:Arial;font-size:10pt;color:#212121;">l </font><font style="font-family:Arial;font-size:10pt;color:#303030;">not, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t any </font><font style="font-family:Arial;font-size:10pt;color:#212121;">ti</font><font style="font-family:Arial;font-size:10pt;color:#303030;">me, eith</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r dir</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">c</font><font style="font-family:Arial;font-size:10pt;color:#212121;">tl</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y or ind</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rect</font><font style="font-family:Arial;font-size:10pt;color:#212121;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">d</font><font style="font-family:Arial;font-size:10pt;color:#303030;">isclose t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o </font><font style="font-family:Arial;font-size:10pt;color:#303030;">any "un</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">uthorized person" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r u</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e </font><font style="font-family:Arial;font-size:10pt;color:#212121;">f</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#212121;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the be</font><font style="font-family:Arial;font-size:10pt;color:#212121;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#212121;">fi</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t of th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Exe</font><font style="font-family:Arial;font-size:10pt;color:#212121;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ut</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ve </font><font style="font-family:Arial;font-size:10pt;color:#212121;">or </font><font style="font-family:Arial;font-size:10pt;color:#303030;">any per</font><font style="font-family:Arial;font-size:10pt;color:#212121;">so</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n oth</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r than th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Company an</font><font style="font-family:Arial;font-size:10pt;color:#212121;">y </font><font style="font-family:Arial;font-size:10pt;color:#303030;">W</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rk P</font><font style="font-family:Arial;font-size:10pt;color:#212121;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">oduct </font><font style="font-family:Arial;font-size:10pt;color:#212121;">or </font><font style="font-family:Arial;font-size:10pt;color:#303030;">any kn</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">wl</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">dg</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">or confi</font><font style="font-family:Arial;font-size:10pt;color:#212121;">de</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ntial information which th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e E</font><font style="font-family:Arial;font-size:10pt;color:#303030;">xecutive may acquire whi</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e employed by the Company (whether be</font><font style="font-family:Arial;font-size:10pt;color:#444445;">f</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ore or after </font><font style="font-family:Arial;font-size:10pt;color:#444445;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he date of </font><font style="font-family:Arial;font-size:10pt;color:#444445;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">his Agreemen</font><font style="font-family:Arial;font-size:10pt;color:#444445;">t) r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ating to (i) </font><font style="font-family:Arial;font-size:10pt;color:#444445;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">he financial, marketing</font><font style="font-family:Arial;font-size:10pt;color:#212121;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">sa</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">es and business plans and affa</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rs</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">financial </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">statemen</font><font style="font-family:Arial;font-size:10pt;color:#444445;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">analyse</font><font style="font-family:Arial;font-size:10pt;color:#444445;">s, f</font><font style="font-family:Arial;font-size:10pt;color:#303030;">orecasts and p</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ojections</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">books, account</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">, records</font><font style="font-family:Arial;font-size:10pt;color:#212121;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">opera</font><font style="font-family:Arial;font-size:10pt;color:#444445;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ing costs and expenses and other </font><font style="font-family:Arial;font-size:10pt;color:#444445;">fi</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nanc</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l </font><font style="font-family:Arial;font-size:10pt;color:#303030;">inf</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rmation of th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e C</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ompany, (ii) int</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rna</font><font style="font-family:Arial;font-size:10pt;color:#212121;">l </font><font style="font-family:Arial;font-size:10pt;color:#303030;">m</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nag</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">m</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nt to</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ols </font><font style="font-family:Arial;font-size:10pt;color:#303030;">and syst</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">m</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ting poli</font><font style="font-family:Arial;font-size:10pt;color:#212121;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ie</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s </font><font style="font-family:Arial;font-size:10pt;color:#303030;">and </font><font style="font-family:Arial;font-size:10pt;color:#212121;">me</font><font style="font-family:Arial;font-size:10pt;color:#303030;">thods, pricing policies </font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nd m</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">thods and oth</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r m</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">thods of d</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ing bu</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">in</font><font style="font-family:Arial;font-size:10pt;color:#212121;">es</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s</font><font style="font-family:Arial;font-size:10pt;color:#212121;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">of the </font><font style="font-family:Arial;font-size:10pt;color:#212121;">C</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ompany, (iii) customers</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">sales</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">cus</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">mer requir</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">m</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nts and usages an</font><font style="font-family:Arial;font-size:10pt;color:#212121;">d </font><font style="font-family:Arial;font-size:10pt;color:#303030;">distr</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">butor lis</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ts</font><font style="font-family:Arial;font-size:10pt;color:#303030;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">f the Comp</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny, (iv) </font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">greements with customers, vendors, </font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ndepende</font><font style="font-family:Arial;font-size:10pt;color:#212121;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t contractors</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">employees a</font><font style="font-family:Arial;font-size:10pt;color:#444445;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">d others</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">of the Company</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">(v) e</font><font style="font-family:Arial;font-size:10pt;color:#444445;">x</font><font style="font-family:Arial;font-size:10pt;color:#303030;">isting an</font><font style="font-family:Arial;font-size:10pt;color:#444445;">d </font><font style="font-family:Arial;font-size:10pt;color:#303030;">future products or services an</font><font style="font-family:Arial;font-size:10pt;color:#444445;">d p</font><font style="font-family:Arial;font-size:10pt;color:#303030;">roduct development p</font><font style="font-family:Arial;font-size:10pt;color:#212121;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ans, </font><font style="font-family:Arial;font-size:10pt;color:#444445;">d</font><font style="font-family:Arial;font-size:10pt;color:#303030;">esigns</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">analyse</font><font style="font-family:Arial;font-size:10pt;color:#444445;">s </font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#444445;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">d reports</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, of th</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e </font><font style="font-family:Arial;font-size:10pt;color:#444445;">C</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#444445;">m</font><font style="font-family:Arial;font-size:10pt;color:#303030;">pany, (vi) computer software and databases deve</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">oped for the Company</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">trade sec</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ets</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">resear</font><font style="font-family:Arial;font-size:10pt;color:#444445;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">h</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ecords of </font><font style="font-family:Arial;font-size:10pt;color:#444445;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">esear</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ch</font><font style="font-family:Arial;font-size:10pt;color:#303030;">, mod</font><font style="font-family:Arial;font-size:10pt;color:#212121;">el</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s, d</font><font style="font-family:Arial;font-size:10pt;color:#212121;">es</font><font style="font-family:Arial;font-size:10pt;color:#303030;">igns</font><font style="font-family:Arial;font-size:10pt;color:#212121;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">d</font><font style="font-family:Arial;font-size:10pt;color:#212121;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">awi</font><font style="font-family:Arial;font-size:10pt;color:#212121;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">gs, tec</font><font style="font-family:Arial;font-size:10pt;color:#212121;">h</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nical d</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ta an</font><font style="font-family:Arial;font-size:10pt;color:#212121;">d </font><font style="font-family:Arial;font-size:10pt;color:#303030;">r</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">po</font><font style="font-family:Arial;font-size:10pt;color:#212121;">rts </font><font style="font-family:Arial;font-size:10pt;color:#303030;">of th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Comp</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny, and (vii) correspondence or othe</font><font style="font-family:Arial;font-size:10pt;color:#212121;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">privat</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">or confid</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ntial matters, in</font><font style="font-family:Arial;font-size:10pt;color:#212121;">f</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ormati</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n </font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r data whe</font><font style="font-family:Arial;font-size:10pt;color:#212121;">th</font><font style="font-family:Arial;font-size:10pt;color:#303030;">er wr</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">tten, or</font><font style="font-family:Arial;font-size:10pt;color:#212121;">al o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r </font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ectronic, which i</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s </font><font style="font-family:Arial;font-size:10pt;color:#303030;">proprietary t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the Company and not g</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ne</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ra</font><font style="font-family:Arial;font-size:10pt;color:#303030;">lly k</font><font style="font-family:Arial;font-size:10pt;color:#212121;">no</font><font style="font-family:Arial;font-size:10pt;color:#303030;">wn </font><font style="font-family:Arial;font-size:10pt;color:#212121;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o the publ</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">c (individually and collectively "Confidential </font><font style="font-family:Arial;font-size:10pt;color:#444445;">I</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nformation"), w</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">thou</font><font style="font-family:Arial;font-size:10pt;color:#444445;">t </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the Company</font><font style="font-family:Arial;font-size:10pt;color:#444445;">'</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s prior written permission</font><font style="font-family:Arial;font-size:10pt;color:#444445;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">For purposes of th</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s Sec. 4</font><font style="font-family:Arial;font-size:10pt;color:#444445;">(</font><font style="font-family:Arial;font-size:10pt;color:#303030;">c) the term </font><font style="font-family:Arial;font-size:10pt;color:#444445;">"</font><font style="font-family:Arial;font-size:10pt;color:#303030;">unauthorized person</font><font style="font-family:Arial;font-size:10pt;color:#444445;">" </font><font style="font-family:Arial;font-size:10pt;color:#303030;">shall mean any person </font><font style="font-family:Arial;font-size:10pt;color:#444445;">wh</font><font style="font-family:Arial;font-size:10pt;color:#303030;">o is not (</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">) an officer or di</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ector of the Company or an employee of the Company </font><font style="font-family:Arial;font-size:10pt;color:#444445;">f</font><font style="font-family:Arial;font-size:10pt;color:#303030;">or whom the disclosure of the know</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">edge or </font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nformatio</font><font style="font-family:Arial;font-size:10pt;color:#212121;">n </font><font style="font-family:Arial;font-size:10pt;color:#303030;">ref</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rr</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">d t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o </font><font style="font-family:Arial;font-size:10pt;color:#303030;">h</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ei</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n </font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s nece</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ss</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ary for his perform</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nce of h</font><font style="font-family:Arial;font-size:10pt;color:#212121;">is </font><font style="font-family:Arial;font-size:10pt;color:#303030;">assign</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ed </font><font style="font-family:Arial;font-size:10pt;color:#303030;">du</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ti</font><font style="font-family:Arial;font-size:10pt;color:#303030;">es, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">or </font><font style="font-family:Arial;font-size:10pt;color:#303030;">(ii) a </font><font style="font-family:Arial;font-size:10pt;color:#212121;">pe</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r</font><font style="font-family:Arial;font-size:10pt;color:#212121;">so</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n e</font><font style="font-family:Arial;font-size:10pt;color:#444445;">x</font><font style="font-family:Arial;font-size:10pt;color:#303030;">pre</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">sly authorized by the Comp</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o </font><font style="font-family:Arial;font-size:10pt;color:#303030;">r</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ceive di</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">cl</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">su</font><font style="font-family:Arial;font-size:10pt;color:#212121;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e o</font><font style="font-family:Arial;font-size:10pt;color:#212121;">f </font><font style="font-family:Arial;font-size:10pt;color:#303030;">su</font><font style="font-family:Arial;font-size:10pt;color:#212121;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">h know</font><font style="font-family:Arial;font-size:10pt;color:#212121;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">edge o</font><font style="font-family:Arial;font-size:10pt;color:#212121;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">inform</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">tion. The C</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">mpany express</font><font style="font-family:Arial;font-size:10pt;color:#212121;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y </font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">cknowle</font><font style="font-family:Arial;font-size:10pt;color:#212121;">d</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ge</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s </font><font style="font-family:Arial;font-size:10pt;color:#303030;">an</font><font style="font-family:Arial;font-size:10pt;color:#212121;">d </font><font style="font-family:Arial;font-size:10pt;color:#303030;">agree</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ha</font><font style="font-family:Arial;font-size:10pt;color:#212121;">t the </font><font style="font-family:Arial;font-size:10pt;color:#303030;">t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rm "C</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nfid</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ntial </font><font style="font-family:Arial;font-size:10pt;color:#444445;">I</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nformation" excludes </font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nformation wh</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ch </font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s (i) in the public domain or otherwise general</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y known to the trade, or (</font><font style="font-family:Arial;font-size:10pt;color:#444445;">ii</font><font style="font-family:Arial;font-size:10pt;color:#303030;">) </font><font style="font-family:Arial;font-size:10pt;color:#444445;">d</font><font style="font-family:Arial;font-size:10pt;color:#303030;">isclosed to third pa</font><font style="font-family:Arial;font-size:10pt;color:#444445;">rti</font><font style="font-family:Arial;font-size:10pt;color:#303030;">es oth</font><font style="font-family:Arial;font-size:10pt;color:#444445;">er </font><font style="font-family:Arial;font-size:10pt;color:#303030;">than by reason of the Executive's breach of his confidentiality ob</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">igations here</font><font style="font-family:Arial;font-size:10pt;color:#444445;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nder, or </font><font style="font-family:Arial;font-size:10pt;color:#444445;">(i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ii</font><font style="font-family:Arial;font-size:10pt;color:#444445;">) </font><font style="font-family:Arial;font-size:10pt;color:#303030;">learned o</font><font style="font-family:Arial;font-size:10pt;color:#444445;">f </font><font style="font-family:Arial;font-size:10pt;color:#303030;">b</font><font style="font-family:Arial;font-size:10pt;color:#444445;">y </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the </font><font style="font-family:Arial;font-size:10pt;color:#212121;">E</font><font style="font-family:Arial;font-size:10pt;color:#303030;">xecutive subsequent to the termination of his employment hereunder from any other party not the</font><font style="font-family:Arial;font-size:10pt;color:#444445;">n </font><font style="font-family:Arial;font-size:10pt;color:#303030;">under an obligat</font><font style="font-family:Arial;font-size:10pt;color:#212121;">io</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n of c</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nfid</font><font style="font-family:Arial;font-size:10pt;color:#212121;">en</font><font style="font-family:Arial;font-size:10pt;color:#303030;">tiality to t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">h</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e Company</font><font style="font-family:Arial;font-size:10pt;color:#444445;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Further, the </font><font style="font-family:Arial;font-size:10pt;color:#212121;">E</font><font style="font-family:Arial;font-size:10pt;color:#303030;">xe</font><font style="font-family:Arial;font-size:10pt;color:#212121;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ut</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ve </font><font style="font-family:Arial;font-size:10pt;color:#212121;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ovenan</font><font style="font-family:Arial;font-size:10pt;color:#212121;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s to the Compan</font><font style="font-family:Arial;font-size:10pt;color:#212121;">y </font><font style="font-family:Arial;font-size:10pt;color:#303030;">that in the </font><font style="font-family:Arial;font-size:10pt;color:#212121;">E</font><font style="font-family:Arial;font-size:10pt;color:#303030;">x</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">cu</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ti</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ve's p</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rformance o</font><font style="font-family:Arial;font-size:10pt;color:#212121;">f h</font><font style="font-family:Arial;font-size:10pt;color:#303030;">is duties her</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">under, he wil</font><font style="font-family:Arial;font-size:10pt;color:#212121;">l </font><font style="font-family:Arial;font-size:10pt;color:#303030;">n</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t viol</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">te </font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny confid</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ntial</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ty obligations he m</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y h</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">v</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny third parties.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#444445;text-decoration:underline;">N</font><font style="font-family:Arial;font-size:10pt;color:#303030;text-decoration:underline;">on-Interference Covenants</font><font style="font-family:Arial;font-size:10pt;color:#303030;">. The Executive covenants to the Company </font><font style="font-family:Arial;font-size:10pt;color:#444445;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">hat </font><font style="font-family:Arial;font-size:10pt;color:#444445;">w</font><font style="font-family:Arial;font-size:10pt;color:#303030;">hile he </font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s emp</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">oyed by or otherwise renders serv</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ces to the Company and for a three (3) year period therea</font><font style="font-family:Arial;font-size:10pt;color:#444445;">ft</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">(the "Restrictive Period"), he will not, for any reason</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">directly or indirec</font><font style="font-family:Arial;font-size:10pt;color:#444445;">tl</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y: (i) so</font><font style="font-family:Arial;font-size:10pt;color:#444445;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">icit</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">induce</font><font style="font-family:Arial;font-size:10pt;color:#444445;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">or o</font><font style="font-family:Arial;font-size:10pt;color:#444445;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">herwise do any act or </font><font style="font-family:Arial;font-size:10pt;color:#212121;">th</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ing whi</font><font style="font-family:Arial;font-size:10pt;color:#212121;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">h may </font><font style="font-family:Arial;font-size:10pt;color:#212121;">ca</font><font style="font-family:Arial;font-size:10pt;color:#303030;">u</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e </font><font style="font-family:Arial;font-size:10pt;color:#212121;">an</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y oth</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r emp</font><font style="font-family:Arial;font-size:10pt;color:#212121;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">oyee of the Comp</font><font style="font-family:Arial;font-size:10pt;color:#212121;">an</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y to </font><font style="font-family:Arial;font-size:10pt;color:#212121;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ve the employ or otherwise interfere with or </font><font style="font-family:Arial;font-size:10pt;color:#212121;">ad</font><font style="font-family:Arial;font-size:10pt;color:#303030;">v</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rsely affect th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">relat</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ons</font><font style="font-family:Arial;font-size:10pt;color:#212121;">h</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ip (contra</font><font style="font-family:Arial;font-size:10pt;color:#212121;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">tual or o</font><font style="font-family:Arial;font-size:10pt;color:#212121;">t</font><font style="font-family:Arial;font-size:10pt;color:#303030;">h</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rwise) of the Company with any p</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">rson who is th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n or ther</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">aft</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r bec</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">mes </font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n </font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">mpl</font><font style="font-family:Arial;font-size:10pt;color:#212121;">oyee o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">f th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Comp</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny; (i</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">) d</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o </font><font style="font-family:Arial;font-size:10pt;color:#303030;">any </font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ct or thing which may interfere with or adversely affect the relationship (contractua</font><font style="font-family:Arial;font-size:10pt;color:#212121;">l </font><font style="font-family:Arial;font-size:10pt;color:#303030;">o</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">otherwise) of the Com</font><font style="font-family:Arial;font-size:10pt;color:#444445;">p</font><font style="font-family:Arial;font-size:10pt;color:#303030;">an</font><font style="font-family:Arial;font-size:10pt;color:#444445;">y </font><font style="font-family:Arial;font-size:10pt;color:#303030;">with any vendor of goods or services to the Company or induce any such vendo</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">to cease do</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ng bu</font><font style="font-family:Arial;font-size:10pt;color:#444445;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">iness with the Company; or (iii) except for Competitive Activities (as defined in Sec</font><font style="font-family:Arial;font-size:10pt;color:#444445;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">4(e) hereof) engaged in </font><font style="font-family:Arial;font-size:10pt;color:#212121;">b</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e E</font><font style="font-family:Arial;font-size:10pt;color:#303030;">x</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">cutiv</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">aft</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">he e</font><font style="font-family:Arial;font-size:10pt;color:#303030;">x</font><font style="font-family:Arial;font-size:10pt;color:#212121;">p</font><font style="font-family:Arial;font-size:10pt;color:#303030;">i</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ra</font><font style="font-family:Arial;font-size:10pt;color:#303030;">tion of th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e R</font><font style="font-family:Arial;font-size:10pt;color:#303030;">estri</font><font style="font-family:Arial;font-size:10pt;color:#212121;">c</font><font style="font-family:Arial;font-size:10pt;color:#303030;">t</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ve Peri</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">d, d</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o </font><font style="font-family:Arial;font-size:10pt;color:#303030;">a</font><font style="font-family:Arial;font-size:10pt;color:#212121;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">y act or thing wh</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">c</font><font style="font-family:Arial;font-size:10pt;color:#212121;">h </font><font style="font-family:Arial;font-size:10pt;color:#303030;">may interfer</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">with </font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">r adver</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ely affect the rela</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ti</font><font style="font-family:Arial;font-size:10pt;color:#303030;">on</font><font style="font-family:Arial;font-size:10pt;color:#212121;">shi</font><font style="font-family:Arial;font-size:10pt;color:#303030;">p (contractual or </font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">therwi</font><font style="font-family:Arial;font-size:10pt;color:#212121;">s</font><font style="font-family:Arial;font-size:10pt;color:#303030;">e) of th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e C</font><font style="font-family:Arial;font-size:10pt;color:#303030;">omp</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny with any customer </font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">f the Comp</font><font style="font-family:Arial;font-size:10pt;color:#212121;">a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny or indu</font><font style="font-family:Arial;font-size:10pt;color:#212121;">ce a</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ny such c</font><font style="font-family:Arial;font-size:10pt;color:#212121;">us</font><font style="font-family:Arial;font-size:10pt;color:#303030;">tomer to </font><font style="font-family:Arial;font-size:10pt;color:#212121;">ce</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ase d</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ing bu</font><font style="font-family:Arial;font-size:10pt;color:#212121;">si</font><font style="font-family:Arial;font-size:10pt;color:#303030;">n</font><font style="font-family:Arial;font-size:10pt;color:#212121;">es</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s w</font><font style="font-family:Arial;font-size:10pt;color:#212121;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">th th</font><font style="font-family:Arial;font-size:10pt;color:#212121;">e </font><font style="font-family:Arial;font-size:10pt;color:#303030;">C</font><font style="font-family:Arial;font-size:10pt;color:#212121;">o</font><font style="font-family:Arial;font-size:10pt;color:#303030;">mpany. The Executive agrees that, othe</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">than re</font><font style="font-family:Arial;font-size:10pt;color:#212121;">l</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ated to events that occurred p</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">io</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r </font><font style="font-family:Arial;font-size:10pt;color:#303030;">to June 20, 2008, he w</font><font style="font-family:Arial;font-size:10pt;color:#444445;">il</font><font style="font-family:Arial;font-size:10pt;color:#303030;">l never make or publish any sta</font><font style="font-family:Arial;font-size:10pt;color:#212121;">te</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ment or communication which is dispa</font><font style="font-family:Arial;font-size:10pt;color:#444445;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">agi</font><font style="font-family:Arial;font-size:10pt;color:#444445;">n</font><font style="font-family:Arial;font-size:10pt;color:#303030;">g, negat</font><font style="font-family:Arial;font-size:10pt;color:#444445;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ve or </font><font style="font-family:Arial;font-size:10pt;color:#444445;">u</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nflattering </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">with respect to Company and/or its direct or indirect stockholders, officers, di</font><font style="font-family:Arial;font-size:10pt;color:#131313;">r</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">ectors, employees, agents or affiliates. PROVIDED, HOWEVER, that in the event the Company is sold, or there is a Change of Control, the Re</font><font style="font-family:Arial;font-size:10pt;color:#131313;">s</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">trictive Period shall be one (1) year from the sale or Change of Control</font><font style="font-family:Arial;font-size:10pt;color:#131313;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Covenant Not To Compete</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. The Executive expressly acknowledges that (i) the performance of his services for the Company hereunder will afford him access to and cause him to become highly knowledgeable about the Company's Confidential Information; (ii) the agreements and covenants contained in th</font><font style="font-family:Arial;font-size:10pt;color:#131313;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">s Sec. 4(e) are essential to protect the Confidential Information, business and goodwill of the Company and the restraints on the Executive imposed by the provisions of this Sec. 4(e) are justified by these legitimate business interests of the Company; and (iii) his covenants to the Company set forth in this Sec</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">4(e) are being made both in consideration of the Company's employment of the Executive and other financial benefits of this Agreement. Accordingly, the Executive hereby agrees that during the Restrictive Period he shall not, directly or indirectly, own any interest in, invest in, lend to,</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">borrow from, manage, control, participate in, consult with, become employed by, render services to, or in any other manner whatsoever engage in, any business which is competitive with any lines of bus</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">ness engaged in by the Company (collectively, "Compet</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">tive Activities"). The preceding to the contrary notwithstanding</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">the Executive shall be free to make investments in the publicly-traded securities of any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">corporation, provided that such investments do not amount to more than ten percent (10%) of the outstanding securities of any class of such corporation. As provided in Sec. 4(d), the Restrictive Period in the event of a sale of the Company or a Change of Control shall be one (1) year.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Rationale for and Scope of Covenants</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. If any of the covenants contained in this Sec. 4 is held to be invalid or unenforceable because of the unreasonableness of the time, geographic area, or range of activities covered thereby, such covenant and the other covenants shall nevertheless be enforced to the maximum extent permitted by law and effective for such period of time, over such geographical area or for such range of activities as may be determined to be reasonable by a court of competent jurisdiction and the parties hereby consent and agree that the scope of such covenants may be judicially modified, accordingly</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">in any proceeding brought to enforce such covenants</font><font style="font-family:Arial;font-size:10pt;color:#131313;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">The Executive agrees that his services hereunder are of a special, unique, extraordinary and intellectual character</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and his position with the Company places him in a position of confidence and trust with the customers</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">suppliers and employees of the Company</font><font style="font-family:Arial;font-size:10pt;color:#131313;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">The Executive and the Company agree that in the course of employment hereunder, the Executive has and will continue to develop a personal relationship with the Company's customers, and a knowledge of these customers</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">' </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">affairs and requirements as well as confidential and proprietary information developed by the Company after the date of this Agreement. The Executive acknowledges that the Company's relationships with its established clientele may therefore be placed in the Executive</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">'</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">s hands in confidence and trust</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">The Executive consequently agrees that it is reasonable and necessary for the protection of the goodwill, confidential and proprietary information</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and legitimate business interests of the Company and its affiliates that the Executive make the covenants contained herein</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">that the covenants are a material inducement for the Company to continue to employ the Executive and to enter into this Agreement, and that the covenants are given as an integra</font><font style="font-family:Arial;font-size:10pt;color:#4f4f4f;">l </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">part of and are incident to this Agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Remedies for Breach</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. The restrictive covenants set forth in this Sec. 4 shall be construed as agreements independent of any other provision in this Agreement, and the existence of any claim or cause of action of the Executive against the Company, whether predicated upon this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of any restrictive covenant. The Company has fully performed all obligations entitling it to the restrictive covenants, and the restrictive covenants therefore are not executory or otherwise subject to rejection under the Federal Bankruptcy Code. If the Executive commits a breach, or threatens to commit a breach, of any of the provisions of th</font><font style="font-family:Arial;font-size:10pt;color:#131313;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">s Sec. 4, the Company shall have the right and remedy, in addition to any other remedy that may be available at law or in equity, to have the provisions of this Sec. 4 specifically enforced by any court having equity jurisdiction, by the entry of temporary, preliminary and permanent injunctions </font><font style="font-family:Arial;font-size:10pt;color:#323232;">and orders of spec</font><font style="font-family:Arial;font-size:10pt;color:#212021;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">fic performance, t</font><font style="font-family:Arial;font-size:10pt;color:#212021;">o</font><font style="font-family:Arial;font-size:10pt;color:#323232;">g</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ther with an accou</font><font style="font-family:Arial;font-size:10pt;color:#212021;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ting </font><font style="font-family:Arial;font-size:10pt;color:#212021;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">h</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">re</font><font style="font-family:Arial;font-size:10pt;color:#212021;">fo</font><font style="font-family:Arial;font-size:10pt;color:#323232;">r, it being expressly acknowledged and agreed by the </font><font style="font-family:Arial;font-size:10pt;color:#212021;">E</font><font style="font-family:Arial;font-size:10pt;color:#323232;">x</font><font style="font-family:Arial;font-size:10pt;color:#212021;">ec</font><font style="font-family:Arial;font-size:10pt;color:#323232;">utive that any </font><font style="font-family:Arial;font-size:10pt;color:#212021;">s</font><font style="font-family:Arial;font-size:10pt;color:#323232;">uch bre</font><font style="font-family:Arial;font-size:10pt;color:#212021;">ac</font><font style="font-family:Arial;font-size:10pt;color:#323232;">h or th</font><font style="font-family:Arial;font-size:10pt;color:#212021;">re</font><font style="font-family:Arial;font-size:10pt;color:#323232;">at</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ned breach wil</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l </font><font style="font-family:Arial;font-size:10pt;color:#323232;">cause irreparable in</font><font style="font-family:Arial;font-size:10pt;color:#424244;">j</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ury to the Company and that money damages will not provide an ad</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">quate rem</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">dy to the Company</font><font style="font-family:Arial;font-size:10pt;">. </font><font style="font-family:Arial;font-size:10pt;color:#424244;">A</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ny such </font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">njunction shall be availab</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">e without the pos</font><font style="font-family:Arial;font-size:10pt;color:#424244;">ti</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ng of any bond o</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r </font><font style="font-family:Arial;font-size:10pt;color:#323232;">other security, and </font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">he E</font><font style="font-family:Arial;font-size:10pt;color:#424244;">xe</font><font style="font-family:Arial;font-size:10pt;color:#323232;">c</font><font style="font-family:Arial;font-size:10pt;color:#424244;">u</font><font style="font-family:Arial;font-size:10pt;color:#323232;">tive hereby consents to the issuance of such in</font><font style="font-family:Arial;font-size:10pt;color:#424244;">j</font><font style="font-family:Arial;font-size:10pt;color:#323232;">unction. The Executive further agrees t</font><font style="font-family:Arial;font-size:10pt;color:#424244;">h</font><font style="font-family:Arial;font-size:10pt;color:#323232;">a</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t </font><font style="font-family:Arial;font-size:10pt;color:#323232;">an</font><font style="font-family:Arial;font-size:10pt;color:#424244;">y </font><font style="font-family:Arial;font-size:10pt;color:#323232;">such injun</font><font style="font-family:Arial;font-size:10pt;color:#424244;">ctiv</font><font style="font-family:Arial;font-size:10pt;color:#323232;">e relief obtained by the Company shall be i</font><font style="font-family:Arial;font-size:10pt;color:#424244;">n </font><font style="font-family:Arial;font-size:10pt;color:#323232;">ad</font><font style="font-family:Arial;font-size:10pt;color:#424244;">d</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ition to</font><font style="font-family:Arial;font-size:10pt;color:#424244;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">a</font><font style="font-family:Arial;font-size:10pt;color:#424244;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">d not </font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">n lieu of</font><font style="font-family:Arial;font-size:10pt;color:#424244;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">monetary da</font><font style="font-family:Arial;font-size:10pt;color:#424244;">m</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ages a</font><font style="font-family:Arial;font-size:10pt;color:#212021;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">d any other remedi</font><font style="font-family:Arial;font-size:10pt;color:#212021;">es </font><font style="font-family:Arial;font-size:10pt;color:#323232;">to which the Company may be entitled</font><font style="font-family:Arial;font-size:10pt;color:#212021;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Furt</font><font style="font-family:Arial;font-size:10pt;color:#212021;">he</font><font style="font-family:Arial;font-size:10pt;color:#323232;">r, in the event of an alleged breach or violati</font><font style="font-family:Arial;font-size:10pt;color:#212021;">o</font><font style="font-family:Arial;font-size:10pt;color:#323232;">n by the Ex</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">cu</font><font style="font-family:Arial;font-size:10pt;color:#212021;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ive of a</font><font style="font-family:Arial;font-size:10pt;color:#212021;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">y of th</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">pr</font><font style="font-family:Arial;font-size:10pt;color:#212021;">o</font><font style="font-family:Arial;font-size:10pt;color:#323232;">visio</font><font style="font-family:Arial;font-size:10pt;color:#212021;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s of Section</font><font style="font-family:Arial;font-size:10pt;color:#212021;">s </font><font style="font-family:Arial;font-size:10pt;color:#323232;">4(c)</font><font style="font-family:Arial;font-size:10pt;color:#424244;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">4(d) or 4(e) hereof</font><font style="font-family:Arial;font-size:10pt;color:#424244;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">the Restrictive Period sh</font><font style="font-family:Arial;font-size:10pt;color:#212021;">a</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ll be tolled until such br</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ach or v</font><font style="font-family:Arial;font-size:10pt;color:#212021;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">olation has b</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">en cured.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#424244;">(</font><font style="font-family:Arial;font-size:10pt;color:#323232;">h)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#323232;text-decoration:underline;">Survival</font><font style="font-family:Arial;font-size:10pt;color:#212021;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Notwithstanding anyth</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ng to </font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">he contrary set forth herein</font><font style="font-family:Arial;font-size:10pt;color:#424244;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">the pro</font><font style="font-family:Arial;font-size:10pt;color:#424244;">v</font><font style="font-family:Arial;font-size:10pt;color:#323232;">isions o</font><font style="font-family:Arial;font-size:10pt;color:#424244;">f this </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Sec</font><font style="font-family:Arial;font-size:10pt;color:#424244;">. 4 </font><font style="font-family:Arial;font-size:10pt;color:#323232;">shall su</font><font style="font-family:Arial;font-size:10pt;color:#424244;">rv</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ive the termination or cessation of this Ag</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r</font><font style="font-family:Arial;font-size:10pt;color:#323232;">eement or the Executive</font><font style="font-family:Arial;font-size:10pt;color:#424244;">'</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s e</font><font style="font-family:Arial;font-size:10pt;color:#424244;">m</font><font style="font-family:Arial;font-size:10pt;color:#323232;">p</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">o</font><font style="font-family:Arial;font-size:10pt;color:#424244;">y</font><font style="font-family:Arial;font-size:10pt;color:#323232;">men</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">, </font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">rrespecti</font><font style="font-family:Arial;font-size:10pt;color:#424244;">v</font><font style="font-family:Arial;font-size:10pt;color:#323232;">e of the reason for such termination or cessa</font><font style="font-family:Arial;font-size:10pt;color:#424244;">ti</font><font style="font-family:Arial;font-size:10pt;color:#323232;">on</font><font style="font-family:Arial;font-size:10pt;color:#424244;">. T</font><font style="font-family:Arial;font-size:10pt;color:#323232;">he Executive </font><font style="font-family:Arial;font-size:10pt;color:#424244;">sh</font><font style="font-family:Arial;font-size:10pt;color:#323232;">all disclose the r</font><font style="font-family:Arial;font-size:10pt;color:#424244;">est</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ric</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ions se</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t </font><font style="font-family:Arial;font-size:10pt;color:#323232;">forth in this </font><font style="font-family:Arial;font-size:10pt;color:#212021;">S</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ec. 4 </font><font style="font-family:Arial;font-size:10pt;color:#212021;">to </font><font style="font-family:Arial;font-size:10pt;color:#323232;">an</font><font style="font-family:Arial;font-size:10pt;color:#212021;">y </font><font style="font-family:Arial;font-size:10pt;color:#323232;">subsequ</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">nt employer or pot</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">n</font><font style="font-family:Arial;font-size:10pt;color:#212021;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">i</font><font style="font-family:Arial;font-size:10pt;color:#212021;">a</font><font style="font-family:Arial;font-size:10pt;color:#323232;">l em</font><font style="font-family:Arial;font-size:10pt;color:#212021;">p</font><font style="font-family:Arial;font-size:10pt;color:#323232;">loyer dur</font><font style="font-family:Arial;font-size:10pt;color:#212021;">in</font><font style="font-family:Arial;font-size:10pt;color:#323232;">g </font><font style="font-family:Arial;font-size:10pt;color:#212021;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">h</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Re</font><font style="font-family:Arial;font-size:10pt;color:#212021;">s</font><font style="font-family:Arial;font-size:10pt;color:#323232;">trictive Period.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">5</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;text-decoration:underline;">Termination of Employment</font><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#424244;">(</font><font style="font-family:Arial;font-size:10pt;color:#323232;">a</font><font style="font-family:Arial;font-size:10pt;color:#424244;">)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#323232;text-decoration:underline;">Dea</font><font style="font-family:Arial;font-size:10pt;color:#424244;text-decoration:underline;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;text-decoration:underline;">h or Disability</font><font style="font-family:Arial;font-size:10pt;color:#323232;">. The Executive's employment a</font><font style="font-family:Arial;font-size:10pt;color:#424244;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">d </font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">he Em</font><font style="font-family:Arial;font-size:10pt;color:#424244;">p</font><font style="font-family:Arial;font-size:10pt;color:#323232;">loyment P</font><font style="font-family:Arial;font-size:10pt;color:#424244;">eri</font><font style="font-family:Arial;font-size:10pt;color:#323232;">od sh</font><font style="font-family:Arial;font-size:10pt;color:#424244;">al</font><font style="font-family:Arial;font-size:10pt;color:#323232;">l terminate automa</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ical</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">y upon the Executive's death d</font><font style="font-family:Arial;font-size:10pt;color:#424244;">ur</font><font style="font-family:Arial;font-size:10pt;color:#323232;">i</font><font style="font-family:Arial;font-size:10pt;color:#424244;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">g the Employment Period. The C</font><font style="font-family:Arial;font-size:10pt;color:#424244;">omp</font><font style="font-family:Arial;font-size:10pt;color:#323232;">a</font><font style="font-family:Arial;font-size:10pt;color:#424244;">ny </font><font style="font-family:Arial;font-size:10pt;color:#323232;">sha</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">l </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">be entitled </font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">o terminate the Executive</font><font style="font-family:Arial;font-size:10pt;color:#424244;">'</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s employment in the even</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t </font><font style="font-family:Arial;font-size:10pt;color:#323232;">o</font><font style="font-family:Arial;font-size:10pt;color:#424244;">f </font><font style="font-family:Arial;font-size:10pt;color:#323232;">th</font><font style="font-family:Arial;font-size:10pt;color:#424244;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Execu</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ive's D</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">sab</font><font style="font-family:Arial;font-size:10pt;color:#424244;">ility </font><font style="font-family:Arial;font-size:10pt;color:#323232;">duri</font><font style="font-family:Arial;font-size:10pt;color:#212021;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">g the Employment Pe</font><font style="font-family:Arial;font-size:10pt;color:#212021;">r</font><font style="font-family:Arial;font-size:10pt;color:#323232;">i</font><font style="font-family:Arial;font-size:10pt;color:#212021;">o</font><font style="font-family:Arial;font-size:10pt;color:#323232;">d. "Disabi</font><font style="font-family:Arial;font-size:10pt;color:#212021;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ity" m</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ans tha</font><font style="font-family:Arial;font-size:10pt;color:#212021;">t </font><font style="font-family:Arial;font-size:10pt;color:#323232;">th</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Exe</font><font style="font-family:Arial;font-size:10pt;color:#212021;">c</font><font style="font-family:Arial;font-size:10pt;color:#323232;">utiv</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">ha</font><font style="font-family:Arial;font-size:10pt;color:#212021;">s </font><font style="font-family:Arial;font-size:10pt;color:#323232;">bee</font><font style="font-family:Arial;font-size:10pt;color:#212021;">n </font><font style="font-family:Arial;font-size:10pt;color:#323232;">unab</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">e</font><font style="font-family:Arial;font-size:10pt;color:#424244;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">for a period of </font><font style="font-family:Arial;font-size:10pt;color:#212021;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">inety (90) consecuti</font><font style="font-family:Arial;font-size:10pt;color:#212021;">v</font><font style="font-family:Arial;font-size:10pt;color:#323232;">e days or one hu</font><font style="font-family:Arial;font-size:10pt;color:#212021;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">dred twenty (120) day</font><font style="font-family:Arial;font-size:10pt;color:#212021;">s </font><font style="font-family:Arial;font-size:10pt;color:#323232;">during any tw</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">lv</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">(12) mon</font><font style="font-family:Arial;font-size:10pt;color:#212021;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">h period to perform th</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Execu</font><font style="font-family:Arial;font-size:10pt;color:#212021;">ti</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ve's dut</font><font style="font-family:Arial;font-size:10pt;color:#212021;">ie</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s under thi</font><font style="font-family:Arial;font-size:10pt;color:#212021;">s </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Agre</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ment as a re</font><font style="font-family:Arial;font-size:10pt;color:#212021;">s</font><font style="font-family:Arial;font-size:10pt;color:#323232;">u</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">t of phys</font><font style="font-family:Arial;font-size:10pt;color:#212021;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">cal or mental </font><font style="font-family:Arial;font-size:10pt;color:#212021;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">llness or inj</font><font style="font-family:Arial;font-size:10pt;color:#424244;">u</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ry, and that the Company has rece</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ved an independent medica</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l </font><font style="font-family:Arial;font-size:10pt;color:#323232;">report a</font><font style="font-family:Arial;font-size:10pt;color:#424244;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">d op</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">nio</font><font style="font-family:Arial;font-size:10pt;color:#424244;">n t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">h</font><font style="font-family:Arial;font-size:10pt;color:#424244;">a</font><font style="font-family:Arial;font-size:10pt;color:#323232;">t </font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">he Executive is disabled.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#323232;text-decoration:underline;">By the Comp</font><font style="font-family:Arial;font-size:10pt;color:#212021;text-decoration:underline;">a</font><font style="font-family:Arial;font-size:10pt;color:#323232;text-decoration:underline;">ny</font><font style="font-family:Arial;font-size:10pt;color:#323232;">. The Company may termi</font><font style="font-family:Arial;font-size:10pt;color:#212021;">na</font><font style="font-family:Arial;font-size:10pt;color:#323232;">te the </font><font style="font-family:Arial;font-size:10pt;color:#212021;">E</font><font style="font-family:Arial;font-size:10pt;color:#323232;">xecutive</font><font style="font-family:Arial;font-size:10pt;color:#424244;">'</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s employment during the Employment Period for Cause or without C</font><font style="font-family:Arial;font-size:10pt;color:#212021;">a</font><font style="font-family:Arial;font-size:10pt;color:#323232;">u</font><font style="font-family:Arial;font-size:10pt;color:#212021;">s</font><font style="font-family:Arial;font-size:10pt;color:#323232;">e. </font><font style="font-family:Arial;font-size:10pt;color:#424244;">"</font><font style="font-family:Arial;font-size:10pt;color:#323232;">Caus</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#424244;">" </font><font style="font-family:Arial;font-size:10pt;color:#323232;">means</font><font style="font-family:Arial;font-size:10pt;color:#424244;">:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#424244;">(</font><font style="font-family:Arial;font-size:10pt;color:#323232;">i)&#160;&#160;&#160;&#160;The continued failure of the Execut</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ve subs</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">antially to perfo</font><font style="font-family:Arial;font-size:10pt;color:#424244;">rm </font><font style="font-family:Arial;font-size:10pt;color:#323232;">hi</font><font style="font-family:Arial;font-size:10pt;color:#424244;">s d</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ut</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">e</font><font style="font-family:Arial;font-size:10pt;color:#424244;">s </font><font style="font-family:Arial;font-size:10pt;color:#323232;">under th</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s Agr</font><font style="font-family:Arial;font-size:10pt;color:#424244;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">emen</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t </font><font style="font-family:Arial;font-size:10pt;color:#323232;">(other than as a resu</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">t of physical or mental </font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">llness or injury), w</font><font style="font-family:Arial;font-size:10pt;color:#424244;">h</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ich has </font><font style="font-family:Arial;font-size:10pt;color:#424244;">not </font><font style="font-family:Arial;font-size:10pt;color:#323232;">been cured by the Ex</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">cutive after be</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ng gi</font><font style="font-family:Arial;font-size:10pt;color:#424244;">v</font><font style="font-family:Arial;font-size:10pt;color:#323232;">en specific wr</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">tt</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">n details of </font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">he alleged breac</font><font style="font-family:Arial;font-size:10pt;color:#424244;">h </font><font style="font-family:Arial;font-size:10pt;color:#323232;">a</font><font style="font-family:Arial;font-size:10pt;color:#424244;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">d the Executiv</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">has been given r</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">as</font><font style="font-family:Arial;font-size:10pt;color:#212021;">o</font><font style="font-family:Arial;font-size:10pt;color:#323232;">n</font><font style="font-family:Arial;font-size:10pt;color:#212021;">a</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ble opportun</font><font style="font-family:Arial;font-size:10pt;color:#212021;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ty wi</font><font style="font-family:Arial;font-size:10pt;color:#212021;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">hin thirty (30) days of re</font><font style="font-family:Arial;font-size:10pt;color:#212021;">c</font><font style="font-family:Arial;font-size:10pt;color:#323232;">eivi</font><font style="font-family:Arial;font-size:10pt;color:#212021;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">g written notice of such bre</font><font style="font-family:Arial;font-size:10pt;color:#212021;">a</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ch from the Compa</font><font style="font-family:Arial;font-size:10pt;color:#212021;">n</font><font style="font-family:Arial;font-size:10pt;color:#323232;">y to </font><font style="font-family:Arial;font-size:10pt;color:#212021;">c</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ur</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">t</font><font style="font-family:Arial;font-size:10pt;color:#212021;">h</font><font style="font-family:Arial;font-size:10pt;color:#323232;">e all</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ged breac</font><font style="font-family:Arial;font-size:10pt;color:#212021;">h </font><font style="font-family:Arial;font-size:10pt;color:#323232;">by </font><font style="font-family:Arial;font-size:10pt;color:#212021;">s</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ubst</font><font style="font-family:Arial;font-size:10pt;color:#212021;">a</font><font style="font-family:Arial;font-size:10pt;color:#323232;">nt</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">a</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l </font><font style="font-family:Arial;font-size:10pt;color:#323232;">p</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">rformanc</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">of the specified duties;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">(</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">i)&#160;&#160;&#160;&#160;a material breach of a materia</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l </font><font style="font-family:Arial;font-size:10pt;color:#323232;">provision of </font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">his Agreement wh</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ch has no</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t </font><font style="font-family:Arial;font-size:10pt;color:#323232;">been cured by the Execu</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">i</font><font style="font-family:Arial;font-size:10pt;color:#424244;">v</font><font style="font-family:Arial;font-size:10pt;color:#323232;">e after being given specific written details of the al</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">eged breach and </font><font style="font-family:Arial;font-size:10pt;color:#424244;">th</font><font style="font-family:Arial;font-size:10pt;color:#323232;">e Exec</font><font style="font-family:Arial;font-size:10pt;color:#424244;">u</font><font style="font-family:Arial;font-size:10pt;color:#323232;">tive has been given thirty (30) </font><font style="font-family:Arial;font-size:10pt;color:#424244;">d</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ays after receiving written no</font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ice of suc</font><font style="font-family:Arial;font-size:10pt;color:#424244;">h </font><font style="font-family:Arial;font-size:10pt;color:#323232;">breach f</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r</font><font style="font-family:Arial;font-size:10pt;color:#323232;">o</font><font style="font-family:Arial;font-size:10pt;color:#424244;">m the </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Company </font><font style="font-family:Arial;font-size:10pt;color:#212021;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">o </font><font style="font-family:Arial;font-size:10pt;color:#212021;">c</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ure th</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e </font><font style="font-family:Arial;font-size:10pt;color:#323232;">al</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">eged brea</font><font style="font-family:Arial;font-size:10pt;color:#212021;">c</font><font style="font-family:Arial;font-size:10pt;color:#323232;">h;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">(iii)&#160;&#160;&#160;&#160;a mat</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">rial </font><font style="font-family:Arial;font-size:10pt;color:#212021;">b</font><font style="font-family:Arial;font-size:10pt;color:#323232;">re</font><font style="font-family:Arial;font-size:10pt;color:#212021;">ac</font><font style="font-family:Arial;font-size:10pt;color:#323232;">h of a material provi</font><font style="font-family:Arial;font-size:10pt;color:#212021;">s</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ion of the C</font><font style="font-family:Arial;font-size:10pt;color:#212021;">o</font><font style="font-family:Arial;font-size:10pt;color:#323232;">nfidential </font><font style="font-family:Arial;font-size:10pt;color:#212021;">I</font><font style="font-family:Arial;font-size:10pt;color:#323232;">nformat</font><font style="font-family:Arial;font-size:10pt;color:#212021;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">on and Inventions Assignment Ag</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r</font><font style="font-family:Arial;font-size:10pt;color:#323232;">eement between the Company and the Executive wh</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">c</font><font style="font-family:Arial;font-size:10pt;color:#424244;">h </font><font style="font-family:Arial;font-size:10pt;color:#323232;">has not bee</font><font style="font-family:Arial;font-size:10pt;color:#424244;">n </font><font style="font-family:Arial;font-size:10pt;color:#323232;">cured by </font><font style="font-family:Arial;font-size:10pt;color:#424244;">t</font><font style="font-family:Arial;font-size:10pt;color:#323232;">he Executive after be</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ng g</font><font style="font-family:Arial;font-size:10pt;color:#424244;">iv</font><font style="font-family:Arial;font-size:10pt;color:#323232;">en specific w</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r</font><font style="font-family:Arial;font-size:10pt;color:#323232;">itten deta</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ls of the alleged breach a</font><font style="font-family:Arial;font-size:10pt;color:#424244;">nd </font><font style="font-family:Arial;font-size:10pt;color:#323232;">the E</font><font style="font-family:Arial;font-size:10pt;color:#424244;">x</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ecutive has been given thirty (30) days after receiving w</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r</font><font style="font-family:Arial;font-size:10pt;color:#323232;">itten notice o</font><font style="font-family:Arial;font-size:10pt;color:#424244;">f </font><font style="font-family:Arial;font-size:10pt;color:#323232;">such breach from the Compan</font><font style="font-family:Arial;font-size:10pt;color:#424244;">y </font><font style="font-family:Arial;font-size:10pt;color:#323232;">to cure the all</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ged breach;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">(i</font><font style="font-family:Arial;font-size:10pt;color:#212021;">v</font><font style="font-family:Arial;font-size:10pt;color:#323232;">)&#160;&#160;&#160;&#160;i</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l</font><font style="font-family:Arial;font-size:10pt;color:#323232;">legal </font><font style="font-family:Arial;font-size:10pt;color:#212021;">or g</font><font style="font-family:Arial;font-size:10pt;color:#323232;">r</font><font style="font-family:Arial;font-size:10pt;color:#212021;">os</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s misconduct by the Ex</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">cutive, as it solely r</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">l</font><font style="font-family:Arial;font-size:10pt;color:#212021;">a</font><font style="font-family:Arial;font-size:10pt;color:#323232;">t</font><font style="font-family:Arial;font-size:10pt;color:#212021;">e</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s to the Company</font><font style="font-family:Arial;font-size:10pt;color:#424244;">'</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s affairs</font><font style="font-family:Arial;font-size:10pt;color:#424244;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">in e</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ther case, that is willful and in the Boa</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r</font><font style="font-family:Arial;font-size:10pt;color:#323232;">d's disc</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r</font><font style="font-family:Arial;font-size:10pt;color:#323232;">etion may result </font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">n materia</font><font style="font-family:Arial;font-size:10pt;color:#424244;">l </font><font style="font-family:Arial;font-size:10pt;color:#323232;">damage to the business or reputat</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">on of the Company and which has not been stopped and cured b</font><font style="font-family:Arial;font-size:10pt;color:#424244;">y </font><font style="font-family:Arial;font-size:10pt;color:#323232;">the Executive afte</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r </font><font style="font-family:Arial;font-size:10pt;color:#323232;">being g</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ven th</font><font style="font-family:Arial;font-size:10pt;color:#212021;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">rty (30) days' wr</font><font style="font-family:Arial;font-size:10pt;color:#212021;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">tten notice of the specific illegal o</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r </font><font style="font-family:Arial;font-size:10pt;color:#323232;">g</font><font style="font-family:Arial;font-size:10pt;color:#424244;">r</font><font style="font-family:Arial;font-size:10pt;color:#323232;">oss m</font><font style="font-family:Arial;font-size:10pt;color:#424244;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">scon</font><font style="font-family:Arial;font-size:10pt;color:#424244;">du</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ct a</font><font style="font-family:Arial;font-size:10pt;color:#212021;">s</font><font style="font-family:Arial;font-size:10pt;color:#323232;">serted by the Company;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(v)&#160;&#160;&#160;&#160;conviction of or plea of no contest to a felony or any crime committed by the Executive involving theft, fraud</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">or dishonesty whether or not committed in the course of performing services for the Company;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(vi)&#160;&#160;&#160;&#160;habitual abuse of drugs or alcohol by the Executive, after ten (10) days prior warning from the Company;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(vii)&#160;&#160;&#160;&#160;intentional act(s) of disloyalty, deliberate dishonesty, fraud, or breach of fiduciary duty by the Executive to the Company or any of its affiliates after adjudication of such alleged acts; or</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(viii)&#160;&#160;&#160;&#160;material non</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">-</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">compliance by the Executive with the Company's written policies which has not been cured by the Executive after being given specific written details of the alleged non-compliance and the Executive has been given thirty (30) days of written notice of such breach from the Company to cure the alleged breach.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">A termination of the Executive's employment by the Company shall be effected by giving him written notice of termination following any cure period set forth herein if the alleged act has not been cured by the Executive. Notwithstanding the foregoing, the Executive shall not be deemed to have been terminated for Cause without an opportunity for the Executive (together with counsel, if requested) to be heard in person by the Board after being provided with all of the specific facts and circumstances in writing relating to the proposed termination at least twenty (20) days in advance of such meeting of the Board, and a good faith </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">best efforts determination by the Board thereafter that the Executive's conduct was of such a substantial or continuing nature which has gone uncured that it would justify a termination for Cause</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Good Reason</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. The Executive may, at his sole option, terminate his employment for Good Reason or without Good Reason. "Good Reason" means:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(i)&#160;&#160;&#160;&#160;the assignment to the Executive of duties materially inconsistent with Sec. 2 of this Agreement, other than an action that is not taken in bad faith and is remedied by the Company within twenty (20) days after receipt of written notice thereof from the Executive; and</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(ii)&#160;&#160;&#160;&#160;any material failure by the Company to comply with Sec. 3 of this Agreement, other than a failure that is not taken in bad faith and is remedied by the Company within thirty (30) days after receipt of written notice thereof from the Executive.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Change of Control</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. In the sole discretion of the Compensation Committee, Executive may be awarded an additional bonus on or before the occurrence of a Change of Control. For purposes of this Agreement, Change of Control is defined as a merger. acquisition or sale of assets resu</font><font style="font-family:Arial;font-size:10pt;color:#5a5a5b;">l</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">ting in the number of shares of all existing Company stockholders with voting power immediately prior to such transaction being reduced to less than fifty percent (50%) voting power following such transaction or if both the vaccine and biopharmaceutical business categories are sold.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Any termination of the Executive's employment by the Executive shall be effected by giving the Company at least thirty (30) days' prior written notice of the termination</font><font style="font-family:Arial;font-size:10pt;color:#5a5a5b;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">Obligations of the Company upon Termination</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">By the Company Other Than for Cause</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">. </font><font style="font-family:Arial;font-size:10pt;color:#191919;">I</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">f (i) the Company terminates the Execut</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ve's employmen</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">during the </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">E</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">mp</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">oyment Period o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">he</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">than f</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">o</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">r Cause or </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">(</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ii) the Execu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e te</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">minates his employment for Good Reason or (iii) in the case of </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">he Execu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ive's Death or </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">D</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">isab</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">l</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ty </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">d</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">u</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ing the Employment Per</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">od, then </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">he Company shall fulfill its obligations as to Ann</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">Base Sa</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">ry </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">under Sec</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">. </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">3(a) hereof through t</font><font style="font-family:Arial;font-size:10pt;color:#191919;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e effective date of termination (the "Termination Date")</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">and the Executive sha</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">l be entitled to receive his Annual Base Salary and accrued but unpaid vacation </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">hrough the dat</font><font style="font-family:Arial;font-size:10pt;color:#191919;">e </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">the</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">eof plus</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">in the </font><font style="font-family:Arial;font-size:10pt;color:#191919;">s</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ole dis</font><font style="font-family:Arial;font-size:10pt;color:#191919;">c</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">etion of the Compensation Comm</font><font style="font-family:Arial;font-size:10pt;color:#191919;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ttee</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">the 2016 and 2017 </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">Maxi</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">mum Optio</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">Bonus sha</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">l be payable in accordance w</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">th </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">he Com</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">p</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">any</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">'</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">s no</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ma</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">pa</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">yr</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ol</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">pract</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ces</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">I</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">n addition</font><font style="font-family:Arial;font-size:10pt;color:#545456;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">all of the Execut</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ve's unvested incentive options set forth in Sections 3(d) and 3(e) will vest immediately in the event milestones for which the options have been awarded are achieved within one (1) year from the dat</font><font style="font-family:Arial;font-size:10pt;color:#191919;">e </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">of termination or upon a Change in Control</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">As a conditio</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">to recei</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">g such payment o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">f </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">acc</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ued bu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">unpaid </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">aca</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ion time and </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">he </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">a</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">gree</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">m</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">en</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t for </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">such contingent opt</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">on accele</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">at</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">on </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">f</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ol</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">owing the Term</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">natio</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">Da</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">the Exec</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">u</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ti</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e shal</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l sign a R</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ease co</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ering all ma</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">tt</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">s relat</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ng to his empl</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">oy</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ment i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">favo</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">of the Co</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">mp</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">any an</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">d i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ts affi</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">li</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">s</font><font style="font-family:Arial;font-size:10pt;color:#545456;">, </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">n such form as the Company shall reasonably request. The Release w</font><font style="font-family:Arial;font-size:10pt;color:#191919;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ll not however release the Executive</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">'</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">s post-termination rights to severance benefits described above in this subsection</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">(</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">b</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">Cause: O</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">her than for Good Reason</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">. If the E</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">xe</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">cutive's emp</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">loy</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ment </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">is term</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">nat</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ed </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">by </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">the Company </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">f</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">or Cause du</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ing the Employment Period or if </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">he E</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">x</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ecu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">ve r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">esigns o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">he</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">h</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">a</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">n fo</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">Goo</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">d </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">Rea</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">s</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">on, the Company shall pa</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">y </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">the Execut</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ve the An</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ual B</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">a</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">se </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">S</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">a</font><font style="font-family:Arial;font-size:10pt;color:#545456;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ary a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">d al</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l oth</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">er </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">be</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">nefi</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">ts </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">and expenses provided under Sec. 3 above that have been accrued or earned through the Termination Date and the Company sha</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">ll </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">have no further obligations under this Ag</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">eement other than for any entit</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ements under the terms of any other plans or programs of the Company in which the Execu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ive part</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">cipated and under </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">w</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">hich the Execu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ive has accrued a benefit.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">Co</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;font-weight:bold;text-decoration:underline;">m</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">p</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;font-weight:bold;text-decoration:underline;">lian</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">ce</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;font-weight:bold;text-decoration:underline;">wit</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;font-weight:bold;text-decoration:underline;">C</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;font-weight:bold;text-decoration:underline;">de Sec</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">ti</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;font-weight:bold;text-decoration:underline;">o</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;font-weight:bold;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;font-weight:bold;text-decoration:underline;">409A</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">. </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">It </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">is t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e inten</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ion of </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">bo</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">h t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">he </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">Com</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">pan</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">y </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">nd </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">the Execut</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ve that the benefits and righ</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">s to which the Executive could be entitled pursuant </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">o this Agreement comply with Sec. 409A of the Internal Revenue Code of 1986</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">as amended </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">f</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">rom time to time</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">and its implementing regulations and guidance ("Sec. 409A")</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">to the extent that the </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">equirements o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">f </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">Sec</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">. </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">409A are applicable the</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">eto, and </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">he prov</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ons of t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">is Agreement s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">all be </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">c</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">nst</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">rued </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">n a manner co</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">sis</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ent </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">wi</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">th that in</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">en</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ion. </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">I</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">f the Executi</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e or the Company be</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ie</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">v</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">s, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t any t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">im</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">e, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">that any such benefit or righ</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">that </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">s sub</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">j</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ect to Sec</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">. 4</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">09A does no</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t s</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">o comp</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">ly, i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">t s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">al</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">promp</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">tly </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">adv</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">se the other and sha</font><font style="font-family:Arial;font-size:10pt;color:#191919;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">l negotiate reasonably and in good faith to amend the terms of such benefits and rights such that they comply with Sec</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">. </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">409A (with the most limited possi</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">b</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">le eco</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">omic effect on the Executive and on the Company). Such p</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ovisions include:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">D</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">st</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">ibu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">ti</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">ons on Account of Separa</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">io</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">n</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">from Se</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">rv</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">ice</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">. </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">If a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">d </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">o </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">th</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e extent </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">requ</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">d to </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">com</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">pl</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">y </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">w</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">i</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">h Sec. 409A, any payment or be</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">efit requ</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">red to </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">b</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e paid u</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">de</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">this Ag</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ee</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">m</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">en</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">n </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">a</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">c</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">co</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">un</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">t of termination of the Execu</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ive</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">'</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">s e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">m</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">p</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">oyment</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">serv</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ce (or any o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">her s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">m</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">lar te</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">rm) </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">s</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">al</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">l </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">be made onl</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">y </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">in connection with a "separation from service" with respect to Executive within the meaning of Sec. 409A.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">N</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">o Accelera</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">ti</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">on of Paymen</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;text-decoration:underline;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;text-decoration:underline;">s</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">. </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">N</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">er t</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">h</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">C</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ompany nor the Executive</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">nd</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">v</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">idu</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">al</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">ly </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">or in combina</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ion</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">may accele</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ate any payment or benefit that is sub</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">j</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">ct </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">to Sec. 409A</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">, </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">e</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">x</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">c</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">e</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">pt </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">n compliance with Sec. 409A and </font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">he p</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">r</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ov</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">sions o</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">f </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">th</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">i</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">s Agreement, and no amoun</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t t</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">ha</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">t </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">is su</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">b</font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">je</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">ct to </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">Sec. 409A shall be paid prior to the earliest date on which it may be paid without violating Sec</font><font style="font-family:Arial;font-size:10pt;color:#3d3d3e;">. </font><font style="font-family:Arial;font-size:10pt;color:#2e2e2e;">409A.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Expense Reimbursements</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. Notwithstanding anything herein to </font><font style="font-family:Arial;font-size:10pt;color:#484848;">t</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">he contrary or othe</font><font style="font-family:Arial;font-size:10pt;color:#484848;">r</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">- wise, except to the extent any expense o</font><font style="font-family:Arial;font-size:10pt;color:#484848;">r </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">reimbursement provided pursuant to this Agreement does not constitute a "deferral of compensation" within the meaning of Sec. 409A, (i) the amount o</font><font style="font-family:Arial;font-size:10pt;color:#484848;">f </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">expenses eligible for reimbursement provided to the Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive </font><font style="font-family:Arial;font-size:10pt;color:#484848;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">n any other calendar year, (ii) the reimbursements for expenses for which the Executive is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(iii) the right to payment or reimbu</font><font style="font-family:Arial;font-size:10pt;color:#484848;">r</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">sement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefi</font><font style="font-family:Arial;font-size:10pt;color:#484848;">t</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">, and (iv) the reimbursements shall be made pursuant to objectively determinable and nondiscretionary Company's pol</font><font style="font-family:Arial;font-size:10pt;color:#484848;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">cies and procedures regarding such reimbursement of expenses.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">8</font><font style="font-family:Arial;font-size:10pt;color:#484848;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;text-decoration:underline;">No Mitigation</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">In no event shal</font><font style="font-family:Arial;font-size:10pt;color:#484848;">l </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">the Executive be ob</font><font style="font-family:Arial;font-size:10pt;color:#484848;">l</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">igated to see</font><font style="font-family:Arial;font-size:10pt;color:#484848;">k </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">other employment or take any other action by way of mitigation of the amounts payab</font><font style="font-family:Arial;font-size:10pt;color:#484848;">l</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">e to the Executive </font><font style="font-family:Arial;font-size:10pt;color:#484848;">u</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">nder any of the provisions of this Agreement and such amounts shall not be reduced</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">regar</font><font style="font-family:Arial;font-size:10pt;color:#484848;">d</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">less of whether the Executive obtains other employment</font><font style="font-family:Arial;font-size:10pt;color:#060606;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;text-decoration:underline;">Successors</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">This Agreement is personal to the Executive and, without the prior written consent of the Company, shall no</font><font style="font-family:Arial;font-size:10pt;color:#484848;">t </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">be assignable by the Executive. Sub</font><font style="font-family:Arial;font-size:10pt;color:#484848;">j</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">ect to the preceding sen</font><font style="font-family:Arial;font-size:10pt;color:#484848;">t</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">ence, this Agreement shall inure to the benefit of, be binding upon and be enforceable b</font><font style="font-family:Arial;font-size:10pt;color:#484848;">y </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">the Executive</font><font style="font-family:Arial;font-size:10pt;color:#484848;">'</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">s successors, assigns and lega</font><font style="font-family:Arial;font-size:10pt;color:#484848;">l </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">representatives. This Agreement shall inure to the benefi</font><font style="font-family:Arial;font-size:10pt;color:#484848;">t </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">of and be binding upon the Company and its successors and assigns.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">10.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">Miscellaneous</font><font style="font-family:Arial;font-size:10pt;color:#060606;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(a)&#160;&#160;&#160;&#160;This Agreement shall be governed by, and construed in accordance with the laws of the State of Florida</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">without reference to pr</font><font style="font-family:Arial;font-size:10pt;color:#484848;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">nciples of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect</font><font style="font-family:Arial;font-size:10pt;color:#060606;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">This Agreement may no</font><font style="font-family:Arial;font-size:10pt;color:#484848;">t </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">be amended or modified except by a written agreement executed by the parties hereto or their respective successors and legal representatives.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(b)&#160;&#160;&#160;&#160;Whe</font><font style="font-family:Arial;font-size:10pt;color:#484848;">n </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">a refe</font><font style="font-family:Arial;font-size:10pt;color:#484848;">r</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">ence is made in this Agreement to a section or schedule</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">such reference shall be deemed to be to this Agreement unless otherwise indicated. Wheneve</font><font style="font-family:Arial;font-size:10pt;color:#484848;">r </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">t</font><font style="font-family:Arial;font-size:10pt;color:#484848;">h</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">e wo</font><font style="font-family:Arial;font-size:10pt;color:#484848;">r</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">ds "include</font><font style="font-family:Arial;font-size:10pt;color:#484848;">," </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"includes" or "including" are used in this Agreement</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">they shall be deemed to be followed by the words "without </font><font style="font-family:Arial;font-size:10pt;color:#484848;">l</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">imitation." As used herein, words in the singular will be held to include the plural and vice versa (unless the context otherwise requires), words of one gender shall be held to include the other gender (or the neuter) as the context requires, and the terms "hereof", "herein", and "herewith" and words of s</font><font style="font-family:Arial;font-size:10pt;color:#484848;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">milar import will, unless otherwise stated</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">be construed to refer to th</font><font style="font-family:Arial;font-size:10pt;color:#484848;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">s Agreement as a whole and not to any particular provision of this Agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(c)&#160;&#160;&#160;&#160;The parties agree and acknowledge that they have jointly participated in the negotiation and drafting of this Agreement. In the event of an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumptions or burdens of proof shall arise favoring any party by virtue of the authorship of any of the provis</font><font style="font-family:Arial;font-size:10pt;color:#484848;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">o</font><font style="font-family:Arial;font-size:10pt;color:#484848;">n</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">s of this Agreement. Any reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promu</font><font style="font-family:Arial;font-size:10pt;color:#484848;">l</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">gated thereunder, unless the context requ</font><font style="font-family:Arial;font-size:10pt;color:#484848;">i</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">res otherwise.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(d)&#160;&#160;&#160;&#160;All notices and other communications under this Agreement shall be in w</font><font style="font-family:Arial;font-size:10pt;color:#484848;">ri</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">ting a</font><font style="font-family:Arial;font-size:10pt;color:#484848;">n</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">d shall be given by hand to the other party or by certified mail or overnight courier service, addressed as follows</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">or by email or fax as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="sEB7573FF3FC1EC27877843F02CB2B79A"></a></div><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">If to the Executive:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark A. Emalfarb</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">193 Spyglass Court </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jupiter, FL 33477 </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">mark@emalfarb.com </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fax: 561-747-9522</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">With a required copy to:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thomas Earl Patton, Esq. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Butzel Long</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1747 Pennsylvania Ave., NW #300</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Washington DC 2006 </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">pattont@butzel.com </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fax: 202-454-2805</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">If to the Company:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dyadic International, Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">140 lntracoastal Pointe Drive #404</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jupiter, FL 33477</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Attn: Board of Directors </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thomas Dubinski </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate Secretary </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">tdubinski@dyadic.com </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fax: 561-743-8343</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">With a required copy to:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark H. Mirkin, Esq. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Rimon Law P.A.</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">112 Via Castilla</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jupiter, FL 33458</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark.mirkin@rimonlaw.com</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fax: 561-935-9678</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">or to such other address as either party furnishes to the other in writing in accordance with this section</font><font style="font-family:Arial;font-size:10pt;color:#4d4d4d;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Any such notice or communication shall be deemed to have been received (</font><font style="font-family:Arial;font-size:10pt;color:#4d4d4d;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">) when delivered, if pe</font><font style="font-family:Arial;font-size:10pt;color:#4d4d4d;">r</font><font style="font-family:Arial;font-size:10pt;color:#303030;">sonally delivered, (ii) on the next business day after dispatch, if sent postage pre-paid by a nationally recognized, overnight courier guaranteeing next business day delivery, and (iii) on the fifth (5</font><font style="font-family:Arial;font-size:10pt;color:#303030;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;color:#303030;">) business day following the date on which the envelope containing such communication is posted</font><font style="font-family:Arial;font-size:10pt;color:#4d4d4d;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">if sent by certified mail, postage prepaid, return receipt requested.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">(e)&#160;&#160;&#160;&#160;The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement</font><font style="font-family:Arial;font-size:10pt;color:#070707;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">If any provision of this Agreement shall be held invalid or unenforceable in part, the remaining portion of such provision, together with all other provisions of this Agreement, shall remain valid and enforceable and cont</font><font style="font-family:Arial;font-size:10pt;color:#4d4d4d;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">nue in full force and effect to the fullest extent consistent with law</font><font style="font-family:Arial;font-size:10pt;color:#070707;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">(f)&#160;&#160;&#160;&#160;The Executive's or the Company's failure to insist upon strict compliance with any provision of, or to assert any right under, this Agreement shall not be deemed to be a waiver of such provision or right or of any other provision of or right under this Agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">(g)&#160;&#160;&#160;&#160;Except as otherwise provided herein, no remedy herein conferred upon a party hereto is intended to be exclusive of any other remedy. No single or partial exercise by a party hereto of any right, power or remedy hereunder shall preclude any other or further exercise thereof. All remedies under this Agreement or otherwise afforded to any party shall be cumulative and not alternative.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">(h)&#160;&#160;&#160;&#160;The Executive hereby agrees tha</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">any suit, action or p</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">ro</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ceeding rela</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">ting i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">n an</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">y w</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">y t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">o this Agreement shall be b</font><font style="font-family:Arial;font-size:9.5pt;color:#0f0f11;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ought and enforced in the Circuit Co</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">u</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">rt of Palm Beach County of the State of Florida or in the federal District Court for </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">he Southern Distr</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ct of Florida</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">and in either case, the Executive hereby submits to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">the jurisdiction of each such court</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">. </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">The Execut</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ve hereby waives and ag</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ees no</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">o assert</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">by way of motion or o</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">he</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">rwi</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">se</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">in any such su</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">t, action </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">or p</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">roceedi</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">g, a</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">ny </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">c</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">l</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">im </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">that he </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">s not perso</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">l</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ly subject </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">o </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">he jurisdicti</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">o</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">n o</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">f t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">he above name</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">d c</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">urt</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">s</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, that the su</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ac</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ion o</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">p</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">oceeding is b</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ough</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">n an </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">n</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">c</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">onven</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ent </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">fo</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">rum or that t</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">h</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">e </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">v</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">en</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">u</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">e of </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">he su</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">t, ac</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">io</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n o</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">r </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">pr</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">c</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">eeding is improper</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">. </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">The Executive consents and agrees to service of process or other legal sum</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">m</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ons for purpose of any such suit</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">action or proceeding by registered mail addressed to the Executive at </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">h</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">is address listed </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">n the business records of the Company or </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">n this section. No</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">hing conta</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ned he</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ei</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">sha</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">ll </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">affect the </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">ri</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ghts of t</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">h</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">e Compan</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">y </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">to b</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">g a sui</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ac</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">io</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">procee</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">d</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">ng </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">an</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">y </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">th</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">er a</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">p</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">p</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">opriate </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">j</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">urisd</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">ict</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">io</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">(i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">)&#160;&#160;&#160;&#160;EACH P</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">A</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">RTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CO</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">TROV</font><font style="font-family:Arial;font-size:9.5pt;color:#0f0f11;">- </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ERSY W</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">H</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPL</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">CATED AND DIFFICULT ISSUES</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND U</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">NCO</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ND</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ONALL</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">Y </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">W</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">A</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">IVES AN</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">Y </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">RIGHT SUCH PA</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">RTY </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">M</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">AY HAV</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">E T</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">O A </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">TR</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">A</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">L BY </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">JU</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">RY IN R</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ESPEC</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">T </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">OF A</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">Y LIT</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">GATION D</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">RECTLY OR I</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">D</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">RE</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">C</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">TL</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">Y A</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">R</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">S</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">IN</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">G OUT OF O</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">R R</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">E</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">LATING T</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">O T</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">H</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">IS </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">A</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">GREEME</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">A</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">NY </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">OR AN</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">Y </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">O</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">TH</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ER </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">NSTRU</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">M</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ENT E</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">X</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ECUTED I</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">C</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">ONNE</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">C</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">ON </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">HEREWITH OR THEREW</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">TH</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">OR IN ANY WAY CONNECTED WITH OR RELATED OR INC</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">DENTAL TO </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">HE DEALINGS OF THE PARTIES OR ANY OF THEM IN RESPECT OF THIS AGREEMENT</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">. </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i) NO REPRES</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">E</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">NTA</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">IVE</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, AG</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">E</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">T OR </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">A</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">TIOR</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">EY OF THE OTHER PARTY H</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">A</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">S REP</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">R</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ESE</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">TED</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">E</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">X</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">P</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">R</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">E</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">S</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">SL</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">Y OR </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">O</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">HE</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">R</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">W</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">SE</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">THAT S</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">U</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">CH OTHER PARTY </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">W</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">OULD </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">NO</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N T</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">HE E</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">V</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">E</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">T OF L</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">ITI</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">GA</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">TI</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">O</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N, S</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">EE</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">K </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">TO E</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">FORCE </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">TH</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">E FOREGOING WAI</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">V</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ER</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, (i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">i) EAC</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">H S</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">UC</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">H </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">PAR</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">TY </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">U</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">DE</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">R</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ST</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">AN</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">DS </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">AND HAS </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">CONSIDERED THE IMPLICATIONS OF THIS WA</font><font style="font-family:Arial;font-size:9.5pt;color:#0f0f11;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">VER, (iii) EACH SUCH PARTY MAKES </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">H</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">S WAIVER VOLUNTARILY</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">AND (</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">v) EACH SUCH PARTY HAS BEEN INDUCED TO </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">E</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">NTER </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">NTO </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">H</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">S AGREEMENT BY</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">AMONG OTHER THINGS</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">THE WAIVERS A</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">D CERTIFICATIONS IN </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">HIS SECTIO</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N. </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">EACH PARTY </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">A</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">GREES THAT THE OTHER </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">MAY FI</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">LE A </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">C</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">O</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">PY O</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">F </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">H</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">S AGREEMENT WITH A</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">Y COURT AS WR</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">TIEN EVIDENCE O</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">F </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">THE CO</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">SE</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">N</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">T OF THE </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">PAR</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ES TO TH</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">E W</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">A</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">VE</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">R </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">OF </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">TS R</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">I</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">GHT T</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">O </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">TRIAL BY J</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">U</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">RY</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#3b3b3b;">(j</font><font style="font-family:Arial;font-size:11pt;color:#2b2b2b;">)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">T</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">h</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">e parties agree that in the event of the institution of any action at law or in equity b</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">y </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">either party to enforce the provisions of this Agreement, the losing party sha</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">l</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">l pay all of the costs and expenses of the prevai</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">l</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ing party, including reasonable fees and expenses of attorneys and accountants</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">incu</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">red </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">n connectio</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n t</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">he</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ew</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">h</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">(</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">k)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">This </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">A</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">g</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ee</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">m</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">nt m</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">y </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">be e</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">x</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ec</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">u</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ted </font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">n counte</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">rp</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">arts</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">eac</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">h </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">f </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">wh</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">c</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">h sha</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">l</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">l be d</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">em</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">e</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">d an </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">o</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">iginal</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">a</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">d said counterparts shall const</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">tute but one and the same instrume</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">n</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">t</font><font style="font-family:Arial;font-size:9.5pt;color:#0f0f11;">. </font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">Delivery of an e</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">x</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ecuted counterpart of a signature page to this Agreement by facs</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">i</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">mile, portable document fo</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">r</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">mat or other e</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">l</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">ectronic means shall be effective as delivery of a manually executed counterpart to the A</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">greem</font><font style="font-family:Arial;font-size:9.5pt;color:#2b2b2b;">en</font><font style="font-family:Arial;font-size:9.5pt;color:#3b3b3b;">t.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">S</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;font-weight:bold;">IGNATURE PAGE FOLLOWS</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><a name="s7B7460F19505C8F9707743F02E69C13D"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:9.5pt;color:#393739;font-weight:bold;">IN WITNESS WHEREOF, </font><font style="font-family:Arial;font-size:10.5pt;color:#393739;">the parties have entered into th</font><font style="font-family:Arial;font-size:10.5pt;color:#4c4c4c;">i</font><font style="font-family:Arial;font-size:10.5pt;color:#393739;">s Agreement as of the day and yea</font><font style="font-family:Arial;font-size:10.5pt;color:#4c4c4c;">r </font><font style="font-family:Arial;font-size:10.5pt;color:#393739;">first above written</font><font style="font-family:Arial;font-size:10.5pt;color:#4c4c4c;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:right;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.04273504273504%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:13%;"></td><td style="width:80%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Michael P. Tarnok</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Michael P. Tarnok</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chairman, Compensation Committee</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Mark A. Emalfarb</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark A. Emalfarb</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><a name="s72255D92E50286988B5143F02E7165E2"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353536;">June 16, 2016</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353536;">Mark A</font><font style="font-family:Arial;font-size:10pt;color:#454545;">. </font><font style="font-family:Arial;font-size:10pt;color:#353536;">Emalfarb</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#454545;">1</font><font style="font-family:Arial;font-size:10pt;color:#353536;">93 Spyglass </font><font style="font-family:Arial;font-size:10pt;color:#454545;">C</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ourt</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#454545;">J</font><font style="font-family:Arial;font-size:10pt;color:#353536;">up</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ter</font><font style="font-family:Arial;font-size:10pt;color:#454545;">, F</font><font style="font-family:Arial;font-size:10pt;color:#353536;">L 3</font><font style="font-family:Arial;font-size:10pt;color:#454545;">3</font><font style="font-family:Arial;font-size:10pt;color:#353536;">4</font><font style="font-family:Arial;font-size:10pt;color:#454545;">77</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353536;font-weight:bold;">Re</font><font style="font-family:Arial;font-size:10pt;color:#454545;font-weight:bold;">: </font><font style="font-family:Arial;font-size:10pt;color:#353536;font-weight:bold;">Change of Cont</font><font style="font-family:Arial;font-size:10pt;color:#454545;font-weight:bold;">r</font><font style="font-family:Arial;font-size:10pt;color:#353536;font-weight:bold;">ol Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353536;">Dear Mark,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353536;">Simultaneously here</font><font style="font-family:Arial;font-size:10pt;color:#454545;">with, </font><font style="font-family:Arial;font-size:10pt;color:#353536;">yo</font><font style="font-family:Arial;font-size:10pt;color:#454545;">u </font><font style="font-family:Arial;font-size:10pt;color:#353536;">ar</font><font style="font-family:Arial;font-size:10pt;color:#454545;">e </font><font style="font-family:Arial;font-size:10pt;color:#353536;">enter</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ng into a</font><font style="font-family:Arial;font-size:10pt;color:#454545;">n </font><font style="font-family:Arial;font-size:10pt;color:#353536;">Emp</font><font style="font-family:Arial;font-size:10pt;color:#454545;">loyme</font><font style="font-family:Arial;font-size:10pt;color:#353536;">nt </font><font style="font-family:Arial;font-size:10pt;color:#454545;">A</font><font style="font-family:Arial;font-size:10pt;color:#353536;">greem</font><font style="font-family:Arial;font-size:10pt;color:#454545;">en</font><font style="font-family:Arial;font-size:10pt;color:#353536;">t </font><font style="font-family:Arial;font-size:10pt;color:#454545;">w</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ith Dyadic wh</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ch </font><font style="font-family:Arial;font-size:10pt;color:#454545;">supe</font><font style="font-family:Arial;font-size:10pt;color:#353536;">r</font><font style="font-family:Arial;font-size:10pt;color:#454545;">s</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e</font><font style="font-family:Arial;font-size:10pt;color:#454545;">des y</font><font style="font-family:Arial;font-size:10pt;color:#353536;">our </font><font style="font-family:Arial;font-size:10pt;color:#454545;">E</font><font style="font-family:Arial;font-size:10pt;color:#353536;">mp</font><font style="font-family:Arial;font-size:10pt;color:#454545;">l</font><font style="font-family:Arial;font-size:10pt;color:#353536;">o</font><font style="font-family:Arial;font-size:10pt;color:#454545;">ym</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ent </font><font style="font-family:Arial;font-size:10pt;color:#454545;">A</font><font style="font-family:Arial;font-size:10pt;color:#353536;">greeme</font><font style="font-family:Arial;font-size:10pt;color:#454545;">nt fr</font><font style="font-family:Arial;font-size:10pt;color:#353536;">om October 23, 2013 (th</font><font style="font-family:Arial;font-size:10pt;color:#454545;">e "</font><font style="font-family:Arial;font-size:10pt;color:#353536;">Origin</font><font style="font-family:Arial;font-size:10pt;color:#454545;">a</font><font style="font-family:Arial;font-size:10pt;color:#353536;">l Contra</font><font style="font-family:Arial;font-size:10pt;color:#454545;">c</font><font style="font-family:Arial;font-size:10pt;color:#353536;">t</font><font style="font-family:Arial;font-size:10pt;color:#626262;">"</font><font style="font-family:Arial;font-size:10pt;color:#353536;">) that se</font><font style="font-family:Arial;font-size:10pt;color:#454545;">t t</font><font style="font-family:Arial;font-size:10pt;color:#353536;">he </font><font style="font-family:Arial;font-size:10pt;color:#454545;">term</font><font style="font-family:Arial;font-size:10pt;color:#353536;">s </font><font style="font-family:Arial;font-size:10pt;color:#454545;">for yo</font><font style="font-family:Arial;font-size:10pt;color:#353536;">u</font><font style="font-family:Arial;font-size:10pt;color:#626262;">r </font><font style="font-family:Arial;font-size:10pt;color:#353536;">emplo</font><font style="font-family:Arial;font-size:10pt;color:#454545;">y</font><font style="font-family:Arial;font-size:10pt;color:#353536;">m</font><font style="font-family:Arial;font-size:10pt;color:#454545;">e</font><font style="font-family:Arial;font-size:10pt;color:#353536;">nt a</font><font style="font-family:Arial;font-size:10pt;color:#454545;">s </font><font style="font-family:Arial;font-size:10pt;color:#353536;">D</font><font style="font-family:Arial;font-size:10pt;color:#454545;">y</font><font style="font-family:Arial;font-size:10pt;color:#353536;">adic</font><font style="font-family:Arial;font-size:10pt;color:#454545;">'</font><font style="font-family:Arial;font-size:10pt;color:#353536;">s </font><font style="font-family:Arial;font-size:10pt;color:#454545;">P</font><font style="font-family:Arial;font-size:10pt;color:#353536;">res</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">dent and Chief Ex</font><font style="font-family:Arial;font-size:10pt;color:#454545;">e</font><font style="font-family:Arial;font-size:10pt;color:#353536;">cut</font><font style="font-family:Arial;font-size:10pt;color:#454545;">iv</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e Offic</font><font style="font-family:Arial;font-size:10pt;color:#454545;">er.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353536;">Sec. 6(a) of the Original Contract provided you with certain rights in the event of a Cha</font><font style="font-family:Arial;font-size:10pt;color:#454545;">n</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ge of C</font><font style="font-family:Arial;font-size:10pt;color:#454545;">o</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ntrol as defined in that subsection, includ</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ng the right to receive a lump sum </font><font style="font-family:Arial;font-size:10pt;color:#454545;">p</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ayment of $1,335</font><font style="font-family:Arial;font-size:10pt;color:#454545;">,</font><font style="font-family:Arial;font-size:10pt;color:#353536;">000 (the equivalent of three years</font><font style="font-family:Arial;font-size:10pt;color:#454545;">' </font><font style="font-family:Arial;font-size:10pt;color:#353536;">of total compensation) upon giving Notice of Term</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">nation for Good Reason be</font><font style="font-family:Arial;font-size:10pt;color:#454545;">for</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e D</font><font style="font-family:Arial;font-size:10pt;color:#454545;">e</font><font style="font-family:Arial;font-size:10pt;color:#353536;">c</font><font style="font-family:Arial;font-size:10pt;color:#454545;">e</font><font style="font-family:Arial;font-size:10pt;color:#353536;">mber </font><font style="font-family:Arial;font-size:10pt;color:#454545;">3</font><font style="font-family:Arial;font-size:10pt;color:#353536;">1, 2016 </font><font style="font-family:Arial;font-size:10pt;color:#454545;">(</font><font style="font-family:Arial;font-size:10pt;color:#353536;">the </font><font style="font-family:Arial;font-size:10pt;color:#454545;">"</font><font style="font-family:Arial;font-size:10pt;color:#353536;">C</font><font style="font-family:Arial;font-size:10pt;color:#454545;">h</font><font style="font-family:Arial;font-size:10pt;color:#353536;">a</font><font style="font-family:Arial;font-size:10pt;color:#454545;">n</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ge o</font><font style="font-family:Arial;font-size:10pt;color:#454545;">f </font><font style="font-family:Arial;font-size:10pt;color:#353536;">C</font><font style="font-family:Arial;font-size:10pt;color:#454545;">ontr</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ol Compen</font><font style="font-family:Arial;font-size:10pt;color:#454545;">s</font><font style="font-family:Arial;font-size:10pt;color:#353536;">a</font><font style="font-family:Arial;font-size:10pt;color:#454545;">t</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ion</font><font style="font-family:Arial;font-size:10pt;color:#454545;">"</font><font style="font-family:Arial;font-size:10pt;color:#353536;">). Dyadic </font><font style="font-family:Arial;font-size:10pt;color:#454545;">'</font><font style="font-family:Arial;font-size:10pt;color:#353536;">s sa</font><font style="font-family:Arial;font-size:10pt;color:#454545;">l</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e of </font><font style="font-family:Arial;font-size:10pt;color:#454545;">a</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ssets tra</font><font style="font-family:Arial;font-size:10pt;color:#454545;">n</font><font style="font-family:Arial;font-size:10pt;color:#353536;">sac</font><font style="font-family:Arial;font-size:10pt;color:#454545;">ti</font><font style="font-family:Arial;font-size:10pt;color:#353536;">on in </font><font style="font-family:Arial;font-size:10pt;color:#454545;">D</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e</font><font style="font-family:Arial;font-size:10pt;color:#454545;">c</font><font style="font-family:Arial;font-size:10pt;color:#353536;">em</font><font style="font-family:Arial;font-size:10pt;color:#454545;">b</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e</font><font style="font-family:Arial;font-size:10pt;color:#454545;">r 20</font><font style="font-family:Arial;font-size:10pt;color:#353536;">15 </font><font style="font-family:Arial;font-size:10pt;color:#454545;">en</font><font style="font-family:Arial;font-size:10pt;color:#353536;">t</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">tled </font><font style="font-family:Arial;font-size:10pt;color:#454545;">y</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ou to </font><font style="font-family:Arial;font-size:10pt;color:#454545;">g</font><font style="font-family:Arial;font-size:10pt;color:#353536;">i</font><font style="font-family:Arial;font-size:10pt;color:#454545;">v</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e suc</font><font style="font-family:Arial;font-size:10pt;color:#454545;">h </font><font style="font-family:Arial;font-size:10pt;color:#353536;">a </font><font style="font-family:Arial;font-size:10pt;color:#454545;">N</font><font style="font-family:Arial;font-size:10pt;color:#353536;">o</font><font style="font-family:Arial;font-size:10pt;color:#454545;">tice</font><font style="font-family:Arial;font-size:10pt;color:#353536;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353536;">Because your new Employment Agreement supersedes </font><font style="font-family:Arial;font-size:10pt;color:#454545;">t</font><font style="font-family:Arial;font-size:10pt;color:#353536;">he Original Contract, as consideration for your executing the new Employment Agreement, the Change of Control Compensation shall be pa</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">d to you in 36 consecutive monthly payments of $37</font><font style="font-family:Arial;font-size:10pt;color:#454545;">,</font><font style="font-family:Arial;font-size:10pt;color:#353536;">083.33 in lieu of a lump sum. If your emplo</font><font style="font-family:Arial;font-size:10pt;color:#454545;">y</font><font style="font-family:Arial;font-size:10pt;color:#353536;">men</font><font style="font-family:Arial;font-size:10pt;color:#454545;">t </font><font style="font-family:Arial;font-size:10pt;color:#353536;">by Dyadic </font><font style="font-family:Arial;font-size:10pt;color:#454545;">t</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ermin</font><font style="font-family:Arial;font-size:10pt;color:#454545;">at</font><font style="font-family:Arial;font-size:10pt;color:#353536;">es </font><font style="font-family:Arial;font-size:10pt;color:#454545;">f</font><font style="font-family:Arial;font-size:10pt;color:#353536;">o</font><font style="font-family:Arial;font-size:10pt;color:#454545;">r a</font><font style="font-family:Arial;font-size:10pt;color:#353536;">n</font><font style="font-family:Arial;font-size:10pt;color:#454545;">y re</font><font style="font-family:Arial;font-size:10pt;color:#353536;">as</font><font style="font-family:Arial;font-size:10pt;color:#454545;">on, </font><font style="font-family:Arial;font-size:10pt;color:#353536;">the ent</font><font style="font-family:Arial;font-size:10pt;color:#454545;">ir</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e unpaid remainin</font><font style="font-family:Arial;font-size:10pt;color:#454545;">g </font><font style="font-family:Arial;font-size:10pt;color:#353536;">ba</font><font style="font-family:Arial;font-size:10pt;color:#454545;">la</font><font style="font-family:Arial;font-size:10pt;color:#353536;">n</font><font style="font-family:Arial;font-size:10pt;color:#454545;">c</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e o</font><font style="font-family:Arial;font-size:10pt;color:#454545;">f t</font><font style="font-family:Arial;font-size:10pt;color:#353536;">he </font><font style="font-family:Arial;font-size:10pt;color:#454545;">C</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ha</font><font style="font-family:Arial;font-size:10pt;color:#454545;">n</font><font style="font-family:Arial;font-size:10pt;color:#353536;">g</font><font style="font-family:Arial;font-size:10pt;color:#454545;">e </font><font style="font-family:Arial;font-size:10pt;color:#353536;">of C</font><font style="font-family:Arial;font-size:10pt;color:#454545;">o</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ntr</font><font style="font-family:Arial;font-size:10pt;color:#454545;">ol </font><font style="font-family:Arial;font-size:10pt;color:#353536;">Compe</font><font style="font-family:Arial;font-size:10pt;color:#454545;">n</font><font style="font-family:Arial;font-size:10pt;color:#353536;">sat</font><font style="font-family:Arial;font-size:10pt;color:#454545;">ion sh</font><font style="font-family:Arial;font-size:10pt;color:#353536;">all be immed</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">at</font><font style="font-family:Arial;font-size:10pt;color:#454545;">e</font><font style="font-family:Arial;font-size:10pt;color:#353536;">l</font><font style="font-family:Arial;font-size:10pt;color:#454545;">y </font><font style="font-family:Arial;font-size:10pt;color:#353536;">due and pa</font><font style="font-family:Arial;font-size:10pt;color:#454545;">y</font><font style="font-family:Arial;font-size:10pt;color:#353536;">able to </font><font style="font-family:Arial;font-size:10pt;color:#454545;">yo</font><font style="font-family:Arial;font-size:10pt;color:#353536;">u i</font><font style="font-family:Arial;font-size:10pt;color:#454545;">n </font><font style="font-family:Arial;font-size:10pt;color:#353536;">f</font><font style="font-family:Arial;font-size:10pt;color:#454545;">u</font><font style="font-family:Arial;font-size:10pt;color:#353536;">l</font><font style="font-family:Arial;font-size:10pt;color:#454545;">l</font><font style="font-family:Arial;font-size:10pt;color:#353536;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353536;">This letter agreement const</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">tutes a legally binding agreement between you and Dyadic</font><font style="font-family:Arial;font-size:10pt;color:#454545;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#454545;">P</font><font style="font-family:Arial;font-size:10pt;color:#353536;">lease acknowledge our </font><font style="font-family:Arial;font-size:10pt;color:#454545;">a</font><font style="font-family:Arial;font-size:10pt;color:#353536;">cceptance of the foregoing by signing you</font><font style="font-family:Arial;font-size:10pt;color:#454545;">r </font><font style="font-family:Arial;font-size:10pt;color:#353536;">na</font><font style="font-family:Arial;font-size:10pt;color:#454545;">m</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e where </font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ndicated b</font><font style="font-family:Arial;font-size:10pt;color:#454545;">e</font><font style="font-family:Arial;font-size:10pt;color:#353536;">low. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#454545;">V</font><font style="font-family:Arial;font-size:10pt;color:#353536;">e</font><font style="font-family:Arial;font-size:10pt;color:#454545;">ry trul</font><font style="font-family:Arial;font-size:10pt;color:#353536;">y </font><font style="font-family:Arial;font-size:10pt;color:#454545;">y</font><font style="font-family:Arial;font-size:10pt;color:#353536;">o</font><font style="font-family:Arial;font-size:10pt;color:#454545;">u</font><font style="font-family:Arial;font-size:10pt;color:#353536;">rs</font><font style="font-family:Arial;font-size:10pt;color:#454545;">,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#454545;">/s/ Michael P. Tarnok</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#454545;">M</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ic</font><font style="font-family:Arial;font-size:10pt;color:#454545;">h</font><font style="font-family:Arial;font-size:10pt;color:#353536;">ael P</font><font style="font-family:Arial;font-size:10pt;color:#454545;">. </font><font style="font-family:Arial;font-size:10pt;color:#353536;">Tarnok</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353536;">Cha</font><font style="font-family:Arial;font-size:10pt;color:#454545;">i</font><font style="font-family:Arial;font-size:10pt;color:#353536;">rman, Compensation Committee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:59.82905982905983%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:13%;"></td><td style="width:80%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accepted and acknowledged this 16th day of June, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Mark A. Emalfarb</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark A. Emalfarb</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><a name="s3f4a3c1a9ac94fe38aa05b62b40fcf3d"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FIRST AMENDMENT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EMPLOYMENT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THIS FIRST AMENDMENT (this "</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">First Amendment</font><font style="font-family:inherit;font-size:10pt;">") is made and entered into by and between DYADIC INTERNATIONAL, INC., a Delaware corporation (the "Company") and MARK A. EMALFARB (the "</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive</font><font style="font-family:inherit;font-size:10pt;">") as of the 23</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;day of January, 2017 .</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECITALS:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A.&#160;&#160;&#160;&#160;The Company and the Executive are parties to that certain Employment Agreement dated June 21", 2016 (the "</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employment Agreement</font><font style="font-family:inherit;font-size:10pt;">"). Each capitalized term used but not expressly defined in this First Amendment shall have the meaning assigned that defined term in the Employment Agreement. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B.&#160;&#160;&#160;&#160;The Company and the Executive wish to amend the exercise price of the options under the Employment Agreement to be priced at an exercise price equal to the average closing price of the Company's publicly-traded shares often (l0) trading days preceding the grant date as provided herein. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AGREEMENT:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:46px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOW, THEREFORE, in consideration of the foregoing Recitals and other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the Company and the Executive hereby amend the Employment Agreement as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Revise Exercise Price on Option</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 3.(c) of the Employment Agreement, entitled "</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">3. Compensation (c) Performance Stock Options</font><font style="font-family:inherit;font-size:10pt;">" is hereby amended to read as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;... which option shall be priced at an exercise price equal to the average closing price of the Company's publicly-traded shares of ten (10) trading days preceding the first business day of 2017 and shall vest on January 2, 2017. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;On the first business day of each of 2018 and 2019, the Company shall grant the Executive an option to purchase up to three hundred thousand (300,000) shares based on the Compensation Committee's evaluation of the Executive's prior year performance objectives established and agreed upon by the Company and the Executive. In each case, the option shall be priced at an exercise price equal to the average closing price of the Company's publicly-traded shares of ten (10) trading days proceeding the first business day of each of 2018 and 2019, respectively, and shall vest on the grant date. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Effect of Amendment</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. </font><font style="font-family:inherit;font-size:10pt;">Except as expressly amended by the provisions of</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">this First Amendment, all of the terms and provisions of the Employment Agreement shall remain in full force and effect.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, the Company and the Executive have executed this First Amendment as of the day and year first above written.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.31623931623932%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:5%;"></td><td style="width:41%;"></td><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:41%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#393739;">THE COMPANY:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#393739;">THE EXECUTIVE:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#393739;">DYADIC INTERNATIONAL, INC., a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Michael P. Tarnok</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark A. Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael P. Tarnok</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark A. Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>11
<FILENAME>exhibit106form10.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s14BBE6CB2BC5719F139744935AB5D72F"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 10.6</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">EMPLOYMENT AGREEMENT </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">("Agreement") made and entered into as of May 1, 2016 by and between </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">DYADIC INTERNATIONAL, INC., </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">a Delaware corporation, with its principal place of business at 140 lntracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477 (the "Company"), and </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">THOMAS L. DUBINSKI, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">a resident of Florida ("Employee"). (The Company and Employee are sometimes hereinafter jointly referred to as the "parties" and individually as a "party.")</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">Recitals:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employee has been employed by the Company as its Vice President and Chief Financial Officer since August 4, 2014 pursuant to an Employment Agreement dated July 15, 2014 (the "Original Contract").</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">The Company wishes to assure itself of the services of Employee for the period provided in this Agreement by entering into this Agreement and thereby superseding the Original Contract.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">NOW, THEREFORE, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">in consideration of the foregoing recitals, and the mutual agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties hereby agree as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">ARTICLE I</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">EMPLOYMENT RELATIONSHIP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">1.1&#160;&#160;&#160;&#160;Recitals. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">The Recitals to this Agreement are hereby incorporated herein and made a part hereof.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">1.2&#160;&#160;&#160;&#160;Employment. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Subject to the terms and conditions of this Agreement, the Company hereby agrees to continue to employ Employee to serve as the Company's Vice President and Chief Financial Officer and Employee hereby accepts such ongoing employment, and agrees to perform all of his assigned duties and responsibilities to the best of his abilities in a diligent, trustworthy, businesslike and efficient manner, and in compliance with the Company's Code of Business Conduct and Ethics, a copy of which appears on the Company's website.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">1.3&#160;&#160;&#160;&#160;Duties; Reporting Authority. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employee shall continue to have the normal and customary duties, responsibilities and authority of a Person (as that term is defined in Article VII below) holding the title and job description set forth in Sec. 1.2 hereof, and in addition, shall perform such other duties on behalf of the Company as may be assigned to him by the Chief Executive Officer ("CEO") of the Company, or by the Company's Board of Directors (the "Board"). Employee shall report to the CEO of the Company in connection with Employee's performance of his duties.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">1.4&#160;&#160;&#160;&#160;Exclusive Employment. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">While employed by the Company, Employee agrees to devote his entire business time, energy, attention and skill to the Company (except for permitted vacation periods and reasonable periods of illness or other incapacity), and use his good faith best efforts to promote the interests of the Company. The foregoing shall not be construed as prohibiting Employee from spending such time as may be reasonably necessary to attend to his investments and personal and other affairs, so long as such activities do not conflict or interfere with Employee's obligations and/or timely performance of his duties to the Company hereunder.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">1.5&#160;&#160;&#160;&#160;Employee Representations. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employee hereby represents and warrants to the Company that:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(a)&#160;&#160;&#160;&#160;the execution, delivery and performance by Employee of this Agreement and any other agreements contemplated hereby to which Employee is a party do not and shall not conflict </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Employee is a party or by which he is bound;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(b)&#160;&#160;&#160;&#160;Employee is not a party to or bound by any employment agreement, non-competition agreement or confidentiality agreement with any other Person or entity; and</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(c)&#160;&#160;&#160;&#160;Employee hereby acknowledges and represents that he has consulted with, or had the opportunity to consult with, independent legal counsel regarding his rights and obligations under this Agreement and fully understands the terms and conditions contained herein.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">1.6&#160;&#160;&#160;&#160;Company Representations. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The Company hereby represents and warrants to Employee that the execution, delivery and performance by the Company of this Agreement and any other agreements contemplated hereby to which the Company is a party do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which the Company is a party or by which it is bound</font><font style="font-family:Arial;font-size:10pt;color:#656565;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">1.7&#160;&#160;&#160;&#160;Indemnification.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;text-decoration:underline;">By Employee</font><font style="font-family:Arial;font-size:10pt;color:#333333;">. Employee shall indemnify and hold the Company harmless from and against any and all claims, demands, losses, judgments, costs, expenses, or liabilities incurred by the Company arising out of or in connection with the breach of any representation or warranty of Employee contained in Sec. 1.5, Article IV and Sec. 6.1 of this Agreement.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;text-decoration:underline;">By the Company</font><font style="font-family:Arial;font-size:10pt;color:#333333;">. The Company shall indemnify and hold Employee harmless from and against any and all claims, demands, losses, judgments, costs, expenses, or liabilities incurred by Employee arising out of or in connection with the breach of any representation or warranty of the Company contained in this Agreement. Further, the Company shall defend, indemnify and hold Employee harmless to the fullest extent permitted by applicable law and the Bylaws of the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">ARTICLE II</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">PERIOD OF EMPLOYMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">2.1&#160;&#160;&#160;&#160;Employment Period. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Employee shall continue to be an employee of the Company until the date fixed by the provisions of Sec. 2.2 hereof, subject to the early termination provisions of Article V hereof (the "Employment Period").</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">2.2&#160;&#160;&#160;&#160;Term of Employment Period. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The Employment Period of this Agreement shall begin on the date hereof and shall continue until April 30, 2018 unless terminated as provided in Article V below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">ARTICLE Ill</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">COMPENSATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">3.1&#160;&#160;&#160;&#160;Annual Base Compensation. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The Company shall pay to Employee an annual base salary (the "Annual Base Compensation") in the amount of two hundred twenty five thousand dollars ($225,000). The Annual Base Compensation shall be paid in regular installments in accordance with the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">'</font><font style="font-family:Arial;font-size:10pt;color:#333333;">s general payroll practices</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">and shall be subject to the payment by the Company of all required federal, state and local withholding taxes. Employee's Annual Base Compensation shall be </font><font style="font-family:Arial;font-size:10pt;color:#323232;">reviewed by the Company</font><font style="font-family:Arial;font-size:10pt;color:#464646;">'</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s CEO and the Compensation Committee of the Board (the "Compensation Committee") annually.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">3.2</font><font style="font-family:Arial;font-size:10pt;color:#323232;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">Potential Bonuses. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">In respect of each of the twelve (12) month periods (each, a "Contract Year") falling within the Employment Period, Employee shall be eligible to earn as a bonus, in the sole discretion of the Compensation Committee, a stock option to purchase up to an aggregate of one hundred sixty thousand (160,000) shares of the Company's common stock (the "2016 and 2017 Maximum Option Bonus</font><font style="font-family:Arial;font-size:10pt;color:#464646;">"</font><font style="font-family:Arial;font-size:10pt;color:#323232;">), provided, however that there shall be no obligation on the part of the Company to pay or award Employee any bonus</font><font style="font-family:Arial;font-size:10pt;color:#464646;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">The amount of such bonus, if any, which is awarded to Employee (the "Bonusable </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">Amount</font><font style="font-family:Arial;font-size:10pt;color:#464646;">"</font><font style="font-family:Arial;font-size:10pt;color:#323232;">) shall be memorialized by the Company at the time of award in a Stock Option Agreement setting forth the number of shares optioned, the term of the option and the exercise price. In the absolute discretion of the Company's Compensation Committee, Employee may be entitled to receive an additional discretionary bonus, as and if the Company shall determine from time to time. Any Bonusable Amount awarded or paid to Employee hereunder will be payable not later than seventy five (75) days after the close of the Company's fiscal year for which the bonus was awarded, in accord with the short-term deferral exemption of Sec. 409A of the Internal Revenue Code and the regulations promulgated thereunder, each as amended ("Sec</font><font style="font-family:Arial;font-size:10pt;color:#464646;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">409A")</font><font style="font-family:Arial;font-size:10pt;color:#666666;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">3.3</font><font style="font-family:Arial;font-size:10pt;color:#323232;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">Stock Option Grants</font><font style="font-family:Arial;font-size:10pt;color:#464646;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Upon the full execution of this Agreement, Employee will be granted a stock option to purchase fifty three thousand three hundred thirty three (53,333) shares of the Company's common stock (the "First Option</font><font style="font-family:Arial;font-size:10pt;color:#464646;">"</font><font style="font-family:Arial;font-size:10pt;color:#323232;">) pursuant to the Company</font><font style="font-family:Arial;font-size:10pt;color:#464646;">'</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s 2011 Equity Incentive Award Plan (the "Plan</font><font style="font-family:Arial;font-size:10pt;color:#464646;">"</font><font style="font-family:Arial;font-size:10pt;color:#323232;">) which share amount comprises one third (1/3) of the 2016 and 2017 Maximum Option Bonus. The exercise price per share of the First Option will be equal to the fair market value per share of the Company's common stock on May 2, 2016. The term of the First Option will be ten (10) years from the grant date. The First Option will vest immediately</font><font style="font-family:Arial;font-size:10pt;color:#464646;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Employee has received a copy of the Plan and agrees to the terms and conditions thereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">Employee will also be granted a five (5) year stock option to purchase two hundred fifty thousand (250,000) shares of the Company's common stock at the same exercise price applicable to the First Opt</font><font style="font-family:Arial;font-size:10pt;color:#464646;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">on</font><font style="font-family:Arial;font-size:10pt;color:#575757;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">which option shall vest and become exercisable </font><font style="font-family:Arial;font-size:10pt;color:#464646;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">f the Company</font><font style="font-family:Arial;font-size:10pt;color:#464646;">'</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s shares of common stock commence trading on the Nasdaq Capital Market or other stock exchange approved by the Board</font><font style="font-family:Arial;font-size:10pt;color:#575757;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">3.4&#160;&#160;&#160;&#160;Expenses</font><font style="font-family:Arial;font-size:10pt;color:#575757;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">During the Employment Period, Employee shall be entitled to reimbursement of all travel, entertainment and other business expenses reasonably incurred in the performance of his duties for the Company, upon submission of all receipts and accounts with respect thereto, and approval by the Company thereof, in accordance with the business expense reimbursement policies adopted by the Company from time to time. Any such reimbursement that would constitute nonqualified deferred compensation subject to Sec. 409A shall be subject to the following additional rules: (a) no reimbursement of any such expense shall affect Employee</font><font style="font-family:Arial;font-size:10pt;color:#464646;">'</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s right to reimbursement of any other such expense in any other taxable year</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">(b) reimbursement of the expense shall be made, if at all, not later than the end of the calendar year following the calendar year in which the expense was incurred, and (c) the right to reimbursement shall not be subject to liquidation or exchange for any other benefit.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">3.5&#160;&#160;&#160;&#160;Vacation</font><font style="font-family:Arial;font-size:10pt;color:#464646;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">In respect of each Contract Year falling within the Employment Period, Employee shall be entitled to four (4) weeks of vacation</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">or if greater, the number of weeks of vacation proscribed by the vacation policies of the Company then in effect from time to time, provided that unused vacation may be used by Employee in the following Contract Year only in accordance with and as permitted by the Company's then current vacation policies in effect from time to time.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">3.6&#160;&#160;&#160;&#160;Other Fringe Benefits. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">During the Employment Period, if</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">as and when they are being provided to other employees of the Company holding positions with the Company comparable to Employee's position</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Employee shall also be entitled to receive the same fringe benefits offered to such </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">employees including, but not limited to, health insurance benefits, disability benefits and retirement benefits.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">3.7&#160;&#160;&#160;&#160;Other Incentive Compensation. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employee shall be eligible to participate during the Employment Period in such incentive plans, stock option plans, stock purchase plans and any other long-term compensation plans, programs or arrangements which may be adopted by the Company and applicable to Employee as determined by the Company's Compensation Committee, in its sole discretion.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">ARTICLE IV </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">COVENANTS OF EMPLOYEE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">4.1&#160;&#160;&#160;&#160;Proprietary Rights. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employee hereby expressly agrees that all research, discoveries, inventions and innovations (whether or not reduced to practice or documented), improvements, developments, methods, designs, analyses, drawings, reports and all similar or related information (whether </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">patentable or unpatentable, and whether or not reduced to writing), trade secrets (being information about the business of the Company which is considered by the Company to be confidential and is proprietary to the Company) and confidential information, copyrightable works, and similar and related information (in whatever form or medium), which (x) either (i) relate to the Company's actual or anticipated business, research and development or existing or future products or services or (ii) result from any work performed by Employee for the Company and (y) are conceived, developed, made or contributed to in whole or in part by Employee during the Employment Period ("Work Product") shall be and remain the sole and exclusive property of the Company. Employee shall communicate promptly and fully all Work Product to the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Work Made for Hire</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. Employee acknowledges that, unless otherwise agreed in writing by the Company, all Work Product eligible for any form of copyright protection made or contributed to in whole or in part by Employee within the scope of Employee's employment by the Company during the Employment Period shall be deemed a "work made for hire" under the copyright laws and shall be owned exclusively by the Company.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Assignment of Proprietary Rights</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. Employee hereby assigns, transfers and conveys to the Company, and shall assign, transfer and convey to the Company, all right, title and interest in and to all inventions, ideas, improvements, designs, processes, trademarks, service marks, trade names, trade secrets, trade dress, data, discoveries and other proprietary assets and proprietary rights in and of the Work Product (the "Proprietary Rights") for the Company's exclusive ownership and use, together with all rights to sue and recover for past and future infringement or misappropriation thereof, which shall enjoy exclusive ownership and use, together with all rights to sue and recover for past and future infringement or misappropriation thereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:56px;text-indent:46px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Further Instruments</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. At the request of the Company, at all times during the Employment Period and thereafter, Employee will promptly and fully assist the Company as the case may be) in effecting the purpose of the foregoing assignment, including but not limited to the further acts of executing any and all documents necessary to secure for the Company such Proprietary Rights and other rights to all Work Product and all confidential information related thereto, providing cooperation and giving testimony.</font></div><div style="line-height:120%;text-align:left;padding-left:56px;text-indent:46px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:56px;text-indent:46px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Inapplicability of Sec. 4.1 in Certain Circumstances</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">. The Company expressly acknowledges and agrees that, and Employee is hereby advised that, this Sec. 4.1 does not apply to any invention for which no equipment, supplies, facilities or trade secret information of the Company was used and which was developed entirely on Employee's own time, unless (i) the invention relates to the business of the Company or to the Company's actual or </font><font style="font-family:Arial;font-size:10pt;color:#323232;">demonstrably anticipated research or development or (ii) the invention results from any work performed by Employee for the Company.</font></div><div style="line-height:120%;text-align:left;padding-left:56px;text-indent:46px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">4.2&#160;&#160;&#160;&#160;Ownership and Covenant to Return Documents. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Employee agrees that all Work Product and all documents or other tangible materials (whether originals, copies or abstracts), including without limitation, price lists, quotation guides, outstanding quotations, books, records, manuals, files, sales literature, training materials, customer records, correspondence, computer disks or print-out documents, contracts, orders, messages, phone and address lists, invoices and receipts, and all objects associated therewith, which in any way relate to the business or affairs of the Company, either furnished to Employee by the Company or prepared, compiled or otherwise acquired by Employee during the Employment Period, shall be the sole and exclusive property of the Company. Employee shall not use, copy or duplicate any of the aforementioned documents or objects, nor remove them from the facilities of the Company, nor use any information concerning them except for the benefit of the Company, either during the Employment Period or thereafter. Employee agrees that he will deliver all of the aforementioned documents and objects that may be in his possession to the Company on the termination of his employment with the Company, or at any other time upon the Company's request, together with his written certification of compliance with the provisions of this Sec. 4.2 in the form of </font><font style="font-family:Arial;font-size:10pt;color:#323232;text-decoration:underline;">Exhibit A</font><font style="font-family:Arial;font-size:10pt;color:#323232;">&#32;to this Agreement in accordance with the provisions of Sec. 5.3 hereof.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">4.3&#160;&#160;&#160;&#160;Non-Disclosure Covenant</font><font style="font-family:Arial;font-size:10pt;color:#505050;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">For a period commencing on the date of this Agreement and ending on the last to occur of five (5) years following the date of execution of this Agreement or three (3) years following the date of the termination of the Employment Period (the "Non-Disclosure Period"), Employee shall not, either directly or indirectly, disclose to any "unauthorized person" or use for the benefit of Employee or any Person other than the Company any Work Product or any knowledge or information which Employee may acquire while employed by the Company (whether before or after the date of this Agreement) relating to (a) the financial, marketing, sales and business plans and affairs, financial statements, analyses, forecasts and projections, books, accounts, records, operating costs and expenses and other financial information of the Company, (b) internal management tools and systems, costing policies and methods, pricing policies and methods and other methods of doing business, of the Company, (c) customers, sales, customer requirements and usages and distributor lists, of the Company, (d) agreements with customers, vendors, independent contractors, employees and others, of the Company, (e) existing and future products or services and product development plans, designs, analyses and reports, of the Company, (f) computer software and databases developed for the Company, trade secrets, research, records of research, models, designs, drawings, technical data and reports of the Company, and (g) correspondence or other private or confidential matters, information or data whether written, oral or electronic, which is proprietary to the Company and not generally known to the public (individually and collectively "Confidential Information"), without the Company's prior written permission. For purposes of this Sec. 4.3, the term "unauthorized person" shall mean any Person who is not (i) an officer or director of the Company or an employee of the Company for whom the disclosure of the knowledge or information referred to herein is necessary for his performance of his assigned duties, or (ii) a Person expressly authorized by the Company to receive disclosure of such knowledge or information. The Company expressly acknowledges and agrees that the term "Confidential Information" excludes information which is (A) in the public domain or otherwise generally known to the trade, or (B) disclosed to third parties other than by reason of Employee's breach of his confidentiality obligations hereunder or (C) learned of by Employee subsequent to the termination of his employment hereunder from any other party not then under an obligation of confidentiality to the Company</font><font style="font-family:Arial;font-size:10pt;color:#505050;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Further, Employee covenants to the Company that in Employee's performance of his duties hereunder, Employee will not violate any confidentiality obligations he may have to any third Persons.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">4.4&#160;&#160;&#160;&#160;Non-Interference Covenants. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Employee covenants to the Company that while Employee is employed by the Company hereunder and for the two (2) year period thereafter (the "Noninterference Period"), he will not, for any reason, directly or indirectly</font><font style="font-family:Arial;font-size:10pt;color:#505050;">: </font><font style="font-family:Arial;font-size:10pt;color:#323232;">(a) solicit, hire, or otherwise do any act or thing which may induce any other employee of the Company to leave the employ or otherwise interfere with or adversely affect the relationship (contractual or otherwise) of the Company, with any person who is then or thereafter becomes an employee of the Company; (b) do any act or thing which may interfere with or adversely affect the relationship ( contractual or otherwise) of the Company with any vendor of goods or services to the Company or induce any such vendor to cease doing business with the Company; or (c) except for Competitive Activities (as defined in Sec</font><font style="font-family:Arial;font-size:10pt;color:#494949;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">4</font><font style="font-family:Arial;font-size:10pt;color:#494949;">.</font><font style="font-family:Arial;font-size:10pt;color:#323232;">5 hereof) engaged in by Employee after the expiration of the Non-Competition Period, do any act or thing which may interfere with or adversely affect the relationship (contractual or otherwise) of the Company with any customer of the Company or induce any such customer to cease doing business with the Company</font><font style="font-family:Arial;font-size:10pt;color:#494949;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">4.5&#160;&#160;&#160;&#160;Covenant Not To Compete</font><font style="font-family:Arial;font-size:10pt;color:#494949;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Employee expressly acknowledges that (a) Employee's performance of his services for the Company hereunder will afford him access to and cause him to become highly knowledgeable about the Company's Confidential Information; (b) the agreements and covenants contained in this Sec. 4.5 are essential to protect the Confidential Information, business and goodwill of the Company and the restraints on Employee imposed by the provisions of this Sec. 4.5 are justified by these legitimate business interests of the Company; and (c) Employee's covenants to the Company set forth in this Sec. 4.5 are being made both in consideration of the Company's employment of Employee and other financial benefits of this Agreement. Accordingly, Employee hereby agrees that while Employee is employed by the Company and for the one (1) year period thereafter (the "Non-Competition Period"), Employee shall not</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">anywhere in the United States, directly or indirectly, own any interest in, invest in, lend to, borrow from, manage, control, participate in, consult with</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">become employed by, render services to, or in any other manner whatsoever engage in, any business which is competitive with any lines of business actively being engaged in by the Company in the development or use of gene expression systems (collectively, </font><font style="font-family:Arial;font-size:10pt;color:#494949;">"</font><font style="font-family:Arial;font-size:10pt;color:#323232;">Competitive Activities")</font><font style="font-family:Arial;font-size:10pt;color:#494949;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">The preceding to the contrary notwithstanding</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Employee shall be free to make investments in the publicly-traded securities of any corporation, provided that such investments do not amount to more than one percent (1%) of the outstanding securities of any class of such corporation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">4.6&#160;&#160;&#160;&#160;Remedies for Breach. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">If Employee commits a breach, or threatens to commit a breach, of any of the provisions of this Article IV, the Company shall have the right and remedy, in addition to any other remedy that may be available at law or in equity, to have the provisions of this Article IV specifically enforced by any court having equity jurisdiction, by the entry of temporary, preliminary and permanent injunctions and orders of specific performance, together with an accounting therefor, it being expressly acknowledged and agreed by Employee that any such breach or threatened breach will cause irreparable injury to the Company and that money damages will not provide an adequate remedy to the Company. Any such injunction shall be available without the posting of any bond or other security, and Employee hereby consents to the issuance of such injunction. Employee further agrees that any such injunctive relief obtained by the Company shall be in addition to, and not in lieu of, monetary damages and any other remedies to which the Company may be entitled</font><font style="font-family:Arial;font-size:10pt;color:#494949;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Further, in the event of an alleged breach or violation by Employee of any of the provisions of Sections 4</font><font style="font-family:Arial;font-size:10pt;color:#494949;">.</font><font style="font-family:Arial;font-size:10pt;color:#323232;">3, 4.4 or 4</font><font style="font-family:Arial;font-size:10pt;color:#494949;">.</font><font style="font-family:Arial;font-size:10pt;color:#323232;">5 hereof</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">the Non-Disclosure Period</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">the Non-Interference Period and/or the Non-Competition Period, as the case may be, shall be tolled until such breach or violation has been cured</font><font style="font-family:Arial;font-size:10pt;color:#494949;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">ARTICLE V </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">TERMINATION OF EMPLOYMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">5.1&#160;&#160;&#160;&#160;Termination and Triggering Events. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Notwithstanding anything to the contrary else- where contained in this Agreement, the Employment Period shall terminate upon the occurrence of any of the following events (hereinafter referred to as "Triggering Events"): (a) Employee's death; (b) Employee's Total Disabil</font><font style="font-family:Arial;font-size:10pt;color:#494949;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">ty</font><font style="font-family:Arial;font-size:10pt;color:#494949;">; </font><font style="font-family:Arial;font-size:10pt;color:#323232;">(c) Employee's Resignation; (d) a Termination by the Company for Cause; or (e) a Termination by the Company without Cause.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">5.2&#160;&#160;&#160;&#160;Rights upon Occurrence of a Triggering Event</font><font style="font-family:Arial;font-size:10pt;color:#494949;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Subject to the provisions of Sec</font><font style="font-family:Arial;font-size:10pt;color:#494949;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">5</font><font style="font-family:Arial;font-size:10pt;color:#494949;">.</font><font style="font-family:Arial;font-size:10pt;color:#323232;">3 hereof, the rights of the parties upon the occurrence of a Triggering Event shall be as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Termination by the Company for Cause: </font><font style="font-family:Arial;font-size:10pt;color:#303030;">If the Triggering Event was a Termination by the Company for Cause, Employee shall be entitled to receive his Annual Base Compensation and accrued but unpaid vacation through the date thereof in accordance with the policy of the Company</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">and to continue to participate in the Company</font><font style="font-family:Arial;font-size:10pt;color:#484848;">'</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s health, insurance and disability plans and programs through that date and thereafter, only to the extent permitted under the terms of such plans and programs</font><font style="font-family:Arial;font-size:10pt;color:#484848;">.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Death or Total Disability: </font><font style="font-family:Arial;font-size:10pt;color:#303030;">If the Triggering Event was Employee</font><font style="font-family:Arial;font-size:10pt;color:#484848;">'</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s death or Total Disability, Employee (or Employee's designated beneficiary) shall be entitled to receive Employee's Annual Base Compensation and accrued but unpaid vacation through the date thereof and to continue to participate in the Company's health, insurance and disability plans and programs through the date of termination and thereafter only to the extent permitted under the terms of such plans and programs</font><font style="font-family:Arial;font-size:10pt;color:#484848;">.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Termination by the Company Without Cause: </font><font style="font-family:Arial;font-size:10pt;color:#303030;">If the Triggering Event was a Termination by the Company Without Cause, Employee shall be entitled to receive his Annual Base Compensation and accrued but unpaid vacation through the date thereof plus, in the discretion of the Company's Compensation Committee, the 2016 and 2017 Maximum Option Bonus, payable in accordance with the Company's normal payroll practices</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">and for the six (6) month period following the date of termination of Employee</font><font style="font-family:Arial;font-size:10pt;color:#484848;">'</font><font style="font-family:Arial;font-size:10pt;color:#303030;">s employment with the Company (the </font><font style="font-family:Arial;font-size:10pt;color:#484848;">"</font><font style="font-family:Arial;font-size:10pt;color:#303030;">Severance Period"), an amount per month equal to one-twelfth (1/12) of Employee's Annual Base Compensation on the date of termination in installments consistent with the Company's normal payroll practices, commencing with the first regular payroll payment date following the termination of the Employment Period (collectively</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the "Severance Benefits"), and to continue to participate in the Company's health, insurance and disability plans and programs for the six (6) month period following the date of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">termination of Employee's employment with the Company (the "Severance Period"); </font><font style="font-family:Arial;font-size:10pt;color:#303030;text-decoration:underline;">provided that</font><font style="font-family:Arial;font-size:10pt;color:#303030;">&#32;Employee shall be entitled to receive such Severance Benefits during the Severance Period if (i) Employee has executed and delivered to the Company an effective and irrevocable General Release substantially in form and substance as set forth in </font><font style="font-family:Arial;font-size:10pt;color:#303030;text-decoration:underline;">Exhibit B</font><font style="font-family:Arial;font-size:10pt;color:#303030;">&#32;to this Agreement within fifty (50) days after his termination date, and (ii) Employee has not breached any of his covenants to the Company set forth in this Agreement. To the extent any payments under this Sec. 5.2(c) are treated as non-qualified deferred compensation subject to Sec. 409A, if the fifty (50) calendar day period from Employee's termination date through the expiration of any applicable revocation period with respect to the General Release begins in one taxable year and ends in the following taxable year, then payments shall not commence being paid or be paid until the beginning of the second taxable year.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Cessation of Entitlements and Company Right of Offset. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Except as other</font><font style="font-family:Arial;font-size:10pt;color:#484848;">- </font><font style="font-family:Arial;font-size:10pt;color:#303030;">wise expressly provided herein, all of Employee's rights to salary, employee benefits, fringe benefits and bonuses hereunder (if any) which would otherwise accrue after the termination of the Employment Period shall cease upon the date of such termination</font><font style="font-family:Arial;font-size:10pt;color:#484848;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">The Company may offset any loans, cash advances or fixed amounts which Employee owes the Company against any amounts it owes Employee under this Agreement. Notwithstanding anything herein to the contrary, if at the time of Employee's separation from service, Employee is a "specified employee" as defined below, any and all amounts payable under this Agreement on account of that separation from service that constitute deferred compensation subject to Sec. 409A as determined by the Company in its discretion and that would, but for this provision, be payable within six (6) months following the date of separation, shall instead be paid on the next business day following the expiration of the six (6) month period. Also, for purposes of this Agreement, the phrase "termination of employment" and correlative phrases mean a </font><font style="font-family:Arial;font-size:10pt;color:#484848;">"</font><font style="font-family:Arial;font-size:10pt;color:#303030;">separation from service" as defined in Treas</font><font style="font-family:Arial;font-size:10pt;color:#484848;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Regs. Sec. 1</font><font style="font-family:Arial;font-size:10pt;color:#484848;">.</font><font style="font-family:Arial;font-size:10pt;color:#303030;">409A-1(h) and the term </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"specified employee" means someone determined by the Company to be a specified employee under Treas. Regs. Sec. 1.409A-1 (i). For the avoidance of doubt, any tax liability to which the Employee is subject under Sec. 409A shall be solely Employee's responsibility. Each payment under this Agreement or any benefit plan of the Company is intended to be treated as one of a series of separate payments for purposes of Sec. 409A and Treas. Regs. Sec. 1.409A-2(b)(2)(iii) (or any similar or successor provisions, including without limitation, any similar state law provisions).</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Resignation for Good Reason. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">If Employee resigns for Good Reason, Employee shall be entitled to receive his Annual Base Compensation and accrued but unpaid vacation through the date thereof plus, in the discretion of the Company's Compensation Committee, the 2016 and 2017 Maximum Option Bonus, payable in accordance with the Company's normal payroll practices, and for the Severance Period, the Severance Benefits and to continue to participate in the Company's health, insurance and disability plans and programs for the Severance Period.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Change of Control. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">In the event of a Change of Control (as defined in the Plan) during the Employment Period, vesting of Employee's stock options theretofore granted shall accelerate and be exercisable on the date of the Change of Control. In the discretion of the Compensation Committee, Employee may be awarded an additional bonus on or before the occurrence of a Change of Control.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">5.3&#160;&#160;&#160;&#160;Survival of Certain Obligations and Termination Certificate. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">The provisions of Articles IV, V, VI and VIII shall survive any termination of the Employment Period, whether by reason of the occurrence of a Triggering Event or the expiration of the Employment Period. Immediately following the termination of the Employment Period, Employee shall promptly return to the Company all property required to be returned to the Company pursuant to the provisions of Sec. 4.2 hereof and execute and deliver to the Company the Termination Certificate attached hereto as </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">Exhibit A</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">&#32;and by this reference made a part hereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">ARTICLE VI </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">ASSIGNMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">6.1&#160;&#160;&#160;&#160;Prohibition of Assignment by Employee. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employee expressly agrees for himself and on behalf of his executors, administrators and heirs, that this Agreement and his obligations, rights, interests and benefits hereunder shall not be assigned, transferred, pledged or hypothecated in any way by Employee, his executors, administrators or heirs, and shall not be subject to execution, attachment or similar process. Any attempt to assign, transfer, pledge, hypothecate or otherwise dispose of this Agreement or any such rights, interests and benefits thereunder contrary to the foregoing provisions, or the levy of any attachment or similar process thereupon shall be null and void and without effect and shall relieve the Company of any and all liability hereunder.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">6.2&#160;&#160;&#160;&#160;Right of Company to Assign. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Except as provided in the next sentence, the rights, but not the obligations of the Company shall be assignable and transferable to any successor-in-interest without the consent of Employee. In the instance of a sale of the Company or the sale of all or substantially all of the assets of the Company, this Agreement and the rights and obligations of the Company hereunder may be assigned to the acquiring party without Employee's consent, and for purposes of this Agreement, such acquirer shall thereafter be deemed to be the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">ARTICLE VII </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">DEFINITIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">"Person" </font><font style="font-family:Arial;font-size:10pt;color:#323232;">means an individual, partnership, limited liability company, trust, estate, association, corporation, governmental body or other juridical being.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">"Resignation" </font><font style="font-family:Arial;font-size:10pt;color:#323232;">means the voluntary termination of employment hereunder by Employee providing the Company with at least thirty (30) days prior written notice of Employee's intention to terminate the Employment Period.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">''Termination by the Company for Cause" </font><font style="font-family:Arial;font-size:10pt;color:#323232;">means termination by the Company of Employee's employment on account of a finding by the Company that Employee has: (i) breached this Agreement or any other agreement between Employee and the Company; (ii) engaged in the diversion of corporate opportunity, fraud, embezzlement, theft, commission of a felony or proven dishonesty, in the course of his performance of his services hereunder; or (iii) disclosed trade secrets or other Confidential Information of the Company to Persons not entitled to receive such information; </font><font style="font-family:Arial;font-size:10pt;color:#323232;text-decoration:underline;">provided that</font><font style="font-family:Arial;font-size:10pt;color:#323232;">&#32;the termination of Employee's employment hereunder by the Company shall not be deemed a Termination by the Company for Cause unless and until there shall have been delivered to Employee a written notice from an authorized officer of the Company (after reasonable notice (in light of the circumstances surrounding the termination) to and an opportunity for Employee, alone and in person, to have a face-to-face meeting with an authorized officer of the Company) stating that in the good faith opinion of the Company, Employee was guilty of the conduct set forth in one or more of the foregoing clauses</font><font style="font-family:Arial;font-size:10pt;color:#505050;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">"Termination by the Company without Cause" </font><font style="font-family:Arial;font-size:10pt;color:#323232;">means a termination of Employee's employment by the Company which is not a Termination by the Company for Cause.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">"Total Disability" </font><font style="font-family:Arial;font-size:10pt;color:#323232;">means Employee's inability, because of illness</font><font style="font-family:Arial;font-size:10pt;color:#505050;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">injury or other physical or mental incapacity, to perform his duties hereunder (as determined by the Company in good faith) for a continuous period of ninety (90) consecutive days, or for a total of ninety (90) days within any three hundred sixty (360) consecutive day period, in which case such Total Disability shall be deemed to have occurred on the last day of such ninety (90) day or three hundred sixty (360) day period, as applicable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">ARTICLE VIII </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">GENERAL</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">8.1&#160;&#160;&#160;&#160;Notices. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">All notices under this Agreement shall be in writing and shall be deemed properly sent, (i) when delivered, if by personal service or reputable overnight courier service, or (ii) when received, if sent (x) by certified or registered mail, postage prepaid, return receipt requested, or (y) via facsimile transmission (provided that a hard copy of such notice is sent to the addressee via one of the methods of delivery or mailing set forth above on the same day the facsimile transmission is sent); to (A) Employee at the address of his principal place of residence on file with the Company from time to time and (B) to the Company, as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">Dyadic International, Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">140 lntracoastal Pointe Drive, Suite 404</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">Jupiter, Florida 33477</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">Attn: Mark A Emalfarb, CEO </font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">Facsimile (561) 743-8343</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">8.2&#160;&#160;&#160;&#160;Governing Law</font><font style="font-family:Arial;font-size:10pt;color:#505050;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">This Agreement shall be subject to and governed by the laws of the State of Florida without regard to any choice of law or conflicts of law rules or provisions (whether of the State of Florida or any other jurisdiction), irrespective of the fact that Employee may become a resident of a different state</font><font style="font-family:Arial;font-size:10pt;color:#505050;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">8.3&#160;&#160;&#160;&#160;Binding Effect</font><font style="font-family:Arial;font-size:10pt;color:#464646;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">The Agreement shall be binding upon and inure to the benefit of the Company, its successors and assigns, and Employee and h</font><font style="font-family:Arial;font-size:10pt;color:#464646;">i</font><font style="font-family:Arial;font-size:10pt;color:#323232;">s executors, administrators, personal representatives and heirs.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">8.4&#160;&#160;&#160;&#160;Complete Understanding</font><font style="font-family:Arial;font-size:10pt;color:#626262;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">This Agreement constitutes the complete understanding between the parties hereto with regard to the subject matter hereof, and supersedes the Original Contract and any and all prior agreements and understandings relating to the terms of Employee's employment by the Company which shall</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">to the extent not inconsistent with the terms and provisions of this Agreement, remain in full force and effect as to any rights and obligations of the parties thereunder in existence prior to the date of this Agreement, </font><font style="font-family:Arial;font-size:10pt;color:#323232;text-decoration:underline;">provided that</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">in the event of any inconsistency between the provisions of this Agreement and the provisions of any other agreements between Employee and the Company, or in the event of any inconsistency between the rights and obligations of the parties under this Agreement and the rights and obligations of the parties under any prior agreement, the provisions of this Agreement shall control</font><font style="font-family:Arial;font-size:10pt;color:#464646;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">8.5&#160;&#160;&#160;&#160;Amendments</font><font style="font-family:Arial;font-size:10pt;color:#464646;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">No change, modification or amendment of any provision of this Agreement shall be valid unless made in writing and signed by both of the parties hereto.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">8.6&#160;&#160;&#160;&#160;Waiver. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">The waiver by the Company of a breach of any provision of this Agreement by Employee shall not operate or be construed as a waiver of any subsequent breach by Employee. The waiver by Employee of a breach of any provision of this Agreement by the Company shall not operate as a waiver of any subsequent breach by the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">8.7&#160;&#160;&#160;&#160;Venue, Jurisdiction, Etc. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Employee hereby agrees that any suit, action or proceeding relating in any way to this Agreement may be brought and enforced in the Circuit Court of Palm Beach County of the State of Florida or in the District Court of the United States of America for the Southern District of Florida</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#323232;">and in either case Employee hereby submits to the jurisdiction of each such court. Employee hereby waives and agrees not to assert, by way of motion or otherwise, in any such suit, action or proceeding, any claim that Employee is not personally subject to the jurisdiction of the above-named courts, that the suit, action or proceeding is brought in an inconvenient forum or that the venue of the suit, action or proceeding is improper. Employee consents and agrees to service of process or other legal summons for purpose of any such suit, action or proceeding by registered mail addressed to Employee at his address listed in the business records of the Company</font><font style="font-family:Arial;font-size:10pt;color:#464646;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Nothing contained herein shall affect the rights of the Company to bring a suit, action or proceeding in any other appropriate jurisdiction</font><font style="font-family:Arial;font-size:10pt;color:#626262;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">Employee and the Company do each hereby waive any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;">right to trial by jury he or it may have concerning any matter relating to this Agreement</font><font style="font-family:Arial;font-size:10pt;color:#464646;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">The parties agree that in the event of the institution of any action at law or in equity by either party to enforce the provisions of this Agreement, the losing party shall pay all of the costs and expenses of the prevailing party, including reasonable legal fees, incurred in connection therewith.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">8.8&#160;&#160;&#160;&#160;Severability. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">If any portion of this Agreement shall be for any reason invalid or unenforceable, the remaining portion or portions shall nevertheless be valid, enforceable and carried into effect.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">8.9&#160;&#160;&#160;&#160;Headings</font><font style="font-family:Arial;font-size:10pt;color:#464646;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">The headings of this Agreement are inserted for convenience only and are not to be considered in the construction of the provisions hereof.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">8.10&#160;&#160;&#160;&#160;Counterparts. </font><font style="font-family:Arial;font-size:10pt;color:#323232;">This Agreement may be executed in counterparts, both of which, taken together, shall constitute one and the same agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#323232;font-weight:bold;">SIGNATURES FOLLOW ON PAGE 11</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="sCCE3BFAAFD663D8114AD4493638B554C"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2e322f;font-weight:bold;">IN WITNESS WHEREOF, </font><font style="font-family:Arial;font-size:10pt;color:#2e322f;">the parties hereto have caused this Agreement to be duly executed as of the date first above-written</font><font style="font-family:Arial;font-size:10pt;color:#636565;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:37.65432098765432%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Mark A. Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Mark A Emalfarb, CEO</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Thomas L. Dubinski</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">THOMAS L. DUBINSIK</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><a name="s715203C825AE5B21A01C449363AAC9FC"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:404px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:150px;"></td><td style="width:253px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:104px;width:133px;"></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">140 lntracoastal Pointe Drive, Ste. 404</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Jupiter, Florida 33477</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Tel: 561-743-8333</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fax: 561-743-8343 </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">www.dyadic.com</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;">May 1, 2016</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;">Thomas L. Dubinski</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;">11015 Legacy Lane APT 103</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;">Palm Beach Gardens, Florida 33410</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;font-weight:bold;">Re: Change of control compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;">Dear Tom,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;">Simultaneously herewith</font><font style="font-family:Arial;font-size:10pt;color:#424642;">, </font><font style="font-family:Arial;font-size:10pt;color:#2c322e;">you are entering into an Employment Agreement with Dyadic today which supersedes the Employment Agreement dated July 15, 2014 (the "Original Contract") that set the terms for your employment as Dyadic's Vice President and Chief Financial Officer effective August 4, 2014. Sec. 5</font><font style="font-family:Arial;font-size:10pt;color:#868686;">.</font><font style="font-family:Arial;font-size:10pt;color:#2c322e;">2(h) of the Original Contract entitled </font><font style="font-family:Arial;font-size:10pt;color:#2c322e;font-style:italic;">Change of Control </font><font style="font-family:Arial;font-size:10pt;color:#2c322e;">provided you with certain rights in the event of a Change of Control, which term is defined in Dyadic's 2011 Equity Incentive Award Plan. Because your new Employment Agreement supersedes the Original Contract, the purpose of this letter agreement is to assure you that the provisions of Sec</font><font style="font-family:Arial;font-size:10pt;color:#424642;">. </font><font style="font-family:Arial;font-size:10pt;color:#2c322e;">5.2(h) continue in full force and effect</font><font style="font-family:Arial;font-size:10pt;color:#424642;">. </font><font style="font-family:Arial;font-size:10pt;color:#2c322e;">Specifically, if your employment is terminated by the Dyadic or if you resign your employment at Dyadic for Good Reason (as that term is defined in Sec</font><font style="font-family:Arial;font-size:10pt;color:#5b5e5b;">. 5</font><font style="font-family:Arial;font-size:10pt;color:#2c322e;">(f) of the Original Contract) before April 30, 2018, you shall be entitled to receive the Severance Benefits (as that term is defined in Sec. 5.2(h) of the Original Contract) and to continue to participate in Dyadic's health insurance and disability plans and programs for the 12 months following the date of your involuntary termination or resignation</font><font style="font-family:Arial;font-size:10pt;color:#5b5e5b;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;">Please acknowledge the foregoing by signing your name where indicated below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;">Very truly yours,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;">/s/ Mark A. Emalfarb</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2c322e;">Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:57.61316872427984%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:13%;"></td><td style="width:80%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Acknowledged this 1</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">st</sup></font><font style="font-family:Arial;font-size:10pt;">&#160;day of May, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Thomas L. Dubinski</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thomas L. Dubinski</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>12
<FILENAME>exhibit107form10.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3E8739129D0F5E558ABA44FF32096A1D"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 10.7</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">CONSULTANT AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">THIS CONSULTANT AGREEMENT</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#32;("Agreement") is made and entered as of the 1st day of January</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">2016 (</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">"</font><font style="font-family:Arial;font-size:10pt;color:#333333;">Effective Date</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">"</font><font style="font-family:Arial;font-size:10pt;color:#333333;">) by and between </font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">DYADIC NEDERLAND B.V.</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#32;(the "Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">"</font><font style="font-family:Arial;font-size:10pt;color:#333333;">)</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">and </font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Sky Blue Biotech kft</font><font style="font-family:Arial;font-size:10pt;color:#333333;">. ("Consultant")</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">As part of the Agreement</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant is required to engage Ronen Tchelet, an individual born on July 20, 1957 and currently residing in Budapest, Hungary</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Ronen Tchelet shall be personally bound by the same obligations and covenants of Consultant in this agreement. The Company and Consultant are each sometimes individually referred to as a </font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">"</font><font style="font-family:Arial;font-size:10pt;color:#333333;">Party</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">" </font><font style="font-family:Arial;font-size:10pt;color:#333333;">and collectively</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">as the </font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">"</font><font style="font-family:Arial;font-size:10pt;color:#333333;">Parties</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font><font style="font-family:Arial;font-size:10pt;color:#333333;">" Capitalized terms used herein shall have the meaning provided in this Agreement including, but not limited to, as set forth in Section 5.8 hereof</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">RECITALS:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">A.&#160;&#160;&#160;&#160;The Company is engaged in the business of developing technology, expression systems and  manufacturing processes related to enzymes and other protein products for use in the pharmaceuticals industry for human and animal applications.</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#333333;">The Company is also in the business of conducting research &amp; development and the licensing of and entering into other forms of collaborations using its research  capabilities, and/or its technologies, including the use of the C1 platform technology</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The Company desires to obtain the benefit of Consultant's experience, technical expertise and contacts in the industry listed above</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">B</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant desires to act as an independent contractor and in this position to fulfill the responsibilities of a </font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Vice President of Research &amp; Business Development</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#32;for the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.  </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The Consultant will provide key know-how in the development of enzymes and other proteins and business development activities</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The Company desires to so engage Consultant subject to the terms and conditions contained in this Agreement and the Consultant by executing the Agreement accepts such commitments, responsibilities and obligations as detailed below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">AGREEMENT:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">in consideration of the foregoing Recitals and other good and valuable consideration the receipt and sufficiency of which are hereby mutually acknowledged, the Parties hereby agree as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">ARTICLE I </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">RELATIONSHIP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">Services of Consultant</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant shall work for the Company for a minimum of one hundred and seventy six (176) hours of a normal work month. Consultant shall not advise competitors in any of the fields in described in the Recitals</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">and all other activities should not interfere with consulting services to the Company. Consultant shall give its best efforts to meet its obligations to the Company listed below including, but not limited to, the following (the "Services"):</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(a)&#160;&#160;&#160;&#160;Subject to Article 1</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font><font style="font-family:Arial;font-size:10pt;color:#333333;">3, Consultant is free to render its services as it deems fit</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant will report primarily to the President and Chief Executive Officer of the Company, Dyadic International, Inc</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. ("Dyadic") </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant acknowledges that its duties and responsibilities are subject to change from time to time, but will include and not be limited to assuming the role of General Manager of Dyadic's Dutch subsidiary, Dyadic Nederland BV, conduct business development, licensing and other collaboration efforts, directly oversee, supervise and direct specified research &amp; development projects carried on at Dyadic Nederland BV, or elsewhere by (i) outside third parties, licensees</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">or affiliated entities of Dyadic or Dyadic Nederland BV) and/or (ii) by direct employees of Dyadic or its subsidiaries in the future. The responsibilities of the Consultant will be in the areas of Business </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Development, licensing and other collaboration efforts, preparing research &amp; development programs with clear objectives, timelines and budgets and will be responsible for the supervision </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">and direction of internal and external research &amp; development projects</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">and whatever other duties the Consultant may be asked to perform from time to time by Dyadic.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">1.2&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">Consultant's Representations</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Consultant hereby represents and warrants to the</font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">Company that</font><font style="font-family:Arial;font-size:10pt;color:#484848;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">(a)&#160;&#160;&#160;&#160;the execution</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">delivery and performance by Consultant of this Agreement and any other agreements contemplated hereby to wh</font><font style="font-family:Arial;font-size:10pt;color:#484848;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">ch Consultant is a party do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Consultant is a party or by which Consultant is bound;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">(b)&#160;&#160;&#160;&#160;Consultant is not a party to or bound by any consulting</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">non</font><font style="font-family:Arial;font-size:10pt;color:#484848;">-</font><font style="font-family:Arial;font-size:10pt;color:#303030;">competition or confidentiality agreement with any other Person which would or might interfere with Consultant's performance of its Services to the Company hereunder; and</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">(c)&#160;&#160;&#160;&#160;upon the execution and delivery of this Agreement by the Company</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">this Agreement shall be the valid and binding obligation of Consultant, enforceable in accordance with its terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">1.3&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">Independent Contractor</font><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">The relationship of Consultant to the Company shall be that of an independent contractor</font><font style="font-family:Arial;font-size:10pt;color:#5f5f5f;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Consultant shall retain sole discret</font><font style="font-family:Arial;font-size:10pt;color:#484848;">i</font><font style="font-family:Arial;font-size:10pt;color:#303030;">on in the manner and means of the performance of the Services and Consultant's duties hereunder, it being expressly acknowledged and mutually agreed that Consultant is under the Company's control as to the results of Consultant's performance of Services hereunder only, and not as to the means by which any such results are accomplished</font><font style="font-family:Arial;font-size:10pt;color:#484848;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Further, the Parties hereby mutually and expressly acknowledge and agree that: (a) Consultant shall not be deemed to be the Company's agent, partner or employee</font><font style="font-family:Arial;font-size:10pt;color:#484848;">, </font><font style="font-family:Arial;font-size:10pt;color:#303030;">the Consultant shall have no authority to bind the Company or incur any obligation on behalf of the Company, and the Company shall not be liable for any obligation incurred by Consultant; and (b) except as otherwise determined by the Company in its absolute discretion, Consultant shall not participate in any employee benefits of the Company, including without limitation, insurance, vacation or retirement plans</font><font style="font-family:Arial;font-size:10pt;color:#484848;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">As independent Contractor, there will be no </font><font style="font-family:Arial;font-size:10pt;color:#303030;font-style:italic;">"zeggenschaps" </font><font style="font-family:Arial;font-size:10pt;color:#303030;">relation between Company and Consultant and Consultant shall be free to render the Services as it deems fit, in accordance with the provisions of this Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;">Consultant shall be solely responsible for payment of VAT, wage taxes and other taxes to the extent applicable and shall indemnify Company for any and all of such costs and expenses. Consultant is obliged to provide Company with a Declaration of Independent Contractor Status from the Hungarian Tax Authorities, which indicates that the Company is not required to withhold any taxes from the fee. Consultant is obliged to maintain such valid declaration during the entire duration of the Agreement. The Tax Declaration currently valid is annexed to this Agreement as Annex 1. Consultant will inform Company within 3 working days if (i) there is a full or partial withdrawal of the declaration or (ii) if there are circumstances that might lead to a full or partial withdrawal of the declaration</font><font style="font-family:Arial;font-size:10pt;color:#484848;">. </font><font style="font-family:Arial;font-size:10pt;color:#303030;">Consultant will at the same time inform the competent Hungarian tax inspector and the social security agency of these circumstances or change of circumstances. The Consultant shall be solely responsible for payment of VAT, wage taxes and other taxes to the extent applicable in Hungary and in the United States if applicable and shall indemnify Company for any and all of such costs and expenses</font><font style="font-family:Arial;font-size:10pt;color:#484848;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#303030;font-weight:bold;text-decoration:underline;">ARTICLE II</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">TERM OF ENGAGEMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">The Company engages Consultant as a consultant of the Company for a period of one (1) year (the "Engagement")</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The Engagement term of one (1) year will automatically renew annually on the anniversary date of this agreement. Consultant hereby accepts such Engagement upon the terms and conditions set forth in this Agreement</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">'</font><font style="font-family:Arial;font-size:10pt;color:#333333;">s engagement hereunder may be terminated by either Consultant or the Company at any time after the one year anniversary date, with or without cause</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">by written notice to the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">other party not less than ninety (90) days prior to the effective date of such termination</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The period that Consultant is engaged by the Company hereunder is sometimes referred to as the </font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">"Engagement Term.</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;font-weight:bold;">"</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">ARTICLE III </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">COMPENSATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">3.1&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">Compensation</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">During the Engagement Term, its the Company shall pay to Consultant the following compensation:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Base Consulting Fee: </font><font style="font-family:Arial;font-size:10pt;color:#333333;">upon receipt of an invoice from the Consultant a base fee of USD $15</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">,</font><font style="font-family:Arial;font-size:10pt;color:#333333;">000 per month payable within 15 days of such invoice. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Technology Licensing Commissions: </font><font style="font-family:Arial;font-size:10pt;color:#333333;">a commission up to one percent (1.0%) of the up-front licensing revenue sourced and developed by the Consultant</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The relative contribution of the Consultant to the project will determine the actual commission percentage and be at the sole discretion of the Company</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Research and Development Commissions: </font><font style="font-family:Arial;font-size:10pt;color:#333333;">a commission up to two and a half percent (2.5%) of the research &amp; development revenue sourced and developed solely by the Consultant</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The relative contribution of the Consultant to the project will determine the actual commission percentage and be at the sole discretion of the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(d)&#160;&#160;&#160;&#160;commissions due under Sections 3.1(b) and 3</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font><font style="font-family:Arial;font-size:10pt;color:#333333;">1(c), if any, will be paid by the first business day of the second month following the quarter except for the fourth quarter which will be by the 15</font><font style="font-family:Arial;font-size:10pt;color:#333333;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#32;of February of the next year to allow Accounting to adjust for collected revenue. The Company reserves the right to review and modify the commission plan yearly. Commissions will be paid for each received invoice, but shall not be paid until the customer has paid the invoice in full</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant shall be eligible for commissions earned by Consultant for such services billed within the Engagement Term which are collected by the Company within a period of up to six (6) months after end of the Engagement Term.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Stock Option Grant: </font><font style="font-family:Arial;font-size:10pt;color:#333333;">On January 19, 2016 Consultant was issued a stock option to purchase 200,000 shares of the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">'</font><font style="font-family:Arial;font-size:10pt;color:#333333;">s common stock (the </font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">"</font><font style="font-family:Arial;font-size:10pt;color:#333333;">Option</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">"</font><font style="font-family:Arial;font-size:10pt;color:#333333;">) pursuant to the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">'</font><font style="font-family:Arial;font-size:10pt;color:#333333;">s 2011 Equity Incentive Award Plan (the "Plan</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">"</font><font style="font-family:Arial;font-size:10pt;color:#333333;">) at $1.57 per share. The exercise price per share of the Option was equal to the fair market value per share of the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">'</font><font style="font-family:Arial;font-size:10pt;color:#333333;">s common stock on the date the Option is granted</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The term of the Option is for 10 years from the grant date, subject to earlier expiration in the event of the termination of Consultant's services to the Company or as otherwise provided by the Plan. The Option will vest and become exercisable at the rate of per year on the annual anniversary date becoming fully vested after four years, first such vesting period will be January 19, 2017 subject to Consultant's continuous service with the Company through each vesting date</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant has received a copy of the Plan and shall adhere thereto</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Annual Bonus: </font><font style="font-family:Arial;font-size:10pt;color:#333333;">in respect of each calendar year falling within the Engagement Term</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant shall be eligible to earn an annual bonus between zero percent (0%) to forty percent (40%)] of Consultant's annual base fee of USD $180,000 for that calendar year based on the</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#333333;">results of operations of the Company, and the performance of Consultant, as determined by the Company in its sole discretion (the "Annual Bonus")</font><font style="font-family:Arial;font-size:10pt;color:#494949;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The amount of the Annual Bonus</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">if any, which is earned by Consultant is subject to Consultant</font><font style="font-family:Arial;font-size:10pt;color:#494949;">'</font><font style="font-family:Arial;font-size:10pt;color:#333333;">s continued Engagement through December 31 of the applicable calendar year.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">3.2&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">Expenses</font><font style="font-family:Arial;font-size:10pt;color:#494949;font-weight:bold;">.  </font><font style="font-family:Arial;font-size:10pt;color:#333333;">During the Engagement Term, Consultant shall be entitled to reimbursement of all business travel of more than 100 kilometers from Budapest</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, Hungry, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">entertainment and other business expenses reasonably incurred in the performance of its duties for the Company, upon submission of all receipts and accounts with respect thereto, and approval by the Company thereof</font><font style="font-family:Arial;font-size:10pt;color:#494949;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant shall bear all of its own expenses including, but not limited to, maintaining office facilities, administrative staff</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">communications</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">general office expenses</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">government business or personal taxes, licenses, pensions, and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">health insurance required for Consultant to meet its obligations pursuant to this Agreement, and Consultant shall not be entitled to nor make any claim of demand upon the Company for payment of any such expenses</font><font style="font-family:Arial;font-size:10pt;color:#494949;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">ARTICLE IV </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">COVENANTS OF THE CONSULTANT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">4.1&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;text-decoration:underline;">Ownership of Work Product</font><font style="font-family:Arial;font-size:10pt;color:#494949;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant hereby expressly agrees that the following shall constitute </font><font style="font-family:Arial;font-size:10pt;color:#494949;font-weight:bold;">"</font><font style="font-family:Arial;font-size:10pt;color:#333333;font-weight:bold;">Work Product" </font><font style="font-family:Arial;font-size:10pt;color:#333333;">which shall remain the sole and exclusive property of the Company, or, as applicable, any of its Subsidiaries or Affiliates: all research, discoveries, inventions and innovations (whether or not reduced to practice or documented), improvements, developments, methods, designs, analyses, drawings</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">reports and all similar or related information (whether patentable or unpatentable, and whether or not reduced to writing), trade secrets (being information about the business of the Company, its Subsidiaries and Affiliates which is (i) considered by the Company or any such Subsidiary or Affiliate to be confidential and (ii) proprietary to the Company or any such Subsidiary or Affiliate and not then generally known to the public) and trademarks, service marks, trade names, trade dress, copyrightable works, and Confidential Information (in whatever form or medium), which </font><font style="font-family:Arial;font-size:10pt;color:#333333;text-decoration:underline;">both</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#32;(x) either (i) relate to the Company's, its Subsidiaries' or their Affiliates' actual or anticipated business, research and development or existing or future products or services or (ii) result from any Services performed by Consultant for the Company, its Subsidiaries or any of their Affiliates </font><font style="font-family:Arial;font-size:10pt;color:#333333;text-decoration:underline;">and</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#32;(y) are conceived, developed, made or contributed to in whole or in part by Consultant during the Engagement Term. Consultant hereby expressly covenants to the Company that it shall communicate promptly and fully all Work Product to the Company</font><font style="font-family:Arial;font-size:10pt;color:#494949;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">The monthly fee is deemed to include a reasonable consideration for assignment of all Work Product by Consultant to Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;text-decoration:underline;">Work Made for Hire</font><font style="font-family:Arial;font-size:10pt;color:#494949;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant acknowledges that, unless otherwise agreed in writing by the Company, all Work Product eligible for any form of copyright protection made or contributed to in whole or in part by Consultant in the performance of the Services during the Engagement Term shall be deemed a "work made for hire</font><font style="font-family:Arial;font-size:10pt;color:#494949;">" </font><font style="font-family:Arial;font-size:10pt;color:#333333;">under the copyright laws and shall be owned by the Company</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;">its Subsidiaries or Affiliates, as applicable.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#333333;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#333333;text-decoration:underline;">Assignment of Ownership of Work Product and Proprietary Rights</font><font style="font-family:Arial;font-size:10pt;color:#494949;">. </font><font style="font-family:Arial;font-size:10pt;color:#333333;">Consultant hereby assigns, transfers and conveys to the Company all right, title and interest in and to all Work Product and all right, title and interest in all proprietary rights whatsoever in and of all such Work Product (the "Proprietary Rights") for the Company's exclusive ownership and use, together with all rights to sue and recover for past and future infringement or misappropriation thereof</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#333333;text-decoration:underline;">provided that</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#32;if a Subsidiary or Affiliate of the Company is the owner thereof, such</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#353535;">assignment, transfer and conveyance shall be made to such Subsidiary or Affiliate, which shall enjoy exclusive ownership and use, together with all rights to sue and recover for past and future infringement or misappropriation thereof.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#353535;text-decoration:underline;">Further Instruments and Cooperation</font><font style="font-family:Arial;font-size:10pt;color:#5e5e5e;">. </font><font style="font-family:Arial;font-size:10pt;color:#353535;">Consultant further covenants and agrees that in connection with the foregoing assignment of its Work Product and all Proprietary Rights therein, at the request of the Company (or its Subsidiaries or Affiliates, as the case may be) at all times during the Engagement Term and thereafter, Consultant will, in all ways</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">promptly and fully cooperate, give testimony in connection with, and assist the Company (its Subsidiaries or Affiliates</font><font style="font-family:Arial;font-size:10pt;color:#5e5e5e;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">as the case may be) in effecting the purpose of that assignment, in obtaining and, from time to time, in enforcing the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">'</font><font style="font-family:Arial;font-size:10pt;color:#353535;">s Proprietary Rights therein, including but not limited to (i) the execution and delivery of all documents necessary to secure for the Company (its Subsidiaries or Affiliates, as the case may be) such Proprietary Rights and other rights to all Work Product, (ii) the filing of applications for and the taking of other actions required to obtain patents on Consultant's Work Product in any and all countries and (iii) the furnishing of testimony in connection with the Company's enforcement of the Proprietary Rights therein, as the Company may desire (except that it is understood and agreed that Consultant will not be involved in the construction of any such patents), </font><font style="font-family:Arial;font-size:10pt;color:#353535;text-decoration:underline;">provided that</font><font style="font-family:Arial;font-size:10pt;color:#353535;">&#32;(A) Consultant's obligation to assist the Company in obtaining and enforcing such patents and any other Proprietary Rights shall survive the Engagement Term of this Agreement and (B) in connection </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;">with any services Consultant may be requested by the Company to provide in connection with its obligations under this Section 4</font><font style="font-family:Arial;font-size:10pt;color:#5e5e5e;">.</font><font style="font-family:Arial;font-size:10pt;color:#353535;">1(c), the Company shall compensate Consultant at customary rates paid by the Company for comparable services rendered.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#353535;text-decoration:underline;">Inapplicability of Section 4</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;text-decoration:underline;">.</font><font style="font-family:Arial;font-size:10pt;color:#353535;text-decoration:underline;">1 In Certain Circumstance</font><font style="font-family:Arial;font-size:10pt;color:#353535;">s</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#353535;">The Company expressly acknowledges and agrees that, and Consultant is hereby advised that</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">this Section 4.1 does not apply to any invention for which no equipment, supplies, facilities or Confidential Information (as that term is hereinafter defined) of the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">its Subsidiaries or any of their Affiliates was used and which was developed entirely on Consultant's own time or on its personnel's own time, unless (i) the invention relates to the business of the Company, its Subsidiaries or any of their Affiliates or to the Company's</font><font style="font-family:Arial;font-size:10pt;color:#5e5e5e;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">its Subsidiaries' or any of their Affiliates' actual or demonstrably anticipated research or development or (ii) the invention results from any Services performed by Consultant for the Company, its Subsidiaries or Affiliates.</font></div><div style="line-height:120%;text-align:justify;padding-left:42px;text-indent:54px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;font-weight:bold;">4.2&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#353535;font-weight:bold;text-decoration:underline;">Ownership and Covenant to Return Documents, etc.</font><font style="font-family:Arial;font-size:10pt;color:#353535;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#353535;">Consultant agrees that all Work Product and all documents or other tangible materials (whether originals, copies or abstracts)</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">includ</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">i</font><font style="font-family:Arial;font-size:10pt;color:#353535;">ng without limitation, books</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">records</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">manuals, files</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">sales literature, training materials, customer records, correspondence, computer disks or print-out documents</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">contracts, orders, messages, phone and address lists, invoices and receipts, and all objects associated therewith, which contain Confidential Information or which in any way relate to the business of the Company either furnished to Consultant by the Company, its Subsidiaries or Affiliates or are prepared, compiled or otherwise acquired by Consultant during the Engagement Term of this Agreement, shall be the sole and exclusive property of the Company, such Subsidiaries or such Affiliates</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#353535;">Consultant shall not, except for the use of the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">its Subsidiaries or Affiliates, use, copy or duplicate any of the aforementioned documents or objects, nor remove them from the facilities of the Company or such Subsidiaries or Affiliates, nor use any information concerning them except for the benefit of the Company, its Subsidiaries and or Affiliates, either during the Engagement Term of the Agreement or thereafter. Consultant agrees to deliver all of the aforementioned documents and objects that may be in its possession to the Company on the termination of its engagement with the Company, or at any other time upon the Company's request</font><font style="font-family:Arial;font-size:10pt;color:#5e5e5e;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;font-weight:bold;">4.3&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#353535;font-weight:bold;text-decoration:underline;">Non-Disclosure Covenant</font><font style="font-family:Arial;font-size:10pt;color:#5e5e5e;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#353535;">For a period commencing on the date of this Agreement and ending on the last to occur of five (5) years following the date of execution of this Agreement or</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#353535;">three (3) years following the date of the termination of the Engagement Term of the Agreement, except as required by law, without the prior written permission of the Company, Consultant shall not</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">either directly or indirectly, disclose to any "unauthorized person</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">" </font><font style="font-family:Arial;font-size:10pt;color:#353535;">or use for the benefit of Consultant or any Person other than the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">its Subsidiaries or their Affiliates, any "Confidential Information,</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">" </font><font style="font-family:Arial;font-size:10pt;color:#353535;">as that term is hereinafter defined</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#353535;">Further, Consultant covenants to the Company that in Consultant's performance of its Services hereunder, Consultant will violate no confidentiality obligations it may have to any other Persons.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;">(a)&#160;&#160;&#160;&#160;As used herein, the term </font><font style="font-family:Arial;font-size:10pt;color:#353535;font-weight:bold;">"Confidential Information" </font><font style="font-family:Arial;font-size:10pt;color:#353535;">shall mean and include Work Product or any knowledge or information which Consultant acquires from the Company or from any customers, vendors or independent contractors of the Company for the benefit of the Company while Consultant is serving as an advisor to the Company hereunder (whether before or after the date of this Agreement) relating to (i) information about the proprietary technologies, animal and clinical trial results</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">products</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">applications</font><font style="font-family:Arial;font-size:10pt;color:#656565;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">host organisms</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">fungal gene expression, fungal high throughput screening, equipment, patent applications</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">know-how, data, reports, contracts, drawings</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">protocols, production processes of the Company, its Subsidiaries and Affiliates, (ii) the name of any existing or prospective investor, partner, employee, supplier, sales agent or consultant of or to the Company, (iii) any sales plan, sales forecast, marketing material, plan or survey, business or financial plan or strategy, or opportunity</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">product or service development plan or specification, business proposal or information relating to the present or proposed business of the Company, (iv) the Company's financial statements, analyses, forecasts and projections, books, accounts</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">records, operating costs and expenses and other financial information about the Company, its Subsidiaries and their Affiliates, (v) internal management tools and systems, costing policies and methods, pricing policies and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;">methods and other methods of doing business, of the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">its Subsidiaries and their Affiliates, (vi) customers, sales, customer requirements and usages, distributor lists, of the Company, its Subsidiaries and Affiliates, (ix) agreements with customers, vendors</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">independent contractors, employees and others, of the Company, its Subsidiaries and their Affiliates, (x) existing and future products or services and product development plans, designs, analyses and reports, of the Company, its Subsidiaries and Affiliates, (xi) computer software and data bases developed for the Company, its Subsidiaries and Affiliates, trade secrets</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">research, records of research</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">models, designs, drawings, technical data and reports of the Company, its Subsidiaries and Affiliates and (xii) correspondence or other private or confidential matters, information or data whether written, oral or electronic, which is proprietary to the Company, its Subsidiaries and Affiliates and not generally known to the public, </font><font style="font-family:Arial;font-size:10pt;color:#353535;text-decoration:underline;">provided that</font><font style="font-family:Arial;font-size:10pt;color:#353535;">&#32;the Company expressly acknowledges and agrees that the term "Confidential Information" excludes information which is:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;">(i)&#160;&#160;&#160;&#160;in the public domain or otherwise generally known to the trade at or subsequent to the time it was communicated to Consultant by the disclosing party through no fault of Consultant;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;">(ii)&#160;&#160;&#160;&#160;was disclosed to other Persons other than by reason of Consultant's breach of its confidentiality obligations hereunder;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;">(iii)&#160;&#160;&#160;&#160;was rightfully in Consultant</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">'</font><font style="font-family:Arial;font-size:10pt;color:#353535;">s possession free of any obligation of confidence at or subsequent to the time it was communicated to Consultant by the Company or its personnel or agents;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#353535;">(iv)&#160;&#160;&#160;&#160;was developed by Consultant or Persons other than the Company, its personnel or agents</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#353535;">independently of and without reference to any information communicated to Consultant by the Company or its personnel;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;">(v)&#160;&#160;&#160;&#160;learned of by Consultant subsequent to the termination of its engagement by the Company hereunder from any other party not then under an obligation of confidentiality to the Company, its Subsidiaries and Affiliates; or</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;">(vi)&#160;&#160;&#160;&#160;is being disclosed by Consultant in response to a valid order by a court or other governmental body, or otherwise as required by law, or as necessary to establish the rights of either Party under this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;">(b)&#160;&#160;&#160;&#160;For purposes of this Section 4</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font><font style="font-family:Arial;font-size:10pt;color:#363636;">3, the term </font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">"unauthorized person</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;font-weight:bold;">" </font><font style="font-family:Arial;font-size:10pt;color:#363636;">shall mean any person who is not (i) an officer or director of the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#363636;">or (ii) an employee, officer or director of a Subsidiary or Affiliate of the Company for whom the disclosure of the knowledge or information referred to herein is necessary for its performance of its assigned duties, or (iii) a person expressly authorized by the Company to receive disclosure of such knowledge or information ..</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">4.4&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">Anti-Pirating and Non-Interference Covenants</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">Consultant covenants to the Company that while Consultant is engaged as a consultant by the Company hereunder and for the five (5) year period thereafter (the </font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;font-weight:bold;">"</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">Non-Solicitation Period")</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;font-weight:bold;">, </font><font style="font-family:Arial;font-size:10pt;color:#363636;">Consultant will not, for any reason, directly or indirectly</font><font style="font-family:Arial;font-size:10pt;color:#5d5d5d;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;">(a)&#160;&#160;&#160;&#160;solicit, hire, or otherwise do any act or thing which may induce any Protected Person (as that term is defined in Section 5.8(c) hereof) to terminate his, its or its business relationship with Company, its Subsidiaries and Affiliates, or otherwise interfere with or adversely affect the relationship (contractual or otherwise) of the Company</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#363636;">its Subsidiaries and Affiliates with any then Protected Person; or</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;">(b)&#160;&#160;&#160;&#160;do any act or thing which may interfere with or adversely affect the relationship (contractual or otherwise) of the Company, its Subsidiaries and Affiliates with any then customer or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;">then Protected Person or induce any such customer or Protected Person to cease doing business with the Company, its Subsidiaries and Affiliates</font><font style="font-family:Arial;font-size:10pt;color:#5d5d5d;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">4.5&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">Remedies For Breach</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">.  </font><font style="font-family:Arial;font-size:10pt;color:#363636;">Consultant hereby expressly acknowledges that the preservation of the confidentiality of the Company's Confidential Information is absolutely essential to commercial success of the Company, and that the improper use and/or disclosure of the Company's Confidential Information would cause the Company irreparable harm, and loss and damage</font><font style="font-family:Arial;font-size:10pt;color:#5d5d5d;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">If Consultant commits a breach, or threatens to commit a breach, of any of the provisions of this Article IV, the Company and its Subsidiaries shall have the right and remedy, in addition to any other remedy that may be available at law or in equity, to have the provisions of this Article IV specifically enforced by any court having equity jurisdiction (without regard to the arbitration provisions of Section 5</font><font style="font-family:Arial;font-size:10pt;color:#5d5d5d;">.</font><font style="font-family:Arial;font-size:10pt;color:#363636;">9 hereof), by the entry of temporary, preliminary and permanent injunctions and orders of specific performance</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#363636;">together with an accounting therefore, it being expressly acknowledged and agreed by Consultant that any such breach or threatened breach will cause irreparable injury to the Company and its Subsidiaries and that money damages will not provide an adequate remedy to the Company and its Subsidiaries</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">Such injunction shall be available without the posting of any bond or other security, and Consultant hereby consents to the issuance of such injunction</font><font style="font-family:Arial;font-size:10pt;color:#5d5d5d;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">The Consultant further agrees that any such injunctive relief obtained by the Company or its Subsidiaries shall be in addition to, and not in lieu of, monetary damages and any other remedies to which the Company or its Subsidiaries may be entitled. Further, in the event of an alleged breach or violation by Consultant of any of the provisions of Sections 4.4 or 4</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font><font style="font-family:Arial;font-size:10pt;color:#363636;">5 hereof, the period of time in which Consultant has covenanted to the Company to refrain from engaging in the applicable activity shall be tolled until such breach or violation has been cured. The parties agree that in the event of the institution of any action at law or in equity by either party to enforce the provisions of this Article IV, the losing party shall pay all of the costs and expenses of the prevailing party, including reasonable legal fees, incurred in connection therewith. If any covenant contained in this Article IV, or any part thereof, is hereafter construed to be invalid or unenforceable, the same shall not affect the remainder of such covenant or any other covenants, which shall be given full effect, without regard to the invalid portions, and any court having jurisdiction shall have the power to modify such covenant to the least extent necessary to render it enforceable and, in its modified form, said covenant shall then be enforceable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">ARTICLE V </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">GENERAL</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">5.1&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">Assignment</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">Consultant expressly agrees for itself and its successors-in-interest, that this Agreement and its obligations, rights, interests and benefits hereunder are personal to it in nature, and shall not be assigned, except in connection with the a sale of all or substantially all of the assets of Consultant and with the consent of the Company, which consent shall not be unreasonably withheld, provided that this Agreement shall be assignable and transferable by the Company to any successor-in-interest who acquires all or substantially all of the assets of the Company without the consent of Consultant, further provided that the Company shall not be relieved of its obligations to Consultant hereunder unless such successor</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">-</font><font style="font-family:Arial;font-size:10pt;color:#363636;">in-interest executes a written instrument assuming all of the Company's obligations under this Agreement and reasonably promptly furnishes a copy of same to Consultant</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">5.2&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">Notices</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">Any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given upon personal delivery to the Party to be notified or upon deposit in the United States Post Office certified or registered mail or with an air courier, postage and fees prepaid, addressed to the Company at  : Nieuwe Kanaal 7, 6709 PA Wageningen, The Netherlands, with a copy to CEO, Dyadic International, Inc. Suite 404, 140 lntracoastal Pointe Drive, Jupiter, Florida 33477 USA or to Consultant at the address set forth below Consultant's signature on this Agreement, or at such other address as a Party may designate by ten (10) day's advance written notice to the other Party. Notwithstanding the foregoing, notice may be given by fax, provided that appropriate confirmation of receipt is received</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">5.3&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">Governing Law</font><font style="font-family:Arial;font-size:10pt;color:#6d6d6d;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">This Agreement shall be subject to and governed by the laws of the Netherlands without regard to any choice of law or conflicts of law rules or provisions (whether of the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;">Netherlands or any other jurisdiction), irrespective of the fact that Consultant may become a resident of a different state or country.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">5.4&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">Binding Effect</font><font style="font-family:Arial;font-size:10pt;color:#6d6d6d;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">The Agreement shall be binding upon and inure to the benefit of the Company, its successors and assigns, and Consultant and its executors, administrators, personal Consultants and heirs</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">5.5&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">Complete Understanding</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">This Agreement contains the entire agreement of the parties relating to the subject matter hereof and supersedes all prior agreements and understanding with respect to such subject matter, and the parties hereto have made no agreements, representations or warranties relating to the subject matter of this Agreement which are not set forth herein.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">5.6&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">Amendments</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">No change</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">, </font><font style="font-family:Arial;font-size:10pt;color:#363636;">modification or amendment of any provision of this Agreement shall be valid unless made in writing and signed by all of the parties hereto</font><font style="font-family:Arial;font-size:10pt;color:#4c4c4c;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">5.7&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">Waiver</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">The waiver by the Company of a breach of any provision of this Agreement by Consultant shall not operate or be construed as a waiver of any subsequent breach by Consultant. The waiver by Consultant of a breach of any provision of this Agreement by the Company shall not operate as a waiver of any subsequent breach by the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">5.8&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;text-decoration:underline;">Certain Definitions</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">As used herein, the following terms shall have the meanings indicated below:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">"Affiliate" </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with that Person, provided that, for purposes of this definition, the terms </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">"controls," "controlled by," or "under common control with" </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">shall mean that Person's possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such other Person, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">"Person" </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">shall mean an individual, partnership, Limited Liability Company, trust, estate, association, corporation, governmental body, or other juridical being.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">"Protected Person" </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">shall mean any employee, contract manufacturer, supplier, vendor, research collaborator, sales agent, Consultant, consultant, agent, advisor, independent contractor, or business collaborator of the Company, its Subsidiaries or their Affiliates.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">"Subsidiary" </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">means, with respect to any person, any corporation, limited liability company, partnership, association or other business entity of which (i) if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or entity or one or more of the other Subsidiaries of such person or entity or a combination thereof, or (ii) if a limited liability company, partnership, association or other business entity, a majority of the partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by any person or entity or one or more Subsidiaries of such person or entity or a combination thereof For purposes hereof, a person or persons shall be deemed to have a majority ownership interest in a limited liability company, partnership, association or other business entity if such person or persons shall be allocated a majority of limited liability company, partnership, association or other business entity gains or losses or shall be or control any managing director or general partner of such limited liability company, partnership, association or other business entity.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">5.9&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;text-decoration:underline;">Dispute</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Subject to the provisions of Section 4.6 hereof, any dispute or claim arising out of or in connection with this Agreement shall be exclusively submitted to the District Court of Midden Nederland.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">5.10&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;text-decoration:underline;">Attorneys' Fees</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">In the event that it is necessary for either Party to undertake to enforce any of the terms, conditions or rights set forth herein, or defend against any such action, the prevailing party in such action shall be entitled to recover from the other Party all reasonable attorneys' fees, costs and expenses relating to such action.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">5.11&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;text-decoration:underline;">Severability</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">If any portion of this Agreement shall be for any reason, invalid or unenforceable, the remaining portion or portions shall nevertheless be valid, enforceable and carried into effect</font><font style="font-family:Arial;font-size:10pt;color:#414141;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">5.12&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;text-decoration:underline;">Headings</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">The headings of this Agreement are inserted for convenience only and are not to be considered in the construction of the provisions hereof.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">5.13&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;text-decoration:underline;">Counterparts</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;font-weight:bold;">. </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">This Agreement may be executed in one or more counterparts, all of which, taken together, shall constitute one and the same agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282c27;font-weight:bold;">IN WITNESS WHEREOF, </font><font style="font-family:Arial;font-size:10pt;color:#282c27;">the Company has caused this Agreement to be signed by one of its duly authorized officers and its corporate seal to be hereunto affixed, and Consultant has hereunto set its hand on the day and year first above written.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:5%;"></td><td style="width:47%;"></td><td style="width:6%;"></td><td style="width:42%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;font-weight:bold;">COMPANY:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;font-weight:bold;">SKY BLUE BIOTECH KFT:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;">/s/ Ronen Tchelet</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;font-weight:bold;">DYADIC NEDERLAND B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;">Name: Ronen Tchelet</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ M.A. Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name: M.A. Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title: Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;font-weight:bold;">RONEN TCHELET:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;">/s/ Ronen Tchelet</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;">Name: Ronen Tchelet</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>13
<FILENAME>exhibit108form10.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s12AB844FDCC38F243E323F7347FEEB2A"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 10.8</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">CONSULTING AGREEMENT</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">THIS CONSULTING AGREEMENT</font><font style="font-family:Arial;font-size:10pt;">&#32;(&#8220;Agreement&#8221;) is made and entered as of the 13th day of March, 2017 (&#8220;Effective Date&#8221;) by and between </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dyadic International, Inc.</font><font style="font-family:Arial;font-size:10pt;">&#32;(the &#8220;Company&#8221;), and </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Novaro Ltd</font><font style="font-family:Arial;font-size:10pt;">&#32;&#8211; acting as the Consulting Company Provider (the &#8220;Provider&#8221;). The Company and Provider are each sometimes individually referred to as a &#8220;Party&#8221; and collectively, as the &#8220;Parties.&#8221; Capitalized terms used herein shall have the meaning provided in this Agreement including, but not limited to, as set forth in Section 5.8 hereof.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">RECITALS:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:Arial;font-size:10pt;padding-right:48px;">A.</font><font style="font-family:Arial;font-size:10pt;">The Company is engaged in the business of developing technology, expression systems and manufacturing processes related to enzymes and other protein products for use in the pharmaceuticals industry for human and animal applications.  The Company is also in the business of conducting research &amp; development and the licensing of and entering into other forms of collaborations using its third party research capabilities, and/or its technologies, including the use of the C1 platform technology.  The Company desires to obtain the benefit of the Provider&#8217;s experience and contacts in the industry listed above in business development.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:Arial;font-size:10pt;padding-right:48px;">B.</font><font style="font-family:Arial;font-size:10pt;">The provider desires to act as an independent contractor and in this position to fulfill the responsibilities for Business Development &amp; Licensing for the Company.  The Provider will provide key knowledge and experience in the execution of business development activities for the Company.  The Company desires to so engage The Provider subject to the terms and conditions contained in this Agreement and the Provider by executing this Agreement accepts such commitments, responsibilities and obligations as detailed below.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AGREEMENT:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:Arial;font-size:10pt;">, in consideration of the foregoing Recitals and other good and valuable consideration the receipt and sufficiency of which are hereby mutually acknowledged, the Parties hereby agree as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">ARTICLE I</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">RELATIONSHIP</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Services of the Provider</font><font style="font-family:Arial;font-size:10pt;">. The Provider shall work for the Company for a minimum of one hundred and seventy-six (176) hours of a normal work month including business travel. The Provider shall not advise competitors in any of the fields described in the Recitals, and all other activities should not interfere with consulting services to the Company. The Provider shall give its best efforts to meet its commitments, obligations and responsibilities to the Company listed below including, but not limited to, the following (the "Services"):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:46px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Subject to Article 1.3, The Provider is free to render its services as it deems fit. The Provider will provide a dedicated resource who will report to the President and Chief Executive Officer of the Company, Dyadic International. Inc. ("Dyadic"). The Provider acknowledges that its duties and responsibilities are subject to change from time to time. but will include and not be limited to conduct business development, licensing and other collaboration efforts, project management and support to specified research &amp; development projects carried on at (i) outside third parties, licensees/collaborators, or affiliated entities of Dyadic or Dyadic Nederland BV. The responsibilities of the Provider will be in the areas of Business Development, licensing and other collaboration efforts and whatever other duties the Provider may be asked to perform from time to time by Dyadic.</font></div><div style="line-height:120%;text-align:justify;padding-left:46px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.2</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Provider's Representations</font><font style="font-family:Arial;font-size:10pt;">. The Provider hereby represents to the Company that: </font></div><div style="line-height:148%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">the execution, delivery and performance by Provider of this Agreement and any other agreements contemplated hereby to which the Provider is a party do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, Instrument, order, judgment or decree to which the Provider is a party or by which the Provider is bound;</font></div><div style="line-height:122%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;The Provider is not a party to or bound by any consulting, non-competition or confidentiality agreement with any other Person which would or might interfere with the Provider's performance of its Services to the Company hereunder; and </font></div><div style="line-height:122%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of the Provider, enforceable in accordance with its terms.</font></div><div style="line-height:104%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.3&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Independent Contractor</font><font style="font-family:Arial;font-size:10pt;">. The relationship of the Provider to the Company shall be that of an independent contractor. The Provider shall retain sole discretion in the manner and means of the performance of the Services and the Provider's duties hereunder, it being expressly acknowledged and mutually agreed that the Provider is under the Company's control as to the results of the Provider's performance of Services hereunder only, and not as to the means by which any such results are accomplished. Further, the Parties hereby mutually and expressly acknowledge and agree that: (a) the Provider shall not be deemed to be the Company's agent, partner or employee, the Provider shall have no authority to bind the Company or incur any obligation on behalf of the Company, and the Company shall not be liable for any obligation incurred by the Provider; and (b) except as otherwise determined by the Company in its absolute discretion, the Provider shall not participate in employee benefits of the Company, including vacation or retirement plans. As independent Contractor, there will be no </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">"authority</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">or</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">control&#8221;</font><font style="font-family:Arial;font-size:10pt;">&#32;relation between Company and the Provider and that the Provider shall be free to render the Services as it deems fit, in accordance with the provisions of this Agreement.</font></div><div style="line-height:127%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Provider shall be solely responsible for payment of wage taxes and other taxes to the extent applicable in the United Kingdom and the European Union. The Company shall be solely responsible for payment of a/l commercially reasonable costs that it incurs in retaining contractors and Providers to carry out its work, including the Provider.</font></div><div style="line-height:152%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">ARTICLE II</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">TERM OF ENGAGEMENT</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:130%;text-align:justify;text-indent:56px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company engages the Provider as a Provider of the Company for a period of one (1) year (the "Engagement"). The Engagement term of one (1) year will automatically renew annually on the anniversary date of this agreement. The Provider hereby accepts such Engagement upon the terms and conditions set forth in this Agreement. The Provider's engagement hereunder may be terminated by either the Provider or the Company at any time, with or without cause, by written notice to the other party not less than ninety (90) days prior to the effective date of such termination. The period that the Provider is engaged by the Company hereunder is sometimes referred to as the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Engagement Term</font><font style="font-family:Arial;font-size:10pt;">."</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">ARTICLE III</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">COMPENSATION</font></div><div style="line-height:142%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Compensation</font><font style="font-family:Arial;font-size:10pt;">.  During the Engagement  Term  the  Company  shall  pay  to  the</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Provider the following compensation:</font></div><div style="line-height:163%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:119%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Base Consulting Fee</font><font style="font-family:Arial;font-size:10pt;">: upon receipt of an invoice from the Provider a base fee of GBP &#163;3,800 per week payable within 5 days of such invoice.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:119%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Stock Option Grant</font><font style="font-family:Arial;font-size:10pt;">: On January 3, 2017 the Provider was issued a stock option to Purchase 40,000 shares of the Company's common stock (the "Option") pursuant to the Company's 2011 Equity Incentive Award Plan (the "Plan") at $ 1.63 per share. The exercise price per share of the Option was equal to the 10 day average of the volume weighted average price ("VWAP") of the Company's common stock proceeding the date the Option was granted. The term of the Option is for 10 years from the grant date, subject to earlier expiration in the event of the termination of the Provider's services to the Company or as otherwise provided by the Plan. The Option will vest and become fully exercisable on the first annual anniversary date (fully vested after one year) subject to the Provider's continuous service with the Company through the vesting date.</font></div><div style="line-height:119%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:119%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Annual Bonus</font><font style="font-family:Arial;font-size:10pt;">: in respect of each calendar year falling within the Engagement Term, the Provider shall be eligible to earn an annual bonus of between zero percent (0%) to forty percent (40%) of the Provider&#8217;s annual base fee of GBP &#163;197,600 for that calendar year based on the results of operations of the Company, and the performance of the Provider, as determined by the Company in its sole discretion (the "Annual Bonus"). The amount of the Annual Bonus, if any, which is earned by the Provider is subject to the Provider's continued Engagement through December 31 of the applicable calendar year.</font></div><div style="line-height:119%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:119%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Expenses</font><font style="font-family:Arial;font-size:10pt;">. During the Engagement Term, the Provider shall be entitled to reimbursement of all business travel, entertainment and other business expenses and trader insurances reasonably incurred in the performance of its duties for the Company, upon submission of all receipts and accounts with respect thereto, and approval by the Company thereof. The Provider shall bear all of its own expenses which are not incurred solely in meeting its obligations to the Company including, but not limited to, maintaining office facilities, administrative staff, general office expenses, government business or personal taxes, licenses, pensions, and health insurance required for the Provider to meet its obligations pursuant to this Agreement, and the Provider shall not be entitled to nor make any claim of demand upon the Company for payment of any such expenses.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">ARTICLE IV</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">COVENANTS OF THE PROVIDER</font></div><div style="line-height:122%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:129%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.1&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Ownership of Work Product</font><font style="font-family:Arial;font-size:10pt;">. The Provider hereby expressly agrees that the following shall constitute "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Work Product</font><font style="font-family:Arial;font-size:10pt;">" which shall remain the sale and exclusive property of the Company. or, as applicable, any of its Subsidiaries or Affiliates: all research, discoveries, inventions and innovations (whether or not reduced to practice or documented), improvements, developments, methods, designs, analyses, drawings, reports and all similar or related information (whether patentable or un-patentable, and whether or not reduced to writing), trade secrets (being information about the business of the Company, its Subsidiaries and Affiliates which is (i) considered by the Company or any such Subsidiary or Affiliate to be confidential and (ii) proprietary to the Company or any such Subsidiary or Affiliate and not then generally known to the public) and trademarks, service marks, trade names, trade dress, copyrightable works, and Confidential Information (in whatever form or medium), which </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">both</font><font style="font-family:Arial;font-size:10pt;">&#32;(x) either (i) relate to the Company's, its Subsidiaries&#8217; or their Affiliates&#8217; actual or anticipated business, research and development or existing or future products or services or (ii) result from any Services performed by the Provider for the Company, its Subsidiaries or any of their Affiliates </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">and</font><font style="font-family:Arial;font-size:10pt;">&#32;(y) are conceived, developed, made or contributed to In whole or In part by the Provider during the Engagement Term. The Provider hereby expressly covenants to the Company that it shall communicate promptly and fully all Work Product to the Company. The monthly fee is deemed to include a reasonable consideration for assignment of all Work Product by the Provider to Company.</font></div><div style="line-height:124%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:124%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Work Made for Hire</font><font style="font-family:Arial;font-size:10pt;">. The Provider acknowledges that, unless otherwise agreed In writing by the Company, all Work Product eligible for any form of copyright protection made or contributed to in whole or in part by the Provider in the performance of the Services during the Engagement Term shall be deemed a ''work made for hire" under the copyright laws and shall be owned by the Company, its Subsidiaries or Affiliates, as applicable.</font></div><div style="line-height:124%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:124%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Assignment of Ownership of Work Product and Proprietary Rights</font><font style="font-family:Arial;font-size:10pt;">. The Provider hereby assigns, transfers and conveys to the Company all right. title and interest in and to all Work Product and all right, title and interest in all proprietary rights whatsoever in and of all such Work Product (the "Proprietary Rights") for the Company's exclusive ownership and use, together with all rights to sue and recover for past and future infringement or misappropriation thereof. provided that if a Subsidiary or Affiliate of the Company is the owner thereof, such assignment, transfer and conveyance shall be made to such Subsidiary or Affiliate, which shall enjoy exclusive ownership and use, together with all rights to sue and recover for past and future infringement or misappropriation thereof.</font></div><div style="line-height:124%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:124%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Further Instruments and Cooperation</font><font style="font-family:Arial;font-size:10pt;">. The Provider further covenants and agrees that in connection with the foregoing assignment of its Work Product and all Proprietary Rights therein, at the request of the Company (or its Subsidiaries or Affiliates, as the case may be) at all times during the Engagement Term and thereafter, Provider will, in all ways, promptly and fully cooperate, give testimony in connection with, and assist the Company (its Subsidiaries or Affiliates, as the case may be) in effecting the purpose of that assignment, in obtaining and, from time to time, in enforcing the Company's Proprietary Rights therein, including but not limited to (i) the execution and delivery of all documents necessary to secure for the Company (its Subsidiaries or Affiliates, as the case may be) such Proprietary Rights and other rights to all Work Product, (ii) the filing of applications for and the taking of other actions required to obtain patents on the Provider's Work Product in any and all countries and (iii) the furnishing of testimony in connection with the Company's enforcement of the Proprietary Rights therein. as the Company may desire (except that it is understood and agreed that Provider will not be involved in the construction of any such patents), </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">provided that</font><font style="font-family:Arial;font-size:10pt;">&#32;(A) Provider's obligation to assist the Company in obtaining and enforcing such patents and any other Proprietary Rights shall survive the Engagement Term of this Agreement and (8) in connection with any services the Provider may be requested by the Company to provide in connection with its obligations under this Section 4.1 (c), the Company shall compensate the Provider at customary rates paid by the Company for comparable services rendered. </font></div><div style="line-height:124%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:124%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Inapplicability of Section 4.1 in Certain Circumstances</font><font style="font-family:Arial;font-size:10pt;">. The Company expressly acknowledges and agrees that, and the Provider is hereby advised that, this Section 4.1 does not apply to any invention for which no equipment, supplies, facilities or Confidential Information (as that term is hereinafter defined) of the Company, its Subsidiaries or any of their Affiliates was used and which was developed entirely on the Provider's own time or on its personnel's own time, unless (I) the invention relates to the business of the Company, its Subsidiaries or any of their Affiliates or to the Company's, its Subsidiaries' or any of their Affiliates' actual or demonstrably anticipated research or development or (ii) the invention results from any Services performed by the Provider for the Company, its Subsidiaries or Affiliates.</font></div><div style="line-height:125%;text-align:justify;text-indent:49px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:125%;text-align:justify;text-indent:49px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.2&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Ownership and Covenant to Return Documents. etc</font><font style="font-family:Arial;font-size:10pt;">. The Provider agrees that all Work Product and all documents or other tangible materials (whether originals, copies or abstracts), including without limitation, books, records, manuals, files, sales literature, training materials, customer records, correspondence, computer disks or print-out documents, contracts, orders, messages, phone and address lists, invoices and receipts, and all objects associated therewith, which contain Confidential Information or which in any way relate to the business of the Company either furnished to the Provider by the Company, its Subsidiaries or Affiliates or are prepared, compiled or otherwise acquired by the Provider during the Engagement Term of this Agreement, shall be the sole and exclusive property of the Company, such Subsidiaries or such Affiliates. The Provider shall not, except for the use of the Company, its Subsidiaries or Affiliates, use, copy or duplicate any of the aforementioned documents or objects, nor remove them from the facilities of the Company or such Subsidiaries or Affiliates, nor use any information concerning them except for the benefit of the Company, its Subsidiaries and or Affiliates, either during the Engagement Term of the Agreement or thereafter. The Provider agrees to deliver all of the aforementioned documents and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">objects that may be in its possession to the Company on the termination of its engagement with the Company, or at any other time upon the Company's request.</font></div><div style="line-height:125%;text-align:justify;text-indent:49px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:125%;text-align:justify;text-indent:49px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.3&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Non-Disclosure Covenant</font><font style="font-family:Arial;font-size:10pt;">. For a period commencing on the date of this Agreement and ending on the last to occur of five (5) years following the date of execution of this Agreement or three (3) years following the date of the termination of the Engagement Term of the Agreement, except as required by law, without the prior written permission of the Company, the Provider shall not, either directly or indirectly, disclose to any "unauthorized person" or use for the benefit of the Provider or any Person other than the Company, its Subsidiaries or their Affiliates, any "Confidential lnformation," as that term is hereinafter defined. Further, Provider covenants to the Company that in the Providers performance of its Services hereunder, the Provider will violate no confidentiality obligations it may have to any other Persons.</font></div><div style="line-height:125%;text-align:justify;text-indent:49px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;As used herein, the term "Confidential Information" shall mean and include Work Product or any knowledge or information which the Provider acquires from the Company or from any customers, vendors or independent contractors of the Company for the benefit of the Company while the Provider is serving as an advisor to the Company hereunder (whether before or after the date of this Agreement) relating to (i) information about the proprietary technologies. animal and clinical trial results, products, applications, host organisms, fungal gene expression, fungal high throughput screening, equipment, patent applications, know-how, data, reports, contracts, drawings, protocols, production processes of the Company, its Subsidiaries and Affiliates, (ii) the name of any existing or prospective investor, partner, employee, supplier, sales agent or the Provider of or to the Company, (iii) any sales plan, sales forecast, marketing material, plan or survey, business or financial plan or strategy, or opportunity, product or service development plan or specification, business proposal or information relating to the present or proposed business of the Company, (iv) the Company's financial statements, analyses, books, accounts, records, operating costs and expenses and other financial information about the Company, its Subsidiaries and their Affiliates, (v) internal management tools and systems, costing policies and methods, pricing policies and methods and other methods of doing business, of the Company, its Subsidiaries and their Affiliates, (vi) customers, sales, customer requirements and usages, distributor lists, of the Company, its Subsidiaries and Affiliates, (ix) agreements with customers, vendors, independent contractors, employees and others, of the Company, its Subsidiaries and their Affiliates, (x) existing and future products or services and product development plans, designs, analyses and reports, of the Company, its Subsidiaries and Affiliates, (xi) computer software and data bases developed for the Company, its Subsidiaries and Affiliates, trade secrets, research, records of research, models, designs, drawings, technical data and reports of the Company, its Subsidiaries and Affiliates and (xii) correspondence or other private or confidential matters</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">,</font><font style="font-family:Arial;font-size:10pt;">&#32;information or data whether written, oral or electronic, which is proprietary to the Company</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">,</font><font style="font-family:Arial;font-size:10pt;">&#32;its Subsidiaries and Affiliates and not generally known to the public, </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">provided that</font><font style="font-family:Arial;font-size:10pt;">&#32;the Company expressly acknowledges and agrees that the term "Confidential Information" excludes information which is:</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(i)&#160;&#160;&#160;&#160;In the public domain or otherwise generally known to the trade at or subsequent to the time it was communicated to the Provider by the disclosing party through no fault of the Provider;</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;was disclosed to other Persons other than by reason of the Providers breach of its confidentiality obligations hereunder;</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;was rightfully in the Provider's possession free of any obligation of confidence at or subsequent to the time it was communicated to the Provider by the Company or its personnel or agents;</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;was developed by the Provider or Persons other than the Company, its personnel or agents, independently of and without reference to any information communicated to the Provider by the Company or its personnel;</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(v)&#160;&#160;&#160;&#160;learned of by the Provider subsequent to the termination of its engagement by the Company hereunder from any other party not then under an obligation of confidentiality to the Company, its Subsidiaries and Affiliates; or</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(vi)&#160;&#160;&#160;&#160;is being disclosed by the Provider in response to a valid order by a court or other governmental body, or otherwise as required by law</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">, </font><font style="font-family:Arial;font-size:10pt;">or as necessary to establish the rights of either Party under this Agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:116%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;For purposes of this Section 4.3, the term "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">unauthorized</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">person</font><font style="font-family:Arial;font-size:10pt;">" shall mean any person who is not (I) an officer or director of the Company, or (ii) an employee, officer or director of a Subsidiary or Affiliate of the Company for whom the disclosure of the knowledge or information referred to herein is necessary for its performance of its assigned duties, or (iii) a person expressly authorized by the Company to receive disclosure of such knowledge or information.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:116%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.4&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Anti-Pirating and Non-Interference Covenants</font><font style="font-family:Arial;font-size:10pt;">. The Provider covenants to the Company that while the Provider is engaged by the Company hereunder and for the five (5) year period thereafter (the "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Non-Solicitation Period</font><font style="font-family:Arial;font-size:10pt;">"), the Provider will not, for any reason, directly or indirectly:</font></div><div style="line-height:121%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:119%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;solicit</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">,</font><font style="font-family:Arial;font-size:10pt;">&#32;hire, or otherwise do any act or thing which may induce any Protected Person (as that term is defined in Section 5.8(c) hereof) to terminate his relationship with Company, its Subsidiaries and Affiliates, or otherwise interfere with or adversely affect the relationship</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">(contractual or otherwise) of the Company, its Subsidiaries and Affiliates with</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">any</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">then Protected Person; or</font></div><div style="line-height:119%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:119%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;do any act or thing which may interfere with or adversely affect the relationship (contractual or otherwise) of the Company, its Subsidiaries and Affiliates with any then customer or then Protected Person or induce any such customer or Protected Person to cease doing business with the Company, its Subsidiaries and Affiliates.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.5&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Remedies for Breach</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:100%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a.&#160;&#160;&#160;&#160;The Provider hereby expressly acknowledges that the preservation of the confidentiality of the Company's Confidential Information is absolutely essential to commercial success of the Company, and that the improper use and/or disclosure of the Company's Confidential Information would cause the Company harm. If the Provider commits a breach, or threatens to commit a breach, of any of the provisions of this Article IV, the Company and its Subsidiaries shall have the right and remedy, in addition to any other remedy that may be available at law or in equity, to have the provisions of this Article IV specifically enforced by any court having equity jurisdiction (without regard to the arbitration provisions of Section 5.9 hereof), by the entry of temporary, preliminary and permanent injunctions and orders of specific performance, together with an accounting therefore, it being expressly acknowledged and agreed by the Provider that any such breach or threatened breach will cause irreparable injury to the Company and its Subsidiaries and that money damages will not provide an adequate remedy to the Company and its Subsidiaries. Such injunction shall be available without the posting of any bond or other security, and the Provider hereby consents to the issuance of such injunction. Further, in the event of an alleged breach or violation by the Provider of any of the provisions of Sections 4.3 or 4.4 hereof, the period in which the Provider has covenanted to the Company to refrain from engaging in the applicable activity shall </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:132%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">be tolled until such breach or violation has been cured. The parties agree that in the event of the institution of any action at law or in equity by either party to enforce the provisions of this Article IV, Each Party shall pay all their own respective costs and expenses in such action. If any covenant contained in this Article IV, or any part thereof, is hereafter construed to be invalid or unenforceable, the same shall not affect the remainder of such covenant or any other covenants, which shall be given full effect, without regard to the invalid portions, and any court having jurisdiction shall have the power to modify such covenant to the least extent necessary to render it enforceable and, in its modified form, said covenant shall then be enforceable.</font></div><div style="line-height:132%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:132%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.&#160;&#160;&#160;&#160;The Company waives its right to claim monetary damages from the Provider in excess of $100,000; and that this value represents an absolute cap on any /legal claim for monetary damages the Company may raise whatsoever against the Provider for any reason at any time. </font></div><div style="line-height:141%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">ARTICLE V</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">GENERAL</font></div><div style="line-height:131%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.1&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Assignment</font><font style="font-family:Arial;font-size:10pt;">. The Provider expressly agrees for itself and its successors-in-interest, that this Agreement and its obligations, rights, interests and benefits hereunder are personal to it in nature, and shall not be assigned, except in connection with the a sale of all or substantially all of the assets of the Provider and with the consent of the Company, which consent shall not be unreasonably withheld, provided that this Agreement shall be assignable and transferable by the Company to any successor-in-interest who acquires all or substantially all of the assets of the Company without the consent of the Provider, further provided that the Company shall not be relieved of its obligations to the Provider hereunder unless such successor-in-interest executes a written instrument assuming all of the Company's obligations under this Agreement and reasonably promptly furnishes a copy of same to the Provider.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.2&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Notices</font><font style="font-family:Arial;font-size:10pt;">. Any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given upon personal delivery to the Party to be notified or upon deposit in the United States Post Office certified or registered mail or with an air courier, postage and fees prepaid, addressed to the Company at: </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dyadic International, Inc. Suite 404 140</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Intracoastal Pointe Drive, Jupiter, Florida 33477 USA</font><font style="font-family:Arial;font-size:10pt;">&#32;or to the Provider at the address</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">set </font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.3&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Governing Law</font><font style="font-family:Arial;font-size:10pt;">. This Agreement shall be subject to and governed by the laws of the New York, USA without regard to any choice of law or conflicts of law rules or provisions (whether of England or any other jurisdiction), irrespective of the fact that Provider may become a resident of a different state or country.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.4</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Binding Effect</font><font style="font-family:Arial;font-size:10pt;">. The Agreement shall be binding upon and inure to the benefit of the Company, its successors and assigns, and the Provider and its executors, administrators, personal Providers and heirs.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.5&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Complete Understanding</font><font style="font-family:Arial;font-size:10pt;">. This Agreement contains the entire agreement of the parties relating to the subject matter hereof and supersedes all prior agreements and understanding with respect to such subject matter, and the parties hereto have made no agreements, representations or warranties relating to the subject matter of this Agreement which are not set forth herein.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.6&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Amendments</font><font style="font-family:Arial;font-size:10pt;">. No change, modification or amendment of any provision of this Agreement shall be valid unless made in writing and signed by all of the parties hereto.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.7&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Waiver</font><font style="font-family:Arial;font-size:10pt;">. The waiver by the Company of a breach of any provision of this Agreement by the Provider shall not operate or be construed as a waiver of any subsequent breach by the Provider. The waiver </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:123%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">by the Provider of a breach of any provision of this Agreement by the Company shall not operate as a waiver of any subsequent breach by the Company.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.8&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Certain Definitions</font><font style="font-family:Arial;font-size:10pt;">. As used herein, the following terms shall have the meanings indicated below:</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;"</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Affiliate</font><font style="font-family:Arial;font-size:10pt;">" means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with that Person, provided that, for purposes of this definition, the terms "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">controls</font><font style="font-family:Arial;font-size:10pt;">," "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">controlled</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">by</font><font style="font-family:Arial;font-size:10pt;">," or "</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">under common control with</font><font style="font-family:Arial;font-size:10pt;">" shall mean that Person's possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such other Person, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="line-height:123%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;"</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Person</font><font style="font-family:Arial;font-size:10pt;">" shall mean an individual, partnership, Limited Liability Company, trust, estate, association, corporation, governmental body, or other juridical being. </font></div><div style="line-height:123%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;"</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Protected Person</font><font style="font-family:Arial;font-size:10pt;">" shall mean any employee, contract manufacturer, supplier, vendor, research collaborator, sales agent, Provider, agent, advisor, independent contractor, or business collaborator of the Company, its Subsidiaries or their Affiliates. </font></div><div style="line-height:123%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(d)&#160;&#160;&#160;&#160;"</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Subsidiary</font><font style="font-family:Arial;font-size:10pt;">" means, with respect to any person, any corporation, limited liability company, partnership, association or other business entity of which (i) if a corporation, a majority of the total voting power of shares of stock entitled (Without regard to the occurrence of any contingency) to vote In the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or entity or one or more of the other Subsidiaries of such person or entity or a combination thereof, or (ii) if a limited liability company, partnership, association or other business entity, a majority of the partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by any person or entity or one or more Subsidiaries of such person or entity or a combination thereof For purposes hereof. a person or persons shall be deemed to have a majority ownership interest in a limited liability company, partnership, association or other business entity if such person or persons shall be allocated a majority of limited liability company, partnership, association or other business entity gains or losses or shall be or control any managing director or general partner of such limited liability company, partnership, association or other business entity.</font></div><div style="line-height:123%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.9</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Dispute</font><font style="font-family:Arial;font-size:10pt;">. Subject to the provisions of Section 4.6 hereof, any dispute or claim arising out of or in connection with this Agreement shall be exclusively submitted to the District Court of New York, NY.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.10</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Attorneys' Fees</font><font style="font-family:Arial;font-size:10pt;">. In the event that it is necessary for either Party to undertake to enforce any of the terms, conditions or rights set forth herein, or defend against any such action, each Party in such action shall bear their own costs. </font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.11</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Severability</font><font style="font-family:Arial;font-size:10pt;">. If any portion  of this Agreement  shall  be for any reason, invalid or unenforceable, the remaining portion or portions shall nevertheless be valid, enforceable and carried into effect.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.12&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Headings</font><font style="font-family:Arial;font-size:10pt;">. The headings of this Agreement are inserted for convenience only and are not to be considered in the construction of the provisions hereof.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.13&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Counterparts</font><font style="font-family:Arial;font-size:10pt;">. This Agreement may be executed in one or more counterparts. all of which, taken together, shall constitute one and the same agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="sCD441CFC17C55CF1B90D3F734A244F08"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Arial;font-size:10pt;">, the Company has caused this Agreement to be signed by one of its duly authorized officers and its corporate seal to be hereunto affixed, and the Provider has hereunto set its hand on the day and year first above written.</font></div><div style="line-height:123%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:8%;"></td><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:39%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">COMPANY: DYADIC International, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PROVIDER: Novara Ltd:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Thomas Dubinski</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Matthew Jones</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thomas Dubinski</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title:  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Vice President and CFO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Matthew Jones</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Director, Novaro Ltd</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Correspondence </font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Address: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Woodlee, West Hill, Wraxall, Bristol, BS48 1PL, England</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>14
<FILENAME>exhibit109form10.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s76E757DE728F83C3B08B43A6363AD798"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.9</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:404px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:150px;"></td><td style="width:253px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="dyadiclogo.jpg" alt="dyadiclogo.jpg" style="height:104px;width:133px;"></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">140 lntracoastal Pointe Drive, Ste. 404</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Jupiter, Florida 33477</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tel: 561-743-8333</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fax: 561-743-8343 </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">www.dyadic.com</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3e413b;">March 26, 2018</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3e413b;font-weight:bold;">VIA EMAIL AND US MAIL</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3e413b;">Ms. Ping Wang Rawson</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3e413b;">13634 187</font><font style="font-family:inherit;font-size:10pt;color:#3e413b;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;color:#3e413b;">&#32;Place N</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3e413b;">Jupiter, Florida 33478</font></div><div style="line-height:140%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3e413b;">Dear Ping:</font></div><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On behalf of Dyadic International, Inc. (the "Company"), it is my pleasure to provide you with this new compensation package in light of your recent promotion to Chief Accounting Officer.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Accounting Officer</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Status:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Full-time</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Effective date:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 14, 2018</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Reporting to:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer and Vice President and Chief Financial Officer ( should this position be filled in the future)</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Base Salary:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$210,000 per year, payable on a bi-monthly basis, subject to deductions for taxes and other withholdings required by law or the policies of the Company.</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Annual Bonus:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">One-time Option Grant:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A one-time stock option award of 50 thousand options (50,000), priced as of March 19, 2018 which vest in accordance with the Company's standard four-year vesting policy.</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One-time Conditional Stock</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Option Grant:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A one-time conditional award of 50 thousand options (50,000) priced as of March 19, 2018 which will vest upon the Company's becoming an SEC registered company. If for any reason the board determines that the Company will no longer pursue becoming an SEC registered company or in the event of a sale of the Company prior to becoming an SEC registered company, the option will automatically vest.</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Ping Rawson</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 26, 2018</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page 2</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Annual Stock Options:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You will be eligible for annual stock option compensation of up to 100,000 options to be determined based upon the results of operations of the Company and your personal performance (in the sole discretion of the Company's compensation committee), in accordance with the terms of a share-based compensation plan maintained by the Company.</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such options, if any, will be priced as of the date of grant. Any options that are granted shall vest 25% per year beginning one year from the date of grant.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Benefits:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You will be eligible for the benefits outlined in the Company's Employee Benefit Handbook including medical, dental and vision coverage as generally provided to other employees at the Company.</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You will also be able to continue to participate in a 401(k) Plan which the Company will match dollar for dollar up to four percent (4%) of your base salary, subject to any IRS limitations, if any.</font></div><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Vacation:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You will be entitled to four (4) weeks of vacation per year. However, you will not be permitted to take more than 2 weeks consecutively at a time. Additionally, we would expect that you will schedule your vacation plans at times which will not prevent you and your staff from completing our quarterly and annual financial filings in a timely matter.</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">Severance:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the Effective Date noted above, you will be entitled to six (6) months of severance pay ( computed based on your then current base salary) if your services are no longer required for either one of the following reasons:</font></div></td></tr></table><div style="line-height:120%;padding-left:192px;text-indent:-192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:192px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is a change in control, and your services are no longer required, OR</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:192px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You are discharged for any other reason other than for Cause.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of this arrangement, a termination shall be considered to be for "Cause" if it occurs in conjunction with a determination by the Board that any of the following has occurred:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Employee's conviction of, pleading guilty to, or confession to a felony or any crime involving any act of dishonesty, fraud, misappropriation, embezzlement or moral turpitude;</font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;Employee's misconduct or gross negligence in connection with the performance of her duties hereunder, including a violation of the Company's written policies or Code of Conduct and Ethics;</font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;Employee's engaging in any fraudulent, disloyal or unprofessional conduct which is, or is likely to be, injurious to the Company, its financial condition, or its reputation;</font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;Employee's failure to perform her duties with the Company); </font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(v)&#160;&#160;&#160;&#160;Employee's failure to meet performance standards agreed upon by Employee and the Company; or</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company determines that it has grounds to terminate Employee's employment for Cause pursuant to the provisions of clauses (iv) or (v) noted </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Ping Rawson</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 26, 2018</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page 3</font></div></div><div><br></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">above, then it will first deliver to Employee a written notice setting forth with specificity the occurrence deemed to give rise to a right to terminate her employment for Cause, and Employee will have 15 days after the receipt of such written notice to cease such actions or otherwise correct any such failure or breach. If Employee does not cease such actions or otherwise correct such failure or breach within such 15-day period, or having once received such written notice and ceased such actions or corrected such failure or breach, Employee at any time thereafter again so acts, fails, or breaches, the Company may terminate her employment for Cause immediately. The Company may terminate Employee's employment without Cause, or for Cause pursuant to the provisions of clauses (i), (ii), or (iii) noted above, immediately.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Your severance benefit will increase to 12 months (computed based on your then current base salary) one year from the Effective Date noted above or upon the Company becoming an SEC reporting entity, whichever occurs first.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Ping Rawson</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 26, 2018</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page 4</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Your employment with the Company is at-will and either party can terminate the relationship at any time with or without cause and with or without notice.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The revised details of your compensation and benefits outlined in this letter, replace any arrangement that has existed prior to the Effective Date noted above.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please evidence your agreement with and acceptance of the foregoing by signing, dating and returning a copy of this letter to me at your earliest convenience.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once again, we are excited about your promotion and look forward to working with you.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Very truly yours,</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:32.05128205128205%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:27%;"></td><td style="width:73%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title:  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Employee Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AGREED TO AND ACCEPTED</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This 26th day of March, 2018:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:32.05128205128205%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:27%;"></td><td style="width:73%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Ping Rawson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ping Rawson</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>15
<FILENAME>exhibit1010form10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s22011573DBBD7CE9922348995A691F42"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 10.10</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">INDEMNIFICATION AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">THIS INDEMNIFICATION AGREEMENT </font><font style="font-family:Arial;font-size:10pt;">(this "Agreement") is made as of the __ day of ____, ____, by and between </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font><font style="font-family:Arial;font-size:10pt;">, a Delaware corporation (the "Company"), and [</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">NAME OF OFFICER OR DIRECTOR</font><font style="font-family:Arial;font-size:10pt;">] ("Indemnitee").</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">RECITALS:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A.&#160;&#160;&#160;&#160;The Company and Indemnitee recognize the significant cost of directors' and officers' liability insurance and the general reductions in the coverage of such insurance.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">B.&#160;&#160;&#160;&#160;The Company and Indemnitee further recognize the substantial increase in corporate litigation in general, subjecting officers and directors to expensive litigation risks at the same time as the coverage of liability insurance has been severely limited.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">C.&#160;&#160;&#160;&#160;The Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve as officers and directors of the Company and to indemnify its officers and directors so as to provide them with the maximum protection permitted by law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AGREEMENT:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:Arial;font-size:10pt;">, in consideration for Indemnitee's services as an officer or director of the Company, the Company and Indemnitee hereby agree as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.&#160;&#160;&#160;&#160;INDEMNIFICATION.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Third Party Proceedings</font><font style="font-family:Arial;font-size:10pt;">. The Company shall indemnify Indemnitee if Indemnitee is or was a party or is threatened to be made a party to any threatened, pending or completed action, suit, proceeding or any alternative dispute resolution mechanism, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys, fees), judgments, fines and amounts paid in settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld) actually and reasonably incurred by Indemnitee in connection with such action, suit or proceeding if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe Indemnitee's conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had reasonable cause to believe that Indemnitee's conduct was unlawful.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Proceedings By or in the Right of the Company</font><font style="font-family:Arial;font-size:10pt;">. The Company shall indemnify Indemnitee if Indemnitee was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Company or any subsidiary of the Company to procure a judgment in its favor by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys, fees) and, to the fullest extent </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">permitted by law, amounts paid in settlement actually and reasonably incurred by Indemnitee in connection with the defense or settlement of such action or suit if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, except that no indemnification shall be made in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable to the Company unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of the State of Delaware or such other court shall deem proper.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Mandatory Payment of Expenses</font><font style="font-family:Arial;font-size:10pt;">. To the extent that Indemnitee has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Subsections (a) and (b) of this Section 1, or in defense of any claim, issue or matter therein, Indemnitee shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by Indemnitee in connection therewith.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.&#160;&#160;&#160;&#160;EXPENSES; INDEMNIFICATION PROCEDURE.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Advancement of Expenses</font><font style="font-family:Arial;font-size:10pt;">. The Company shall advance all expenses incurred by Indemnitee in connection with the investigation, defense, settlement or appeal of any civil or criminal action, suit or proceeding referenced in Section 1(a) or (b) hereof (but not amounts actually paid in settlement of any such action, suit or proceeding). Indemnitee hereby undertakes to repay such amounts advanced only if, and to the extent that, it shall ultimately be determined that Indemnitee is not entitled to be indemnified by the Company as authorized hereby. The advances to be made hereunder shall be paid by the Company to Indemnitee within thirty (30) days following delivery of a written request therefor by Indemnitee to the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Notice/Cooperation by Indemnitee</font><font style="font-family:Arial;font-size:10pt;">. Indemnitee shall, as a condition precedent to his right to be indemnified under this Agreement, give the Company notice in writing as soon as practicable of any claim made against Indemnitee for which indemnification will or could be sought under this Agreement. Notice to the Company shall be directed to the President of the Company at the address shown on the signature page of this Agreement (or such other address as the Company shall designate in writing to Indemnitee). Notice shall be deemed received three business days after the date postmarked if sent by domestic certified or registered mail, properly addressed, five business days if sent by airmail to a country outside of North America; otherwise notice shall be deemed received when such notice shall actually be received by the Company. In addition, Indemnitee shall give the Company such information and cooperation as it may reasonably require and as shall be within Indemnitee's power.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Procedure</font><font style="font-family:Arial;font-size:10pt;">. Any indemnification and advances provided for in Section 1 and this Section 2 shall be made no later than thirty (30) days after receipt of the written request of Indemnitee. If a claim under this Agreement, under any statute, or under any provision of the Company's Certificate of Incorporation or Bylaws providing for indemnification, is not paid in full by the Company within thirty (30) days after a written request for payment thereof has first been received by the Company, Indemnitee may, but need not, at any time thereafter bring an action against the Company to recover the unpaid amount of the claim and, subject to Section 12 of this Agreement, Indemnitee shall also be entitled to be paid for the expenses (including attorneys' fees) of bringing such action. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in connection with any action, suit or proceeding in advance of its final disposition) that Indemnitee has not met the standards of conduct which make it permissible under applicable law for the Company to indemnify Indemnitee for the amount claimed. However, Indemnitee shall be entitled to receive interim payments of expenses pursuant to Subsection 2(a) unless and until such defense may be finally adjudicated by court order or judgment from which no further right of appeal exists. It is the parties, intention that if the Company contests Indemnitee's right to indemnification, the question of Indemnitee's right to indemnification shall be for the court to decide, and neither the failure of the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its stockholders) to have made a determination that indemnification </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct required by applicable law, nor an actual determination by the Company (including it Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its stockholders) that Indemnitee has not met such applicable standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Notice to Insurers</font><font style="font-family:Arial;font-size:10pt;">. If, at the time of the receipt of a notice of a claim pursuant to section 2(b) hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Selection of Counsel</font><font style="font-family:Arial;font-size:10pt;">. In the event the Company shall be obligated under Section 2(a) hereof to pay the expenses of any proceeding against Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, with counsel approved by Indemnitee, upon the delivery to Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same proceeding, provided that (i) Indemnitee shall have the right to employ his counsel in any such proceeding at Indemnitee's expense; and (ii) if (A) the employment of counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense, or (C) the Company shall not, in fact, have employed counsel to assume the defense of such proceeding, then the fees and expenses of Indemnitee's counsel shall be at the expense of the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.&#160;&#160;&#160;&#160;ADDITIONAL INDEMNIFICATION RIGHTS; NONEXCLUSIVITY.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Scope</font><font style="font-family:Arial;font-size:10pt;">. Notwithstanding any other provision of this Agreement, the Company hereby agrees to indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification is not specifically authorized by the other provisions of this Agreement, the Company's Certificate of Incorporation, the Company's Bylaws or by statute. In the event of any change, after the date of this Agreement, in any applicable law, statute, or rule which expands the right of a Delaware corporation to indemnify a member of its board of directors or an officer, such changes shall be, ipso facto, within the purview of Indemnitee's rights and Company's obligations, under this Agreement. In the event of any change in any applicable law, statute or rule which narrows the right of a Delaware corporation to indemnify a member of its board of directors or an officer, such changes, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement shall have no effect on this Agreement or the parties' rights and obligations hereunder.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Nonexclusivity</font><font style="font-family:Arial;font-size:10pt;">. The indemnification provided by this Agreement shall not be deemed exclusive of any rights to which Indemnitee may be entitled under the Company's Certificate of Incorporation, its Bylaws, any agreement, any vote of stockholders or disinterested Directors, the General Corporation Law of the State of Delaware, or otherwise, both as to action in Indemnitee's official capacity and as to action in another capacity while holding such office. The indemnification provided under this Agreement shall continue as to Indemnitee for any action taken or not taken while serving in an indemnified capacity even though he may have ceased to serve in such capacity at the time of any action, suit or other covered proceeding.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.&#160;&#160;&#160;&#160;PARTIAL INDEMNIFICATION. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties actually or reasonably incurred by him in the investigation, defense, appeal or settlement of any civil or criminal action, suit or proceeding, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines or penalties to which Indemnitee is entitled.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.&#160;&#160;&#160;&#160;MUTUAL ACKNOWLEDGEMENT. Both the Company and Indemnitee acknowledge that in certain instances, Federal law or applicable public policy may prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise. Indemnitee understands and acknowledges that the Company has undertaken or may be required in the future to undertake with the Securities and Exchange Commission to submit the question of indemnification to a court in certain circumstances for a determination of the Company's right under public policy to indemnify Indemnitee.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.&#160;&#160;&#160;&#160;OFFICER AND DIRECTOR LIABILITY INSURANCE. The Company shall, from time to time, make the good faith determination whether or not it is practicable for the Company to obtain and maintain a policy or policies of insurance with reputable insurance companies providing the officers and directors of the Company with coverage for losses from wrongful acts, or to ensure the Company's performance of its indemnification obligations under this Agreement. Among other considerations, the Company will weigh the costs of obtaining such insurance coverage against the protection afforded by such coverage. In all policies of director and officer liability insurance, Indemnitee shall be named as an insured in such a manner as to provide Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company's directors, if Indemnitee is a director; or of the Company's officers, if Indemnitee is not a director of the Company but is an officer. Notwithstanding the foregoing, the Company shall have no obligation to obtain or maintain such insurance if the Company determines in good faith that such insurance is not reasonably available, if the premium costs for such insurance are disproportionate to the amount of coverage provided, if the coverage provided by such insurance is limited by exclusions so as to provide an insufficient benefit, or if Indemnitee is covered by similar insurance maintained by a subsidiary or parent of the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.&#160;&#160;&#160;&#160;SEVERABILITY. Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company's inability, pursuant to court order, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. The provisions of this Agreement shall be severable as provided in this Section 7. If this Agreement or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify Indemnitee to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated, and the balance of this Agreement not so invalidated shall be enforceable in accordance with its terms.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.&#160;&#160;&#160;&#160;EXCEPTIONS. Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Claims Initiated by Indemnitee</font><font style="font-family:Arial;font-size:10pt;">. To indemnify or advance expenses to Indemnitee with respect to proceedings or claims initiated or brought voluntarily by Indemnitee and not by way of defense, except with respect to proceedings brought to establish or enforce a right to indemnification under this Agreement or any other statute or law or otherwise as required under Section 145 of the Delaware General Corporation Law, but such indemnification or advancement of expenses may be provided by the Company in specific cases if the Board of Directors has approved the initiation or bringing of such suit; or</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Lack of Good Faith</font><font style="font-family:Arial;font-size:10pt;">. To indemnify Indemnitee for any expenses incurred by the Indemnitee with respect to any proceeding instituted by Indemnitee to enforce or interpret this Agreement, if a court of competent jurisdiction determines that each of the material assertions made by the Indemnitee in such proceeding was not made in good faith or was frivolous; or</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Insured claims</font><font style="font-family:Arial;font-size:10pt;">. To indemnify Indemnitee for expenses or liabilities of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) which have been paid directly to Indemnitee by an insurance carrier under a policy of officers' and directors' liability insurance maintained by the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Claims Under Section 16(b)</font><font style="font-family:Arial;font-size:10pt;">. To indemnify Indemnitee for expenses and the payment of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9.&#160;&#160;&#160;&#160;CONSTRUCTION OF CERTAIN PHRASES.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;For purposes of this Agreement, references to the "Company" shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that if Indemnitee is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting or surviving corporation as Indemnitee would have with respect to such constituent corporation if its separate existence had continued.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;For purposes of this Agreement, references to "other enterprises" shall include employee benefit plans; references to "fines" shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to "serving at the request of the Company" shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants, or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner "not opposed to the best interests of the Company" as referred to in this Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.&#160;&#160;&#160;&#160;COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which shall constitute an original.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.&#160;&#160;&#160;&#160;SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon the Company and its successors and assigns, and shall inure to the benefit of Indemnitee and Indemnitee's estate, heirs, legal representatives and assigns.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12.&#160;&#160;&#160;&#160;ATTORNEYS' FEES. In the event that any action is instituted by Indemnitee under this Agreement to enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be paid all court costs and expenses, including reasonable attorneys' fees, incurred by Indemnitee with respect to such action, unless as a part of such action, the court of competent jurisdiction determines that each of the material assertions made by Indemnitee as a basis for such action were not made in good faith or were frivolous. In the event of an action instituted by or in the name of the Company under this Agreement or to enforce or interpret any of the terms of this Agreement, Indemnitee shall be entitled to be paid all court costs and expenses, including attorneys' fees, incurred by Indemnitee in defense of such action (including with respect to Indemnitee's counterclaims and cross claims made in such action), unless as a part of such action the court determines that each of Indemnitee's material defenses to such action were made in bad faith or were frivolous.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13.&#160;&#160;&#160;&#160;NOTICE. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed duly given (i) if delivered by hand and receipted for by the party addressee, on the date of such receipt, or (ii) if mailed by domestic certified or registered mail with postage prepaid, on the third business day after the date postmarked. Addresses for notice to either party are as shown on the signature page of this Agreement, or as subsequently modified by written notice.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14.&#160;&#160;&#160;&#160;CONSENT TO JURISDICTION. The Company and Indemnitee each hereby irrevocably consent to the jurisdiction of the courts of the State of Delaware for all purposes in connection with any action </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">or proceeding which arises out of or relates to this Agreement and agree that any action instituted under this Agreement shall be brought only in the state courts of the State of Florida.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15.&#160;&#160;&#160;&#160;CHOICE OF LAW. This Agreement shall be governed by and its provisions construed in accordance with the laws of the State of Delaware, as applied to contracts between Delaware residents entered into and to be performed entirely within Delaware without regard to the conflict of law principles thereof.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16.&#160;&#160;&#160;&#160;PERIOD OF LIMITATIONS. No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against Indemnitee, Indemnitee's estate, spouse, heirs, executors or personal or legal representatives after the expiration of two (2) years from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action, such shorter period shall govern.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.&#160;&#160;&#160;&#160;SUBROGATION. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company effectively to bring suit to enforce such rights.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18.&#160;&#160;&#160;&#160;AMENDMENT AND TERMINATION. No amendment, modification, termination or cancellation of this Agreement shall be effective unless it is in writing signed by both the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19.&#160;&#160;&#160;&#160;INTEGRATION AND ENTIRE AGREEMENT. This Agreement sets forth the entire understanding between the parties hereto and supersedes and merges all previous written and oral negotiations, commitments, understandings and agreements relating to the subject matter hereof between the parties hereto.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="sA8712149455612C69E1148995F63D90C"></a></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Arial;font-size:10pt;">, the parties hereto have executed this Agreement as of the date first above written.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:50.427350427350426%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#393739;font-weight:bold;">DYADIC INTERNATIONAL, INC., </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a Delaware corporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name:  Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title:  President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">[Name of Officer or Director]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>16
<FILENAME>exhibit1011form10.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7BE588373D24B82885E258693605940A"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.11</font></div></div><div><br></div><div style="padding:0px 0px 0px 0px; border:1pt solid #000000;"><div style="line-height:100%;padding-top:5px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6.5pt;"><font style="font-family:inherit;font-size:6.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:271%;padding-top:1px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">INTRACOASTAL POINTE  OFFICE  BUILDING </font></div><div style="line-height:271%;padding-top:1px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">LEASE AGREEMENT</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-top:1px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">TENANT:</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12.5pt;"><font style="font-family:Arial;font-size:12.5pt;">DYADIC  INTERNATIONAL,  INC.</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">LANDLORD:</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:129%;text-align:center;font-size:12.5pt;"><font style="font-family:Arial;font-size:12.5pt;">QUENTIN  PARTNERS  CO. </font></div><div style="line-height:129%;text-align:center;font-size:12.5pt;"><font style="font-family:Arial;font-size:12.5pt;">as Agent for</font></div><div style="line-height:120%;text-align:center;font-size:12.5pt;"><font style="font-family:Arial;font-size:12.5pt;">lntracoastal  Pointe,  Inc.</font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:12.5pt;"><font style="font-family:Arial;font-size:12.5pt;">851  S.E. Johnson Avenue,  Suite 100</font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:12.5pt;"><font style="font-family:Arial;font-size:12.5pt;">Stuart,  Florida 34994</font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:12.5pt;"><font style="font-family:Arial;font-size:12.5pt;">772-220-4127</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;">December,  2010</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sC43299EDBDF389396103586936385BC9"></a></div><div></div><div><br></div><div style="line-height:126%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-style:italic;font-weight:bold;">INTRACOASTAL POINTE OFFICE BUILDING </font></div><div style="line-height:126%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-style:italic;font-weight:bold;">LEASE AGREEMENT</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">THIS LEASE AGREEMENT  (sometimes hereinafter referred to as the "Lease") is made and entered into this 30th day of December, 2010 by and between Quentin Partners Co. as Agent for lntracoastal Pointe, Inc., (Florida corporations) (hereinafter collectively called "Landlord"), whose address for purposes hereof is 851 S.E. Johnson Avenue, Suite 100, Stuart,  Florida  34994;  and  Dyadic  International,  Inc.,    (hereinafter  called  "Tenant"). Tenant's address, for purposes hereof until commencement of the term of this Lease, being 140 lntracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477 and thereafter being that of the Leased Premises (hereinafter defined).</font></div><div style="line-height:130%;padding-top:1px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WITNESSETH:</font></div><div style="line-height:130%;padding-top:1px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LEASED PREMISES: Subject to and upon the terms, provisions, covenants and conditions  hereinafter  set  forth,  and  each  in   consideration   of  the  duties, covenants and obligations of the other hereunder, Landlord does hereby lease, demise and let to Tenant and Tenant does  hereby lease,  demise and let from Landlord  those  certain  premises  (hereinafter  sometimes  called the  "Leased Premises")  in  the  lntracoastal  Pointe  Office  Building   (hereinafter  sometimes referred to as "Building") located at 140 lntracoastal Pointe Drive, Jupiter, Florida 33477, such Leased Premises being more particularly described as follows:</font></div></td></tr></table><div style="line-height:130%;padding-top:1px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:126%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Suites 404 and 405, 4,872&#177; square feet of Gross Rentable Area, located on the fourth floor of the Building.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The term "Gross Rentable Area" as used herein, shall refer to all area measured from the outside surface of the outer glass or finished walls of the building to the outside surface  of the opposite  outer wall, glass, or in the case of multi-tenant floors, to the midpoint of the walls separating the Leased Premises of adjacent tenants.  The term "Gross Rentable Area" includes a pro rata share of all common areas and facilities of the  Building,  but not limited to, bathrooms,  hallways and service facilities, the  rent and expenses  of which  are to be shared  by Tenant proportionately.   No deductions from Gross  Rentable Area are made for columns or projections necessary to the Building.  The Gross Rentable Area in the Leased Premises has been calculated on the basis of the foregoing definition and is hereby stipulated  for all purposes hereof to be 4,872&#177; square  feet, whether the same should  be  more  or  less  as  a  result  of minor  variations  resulting  from  actual construction and completion of the Leased Premises for occupancy so long as such work is done substantially in accordance with the approved plans.</font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">2.&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;TERM: The term of this Lease Agreement on the Leased Premises shall be for a</font></div><div style="line-height:125%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">period of (36) thirty-six months. The Commencement Date of the term shall be </font></div><div style="line-height:125%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">January 1,  2011.Landlord will make all diligent attempts to have space ready. The</font></div><div style="line-height:125%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">rent for partial months shall be prorated. The Term of the Lease shall expire (unless</font></div><div style="line-height:125%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">sooner terminated as provided  herein) at 11 :59 p.m. E.D.T. on December 31, 2013.</font></div><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">B.&#160;&#160;&#160;&#160;Early Termination:</font></div><div style="line-height:125%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Tenant shall have the right to terminate the Lease with a six (6) month notice  at any time on or after January 1,  2012  by delivering written  notice  ("Early Termination  Notice") to Landlord its intention to do so.</font></div><div style="line-height:120%;text-align:justify;padding-left:16px;text-indent:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">3.&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;Annual Rent:  During the term of this Lease, Tenant agrees and covenants to pay</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">the Landlord Annual Rent as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:16px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">1/01/11  - 12/31/13:  $11.50 per square foot;  $56,028.00/year; $4,669.00/month*</font></div><div style="line-height:130%;padding-top:1px;text-align:justify;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">*Tenant will pay first month's rent plus CAM as defined in the lease (Section 3C, currently at $8.00 psf) and sales tax (currently at 6.5%) totaling $8,431.61, upon lease execution.</font></div><div style="line-height:130%;padding-top:1px;text-align:justify;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Total Annual Rent per year is payable without demand, notice or offset in advance in equal monthly installments of one-twelfth of the Annual Rent due and payable on the first day of each and every calendar month of the term of the Lease, in the currency of the United States of America at the offices of Landlord or elsewhere as designated from time to time by Landlord's written notice to Tenant.  The monthly installment of Annual  Rent shall be   prorated in the case of partial months.   In addition to the Annual Rent,  Tenant shall pay to the Landlord  on the first day of each month a sum equal to any sales tax, tax on rentals, and any other charges, taxes  or impositions,  now in  existence  or  hereafter  imposed  based  upon  the privilege of renting the Leased Premises or upon the amount of Annual Rent, pro rata expenses, and all other amounts owed by Tenant hereunder.  Nothing herein shall,  however,  require Tenant to  pay any  Federal  or  State  taxes  on  income imposed upon Landlord.</font></div><div style="line-height:130%;text-align:justify;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:126%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The  Tenant  will  pay for  the  electric  for  the  Leased  Premises,  which  shall  be separately metered. The Tenant will be responsible to maintain its Leased Premises space (including all water connections, appliances and kitchens).</font></div><div style="line-height:126%;padding-top:2px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:126%;padding-top:2px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LATE CHARGES.  The parties agree that late payment by Tenant to Landlord  of rent will cause Landlord to incur costs not contemplated  by this lease, the amount of which is extremely difficult to ascertain.  Therefore, the parties agree that if any installment of rent is not received by Landlord within 7 days after rent is due, Tenant will pay to Landlord a sum equal to 15% of monthly rent as a late charge.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:130%;text-align:left;padding-left:48px;font-size:12.5pt;"><font style="font-family:Arial;font-size:11pt;">INSUFFICIENT FUNDS.  If any of Tenant's checks bounce, Landlord will charge a fee of $100.00</font><font style="font-family:inherit;font-size:12.5pt;">&#32;</font><font style="font-family:Arial;font-size:11pt;">for administrative  cost plus all bank fees.</font></div><div style="line-height:130%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">PRORATA SHARE OF EXPENSES AS ADDITIONAL RENT: In addition to the Annual Rent and other sums to be paid hereunder by Tenant,  Tenant shall pay a prorata share of all expenses incurred by Landlord in connection with the ownership, operation, maintenance and management of the Building and the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:126%;padding-left:96px;text-align:left;"><font style="font-family:Arial;font-size:11pt;">land upon which it is located.  Tenant's pro-rata share shall be $8.00 per square foot.</font></div><div style="line-height:130%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:126%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The expenses for which the Tenant shall pay a prorata  share  according to the aforesaid formula include but are not limited to the following:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Real Property Taxes and Assessments.  Tenant shall pay its pro-rata share of all real property taxes and assessments and all tangible personal property taxes which may be levied or assessed by any lawful authority against the land, the improvements located on the land (including the Building) and all personal  property  owned  by Landlord  and  used  in  connection  with  the operation  and  management  thereof.    A  tax  bill  or  photocopy  thereof submitted  by Landlord to Tenant shall be sufficient evidence of the amount of taxes assessed or levied against the property to which the bill relates. The real property taxes and assessments herein referred to shall be the real property taxes and assessments on the property with a physical address of 140  lntracoastal  Pointe  Drive,  Jupiter,  Florida  33477.    Tenant shall  be responsible for paying all taxes on Tenant's own personal property and all taxes due with respect to any leasehold improvements which exceed the value of the improvements provided by Landlord to Tenant.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:96px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Insurance.  Tenant shall pay its prorata share of the cost of all insurance coverage carried by Landlord with respect to the Building and land, including without limitation insurance against liability, casualty, loss of damage to the Building, rent loss, flood insurance,  and worker's compensation.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:96px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Utilities.  Tenant shall pay its prorata share of the cost of all utilities including electricity, water, gas, fuel, trash and garbage collection fees, Tenant Association fees, drainage district tax, and any sewer service charges for the Building  (but as provided  in Section  10, Tenant  shall be  responsible  for paying all electricity to the Leased Premises).</font></div></td></tr></table><div style="line-height:130%;padding-top:1px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:123%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">(4)&#160;&#160;&#160;&#160;General Services and Expenses (for the Building Common Areas): </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:123%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:123%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Janitorial services.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Maintenance and repair.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Landscaping maintenance, supplies and refurbishing.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Cleaning, maintaining,  resurfacing, and striping of the parking area. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Operatorless elevator service and maintenance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:123%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:123%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Supplies for restrooms and other public portions of the Building and the property.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:123%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:123%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Maintenance of air conditioning, heating, sprinkler, access control and other mechanical systems.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Building management fees.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Expenses for access control if and to the extent provided by Landlord. In the event Landlord does provide access control, Tenant specifically agrees that Landlord shall not be liable in the event of any loss or </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-top:2px;text-align:left;"><font style="font-family:Arial;font-size:11pt;">damage  suffered  by Tenant as a result  of any failure to exclude access to any unauthorized  personnel.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(j)</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Reserve for renewal, replacement, and capital improvements of ten percent of annual expenses  excluding the reserve for renewal and replacement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(k)</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Amortization  of the cost of capital  improvements  (together with  a reasonable  finance charge) as may be required  by governmental authority.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(I)</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Professional fees (including attorneys and accountants)  incurred in connection with the operation of the Building; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:123%;font-size:11pt;padding-left:96px;"><font style="font-family:Arial;font-size:11pt;">(m)</font></div></td><td style="vertical-align:top;"><div style="line-height:123%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Compensation  of employees  at the level of building  manager and below in connection with operation of the Building.</font></div></td></tr></table><div style="line-height:130%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The costs to be shared on a prorata basis by Tenant shall not include payments of principal and interest on any mortgage or deed of trust upon the building,  or the costs of improvements made for particular tenants.</font></div><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Landlord does not warrant that any of the services will be free from interruption caused by repairs, renewal, improvement, alterations, strikes, lockouts, accidents, inability of Landlord to obtain fuel or supplies  or any other causes.   Any  such interruption of service shall never be deemed an eviction or disturbance of Tenant's use and possession of the premises or any part thereof or render the Landlord liable to the Tenant for damages or relieve the Tenant from performance of the Tenant's obligations under this Lease.  Landlord agrees, however, that Landlord will make reasonable  efforts  at  all times  to  promptly remedy  any  situation  which  might interrupt such services.</font></div><div style="line-height:130%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">OTHER  PROVISIONS  AFFECTING  RENTAL  PAYMENTS  AND ADDITIONAL   RENT:  Notwithstanding   anything  in  the  foregoing  to  the contrary, the Tenant's obligations under Section 3(B) shall be computed as the costs of owning,  operating and managing  the Building  is $8.00*  per square foot (base CAM rate).   The prorata share shall be $8.00 p.s.f.  over the term of the Lease.  Tenant shall pay in advance, in monthly installments as herein set forth. The amount due under this Section shall be paid  by Tenant to Landlord without notice or demand and without abatement, deduction or set-off in monthly installments, in advance on the first day of each calendar month during the term of this Lease as provided for herein. Landlord shall have all the rights and remedies provided herein or by law for the purposes of collection thereof. Tenant may not disclose any information regarding Building expenses without the approval of Landlord.</font></div></td></tr></table><div style="line-height:130%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SECURITY DEPOSIT: Tenant concurrently with the execution of this Lease shall pay the sum of zero dollars.  It is understood that Tenant paid a previous Landlord a security deposit of four thousand four hundred twenty-three dollars and 84 cents ($4,423.84),  which was  never  transferred  to the current  Landlord  because  the previous  Landlord went  out  of business.   Tenant's  lease  signed June 28, 2001 stated  that  Quentin  Partners Co. would  assume  responsibility for this  security deposit of $4,423.84 provided Tenant remained in good standing through December 31, 2005, which was the case.  As a courtesy for tenant goodwill, this sum shall be deemed by Landlord as security for the payment by Tenant of the rents and all other payments herein agreed to be paid by Tenant and for the faithful </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:126%;padding-left:48px;text-align:justify;"><font style="font-family:Arial;font-size:11pt;">performance by Tenant  of the  terms,  provisions,  and  conditions  of this  Lease.    Landlord,  at Landlord's option, may at the time of any default by Tenant under any of the terms, provisions, covenants or conditions of this Lease apply said sum or any part thereof towards the payment of the rents and all other sums payable by Tenant under this Lease. Landlord will notify the Tenant in writing when this action has been taken. Tenant shall remain liable for any amounts that such sum shall be insufficient to pay and shall within three (3) days after demand by Landlord restore the security deposit to the amount originally required hereby.  Landlord may exhaust any or all rights and remedies against Tenant before resorting to the security deposit, but nothing herein contained shall require or be deemed to require Landlord to do so.  In the event the deposit shall  not be utilized for  any such purpose,  then such deposit  shall  be returned  by Landlord  to Tenant after the  expiration  of the term  of this  Lease. Landlord shall not be required to pay Tenant any interest on the security deposit.</font></div><div style="line-height:130%;text-align:justify;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">USE: The Tenant will use and occupy the Leased Premises for the following use or purpose and for no other use or purpose: Office. </font></div></td></tr></table><div style="line-height:126%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:126%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Notwithstanding anything to the contrary in this Lease, the Leased Premises shall not be used for any purpose which would (i) adversely affect the appearance of the Building, (ii) except for general office use,  be visible from the exterior of, or the public areas of the Building, (iii) adversely affect ventilation in other areas of the Building  (including without limitation the creation of offensive odors),  (iv) create unreasonable elevator loads, (v) cause structural loads to be exceeded, (vi) create unreasonable noise levels, (vii) violate building codes, zoning ordinances, or other applicable laws or otherwise constitute illegal use, (viii) adversely affect the mechanical, electrical, plumbing or other base Building systems, (ix) result in the generation, treatment, storage, discharge, disposal, possession, processing or other handling  of chemicals  or any hazardous material  in the  Leased  Premises,  the Building,  or any  Building  systems,  including  in  particular  disposal  in  the  base Building  plumbing,  heating,  ventilating  or air-conditioning  systems,  (x)  involve printing,  photographic processing or other process involving the use of chemicals and equipment not generally used in office buildings, or (xi) otherwise unreasonably interfere with Building operations or other tenants of the Building.  (xii) Tenant is responsible for any and all damage throughout the building which might result from its shipping and/or receiving operations.  In all events, Tenant shall not engage in any activity which is not in keeping with the standards of the Building.</font></div><div style="line-height:126%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">IMPROVEMENTS: Tenant may create two offices from a conference room and hallway in the southwest corner of Suite 405 (see plan). Tenant shall maintain all improvements installed in accordance with said plans. The final plans for Tenant's interior improvements ("Tenant Improvements") shall be submitted to Landlord  and shall be subject to approval by Landlord and the Town of Jupiter prior to commencement  of construction.   Landlord's  approval shall not be unreasonably withheld provided that such improvements do not adversely affect Building structure or Building systems and are not visible from the exterior of the Leased Premises. The plans submitted by Tenant shall not be deemed final unless they are sufficient to meet all requirements  necessary to allow Landlord to obtain a building </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;padding-left:48px;padding-top:2px;text-align:justify;"><font style="font-family:Arial;font-size:11pt;">permit. After the plans have been submitted to and approved by Landlord no changes shall be permitted without Landlord's written consent.</font></div><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Should Tenant desire water and sewer service within the Leased Premises other than those existing, said installation and connection  shall be at the Tenant's sole expense.  Tenant shall be responsible for damages, if any, to the Building or to the Leased Premises, as a result of the original installation, leaks, water pipe breakage or other failure in the system which may occur after the original installation.</font></div><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:123%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">All Tenant Improvements made to the Leased Premises shall become the property of the Landlord  upon expiration or termination of this Lease.</font></div><div style="line-height:130%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">CONTRACTORS.   All outside contractors will be licensed, insured for liability and carry an occupational  license valid in the municipality in which they are going to work.   Landlord must be notified  of the names of these contractors and provided with a copy of their licenses and insurance.   (see Section 14 - Liens.)</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">TENANT'S RIGHTS AND RESTRICTIONS AS TO BUSINESS SIGNS: Tenant may, at its own expense, erect or place, of a quality, size, and in a manner approved in writing by Landlord, and based on Landlord's building standard, graphics identifying Tenant  on  the  main  entrance  door  of the  Leased  Premises  or as  otherwise designated by Landlord. Such signs shall be kept in a good state of repair and Tenant shall repair any damage that may have been done to the Leased Premises by the erection, existence or removal of such signs.  At the end of the Lease term, Tenant shall remove the signs at its expense.</font></div></td></tr></table><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Except as provided above, no sign, notice or other advertisement shall be inscribed, painted, affixed or displayed on any of the windows or on the exterior of any of the doors  of the  Leased  Premises,  nor anywhere  visible  from  outside the  Leased Premises  without prior written consent  of Landlord  (which  may  be granted  or withheld by Landlord in its sole discretion).</font></div><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Landlord agrees that during the entire term of this Lease Landlord shall make space available on the building directory board of the building for the name of Tenant's firm, company, corporation or business entity.  Landlord shall maintain the Tenant's name on the sign, unless a federal, state or local code prohibits either the sign or limits  use  of  such  sign.  Landlord  has  the  right  to  approve  signage  prior  to installation.</font></div><div style="line-height:130%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">CONDITION OF PREMISES: Tenant is in possession of the Leased Premises and Tenant acknowledges the Leased Premises are  in good and satisfactory condition.</font></div></td></tr></table><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">QUIET POSSESSION: Upon payment by Tenant of the rental herein provided, and upon the observance  and performance  of all terms,  provisions, covenants and conditions on Tenant's part to be observed and performed, Tenant shall, subject to all of the terms, provisions, covenants and conditions  of this Lease Agreement, peaceably and quietly hold and enjoy the Leased Premises for the term hereby leased.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">TENANT'S  ELECTRICAL:  Tenant shall use only office  machines and equipment that operate  on the  Building's standard  electric circuits,  but which  in  no event overload the Building's standard electrical circuits from which the Tenant obtains electric current or which will, in the opinion of Landlord, interfere with the reasonable use of the Building by Landlord or other tenants  or which shall create a hazard within the Leased Premises. Tenant shall comply with all governmental mandates regarding  temperature  control.  Tenant shall  be responsible  for  payment of all charges for electric consumption within the Leased Premises.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">CHARGES  FOR  SERVICE:  Any  charges  against  Tenant  by  Landlord  or  its subsidiaries  or agents for services or for work done on the Leased Premises  by order of Tenant, or otherwise accruing under this Lease, shall be considered as rent due hereunder for all purposes.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">REMEDIES UPON TENANT'S  DEFAULT. In the event Tenant shall abandon or vacate the Leased Premises or at any time be in default in the payment when due of Annual Base Rent,  or other charges herein required  to be paid by Tenant or in the observance  or performance  of any of the other covenants and agreements required to be performed and observed by Tenant hereunder and any such default shall continue  for  a period  of three (3) days  after written  notice to Tenant for monetary obligations and ten (10) days after written notice to Tenant for all other obligations, then Tenant shall be in default hereunder and Landlord shall be entitled to  any and  all  remedies  available  at  law or  in  equity and  all other  remedies specifically  provided  herein.  Without  limiting  the  generality  of  the  foregoing, Landlord may:</font></div></td></tr></table><div style="line-height:130%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Terminate  this  Lease  and  Tenant's  right  to  possession  of the  Leased Premises by any lawful means, in which case this Lease shall terminate and Tenant shall immediately surrender possession of the Leased Premises to Landlord. In such event Landlord shall be entitled to recover from Tenant all damages incurred by Landlord  by reason of Tenant's default including,  but not limited to, the cost of recovering possession of the Leased Premises, expenses  of reletting,  reasonable  attorney's  fees,  and  any  real  estate commission paid; and the difference at the time of termination between the amount by which the unpaid Annual Base Rent (as is reasonably projected  by Landlord) for the balance of the term.</font></div></td></tr></table><div style="line-height:150%;text-align:left;padding-left:96px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Maintain  this  Lease  in  full  force  and  effect  and  allow  Tenant to retain possession of the Leased Premises, in which case this Lease shall continue in effect whether or not Tenant shall have abandoned the Leased Premises. In such event,  Landlord shall be entitled to enforce all of Landlord's rights and remedies under this Lease, including the right to recover the Annual Base Rent and other charges as they become due hereunder; and/or</font></div></td></tr></table><div style="line-height:130%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(C)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Terminate Tenant's  right of possession,  but  not this  Lease, whereupon Landlord  will  use commercially  reasonable  efforts  to attempt to relet the Leased Premises for Tenant's account;  in which case Tenant shall remain liable  to  Landlord  for  the  amount,  if  any,  by which the  rental  and other charges  required to be paid  </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:96px;text-align:justify;"><font style="font-family:Arial;font-size:11pt;">hereunder  exceed  the  net amount actually received by Landlord from any such reletting (after deducting from the rental received from the new tenant any amounts paid by Landlord in obtaining the new lease including all real estate commissions,  concessions, and other costs).  Such amounts owed by Tenant shall be paid to Landlord from time to time upon demand; and/or</font></div><div style="line-height:130%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(D)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Declare the balance of the Annual Rent and the balance of Tenant's pro rata share of expenses (agreed at $8.00. Psf) for the entire remaining term of this Lease to be immediately due and payable the space would then continue to be available to Tenant; and/or</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:justify;padding-left:96px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(E)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Charge a fifteen percent (15%) fee on any outstanding balance; and/or</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(F)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Pursue any other remedy now or hereafter available to Landlord at law or equity.</font></div></td></tr></table><div style="line-height:100%;text-align:justify;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:126%;padding-top:1px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">During any period in which Tenant is in default beyond any applicable grace period Tenant shall not be entitled to exercise any options,  privileges, or rights contained in this Lease.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">ALTERATIONS AND REPAIRS: Tenant will, at Tenant's own expense,  keep the Leased Premises in  good repair and tenantable  condition during the Lease term and will replace at its own expense any and all broken glass caused by Tenant in and about said Leased Premises.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:126%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Tenant will make  no alteration, additions  or improvements in or to the  Leased Premises without the written consent of Landlord, and all additions, fixtures, carpet or improvements,  except office furniture and trade fixtures which shall be readily removable without injury to the Leased Premises, shall be and remain a part of the Leased Premises at the expiration of this Lease: provided, however, if Landlord requests removal of any alterations, additions or fixtures installed by Tenant, Tenant shall cause them to be removed at Tenant's cost.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LIENS: Tenant agrees to pay all liens of contractors, subcontractors,  mechanics, laborers, material men, and other items of like costs and charges, including bond premiums for release of liens and attorney's fees reasonably incurred in and about the defense of any suit in discharging the Leased Premises or any part thereof from any liens, judgments or encumbrances  caused or suffered by Tenant.  In the event any such lien shall be made or filed, Tenant shall bond against or discharge the same within ten (10) days after the same has been made or filed. The expenses, costs  and  charges  above  referred  to  shall  be considered  as  rent  due  for  all purposes of this Lease.</font></div></td></tr></table><div style="line-height:125%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:129%;padding-top:2px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Tenant shall not have any authority to create any liens for labor or materials on the Landlord's  interest  in  the Leased  Premises  or the Building  and all persons contracting with  the Tenant for the destruction  or removal of any facilities or other improvements or for the erection, installation, alteration or repair  of  any  facilities  or  other  improvements  on  or  about  the  Leased Premises,  and all material  men, contractors,  mechanics  and laborers,  are hereby charged with notice that they must look only to the Tenant's interest in the Leased Premises to secure the payment of any bill for work done or material furnished at the request or instruction of Tenant.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">PARKING: Landlord grants to Tenant the right to use in common with other tenants entitled to similar use thereof the parking areas for parking automobiles of Tenant's customers,  clients and invitees.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Landlord may require Tenant and its employees to use a parking area designated by Landlord  as an employee  parking area and Tenant shall take all necessary action  to  assure that Tenant's  employees  shall  use  the  designated  employee parking area as designated by Landlord.</font></div><div style="line-height:130%;text-align:justify;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Any reserved parking spaces shall be in areas designated  by Landlord. Landlord shall not be liable for any damage of any nature whatsoever  to, or any theft of, automobiles or other vehicles  or appurtenant parking areas.   Tenant has three reserved parking spaces, numbered 6, 7, 8.</font></div><div style="line-height:130%;text-align:justify;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">ESTOPPEL CERTIFICATE:  Tenant agrees that from time to time,  upon  not less than seven (7) days prior request by Landlord, Tenant will deliver to Landlord a statement in writing certifying: (a) that this Lease is unmodified and in full force and effect or,  if there  have  been modifications,  that the Lease,  as modified,  is  in  full force and effect and stating the modifications;  (b) the dates to which the rent and other charges  have  been  paid;  (c) that  Landlord  is  not  in  default  under any provisions of this Lease, or if in  default,  the nature thereof in  detail; and (d) such other matters as Landlord shall reasonably request.</font></div></td></tr></table><div style="line-height:130%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LANDLORD'S MORTGAGE: If the Building and/or Leased Premises are at anytime subject to a mortgage, and Tenant has received written notice from Mortgagee of same, then in any instance in which Tenant gives notice to Landlord alleging default by Landlord hereunder, Tenant will also simultaneously give a copy of such notice to Landlord's Mortgagee and Landlord's Mortgagee shall have the right (but not the obligation)  to cure or remedy such default during the period that is permitted to Landlord hereunder, plus an additional period of thirty (30) days, or such greater period as may reasonably be required for the Mortgagee to effect the cure (including if title or possession  by the Mortgagee  is required to effect the cure any period required  by Mortgagee  to foreclose  or otherwise  obtain  title  and  possession). Tenant will accept such curative or remedial  action (if any) taken  by Landlord's Mortgagee with the same effect as if such action had been taken by Landlord.</font></div></td></tr></table><div style="line-height:130%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">This Lease shall be subject and subordinate  to any mortgage  now or hereafter covering the Building or Leased Premises. The foregoing provision shall be self&#8226; operative  but,  Tenant  shall  upon  Landlord's   request  promptly  execute  any instrument or instruments which  Landlord  may deem necessary or desirable  to further evidence  the subordination of the Lease to any and all such mortgages and/or deeds of trust. Tenant hereby appoints Landlord and or Landlord's successor(s) in interest as Tenant's attorney-in-fact to execute any and all documents necessary to effectuate all the provisions of this Section.</font></div><div style="line-height:130%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">ASSIGNMENT  BY LANDLORD:  If the interests of Landlord under this Lease shall be  transferred voluntarily or by reason  of foreclosure or other  proceedings  for enforcement </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;padding-left:48px;text-align:justify;"><font style="font-family:Arial;font-size:11pt;">of any mortgage on the Leased Premises, Tenant shall be bound to such transferee (herein sometimes called the "Purchaser"), for the balance of the term  hereof remaining  and any extensions  or renewals  thereof which  may  be effected  in accordance with the terms and provisions hereof, with the same force and effect as if the Purchaser were the Landlord under this Lease, and Tenant does hereby agree to attorn to the Purchaser, as its Landlord, said attornment to be effective and self-operative without the execution of any further instruments upon the  Purchaser succeeding  to  the  interest  of Landlord  under this  Lease.  The respective rights and obligations of Tenant and the Purchaser upon such attornment to the extent of the then remaining balance of the term of this Lease and any such extensions and renewals shall be and are the same as those set forth herein. In the event of such transfer of Landlord's interest, Landlord shall be released and relieved from all liability and responsibility thereafter accruing to Tenant under this Lease or otherwise, and Landlord's successor by acceptance of rent from Tenant hereunder shall become liable and responsible  to Tenant in respect to all obligations of the Landlord  under this Lease.</font></div><div style="line-height:125%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">ASSIGNMENT  AND SUBLEASING  BY TENANT: Without the written consent of Landlord first obtained in each case, Tenant shall not assign, transfer, mortgage, pledge, or otherwise  encumber or dispose of this Lease for the term hereof, or underlet the Leased Premises or any part thereof or permit the Leased Premises to be occupied by anybody other than the Tenant. No assignment of this Lease nor sublease  of the  Leased  Premises  shall  release  Tenant  from  any  obligations contained herein. The Landlord  may after default by the Tenant collect or accept rent from  the  assignee,  undertenant,  or occupant  and  apply  the  net  amount collected or accepted to the rent and other amounts herein reserved, but no such collection or acceptance shall be deemed a waiver of this covenant or the acceptance  of the assignee, undertenant or occupant as Tenant, nor shall it be construed as, or implied to be, a release of the Tenant from the further observance and performance by the Tenant of the terms, provisions, covenants and conditions herein contained. In the event Tenant desires Landlord's consent to any assignment or sublease Tenant shall provide such information as Landlord shall reasonably require to evaluate the proposed assignee or subtenant, including without limitation, name, references, audited financial statements and nature of business. Any assignee or subtenant must agree in writing to be bound by all terms and provisions hereof (except that as to subtenants, the subtenant's rental will be governed by its sublease).</font></div></td></tr></table><div style="line-height:130%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SUCCESSORS AND ASSIGNS: All terms, provisions, covenants and conditions to be observed  and performed by Tenant shall be applicable to and binding upon Tenant's respective heirs, administrators, executors, successors and assigns, subject, however, to the restrictions as to assignment or subletting by Tenant as provided herein. All expressed covenants of this Lease shall be deemed  to be covenants running with the land.</font></div></td></tr></table><div style="line-height:130%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">INSURANCE; TENANT'S INDEMNIFICATION: Tenant shall, during the entire Lease term, at its sole cost and expense, provide and keep in full force and effect a policy of Commercial General Liability insurance covering the Leased Premises, and the business  operation  by Tenant  in  an  amount  of  not  less  than  $3,000,000.00 combined single limit liability for bodily injury and property damage. The policy shall name Quentin Partners Co. and lntracoastal Pointe Inc., and any person, firms or corporations  designated  by Landlord  as </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;padding-left:48px;text-align:justify;"><font style="font-family:Arial;font-size:11pt;">an additional  insured,  and Tenant as insured, and shall contain  a clause  that the insurance carrier will not cancel or change the insurance without first giving the Landlord ten (10) days prior written notice. The insurance shall be with an insurance company acceptable to Landlord and the insurance carrier shall provide Landlord a true copy of said policy and a certificate of insurance.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:126%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Tenant agrees to pay any increase  in  premiums for fire  and extended coverage insurance  that may be charged during  the term of this Lease resulting  from the activity  of Tenant  or merchandise  stored  by Tenant  in  the  Leased  Premises, whether or not  Landlord  has  consented  to the  same.  Bills for  such  additional premiums shall be rendered by Landlord to Tenant at such times as Landlord may elect, and shall  be due from,  and payable  by Tenant  when  rendered,  and the amount thereof shall be deemed to be additional rent.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Tenant will indemnify Landlord and </font><font style="font-family:Arial;font-size:10.5pt;">save</font><font style="font-family:Arial;font-size:10.5pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:11pt;">it harmless from and against any and all claims,  actions,  damages,  liability and expense  in  connection  with  loss by fire, personal injury and/or damage to property arising from or out of any occurrence in, upon or at the Leased Premises or any part thereof, or occasioned wholly or in part by any act or omission  of Tenant,  its agents,  guests,  contractors,  employees, servants, subtenants,  assignees,  or concessionaires.  Tenant  shall also pay all costs, expenses  and reasonable attorneys' fees (including appeals) that may be incurred or paid by Landlord in enforcing the covenants and agreements in this Lease.</font></div><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Tenant shall replace, at the expense of Tenant, any and all plate and other glass damaged or broken arising from or out of any act of Tenant, its agents, guests, contractors,  employees,  servants, subtenants or concessionaires.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Landlord and Tenant hereby waive any and all rights of </font><font style="font-family:Arial;font-size:10.5pt;">recovery</font><font style="font-family:Arial;font-size:10.5pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:11pt;">against each other, their officers, employees and agents, for loss occurring to the Leased Premises to the extent </font><font style="font-family:Arial;font-size:10.5pt;font-style:italic;">covered  </font><font style="font-family:Arial;font-size:11pt;">by insurance proceeds provided that the applicable insurance policy contains a </font><font style="font-family:Arial;font-size:10.5pt;font-style:italic;">waiver  </font><font style="font-family:Arial;font-size:11pt;">of a right of subrogation.  Each party shall use reasonable efforts to obtain a waiver of subrogation from the insurance carrier providing their insurance.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">MUTUAL INDEMNITIES: In consideration of the Leased Premises being leased to Tenant for the </font><font style="font-family:Arial;font-size:10.5pt;">above </font><font style="font-family:Arial;font-size:11pt;">rental, Tenant agrees: that Tenant, at all times, will indemnify and hold  harmless Landlord from all losses, damages,  liabilities and expenses, which may arise or be claimed against Landlord and be in </font><font style="font-family:Arial;font-size:10.5pt;">favor  </font><font style="font-family:Arial;font-size:11pt;">of any persons, firms or corporations, for any injuries or damages to person or property, consequent upon or arising from any acts, omissions, neglect or fault of Tenant, its agents, servants, employees, licensees, visitors, customers, patrons or invitees, or consequent upon or arising from Tenant's failure to comply with any laws, statutes, ordinances, codes or regulations or any provisions of this Lease. Landlord shall not be liable to Tenant for any damages,  losses or injuries to the persons or property of Tenant which may be caused by the acts, neglect, omissions or faults of any persons,  firms  or corporations,  except when such injury,  loss  or damage results from gross  negligence or willful misconduct of Landlord, its agents or employees. All personal property placed or moved into the Leased Premises or the Building shall be at the risk of Tenant or </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;padding-left:48px;text-align:justify;"><font style="font-family:Arial;font-size:11pt;">the owners thereof, and Landlord shall not be liable to Tenant for any damages to said personal property. Tenant shall maintain at all times during the term of this Lease an insurance policy or policies in an amount or amounts sufficient to indemnify Landlord and to pay Landlord's damages, if any, resulting from any matter set forth in this Section.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:126%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In case Landlord shall be made a party to any </font><font style="font-family:Arial;font-size:11pt;font-style:italic;text-decoration:underline;">third party</font><font style="font-family:Arial;font-size:11pt;">&#32;litigation commenced by or against Tenant, Tenant shall protect and hold Landlord  harmless and shall pay all cost, expenses and reasonable attorney's fees incurred or paid by Landlord in connection with such litigation.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In consideration of the Leased Premises  being leased to Tenant for the above rental, Landlord agrees: that Landlord, at all times, will indemnify and hold harmless Tenant from all losses, damages, liabilities and expenses, which may arise or be claimed against Tenant and be in favor of any persons, firms or corporations, for any injuries or damages to person or property, consequent upon or arising from any acts,  omissions,  neglect or fault  of Landlord,  its  agents,  servants,  employees, licensees,  visitors,  customers, patrons or invitees,  or consequent upon  or arising from Landlord's failure to comply with any laws, statutes, ordinances,  codes or regulations or any provisions of this Lease.  Tenant shall not be liable to Landlord for any damages,  losses or injuries to the persons or property of Landlord which may be caused by the acts, neglect, omissions or faults of any persons, firms or corporations,  except  when  such  injury,  loss  or  damage  results  from  gross negligence or willful misconduct of Tenant, its agents or employees.  Landlord shall maintain at all times during the term of this Lease an insurance policy or policies in an amount or amounts sufficient to indemnify Tenant and to pay Tenant's damages, if any,  resulting from any matter set forth in this Section.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In case Tenant shall be made a party to any third party litigation commenced by or against Landlord, Landlord shall protect and hold Tenant harmless and shall pay all cost, expenses and reasonable attorneys' fees and disbursements incurred or paid by Tenant in connection with such litigation.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">ATTORNEY'S  FEES: If the Tenant defaults in the performance of any of the terms, provisions,  covenants and  conditions  of this  Lease  and by reason  thereof the Landlord  employs the services of an attorney to enforce performance of same by the Tenant or to perform any services based upon said default, the Tenant agrees to pay reasonable attorney's fees and all expenses, costs and charges incurred by the Landlord pertaining thereto and enforcement of any remedy available to the Landlord.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In the event of the institution of litigation to enforce the provisions of the Lease to evict Tenant, or to collect moneys due from the date of default in the event of a money judgment,  Tenant  shall  be  responsible  for  cost  of such  litigation  and reasonable attorney's fees at the trial  level and at all levels of appeal.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In the event Landlord is the prevailing party, the awardable sums with all costs, interest and damages shall be deemed additional rent hereunder and shall be due from Tenant to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Landlord on the first day of the month following the month in which the respective expenses, etc., were incurred.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:126%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In the event the Tenant is the prevailing party, the awardable sums with all costs shall be bourne by Landlord.</font></div><div style="line-height:100%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">GOVERNMENTAL REGULATIONS: Tenant shall faithfully observe in the use of the Leased Premises all municipal and county ordinances and codes and state, local and federal statutes or laws, rules, regulations, or other governmental requirements now in force or which may hereafter be in force.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">FIRE OR CASUALTY: In the event the Building shall be destroyed, or so damaged, or injured by fire or other casualty during the term of this Lease whereby the Leased Premises shall  be  rendered  untenantable, the Landlord  shall have the right to render the Leased Premises tenantable by repairs within one hundred eighty (180) days therefrom.  If the Leased Premises are not or will not be rendered tenantable within said time, it shall be optional with either party hereto to cancel this Lease, and in the event of such cancellation, the rent shall be paid only to the date of such fire or casualty. Landlord shall also have the option to cancel this Lease in the event the Building  is  damaged  to  such  an  extent  that  Landlord  elects  not to  repair the damage. Any cancellation shall be evidenced in writing. During any time that the Leased Premises are untenantable due to causes set forth in this Section, the rent or a just and fair proportion thereof (based upon the portion of the Leased Premises that are not untenantable)shall  be abated.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:126%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Landlord shall not restore fixtures and improvements  installed  by Tenant either at the commencement of the Lease or during the leasehold term.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">EMINENT DOMAIN:  If there shall be taken during the term of this Lease any part of the  Leased  Premises,  parking  facilities  or  Building,  other than  a  part  not interfering with  maintenance,  operation  or use of the Leased Premises, Landlord may elect to terminate this Lease or to continue same in effect.  If Landlord elects to continue the Lease, the rental shall be reduced in proportion to the area of the Leased Premises so taken and Landlord shall repair any damage to the Leased Premises, parking facilities, or Building resulting from such taking. If any part of the Leased Premises is taken by condemnation  or eminent domain and the Landlord elects to continue the Lease, the rental assessment shall be reduced in proportion to the area of the Leased Premises so taken and Landlord shall repair any damage to the Leased Premises resulting from such taking. All sums awarded  or agreed upon between Landlord and the condemning authority for the taking of the interest of Landlord and/or Tenant, whether as damages or as compensation, and whether for partial or total condemnation, will be the property of the Landlord, except that Tenant shall be entitled to any award for Tenant's moving expenses or personal property (but in  no event shall Tenant be entitled to any award for the loss of the leasehold  estate).  If this Lease should be terminated  under any provisions of this Section, rental shall be payable up to the date that possession is taken by the taking authority, and Landlord will refund to Tenant any prepaid unaccrued rent less any sum or amount then owing by Tenant to Landlord.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">ABANDONMENT:  If,  during the term of the Lease, Tenant shall abandon, vacate or remove from  the  Leased  Premises the  major  portion  of the  goods, wares, equipment or furnishings usually kept on said Leased Premises,  and shall cease doing business in said Leased Premises, or shall suffer the rent to be in arrears, Landlord  may,  at  its  option,  cancel  this  Lease  by written  notice  to Tenant  at Tenant's address, or Landlord may enter said Leased Premises as the agent of Tenant by force or otherwise, without being liable in any way therefore, and rel et the Leased Premises with or without any furniture that may be therein as the agent of Tenant,  at such  price and  upon  such terms  and for such  duration  of time  as Landlord may determine  and receive the rent and for such expenses therefore, applying the same to the payment of the sums due by Tenant, and if the full rental herein provided shall not be realized by Landlord over and above the expense to Landlord of such  reletting,  Tenant shall  pay any   deficiency provided  that the Landlord has made reasonable efforts to achieve a fair lease.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">BANKRUPTCY: It is agreed between the parties hereto that: if Tenant shall be adjudicated bankrupt or insolvent or take the benefit of any federal reorganization or compensation  proceeding or make a general assignment or take the benefit of any insolvency law; or, if Tenant's leasehold interest under this Lease shall be sold under any execution or process of law; or if a trustee in bankruptcy or a receiver be appointed or elected or had for Tenant (whether under Federal or State Laws); or if said Premises shall be abandoned or deserted; or if Tenant shall fail to perform any of the terms, provisions, covenants or conditions of this Lease on Tenant's part to be performed; or if this Lease or the Term thereof be transferred or pass to or devolve upon any persons, firms, officers or corporations,  then and in any such event this Lease and the Term of this Lease, at Landlord's option, shall expire and end five  (5)  days  after Landlord  has given Tenant written  notice  of such  act, condition or default and Tenant hereby agrees immediately then to quit and surrender said Leased Premises to Landlord; but this shall not impair or affect Landlord's right to maintain summary proceeding for the recovery of the possession of the Leased Premises in all cases as provided for by law.  If the term of this Lease shall be so terminated, Landlord may immediately or at any time thereafter, re-enter or repossess the Leased Premises and remove all persons and property therefrom without being liable for trespass or damages.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">30.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">(DELETED).</font></div></td></tr></table><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">31.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WAIVER: Failure of Landlord to declare any default immediately upon occurrence thereof, or delay in taking any action in connection therewith, shall not waive such default, but Landlord shall the right to declare any such default at any time and take such action as might be lawful or authorized hereunder, in law and/or in equity. No waiver by Landlord of a default by Tenant shall be effective unless contained in a written instrument signed by Landlord.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:126%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">No waiver of any term, provision, condition or covenant of this Lease by Landlord shall be deemed to imply or constitute a further waiver by Landlord of any other term, provision,  condition or covenant of this Lease.</font></div><div style="line-height:125%;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">32.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">RIGHT OF ENTRY: Landlord, or any of his agents, shall have the right to enter the Leased Premises at any time for exigent circumstances and during all reasonable hours with  reasonable  notice,  to  examine  the same  or to  make such  repairs, additions or alterations as may be deemed necessary for the safety, comfort or preservation  thereof,  or of the Building, or to exhibit the Leased Premises at any time within one hundred  eighty  (180)  days before  the expiration of this  Lease. Landlord will retain pass keys and any passcodes to gain entry to the entire Premises.  Said right of entry shall also exist for the purpose of removing placards, sign fixtures,  alterations or additions which do not conform to this Lease. </font></div></td></tr></table><div style="line-height:125%;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">33.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">NOTICES: Any notice to be given shall be sent by certified mail, or hand delivered to the Parties designated address or to such other place or places as The Parties may specify in writing.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">34.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">RULES AND REGULATIONS:  Tenant agrees to comply with all reasonable rules and regulations Landlord may adopt from time to time of operation of the Building and  parking  facilities  and  protection  and welfare  of the  Building  and  parking facilities, the tenants, visitors, and occupants of the Building. The present rules and regulations, with respect to which Tenant hereby agrees to comply, entitled "Rules and Regulations" (Exhibit A) are attached hereto and are by this reference incorporated herein. Any future rules and regulations shall become a part of this Lease and Tenant hereby agrees to comply with the same upon delivery of a copy thereof to Tenant, providing the same are reasonable and do not deprive Tenant of its  rights established under this Lease.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">35.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">CONTROL OF COMMON AREAS AND PARKING FACILITIES BY LANDLORD: All automobile parking areas, driveways, entrances and exits thereto, Common Areas and other facilities furnished by Landlord, including all parking areas, truck way or ways, loading areas, pedestrian walkways and ramps, landscaped areas, stairways, corridors, Common Areas and other areas and improvements provided by Landlord for the general use,  in common,  of tenants,  their officers,  agents,  employees, servants, invitees, licensees, visitors, patrons, and customers, shall be at all times subject to the exclusive control and management of Landlord and Landlord shall have  the right from time to time  to change location  and arrangement of parking areas and other facilities herein above referred to; to restrict parking by and enforce parking </font><font style="font-family:Arial;font-size:11pt;text-decoration:line-through;">charges (by operation of meters or otherwise)</font><font style="font-family:Arial;font-size:11pt;">&#32;upon visitors, patrons, and customers; to close all or any portion of said areas legally sufficient to prevent a dedication thereof or the  accrual  of any rights to any  person  or public  areas, common areas or facilities; to discourage non-tenant parking; and to do and perform such other acts in and to said areas and improvements, as, in the sole judgment of Landlord,  the  Landlord  shall  determine  to  be  advisable  with  a  view  to  the convenience  and  use  thereof  by  tenants,  their  officers,  agents,  employees, servants, invitees, visitors, patrons, licensees and customers. Landlord will operate and maintain the Common Areas and other facilities referred to in such reasonable manner as Landlord shall determine from time to time. Without limiting the scope of such discretion,  Landlord shall have the full  right and authority to designate  a manager of the parking facilities and/or Common Area and other facilities who shall have full authority to make and enforce rules and regulations regarding the use of the  same  or to  employ  all  personnel  and to  make  and  enforce  all  rules  and regulations pertaining to and necessary for the proper operation and </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;padding-left:48px;text-align:justify;"><font style="font-family:Arial;font-size:11pt;">maintenance of the parking areas and/or common areas and other facilities.  Reference in this Section to parking areas and/or facilities shall in no way be construed  as giving Tenant hereunder any rights and/or privileges in connection with such parking areas and/or facilities unless such rights and/or privileges are expressly set forth in this Lease.</font></div><div style="line-height:100%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">36.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SURRENDER  OF LEASED PREMISES: Tenant agrees to surrender lo Landlord, at the end of the term of this Lease and/or upon any cancellation of this Lease, said Leased  Premises  in  as  good  condition  as the  Leased  Premises  were  at the beginning of the term of the Lease,  ordinary wear and tear and damage by fire or other casually not caused by Tenant's negligence, excepted. Tenant agrees that if Tenant does not surrender said Leased Premises lo Landlord at the end of the term of this Lease, then Tenant will pay to Landlord two (2) times the monthly rent paid in the final month of Tenant's term hereunder for each month that Tenant  holds over; in addition Tenant shall pay all damages that Landlord may suffer on account of Tenant's failure to so surrender to Landlord possession of the Leased Premises, and will indemnify and save Landlord  harmless from and against all claims made by  any  succeeding  tenant  of the  Leased  Premises  so  far  as  such  delay  is occasioned by failure of Tenant to so surrender the Leased Premises in accordance herewith or otherwise.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">No receipt of money by Landlord from Tenant after termination of this Lease or the service of any suit or final judgment for possession  shall reinstate,  continue or extend the term of this Lease or affect any such notice, demand, suit or judgment.</font></div><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">No act or thing done by Landlord or its agents during the term hereby granted shall be  deemed  an  acceptance  of  a  surrender  of the  Leased  Premises  and  no agreement to accept a surrender of the Leased Premises shall be valid unless it be made in writing and subscribed by a duly authorized officer or agent of Landlord.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">37.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">TAXES ON TENANT'S PERSONAL PROPERTY: Tenant shall be responsible for and pay before delinquency all municipal, county or state taxes assessed during the term of this Lease against any occupancy interest or personal property of any kind, owned by or placed in, upon or about the Leased Premises by the Tenant.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">38.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">PRIOR OCCUPANCY: If Tenant, with Landlord's consent, shall occupy the Leased Premises prior to the beginning of the Lease term specified in Section 2 hereof, all provisions of this Lease shall be in full force and effect commencing upon such occupancy, and rent for such period shall be paid by Tenant at the same rate herein specified.</font></div></td></tr></table><div style="line-height:125%;padding-top:2px;text-align:justify;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">39.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SHORT  FORM  LEASE:  Tenant shall,  if so  required  by Landlord  at any time, execute a short form Lease in recordable form setting forth the name of the parties, the term of the  Lease (stating the  commencement  of Lease term called for  in Section 2), and the description of the Leased Premises, and such other matters as Landlord shall reasonably request.  In no event shall the Tenant record this Lease, any memorandum thereof or reference thereto, amongst the Public Records of any County of the State of Florida without the prior written consent of Landlord. Any violation of this provision by Tenant shall be immediate default hereunder.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:125%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">40.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WAIVER OF TRIAL BY JURY: Landlord and Tenant hereby waive trial by jury in any action, proceeding or counterclaim brought by either of the parties hereto against the other on any matter arising about, of or in any way connected with the Lease, the relationship  of Landlord and Tenant or Tenant's  use of or occupancy  of the Premises. Tenant further agrees  that it shall not interpose any counterclaim or counterclaims in a summary proceeding or in any action based upon nonpayment of rent or any other payment required of Tenant hereunder.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">41.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">(DELETED)</font></div></td></tr></table><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">42.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SEVERABILITY: If any terms, provision, covenant or condition of this Lease or the application thereof to any person or circumstance shall, to any extent be invalid or unenforceable,  the  remainder of this  Lease,  or the  application  of such  terms, provisions, covenant or condition to persons or circumstances other than those as to which it is held invalid or unenforceable shall not be affected thereby and each term,  provision,  covenant  or  condition  of  this  Lease  shall  be  valid  and  be enforceable to the fullest extent permitted by law. This Lease shall be construed in accordance with the laws of the State of Florida.</font></div></td></tr></table><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">43.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">TIME: It is understood and agreed between the parties hereto that time is of the essence of all the terms,  provisions,  and covenants and conditions of the Lease.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">44.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">DEFINITIONS.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The terms  Landlord and Tenant, as herein contained, shall include singular and/or plural, masculine, feminine, and/or neuter, heirs, successors, executors, administrators, personal representatives and/or assigns wherever the context so requires or admits. The terms provisions, covenants and conditions of this Lease are expressed in the total language of this Lease Agreement and the Section headings are solely for the convenience  of the reader and are not intended to be all inclusive.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:123%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:123%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Calendar Year shall be a twelve month period ending on each December 31. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:123%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(C)</font></div></td><td style="vertical-align:top;"><div style="line-height:123%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Base Year is  the Calendar Year in  which the Lease Commencement  Date occurs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(D)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Base Month is the month in which the lease commences.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(E)</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The Consumer Price Index is the United States Bureau of Labor Statistics, "Revised   Consumer  Price  Index,  for  Urban  Wage  Earners  and  Clerical Workers,  All terms (1967=100)" or any successor  thereto published  by the United States Department of Labor, Bureau of Labor Statistics; provided, that should the said Consumer Price Index or the manner of computing or reporting same be discontinued or changed, the parties shall attempt to agree upon a substitute formula, and failing such agreement the matter shall be determined by  arbitration  in  Jupiter  under  the  Rules  of  the  American   Arbitration Association  then prevailing.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:123%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(F)</font></div></td><td style="vertical-align:top;"><div style="line-height:123%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Code  shall mean  the City of Jupiter (County,  State, or Federal)  building, Electrical, Air Conditioning, Plumbing or other, as the same may be applicable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(G)</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Building means the actual structure wherein the Leased Premises are located. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">(H)</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Pro ration of rent shall be over a thirty (30) day month.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:72px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">45.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">TENDER   AND   DELIVERY  OF  LEASE   INSTRUMENT:  Submission   of  this instrument for examination  does  not  constitute  an offer,  right of first  refusal, reservation of or option for the Leased Premises or any other space or premises in, on or about the Building. This instrument becomes effective as a Lease upon execution and delivery by both Landlord and Tenant.</font></div></td></tr></table><div style="line-height:125%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">46.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SERVICES: Services to be provided to Tenant shall be common area janitorial service (weekday nights), automatic elevator service, public stairs, water at points of supply for general use by Tenant throughout the year, electricity, heat and air conditioning as noted herein to be operated Monday through  Friday 7:00 a.m. to 8:00 p.m. and 8:00 a.m. to 1:00 p.m. Saturdays,  excluding legal  holidays.</font></div></td></tr></table><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">47.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">JANITORIAL SERVICES: Tenant shall be responsible  for contracting with and payment of janitorial services within their Leased Premises to a quality standard commensurate with other similar quality buildings  in the area. (See Section  7.) Landlord will make available to Tenant a suitable janitorial service.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">48.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WRITTEN AGREEMENT: This Lease contains the entire agreement between the parties hereto and all previous negotiations leading thereto, and it may be modified only by an agreement in writing signed by Landlord  and Tenant.  No surrender of the Leased Premises or of the remainder of the terms of the Lease shall be valid unless accepted by Landlord in writing. Tenant acknowledges  and agrees that Tenant  has not relied upon any statement, representation, prior written or prior contemporaneous oral promises, agreements or warranties  except such as are expressed herein.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">49.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">RIGHT TO SELL CONDOMINIUM UNITS: Landlord reserves the right to cause the building and surrounding property, including the leasehold premises, to be converted to a condominium to be created by the Landlord as may be reasonably necessary regarding the creation of the condominium and agrees to execute any and all documents which may be required to create said condominium, provided that such action required  by the Tenant  shall be at no cost to the Tenant.  This action shall not intefere with Tenants Leasehold rights.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">50.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LIMITATIONS  OF  LANDLORD'S  PERSONAL  LIABILITY.  Tenant  specifically agrees to look solely to Landlord's interest in the Building for the recovery of any judgment from  Landlord,  it  being agreed  that  Landlord  (and  any  partners of Landlord and any trustees, officers, shareholders or employees of Landlord) shall never be personally liable for any such judgment. The provisions contained in the foregoing sentence are not intended to, and shall not, limit any right that Tenant might otherwise have to obtain  injunctive relief against  Landlord or Landlord's successors  in interest, or any other action not involving the personal  liability of Landlord's to respond in monetary damages from assets other than Landlord's interest in the Building  of any suit or action in connection with enforcement or collection of amounts which may become owing or payable under or on account of insurance maintained  by Landlord.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">51.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SMOKING.  This is a non-smoking building.  Tenant and its employees shall smoke outside the building.  Under no circumstances shall Tenant allow its employees to smoke in the suite, hallways, stairwells, entry way, or elevators of the Building. Tenant and its employees shall not leave remnants or partially smoked items on the grounds except in receptacles specifically designed for the purpose.</font></div></td></tr></table><div style="line-height:130%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">52.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">BROKERAGE.  All  parties  agree  that  there  are  no  brokers  involved  in  this transaction.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:123%;font-size:11pt;padding-left:0px;"><font style="font-family:Arial;font-size:11pt;">53.</font></div></td><td style="vertical-align:top;"><div style="line-height:123%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Authority. The undersigned represent and warrant that they are duly authorized to enter this contract.</font></div></td></tr></table><div style="line-height:100%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="sf783dfbb88ba4688bc15877f87b670b3"></a></div><div></div><div><br></div><div style="line-height:126%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">IN  WITNESS  WHEREOF,  the parties  hereto  have  signed and delivered this Lease in duplicate at Palm Beach County,  Florida,  on the date written below.</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LANDLORD:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">TENANT:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">QUENTIN  PARTNERS CO.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">DYADIC INTERNATIONAL,  INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">As Agent For:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">lntracoastal  Pointe, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ James Q. Riordan, Jr.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">By: James Q. Riordan, Jr.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">President</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">President &amp; CEO</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WITNESS:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WITNESS:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ Sharon L. Wood</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ Michael I. Faby</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Sharon L. Wood</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Michael I. Faby</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">(Printed name of Witness)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">1/5/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">28 December 2010</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Date</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><a name="s5F1CDA1B06E22313339C58693A7121E0"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-style:italic;font-weight:bold;text-decoration:underline;">EXHIBIT A</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-style:italic;font-weight:bold;text-decoration:underline;">RULES  AND REGULATIONS</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Landlord reserves the right to refuse access to any persons Landlord in good faith judges to be a threat to the safety, reputation,  or property of the Office  Building  Project and its occupants.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:127%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:127%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tenant shall not suffer or permit the obstruction of any Common  Areas,  including driveways,  walkways, stairways, and doorways of the Building.  These shall not be obstructed or used for any purpose other than ingress to and egress from the units. No furniture, equipment, or other personal articles shall be placed in the entrances, stairways or other common  elements.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">No exterior of any premises or the windows or doors thereof or any other portions of the common elements shall be painted or decorated in any manner by any Tenant. No sign, notice, lettering, or advertising shall be inscribed or exposed on or at any window, door, or at any other part of the Building; nor shall anything be projected out of any window of the building. Tenant shall not be allowed to put their names on any entry to the building or entrance to any unit, except In the proper place provided by the Landlord for such purpose. No protective window film, shades, awnings, window guards, ventilators, fans or air-conditioning devices shall be used in or about the Building or common  elements except such as shall have been approved in writing by Landlord.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">No Tenant shall make or permit any noise or objectionable odor that will disturb  or annoy the occupants  of any of the premises  in  the Building  or do or perm it anything  to be done therein which will interfere with the rights,  comfort, or convenience of other Tenants.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:127%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:127%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Each Tenant shall keep his unit in a good state of preservation and cleanliness and shall not sweep or throw or permit to be swept or thrown therefrom, or from the doors or windows thereof, any dirt or other substances. All garbage and refuse from the Building shall be deposited with care In receptacles intended for such purpose only at such times and in  such manner as Landlord  may direct.  Disposal  for all garbage  that is  not in  the course of normal day to day operations -- i.e. shipping boxes for computers printers, filing cabinets, and other large  Items -- must be handled  by tenant at tenant's cost.</font></div></td></tr></table><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:127%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:127%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Water closets and other water apparatus  in the Building shall not be used for any purpose other than those for which they were constructed nor shall any sweepings, rubbish, rags, paper, ashes, or any other article be thrown into the same.  Any damage resulting from misuse of any water closet or other apparatus shall be paid for by the Tenant causing such damage.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The agents of the Landlord and any contractor or workman authorized  by the Landlord may enter any unit at any reasonable hour of the day for any purpose permitted under the terms of the Lease or Building Rules. No Tenant shall engage  any employee of the Landlord for any private  business of the Tenant without prior consent of the Landlord.  Tenant shall  not employ any service  or contractor for services  or work  to  be performed in the Building, except as approved by Landlord.</font></div></td></tr></table><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">No bird or animal shall be kept or harbored In the Building unless the same  in each instance be expressly permitted  in writing by the Landlord.   In  no event shall dogs be permitted  in  any of the public portions of the buildings or development unless carried or on a leash.  The Tenant shall Indemnify the Landlord and hold It harmless against any loss or liability of any kind or character whatsoever arising from or as a result of having any animal in the building.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">No  radio or television aerial shall be attached to or hung from  the exterior of the building without written approval by the Landlord.</font></div></td></tr></table><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:127%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:127%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Landlord shall retain a passkey to each unit.  No Tenant shall alter any lock on any door leading  into his unit without prior consent of the Landlord. Tenant shall not alter any lock or Install new or additional locks or bolts to the common areas of the property.</font></div></td></tr></table><div style="line-height:100%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">No Tenant, or any employee or any client, visitor, or guest of a  Tenant shall be allowed on the roof of the building without the express permission of the Landlord.</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">All damage to the building or common elements caused by the moving or carrying of any article therein shall be paid by the Tenant responsible for the presence of such article.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">No Tenant shall interfere In any manner with any portion of the electrical system and lighting apparatus which are  part of the common  elements and not part of the Tenant's.</font></div></td></tr></table><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:132%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:132%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">No Tenant shall use or permit to be brought into the building any flammable  oils or fluids such as gasoline, kerosene,  naptha,  benzine or other explosives  or any hazardous  materials  or articles  deemed  hazardous to life,  limb or property.</font></div></td></tr></table><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Tenant must keep the Interiors of the leased  premises clean and free from obstructions.  The Landlord assumes no liability for loss or damage to articles stored  or placed In  the building.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tenant shall be held responsible for the actions of Its employees, visitors, clients, or guests. Any damage to the building or equipment caused by Tenant, its employees, guests, visitors, or clients shall be repaired at the expense of the Tenant.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Complaints regarding the management of the building and grounds or regarding the actions of other Tenants shall be made in writing to the Landlord.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Parking of motor vehicles, including  motorcycles, mopeds, trailers,  or bicycles by Tenant, its employees, guests, clients, or visitors shall be only in the space designated as parking; no unattended vehicle shall at any time by left in such a manner as to impede the passage of traffic or to Impair proper access to parking areas. No repair,  cleaning, or maintenance of motor vehicles, Including  motorcycles,  mopeds, trailers, or bicycles shall occur on the property, with exception of emergency repair to have vehicle removed to a qualified  repair facility.  No storage of motor vehicles, including  motorcycles,  mopeds, trailers, bicycles or any objects shall be permitted on the driveway and parking areas and the same shall at all times be kept free of unreasonable accumulation of debris or rubbish  of any kind.</font></div></td></tr></table><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:129%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:129%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Supplies, goods,  and packages  of every kind  are  to be delivered in  such a manner as the Landlord or  Its agents  may prescribe  and the Landlord  Is  not responsible for the loss or damage of any such property.</font></div></td></tr></table><div style="line-height:100%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:127%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:127%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">No  unit shall be  used or occupied  in such manner as to obstruct or interfere with the enjoyment of other occupants, or other residents of adjoining  units,  nor shall any nuisance or immoral or illegal activity be committed or permitted to occur In or about any unit or upon any part of the common element of the property.</font></div></td></tr></table><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The common elements are intended for use for the purpose of affording vehicular and pedestrian movement within the property and of providing access to the units.  No part of the common elements shall be obstructed so as to Interfere with Its use for the purposes herein above recited nor shall any part of the common elements be used for general storage purposes, nor anything done thereon in any manner which shall increase the rate of hazard and liability insurance covering said area and Improvements situated  thereon.</font></div></td></tr></table><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tenant shall be responsible for the inappropriate use of any toilet rooms, plumbing or other utilities. No foreign substances  of any kind are to be inserted  therein.</font></div></td></tr></table><div style="line-height:110%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tenant shall not deface the walls, partitions or other surfaces of the premises or Office Building  Project.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:127%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:127%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Furniture, significant freight and equipment shall be moved Into or out of the building only with the Landlord's knowledge  and consent,  and subject to such  reasonable limitations, techniques  and timing,  as  may be designated by Landlord. Tenant shall be responsible for any damage to the Office Building Project arising from any such  activity.   Tenant may be  asked  to provide  a deposit against possible  damage  resulting  from movements of the aforementioned.</font></div></td></tr></table><div style="line-height:100%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:127%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:127%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Landlord reserves the right to close and lock the Building on Saturdays, Sundays and legal holidays, and on other days  between the hours of 6:00 P.M. and 6:00 A.M. of the following day. If Tenant uses the Premises during such periods, Tenant shall be responsible for securely locking any doors it may have opened for entry.</font></div></td></tr></table><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tenant shall return all keys at the termination of its tenancy and shall be responsible for the cost of replacing any keys that are  lost.</font></div></td></tr></table><div style="line-height:100%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">No Tenant,  employee or invitee shall go up on the roof of the Building.</font></div></td></tr></table><div style="line-height:110%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tenant shall  not suffer or permit smoking  or carrying  of lighted  cigars or cigarettes  in areas  reasonably designated  by Landlord or by applicable governmental agencies as non-smoking  areas.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tenant shall not use any method of heating  or air conditioning other than as provided  by Landlord.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">30.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tenant shall not  install,  maintain  or operate any vending machines upon  the Premises without Landlord's written  consent.</font></div></td></tr></table><div style="line-height:110%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">31.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Premises shall not be used for loading  or manufacturing, cooking or food preparation.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">32.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tenant shall comply with all safety, fire protection and evacuation regulations established by Landlord or any applicable governmental agency.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">33.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Tenant assumes all risks from theft or vandalism and agrees to keep its Premises locked as may be required.</font></div></td></tr></table><div style="line-height:110%;padding-top:1px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">34.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Landlord reserves the right to waive any one of these rules or regulations, and/or as to any particular Tenant, and any such waiver shall not constitute a waiver of any other rule or regulation or any subsequent application thereof to such Tenant.</font></div></td></tr></table><div style="line-height:110%;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:125%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">35.</font></div></td><td style="vertical-align:top;"><div style="line-height:125%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Landlord reserves the right to make such other reasonable rules and  regulations as it may from time to time deem necessary for the appropriate  operation  and safety of the Building  Project and its  occupants. Tenant agrees to abide by these rules and regulations. These Building Rules may be added to or repealed at anytime by the Landlord.</font></div></td></tr></table><div style="line-height:127%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sc5038bad9c4a4539ba0dd547d97240e6"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#5f6262;font-weight:bold;">INTRACOASTAL POINTE OFFICE BUILDING </font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#5f6262;font-weight:bold;">AMENDMENT TO OFFICE LEASE</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">This Amendment to Office Lease Agreement made and entered into this 8th day of June, 2018 by and between Quentin Partners Co. as Agent for lntracoastal Pointe, Inc. (both Florida corporations), as "Landlord;" and Dyadic International, Inc., as "Tenant."</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WITNESSETH:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WHEREAS, Landlord and Tenant entered into that Office Lease dated December 30, 2010, and the subsequent Amendments; relative to the Leased Premises set forth therein. Premises currently consist of Suite 404 and 405 (4,872 &#177; s.f.); and</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WHEREAS, Landlord and Tenant now desire to extend the term of the lease by twelve months.</font></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">TERM: Term will begin on July 1, 2018 and end on June 30, 2019 (unless otherwise terminated</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">as provided in the Lease).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">TOTAL RENT:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">7/01/18-6/30/19: $12.50 per square foot; $60,900.00 </font><font style="font-family:Arial;font-size:11pt;font-style:italic;">I </font><font style="font-family:Arial;font-size:11pt;">year; $5,075.00 </font><font style="font-family:Arial;font-size:11pt;font-style:italic;">I </font><font style="font-family:Arial;font-size:11pt;">month*</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">*All rates plus CAM (which shall never be less than $9.30 psf) plus sales tax (currently at 6.8%).</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">PREMISES: Landlord will deliver premises in an "as is" condition.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Except as set forth herein, all other terms, conditions, provisions and requirements of the Lease remain unchanged and in full force and effect.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed on the day and year first above written.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LANDLORD:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">TENANT:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">QUENTIN  PARTNERS CO.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">DYADIC INTERNATIONAL,  INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">As Agent For: lntracoastal  Pointe, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ James Q. Riordan, Jr.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#160;By: James Q. Riordan, Jr., President</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Mark Emalfarb, CEO</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WITNESS:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">WITNESS:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ Sharon Wood</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ Heidi Zosiak</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Sharon Wood</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Heidi Zosiak</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>17
<FILENAME>exhibit1012form10.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s47387C8C151C8A43E20A90D779F20877"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.12</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXECUTION VERSION</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*] indicates that a confidential portion of the text of this agreement has been omitted. The non-public</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">information has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PHARMA LICENSE AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This PHARMA LICENSE AGREEMENT (the &#8220;Agreement&#8221;) is made as of December 31, 2015, and effective as of the Effective Date (as that term is defined below) by and between Danisco US, Inc., a Delaware corporation having a place of business at Building 356, DuPont Experimental Station, Wilmington, Delaware (&#8220;Danisco&#8221;) and Dyadic International, Inc., a Delaware corporation having its principal office at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida (&#8220;Dyadic&#8221;). Danisco and Dyadic are each referred to herein by name or, individually, as a &#8220;Party&#8221; or, collectively, as &#8220;Parties.&#8221; As used in this Agreement, capitalized terms shall have the meanings indicated in Article 1 of this Agreement or as specified elsewhere in the Agreement. Other capitalized terms used but not otherwise defined herein shall have the meanings assigned to them in the Asset Purchase Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, pursuant to and in accordance with the terms of the Asset Purchase Agreement, Danisco will acquire all patents, know-how and assets relating to the generation and use of Dyadic&#8217;s proprietary </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Myceliopthora thermophila </font><font style="font-family:inherit;font-size:12pt;">(formerly classified as </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Chrysosporium lucknowense</font><font style="font-family:inherit;font-size:12pt;">, &#8220;C1&#8221;) technology for the expression of genes and secretion of certain corresponding substances and, in connection therewith, Danisco will acquire ownership of all C1 Strains, as well as the Dyadic Know-How, and Dyadic Materials, including, without limitation, certain Genetic Tools;</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Dyadic desires to obtain, and Danisco is willing to grant to Dyadic access and a co- exclusive license, with the right to enforce, with respect to certain patent rights, materials and related know-how, as more specifically provided for hereinafter, in order to permit Dyadic and its Sublicensees to use the C1 Strains, or the Danisco Improved Strains, as well as certain related Know-How and Dyadic Materials, to offer services and to make, use, sell, offer to sell, have made, import and export compositions of matter, but in each case, solely in the Pharmaceutical Field and on the terms and conditions herein;</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Danisco is willing to provide certain Services, when and if agreed, related to the use of the C1 Strains as a Pharmaceutical Platform, all on the terms and conditions herein, and</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, in the event Danisco, Dyadic or its Sublicensees use, as applicable, the C1 Strains or the Danisco Improved Strains to make, have made, use, sell, offer to sell, import or export, Pharmaceutical Products or provide services in the Pharmaceutical Field, the Parties have agreed that certain royalties may be payable based on such sales, in all events in accordance with the terms and conditions herein;</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, in consideration of the mutual covenants and agreements provided herein below and other consideration, the receipt and sufficiency of which is hereby acknowledged, Danisco and Dyadic hereby agree as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 1 DEFINITIONS</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Affiliate&#8221; means, with respect to any Person, any other Person that is controlled by, controls, or is under common control with such first Person, as the case may be. For purposes of this definition of &#8220;Affiliate&#8221;, the term &#8220;control&#8221; means (a) direct or indirect ownership of fifty percent (50%) or more of the voting interest in the entity in question, or fifty percent (50%) or more interest in the income of the entity in question; provided, however, that if local Law requires a minimum percentage of local ownership of greater than fifty percent (50%), control will be established by direct or indirect beneficial ownership of such greater percentage, or (b) possession, directly or indirectly, of the power to direct or cause the direction of management or policies of the entity in question (whether through ownership of securities or other ownership interests, by contract or otherwise).</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Asset Purchase Agreement&#8221; means the Asset Purchase and Sale Agreement dated November 9, 2015 between Danisco, Dyadic and Dyadic International (USA), Inc., a Florida corporation, pursuant to which Danisco will acquire certain assets related to C1 Strains, on the terms and subject to the conditions set forth therein.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;C1 Genomic Information&#8221; means the genome sequence of C1 Strains and any associated annotations, software, software tools related thereto, all as more fully described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;C1 Strain(s)&#8221; means, individually and collectively, the </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Myceliophthora thermophila </font><font style="font-family:inherit;font-size:12pt;">strains acquired by Danisco from Dyadic or its Affiliates pursuant to the Asset Purchase Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Confidential Information&#8221; means any information of a confidential and proprietary nature, whether oral, written, visual, electromagnetic, or in any other form, which is disclosed by a Party or Licensed Party and which is designated as being confidential in writing within three (3) Business Days of the date of disclosure. Confidential Information does not include information which (i) is or becomes generally available to the public other than as a result of a disclosure by the receiving Party or its Representatives in breach of this Agreement, (ii) is or becomes available to the receiving Party or its Representatives from a source other than the disclosing Party or its Representatives, which such source is not known by the receiving Party to be subject to a contractual obligation to the Disclosing Party prohibiting such disclosure, or (iii) is independently developed by the receiving Party or its Representatives by persons who, the receiving Party can demonstrate by clear and convincing evidence, had no access to, and developed such information without reference to the Confidential Information of the disclosing Party.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Control&#8221; or &#8220;Controlled&#8221; means ownership or possession of the ability to assign, grant access, license or sublicense, with the right, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">inter alia</font><font style="font-family:inherit;font-size:12pt;">, to use, as provided for, in any case without violating the applicable terms of any agreement or other arrangement with any Third Party.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Danisco Background Technology&#8221; means Know-How and Genetic Tools known to Danisco and its Affiliates prior to the Effective Date.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Danisco Background Tool&#8221; means any Genetic Tool that consists essentially of either (a) a Genetic Tool owned or controlled by Danisco or any Affiliate of Danisco prior to the Effective </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date or that is developed or obtained by Danisco or any Affiliate of Danisco not pursuant to the Services, or (b) such a Genetic Tool that is modified as part of the provision of the Services solely in order to enable use of such Genetic Tool in a C1 Strain or a Danisco Improved Strain. For the avoidance of doubt, the foregoing does not include, and expressly, excludes the Genetic Tools acquired pursuant to the Asset Purchase Agreement and any Services Generated Genetic Tools.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Danisco Confidential Information&#8221; means (i) Confidential Information, created after the Effective Date, relating to any C1 Strain, C1 Genomic Information, Dyadic Material, Danisco Improved Strain, Genetic Tool, Dyadic Know-How, or Danisco Know-How licensed by Danisco under this Agreement, and (ii) Confidential Information of Danisco learned by Dyadic as a result of Danisco&#8217;s performance of the Services or the transfer of technology pursuant to Article 3.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Danisco Know-How&#8221; means Know-How regarding C1 Strains or Danisco Improved Strains (i) which is actually used and/or developed by the Designated Employees in the course of providing Services to grow any C1 Strain or Danisco Improved Strain to express any Pharmaceutical Product, (ii) which Danisco is free to disclose without breaching any bona fide obligations of confidentiality to any Third Party, and (iii) which is useful with respect to the use of the C1 Strains or Danisco Improved Strains in the Pharmaceutical Field. Notwithstanding anything herein to the contrary, Know-How not actually used in the course of providing Services and included in the definition of Danisco Background Technology is not included in Danisco Know- How unless necessary to grow any C1 Strain or Danisco Improved Strain transferred to Dyadic to express any Pharmaceutical Product. Know-How developed under the Services provided for in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">&#32;which has no known utility in the Pharmaceutical Field shall not be deemed to be Danisco Know-How.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Danisco Improved Strain&#8221; means a C1 Strain modified to express or secrete a Pharmaceutical Product where the performance or characteristics of such C1 Strain, including, without limitation, with respect to any composition of matter produced or expressed therein, has been materially altered as a result of work done by or on behalf of Danisco pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">&#32;and where such C1 Strain, as materially altered, would, to one reasonably skilled in the art, be useful in the Pharmaceutical Field.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Danisco Patents&#8221; means those Patents, other than the Dyadic Patents, Controlled by Danisco after the Effective Date reasonably necessary for the use of any C1 Strain or modified C1 Strain in the Pharmaceutical Field, including, but not limited to, use thereof as a Pharmaceutical Platform but excluding any claim of such a Patent that exclusively covers, as a composition of matter or method of manufacture, (a) the specific structure, other than as a generic claim, of a Pharmaceutical Product, or (b) an industrial enzyme; </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, that the foregoing shall not be interpreted in a manner which limits or </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">otherwise interferes with Dyadic or its Sublicensees&#8217; right hereunder with respect to any Pharmaceutical Product that has a different structure, including, without limitation, a distinct amino acid or chemical structure.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Dyadic Confidential Information&#8221; means (i) the identity, characteristics, uses, including any indication, and/or genetic sequence of any Pharmaceutical Product owned, Controlled or being worked on by Dyadic or its Sublicensee, including with respect to which Services will be provided under Exhibit B (ii) Dyadic&#8217;s selection criteria or assay for identifying Pharmaceutical</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Products that can be expressed by C1 Strains, (iii) Confidential Information which Danisco, through its Relationship Manager, agrees in writing to receive after Dyadic discloses in writing and in general the contents of such Confidential Information, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, the Relationship Manager shall not refuse to except such information as Confidential Information, if such information is reasonably necessary for Danisco to perform the Services provided in Exhibit B and (iv) all Confidential Information disclosed by Dyadic pursuant to Section 2.1(b). Notwithstanding the foregoing, in the event that the identity of a Pharmaceutical Product and/or the identity of any pharmaceutical companies interested in such Pharmaceutical Product becomes publicly available, then the identity, characteristics, uses, including any indication, of such Pharmaceutical Product, the fact that Dyadic is interested in producing such Pharmaceutical Product, and/or the fact that Dyadic is working with any such pharmaceutical company with respect to such Pharmaceutical Product shall not be considered to be Dyadic Confidential Information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Dyadic Know-How&#8221; means the Transferred Know-How relating to the engineering, production, fermentation, composition and use of C1 Strains, as such information existed as of the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Dyadic Material(s)&#8221; means the materials set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Dyadic Patents&#8221; means the Transferred Patents related to the composition and use of C1 Strains.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Dosage Forms&#8221; means the final dosage form in which a Pharmaceutical Product will be administered to a human or animal.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Effective Date&#8221; means the Closing Date of the Asset Purchase Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Genetic Tools&#8221; means any composition of matter and genetic elements useful for using, manipulating, engineering, transforming, transfecting, modifying or altering a C1 Strain that was transferred to Danisco pursuant to the Asset Purchase Agreement. Without limiting or expanding the foregoing, Genetic Tools shall include those identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Improvement&#8221; means (a) with respect to each licensee of Dyadic or its Affiliates under a Transferred Agreement, the definition given to that term in the applicable Transferred Agreement, and (b) any modification to a C1 Strain, Genetic Tool, Dyadic Know-How, or </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dyadic Material which improves the ability or characteristics of a C1 Strain with respect to the expression or screening of products other than Pharmaceutical Products.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Industrial C1 Strain&#8221; means any C1 Strain which, to one ordinarily skilled in the art, is primarily useful outside the Pharmaceutical Field and has no significant utility inside the Pharmaceutical Field.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Industrial C1 Patents&#8221; means Patents exclusively covering the practice or use of the Industrial C1 Strains.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Know-How&#8221; means, to the extent necessary or reasonably useful to the use of a C1 Strain or Danisco Improved Strain, any and all technical information, regulatory information, processes, </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">procedures, methods, formulae, protocols, and techniques relating thereto, including, without limitation, the information and fermentation protocols listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">. Expressly included in Know-How is any such Know-How relating to C1 Genomic Information or Genetic Tools.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Law&#8221; means, individually and collectively, any and all laws, ordinances, orders, rules, rulings, directives and regulations of any kind whatsoever of any governmental, court or regulatory authority within the applicable jurisdiction, including the Patent laws of any relevant jurisdiction.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Licensed Parties&#8221; means (a) Dyadic and (b) direct and indirect Sublicensees of Dyadic.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Net Sales&#8221; means all revenues received in connection with the sale of a Pharmaceutical Product or a Dosage Form which was produced, with respect to sales by Danisco, using a C1 Strain or an improved C1 Strain, or, with respect to sales by a Licensed Party, using any C1 Strain or improved C1 Strain where such production is covered by a Danisco Patent minus (i) import, export, excise and sales taxes, and custom duties; (ii) costs of insurance, packing, and transportation customarily charged in the industry; and (iii) rebates, credits and allowances provided with respect to such sales.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Patents&#8221; means (a) United States, Patent Cooperation Treaty, and non-US national patents, re- examinations, reissues, renewals, extensions and term restorations, utility models and registrations, design patents, inventors&#8217; certificates and counterparts thereof; and (b) pending applications for United States and foreign patents, including, without limitation, provisional applications, continuations, continued prosecution, divisional and substitute applications, and counterparts thereof.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Person&#8221; means any individual, corporation, partnership, association, joint-stock company, trust, unincorporated organization or government or political subdivision thereof.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Pharmaceutical Field&#8221; means the development and use of a C1 Strain as a Pharmaceutical Platform for the research, discovery, development, manufacture or commercialization of any Pharmaceutical Product.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Pharmaceutical Improvement&#8221; means any modification to a C1 Strain, Genetic Tool, Dyadic Know-How, or Dyadic Material which improves the ability or characteristics of a C1 Strain with respect to the expression or screening of Pharmaceutical Products.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Pharmaceutical Patent&#8221; means the claim of any Patent covering a composition of matter consisting of a specific Pharmaceutical Product identified by biologic activity relevant to the Pharmaceutical Field, chemical structure or amino acid sequence or the expression of such amino acid sequence for such specific Pharmaceutical Product in a C1 Strain. For the avoidance of doubt, a Pharmaceutical Patent does not include a Patent which claims the production of a class of Pharmaceutical Products (e.g., vaccines or antibodies) in a C1 Strain or Danisco Improved Strain or using any Know-How, including Dyadic Know-How, Dyadic Materials, or Danisco Know-How, specifically relating thereto.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Pharmaceutical Platform&#8221; means a C1 Strain useful for the discovery, development, expression, modification, improvement, manufacture or commercialization of a composition of matter comprising a Pharmaceutical Product.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Pharmaceutical Product&#8221; means (i) an active pharmaceutical ingredient or active moiety intended for the treatment, diagnosis or prophylaxis of any disease or medical condition in a human or any other animal, (ii) an intermediate which is subsequently processed into an active pharmaceutical ingredient, or (iii) a processing aid used in the production of an active pharmaceutical ingredient. Notwithstanding the foregoing, a Pharmaceutical Product does not mean any enzyme, protein, reactant or biosynthetic product sold as an industrial enzyme and used industrially in grain sugar or fiber processing, animal nutrition, food applications, personal care, fabric and home care, or biofuels and any other application for which industrial enzymes have been traditionally used. With respect to the foregoing sentence, it is understood that a composition of matter that also may have functionality with respect to the excluded categories set forth therein shall not be deemed to be excluded from the definition of a Pharmaceutical Product when intended for the treatment, diagnosis or prophylaxis of any disease or medical condition in a human or any other animal.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Sanofi Agreement" means an agreement titled "Proof of Concept, Exclusive License Option &amp; Technology Transfer Agreement" entered into between Sanofi Pasteur S.A., EnGen BIO, Inc., and Dyadic Nederland B.V., dated March 30, 2011, as amended.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Services&#8221; means the activities set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">, as such Exhibit B may be amended or supplemented, the operative and other provisions of which are incorporated herein as if set forth in full.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Services Generated Tools&#8221; means Genetic Tools generated in the course of the provision of the Services. For the avoidance of doubt expressly excluded from the definition of Services Generated Tools is any Danisco Background Tool.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Sublicensee&#8221; means any Person doing business in the Pharmaceutical Field (other than Sanofi Pasteur S.A. and its Affiliates and then solely to the extent relating to a sublicense granted pursuant to Section 2.1(a)(v) hereof) which is a direct or indirect sublicensee of Dyadic in accordance with the terms of this Agreement or to which any C1 Strain, Dyadic Know-How, Dyadic Materials, Danisco Improved Strain, Danisco Know-How, Genetic Tool, or any Dyadic Patent or Danisco Patent is sub-licensed by Dyadic under a written Sublicense Agreement granted in all events in compliance with the requirements of Section 2.1(b) of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Sublicense Agreement&#8221; means an agreement between Dyadic and a Sublicensee that meets the requirements set forth in Section 2.1(b).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Third Party&#8221; means any Person other than Danisco, Dyadic, any Affiliate of either Danisco or Dyadic, or any Sublicensee.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Transferred Contract Party&#8221; means a party to a Transferred Contract other than Dyadic, Dyadic International (USA), Inc., a Florida corporation, or Dyadic Netherland BV. For the purposes of this Agreement, each reference to a Transferred Contract shall be a reference to the Transferred </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contract as it exists as of the Effective Date, it being understood that Danisco may enter into amendments to or extend the term of any Transferred Contract where (i) such amendment or term extension is unrelated to the Pharmaceutical Field; (ii) does not extend any additional rights to the counterparty to the Transferred Contract in the Pharmaceutical Field and (iii) such amendment does not alter, waive, amend or diminish the rights of Licensed Parties with respect to the Pharmaceutical Field.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 2 LICENSE AND TECHNOLOGY TRANSFER</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1 Grants to and Covenants by Dyadic and Dyadic Sublicensees and Sublicensing</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">License Grants</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Subject to the terms and conditions of this Agreement, Danisco on behalf of itself and its Affiliates hereby grants to Dyadic:</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A) a co-exclusive (as between Danisco and Dyadic, but subject to the rights of any Third Party under any Transferred Contract), a non- transferable (except as provided in Section 10.3), worldwide, royalty free, perpetual (subject to Section 9.2) license, with the right to enforce (subject to Section 4.2), and grant sublicenses pursuant to and in accordance with this Section 2.1(a) and Section 2.1(b), to use the C1 Strains, the Dyadic Materials, and the Danisco Improved Strains, and practice under the Dyadic Patents,</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B) a non-exclusive, non-transferable (except as provided in Section 10.3), worldwide, royalty free, perpetual (subject to Section 9.2) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">license, with the right to grant sublicenses pursuant to and in accordance with this Section 2.1(a)(i) and Section 2.1(b), to use the Genetic Tools (excluding Danisco Background Technology and Danisco Background Tools), the Services Generated Tools, the Dyadic Know-How and Danisco Know-How,</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">in the case of (A) and (B) solely to: (1) make, have made (subject to Section 2.1(b)), use, sell, offer to sell, export and import Pharmaceutical Products and (2) provide services using the C1 Strains and any improved C1 Strain, including Danisco Improved Strains but excluding any Danisco Background Technology or Danisco Background Tool embodied therein, as a Pharmaceutical Platform, in both cases, solely for use in the Pharmaceutical Field. Such right to grant sublicenses does not include the further right of any Sublicensee to further sublicense the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Danisco Know-How, the Dyadic Materials, the Genetic Tools, the Services Generated Tools, and the Dyadic Patents for any purpose except to the extent necessary to have Third Parties conduct contract research on behalf of a Licensed Party regarding use of C1 Strains, Dyadic Materials or the Dyadic Know-How or modifications thereto as a Pharmaceutical Platform or for a Sublicensee to exercise its &#8220;have made&#8221;</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">rights or, with respect to a Pharmaceutical Product, to grant limited sublicenses within multiple tiers of Sublicensee Affiliates or Third Parties solely to permit manufacturing, distributing or marketing such Pharmaceutical Product on behalf of such Sublicensee.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii) Subject to the terms and conditions of this Agreement, Danisco on behalf of itself and its Affiliates hereby grants to Dyadic a non-exclusive, non-transferable (except as provided in Section 10.3), worldwide, royalty free, perpetual (subject to Section 9.2) license with the right to grant sublicenses pursuant to and in accordance with this Section 2.1(a)(i) and Section 2.1(b), to use the Danisco Background Technology and the Danisco Background Tools solely to express the specific polypeptide expressed by the Danisco Improved Strain as to which the Services were provided using such Danisco Background Technology or such Danisco Background Tool. Such right to grant sublicenses does not include the further right of any Sublicensee to further sublicense the Danisco Background Technology and the Danisco Background Tools except to permit the expression of the specific polypeptide expressed by the Danisco Improved Strain as to which the Services were provided with respect to such Danisco Background Tool or Danisco Background Technology.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii) Subject to the terms and conditions of this Agreement, Danisco on behalf of itself and its Affiliates hereby grants to Dyadic a co-exclusive (as between Danisco and Dyadic, but subject to the rights of any Third Party under any Transferred Contract), non-transferable (except as provided in Section 10.3), worldwide, royalty bearing, perpetual (subject to Section 9.2) right and license, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">with the right to grant sublicenses and to enforce (subject to Section 4.2), pursuant to and in accordance with this Section 2.1(a)(ii) and Section 2.1(b), to practice under the Danisco Patents to (A) make, have made (subject to Section 2.1(b)), use, sell, offer to sell, export and import Pharmaceutical Products and (B) provide services using the C1 Strains or a Danisco Improved Strain as a Pharmaceutical Platform, in both cases, solely for use in the Pharmaceutical Field. Such right to grant sublicenses does not include the further right of any Sublicensee to further sublicense the Danisco Patents for any purpose except to the extent necessary to have Third Parties conduct contract research using the C1 Strains or for a Sublicensee to exercise its &#8220;have made&#8221; rights or, with respect to a Pharmaceutical Product, to grant limited sublicenses within multiple tiers of Sublicensee Affiliates or Third Parties solely to permit manufacturing, distributing or marketing such Pharmaceutical Product on behalf of such Sublicensee.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)With respect to the grant provided for in Section 2.1(a)(iii), such grant shall be royalty bearing in accordance with the following table:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Such royalty shall be payable to Danisco within thirty (30) Business Days from the end of each calendar quarter by Dyadic or its Sublicensee and a report regarding Net Sales shall be provided to Danisco. Dyadic and its Sublicensees, no more than once every twelve (12) months, shall permit an audit of their books and records by a national accounting firm designated by Danisco. Such accounting firm shall confirm the accuracy of any royalty calculation and shall not disclose to Danisco any other information of Dyadic or its Sublicensees other than the correct calculation of Net Sales and the amount of the royalty payable to Danisco. In the event that such audit reveals an underpayment of any royalty of more than one percent (1%), the Licensed Party which is obligated to pay such royalty shall reimburse Danisco for the cost of such audit.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding the foregoing, in the event that Danisco owes a royalty or other payment to a Third Party as a result of the use by a Licensed Party of the rights licensed under Section 2.1, the Licensed Party, exercising its sole judgment, shall either forego the right to proceed under such licensed right or, in addition to the royalties provided for above, reimburse Danisco for all payments due to any such Third Party arising from such use upon delivery of an invoice therefor. With respect to any rights provided for in this paragraph, the Licensed Parties shall abide by any conditions for such use applicable to Danisco activities in the Pharmaceutical Field and negotiated in good faith. During the period in which Services are provided, if either Party identifies potential opportunities for in-licensing technology suitable for use in improving C1 Strains as Pharmaceutical Platform, then such Party may provide notice to the patent committee referenced below for consideration. Subject to obligations of confidentiality, prior to using any technology which would result in application of the first sentence of this paragraph, notice will be provided to Dyadic. Within a reasonable time after such notice, but in any event within sixty (60) days after receipt of such notice, Dyadic shall be free to provide alternatives or </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">comment on such technology and Danisco shall consider such advice; provided however Danisco may proceed or not in its sole discretion exercised in objective good faith.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Except with respect to rights foregone by a Licensed Party pursuant to the preceding paragraph, Danisco and its Affiliates shall not assert, subject to the payment of any royalty provided for herein, as applicable, any Dyadic Patent or Danisco Patent or make a claim of misappropriation or breach of confidentiality, with respect to any Danisco Background Technology (but only to the extent rights are granted to such Danisco Background Technology as set forth in the next sentence), Danisco Know-How, Dyadic Know-How, Dyadic Materials or Genetic Tools against any Licensed Party which, in accordance with the limitations provided for herein, is using a C1 Strain, Dyadic Know-How, Dyadic Materials, Danisco Improved Strain, Danisco Know-How, or Genetic Tool in providing services using C1 Strains as a Pharmaceutical Platform or to produce Pharmaceutical Products, in each case, in compliance with its obligations to Danisco under this Agreement and any Sublicense Agreement. For the purposes of the foregoing, the right granted with respect to any Danisco Background Technology only extends so far as is reasonably necessary for a Licensed Party to actually grow any C1 Strain, C1 Improved Strain or any progeny thereof actually provided by Danisco pursuant to the provision of Services under this Agreement, or express or purify any Pharmaceutical Product which is the subject of a Service, or if such Danisco Background Technology is publically available.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v) Danisco, on behalf of itself and its Affiliates, hereby grants to Dyadic an exclusive, but subject to the rights of any Third Party under any Transferred Contract, non-transferable, worldwide, royalty free, license, with the right to enforce (subject to Section 4.2), and grant a sublicense solely to Sanofi Pasteur S.A. or its Affiliates in accordance with the terms of the Sanofi Agreement, to use the C1 Strains, the Dyadic Materials, and practice under the Dyadic Patents solely to make, have made, use, sell, offer for sale, or import Products (as that term is defined in Exhibit B to the Sanofi Agreement) for use solely in </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#32;vaccines. Dyadic shall promptly notify Danisco in the event that (A) Sanofi Pasteur S.A. (or its affiliate, assignee or successor) exercises the License Option (as defined in the Sanofi Agreement), (B) the Option Period (as defined in the Sanofi Agreement) expires, (C) the Sanofi Agreement terminates or expires prior to the exercise of the License Option and/or (D) the license agreement contemplated by the Sanofi Agreement or any sublicense agreement executed among the parties in connection therewith and pursuant to this Section 2.1(a)(iv) terminates or expires. In the event that the Option Period expires prior to the exercise of the License Option, the Sanofi Agreement terminates or expires prior to the exercise of the License Option or the license agreement contemplated by the Sanofi Agreement or any sublicense agreement executed among the parties in connection therewith and pursuant to this Section 2.1(a)(v) terminates or expires, the license set forth in this Section 2.1(a)(v) shall automatically terminate and this Section 2.1(a)(v) shall be of no further force or effect.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Sublicenses. The license granted pursuant to Section 2.1(a)(i) and (ii) includes the right to grant sublicenses within the scope of such license solely as set forth in this Section 2.1(b) pursuant to a written agreement (each a &#8220;Sublicense Agreement&#8221;) which will contain provisions consistent with the following:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Sublicense Agreement shall include this Agreement as an attachment after redaction of Sections 3.2, 3.3 and 3.4.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Sublicense Agreement shall include a provision which reads as follows: </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Sublicensee acknowledges that it has read the Pharma License Agreement entered into between Danisco US Inc. and Dyadic International Inc. and agrees to be bound by the provisions of such License Agreement as if it were a party to such License Agreement. For the avoidance of doubt, this includes the provisions of Section 10.7 regarding resolution of disputes.&#8221;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Sublicense Agreement shall include a provision which reads as follows:</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Sublicensee agrees that Danisco US Inc. or any authorized assignee of Danisco US Inc. is an intended third party beneficiary to any Sublicense Agreement and shall be entitled to enforce the terms of this Agreement directly against Sublicensee.&#8221;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Sublicense Agreement shall include a provision which reads as follows:</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;This Sublicense Agreement shall not be further sublicensed except that, as applicable, the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools and the Danisco Patents may be further sublicensed to the extent necessary to Third Parties having no economic interest in the Pharmaceutical Product under development to provide contract research services or contract manufacturing services for a Licensed Party, for a Sublicensee to exercise its &#8216;have made&#8217; rights or, with respect to a Pharmaceutical Product, to grant limited sublicenses within multiple tiers of Sublicensee Affiliates or Third Parties solely to permit manufacturing, distributing or marketing such Pharmaceutical Product on behalf of such Sublicensee under terms no less restrictive than the terms set forth in Section 2.2 of the Pharma License Agreement entered into between Danisco US Inc. and Dyadic International Inc. &#8221;</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">During January of each year during the Term of this Agreement, Dyadic shall notify Danisco in writing of the identity and address of each active Sublicensee, and when publicly available, shall promptly report to a designated risk manager at Danisco or an Affiliate of Danisco, who shall not share the information except as needed to assess and manage risk, the identity and proposed indication of the Pharmaceutical Product that is the subject of the Sublicense. All such disclosures shall be deemed to be Dyadic Confidential Information.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2 Covenants by Licensed Parties</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Licensed Parties shall not (i) use any C1 Strain, improved C1 Strain, Dyadic Know-How, Dyadic Materials, Danisco Know-How, Danisco Improved Strain, Genetic Tools, or practice under the Dyadic Patents or Danisco Patents outside of the Pharmaceutical Field and shall exercise the rights licensed hereunder in compliance with applicable law, or (ii) transfer, license or grant access to any C1 Strain, improved C1 Strain, Dyadic Know-How, Dyadic Materials, Genetic Tools, Danisco Know-How, Danisco Improved Strain, Dyadic Patents or Danisco Patents or derivatives thereof to any Third Party other than in accordance with this Agreement. Any uncured breach of this covenant by a Sublicensee or Dyadic, when finally adjudicated in accordance with Article 10, shall be a material breach of, as applicable, this Agreement or the Sublicense Agreement. Dyadic agrees to notify Danisco in writing within fifteen (15) Business Days if Dyadic has a reasonable basis to believe that any Sublicensee has breached this covenant. In addition to the right of Danisco to proceed separately against any such Sublicensee, Dyadic shall take all commercially reasonable measures to prevent any such Sublicensee from continuing such breach, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, that Danisco shall be given the right to elect which entity takes the initial enforcement step within ten (10) Business Days of the report of a potential breach. Subject to the foregoing sentence and Danisco&#8217;s right pursuant to Section 9.2(a) hereof, the Parties will work in good faith to allocate the responsibility for resolving such allegations of unlicensed use cooperatively, it being understood that Danisco shall have the final say.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;In the event that Danisco has a reasonable basis to believe that any Licensed Party or Sanofi is using or has used C1 Strain, Dyadic Know-How, Dyadic Materials, Genetic Tools, Danisco Know-How, Danisco Improved Strain or derivatives thereof or practiced under the Dyadic Patents or Danisco Patents in a manner that is inconsistent with the terms of this Agreement, Danisco shall, within fifteen (15) Business Days of its first having such a reasonable basis, provide written notice to Dyadic describing such use and providing reasonable detail as to the basis for the allegation that such use is not permitted by this Agreement. As soon as practicable, but in no event later than fifteen (15) Business Days after Dyadic&#8217;s receipt of such written notice, the Parties shall confer, either in person or by telephone, to discuss and attempt to resolve Danisco&#8217;s concerns. In the event that Danisco&#8217;s concerns are not resolved in such conference, Dyadic will initiate an investigation regarding Danisco&#8217;s concerns and will, subject to any confidentiality obligations it may have, provide to Danisco a summary of its findings. The Parties will work in good faith to allocate the responsibility for resolving such allegations of unlicensed use cooperatively. In addition to the right of Danisco to proceed separately against any such Sublicensee, Dyadic shall take all commercially reasonable measures to prevent any such Sublicensee from continuing such breach, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, that Danisco shall be given the right to elect which entity takes the initial enforcement step within ten (10) Business Days of the report of a potential breach. Subject to the foregoing sentence and Danisco&#8217;s right pursuant to Section 9.2(a) hereof, the Parties will work in good faith to allocate the responsibility for resolving such allegations of unlicensed use cooperatively, it being understood that Danisco shall have the final say.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;In all circumstances of an actual or alleged breach of the obligations provided for under this Section 2.2, Dyadic or the applicable Sublicensee shall be free to deny that the allegations are true, that the allegations are not prohibited by this Agreement, or contend that the operative provisions of the Sublicense Agreement are immaterial. In such a case, no breach will be deemed to have occurred unless and until it has been finally adjudicated under the dispute resolution procedures of Section 10.7 of this Agreement or the applicable Sublicense Agreement that there has been a material breach of the obligations provided for under this Agreement and that Danisco will suffer or has suffered more than a de minimis injury as a result thereof.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;Dyadic (on behalf of itself, its predecessors, successors, and their respective successors, parent and subsidiary corporations, together with each of their assigns, and legal representatives) hereby covenants and agrees, and shall cause its Affiliates and Sublicensees and Sanofi (each a &#8220;Dyadic Party&#8221;) to covenant and agree in a written agreement not to commence, aid, prosecute or cause to be commenced or prosecuted, any legal action or other proceeding against any Transferred Contract Party or any of its Affiliates, or any of its or their successors and assigns, or any of its or their licensees, sublicensees, third-party toll manufacturers, or direct or indirect customers or distributors solely in connection with the exercise of the rights granted to such Transferred Contract Party in accordance with the applicable Transferred Contract wherein any Dyadic Party alleges infringement (direct or contributory) or inducement of infringement of any Patent owned or Controlled by such Dyadic Party claiming an Improvement as defined in Part (a) of that definition. Nothing in the foregoing shall be deemed to include a Pharmaceutical Patent not required to be included in such covenant unless adjudicated to be so included.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3 Ownership of Patents and Grant of Rights to Danisco</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Patents based on inventions created or made by Danisco, a Third Party under Danisco&#8217;s Control, or jointly with such Third Party that (i) arise out of the Services and (ii) which would constitute a Pharmaceutical Patent, shall be solely owned by Dyadic. All other Patents which are based on inventions created or made by Danisco, a Third Party under Danisco&#8217;s Control or jointly with such Third Party as a result of the Services or inventions made by Danisco outside of the Services shall be owned solely by Danisco.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Inventions, Pharmaceutical Improvements, or Know-How made by a Licensed Party, a Third Party under a Licensed Party&#8217;s control, or jointly with such Third Party, and any resulting Patents, which relate solely to the Pharmaceutical Field, including, without limitation, any improvements to the C1 Strains, Dyadic Know-How or Dyadic Materials which relate solely to the Pharmaceutical Field shall be, as between Dyadic and Danisco, solely owned by Dyadic. Such Patents, when disclosed publically, are hereby licensed to Danisco in accordance with the other terms of this Agreement, including, without limitation, the royalty provisions of Section 3.4. Each Licensed Party, on its own behalf and on behalf of any Third Party it Controls will not attempt to make any Improvements or inventions solely outside of the Pharmaceutical Field and will not, without Danisco&#8217;s prior written consent, file for Patents or make any disclosure of any invention with applicability </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">solely outside of the Pharmaceutical Field. In the event that any Industrial C1 Strain or Industrial C1 Patents or any invention, Improvement, or Know-How relating exclusively thereto is created, each Licensed Party will promptly disclose such invention, Improvement, or Know-How relating exclusively thereto to Danisco and, in accordance with the provisions of this Agreement will immediately assign, without consideration, all such Industrial C1 Strains or Industrial C1 Patents or any invention, Improvement, or Know-How relating exclusively thereto to Danisco.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;Inventions, Improvements, or Know-How made by a Licensed Party, a Third Party under a Licensed Party&#8217;s Control, or jointly with such Third Party, and any resulting Patents, which have applicability both within and without the Pharmaceutical Field shall be solely owned by Danisco, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, if a Licensed Party, using objective evidence, can establish that the potential use of such inventions, Improvements, or Know-How outside the Pharmaceutical Field is de minimis, it shall be owned by the Licensed Party, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, that if Danisco, in good faith, objectively exercised, concludes that the dissemination of any C1 Strain or Danisco Improved Strain or Know-How that embodies such an Improvement could cause more than a de minimis injury to Danisco&#8217;s activities outside of the Pharmaceutical Field, then Danisco shall own such inventions, Improvements, or Know-How and any resulting Patents. Such Patents, inventions, Improvements, or Know-How covered by this Section 2.3(c) are hereby licensed under Section 2.1 to Dyadic or under Section 2.3(f), 2.3(g) and 2.3(h) to Danisco in accordance with the other terms of this Agreement, including, without limitation, as applicable the royalty provisions of Sections 2.1 and 3.4, it being understood that any such Patent, invention, Improvement, or Know-How made by a Licensed Party, a Third Party under a Licensed Party&#8217;s Control, or jointly with such Third Party and as to whose ownership is transferred to Danisco shall not be royalty-bearing with respect to any use under this Section 2.3 with respect to any Licensed Party. For the avoidance of doubt, inventions, and any Patent claims arising therefrom, comprising any modification of any C1 Strain, the Dyadic Know-How or the Dyadic Materials to enable or improve the production of Pharmaceutical Products, including without limitation, claims relating to compositions of matter that meet the definition of Pharmaceutical Product and that contain non-immunogenic or human-like proteins or groups, sugars and acids, are solely inside the Pharmaceutical Field. For the further avoidance of doubt, subject to rights granted to Third Parties under the Transferred Contracts, Danisco shall have no right and shall quitclaim any right or license under this Agreement under any Patent claim owned by a Sublicensee covering exclusively the use of specific production hosts other than C1 Strains to produce Pharmaceutical Products and such Patent rights shall be owned by the Sublicensee which made the invention which resulted in the Patent.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;Where Dyadic physically transfers to a Sublicensee any untransformed or untransfected C1 Strain or Danisco Improved Strain, all such physical transfers shall be under a valid, written Sublicense Agreement containing provisions extending to Danisco the rights provided for in Section 2.3(b) and (c). In the event that Dyadic is unable to obtain such rights from any potential transferee, then Dyadic may not physically transfer to such Sublicensee any C1 Strain or Danisco Improved Strain other than a C1 Strain that has been transformed or transfected to express or secrete a specific Pharmaceutical Product and </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">under conditions prohibiting such Sublicensee from reverse engineering such transformed or transfected C1 Strain to its untransformed or untransfected state.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;All inventions, Improvements, Pharmaceutical Improvements, or Know-How developed or used in the performance of Services by Danisco, a Third Party under Danisco&#8217;s Control, or jointly with such Third Party, not otherwise covered by Sections 2.3(a), (b) or (c), shall be owned by Danisco.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;With respect to any Patent where the ownership rights are assigned to a Licensed Party under this Agreement, the Licensed Party hereby grants to Danisco an exclusive, irrevocable, worldwide, royalty free license, with the right to sublicense, to make, have made, use, sell, offer for sale, import or export any product that is outside of the Pharmaceutical Field, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, that such license shall not cover the production of the Pharmaceutical Products in production hosts other than C1 Strains.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;With respect to any Patent where the ownership rights are assigned to a Licensed Party under this Agreement, the Licensed Party hereby grants to Danisco a non-exclusive, irrevocable, worldwide, royalty bearing license, without the right to sublicense, to make, have made, use, sell, offer for sale, import or export any product in the Pharmaceutical Field.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;Subject to the restrictions set forth in Section 3.3, with respect to any Patent where the ownership rights are assigned to a Licensed Party under this Agreement, the Licensed Party hereby grants to Danisco a non-exclusive, irrevocable, worldwide, royalty free license without the right to sublicense, to research and develop any product in any field including the Pharmaceutical Field.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.4&#160;&#160;&#160;&#160;No Implied Licenses. Neither Danisco nor any Licensed Party (or any sublicensee of any Licensed Party) has any rights or obligations under this Agreement except as expressly stated herein. Danisco retains all rights in and to the C1 Strains, Danisco Improved Strains, Genetic Tools, Dyadic Know-How, Danisco Know-How, Danisco Background Technology, Dyadic Materials, Dyadic Patents, and Danisco Patents except for the grants of rights for the periods as expressly provided under the terms of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 3 SERVICES TO BE PROVIDED BY DANISCO AND PAYMENTS</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1 Services</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Party shall appoint a single individual (the &#8220;Relationship Manager&#8221;), who may be replaced on written notice to the other Party, to manage the provision of the Services and to discuss any potential deviations or changes in the deliverables or work-plans that may be agreed hereunder. The Relationship Manager shall not have the authority to modify this Agreement, including, without limitation, the Services, deliverables and work-plans provided for in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">, or to otherwise bind, as applicable, Danisco or Dyadic. Any modification to any work-plans shall be agreed to by the Parties in writing. The </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Relationship Manager will be primarily responsible for all communications regarding the Services and coordinating the activities to be performed by each Party related to the Service.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Promptly after the Effective Date, Danisco shall ask Transferred Employees, to the extent such Transferred Employees remain employed by Danisco or its Affiliates, to continue the work in the Pharmaceutical Field that they were performing prior to the Effective Date, and the Relationship Managers shall meet to review the current status of Dyadic&#8217;s work to use C1 Strains for the production of Pharmaceutical Products and Dyadic&#8217;s objectives for the Services including the identity of the Pharmaceutical Products to be produced, and realistic milestone objectives for expression of such Pharmaceutical Products in the C1 Strains listed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">. Based on the available information and such preliminary work with the C1 Strains as Danisco may believe to be necessary to determine the feasibility of using C1 Strains for production of the Pharmaceutical Products designated by Dyadic, the Parties, using commercially reasonable efforts for a period of up to sixty (60) days from the Effective Date, shall negotiate in good faith to agree upon a work plan covering those subjects set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">&#32;that sets forth in greater detail the Services and the objectives of the Parties. Upon agreement to such work plan, Danisco will designate employees of Danisco or any Affiliate of Danisco (herein the &#8220;Designated Employees&#8221;) who will be assigned to implement the work plan. Such work-plan shall be signed by the Parties and become Exhibit B to this Agreement. Nothing shall require Danisco to agree to any Services, objective or milestone that in its judgment cannot realistically be accomplished in C1 Strains, in facilities maintained by Danisco and its Affiliates or by the Designated Employees. Subject to this Section 3, if the Parties shall execute Exhibit B, for a period of three (3) years from the Effective Date or until Dyadic terminates the Services, Danisco shall use its good faith efforts to provide the Designated Employees with the necessary time and laboratory resources to enable them to perform the Services and attempt to achieve Dyadic&#8217;s objectives. Danisco may change the identity of the Designated Employees at any time and from time to time by written notice to Dyadic. Dyadic acknowledges that the Services involve research and that the results of research and the timing of such results will always be uncertain.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dyadic agrees that it will minimize to the maximum extent possible the disclosure of Dyadic Confidential Information to Danisco and shall only provide such information to those Designated Employees who have a need to know.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Through the Relationship Manager, Danisco will inform and obtain written consent from Dyadic's relationship manager prior to the application of any Danisco Background Technology in the course of providing Services. In the event such Danisco Background Technology is applied in the course of providing Services, Dyadic or, as applicable, a Licensed Party, shall be free to use, royalty-free, with, a right of sub-license as provided for in Section 2.1(a)(i) and 2.1(a)(ii), such Danisco Background Technology and/or any Danisco Background Tools, solely as is reasonably necessary to grow the C1 Strain or Danisco Improved Strain to express the Pharmaceutical Product with which it has been transformed or transfected, in each case, to the extent such C1 Strain, Danisco Improved Strain or Pharmaceutical Product were the subject of Services provided hereunder.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the event that the Parties do not agree to a detailed Exhibit B within sixty (60) days of the Effective Date or at any time after such detailed Exhibit B has been in effect for six (6) months, Dyadic may terminate the obligation of Danisco to provide the Services and the obligation of Dyadic to pay for Services (other than any Services rendered prior to the effectiveness of such termination) by providing Danisco with thirty (30) days prior written notice of such termination. In such event, during such thirty (30) day period Danisco shall, pursuant to the license set forth in Section 2.1, transfer progeny of such C1 Strains, or if applicable Danisco Improved Strains, that have been developed pursuant to the Services, as well as any Dyadic Know-How, Danisco Know-How, the Genetic Tools listed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, and any Services Generated Tools which relate to C1 Strains in the Pharmaceutical Field, and Danisco shall submit its final invoice to Dyadic for the FTEs used in performing work in the Pharmaceutical Field for Dyadic and in transferring technology to Dyadic pursuant to the following paragraph.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">During the period when Danisco is providing Services, or during the 60 day period after the Effective Date, Danisco will, upon request by Dyadic, use commercially reasonable efforts to transfer to Dyadic or, if Dyadic does not currently employ or have access to Persons with technical training, Sanofi or its Affiliates, or a Sublicensee information sufficient to enable persons of ordinary skill in the art to grow Danisco Improved Strains and express Pharmaceutical Products in such Danisco Improved Strains, and use and grow the Danisco Improved Strains and the C1 Strains and the Genetic Tools and information listed in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, and any Services Generated Tool to express Pharmaceutical Products (hereinafter defined as &#8220;Technology Transfer Services&#8221;), </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, it being understood that any such use by the Licensed Parties of the information to be provided pursuant to the Technology Transfer Services shall in all events be subject to the terms of this Agreement. Nothing herein shall require Danisco to (i) transfer technology regarding how to use Danisco Background Technology or Danisco Background Tools except with respect to the use of such Danisco Background Technology or Danisco Background Tools to grow a Danisco Improved Strain and express a Pharmaceutical Product in such Danisco Improved Strain or (ii) transfer technology that has been previously transferred five times to an employee or contractor of Dyadic with technical training. During the 60 day period after the Effective Date, and during the period Services are provided, if any, and at the end of such period, Danisco shall engage in regular technology transfer activities as reasonably requested by Dyadic, and also transfer activities as relating to the Services and any deliverables to be provided pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, that any such use by the Licensed Parties of such transferred technology shall in all events be subject to the terms of this Agreement. Dyadic shall have a period of six (6) months after termination of the period during which Danisco is obligated to provide Services to request additional technology transfer services with respect to the technology to be transferred under this paragraph. After such six (6) month period, Danisco&#8217;s obligation to transfer under this paragraph shall be deemed to be complete.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Danisco makes no and expressly disclaims any, and Dyadic disclaims reliance on any, express or implied representation or warranty regarding the success of such efforts, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">training and education, and Dyadic acknowledges that not all Pharmaceutical Products will be able to be produced in C1 Strains.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Danisco shall keep Dyadic reasonably informed of progress with respect to data, Services, Services Generated Tools, and the Danisco Improved Strains generated under the Services other than Danisco Background Tools. Danisco shall provide Dyadic with detailed quarterly written reports regarding details and results of the Services.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">During the 60 day period after the Effective Date, and during the period that Services are being provided under this Agreement, and for six (6) months after termination of Services, Danisco shall provide Dyadic reasonable access to, and use rights and Know-How related to, (i) the Transferred Books and Records pertaining how to modify, use and grow C1 Strains in the Pharmaceutical Field, including without limitation, any records evidencing lab notebooks, inventions or discoveries made by employees of Dyadic or any Affiliate of Dyadic prior to the Effective Date, (ii) all genomic and other data, regulatory filings and approvals relating to C1 Strains obtained or made by Dyadic prior to the Effective Date, and (iii) all toxicity and pathogenicity data including but not limited to the data generated as part of the submission and approval of the U.S. Food and Drug Administration Generally Regarded as Safe (&#8220;GRAS&#8221;) Notification #292, and any and all additional data generated subsequent to the GRAS #292 Notification, but prior to the Effective Date of the Pharma License. Licensed Parties acknowledge that Danisco makes no and expressly disclaims any, and Licensed Parties disclaim reliance on any express or implied representations or warranties regarding any strain produced by Danisco for Dyadic or any other Licensed Party, that Danisco makes no makes no and expressly disclaims any, and Licensed Parties disclaim reliance on any, express or implied representation or warranty regarding the safety or efficacy of any Pharmaceutical Product produced by such strain, and that Danisco makes no and expressly disclaims any, and Licensed Parties disclaim reliance on any, express or implied representation or warranty regarding the Services or that any strain or any Pharmaceutical Product or that the manufacture of such Pharmaceutical Product does not infringe the intellectual property rights of any Third Party.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">After the termination of the Services or with Danisco&#8217;s prior written consent, Dyadic will be free, without liability of any kind, to solicit up to five (5) employees of Danisco who are Transferred Employees and who have been providing Services to Dyadic with respect to the Pharmaceutical Field to resign from Danisco and become employees of Dyadic. Prior to such solicitation, Dyadic will give the Relationship Manager thirty (30) days notice indicating the names of the Transferred Employees to be solicited and Dyadic will cooperate with Danisco to permit the transition of any work activities being undertaken by such employee to another employee, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, that in no event shall any such employee be delayed more than sixty (60) days in accepting employment and working for a Licensed Party.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2  Dyadic Payments To Danisco for Services</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dyadic shall make payments to Danisco for Full Time Equivalents (which is 1,720 hours per year or an &#8220;FTE&#8221;) used by Danisco to provide the Services. Without Dyadic&#8217;s prior written consent, Danisco will not assign more than </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">. FTEs to provide such Services. Danisco shall keep records with respect to the allocation of time spent by Designated Employees in providing Services and shall invoice Dyadic at the end of each calendar quarter for Services provided pursuant to Section 3.1 at the greater of (a) </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#32;annual rate per FTE multiplied by FTEs utilized during that quarter, and (b) </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#32;per calendar quarter. In addition, Dyadic shall reimburse Danisco for any Third Party costs reasonably incurred in providing Services. Danisco shall request Dyadic&#8217;s approval for any Third Party expenditure in excess of </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#32;in the aggregate during any calendar year. Dyadic shall pay such invoice within thirty (30) days from receipt.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the event that Dyadic does not consent to reimburse Danisco for Third Party costs contemplated by Exhibit B, Danisco shall have no obligation to perform the Services associated with such Third Party expenditures.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.3 Danisco Business Activities</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Except as expressly set forth in this Section 3.3, nothing in this Agreement shall prevent Danisco or any Affiliate of Danisco from engaging in any business using any strain, Know-How or Dyadic Materials licensed or developed hereunder, from selling any Pharmaceutical Product, from providing services to any Third Party, or from using the C1 Strains, Dyadic Know-How, Dyadic Materials and Danisco Improved Strains, Genetic Tools, Danisco Know-How, Dyadic Patents, Danisco Patents or any other Know-How in any business or field, including, but not limited to, engaging in business in the Pharmaceutical Field or in the business of researching, developing, producing or selling any Pharmaceutical Product or Dosage Form. As an express limitation on the foregoing, until the sooner of </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">, Danisco will not grant sublicenses to Third Parties to use any C1 Strain (which for the purposes of all of Section 3.3 includes a Danisco Improved Strain) in the Pharmaceutical Field or provide any C1 Strain, Dyadic Know-How (only as it relates to the Pharmaceutical Field) or Dyadic Material or modified C1 Strain or modified Dyadic Materials or Know-How relating thereto (which for the purposes of this Section 3.3 shall include Danisco Know-How (only as it relates to the Pharmaceutical Field)) (&#8220;Restricted Materials&#8221;) to any Third Party, for use in the Pharmaceutical Field except that (i) Danisco may provide Restricted Materials for use in the Pharmaceutical Field to Third Parties pursuant to and in accordance with the terms and conditions of any Transferred Contract and (ii) Danisco may provide, but not sublicense, Restricted Materials to any Third Party providing contract research services, tolling services, or manufacturing services for Danisco or any Affiliate of Danisco where such use is solely in providing such services for Danisco or such Affiliate and where such Third Party is not directly or indirectly the entity that sells, markets or distributes the Dosage Form (each a &#8220;Service Provider&#8221;), and (iii) without limitation to the foregoing, Danisco may provide Know-How concerning C1 Strains, Genetic Tools, the Dyadic Know-How, the Danisco Know-How, the Dyadic Materials, Danisco Improved Strains or any derivatives thereof useful for creating or modifying such C1 Strains, Danisco Improved </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Strains or any derivatives thereof to any Third Party or government agency to the extent that such information is necessary for legal or regulatory reasons. For the avoidance of doubt, Danisco is not subject to any restriction regarding use of or sublicensing of any C1 Strain or modified C1 Strain for uses outside the Pharmaceutical Field nor is Danisco subject to any restriction regarding the transfer of any C1 Strain or modified C1 Strain for uses outside of the Pharmaceutical Field.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Any transfer of a C1 Strain for use in the Pharmaceutical Field permitted by this Section 3.3, which such transfer is made prior to the sooner of </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">, will be accompanied by a valid written agreement, directly enforceable by Dyadic against the transferee, that: (i) implements the restrictions provided for by this Section 3.3; (ii) expressly excludes the right to use such Restricted Materials in the Pharmaceutical Field except as permitted above, and (iii) gives written notice that Dyadic has co-exclusive rights, with the rights to enforce the contractual restrictions set forth in Section 3.3, to use the C1 Strains and the Dyadic Materials in the Pharmaceutical Field and that Dyadic is an intended third party beneficiary of such restrictions on the use of the Restricted Materials in the Pharmaceutical Field.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nothing herein (including, but not limited to, the previous sentence) shall require Danisco to commence any proceeding against any Third Party to enforce any restriction on the use of any Restricted Materials in the Pharmaceutical Field or otherwise, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, Danisco will use commercially reasonable efforts to prevent such use and will cooperate fully with Dyadic at Dyadic&#8217;s expense to enforce its rights under this License Agreement and the written agreement required herein. In the event that Dyadic identifies to Danisco any Third Party which it believes is using any Restricted Materials in ways that are inconsistent with the foregoing, Dyadic may provide the name of such Third Party to Danisco and Danisco will advise Dyadic if such Third Party has received such Restricted Materials pursuant to an agreement with Danisco contemplated by this Section 3.3. Once each calendar year, Dyadic may provide Danisco with a written notice requesting confirmation that Danisco has not provided Restricted Materials to Third Parties for use in the Pharmaceutical Field except to the extent that such transfer is permitted by Article 3 of this Agreement. In such event, Danisco shall respond to such Dyadic request.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4 Danisco Payments to Dyadic</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to any Pharmaceutical Product produced in a C1 Strain by Danisco or an Affiliate of Danisco, Danisco shall, at the end of each calendar quarter commencing on the first commercial sale of such Pharmaceutical Product and until </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#32;after the first commercial sale of such Pharmaceutical Product, pay to Dyadic the royalty provided for in the table below.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to any Pharmaceutical Product produced in a C1 Strain by Danisco or an Affiliate of Danisco, Danisco shall at the end of each calendar quarter commencing on the </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#32;anniversary of the first commercial sale of such </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pharmaceutical Product and until </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#32;after the first commercial sale of such Pharmaceutical Product, pay to Dyadic the royalty provided for in the table below provided that, and only as long as, (i) Dyadic owns at least one non-expired valid patent claiming the production, use or sale of such Pharmaceutical Product by Danisco, or (ii) Danisco is practicing under a non-expired Dyadic Patent to produce, use or sell such Pharmaceutical Product.</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Danisco agrees that where the production or sale of a Pharmaceutical Product or Dosage Form that is produced in a C1 Strain or Danisco Improved Strain, and where such production or sale is covered by a valid claim of a Patent owned by a Sublicensee of Dyadic pursuant to the terms of this Agreement, whether such Patent is subsequently assigned to Danisco or Dyadic, the applicable royalty rate will be increased by </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">. Thus, as an illustrative example, the applicable rate for the use of such C1 Strain or Danisco Improved Strain with respect to arm&#8217;s length sales of a Dosage Form where Danisco is the selling party of such Dosage Form and a C1 Strain or Danisco Improved Strain covered by a valid claim of a Patent owned by a Sublicensee of Dyadic is used to produce a composition of matter that is not an active ingredient but that is used to create an active ingredient included in a Dosage Form would be </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#32;and not </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Such royalty shall be payable to Dyadic within thirty (30) Business Days from the end of each calendar quarter by Danisco and a report regarding Net Sales shall be provided to Dyadic. Danisco, no more than once every twelve (12) months, shall permit an audit of their books and records by a national accounting firm designated by Dyadic. Such accounting firm shall confirm the accuracy of any royalty calculation and shall not disclose to Dyadic any other information of other than the correct calculation of Net Sales and the amount of the royalty payable to Dyadic. In the event that such audit reveals an underpayment of any royalty of more than one percent (1%), Danisco shall reimburse Dyadic for the cost of such audit.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 4 DISCLOSURE OF INVENTIONS AND RESULTS; PROSECUTION, MAINTENANCE AND ENFORCEMENT OF PATENTS</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1&#160;&#160;&#160;&#160;Disclosure Obligations</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">During the period for which Services are being provided by Danisco to Dyadic, Danisco shall provide to Dyadic pursuant to the terms of the licenses set forth in Article 2 the deliverables specified under the Work Plan, any Dyadic Material, Danisco Improved Strain, and Danisco Know-How, in each case which is developed by the Designated Employees in the course of providing Services during the Services period and that has utility in the Pharmaceutical Field. Notwithstanding the foregoing, nothing shall require Danisco to disclose information which is subject to confidentiality obligations to Third Parties or disclose Danisco Background Technology, except where such disclosure of Danisco Background Technology is necessary to grow the C1 Strain or Danisco Improved </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Strain to express the Pharmaceutical Product with respect to which such C1 Strain and/or Danisco Improved strain has been transformed or transfected.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">After the sooner of three (3) years from the Effective Date or, in the event Dyadic terminates Services, the date of such termination, except for Dyadic&#8217;s and, as applicable, its Sublicensee&#8217;s obligations relating to inventions relating to the Industrial C1 Strains or Industrial C1 Patents, neither Party nor any Licensed Party shall be obligated to disclose any invention, Improvement, Pharmaceutical Improvement, or Know-How to the other Party or any Licensed Party.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.2 Prosecution and Enforcement of Patents</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Danisco shall have the exclusive right to control, at its sole expense, the filing, registration, prosecution, maintenance, enforcement and defense (such as responding to oppositions, nullity actions, re-examinations, revocation actions and similar proceedings) including the right to refrain from filing or maintaining, any Patents or patent applications, covering an invention where ownership is allocated to Danisco or such Patents are otherwise Controlled by Danisco. Notwithstanding the foregoing in the case of substantiated allegations of infringement activity in the Pharmaceutical Field under any Patents owned or Controlled by Danisco pursuant to this Agreement or the Asset Purchase Agreement, Dyadic, shall have the first option to enforce and to control any such action for infringement claim asserted by Dyadic. Danisco shall have the option to join in asserting a claim for infringement and participate in any settlement discussions and shall have a share in the recovery of any damages or settlement terms, after appropriate compensation to Dyadic and, if applicable, Danisco for expenses incurred including, without limitation, attorney&#8217;s fees, in proportion to the damages established by each Party. Without limiting the foregoing, Dyadic&#8217;s enforcement rights shall include the right to cause Danisco to execute such documents, including joining litigation as a party, as may be required to permit Dyadic to enforce any applicable Patents against any infringers, but solely with respect to the Pharmaceutical Field. No settlement agreement may without Danisco&#8217;s written consent limit Danisco&#8217;s rights with respect to C1 Strains, Dyadic Materials, or Dyadic Know-How or Danisco&#8217;s rights under this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Each Licensed Party shall have the exclusive right to control, at its sole expense, the filing, registration, prosecution, maintenance, enforcement and defense (such as responding to oppositions, nullity actions, re-examinations, revocation actions and similar proceedings) including the right to refrain from filing or maintaining, any Patents or patent applications, covering an invention where ownership is allocated to the Licensed Party.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;If a Party decides to decline to control the filing, registration, prosecution or maintenance of any Patents or patent applications it owns or Controls pursuant to Section 2.3 of this Agreement (the &#8220;Declining Party&#8221;), the Declining Party will immediately notify the other Party of such decision in writing, in order to give the other Party (the &#8220;Acting Party&#8221;) the opportunity, at its sole discretion, to assume responsibility for the filing, registration, prosecution or maintenance of such Patents or patent applications before such Patents or patent applications are potentially negatively impacted by the Declining Party&#8217;s </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">decision, including without limitation the Acting Party being barred from acting by virtue of the lapse of any official Patent Registry deadlines. If the Acting Party provides the Declining Party with written notice of its decision to assume responsibility for the filing, registration, prosecution or maintenance of these Patents or patent applications no later than thirty (30) days after receipt of the Declining Party&#8217;s notice, then Declining Party promptly will assign all right, title and interest the Declining Party has in such Patents or patent applications to the Acting Party, and the Acting hereby grants to the Declining Party an irrevocable non-assert to the Declining Party and the Declining Party&#8217;s Affiliates and Customers under such assigned Patent or patent applications provided that such non-assert as it applies to Dyadic shall be limited to the scope of rights granted to Dyadic in Section 2.1.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;Within thirty (30) days of the execution of this Agreement, the Parties will establish a patent committee to review ownership allocations in accordance with Section 2.3 of this Agreement as well as receive updates on the filing, prosecution and maintenance of Patents that are subject to this Agreement. Such patent committee shall meet on a regular basis when determined by such committee. The patent committee shall be comprised of one (1) representative of each Party and include representation of the Party&#8217;s patent groups. The Parties agree that, to the extent possible and to the extent consistent with either Party&#8217;s internal patent strategy, any Patents containing inventions specifically related to the Pharmaceutical Field will be filed as independent Patents from inventions relating within and without the Pharmaceutical Field. The Parties also agree that prior to imitating any interferences relating to Patents within the Pharmaceutical Field, the matter will be reviewed in the first instance by the patent committee who shall attempt to resolve any matters in good faith. The Parties also agree that disputes relating to the characterization of inventions arising under this Agreement will first be presented to the patent committee, where the Parties will discuss in good faith how to characterize the invention. If the Parties are unable to reach a conclusion, the patent committee shall have the authority to decide the matter, subject to the dispute resolution procedures provided for in Section 10.7.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 5 CONFIDENTIALITY</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1 Confidentiality Obligations. Each Party agrees that for seven (7) years after the termination or expiration of this Agreement, all Danisco Confidential Information and all Dyadic Confidential Information disclosed under this Agreement shall be maintained in strict confidence by the receiving Party, and shall not be used by the receiving Party for any purpose other than the purposes expressly permitted by this Agreement, and shall not be disclosed by the receiving Party to any Third Party except to Sublicensees and to permitted Third Parties such as contract research and/or manufacturing entities which have agreed in writing to obligations of confidentiality and non-use consistent with the obligations of the Parties under this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2 Permitted Usage. Each of Danisco and any Licensed Party may use and disclose Confidential Information of the other Party as follows: (a) under appropriate confidentiality provisions no less restrictive than those in this Agreement, in connection with the performance of its obligations or exercise of rights granted to such Party in this </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Agreement, including, without limitation Sublicensee and Third Party acting as contract researchers; (b) in connection with the filing for, prosecution, maintenance and enforcement of Patents where ownership of the invention to which such Patent relates is assigned to such Licensed Party in accordance with this Agreement; (c) in connection with prosecuting or defending litigation, complying with applicable governmental regulations, filing for, obtaining and maintaining regulatory approvals, or as otherwise required by Law or as permitted by this Agreement; (d) in communication with potential or actual Sublicensees who prior to such disclosure have agreed in writing to be bound by obligations of confidentiality and non-use no less restrictive than the obligations set forth in this Article 5; (e) in confidence to potential or actual investment bankers, advisors (including without limitation financial advisors and accountants), investors, lenders, acquirers, merger partners, or other potential financial or strategic partners, and their attorneys and agents) on a need to know basis who, prior to such disclosure, have agreed in writing to be bound by obligations of confidentiality and non-use no less restrictive than the obligations set forth in this Article 5; </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:12pt;">, that the receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Section 5.2 to treat such Confidential Information as required under this Article 5; (f) to the extent mutually agreed to by the Parties in writing, or (g) under appropriate confidentiality provisions no less restrictive than those in this Agreement, in connection with, and solely to the extent necessary for, Danisco&#8217;s performance of its obligations to any Third Party under any Transferred Contract. For clarity, nothing in this Section 5.2 expands the permitted use or disclosure of any C1 Strain, Dyadic Materials, Danisco Improved Strain, Genetic Tools, Dyadic Know-How, Danisco Know-How, Dyadic Patents or Danisco Patents beyond the rights expressly licensed under Article 2.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3 Confidential Terms. Except as provided herein, each of the Parties agrees not to disclose to any Third Party the terms and conditions of this Agreement without the prior approval of the other Party. Notwithstanding the foregoing, a Party may disclose the terms of this Agreement in confidence to its Affiliates in connection with the performance of this Agreement and solely on a need-to-know basis; to potential or actual Sublicensees, who prior to disclosure must agree to be bound by obligations of confidentiality and non-use no less restrictive than the obligations set forth herein; or in confidence to potential or actual investment bankers, advisors (including without limitation financial advisors and accountants), investors, lenders, acquirers, merger partners, or other potential financial or strategic partners, and their attorneys and agents) on a need to know basis who, prior to such disclosure, have agreed in writing to be bound by obligations of confidentiality and non-use no less restrictive than the obligations set forth in this Article 5; provided, however, that the receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Section 5.3 to treat such Confidential Information as required under this Article 5. In addition, a Party may disclose the existence (but not the terms and conditions) of this Agreement to Third Parties, subject to Section 5.5.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4 Exceptions for Applicable Law or Regulation. Notwithstanding anything to the contrary in this Article 5, a Party may disclose any Confidential Information of the other Party or the terms of this Agreement that is required to be disclosed under Law (including, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">without limitation, the requirements of securities filings); provided that, except where impracticable, such Party shall give the other Party reasonable advance notice of such disclosure requirement (which shall include a copy of any applicable subpoena or order) and shall afford the other Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required disclosure. In the event of any such required disclosure, a Party shall disclose only that portion of the Confidential Information of the other Party that is required by Law to be disclosed and, in the event a protective order is obtained by the other Party, nothing in this Article 5 shall be construed to authorize the Party that is subject to the disclosure requirement to use or disclose any Confidential Information of the other Party to any Person other than as required by Law or beyond the scope of the protective order. A Party may disclose this Agreement if required to be disclosed by Law to the extent, and only to the extent, such Law requires such disclosure and, in such an event, such Party provides the other Party a reasonable opportunity to review and comment on the general text of such disclosure, which comments shall be incorporated by the disclosing Party if reasonable under the circumstances.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5 Public Announcements. Except to the extent required by Law, no Party shall make any public announcement concerning this Agreement or the terms hereof without the prior written consent of the other Party, such consent not to be unreasonably withheld or delayed. Once such consent has been given, the Party as to whom consent has been given shall be free to make public announcements or disclosures substantially similar to that already approved by the other Party. Upon the Effective Date, Dyadic may make a public announcement in a form to be reasonably agreed to by Danisco advising Third Parties that it is licensed to use certain C1 Strains and related technology in the Pharmaceutical Field and, after agreement by the Parties with respect to a detailed Exhibit B, that Danisco is providing certain services for Dyadic. In addition, Dyadic may advise potential Sublicensees of the existence and terms of this Agreement except that the provisions of Article 3 shall not be disclosed to any Third Party. Within sixty (60) days of the Effective Date, the Parties shall negotiate in good faith with respect to those Sections of this Agreement and the rights of the Parties hereunder that may be disclosed without further consent of both Parties. Notwithstanding the foregoing, after notice to the other Party and after appropriate consideration of any objection from such other Party, each Party shall be free to make all such disclosures as may be required by applicable securities or disclosures law.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 6 INDEMNIFICATION</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1 Indemnification of Danisco. The Licensed Parties shall indemnify, defend and hold Danisco and its Affiliates, agents, employees, officers, and directors (the &#8220;Danisco Indemnitees&#8221;) harmless from and against any and all liability, damage, loss, cost, or expense (including without limitation reasonable attorneys&#8217; fees) arising out of claims or suits related to: (a) breach by any Licensed Party of any of its representations, warranties, or covenants under this Agreement; (b) the negligence or willful misconduct of Dyadic or its Affiliates or Sublicensees, and it&#8217;s or their directors, officers, agents, employees, or consultants; (c) any use, exploitation or sublicense by, or under the authority of, Dyadic, any Affiliate of Dyadic or any Sublicensee of the licenses granted under Section 2.1,</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;including, without limitation, any development, manufacture, distribution, offer for sale, sale, export, or transfer of any C1 Strain, Dyadic Material, Danisco Improved Strain or any Pharmaceutical Product or Dosage Form; and (d) any Service provided by Danisco or its Affiliates pursuant to Article 3; provided, however, that Dyadic&#8217;s obligations under Section 6.1(d) will not apply if it has been determined pursuant to Section 10.7 that such liability is due primarily to the willful and knowing misconduct of any of the Danisco Indemnitees.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2 Indemnification of Dyadic. Danisco shall indemnify, defend and hold Dyadic and its Affiliates, agents, employees, officers, and directors (the &#8220;Dyadic Indemnitees&#8221;) harmless from and against any and all liability, damage, loss, cost, or expense (including without limitation reasonable attorneys&#8217; fees) arising out of claims or suits related to intentional misconduct in the performance of the Services (if applicable) which irreversibly injures Dyadic.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2 Procedure. As a condition for either a Danisco Indemnitee or a Dyadic Indemnitee to receive indemnification under this Agreement, it shall: (a) promptly deliver notice in writing (a &#8220;Claim Notice&#8221;) to the Party from whom it seeks an indemnification as soon as it becomes aware of a claim or suit for which indemnification may be sought (provided that the failure to give a Claim Notice promptly shall not prejudice the rights of the applicable Danisco Indemnitee or Dyadic Indemnitee except to the extent that the failure to give prompt notice materially adversely affects the ability of the indemnifying party to defend the claim or suit); (b) cooperate with the indemnifying party in the defense of such claim or suit; and (c) if the indemnifying party confirms in writing to the Danisco Indemnitee or Dyadic Indemnitee its intention to defend such claim or suit within ten (10) days after receipt of the Claim Notice, permit the indemnifying party to control the defense of such claim or suit, including without limitation the right to select defense counsel; provided that, if the indemnifying party fails to (i) provide such confirmation in writing within such ten (10) day period or (ii) after providing such confirmation, diligently and reasonably defend such suit or claim at any time, the indemnifying party&#8217;s right to defend the claim or suit shall terminate immediately and the Danisco Indemnitee or Dyadic Indemnitee may assume the defense of such claim or suit at the sole expense of the indemnifying party but may not settle or compromise such claim or suit without the consent of the indemnifying party, not to be unreasonably withheld or delayed. In no event, however, may the indemnifying party compromise or settle any claim or suit in a manner which admits fault or negligence on the part of any Danisco Indemnitee or Dyadic Indemnitee or that otherwise materially affects such Danisco Indemnitee or Dyadic Indemnitee&#8217;s rights under this Agreement or otherwise, or requires any payment by an Danisco Indemnitee or Dyadic Indemnitee without the prior written consent of such Danisco Indemnitee or Dyadic Indemnitee. Except as expressly provided above, the indemnifying party will have no indemnity liability under this Agreement with respect to claims or suits settled or compromised without its prior written consent.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 7 REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1 General. Each Party represents and warrants to the other that: (a) it is duly organized and validly existing under the Law of the jurisdiction of its incorporation, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; (b) it is qualified to do business and is in good standing in each jurisdiction in which it conducts business; (c) duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action; (d) this Agreement is legally binding upon it and enforceable in accordance with its terms and the execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material Law; and (e) it is not aware of any action, suit or inquiry or investigation instituted by any Person which questions or threatens the validity of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2 Representations and Covenants by Danisco. Danisco represents and warrants that, subject to any deficiencies in title with respect to assets acquired from Dyadic under the Asset Purchase Agreement, it has good legal title to all Dyadic Patents, Danisco Patents, Dyadic Know-How, Danisco Know-How, Dyadic Materials and Danisco Improved Strains that are licensed pursuant to Article 2 and that it is not party to any agreement (other than any Transferred Contract) with any Third Party that is inconsistent with the terms of this Agreement. Except to the extent contemplated by any Transferred Contract, Danisco shall take no action that would permit any Person that is a party to a Transferred Contract to assert any Patent covering an Improvement against any Licensed Party.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3 Representations, Warranties and Covenants By Licensed Parties. Each Licensed Party represents and warrants that: (i) it has the all rights to any Pharmaceutical Product that will be the subject of any Service provided by Danisco pursuant to Article 3; and (ii) it is and will continue to be in compliance with all Laws relating to the research, development, manufacture, commercialization and sale of any Pharmaceutical Product or Dosage Form that is produced pursuant to the license granted in Article 2 or with respect to which Danisco provides Services pursuant to Article 3.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.4 Disclaimer. EXCEPT AS PROVIDED IN THIS ARTICLE 7 (AND WITHOUT LIMITATION TO ARTICLE 3 HEREOF), DANISCO MAKES NO, AND THE LICENSED PARTIES DISCLAIM RELIANCE ON ANY, REPRESENTATION OR WARRANTY (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING WITHOUT LIMITATION WITH RESPECT TO THE SERVICES, ANY DYADIC MATERIALS, DYADIC KNOW-HOW, DANISCO IMPROVED STRAINS AND DANISCO KNOW-HOW LICENSED HEREUNDER OR USED IN PERFORMING SERVICES, OR ANY PHARMACEUTICAL PRODUCT PRODUCED USING ANY SUCH DYADIC MATERIALS, DYADIC KNOW-HOW, DANISCO IMPROVED STRAINS AND DANISCO KNOW-HOW, AND DANISCO SPECIFICALLY DISCLAIMS, AND THE LICENSED PARTIES DISCLAIM RELIANCE ON, ANY AND ALL IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, ALL WARRANTIES THAT THE </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">DYADIC PATENTS OR DANISCO PATENTS ARE VALID AND ENFORCEABLE, AND THAT THE USE OF THE DYADIC MATERIALS, THE DANISCO IMPROVED STRAINS, DYADIC KNOW-HOW, OR DANISCO KNOW-HOW TO PRODUCE PHARMACEUTICAL PRODUCTS DOES NOT INFRINGE THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. DANISCO SPECIFICALLY DISCLAIMS, AND THE LICENSED PARTIES DISCLAIM RELIANCE ON, ANY REPRESENTATION OR WARRANTY THAT THE STRAINS LICENSED UNDER THIS AGREEMENT AND ANY DERIVATIVES OR MODIFICATIONS (A) ARE ANYTHING OTHER THAN EXPERIMENTAL IN NATURE, (B) HAVE CHARACTERISTICS THAT ARE ALL KNOWN, AND (C) ARE SUITABLE FOR USE IN PRODUCING ANY PHARMACEUTICAL PRODUCT.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 8 LIMITATION OF LIABILITY</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1 EXCEPT WITH RESPECT TO THE WRONGFUL DISCLOSURE OR USE OF C1 STRAINS BY DANISCO OR A LICENSED PARTY, OR THE FAILURE OF DANISCO OR A LICENSED PARTY TO MAKE PAYMENTS PROVIDED FOR BY THIS AGREEMENT, OR THE BREACH OF ARTICLES 2 THROUGH 7 OF AGREEMENT BY A LICENSED PARTY, NEITHER DANISCO NOR ANY LICENSED PARTY NOR ANY OF THEIR RESPECTIVE AFFILIATES WILL BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF THE PERFORMANCE OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT, EXCEPT TO THE EXTENT SUCH DAMAGES ARE PAYABLE IN CONNECTION WITH A THIRD PARTY CLAIM. DANISCO&#8217;S MAXIMUM LIABILITY TO DYADIC AND DYADIC LICENSEES UNDER THIS AGREEMENT PURSUANT TO SECTION 6.2 SHALL BE THE AMOUNT PAID TO DANISCO FOR THE SERVICES WHICH RELATE TO THE CLAIM. NEITHER PARTY SHALL HAVE ANY LIABILITY TO THE OTHER PARTY FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING FROM, IN THE CASE OF DYADIC, ANY USE OF RESTRICTED MATERIALS BY ANY THIRD PARTY OR SUBLICENSEE OUTSIDE THE PHARMACEUTICAL FIELD AND, IN THE CASE OF DANISCO, ANY USE OF RESTRICTED MATERIALS BY ANY THIRD PARTY OR LICENSEE OF DANISCO IN THE PHARMACEUTICAL FIELD IN WAYS PROHIBITED BY THIS AGREEMENT UNLESS DYADIC OR DANISCO EXPRESSLY AND KNOWINGLY GRANTED A LICENSE PERMITTING SUCH IMPROPER USE.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE 9 TERM AND TERMINATION</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1 Term. Subject to Section 9.2, the term of this Agreement shall commence on the Effective Date and continue in full force and effect so long as any Licensed Party is using any C1 Strain or Danisco Improved Strain, Dyadic Know-How, or Dyadic Materials, or is practicing under any Patents licensed hereunder, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">however</font><font style="font-family:inherit;font-size:12pt;">, that any inactivity by </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dyadic with respect to the Pharmaceutical Field for less than one (1) year shall not be deemed a basis for expiration of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2 Termination and Patent Challenges</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Termination For Breach. Notwithstanding anything herein to the contrary, if any Licensed Party shall at any time breach any material term or condition of its Sublicense Agreement, Dyadic shall advise Danisco in writing of such breach and provide Danisco with all facts known to Dyadic relating to such breach. Dyadic shall use reasonable efforts to remedy or cause its Sublicensee to remedy such breach. In addition, Danisco may commence a dispute against any Licensed Party pursuant to Section 10.7 to recover damages from and obtain injunctive or any other form of equitable relief against the Licensed Party which has breached its obligations. If the breaching Licensed Party shall fail to have cured such breach within sixty (60) days after it has been determined pursuant to Section 10.7 that such Licensed Party is in default, then Danisco may, at its option, and without liability to Dyadic or such Licensed Party terminate and revoke the sublicense running to the applicable Dyadic Sublicensee or if Dyadic is the breaching Party terminate the license grants running to Dyadic in Section 2.1. Any such termination of the license grants running to Dyadic shall not affect the rights of any Dyadic Sublicensee under a Sublicense granted prior to the effective date of such termination.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Dyadic Remedies. In the event that Dyadic provides written notice to Danisco of the breach of its obligations under any section of this Agreement and Danisco does not cure such breach within sixty (60) days after receipt of such written notice, then Dyadic shall be free to initiate arbitration with respect to such allegations of breach. Such arbitration shall be conducted in an expedited manner, but in no case shall the matter not be decided in less than one year without Dyadic&#8217;s consent. If Danisco by the end of such arbitration has not cured such breach and the arbitrators find such a breach exists, the arbitrators shall award equitable relief directing Danisco to discontinue conduct found to violate this Agreement and award such other relief as may be appropriate.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;Patent Challenge. To the extent permitted by Law, in the event that a Party or a Licensed Party wishes to challenge the validity of any Patent subject to this Agreement, other than a Pharmaceutical Patent, such Party or Licensed Party shall first provide sixty (60) days prior written notice of such intent and if such patent challenge is unsuccessful in whole or in part reimburse the other Party&#8217;s or Licensed Party&#8217;s reasonable attorney&#8217;s fees and costs incurred in defending the validity of the Patent in question.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;Danisco Remedies. Danisco may, by delivering written notice to Dyadic, terminate this Agreement immediately and without liability to any Licensed Party, in the event that any court or arbitrator of competent jurisdiction shall determine that Danisco does not have the right to license any C1 Strain, improved C1 Strain, Dyadic Know-How, Dyadic Material, Danisco Know-How, Danisco Improved Strain, Genetic Tool, Dyadic Patent or Danisco Patent for use in the Pharmaceutical Field.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3 Effect of Termination</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Rights and Obligations Upon Termination by Danisco for Breach. As of the effective date of a termination of any license to a Licensed Party pursuant to Section 9.2(a): (i) Section 2.1 shall terminate with respect to the rights granted to the Licensed Party which has breached and all rights in any Dyadic Material, Danisco Improved Strain or any derivative or modification thereof, Dyadic Know-How and Danisco Know-How licensed to the Licensed Party which has breached shall terminate and revert to Danisco; (ii) Dyadic, in the case of a termination of Dyadic&#8217;s rights, shall return to Danisco, and the applicable Sublicensee, in the case of a termination of such Sublicensee&#8217;s rights, shall return to Dyadic any Dyadic Materials or Danisco Improved Strains and derivatives and modifications thereof, Dyadic Know-How and Danisco Know-How provided to or created by or under the authority of such Party; and (iii) the Licensed Party which has breached shall return to Danisco and cease using all Confidential Information of Danisco including, but not limited to, Dyadic Know-How and Danisco Know-How.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Accrued Rights. Termination or expiration of this Agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration will not relieve a Party from accrued payment obligations or from obligations which are expressly indicated to survive termination or expiration of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4 Survival. Sections 2.1(a)(iii) (insofar as it relates to the payment of any royalty incurred prior to the expiration or termination of this Agreement), 2.2(a), 2.2(d), 2.3, 2.4, 3.2, 3.4 (insofar as it relates to the payment of any royalty incurred prior to the expiration or termination of this Agreement), 4.2, 9.3, and 9.4, and Articles 5, 6, 7, 8 and 10, together with any other provisions necessary to give effect thereto, shall survive any expiration or termination of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Article 10 GENERAL PROVISIONS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.1 Entire Agreement of the Parties; Amendments. This Agreement constitutes and contains the entire understanding and agreement of the Parties respecting the subject matter hereof and cancels and supersedes any and all prior and contemporaneous negotiations, correspondence, understandings, and agreements between the Parties, whether oral or written, regarding such subject matter. No waiver, modification, amendment or alteration of any provision of this Agreement will be valid or effective unless made in writing and signed by each of the Parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.2 Further Actions. Each Party agrees to execute, acknowledge, and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the express provisions of this Agreement.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.3 Assignments. Neither this Agreement nor any interest hereunder may be assigned, nor any other obligation delegated, by a Party without the prior written consent of the other Party; provided, however, that a Party shall have the right to assign this Agreement without consent of the other Party to an Affiliate of the assigning Party provided or to any successor in interest to the assigning Party by operation of law, merger, consolidation, or other business reorganization or the sale of all or substantially all of its assets relating to the subject matter of this Agreement. This Agreement shall be binding upon successors and permitted assigns of the Parties. Any assignment not in accordance with this Section 10.3 will be null and void. Notwithstanding any assignment or transfer by operation of law, merger, consolidation or otherwise, the assigning Party shall remain primarily liable for any breaches of the assignee under this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.4 Performance by Affiliates. The Parties recognize that each may perform some or all of its obligations under this Agreement through wholly owned Affiliates or may exercise some or all of its rights under this Agreement through wholly owned Affiliates, provided, however, that each Party shall remain responsible and be guarantor of the performance by such Affiliates and shall cause such Affiliates to comply with the provisions of this Agreement in connection with such performance. In particular and without limitation, (i) all Affiliates of a Party that receive Confidential Information of the other Party pursuant to this Agreement shall be governed and bound by all obligations set forth in Article 5, and (ii) all Affiliates of, as applicable, Dyadic or Danisco, that have access to C1 Strains, Danisco Improved Strains, Improvements, Pharmaceutical Improvements, Dyadic Materials, Genetic Tools or Know-How relating thereto shall be governed and bound by all obligations set forth in this Agreement. Each Party will prohibit all of its Affiliates from taking any action that such Party is prohibited from taking under this Agreement as if such Affiliates were parties to this Agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.5 Relationship of the Parties. The Parties shall perform their obligations under this Agreement as independent contractors and nothing in this Agreement is intended or will be deemed to constitute a partnership, agency or employer-employee relationship between the Parties. Neither Party will have any right, power or authority to assume, create, or incur any expense, liability, or obligation, express or implied, on behalf of the other.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.6 Notices. Any notice, request, delivery, approval or consent required or permitted to be given under this Agreement will be in writing and will be deemed to have been sufficiently given if delivered in person, transmitted by facsimile (receipt verified) or by express courier service (signature required) or five (5) days after it was sent by registered letter, return receipt requested (or its equivalent) to the Party to which it is directed at its address or facsimile number shown below or such other address or facsimile number as such Party will have last given by notice to the other Party.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If to Danisco:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Danisco US Inc.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c/o President &#8211; DuPont Industrial Biosciences</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Building 356</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Danisco Experimental Station</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Wilmington, DE 19880</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With a copy to: E. I. du Pont de Nemours and Company</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: Legal Department &#8211; General Counsel</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Fax: 302-773-4679</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If to Dyadic: Dyadic International, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">140 Intracoastal Pointe Drive, Suite 404</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Jupiter, FL 33477-5094</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: Mark A. Emalfarb</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Fax: (561) 743-8343</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With a copy to:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cahill Gordon &amp; Rekindle LLP</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">80 Pine Street</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">New York, New York 10005</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: Michael B. Weiss</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">mweiss@cahill.com</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.7 Governing Law; Dispute Resolution.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The rights and obligations of the Licensed Parties under this Agreement shall be governed, and shall be interpreted, construed, and enforced, in all respects by the Law of the State of Delaware without giving effect to any conflict of Law rule that would result in the application of the Law of any jurisdiction other than the internal Law of the State of Delaware to the rights and duties of the Parties.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If Danisco and any Licensed Party are unable to resolve any dispute between them arising out of this Agreement, either Danisco or any Licensed Party, by written notice to the other, may have such dispute referred to the President of DuPont Industrial Biosciences and the Chief Executive Officer of Dyadic or any other Licensed Party, for attempted resolution by good faith negotiations within fifteen (15) days after such notice is received.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If Danisco and Dyadic or the relevant other Licensed Party do not agree upon a resolution of the dispute, Danisco and the Licensed Parties agree that any dispute that remains unresolved rising out of or relating to this Agreement, including the breach, termination or validity thereof, shall be finally resolved by arbitration in accordance with the International Institute for Conflict Prevention and Resolution (&#8220;CPR&#8221;) Rules for Administered Arbitration (the &#8220;Administered Rules&#8221; or &#8220;Rules&#8221;) by three arbitrators, of whom each party to the dispute shall designate one, with the third arbitrator to be designated by the two party-appointed arbitrators. The arbitration shall </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">be governed by the Federal Arbitration Act, 9 USC &#167;&#167; 1 et seq., and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof. The place of the arbitration shall be New York, New York and shall be conducted in accordance with the requirements of CPR&#8217;s Appeal Procedure. An appeal may be taken under the CPR Arbitration Appeal Procedure from any final award of an arbitral panel in any arbitration arising out of or related to this agreement that is conducted in accordance with the requirements of such Appeal Procedure. Unless otherwise agreed by the parties and the appeal tribunal, the appeal shall be conducted at the place of the original arbitration.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Danisco and the Licensed Parties agree that money damages alone will be inadequate to compensate for any breach of this Agreement and that injunctive relief will be awarded to the extent necessary to restrain any Licensed Party from using any Dyadic Material, Danisco Improved Strain, Dyadic Know-How, Danisco Know-How, Danisco Background Technology, Danisco Background Tool, or Services Generated Tool outside of the Pharmaceutical Field or to restrain Danisco from violating the provisions of Section 3.3.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.8 Rights in Bankruptcy. The Parties acknowledge and agree that this Agreement constitutes a license of rights to &#8220;intellectual property&#8221; as that term is defined in Section 101(35A) of Title 11, United States Code (the &#8220;Bankruptcy Code&#8221;) and is therefore governed by Section 365(n) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. Notwithstanding anything to the contrary, if a Chapter 11 petition is filed by or against Dyadic, Dyadic shall seek approval of the bankruptcy court to assume this Agreement pursuant to 11 U.S.C. &#167; 363.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.9 Captions. The captions to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.10 Waiver. A waiver by a Party of any of the terms and conditions of this Agreement in any instance will not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach hereof. All rights, remedies, undertakings, obligations, and agreements contained in this Agreement will be cumulative and none of them will be in limitation of any other remedy, right, undertaking, obligation, or agreement of either Party.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.11 Severability. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under Law, but, if any provision of this Agreement is held to be prohibited by or invalid under Law, such provision will be ineffective but only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or of this Agreement. The Parties will make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.12 Force Majeure. No liability shall result from a force majeure event or any delay in performance or nonperformance, directly or indirectly caused by circumstances beyond the control of the Party affected, including, but not limited to, act of God, fire, explosion, flood, war, utility failure, order of any court, act or inaction of or by any local or national government or agency, accident, labor strike, pandemic, death, termination or resignation of key employees, inability to obtain material, failure of equipment transportation, or failure of usual transportation mode.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.13 Counterparts. This Agreement may be executed simultaneously in counterparts, any one of which need not contain the signature of more than one Person but all such counterparts taken together will constitute one and the same agreement.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.14 Rules of Construction</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">When a reference is made in this Agreement to an Article, a Section, an Exhibit or a Schedule, such reference shall be to an Article of, a Section of, or an Exhibit or a Schedule to this Agreement unless otherwise indicated.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation.&#8221;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:-36px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:36px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Parties hereto have participated jointly in the negotiation and drafting of this Agreement with the assistance of counsel and other advisors and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the parties hereto and thereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.</font></div></td></tr></table><div><a name="s7F69AF12950E40A9DBF090D77F7E7FB9"></a></div><div style="line-height:127%;padding-top:5px;text-align:left;padding-left:8px;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">IN WITNESS WHEREOF,  the Parties have executed this Agreement  in  duplicate originals by their duly authorized representatives as of the Effective Date.</font></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:right;padding-left:0px;text-indent:0px;font-size:11.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="6"></td></tr><tr><td style="width:9%;"></td><td style="width:37%;"></td><td style="width:4%;"></td><td style="width:9%;"></td><td style="width:37%;"></td><td style="width:4%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Danisco USA Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Dyadic International, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ [*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President &amp; CEO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><a name="sAE87B00844012BA9840E90D77F9A092D"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXHIBIT A </font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">DYADIC MATERIALS</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:140%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><a name="s07E68B8BC5C0949A0E5490D7803F8D8E"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXHIBIT B</font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SERVICES</font></div><div style="line-height:130%;padding-top:1px;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>18
<FILENAME>exhibit1013form10.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB538CD8BD16439E8E82A5CD910C810FB"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.13</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Execution Version</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*] indicates that a confidential portion of the text of this agreement has been omitted. The non-public</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">information has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">COMMISSION CONTRACT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">PARTIES</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">VTT Technical Research Centre of Finland Ltd.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Business ID: 2647375-4</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Country of residence: Finland</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(hereinafter "VTT")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">and</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic International, USA, Inc. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Business ID: 45-0486747</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Country of residence: United States</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(hereinafter the "Dyadic")</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">OBJECT OF THE CONTRACT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The object of the Contract is a commission where VTT develops Dyadic's C1 fungal expression system for therapeutic protein production (hereinafter the Commission), as specified in the project plan in </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Annex 1.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Commission is divided into milestones, as specified in the project plan (</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Annex 1</font><font style="font-family:Arial;font-size:9pt;">). The purpose of</font><font style="font-family:Arial;font-size:9pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:9pt;">the milestones are to monitor and measure the progress of the Commission.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">After each milestone and at the end of each Work Package (WP1, WP2 and WP3) of the Commission, VTT will deliver to Dyadic the relevant Foreground (e.g. Development strains and associated molecular tools).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">1.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Commission includes bonus targets, as specified in the project plan (Annex 1). Accomplishment of a bonus target in certain time limit triggers a bonus payment to VTT. Bonus targets, time limits and bonus sums are defined in the project plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">1.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">DEFINITIONS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">1.5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Development Strains: All strains developed as part of the Foreground in the Commission.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">1.5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreground Materials: lab data, reports, all physical and genetic materials, including, but not limited to the Development Strains and associated molecular tools, DNA fragments, vectors, markers, promoters, other genetic elements, fermentation media and processes and proteins included in the Foreground.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">1.5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">C1 Strains: any fungal strains that have the taxonomy of either (a) </font><font style="font-family:Arial;font-size:9pt;font-style:italic;">Myceliopthora, </font><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">VTT'S GENERAL TERMS OF CONTRACT</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">VTT's General Terms of Contract, as specified in </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Annex 2</font><font style="font-family:Arial;font-size:9pt;">&#32;are applicable to this Contract to the extent not otherwise stated in this Contract. However, if there are any conflicts, the terms and conditions of this Contract will supersede the terms and conditions in Annex 2.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">BACKGROUND</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic will provide VTT with certain materials and proprietary information as set forth in the Material Transfer Agreement between the Parties dated 10.5.2016 (Annex 3). These materials, and proprietary information which are necessary for the execution of the Commission by VTT</font><font style="font-family:Arial;font-size:9pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:9pt;">is specified in </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Annex 1.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">PROJECT STARTING DATE</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The starting date of the project 15.9.2016</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">MODIFICATION OF THE COMMISSION</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">As it might be necessary to modify the Commission after signing this Contract, its technical description as set out in the Project Plan (Annex 1) and Evaluation Protocol (Annex 5) may be modified by mutual written agreement of the Parties. Such modifications and specifications shall be deemed to be incorporated into this Contract</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">PROJECT MANAGEMENT AND CO-OPERATIVE ORGANISATION</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">6.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Project Managers - VTT and Dyadic will nominate two project managers one on behalf of each party. The project managers will be: Dyadic representative is [*] VTT representative is [*]. The nominated project managers may be modified by mutual written agreement of the Parties. Such modifications and specifications shall be deemed to be incorporated into this Contract.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The project managers will be responsible for managing, monitoring and reporting on the progress and status of the Commission including the exchange the development information, notifications to the Technical Group of any delay or problem that might affect the deliveries of the Commission.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><font style="font-family:Arial;font-size:9pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The project Managers will communicate by weekly telephone calls or more often if needed.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">6.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Technical Group - The Technical Group shall review and direct the development work within the limits of the Contract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><font style="font-family:Arial;font-size:9pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The members of the Technical Group shall be: the Project Managers, Dyadic representatives [*], VTT representatives: [*]. The nominated members of the Technical Group may be modified by mutual written agreement of the Parties. Such modifications and specifications shall be deemed to be incorporated into this Contract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><font style="font-family:Arial;font-size:9pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Technical Group shall review and manage the scientific and technical progress of the Commission</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><font style="font-family:Arial;font-size:9pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Technical Group will review the objectives of the Commission and will notify The Governing Group of any revisions of the project plans that might be needed according of the progress status.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><font style="font-family:Arial;font-size:9pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Technical Group will be responsible for the revisions of and modifications in the Project plan, and present them, when necessary, to the Governing Group for approval,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><font style="font-family:Arial;font-size:9pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The technical Group shall meet every month by face to face meetings, by teleconferences or as otherwise agreed by the parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">6.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Governing Group - The Governing Group shall direct the execution of the project within the limits of the Contract. The members of the Governing Group shall be: Dyadic representatives, [*]</font><font style="font-family:Arial;font-size:9pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:9pt;">and VTT representatives, [*].</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The governing group shall handle matters concerning the Commission and particularly control and direct the execution of the Commission within the limits of the Contract. Therefore the governing group:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:72px;"><font style="font-family:Arial;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">shall specify the objectives of the Commission and accept the Project plans,</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:72px;"><font style="font-family:Arial;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">handle the revisions of and modifications in the Project plan, and present them, when necessary, to the Parties for acceptance,</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:72px;"><font style="font-family:Arial;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">control the progress of the Commission and support the activities of the Project manager,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:72px;"><font style="font-family:Arial;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">accept the achievement of milestones and bonus targets that have been reported since the last meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">6.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The governing group shall meet every three months or as otherwise agreed to by the parties either in person or by audio or video conference.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">6.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The governing group cannot modify the Contract or its appendices unless separately agreed upon in writing between the Parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Deliveries</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Progress/Interim Deliverables, Final Deliverables/Report(s):</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">7.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">VTT will continuously keep separate laboratory books in which the research and development activities of the Commission is documented.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">7.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Each month VTT will share with The Technical group a Power Point presentation of the status of projects.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">7.1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">By the end of each milestone and bonus target, VTT will prepare a report of the work summary to be provided to the Technical Group for review and for presentation to the Governing group.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Final project deliveries</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">8.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">By the end of each Work Package VTT will prepare a report summarizing the achievement and status of the project which will be provided to the Technical Group for review and presentation to the Governing group.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">8.1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">After the end of each Work Package, upon Dyadic's request, VTT agrees to provide Dyadic with copies of the Foreground Materials in both physical and electronical form. VTT agrees to keep copies of the Foreground Materials and store them in accordance with VTT's normal procedures solely on behalf of and for the exclusive benefit of Dyadic for a period of five years after the Commission has ended and VTT will provide Dyadic access to, and copies of the Foreground Materials if requested by Dyadic. VTT further agrees to physically destroy any copies of the Foreground Materials at any time within that five year period if such instructions are given to VTT in writing by Dyadic</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">THE OBLIGATIONS OF DYADIC</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">9.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic commits to deliver the items needed for the execution of the work (as specified in the project plan) before the start date of the Commission.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">SUBCONTRACT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">10.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">It is expected that Dyadic shall use subcontractors as needed (hereinafter Subcontractors), to carry out glycosylation analytical services required in order to perform the Commission. Costs for such services are paid separately outside of the Commission budget by Dyadic. It shall be the obligation of Dyadic to enter into a subcontract with the Subcontractor(s) and to oblige the Subcontractor to perform its services with sufficient care and diligence and to provide results with sufficient quality and in a way that enables VTT to perform the Commission. All glycosylation Subcontractors will be approved by the Technical Group, who shall also determine the required quality specifications for the services of the Subcontractor(s).</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">11</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">SCHEDULE</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">11.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Commission shall be carried out between 15.9.2016 and 15.3.2019. The specified schedule is in </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Annex 1</font><font style="font-family:Arial;font-size:9pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">11.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">VTT shall have the right to postpone the schedule of the Commission corresponding the delay if the delivery of any material or data by Dyadic or Subcontractor is delayed, or if the Subcontractor's work does not fulfil the agreed quality specifications, or in the cases mentioned in Section 8.1 of the VTT General Terms and Conditions.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">12</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">ACCEPTANCE AND GO </font><font style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">I </font><font style="font-family:Arial;font-size:9pt;font-weight:bold;">NO GO DECISION</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">12.1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The acceptance of the Development Strains, milestones and the bonus targets will be based on the evaluation process that will be performed according to the Evaluation Protocols as set forth in Annex 5, in each of the Work Packages (WP1, WP2 and WP3).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">12.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Commission shall be deemed to have been accepted 30 days after the delivery by VTT of the final report to Dyadic.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">12.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic retains the right to stop the Commission after one year from the start of the Commission. However, Dyadic will be required to provide VTT 90 days' notice to stop the Commission, and the notice must be given at the earliest one week prior to the one year anniversary of the Contract. If the notice is given, VTT will continue the ongoing experiments and wind down its activities during the 90 days period. In case Dyadic decides to stop the Commission, Dyadic shall be liable to pay VTT for the work performed until the end of the 90 days period and any confirmed bonus targets accomplished through the date of notification to stop the Commission.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">13</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">PAYMENTS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">13.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Unless as otherwise permitted in Paragraphs 12.3 above and 17 below Dyadic shall pay VTT for the Commission, Work Packages 1 and 3 (as specified in Annex 1) a total sum of [*] euros. The payment is invoiced monthly, in the beginning of the month, in 30 equal instalments of [*] euros.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">13.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic shall pay VTT for the Commission, Work Package 2 (as specified in Annex 1) depending on the number of target proteins: [*] &#8364; for one target protein, [*] &#8364; for two target proteins, [*] &#8364; for three target proteins, [*] &#8364; for four target proteins, [*] &#8364; for five target proteins and [*] &#8364; for six target proteins. The payment is invoiced in monthly equal instalments for the duration of WP 2.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">13.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic shall pay VTT for accomplishment of bonus targets, as specified in the project plan (Annex 1 ). Bonus payments shall be invoiced in 30 days from the date of the Governing Group meeting, where the achievement of the bonus targets have been accepted in writing by both VTT and Dyadic.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">13.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The invoicing address of Dyadic is</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic International (USA), Inc.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">140 lntracoastal Pointe Drive, Suite 404</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Jupiter, Florida 33477-5094 USA</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Additionally all invoices are to be emailed to </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">jlatiuk@dyadic.com</font><font style="font-family:Arial;font-size:9pt;">&#32;and cc to </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">tdubinski@dyadic.com</font><font style="font-family:Arial;font-size:9pt;">&#32;and </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">rtchelet@dyadic.com</font><font style="font-family:Arial;font-size:9pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">13.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">In addition. Dyadic undertakes to reimburse VTT for travelling (e.g. to project meetings) expenses at actual costs as defined in the Travelling Compensation Regulations of VTT. All travelling VTT personnel will need to be agreed to and approved by Dyadic in writing in advance.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">13.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The term of payment is 45 days from the date the date of the invoice. The interest on overdue payments shall be charged according to the Finnish Interest Act (20.8.1982/633). Possible debt collection charges shall be added, when applicable. Value added tax (VAT) and any other taxes and fees imposed by authorities outside of Finland shall be added, when applicable, to the price agreed upon in the Contract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">14</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">CONFIDENTIALITY AND RIGHT TO PUBLISH FOREGROUND</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">14.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-disclosure agreement between the parties is as </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Annex 4</font><font style="font-family:Arial;font-size:9pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">14.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">VTT is entitled to publish information concerning the Commission and its Foreground as follows. In scientific publications and conference presentations solely with a written separate approval by Dyadic's CEO, which may be withheld by Dyadic in its sole discretion.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">14.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">In case Dyadic is publishing the Foreground, VTT contribution and people involved should be mentioned in appropriate manner.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">14.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">All use of VTT's and/or Dyadic's name and logotype for advertising and other sales promotion purposes (including press releases) is subject to prior written consent of VTT and Dyadic.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">15</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">OWNERSHIP AND USER RIGHTS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">15.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">All Dyadic's Background (including genetic materials, molecular tools, data and proprietary information) provided to VTT will be owned solely by Dyadic and VTT will only be granted a research license to utilize such materials, information and Background within the Dyadic funded projects and work being done for or on Dyadic's behalf. For the avoidance of doubt, all improvements, including any inventions, discoveries and all intellectual property relating there to. other than those improvement specificaly covered by Section 15.2, that arise out of the Commission or relate to the Dyadic Background shall be solely owned by Dyadic.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">15.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Foreground Materials of the Commission (including possible intellectual property rights) shall be the sole property of Dyadic. However, all improvements (including possible intellectual property rights) to VTT Synthetic Promoter Technology, even if included in the Foreground, shall be the property of VTT.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">15.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic and its licensees and their sub-licensees will have the rights to use, royalty free any and all Foreground Materials worldwide, including any and all Development Strains developed using VTT's Synthetic Promoter Technology if a separate license agreement has been concluded and signed between VTT and Dyadic on VTT's Synthetic Promoter technology. VTT will not incorporate the use of synthetic promoters in the Commission unless VTT and Dyadic have executed such license agreement and have entered into such license.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">15 4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">VTT agrees it will not work on</font><font style="font-family:Arial;font-size:9pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:9pt;">C1 Strains for anyone other than Dyadic on pharmaceutical applications and/or processes (animal or human. including but not limited to active pharmaceutical ingredients or catalysts) during the Commission or for a period of three years afterwards, unless so authorized in writing by the CEO of Dyadic. Dyadic will have a first right of refusal if VTT is presenting new ideas related to C1 Strains for pharmaceutical applications and/or processes during the Commission.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">15.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Upon Dyadic's CEO's consent by written notice, VTT shall have the right to use the Foreground in its internal, non-commercial R&amp;D in the pharmaceutical field. However, this consent can be withheld, or withdrawn at any time at Dyadic's sole option. VTT also agrees that it will not file any patent(s) or make any disclosures such as publications or at conferences or otherwise directly to, or in any way relating to Dyadic owned Background or Foreground of the Commission without Dyadic's CEO's written permission.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">15.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Value Added Tax and any other taxes, fees or charges imposed by authorities outside Finland shall be added, when applicable, to all payments and fees in accordance with applicable legislation</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">16</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">VTT REPRESENTATIONS &amp; WARRANTIES TO DYADIC</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">16.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">VTT represents that on the Effective Date to its reasonable knowledge, it is not aware of any third party patents or agreements that would prevent VTT from conducting the research under this Contract</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">The Parties agree in good faith to keep each other informed of possible patents or publications that have come to their attention during the Commission and that may, to their</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">reasonable understanding, interfere with or affect the performance of the Commission. In such cases VTT will discuss the strategies that will be taken in the project with Dyadic and these strategies will be decided and approved by Dyadic. However, all Foreground is provided "AS IS" and with the exception of what has been explicitly set forth in this Section 16, VTT makes no representations or warranties of any kind, whether express or implied, with respect to its services, the Foreground or any other materials provided under this Contract, including but not limited to accuracy, completeness, merchantability, fitness for a particular purpose and non-infringement of third party rights such as copyrights, trade secrets or any patent. VTT shall not have any liability whatsoever for the use of the Foreground or any other materials by Dyadic.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">16.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">VTT may, at its sole discretion, during the Commission, reasonably assist Dyadic, at Dyadic's expense in certain legal or other proceedings, relating to scientific evaluations, patent prosecution and potential expert opinions. Such additional work shall be charged separately in accordance with VTT's fees.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">17</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">TERMINATION</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">17.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic has the right to stop the Commission at its sole decision, after one year from the start of the Commission as set forth in Section 12. Otherwise the Commission will continue as planned. For the sake of clarity, Section 13 of VTT's General Terms and Conditions shall also apply.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">18</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">DISPUTES</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">18.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">All disputes arising out of or in connection with this Contract which cannot be solved amicably shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with said Rules. The language of the arbitration shall be English. The arbitration shall be held in Bern, Switzerland. The award of the arbitration will be final and binding upon the Parties. Nothing in this Contract shall limit the Parties' right to seek temporary injunctive relief or to enforce an arbitration award in any applicable competent court of law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">18.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This Contract and all transactions contemplated by this Contract shall be governed by, and construed and enforced in accordance with, the laws of Switzerland (Bern) without regard to principles of conflicts of laws.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">19</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">NOTICES</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">19.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">VTT's contact person in connection with this contract is Jouni Ahtinen</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">19.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic's contact person in connection with this contract is Mark Emalfarb.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Any notice to be given under this contract shall be sent by mail or in electric form to the following address: </font></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">VTT</font></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Address: Tietotie 2, 02044 Espoo, Finland</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">E-mail: </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Jouni.ahtinen@vtt.fi</font></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Dyadic International, USA, Inc.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Address: 140 lntracoastal Pointe Drive, Suite# 404, Jupiter, Florida, 33477 USA</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:60px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">E-mail: </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">memalfarb@dyadic.com</font><font style="font-family:Arial;font-size:9pt;">&#32;Including a copy to: </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">tdubinski@dyadic.com</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">20</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">DURATION OF THE CONTRACT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:Arial;font-size:9pt;">20.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This Contract shall enter into force on the latest date of signature by the Parties ("Effective Date") and shall be in force until the Commission has been carried out, and any extensions thereof, excluding the Articles, the legal effects of which are meant to survive the termination or expiration of the Contract.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="sB87193627B61869D595E5CD91287A479"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.3076923076923%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Place: Espoo, Finland</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Place: Jupiter,  Florida, USA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: Sept 5, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: Sept 2, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">VTT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dyadic International USA, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Jussi Manninen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jussi Manninen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Executive Vice President</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">CEO</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ANNEXES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Annex  1: Project plan</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Annex  2: VTT</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:Arial;font-size:10pt;">General Terms of contract</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Annex  3: Material Transfer Agreement</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Annex 4: NOA executed between the parties</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Annex 5: Evaluation  protocol</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="s0487004198AA07F7A0AB5CD9132EB78E"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:41%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="ex1012vttlogo.jpg" alt="ex1012vttlogo.jpg" style="height:30px;width:85px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Annex 1: Project plan</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">5.9.2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:48px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">VP Research &amp; Business Development</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ronen Tchelet</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dyadic International Inc.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">CONFIDENTIAL</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Therapeutic protein production in Dyadic's C1 fungal expression system</font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dyadic International is developing its fungal C1 </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">(Myceliopthora thermophila) </font><font style="font-family:Arial;font-size:10pt;">expression system to be a platform for therapeutic protein production. This project plan describes three work packages that provide the important first steps to realise this goal. The project comprises general improvement of the C1 system to be more robust, versatile and efficient therapeutic protein production platform, production of 1-3 model antibodies in the system and modification of the C1 glycosylation pathway to allow production of proteins with humanised glycans.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">WP1 - Improving the efficiency and robustness of the C1 production system</font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">WP2 - Production of 1-6 target proteins in C1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This WP description provides two options 1) a 'minimal' project where one to six target proteins (mostly non-glycosylated proteins, antibodies, antibody fragments, and FC-Fusion proteins) are expressed and the productivity is analysed and 2) an 'extended' project where one to six target proteins are expressed, productivity is analysed and the expression strategy is optimised in a second wave of production strains, whose productivity is analysed. One of the target antibodies of the project would come from Dyadic's client and one from Dyadic.</font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Work plan</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">WP3: Glycoengineering of C1</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The aim of WP3 is to modify the C1 glycosylation pathway to produce human glycoforms.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The general goals for the project</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Two major approaches will be used to introduce the first steps of the human-like glycosylation pathway: </font><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">It can be expected that moderate levels of the specific human glycoforms may be reached by the first modification attempts for each step of the pathway. However, it is foreseen that for reaching the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="ex1012vttlogo.jpg" alt="ex1012vttlogo.jpg" style="height:29px;width:82px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;"><font style="font-family:Arial;font-size:10pt;">desired humanisation of glycosylation, optimisation is needed for the steps. This work will include e.g. testing of alternative heterologous glycan modifying enzymes and their localisation signals and varying their expression levels.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The major goals for the first year of this WP are to obtain good levels of the GlcNac2Man5 and G0 glycoforms. The major goals for the rest of the time are to reach high G0 levels and construct the galactosylation and fucosylation pathways into C1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Time line and milestones</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total duration of the project will be 2 years and six months. The timeline of the different tasks are given in the table below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The milestones of the project are the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Resources and costs</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The price for one FTE is </font><font style="font-family:Arial;font-size:9pt;">[*]</font><font style="font-family:Arial;font-size:10pt;">&#32;k&#8364;. This covers all VTT's costs including reagents and consumables. The costs of glycan analytics by an external service provider are not included.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Bonus targets</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dyadic will pay VTT bonus fees based on the success of the project according to the following bonus targets:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT1</font><font style="font-family:Arial;font-size:10pt;">: Production of at least 1 full-length antibody at </font><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT2</font><font style="font-family:Arial;font-size:10pt;">: Production of at least 1 full-length antibody at </font><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT3</font><font style="font-family:Arial;font-size:10pt;">: Production of at least 1 full-length antibody at </font><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT4</font><font style="font-family:Arial;font-size:10pt;">: Production of at least 1 full-length antibody at </font><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT5</font><font style="font-family:Arial;font-size:10pt;">: </font><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT6</font><font style="font-family:Arial;font-size:10pt;">: </font><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT7</font><font style="font-family:Arial;font-size:10pt;">: </font><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT8</font><font style="font-family:Arial;font-size:10pt;">: </font><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The bonus payment sums are given in Euros in Table 1 below.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="ex1012vttlogo.jpg" alt="ex1012vttlogo.jpg" style="height:29px;width:82px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Table</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">1</font><font style="font-family:Arial;font-size:10pt;">&#32;- Milestone bonuses for the best 3 mAbs and glycoengineering work.</font></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:30%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:14%;"></td><td style="width:14%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Year 1</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Year 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Year 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">H1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">H2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">H3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">H4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">H5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BT8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Arial;font-size:10pt;">(*)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The BT1 - BT4 milestones are for each antibody for a maximum of 3 mAbs.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[*]</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">VTT Background includes VTT Synthetic Promoter technology (applied patent FI20165137 EXPRESSION SYSTEM FOR EUKARYOTIC MICROORGANISMS)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="sCA63651569C7EE3D1A1C5CD9147B3895"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="ex1012vttlogo.jpg" alt="ex1012vttlogo.jpg" style="height:30px;width:85px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:49%;'><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT GENERAL TERMS OF CONTRACT 1.4.2016 </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">SCOPE OF APPLICATION</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">These VTT General terms of contract (hereinafter referred to as General Terms) shall be applied as a part of a project agreement (hereinafter referred to as Project agreement) between VTT Technical Research Centre of Finland Ltd (hereinafter referred to as VTT) and the client (hereinafter referred to as Client) with which they (hereinafter VTT and the Client together referred to as Parties, each a Party) agree on work done or service offered by VTT (hereinafter referred to as Project) provided that the contract documentation includes a reference to these General Terms (hereinafter the entire contract documentation is referred to as Contract)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">An offer to which these General Terms are attached shall be valid for one (1) month from the data of the offer</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">1.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Contract or any rights and/or obligations arising therefrom cannot be transferred to a third party unless the other Party has accepted the transfer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">1.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">No modification in or addition to single provisions of the Contract shall be valid unless made in writing and signed by authorized representatives of the Parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">1.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">If the Contract documentation has contradictory contents, the documents shall prevail in the in the following order 1) Project agreement, 2) order confirmation,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;offer,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;order, 5) these General Terms and 6) request for offer Notwithstanding the foregoing if VTT has acquired funding for the Project from any third party, any possible terms imposed by the financer(s) shall prevail</font></div></td></tr></table><div style="line-height:120%;padding-left:36px;text-indent:-36px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">PROJECT GOVERNING GROUP</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Parties shall appoint a responsible contact person for the Project A Party shall be notified of a change of the other Party's responsible contact person.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">If it is mentioned in the Contract that the Project is directed by a governing group (or a similar management body), the Project shall be directed by a governing group with an equal amount of members from both Parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">2.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The governing group shall handle matters concerning the Project and particularly control and direct the execution of the Project within the limits of the Contract Therefore the governing group shall</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:36px;"><font style="font-family:Arial;font-size:8pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">specify the objectives of the Project and accept the Project plans,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:36px;"><font style="font-family:Arial;font-size:8pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">handle the revisions of and modifications in the Project plan and present them, when necessary, to the Parties for acceptance,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:36px;"><font style="font-family:Arial;font-size:8pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">control the progress of the Project and support the activities of the Project manager,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:36px;"><font style="font-family:Arial;font-size:8pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">accept the results of the Project end state when the Project has been finalized.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">2.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The governing group cannot modify the Contract or its appendices unless separately agreed upon in writing between the Parties</font></div></td></tr></table><div style="line-height:120%;padding-left:36px;text-indent:-36px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">PAYMENTS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Payments for the Project shall be agreed upon in the Contract. The price shall be stated in euros</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">3.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Value Added Tax(VAT) and any other taxes and fees imposed by authorities outside of Finland shall be added, when applicable, to the price agreed upon in the Contract.</font></div></td></tr></table></div><div style='width:2%; float:left;'>&#160;</div><div style='float:right; width:49%;'><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">3.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">If the objective or schedule of the Project is modified or if any essential modifications, mutually agreed by the Parties, occur in the cost level during the validity period of the Contract, the payments shall be adjusted accordingly from the data the modifications take place</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">3.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Unless otherwise agreed upon in writing, VTT shall  invoice the agreed price in monthly installments in accordance with the schedule of the Project.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">3.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT shall retain the ownership of the Foreground (as defined in section 5.3) until the Client has fulfilled its obligation for payment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">3.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Invoices shall be paid within twenty-one (21) days of date of the relevant invoice. Interest on overdue payments shall be charged in accordance with the Finnish Interest Act (20 8.1982/633). Possible debt collection charges shall be added to invoices. All remarks to invoices shall be made within eight (8) days of the date of the relevant invoice.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">CONFIDENTIALITY</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Confidential information shall mean all information (including but not limited to any knowledge, know-how, trade secrets, technological and commercial information, device and software (including software code)), whether or not subject to or capable of protection by copyright, patent, trademark or other intellectual property rights which relates to the Project and is disclosed by or on behalf of one Party (hereinafter referred to as Disclosing Party) to the other Party (hereinafter referred to as Receiving Party) In whatever form including but not limited to in writing, orally, electronically or by observation (hereinafter referred to as Confidential lnformation).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Receiving Party shall keep Confidential Information disclosed to it in strict confidence and not disclose it to any third parties without the prior written consent of the Disclosing Party. The Receiving Party shall have the right to use Confidential Information solely for the purposes of carrying out its rights and obligations under the Contract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">4.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Information disclosed shall not be regarded as Confidential Information to the extent that the Receiving Party demonstrates that the Information:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:36px;"><font style="font-family:Arial;font-size:8pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">is or becomes published or otherwise generally available to the public without violation of the Contract, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:36px;"><font style="font-family:Arial;font-size:8pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">is already known to the Receiving Party at the time of disclosure; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:36px;"><font style="font-family:Arial;font-size:8pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Is lawfully obtained by the Receiving Party from a third party without any restrictions on confidentiality: or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:36px;"><font style="font-family:Arial;font-size:8pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">is developed by the Receiving Party without any use of Confidential Information.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">4 4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">If the Receiving Party is required, pursuant to an administrative or a judicial action or subpoena, to disclose the Disclosing Party's Confidential Information, the Receiving Party shall have the right to make such disclosure, provided that the Receiving Party shall prior to any such disclosure notify the Disclosing Party to the extent the Receiving Party is lawfully allowed to do so, and that the Receiving Party shall give the Disclosing Party the opportunity to seek any legal remedy the Disclosing Party considers necessary to protect its Confidential lnformation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">4 5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The obligation for confidentiality shall be in force for a period of five (5) years after the termination or expiry of the Contract, unless a different confidentiality period is separately agreed in writing between the Parties.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="ex1012vttlogo.jpg" alt="ex1012vttlogo.jpg" style="height:30px;width:85px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:49%;'><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">4.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Notwithstanding the confidentiality obligation stated above, VTT has a right, if necessary for the performance of the Project. to disclose Confidential Information to its subcontractors and to organizations belonging to VTT Group, provided that they have a legitimate need to know and that they are bound by similar confidentiality obligations as those contained herein.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">4 7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT has a right to mention the Project and the name of the Client as a reference.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">OWNERSHIP AND USER RIGHTS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">5 1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Information, ideas, methods, solutions, devices, data and other material supplied by one Party to the other Party, irrespective of whether they are or can be protected by intellectual property rights, that are generated outside the Project (hereinafter referred to as Background), belong to the supplier Party if the Background of VTT is needed for exploitation of the Foreground, the conditions for such user rights to the Background shall be subject to a separate written agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">5 2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Information, ideas, methods, solutions, devices, data and other material irrespective of whether they are or can be protected by intellectual property rights, which are presented or generated by VTT for the achievement of Foreground but which will not form a part of the Foreground (for example research tools generated to achieve certain Foreground), shall be the property of VTT.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">5 3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Information, ideas, methods, solutions, devices, date and other material, including also reports, irrespective of whether they are or can be protected by intellectual property rights, which are generated in the Project and which will form a part of the results (hereinafter referred to as Foreground) shall be the property of the Client unless</font></div></td></tr></table><div style="line-height:120%;padding-left:36px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">a) It is stated in the Contract that the subject of the Project concerns the core technology of VTT</font><font style="font-family:Arial;font-size:8pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:8pt;">and/or</font></div><div style="line-height:120%;padding-top:1px;text-align:justify;padding-left:36px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">b) the Foreground consists of software, database(s), layout-design(s) of an integrated circuit or  a biological finding (including but not limited to gene sequence(s), target molecule(s), micro organism(s) etc).In these cases, VTT</font><font style="font-family:Arial;font-size:8pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:8pt;">shall retain the ownership of the Foreground intellectual property rights and other rights whereas the Client shall be granted separately defined user rights to such Foreground in accordance with the Client's reasonable needs and the technical scope of the Project.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">5.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Each Party is entitled to use the Background obtained from the other Party only for the performance of the Project.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">5 5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The devices and instruments acquired for the performance of the Project by VTT</font><font style="font-family:Arial;font-size:8pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:8pt;">shall be the property of VTT</font><font style="font-family:Arial;font-size:8pt;font-style:italic;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">5 6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT shall be entitled to use general expertise and experience originating from the Project also in its work and activities outside the scope of the Contract</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:36px;text-indent:-36px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">RIGHT TO EMPLOYEE INVENTION</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">6.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Client shall have ownership to inventions that are part of the Foreground and that under the Contract shall become the property of the Client.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">6 2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">An Inventor that is an employee of VTT shall notify VTT in writing of the employee invention according to the Finnish Act on the Right in Employee Inventions (29.12.19671656). After VTT has received said notification from the Inventor, VTT Shall notify the Client of the invention without undue delay.</font></div></td></tr></table></div><div style='width:2%; float:left;'>&#160;</div><div style='float:right; width:49%;'><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">6 3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Client shall notify VTT in writing about its claim to the invention within two (2) months from the dale of VTT's notification to the Client (as provided in clause 6.2 above) at the risk of losing all its rights to the invention.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">6.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Parties shall see to it that premature publication of inventions is prevented</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">6 5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The inventor(s) shall always be credited with having generated the invention in accordance with applicable legislation. The inventor shall be entitled to a fair compensation for the invention. The costs related to patenting and compensation to the inventor shall be paid by the Party that under the Contract is the owner of the invention. The amount of the fair compensation to the inventor shall be determined in accordance with applicable legislation and in accordance with the inventor compensation scheme of the Party who is the owner of the invention under the Contract, and in case the Client does not have a compensation scheme, VTT's compensation scheme shall be applied.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">DOCUMENTS AND MATERIAL PROVIDED BY THE CLIENT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">7 .1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Documents obtained from the Client shell be handled in accordance with the confidentiality obligations stated herein.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">7.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Material, samples or specimens delivered by the Client to VTT for the performance of the Project shall be kept by VTT at maximum for three (3) months from the date the Foreground is delivered to the Client The Client shall not be entitled to compensation if the appropriate execution of the Project has required measures resulting in destruction, deterioration or decrease of the material or test item.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">THE RIGHTS AND OBLIGATIONS OF VTT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">8.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT shall carry out the Project within the agreed schedule. If no schedule has been agreed upon, the Project shall be carried out without undue delay VTT shall have the right to postpone the agreed schedule in case a delay is caused by Force Majeure (as defined in clause 12), by the Client, or a cause the Client is responsible for</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">8.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT shall carry out the tasks defined lo the Contract using reasonable skill, care and diligence. VTT shall take care that the personnel carrying out the Project has suitable competence. The Client has to invoke a defect in the performance of the Project: in two (2) weeks after the delivery of the Foreground. In case of defect, VTT shall always have the right to correct or replace its performance before the Client may invoke any other remedies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">8.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT shall not be entitled to use subcontractors, except organizations belonging to the VTT Group, to carry out the Project or a major part of it without written consent from the Client.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">8.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">If damage is caused to VTT or the scope of the Project is changed, delayed or suspended because of the Client, or due to a cause the Client is responsible for, VTT shall be entitled to compensation for the resulting expenses and damage.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">8.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT shall not give any warranty or guarantee, expressed or implied, for the performance of the Project, Foreground, Background, devices, Instruments, material or goods&#8226; delivered by VTT.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">8 6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The terms of delivery of VTT's devices, instruments, material or goods shall be "Ex Works VTT (lncoterms 2010)".</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="ex1012vttlogo.jpg" alt="ex1012vttlogo.jpg" style="height:30px;width:85px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:49%;'><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">THE RIGHTS AND OBLIGATIONS OF THE CLIENT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">9.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Client shall have the right to follow the progress of the Project.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">9 2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Client shall give VTT all the necessary data and information needed for carrying out the Project and access to necessary equipment and other resources in case the use of such equipment and other resources has been agreed upon.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">9.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The risk of damage for accidental destruction of foreground shall be transferred to the Client at the the time the Foreground or part thereof has been delivered to the Client. If the Foreground has not been delivered on the agreed date due to a delay caused by the Client. the risk of damage shall be transferred to the Client on the day when the delivery should have taken place.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">9.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">If the Project is carried out in the Client's premises or at premises the Client is responsible for, the Client shall attend to health and safety at work for the employees of VTT or other persons working for VTT for the carrying out of the Project.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:36px;text-indent:-36px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">PUBLICATION OF FOREGROUND</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">10.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The owner of the Foreground is entitled, at its discretion. to publish the final research report Included In the Foreground, in its entirety. Partial publication of the research report Is only permissible by prior written authorization from VTT.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">10.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">In publication of the Foreground. the name of VTT shall be mentioned in an appropriate manner.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">10.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">All use of VTT's name and logotype for advertising and other sales promotion purposes Is subject to prior written consent of VTT.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">10.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">For verifying (or, rectifying as the case may be) claims or statements regarding the Project presented In public, VTT shall have the right to disclose information of the Foreground to a third party or the public: only to the extent and in ease needed to verify or rectify such claims.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT's LIABILITIES</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">11.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT shall be liable for carrying out the Project as stipulated in the Contract. VTT shall be liable for the work of a subcontractor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">11.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT shall be liable only for direct damage suffered by the Client as a result of VTT's negligent or international act or omission.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">11.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The liability of VTT shall, however, in all cases be limited to the price paid to VTT for the Project. VTT shall not be responsible for indirect damage or consequential losses.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">11.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Parties expressly affirm that they are aware of the technical and other risks attached to the Project and knowingly accept these uncertainties, and the fact that the results and the goals of the Project may not necessarily be achieved, as inherent in the nature of research and development work.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">11.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">When granting user rights to Background and/or Foreground, the Parties undertake to use reasonable endeavours to ensure the accuracy thereof. However, the Party granting such user rights shall be under no further obligation or liability in respect of the same and no warranty, condition or representation of any kind is made, given or to be implied and the recipient Party shall in any case be entirely responsible for the user of such Background and/or Foreground. Furthermore, VTT shall not in any case be liable for damage or claims related to product liability and the Client shall indemnify and hold </font></div></td></tr></table></div><div style='width:2%; float:left;'>&#160;</div><div style='float:right; width:49%;'><div style="line-height:120%;padding-left:36px;text-align:justify;"><font style="font-family:Arial;font-size:8pt;">VTT harmless from and against any such damage, liabilities or claims. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">11 6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The liability of VTT shall expire at the latest one (1) year after the delivery of the Foreground. If the Foreground has not been delivered at tho agreed moment due to a delay caused by the Client, the above mentioned period shall start on the day the delivery about have taken place.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">11.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Any claims regarding the Project shall be presented within she (6) months from the date VTT's liability expires at the risk of</font><font style="font-family:Arial;font-size:8pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:8pt;">the Client losing its right to claim compensation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FORCE MAJEURE</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">12 1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Force Majeure is an event that prevents, or makes unduly difficult, the performance of the Project within the agreed schedule. Such events shall be war, rebellion, natural catastrophe, general interruption in energy distribution, fire, a limit imposed by the state budget or the Government of Finland to the activity of VTT strike, embargo, or some other equality significant and unusual event independent of the Parties (hereinafter referred to as Force Majeure). The delay of an approved subcontractor caused by the above mentioned events is also considered Force Majeure.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">TERMINATION OF THE CONTRACT</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">13.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">If a Party essentially bleaches the terms of the Contract, the other Party shall have the right to terminate the Contract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">13.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">If the Client breaches the terms of the Contract, VTT shall be entitled to temporarily suspend the Protect lnstead of terminating the Contract until it is determined whether the breach of Contract leads to termination of the Contract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">13.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Either Party shall have the right to terminate the Contract if the other Party is obviously insolvent or is filed for bankruptcy or liquidation or any other arrangement for the benefit of its creditors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">13.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Either Party shall have the right to terminate the Contract if the fulfillment of Contract as a result of continued Force Majeure becomes impossible or is essentially delayed or delayed for over twelve (12) months.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">13 5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">In case of early termination, the Client shall be obliged to pay VTT for the part of the Project acceptably performed until the date of termination, or if it is agreed that VTT shall finalized the Project of a specific part thereof, until the date the Project was finalized Correspondingly VTT shall deliver the Foreground generated and that under the Contract shall become the property of the Client, once has fulfilled its payment obligation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">13.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">VTT shall be entitled to compensation for reasonable expenses and damage due to the early termination if the termination is caused by he Client or a cause it is responsible for.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">DISPUTES</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">14.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Any disputes, controversy or claim arising out of or relating to the Contract or the breach, termination or validity thereof which cannot be solved amicably shall be submitted:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:36px;"><font style="font-family:Arial;font-size:8pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">in case the Client Is established In the EFTA or EU stales, to tho District Court of Helsinki, Finland (court of first Instance),</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:36px;"><font style="font-family:Arial;font-size:8pt;">&#8211;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">In case the Client is established outside the EFTA and EU states, to arbitration procedure and shall be finally settled in accordance With the Arbitration Rules of</font><font style="font-family:Arial;font-size:8pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:8pt;">the Finland Chamber of Commerce by one </font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="ex1012vttlogo.jpg" alt="ex1012vttlogo.jpg" style="height:30px;width:85px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:49%;'><div style="line-height:120%;padding-left:60px;text-align:justify;"><font style="font-family:Arial;font-size:8pt;">or more arbitrators appointed in accordance with said rules. The language of arbitration shall be English and the place of arbitration shall be Helsinki, Finland.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:Arial;font-size:8pt;">14.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">The Contract shall be governed by the laws of Finland, excluding choice of law provisions.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><a name="sA9713C8D0B995B32BCEC5CD915C983F4"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">MATERIAL TRANSFER AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">THIS MATERIAL TRANSFER AGREEMENT</font><font style="font-family:Arial;font-size:10pt;">&#32;("Agreement") is made and entered</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">into as of May 10th 2016 (the "Effective Date"), by and between </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC.</font><font style="font-family:Arial;font-size:10pt;">, a Florida corporation, with its principal place of business at 140 lntracoastal Pointe Drive, Suite 404, Jupiter, FL 33477 ("Dyadic") and the undersigned party ("Recipient").</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Arial;font-size:10pt;">, the parties hereto have entered into that certain Mutual Non-Disclosure Agreement dated 12.4.2016 (the "Confidentiality Agreement') which remains in full force and effect; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Arial;font-size:10pt;">, Recipient desires to obtain and Dyadic Is willing to provide samples of certain proprietary and/or patented materials for testing and evaluation In accordance with the terms and conditions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NOW THEREFORE</font><font style="font-family:Arial;font-size:10pt;">, for good end valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Scope of Use</font><font style="font-family:Arial;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Materials</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;The materials covered by this Agreement include certain of Dyadic's proprietary and/or patented materials Including, but not limited to, genes, promoters, vectors, microorganisms, other genetic materials, enzymes, enzyme mixes and technologies (the "Materials"). The Materials also Include any biological or chemical material that represents a substantially unmodified copy of the Materials such as. but not limited to, material produced by growth of cells or microorganisms or amplification of the Materials as well as materials created from the Materials that are modified lo have new properties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Shipment</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;Materials will be delivered DDP (lncoterms 2010) "VTT".</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Use and Evaluation</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;Recipient agrees that the Materials will only be used for research purposes In Recipient's laboratory and tor no other purpose at any other location without the prior written consent of Dyadic. Recipient will use the Materials only In R&amp;D collaboration with Dyadic as defined In separate agreements(s).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">SUBJECT TO 1(b), RECIPIENT ASSUMES ALL RISK AND RESPONSIBILITY IN CONNECTION WITH THE RECEIPT, HANDLING, STORAGE, DISPOSAL, TRANSFER AND USE OF THE MATERIALS INCLUDING, WITHOUT LIMITATION, TAKING ALL APPROPRIATE SAFETY AND HANDLING PRECAUTIONS TO MINIMIZE HEALTH OR ENVIRONMENTAL RISK.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Dissemination</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;Recipient agrees that It will not give, sell, lend, distribute, disseminate or otherwise transfer the&#183;Materials or share any information about the Materials with or to any third party except to those employees of Recipient with a special need to know and work with such Materials who have agreed to abide by the terms of this Agreement. Recipient shall Immediately notify Dyadic upon discovery of any unauthorized distribution or dissemination of the Materials.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Warranty Disclaimer</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;THE MATERIALS PROVIDED HEREBY ARE EXPERIMENTAL IN NATURE AND ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTIBILITY OR FITNESS FOR A PARTICULAR PURPOSE, TYPICALITY, SAFETY, ACCURACY AND NON-INFRINGEMENT.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(f)&#160;&#160;&#160;&#160;Compliance with Laws.&#160;&#160;&#160;Recipient agrees that any activity undertaken with the Materials will be conducted in compliance with all applicable foreign and domestic laws, regulations and guidelines.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Intellectual Property Ownership</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Ownership</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;The Materials are of great value and Importance to Dyadic and have been developed over a long period of time at substantial expense to Dyadic. Recipient acknowledges that (i) Dyadic or Its affiliates own all right, title and interest in the Materials and provided that the Parties have agreed separately in writing which on Dyadic's behalf must be in writing by its CEO, that findings arising out of the evaluation and improvement of the Materials by the Recipient (including but not limited to improvement, useful composition, structural modification or derivative of the Material and particular use of the Material) are owned by Dyadic, any modifications and/or Improvements to the Materials; and (ii) no rights under any intellectual property of Dyadic or its affiliates or rights In any other materials or Confidential Information (as defined in the Confidentiality Agreement") that could not have been attained without the use of the Materials, Is granted or implied as a result of providing the Materials to Recipient. Nothing contained In this Agreement shall restrict Dyadic's right to use, disclose, sell, assign, distribute or otherwise transfer the Materials to any person or entity for any purpose.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Filing of Patents</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;Provided that the Parties have agreed separately in writing which on Dyadic's behalf must be in writing by its CEO, that findings arising out of the evaluation and Improvement of the Materials by the Recipient (including but not limited lo improvement, useful composition, structural modification or derivative of the Material and particular use of the Material) are owned by Dyadic, Recipient agrees that It will not file any patent directed to or Including any claim covering the Materials, any improvement, useful composition, structural modification or derivative of the Material or any particular use or the Material as contemplated by this Agreement, unless and until either (i) a license agreement is entered Into between the Parties which shall Include provisions under which such a patent may be filed and such other terms and conditions as are typical of such agreements, Including, but not limited to, provisions for exclusivity, ownership of intellectual property, license fees and/or royalties; or (ii) Dyadic's CEO provides his prior written consent If Recipient files a patent application In breach of this Agreement, Recipient hereby agrees that Dyadic shall own all right, title and Interest in and to such patent. Notwithstanding the foregoing, nothing shall prevent or prohibit Dyadic from filing a patent directed to or Including a claim covering the Materials that does not include claims or findings which arose out of the evaluation of the Materials by Recipient.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Commercialization: Publication</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Commercialization</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;Provided that the Parties have agreed separately in writing, which on Dyadic's behalf must be in writing by its CEO, that findings, Improvements, strains and genetic materials arising out of the evaluation or the Materials by the Recipient (including but not limited to improvement, useful composition, structural modification or derivative or the Material and particular use of the Material) are owned by Dyadic, any commercial use of the Materials, products containing or derived from the Materials, or any other material that could not have been made without the Materials, without Dyadic's prior written consent, Is expressly prohibited. None of the Materials provided hereunder shall be used, directly or indirectly, for </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">any </font><font style="font-family:Arial;font-size:10pt;">commercial development unless a license granting the same or a specific agreement is executed between the Parties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Publication</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;Recipient will not publish the results of its experiments on or analysis of the Materials without the prior written approval of Dyadic's CEO. Recipient agrees to acknowledge Dyadic and any contributor Indicated by Dyadic as the source of the Materials In all publications end patent applications that reference the Materials.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Indemnification</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;Subject to limitation of liability contained in 6 (k) below, the Recipient agrees to Indemnify, defend, and hold harmless Dyadic and its officers, directors, employees end consultants (each, an "Indemnitee") against ell direct damages incurred by Indemnitee directly arising under this Agreement from the use, receipt, handling, storage, transfer, disposal and other activities relating to the Materials or related know-how thereunder by Recipient, Its employees, directors, consultants, agents or any third parties to whom VTT has delivered the Materials, unless caused by the negligence of Dyadic.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Term: Termination</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Term</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;The term of the Evaluation shall be for a period of two (2) years commencing on the Effective Dale and ending on the second anniversary of the Effective Dale, unless otherwise agreed on a separate agreement. The obligations of the Recipient hereunder shall remain in force for a period of five (5) years from the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Termination</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;Either party hereto may terminate this Agreement by providing the other party with thirty (30) days prior written notice. Upon termination of this Agreement, nothing herein shall be construed to release the parties hereto from any obligation that matured prior lo the effective date of such termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Return or Destruction of Materials</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;Upon the expiration of this Agreement, by a written request by Dyadic, Recipient agrees to destroy any surplus Materials, return all documents, samples, and other tangible items containing or representing Confidential Information, and all copies thereof, erase or destroy all Confidential Information contained in</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">computer memory or data storage apparatus, end certify in writing that it has compiled with the terms of this Section 5(c).</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Miscellaneous</font><font style="font-family:Arial;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Governing Law</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;This Agreement and all transactions contemplated by this Agreement shall be governed by, and construed and enforced In accordance with, the laws of Switzerland (Bern) without regard to principles or conflicts of laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Jurisdiction and Venue</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;All disputes arising out of or in connection with this Agreement which cannot be solved amicably shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed In accordance with said Rules. The language of the arbitration shall be English. The arbitration shall be held in Bern, Switzerland. The award of the arbitration will be final and binding upon the Parties. Nothing in this Agreement shall limit the Parties' right to seek temporary Injunctive relief or to enforce an arbitration award in any applicable competent court of law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Waivers</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;The failure or delay of any party at any time lo require performance by another party of any provision of this Agreement, even If known, shall not affect the right of such party to require performance of that provision or to exercise any right, power or remedy hereunder. Any waiver by any party of any breach of any provision of this Agreement should not be construed as a waiver of any continuing or succeeding breach of such provision, a waiver of the provision itself, or a waiver of any right, power or remedy under this Agreement. No notice to or demand on any party in any case shall, of itself, entitle such party to any other or further notice or demand in similar or other circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Severability</font><font style="font-family:Arial;font-size:10pt;">. If any provision of this Agreement or any other agreement entered into pursuant hereto is contrary to, prohibited by or deemed invalid under applicable law or regulation, such provision shall be Inapplicable and deemed omitted to the extent so contrary, prohibited or invalid, but the remainder hereof shall not be invalidated thereby and shall be given full force and effect so far as possible. If any provision or this Agreement may be construed in two or more ways, one of which would render the provision invalid or otherwise voidable or unenforceable and another of which would render the provision valid and enforceable, such provision shall have the meaning which renders it valid and enforceable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Assignments</font><font style="font-family:Arial;font-size:10pt;">. Neither Party shall assign its rights and/or obligations hereunder without the prior written consent of the other Party other than by sate and/or license by Dyadic of its interest in such rights and obligations to a third party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Amendments</font><font style="font-family:Arial;font-size:10pt;">. The provisions of this Agreement may not be amended, supplemented, waived or changed without written consent of the Parties.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Binding Effect</font><font style="font-family:Arial;font-size:10pt;">. All of the terms and provisions of this Agreement, whether so expressed or not, shall be binding upon, inure to the benefit of, and be enforceable by the parties and their respective legal representatives, successors and permitted assigns.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Counterparts</font><font style="font-family:Arial;font-size:10pt;">. This Agreement may be executed in one or more counterparts, each or which shall be deemed an original, but all of which together shall constitute one and the same instrument. Confirmation or execution by telefax or e-mail of a signature page shall be binding upon any party so confirming.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Headings</font><font style="font-family:Arial;font-size:10pt;">. The headings contained in this Agreement are for convenience of reference only, are not to be considered a part hereof and shall not limit or otherwise affect in any way the meaning or interpretation of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Third Parties</font><font style="font-family:Arial;font-size:10pt;">. Unless expressly stated herein to the contrary, nothing in this Agreement, whether express or implied, is intended to confer any rights or remedies under or by reason of this Agreement on any persons other than the parties hereto and their respective legal representatives, successors and permitted assigns. Nothing in this Agreement is Intended to relieve or discharge the obligation or liability of any third persons to any party to this Agreement, nor shall any provision give any third persons any right of subrogation or action over or against any party to this Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(k)&#160;&#160;&#160;&#160;Limitation of Liability. IN NO EVENT WILL EITHER PARTY OR ITS EMPLOYEES BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR THE MATERIALS (WHETHER IN CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, STATUTE OR OTHERWISE) EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. Both Parties agree that the limitations of liability set forth in this Agreement shall apply even if a limited remedy provided hereunder fails or its essential purpose. The Recipient's liability under this Agreement (Including but not limited to 4. Indemnification) shall be limited as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(i) If the Parties have entered into a separate written agreement on the research work carried out by VTT for the Materials (a commission agreement), !he Recipient's liability under this Agreement is limited to the agreed total price of the commission</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The limitations of liability contained in this Agreement shall not apply in case of gross negligence or willful misconduct.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Arial;font-size:10pt;">, the parties have executed this Agreement as of the date first above written</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:7%;"></td><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:42%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dyadic International (USA) Inc.,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">VTT Technical Research Centre of Finland Ltd.,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Mark A. Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Jouni Ahtinen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark A. Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jouni Ahtinen</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Key Account Manager</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Address: Tietolie 2, 02044 Espoo, Finland</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="s8C361A1F6902BA8AA3955CD916A0C53A"></a></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">MUTUAL NONDISCLOSURE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This MUTUAL NONDISCLOSURE AGREEMENT ("Agreement") is made and entered into as of 12.4.2016 (the "Effective Date"), between </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL (USA), INC.</font><font style="font-family:Arial;font-size:10pt;">, a Florida corporation, with its principal place of business at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477 and VTT</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">Technical Research Centre of Finland Ltd., with its principal place of business at Vuorimiehentie 3, 00210 Espoo, Finland.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Purpose</font><font style="font-family:Arial;font-size:10pt;">. The parties wish to pursue a business opportunity of mutual interest related to development of fungal expression systems (such activity, the "Purpose") end in connection with the Purpose, each party may disclose to the other certain confidential technical end business information which the disclosing party desires the receiving party to treat as confidential.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.&#160;&#160;&#160;&#160;"</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Confidential Information</font><font style="font-family:Arial;font-size:10pt;">" means any information disclosed in connection with the Purpose by either party to the other party, either directly or indirectly, in writing, orally or by inspection of tangible objects (including without limitation documents, prototypes, samples, plant and equipment). Confidential Information may also include information disclosed to a disclosing party by third parties. Confidential Information shall not, however, include any information which (i) was publicly known or made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes publicly known or made generally available after disclosure by the disclosing party to the receiving party through no action or inaction of the receiving party; (iii) is already in the possession of the receiving party at the time of disclosure by the disclosing party as shown by the receiving party's files and records; (iv) is obtained by the receiving party from a third party without a breach of such third party's obligations of confidentiality; or (v) is independently developed by the receiving party without use of or reference to the disclosing party's Confidential Information, as shown by documents and other competent evidence in the receiving party's possession.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Non-use and Non-disclosure</font><font style="font-family:Arial;font-size:10pt;">. Each party agrees not to use any Confidential Information of the other party other than for the Purpose. Each party agrees not to disclose any Confidential Information of the other party to third parties or to such party's employees, except to those employees of the receiving party who are required to have the information as needed for the Purpose. Neither party shall reverse engineer, disassemble or decompile any prototypes, software or other tangible objects which embody the other party's Confidential Information and which arc provided to the party hereunder. Notwithstanding the foregoing. if the receiving party is required by an administrative or judicial action or subpoena or law to disclose Confidential Information, the receiving party may disclose such information to the extent required by law; provided, however, that the receiving party gives, to the extent it is lawfully allowed to do so, the disclosing party prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from public disclosure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Maintenance of Confidentiality</font><font style="font-family:Arial;font-size:10pt;">. Each party agrees that it shall take reasonable measures to protect the secrecy of and avoid disclosure and unauthorized use of the Confidential Information of the other party. Without limiting the foregoing, each party shall take at least those measures that it takes to protect its own confidential information and shall ensure that its employees who have access to Confidential Information of the other party have signed a non-use and non-disclosure agreement in content similar to the provisions hereof, prior to any disclosure of Confidential Information to such employees. Neither party shall make any copies of the Confidential Information of the other party unless the same are previously approved in writing by the other party. Each party shall reproduce the other party's proprietary rights notices on any such approved copies, in the same manner in which such notices were set forth in or on the original.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">No Obligation</font><font style="font-family:Arial;font-size:10pt;">. Nothing herein shall obligate either party to proceed with any transaction between them, and each party reserves the right, in its sole discretion, to terminate the discussions contemplated by this Agreement concerning the Purpose.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">No Warranty</font><font style="font-family:Arial;font-size:10pt;">.  ALL CONFIDENTIAL INFORMATION IS PROVIDED "AS IS". EACH PARTY MAKES NO WARRANTIBS, EXPRESS, IMPLIED OR OTHERWISE, REGARDING ITS ACCURACY, COMPLETENESS OR PERFORMANCE.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Return of Materials</font><font style="font-family:Arial;font-size:10pt;">. All documents and other tangible objects containing or representing Confidential information which have been disclosed by either party to the other party, and all copies thereof which are in the possession of the other party, shall be and remain the property of the disclosing party and shall be promptly returned to the disclosing party upon the disclosing party's written request, except for a single copy kept solely for archival and compliance purposes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">No License</font><font style="font-family:Arial;font-size:10pt;">. All Confidential Information shall remain the property of the disclosing party. Nothing in this Agreement is intended to grant any rights to either party under any intellectual property right (including but not limited to patent, mask work right or copyright of the other party), nor shall this Agreement grant any party any rights in or to the Confidential Information of the other party except as expressly set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Term</font><font style="font-family:Arial;font-size:10pt;">. The obligations of each receiving party hereunder shall survive for a period of five (5) years from the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Remedies</font><font style="font-family:Arial;font-size:10pt;">. Each party agrees that any violation or threatened violation of this Agreement may cause irreparable injury to the other party, entitling the other party to seek injunctive relief in addition to all legal remedies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Miscellaneous</font><font style="font-family:Arial;font-size:10pt;">. A Party may not transfer or assign any of its rights and/or obligations under this Agreement to a third party without the prior written consent of the other Party. This Agreement shall bind and inure to the benefit of the parties hereto and their successors and assigns. This Agreement shall be governed by the laws of Switzerland (Bern) without reference to conflict of laws principles. All disputes arising out of or in connection with this Agreement which cannot be solved amicably shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with said Rules. The language of the arbitration shall be English. The arbitration shall be held in Bern, Switzerland. The award of the arbitration will be final and binding upon the Parties. Nothing in this Agreement shall limit the Parties' right to seek temporary injunctive relief or to enforce an arbitration award in any applicable competent court of law. This document contains the entire agreement between the parties with respect to the subject matter hereof, and neither party shall have any obligation, express or implied by law, with respect to trade secret or proprietary information of the other party except as set forth herein. Any failure to enforce any provision of this Agreement shall not constitute a waiver thereof or of any other provision. This Agreement may not be amended, nor any obligation waived, except by a writing signed by both parties hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Arial;font-size:10pt;">, the parties have caused this Agreement to be executed by their duly authorized representative.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:5%;"></td><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:45%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DYADIC INTERNATIONAL (USA) INC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">VTT Technical Research Centre of Finland Ltd.,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Mark A. Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Kirsi-Marja Oksman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name: Mark A. Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name: Kirsi-Marja Oksman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title: President and CEO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Title: Head of Industrial Biotechnology</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>19
<FILENAME>exhibit1014form10.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s794235C6CF5BEA3E62E044D79A454A41"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.14</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Execution Version</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*] indicates that a confidential portion of the text of this agreement has been omitted. The non-public</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">information has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RESEARCH SERVICES AGREEMENT</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RESEARCH SERVICES AGREEMENT</font><font style="font-family:inherit;font-size:12pt;">&#32;(this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), signed as of June 30, 2017, is entered into by and between DYADIC INTERNATIONAL, INC., a Delaware corporation with headquarters located at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477-5094 USA and U.S. tax identification number 45-04867472 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY IN PHARMACEUTICALS, S.L.U., a company incorporated under the laws of Spain having its registered office at Louist Proust 13, 47151 Boecillo (Valladolid), Spain, and identification code -CIF number- B-86206695 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI Pharmaceuticals</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Dyadic and BDI Pharmaceuticals are sometimes collectively referred to as the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221; and individually as a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:12pt;">.&#8221; Certain capitalized terms used herein have the meanings assigned them in Article 1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RECITALS:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BDI Pharmaceuticals provides services for strain improvement, bioprocess development, bioprocess scale-up, bioengineering and contract production;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">II.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biotechnology Developments for Industry, S.L (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI Holdings</font><font style="font-family:inherit;font-size:12pt;">&#8221;) holds 100% of the shares of BDI Pharmaceuticals and 79.2% of the shares of VLP-The Vaccines Company, S.L.U. (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">VLPbio</font><font style="font-family:inherit;font-size:12pt;">&#8221;), which develops human and animal vaccines based on a proprietary chimeric virus like particles technology platform;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">III.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dyadic is a global biotechnology company that has a proprietary biopharmaceutical protein production system based on the fungus </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Myceliopthora thermophila, </font><font style="font-family:inherit;font-size:12pt;">nicknamed Cl. The Cl Technology (defined below) and other technologies may be used by BDI Pharmaceuticals pursuant to this Agreement for research and development activities in accordance with the terms of the Pharma License Agreement and solely on behalf of Dyadic;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">IV.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Agreement is being executed as a condition to the closing of the transactions contemplated by that certain Investment Agreement dated June 30, 2017 among Dyadic International (USA), Inc. (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Florida</font><font style="font-family:inherit;font-size:12pt;">&#8221;), BDI Holding and Inveready Innvierte Biotech II, S.C.R., S.A. (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investment Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to which Dyadic Florida is making a strategic investment in BDI Holding and its subsidiary, VLPbio, to, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">inter alia, </font><font style="font-family:inherit;font-size:12pt;">enable BDI Holding and its subsidiary, BDI Pharmaceuticals, to fund BDI Pharmaceutical&#8217;s business plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">V.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contemporaneous with the Agreement and also as a condition to closing under the Investment Services Agreement, a Service Framework Agreement is being executed by the Parties, pursuant to which all contract research services other than the Services shall be provided by BDI Pharmaceuticals on behalf of Dyadic (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Service Framework Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">VI.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Parties wish to collaborate to develop results (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Results</font><font style="font-family:inherit;font-size:12pt;">&#8221;) for a biologic drug and/or vaccine for animal and/or human health using C1 Technology as an expression host in </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">accordance with the project described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto and made a part hereof (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project</font><font style="font-family:inherit;font-size:12pt;">&#8221;);</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">VII.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BDI Pharmaceuticals will assign, and will cause each of its permitted subcontractors hereunder to assign, all rights in and to any and all intellectual property developed during the commissioning of or yielded from the Project to Dyadic, or as directed by Dyadic; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">VIII.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Parties desire to develop, for commercialization, one product candidate based upon the Results of the Project, which the Parties plan to commercialize under the terms and conditions set forth in the form Commercialization Agreement attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit E</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AGREEMENT:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and the foregoing Recitals, which are incorporated herein and by this reference made a part hereof, and for other good and valuable consideration the receipt and adequacy of which hereby are mutually acknowledged by Dyadic and BDI Pharmaceuticals, the Parties hereby agree as follows:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 1</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEFINITIONS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Capitalized terms used in this Agreement shall have the meaning ascribed to them below, or as otherwise defined above or  in the text of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AAA</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 11.10 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Action&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in Section 9.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Affiliate&#8221; </font><font style="font-family:inherit;font-size:12pt;">means any person, corporation or other entity that controls, is controlled by, or is under common control with a Party. Control, with respect to such other corporation or entity, includes a person, corporation or other entity (i) owning or directly or indirectly controlling a majority of the voting stock or other ownership interest, (ii) possessing, directly or indirectly, the power to direct or cause the direction of the management and policies, or (iii) possessing the power to elect or appoint a majority of the members of the governing body. For the avoidance of doubt, the term Affiliate when used with respect to BDI Pharmaceuticals shall include BDI Holdings and VLPbio.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Agreement&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in the Preamble.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Applicable Project Spend&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in Section 2.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Background IP&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in Section 5.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;BDI Holdings&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in Recital II.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;BDI Pharmaceuticals&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in the Preamble.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI Services Generated Tools</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Genetic Tools generated in the course of the provision of the Services by BDI Pharmaceuticals and its Affiliates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Best Efforts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the efforts that a prudent Person desirous of achieving a result would use in similar circumstances to ensure that such result is achieved as expeditiously as practical.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">C1 Strains</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, individually and collectively, the </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Myceliophthora thermophile </font><font style="font-family:inherit;font-size:12pt;">strains transferred to and/or derived or generated therefrom in the Project or under this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">C1 Technology</font><font style="font-family:inherit;font-size:12pt;">&#8221; includes any and all Dyadic Materials, Dyadic Know-How, Dyadic C1 Genomic Information, C1 Strains, Dyadic Improved Strains and Genetic Tools.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(m)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaboration IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.2 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(n)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7. I hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(o)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Danisco Improved Strains</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(p)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Danisco Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth m the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(q)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Danisco Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(r)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(s)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(t)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic C1 Genomic Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the current and future genome sequence of C1 Strains, genes and other genetic elements including genomic data derived from C1 and any associated annotations, software, software tools related thereto including any subsequent Dyadic C1 Genomic Information coming from Dyadic, or identified or developed in the Project or under this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(u)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Florida</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Recital IV hereto.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Follow-On IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.6 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(w)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Improved Strains</font><font style="font-family:inherit;font-size:12pt;">&#8221; means one or more C1 Strains modified to express intracellularly or extracellularly whether it is secreted or not a Pharmaceutical Product where the performance or characteristics of such C1 Strains, including, without limitation, with respect to any composition of matter produced or expressed therein has been materially alerted as a result of work done by or on behalf of Dyadic pursuant to this Agreement, where such C1 Strains, as materially altered, would, to one reasonably skilled in the art, be useful in the Pharmaceutical Field.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(x)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all information relating to the C1 genome, engineering, production, fermentation, composition and use of C1 Strains, as such information existed as of the Effective Date, and any and all subsequently transferred know-how and/or know-how that is developed by BDI Pharmaceuticals or its Affiliates that relates in any way to C1, the C1 Technology or fermentation process and media development.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(y)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Materials</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the materials set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">&#32;and any subsequent transferred Dyadic Materials including any C1 Strains, Dyadic Improved Strains, Danisco Improved Strains, Genetic Tools, Dyadic C1 Genomic Information, Dyadic Know-How and/or any modifications or improvements identified and/or developed by BDI Pharmaceuticals or its Affiliates that relate in any way to C1 or the C1 Technology.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(z)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(aa)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 10.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(bb)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Genetic Tools</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any composition of matter and genetic elements useful for using, manipulating, engineering, transforming, transfecting, modifying or altering a C1 Strain that was transferred to BDI Pharmaceuticals. Without limiting or expanding the foregoing Genetic Tools shall include those identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit C</font><font style="font-family:inherit;font-size:12pt;">&#32;and any subsequently transferred Genetic Tools and/or developed Genetic Tools developed by BDI Pharmaceuticals or its Affiliates that relate in any way to C1 Strains, and/or the C1 Technology. For the avoidance of doubt, Genetic Tools shall exclude the Danisco Background Technology and the Danisco Background Tools (each as defined in the Pharma License Agreement).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(cc)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Governing Group</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 3.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(dd)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Government Official</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 11.5 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ee)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnified Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 9.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ff)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnifying Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 9.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(gg)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Infringement Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 9.3 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(hh)&#160;&#160;&#160;&#160;&#8220;Initial Product&#8221; has the meaning set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;hereto.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investment Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Recital IV hereto.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(jj)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Key Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; means those persons listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit D</font><font style="font-family:inherit;font-size:12pt;">&#32;hereto.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(kk)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Negotiation Period</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 6.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ll)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(mm)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a natural person, a corporation, a partnership, a trust, a joint venture, any governmental authority or any other entity or organization.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(nn)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pharmaceutical Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(oo)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pharma License Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the agreement between Danisco and Dyadic dated December 31, 2015, a redacted copy of which has been provided to BDI Pharmaceuticals for review in advance of executing this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(pp)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Phase</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a distinct period or stage in the development of the Project. In the first Phase, for example, BDI Pharmaceuticals will evaluate the expression of six (6) products. In the second Phase, BDI Pharmaceuticals and Dyadic will review expression of certain product candidates. In the third Phase, a single product candidate to be developed will be selected by the Parties for Dyadic&#8217;s commercialization. Each of the Phases is meant to be exemplary and the Parties may change the Phases as provided herein.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(qq)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project A</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Recital VI and as more particularly set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto and made a part hereof, as may be amended by the Parties from time to time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(rr)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project Managers</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 3.4 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ss)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project Objective</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 8.3(d) hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(tt)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project Spend Measurement Period</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 2.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(uu)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Quarterly Project Certificate</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 2.2 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vv)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ww)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Results</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Recital VI. For the sake of clarity, Results, as defined herein, shall only include findings as they relate to the Project.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xx)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">R&amp;D License</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.4 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(yy)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Selected Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 6.1.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(zz)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Service Framework Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Recital V hereto.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(aaa)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Services</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the activities set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, and any other Services that BDI Pharmaceuticals may perform or have performed on its behalf hereunder.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(bbb)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sublicensee</font><font style="font-family:inherit;font-size:12pt;">&#8221; as used herein shall refer to BDI Pharmaceuticals and its Affiliates and also have the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ccc)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sublicense Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth m the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ddd)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Data</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 4.2 hereof.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(eee)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Technical Group&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning provided in Section 3.2 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(fff)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Term&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in Section 10.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ggg)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Third Party&#8221; </font><font style="font-family:inherit;font-size:12pt;">means any Person that is not a Party (or an Affiliate of a Party) to this Agreement, including without limitation other collaboration Partners.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(hhh)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;VLPbio&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in Recital II hereto.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 2</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI PHARMACEUTICALS R&amp;D PROGRAM</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">2.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commitment of BDI Pharmaceuticals to Engage in the Project. </font><font style="font-family:inherit;font-size:12pt;">BDI Pharmaceuticals covenants to Dyadic that over the two (2) year period commencing with the date hereof (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project Spend Measurement Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;),</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">BDI Pharmaceuticals will spend not less than EUR 936,000 on the conduct of the Project in the performance of its obligations under this Agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Applicable Project Spend</font><font style="font-family:inherit;font-size:12pt;">&#8221;),</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">including, but not limited to, by way of illustration, and not in limitation: (i) the employment of scientific and non-scientific personnel to perform such activities; (ii) the engagement of consultants and other independent contractors to perform such activities for the Project&#8217;s benefit in whole or in part; (iii) the engagement of contract research organizations, which may include the engagement of VLPbio through an agreement that includes necessary protections for Dyadic including VLPbio&#8217;s consent to abide by all of the terms and conditions of this Agreement, to perform certain of such activities; and (iv) materials and supplies for use in connection therewith, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided that</font><font style="font-family:inherit;font-size:12pt;">&#32;in calculating the amount of BDI Pharmaceuticals&#8217; Applicable Project Spend, for each (a) of the costs relating to (ii) through (iv), which are provided by non-Affiliate third-parties, BDI Pharmaceuticals shall be deemed to have incurred an amount equal to BDI Pharmaceuticals contracted price plus 10%; and (b) full time equivalent position listed below appointed by the Technical Group during the Project Spend Measurement Period and providing services to the Project, BDI Pharmaceuticals shall be deemed to have incurred the amount listed below opposite the position title of Applicable Project Spend for each year during the Project Spend Measurement Period in which such employee is so employed and engaged on the Project, pro-rated for any partial year:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:62.82051282051282%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Project Manager</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#160;EUR</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Senior Scientist</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#160;EUR</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Junior Scientist</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#160;EUR</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Technician</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font><font style="font-family:inherit;font-size:12pt;">&#160;EUR</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">2.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project Reporting. </font><font style="font-family:inherit;font-size:12pt;">Within thirty (30) days following the close of each calendar quarter beginning or ending within the Project Spend Measurement Period, BDI Holdings&#8217; Chief Financial Officer and/or Chief Executive Officer shall furnish the Governing Group members with a detailed written report (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Quarterly Project Certificate</font><font style="font-family:inherit;font-size:12pt;">&#8221;)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">certifying (i) the amount of the Applicable Project Spend made by BDI Pharmaceuticals in the quarter then ended and the cumulative amount of Applicable Project Spend made by BDI Pharmaceuticals since the Effective Date, (ii) the actual to budget comparison of Applicable Project Spend for the quarter then ended and cumulatively since the Effective Date against the budgeted amount for the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Project as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, or as superseded subsequent to the Effective Date by approval of the Governing Group indicating, as applicable, if there are spend variances for any monthly period in excess of ten percent (10%) of the approved budgeted amount, and (iii) an updated Project timeline which indicates all changes made since the prior timeline reported and cumulatively against the timeline set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, with a final Quarterly Project Certificate to be furnished by BDI Pharmaceuticals to Dyadic within thirty (30) days of the completion date of the Project; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided that</font><font style="font-family:inherit;font-size:12pt;">&#32;the representatives of Dyadic, upon reasonable advance notice and at Dyadic&#8217;s expense, shall have the right to have an independent accounting firm review the books and records of BDI Pharmaceuticals and BDI Holdings upon the condition that such independent accounting firm execute and deliver to BDI Holding&#8217;s legal counsel, to verify the accuracy of the calculations set forth in the Quarterly Project Certificate(s), further provided that if such examination shall disclose a more than five percent (5%) negative variance between the amount of the Applicable Project Spend for the applicable quarter, BDI Pharmaceuticals shall pay all of the expenses for such independent accounting firm.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">2.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Scope of the Project.</font><font style="font-family:inherit;font-size:12pt;">&#32;BDI Pharmaceuticals shall use its good faith Best Efforts to supply the necessary scientific staff, materials, laboratories, offices and other facilities to perform the Project described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">. The Parties may amend the scope from time to time as provided herein.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">2.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Funding of the Project.</font><font style="font-family:inherit;font-size:12pt;">&#32;BDI Pharmaceuticals shall be solely responsible for all costs associated with funding its performance of the Project.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">2.5</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commencement of Project.</font><font style="font-family:inherit;font-size:12pt;">&#32;BDI Pharmaceuticals shall commence performance of the Project immediately following the Effective Date.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 3</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THE GOVERNING GROUP, THE TECHNICAL GROUP AND PROJECT MANAGERS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">3.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Governing Group.</font><font style="font-family:inherit;font-size:12pt;">&#32;The Parties shall establish and maintain throughout the Term of this Agreement a Governing Group (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Governing Group</font><font style="font-family:inherit;font-size:12pt;">&#8221;) to oversee and direct the execution of the Project, as well as to oversee the Technical Group and the Project Managers. Except to the extent otherwise provided by mutual written agreement of the Parties, the Governing Group shall not disband until the expiration of the Term or earlier termination of the Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Functions of the Governing Group.</font><font style="font-family:inherit;font-size:12pt;">&#32;The functions of the Governing Group shall be to: (i) review and approve modifications of the Project when presented by the Technical Group; (ii) review the most recent Quarterly Project Certificate and vote upon any matters, such as change of budget or time line, that arise based on such reporting; (iii) specify and approve the objectives of the Project; (iv) review and approve the results of each Phase as submitted to the Governing Group by the Technical Group; (v) review and approve revisions of and modifications to the Project plan, as submitted to the Governing Group by the Technical Group, and present them, when necessary, to BDI Pharmaceuticals and Dyadic for acceptance; (vi) control the progress of the Project and support the activities of the Project Managers; (vii) accept the achievement of milestones that have been reported since the last meeting and provide overall guidance to the Parties and Project Managers with regard thereto; (viii) monitor and control the Project budget and timeline and consider whether any proposed changes should be made; (ix)</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">exchange suggestions, ideas and recommendations pertaining to the overall achievement of the Project; (x) evaluate the commercialization recommendation, if any, submitted to the Governing Group by the Technical Group; and (xi) make commercial recommendations to the Parties when required under Section 6.1.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Composition. </font><font style="font-family:inherit;font-size:12pt;">The Governing Group shall comprise the following members: Ronen Tchelet, Arin Bose, Matthew Jones, Tom Dubinski, Michael Weiss and Mark Emalfarb, who shall be Dyadic&#8217;s representatives and Pablo Gutierrez, Ana Gomez, </font><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font><font style="font-family:inherit;font-size:12pt;">, who shall be BDI Pharmaceuticals&#8217; representatives. The chair of the Governing Group shall be appointed by Dyadic and shall initially be Mark Emalfarb. Only representatives designated pursuant to this Section 3.1 (b) shall have the right to vote in the Governing Group, provided that if any representative of a Party is unable to attend a meeting of the Governing Group, another representative of that Party shall be entitled to attend and vote in his or her stead. The number of voting representatives may be increased upon mutual written agreement of the Parties. Each Party shall appoint or nominate its respective representatives to the Governing Group and, from time to time, may substitute one or more of its representatives. Additional representatives or consultants of a Party may from time to time, with the consent of the other Party (with such consent not to be unreasonably withheld or delayed) attend meetings of the Governing Group, subject to such representative&#8217;s and/or consultant&#8217;s agreement to comply with the confidentiality obligations at least equivalent to those set forth in this Agreement and provided that such additional representatives shall have no vote.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Governance. </font><font style="font-family:inherit;font-size:12pt;">Decisions of the Governing Group shall be made by majority vote with each Party&#8217;s voting representatives participating in the vote collectively having one (1) vote.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Meetings. </font><font style="font-family:inherit;font-size:12pt;">The Governing Group shall meet at least every three (3) months or as otherwise agreed in accordance with a schedule established by mutual written agreement of the Parties, with the location for such meetings determined by agreement of the Parties. Either Party may call for nonscheduled meetings of the Governing Group for good cause, which shall occur at mutually agreeable times. The Governing Group, upon mutual agreement, may meet by means of in person, teleconference, videoconference or other similar communications equipment. No meeting may be conducted unless at least two (2) voting representatives of each Party are participating.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">3.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Technical Group. </font><font style="font-family:inherit;font-size:12pt;">The Parties shall establish a Technical Group (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Technical Group</font><font style="font-family:inherit;font-size:12pt;">&#8221;)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">to review and oversee the scientific and technical progress of the Project. Except to the extent otherwise provided by mutual written agreement of the Parties, the Technical Group shall not disband until the expiration of the Term or the earlier termination of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Functions of the Technical Group</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">. </font><font style="font-family:inherit;font-size:12pt;">The functions of the Technical Group shall be to: (i) review and manage the scientific and technical progress of the Project; (ii) review the objectives of the Project and notify the Governing Group of any proposed revisions of the Project plans that might be needed; (iii) notify the Governing Group of the results of each Phase of the Project; (iv) control the progress of the Project and support activities of the Project Managers; (v) handle and execute revisions of and modifications to the Project and present the same to the Governing Group for approval; (vi) monitor progress in achieving any performance benchmarks and provide overall guidance to the Parties and Project Managers with regard </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">thereto; (vii) exchange suggestions, ideas and recommendations pertaining to the Project; and (viii) make commercialization recommendations to the Governing Group.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Composition</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">. </font><font style="font-family:inherit;font-size:12pt;">Each Party shall nominate its respective representatives to the Technical Group. Such nominees shall be subject to the mutual written approval of the Parties. Initially, the Technical Group shall comprise the following members: Ronen Tchelet, Arin Bose and Mark Emalfarb, who shall be Dyadic&#8217;s representatives and two persons to be appointed by DBI Pharmaceuticals&#8217; promptly following the Effective Date of this Agreement by written notice to Dyadic. The chair of the Technical Group shall be appointed by Dyadic and shall initially be Ronen Tchelet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Meetings</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">. </font><font style="font-family:inherit;font-size:12pt;">The Technical Group shall meet every month or as otherwise agreed in accordance with a schedule established by mutual written agreement of the Parties, with the location for such meetings determined by agreement of the Parties. The Technical Group, upon mutual agreement, may meet by means of in person, teleconference, videoconference or other similar communications equipment.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">3.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Records of Governing Group and Technical Group. </font><font style="font-family:inherit;font-size:12pt;">The chair of each of the Governing Group and Technical Group, or his/her designee(s), shall have responsibility for preparing minutes of each respective meeting. Such minutes shall provide a description, in reasonable detail, of the discussions at the meeting and decisions made by the Governing Group or Technical Group, as the case may be. Such minutes shall be circulated on a confidential basis to all members of the Governing Group or Technical Group, respectively and as appropriate, within thirty (30) days following such meeting. Following circulation and review and incorporation of any comments received on the minutes, the chair of the Governing Group or Technical Group, as appropriate, shall sign and file or cause to be filed the minutes within the corporate documents of BDI Pharmaceuticals.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">3.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project Managers. </font><font style="font-family:inherit;font-size:12pt;">There shall be a person from BDI Pharmaceuticals and a person from Dyadic chosen to manage the Project (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project Managers</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Initially, the Dyadic Project Manager shall be Ronen Tchelet and the BDI Pharmaceuticals Project Manager shall be Ana Gomez. Project Managers may be changed by mutual written agreement of the Parties. The Project Managers will be responsible for managing, monitoring and reporting on the progress and status of the Project, including the exchange of development information, notifications to the Technical Group and/or Governing Group, if necessary, and any delay or problem that might affect deliveries within the Project. The Project Managers will communicate by weekly telephone calls, or any other chosen method effective for communication, or more often if needed.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 4</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AUDITS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">4.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">For Cause Audits. </font><font style="font-family:inherit;font-size:12pt;">If Dyadic reasonably believes that the Project is not being performed, or was not performed, in compliance with the terms of this Agreement, Dyadic may audit BDI Pharmaceuticals and/or any Affiliate of BDI Pharmaceuticals subcontracted hereunder upon reasonable advance notice to BDI Pharmaceuticals of not less than two (2) business days and during BDI Pharmaceuticals&#8217;, or its Affiliates, if applicable, regular business hours. Dyadic </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or its agents may inspect BDI Pharmaceuticals&#8217;, or its Affiliates&#8217;, if applicable, facilities and may audit all records, including, but not limited to, Study Data and accounting records, relating to the Project, subject to all confidentiality obligations and other restrictions herein or otherwise reasonably required by BDI Pharmaceuticals, or its Affiliate, prior to such inspection. BDI Pharmaceuticals will make or cause to be made available all such records and will provide reasonable assistance in the inspection or audit. Dyadic&#8217;s right to audit will survive the expiration or earlier termination of this Agreement. Audits in accordance with the terms and conditions of this Section 4.1 may occur no more than four (4) times per calendar year. Audits conducted under this Section 4.1 shall be at Dyadic&#8217;s expense provided, however, that if any audit under this Section 4.1 results in material findings, the cost of such audit shall be paid by BDI Pharmaceuticals. Dyadic will issue an audit report to BDI Pharmaceuticals and allow BDI Pharmaceuticals twenty (20) business days to correct and/or issue corrective actions for any non-conformities found in the course of an audit. BDI Pharmaceuticals lack of adherence to this time line will result in a material breach of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">4.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Records.</font><font style="font-family:inherit;font-size:12pt;">&#32;BDI Pharmaceuticals shall maintain and cause any subcontractors that it may use hereunder to maintain books and records, including, but not limited to protocols, protocol amendments, lab notebooks and raw data relating to the conduct of any study conducted as part of the Project and reports of the Governing Group and Technical Group (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Data</font><font style="font-family:inherit;font-size:12pt;">&#8221;) for the longer of fifteen (15) years or five (5) years following regulatory approval of the product to which the Study Data relates. BDI Pharmaceuticals shall provide Dyadic with access to, or copies of the Study Data, at Dyadic&#8217;s expense, within five (5) business days&#8217; following Dyadic&#8217;s written request therefor. In the event that BDI Pharmaceuticals plans to dispose of any Study Data following the conclusion of the time-frame stated above, BDI Pharmaceuticals shall provide Dyadic with thirty (30) days prior written notice and an option to transfer such records to Dyadic, at Dyadic&#8217;s expense.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 5</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Background IP.</font><font style="font-family:inherit;font-size:12pt;">&#32;As between the Parties, each Party will own and retain all right, title and interest in and to their Background IP. &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Background IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Party, any inventions, technology, know-how, trade secrets and any other intellectual property owned or controlled by such Party prior to the Effective Date or developed or otherwise obtained by such Party outside the scope of this Agreement. Background IP shall also mean, with respect to Dyadic, intellectual property that is developed other than Collaboration IP, as provided herein. For the sake of clarity, without limitation, Background IP with respect to Dyadic shall include C1 Strains, Dyadic Improved Strains, Dyadic C1 Genomic Information, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents and/or any derivatives or modifications thereof and the Dyadic Follow-On IP and any results related thereto. Nothing in this Agreement grants or implies a license in any intellectual property of either Party except that BDI Pharmaceuticals hereby provides Dyadic with a non-exclusive, perpetual and royalty free license to use the BDI Pharmaceuticals&#8217; Background IP as far as necessary for Dyadic to make use of the Results.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaboration IP.</font><font style="font-family:inherit;font-size:12pt;">&#32;Inventorship shall be determined according to United States practice. &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaboration IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Party, any inventions, technology, know-how, trade</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">secrets and any other intellectual property, whether patentable or not, that has been conceived or reduced to practice pursuant to this Agreement or that is related to the Project. Subject to the restrictions set forth in Section 5.1, and any permissions BDI Pharmaceuticals may have to use Results as provided herein, Dyadic shall own all right, title and interest in and to the Collaboration IP and the Results, regardless of inventorship.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Responsibility for Preparation and Prosecution of IP.</font><font style="font-family:inherit;font-size:12pt;">&#32;BDI Pharmaceuticals shall notify Dyadic promptly in writing of all Collaboration IP or Dyadic Follow-On IP conceived or generated by BDI Pharmaceuticals. BDI Pharmaceuticals agrees to assign, as applicable, and hereby irrevocably assigns to Dyadic all of its right, title and interest in and to the Collaboration IP and the Results or the Dyadic Follow-On IP, as necessary to affect Dyadic&#8217;s sole ownership. Dyadic shall have the sole right and authority, but not the obligation, for the filing, prosecution and maintenance of the Collaboration IP. BDI Pharmaceuticals shall render all necessary assistance reasonably requested by Dyadic in preparing, filing and prosecuting the Collaboration IP. If necessary and when requested, BDI Pharmaceuticals shall (i) sign and execute all such forms and documents as may be necessary to assure and perfect rights in the Collaboration IP and the Dyadic Follow-On IP; and (ii) cause its current and/or former directors, employees, researchers, students, consultants and/or contractors to sign and execute all such forms and documents as may be necessary to perfect the Collaboration IP or the Dyadic Follow-On IP. Dyadic shall bear the costs and expenses for preparing, filing and prosecuting the Collaboration IP pursuant to this Section 5.3.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Non-Exclusive Limited Use Research License Grant from Dyadic to BDI Pharmaceuticals.</font><font style="font-family:inherit;font-size:12pt;">&#32;Dyadic hereby grants to BDI Pharmaceuticals (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sublicensee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) a non-exclusive, non-transferable, non-sub-licensable, except as set forth herein, and fully paid license of the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents and Dyadic Follow-On IP, the grant of the non-exclusive license being for the sole purpose of conducting research as contemplated by the Project and only broad enough to perform the Project in accordance with the terms of this Agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">R&amp;D License</font><font style="font-family:inherit;font-size:12pt;">&#8221;). The C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools and the Danisco Patents, any components of the C 1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools and the Danisco Patents, and any derivatives or modifications of any of the foregoing, shall be used by Sublicensee and its Affiliates only in accordance with and for the execution of this Agreement, the completion of the Project and in compliance with applicable law. For the sake of clarity, (i) Sub licensee shall not transfer or deliver any C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools or the Danisco Patents, any components of the Cl Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools or the Danisco Patents, or any derivatives or modifications of any of the foregoing, to any Third Party without the prior written consent of Dyadic, which consent may be withheld in Dyadic&#8217;s absolute discretion, and (ii) Sublicensee may not transfer or sublicense the R&amp;D License for any purpose (a) except to the extent necessary to have Third Parties conduct contract research on behalf of the Sublicensee or for the Sub licensee to exercise its &#8220;have made&#8221; rights; (b) unless such subcontractor agrees in a signed writing to relinquish any and all rights to the commercial product and/or process of using C1 to </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">make and sell the product without payment in addition to the amount negotiated for the provision of contract research services; and (c) unless such subcontractor agrees in a signed writing to protect, abide by and not otherwise violate the terms of the Pharma License Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.5</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Additional Conditions Incorporated from Pharma License Agreement. </font><font style="font-family:inherit;font-size:12pt;">Sublicensee acknowledges that it has read the Pharma License Agreement entered into between Danisco US Inc. and Dyadic International, Inc. and agrees to be bound by the provisions of such Pharma License Agreement as if it were a party to such Pharma License Agreement. For the avoidance of doubt, this includes the provisions of Section 10.7 of the Pharma License Agreement regarding resolution of disputes. Sublicensee agrees that Danisco US Inc. or any authorized assignee of Danisco US Inc. is an intended third party beneficiary to any Sub license Agreement and shall be entitled to enforce the terms of this Agreement directly against Sublicensee. This Sublicense Agreement shall not be further sublicensed except that, as applicable, the C1 Strains (as defined in the Pharma License Agreement), the Danisco Improved Strains, the Dyadic Know-How (as defined in the Pharma License Agreement), the Dyadic Materials (as defined in the Pharma License Agreement), Dyadic Patents, Danisco Know-How, the Genetic Tools (as defined in the Pharma License Agreement) and the Danisco Patents may be further sublicensed to the extent necessary to Third Parties having no economic interest in the Pharmaceutical Product under development to provide contract research services or contract manufacturing services for a Licensed Party (as defined in the Pharma License Agreement), for a Sublicensee to exercise its &#8216;have made&#8217; rights or, with respect to a Pharmaceutical Product, to grant limited sublicenses within multiple tiers of Sublicensee Affiliates (as defined in the Pharma License Agreement) or Third Parties solely to permit manufacturing, distributing or marketing such Pharmaceutical Products on behalf of such Sublicensee under terms no less restrictive than the terms set forth in Section 2.2 of the Pharma License Agreement entered into between Danisco US Inc. and Dyadic International Inc.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.6</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Follow-On IP. </font><font style="font-family:inherit;font-size:12pt;">Dyadic shall own all Dyadic Follow-On IP, regardless of (i) inventorship; (ii) whether the Dyadic Follow-On IP is conceived or reduced to practice pursuant to this Agreement; and (iii) whether the Follow-On IP is related to the Project. As used herein, Dyadic Follow-On IP shall include all inventions, technology, know-how, trade secrets and any other intellectual property or results related to the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic C1 Genomic Information, Dyadic Patents, Danisco Know-How, the Dyadic Improved Strains, the Genetic Tools, the Danisco Patents and/or any derivatives or modifications thereof, BDI Services Generated Tools, Dyadic C1 Genomic Information and/or improved media and fermentation development and processes (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Follow-On IP</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.7</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Results. </font><font style="font-family:inherit;font-size:12pt;">All Results shall be owned by Dyadic and Dyadic shall be free to exploit the same at its own discretion. BDI Pharmaceuticals hereby assigns and transfers all intellectual property rights attached to the Results to Dyadic without any additional cost. BDI Pharmaceuticals shall take all acts necessary for the intellectual property rights to vest with Dyadic or sign any documents necessary to record the intellectual property rights in the name of Dyadic.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.8</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Restrictions on Use and Transfer of the Dyadic Materials and C1 Strains.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;The Dyadic Materials, the C1 Strains, any components of the Dyadic Materials and C1 Strains, and any derivatives or modifications of any of the foregoing, shall be used by BDI Pharmaceuticals and its Affiliates only in accordance with and for the execution of this Agreement, the R&amp;D License, the Pharma License Agreement and in compliance with applicable law.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;BDI Pharmaceuticals and its Affiliates shall not transfer, deliver or sub license any C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic C1 Genomic Information, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents, the Dyadic Background IP, Collaboration IP or Dyadic Follow-On IP, any components of the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic C1 Genomic Information, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents, the Dyadic Background IP, the Collaboration IP or the Dyadic Follow-On IP, or any derivatives or modifications of the foregoing or results related thereto without the prior written consent of Dyadic, which consent may be withheld in its absolute discretion.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 6</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SELECTED PRODUCT </font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">/ </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NET SALES SHARING</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">6.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Product Benefit Sharing.</font><font style="font-family:inherit;font-size:12pt;">&#32;According to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;of this Agreement (Project Scope) there will be a first Phase where up to six (6) product candidates will be analyzed for expression and only one of them will be selected for further development under the Agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Selected Product</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Dyadic shall be free to use any and all of the results, and technologies developed under this Agreement and/or related to any and all of the other products other than the Selected Product. For the sake of clarity, Dyadic will not owe any monies, royalty or future payment to BDI Pharmaceuticals or its Affiliates for the use of any of the research, or products or processes derived directly or indirectly from the research carried out by BDI Pharmaceuticals and its Affiliates under this Agreement other than with respect to the Selected Product.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;In relation to the Selected Product, BDI Pharmaceuticals will decide, in its sole discretion, to further develop the Selected Product. Such decision will be communicated in writing to Dyadic within one hundred and twenty (120) days (or such longer period as the Parties may agree in writing) following the Term.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;Should BDI Pharmaceuticals decide to enter into the development of the Selected Product, the Parties shall use diligent and good faith efforts to negotiate and enter into a development and net sales sharing agreement, which shall include all necessary economic terms and intellectual property licenses for the further development and sales of the Selected Product (provided, however, that in no event shall such requirement be interpreted to require Dyadic to issue licenses that in their sole opinion would constitute a violation of the Pharma License Agreement), which shall be substantially in the form of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit E</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto and made a part hereof, within ninety (90) days (or such longer period as the Parties may agree in writing) after the approval of such commercialization by BDI Pharmaceuticals (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Negotiation Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;). For the sake of clarity, Exhibit E does not imply a current commitment by BDI Pharmaceutical&#8217;s to invest in or commercialize the Selected Product.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;Should BDI Pharmaceuticals decide not to enter into the development and net sales sharing agreement during the Negotiation Period, Dyadic may, in its sole discretion, continue the development of the Selected Product at its sole expense; provided, however that any Project funding remaining at such time may be used to transfer the Project to Dyadic. Thereafter, Dyadic shall pay to BDI Pharmaceuticals an amount equal to One Million Five Hundred Thousand Euros (&#8364;1,500,000) upon commercialization of the Selected Product. Such payment shall be paid by directing 100% of the Product Net Income ( as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit E</font><font style="font-family:inherit;font-size:12pt;">) on the Selected Product to BDI Pharmaceuticals until an amount equal to One Million Five Hundred Thousand Euros (&#8364;1,500,000) has been paid by Dyadic to BDI Pharmaceuticals.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 7</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONFIDENTIALITY</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">7.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Definition.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any information disclosed by one Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) to the other (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), whether oral, written, visual, electromagnetic, electronic or in any other form, and whether contained in memoranda, summaries, notes, analyses, compilations, studies or other documents, and whether the same have been prepared by the Disclosing Party or the Receiving Party: (i) which, if in written, graphic, machine-readable or other tangible form is marked as &#8220;Confidential&#8221; or &#8220;Proprietary,&#8221; or which, if disclosed orally or by demonstration, is identified at the time of initial disclosure as confidential and is summarized in writing and similarly marked and delivered to the Receiving Party within thirty (30) days after initial disclosure; and (ii) which includes but is not necessarily limited to (A) technical data or information, including proprietary host organisms and their strains, plasmids/vectors, DNA sequences, gene expression, fungal high throughput screening, enzymes and their applications, research and manufacturing protocols and practices, formulae, charts, analyses, reports, patent applications, trade secrets, ideas, methods, processes, know-how, computer programs, products, equipment, raw materials, designs, data sheets, schematics, configurations, specifications, techniques, drawings, and the like, whether or not relating to experimental data, projects, products, processes, research practices and the like; (B) past, present and future business, financial and commercial data or information, prices and pricing methods, marketing and customer information, financial forecasts and projections, and other data or information relating to strategies, plans, budgets, sales and the like; and (C) any other data or information delivered by the Disclosing Party to the Receiving Party or which the Receiving Party has acquired from the Disclosing Party by way of the former&#8217;s inspection or observation during visits to the research laboratory, manufacturing plan or other type of facility of the latter Party. The Parties expressly acknowledge and agree that all information of a proprietary and/or confidential nature furnished by the Disclosing Party to the Receiving Party in furtherance of the Disclosing Party&#8217;s obligations under this Agreement shall be deemed Confidential Information. Subject to the restrictions and permissions set forth herein, the Results, Collaboration IP, Follow-On IP and Background IP shall be Confidential Information of Dyadic. Notwithstanding anything to the contrary contained herein, any failure by the Disclosing Party to mark, identify or confirm the Confidential Information shall not relieve Receiving Party of its obligations under this Agreement where Receiving Party knows or has reason to know that the information disclosed to it is Confidential Information.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">7.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential Information Exclusions.</font><font style="font-family:inherit;font-size:12pt;">&#32;Confidential Information will exclude information the Receiving Party can demonstrate is: (i) now or hereafter, through no </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">unauthorized act or failure to act on Receiving Party&#8217;s part, in the public domain; (ii) known to the Receiving Party from a source other than the Disclosing Party (including former employees of the Disclosing Party) without an obligation of confidentiality at the time Receiving Party receives the same from the Disclosing Party, as evidenced by contemporaneous written records; (iii) furnished to others by the Disclosing Party without restriction on disclosure; or (iv) independently developed by the Receiving Party without use of the Disclosing Party&#8217;s Confidential Information, as evidenced by contemporaneous written records.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">7.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidentiality Obligation.</font><font style="font-family:inherit;font-size:12pt;">&#32;For a period commencing on this date and ending on the tenth (10th) anniversary after the termination of the Agreement, the Receiving Party shall treat as confidential all of the Disclosing Party&#8217;s Confidential Information and shall not use such Confidential Information for any purpose whatsoever other than for the purposes set forth herein, except as expressly otherwise permitted under this Agreement. Without limiting the foregoing, the Receiving Party shall use the same degree of care and means that it utilizes to protect its own information of a similar nature, but in any event not less than reasonable care and means, to prevent the unauthorized use or the disclosure of such Confidential Information to Third Parties. The Confidential Information may be disclosed only to employees or contractors of the Receiving Party with a &#8220;need to know&#8221; who are instructed and agree not to disclose the Confidential Information and not to use the Confidential Information for any purpose, except as set forth herein; provided, however, in the case of BDI Pharmaceuticals and its Affiliates, the term &#8220;employees or contractors of a Receiving Party&#8221; shall include employees of each of those of BDI Pharmaceuticals, its Affiliates and any contract research organizations with whom BDI Pharmaceuticals or its Affiliates has written agreements pursuant to which such contract research organization is performing or will perform work under a Project and is bound by an obligation of confidence to BDI Pharmaceuticals or its Affiliates that makes such contract research organization liable for any breach by its employees of those confidentiality obligations to BDI Pharmaceuticals or its Affiliates. The Receiving Party shall have appropriate written agreements with any such employees or contract research organizations sufficient to comply with the provisions of this Agreement. A Receiving Party may not alter, decompile, disassemble, reverse engineer or otherwise modify any Confidential Information received hereunder and the mingling of the Confidential Information with information of the Receiving Party shall not affect the confidential nature or ownership of the same as stated hereunder.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">7.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Permitted Disclosures of Confidential Information.</font><font style="font-family:inherit;font-size:12pt;">&#32;Nothing in this Agreement shall prevent the Receiving Party from disclosing Confidential Information to the extent the Receiving Party is legally compelled to do so by any governmental investigative or judicial agency pursuant to proceedings over which such agency has jurisdiction; provided, however, that prior to any such disclosure and to the extent permitted by law, the Receiving Party shall (i) assert the confidential nature of the Confidential Information to the agency; (ii) immediately notify the Disclosing Party in writing of the agency&#8217;s order or request to disclose; and (iii) cooperate fully with the Disclosing Party in protecting against any such disclosure and/or obtaining a protective order narrowing the scope of the compelled disclosure and protecting its confidentiality. In addition and notwithstanding Section 7.3, BDI Pharmaceuticals may disclose the Results to a Third Party if it has received written consent to such disclosure from Dyadic. In requesting such consent, BDI Pharmaceuticals shall provide the following information to Dyadic: (i) evidence that the Third Party to whom the disclosure is proposed to be made has executed, or will execute prior to receipt of Results, a confidentiality agreement with BDI Pharmaceuticals that prevents</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">such Third Party from further disclosure of such information and contains restrictions on disclosure of Confidential Information at least as stringent as those found herein; and (ii) the proposed disclosure of Results. BDI Pharmaceuticals agrees that Dyadic may, in its sole discretion, refuse to consent to the disclosure and/or may require BDI Pharmaceuticals to delete any Dyadic Confidential Information from the proposed disclosure.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 8</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">8.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Representations and Warranties of the Parties.</font><font style="font-family:inherit;font-size:12pt;">&#32;Each of the Parties represents and warrants to the other Party that:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;it is a company duly organized, validly existing and in good standing under the laws of, in the case of Dyadic, Delaware, and in the case of BDI Pharmaceuticals, Spain;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;the execution of this Agreement on its behalf has been properly authorized by all necessary corporate or company action, as the case may be;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;this Agreement is valid and binding on it and enforceable against it in accordance with the terms hereof, subject to applicable bankruptcy and similar laws affecting creditors&#8217; rights and remedies generally, and subject, as to enforceability, to general principles of equity;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;neither the execution nor the performance of this Agreement will constitute a breach or violation of the terms of its charter or organizational documents or any contract, agreement or other commitment to which it is a party or by which it or any of its properties are bound;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;there are no bankruptcy, insolvency, receivership or similar proceedings involving it or any of its Affiliates either pending or contemplated, or any other pending or threatened actions, suits, arbitrations or other proceedings by or against it;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;the execution, delivery and performance of this Agreement does not and will not conflict with or result in breach of any term, condition, obligation or restriction of any other agreement of the Parties with any Third Party; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;it has not used and shall not use in the course of its performance hereunder, and shall not disclose to the other, any confidential information of any other Person, unless it is expressly authorized in writing by such Person to do so.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">8.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Representations and Warranties of Dyadic.</font><font style="font-family:inherit;font-size:12pt;">&#32;Dyadic represents and warrants to BDI Pharmaceuticals that the Dyadic Materials do not contain any intellectual property, proprietary information or materials, content, software or other materials of any Third Party that would require BDI Pharmaceuticals or its Affiliates to acquire a license or otherwise pay a Third Party for the use thereof in accordance with the terms of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">8.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Representations and Warranties of BDI Pharmaceuticals.</font><font style="font-family:inherit;font-size:12pt;">&#32;BDI Pharmaceuticals hereby represents and warrants to Dyadic that:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;all licenses or other material rights or permissions to use any Third Party intellectual property used by BDI Pharmaceuticals or its Affiliates in the operation of their respective businesses have been obtained by the BDI Pharmaceuticals or its Affiliates and all license fees, royalties and any other amounts (if any) due and payable under such license agreements have been paid;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;no activities will be carried out by BDI Pharmaceuticals or its Affiliates or subcontractors hereunder on behalf of Dyadic or any third party that directly or indirectly incorporates or uses the C1 Technology in any manner that will require a license, milestones, royalties or payments of any kind other than those payments set forth herein or on a Statement of Work signed by both Parties;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;it shall have the necessary facilities, lab equipment and personnel to timely and efficiently carry out all work as may be set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;it will perform the Project using its good faith Best Efforts to achieve the expected outcomes indicated in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;for each Project task in accordance with prevailing industry standards and as guided by the Governing Group and the Technical Group (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Project Objective</font><font style="font-family:inherit;font-size:12pt;">&#8221;);</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;it will perform the Projects in accordance with all applicable laws, rules, regulations and guidances;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;it shall use commercially reasonable efforts to ensure that the condition and calibration of all equipment used to perform the Projects hereunder is properly and adequately maintained;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;it will comply with all appropriate animal welfare rules, as specified by law, Dyadic or the Institutional Animal Care and Use Committee (IACUC) that governs animal studies conducted by BDI Pharmaceuticals;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;no individual that has been debarred or disqualified by the FDA pursuant to 21 U.S.C. &#167;335a (a) or (b) or by the European Medicines Agency, the European Commission, or the Regulatory Authority of an European Union Member State under any foreign equivalent thereof will perform or render, any Services or assistance to BDI Pharmaceuticals;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;it has no knowledge of any circumstances which may affect the accuracy of the foregoing warranties and representations, including, but not limited to, the US Food and Drug Administration, European Medicines Agency or other governmental investigations of, or debarment proceedings against, BDI Pharmaceuticals or any person or entity performing Services or rendering assistance relating to activities taken pursuant to this Agreement, and BDI Pharmaceuticals will immediately notify Dyadic if BDI Pharmaceuticals becomes aware of any such circumstances during the Term;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)&#160;&#160;&#160;&#160;it shall attract, hire and/or otherwise retain the Key Persons within thirty (30) days of the Effective Date and thereafter, it shall notify Dyadic within five (5) business days of the date it becomes aware of the pending or actual termination of services of any Key Person; and</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)&#160;&#160;&#160;&#160;to the extent it uses confidential information of any other Person in the course of its performance hereunder, it has been expressly authorized to do so in writing and warrants that there will be no cost to Dyadic now, or in the future, related to the use of such information, in excess of the amounts mutually agreed to be paid pursuant to the commercialization agreement to be entered into pursuant to Section 6.1.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">8.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclaimer. </font><font style="font-family:inherit;font-size:12pt;">Except for the foregoing warranties, THE FOREGOING WARRANTIES OF EACH PARTY ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY AND FITNESS FOR PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY DISCLAIMED.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 9</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INDEMNIFICATION</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">9.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">In General. </font><font style="font-family:inherit;font-size:12pt;">Subject to the provisions of Section 9.4, each Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnifying Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">shall defend, indemnify and hold harmless the other Party, its Affiliates, and its and their employees, officers, directors, agents and licensees (each an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnified Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">against any loss, damage, expense or cost, including reasonable attorneys&#8217; fees, arising out of any claim, demand, action, suit, investigation, arbitration or other proceeding by a Third Party (an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Action</font><font style="font-family:inherit;font-size:12pt;">&#8221;)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">based on (i) the Indemnifying Party&#8217;s breach of this Agreement; or (ii) negligence, willful misconduct or violation of any law or regulation by the Indemnifying Party, its Affiliates, or its or their employees, officers, directors or agents. This requirement for indemnification is meant by the Parties to extend to the Representations and Warranties set forth in Article 8.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">9.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Procedure. </font><font style="font-family:inherit;font-size:12pt;">If an Indemnified Party becomes aware of any Action it believes is indemnifiable under Section 9.1, (i) the Indemnified Party shall give the Indemnifying Party prompt written notice of such Action; (ii) the Indemnifying Party shall assume, at its expense, the sole defense of such claim or cause of action through counsel selected by it and reasonably acceptable to the Indemnified Party, except that in the case of a conflict of interest between the Parties, the Indemnifying Party shall, at the Indemnifying Party&#8217;s expense, provide separate counsel for the Indemnified Party selected by the Indemnified Party; (iii) the Indemnifying Party shall maintain control of such defense, including any decision as to settlement, except that any settlement of an Action shall require the written consent of both Parties, which consent shall not be withheld or delayed unreasonably; (iv) the Indemnified Party may, at its option and expense, participate in such defense, and in any event, the Parties shall cooperate with one another in such defense; and (v) the Indemnifying Party shall bear the total costs of any court award or settlement in such Action.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">9.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party Infringement. </font><font style="font-family:inherit;font-size:12pt;">Each of the Parties shall indemnify, defend and hold harmless the other Party and its Affiliates and their respective officers, directors and employees from any losses, damages, liabilities, fines, penalties and expenses (including reasonable attorneys&#8217; fees) that arise out of or result from any Third Party claims of infringement of any patent or copyright, or misappropriation of any trademark, trade secret or other intellectual property right, private right or any other proprietary or personal interest related by circumstances to the existence of this Agreement or the Project (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Infringement Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Dyadic&#8217;s obligation with regard to indemnifying BDI Pharmaceuticals hereunder shall be limited to breaches of its (i)</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">18</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">obligations under Article 5, or (ii) representations and warranties set forth in Section 8.2 with respect to the status of the intellectual property discussed therein as of the date hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">9.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Limitation of Liability.</font><font style="font-family:inherit;font-size:12pt;">&#32;NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, BOTH PARTIES AGREE THAT IN NO EVENT SHALL EITHER PARTY, OR ANY OF ITS AFFILIATES, OR ANY OF THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, MEDICAL OR PROFESSIONAL STAFF, EMPLOYEES OR AGENTS BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE RIGHTS GRANTED HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, REGARDLESS OF WHETHER SUCH PARTY SHALL BE OR HA VE BEEN ADVISED, SHALL HAVE REASON TO KNOW OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING. A PARTY&#8217;S MAXIMUM LIABILITY FOR ALL DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT SHALL IN NO EVENT EXCEED, IN THE AGGREGATE, EUR 936,000; PROVIDED HOWEVER, THAT IN NO EVENT SHALL EITHER PARTY&#8217;S LIABILITY FOR INFRINGEMENT UNDER SECTION 9.3, INFRINGEMENT BY ONE PARTY OR ITS AFFILIATES OF THE OTHER PARTY&#8217;S INTELLECTUAL PROPERTY, BREACH OF CONFIDENTIALITY, FRAUD OR WILLFUL MISCONDUCT BE LIMITED BY THIS SECTION 9.4.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN ADDITION, EACH PARTY HEREBY ACKNOWLEDGES THAT THE OTHER PARTY CANNOT AND DOES NOT ASSURE THE FIRST PARTY THAT THE PROJECT WILL CULMINATE IN THE SUCCESSFUL ACHIEVEMENT OF THE PROJECT OBJECTIVES. ACCORDINGLY, EACH PARTY HEREBY EXPRESSLY AGREES EXCEPT IN THE INSTANCE OF A MATERIAL BREACH BY THE OTHER PARTY OF ITS OBLIGATIONS HEREUNDER, NO PARTY SHALL HAVE LIABILITY OF ANY KIND WHATSOEVER TO THE OTHER PARTY BY REASON OF FAILURE OF THE PROJECT TO SUCCESSFULLY ACHIEVE THE PROJECT OBJECTIVES.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 10</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TERM AND TERMINATION</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term.</font><font style="font-family:inherit;font-size:12pt;">&#32;This Agreement shall enter into force upon the closing of the transactions contemplated by the Investment Agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and shall end upon completion of the Project (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term</font><font style="font-family:inherit;font-size:12pt;">&#8221;), excluding the Articles and Sections and their legal effects of which are meant to survive the termination or expiration of the Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Termination in the Event of Insolvency.</font><font style="font-family:inherit;font-size:12pt;">&#32;Either Party may terminate this Agreement if the other Party becomes insolvent, voluntarily files a petition for relief under bankruptcy or any similar or other insolvency laws (or has a petition filed against it and the same remains undischarged or unstayed for sixty (60) days) or voluntarily or involuntarily enters receivership or any similar or other insolvency proceeding.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Termination for Breach.</font><font style="font-family:inherit;font-size:12pt;">&#32;Without prejudice to any other damages or remedies available under applicable law and/or this Agreement, either Party has the right, at any time, to terminate this Agreement by written notice and without further formality upon a breach by the other Party</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">19</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">in the performance of the provisions of this Agreement, provided such breach is not cured within thirty (30) days following receipt by the defaulting Party of a written notice from the non-defaulting Party to remedy such breach. However, (i) in case of a breach, which is not capable of being cured; or (ii) where any Party repeatedly or consistently fails to meet its contractual obligations following an initial cure period, the other Party has the right to terminate this Agreement immediately, by written notice and without any further formality and (additional) cure period.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Termination by Dyadic. </font><font style="font-family:inherit;font-size:12pt;">Dyadic may terminate this Agreement (i) at any time upon one-hundred eighty (180) days written notice to BDI Pharmaceuticals; (ii) within ninety (90) days before or after the one-year anniversary of the Effective Date, upon ninety (90) days written notice to BDI Pharmaceuticals; (iii) upon thirty (30) days written notice to BDI Pharmaceuticals, in the event that the Parties fail to timely enter into a commercialization agreement prior to the expiration of the Negotiation Period; or (iv) immediately upon the termination of the services of any Key Person or failure to hire any Key Person within the time allotted herein.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.5</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effect of Termination.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accrued Rights and Obligations.</font><font style="font-family:inherit;font-size:12pt;">&#32;Termination of this Agreement hereunder for any reason shall not release any Party from any obligation which, at the time of such termination, has already accrued and become due to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Return of Confidential Information and Materials.</font><font style="font-family:inherit;font-size:12pt;">&#32;Upon any termination of this Agreement, BDI Pharmaceuticals shall promptly return to Dyadic all Confidential Information received from Dyadic. BDI Pharmaceuticals may retain a copy of the Confidential Information that must thereafter be used solely as a legal record of the Confidential Information under this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Destruction of Confidential Information and Materials.</font><font style="font-family:inherit;font-size:12pt;">&#32;Upon any termination of this Agreement, Dyadic may request BDI Pharmaceuticals to destroy all Confidential Information received from Dyadic instead of returning it in accordance with paragraph (b) above. BDI Pharmaceuticals may retain a copy of the Confidential Information that must thereafter be used solely as a legal record of the Confidential Information under this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rights in IP.</font><font style="font-family:inherit;font-size:12pt;">&#32;In the event of termination of this Agreement either on or prior to the expiration of the Term by either Party, all rights and licenses of BDI Pharmaceuticals to Background IP and Results shall automatically terminate and/or revert back to Dyadic and any license grants from Dyadic to BDI Pharmaceuticals, such, for example, without limitation, the license grants provided in Article 5, shall terminate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Other Remedies Available.</font><font style="font-family:inherit;font-size:12pt;">&#32;Notwithstanding anything in this Agreement to the contrary, in the event of termination of this Agreement, each Party shall have available every remedy allowed under law and equity, including but not limited to specific performance, suit for damages and rescission.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">20</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.6</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Survival.</font><font style="font-family:inherit;font-size:12pt;">&#32;Notwithstanding anything to the contrary contained herein, the provisions of Recital VII, Article 1, Section 2.2, Article 4, Sections 5.1 through 5.3, Sections 5.4 through Section 5.8, Articles 6 through Article 9, Section 10.5, Section 10.6 and Article 11 shall survive any termination of this Agreement.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 11</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MISCELLANEOUS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Relationship between Parties.</font><font style="font-family:inherit;font-size:12pt;">&#32;Dyadic and BDI Pharmaceuticals are separate business entities, and shall not be considered as joint ventures, partners, agents, servants, employee or fiduciaries of each other. The Parties specifically agree that any obligation to act in good faith and to deal fairly with each other which may be implied in law shall be deemed satisfied by the Parties&#8217; compliance with the express terms of this Agreement</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">No Implied Rights.</font><font style="font-family:inherit;font-size:12pt;">&#32;Other than expressly provided for in this Agreement, nothing in this Agreement grants or shall be construed to grant to any Party any right and/or any license to any intellectual property right or application therefor (including but not limited to patent applications or patents) which are held by and/or in the name of the other Party and/or which are controlled by or licensed by the other Party, or to any Confidential Information received from the other Party.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Entire Agreement; Amendment.</font><font style="font-family:inherit;font-size:12pt;">&#32;This Agreement constitutes the entire Agreement between the Parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, commitments and writings in respect thereof. No amendment or addition to this Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the Parties.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Force Majeure.</font><font style="font-family:inherit;font-size:12pt;">&#32;Neither Party shall be held in breach of its obligations hereunder to the extent only that due performance or observance of such obligation is prevented or delayed by war and other hostilities, civil commotion, accident, trade disputes, acts or restraints of government imposition or restrictions of imports or exports or any other cause not within the control of the Party concerned. The Party concerned shall forthwith notify the other Party of the nature and effect of such event and both Parties shall, where the same is practicable, use every reasonable endeavor to minimize such effect and to comply with the respective obligation herein contained as nearly as may be in their original form.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.5</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Foreign Corrupt Practices Act and Anti-Bribery Provisions.</font><font style="font-family:inherit;font-size:12pt;">&#32;During the Term, the Parties will not, and shall cause their Affiliates to not, make or provide any payments or gifts or any offers or promises of any kind, directly or indirectly, to any official of any government or to any official of any agency or instrumentality of any government, or to any political party or to any candidate for political office (the foregoing individually and collectively referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Government Official</font><font style="font-family:inherit;font-size:12pt;">&#8221;). If, on the Effective Date, or at any time during the Term any Government Official or an active member of the armed services of any government (i) owns an interest in that certain Party or its Affiliate, (ii) has any legal or beneficial interest in this Agreement or in payments to be received by that certain Party or its Affiliate in connection with the Services to be provided by hereunder, or (iii) is a director, officer or employee of that certain Party or its Affiliate, that certain Party will notify the other Party and will take such actions to</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">21</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">assure that the affected person does not take any action, official or otherwise and/or use any influence in connection with the other Party&#8217;s business.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.6</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Assignment.</font><font style="font-family:inherit;font-size:12pt;">&#32;Except as otherwise set forth herein, neither Party shall assign all or part of its rights or obligations under this Agreement without the prior written consent of the other Party, which consent may be withheld in their absolute discretion; provided, however, that this Agreement may be assigned at any time by either Party in connection with the merger or acquisition of the respective Party or the sale of all or substantially all of the assets of the Party to which this Agreement relates. The Parties rights under this Agreement shall bind and inure to the benefit of their respective successors, heirs, executors, administrators and permitted assigns.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.7</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Severability.</font><font style="font-family:inherit;font-size:12pt;">&#32;In the event any one or more of the provisions of this Agreement should for any reason be held by any court or authority having jurisdiction over this Agreement or any of the Parties hereto be invalid, illegal or unenforceable, such provision(s) shall be validly reformed to as nearly approximate the intent of the Parties as possible and if unreformable, the Parties shall meet to discuss in good faith what steps should be taken to remedy the situation.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.8</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Publicity; Use of Name.</font><font style="font-family:inherit;font-size:12pt;">&#32;Notwithstanding anything to the contrary in this Agreement, Dyadic may issue any press releases or make any other public statement with respect to the transactions contemplated hereby or the Results yielded hereunder without the prior consent of BDI Pharmaceuticals and notwithstanding the existence of any confidentiality or non-disclosure obligations that Dyadic may have, which, for the avoidance of doubt, may include the filing of this Agreement or any Exhibit hereto and/or summaries thereof with the U.S. Securities and Exchange Commission by Dyadic as required by U.S. federal securities law (such requirement to be determined by Dyadic in its sole discretion) and industry and investor conferences and presentations. BDI Pharmaceuticals may not issue any press releases or make any other public statement with respect to the transactions contemplated hereby or the Results yielded hereunder without the prior written consent of Dyadic, which may be withheld in Dyadic&#8217;s sole discretion. The Parties may (i) disclose the terms of this Agreement to such Party&#8217;s auditors, attorneys, bankers or investment bankers as necessary for their rendition of services to such Party; and (ii) disclose the terms of this Agreement to bona fide prospective investors, merger partners, strategic partners, or acquirors and their respective professional advisors, in connection with the negotiation, entry into and/or performance of a business transaction between such parties, including the conduct of due diligence involved in such transaction, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided, however, that </font><font style="font-family:inherit;font-size:12pt;">such parties are subject to obligations of confidentiality and non-use at least as restrictive as those set forth in Article 7. During the Term and for a reasonable time thereafter, Dyadic may use BDI Pharmaceuticals&#8217; and its Affiliates&#8217; names and logos in press releases, marketing material and/or advertisements disclosing the existence of this Agreement. Except for disclosures permitted pursuant to this Section 11.8, neither Party will use the other&#8217;s name for advertising or external publicity purposes without its consent, except that Dyadic may include in its promotional materials references to and quotations from publications of results of the Projects.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.9</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Notices.</font><font style="font-family:inherit;font-size:12pt;">&#32;All notices, requests, reports and other communications provided in this Agreement shall be in writing and shall be deemed to have been made or given: (i) when delivered, if delivered by hand; (ii) when confirmation of transmission received, if sent by facsimile or by email; (iii) two days following deposit with an overnight courier; or (iv) on the</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">22</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">date ten business days following deposit, as certified or registered mail, with the postal service of the country of the Party providing notice:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">To Dyadic:</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Att: Mark Emalfarb</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Address: 140 Intracoastal Pointe Drive,</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite# 404, Jupiter, Florida, 33477 USA </font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">E-mail: memalfarb@dyadic.com</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tel: (561) 743-8333</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Fax: (561) 743-8513</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With a copy to:</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Att: Laura Nemeth</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Squire, Patton Boggs (US) LLP</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">127 Public Square, Suite 4900</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cleveland, Ohio 44114</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email: laura.nemeth@squirepb.com</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tel: 216-479-8552</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Fax: 216-479-8780</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">To BDI Pharmaceuticals:</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Att: Emilio Gutierrez</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biotechnology Developments for</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Industry in pharmaceuticals S.L.U </font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Louist Proust 13</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4 7151 Boecillo (Valladolid) Spain</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">E-mail: egutierrez@bdibiotech.com</font></div><div style="line-height:120%;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tel: 983 548 563/ 983 010 722</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Fax: None</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.10</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Applicable Law and Arbitration.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;This Agreement shall be governed by, and interpreted under, the laws of Florida, USA, without application of rules on conflicts of laws.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Disputes between the Parties shall be resolved as provided by this Section 11.10. Any Party shall give the other Party written notice of any dispute under this or in connection with this Agreement. The Parties shall attempt to resolve such dispute promptly by negotiation among the chief executive officers of the Parties and his/her advisors and executive officers of the BDI Group and Dyadic, as applicable. Within thirty (30) days after delivery of the notice, the Party(ies) receiving the notice shall submit to the other a written response. The notice and response shall include: (A) a statement of each Party&#8217;s position and a summary of arguments supporting that position; and (B) in the case of any member of the BDI Group or Dyadic, the name and title of the executive officer of such Party who will represent such Party and, in the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">case of any Party, the name and title of any other person who will accompany such Party during the negotiations. Within thirty (30) days after delivery of the disputing Party&#8217;s notice, the Parties shall meet at a mutually acceptable time and place, and thereafter as often as they deem reasonably necessary, to attempt to resolve the dispute.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;If any dispute has not been resolved by the Parties in accordance with Section 11.10(b) within forty-five (45) days after the disputing Party&#8217;s request notice, or if the Parties fail to meet within thirty (30) days after such request notice, then each of the Parties agrees that such dispute shall be finally and exclusively settled without appeal by arbitration in New York City, New York, administered by the American Arbitration Association (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AAA</font><font style="font-family:inherit;font-size:12pt;">&#8221;) under its Commercial Arbitration Rules in effect as of the date of the request for arbitration, which rules are deemed to be incorporated into this Section 11.10(c) </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that in the event of any conflict between such rules and the other provisions of this Agreement, such other provisions of this Agreement shall control. The arbitration shall be conducted before a single arbitrator. The decision of the arbitrator shall be in writing, shall set forth the facts found by the arbitrator to exist, his/her decision and the basis for that decision and shall be final and binding upon the Parties and not subject to appeal. Judgment upon any award rendered by the arbitrator may be entered in any court having jurisdiction thereof, including any court having jurisdiction over any of the Parties or their assets. Each Party shall bear its own costs and expenses in connection with the arbitration, including reasonable attorneys&#8217; fees, disbursements, arbitration expense; arbitrators&#8217; fees and the administrative fee of the AAA.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.11</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Independent Parties; No Authority to Bind. </font><font style="font-family:inherit;font-size:12pt;">The relationship of BDI Pharmaceuticals and Dyadic is that of independent contractors. Neither Party nor their employees are agents, partners, employers, employees, joint venturers, have any other kind of relationship with the other Party except as specified in the Service Framework Agreement and the Investment Agreement. Neither Party shall have any authority to bind the other party to any obligation by contract or otherwise.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.12</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Non-Compete. </font><font style="font-family:inherit;font-size:12pt;">During the term of this Agreement and for a period of five (5) years thereafter, BDI Pharmaceuticals agrees that it will not work on C1 Strains for anyone other than Dyadic on pharmaceutical applications and/or processes (animal or human, including but not limited to active pharmaceutical ingredients or catalysts) unless so authorized in writing by the CEO of Dyadic. BDI Pharmaceuticals shall cause the substance of this clause to be included in any sub-contract for performance of Services hereunder. For the purposes of this Section, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">C1 Strains</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">shall be defined as any fungal strains that have the taxonomy of either (i) </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Myceliopthora, </font><font style="font-family:inherit;font-size:12pt;">(ii) </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Corynascus </font><font style="font-family:inherit;font-size:12pt;">or (iii) </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Sporotrichium </font><font style="font-family:inherit;font-size:12pt;">and any strains derived or generated from the C1 Strains transferred hereunder in the Project or under this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.13</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Construction of Agreement. </font><font style="font-family:inherit;font-size:12pt;">The Parties acknowledge that they thoroughly have reviewed this Agreement and bargained over its terms. Accordingly, this Agreement shall be construed without regard to the Party or Parties responsible for its preparation and shall be deemed to have been prepared jointly by the Parties.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.14</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cumulative Rights and Remedies. </font><font style="font-family:inherit;font-size:12pt;">The rights and remedies provided in this Agreement and all other rights and remedies available to either Party at law or in equity are, to the extent permitted by law, cumulative and not exclusive of any other right or remedy now or hereafter</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">available at law or in equity. Neither asserting a right nor employing a remedy shall preclude the concurrent assertion of any other right or employment of any other remedy, nor shall the failure to assert any right or remedy constitute a waiver of that right or remedy.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.15</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Headings. </font><font style="font-family:inherit;font-size:12pt;">All headings in this Agreement are included solely for convenient reference, are not intended to be full and accurate descriptions of the contents of this Agreement, shall not be deemed a part of this Agreement, and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.16</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendments. </font><font style="font-family:inherit;font-size:12pt;">This Agreement may be modified or amended only by written agreement of the Parties.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.17</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">English Language. </font><font style="font-family:inherit;font-size:12pt;">The Parties shall use the English language in all communications relating to this Agreement, and the English language version of this Agreement signed by the Parties shall control over any and all translations.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.18</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Entire Agreement. </font><font style="font-family:inherit;font-size:12pt;">This Agreement, together with any supporting documents recited herein, constitutes the entire agreement between the Parties concerning the subject matter of this Agreement and supersedes all prior agreements between the Parties concerning the subject matter hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.19</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Counterparts. </font><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Signature Page Follows</font><font style="font-family:inherit;font-size:12pt;">]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">25</font></div></div><hr style="page-break-after:always"><div><a name="s1985BDB1FCD190EC65E444D7A2449AC6"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in two counterparts by their duly authorized representatives, each Party acknowledging receipt of one original.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:40%;"></td><td style="width:3%;"></td><td style="width:8%;"></td><td style="width:40%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BIOTECHNOLOGY </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEVELOPMENTS FOR </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INDUSTRY IN </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PHARMACEUTICALS, S.L.U.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ Mark A. Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Mark A. Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Chief Executive Office</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6/30/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Signature Page to Research Services Agreement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">26</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in two counterparts by their duly authorized representatives, each Party acknowledging receipt of one original.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:40%;"></td><td style="width:3%;"></td><td style="width:8%;"></td><td style="width:40%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BIOTECHNOLOGY </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEVELOPMENTS FOR </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INDUSTRY IN </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PHARMACEUTICALS, S.L.U.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ Emilio Gutierrez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Emilio Gutierrez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attorney</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">30-6-2017</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">27</font></div></div><hr style="page-break-after:always"><div><a name="s7B544A2A7FCFFC2207D444D7A3945A46"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PROJECT SCOPE</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Project A</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">1. Project</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160; </font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="s523c132a608d41519c199513c1e746b7"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Appendix I:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">29</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Appendix II</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div></div><hr style="page-break-after:always"><div><a name="s0FD6E6B3F687148BB79944D7B386A16E"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT B </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DYADIC MATERIALS</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">31</font></div></div><hr style="page-break-after:always"><div><a name="sD1F07BFE3202485AC3A344D7B3A96759"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT C</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GENETIC TOOLS</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">32</font></div></div><hr style="page-break-after:always"><div><a name="s5BA621AE1FEFEE9A0EB544D7B3DD49C7"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT D</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">KEY PERSONS</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">33</font></div></div><hr style="page-break-after:always"><div><a name="sABA87E4C9B1CA35FAC5B44D7B3FCF6D5"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">SPB Draft June 28, 2017</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT E</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">FORM OF</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SELECTED PRODUCT DEVELOPMENT AND NET SALES SHARING AGREEMENT</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS SELECTED PRODUCT DEVELOPMENT AND NET SALES SHARING AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is made and entered into on [&#9679;] (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Execution Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), by and between DYADIC INTERNATIONAL, INC., a Delaware corporation with headquarters located at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY IN PHARMACEUTICALS, S.L.U., a company incorporated under the laws of Spain having its registered office at Louist Proust 13, 47151 Boecillo (Valladolid), Spain, and identification code -CIF number- B-86206695 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI Pharmaceuticals</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Dyadic and BDI Pharmaceuticals are sometimes collectively referred to as the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221; and individually as a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Party.</font><font style="font-family:inherit;font-size:12pt;">&#8221; Certain capitalized terms used herein have the meanings assigned them in Article I hereof.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:12px;"><font style="font-family:inherit;font-size:12pt;">I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pharmaceuticals provides services for strain improvement, bioprocess development, bioprocess scale-up, bioengineering and contract production;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:12px;"><font style="font-family:inherit;font-size:12pt;">II.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dyadic is a global biotechnology company that controls a biopharmaceutical protein production system based on the fungus </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Myceliopthora thermophila, </font><font style="font-family:inherit;font-size:12pt;">nicknamed C1. The C1 technology and other technologies may be used for the aims set forth in this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:12px;"><font style="font-family:inherit;font-size:12pt;">III.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Parties have entered into a Research Services Agreement dated [&#9679;], 2017 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Research Services Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:12px;"><font style="font-family:inherit;font-size:12pt;">IV.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BDI Pharmaceuticals and Dyadic now wish to commercialize the Selected Product resulting from the Research Services Agreement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:12px;"><font style="font-family:inherit;font-size:12pt;">V.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each of Dyadic and BDI Pharmaceuticals understand and acknowledge that the terms and conditions of the Pharma License Agreement govern the ability of Dyadic to commercialize and sublicense any product governed thereby and that Dyadic has determined that the Selected Product [is] governed by the Pharma License Agreement. [Therefore, pursuant to the terms of the Pharma License Agreement, BDI Pharmaceuticals understands and agrees that for it and Dyadic to maintain compliance with the Pharma License Agreement that it may only commercialize the Selected Product directly and not through a sublicense arrangement.] [NOTE: Prior to signing this agreement, Dyadic shall reevaluate and confirm that the Selected Product is covered by the Pharma License Agreement]</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AGREEMENT:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and the foregoing recitals, which are incorporated herein and by this reference made a part hereof, and for other good and valuable consideration the receipt and adequacy of which </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">34</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">hereby are mutually acknowledged by Dyadic and BDI Pharmaceuticals, the Parties hereby agree as follows:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 1</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEFINITIONS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Capitalized terms used in this Agreement shall have the meaning ascribed to them below, or as otherwise defined above or in the text of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AAA</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 14.10 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Action</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; with respect to Dyadic only shall mean any person, corporation, or other entity that controls, is controlled by, or is under common control with Dyadic. Control, with respect to such other corporation or entity, includes a person, corporation or other entity (i) owning or directly or indirectly controlling a majority of the voting stock or other ownership interest, (ii) possessing, directly or indirectly, the power to direct or cause the direction of the management and policies, or (iii) possessing the power to elect or appoint a majority of the members of the governing body. The term Affiliate when used with respect to BDI Pharmaceuticals shall include only BDI Holdings and VLPbio.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Alliance Manager</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 4.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Adverse Event</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 6.2 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Background IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI Holdings</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI Pharmaceuticals</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">C1 Strains</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CMC</font><font style="font-family:inherit;font-size:12pt;">&#8221; means chemistry, manufacturing and controls as specified by the FDA.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaboration IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(m)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercialization</font><font style="font-family:inherit;font-size:12pt;">&#8221; with a correlative meaning for &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercialize</font><font style="font-family:inherit;font-size:12pt;">&#8221; and &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercializing</font><font style="font-family:inherit;font-size:12pt;">&#8221;, means all activities undertaken before and after obtaining Regulatory Approvals relating specifically to the pre-launch, launch, promotion, detailing, medical education and medical liaison activities, marketing, pricing, reimbursement, sale and distribution of the Product(s), including: (a) strategic marketing, sales force detailing, advertising, medical education and liaison, and market and Product support; (b) any post-marketing clinical studies </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">35</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">for use in generating data to be submitted to Regulatory Authorities (and all associated reporting requirements); and (c) all customer support, Product distribution, invoicing and sales activities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(n)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercialization Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(o)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercially Reasonable Efforts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means those efforts consistent with the exercise of prudent scientific and business judgment in an active and ongoing program as applied by a Party to the Development and Commercialization of its own pharmaceutical products at a similar stage of development and with similar market potential. Commercially Reasonable Efforts requires that a Party, at a minimum, assigns responsibility for such obligations to qualified employees, sets annual goals and objectives for carrying out such obligations and allocates resources designed to meet such goals and objectives.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(p)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 10.1 hereof. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(q)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Danisco</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(r)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Danisco Improved Strains</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(s)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Danisco Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth m the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(t)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Danisco Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(u)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Develop</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all activities relating to preparing and conducting preclinical testing, toxicology testing, human clinical studies and regulatory activities (e.g., regulatory applications) with respect to the Product(s), together with the manufacturing of the Product(s).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Activities</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.2 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(w)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Costs</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the internal costs and out-of-pocket costs incurred as an expense by or on behalf of a Party or its Affiliates in carrying out the Development of the Product(s) in accordance with the approved Development Plan, including, without limitation, (i) the costs of clinical trials (including costs of procuring the Product(s), placebos and comparator drugs used in such clinical trials), (ii) filing fees and other costs associated with any Regulatory Filings; (iii) costs related to manufacturing development; and (iv) all other costs that are directly attributable and reasonably allocable to the Development Activities for the Product(s). For purposes of this definition out-of-pocket costs mean the actual expense incurred with respect to a Third Party for specific Development Activities relating to the Product(s).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(x)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(y)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 10.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(z)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Preamble.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">36</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(aa)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Follow-On IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(bb)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(cc)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Materials</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(dd)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dyadic Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ee)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Execution Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ff)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FDA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the United States Food and Drug Administration and any successors thereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(gg)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Field</font><font style="font-family:inherit;font-size:12pt;">&#8221; means [&#9679;] [all uses].</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(hh)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Genetic Tools</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Government Official</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 14.5 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(jj)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnified Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 13.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(kk)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnifying Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 13.1 hereof. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ll)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Infringement Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 13.3 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(mm)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JSC</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 4.2.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(nn)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(oo)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Pharma License Agreement and &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; is a single one of the Licensed Parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(pp)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Manufacture</font><font style="font-family:inherit;font-size:12pt;">&#8221; with a correlative meaning for &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Manufacturing</font><font style="font-family:inherit;font-size:12pt;">,&#8221; means all activities related to the manufacturing of a pharmaceutical product, or any ingredient thereof, including manufacturing Product in finished form for Development, manufacturing finished Product for Commercialization, packaging, in-process and finished Product testing, release of Product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of Product, ongoing stability tests and regulatory activities related to any of the foregoing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(qq)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Material Finding</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a finding that would cause Product to become adulterated and/or misbranded or otherwise constitute a violation of the applicable regulatory requirements according to a Regulatory Authority, comprises of at least two objectionable conditions and/or violations of Good Manufacturing Practices in the Territory, or is otherwise a violation of Territory law or regulation.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">37</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(rr)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Party&#8221; </font><font style="font-family:inherit;font-size:12pt;">or</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#8220;Parties&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in the Preamble.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ss)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Person&#8221; </font><font style="font-family:inherit;font-size:12pt;">means a natural person, a corporation, a partnership, a trust, a joint venture, any governmental authority or any other entity or organization.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(tt)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Pharmaceutical Product&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(uu)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Pharma License Agreement&#8221; </font><font style="font-family:inherit;font-size:12pt;">means the agreement between Danisco and Dyadic dated December 31, 2015, a redacted copy of which has been provided to BDI Pharmaceuticals for review in advance of executing this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vv)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Pharmaceutical Product&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ww)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Pharmacovigilance Agreement&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in Section 6.2 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xx)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Product&#8221; </font><font style="font-family:inherit;font-size:12pt;">means any formulation that includes the Selected Product that is suitable for use in the Field.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(yy)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Product IP&#8221; </font><font style="font-family:inherit;font-size:12pt;">means any inventions, technology, know-how, trade secrets and any other intellectual property developed pursuant to this Agreement in relation to any Product and/or any derivatives or modifications thereof and any results related thereto. Product IP shall exclude any component of the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, the Dyadic Patents, the Danisco Know-How, the Genetic Tools, the Danisco Patents, the Collaboration IP and the Dyadic Follow-on IP.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(zz)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Product Marks&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in Section 7.2 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(aaa)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Product Net Income&#8221; </font><font style="font-family:inherit;font-size:12pt;">means total revenues received by Dyadic or its Affiliates with respect to the license or grant of other rights by Dyadic or its Affiliates to one or more Third Parties in and to the Product(s), whether in the form of royalties, license or other fees (but excluding, however, any amounts received by Dyadic or its Affiliates in consideration of any research, regulatory or other services performed by Dyadic or its Affiliates for such Third Party(ies)), less any taxes or other expenses payable by Dyadic with respect thereto, including, without limitation, any royalties or other fees payable by Dyadic to Danisco.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(bbb)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Product Results&#8221; </font><font style="font-family:inherit;font-size:12pt;">refers to any results that are developed pursuant to this Agreement as they relate to the Commercialization or Development of the Selected Product, including, without limitation, inventions and/or discoveries, whether patentable or not, know-how, protocols, procedures, composition of matter, raw and analyzed data, methods, technical data and information generated or developed in the course of the Commercialization or Development of the Selected Product.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ccc)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;R&amp;D License&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in Section 2.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ddd)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Receiving Party&#8221; </font><font style="font-family:inherit;font-size:12pt;">has the meaning set forth in Section 10.1 hereof.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">38</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(eee)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Approval</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Product in any country or jurisdiction, all approvals (including, where required, pricing and reimbursement approvals), registrations, licenses or authorizations from the relevant Regulatory Authority in a country or jurisdiction that is specific to Product and necessary to market and sell such Product in such country or jurisdiction.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(fff)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Authority</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, in a particular country or regulatory jurisdiction, any applicable governmental authority involved in granting and enforcing Regulatory Approval and/or, to the extent required in such country or regulatory jurisdiction, pricing or reimbursement approval of a Product in such country or regulatory jurisdiction.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ggg)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Documentation</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all Regulatory Filings, registrations, filings, applications, licenses, authorizations and approvals (including Regulatory Approvals), all correspondence submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authorities), and all supporting documents for clinical studies, data and supporting documents relating to the Product(s), and all data contained in any of the foregoing (including advertising and promotional and marketing documents, Adverse Event files, periodic safety update reports, medical event reports, compliant files and the like).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(hhh)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Filings</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to the Product(s), any submission to a Regulatory Authority of any appropriate regulatory application specific to Product, and shall include, without limitation, any responses to any enforcement actions and submission to a regulatory advisory board and any supplement or amendment thereto.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Remedial Action</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 6.6 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(jjj)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Research Services Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; refers to the agreement referenced m the recitals, which Research Services Agreement is incorporated herein in its entirety.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(kkk)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Selected Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Research Services Agreement; however, for purposes of this Agreement, the &#8220;Selected Product&#8221; shall be a single active pharmaceutical ingredient in the Product(s) to which this Agreement is applicable, the sequence or structure of which is identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(lll)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Serious Adverse Event</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 6.2 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(mmm)&#160;&#160;&#160;&#160;&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Data</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 12.2 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(nnn)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sublicensee</font><font style="font-family:inherit;font-size:12pt;">&#8221; refers to BDI Pharmaceuticals&#8217; permitted sublicensees under this Agreement and also has the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ooo)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sublicense Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ppp)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 11.1 hereof.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">39</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(qqq)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Person that is not a Party (or an Affiliate of a Party) to this Agreement, including without limitation other collaboration Partners.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(rrr)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Territory</font><font style="font-family:inherit;font-size:12pt;">&#8221; means worldwide.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 2</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LICENSES</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">2.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Non-Exclusive License Grant from Dyadic to BDI Pharmaceuticals.</font><font style="font-family:inherit;font-size:12pt;">&#32;Dyadic hereby grants to BDI Pharmaceuticals a non-exclusive, non-transferable, non-sub-licensable, except as set forth herein, and fully paid license of the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents, the Dyadic Follow-On IP, the Collaboration IP, the Product Results and the Product IP, the grant of the non-exclusive license being only broad enough to permit BDI Pharmaceuticals and its Affiliates to assist Dyadic in the commercialization of the Selected Product in accordance with the terms of this Agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">R&amp;D License</font><font style="font-family:inherit;font-size:12pt;">&#8221;). The C 1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools and the Danisco Patents, the Dyadic Follow-On IP, the Collaboration IP, the Product Results and the Product IP, any components of the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents, the Dyadic Follow-On IP, the Collaboration IP, the Product Results and the Product IP and any derivatives or modifications of any of the foregoing, shall be used by BDI Pharmaceuticals only in accordance with and for the execution of this Agreement and with applicable law. For the sake of clarity, BDI Pharmaceuticals and its Affiliates shall not transfer or deliver any C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Dyadic Follow-On IP, the Collaboration IP, the Product Results and the Product IP or any components of the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents, the Dyadic Follow-On IP, the Collaboration IP, the Product Results and the Product IP or any derivatives or modifications of any of the foregoing, to any Third Party without the prior written consent of Dyadic, which consent may be withheld in its sole discretion.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">2.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Right to Sublicense.</font><font style="font-family:inherit;font-size:12pt;">&#32;Subject to Section 2.3, Dyadic may grant BDI Biopharmaceuticals the right to sub license the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, Dyadic Materials, the Dyadic Patents, the Danisco Know-How, the Genetic Tools, the Danisco Patents, the Dyadic Follow-On IP, the Collaboration IP, the Product Results and/or the Product IP to Third Parties having no economic interest in the Pharmaceutical Product under development, but only to the extent necessary to provide contract research services. Any sublicense entered into under this Section 2.2 shall require the prior written consent of Dyadic and shall be on terms consistent with the terms and provisions of this Agreement and on terms acceptable to Dyadic, in its sole discretion.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">2.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Additional Conditions Incorporated from Pharma License Agreement.</font><font style="font-family:inherit;font-size:12pt;">&#32;Sublicensee acknowledges that it has read the Pharma License Agreement entered into between Danisco US Inc. and Dyadic International, Inc. and agrees to be bound by the provisions of such </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">40</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pharma License Agreement as if it were a party to such Pharma License Agreement. For the avoidance of doubt, this includes the provisions of Section 10.7 of the Pharma License Agreement regarding resolution of disputes. Sublicensee agrees that Danisco US Inc. or any authorized assignee of Danisco US Inc. is an intended third party beneficiary to any Sublicense Agreement and shall be entitled to enforce the terms of this Agreement directly against Sublicensee. This Sublicense Agreement shall not be further sublicensed except that, as applicable, the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools and the Danisco Patents may be further sublicensed to the extent necessary to Third Parties having no economic interest in the Pharmaceutical Product under development to provide contract research services or contract manufacturing services for a Licensed Party or for a Sublicensee to exercise its &#8220;have made&#8221; rights or, with respect to a Pharmaceutical Product, to grant limited sublicenses within multiple tiers of Sublicense Affiliates or Third Parties solely to permit manufacturing, distributing or marketing such Pharmaceutical Product on behalf of such Licensed Party under terms no less restrictive than the terms set forth in Section 2.2 of the Pharma License Agreement entered into between Danisco US, Inc. and Dyadic International, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 3</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PRODUCT NET INCOME SHARING</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">3.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Product Net Income Share Payments. </font><font style="font-family:inherit;font-size:12pt;">In consideration of the obligations to be performed and the costs to be incurred by BDI Pharmaceuticals under this Agreement, Dyadic shall pay to BDI Pharmaceuticals in US dollars within thirty (30) days after the end of each March 31, June 30, September 30 and December 31 during the Term, commencing on the first occurrence of any such date after Dyadic or any of its Affiliates have Product Net Income, the applicable percentage set forth below of Dyadic&#8217;s Product Net Income for the calendar quarter ended on such date:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:18%;"></td><td style="width:31%;"></td><td style="width:30%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Phase</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI Pharmaceuticals&#8217;</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Minimum </font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Cost Spend</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">in Phase </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">(1)</sup></font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8364;</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI Pharmaceuticals&#8217;</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Aggregate Minimum</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Cost </font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Spend</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8364;</font></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pharmaceuticals&#8217;</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Product Net</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Income Share</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Proof of Claim</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&gt;</font><font style="font-family:inherit;font-size:12pt;">1,000,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&gt;</font><font style="font-family:inherit;font-size:12pt;">1,000,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">50</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pre-Clinical</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&gt;</font><font style="font-family:inherit;font-size:12pt;">3,000,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&gt;</font><font style="font-family:inherit;font-size:12pt;">4,000,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">65</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Clinical</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">(4)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&gt;</font><font style="font-family:inherit;font-size:12pt;">4,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&gt;</font><font style="font-family:inherit;font-size:12pt;">8,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">75</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount of BDI Pharmaceuticals&#8217; Development Cost spend shall be determined by the JSC in accordance with Article 4 of this Agreement</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Proof of Claim Phase is intended by the Parties as the conduct of Project A under and in accordance with the Research Services Agreement. At such time as BDI Pharmaceuticals shall have spent at least &#8364; 1,000,000 in Development Cost in the performance of its obligations under the Research Services </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">41</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Agreement and under this Agreement, BDI Pharmaceuticals shall be entitled to 50% of the Product Net Income.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Pre-Clinical Phase is intended by the Parties to commence on the Execution Date of this Agreement and to continue until the submission of a Regulatory Filing. At such time after the Execution Date as BDI Pharmaceuticals shall have spent at least &#8364;4,000,000 in Development Cost in the performance of its obligations under the Research Services Agreement and under this Agreement, BDI Pharmaceuticals thereafter shall be entitled to 65% of the Product Net Income.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Clinical Phase is intended by the Parties to commence upon the submission of an initial Regulatory Filing under this Agreement. At such time after commencement of the Clinical Phase as BDI Pharmaceuticals shall have spent at least &#8364;8,000,000 in Development Cost in the performance of its obligations under the Research Services Agreement and this Agreement, BDI Pharmaceuticals thereafter shall be entitled to 75% of the Product Net Income.</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">3.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Off-Set Rights. </font><font style="font-family:inherit;font-size:12pt;">Dyadic shall have the right to offset any and all costs, expenses and overhead incurred by Dyadic under or in connection with this Agreement, including, without limitation, research and development, scale up, regulatory and marketing, Manufacturing, Development and Commercialization costs, against any amounts due and owing BDI Pharmaceuticals under this Article 3.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">3.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Product Net Income Reporting. </font><font style="font-family:inherit;font-size:12pt;">Dyadic shall notify BDI Pharmaceuticals promptly after it has entered into a definitive agreement for the license or other transfer of any rights in or to any Product to a Third Party and shall provide to BDI Pharmaceuticals a copy of such agreement or an abstract therefrom relating to the consideration due under this Article 3. BDI Pharmaceuticals agrees to be bound by whatever confidentiality constraints are required by Dyadic with respect to such Third-Party agreement or abstract therefrom. Dyadic shall submit to BDI Pharmaceuticals, together with each payment made under this Section 3.1, a report for the relevant calendar quarter setting forth at least the following information: a reasonably detailed calculation of the Product Net Income, the currency of payment and a reasonably detailed calculation of the amount of any Product Net Income due and payable to BDI Pharmaceuticals.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">3.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Records and Inspection. </font><font style="font-family:inherit;font-size:12pt;">As long as Dyadic is under an obligation to make payments to BDI Pharmaceuticals under Section 3.1, (i) Dyadic shall maintain or cause to be maintained a true and correct set of records pertaining to the Product Net Income and information pursuant to which the payments are calculated under this Agreement; and (ii) Dyadic agrees to permit an accountant selected and paid by BDI Pharmaceuticals and reasonably acceptable to Dyadic to have, upon not less that fifteen (15) days prior written notice, reasonable access during ordinary business hours to such records as are maintained by Dyadic to the extent necessary to determine the correctness of any report submitted and/or payment made by Dyadic under this Article 3. BDI Pharmaceuticals shall provide to Dyadic a copy of its accountant&#8217;s report. In the event that the audit reveals an underpayment to BDI Pharmaceuticals, Dyadic shall pay to BDI within five (5) business days after receipt of the report, the amount so underpaid. In the event that the audit reveals an overpayment to BDI Pharmaceuticals, Dyadic shall have the right to off-set the amount so overpaid against payments of Product Net Income to BDI Pharmaceuticals thereafter coming due. Inspections in accordance with the terms and conditions of Section 3.4 may occur no more than once per calendar year.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">42</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 4</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MANAGEMENT; JOINT STEERING COMMITTEE</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">4.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Alliance Manager.</font><font style="font-family:inherit;font-size:12pt;">&#32;Within thirty (30) days following the Effective Date, BDI Pharmaceuticals will appoint (and notify Dyadic Pharmaceuticals of the identity of) a representative to act as its alliance manager under this Agreement (the &#8220;Alliance Manager&#8221;). The Alliance Manager will serve as the primary contact point between the Parties for the purpose of providing each Party with information on the progress of BDI Pharmaceuticals&#8217; research, Development scale-up, regulatory, marketing and Commercialization activities with respect to the Selected Product. The Alliance Manager will also be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration to Dyadic. BDI Pharmaceuticals may replace its Alliance Manager at any time upon written notice to Dyadic.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">4.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Steering Committee.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Within thirty (30) days after the Effective Date, the Parties will establish a joint steering committee (the &#8220;JSC&#8221;) to plan, administer, evaluate and carry out all aspects of the research, Development, marketing, Manufacture, regulatory and Commercialization activities by BDI Pharmaceuticals on behalf of Dyadic hereunder with respect to the Selected Product and to review and recommend the Development Costs to be incurred by BDI Pharmaceuticals in connection therewith.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;The JSC will consist of representatives of Dyadic and BDI Pharmaceuticals and potentially outside consultants and Third Parties. The representatives may be from various functional groups (e.g., clinical development, regulatory, medical affairs, pharmacovigilance, research and development, scale-up, regulatory, marketing commercial and manufacturing). Dyadic will appoint the chair of the JSC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;The Parties shall schedule half-yearly JSC meetings and agree to such schedule at least quarterly in advance. Either Party may call additional ad hoc meetings of the JSC as the needs arise with reasonable advance notice to the other Party, and such ad hoc meetings shall be conducted at times that are mutually agreed upon by the Parties. All meetings and other communications of the JSC shall be conducted in English. No later than five (5) business days prior to any regularly scheduled meeting of the JSC, the chairperson of the JSC shall prepare and circulate an agenda for such meeting and, as soon as practicable, all materials, documents and information for the meeting for distribution to both Parties; provided, however, that either Party may propose additional topics to be included on such agenda, either prior to or in the course of such meeting. The JSC may meet in person, by videoconference or by teleconference or any other method that is convenient. The chairperson of the JSC will be responsible for preparing reasonably detailed written minutes of all JSC meetings that reflect, without limitation, material decisions made at such meetings. The JSC chairperson shall send draft meeting minutes to BDI Pharmaceuticals and Dyadic for review within five (5) business days following each JSC meeting. The Parties will approve the draft minutes within fifteen (15) business days after each JSC meeting. Such minutes will be deemed approved unless one or more members of the JSC objects to the accuracy of such minutes within ten (10) business days after receipt. The Parties shall also maintain regular, frequent and informal communications for </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BDI Pharmaceuticals to obtain updates from Dyadic and for the Parties to discuss the progress of the Development of the Selected Product in the Field within the Territory.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;The JSC shall strive to seek consensus in its actions and decision making process. In the event of a disagreement between the Dyadic members and the BDI Pharmaceuticals members of the JSC, either Party may refer the matter to one senior executive of each Party (i.e., the Chief Executive Officer or Managing Director of such Party or an executive of such Party who reports directly to the Chief Executive Officer or Managing Director) for resolution. If such senior executives cannot resolve the matter within ten (10) business days, then such senior executive of BDI Pharmaceuticals shall have the final decision making authority on such matter, provided that any final determination made by such senior executive of Dyadic shall be consistent with the terms of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">4.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Costs of Governance.</font><font style="font-family:inherit;font-size:12pt;">&#32;The Parties agree that the costs incurred by the Parties and any other participants invited by Dyadic in connection with such participation at any meetings under this Article shall be borne solely by BDI Pharmaceuticals, including, but not limited to, the costs of necessary translations and translators.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 5</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEVELOPMENT</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;text-indent:0px;"><font style="padding-bottom:12px;text-align:left;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Within sixty (60) days after the Effective Date (or such longer period of time as recommended by the JSC), the Parties will agree upon a development plan for the Development of the Product(s) in the Territory (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221;). The Development Plan shall include all clinical and other studies to be performed for the Product(s), including those that are required for Regulatory Approval for the Product(s) in the Territory. In the event there is any disagreement between the Parties regarding the elements to be contained within the Development Plan, BDI Pharmaceuticals shall have the final authority to decide such disputed item(s).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;From time to time during the Term, BDI Pharmaceuticals shall update and amend, as appropriate, the then-current Development Plan and submit such updated or amended Development Plan for the JSC&#8217;s review and recommendations. Once reviewed by the JSC and any recommendations by the JSC have been accepted or rejected by BDI Pharmaceuticals, each updated or amended Development Plan shall become effective and supersede the previous Development Plan with respect to any overlapping time periods as of the date of such approval.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI Pharmaceuticals Development Activities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Solely on behalf of Dyadic or a Licensed Party, BDI Pharmaceuticals shall Develop the Product(s) and seek Regulatory Approval by timely and diligently conducting all Development activities under the Development Plan (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Activities</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;The status, progress and results of the Development Activities in the Territory shall be discussed at meetings of the JSC, and BDI Pharmaceuticals shall provide the JSC with a written report on the status and progress of such Development Activities on a half-yearly basis at</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">least five (5) business days prior to each scheduled JSC meeting. In addition, BDI Pharmaceuticals shall make available to Dyadic such information about such Development Activities as may be reasonably requested by Dyadic from time to time.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Compliance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;BDI Pharmaceuticals agrees that in performing its obligations under this Agreement: (i) it shall comply with all applicable laws; and (ii) it will not employ or engage any person who has been debarred by any Regulatory Authority, or, to such Party&#8217;s knowledge, is the subject of debarment proceedings by a Regulatory Authority. BDI Pharmaceuticals shall have the right to engage subcontractors for the performance of its obligations under the Development Plan. BDI Pharmaceuticals remains responsible for the performance and costs and expenses of such subcontractor(s) and the engagement of such subcontractors shall not relieve BDI Pharmaceuticals from its obligations to comply with the terms and conditions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;BDI Pharmaceuticals shall cause the Sublicensees to maintain complete, current and accurate records of all work conducted by such Sublicensees under the Development Plan, and all data and other information resulting from such work. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory purposes. Dyadic shall have the right to review all records maintained by BDI Pharmaceuticals or such Sublicensees at reasonable times, upon Dyadic&#8217;s written request.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;BDI Pharmaceuticals shall document all preclinical studies and clinical trials conducted by or for it in written study reports and shall provide Dyadic with a summary of each such report in English promptly after its completion.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Costs.</font><font style="font-family:inherit;font-size:12pt;">&#32;As between the Parties, BDI Pharmaceuticals shall bear all Development Costs for Development: (a) conducted by or for BDI Pharmaceuticals and incurred by Dyadic, BDI Pharmaceuticals or other parties engaged by BDI Pharmaceuticals and/or Dyadic; or (b) conducted by Dyadic for BDI Pharmaceuticals and incurred by Dyadic, in each case after the Effective Date in connection with the research and Development, scale-up, regulatory, marketing, Manufacture and Commercialization (including Development of Manufacturing processes and other CMC matters) of the Product(s) in accordance with the Development Plan or the other provisions of this Agreement, as well as any other research and Development, scale-up, regulatory, marketing, Manufacture and Commercialization of the Product(s) related to this Agreement.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 6</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">REGULATORY MATTERS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">6.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BDI Pharmaceuticals Regulatory Responsibilities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Subject to the termination of this Agreement, BDI Pharmaceuticals shall be responsible for all Regulatory Filings and Regulatory Approvals for the Product(s) in the Territory, and shall be solely responsible for preparing any and all Regulatory Filings for the Product(s) in the Territory at its sole expense in accordance with the Development Plan, in each case, on behalf of Dyadic. Dyadic shall assist BDI Pharmaceuticals or a Licensed Party as they </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">may reasonably request in connection with the preparation and filing of such Regulatory Filings, at BDI Pharmaceuticals&#8217; or the Licensed Parties reasonable request and all direct and indirect costs incurred by Dyadic or consultants or other third parties hired by Dyadic will be at BDI Pharmaceuticals&#8217; sole expense.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;BDI Pharmaceuticals shall keep Dyadic informed of regulatory developments. BDI Pharmaceuticals shall provide Dyadic with all data, support and copies of the Regulatory Filings specific to Product throughout the Territory within thirty (30) days after the mailing date of such Regulatory Documentation, and Dyadic shall have the right, but not obligation, to contribute to the regulatory plans and strategies for the Product(s) in the Territory.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;BDI Pharmaceuticals shall lead Development and Commercialization discussions with any Regulatory Authority related to any Development of any Product. BDI Pharmaceuticals will ensure it reasonably considers any input from Dyadic in preparation for such discussions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;BDI Pharmaceuticals shall ensure, at its sole expense, that the Development, Manufacture and Commercialization of the Product(s) in the Territory are in compliance with all applicable laws, including without limitation all rules and regulations promulgated by any of the Regulatory Authorities in the Territory. Specifically and without limiting the foregoing, BDI Pharmaceuticals shall file all compliance filings, certificates and safety reporting in the Territory at its sole expense.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;To the extent permitted by the applicable Regulatory Authority and as requested by Dyadic, BDI Pharmaceuticals shall allow representatives of Dyadic to participate in any scheduled conference calls and meetings between BDI Pharmaceuticals and the Regulatory Authority at BDI Pharmaceuticals&#8217; expense. If Dyadic elects not to participate in such calls or meetings, BDI Pharmaceuticals shall, and shall provide Dyadic with written summaries of such calls and meetings in English as soon as practicable after the conclusion thereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;With respect to all Regulatory Filings, BDI Pharmaceuticals shall (i) submit only data and information that are free from fraud or material falsity; (ii) not use bribery or the payment of illegal gratuities in connection with its Regulatory Filings for a Product; and (iii) submit only data and information that are accurate and reliable in all material respects for purposes of supporting Regulatory Approval.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">6.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Adverse Events.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Within one (1) year prior to the planned first Regulatory Approval of each Product in the Territory, the Parties shall discuss in good faith and enter into a pharmacovigilance and Adverse Event reporting agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to such Product, such as safety data sharing, Adverse Events reporting and prescription events monitoring (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pharmacovigilance Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Each such Pharmacovigilance Agreement shall govern the global pharmacovigilance procedures to be agreed upon by BDI Pharmaceuticals and Dyadic and the commercial partners of each Party and take into account the laws and regulations of the Territory in which the subject Product receives Regulatory Approval.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Prior to the execution of a Pharmacovigilance Agreement, the Parties agree to coordinate the pharmacovigilance procedures in connection with the Development of each Product. Each Party shall notify the other Party within twenty-four (24) hours of such Party&#8217;s learning of any Serious Adverse Events that is attributed to or potentially attributable to the use of a Product. BDI Pharmaceuticals shall report any Serious Adverse Events that are attributed or potentially attributable to the use of a Product according to the various laws and regulations of the Territory. Each Party shall also provide the other Party, on an annual basis and more frequently as reasonably requested by the other Party, a summary report of Adverse Events, as well as those Serious Adverse Events that are not attributable to the use of the Product(s) that are not otherwise subject to Pharmacovigilance Agreements. As used herein, unless defined differently by the relevant Regulatory Authority, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Adverse Events</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, and &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Serious Adverse Events</font><font style="font-family:inherit;font-size:12pt;">&#8221; is an Adverse Event that is considered &#8220;serious&#8221;, because, in the view of either the investigator or sponsor, it results in any of the following outcomes: death, a life-threatening Adverse Event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or a congenital anomaly/birth defect.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;After the execution of a Pharmacovigilance Agreement, the Parties shall comply with such Pharmacovigilance Agreement with respect to all aspects of pharmacovigilance activities with respect to the subject Product, and Section 6.2(b) above shall be of no further effect with respect to such Product.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">6.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">No Harmful Actions.</font><font style="font-family:inherit;font-size:12pt;">&#32;If either Party believes that the other Party, as the case may be, is taking or intends to take any action with respect to a Product that could reasonably be expected to have a material adverse impact upon the regulatory status of such Product, such Party shall have the right to bring the matter to the attention of the JSC.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">6.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Notification of Threatened Action.</font><font style="font-family:inherit;font-size:12pt;">&#32;Each Party shall immediately notify the other Party of any information it receives regarding any threatened or pending action, inspection or communication by or from any Person, including, without limitation, a Regulatory Authority, which may affect the safety or efficacy claims of a Product or the continued marketing of a Product. Upon receipt of such information, the Parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">6.5</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Data Exchange and Use.</font><font style="font-family:inherit;font-size:12pt;">&#32;This Section 6.5 shall not apply to any pharmacovigilance data (which is addressed in Section 6.2). BDI Pharmaceuticals shall provide Dyadic with copies of all final submissions and correspondence to and from all Regulatory Authorities within seven (7) days of submission or receipt, as applicable, and shall provide Dyadic a summary of each significant submission in English as soon as practicable but in any event within ten (10) business days after such submission. Each Party shall permit the other Party to access, and shall provide the other Party with rights to reference and use in association with the Product(s) in the Field, all of its, its Affiliates&#8217;, and its or their licensees&#8217; and Sublicensees&#8217; regulatory, preclinical and clinical data documentation when allowed by the applicable laws and regulations of the Territory, Regulatory Filings and Regulatory Approvals with respect to the Product(s) in the Field.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">6.6</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Remedial Actions.</font><font style="font-family:inherit;font-size:12pt;">&#32;Each Party will, and will ensure that its Affiliates and Sublicensees will notify the other Party immediately, and promptly confirm such notice in writing, if it obtains information indicating that a Product may be subject to any recall, corrective action or other regulatory action with respect to a Product taken by virtue of applicable law in the Territory (a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Remedial Action</font><font style="font-family:inherit;font-size:12pt;">&#8221;). The Parties will assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. BDI Pharmaceuticals shall, and shall ensure that its Affiliates and Sublicensees will, maintain or have maintained adequate records to permit the Parties to trace the Manufacture of the Product(s) and the distribution and, to the extent feasible, the use of the Product(s). In the event BDI Pharmaceuticals or its any Sublicensee determines that any Remedial Action with respect to a Product in the Field within the Territory should be commenced or Remedial Action is required by any Regulatory Authority having jurisdiction over the matter, BDI Pharmaceuticals will, and will ensure that its Sublicensees will, as the case may be, control and coordinate all efforts necessary to conduct such Remedial Action.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 7</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">COMMERCIALIZATION</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">7.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Overview of Commercialization in the Territory.</font><font style="font-family:inherit;font-size:12pt;">&#32;Subject to the provisions of Article 4, BDI Pharmaceuticals and its Affiliates will have responsibility for all decisions related to and implementation of Commercialization activities, including, but not limited to, price, reimbursement and distribution, for the Product(s) in the Territory. At its sole expense, BDI Pharmaceuticals will prepare and submit to the JSC a commercialization plan no later than six (6) months prior to the anticipated date of Regulatory Approval for the first Product in the Territory (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercialization Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221;). The cost of the Commercialization Plan shall be solely borne by BDI Pharmaceuticals. The Commercialization Plan shall incorporate the Commercialization diligence requirements set forth below. BDI Pharmaceuticals will update such Commercialization Plan on a yearly basis and will provide quarterly reports to Dyadic describing BDI Pharmaceuticals&#8217; progress against such Commercialization Plan. BDI Pharmaceuticals shall use Commercially Reasonable Efforts to maximize sales of the Product(s) throughout the Territory in accordance with the Commercialization Plan.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">7.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Trademark.</font><font style="font-family:inherit;font-size:12pt;">&#32;Dyadic shall have the right to brand the Product(s) using Dyadic&#8217;s related trademarks and any other trademarks and trade names it determines appropriate for the Product(s) in consultation with BDI Pharmaceuticals (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Product Marks</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Dyadic shall own all rights in the Product Marks and register and maintain the Product Marks in the countries and regions it determines reasonably necessary. Notwithstanding any provisions in this Agreement, Dyadic shall be the exclusive sole owner for the Product Marks even after the termination of this Agreement for whatever reasons.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 8</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">REPRESENTATIONS, WARRANTIES AND COVENANTS; DISCLAIMER</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">8.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Representations and Warranties of the Parties</font><font style="font-family:inherit;font-size:12pt;">: Each of the Parties represents and warrants to the other Party that:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;it is a company duly organized, validly existing and in good standing under the laws of, in the case of Dyadic, Delaware, and in the case of BDI Pharmaceuticals, Spain;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;the execution of this Agreement on its behalf has been properly authorized by all necessary corporate or company action, as the case may be;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;this Agreement is valid and binding on it and enforceable against it in accordance with the terms hereof, subject to applicable bankruptcy and similar laws affecting creditors&#8217; rights and remedies generally, and subject, as to enforceability, to general principles of equity;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;neither the execution nor the performance of this Agreement will constitute a breach or violation of the terms of its charter or organizational documents or any contract, agreement or other commitment to which it is a party or by which it or any of its properties are bound;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;there are no bankruptcy, insolvency, receivership or similar proceedings involving it or any of its Affiliates either pending or contemplated, or any other pending or threatened actions, suits, arbitrations or other proceedings by or against it;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;the execution, delivery and performance of this Agreement does not and will not conflict with or result in breach of any term, condition, obligation or restriction of any other agreement of the Parties with any Third Party; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;it has not used and shall not use in the course of its performance hereunder, and shall not disclose to the other, any confidential information of any other Person, unless it is expressly authorized in writing by such Person to do so.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">8.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Representations and Warranties of Dyadic.</font><font style="font-family:inherit;font-size:12pt;">&#32;Dyadic represents and warrants to BDI Pharmaceuticals that:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Dyadic has full right and authority to enter into this Agreement and to grant the licenses to BDI Pharmaceuticals as herein described; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Dyadic has not granted as of the Effective Date, and will not grant during the Term, any licenses to any Affiliate or Third Party which would conflict with the licenses granted to BDI Pharmaceuticals hereunder.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">8.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Representations, Warranties and Covenants of BDI Pharmaceuticals.</font><font style="font-family:inherit;font-size:12pt;">&#32;BDI Pharmaceuticals covenants, and represents and warrants to Dyadic that:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;BDI Pharmaceuticals has not granted, as of the Execution Date, and will not grant during the Term, any licenses to any Affiliate or Third Party which would conflict with the licenses granted to Dyadic hereunder;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;BDI Pharmaceuticals has not, as of the Execution Date, knowingly performed any acts that are inconsistent with the terms and purposes of this Agreement;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;any sublicense granted hereunder by BDI Pharmaceuticals shall be subject to the terms and conditions of this Agreement and the Pharma License Agreement;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;BDI Pharmaceuticals has made a commercial investigation and Commercialization of the Selected Product does not infringe upon the rights of any Third Parties;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;BDI Pharmaceuticals will perform its obligations under this Agreement in accordance with all applicable laws, rules, regulations and guidelines, including, without limitation, all appropriate animal welfare rules, as specified by law, Sponsor or the Institutional Animal Care and Use Committee (IACUC) that governs animal studies conducted by Dyadic;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;no individual that has been debarred or disqualified by the FDA pursuant to 21 U.S.C. &#167;335a (a) or (b) or by the European Medicines Agency, the European Commission, or the Regulatory Authority of an European Union Member State under any foreign equivalent thereof will perform or render, any services or assistance to BDI Pharmaceuticals;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;BDI Pharmaceuticals has no knowledge of any circumstances which may affect the accuracy of the foregoing warranties and representations, including, but not limited to, the FDA, European Medicines Agency or other governmental investigations of, or debarment proceedings against, BDI Pharmaceuticals or any person or entity performing services or rendering assistance relating to activities taken pursuant to this Agreement, and BDI Pharmaceuticals will immediately notify Dyadic if BDI Pharmaceuticals becomes aware of any such circumstances during the Term;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;that neither the Selected Product nor any Product contains or will contain any intellectual property, proprietary information or materials, content, software or other materials of any Third Party that would require Dyadic or its Affiliates or any Licensed Party to acquire a license or otherwise pay a Third Party for the use thereof;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;all licenses or other material rights or permissions to use any Third Party intellectual property used by BDI Pharmaceuticals and its Affiliates in the operation of their respective businesses have been obtained by the BDI Pharmaceuticals and its Affiliates and all license fees, royalties and any other amounts (if any) due and payable under such license agreements have been paid; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)&#160;&#160;&#160;&#160;to the extent BDI Pharmaceuticals or its Affiliates use confidential information of any other Person in the course of its performance hereunder, it has been expressly authorized to do so in writing and warrants that there will be no cost to Dyadic now, or in the future, related to the use of such information, in excess of the amounts to be paid by Dyadic to BDI Pharmaceuticals pursuant to Section 3 .1 of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">8.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Performance by Affiliates. </font><font style="font-family:inherit;font-size:12pt;">The Parties recognize that each Party may perform some or all of its obligations under this Agreement through Affiliates and Third Party contractors provided, however, that each Party shall remain responsible and liable for the performance by its Affiliates and Third Party contractors and shall cause its Affiliates and Third Party contractors to comply with the provisions of this Agreement in connection with such performance.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 9</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">9.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ownership of Inventions; Assignment. </font><font style="font-family:inherit;font-size:12pt;">Inventorship shall be determined according to United States practice. Regardless of inventorship. Dyadic shall own all right, title and interest in and to any inventions made solely or jointly by either Party&#8217;s employees, agents, independent contractors and Sublicensees in the course of conducting its activities under this Agreement during the Term, together with all intellectual property rights therein, including any rights to applications or other protections for any of the foregoing. For the sake of clarity, Dyadic shall own all Cl Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents, the Collaboration IP, the Dyadic Follow-On IP and Product IP, the Cl Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents, the Collaboration IP, the Dyadic Follow-On IP and Product IP or any components, derivatives or modifications of any of the foregoing and BDI Pharmaceuticals agrees to assign and hereby does assign and transfer to Dyadic, or to Danisco if required by the Pharma License Agreement, all of its right, title and interest in and to any such solely owned or jointly owned inventions that relate to any of the above or any Product IP, Collaboration IP or Dyadic Follow-On IP and agrees to take, and to cause its employees, agents, consultants, Licensed Parties and Sublicensees to take, all further acts reasonably required to evidence such assignment and transfer to Dyadic or to Danisco if required by the Pharma License Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">9.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Enforcement of Product IP. </font><font style="font-family:inherit;font-size:12pt;">The JSC shall make recommendations to BDI Pharmaceuticals and Dyadic on how to enforce Product IP. In the event of a disagreement between BDI Pharmaceuticals and Dyadic with regard to Product IP enforcement strategy or actions, BDI Pharmaceuticals shall decide the Product IP enforcement strategy that the Parties will follow, provided, however, that in no event shall the Product IP enforcement strategy conflict with the Pharma License Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">9.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Responsibility for Preparation and Prosecution of Product IP. </font><font style="font-family:inherit;font-size:12pt;">BDI Pharmaceuticals shall notify Dyadic promptly in writing of all Product IP conceived or generated hereunder. BDI Pharmaceuticals agrees to assign, as applicable, and hereby irrevocably assigns to Dyadic all of its right, title and interest in and to the Product IP, as necessary to affect Dyadic&#8217;s sole ownership. Dyadic shall have the sole right and authority, but not the obligation, for the filing, prosecution and maintenance of the Product IP. BDI Pharmaceuticals shall render all necessary assistance reasonably requested by Dyadic in preparing, filing and prosecuting the Product IP. If necessary and when requested, BDI Pharmaceuticals shall (i) sign and execute all such forms and documents as may be necessary to assure and perfect Dyadic&#8217;s rights (or rights of Danisco, if required by the Pharma License Agreement) in the Product IP, and (ii) cause its directors, employees, researchers, students, consultants and/or contractors, the Licensed Parties and Sublicensees to sign and execute all such forms and documents as may be necessary to perfect the Product IP. BDI Pharmaceuticals will be solely responsible for all costs of the Product IP. To the extent any monies are owned by BDI Pharmaceuticals to Dyadic for the prosecution of the Product IP, Dyadic may exercise set off rights to re-coup such amounts from any payments due under Section 3 .1 hereof.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 10</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONFIDENTIALITY/PUBLICATIONS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidentiality. Definition. &#8220;Confidential Information&#8221; </font><font style="font-family:inherit;font-size:12pt;">means any information disclosed by one Party (the </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Disclosing Party&#8221;) </font><font style="font-family:inherit;font-size:12pt;">to the other (the </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;Receiving Party&#8221;), </font><font style="font-family:inherit;font-size:12pt;">whether oral, written, visual, electromagnetic, electronic or in any other form, and whether contained in memoranda, summaries, notes, analyses, compilations, studies or other documents, and whether the same have been prepared by the Disclosing Party or the Receiving Party: (i) which, if in written, graphic, machine-readable or other tangible form is marked as &#8220;Confidential&#8221; or &#8220;Proprietary,&#8221; or which, if disclosed orally or by demonstration, is identified at the time of initial disclosure as confidential and is summarized in writing and similarly marked and delivered to the Receiving Party within thirty (30) days after initial disclosure; and (ii) which includes but is not necessarily limited to (A) technical data or information, including proprietary host organisms and their strains, plasmids/vectors, DNA sequences, gene expression, fungal high throughput screening, enzymes and their applications, research and manufacturing protocols and practices, formulae, charts, analyses, reports, patent applications, trade secrets, ideas, methods, processes, know-how, computer programs, products, equipment, raw materials, designs, data sheets, schematics, configurations, specifications, techniques, drawings and the like, whether or not relating to experimental data, projects, products, processes, research practices and the like, (B) past, present and future business, financial and commercial data or information, prices and pricing methods, marketing and customer information, financial forecasts and projections, and other data or information relating to strategies, plans, budgets, sales and the like; and (C) any other data or information delivered by the Disclosing Party to the Receiving Party or which the Receiving Party has acquired from the Disclosing Party by way of the farmer&#8217;s inspection or observation during visits to the research laboratory, manufacturing plan or other type of facility of the latter Party. The Parties expressly acknowledge and agree that all information of a proprietary and/or confidential nature furnished by the Disclosing Party to the Receiving Party in furtherance of the Disclosing Party&#8217;s obligations under this Agreement shall be deemed Confidential Information. For the sake of clarity, all information with respect to the Cl Strains, the Danisco Improved Strains, the Dyadic Know-How, Dyadic Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools and the Danisco Patents, the Dyadic Follow-On IP, the Collaboration IP and the Product Results and any components of the C 1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Dyadic Materials, Dyadic Patents, Danisco Know&#8226; How, the Genetic Tools, the Danisco Patents, the Dyadic Follow-On IP the Collaboration IP, on IP or any derivatives or modifications of any of the foregoing and the Product Results shall be owned or controlled by Dyadic and shall constitute its Confidential Information. Notwithstanding anything to the contrary contained herein, any failure by the Disclosing Party to mark, identify or confirm the Confidential Information shall not relieve Receiving Party of its obligations under this Agreement where Receiving Party knows or has reason to know that the information disclosed to it is Confidential Information.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential Information Exclusions. </font><font style="font-family:inherit;font-size:12pt;">Confidential Information will exclude information the Receiving Party can demonstrate is: (i) now or hereafter, through no unauthorized act or failure to act on Receiving Party&#8217;s part, in the public domain; (ii) known to the Receiving Party from a source other than the Disclosing Party (including former employees of the Disclosing Party) without an obligation of confidentiality at the time Receiving Party receives the same from the Disclosing Party, as evidenced by contemporaneous written records;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii) furnished to others by the Disclosing Party without restriction on disclosure; or (iv) independently developed by the Receiving Party without use of the Disclosing Party&#8217;s Confidential Information, as evidenced by contemporaneous written records.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidentiality Obligation. </font><font style="font-family:inherit;font-size:12pt;">For a period commencing on this date and ending on the tenth (10</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">) anniversary after the termination of this Agreement, the Receiving Party shall treat as confidential all of the Disclosing Party&#8217;s Confidential Information and shall not use such Confidential Information for any purpose whatsoever other than for the purposes set forth herein, except as expressly otherwise permitted under this Agreement. Without limiting the foregoing, the Receiving Party shall use the same degree of care and means that it utilizes to protect its own information of a similar nature, but in any event not less than reasonable care and means, to prevent the unauthorized use or the disclosure of such Confidential Information to Third Parties. The Confidential Information may be disclosed only to employees or contractors of the Receiving Party with a &#8220;need to know&#8221; who are instructed and agree not to disclose the Confidential Information and not to use the Confidential Information for any purpose, except as set forth herein; provided, however, in the case of BDI Pharmaceuticals and its Affiliates, the term &#8220;employees or contractors of a Receiving Party&#8221; shall include employees of each of those of BDI Pharmaceuticals, its Affiliates and any contract research organizations with whom BDI Pharmaceuticals or its Affiliates has written agreements pursuant to which such contract research organization is performing or will perform work under the Development Plan or Commercialization Plan and is bound by an obligation of confidence to BDI Pharmaceuticals or its Affiliates that makes such contract research organization liable for any breach by its employees of those confidentiality obligations to BDI Pharmaceuticals or its Affiliates. The Receiving Party shall have appropriate written agreements with any such employees or contract research organizations sufficient to comply with the provisions of this Agreement. A Receiving Party may not alter, decompile, disassemble, reverse engineer or otherwise modify any Confidential Information received hereunder and the mingling of the Confidential Information with information of the Receiving Party shall not affect the confidential nature or ownership of the same as stated hereunder.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Permitted Disclosures of Product Results by BDI Pharmaceuticals. </font><font style="font-family:inherit;font-size:12pt;">Dyadic shall own the Product Results. BDI Pharmaceuticals may disclose the Product Results to a Third Party if it has received written consent to such disclosure from Dyadic. In requesting such consent, BDI Pharmaceuticals shall provide the following information to Dyadic: (i) evidence that the Third Party to whom the disclosure is proposed to be made has executed, or will execute prior to receipt of Product Results, a confidentiality agreement with BDI Pharmaceuticals that prevents such Third Party from further disclosure of such information and contains restrictions on disclosure of Confidential Information at least as stringent as those found herein; and (ii) the proposed disclosure of Product Results. BDI Pharmaceuticals agrees that Dyadic may, in its sole discretion, refuse to consent to the disclosure and/or may require BDI Pharmaceuticals to delete any Dyadic Confidential Information from the proposed disclosure.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.5</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Permitted Disclosures of Confidential Information. </font><font style="font-family:inherit;font-size:12pt;">Nothing in this Agreement shall prevent the Receiving Party from disclosing Confidential Information to the extent the Receiving Party is legally compelled to do so by any governmental investigative or judicial agency pursuant to proceedings over which such agency has jurisdiction; provided, however, that prior to any such disclosure, and to the extent permitted by law, the Receiving Party shall (i)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">assert the confidential nature of the Confidential Information to the agency; (ii) immediately notify the Disclosing Party in writing of the agency&#8217;s order or request to disclose; and (iii) cooperate fully with the Disclosing Party in protecting against any such disclosure and/or obtaining a protective order narrowing the scope of the compelled disclosure and protecting its confidentiality.</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">1</sup>&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 11</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TERM AND TERMINATION</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term. </font><font style="font-family:inherit;font-size:12pt;">This Agreement shall become effective on the Effective Date. Unless sooner terminated in accordance with any other provision of this Agreement, the term of this Agreement shall expire on the tenth (10</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">) anniversary of the date of the last commercial sale by Dyadic (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term</font><font style="font-family:inherit;font-size:12pt;">&#8221;),</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">excluding the Articles and Sections and their legal effects of which are meant to survive the termination or expiration of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Termination by Either Party.</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">2</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Notwithstanding the stipulation in Section 11.1, either Party may terminate this Agreement upon the occurrence of any of the following itemized events:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Without prejudice to any other damages or remedies available under applicable law and/or this Agreement, either Party has the right, at any time, to terminate this Agreement by written notice and without further formality upon a breach by the other Party in the performance of the provisions of this Agreement, provided such breach is not cured within sixty (60) days following receipt by the defaulting Party of a written notice from the non-defaulting Party to remedy such breach. However, (i) in case of a breach, which is not capable of being cured; or (ii) where any Party repeatedly or consistently fails to meet its contractual obligations following an initial cure period, the other Party has the right to terminate this Agreement immediately, by written notice and without any further formality and (additional) cure period; or</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Either Party may terminate this Agreement if the other Party becomes insolvent, voluntarily files a petition for relief under bankruptcy or any similar or other insolvency laws (or has a petition filed against it and the same remains undischarged or unstayed for sixty (60) days) or voluntarily or involuntarily enters receivership or any similar or other insolvency proceeding.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.3</font><font style="font-family:inherit;font-size:12pt;">Effects of Termination or Expiration.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accrued Rights and Obligations</font><font style="font-family:inherit;font-size:12pt;">. Termination of this Agreement hereunder for any reason shall not release any Party from any obligation which, at the time of such</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_____________________</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">1</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Deleted Section 10.6 was moved to Reps and Warranties</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">2</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Revised (a) and (b) to mirror RSA provisions, but kept 60 day cure for default that was previously included in this section.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">termination, has already accrued and become due to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rights in IP</font><font style="font-family:inherit;font-size:12pt;">. In the event of termination of this Agreement either on or prior to the expiration of the Term by either Party, all rights and licenses of BDI Pharmaceuticals to Product IP shall automatically terminate and/or revert back to Dyadic and any license grants from Dyadic to BDI Pharmaceuticals, such, for example, without limitation, the license grants provided in Article 2, shall terminate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Adverse Termination Consequences</font><font style="font-family:inherit;font-size:12pt;">. [To be negotiated] </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Inventory Sell-Off</font><font style="font-family:inherit;font-size:12pt;">. [To be negotiated]</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transfer of Regulatory Approvals</font><font style="font-family:inherit;font-size:12pt;">. [To be negotiated]</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Other Remedies Available</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding anything in this Agreement to the contrary, in the event of termination of this Agreement, each Party shall have available every remedy allowed under law and equity, including but not limited to specific performance, suit for damages and rescission.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Survival. </font><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything to the contrary contained herein, the provisions of Articles 1, 8, 10, 12, 13 and 14 and Sections 2.3, 9.1, 9.3, 11.3 and 11.4 shall survive any termination of this Agreement.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 12</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AUDIT</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">12.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">For-Cause Audits. </font><font style="font-family:inherit;font-size:12pt;">If Dyadic reasonably believes that BDI Pharmaceuticals is not in compliance with the terms of this Agreement or other Agreements between Dyadic and BDI Pharmaceuticals, Dyadic may schedule audits upon reasonable advance notice of not less than two (2) business days and during BDI Pharmaceuticals&#8217; regular business hours. Dyadic or its agents may inspect BDI Pharmaceuticals&#8217; facilities and may audit records, including records relating to the implementation of, including the accounting of costs incurred, the Development Plan and/or Commercialization Plan, subject to all confidentiality obligations and other restrictions herein or otherwise reasonably required by BDI Pharmaceuticals prior to such inspection. BDI Pharmaceuticals will make available all such records and will provide reasonable assistance in the inspection or audit. Audits in accordance with the terms and conditions of Section 12.1 may occur more frequently than one (1) time per calendar year, but in no case more than four (4) times per calendar year. In the event any audit under Section 12.1 results in Material Findings, the cost of such audit shall be paid by BDI Pharmaceuticals. Dyadic will issue an audit report to BDI Pharmaceuticals and allow BDI Pharmaceuticals twenty (20) business days to correct and/or issue corrective actions for any nonconformities found in the course of an audit. BDI Pharmaceuticals&#8217; lack of adherence to this timeline will result in a material breach of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">12.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Records. </font><font style="font-family:inherit;font-size:12pt;">BDI Pharmaceuticals shall maintain books and records, including, but not limited to protocols, protocol amendments, lab notebooks and raw data, relating to the </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">conduct of any study conducted as part of the Development Plan or Commercialization Plan or that otherwise may be required to be disclosed or reported to a Regulatory Authority (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Data</font><font style="font-family:inherit;font-size:12pt;">&#8221;) for the longer of fifteen ( 15) years or five (5) years following regulatory approval of any Product that the Study Data relates to and shall provide Dyadic with access to or copies of such records, subject to applicable Territory law and regulation, at Dyadic&#8217;s expense, subject to applicable Territory law and regulation, upon thirty (30) business day notice by Dyadic. In the event that BDI Pharmaceuticals plans to dispose of such records following the conclusion of the time-frame stated above, BDI Pharmaceuticals shall provide Dyadic with thirty (30) days prior notice and an option to transfer such records to Dyadic, subject to applicable Territory law and regulation, at Dyadic&#8217; s expense.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 13</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INDEMNIFICATION AND INSURANCE</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">13.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">In General.</font><font style="font-family:inherit;font-size:12pt;">&#32;Subject to the provisions hereof, each Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnifying Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall defend, indemnify and hold harmless the other Party, its Affiliates, and its and their employees, officers, directors, agents, distributors and licensees (each an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnified Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) against any Action based on (a) the Indemnifying Party&#8217;s breach of this Agreement; or (b) negligence, willful misconduct or violation of any law or regulation by the Indemnifying Party, its Affiliates, or its or their employees, officers, directors or agents. This requirement for indemnification is meant by the Parties to extend to the representations and Warranties set forth in Article 8.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">13.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Procedure.</font><font style="font-family:inherit;font-size:12pt;">&#32;If an Indemnified Party becomes aware of any Action it believes is indemnifiable under Section 13.1, (a) the Indemnified Party shall give the Indemnifying Party prompt written notice of the Action; (b) the Indemnifying Party shall assume, at its expense, the sole defense of such claim or cause of action through counsel selected by it and reasonably acceptable to the Indemnified Party, except that in the case of a conflict of interest between the Parties, the Indemnifying Party shall, at the Indemnifying Party&#8217;s expense, provide separate counsel for the Indemnified Party selected by the Indemnified Party; (c) the Indemnifying Party shall maintain control of such defense, including any decision as to settlement, except that any settlement of an Action shall require the written consent of both Parties, which consent shall not be withheld or delayed unreasonably; (d) the Indemnified Party may, at its option and expense, participate in such defense, and in any event, the Parties shall cooperate with one another in such defense; and (e) the Indemnifying Party shall bear the total costs of any court award or settlement in such Action.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">13.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party Infringement.</font><font style="font-family:inherit;font-size:12pt;">&#32;Each of the Parties shall indemnify, defend and hold harmless the other Party and its Affiliates and their respective officers, directors and employees from any losses, damages, liabilities, fines, penalties and expenses (including reasonable attorneys&#8217; fees) that arise out of or result from any Third Party claims of infringement of any patent or copyright, or misappropriation of any trademark, trade secret or other intellectual property right, private right, or any other proprietary or personal interest related by circumstances to the existence of this Agreement or any Product (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Infringement Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Dyadic&#8217;s obligation with regard to indemnifying BDI Pharmaceuticals hereunder shall be limited to breaches of its (a) obligations under Article 9, or (b) representations and warranties set forth in</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 8.2 with respect to the status of intellectual property discussed therein as of the date hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">13.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Liability and use of Product Results.  </font><font style="font-family:inherit;font-size:12pt;">BDI Pharmaceuticals shall indemnify, defend and hold harmless Dyadic and its Affiliates and their respective officers, directors and employees from any losses, damages, liabilities, fines, penalties and expenses (including reasonable attorneys&#8217; fees) that arise out of or result from any liability claim related to any Product or use of any Product Results.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">13.5</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exception to Indemnification.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Neither Party shall be required to indemnify the other Party to the extent that any such claims or suits arose out of or resulted from the other Party&#8217;s gross negligence, recklessness or willful misconduct or fraud.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">13.6</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Insurance.  </font><font style="font-family:inherit;font-size:12pt;">BDI Pharmaceuticals will produce and maintain adequate insurance in order to be able to cover claims under this Agreement.  Upon request, BDI Pharmaceuticals shall provide proof of adequate coverage to Dyadic.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 14</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MISCELLANEOUS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Relationship between Parties.  </font><font style="font-family:inherit;font-size:12pt;">Dyadic and BDI Pharmaceuticals are separate business entities, and shall not be considered as joint ventures, partners, agents, servants, employee or fiduciaries of each other.  The Parties specifically agree that any obligation to act in good faith and to deal fairly with each other which may be implied in law shall be deemed satisfied by the Parties&#8217; compliance with the express terms of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">No Implied Rights.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Other than expressly provided for in this Agreement, nothing in this Agreement grants or shall be construed to grant to any Party any right and/or any license to any intellectual property right or application therefor (including but not limited to patent applications or patents) which are held by and/or in the name of the other Party and/or which are controlled by or licensed by the other Party, or to any Confidential Information received from the other Party.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Entire Agreement; Amendment.  </font><font style="font-family:inherit;font-size:12pt;">This Agreement constitutes the entire Agreement between the Parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, commitments and writings in respect thereof.  No amendment or addition to this Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the Parties.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.4</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Force Majeure.  </font><font style="font-family:inherit;font-size:12pt;">Neither Party shall be held in breach of its obligations hereunder to the extent only that due performance or observance of such obligation is prevented or delayed by war and other hostilities, civil commotion, accident, trade disputes, acts or restraints of government imposition or restrictions of imports or exports or any other cause not within the control of the Party concerned.  The Party concerned shall forthwith notify the other Party of the nature and effect of such event and both Parties shall, where the same is practicable, use every reasonable endeavor to minimize such effect and to comply with the respective obligation herein contained as nearly as may be in their original form.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.5</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Foreign Corrupt Practices Act and Anti-Bribery Provisions.</font><font style="font-family:inherit;font-size:12pt;">&#32;During the Term, the Parties will not, and shall cause their Affiliates to not, make or provide any payments or gifts or any offers or promises of any kind, directly or indirectly, to any official of any government or to any official of any agency or instrumentality of any government, or to any political party or to any candidate for political office (the foregoing individually and collectively referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Government Official</font><font style="font-family:inherit;font-size:12pt;">&#8221;). If on the date hereof or at any time during the Term any Government Official or an active member of the armed services of any government (a) owns an interest in that certain Party or its Affiliate, (b) has any legal or beneficial interest in this Agreement or in payments to be received by that certain Party or its Affiliate in connection with the services to be provided by hereunder, or (c) is a director, officer or employee of that certain Party or its Affiliate, that certain Party will notify the other Party and will take such actions to assure that the affected person does not take any action, official or otherwise, and/or use any influence in connection with the other Party&#8217;s business.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.6</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Assignment.</font><font style="font-family:inherit;font-size:12pt;">&#32;Dyadic may freely assign this Agreement. BDI Pharmaceuticals may transfer or assign its rights and obligations under this Agreement to any Affiliate or to any Third Party who purchases all or substantially all of the assets of the business to which this Agreement pertains. No other assignment of this Agreement by BDI Pharmaceuticals, or any rights or obligations thereunder may be made without the consent of the Dyadic, which consent may be withheld in its absolute discretion. Subject to the foregoing, this Agreement shall be binding legal representatives.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.7</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Severability.</font><font style="font-family:inherit;font-size:12pt;">&#32;In the event any one or more of the provisions of this Agreement should for any reason be held by any court or authority having jurisdiction over this Agreement or any of the Parties hereto be invalid, illegal or unenforceable, such provision(s) shall be validly reformed to as nearly approximate the intent of the Parties as possible and if unreformable, the Parties shall meet to discuss in good faith what steps should be taken to remedy the situation.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.8</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Publicity; Use of Name.</font><font style="font-family:inherit;font-size:12pt;">&#32;Notwithstanding anything to contrary in this Agreement, Dyadic may issue any press releases or make any other public statement with respect to the transactions contemplated hereby or the Product Results without the prior consent of BDI Pharmaceuticals or its Affiliates and notwithstanding the existence of any confidentiality or non-disclosure obligations that Dyadic may have, which, for the avoidance of doubt, may include the filing of this Agreement or and/or summaries thereof with the U.S. Securities and Exchange Commission by Dyadic as required by U.S. federal securities law (such requirement to be determined by Dyadic in its sole discretion) and industry and investor conferences and presentations. BDI Pharmaceuticals may not issue any press releases or make any other public statement with respect to the transactions contemplated hereby or the Product Results without the prior written consent of Dyadic, which may be withheld in Dyadic&#8217;s sole discretion. The Parties may (i) disclose the terms of this Agreement to such Party&#8217;s auditors, attorneys, bankers or investment bankers as necessary for their rendition of services to such Party; and (ii) disclose the terms of this Agreement to bona fide prospective investors, merger partners, strategic partners or acquirors and their respective professional advisors, in connection with the negotiation, entry into and/or performance of a business transaction between such parties, including the conduct of due diligence involved in such transaction, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided, however, that </font><font style="font-family:inherit;font-size:12pt;">such parties are subject to obligations of confidentiality and non-use at least as restrictive as those set forth in this</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Agreement. During the term of this Agreement and for a reasonable time thereafter, Dyadic may use BDI Pharmaceuticals&#8217; and its Affiliates&#8217; names and logos in press releases, marketing material and/or advertisements disclosing the existence of this Agreement. Except for disclosures permitted pursuant to this Section 14.8, neither Party will use the other&#8217;s name for advertising or external publicity purposes without its consent.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.9</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Notices.</font><font style="font-family:inherit;font-size:12pt;">&#32;All notices, requests, reports and other communications provided in this Agreement shall be in writing and shall be deemed to have been made or given: (a) when delivered, if delivered by hand; (b) when confirmation of transmission received, if sent by email; (c) two (2) days following deposit with an overnight courier; or (d) on the date ten (10) business days following deposit, as certified or registered mail, with the postal service of the country of the Party providing notice:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:228px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">To Dyadic</font><font style="font-family:inherit;font-size:12pt;">:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">140 Intracoastal Pointe Drive,</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite # 404, Jupiter, Florida, 334 77 USA </font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Mark Emalfarb</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email: memalfarb@dyadic.com</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Telephone: (561) 743-8333</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">With a copy to</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Squire, Patton Boggs (US) LLP</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">127 Public Square, Suite 4900</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cleveland, Ohio 44114</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Laura Nemeth</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email: laura.nemeth@squirepb.com</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Telephone: 216-479-8552</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">To BDI Pharmaceuticals</font><font style="font-family:inherit;font-size:12pt;">:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Biotechnology Developments for</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Industry in pharmaceuticals S.L.U </font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Louist Proust 13</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4 7151 Boecillo (Valladolid) Spain</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Emilio Gutierrez</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email: egutierrez@bdibiotech.com</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Telephone: (+34) 983 54 85 63</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.10</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Applicable Law and Arbitration.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;This Agreement shall be governed by, and interpreted under, the laws of Florida, USA, without application of rules on conflicts of laws.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;Disputes between the Parties shall be resolved as provided by this Section 14.10. Any Party shall give the other Party written notice of any dispute under this or in connection with this Agreement. The Parties shall attempt to resolve such dispute promptly by negotiation among the chief executive officers of the Parties and his/her advisors and executive officers of the BDI Group and Dyadic, as applicable. Within thirty (30) days after delivery of the notice, the Party(ies) receiving the notice shall submit to the other a written response. The notice and response shall include: (A) a statement of each Party&#8217;s position and a summary of arguments supporting that position; and (B) in the case of any member of the BDI Group or Dyadic, the</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">name and title of the executive officer of such Party who will represent such Party and, in the case of any Party, the name and title of any other person who will accompany such Party during the negotiations. Within thirty (30) days after delivery of the disputing Party&#8217;s notice, the Parties shall meet at a mutually acceptable time and place, and thereafter as often as they deem reasonably necessary, to attempt to resolve the dispute.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;If any dispute has not been resolved by the Parties in accordance with Section 14.10(ii) within forty-five (45) days after the disputing Party&#8217;s request notice, or if the Parties fail to meet within thirty (30) days after such request notice, then each of the Parties agrees that such dispute shall be finally and exclusively settled without appeal by arbitration in New York City, New York, administered by the American Arbitration Association (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AAA</font><font style="font-family:inherit;font-size:12pt;">&#8221;) under its Commercial Arbitration Rules in effect as of the date of the request for arbitration, which rules are deemed to be incorporated into this Section 14.10(iii) </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that in the event of any conflict between such rules and the other provisions of this Agreement, such other provisions of this Agreement shall control. The arbitration shall be conducted before a single arbitrator. The decision of the arbitrator shall be in writing, shall set forth the facts found by the arbitrator to exist, his/her decision and the basis for that decision and shall be final and binding upon the Parties and not subject to appeal. Judgment upon any award rendered by the arbitrator may be entered in any court having jurisdiction thereof, including any court having jurisdiction over any of the Parties or their assets. Each Party shall bear its own costs and expenses in connection with the arbitration, including reasonable attorneys&#8217; fees, disbursements, arbitration expense, arbitrators&#8217; fees and the administrative fee of the AAA.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.11</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Independent Parties; No Authority to Bind. </font><font style="font-family:inherit;font-size:12pt;">The relationship of BDI Pharmaceuticals and Dyadic is that of independent contractors. Neither Party nor their employees are agents, partners, employers, employees, joint venturers, have any other kind of relationship with the other Party except as specified in the Investment Agreement, the Research Services Agreement, and the Service Framework Agreement. Neither Party shall have any authority to bind the other party to any obligation by contract or otherwise.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.12</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Construction of Agreement. </font><font style="font-family:inherit;font-size:12pt;">The Parties acknowledge that they thoroughly have reviewed this Agreement and bargained over its terms. Accordingly, this Agreement shall be construed without regard to the Party or Parties responsible for its preparation and shall be deemed to have been prepared jointly by the Parties.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.13</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cumulative Rights and Remedies. </font><font style="font-family:inherit;font-size:12pt;">The rights and remedies provided in this Agreement and all other rights and remedies available to either Party at law or in equity are, to the extent permitted by law, cumulative and not exclusive of any other right or remedy now or hereafter available at law or in equity. Neither asserting a right nor employing a remedy shall preclude the concurrent assertion of any other right or employment of any other remedy, nor shall the failure to assert any right or remedy constitute a waiver of that right or remedy.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.14</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Headings. </font><font style="font-family:inherit;font-size:12pt;">All headings in this Agreement are included solely for convenient reference, are not intended to be full and accurate descriptions of the contents of this Agreement, shall not be deemed a part of this Agreement, and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.15</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendments. </font><font style="font-family:inherit;font-size:12pt;">This Agreement may be modified or amended only by written agreement of the Parties.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.16</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">English Language. </font><font style="font-family:inherit;font-size:12pt;">The Parties shall use the English language in all communications relating to this Agreement, and the English language version of this Agreement signed by the Parties shall control over any and all translations.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.17</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Entire Agreement. </font><font style="font-family:inherit;font-size:12pt;">This Agreement, together with any supporting documents recited herein, constitutes the entire agreement between the Parties concerning the subject matter of this Agreement and supersedes all prior agreements between the Parties concerning the subject matter hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">14.18</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Counterparts. </font><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Signature Page Follows</font><font style="font-family:inherit;font-size:12pt;">]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">43</font></div></div><hr style="page-break-after:always"><div><a name="sffef27c9372d41939ff6ba554794afe5"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in two counterparts by their duly authorized representatives, each Party acknowledging receipt of one original.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:40%;"></td><td style="width:3%;"></td><td style="width:8%;"></td><td style="width:40%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY IN </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PHARMACEUTICALS, S.L.U.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">44</font></div></div><hr style="page-break-after:always"><div><a name="sf5fe91a87c69467e9f3a8949ab9f3825"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exhibit A</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">to</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">SELECTED PRODUCT DEVELOPMENT AND NET SALES SHARING AGREEMENT</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Selected Product</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">45</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>20
<FILENAME>exhibit1015form10.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFB0BC74BCD877D9B742B5CF62BC04EC0"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.15</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Execution Version</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*] indicates that a confidential portion of the text of this agreement has been omitted. The non-public</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">information has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">SERVICE FRAMEWORK AGREEMENT</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">This </font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">SERVICE FRAMEWORK AGREEMENT</font><font style="font-family:inherit;font-size:11pt;color:#212121;">&#32;(this "</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"), signed as of June 30, 2017, is entered into by and between DYADIC INTERNATIONAL, INC., a Delaware corporation with headquarters located at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477-5094 USA and U.S. tax identification number 45-04867472 ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Dyadic</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"), and BIOTECHNOLOGY DEVELOPMENTS FOR INDUSTRY IN PHARMACEUTICALS, S.L.U., a company incorporated under the laws of Spain having its registered office at Louist Proust 13, 4 7151 Boecillo (Valladolid), Spain, and identification code -CIF number- B-86206695 ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">BDI Pharmaceuticals</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"). Dyadic and BDI Pharmaceuticals are sometimes collectively referred to as the "</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:11pt;color:#212121;">" and individually as a "</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Party.</font><font style="font-family:inherit;font-size:11pt;color:#212121;">" Certain capitalized terms used herein have the meanings assigned them in Article 1 hereof.</font></div><div><a name="s5e31ba5916ed46a69d36a97305929030"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">RECITALS:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#212121;">I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">BDI Pharmaceuticals provides services for strain improvement, bioprocess development, bioprocess scale-up, bioengineering and contract production;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#212121;">II.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">Biotechnology Developments for Industry, S.L ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">BDI Holdings</font><font style="font-family:inherit;font-size:11pt;color:#212121;">") holds 100% of the shares of BDI Pharmaceuticals and 79.2% of the shares of VLP-The Vaccines Company, S.L.U. ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">VLPbio</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"), which develops human and animal vaccines based on a proprietary chimeric virus like particles technology platform;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#212121;">III.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">Dyadic is a global biotechnology company that has a proprietary biopharmaceutical protein production system based on the fungus </font><font style="font-family:inherit;font-size:11pt;color:#212121;font-style:italic;">Myceliopthora thermophila, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">nicknamed Cl. The Cl Technology (defined below) and other technologies may be used by BDI Pharmaceuticals pursuant to this Agreement for research and development activities in accordance with the terms of the Pharma License Agreement and solely on behalf of Dyadic;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#212121;">IV.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">This Agreement is being executed as a condition to the closing of the transactions contemplated by that certain Investment Agreement dated June 30, 2017 among Dyadic International (USA), Inc. ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Dyadic Florida</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"), BDI Holding and Inveready Innvierte Biotech II, S.C.R., S.A. (the "</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Investment Agreement</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"), pursuant to which Dyadic Florida is making a strategic investment in BDI Holding and its subsidiary, VLPbio, to, </font><font style="font-family:inherit;font-size:11pt;color:#212121;font-style:italic;">inter alia, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">enable BDI Holding and its subsidiary, BDI Pharmaceuticals, to fund BDI Pharmaceutical' s business plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#212121;">V.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">The Parties desire to enter into this Agreement to set forth the terms and conditions upon which BDI Pharmaceuticals will perform certain Services (defined below) for Dyadic, including preclinical research and /</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#212121;">or service Projects (defined below) involving Sponsor Materials (defined below); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:122%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;color:#212121;">VI.</font></div></td><td style="vertical-align:top;"><div style="line-height:122%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">BDI Pharmaceuticals will assign, and will cause each of its permitted subcontractors hereunder to assign, all rights in and to any and all intellectual property developed during the commissioning of or yielded from the Projects to Dyadic, or as directed by Dyadic.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;1</font></div></div><hr style="page-break-after:always"><div><a name="sff291168e19c4ef8b1e2de642f6d3698"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">AGREEMENT:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">NOW, THEREFORE, IN CONSIDERATION </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">of the mutual covenants contained in this Agreement, and the foregoing Recitals, which are incorporated herein and by this reference made a part hereof, and for other good and valuable consideration the receipt and adequacy of which hereby are mutually acknowledged by Dyadic and BDI Pharmaceuticals, the Parties hereby agree as follows:</font></div><div><a name="s91a98a8a23a04856b3923c0d1a95dc34"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">ARTICLE 1</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">DEFINITIONS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">Capitalized terms used in this Agreement shall have the meaning ascribed to them below, or as otherwise defined above or in the text of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(a)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">AAA</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 9.10 hereof</font><font style="font-family:inherit;font-size:11pt;color:#656565;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">"Action"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">&#32;has the meaning set forth in Section 7 .1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(c)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Affiliate</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" means any person, corporation, or other entity that controls, is controlled by, or is under common control with a Party. Control, with respect to such other corporation or entity, includes a person, corporation or other entity (i) owning or directly or indirectly controlling a majority of the voting stock or other ownership interest, (ii) possessing, directly or indirectly, the power to direct or cause the direction of the management and policies, or (iii) possessing the power to elect or appoint a majority of the members of the governing body. For the avoidance of doubt, the term Affiliate when used with respect to BDI Pharmaceuticals shall include BDI Holdings and VLPbio.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(d)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in the Preamble</font><font style="font-family:inherit;font-size:11pt;color:#747474;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(e)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Background IP</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 4.1 hereof</font><font style="font-family:inherit;font-size:11pt;color:#656565;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">"BDI Holding"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">&#32;has the meaning set forth in Recital II</font><font style="font-family:inherit;font-size:11pt;color:#747474;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(g)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">BDI Pharmaceuticals</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in the Preamble.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(h)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">BDI Services Generated Tools</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" means Genetic Tools generated in the course of the provision of the Services by BDI Pharmaceuticals and its Affiliates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(i)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Best Efforts</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" means the efforts that a prudent Person desirous of achieving a result would use in similar circumstances to ensure that such result is achieved as expeditiously as practical.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(j)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">C1 Strains</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" means, individually and collectively, the </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-style:italic;">Myceliophthora thermophile </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">strains transferred to and/or derived or generated therefrom in the Project or under this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(k)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">C1 Technology</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" includes any and all Sponsor Materials, Dyadic Know-How, Dyadic C 1 Genomic Information, C1 Strains, Dyadic Improved Strains and Genetic Tools.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(I)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Collaboration IP" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">has the meaning set forth in Section 4.2 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(m)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Confidential Information" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">has the meaning set forth in Section 5.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(n)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Danisco Improved Strains" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">has the meaning set forth in Pharma License Agreement</font><font style="font-family:inherit;font-size:11pt;color:#505050;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(o)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Danisco Know-How" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">has the meaning set forth m the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(p)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Danisco Patents" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">has the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(q)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Directed Projects"  </font><font style="font-family:inherit;font-size:11pt;color:#232323;">means  projects  contracted by Dyadic  to BDI Pharmaceuticals under this Agreement whose direct beneficiary will be a Third Party introduced by Dyadic and whose aim, planning and budgets shall be agreed in writing by the Parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(r)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Disclosing Party" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">has the meaning set forth in Section 5.1 hereof. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(s)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Dyadic" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">has the meaning set forth in the Preamble.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(t)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Dyadic Cl Genomic Information" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">means the current and future genome sequence of C 1 Strains, genes and other genetic elements including genomic data derived from C 1 and any associated annotations, software, software tools related thereto including any subsequent Dyadic C 1 Genomic Information coming from Dyadic, or identified or developed in a Project or under this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(u)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Dyadic Follow-On IP" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">has the meaning set forth in Section 4.6 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Dyadic Improved Strains" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">means one or more Cl Strains modified to express intracellularly or extracellularly whether it is secreted or not a Pharmaceutical Product where the performance or characteristics of such C1 Strains, including, without limitation, with respect to any composition of matter produced or expressed therein has been materially alerted as a result of work done by or on behalf of Sponsor pursuant to this Agreement, where such Cl Strains, as materially altered, would, to one reasonably skilled in the art, be useful in the Pharmaceutical Field.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(w)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Dyadic Know-How" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">means any and all information relating to the Cl genome, engineering, production, fermentation, composition and use of C 1 Strains, as such information existed as of the Effective Date, and any and all subsequently transferred know-how and/or know-how that is developed by BDI Pharmaceuticals or its Affiliates that relates in any way to Cl, Cl Technology or fermentation process and media development or the Cl Technology.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Dyadic Patents" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">has the meaning set forth in Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(y)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">"Dyadic Projects" </font><font style="font-family:inherit;font-size:11pt;color:#232323;">means projects contracted by Dyadic to BDI Pharmaceuticals under this Agreement whose direct beneficiary will be Dyadic and whose aim, planning and budgets shall be agreed in writing and signed by the Parties.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(z)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 8.1 hereof. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(aa)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">FTE</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 2.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(bb)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Genetic Tools</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" means any composition of matter and genetic elements useful for using, manipulating, engineering, transforming, transfecting, modifying or altering a C1 Strain that was transferred to BDI Pharmaceuticals. Without limiting or expanding the foregoing Genetic Tools shall include those identified on Exhibit 2 of each Statement of Work and any subsequently transferred Genetic Tools and/or developed Genetic Tools developed by BDI Pharmaceuticals or its Affiliates that relate in any way to C1 Strains, and/or the C1 Technology. For the avoidance of doubt, Genetic Tools shall exclude the Danisco Background Technology and the Danisco Background Tools, each as defined in the Pharma License Agreement).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(cc)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Government Official</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 9.5 hereof. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(dd)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Indemnified Party</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 7 .1 hereof. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(ee)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Indemnifying Party</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 7.1 hereof. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(ff)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Infringement Claim</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 7 .3 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(gg)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Investment Agreement"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">&#32;has the meaning set forth in Recital IV hereto.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(hh)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Key Person</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" means those persons listed on </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">&#32;hereto. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(ii)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Party" or "Parties</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in the Preamble. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(jj)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Payee</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 2.3(b) hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(kk)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Pharmaceutical Product</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(ll)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Pharma License Agreement</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" means the agreement between Danisco and Dyadic dated December 31, 2015, a redacted copy of which has been provided to BDI Pharmaceuticals for review in advance of executing this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(mm)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Projects</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" means Dyadic Projects and Directed Projects.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(nn)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Quality Audit</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 3.1 hereof. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(oo)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 5.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(pp)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">R&amp;D License</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" has the meaning set forth in Section 4.4 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">(qq)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Results</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">" means the results of the Projects that are required to be delivered and/ or actually delivered by BDI Pharmaceuticals to Sponsor pursuant to a Statement of Work and any research and development information, inventions and/or discoveries, whether patentable or not, know-how, protocols, procedures, composition of matter, raw and analyzed data, methods,</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">technical data and information generated or developed in the course of the Projects by or on behalf of BDI Pharmaceuticals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(rr)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Services</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" means the activities set forth on the Statements of Work, and any other Services that BDI Pharmaceuticals may perform or have performed on its behalf hereunder.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(ss)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Sponsor</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" means Dyadic and/or a Third Party beneficiary of a Directed Project. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(tt)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Sponsor Materials</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" means the materials set forth on Exhibit 1  to each Statement of Work and any subsequent transferred Sponsor Materials including any C1 Strains, Dyadic Improved Strains, Danisco Improved Strains, Genetic Tools, Dyadic Cl Genomic Information, Dyadic Know-How and/or any modifications or improvements identified and/or developed by BDI Pharmaceuticals or its affiliates that relate in any way to Cl or the Cl Technology.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(uu)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Statement of Work</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" has the meaning set forth in Article 2 hereof. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(vv) "</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Study Data</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" has the meaning set forth in Section 3.4 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(ww)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Sublicensee</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" as used herein shall refer to BDI Pharmaceuticals and its Affiliates and also have the meaning set forth in the Pharma License Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(xx)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Term</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" has the meaning set forth in Section 8.1 hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(yy)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Third Party</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" means any Person that is not a Party (or an Affiliate of a Party) to this Agreement, including without limitation other collaboration Partners.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(zz)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">VAT</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" has the meaning set forth in Section 2.3(b) hereof. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(aaa)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">VLPbio</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" has the meaning set forth in Recital II.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(bbb)&#160;&#160;&#160;&#160;"</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Withholding Party</font><font style="font-family:inherit;font-size:11pt;color:#232323;">" has the meaning set forth in Section 2.3(b) hereof</font><font style="font-family:inherit;font-size:11pt;color:#363636;">.</font></div><div><a name="s1c3809438fd24a1d9a8d1cd2433814ae"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">ARTICLE 2</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">FRAMEWORK AGREEMENT</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">Any Projects to be carried out by BDI Pharmaceuticals by virtue of this Agreement will require a specific common definition of the Project which will determine the aim, planning and budget. The definition of the Projects shall be carried out jointly by both Parties' teams, and will be subject to final written approval by the representatives of each of the Parties, who shall initially be:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.64102564102564%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:7%;"></td><td style="width:57%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">Ronen Tchelet</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">Dyadic representative</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">BDI Pharmaceuticals representative</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">Each Project shall be defined in a document (a "</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Statement of Work</font><font style="font-family:inherit;font-size:11pt;color:#232323;">") to be attached to this Agreement in the form attached as </font><font style="font-family:inherit;font-size:11pt;color:#232323;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:11pt;color:#232323;">. The Parties agree that the definition of each of the Projects shall be made under the following basis:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#4f4f4f;font-weight:bold;padding-right:48px;">2.1</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;font-weight:bold;">Project Quotation Conditions. </font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">BDI Pharmaceuticals will quote the Projects under the conditions set forth herein:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;text-decoration:underline;">Fees.</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Set forth below are the agreed upon costs per full time equivalent ("</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;font-weight:bold;">FTE</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">") position that is expected to service the Projects. Such costs are shown per person per position at a 100% dedicated rate for one year. FTE costs will be quoted proportionately to time and effort needed per Project. The FTE rates set forth below shall not increase prior to July 1, 2019 and may be increased at a rate of no more than 5% per year for the years 2019, 2020 and 2021.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:96px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.95726495726496%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Project Manager:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*] EUR</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Senior Scientist:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*] EUR</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Junior Scientist:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*] EUR</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">Technician:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*] EUR</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;color:#626262;text-decoration:underline;">S</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;text-decoration:underline;">u</font><font style="font-family:inherit;font-size:11pt;color:#626262;text-decoration:underline;">pplies. Mate</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;text-decoration:underline;">r</font><font style="font-family:inherit;font-size:11pt;color:#626262;text-decoration:underline;">i</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;text-decoration:underline;">als and Subcontractin</font><font style="font-family:inherit;font-size:11pt;color:#626262;text-decoration:underline;">g</font><font style="font-family:inherit;font-size:11pt;color:#626262;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#717171;text-decoration:underline;">E</font><font style="font-family:inherit;font-size:11pt;color:#626262;text-decoration:underline;">xpe</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;text-decoration:underline;">n</font><font style="font-family:inherit;font-size:11pt;color:#626262;text-decoration:underline;">ses.</font><font style="font-family:inherit;font-size:11pt;color:#626262;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">BDI agrees that all supplies, materials, not otherwise negotiated and evidenced under a Statement of Work, an amendment thereto, or a countersigned quote related thereto, to the extent necessary to carry out the Projects on behalf of Sponsor, will be at BDI's sole expense. Additionally, BDI Pharmaceuticals agrees that the cost to Dyadic of services provided by non-Affiliate third-party subcontractors shall be separately called out in each Statement of Work and shall be equal to BDI Pharmaceutical's contracted price plus 10%.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;text-indent:0px;"><font style="padding-bottom:12px;text-align:left;font-family:inherit;font-size:11pt;color:#4f4f4f;font-weight:bold;padding-right:48px;">2.2</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;font-weight:bold;">Contracting Commitments</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">. Subject to Section 9,</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">(a)&#160;&#160;&#160;&#160;For the twenty-four (24) month period following the effective date of the first Statement of Work to be executed hereunder (the "</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;font-weight:bold;">Initial Commitment Period</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">"), Dyadic expressly undertakes to contract Projects to BDI Pharmaceuticals a minimum cumulative amount of US$500,000 for each twelve (12) month period, to be paid at the rates indicated above, and BDI Pharmaceuticals agrees to make available qualified and skilled personnel and resources for them as and when required.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">(b)&#160;&#160;&#160;&#160;For a period of thirty</font><font style="font-family:inherit;font-size:11pt;color:#717171;">-</font><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">six (36) months following the Initial Commitment Period, at Dyadic's sole option, Projects may continue minimally at the same level of FTE's or greater, and BDI Pharmaceuticals represents that it will make the necessary qualified and skilled personnel and additional resources available to carry out such Projects for Sponsor.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">(c)&#160;&#160;&#160;&#160;If Dyadic, or its Affiliates, requests to lease lab space or gain access to equipment and personnel in order to qualify for European Union or other funding opportunities, BDI its Affiliates (such as, for example, without limitation, Dyadic Nederland BV) under equal terms and conditions as set forth in Section 2.1 and availability of such FTEs will managed through reasonable schedules and conditions to avoid affecting other works being developed by BDI Pharmaceuticals or Affiliates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4f4f4f;">(d)&#160;&#160;&#160;&#160;BDI Pharmaceuticals shall not at any time sell services at FTF rates or charge or charge lower percent margin on out-of-pocket expenses to a different sponsor of research services at prices below those stated in this Agreement. If BDI Pharmaceuticals charges a different sponsor a lower price for these service components, BDI Pharmaceuticals must immediately apply the</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">lower price for the services under this Agreement. If BDI Pharmaceuticals fails to meet the lower price, Dyadic, at its sole option may terminate this Agreement without any liability pursuant to this Agreement's termination provisions.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">2.3</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Invoicing and Payment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(a)&#160;&#160;&#160;&#160;Sponsor shall pay BDI Pharmaceuticals the charges set forth in the applicable Statement of Work as invoiced. BDI Pharmaceuticals shall invoice Sponsor on a monthly basis and all undisputed payments should be made within thirty (30) days from the invoice date. Sponsor will provide prompt notice of and basis for any disputed amounts. The Parties shall cooperate in good faith to promptly resolve any invoicing disputes.  Undisputed amounts due may not be withheld or offset by Sponsor except as set forth herein. All payments shall be made in Euros.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(b)&#160;&#160;&#160;&#160;Each Party shall be responsible for any and all taxes levied as a result of the performance of each Party's respective activities under this Agreement, unless separately addressed in another section of this Agreement. All amounts payable under this Agreement are exclusive of withholding tax and value added, goods and services, sales or similar taxes ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">VAT</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"), if applicable. For the avoidance of doubt, either Party may withhold from payments such taxes as are required to be withheld under applicable law and to the extent permitted by applicable law, BDI Pharmaceuticals shall not include VAT on the applicable invoices based on the nature of the Services. If VAT or any other tax is withheld by a Party ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Withholding Party</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"), such Withholding Party shall provide to the other Party ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Payee</font><font style="font-family:inherit;font-size:11pt;color:#212121;">") receipts or other evidence of such withholding and payment thereof to the appropriate tax authorities. The Withholding Party agrees not to withhold any taxes, or to withhold at a reduced rate, to the extent that the Payee is entitled to an exemption from, or reduction in the rate of, as appropriate, withholding under any applicable income tax treaty. If, after any remuneration is paid, it is determined by the appropriate taxing authorities that additional withholding taxes are due with respect to such withholding taxes, Payee shall directly pay such taxes or reimburse Withholding Party for any payment of such withholding taxes that Withholding Party makes.</font></div><div><a name="sa2ed34effed24c2a83fdec0e6db086b0"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">ARTICLE 3</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">AUDITS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">3.1</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">For Cause Audits. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">&#32;If Sponsor reasonably believes that the Projects are not being performed, or were not performed, in compliance with the terms of this Agreement or a Statement of Work hereunder, Sponsor may audit BDI Pharmaceuticals and/or any Affiliate of BDI Pharmaceuticals subcontracted hereunder upon reasonable advance notice to BDI Pharmaceuticals of not less than two (2) business days and during BDI Pharmaceuticals' or its Affiliates, if applicable, regular business hours. Sponsor or its agents may inspect BDI Pharmaceuticals' or its Affiliates', if applicable, facilities and may audit all records, including, but not limited to, Study Data and accounting records, relating to the Projects, subject to all confidentiality obligations and other restrictions herein or otherwise reasonably required by BDI Pharmaceuticals, or its Affiliate, prior to such inspection. BDI Pharmaceuticals will make or cause to be made available all such records and will provide reasonable assistance in the inspection or audit. Sponsor's right to audit will survive the expiration or earlier termination of this Agreement. Audits in accordance with the terms and conditions of this Section 3.1 may</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#525252;">occur no more than four (4) times per calendar year. Audits conducted under this Section 3.1 shall be at Sponsor's expense, provided, however, that if any audit under this Section 3.1 results in material findings, the cost of such audit shall be paid by BDI Pharmaceuticals. If Sponsor issues an audit report to BDI Pharmaceuticals, BDI Pharmaceuticals shall be allowed twenty (20) business days to correct and</font><font style="font-family:inherit;font-size:11pt;color:#656565;">/</font><font style="font-family:inherit;font-size:11pt;color:#525252;">or issue corrective actions for any non-conformities found in the course of the audit</font><font style="font-family:inherit;font-size:11pt;color:#656565;">. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">BDI Pharmaceuticals lack of adherence to this timeline will result in a material breach of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;padding-right:48px;">3.2</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Quality Audits. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">At Sponsor's request</font><font style="font-family:inherit;font-size:11pt;color:#656565;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">BDI Pharmaceuticals shall permit each Sponsor to perform one quality audit per year without cause, and additional visits if warranted. A Sponsor is allowed to review and access: BDI Pharmaceuticals quality systems, original study records and other primary documents, redacted government inspection reports such as FDA redacted 483s, areas of the BDI Pharmaceuticals facility relevant to provision of Services to the Sponsor, including laboratories and warehousing facilities ("</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Quality Audit</font><font style="font-family:inherit;font-size:11pt;color:#525252;">"). A Sponsor may request a Quality Audit only upon reasonable advance notice of not less than ten (10) business days and during BDI Pharmaceutical's regular business hours and one (I) time per calendar year during the term of this Agreement. BDI Pharmaceuticals will not be asked to identify its non&#8226; Sponsor clients or disclose any confidential business information provided by those clients. Sponsor shall cause its accounting firm to retain all such information subject to the confidentiality restrictions of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;padding-right:48px;">3.3</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Corrective Measures. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">BDI Pharmaceuticals agrees to institute reasonable corrective measures in BDI Pharmaceuticals' reasonable discretion to address deficiencies identified in a Sponsor audit.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;padding-right:48px;">3.4</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Study Records. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">BDI Pharmaceuticals shall maintain and cause any subcontractors that it may use hereunder to maintain books and records, including, but not limited to protocols</font><font style="font-family:inherit;font-size:11pt;color:#656565;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">protocol amendments, lab notebooks and raw data, relating to the conduct of any study conducted as part of the Projects (the "</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Study Data</font><font style="font-family:inherit;font-size:11pt;color:#525252;">") for the longer of fifteen (15) years or five (5) years following regulatory approval of the product to which the Study Data relates. BDI Pharmaceuticals shall provide Sponsor with access to or copies of the Study Data, at Sponsor's expense, within five (5) business days' following Sponsor</font><font style="font-family:inherit;font-size:11pt;color:#656565;">'</font><font style="font-family:inherit;font-size:11pt;color:#525252;">s written request therefor. In the event that BDI Pharmaceuticals plans to dispose of any Study Data following the conclusion of the time-frame stated above</font><font style="font-family:inherit;font-size:11pt;color:#656565;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">BDI Pharmaceuticals shall provide Sponsor with thirty (30) days prior written notice and an option to transfer such records to Sponsor</font><font style="font-family:inherit;font-size:11pt;color:#656565;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">at Sponsor's expense.</font></div><div><a name="sa2988dc31e0f4dad97c3971a3d2df354"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">ARTICLE 4</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;padding-right:48px;">4.1</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Background IP. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">As between the Parties</font><font style="font-family:inherit;font-size:11pt;color:#656565;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">each Party will own and retain all right, title and interest in and to their Background IP. "</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Background IP</font><font style="font-family:inherit;font-size:11pt;color:#525252;">" means, with respect to a Party, any inventions, technology, know-how, trade secrets and any other intellectual property owned or controlled by such Party or its Affiliates prior to the Effective Date or developed or otherwise obtained by such Party outside the scope of this Agreement. Background IP shall also mean</font><font style="font-family:inherit;font-size:11pt;color:#656565;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">with respect to Sponsor</font><font style="font-family:inherit;font-size:11pt;color:#656565;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">intellectual property that is developed other than Collaboration IP</font><font style="font-family:inherit;font-size:11pt;color:#656565;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">as provided herein. For the sake of clarity, without limitation, Background IP with respect to Dyadic shall include C1 Strains, Dyadic Improved Strains, Dyadic C1 Genomic Information, the</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">Danisco Improved Strains, the Dyadic Know-How, the Sponsor Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents and/or any derivatives or modifications thereof and the Dyadic Follow-On IP and any results related thereto. Nothing in this Agreement grants or implies a license in any intellectual property of either Party except that BDI Pharmaceuticals hereby provides Sponsor with a non-exclusive, perpetual and royalty free license to use the BDI Pharmaceuticals' and its Affiliates Background IP as far as necessary for Sponsor to make use of the Results.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">4.2</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Collaboration IP. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Inventorship shall be determined according to United States practice. "</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Collaboration IP" </font><font style="font-family:inherit;font-size:11pt;color:#212121;">means, with respect to a Party, any inventions, technology, know-how, trade secrets, and any other intellectual property, whether patentable or not, that has been conceived or reduced to practice pursuant to this Agreement, a Statement of Work hereunder or that is related to a Project. Subject to the restrictions set forth in Section 4.1, Sponsor, shall own all right, title and interest in and to the Collaboration IP and the Results directly related to each Project for which they are a Sponsor, regardless of inventorship.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">4.3</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Responsibility for Preparation and Prosecution of IP. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">BDI Pharmaceuticals shall notify Dyadic promptly in writing of all Collaboration IP or Dyadic Follow-On IP conceived or generated by BDI Pharmaceuticals. BDI Pharmaceuticals agrees to assign, as applicable, and hereby irrevocably assigns to Dyadic all of its right, title and interest in and to the Collaboration IP and the Results or the Dyadic Follow-On IP, as necessary to affect Dyadic's sole ownership. Dyadic shall have the sole right and authority, but not the obligation, for the filing, prosecution and maintenance of the Collaboration IP. BDI Pharmaceuticals shall render all necessary assistance reasonably requested by Dyadic in preparing, filing and prosecuting the Collaboration IP. If necessary and when requested, BDI Pharmaceuticals shall (i) sign and execute all such forms and documents as may be necessary to assure and perfect rights in the Collaboration IP and the Dyadic Follow-On IP; and (ii) cause its current and/or former directors, employees, researchers, students, consultants and/or contractors to sign and execute all such forms and documents as may be necessary to perfect the Collaboration IP or the Dyadic Follow-On IP. Dyadic shall bear the costs and expenses for preparing, filing and prosecuting the Collaboration IP pursuant to this Section 4.3. Notwithstanding the foregoing, Dyadic my assign all rights to receive assignment of Collaboration IP to a Third Party and thereby direct such assignment to be made directly from BDI Pharmaceuticals to such Third Party, who shall have all rights to enforce this Section 4.3 as if it were Dyadic.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">4.4</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Non-Exclusive Limited Use Research License Grant from Dyadic to BDI Pharmaceuticals. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">&#32;Dyadic hereby grants to BDI Pharmaceuticals ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Sublicensee</font><font style="font-family:inherit;font-size:11pt;color:#212121;">") a non-exclusive, non-transferable, non-sub-licensable, except as set forth herein, and fully paid license of the Cl Strains, the Danisco Improved Strains, the Dyadic Know-How, the Sponsor Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents and Dyadic Follow-On IP, the grant of the non-exclusive license being for the sole purpose of conducting research as contemplated by the Project and only broad enough to perform the Project in accordance with the terms of this Agreement ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">R&amp;D License</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"). The C 1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Sponsor Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools and the Danisco Patents, any components of the Cl Strains, the Danisco Improved Strains, the Dyadic Know-How, the Sponsor Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools and the Danisco Patents, and any derivatives or</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">modifications of any of the foregoing, shall be used by Sublicensee and its Affiliates only in accordance with and for the execution of this Agreement, the completion of the Project and in compliance with applicable law. For the sake of clarity, (i) Sublicensee shall not transfer or deliver any Cl Strains, the Danisco Improved Strains, the Dyadic Know-How, the Sponsor Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools or the Danisco Patents, any components of the C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Sponsor Materials, Dyadic Patents, Danisco Know-How, the Genetic Tools or the Danisco Patents, or any derivatives or modifications of any of the foregoing, to any Third Party without the prior written consent of Dyadic, which consent may be withheld in Dyadic's absolute discretion, and (ii) Sublicensee may not transfer or sublicense the R&amp;D License for any purpose (a) except to the extent necessary to have Third Parties conduct contract research on behalf of the Sub licensee or for the Sublicensee to exercise its "have made" rights; (b) unless such subcontractor agrees in a signed writing to relinquish any and all rights to the commercial product and/or process of using C1 to make and sell the product without payment in addition to the amount negotiated for the provision of contract research services; and (c) unless such subcontractor agrees in a signed writing to protect, abide by and not otherwise violate the terms of the Pharma License Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;padding-right:48px;">4.5</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;">Additional Conditions Incorporated from Pharma License Agreement. </font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">Sublicensee acknowledges that it has read the Pharma License Agreement entered into between Danisco US Inc, and Dyadic International, Inc. and agrees to be bound by the provisions of such Pharma License Agreement as if it were a party to such Pharma License Agreement. For the avoidance of doubt, this includes the provisions of Section 10.7 of the Pharma License Agreement regarding resolution of disputes. Sublicensee agrees that Danisco US Inc. or any authorized assignee of Danisco US Inc. is an intended third party beneficiary to any Sub license Agreement and shall be entitled to enforce the terms of this Agreement directly against Sub licensee. This Sub license Agreement shall not be further sublicensed except that, as applicable, the C1 Strains (as defined in the Pharma License Agreement), the Danisco Improved Strains, the Dyadic Know-How (as defined in the Pharma License Agreement), the Sponsor Materials (as defined in the Pharma License Agreement), Dyadic Patents, Danisco Know-How, the Genetic Tools (as defined in the Pharma License Agreement) and the Danisco Patents may be further sublicensed to the extent necessary to Third Parties having no economic interest in the Pharmaceutical Product under development to provide contract research services or contract manufacturing services for a Licensed Party (as defined in the Pharma License Agreement), for a Sublicensee to exercise its 'have made' rights or, with respect to a Pharmaceutical Product, to grant limited sublicenses within multiple tiers of Sublicensee Affiliates (as defined in the Pharma License Agreement) or Third Parties solely to permit manufacturing, distributing or marketing such Pharmaceutical Products on behalf of such Sub licensee under terms no less restrictive than the terms set forth in Section 2.2 of the Pharma License Agreement entered into between Danisco US Inc. and Dyadic International Inc.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;padding-right:48px;">4.6</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;">Dyadic Follow-On IP. </font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">Dyadic shall own all Dyadic Follow-On IP, regardless of (i) inventorship; (ii) whether the Dyadic Follow-On IP is conceived or reduced to practice pursuant to this Agreement; and (iii) whether the Follow-On IP is related to a Project. As used herein, Dyadic Follow-On IP shall include all inventions, technology, know-how, trade secrets and any other intellectual property or results related to the C1  Strains, the Danisco Improved Strains, the Dyadic Know-How, the Sponsor Materials, Dyadic Cl Genomic Information,</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">Dyadic Patents, Danisco Know-How, the Dyadic Improved Strains, the Genetic Tools, the Danisco Patents and/or any derivatives or modifications thereof, BDI Services Generated Tools, Dyadic Cl Genomic Information and/or improved media and fermentation development and processes ("</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Dyadic Follow-On IP</font><font style="font-family:inherit;font-size:11pt;color:#212121;">").</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">4.7</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Results. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">All Results shall be owned by Dyadic and Dyadic shall be free to exploit the same at its own discretion. BDI Pharmaceuticals hereby assigns and transfers all intellectual property rights attached to the Results to Dyadic without any cost other than the price as specified in each of the Statements of Work relating thereto. BDI Pharmaceuticals shall take all acts necessary for the intellectual property rights to vest with Dyadic or sign any documents necessary to record the intellectual property rights in the name of Dyadic.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">4.8</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Restrictions on Use and Transfer of the Sponsor Materials and Cl Strains.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(a)&#160;&#160;&#160;&#160;The Sponsor Materials, the C1</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#212121;">Strains, any components of the Sponsor Materials and C1 Strains, and any derivatives or modifications of any of the foregoing, shall be used by BDI Pharmaceuticals and its Affiliates only in accordance with and for the execution of this Agreement, the R&amp;D License, the Pharma License Agreement and in compliance with applicable law.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(b)&#160;&#160;&#160;&#160;BDI Pharmaceuticals and its Affiliates shall not transfer, deliver or sublicense any C1 Strains, the Danisco Improved Strains, the Dyadic Know-How, the Sponsor Materials, Dyadic C1 Genomic Information, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents, the Dyadic Background IP or Collaboration IP, any components of the Cl Strains, the Danisco Improved Strains, the Dyadic Know-How, the Sponsor Materials, Dyadic Cl Genomic Information, Dyadic Patents, Danisco Know-How, the Genetic Tools, the Danisco Patents, the Dyadic Background IP, Collaboration IP or any derivatives or modifications of any of the foregoing or results related therero, to any Third Party without the prior written consent of Dyadic, which consent may be withheld in its absolute discretion.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(c)&#160;&#160;&#160;&#160;Each Third Party Sponsor is an intended beneficiary of this Agreement with respect to any terms regarding such Sponsor's Sponsor Materials, any components of such Sponsor Materials and Results of Directed Projects engaged by such Sponsor.</font></div><div><a name="s4f1be19df4c54852b4a64de33dd3c4c4"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">ARTICLE 5</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">CONFIDENTIALITY</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">5.1</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Definition. "Confidential Information" </font><font style="font-family:inherit;font-size:11pt;color:#212121;">means any information disclosed by one Party (the "</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:11pt;color:#212121;">") to the other (the "</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"), whether oral, written, visual, electromagnetic, electronic or in any other form, and whether contained in memoranda, summaries, notes, analyses, compilations, studies or other documents, and whether the same have been prepared by the Disclosing Party or the Receiving Party: (i) which, if in written, graphic, machine-readable or other tangible form is marked as "Confidential" or "Proprietary," or which, if disclosed orally or by demonstration, is identified at the time of initial disclosure as confidential and is summarized in writing and similarly marked and delivered to the Receiving Party within thirty (30) days after initial disclosure; and (ii) which includes but is not necessarily limited to, (A) technical data or information, including proprietary host organisms and their</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">strains, plasmids/vectors, DNA sequences, gene expression, fungal high throughput screening, enzymes and their applications, research and manufacturing protocols and practices, formulae, charts, analyses, reports, patent applications, trade secrets, ideas, methods, processes, know-how, computer programs, products, equipment, raw materials, designs, data sheets, schematics, configurations, specifications, techniques, drawings, and the like, whether or not relating to experimental data, projects, products, processes, research practices and the like; (B) past, present and future business, financial and commercial data or information, prices and pricing methods, marketing and customer information, financial forecasts and projections, and other data or information relating to strategies, plans, budgets, sales and the like; and (C) any other data or information delivered by the Disclosing Party to the Receiving Party or which the Receiving Party has acquired from the Disclosing Party by way of the former's inspection or observation during visits to the research laboratory, manufacturing plan or other type of facility of the latter Party. The Parties expressly acknowledge and agree that all information of a proprietary and/or confidential nature furnished by the Disclosing Party to the Receiving Party in furtherance of the Disclosing Party's obligations under this Agreement shall be deemed Confidential Information. Subject to the restrictions and permissions set forth herein, the Results, Collaboration IP, Follow On IP and Background IP shall be Confidential Information of Dyadic. Notwithstanding anything to the contrary contained herein, any failure by the Disclosing Party to mark, identify or confirm the Confidential Information shall not relieve Receiving Party of its obligations under this Agreement where Receiving Party knows or has reason to know that the information disclosed to it is Confidential Information.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;padding-right:48px;">5.2</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;">Confidential Information Exclusions.  </font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">Confidential Information will exclude information the Receiving Party can demonstrate is: (i) now or hereafter, through no unauthorized act or failure to act on Receiving Party's part, in the public domain; (ii) known to the Receiving Party from a source other than the Disclosing Party (including former employees of the Disclosing Party) without an obligation of confidentiality at the time Receiving Party receives the same from the Disclosing Party, as evidenced by contemporaneous written records; (iii) furnished to others by the Disclosing Party without restriction on disclosure; or (iv) independently developed by the Receiving Party without use of the Disclosing Party's Confidential Information, as evidenced by contemporaneous written records.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#4c4c4c;padding-right:48px;">5.3</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;">Confidentiality Obligation. </font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">For a period commencing on this date and ending on the tenth (10th) anniversary after the termination of the Agreement, the Receiving Party shall treat as confidential all of the Disclosing Party's Confidential Information and shall not use such Confidential Information for any purpose whatsoever other than for the purposes set forth herein, except as expressly otherwise permitted under this Agreement. Without limiting the foregoing, the Receiving Party shall use the same degree of care and means that it utilizes to protect its own information of a similar nature, but in any event not less than reasonable care and means, to prevent the unauthorized use or the disclosure of such Confidential Information to Third Parties. The Confidential Information may be disclosed only to employees or contractors of the Receiving Party with a "need to know" who are instructed and agree not to disclose the Confidential Information and not to use the Confidential Information for any purpose, except as set forth herein; provided</font><font style="font-family:inherit;font-size:11pt;color:#656565;">, </font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">however, in the case of BDI Pharmaceuticals and its Affiliates, the term "employees or contractors of a Receiving Party" shall include employees of each of those of BDI Pharmaceuticals, its Affiliates and any contract research organizations with whom BDI Pharmaceuticals or its Affiliates has written agreements pursuant to which such contract research</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">organization is performing or will perform work under a Project and is bound by an obligation of confidence to BDI Pharmaceuticals or its Affiliates that makes such contract research organization liable for any breach by its employees of those confidentiality obligations to BDI Pharmaceuticals or its Affiliates. The Receiving Party shall have appropriate written agreements with any such employees or contract research organizations sufficient to comply with the provisions of this Agreement. A Receiving Party may not alter, decompile, disassemble, reverse engineer or otherwise modify any Confidential Information received hereunder and the mingling of the Confidential Information with information of the Receiving Party shall not affect the confidential nature or ownership of the same as stated hereunder.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">5.4</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Permitted Disclosures of Confidential Information. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Nothing in this Agreement shall prevent the Receiving Party from disclosing Confidential Information to the extent the Receiving Party is legally compelled to do so by any governmental investigative or judicial agency pursuant to proceedings over which such agency has jurisdiction; provided, however, that prior to any such disclosure and to the extent permitted by law, the Receiving Party shall (i) assert the confidential nature of the Confidential Information to the agency; (ii) immediately notify the Disclosing Party in writing of the agency's order or request to disclose; and (iii) cooperate fully with the Disclosing Party in protecting against any such disclosure and/or obtaining a protective order narrowing the scope of the compelled disclosure and protecting its confidentiality.</font></div><div><a name="sc80e37abdcde47488cef00cbe44eaf2f"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">ARTICLE 6</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">6.1</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Representations and Warranties of the Parties. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Each of the Parties represents and warrants to the other Party that:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(a)&#160;&#160;&#160;&#160;it is a company duly organized, validly existing and in good standing under the laws of, in the case of Dyadic, Delaware, and in the case of BDI Pharmaceuticals, Spain;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(b)&#160;&#160;&#160;&#160;the execution of this Agreement on its behalf has been properly authorized by all necessary corporate or company action, as the case may be;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(c)&#160;&#160;&#160;&#160;this Agreement is valid and binding on it and enforceable against it in accordance with the terms hereof, subject to applicable bankruptcy and similar laws affecting creditors' rights and remedies generally, and subject, as to enforceability, to general principles of equity;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(d)&#160;&#160;&#160;&#160;neither the execution nor the performance of this Agreement will constitute a breach or violation of the terms of its charter or organizational documents or any contract, agreement or other commitment to which it is a party or by which it or any of its properties are bound;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(e)&#160;&#160;&#160;&#160;there are no bankruptcy, insolvency, receivership or similar proceedings involving it or any of its Affiliates either pending or contemplated, or any other pending or threatened actions, suits, arbitrations or other proceedings by or against it;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(f)&#160;&#160;&#160;&#160;the execution, delivery and performance of this Agreement does not and will not conflict with or result in breach of any term, condition, obligation or restriction of any other agreement of the Parties with any Third Party; and</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;13</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#535353;">(g)&#160;&#160;&#160;&#160;it has not used and shall not use in the course of its performance hereunder, and shall not disclose to the other, any confidential information of any other Person, unless it is expressly authorized in writing by such Person to do so.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#535353;font-weight:bold;padding-right:48px;">6.2</font><font style="font-family:inherit;font-size:11pt;color:#535353;font-weight:bold;">Representations and Warranties of Dyadic. </font><font style="font-family:inherit;font-size:11pt;color:#535353;">Dyadic represents and warrants to BDI Pharmaceuticals that the Sponsor Materials do not contain any intellectual property, proprietary information or materials, content, software or other materials of any Third Party that would require BDI Pharmaceuticals or its Affiliates to acquire a license or otherwise pay a Third Party for the use thereof in accordance with the terms of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#535353;font-weight:bold;padding-right:48px;">6.3</font><font style="font-family:inherit;font-size:11pt;color:#535353;font-weight:bold;">Representations and Warranties of BDI Pharmaceuticals. </font><font style="font-family:inherit;font-size:11pt;color:#535353;">BDI Pharmaceuticals represents and warrants to Dyadic that:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#535353;">(a)&#160;&#160;&#160;&#160;all licenses or other material rights or permissions to use any Third Party intellectual property used by BDI Pharmaceuticals or its Affiliates in the operation of their respective businesses have been obtained by the BDI Pharmaceuticals or its Affiliates and all license fees, royalties and any other amounts (if any) due and payable under such license agreements have been paid;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#535353;">(b)&#160;&#160;&#160;&#160;no activities will be carried out by BDI Pharmaceuticals or its Affiliates or subcontractors hereunder on behalf of Sponsor that directly or indirectly incorporates or uses the C1 Technology in any manner that will require a license, milestones, royalties or payments of any kind other than those payments set forth herein or on a Statement of Work signed by both Parties;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#535353;">(c)&#160;&#160;&#160;&#160;it shall have the necessary facilities, lab equipment and personnel to timely and efficiently carry out all work as may be set forth in the Statements of Work;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#535353;">(d)&#160;&#160;&#160;&#160;it will perform the Projects using its good faith Best Efforts to achieve the expected outcomes indicated in each Statements of Work in accordance with prevailing industry standards;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#535353;">(e)&#160;&#160;&#160;&#160;it will perform the Projects in accordance with all applicable laws</font><font style="font-family:inherit;font-size:11pt;color:#666666;">, </font><font style="font-family:inherit;font-size:11pt;color:#535353;">rules</font><font style="font-family:inherit;font-size:11pt;color:#666666;">, </font><font style="font-family:inherit;font-size:11pt;color:#535353;">regulations and guidances;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#535353;">(f)&#160;&#160;&#160;&#160;all work</font><font style="font-family:inherit;font-size:11pt;color:#666666;">, </font><font style="font-family:inherit;font-size:11pt;color:#535353;">Services or Results</font><font style="font-family:inherit;font-size:11pt;color:#666666;">, </font><font style="font-family:inherit;font-size:11pt;color:#535353;">or any part thereof, delivered to a Sponsor under a Statement of Work</font><font style="font-family:inherit;font-size:11pt;color:#666666;">, </font><font style="font-family:inherit;font-size:11pt;color:#535353;">does not, and will not</font><font style="font-family:inherit;font-size:11pt;color:#666666;">, </font><font style="font-family:inherit;font-size:11pt;color:#535353;">upon delivery to Dyadic or such Third Party beneficiary infringe any patent right, copyright, trade secret right or other intellectual property right of a Third Party;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#535353;">(i)&#160;&#160;&#160;&#160;it shall use commercially reasonable efforts to ensure that the condition and calibration of all equipment used to perform the Projects hereunder is properly and adequately maintained;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#535353;">(g)&#160;&#160;&#160;&#160;it will comply with all appropriate animal welfare rules, as specified by law</font><font style="font-family:inherit;font-size:11pt;color:#666666;">, </font><font style="font-family:inherit;font-size:11pt;color:#535353;">Dyadic or the Institutional Animal Care and Use Committee (IACUC) that governs animal studies conducted by BDI Pharmaceuticals;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;14</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(h)&#160;&#160;&#160;&#160;no individual that has been debarred or disqualified by the FDA pursuant to 21 U.S.C. &#167;335a (a) or (b) or by the European Medicines Agency, the European Commission, or the Regulatory Authority of an European Union Member State under any foreign equivalent thereof will perform or render, any Services or assistance to BDI Pharmaceuticals;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(i)&#160;&#160;&#160;&#160;it has no knowledge of any circumstances which may affect the accuracy of the foregoing warranties and representations, including, but not limited to, the US Food and Drug Administration, European Medicines Agency or other governmental investigations of, or debarment proceedings against, BDI Pharmaceuticals or any person or entity performing Services or rendering assistance relating to activities taken pursuant to this Agreement, and BDI Pharmaceuticals will immediately notify Dyadic if BDI Pharmaceuticals becomes aware of any such circumstances during the Term;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(j)&#160;&#160;&#160;&#160;it shall attract, hire and/or otherwise retain the Key Persons within thirty (30) days of the Effective Date and thereafter, it shall notify Dyadic within five (5) business days of the date it becomes aware of the pending or actual termination of services of any Key Person; and</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">(k)&#160;&#160;&#160;&#160;to the extent it uses confidential information of any other Person in the course of its performance hereunder, it has been expressly authorized to do so in writing and warrants that there will be no cost to Dyadic now, or in the future, related to the use of such information, in excess of the amounts mutually agreed to be paid pursuant to a Statement of Work.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;padding-right:48px;">6.4</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Disclaimer. </font><font style="font-family:inherit;font-size:11pt;color:#232323;">Except for the foregoing warranties, THE FOREGOING WARRANTIES OF EACH PARTY ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY AND FITNESS FOR PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY DISCLAIMED.</font></div><div><a name="s9ac4353aebd4464c87deeb843adc3784"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">ARTICLE 7</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">INDEMNIFICATION</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;padding-right:48px;">7.1</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">In General</font><font style="font-family:inherit;font-size:11pt;color:#232323;">. Subject to the provisions of Section 7.4, each Party (the "</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Indemnifying Party</font><font style="font-family:inherit;font-size:11pt;color:#232323;">") shall defend, indemnify and hold harmless the other Party, its Affiliates, and its and their employees, officers, directors, agents, and licensees (each an "</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Indemnified Party</font><font style="font-family:inherit;font-size:11pt;color:#232323;">") against any loss, damage, expense, or cost, including reasonable attorneys' fees, arising out of any claim, demand, action, suit, investigation, arbitration or other proceeding by a Third Party (an "</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Action</font><font style="font-family:inherit;font-size:11pt;color:#232323;">") based on (i) the Indemnifying Party's breach of this Agreement; or (ii) negligence, willful misconduct or violation of any law or regulation by the Indemnifying Party, its Affiliates, or its or their employees, officers, directors or agents. This requirement for indemnification is meant by the Parties to extend to the Representations and Warranties set forth in Article 6.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;padding-right:48px;">7.2</font><font style="font-family:inherit;font-size:11pt;color:#232323;font-weight:bold;">Procedure</font><font style="font-family:inherit;font-size:11pt;color:#232323;">.  If an Indemnified Party becomes aware of any Action it believes is indemnifiable under Section 7 .1, (i) the Indemnified Party shall give the Indemnifying Party prompt written notice of such Action; (ii) the Indemnifying Party shall assume, at its expense, the sole defense of such claim or cause of action through counsel selected by it and reasonably acceptable to the Indemnified Party, except that in the case of a conflict of interest between the Parties, the Indemnifying Party shall, at the Indemnifying Party's expense, provide separate</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#505050;">counsel for the Indemnified Party selected by the Indemnified Party; (iii) the Indemnifying Party shall maintain control of such defense, including any decision as to settlement, except that any settlement of an Action shall require the written consent of both Parties, which consent shall not be withheld or delayed unreasonably; (iv) the Indemnified Party may, at its option and expense, participate in such defense, and in any event, the Parties shall cooperate with one another in such defense; and (v) the Indemnifying Party shall bear the total costs of any court award or settlement in such Action.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;padding-right:48px;">7.3</font><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">Third Party Infringement. </font><font style="font-family:inherit;font-size:11pt;color:#505050;">Each of the Parties shall indemnify, defend and hold harmless the other Party and its Affiliates and their respective officers, directors and employees from any losses, damages, liabilities, fines, penalties and expenses (including reasonable attorneys' fees) that arise out of or result from any Third Party claims of infringement of any patent or copyright, or misappropriation of any trademark, trade secret or other intellectual property right, private right or any other proprietary or personal interest related by circumstances to the existence of this Agreement or the Project ("</font><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">Infringement Claim</font><font style="font-family:inherit;font-size:11pt;color:#505050;">").</font><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#505050;">Dyadic's obligation with regard to indemnifying BDI Pharmaceuticals hereunder shall be limited to breaches of its (i) obligations under Article 4, or (ii) representations and warranties set forth in Section 6.2 with respect to the status of the intellectual property discussed therein as of the date hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;padding-right:48px;">7.4</font><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">Limitation of Liability. </font><font style="font-family:inherit;font-size:11pt;color:#505050;">NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, BOTH PARTIES AGREE THAT IN NO EVENT SHALL EITHER PARTY, OR ANY OF ITS AFFILIATES, OR ANY OF THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, MEDICAL OR PROFESSIONAL STAFF, EMPLOYEES OR AGENTS BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE RIGHTS GRANTED HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, REGARDLESS OF WHETHER SUCH PARTY SHALL BE OR HAVE BEEN ADVISED, SHALL HAVE REASON TO KNOW OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING. A PARTY'S MAXIMUM LIABILITY FOR ALL DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT SHALL IN NO EVENT EXCEED, IN THE AGGREGATE, THE TOTAL AMOUNTS ACTUALLY PAID BY DYADIC TO BDI PHARMACEUTICALS UNDER THIS AGREEMENT IN THE TWENTY-FOUR (24) MONTHS IMMEDIATELY PRECEDING THE EVENT THAT GAVE RISE TO THE CLAIM; PROVIDED, HOWEVER, THAT IN NO EVENT SHALL EITHER PARTY'S LIABILITY FOR INFRINGEMENT UNDER SECTION 7.3, INFRINGEMENT BY ONE PARTY OR ITS AFFILIATES OF THE OTHER PARTY'S INTELLECTUAL PROPERTY, BREACH OF CONFIDENTIALITY, FRAUD OR WILLFUL MISCONDUCT BE LIMITED BY THIS SECTION 7.4.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#505050;">IN ADDITION, EACH PARTY HEREBY ACKNOWLEDGES THAT THE OTHER PARTY CANNOT AND DOES NOT ASSURE THE FIRST PARTY THAT ANY PROJECT WILL CULMINATE IN THE SUCCESSFUL ACHIEVEMENT OF THE PROJECT'S OBJECTIVES. ACCORDINGLY, EACH PARTY HEREBY EXPRESSLY AGREES EXCEPT IN THE INSTANCE OF A MATERIAL BREACH BY THE OTHER PARTY OF ITS OBLIGATIONS HEREUNDER, NO PARTY SHALL HAVE LIABILITY OF ANY KIND WHATSOEVER TO</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;16</font></div></div><hr style="page-break-after:always"><div><a name="se6d85d1ca7e04fe9a74ab75c2e33e76a"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">THE OTHER PARTY BY REASON OF FAILURE OF ANY PROJECT TO SUCCESSFULLY ACHIEVE ITS OBJECTIVES.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">ARTICLE 8</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">TERM AND TERMINATION</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">8.1.</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Term. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">This Agreement shall enter into force upon the closing of the transactions contemplated by the Investment Agreement (the</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">&#32;"Effective Date</font><font style="font-family:inherit;font-size:11pt;color:#212121;">")</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#212121;">and shall expire five (5) years as of from the Effective Date (the "</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Term</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"),</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#212121;">excluding the Articles and Sections and their legal effects of which are meant to survive the termination or expiration of the Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">8.2.</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Termination in the Event of Insolvency. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Either Party may terminate this Agreement if the other Party becomes insolvent, voluntarily files a petition for relief under bankruptcy or any similar or other insolvency laws (or has a petition filed against it and the same remains undischarged or unstayed for sixty (60) days) or voluntarily or involuntarily enters receivership or any similar or other insolvency proceeding.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">8.3.</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Termination for Breach. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Without prejudice to any other damages or remedies available under applicable law and/or this Agreement, either Party has the right, at any time, to terminate this Agreement or any Statement of Work hereunder by written notice and without further formality upon a breach by the other Party in the performance of the provisions of this Agreement or such Statement of Work, provided such breach is not cured within thirty (30) days following receipt by the defaulting Party of a written notice from the non-defaulting Party to remedy such breach. However, (i) in case of a breach, which is not capable of being cured; or (ii) where any Party repeatedly or consistently fails to meet its contractual obligations following an initial cure period, the other Party has the right to terminate this Agreement or such Statement of Work immediately, by written notice and without any further formality and (additional) cure period.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">8.4.</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Termination by Dyadic or Sponsor. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Dyadic may terminate this Agreement, at its sole option, in its entirety or Sponsor may terminate any Statement of Work, at any time upon either (i) thirty (30) days written notice to BDI Pharmaceuticals, if no Statements of Work are operational under the Agreement at the time of termination and the date of termination is on or after July 1, 2019; (ii) upon ninety (90) days written notice to BDI Pharmaceuticals; or (iii) immediately upon the termination of the services of any Key Person or failure to hire any Key Person within the time allotted herein.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">8.5.</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Termination by BDI Pharmaceuticals. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">After July 1</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">, </font><font style="font-family:inherit;font-size:11pt;color:#212121;">2019, BDI Pharmaceuticals may terminate this Agreement in writing, at its sole option, in its entirety at any time upon one hundred and eighty (180) days written notice to Dyadic, if there are no active Statements of Work and no Projects have been contracted by Dyadic under this Agreement during the six (6) month period immediately prior to the termination date.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">8.6.</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Effect of Termination.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#212121;">(a) </font><font style="font-family:inherit;font-size:11pt;color:#212121;text-decoration:underline;">Accrued Rights and Obligations</font><font style="font-family:inherit;font-size:11pt;color:#212121;">. Termination of this Agreement or a Statement of Work hereunder for any reason shall not release any Party from any obligation which, at the time of such termination, has already accrued and become due to the other Party or which is</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;17</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">(b) </font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;text-decoration:underline;">Return of Confidential Information and Materials.</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">Upon any termination of this Agreement, BDI Pharmaceuticals shall promptly return to Sponsor all Confidential Information received from Sponsor. BDI Pharmaceuticals may retain a copy of the Confidential Information that must thereafter be used solely as a legal record of the Confidential Information under this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">(c) </font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;text-decoration:underline;">Destruction of Confidential Information and Materials.</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">Upon any termination of this Agreement, Sponsor may request BDI Pharmaceuticals to destroy all Confidential Information received from Sponsor instead of returning it in accordance with paragraph (b) above. BDI Pharmaceuticals may retain a copy of the Confidential Information that must thereafter be used solely as a legal record of the Confidential Information under this Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">(d) </font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;text-decoration:underline;">Rights in IP.</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">In the event of termination of this Agreement either on or prior to the expiration of the Term by either Party, all rights and licenses of BDI Pharmaceuticals to Background IP and Results shall automatically terminate and/or revert back to Sponsor and any license grants from Dyadic to BDI Pharmaceuticals, such, for example, without limitation, the license grants provided in Article 4 shall terminate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:66px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">(e) </font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;text-decoration:underline;">Other Remedies Available.</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">Notwithstanding anything in this Agreement to the contrary, in the event of termination of this Agreement, each Party shall have available every remedy allowed under law and equity, including but not limited to specific performance, suit for damages, and rescission.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;padding-right:48px;">8.7.</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;text-decoration:underline;">Survival.</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">Termination of a Statement of Work shall not result in a termination of the entire Agreement unless so stated in the termination notice. Notwithstanding anything to the contrary contained herein, the provisions of Recital VI, Article 1, Section 2.3, Section 3.1, Section 3.4, Section 4.1 through Section 4.3, Section 4.5 through Section 4.8, Article 5 through Article 7, Section 8.6, Section 8.7, Article 9 shall survive any termination of this Agreement.</font></div><div><a name="s6f4f9604cf924253b45893f20fef6f5c"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;">ARTICLE 9</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;">MISCELLANEOUS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;padding-right:48px;">9.1</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;">Relationship between Parties. </font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">Dyadic and BDI Pharmaceuticals are separate business entities, and shall not be considered as joint ventures, partners, agents, servants, employee, or fiducairies of each other. The Parties specifically agree that any obligation to act in good faith and to deal fairly with each other which may be implied in law shall be deemed satisfied by the Parties' compliance with the express terms of this Agreement</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;padding-right:48px;">9.2</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;font-weight:bold;">No Implied Rights</font><font style="font-family:inherit;font-size:11pt;color:#4c4c4c;">. Other than expressly provided for in this Agreement, nothing in this Agreement grants or shall be construed to grant to any Party any right and/or any license to any intellectual property right or application therefor (including but not limited to patent applications or patents) which are held by and/or in the name of the other Party and/or which are controlled by or licensed by the other Party, or to any Confidential Information received from the other Party.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;18</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">9.3</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Entire Agreement; Amendment. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">This Agreement constitutes the entire Agreement between the Parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, commitments and writings in respect thereof. No amendment or addition to this Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the Parties.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">9.4</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Force Majeure. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Neither Party shall be held in breach of its obligations hereunder to the extent only that due performance or observance of such obligation is prevented or delayed by war and other hostilities, civil commotion, accident, trade disputes, acts or restraints of government imposition or restrictions of imports or exports or any other cause not within the control of the Party concerned. The Party concerned shall forthwith notify the other Party of the nature and effect of such event and both Parties shall, where the same is practicable, use every reasonable endeavor to minimize such effect and to comply with the respective obligation herein contained as nearly as may be in their original form.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">9.5</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Foreign Corrupt Practices Act and Anti-Bribery Provisions. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">During the Term, the Parties will not, and shall cause their Affiliates to not, make or provide any payments or gifts or any offers or promises of any kind, directly or indirectly, to any official of any government or to any official of any agency or instrumentality of any government, or to any political party or to any candidate for political office (the foregoing individually and collectively referred to as "</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Government Official</font><font style="font-family:inherit;font-size:11pt;color:#212121;">"). If, on the Effective Date, or at any time during the Term of this Agreement any Government Official or an active member of the armed services of any government (i) owns an interest in that certain Party or its Affiliate, (ii) has any legal or beneficial interest in this Agreement or in payments to be received by that certain Party or its Affiliate in connection with the Services to be provided by hereunder, or (iii) is a director, officer or employee of that certain Party or its Affiliate, that certain Party will notify the other Party and will take such actions to assure that the affected person does not take any action, official or otherwise, and/or use any influence in connection with the other Party's business.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">9.6</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Assignment. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">Except as otherwise set forth herein, neither Party shall assign all or part of its rights or obligations under this Agreement without the prior written consent of the other Party, which consent may be withheld in their absolute discretion; provided, however, that this Agreement may be assigned at any time by either Party in connection with the merger or acquisition of the respective Party or the sale of all or substantially all of the assets of the Party to which this Agreement relates. The Parties rights under this Agreement shall bind and inure to the benefit of their respective successors, heirs, executors, administrators and permitted assigns. Notwithstanding the foregoing, BDI Pharmaceuticals shall be entitled to retain from time to time, the services of subcontractors to provide Services under this Agreement, provided, however, that any such subcontractors to be used by BDI Pharmaceuticals to provide Services hereunder shall be consented to by Dyadic, which consent shall not be unreasonably withheld or delayed. Fees for such subcontractors shall be applied to and paid by BDI Pharmaceuticals as part of the fees paid by Dyadic to BDI Pharmaceuticals hereunder.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;padding-right:48px;">9.7</font><font style="font-family:inherit;font-size:11pt;color:#212121;font-weight:bold;">Severability. </font><font style="font-family:inherit;font-size:11pt;color:#212121;">In the event any one or more of the provisions of this Agreement should for any reason be held by any court or authority having jurisdiction over this Agreement or any of the Parties hereto be invalid, illegal or unenforceable, such provision(s) shall be validly</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;19</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">reformed to as nearly approximate the intent of the Parties as possible and if unreformable, the Parties shall meet to discuss in good faith what steps should be taken to remedy the situation.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;padding-right:48px;">9.8</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Publicity; Use of Name. </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">&#32;Notwithstanding anything to the contrary in this Agreement, Dyadic may issue any press releases or make any other public statement with respect to the transactions contemplated hereby or the Results yielded hereunder without the prior consent of BDI Pharmaceuticals and notwithstanding the existence of any confidentiality or non-disclosure obligations that Dyadic may have, which, for the avoidance of doubt, may include the filing of this Agreement or any Statement of Work and/or summaries thereof with the U.S. Securities and Exchange Commission by Dyadic as required by U.S. federal securities law (such requirement to be determined by Dyadic in its sole discretion) and industry and investor conferences and presentations. BDI Pharmaceuticals may not issue any press releases or make any other public statement with respect to the transactions contemplated hereby or the Results yielded hereunder without the prior written consent of Dyadic, which may be withheld in Dyadic's sole discretion. The Parties may (i) disclose the terms of this Agreement to such Party's auditors, attorneys, bankers or investment bankers as necessary for their rendition of services to such Party; and (ii) disclose the terms of this Agreement to bona fide prospective investors, merger partners, strategic partners, or acquirors and their respective professional advisors, in connection with the negotiation, entry into and/or performance of a business transaction between such parties, including the conduct of due diligence involved in such transaction, </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-style:italic;">provided, however, that </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">such parties are subject to obligations of confidentiality and non-use at least as restrictive as those set forth in Article 5. During the Term and for a reasonable time thereafter, Dyadic may use BDI Pharmaceuticals' and its Affiliates' names and logos in a press releases, marketing material and/or advertisement disclosing the existence of this Agreement. Except for disclosures permitted pursuant to this Section 9.8, neither Party will use the other's name for advertising or external publicity purposes without its consent, except that Dyadic may include in its promotional materials references to and quotations from publications of results of the Projects. In addition, in the event there is a Third Party beneficiary to a Directed Project, such Third Party Sponsor may issue press releases or make any other public statement with respect to the Directed Project or the Results yielded thereunder without the prior written consent of BDI Pharmaceuticals.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;padding-right:48px;">9.9</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;font-weight:bold;">Notices. </font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">All notices, requests, reports and other communications provided in this Agreement shall be in writing and shall be deemed to have been made or given: (i) when delivered, if delivered by hand; (ii) when confirmation of transmission received, if sent by facsimile or by email; (iii) two days following deposit with an overnight courier; or (iv) on the date ten business days following deposit, as certified or registered mail, with the postal service of the country of the Party providing notice:</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#626262;text-decoration:underline;">To Dyad</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;text-decoration:underline;">i</font><font style="font-family:inherit;font-size:11pt;color:#626262;text-decoration:underline;">c</font><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;text-decoration:underline;">:</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">Att: Mark Emalfarb</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">Address: 140 Intracoastal Pointe Drive, </font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">Suite# 404, Jupiter, Florida, 33477 USA </font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">E-mail: </font><a style="font-family:inherit;font-size:11pt;color:#4d4d4d;text-decoration:none;" href="#"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;text-decoration:none;">m</font></a><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">emalfarb@dyadic.com</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">Tel: (561) 743-8333</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#4d4d4d;">Fax: (561) 743-8513</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;20</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">With a copy to:</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Att: Laura Nemeth</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Squire Patton Boggs (US) LLP</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">127 Public Square, Suite 4900</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Cleveland, Ohio 44114</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">E-mail: </font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;text-decoration:underline;">laura.n</font><font style="font-family:inherit;font-size:11pt;color:#5e5e5e;text-decoration:underline;">e</font><font style="font-family:inherit;font-size:11pt;color:#484848;text-decoration:underline;">m</font><font style="font-family:inherit;font-size:11pt;color:#5e5e5e;text-decoration:underline;">e</font><font style="font-family:inherit;font-size:11pt;color:#484848;text-decoration:underline;">t</font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;text-decoration:underline;">h</font><font style="font-family:inherit;font-size:11pt;color:#747474;text-decoration:underline;">@</font><font style="font-family:inherit;font-size:11pt;color:#747474;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#484848;text-decoration:underline;">quirepb.com</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Telephone: 216-4 79-8552</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Facsimile: 216-4 79-8780</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;text-decoration:underline;">To BDI Pharmaceuticals:</font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Att: Emilio Gutierrez</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Biotechnology Developments for </font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Industry in pharmaceuticals S.L.U </font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Louist Proust 13</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">47151 Boecillo (Valladolid) Spain</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">E-mail: </font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;text-decoration:underline;">egutierrez@bdibiotech.com</font></div><div style="line-height:120%;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Tel: 983 548 563/ 983 010 722</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:84px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">Fax: None</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#2a2a2a;font-weight:bold;padding-right:48px;">9.10</font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;font-weight:bold;">Applicable Law and Arbitration.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">(a)&#160;&#160;&#160;&#160;This Agreement shall be governed by, and interpreted under</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">the laws of Florida</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">United States, without application of rules on conflicts of laws.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">(b)&#160;&#160;&#160;&#160;Disputes between the Parties shall be resolved as provided by this Section 9.10. Any Party shall give the other Party written notice of any dispute under this or in connection with this Agreement. The Parties shall attempt to resolve such dispute promptly by negotiation among the chief executive officers of the Parties and his/her advisors and executive officers of the BDI Group and Dyadic, as applicable. Within thirty (30) days after delivery of the notice, the Party(ies) receiving the notice shall submit to the other a written response. The notice and response shall include: (A) a statement of each Party's position and a summary of arguments supporting that position; and (B) in the case of any member of the BDI Group or Dyadic</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">the name and title of the executive officer of such Party who will represent such Party and, in the case of any Party</font><font style="font-family:inherit;font-size:11pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">the name and title of any other person who will accompany such Party during the negotiations. Within thirty (30) days after delivery of the disputing Party's notice, the Parties shall meet at a mutually acceptable time and place, and thereafter as often as they deem reasonably necessary, to attempt to resolve the dispute.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">(c)&#160;&#160;&#160;&#160;If any dispute has not been resolved by the Parties in accordance with Section 9.10(b) within forty-five (45) days after the disputing Party's request notice, or if the Parties fail to meet within thirty (30) days after such request notice, then each of the Parties agrees that such dispute shall be finally and exclusively settled without appeal by arbitration in New York City, New York, administered by the American Arbitration Association ("</font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;font-weight:bold;">AAA</font><font style="font-family:inherit;font-size:11pt;color:#2a2a2a;">") under its Commercial Arbitration Rules in effect as of the date of the request for arbitration, which rules are deemed to</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;21</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#525252;">be incorporated into this Section 9 .10(c) </font><font style="font-family:inherit;font-size:11pt;color:#525252;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;color:#525252;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:11pt;color:#525252;">, that in the event of any conflict between such rules and the other provisions of this Agreement, such other provisions of this Agreement shall control. The arbitration shall be conducted before a single arbitrator. The decision of the arbitrator shall be in writing, shall set forth the facts found by the arbitrator to exist, his/her decision and the basis for that decision and shall be final and binding upon the Parties and not subject to appeal. Judgement upon any award rendered by the arbitrator may be entered in any court having jurisdiction thereof</font><font style="font-family:inherit;font-size:11pt;color:#636363;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">including any court having jurisdiction over any of the Parties or their assets. Each Party shall bear its own costs and expenses in connection with the arbitration, including reasonable attorneys' fees, disbursements</font><font style="font-family:inherit;font-size:11pt;color:#636363;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">arbitration expense, arbitrators' fees and the administrative fee of the AAA.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;padding-right:48px;">9.11</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Independent Parties; No Authority to Bind. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">The relationship of BDI Pharmaceuticals and Dyadic is that of independent contractors. Neither Party nor their employees are agents, partners, employers, employees, joint venturers, have any other kind of relationship with the other Party except as specified in the Research Services Agreement and Investment Agreement</font><font style="font-family:inherit;font-size:11pt;color:#636363;">. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">Neither Party shall have any authority to bind the other party to any obligation by contract or otherwise.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;padding-right:48px;">9.12</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Non-Compete</font><font style="font-family:inherit;font-size:11pt;color:#636363;font-weight:bold;">. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">During the term of this Agreement and for a period of five (5) years thereafter, BDI Pharmaceuticals agrees that it will not work on Cl Strains for anyone other than Dyadic on pharmaceutical applications and/or processes (animal or human, including but not limited to active pharmaceutical ingredients or catalysts) unless so authorized in writing by the CEO of Dyadic. BDI Pharmaceuticals shall cause the substance of this clause to be included in any sub-contract for performance of Services hereunder. For the purposes of this Section</font><font style="font-family:inherit;font-size:11pt;color:#636363;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">"C1 Strains" </font><font style="font-family:inherit;font-size:11pt;color:#525252;">shall be defined as any fungal strains that have the taxonomy of either (i) </font><font style="font-family:inherit;font-size:11pt;color:#525252;font-style:italic;">Myceliopthora, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">(ii) </font><font style="font-family:inherit;font-size:11pt;color:#525252;font-style:italic;">Corynascus </font><font style="font-family:inherit;font-size:11pt;color:#525252;">or (iii) </font><font style="font-family:inherit;font-size:11pt;color:#525252;font-style:italic;">Sporotrichium </font><font style="font-family:inherit;font-size:11pt;color:#525252;">and any strains derived or generated from the Cl Strains transferred hereunder in the Project or under this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;padding-right:48px;">9.13</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Construction of Agreement.  </font><font style="font-family:inherit;font-size:11pt;color:#525252;">The Parties acknowledge that they thoroughly have reviewed this Agreement and bargained over its terms. Accordingly, this Agreement shall be construed without regard to the Party or Parties responsible for its preparation and shall be deemed to have been prepared jointly by the Parties.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;padding-right:48px;">9.14</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Cumulative Rights and Remedies. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">The rights and remedies provided in this Agreement and all other rights and remedies available to either Party at law or in equity are, to the extent permitted by law</font><font style="font-family:inherit;font-size:11pt;color:#636363;">, </font><font style="font-family:inherit;font-size:11pt;color:#525252;">cumulative and not exclusive of any other right or remedy now or hereafter available at law or in equity. Neither asserting a right nor employing a remedy shall preclude the concurrent assertion of any other right or employment of any other remedy, nor shall the failure to assert any right or remedy constitute a waiver of that right or remedy.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;padding-right:48px;">9.15</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Headings. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">All headings in this Agreement are included solely for convenient reference, are not intended to be full and accurate descriptions of the contents of this Agreement, shall not be deemed a part of this Agreement, and shall not affect the meaning or interpretation of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;padding-right:48px;">9.16</font><font style="font-family:inherit;font-size:11pt;color:#525252;font-weight:bold;">Amendments. </font><font style="font-family:inherit;font-size:11pt;color:#525252;">This Agreement may be modified or amended only by written agreement of the Parties.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;22</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#242424;font-weight:bold;padding-right:48px;">9.17</font><font style="font-family:inherit;font-size:11pt;color:#242424;font-weight:bold;">English Language. </font><font style="font-family:inherit;font-size:11pt;color:#242424;">The Parties shall use the English language in all communications relating to this Agreement, and the English language version of this Agreement signed by the Parties shall control over any and all translations.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#242424;font-weight:bold;padding-right:48px;">9.18</font><font style="font-family:inherit;font-size:11pt;color:#242424;font-weight:bold;">Entire Agreement. </font><font style="font-family:inherit;font-size:11pt;color:#242424;">This Agreement, together with any supporting documents recited herein, constitutes the entire agreement between the Parties concerning the subject matter of this Agreement and supersedes all prior agreements between the Parties concerning the subject matter hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#242424;font-weight:bold;padding-right:48px;">9.19</font><font style="font-family:inherit;font-size:11pt;color:#242424;font-weight:bold;">Counterparts. </font><font style="font-family:inherit;font-size:11pt;color:#242424;">This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute this Agreement.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#242424;">[</font><font style="font-family:inherit;font-size:11pt;color:#242424;font-style:italic;">Signature Page Follows</font><font style="font-family:inherit;font-size:11pt;color:#242424;">]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;23</font></div></div><hr style="page-break-after:always"><div><a name="s9a1e5b1bc64c480b8a203f6b95cf6da9"></a></div><div></div><div><br></div><div style="line-height:118%;padding-top:2px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#585858;">IN WITNESS WHEREOF, the parties have caused this Agreement to  be executed in  two counterparts by their duly authorized  representatives, each Party acknowledging receipt of one original.</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:7%;"></td><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:47%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BIOTECHNOLOGY DEVELOPMENTS </font></div><div style="padding-top:2px;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FOR INDUSTRY  IN</font></div><div style="padding-top:2px;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PHARMACEUTICALS, S.L.U.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Mark A. Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mark A. Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Executive Office</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6-30-17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#202020;font-style:italic;">Signature Page to Service Framework Agreement</font></div><div style="line-height:118%;padding-top:2px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;24</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:118%;padding-top:2px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#585858;">IN WITNESS WHEREOF, the parties have caused this Agreement to  be executed in  two counterparts by their duly authorized  representatives, each Party acknowledging receipt of one original.</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:7%;"></td><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:47%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BIOTECHNOLOGY DEVELOPMENTS <br>FOR INDUSTRY  IN<br>PHARMACEUTICALS, S.L.U.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Emilio Gutienna</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Emilio Gutienna</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attorney</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30-6-2017</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:144px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#202020;font-style:italic;">Signature Page to Service Framework Agreement</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;25</font></div></div><hr style="page-break-after:always"><div><a name="s335f2b242f9b48a784aba8857e936ac0"></a></div><div></div><div><br></div><div style="line-height:124%;padding-top:4px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#272727;font-weight:bold;">EXHIBIT  A</font></div><div style="line-height:124%;padding-top:4px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#272727;font-weight:bold;">KEY PERSONS</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#232323;">[*]</font></div><div style="line-height:126%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-1</font></div></div><hr style="page-break-after:always"><div><a name="s79e293adc63e449fbda0cdc5f0b31c1f"></a></div><div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Service Framework Agreement</font></div><div style="line-height:124%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Statement of Work No. [_]</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">EXHIBITB</font></div><div style="line-height:124%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">FORM OF STATEMENT OF WORK </font></div><div style="line-height:124%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">Statement of Work No.[_]</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">to</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">Service Framework Agreement</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:20%;"></td><td style="width:80%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Overview of Statement of Work</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Work Related</font></div><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;To</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[insert general description of task and/or compound being studies]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Timeline</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[From [date] to [date]] or [ ______ weeks]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Total SOW</font></div><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;Value</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[Insert total cost in Euros]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Payment</font></div><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;Schedule</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[50%] upon execution of this agreement</font></div><div style="text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[40%] upon delivery of draft report</font></div><div style="text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[10%] upon delivery of final report</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BDI</font></div><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Pharmaceuticals</font></div><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;contact</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[insert name and contact details of BDI Pharmaceuticals project manager]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Sponsor </font></div><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">contact</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[insert name and contact details of Sponsor project manager]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Sponsor </font></div><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Materials</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">See Exhibit 1 for a list of Sponsor Materials to be provided hereunder for use in preforming the Project</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Genetic Tools</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">See Exhibit 2 for a list of Genetic Tools to be provided hereunder for use in preforming the Project</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:125%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">THIS STATEMENT OF WORK </font><font style="font-family:inherit;font-size:11pt;color:#505050;">(the "</font><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">SOW</font><font style="font-family:inherit;font-size:11pt;color:#505050;">") is by and between Dyadic International, Inc., [on behalf </font><font style="font-family:inherit;font-size:11pt;color:#626262;">o</font><font style="font-family:inherit;font-size:11pt;color:#797979;">f _________ </font><font style="font-family:inherit;font-size:11pt;color:#505050;">("</font><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">Sponsor</font><font style="font-family:inherit;font-size:11pt;color:#505050;">") and Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. ("BDI Pharmaceuticals") and upon execution this SOW will be incorporated into the Service Framework Agreement between Sponsor and BDI Pharmaceuticals dated June ___, 2017 (the "</font><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:11pt;color:#505050;">"). Capitalized terms in this SOW will have the same meaning as set forth in the Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:127%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#505050;">This SOW provides an outline of the tasks related to the testing of [insert] (the </font><font style="font-family:inherit;font-size:11pt;color:#505050;font-weight:bold;">"Project"</font><font style="font-family:inherit;font-size:11pt;color:#505050;">) that will be performed by BDI Pharmaceuticals based on the direct request and funding support by Sponsor in the amount of $ [insert total cost in Euros].</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;color:#505050;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:11pt;color:#505050;">DELIVERABLES</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#505050;">The key deliverables of BDI Pharmaceuticals under this SOW are [insert]. A draft report is due before or on [date] and the final report due ten (10) days after receiving comments and discussio</font><font style="font-family:inherit;font-size:11pt;color:#626262;">n </font><font style="font-family:inherit;font-size:11pt;color:#505050;">fro</font><font style="font-family:inherit;font-size:11pt;color:#626262;">m </font><font style="font-family:inherit;font-size:11pt;color:#505050;">Sponsor.</font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:11pt;color:#505050;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:11pt;color:#505050;">SERVICES</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Service Framework Agreement</font></div><div style="line-height:124%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Statement of Work No. [_]</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:100%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;text-indent:0px;"><font style="padding-bottom:12px;text-align:left;font-family:inherit;font-size:11pt;color:#303030;padding-right:48px;">2.1</font><font style="font-family:inherit;font-size:11pt;color:#303030;">[INSERT PROJECT TITLE IN ALL CAPS]</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">Project Investigator</font><font style="font-family:inherit;font-size:11pt;color:#303030;">: [Insert name and contact details]</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#303030;padding-right:48px;">2.1.1</font><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;text-decoration:underline;">Objective 1</font><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">:</font><font style="font-family:inherit;font-size:11pt;color:#303030;">&#32;[Insert first project objective] </font><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">[Make duplicate copies of this Section 2.1.1 as needed]</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">The following table sets forth the supported tasks, their durations and costs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">[Below is an example table to be filled in to break the project down into subpart tasks, duration and cost]</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:13%;"></td><td style="width:29%;"></td><td style="width:29%;"></td><td style="width:29%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:5px;text-align:left;padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">Task</font></div><div style="padding-top:1px;text-align:left;padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">Number</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">Task Description</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">Duration</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">Task 1</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#212121;">.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">Tas</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#212121;">k </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">1</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#0e0e0e;">.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">Tas</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#212121;">k </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">1</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#0e0e0e;">.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">Task </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#212121;">1.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">Task 1</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#212121;">.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">Task 1</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#212121;">.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;color:#303030;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#303030;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:11pt;color:#303030;">PROJECT PROGRESS TRACKING</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">BDI Pharmaceuticals shall provide [bi-weekly] progress reports with all completed units of work (study reports, etc.) attached to the reports as exhibits.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#303030;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:11pt;color:#303030;">COMPENSATION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">Payments shall be made in accordance with the following schedule:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">&#8364;[______] upon execution of this agreement</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;color:#303030;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">&#8364;[______] upon delivery of draft progress report</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;color:#303030;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">&#8364;[______] upon delivery of draft progress report</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">Payment can be made by sending a check or wire transfer to in accordance with the terms set forth in the</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">Agreement the account listed below.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">[Insert BDI Pharmaceuticals wire transfer information]</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">Any increase to the price of any above listed activity shall be agreed upon by the parties in writing.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#303030;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:11pt;color:#303030;">CONFIDENTIAL INFORMATION </font><font style="font-family:inherit;font-size:11pt;color:#303030;font-style:italic;">I </font><font style="font-family:inherit;font-size:11pt;color:#303030;">ARCHIVE</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#303030;">All materials (e.g., protocol, raw data, reports) received by BDI Pharmaceuticals due to performance hereunder will be archived shall be deemed Confidential Information of Sponsor in accordance with Article 5 of the Agreement and shall by archived in accordance with Section 3.4 of the Agreement. All study samples shall be stored in accordance with Sponsor protocol after study completion.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:justify;text-indent:0px;"><font style="padding-bottom:12px;text-align:justify;font-family:inherit;font-size:11pt;color:#303030;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:11pt;color:#303030;">MISCELLANEOUS</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Service Framework Agreement</font></div><div style="line-height:124%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Statement of Work No. [_]</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:123%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#585858;">All terms and conditions of the Agreement remain the same, except as modified herein. The work described in this SOW will be done in strict accordance with any protocol provided by Sponsor for such work or agreed to by Sponsor. This SOW is incorporated into and made a part of the Agreement. This SOW may be executed in one or more duplicate counterparts, each of which shall be deemed an original, but which collectively shall constitute one and the same instrument. Any term or provision of this SOW may be amended</font><font style="font-family:inherit;font-size:11pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:11pt;color:#585858;">and the observance of any term of this Agreement may be waived, only by a Change Order signed by both parties to be bound thereby.</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:140%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#585858;">[Signatures Follow]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s2261a5dc8341457ca6b6a39de266d9b5"></a></div><div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Service Framework Agreement</font></div><div style="line-height:124%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Statement of Work No. [_]</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;font-weight:bold;">IN WITNESS  WHEREOF,  </font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">the parties hereto, intending to be l</font><font style="font-family:inherit;font-size:11pt;color:#464646;">eg</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">ally bound, have caused this SOW</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">to be executed by their duly authorized  representatives  as of the </font><font style="font-family:inherit;font-size:11pt;color:#464646;">[date]</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">.</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:7%;"></td><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:42%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SPONSOR:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">DYADIC INTERNATIONAL, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">BIOTECHNOLOGY DEVELOPMENTS FOR</font></div><div style="padding-top:2px;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;INDUSTRY  IN PHARMACEUTICALS, S.L.U.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mark Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Executive Office</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B-1</font></div></div><hr style="page-break-after:always"><div><a name="s7fcaa5edc4334a13b67bee04026ee88a"></a></div><div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Service Framework Agreement</font></div><div style="line-height:124%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Statement of Work No. [_]</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#575757;font-weight:bold;">EXHIBIT 1</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#575757;font-weight:bold;">SPONSOR MATERIALS</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#575757;">[Insert list of Sponsor Materials to be Provided for use in performing the Project.]</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><a name="s84a595c4c78144d4bcfbc798208355f5"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#575757;font-weight:bold;">EXHIBIT 2</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#575757;font-weight:bold;">GENETIC TOOLS</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#575757;">[Insert list of Genetic Tools to be Provided for use in performing the Project</font><font style="font-family:inherit;font-size:11pt;color:#787878;">.</font><font style="font-family:inherit;font-size:11pt;color:#575757;">]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B-2</font></div></div><hr style="page-break-after:always"><div><a name="s2fcec57997a6490280f42345cc0db972"></a></div><div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Service Framework Agreement</font></div><div style="line-height:124%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#505050;">Statement of Work No. [_]</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:124%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#272727;font-weight:bold;">CHANGE ORDER No. ____ TO </font></div><div style="line-height:124%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#272727;font-weight:bold;">STATEMENT OF WORK No. ____</font></div><div style="line-height:124%;padding-top:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:110%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#272727;">Upon  execution  hereof,  this  Change  Order  No.  _ to  Statement  of  Work  No.  _ (this  "</font><font style="font-family:inherit;font-size:11pt;color:#272727;font-weight:bold;">Change Order</font><font style="font-family:inherit;font-size:11pt;color:#272727;">")  shall  amend  and  supersede  the  terms  of that  certain  Statement  of Work  between  BDI Pharmaceuticals  and  Sponsor  dated  as  of </font><font style="font-family:inherit;font-size:11pt;color:#272727;text-decoration:underline;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:11pt;color:#272727;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#414141;">,   </font><font style="font-family:inherit;font-size:11pt;color:#272727;">20__  ("</font><font style="font-family:inherit;font-size:11pt;color:#272727;font-weight:bold;">SOW No.</font><font style="font-family:inherit;font-size:11pt;color:#272727;">&#32;&#32;_")  with respect to the subject matter hereof.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#272727;">[INSERT REVISED TERMS]</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:118%;padding-top:2px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#585858;text-decoration:underline;">Effect of Change Order</font><font style="font-family:inherit;font-size:11pt;color:#585858;">. Except as expressly amended herein, the terms of SOW No.__ shall remain unchanged and in full force and effect. This Change Order shall be subject to the terms and conditions of that certain Service Framework Agreement between BDI Pharmaceuticals and Sponsor. </font></div><div style="line-height:118%;padding-top:2px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:118%;padding-top:2px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#585858;font-weight:bold;">IN WITNESS WHEREOF,</font><font style="font-family:inherit;font-size:11pt;color:#585858;">&#32;</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">the parties hereto, intending to be l</font><font style="font-family:inherit;font-size:11pt;color:#464646;">eg</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">ally bound, have caused this SOW</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">to be executed by their duly authorized  representatives  as of the </font><font style="font-family:inherit;font-size:11pt;color:#464646;">[date]</font><font style="font-family:inherit;font-size:11pt;color:#2b2b2b;">.</font></div><div style="line-height:100%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:41%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SPONSOR:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">DYADIC INTERNATIONAL, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">BIOTECHNOLOGY DEVELOPMENTS FOR</font></div><div style="padding-top:2px;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;INDUSTRY  IN PHARMACEUTICALS, S.L.U.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mark Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Executive Office</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B-3</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>21
<FILENAME>exhibit1016form10.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8E833E634B6ABAB35F2569556F82DF57"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.16</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Execution Version</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*] indicates that a confidential portion of the text of this agreement has been omitted. The non-public</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">information has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:13pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;"><br></font></div><div style="text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;font-weight:bold;">Feasibility Study Agreement</font></div><div style="text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">BY AND BETWEEN</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Sanofi-Aventis Deutschland GmbH</font><font style="font-family:Arial;font-size:11pt;">, a German corporation with its principal place of business at lndustriepark H&#246;chst, 65926 Frankfurt am Main, Germany,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">hereinafter referred to as </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"SANOFl",</font></div><div style="line-height:120%;padding-bottom:16px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">DYADIC INTERNATIONAL, INC., </font><font style="font-family:Arial;font-size:11pt;">with a principal office at lntracoastal Pointe Drive, Suite 404, Jupiter, FL 33477-5094, USA,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">hereinafter referred to as </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"COMPANY".</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI and COMPANY are hereinafter individually or collectively referred to as a</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#32;"Party" </font><font style="font-family:Arial;font-size:11pt;">or the </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"Parties".</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">PREAMBLE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI is, within the sanofi pharmaceutical group, one of the companies specialized in research, development and manufacturing of pharmaceutical products for human health;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI desires to appoint COMPANY to provide certain Services (as defined in Section 2.1 below and in </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Annex 1</font><font style="font-family:Arial;font-size:11pt;">)</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:11pt;">and selects COMPANY due to its expertise, quality of service, personnel, systems, and the ability to provide the Services within the required timeframe;</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The Parties have agreed that COMPANY shall provide the Services under the terms of this Agreement and formalized by one or more purchase order(s) referencing this Agreement which SANOFI sends to COMPANY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">NOW, THEREFORE, </font><font style="font-family:Arial;font-size:11pt;">the Parties agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">1&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Definitions</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">For the purpose of this Agreement, the capitalized terms used herein shall have the meanings set forth below:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"Affiliate(s)" </font><font style="font-family:Arial;font-size:11pt;">shall mean any person, corporation or other entity which, directly or indirectly, controls, is controlled by or is under common control with a Party hereto by means of ownership of more than fifty (50) percent of the voting stock or similar interest in that entity.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"Confidential Information" </font><font style="font-family:Arial;font-size:11pt;">shall mean the confidential information as defined in Section 10.1 hereof.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"COMPANY Technology" </font><font style="font-family:Arial;font-size:11pt;">shall mean any and all information, data, know-how, methodologies, discoveries, inventions, whether patentable or not, patent applications or issued patents owned or controlled by COMPANY (including its Affiliates) on the Effective Date, including improvements thereto generated in the course of providing the Services, which COMPANY uses to perform the Services. </font><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">1.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"Deliverables" </font><font style="font-family:Arial;font-size:11pt;">shall mean such items that COMPANY is expressly obligated to furnish SANOFI under this Agreement and its </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1, </font><font style="font-family:Arial;font-size:11pt;">including (1) the </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:Arial;font-size:11pt;">, being part of the "Results", as further defined in Section 1.7, and (2) the final report, being part of the "Documentation", as hereinafter defined.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">1.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"Documentation" </font><font style="font-family:Arial;font-size:11pt;">shall mean all written reports and any supporting documentation and data generated in the performance of the Services, including but not limited to final report, batch records, laboratory notebooks, original data and slides.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">1.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"Effective Date" </font><font style="font-family:Arial;font-size:11pt;">shall mean the date of last signature by a Party to this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">1.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"Results" </font><font style="font-family:Arial;font-size:11pt;">other than the COMPANY Technology (which in all cases will remain the sole property of the COMPANY) shall mean (i) any material which COMPANY (including its Affiliates) generates from SANOFI Material and SANOFI Technology received under this Agreement or which COMPANY manufactures in connection with the performance of the Services under the relevant purchase order, in particular, </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:Arial;font-size:11pt;">&#32;as described in </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1</font><font style="font-family:Arial;font-size:11pt;">)</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:11pt;">which will be generated by COMPANY as a result of the performance of the Services and, if stipulated in </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1, </font><font style="font-family:Arial;font-size:11pt;">provided to SANOFI; and/or (ii) any and all information, data (including raw data), know-how, techniques, processes, formulations, developments, discoveries, improvements, inventions, methodologies, whether patentable or not, patent applications or issued patents or any other intellectual property generated by COMPANY (including its Affiliates) including the Documentation conceived, developed, generated, and/or acquired under or in connection with the performance of the Services under the relevant purchase order.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">1.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"SANOFI Material" </font><font style="font-family:Arial;font-size:11pt;">shall mean any data, chemical or biological material including, without limitation, </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:Arial;font-size:11pt;">, which will be generated by COMPANY, which is supplied by SANOFI (including its Affiliates) to COMPANY (including its Affiliates) under any purchase order or under this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">1.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"SANOFI Technology" </font><font style="font-family:Arial;font-size:11pt;">shall mean any and all information, data, documents, know-how, methods, discoveries, processes, inventions, whether patentable or not, patent applications or issued patents owned or controlled by SANOFI on the Effective Date, including improvements thereto generated in the course of providing the Services, which COMPANY uses as tool to perform the Services. SANOFI Technology shall exclude COMPANY Technology.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">1.10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"Publication Data Collection" </font><font style="font-family:Arial;font-size:11pt;">shall refer to a document containing all data from COMPANY Technology and Results relating to molecules 1, 3 to 7 according to </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1 </font><font style="font-family:Arial;font-size:11pt;">which are intended to be used for publication by COMPANY in accordance with Section 11.2 hereof.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">2</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">2&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Services</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY undertakes to perform the following services (</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"Services</font><font style="font-family:Arial;font-size:11pt;">"):</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Evaluation of the expression of selected molecules in the C1 expression platform</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">as offered by COMPANY in the Project Plan attached hereto as </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1</font><font style="font-family:Arial;font-size:11pt;">.</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:11pt;">SANOFI shall send to COMPANY one or more corresponding purchase order(s), each indicating a specific purchase order number, so that the Services shall become firmly ordered.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The fees to be paid by SANOFI according to the Project Plan of COMPANY as outlined in </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1 </font><font style="font-family:Arial;font-size:11pt;">are fixed and shall cover all Services to be provided under the Project Plan and this Agreement to SANOFI. No additional costs shall be charged to SANOFI.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Any purchase order shall explicitly refer to this Agreement. To the extent that any purchase order should be inconsistent to the terms of this Agreement, this Agreement shall control.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">2.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Any modification of the Services agreed by the Parties might cause an updated or fresh purchase order sent by SANOFl.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Term</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Without prejudice to either Party's right to terminate this Agreement in accordance with Section 19 hereof, this Agreement shall commence as of the Effective Date and unless otherwise terminated as provided herein, shall expire: (i) two [2] years after the Effective Date; or (ii) upon termination or completion of the Project Plan whichever is later. The term of this Agreement can be extended by written instrument signed by both Parties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">4&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Payments</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In consideration of the Services by COMPANY, SANOFI shall pay to COMPANY the distinct fees and the fees shall become due and payable as soon as COMPANY has completed each distinct service and as soon as SANOFI has received from COMPANY the Deliverables as specified in any purchase order in accordance with the offer as per </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1 </font><font style="font-family:Arial;font-size:11pt;">hereof.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">All fees are exclusive of VAT which shall be added, if applicable. Each invoice shall refer to the purchase order number indicated in the applicable purchase order. The amounts due by SANOFI shall be payable within sixty (60) calendar days after the receipt of each invoice. The invoices shall be addressed to:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:41.13785557986871%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Sanofi-Aventis Deutschland GmbH</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Rechnungspr&#252;fung</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Postfach 60 23 29</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">22233 Hamburg</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Germany</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">3</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">5&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Scientific Interlocutors</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY has designated Dr. Ronen Tchelet to be the scientific interlocutor for COMPANY (hereinafter the "</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">COMPANY's Project Leader</font><font style="font-family:Arial;font-size:11pt;">").</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI has designated Dr. </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:Arial;font-size:11pt;">&#32;to be the scientific interlocutor for SANOFI (hereinafter the "</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">SANOFl's Project Leader</font><font style="font-family:Arial;font-size:11pt;">")</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">6&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Obligations of COMPANY</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY undertakes to perform the Services under any purchase order in a manner commensurate with professional standards, by implementing all necessary means, in accordance with the terms of this Agreement and in accordance with applicable laws and regulations.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">To the extent required in a purchase order, COMPANY shall perform the Services in accordance with Good Laboratory Practices (GLP), or any other applicable guideline. Such conformity shall be controlled by COMPANY's Quality Assurance staff according to its standard operating procedures.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY will keep SANOFI regularly informed (i) of the performance of the Services as and when they occur, and (ii) as soon as possible, of any problem or difficulty that could affect the performance, agreed timelines or milestones of the Services as defined in </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Upon reasonably prior written notice, SANOFI shall have access during ordinary business hours to COMPANY's (including its Affiliates') sites where the Services are performed and access to all documents related to the performance of the Services.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY undertakes (i) to assign to the performance of the Services skilled personnel with expertise in the domains required by the Services (hereinafter the "</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Participants</font><font style="font-family:Arial;font-size:11pt;">")</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:11pt;">in order to ensure the proper quality and timely performance of the Services and (ii) to take any and all necessary measures to overcome any problem or difficulty arising from the unavailability, absence or holidays of the Participants and likely to affect the performance of the Services. COMPANY shall inform SANOFI in writing of any significant modification to its premises, equipment or any unavailability of or replacement of any Participant likely to affect the quality or the timely delivery of the Services. Any such significant modification shall be approved in writing by SANOFI before implementation.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Should one of the Participants become absent or unavailable, COMPANY shall make reasonable best efforts to maintain the continuity of the Services. In this respect, COMPANY undertakes to replace the Participant, as soon as possible, by a person at least as skilled and experienced as such unavailable Participant.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Upon specific request, COMPANY shall communicate to SANOFI the Results including, without limitation, raw data obtained in the course of performing the Services electronically or as paper copy, at no cost to SANOFI.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6. 7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Upon completion of the Services and if not otherwise defined in the Project Plan COMPANY shall supply SANOFI with a final report as defined in the Project Plan and all Results obtained. Such final report shall be signed by COMPANY's Project </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">4</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:Arial;font-size:11pt;">Leader and be addressed to SANOFl's Project Leader for acceptance. Further, COMPANY shall supply SANOFI with a Publication Data Collection together with the final report if publication of COMPANY technology and Results in accordance with Section 11.2, below, is intended by COMPANY.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY shall not be entitled to subcontract any of the Services without prior written consent by SANOFI. The Parties agree that Bdi (Biotechnology Development for Industry) Health, c/Louis Proust 13, 47151 Boecillo (Valladolid), Spain, and VTT Technical Research Centre of Finland Ltd, Vuorimiehentie 3, Espoo, Finland, shall be considered as approved subcontractors of COMPANY.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI acknowledges that COMPANY may require SANOFI Material and SANOFI Technology including, without limitation, related Confidential Information, as defined in Section 10.1 below, and interaction with SANOFI in order to properly perform the Services hereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6.10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY will perform the Services with the same degree of skills and professional diligence on the basis of the applicable standards in the biotechnological industry which a comparable organization would apply.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">6.11</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY will comply with its own standards and standard operating procedures to secure good scientific practice.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">7&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">SANOFI Material and SANOFI Technology</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">7.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI shall supply COMPANY as soon as reasonably possible with the SANOFI Material including, without limitation, any and all information, data and documents (i) which is in SANOFl's (including its Affiliates') possession, and (ii) which in SANOFl's reasonable judgment is necessary for COMPANY to perform the Services.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">7.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">All SANOFI Material and SANOFI Technology supplied by SANOFI to COMPANY shall remain in the exclusive ownership of SANOFI and shall be used by COMPANY solely for the purpose of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">7.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Upon expiration or termination of any purchase order or this Agreement or at any time upon written request by SANOFI, COMPANY shall return to SANOFI or destroy any and all SANOFI Material and shall transfer any and all Results as specified in Section 19.7 hereof. In no event shall COMPANY destroy SANOFI Material or Results without the prior written consent by SANOFI.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">8&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Results and Documentation</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Within six [6] months (i) upon expiration or termination of this Agreement, (ii) after submission of the Results, including the final report as defined in the Project Plan according to Section 6.7, COMPANY shall destroy any and all Documentation and Results except for the Publication Data Collection if publication of COMPANY Technology and Results in accordance with Section 11.2 below is intended by COMPANY.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">5</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">9&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Ownership in Intellectual Property</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">10&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Confidentiality - Restricted Use</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">10.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY shall restrict the use, keep confidential and not disclose to any third party other than to the parties as allowed in 6.8 above and to GeneScript, 860 Centennial Ave., Piscataway, NJ 08854, USA, who will optimize the DNA sequences and who Dyadic will order synthetic fragments for the target proteins from (i) any and all SANOFI Material and SANOFI Technology, as well as (ii) the Results (hereinafter collectively referred to as </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">"Confidential Information"</font><font style="font-family:Arial;font-size:11pt;">).</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:11pt;">This obligation of confidentiality shall remain in force for the term of this Agreement and for a ten (10) year period following its expiration or early termination.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">10.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY may disclose the Confidential Information only to its directors, officers, or Participants on a need-to-know basis and shall bind them to confidentiality obligations at least as stringent as those set forth herein.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">10.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The confidentiality and restricted use obligations shall not apply to Confidential Information which:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">was known to COMPANY prior to receipt from SANOFI;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">was or becomes public knowledge through no fault of COMPANY (including its Affiliates);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">was developed by COMPANY (including its Affiliates) independently of performing the Services under this Agreement; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY is required by law to disclose.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">11&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Publications</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">11.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI shall be free to publish and to communicate on the SANOFI Material, SANOFI Technology and the Results, using all existing or future means of communication.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">11.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Notwithstanding anything to the contrary contained in this entire Agreement, COMPANY, its directors, officers, Participants, and/or Affiliates shall not publish any part of the SANOFI Material, SANOFI Technology and/or the Results. As an exception from the foregoing, COMPANY may publish COMPANY Technology and the Results relating to molecules 1, 3 to 7 according to </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1 </font><font style="font-family:Arial;font-size:11pt;">provided that COMPANY has provided to SANOFI a Publication Data Collection together with the final report containing all data intended for publication and a written request for publication of said data and SANOFI has given its prior written consent, which SANOFI will not unreasonably withhold, to the publication of the data contained in the Publication Data Collection. In any one of such publications, COMPANY must refer to molecules 1 and 3 to 7 according to </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1 </font><font style="font-family:Arial;font-size:11pt;">generically, namely to a </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:Arial;font-size:11pt;">&#32;for molecule 1, a </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:Arial;font-size:11pt;">&#32;for molecule 3, a </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:Arial;font-size:11pt;">&#32;for molecule 4, an </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:Arial;font-size:11pt;">&#32;for molecule 5 and a </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:Arial;font-size:11pt;">&#32;for molecules 6 and 7 according to </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1. </font><font style="font-family:Arial;font-size:11pt;">Under no circumstances, the involvement of a party in addition to COMPANY, the name of </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">6</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:Arial;font-size:11pt;">SANOFI or any of its Affiliates, the trade or INN name of the individual protein(s), the amino acid sequence(s) and/or related genetic information of the recombinant proteins shall be published. All data intended for publication contained in the Publication Data Collection must have been generated as Results under this Agreement. Under no circumstances, SANOFI Material, SANOFI Technology and/or the Results relating to molecule 2 according to </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Annex 1 </font><font style="font-family:Arial;font-size:11pt;">shall be published.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">11.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">If disclosure of COMPANY Technology and Results is necessary for not being in violation of any applicable law, regulation, order, or other similar requirement of any governmental, regulatory, or supervisory authority or any applicable rules and regulations of any national securities exchange the name of SANOFI or any of its Affiliates shall not be used without the prior written consent of the Party named, which SANOFI will not unreasonably withhold.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Publicity</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Within 4 (four) days of execution of this Agreement COMPANY will be required to make a public disclosure </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">("Press Release") </font><font style="font-family:Arial;font-size:11pt;">not to be in violation of any applicable law, regulation, order, or other similar requirement of any governmental, regulatory, or supervisory authority or any applicable rules and regulations of any national securities exchange party named. The wording of such Press Release is attached </font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">(Annex 2) </font><font style="font-family:Arial;font-size:11pt;">to this Agreement. COMPANY shall not deviate therefrom.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">13&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Audit, Inspections</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">13.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">During the term of this Agreement SANOFI shall be entitled (upon reasonably prior written notice and during normal business hours) to audit COMPANY's (including its Affiliates') premises where the Services are performed, to assess the conduct of Services and to have access to relevant documentation. COMPANY shall secure that SANOFl's employees are awarded adequate assistance by personnel capable of addressing questions. SANOFI shall bear its own costs of the audit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">13.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">During the term of this Agreement and even after its expiration or early termination, COMPANY shall allow any competent governmental health agency upon their request to inspect COMPANY's (including its Affiliates') premises where the Services are performed.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">13.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Upon receipt of the health agency request to inspect its premises and provided such request of inspection relates to the performance of the Services, COMPANY shall (i) promptly notify SANOFI in writing thereof and (ii) prepare, in collaboration with SANOFI, the documents to be made available to the health agency for review at the premises. To the extent possible, COMPANY shall enable SANOFI to attend any inspection or post-inspection meeting with the health agency.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">13.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY shall supply SANOFI with a list of any and all documents and materials (reports, analyses, product samples, photographs, etc.) exchanged with the health agency during or after the inspection. Upon request by SANOFI, COMPANY shall supply SANOFI with a copy of all these documents and materials. COMPANY undertakes to communicate to SANOFI in writing any comment, remark or request made by such health agency to the extent related to the Services.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">7</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">13.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Where part of the Services have been subcontracted by COMPANY to a third party previously approved by SANOFI according to Section 6.8 hereof, COMPANY undertakes, as part of its contractual negotiations with its subcontractor, to require subcontractor to comply with such commitments towards governmental health agencies inspections.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In this respect, COMPANY shall ensure that its subcontractor commits itself to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:132px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">a)&#160;&#160;&#160;&#160;give access to its premises to the requesting health agency accompanied by representatives of COMPANY and SANOFI;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:132px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">b)&#160;&#160;&#160;&#160;prepare the inspection and the documents and materials to be supplied to the health agency under the control and supervision of COMPANY and SANOFI;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:132px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">c)&#160;&#160;&#160;&#160;supply COMPANY and SANOFI with a copy of all documents and materials exchanged with the health agency.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">13.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">If the health agency inspection reveals any problem, COMPANY undertakes to implement, or have its subcontractor implement, at their respective own costs, any necessary corrective actions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">14&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Representations, Warranties, Liability</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">14.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY represents and warrants that it will perform the Services with the same degree of skills which a comparable organization would apply.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">14.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY represents and warrants that it will store, handle and use the SANOFI Material with due care while in its custody.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">14.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY represents and warrants that it will comply with its own standards and standard operating procedures to secure good scientific practice.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">14.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY represents and warrants the accuracy of the activities encompassed by the Services, the accuracy of the information and data including, without limitation, the Results, the accuracy of any scientific assessment of those information and data, and the accuracy of the final report referenced in Section 6.7 hereof.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">14.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY represents and warrants that (a) it will comply with the requirements of all applicable anti-bribery legislation, national or foreign, including without limitation the US Foreign Corrupt Practices Act, the UK Bribery Act and the OECD Convention dated 17</font><font style="font-family:Arial;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:Arial;font-size:11pt;">&#32;December 1997; (b) that it has not and will not make, promise or offer to make any payment or transfer anything of value (directly or indirectly) to an individual, any company or any public body who are in a position to influence, secure or retain any business for SANOFI by performing in an improper way a function of public nature or of business nature; and (c) in case that COMPANY is a public institution, COMPANY represents and warrants that COMPANY or individuals, have not accepted nor have been offered any payment of money or transfer of anything of value for the purpose of influencing decisions or actions to help SANOFI obtain or maintain business or obtain a business advantage.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">8</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">14.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY will be solely responsible for the performance of the Services. In no event shall SANOFI be liable for any direct or indirect damages, losses of property, injuries to any person, handling of the samples and/or implementation of a method and/or process within COMPANY's facilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">14.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Except as otherwise set forth in this Section 14.7, in no event shall either Party be liable to the other for lost profits, punitive or other indirect, special, exemplary, incidental or consequential damages of any kind arising out of, or in connection with this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">14.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Each Party's liability for any breach of this Agreement shall not exceed three (3) times the overall amount due by SANOFI to COMPANY under the relevant purchase order.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">14.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Notwithstanding the foregoing, nothing in this Agreement shall limit the liability of either Party (i) for death or personal injury arising from the negligence of that Party, (ii) breach by COMPANY of its confidentiality obligations or (iii) to any infringement of third party intellectual property rights to the extent COMPANY is culpable of such infringement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">15&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Indemnification</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">15.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI agrees to indemnify, defend and hold harmless COMPANY (including its Affiliates) from any and all damages, expenses (including reasonable attorney's fees), claims, demands, suits or other actions arising directly from the SANOFI Material and SANOFI Technology, except to the extent such events are the direct result of COMPANY's (including its Affiliates') gross negligence or willful misconduct or COMPANY's publications according to 11.2.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">15.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY agrees to indemnify, defend and hold harmless SANOFI (including its Affiliates) from any and all damages, expenses (including reasonable attorney's fees), claims, demands, suits or other actions arising directly from COMPANY's (including its Affiliates') conduct of the Services or use of COMPANY Technology, except to the extent such events are the direct result of SANOFl's and/or its Affiliates' gross negligence or willful misconduct.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">16&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Debarment</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY represents and warrants that in performing the Services it has not and it will not employ any of its employees or contractors or subcontractors who have been or are currently under investigation for debarment or are actually debarred pursuant to the United States Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167; 335(a)), as amended, or are excluded from participating in any United States federal or state health care program pursuant to United States 42 U.S.C. &#167; 1320a-7, et seq. Upon written request by SANOFI, COMPANY will provide and sign an appropriate written confirmation which SANOFI will propose.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">17&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Force Majeure</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">17 .1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Neither Party shall be liable to the other for any failure to fulfill its obligations under this Agreement to the extent that such failure is attributable to "Force Majeure".</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">9</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">17.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">As used herein, "Force Majeure" shall mean any event beyond the reasonable control of the respective Party including, without limitation, new legislation, new decrees enacted, court judgments or orders issued by any authority, fire, flood, earthquake, or strikes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">17 .3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The Party affected by Force Majeure shall (i) promptly inform the other Party and (ii) shall make all reasonable efforts to mitigate the consequences of such Force Majeure.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">17.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In the event that after three (3) consecutive months from the notice of occurrence, the Force Majeure event persists, then either Party may terminate this Agreement by giving written notice to the other Party.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">18&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Notice</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Any notice to be given hereunder shall be in writing. Notices shall be served either personally, by fax, by registered letter postage prepaid, or by deposit with an overnight courier, charges prepaid, and addressed to the address or fax number stated herein below or to any new address designated by one of the Parties. Any such notice shall be deemed to have been given: (a) upon delivery in the case of personal delivery; (b) upon the first business day following facsimile receipt; (c) seven (7) calendar days after deposit in the mail in the case of a registered letter, (d) seven (7) calendar days after deposit with an overnight courier:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">For notices to be served upon COMPANY:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Attn: CEO</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">DYADIC INTERNATIONAL, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">lntracoastal Pointe Drive, Suite 404</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Jupiter, FL 33477-5094,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">USA</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">For notices to be served upon SANOFI:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Sanofi-Aventis Deutschland GmbH</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Legal Department</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">lndustriepark H&#246;chst</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">65926 Frankfurt/Main</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Germany</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Fax: +49 (0)69 305 24590</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">19&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Termination</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">19.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Either Party shall be entitled to terminate any purchase order or this Agreement at any time immediately by giving written notice to the other Party if the other Party is in material breach of such purchase order or this Agreement and fails to cure such breach within thirty (30) calendar days after having received a written notice of that breach. Termination shall become effective upon first presentation to the defaulting Party of a second registered letter with return receipt requested, notifying the decision of termination.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">10</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">19.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Either Party shall be entitled to terminate any purchase order or this Agreement as specified in Section 17.4 hereof by giving written notice to the other Party having immediate effect.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">19.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI may immediately terminate any purchase order and/or this Agreement by giving written notice to COMPANY in the event that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY is in breach of its obligations under Section 6.2, 6.3, 6.4, 10.1, 10.2 and 16 hereof as soon as SANOFI knows of such breach;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY becomes insolvent, falls into liquidation or has a receiver to its assets appointed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">a third party, directly or indirectly, acquires equity in the COMPANY and as a result owns more than fifty (50) percent of the equity in the COMPANY and prior to such acquisition did not own more than fifty (50) percent of the equity in the COMPANY;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">19.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI may terminate any purchase order and/or this Agreement with prior written notice of 90 (ninety) days if SANOFI considers that the project within which SANOFI appointed COMPANY to perform Service is not of interest any more.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">19.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Expiration or termination of this Agreement shall not affect any obligation which has arisen before the termination becomes effective including, without limitation, the obligation of SANOFI to make payments of those amounts which have become due in accordance with Section 4 hereof or the obligation of confidentiality and respect of restricted use in accordance with Section 10 hereof, and to provide written confirmation in accordance with Section 16 hereof.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">19.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Termination of this Agreement does not affect other remedies available under statute or common law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">19. 7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Upon expiration of any purchase order or this Agreement pursuant to Section 3 hereof or termination of any purchase order or this Agreement by SANOFI pursuant to Section 19.1, 19.2, 19.3 or 19.3 hereof, COMPANY shall</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">transfer, assign and convey to SANOFI without delay any SANOFI Material and/or SANOFI Technology in COMPANY's (including its Affiliates') possession and the Results generated until the date on which the expiration or termination becomes effective;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">complete without delay a de-facto final report as specified in Section 6.7 hereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">continue to be bound by the obligations to maintain the SANOFI Material, SANOFI Technology and the Results confidential and to not use the same, all this in accordance with Section 10 hereof, and to provide written confirmation in accordance with Section 16 hereof; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">in the event of termination by SANOFI in accordance with Section 19.4 hereof, COMPANY shall be entitled to payment of the fees and costs due in consideration of the Services actually rendered up to the effective date of termination.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">11</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">20&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Transparency Requirements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI is committed to transparency in its interactions with healthcare professionals and health care organizations/institutions consistent with applicable laws in countries in which SANOFI has Affiliates. Information relating to payments or other transfers of value to U.S. "covered recipients" under or related to this Agreement will be collected and reported as required under U.S. federal and state laws and regulations, including the "sunshine" regulations set forth in 42 CFR Parts 402 and 403, which require that certain payments, and other transfers of value, whether direct or indirect (through a third party), be collected and reported to the U.S. government for subsequent public reporting.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">To the extent that the services provided as part of this Agreement are "Research" as defined in the federal regulations to include "a systematic investigation designed to develop or contribute to generalizable knowledge relating broadly to public health, including behavioral and social-sciences research", which encompasses both basic and applied research, (42 CFR &#167; 403.902), and which is subject to a written agreement, a research protocol or both, will be reported consistent with the special rules for research payments. (42 CFR &#167;403.904(f)).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">To the extent that any payments or transfers of value fall outside the "Research" as defined in the federal regulations, they will be reported as required consistent with applicable federal regulations. All state reporting will be consistent with state requirements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Representation Regarding Transfers of Value to Physicians or Teaching Hospitals for U.S. "Sunshine" Reporting Purposes:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">COMPANY represents that no portion of any payment made under this Agreement is or will be passed on to:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">any physician (Medical Doctor (MD), Doctor of Osteopathic Medicine (DO), MD or DO Fellow, Dentist, Dental surgeon, Podiatrist, Optometrist, or Chiropractor), licensed in the U.S. ("Physician"). Salary paid to a Physician shall not be considered to include amounts passed on under this Agreement if the amount of the salary is determined without consideration of the amounts paid under this Agreement and COMPANY has not used and will not use any portion of payments made under this Agreement in determining the amount of non-salary compensation to any Physician; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:32px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">any U.S. Teaching Hospital</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">21&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Assignment</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Neither Party may assign its rights or its obligations hereunder or this entire Agreement without the prior written consent of the other Party except that SANOFI may assign this Agreement to any of its Affiliates. This Agreement shall be binding on each Party and, if applicable, its legal successor(s).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">22&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Severability</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">If any provision of this Agreement shall for any reason and to any extent be determined to be invalid or unenforceable under applicable law, then such invalidity or unenforceability shall not affect the remainder of this Agreement, unless the invalid or unenforceable provision is of such importance that it can be reasonably assumed that the Parties would not have entered into this Agreement without the invalid or unenforceable provision. The </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">12</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Parties agree to replace any such invalid or unenforceable provision with a valid and enforceable provision designed to achieve, to the extent possible, the business purposes and intent of such invalid and unenforceable provision.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">23&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Waiver</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">No delay or failure by either Party to exercise or enforce at any time any right or provision of this Agreement shall be considered a waiver thereof or of such Party's right thereafter to exercise or enforce each and every right and provision of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">24&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Amendments</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">This Agreement may not be modified or amended, in whole or in part, except in a written instrument signed by both Parties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">25&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Applicable Law, Venue</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">This Agreement shall be governed by and construed in accordance with the laws of Switzerland. Place of jurisdiction shall be Zurich, Switzerland.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.41317365269461%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page </font><font style="font-family:Arial;font-size:10pt;">13</font><font style="font-family:Arial;font-size:10pt;">&#160;of </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#s9d88fc5882c1407eaee98ba3153df39e">27</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s2AA9D2461E548387129F695571C89D0C"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Arial;font-size:11pt;">, the Parties hereto have caused this Agreement to be executed.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:13%;"></td><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:26%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Sanofi-Aventis Deutschland GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Dyadic International Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Signature:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Signature:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">CEO</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">7/8/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">9/7/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Signature:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Signature:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><a name="s8879E06A5E086642BEE56955721DCD9E"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Annex 1</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Services</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Project proposal:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Development of Dyadic's C1 fungal expression system as production platform for therapeutic proteins for Sanofi</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Introduction</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Sanofi-Aventis (Sanofi) and Dyadic have agreed to enter into a feasibility study using Dyadic's C1 fungal expression system as a therapeutic protein production platform. The aim of the project is to study the feasibility of production of seven different target therapeutic proteins of Sanofi in the C1 fungal expression system of Dyadic. The goal is to obtain high production levels of these proteins with the best possible quality, and to provide supernatant samples containing the target purified proteins to Sanofi for further analysis.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The target proteins are:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The work plan will be carried out by VTT R&amp;D group and will be supervised by Dyadic R&amp;D team.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Dyadic/VTT Work Plan</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">Design and constructing the expression vectors (WP1)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">First set of protein expression {WP2)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">First set laboratory scale fermentations (WP3)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">Second set protein expression {WP4)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;text-decoration:underline;">Second set laboratory scale fermentation (WP5)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Project timeline</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The total duration of the project is 12 months excluding the time needed for gene synthesis by a gene synthesis company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Progress/Interim Meetings and Final Report:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Frequency of teleconferences and/or face-to-face meetings: Throughout the project timeline monthly teleconferences or face to face meetings will be held between the project teams.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Reports to be provided to Sanofi Project Manager: At the end of the project timeline, Dyadic will provide a written summary of the findings in the form of a technical report to Sanofi (in Word format) and a slide deck summarizing key outcomes (in PowerPoint format)</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Final Materials Deliverables</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">By the end of the project Dyadic will provide Sanofi:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Project resources</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">As it is outlined above, Dyadic's (VTI) will use </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:Arial;font-size:11pt;">&#32;for expressing the proteins for Sanofi.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The project-plan cost includes Dyadic management &amp; scientific support. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">c. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The total cost of the project is estimated to be 961,000 EUR.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:Arial;font-size:11pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The project cost estimate includes the costs of reagents and consumables.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Payment schedule</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:72%;"></td><td style="width:6%;"></td><td style="width:22%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">After signature of Feasibility Study Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">After completion of WP3 (month 5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">After completion of WP5 and delivery of Report</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">DYADIC point of contact:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Ronen Tchelet</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Dyadic International (USA), Inc.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">140 lntracoastal Pointe Drive</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Suite #404</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Jupiter, Florida 33477, USA</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">+36 30 864 6060</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Email: </font><a style="font-family:Arial;font-size:11pt;color:#000000;text-decoration:none;" href="#"><font style="font-family:Arial;font-size:11pt;color:#000000;text-decoration:none;">rt</font></a><font style="font-family:Arial;font-size:11pt;">chelet@dyadic.com</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI point of contact:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI PASTEUR</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">1541, AVENUE MARCEL MERIEUX</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">69280 MARCY L'ETOILE, FRANCE</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">+33 7 89 86 21 06</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Email: </font><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><a name="s41A6CAB20C9C64F6D05D695573172C98"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">IN WITNESS WHEREOF, duly-authorized representatives of the parties have signed as of the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:17%;"></td><td style="width:32%;"></td><td style="width:4%;"></td><td style="width:16%;"></td><td style="width:31%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">DYADIC INTERENATIONAL (USA), INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">SANOFI</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ Mark Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">/s/ </font><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Printed Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Mark Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Printed Name:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">CEO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Title:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">9/7/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Date:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">7/8/2018</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><a name="s3cbfb7e6bc6845ccbcb4fc19b780aad8"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Exhibit 1</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Feasibility Study Agreement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Candidate Molecules</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Molecule No 1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><a name="sB38415C3867259B7AE1169557337C9E3"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Molecule No 2</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="s7262EBC6A4744FB056366955736A5262"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Molecule No 3</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><a name="s16113E0C6FCF093183F169557432A19C"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Molecule No 4</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><a name="sE0F7351326A828E966A96955746569AC"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Molecule No 5</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><a name="s6A5CA5BD5A988E36D8A1695574B65240"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Molecule No 6</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><a name="s25943A71EB3C26284229695574E00078"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Molecule No 7</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="sF3EADFEF6729BE7333AE69557548B782"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Annex 2</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Press Release</font></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), JUPITER, FL - MONTH, DAY, 2018 (XXX NEWSWIRE) </font><font style="font-family:Arial;font-size:11pt;">- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to expedite the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a fully funded proof of concept research collaboration to explore the potential of its C1 technology to produce multiple types of biologic vaccines and drugs of interest for human health indications with Sanofi-Aventis Deutschland GmbH, a company of the Sanofi group, one of the World's top tier biopharmaceutical companies.</font></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">"We are very pleased to have the opportunity to collaborate with Sanofi to express multiple types of important therapeutic compounds using our C1 production platform", said Mark Emalfarb, Dyadic's CEO. "This research and development program is aiming to overcome specific gene expression challenges and to further demonstrate the potential of C1 to become a platform of choice for manufacturing protein-based biologics because of its speed of development and low cost of goods."</font></div><div style="line-height:174%;padding-bottom:32px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Under the agreement, Sanofi will fund the collaborative research which will utilize the proprietary and patented C1 Gene Expression Platform Technology to express multiple genes for vaccine and drug applications. The research is expected to be completed in Q2 of 2019. Other terms of the research collaboration are confidential. </font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">About Dyadic International, Inc.</font></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">monoclonal antibodies, biosimilars/biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.</font></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Please visit Dyadic's website at www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.</font></div><div style="line-height:174%;padding-bottom:32px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic in the Company's annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at www.otcmarkets.com/stock/DYAl/quote.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Safe Harbor Regarding Forward-Looking Statements</font></div><div style="line-height:174%;padding-bottom:32px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic, political and market conditions; (2) our ability to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic's and third parties research and development </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:174%;padding-bottom:32px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on key customers and collaborators; (8) the pharmaceutical and biotech industry, governmental regulatory and other agencies' willingness to adopt, utilize and approve the use of the C1 gene expression platform; and (9) other factors discussed in Dyadic's publicly available filings, including information set forth under the caption "Risk Factors" in our December 31, 2017 Annual Report filed with the OTC Markets on March 27, 2018, and our March 31, 2018 Quarterly Report filed with the OTC Markets on May 10, 2018. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Contact:</font></div><div style="line-height:174%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Dyadic International, Inc. </font></div><div style="line-height:174%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Ping W. Rawson</font></div><div style="line-height:174%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Chief Accounting Officer</font></div><div style="line-height:174%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Phone: +1 (561) 743-8333</font></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Email: </font><a style="font-family:Arial;font-size:11pt;color:#000000;text-decoration:none;" href="#"><font style="font-family:Arial;font-size:11pt;color:#000000;text-decoration:none;">p</font></a><font style="font-family:Arial;font-size:11pt;">rawson@dyadic.com</font></div><div><a name="s9d88fc5882c1407eaee98ba3153df39e"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>22
<FILENAME>exhibit1017form10.htm
<DESCRIPTION>EXHIBIT 10.17
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBBEAFDDD26E5A92595898D214C2635A7"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">/(9)</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.17</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Execution Version</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*] indicates that a confidential portion of the text of this agreement has been omitted. The non-public</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">information has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;color:#353535;">LICENSE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">This Agreement is entered into by and between</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">VTT Technical Research Centre of Finland Ltd, (hereinafter referred to as "VTT") </font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">Business ID: 2647375-4</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">Address: Vuorimiehentie 3, P.O</font><font style="font-family:inherit;font-size:11.5pt;color:#4b4b4b;">. </font><font style="font-family:inherit;font-size:11.5pt;color:#353535;">Box 1000, FI-02044 VTT, Finland </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">and</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">Dyadic International (USA), Inc. (hereinafter referred to as the "Licensee") </font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">Business ID: 45-0486747</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">Address: 140 Intracoastal Pointe Drive, Jupiter, FL 33477-5094</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">The above mentioned parties hereinafter also referred to as "Party" or "Parties".</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">WHEREAS, VTT has developed certain technology related to expression systems for micro- organisms and to promoters in expression systems;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">WHEREAS, VTT has made an invention(s) related to the aforementioned technology and has filed patent application for the purpose of protecting the invention.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">WHEREAS, the Licensee is interested in obtaining a right to use the invention and/or related patent(s) defined in more detail below in this Agreement, in its business; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">WHEREAS, VTT is desirous of granting such right to the Licensee in accordance with the terms and conditions of this Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">NOW THEREFORE, in consideration of the foregoing, the Parties agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">1.&#160;&#160;&#160;&#160;DEFINITIONS</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#353535;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">"Patent Rights" shall mean VTT's patent rights under the patent application nr. FI 20165137 (filed 22.2.2016) titled "Expression system for eukaryotic micro-organisms", and its counterparts in different countries claiming priority from this patent application.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#353535;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">"Licensed Products" shall mean any and all products that are within the Patent Rights manufactured</font><font style="font-family:inherit;font-size:12pt;color:#4b4b4b;">, </font><font style="font-family:inherit;font-size:12pt;color:#353535;">have manufactured, sold or otherwise supplied by the Licensee, Dyadic </font><font style="font-family:inherit;font-size:11.5pt;color:#353535;">Group Companies and their sub-licensee(s).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#353535;">1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">"Effective Date" shall mean the date of the latest signature of this Agreement by the Parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">1.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#353535;">"Invention" shall mean inventions described in the Patent Rights, i.e. an expression system for a eukaryotic microorganism, host, a host comprising said expression system, and a method for producing a desired protein product by using said host; a method for identifying a universal core promoter, a universal core promoter obtainable by said </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font><font style="font-family:inherit;font-size:10pt;">/(9)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">method, and an expression system, a eukaryotic micro-organism host and method for producing a protein product by using a universal core promoter.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#363636;">1.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">"Field" shall mean protein production in pharmaceutical applications in connection with Cl strains.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#363636;">1.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">"Cl strain" shall mean any fungal strains that have taxonomy of either (a) </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;color:#363636;">, (b) </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;color:#363636;">&#32;or (c) </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:12pt;color:#363636;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#363636;">1.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">"Sub-license Agreement" means a written agreement between the Licensee and its sub&#8226; licensee (including also Dyadic Group Companies) concerning user rights granted to the Patent Rights and/or the Invention covered by the Patent Rights.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#363636;">1.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">"Dyadic Group Companies" shall mean Licensee and companies that are controlled by the Licensee. Control shall mean the holding of more than 50% of the nominal value of the issued share capital in the legal entity concerned, or of a majority of the voting rights of the shareholders of that entity.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#363636;">1.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">"Commission" shall mean Commission Contract between VTT Technical research Centre of Finland and Dyadic International, signed 5.9.2016.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">2.&#160;&#160;&#160;&#160;GRANT OF LICENSE; RIGHTS BY LICENSEE</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#363636;">2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">Grant of License</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">VTT hereby grants to Licensee, a worldwide, non-exclusive, and non-transferable right and license to use the Invention covered by the Patent Rights to manufacture, have manufactured, sell, use, distribute, and market Licensed Products in the Field . Furthermore, the Licensee and its sub-licensees are allowed to modify, improve and/or develop independently the Cl Strains, using Patent Rights, e.g. in case of expressing new target proteins or modification of the functional components of the synthetic promoter system after the project performed under the Commission between the Parties has ended. Such improvements made after the project under the Commission shall be the property of the Licensee. The right to modify, improve and/or develop improvements and/or the use of such improvements is limited to CI Strains in the Field. For the avoidance of doubt, improvements made by VTT to the technology covered by Patent Rights shall be the property of VTT.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">The Patent Rights shall remain the property of VTT and it is understood that, in addition to the rights expressly granted to the Licensee under this Agreement, no licence or right of use under any patent or patentable right, copyright, trademark or other proprietary right, or pertaining to any materials or information belonging to VTT is granted or conveyed to the Licensee by this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#363636;">The use of VTT's name or logo in connection with the advertising or sale of Licensed Products is prohibited, without prior written consent of VTT.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">/(9)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">2.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">Right to Sub-license</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">Licensee, and Dyadic Group Companies with whom the Licensee concludes a Sub-License Agreement shall, subject to the payment by the Licensee of the sub-license fee(s) stated in Clause 3.2, have the right to grant sub-licenses to the Patent Rights (the promoter technology) non-exclusively solely in connection with sales and/or licensing of the Licensee's Cl platform and/or sales or licensing of Licensed Products in the Field. The sub&#8226; licenses shall solely be made through Sub-license Agreements. The Licensee shall inform VTT of all of its sub-licensees, and Sub-license Agreements under this Agreement immediately when such Sub-license Agreement is concluded. Sub-licensees of the Licensee except Dyadic Group Companies shall not have the right to further sub-license the Patent Rights. The Licensee shall, however, in any case remain the sole point of contact towards VTT regarding the Patent Rights and sub-licenses granted. Furthermore, the Licensee shall ensure that the Sub-license Agreements contain the same limitations regarding the use of the Patent Rights as stated in this Agreement and the Licensee shall be responsible for the actions of Dyadic Group Companies and actions of sub-licensees regarding the Patent Rights and compliance with said limitations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">3.&#160;&#160;&#160;&#160;PAYMENTS</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">First Lump Sum Payment</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">The Licensee shall pay VTT for the license herein granted a non-refundable lump sum payment in the amount of </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:11.5pt;color:#333333;">&#32;euros when the Licensee a) first uses the technology covered by the Patent Rights to manufacture or to have manufactured Licensed Products; b) makes the first sale of a Licensed Product; c) concludes a Sub-license Agreement; or d) on the 31st of July 2019, whichever occurs first. The Licensee shall promptly notify VTT of the aforementioned triggering events by e-mail to the address identified in Clause 8.1, and VTT shall invoice the first lump sum payment promptly after receipt of said notice, or in case d) occurs first, VTT shall invoice the first lump-sum payment on the 31st of July 2019.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">3.2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">Sub-license Fee</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">Licensee shall pay a sub-license fee in the amount of </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:11.5pt;color:#333333;">&#32;euros for each Sub-license Agreement concluded by the Licensee and/or by Dyadic Group Companies. Said sub-license fee shall be invoiced by VTT promptly after receipt of the Licensee's notification(s) that a Sub-license Agreement(s) has been concluded by the Licensee or Dyadic Group Companies. The sub-license fee shall not apply to sub-licenses granted by Licensee to Dyadic Group Companies.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">3.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">Annual Fee</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">The Licensee shall pay VTT a non-refundable annual fee in the amount of </font><font style="font-family:inherit;font-size:10pt;">[*]</font><font style="font-family:inherit;font-size:11.5pt;color:#333333;">&#32;euros.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">The payment shall be invoiced by VTT in February of each year this Agreement is in force, starting in February 2020.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">3.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">Audit</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">/(9)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#303030;">Licensee shall keep, and shall cause Dyadic Group Companies and sub-licensees to keep, accurate records and books of account of all development processes related to the technology covered by the Patent Rights. Furthermore, Licensee and Dyadic Group Companies shall keep accurate records of any Sub-license Agreements concluded under this Agreement. The Licensee and shall permit VTT to engage a certified public accounting firm to examine such books and records for auditing purposes at any time during normal business hours. In case the audit shows that the Licensee has failed to notify VTT of Sub-license Agreements concluded, the Licensee shall immediately pay VTT the sub-license fee(s) that should have been paid under this Agreement and the interest stated in Clause 3.5 calculated from the day when the Sub-license Agreement was concluded.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#303030;">3.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#303030;">Payment Terms</font></div></td></tr></table><div style="line-height:120%;padding-bottom:9px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#303030;">All invoices shall be payable within thirty (30) days from the date of the relevant invoice. Value added tax and any taxes, duties or charges imposed by authorities outside of Finland shall be added, if applicable, to the payments. Interest on late payments shall be determined in accordance with the Finnish Interest Act 633/1982. Possible debt collection charges shall be added to the invoice.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#303030;">4.&#160;&#160;&#160;&#160;LIABILITY</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#303030;">4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#303030;">No Warranties</font></div></td></tr></table><div style="line-height:120%;padding-bottom:9px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#303030;">VTT warrants that it is the owner of the Patent Rights. VTT warrants that up until the Effective Date, the validity of the Patent Rights has not been challenged and there have been no past claim and that there are no pending claims or actions brought against VTT regarding the Patent Rights.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#303030;">Apart from the aforementioned, the Patent Rights are provided "AS IS" and VTT makes no representations or warranties with respect to the Patent Rights and/or inventions covered by the Patent Rights, including but not limited to warranties regarding commercial utility, merchantability or fitness for any particular purpose, absence of a latent or other defect, validity, enforceability or that the use of the Patent Rights, and/or inventions covered by the Patent Rights will not infringe any patent, copyright, other proprietary or property rights of others. VTT does not guarantee the patentability of any inventions included in the Patent Rights.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#303030;">4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#303030;">Liability</font></div></td></tr></table><div style="line-height:120%;padding-bottom:9px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#303030;">The Licensee shall bear any product liability as well as any other liability for the commercial utilization of the Patent Rights and/or the inventions covered by the Patent Rights. The Licensee shall be solely responsible for, and VTT shall have no obligation to honour, any warranties that Licensee provides to its customers with respect to the Patent Rights and /or Licensed Products. The Licensee shall indemnify and hold VTT harmless from and against damages and losses regarding the aforementioned.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#303030;">VTT shall not be liable to Licensee, its successors, assigns,sub-licensees, or affiliates for any loss of profits, loss of business, interruption of business, nor for indirect, special or consequential damages of any kind whether under this Agreement or otherwise, even if VTT has been advised of the possibility of such loss. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">/(9)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">VTT's liability shall, in all cases be limited to the sum of payments received from the Licensee under this Agreement, unless damages are caused by wilful act or gross negligence.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">5.&#160;&#160;&#160;&#160;PATENTS AND PATENT INFRINGEMENT</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#353535;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">Patents</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">For the term of this Agreement, VTT shall be responsible for the application, maintenance and prosecution of the Patent Rights. VTT shall also pay the costs arising out of the application, maintenance and prosecution of the Patent Rights. VTT shall take reasonable steps to apply and maintain the Patent Rights.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">The Patent Rights will enter into PCT phase and national phase already during the Commission and it is agreed that VTT shall continue the patent application process regarding said patent application in the USA and in Europe as an EP patent application aiming at validations in DE, GB, and FR. Should the Licensee wish to continue the patent application in any other countries, it may request VTT to do so at least 45 days prior to the relevant deadline in the application process, in which case the Licensee shall pay VTT all the patenting costs arising out of such other countries as they occur.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">VTT does not, however, guarantee the patentability of any inventions included in the Patent Rights.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#353535;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">Patent Infringement by Licensee</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">In the event that Licensee is sued by a third party for patent infringement because of its exercise of the license granted herein, Licensee shall defend the suit at its expense, but VTT may reasonably cooperate, at Licensee's request and expense, in the conduct of the defence, however, VTT shall have no obligation to participate in the defence of any infringement suits or actions.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;color:#353535;">5 .3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">Patent Infringement by Others</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">In the event that any infringement or suspected infringement of the Patent Rights comes to the attention of either Party, it shall promptly notify the other Party thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">Upon the occurrence of any infringement or suspected infringement of the Patent Rights, VTT and the Licensee shall as soon as practicable consult to decide what steps shall be taken to prevent or terminate such infringement. VTT or the Licensee shall take all such steps as may be agreed by them, including the institution of legal proceedings, where necessary, in the name of one of the Parties or in the joint names of VTT and the Licensee as appropriate. For the avoidance of doubt, neither Party shall have any obligation to initiate or take part in any specific actions or proceedings.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">6.&#160;&#160;&#160;&#160;CONFIDENTIALITY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#353535;">Both Parties shall keep confidential and not disclose to third parties during the term of this</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font><font style="font-family:inherit;font-size:10pt;">/(9)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">as any other confidential information received from the other Party in connection with this Agreement. The confidential information received from the other Party shall only be used for the purposes of performing the Parties' rights and obligations under this Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">The obligations regarding confidentiality shall not concern information that the receiving Party can show:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">is or becomes published or otherwise generally available to the public without violation of this Agreement; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">is already known to the receiving Party at the time of disclosure; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">is lawfully obtained by the receiving Party from a third party without any restrictions on confidentiality; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:96px;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">is independently developed by the receiving Party without any use of confidential information.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">If the receiving Party is required, pursuant to an administrative or a judicial action or subpoena, to disclose disclosing Party's confidential information, the receiving Party shall have the right to make such disclosure, provided to the extent it is lawfully allowed to do so, it shall prior to any such disclosure notify the disclosing Party and give the disclosing Party the opportunity to seek any legal remedy it considers necessary to protect its confidential information.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">Notwithstanding the foregoing, it is acknowledged that this is a non-exclusive license and VTT has also other commitments regarding the Patent Rights and therefore it is agreed that VTT shall have the right to disclose the general content of this Agreement to other licensees or research partners in case needed to show compliance with such other commitments or licenses.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">7.&#160;&#160;&#160;&#160;TERM AND TERMINATION</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">7.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">Term</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">The term of this Agreement and the rights and licenses granted hereunder shall commence on the Effective Date and shall expire when the last patent included in the Patent Rights expires, unless terminated earlier in accordance with this Section 8. in case this Agreement expires due to the expiration of all patents included in the Patent Rights the Licensee, Dyadic Group Companies and their sub-licensees shall retain a fully paid up, worldwide right to utilise the technology covered by the Patent Rights as they see fit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#333333;">Notwithstanding the foregoing, the Licensee, in its discretion can terminate this agreement by a written notice to VTT at least thirty (30) days prior to the termination. In case of termination of this Agreement for any other reason except expiration of all the patents included in Patent Rights all user rights and licenses granted to the Licensee and to Dyadic Group Companies under this Agreement shall lapse from the date of termination. The termination does not have any effect on payment obligations accrued prior to such termination. Furthermore, the termination does not have any effect on the user rights of sub-licensees of the Licensee or sub-licensees of Dyadic Group Companies, provided that the Licensee has paid VTT the sub-license fee regarding each Sub-license Agreement and that the sub-licensees comply with the user rights and limitations thereto as stated in this Agreement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font><font style="font-family:inherit;font-size:10pt;">/(9)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">7.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Default</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">If Licensee shall at any time default in the making of any payments, or shall commit breach of any covenant or agreement herein contained, and shall fail to remedy any such default or breach within thirty (30) days after receipt by Licensee of written notice thereof from VTT, VTT may, at its option, cancel this Agreement and revoke the rights and licenses herein granted, by notice in writing to such effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Both Parties shall have the right to terminate this Agreement immediately in case the other Party essentially breaches the terms of this Agreement and does not remedy such breach within 30 days after it has received a written notice from the other party identifying the said breach. In case of termination all rights granted to the Patent Rights shall lapse. The termination does not have any effect on payment obligations accrued prior to such termination.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">7 .3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Insolvency</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">If the Licensee becomes insolvent, enters into bankruptcy or liquidation or any other arrangement for the benefit of its creditors, this Agreement and the licenses herein granted shall thereupon automatically terminate</font><font style="font-family:inherit;font-size:11.5pt;color:#484848;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">7.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Survival of Rights</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Provisions the legal effects of which are meant to survive the expiration or termination of this Agreement shall survive the termination or expiration of this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:center;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">MISCELLANEOUS</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">8.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">All notices, documents, statements, reports and other writings required or permitted to be given by the terms of this Agreement shall be sent either by mail or by e-mail, properly addressed to VTT or Licensee at their following addresses:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">VTT:</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Address: VTT, IPR Management </font><font style="font-family:Arial;font-size:11.5pt;color:#363636;font-style:italic;">I </font><font style="font-family:inherit;font-size:11.5pt;color:#363636;">License Agreements, P.O. Box 1000, FI-02044 VTT, Finland</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">E-mail: IP</font><a style="font-family:inherit;font-size:11.5pt;color:#363636;" href="#"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">.</font></a><font style="font-family:inherit;font-size:11.5pt;color:#363636;">agreements@vtt.fi</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:108px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Contact person: </font><font style="font-family:inherit;font-size:10pt;">[*]</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Licensee:</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Address: 140 Intracoastal Pointe Drive, Jupiter, FL 33477-5094</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">E-mail: </font><font style="font-family:inherit;font-size:11.5pt;color:#363636;text-decoration:underline;">memalfarb@dyadic.com</font><font style="font-family:inherit;font-size:11.5pt;color:#363636;">, </font><font style="font-family:inherit;font-size:11.5pt;color:#363636;text-decoration:underline;">JLatiuk@dyadic.com</font><font style="font-family:inherit;font-size:11.5pt;color:#363636;">&#32;or HZosiak@dyadic.com</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:108px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Contact person: Mark Emalfarb</font><font style="font-family:inherit;font-size:11.5pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Julie Latiuk or Heidi Zosiak (phone 1-561-743-8333)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Invoices shall be sent to the Licensee to the following address: 140 Intracoastal Pointe Drive</font><font style="font-family:inherit;font-size:11.5pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11.5pt;color:#363636;">Jupiter</font><font style="font-family:inherit;font-size:11.5pt;color:#484848;">, </font><font style="font-family:inherit;font-size:11.5pt;color:#363636;">FL 33477-5094.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font><font style="font-family:inherit;font-size:10pt;">/(9)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">8.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">No Waiver</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">A waiver by either party of a breach or violation of any provision of this Agreement will not constitute or be construed as a waiver of any other breach or violation of this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">8.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">Governing Law and Settlement of Disputes</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">This Agreement shall be subject to laws of Finland excluding its principles on conflict of laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">Any disputes arising out of or in connection with this Agreement which cannot be solved amicably, shall be submitted to arbitration procedure and shall be finally settled under the Arbitration Rules of the International Chamber of Commerce by one or three arbitrators appointed by the said the Rules. The proceedings shall take place in Helsinki, Finland, and shall be held in English.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">8.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">Entire Agreement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">This Agreement constitutes the entire understanding of the Parties relating to the Patent Rights and supersedes all prior understandings and agreements. No modification or amendment of this Agreement shall be valid or binding except if in writing signed by each of the Parties.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">8.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">Assignment, Binding effect</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">No rights hereunder may be assigned and no duties hereunder may be delegated by Licensee except with the express prior written consent of VTT. This Agreement may not be transferred in any manner including to a successor in interest by merger, by operation of law, assignment, purchase or otherwise, except with the prior written consent of VTT. Notwithstanding the foregoing, in case such transfer or merger is incident to transfer or merger of the entire business of Licensee, or if the business operations of the Licensee related to the Patent Rights are sold to a third party, a transfer is allowed provided that the Licensee promptly notifies VTT of such transfer. All prohibited transfers and/or assignments shall be null and void.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">Subject to the foregoing, this Agreement and the rights and licenses herein granted shall be binding upon and shall inure to the benefit of VTT, Licensee and their successors and permitted assigns.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:48px;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">8.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">Counterparts</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#323232;">This Agreement has been drawn up in two (2) originals, one for each party.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sC0A794539E6FDE1949688D214D8ACEF0"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font><font style="font-family:inherit;font-size:10pt;">/(9)</font></div></div><div><br></div><div style="line-height:100%;padding-top:4px;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#2f3633;">IN WITNESS WHEREOF</font><font style="font-family:inherit;font-size:11.5pt;color:#575a58;">, </font><font style="font-family:inherit;font-size:11.5pt;color:#2f3633;">the Parties hereto have duly executed this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:51.70940170940172%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:6%;"></td><td style="width:12%;"></td><td style="width:75%;"></td><td style="width:7%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;color:#2f3633;font-weight:bold;">VTT Technical Research Centre of Finland Ltd</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">17.3.2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">/s/ </font><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Name: </font><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Title: </font><font style="font-family:inherit;font-size:10pt;">[*]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">Licensee: Dyadic International (USA), Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">3/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">/s/ Mark Emalfarb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Name: Mark Emalfarb</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">Title: CEO</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>23
<FILENAME>exhibit211form10.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s767ad2e522ea4901bbc29e041677d60f"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 21.1</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:15%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="3" style="vertical-align:middle;background-color:#4f81bd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">Dyadic International, Inc.</font></div><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">(Delaware)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #4f81bd;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #4f81bd;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="3" style="vertical-align:middle;background-color:#4f81bd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">Dyadic International</font></div><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">(USA), Inc.</font></div><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">(Florida)</font></div><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #4f81bd;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #4f81bd;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #4f81bd;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #4f81bd;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #4f81bd;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #4f81bd;border-top:1px solid #4f81bd;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #4f81bd;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #4f81bd;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" rowspan="3" style="vertical-align:middle;background-color:#4f81bd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">Geneva Investment</font></div><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">Holdings Limited (British</font></div><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">Virgin Islands) 100% - Inactive</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="3" style="vertical-align:middle;background-color:#4f81bd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">Dyadic Nederland BV</font></div><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">(The Netherlands)</font></div><div style="padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#ffffff;">100%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>a31image2.jpg
<TEXT>
begin 644 a31image2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#H17AI9@  34T *@    @ ! $[  (
M   *   (2H=I  0    !   (5)R=  $    4   0S.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MR:7,N4W1O
M=P  !9 #  (    4   0HI $  (    4   0MI*1  (    #,C   )*2  (
M   #,C   .H<  <   @,   (E@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
MM1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!
M"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=8
M65IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ
M_]H # ,!  (1 Q$ /P#Z1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3
M<I8J"-P )&>0#_\ J-,N;F"SM9;J\FC@MX4,DLLKA4C4#)9B>  !DDU\R+K-
MWXD\>Z]XQM[N.PNH-0@M;37;PR11:!I\FU()Q!+D2BY25^" $;,A*!]P /I^
MBO&_!_C+Q79^+)=-U_BRBO8+:^L;F=;F;0DE3;:H9U53<M/*Z?-F0HB?.Q9F
M9?5M+UG3M:CN7TN[CN1:W4MI.$/,4T;;71@>001^(((R""0"/7M=M?#VE/>W
M<=Q<-RL-K:0F6>Y?:6\N*,<LQ"D^@ +$A02/,])\?:O:^(;RZ=$UB'4I-B1V
M-T\]I$XVK'-!+C LT3"W$VPE9B<+@XKE_'2#Q5\3WO?$EE-JFB1++8:/H,$1
M:75E@<_;GC8/F&6)TW#&PS+&L8)#',EKJO\ :]K/K]S9Z3K*C4AK0U1)9H-T
M4#.B:D+<NK^7;*HA:V +.0#O.0S 'N&E>(=+UO=_9MSYN,E=T;)YJ<8DCW >
M9&<C$BY1NQ-:5?/-Y)<6EG+X@L9--L(_M?\ ;T5F\^Y96;D:VT>YIUAE!\@V
MP!*"0L#O7-;OB/XR:KI7AI+#4H;/P_XB5#:ZM=2%KB'2+EXGDMCL16\T3+&Q
M&TN(N-^_&U@#TG7_ !AIVA^= DD=WJ,2"3^SXW_>R#KY:@ YE9 YCC.#(48#
M 5F7@)?'^LZ/XMU#4'MK/6EF\N&/3=/DE2Z>W$I:-8H'4L]W''+*]Q$0FU6M
MSE><\CI5O!>,UQ+>R/:NYT:XN6N!/*RR2@MX<C$C@RG,F1>!N%'#*JY#K6U.
MLRMX:L8=-ETQ;>6"7PKY[6@N9[;8YTU)L$F2W=VF:Y##SVFQ]Q6,8!]"65[:
MZC9Q7FGW,-W;3+NCG@D#HX]0PX(J>O&_A]XVU(W&GS:UJEO?6FI0RS2ZY<3R
M)%>I!&QFDAA;:EJL#[8FW(AF#>9QM(/IL_BC1H8PT>I6<Y-JE\4CNX@1:%@#
M<_,P'E*"6+], XR< @&O4,=W;2W4UM%<1// %,L2N"T8;.W<.HS@XSUQ7@/B
M'QOXLUS4%SKT?AZ*PM8[K5?(5UAT,B2-XIWEQ_IAN(F<);<#YU#*60M3O#OB
MU/!5QHWB#5[E1X9NY9;>)[NY^U7FEPSP_:0\XBRSS7DJ),<AA&JX!&_Y0#Z"
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%K?C70/#LB)JMZR,\
MK0_N;>2?;(L8E,;>6K;7,9#!3@L.0#3-)\=>&]9TV"_L]4CCMKG<;=[Q'M3.
M%V[F190I=1O4;E!&3C.:\@\4VUSJGQ$\>Z'9FS\S5KW38/(+,6N<6T9_TG9*
M'BM5)"ET4,TDR+O(!0Y">*]"NO$MW;61C\1:'J3QW5S=ZC>6\8U.1)8_WNHR
MNH>TMX"52*$1*LAX&X/M8 ]\7QGX7=8V3Q)I#"6-Y8R+Z([T12SL/FY"J"2>
M@ R:^8?$>H6WBGXJ7?BJSL+6WANKB$PS:[#))8F%#Y$=U,&M2%MYE'E@;P5D
MRQ8;01F^(/&NEV6IV5W9ZC?7UZ;XWLMVTGGVT\F_Y-32V6=1#<KM*BWD&S9L
MR%Z'G([:^^*7CBSLM/LOE@A$=S?6>GL9Y8$8E[VXC5V,DY#9;#$NVU1EB,@&
MK<>.K:QNDU#PU<7URND1"T\/7FKI$USIBA5=O-VPLLP;]['"I<B,;CM7Y2,W
M2/ FK^*_L1O4:RU+6=2V1ZIK&HK'',9(3*H,10RLTAY67)5BP7&3FJ,T6E>$
MY-4TR>Y75;ZXM);1KFQ:)X+=_,1XY8)E9O,5T4HX*QLJR,O)R*MVW@?7/$'A
M.7Q9=)_9V@PS?9+!6+M&&D=RL<9D;;' LK8:61U4%FY=\J0 U#4/#FF>&;"V
MTRSN+>ZO-PU,07T=Q]NL6F2:-&E_Y83QM$$($(SC>>"%-Z['BKQ1KDHT2Q_X
M1BU6&;0[334F:U01QD/+9O(V SXD:1S,5WG=WVI5[2X++3[^_P!%T:*.[N[G
M[;YK:9JT5O:W'EA'-N\K2F3["L(F<L71IBP4X:+<MF^^+=K>6 ^T6LEU;+IC
M:8=-N((!#?IEGC681%/*%L77RWC0%]C$>268  ;INFZ7X-OK:*?2;&ZU6"T:
MYM->M]0N)(0ZRRF/4$C$>TQ1/'L=6#>9MC:-6!/F:4.NZIH_AY_[6N]6TV_U
M>4:V+&:/F.\\^,C59#'!@6V8I<V[*Q^1&4-O5TYA]>\276C/X>\0W]GIMOJC
MS2:S>7,J3ZC=&U^81SB20R(Z>5LBC/E!B<?Q%JK:;HFG7.IQ7NK?;/%3K:RZ
MIKYTVYW/;VTJ1A9 [ %KB)Y6>0?,G"@GB3 !T6C:YI4^HOK>M^*]--[8V[0V
MEQ=PO=_:92OE21WBM;">>&XC$A5@S>0A"G!*J<C5/%.E1Z5IBZ5I;2Z7,K->
M:7*7\RUL1>"7[&+G:N^-Y5WB3!=2P3=PV^EIM[9WGAV\AT$+8WYTHR:GMLD:
M5A"&CVVC[]X66.0/<?=PL<K99,QU=\52ZCH'BS2K*'4M%U6&>4W@MK1F72=L
MMUO^RJSLJ/;!XE8]$5BX)RA- $-KJFDS6U_>/\/8[BWCU".6=5NRC1Z>T>Z*
MW"A=P_U08W*C>W(8_O#NJSZSK%[I]Q8^)M(UBYMYM3FUK51"_D&9WC*HX!B9
M(=I\XE@N'#8/W%(A\)>)-5G\3:1!)?6)9%^QF77;J4VKVN%*V\P+;?(4KD*
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M-D3RVV#E&(PR3^&(/%/@477A;R[:\T"U2?4=%6_$XDC, >;4E9G"J6VQH\*
MLA50<' J]:W:7D5S/IEUJ$@N9H9;62WN66ZN"+ZYDC6Y>-')U)RJB(@$!&+'
M@&LA/ -E_P (U=PSWTEOXIM[J,16SJYANU:*,M:Q!8RS7B2S1H\9QMW<\!F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***R/$>L7>C::9]/TR34[E\QV]M&),RRG[BEE1A
M&IP<R/A%.,D Y !KT5YOK?Q5NM$T[499=$M)KG38Y9+R-=4V):B, 8E9X@R-
M*YQ  A\T$-\HSC!U[XA^-%\(M<65JT-XVFS7DT0L5L[W3XHI&#74D4\DB!,*
M%6'YFE&]E=,84 YJWO9M6\=>,M,U_4K6.]COKZ%O[3L5W:?IQ,9@N6EE94DM
MU8(%MLA6,QD(? %>=_%;Q,8/$VLZ7Y6K6TLUO;P31W4X2662,89[Y-K)<.0
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MV9V"_>4URFL>(;+3K5X?#-WYC7^GQVLLD4,42QVK!6:UF3[.ADG611FX#?.
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MN=:T_75^' \/^$8O[.TN?3%UG4-(F9'EOK5 C#5/,)81[RB@VZR;D*# 8,2
M#@;;Q#?1ZE<SZ3]E328KA9Y-,G:.&&[C29IHXYH@R^> 21@[B!A00 HKI8[F
MZ^(?CR :Y<KX9\4)J6Q[\O*KAC,[")8 C2F="VQ"9% 6*./@[27>)O"H\-WK
M:]X3U7^P9]/11>6ZW+QR6+/#_H^R7<6E:Y0.^U ?+#%7*JI(R]3U6].IZ;X6
MTG48=$M@KV+M'J8:WCBN'7<LMQ%(T<R$!'D?:OS,RE=D<:J =!9^,XKF231_
M%\-UIFI6-Q%'<"QNEMC))%(#)=@N"JZB'49F=@)(_,3*,5+7?&/@Q/&DL5WX
M9TO3;34[NX:/3K?2YHX['4+=>HMAY",\D98^:\K*!L)7(8+'H'4X?$?PXL_#
MK7T>MZK--<:79Z7)K$<0LQ$ EI#\KI%,>3*+H*0YC$.?W@QS_A;4=5;Q+JGA
MWQ"T?B1-8?YXY;YD'B5H91# B7LA^5$9)'1UQO*&,[MRJH _39;;7X+?2]?D
M:"_T^W,UJET(KB99%B5XY6=X/+&F*FY_(C+G#,P5UP1B:=XHM_!,YTRWBL-1
MM4D>:4;OMEKJ#>24"7$?[L2Q^:B2Q9(,(D8D.QP.F\=>%I]5N8/$OAR[U#^W
MK;3(=6E-Q*1/>6D<>3JHD,K"'+@(MNIWJ%4@#H,W5+R3XA>#3XAUZ_U"[;3I
MD.K3Q.\W]EARZ*T<$LRHWVAS'E8RHC\C@!6"@ ],U6/2H-0M;+1]:34'$(\Z
M6XOUEU:]9YV6.<E5VRR",Q&SD+@H9$)&U\KZK\,8!%X.\Q4A7S;N?<1;&*X9
MD<Q$W3$_O;G,9\R08!;.,@!F^8O &NZE#&/"5QJ'VVP5WMQ8-=Q[7N)F=&M8
M2LI#QSJ-AG53Y33%QM!9I/J3X;6L%CX L+2UT6/04@>>,Z;'J O1;L)W#+YP
M)W'=DD9^4DKVH ZFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "LV^\0Z7IM^+2]N?*E$+7$C>6QCMXE#'S)9 -L2G8^"Y4
M,58#)!K2KS_XA-::7JEI?M';BZU%$M8WNY+CR7GMY1<6PV1!B[JPE98QM,AR
MF[D"@#-L/BZ_BC2FGT.SM]-AN89;F"YU"[7S;:RB5EFOI($# *DP"+'OS(=Q
MRBJ2/)G\?^+=936W\2:U?#2X--1;HG2$:WBM)X%-O.5CN &N)F=!Y+;D'FL3
M\J%5U8[O57\J?5IKB163^T=6FM[J[6!]03 A%PP$@ANX\(/L2B-"ZQ#>?W<2
M^?\ Q!U>72)%M-&EO(+/[4+N$237#317^V)I9YYBR@WP&P/&H9(O-(&'R: .
M%U^YAEU:>"REMKBSMYG2WN8+,6_VA <"0KC(W ;MI/RY(&!Q6MJ175-6?1_#
M6EV]H9]OVBUBE$L,$L2D2,EPTC!HL(9?,9L(&<!MFYGT/##ZAX+TAO%UA-:V
M-UM4:;?7-M*9I)&$BR+:J?W4JJ/EE>0$)N&WYBNZ#P/;7-O-)-+#>):3(DUV
M+=+I6N=/#NMP'>'A;4E=LCX9@57:IPXH VO!ND*;O^RM%M+35[RY+V\D4CQL
M]W<HOF_92B79#6@:)9!<!1EE RH.1AQZ3!K^JP/8?91HWF^5+>W/D::TTB1O
M+L<[I$MW==T<9X1R@)!97(Z_7-7M+?1[O1-,U&/3[R^VPO)>FXOF32V3SX(H
M7,9,-HD;(W ,S-@LD87 YFP2?2-1M?#=_'8Z5&]N\VKV^KO?VB3E5>1$NXT<
M%F7 :(1#YMZ9RQ*@ P?$4L*_9;>QBLQ9F%'BFBCC6:<#*AY@LDGEN0.8]P'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"#Y@RI(959FC\<0Z%J]SH<WA1+A]:OD:+4].^T/?S-<^9\LIN,;97F# E8P
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M22?OR78=^,*0PKU^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$@5(U P%4#@  8 %1:;I]KI&E6FFZ?%Y-I9PI!!'N+;$10JC)))P .2<U9H
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M)!;@$ 9>M_M!>$[;4X='\+B;Q+K%S<?98(+3$4)F+A%4S/A=K$\,N\<9Z8)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-0@OB;H*A^_:O);EK9D)WR[BOFLF(L*0M9GAV;1=6T^2T\20P2)=W4ETZZ9
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M(9O-A2, W7FQV[,EJ/)BDX+X8/C_ %C9]$^$?Q<_X6I_:_\ Q)/[*_LWR?\
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MZMK5W'9V-JF^::0\*.G;DDD@ #))( !)KQ[Q7\5K[QY9Z=X=^$DK+J&M7%Q
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M15VTBTI[JU6_O+R&W9&-U)#:+(\39;:$4R*'! 3))7&YN#M!8 I45I>1H?\
MT$=0_P"/+?\ \>"?\?7_ #R_UW^K_P"FGWO^F=9M '5^'/#]U;ZK:7]PMTEA
M):37-O?16,LD+,L?S;@T1#Q1.P$WRL-BR ;LKNU-7TW2]<FO?$+V]O9V\FV(
MQ63M;PQEG,:W\<8M/^/(.GEE1F7?@,VYAGDO#\Z0ZY;1W.IW&EV5TXMKVYMR
MVY+=R%EX7EAM)RO.>F#7<_$YTT[1+'3196*+?W<VJV<RV^)/L3DF%H"#^XMI
M#)(PMCED9"S,=X  #PAHT5B]O?Z/+:ZC/J$0"V[3K=6MK'#/$MP^IPM""EL_
M,J-P4VH3D@,+<.JO]K<P3206T]K;NK>+(UO+6$&TG;?<9C.ZX^1?LS*F6B"C
M:0Q4^;:-JCZ+K-MJ,=K9WAMWW&WOK=9X91T*NC<$$$CL1U!! (ZV5WT[2_.U
MUG53IL<*6\LT%T9I7M7-N[P^:KA5AN%,<V#Y6 FUB* -32M-B\/_ &[^RVU5
MDU#4HK5[>SM VIV%K]IEB:&1Q'^YNY H"QJ^UU$@<<H#5T]TT>2XU"6&STR^
MM+7[/<O+;-;@&!;,>79EXF9-0#%Q(Y4A"Y<$#YJU8(M374IHK**9]2@OHK*Z
MB-U$+A;Z2^N@J/,X*RWFPL4NU7$:@C;G##,UB32],DU#1]=,WV&S5$.EV=[Y
M(-]%':Q. BAE29/WX>Y='2;:^Q5)!4 X998KA)+C4)?,V92.UC8QMEQ(P9?D
M*!%?!9?E)W87&2RFE:-J.N736^E6DER\:&64J,)#&" 9)'/RH@R,NQ"CJ2*K
M+<.MK);@1[)'5R3&I<%0P&'QN ^8Y .#P2#M&+UI<W6DV5TDL-Q';ZO9&,$
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MD/7M]% &;HGAW1_#EJ;?0].M[)'P9#$F'E(&-SO]YV]68DGJ36E110 4444
M%>)?&'XD>!KFWU'PE';7&M>)9D:UMSIMON>UNU(,(\P%3D2D?*A8@JRD9X+K
MBP^,/Q%BG\.^*]/L?"&B7+;KF]L9EEFDA&0;? E;)?*Y/R#"MG(.P]3X ^"O
MA/X>W2W^GPS7VJJK*+^\<,T890&"* %4<'G!;#,-Q!Q0!\XZA8)X&^(6F)\0
M=,\2VFC6DC3VL%E(80DRLK;X6,TH;>%B:39*K*\A 8;%W=K!\/O@)XGO[J]T
MOQK)I=J-BK9O>K;"-L<E3<IO8'@]3@YYY 'T;K.C:=XAT:YTG6K2.\L;I-DT
M,@X8=>HY!! ((P00"""*\YO_ -G3P%<VLT&FPZEHZSJJ3&QOW/FH&W;&$F\%
M2P1L$=8T(QSD \+U*;X;>'=4L)?AIJ'B3Q'K\#Q?V?'=0))9NS2X:!XS&DAW
M*7X0<EQ@YSCV;X5_ ;0?#F@Z;J'BS2(;SQ*K-/*99C+' 3D*@0?(2JX.2&P^
M2&("D=3X-^#W@SP/,UQI6EK<79:-DNK[$TL11 N4)'R$G<QVXR6/\(55[F@"
M"TLK6PB,5C;0VT9;<4AC" GUP._ KS3XR_$>W\'R:-H5_#(FG^(//M]0OHW=
M)+2W*A&DB(5LNID#]#PF,?."/4JQ/$G@WP]XO^Q?\)+I-OJ/V";S[?S@?D;N
M./O*<#*'*M@9!P* /&/A9\([/Q+;Z-XSURRAL;3RFBMM&%J@$]JJJL+S,$0O
M(Q#N[X(E5U'RH2A][LK*UTZSBL]/MH;2VA7;'!!&$1!Z!1P!4]% 'S/X;T#Q
MM\4/BA=W?B>PA31;#6//>^O; !C%"\D1L820"T3?,KH25!4LWS,1)] Z!X6T
M7PO80V>A:?';10H8T8EI)-N<[3(Q+$>@)X  ' %:]% 'DGQ<T/Q)HWB33/B/
MX$M)-4U>PA_LZXTTVYF22W;>0X52')5WY"YZ@\!6SS<'Q2^-=]<VVGV'P_MW
MNY,NUQ-IUU;P8,:L$S,R!64AU)+$,<!>@+>_T4 >#0_#7XD_$B22X^(WB2^\
M.VA813:193I)'<Q^8SG:L;!$4*RH#)YKDJ2W&T5ZCX'\!:5X'TA(+.*":_<,
M;J_6UCA>=F8N0%0 )&&)VQCA1@<\D]110!P6N_!OPKK/B"UUN"!M+O[>5I?,
MLX(&65BB(-Z31NI"B,;0  "68?,<UF0?L^^"7*G71J6OO'$(H7U"[*M&H9V/
MS0B,L27/+[B % P!BO4** ,[3/#VBZ(TC:-I%AI[2$ES:6R1%B<9SM SG _(
M5HT44 9U[X>T74IO.U'2+"[EW*^^>V1VW+]TY(ZC P>U6K:RM;)=MG;0VZ[0
MN(HPHP"3CCMEF/XGUJ>B@"MJ6GVNKZ5=Z;J$7G6EY"\$\>XKO1U*L,@@C()Y
M!S6)X,\!:'X#M;R#0(9%%Y-YLDD[^9)M PD>\\E$7A02<#/)))/244 %5-3T
MG3M:LS9ZSI]KJ%L6#&"ZA65"1T.U@1FK=% '-_\ "N/!'_0F^'__  5P?_$U
MKZ7HNE:);F#1=,L].A/6.TMUB4\D]% [D_F:NT4 %%%% 'SE\<?BE>W6OGPA
MX9EDFMT<V=W;6S)-_:DY:$FV81N)HT"LR%E(+L7CQ\I8>C_!KX7VOP[\+)+<
M0,NNZA$CZ@[RB3RR!_JE(X"@DYQG)_B("XZNR\%^&M/UZXUNRT'3XM4N)FGD
MO1;KYN]EVL0V,KD=0, EF)Y8D[= !1110!X)J/A37_'O[1>[Q'I%Y!H6E?O$
MEN(2(6BC+ 0Q2#,<JS^8DDBN X&^/(V?-[W110!Y3\<OBOJOPQM=&70[&SN;
MC4GF+27FYD18PF0%4J229!SGC:>#G(Y&W\+?%'XNZR9?&5]>>'O"!=U^Q1K]
MBFN(N5_U&7.2T:DB9F WDIN%?0E% 'A/CG]GRQC^'&GZ-X(@N)KFUU,7-Q--
M.K3SQ.-DF%+)$S*-A4$H,(V""S;N?L_C!\;EM6@;P/'=7%FD*S^;I-P+AMX<
M+(T:N#AC%)EE4*",<9 KZ6HH \2T?X>_%3Q4VEW7Q"\;7%E:1Y:[TFT"PO*/
M-(>%VMF165HU4A\DKO8;1@DZ%W\,?"WPM^'_ (AUG3M&7Q'J$%HTJ2:XB73*
MJQ[0@PH C"Y)  )&03@#'KM% 'S)X*^#TWQ&L[*;Q+;W%IX>MK5Y+#6!!':Z
MGJK2NI#3@M-E$"L$)(^4H5R"<>_>%/!>A>#-(M[#0;"& 0Q"-KCRU$TYP,M(
MX W,< GZ=  !6[10!S_CKPG!XY\$ZEX<NKF2T2]10)XU#&-E=74X/4;E&1QD
M9&1U'@^B^'?C]\.6CTS0UAU?2;:53'&9X9H'W!1M7S"LJ(#U V@$,>A)/TQ1
M0!XAIOPC\9>-+JPU3XJ^+;YX8EV2Z)#&D(D3;\R,T#[ "Y8$@%FC"Y*$[4Y/
MX[:)I?AM_!_@ZSL[?1/"8>>[:Y>9F,DF?G3<(Y95(5@ V&4F5<C$?'TW5'5=
M%TK7K5;77-,L]2MT<2+%>6ZS(K $!@&!&<$C/N: / I?B5K?CJXT7PK\%K"^
MM-&\I$U*Y*F.>U4M(K(]PPD6(E%WB4;W+$8RP*GO? OP;MM%NGUOQQ=Q>*/$
M,T,<?GW, :*V"J,A WWF+ DRD!FZX!9RWI5M;06=K%:V<,<%O"@CBBB0*D:@
M8"J!P  , "I* /%-?^"6MV_C.\UCP1XBNK2UUBXDNM5@%^;*X,I9V417$<+D
M1YD.4*_PC)8X*.D^#GCVXU..9_BQJD<,=K;+Y<BO.DDJ(%D#QEU1D)4'Y@Q?
M<P<$@L_M-% 'F6F? 7PK:74,NJWFL>((8'\V*UU:[66(297#$*J[\!<;6)7#
M-\O-6OB-\)M.\7^&IH-!$&B:LC>=;W-O&(T>0;<"0*.?N* X^9<<9&Y6]#HH
M ^8-9TWQM8V*^$-17Q)- ++^TKJTTW46FW0NLL,=FSP6+;9"$^8L3%(R2,<,
M^X:^C>+OC9HGANPL=.\)V=Y;Q?9[:T6YTZ=)@DGF!5<#RD01>5Y;L50#Y&Y5
MPY^B** /";*/X_:W>7!2\M](ADA:2"XG^SK 7,V5VQ&W:=5\HX"2@.",LP/R
M5QGCO3;0_';3(?BFFISQWUM;P+;:;?&[:7#(JOA8(\1.PD#1QJ'WK(R@!D#?
M5-9NK^'-#\0>3_;VC:?J?D;O*^VVJ3>7NQG;N!QG SCT% 'B7@SQ)??%']I$
M:W'8:AHMEX9T^:VEMK@,QD8NZ!91P(G._<4.[F C)QD>WR:!H\TKRS:38R2.
MQ9G:V0EB>I)QR:=I6BZ5H-JUKH>F6>FV[N9&BL[=849B "Q"@#. !GV%7J (
M[>V@M(%@M(8X(ESMCB0*HR<\ >]2444 -DC2:)XID62-U*LC#(8'J".XKQVW
M_9C\%V[ZB!<ZILND1;=UN-LUH<OY@5@-K*ZLJX=6( //S<>R44 >?>$/@CX)
M\&R+/:Z>^HWB*R+=:DXF958Y("X"+WY"@X)&>37H-%% !1110 4444 %%%%
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M:,\J>G?@@@D$'(()!!!KT#0;S4?%MW?:7)Y>I1_VF-0N-3,/F1PW4MRH>[2
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M,+-"Z:6[QJOEDB)MUQ&"A\PJ>A6O.:]6U2Q&J^%;;2)]-CLDWQ-#J5W<1/\
M8I&N/*VI*9'D&E*CMMD 9?./WSG!\VN]*GL=/M[JZ:.-[AV46K$B9%\N.19&
M0CA'64%&_BVMZ<@%*BBB@"[=ZWJM_:QVM]J=Y<V\21QQQ37#.B+&&$:@$X 4
M.X4=M[8ZFJ5%% !1110 4444 %22W,\\<,<\TDB6Z&.%7<D1KN+;5!Z#<S'
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M2UNX='LXH(Y+F"2&"\9A=2.-/M501V]JB;RDL$7F$"["E97E(#;MX;+^(/\
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M>2:X:-G? L[^5\B*]!*[DSMRX10OR*P!ZE1110 4444 %%%% !1110 4444
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M_*>5VM\[?-]W$L?P9\5QZ?#$?BKKDMTKSF2>22ZQ(KQJL8VK<C!C8.X.?F+
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M?_51_B!_X//_ +"I8OA D<<ROX_\>2F1 JN^NMF([@=RX4#. 5^;(PQXS@@
M]$HKSF3X.AY7=?B'X^C5F)"+KIPH]!E"<?4FM#_A6G_%5?VW_P )KXP_X_?M
M?V#^U?\ 1?O[_*\O;_J_X=N?N\9H [:BO.X/A$]M(7C^(OCPDHZ$2:PKC#*5
M/#1D9P3@]0<$$$ U(OPJF3RL?$3QQ^ZA>!<ZI&<J^[).8OF;YSASEEPN"-JX
M /0**\VD^#4<UA>65SX_\<7%M>PF">*XU5)5="02/FC.,XP2,$@E>C$%NO\
MP3T_Q3I\=EXA\6>)K^")80HEFML_NA($)809+8FDRQ)+9^8G P >ET5YW<_"
M"*]NI;B]\;>++EYG+.)[JWD0JQR\00PE1$W&Z(#RVVJ&4[5Q6T_X'V&E:98Z
M;8>,?%D-CI]T+NWM1>0F)9 ZR E##A@'16"L"H;) RS9 /3:*\MM?@+H=GJM
MCJ,&OZX+G3YI+BV+"T9$F=MS2[#;E6?./G()&Q " BX;-^SSX-NH<7LVI7=P
M\4\<]Y/)$T]P9'\P2._EY,BN<AQAB/E8NGRT >J45Y6/V>_";V?V.\N]2NK5
M+1K6*%A;1K"3M_?+Y<*_OOW:9D.68*%<LO%.O/V?/!M[_:?F?:(_[2A@B?R+
M>TC\EHMG[R';"/*9MAWA<*V]OE^[M /4J*\]M/@=X#MKJ>6;18;M);M+U(9H
MHPL,JK@A=BJQC8\F)B8\_=11Q3;;X%> K:ZBNQHT<MW&X<RRJC(_.7#0[?)P
MWS9&SY=WR;-J;0#T2BN"M_@E\/K>W-N?#=K-$%E2(2C+1I(H##?]]CD%E9RS
M(6.UE& '7WP3^'.HVMI;W'A2S1+--D9MV>!V& /G=&#2'Y1RY)ZG/)R =W17
MG\GP+^&TLUY*WA:W#7F?,"SRJJY</\@#XCY ^YMP,K]TD&U?_!SP!J=FEM?>
M&[>54\H+)YLBR@10K"B^:&W[0B*-N<$C<06YH [:BN$MO@I\/;/7XM:L_#D<
M%]#="[B>*YF5(Y V\%8P^P $<*!M[8QQ4"? CX:I%#&/"\)6&4RJ3<S$ECMR
M&)?++\HPK9 ^; ^9L@'?+<P-=26JS1FXC19'B#C>JL6"L1U )1@#WVGT-5=2
MUO2M&C,FL:G9V"!#(6NKA8AM#*I;+$<!I$&?5U'<5R3_  4^'LD=I'+X<CE2
MRM9+2W62YF81QNTC,,%^3NE<AC\RD@@C PVW^"'P\M;2YMK?PZL<5W;BVG N
MY\R1B590"=^<[T4YZ\ 9QQ0!TU]XL\.:7:VEUJ>OZ79V]\GF6LMQ>QQI<+@'
M<A) 8893D9ZCUIJ>,?#,FJ2:;'XBTE[^)G62U6^B,J% 2X*;L@J%8GCC!STK
MEI_@1\-;@$2>%X1\L:_N[F9.$7:/NN.<=3_$>6R>:LZC\%_AWJFH17ESX4L4
MEB4*JVVZWC(!)YCC*JQYZD'(P#P!0!J_\+'\$?\ 0Y>'_P#P:0?_ !5'_"Q_
M!'_0Y>'_ /P:0?\ Q55H/A3X"M_LWE^$-'/V:$P)YEHCY4[>7W [V^0?.V6Y
M;GYFR#X5^!DA:.'PQI]ON\\&2WC\J0B9)$D7>N&VE97 7.%&-H&U< %G_A8_
M@C_H<O#_ /X-(/\ XJC_ (6/X(_Z'+P__P"#2#_XJJVH?"GP%J=A):7/A#1T
MBDQN:VM$MY!@@\21A6'3L1D<=#18_"SP5I\QEA\/V\K-9+8.+IWN%D@5U=4<
M2,P?:43:6R5"*H(50  6?^%C^"/^AR\/_P#@T@_^*H_X6/X(_P"AR\/_ /@T
M@_\ BJHV/PD\#V%U=W"Z#'=/>OYMR-0GEO$FDR3YC),S*7^9OGQN&]AGYCEL
MGPA\#.P9-"6W*W8O8OLMS- +>8#&^((X\HG"YV;0=B$Y*+@ T/\ A8_@C_H<
MO#__ (-(/_BJ/^%C^"/^AR\/_P#@T@_^*HM/AYX4L[^^O(]$MY9K^::><W1:
M==\P(F*K(6";U.U@H 8  Y  !_PKCP1_T)OA_P#\%<'_ ,30 ?\ "Q_!'_0Y
M>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\545S\,O!-S:RVQ\+:7!%.ACE6UME
MM_-4C[K&/:6 .& /1E1AAE4BXW@;PD]N]N_A;16AD:-GC.GQ%6**50D;<$JK
M,!Z D#K0!!_PL?P1_P!#EX?_ /!I!_\ %4?\+'\$?]#EX?\ _!I!_P#%59U#
MP5X5U>_DOM5\-:/?7<N/,N+FPBDD?  &6923@ #Z"C_A"O"O]E?V9_PC6C_V
M?YWVC[)]@B\KS=NWS-FW&[;QG&<<4 "^-?"K^5L\2Z.WG0O<18OXCYD2;M\@
M^;E5\M\D<#8V>AJ"3XA>"XF"R^+]!1BH8!M3A!P1D'[W0@@_C4Z^"O"J>5L\
M-:.ODPO;Q8L(AY<3[M\8^7A6\Q\@<'>V>IIH\#>$E695\+:*%GB6&4#3XL21
MJ5*HWR\J"B$ \#:OH* *LGQ+\#1J&;QCH)!8+\NI0L<DXZ!NG/7MU/%2VOQ"
M\&WNH1V-GXKT6>YE9%CBCOXF,C,<*JX;YF)&,#GD>HIR^ ?!ZVLEJOA/0Q;R
M.LCQ#38=C,H8*Q&W!(#L >VX^IJ/_A7'@C_H3?#_ /X*X/\ XF@!D/Q)\%7-
MQ;6]KXITFXGNK@6T,,-VCN\A;: %!)P3T/0Y'/(HU'XD>#M(NQ:ZIXBL;28K
M(P2:3;D1N\;]>X>)UQW*X%/_ .%<>"/^A-\/_P#@K@_^)J[!X3\.6NLG5[70
M-+AU-G>0WL=E&LQ9\[FW@;LG<<G/.3ZT 8D7Q<\!SQS20>)K.1+=!),R;B(U
MW!=S$#@;F49/=@.]2M\4_!2>;O\ $%NODPI<2Y1QY<3[=DA^7A6\Q,$\'>N.
MHJ[<^ ?!]Y=2W5YX3T.>XF<R2RRZ;"SR,3DLQ*Y)).234?\ PKCP1_T)OA__
M ,%<'_Q- %.'XL>!+B(RQ>)[$PK*D+3%BL:.^XJK.1M4D*Q&2.%8]C3;;XN>
M [RZBM;/Q-9SW$SB.**+<SR,3@*H R22< "KW_"N/!'_ $)OA_\ \%<'_P 3
M4ESX!\'WEU+=7GA/0Y[B9S)+++IL+/(Q.2S$KDDDY)- &?!\5_ ]R ;;Q':S
M K(P\L.W$:[W/ Z*OS'T')XH;XK^!TA29_$=JL4D7G(Y#A6CWE-X..5W@KGI
MD$=:N?\ "N/!'_0F^'__  5P?_$T?\*X\$?]";X?_P#!7!_\30!6;XI^"D\W
M?X@MU\F%+B7*./+B?;LD/R\*WF)@G@[UQU%,?XK^!XXII9/$=JL=O*(9G(<"
M.0[L(QQPQV/@'GY6]#6S!X3\.6L9CM= TN%&M7LRL=E&H,#L6:+ 'W"S$E>A
M))QS6@EE:QRPRI;0K);Q&&%Q& 8XSMRBGLIV)D#CY5]!0!S/_"T_!7]J_P!F
M?\)!;_VAYWV?[)L?S?-W;?+V;<[MW&,9SQ4C_$KPC'(\<FLQH\;S1NK12 JT
M*[IE(V\%%(+#^$<G%=%:V5K911Q65M#;QQQ)"B11A L:?=0 =%&3@=!FIZ .
M6@^)7A&ZC,EKK,<R+:O>%HXI& @1BK2Y"_<#*06Z @C/%$GQ+\'P/=I<:[;P
MO90I<7"2JR-%&Y0*Q!&<$R1X]=P]:V[#1=*TN.WCTS3+.S2V1XX%M[=8Q$KL
M&=5  VAF520.I )Z5/#96MM*9;>VABD,20ETC"DQINV)D?PKN; Z#<<=30!S
M=S\3_!=G&TEUX@M8XU6%F<[MJB:/S(LG& 60%@.X!]#277Q2\#V-Y<6EYXHT
MZ"XMKD6LT4DNUDD+[,$>@8<MT4<D@<UUE% '#?\ "Y_A^VKQ:9!XDAN;R:X%
MM%':P2S"20D !61"""6 !!P>>>#5=/CM\-I+B.%?%, :0$J6MYE48)'+%,#H
M>I&>,=1GT&B@#S\?'/X<&-)#XEC17A:="]K.NY Q4XRG)RI&WJ<<"DN?CM\-
MK4H)?%,#;X5F'E6\TGRMC .U#AN>5/S#N!BO0:* .=TSQYX=UG7H]&TZ\FEO
MI;07T2&SF19+<XQ*KL@4H<@!@<$\=:Z*BB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(0Y$,F/,(!SE6#1@-(,[.+>C6T-[IBG4)K>"%\V$7EFS$LKEUE0-YC*\*YW
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M,YXKS_\ :4UZ^T3X1M#I\GE?VI>QV,[AF#"(H[L 01][RPISD%688YK(T_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;1;N.\L;I-\,T9X8=._(((((."""" 10!>HHHH **** "BBB@ HHHH ****
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MX#8#%<YKV3XV:5/K/P6\2VMJT:/':BZ)D) VPNLS#@'DK&0/?'3K0!P6O?$
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M@_O 3P,@<@@'5_ _XD77Q3\*ZM8>*K:WN+NQ\N&X(MP(KJ&1"!O4D@L2DFX
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M0J;386=B@ $Z_NAM^7< <AXCOI_$?B:Y>R5KB*)9###:EWAAB0-(_D(RJT<
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MBGXH^)=S=R:MH=I::99P;'OK?>%DN2^0BAB>/+(R,D@@$G#J!S/[5GB/3O\
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M9X]D:JQ+*V^0X9BIR21@1K+I%WX?O)]7O-1EUM%BBLE5@\3H-B@.6&5$<<;
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M7*S;W@<3:#\0[)[FZM=*BO(C'<6^L[89[OSD1H3%D!FOB5B^U#.&9H^&.P@
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MKO*<DKP" %0%F9MH SA<,S>S?%WX=S_$OPC:Z/:ZA'8/!J$5T9)(RX*@,C#
M(Y"R%AZE0.,[@ 4/@EX@\5>)?A<==\47*:E>75S,UD=L<6Z) $"G8H _>))R
M03@BO$;3XJ?&C7OB%+X7T_5(;?5GNYH39+;6OEP,A8NH=E;*J%;G<Q(7JQZ_
M2/A+P[:_#?X<VND1W$UY!I5O))),R@-(26D<A>@&6; SP, D]:^4/ 'B;PW<
M_&R]\7^+M3O/#]N;J;4K8VC.Y\YI@WD.40ED*-(K<+D<9&<4 ?0\D/Q;MOA
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M D1F^;.>O0CZGN_'M@FC?!/7].T6VC%O9Z%-;PPR3, D*PE?O$,250$@'[Q
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M )E:*5Y5/F%N!N89&TY /(SD &SJ:>-$^%:1Z3):R>,/L,*/+,%\L3D*)7&
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MW<IAEM[11'$&105D15QL;C!QP>#P<EOJ*VN$NK6*XB$BI,@=1+&T;@$9&Y&
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M>3((&, Y.<+].V4=Q#I]O%?7"W-RD2K-.L?EB5P/F8+D[03DXR<>M $]%%%
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MHTP0WS*&)\.O"]E(FFSQQWEY!J$/FM]NWR-=NORZ&XC8*I;:V;P (&5EP"I
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M1WL-P\TKJ=V3(A8MO)4XVDH/D'/S'$_B/]GOQ9XC\4QZ]J/Q&:[U"*+,5V;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP00$"SWGQ,F\0Q/#XSTN'61):6UD;K<J7<,4&2IAF97*N[LS2,P?>&P-H P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8W<MXP@U;]GSXO)<^%I+J+P_J#1W*6OFDQW$2M^\MV9E(W*2P!^9E61#G)-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#SNW^$]K))KD.HW<GV2YT]=&TN2V<K<6>G;5+6Y;[C#>&"ED9]OWG?=
MA>RL?#VEZ>Q>WMM\IF6X\VXD::3S5@6 2;W);=Y2A2<Y(SG)8DZ5% $=S$\]
MK+%%/);/(A59H@I>,D8#+N!7(ZC((]0:^5#INJZ7<R2^(-%M8=7TO4KF]U'7
M[E)8Q8RM=1[=312T:3HXW+';[3N:V+*#N=#]7UP_CGP;#JNHIXBGGO98M-L9
M6:PM(C+,\J O#-;C<%6X1BX4LK@[R,#.: /$TU2[TZ%[QCJ%JUQ"WB@(T5O*
MT+%$0:P & W2EF0699E4N[%E4)59;VZTF_LHY+W_ (0I/#-[*,R6PN%\."X%
MPHMT5V+WS7 5)"X!" ;EPI(7J=&^'6M:GK,]W:IJ%CJ$EZ+F&[O;=D2PAN;8
M-]HPP7??;[>(3!"T8,I QR4]9B^&'@N*UM+9O#]K<6UBTK6MO=;IXH#(Q9]J
M2$JH).< =AZ"@#Y_U9)?.U"VUG0X;O4=4U*#3HH)]9EDF=1<VTKZ2"S_ "L"
M1*UV-R'?@D/)A<O_ (1G3C']FU.[T_7=<M8?*DTZZB^R>;<6UKY4EJ]P)%$<
M=HBK(9 RK<9(W$H"OT;X[\$P:[:W>KZ=!(VO1:?+;1+'*$2_CP6%I,#P8G?&
M[E6ZX9<FO%H+ZPU_P_ ;1Y&A=%B\S5F:'10(B0%GP%D6R#%Q:;CO,PD5^4H
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M2( QW=2<YSSUK-\,^ X?"VO?;+&[\RV&F6^G*DBR>:RPJJH782")L!6/^J#
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MU5CRN#7O]?$^F?$'0-%_:$?QQ86NI2Z/)=SW+0S",7 ,T3"3 !VX#R,0,_=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?<J\;T?]I3PYXA\5Z/HFCZ)K#MJ-T+=Y)DC7R=W"L%5VW#.-W(PN3SC!]DH
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M_&'Q6TCQK\1]*\NVM?WSS7,4=I-*\61#F*,*Y8/M.74 HF,D;0?IN@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,CQ/X8T
MKQ?H%QI&N6L<]O,C*K-&K/ Q4J)(RP(5P&.&QQ7@]K\ _B3H^IR67AOQVVE>
M'OM;&%(=2N1*D)?AC&B*ADVX) (!/<#FOH^B@#B?AG\+='^&.E7$&ESW%W=W
MOEF\NISCS"BD *@X506<@<GYL%C@8ZO5K$ZGHM[8+.UNUU;R0B95#&,LI7<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>a31image3.jpg
<TEXT>
begin 644 a31image3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#H17AI9@  34T *@    @ ! $[  (
M   *   (2H=I  0    !   (5)R=  $    4   0S.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MR:7,N4W1O
M=P  !9 #  (    4   0HI $  (    4   0MI*1  (    #-C@  )*2  (
M   #-C@  .H<  <   @,   (E@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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ME$:PBX ;;)'&S .KXQ@JO94 %%1W-S!9VLMU>31P6\*&2665PJ1J!DLQ/
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MDS)Y9W_,%=G4L* .IU'XS:CJ.I6G]HZ?8ZG86+-MCDA:#[=MA\N$S('8+&"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BN;\?:YJGA_P )RWVAKIXN_.BB%QJDZQ6ELK. TDS%U.T D87+
M%BN%/-<1!\:+Y83+=:#;_9$TQ[D7DEXUN9KH(2MEY11PERY 80^8[!&#9;H0
M#UNN$^,>JV6G?#N>#48Y)(=0FCMF5+5[@;!F64LB.C;1%%*Q(92 ,YK'L/CK
MHTFEVEYJ=J\+SVLCM:V27%S*MRK-_HG^I51(%0EM[)C*D;D.^O%_BQ\2]/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC(QRC>N? C4#J/@&ZD=[625=2E65HXF6XW%$;;=.T<?FW"[@KR!<-M!R3DT
M>ET444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%5M0O5T^PDN6BDF*X"0Q8WRNQ"JB[B!DL0
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MJT8'RH!6OJ%J/%$<46EVVGW%^EK)9^;I.F.B:TZMY^;:)+-?+DB#(LA.TL@
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MWLHI46\@,.H6K?<(O4 \M7E(>1 F/D7) W+0!Z!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJQ0Y".&;:I",-W!% $?BK5=.USQ1?:EHVCQZ)9W+ATL(I?,2$[1NVG X+9(
M  S@# %4K."UN+JUBN;O[(DLP2:9XBR0H2!O^7+-C+$@#/ QG/%[4M*U6:YG
MOG:355F\RY>_B+2B5?,=3*Y(WKN:-S^\"L1R1S5*:^NSIL.ES.1;6L\LR0E
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MC9:'I<<8$* SS(FTW,V 'E;))RQ'3)P,*. * .@HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEW$GMI-6TK7[5=:CGLQKUPCKC6M24RZTK QO'-+'+']C$,64!)C^TKCY>2E
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MZ.2QR6<E\A]Q;O?AQ\/-3^*WC"^\;?%&*ZGL%8?V?;R*\<%TK9=?+#D.(%#
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M41M,5[J>TNI6B+,X#Q,@DWA6 6Z4(%5%C"@C<9+'Q):VM];QC4-8TV#3]/\
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MR, [V\8"XD;: <E8P17!OK:V,<]G'"UR6N)+>TF)1&"[6<L3AGR8D),@7ID
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M_@;XP\0>-_AU_:OBE%-PMV\$-PL'E"YC55_>8^Z3O+KE0!\N,9!H ]&HHHH
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M7GOB#XD_%VTC1-8>Q\-7=_;@Z=;6^GO))/<)(5-NJLLI9W5P<CY 1$-R$N&
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MU)U0&)5!8 $YR#\C\D8^Z.2>-[4-2L=(L)+[5;RWL;2+'F7%S*L<:9( RS$
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MOSA0$1 #@[;X6^//B)'+<?%CQ)>:=:W#\Z+I5RJQI&K.51E :,G>48.2[!4
M.204]%L?A3X"T^$Q6_A#1W4[>;BT29OE14'+@GHHSZG+'+,2>MHH HP6VE>'
M-&,=K#9Z5IEFCR%8T6"&!>69L#"J.I)^IHTK6]*UZU:ZT/4[/4K=',;2V=PL
MR*P )4E21G!!Q[BOG'XL>/O$?Q*\71^"_A>][=:>ML'N3:*8OM9=<$NY(_<;
M74?-M4ECG<-AKV;X3?#W_A6O@=-'EO/MEW/,;N[D48C$K*JE4XSM 11D\DY/
M&=H .VHHK@M>^+/A^*WN-/\ "&I6OB#Q'+;LVGV%@?M FDVN5RRD+M&PLPW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "H[FY@L[66ZO)HX+>%#)++*X5(U R68G@
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M8L?E.(^!PPR:%S=:=>RM.Y-FWV9O+MK:Q3RXY-Y"Q;C)N*["#YK;GSP0V-]
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MS9,L0 B5AYN&"  *#]W QBNML=%TK2[J[NM,TRSL[B^?S+J6WMUC>X;).YR
M"QRS')SU/K5ZB@#S;QO\++KQ7X^L_$5IJMO9J+)-/FWV8DGMD65I?/MI"2(Y
M\X0-MR@9F!W "NN\(>$-'\#^&X-$\/V_DVT7S.[<R3N<;I';^)C@>P
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M 9R!_$=HR>_7K5N@#YWE^)?QVN?[2L%\#1VMS!#+B>'2YB R\$H[RE'(&2N
M^X@ *P-<C\.-4\ :;#=VWCWQ1<16T$UM%_84<,DUI<&W0L6=T\T21FXEE<(K
MJC,-Y7#!5^MJX^[^%7@V^EN'GTA@ERL*W$$-Y/%#,L7^J5XD<(RI@!05(
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M@8*,G:&R<8% 'I=%>;?\7O\ ^J?_ /D[1_Q>_P#ZI_\ ^3M 'I-%>;?\7O\
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M7FW_  IO_JH_Q _\'G_V%'_"F_\ JH_Q _\ !Y_]A0!Z317FW_"F_P#JH_Q
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ME=Z@Y7(Y&>HHGU*QM?M/VF\MX?LD(N+CS)57R8CNQ(^3\J_(_)X^5O0UPC?
M7X;M:QVK>'Y#;QNTB1'4KK8K,%#,!YN 2$4$]]H]!4B_ [X?)Y6S1;A?)A>W
MBQJEV/+B?=OC'[WA6\Q\@<'>V>IH ["XU_1[09NM6L81Y0F_>7*+^[*NX?D_
M=*Q2MGIB-ST4XSU\?>#VM9+I?%FAFWC=8WE&I0[%9@Q52=V 2$8@=]I]#7-S
M_ 7X;W4@DNO#\DSJB1AI-2NF(5%"JN3+T"J !V  [5)-\#OA]<0M#/HMQ+$_
ME;D?5+ME;RD*1Y!E_@0E5] 2!@4 ;G_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\
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MCMV:5;MIVFA)@1S;#%Z!L=YAG<#&.H", 8'VNUM4M[>=(83(R><8(A=+;PO
MJL\8:8HTKARS*0I1XTVLARJY=\]K-,)K1/)\W<\ENJ$1P$NV$0L[,RA=O+'.
M20<XW'432;K5[6UM-)2;4KYI0(K>SBE<39@1F$<8B'SQ[,2-N.[<I (!<U->
MTJ'2=5>&QO?[1T^3+V=^+>2%;J+<5WA9 "/F5E/4!E8 G&: ,VBBB@ HHHH
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MR;XN^)M9T/XB?#>QTC4)K2VU/53#>11D8G3S;<;6]L.P_&@#UFBBB@ HHHH
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MZ>0R,$*>6RXW54^T:S)I6G6T>L6HF\\0V.DV\UT+2(K*DBV2-=$SQRE',K<
M%" 2,@Q6MEKL%S<W-AIES")+9IGBM99=EU9L8U:&5A<;A9*$=?-!(.,,W0H
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MK+\1^)/&WQ+^#^K^,+OQ'9^'=#LDCM_[*L2S&]DP(Y1*Z$N@<RX6-LJ05W
M"5@#V?Q+\0&TCX*MXXM8 ))-.@NH(9(]X#S; BL R\;I!DAL@9(SC!X[PM\0
M/BIX]\%)K_A;1?"\(B\R.2*\FF+W<B ',2@A4!SM =^HR2!S5+Q?J5CJ/[&R
M_P!GWEO=_9M,TRWG\B57\J57M]T;8/RL,C(/(S76_L^?\D)\/?\ ;S_Z4RT
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ML_O$R0#N_P!G7Q2=4TOQ!X=ANYM1L-!NU33]0G=MTUJY<1+L;E !%D#C 8#
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M!U[(OB^TND6&:RU%I9HY(F D:<!ML1[_ "A6W@8  ;'K'C^PLOB+^SRVK:S
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MEMA#>8PP6^8 '+>#;:+0/C7X9UGP!X6U_1_#GB&V,$@U*(/'(C!FPC9<J/W
ME^9]Q ) "$9^G*\I\._$OQ[XD\0:99O\-+S0[*68&\O+Z5V"0X?. R1X;*CK
MGC^'Y@:]6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMG%$JW.IWR?:-/L8Q&X#3P&-A,^!B%"RCS%0?-G%>A:7>3ZCJMU+J=G'9:A
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M>:3:JEV)X!(09"@+Z 5N7-M!>6LMK>0QSV\R&.6*5 R2*1@JP/!!!P0:DHH
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MBL 0& 8$9P2,^YHTK1=*T&U:UT/3+/3;=W,C16=NL*,Q !8A0!G  S["KU%
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MP1]""1^--HH *LP6$UQ]F\M[<?:9C GF7,:88;>7W,-B_./G;"\-S\K8K44
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MT/$>I32:EJ$>D:A(LNM[;..66XDAM],L?M$J26T,BDPR6>\1J)<JN$(V+DX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3'&9I!D*B2OC;G>?E+*&(48+!10!N_#FTLM4U"\TV^L[R9)4CDDE@=UA2-)
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M953A&"_>R1]Y6V=;TR*W6.V\.07%S'96IFO#-:%I#OBBWW0)A4K;/O7RMY+
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MLW7A;3](\.W.M1Z]]BU2WO9##;VLB$7%G)&1#- QD!<>:KQ2!6D9 3N *$,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^SK-+'4(X8W-S?6$(BN(I)TC.[R L<*K<*$RI4%R,&@#?TWPM9O?7>B+H?\
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M29Q9PARO!V^9<*6 /&1QD$9R#7:65Q)=6<4T]I-9R.N6MYRA>,^A*,RY^A-
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MP,$[5.ZL9+?XZ7]]IEW<7?A/3K:WF#W5A;M(&ND##*,[1R[<@$ H01NYR0,
M'JU%9'A>+7X?#L"^+Y[.?5R\K3O8@B$ R,45,@'"H57GGCDD\G7H **\-^*O
MQ0\4#3]:N/AQ-'9Z;X9F6'5=3GM\M+<-+Y1MHED0J=A8,Q]UP0,;_5_!6H76
MK^ ?#^I:A+YUW>:9;3SR;0N]WB5F.  !DD\ 8H VZ**\;TS6OB;\4;I=7\):
MKI_A3PD9IDM+IK9+JZNT4E YC<$#YT/&8R Q^_@$@'LE%>.IXL\>_#37K*#X
MFWFFZWX;U.^^R1:W $MY;5W_ -7YJ?*H3",S<';DG><!3[%0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5Y-'X&^)'C"TEN_&GC:;P[+)$6M=-\.?NUM9"BX,DN=T@!W;H]Q
M&>5<#BO6:Q/&/BNQ\$>$[SQ#JL5Q-:6>SS$ME5I#O=4& Q ZL._2@#S&UO\
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MN)\0_#C_ (3#7KB3Q7K^H7N@';]GT"W;[- /E&[SF0AYOG577)&TCN#7;44
M>+>,OA+9>!- NO%OPHN9/#6KZ1:S33?OGGBNX NYXV64N,@+N7C&X#(SAE],
M\$>(3XL\"Z-KKA1+?6B23*D;(JRXQ(%#<[0P8 \Y&""0<GQ3XC^.O&OB?[1X
M:O?#&N>$/#RS2Q:MK4%E+>[K=<C=D*@$7!+E6.5Z$C*O[MX=.C_\(W81^&;B
MWN-)@A6"TDMI_.CV1_( 'R=V-N,Y)R.>: #Q%KUCX7\-W^MZK)LM+&%II,,H
M9L=$7<0"S'"@9&20.]>2>$/A5:_$FP@\=?%4W&IZEJ\/F0:>LYBMK.W8@PJ@
MC;=]WYN6_P"6AW OECN_M%7:6_P0U>)PQ:YEMXDP. 1,C\^V$/Z5ZA0!XSX4
MN-4^%_Q<M_ .H:C?:CX8U>T#Z)<7S^:]O+&@#0^80JA<(PV*&QNAP!N;/LU>
M9?&:V@:Z^']TT,9N(_&%C&DI0;U5BQ90>H!**2.^T>@KTV@#R;QW>CQS\5-,
M^&#JLFBK;C5-<,$Y\QU4DQV[;1\BEO*8YP2'7!7@LFL_!/1?#EG)KOPVFO?#
MFM6$+2Q^1=RR0WFTJ_E3*S$LAV8P"!\V2&P!6CX)_P"2[?$__N$_^DS5Z30!
MD>%/$$'BKPCI>NVOEJFH6J3&..42")B/FCW#&2K94\#E3P.E:]>2?LT:I]O^
M#=O;9S_9U[/;8\K9C)$O7<=W^MZX7TQQN;UN@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "JFJZ59:YI%UI>JVZW-E=Q-%-$Q(#*1@\CD'W'(Z
MBK=% 'Q/#/J-_#<O=R-J#7,K)-_:6H-&NJ"-RJ?VF3>K]F:, >4"!N(P"W4W
M[JYU"RENX8;V_P!51YP?M!CD=F8.N-1C4WF]-07:,184^4,L I:OIS_A6/A5
M_&7_  DT^EV\NH)-]HM_]'BC6&4CYI/D13(Q;YLRERK<KMKIK:RM;-IVM+:&
M!KB4S3&*,*99" "[8ZMA0,GG@>E 'RE)X8\9Z9X;?79M)U+3]-+&_?7+7,FH
M0*4YO%3[;N66=7Q.G"*J*>2OR\_Y=T(HX?L]J(X5=8[1=3)L[(/PT=I)]O\
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MK@\G3]7UJ2YT^W\\/E2\A,NT$A=ZM&/[WR<@8&<3X(:A=2^/OBEIKRYM+?Q
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M.T';M4DA%P 6OC9I^F-\/)];O;6>34M%DCN-)N+0#SX;II$6/![J7*;E[@9
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M0 S[0"2%903D8'4^/O!T?CWPG+H%SJ-Q86T\T3SM;HC-*B.&*?,#C..",$$
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MD,JQ3PSEUW.K%E(7 "D\@,T9., C9O?@QX>?4+B]\/ZEKWA>>\E:6\.AZF\
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M&\%Z#%H_AVS6UM$8NW)9I'/5W8\LQP.3T  &  !LT44 %%%% !1110 4444
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MYFY8Y/&<#H/$6IW6B^&[_4M/TNXU>YM86DCL;8@23D?PC/\ 0$XZ!CA3I44
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M=\0K-!=?VC&%O5C'F*>0!&K(H^<[@&.S.[Y3U$OC[XF0R0H_PAD)F<HI3Q#
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M?\1;;5;N#3_A=]NM(IG2"Z_X2"WC\] Q"OL*Y7(P<'D9Q7H%% 'AOPW?XI^
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MBR,HWX&2?X,CJ"/8J* ,3PIJFNZOI4D_B?PY_P (]=K,42U^W)=;TVJ0^]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4A'9R/NG"Y4D9&"&JWHOC>[G\6?\(UXJT)M!U*6)YK)OM:SP7Z(Q#>5( I+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *YO\ X6/X(_Z'+P__ .#2#_XJNDKRO7O WA*'XL>$+.'PMHL=
MM<6FHM- NGQ!)2H@VEEVX)&XXSTR?6@#L/\ A8_@C_H<O#__ (-(/_BJZ"VN
M8+RUBNK.:.>WF0212Q.&212,AE(X((.017/_ /"N/!'_ $)OA_\ \%<'_P 3
M7G^O:<_P5U^Q\2Z+>7C>#+B9;'4-%DDFD@TQ96W-=1 %@H# 94J>790?G&T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?$7_)9/!/\
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MJ](HH \DU#3/B'\3+ZTTWQ1X>T_PMX7@NH+B^MI;T7D^H!&9S$#&0H0D("&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*2.^T>@J2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>auditreport2018001.jpg
<TEXT>
begin 644 auditreport2018001.jpg
M_]C_X  02D9)1@ ! 0( E "4  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0* Q\# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            4&! <! @,("0K_Q !8$  !! $$ 0,"! ,$
M!P(* !<! @,$!08 !Q$2(0@3,10B%3)!418C81<S0G$D4E:!E:'2&)$))31#
M4V)UDK/P-SA5<I2QLO%4@L'1)B<UA41&8V5S=.'_Q  < 0$  @,! 0$
M         0,"! 4&!PC_Q  \$0$  @( ! 0#!@4# P,%     0(#$002(3$%
M$T%187&1%"(R@:&Q!C-2P? T0M$CX?$5%B5#4W*"HO_:  P# 0 "$0,1 #\
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MH&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H./VT'Y(_^$]_^F;3_P"P(?\
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MO1\4>HN.N+OKN6TL<*3?V/\ \=9'_(ZMCL\UQ4:XJ_SG]W[A[<?_ $/L9_\
M9D7_ ."C6K/=])P_RJ_*%CU"XT#0- T#0- T#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
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MH&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H./VT'Y(_^$^_^F;1_P"P(?\
M]V_K8Q=G@O&_]3^3Y(U:\^]&F5ONH::0IQU:@A*$CDJ)\  ?OSK&UHI&Y[0S
MK6;VBM8W,OL?8?9M.W=4;*R;"LAF(X<!\_3-_/MC^OQV/^[]-?)?'/%_MV3R
ML?X(_7XOMW\/>"1X=B\[+'_4M^D>RW[D;A5^VN..V<XAQT\HC1 KA4AS_5']
M!\D_H-<GP_@,GB&:,5.WK/M#L^*>)8O#,$Y;SN?2/>7PWE.46.97LJWM'R_,
MD*Y)_1*1^5"1^B0/ &OM'"\-CX3%&+%&HA\"XSB\O&YK9LL[F43K::3AS^Z<
M_P#K#_\ :U$LJ_BA_0)MQ_\ 0^QG_P!F1?\ X*-:D]WU7#_*K\H6/4+C0- T
M#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T
M#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T
M#0- T#0- T#0- T#0- T#0-!Q^V@_)'_ ,)]_P#3-H_]@0__ +M_6QB[/!>-
M_P"I_)\D?[^/ZZMZ>KS[Z>]/6R @PT9/?,%,U]!,&,X!_)01X=(_UC^G[#S\
MG7S3^(?%YS;X3!/3UF/V?6OX:\"C#$<;Q,?>_P!L>WQ;-$>299C#N7@KKQV.
MOE.LDWY-OJ/W(KS:4;U([=?B6 M6[!4Y,IU%UP\\]VE<!?\ [I /_?KZ1_"_
M%?9>(G!:>E_W?/\ ^+.!GBN$CB*1UI^SY./SKZR^*.-!PY_=.?\ UA_^UJ)9
M5_%#^@3;C_Z'V,_^S(O_ ,%&M2>[ZKA_E5^4+'J%QH&@:!H&@:!H&@:!H&@:
M!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H..=!QV_KYT'//
M]=$'8'1)SH'.@<^= YT 'G1#G1)H..?ZZ(<Z)<<^= YT#G0.?&B 'G1+G0-
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M_JPP=,VEA93'1_/A*$:41^K2C]A/^2CQ_DK7M_X8XSDR6X6T])ZQ\WS[^,.
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M:^C.^.<?25#N[RSL]];*A5<97#KXT2M<CM4,5M<5*W5O^X9#BFEE(/MI'R/
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MO36\WH&_J)]>T^YU'/">RDD\#D^/ZZG<J;8<>2>:]8E'?V*[??[!XS_P>/\
M]&FY8_9L']$?0_L5V^_V#QG_ (/'_P"C3<GV;!_1'T/[%=OO]@\9_P"#Q_\
MHTW)]FP?T1]&57;5874/EZ!B%%"=4GJ5QZQEM1'[$A(\:JR4KEC62-Q\5N*E
M<,\V*.6?AT2/\&T'_P!0ZW_[$;__ #:U_L?#_P#VX^D-J<^6?]T_5%S=H\&L
MI*I$O#,?E/KX[.OU;"UGCP.24<ZVJ5KCKRTC4-3)BQY;<^2L3/O+P.RFWI'!
MP/&>#_\ V>/_ -&K-RK^S8/Z(^D+C'8;C,H::;2TTA(2AM X2E('  'Z :Q;
M$=.STT2:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:"(RW&H>98Q;4-A[H@V<5R&^65=5]%I*5=3YX/!^=&%JQ>)K/95X6RF-UU
M](N(S4EJ;(N&KQTA[[52&XQCI\<>$]%*) ^5$G]=9;4Q@I$[^.T37^GFBB5C
MU>]:7,Z&:=^@8:?D( C0G5(46T=4#[A[:0%GE1 ')/ TVQCAZQT^'[IJ3L[0
MRKN1:K,SZI^ZBWJ^'N$_4L,)8;X''Y.B1RG]3YYU&UGDUC]UB@XXW#I)%6[+
MFSV7R_W=ER"I[JZI1*0L<$!/;JGCX  _319%8B-*0WL%3R(EBU;V]U?ORH+5
M:U+L)*2]$9:<#C?M*0A/"TN)0OW""HJ0DDGC3:C[/$[W.Y[.\G8JML,5RFGG
M7=U*DY. W;6_O-HER&PW[8;!2WT0CIRGA*1^91^23J4^1$UFLSW[RECM:PY3
MIK7,@R%<=-3^$\IG^VKKV"@_RA*>'AP %C]/'&HVSC'$1K<^S&8VB88I[!G^
M(+LW,Z6U.>ODOH1+4ZT$I;'VH#9;"4\>V4%)!5R"23IMCY.JS'-.Y]?5DQ]H
M,;&)+H9L3\7;<^H4[-L4(>DN.ODEUTK*?"U$_(  X  X &FTQBI%>76V/_8U
M4LXS&H(=C;UM7%K8];'9@S/9#/LK"T/IZ@?SNR1RKX4/!!!(TV>3$5Y:S,,5
M6R-<]7\OW%L_>_BJ+H7RW&Q+3*0W[22 $!OH&N6_;Z=2DGD>>=3MCY$:ZS.^
M^W)V4BQJFNB5F29#3R(OU7NSXDM'OS#(7W?4]V04*65?<%A(*3^4@>-1LG#$
M1JLS#QMM@J*PC-0XLZTJ*TUD>GF0H$A*&YT1DDMMN\I*N>%*25)(44K4">#J
M=Z)P5GX+7FV#P<[QXT\Y;S$4N(7S&(2H=3R .01QK6S8:YZ<ENS;I:<<[A@[
M>;95FVL::Q6/2GD2UI<69*PH@I' XX _?6'#\/7AXF*^K*^2<DQM+P,5AUV3
MVU\U[AG6;$=A\*7R@)9]SIU''@_S5<_OX_;6VUXI$6FWK*KWNS-7?Y)+M7K&
MT9:F2H<Z37L/(2P](BE/LK5]O;CA"04]NIX!XY\Z;5VPQ:W-,_Y#NSLU3PG[
M:5!FVE;86D:1'F3X<H-ONEUTN>Z5A/\ >-E1#:O\*3U^--IC#6)F8]4WE.''
M)8$!ENWLJB7!>2_'G0'4AT*"2@A84E27$D*/*5)(/SX(!TVSM3FC43J5:7LA
M7L5-/&K;N[JK&M5*4FXC2$*EOF2KM(]U2T*2ONKA1/4<*2DCC@:;53@C41$S
M$QZ_/NYF[&U#XPQ,6UNJMG$R%0&8<E 2I?13:EN]D**U*2M8)Y'/<GY\ZG9Y
M%9Y==.5Z9GLQ$SAA#,S(\BC(;LS:MB--3PESJ$I0$K0I);01V2D@\*//SQQ&
M])OAC)&IF>^WO<;-8_DN(FBOD.WRBQ].JUL4M.3EI[]O+O0?KX\ >--IMAI>
MO+;K\W=[:> YN-69BW9VD:770UP(]<PZVF$EA905H]OISP2VV?S?*1QP/&IV
M>5'/SQZ(Z[V,K;I+2EWM\Q,,!VJESD2TJ?FPW'"X675J0? *E!*D\*2%$ ^=
M1MC;#%O67>[V,H;BS?D-O3:V',8BQK&MA.)3&G-1CRRAP%)( 'VGH4E2/M/(
MU.T6P5F=_P"=%NA8O$@9/:WS9=,ZR8CQW@M?* ADN% 2/T\NKY_?Q^VH7Q2(
MM-O64-@^VC&#W-]9,W5Q9NW4@2I+=D^AQM+@2E 4@)0GC[$(3\GPD?YZ3+"F
M.,<S.^['W"V@I]R9T.59/S&5Q6U-($9:4@@GD\\@_MK1XCA*<1,3?T;F/+;'
MV6?&J&/C%#!J8JG%QX;09;4Z05$#]^!\ZV<=(QTBD>BJTS:=RI][L9B^0Y/)
MOI;$DV,F;7SW5H?Z@N0^WLCCC\I[$*3_ (O'/QJW;6M@I:TVGO.I^COF^Q^+
MY_:6-A;1WU2;"O9K9!9>Z!;+;X?3^GSV''/^KXTV7PTR3N3/]D,8W)GNS+EB
M0IURH?I2([WM@,.N(<) X\+2IL=5?X>5<?.D3HR8*99W;VTD[W;B!D,.X@RI
MMB*VSJTU+D%N1PPTT.X*VT\?:X0O@J\\A*?'C3;*V.+5FL]I>$G:>DEVTFQ<
M,H2)%M%NE\/?;]1':2VWP./R]4#D?J?UTVCR:;W\8GZ,->R>/.&"5*F_Z'^*
M>UP__P#AZBJ1SX\^2>O[?UTVCR*=)^?Z]W!V2QXPWXW,WVGD5B%?S_/$!04Q
MQX_<#M^_]--I\FNM?+]'O&VF@0\T7D+-E9MH5,<LA5)?"8GU:V?96Z4A/97*
M//52BD*)4!SIM'E1%IM$_P#E4,,]-M? PEJIR6PFW,M5$:)1]\>W$96H+=3'
M(0E0!6E!Y7V/#:!\#C4[4X^&BM=7G<ZTMU5M0Q6HMG#?W;]C:OQ7Y=B9"&WE
M%@)"$IZ("4I*4]5) X()_<ZC:ZN&*[U,[G7Z.:W:2NJ\S>OV;"S]MR4_/%47
MQ]&F2\V&W7.@2">R03U4HI"E*4 ">=-IC%$6YD54[ 4-;#GQ'9UI/BO5#U#%
M;DO)/T$%TDK99(2#_JCLKL>&T#GA.IVPKP]8B8W\/R2,K97'YD]R8X9ONN6%
M=9'J_P #W802&/''Y>$CL/U_IJ-L_)KW_P Z+\-0O<Z!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:!H&@:!H-(>KG?ZS]-VV,;+JVFB7Q59QJYR'*D+8_OU=$K"TI5^4\
M<@CR/U'ZATPOU'JD;TY_MMED&#4R\2J6+QZ]BS"J"J(X.27?<2DL+0/)!*@4
M@JY''&@MJ?4/MO\ @1N7,RJHU6);,%4F4][*4/O(#C*%=P"GW$*2M!/ 4E0*
M20>=!DQ-]<!G8W;WS655WX94S/P^>ZX[T5&DE24I86A0"@XHK0$HXY5W3U!Y
M'(>%AZA-MJBBK[F?FM+7U<Z2]"8E2Y:64*D-<^ZP>W'5Q!2H*0KA0*2"/!T%
M=QKU9;>9KNC0X/CMN+J9<4B[YB;$0I48QPZEI "^/*EJ+G@?E]I05P> 0O&<
M[KXCMJJ,G)L@A4RY#;K[:)+G"O9: +KQ !*6FPI)6X>$I[#L1R-!J.R]3=S9
M^IES:W$<>A7;-;"KK"SF/32TLQY+A]QQD\="&6NKG')+G;JGCCDA*[E[_P!S
M@WJ5VNVPC4T&7"S9J:\;)U]:'(8BMEQ8]L)(7V' 'E/!^>=!<*/U$;9Y'?0:
M2MSJAF7$Z0]$C06YR/>=>:_O6@CGGNG]4_/SXT%"W ]6M+CV[>!87CKM;DJ[
MS(G<=M%LR5!5:\AKW%<$ I6I/Y5(YY22 2#XT&P6M_=O'D72TY=5ENGCO2IS
MH?\ Y;3++GMON=^.JD-N?8M220A7A1!\:#MC^_6WF4R+%FLS&HE*KZY-Q(4)
M(2A$%0Y$H*5P%,_NX"4@@@D$<:#'3ZBMM?PAJT<S.IBP'9K-<E^4][*?J'6P
MXRV>X'!<;(6CG@+20I/(\Z#V1O\ ;=/85(RYG,Z>1CC$S\/<L(\I+J!*[!(8
M 3R2Z2I(#8'8\C@>=!K[9+U95.XN,9Q=9%^'X[#Q_,I6(Q7FY*G19+;]L-*:
M04A1<=+G :2%*\>.=!>K'U&[8U$2ME3LZHHD>RA.6,-QZ8E(D1V^0XM'/R$$
M$* \I(X(!T$7*]3V##<K!L,K[(7$W+J]VU@3('\V*8J1PASW1]J@M7*0$D\=
M23QXY"%]3?J N=B[/;6+5TT&X&8Y)'QOF7(<9^E<>_*]]J5=TC@\I\'X\Z#K
MMGZHX&07F[5-E[$'%W-MIK,:SN!-[5S[;J"M#B7%I24*'!2IL\D'@!2N=!>7
M=^,!8JHD]>3P@W+F.US+/*C(7):!4ZS['7W?<0D%2DE/*4^2 /.@K ]1E)=[
ME8748U>XG=XS=0+";(M&KQOWA["04F.V.0\CPYW4%?8$\GC]0QMP?6'MM@6&
M.Y";@VS?NP668T)EPN/&6LIC+3V2![:PAQ27/RJ2@]2? (7MW>3"F,GB8Z[D
MD%NZE>P&X:W.%A3R5*80KQPA;B4+*$*(4L)/4'C00D;U-[4R\B71-;@X\JX;
M,M+L,ST!QDQ4E<GW 3]GMI"BKMQP$J_8\!FIW_V\.(V63G+*UNDKEM-RI3KA
M1[2W4H4RDH4 KEQ+C90 #W"TE/;D:"L^G/U .;Z3-QV55T:&SBF2OT+,F,\I
MQ,Q"&T+#Q"@"@GOQU\\<?.@TK?\ KRR'$:7=W(;'#JR32;:Y0SCU@U%L7$RI
MK;CH;]]D*;ZA0[)/MJ/GR.X\<A]'SM_]O:J/;/6&6U=>*B2Q#LD2I ;5!??'
M++3P/]VI?Z!7S^F@USB?J^I%[M[E85F3M9BR<7NH53!GNRE=)RI+)=;[E20E
MI7Y4CE7"E'@'G@:"#N/5_:P,RW)QY%1C\-W$\HIZ%F5;W)AM3&YB/<6KLI'"
M74H!ZHY/8@\<GA)#>ECN]AE1F,?%)N25\;('WFXR(*WN%>\XA3C3)/PEQ:$*
M4E!(4H))2"!H,/?3=)K9C:3*<S7$79.U,%Q^- :!*I3_ %_EM#CD_<K@$@'@
M<G]-!SA^\V,93LY3[E.6D6LQF?5M6BYDQX-MQT*2"H+4? *5$I/]1QH.J=]<
M"5CRKH9/!,%-@Y4J'*O>$U *EQO9X]SWDI!46^O8)!5QQYT'G+]0&W$%JH>>
MS2F#%M%:G1'TRDJ;7&=<#33ZECE*&UN*#:5K*4E9Z@\^-!Z7F_.WF-*R,6N8
MU%><<=CL7'U,D(_#UO\ ]P'N?[OW/\)/A7CCYT&/<>HK;+'KZ926F=T-=;0Y
M;,&3"ESD-.LO.CEI"DJ(X*QY'/@^/WT% W ]8&/4D[=3'Z!R&]D^"P([\@WK
MZH%>J2]WZLJ?4GA( 2@E9X2?<2 KY("ZV7J2VYQ9I+.49MCM#9M08TZ5&?L4
M --O!/1P*5QV;)5P%\<'^F@DLCWYV\Q"Q<A7.8T]<\TRS(?4_*2&X[;Q(94Z
MY^1L.$$([D=SX3SH*;ZM/4)+].NQ\K<2IJXF1M1I$5LQ'I*F4NMON);2I+B4
MJ^"M)^/(YT%=W(]0^9;=TV26"H6%3(=6AJ+^(2KMV#&8LB[&*HDA;J.J"6)'
MN)4%'E2>A"3\ALS)_41MKA.1_P /W^;4M3>AV.S^&R982^5OGAD!'R0K]#QQ
M_EH,)CU2;129J(:-R,9^J7[X2RJR;2LEGGW4\$_F3P>4_/CXT%WPS-J#<3'(
ME_C%Q"OJ66%>Q/KWDO,N=5%*@%#QR% @C]""-!-Z!H&@:!H&@:!H&@:!H&@:
M!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:
M!H&@:!H&@^//_"5SJ7(-I:S"7LGQJCO)EK#M&F<BMV("%QV'27""X?NY/"0
M#Y/GC0?.LR=A-57;\;?X[O%MZUMQN+#<L*N;+R1CZVHLEI2517O*ENQU%/3L
M"KJGC@'E7(0>[6YNV@V 9DQ+3&(FX,^\QA%LQ'S)NV<F)KUE >Y2I26F4I)X
M( 4$D]TCJG03^6W6"YGN+F>XIW8P>JES<_QS)H>,+R:*I4F'5-J:6''4++27
M70M2T#L0.B H@GE(';S!9.04EVYNA@+B']XWMQ)M:YDL3F! +8;0WY5U<?4
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MD*'_ (6Q_P!&@?V3X3_LA0_\+8_Z- _LGPG_ &0H?^%L?]&@?V3X3_LA0_\
M"V/^C0/[)\)_V0H?^%L?]&@?V3X3_LA0_P#"V/\ HT#^R?"?]D*'_A;'_1H'
M]D^$_P"R%#_PMC_HT#^R?"?]D*'_ (6Q_P!&@X.TV$GYP^@/_P"ZV/\ HT ;
M382/_P"3Z'_A;'_1H.?[)\)_V0H?^%L?]&@?V3X3_LA0_P#"V/\ HT#^R?"?
M]D*'_A;'_1H']D^$_P"R%#_PMC_HT#^R?"?]D*'_ (6Q_P!&@?V3X3_LA0_\
M+8_Z- _LGPG_ &0H?^%L?]&@?V3X3_LA0_\ "V/^C0/[)\)_V0H?^%L?]&@?
MV3X3_LA0_P#"V/\ HT#^R?"?]D*'_A;'_1H']D^$_P"R%#_PMC_HT#^R?"?]
MD*'_ (6Q_P!&@?V3X3_LA0_\+8_Z- _LGPG_ &0H?^%L?]&@?V3X3_LA0_\
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MH;CJF)JK:/[+K\<*""\RH%2'D!1 44*44E2>P'8<A=>!X/'_ "T'/CYT&O\
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M- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0<<:!P- XT#C0.-
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MJ@=_:"0/N5R'TGNA-R.=Z$\U>S"563,H."V";*34.AR(]($1Q*UMG@#A1'/
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M*E? "QR?_G@Z#LT^T_V]MQ#G4\'JH'C0'GVX[9<=6EM ^5+( '^\Z#TT#0-
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MZ(X6 #]B.2>J> QLB]/6WV6L7+5KCC,HVUDS<2WO?>0\9K2 VU(0ZE86VXE
M" ILI(2./CQH)NVVLQ6\V^?PB=3,2,6>8^G<KU%02I/8*Y[ ]^_8!??GMV^[
MGGSH*]8^G#;BV@7,27C;;S=O.CV<Q:I4@.JF,H"&I*7 YW;>"4@>Z@I6>/).
M@][;T][>7CE [,QB,MVC:7'A.(<=;6&5J"EM.%*@7FUJ'92'>R5*\J!))T$K
M/VEQ&QR1^^D4K*K*0Y'>DJ2I:6Y+D?CV''F@H(=6WPGHI:24]4\$=1P&(K8_
M"%O>\:)LN?C@R3M[[W_[2">OU7Y_[SKXY_;QH*+DWICK9VZN%Y%3LLU=352;
MBPL66)LEB5)ESVVD+>0XA7*5?RR5?<.W;]/U"TW/ILVUOV'&)F*1/IW*MBF6
MQ'<=8;5$9=+K#92VM(Y;<)4A?'9))X4.3H,^7L7@\]Z:\_0MNNS;2+=25K?>
MY=FQPE+#Y/?\R A 3^W1/^J. Q-O\'R!&37V49LJD>R&8W^%Q%433K:&*YMU
MQ;22XX>Y<47"I?!"00 GXY(9-3L3@M&W0MP*%N*BA8E1JM+;[P$-N0.'TM_?
M]H7^O'[#CC@:#5>9>D>%:Y/2(JX5.G#ZRJ9JH-:N1/AOU:6W5N*+3L5Y"GD*
M[(_EN$!);'50[$:#<5OM7099MW'PS)HZLFJ6V&&5JL7%*><4UU*'2X"%!P*2
M%!8(4%#GGGSH,=6R>&&NI8B:;VOP8O*@RF93S<MDNCAX_4)6'5>X.._99[\#
MMR0-!UF[&X-/#@=QV*$+I%8V6VE+;0*U1!5%"4J #9X'( '/&@SX6U>*USL!
MQBG91] XR_'05+4A#C3(8:<ZDD%:&@$)402 !Y\:#"K=DL)J$/(A4349EQJ2
MRAAMUT-1D2%=I"6$=NK </E0:">Q^=!TK-C<%IU0OI<<C(1#I58ZRTM3BVTU
MI^8A0I12IH\#[""/ _8:"":]*NUS5:8/\+)<9$2/!;6[.E..LL,/!]AMIU3I
M6VEMU*5("%#KP..!XT$Q'V"P*(^V^QC[;+S=X<D;<;D/)4BQ4@H6^DA?VE:5
M*"TC[5]E=@>3R#']@=OL7GWDJMQ>&P;OWQ.CJ*W(RP]S[X2PM1;;#G)[A"4]
M_P#%SH/7 ]CL)VUL&I^.TOT4UJO34MR'93\AQN&E?=,=*G5J*6TJ\A \#X'
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MGGQR$@*[  :".1Z9<.:NF;=E5K'LV\@DY+]4U8+2M4N0Q[$@$C_S;C0"2@<
M=04]3YT&!3>DC;REJX-8F'/E5L;'7\47$ESEN-R:QQQ2PP[SY4&RI710(4D$
M^3H,S_LR8J_A"\;GV&16P2_&DQ;:PN7GK&$Y'7WC*8D$]D%I7)!_7D]NW)Y"
MU[>;6T^VJK]ZL=GR9=[.%E8R9\M3ZWY'LML^YYX2GE#2!PD ?:/&@B*G8+%:
M;,;F_C?B/M6[[LR72.3W%U:Y3J2AV1]*3T#BTD]O\))*NO8]M!@1O31AL?&W
M*%P64NK13/X["9DSEN&OK7@D.QHZC]R4J2A">Q*EA*$I"N$@:"0J]A<8I[DV
ML55DU._#*ZH2Z)R_LCP7"Y&2!\?:M2R>>>_=05R#QH//_L_8M'?K)M<)M/<5
M[\^0U:UTCVI"C.=]V8E?CHI+KG"RDIX2I*2GJ4@Z##>],N"J]Q#,&5#CKQIW
M$?IXTM:&Q6NJ[.M@?ZZE?<72>Y))[:#"R#TJ85D4=;#CMS#8DX^G%[%N%9+9
M395R$J2TU( _.4!Q82YX6 M0*B"1H/5_TN88]=JLTN7+3WXS R!#:+-WVT3H
MD=,=MX)//E3*$H7SR% <^#YT'D[Z5,,30U=9!D7E0JFM)=M43JVU<8E5JY*U
M*?:9<'PRONL%M79/!_HG@/7*_2WA65N3%.FWKT6-*K'[5N!9NM)M(1+A")/D
MEQ0+SI#G(7_,6"HA1&@V+*Q*!+QEFA49*(++;33:FY*TO)#124'W >W(*$^2
M?/Z\\G04Y'I\Q)G)ZK(F6I<>\@6DRW^M8D%M4EZ4TAJ0'4I 2I*T-M I ']T
MDCSSR%6B^C7;N-2IJ2BX?KDX_,Q81WK1Q216R' X8_\ DVH#H?S)X')/ T$^
M?3CBYRQK(OK;U,]R''A6B$VKJ6+E#">K*IK0X2\I()';@<@]3RG[=!Z*].6(
M+E_4]; ._P 4C,N1-4!^)]/;]W_ZWI]OM_DX_3013_I2PS\;3=095_2W7XA-
ML%V-5</1GG?K'$.2F5E)^YEQ;:%=./M4D%'4^=!(9-Z9\)RQG*&9T:<(^25\
M&JGLL35MI5%AJ4J.TCC\@25KY*?)['DG03%?LQ1561W]W"D6<6;=6+%O)#4Q
M26A,;8$?WDH_*"IM*$K204JZ ]=!8<+PNHV_QF)04D41:V-[BD-<\\J6XIQQ
M1_JI:UJ/Z<J/  \:"ETGIRQ#'HD:'"1.;KX#$N-4PU2U*:J6Y((>$8$<HY22
ME))44))2CJDD:"XX#A%;MOA=+BU,'DT]/%;A0VY#I=6VRV EM'<^2$I  )\\
M :"D.; 8[1PI*J6/)4B,].LJJF<EGZ*%.DMNI==90?R%1>=\$E*/=64)3V.@
MJ>T7I9J(6R>.8OG\9V^L8V)HQ68Q(G*>888*&Q(;C%(24I6MI"@K\X#;8! 2
M  M:/3=C;M'55UA:9%=.5MG%MF+&TN'7Y?O1E*5&[.J\J0V5*(0?!))5V))(
M+?TU8A<Y5,OW'+9F9)OH>3EIBQ6AE%A'9#"7DH^ 5M)2A8^"!\ ^=!Z5/IOQ
M"D@X_#B&S;AX]?2,BJHYG+*(<E[W>X2#\M\2'P$*Y #A_8<!E5&P.*4,II<%
M,V/!BS95G7UHE'Z6NER X'GXZ#^11]YT@$E*"ZLH2GL=!@T/IEPG&V:)JO;L
MF&J.A<QJ E-DZ"S!6ZVZI (//;NRR>_/;^6D<\<\A)N;+UK%U#LZ^;85\S\>
M.03WXTQQDSWS'#!2\ALI;<26T-IZJ20 CD#L>V@LF5X1 S!I*)KDIOB._%/L
M/%(6T\D)<2I)Y2H$ ?(/'R.#H*2_Z8MOWTW<=54\*NZI8=#-JT2G$QEQX@(B
MJ ![)=;!X2XE0(X2?D Z#F\]-V*9/62V[61<3+A]^)*3D/X@MNR8=BA8C+:>
M1UZ%L..\ #A7NN=@KNKD/2W].&&Y$*C\79G6_P"'09]>/KIBW?J6YJ B67^W
M]ZIQ(2"5?'4=>O&@PW?2]ATJNN(4M^[FMV^.-XG-<E6SKCK]:A3A0TI9/8J'
MNNCW.>Y"U<J.@D)GIVQ"=/GON-3?I[5J&U;P1*5]/:?2I2EA4A'^)02A"24E
M/=*0E?9( T&-?^FK#\A<R&1)-HU8W-Q&R!=A'GK;D1I\=M+3+["A_=*2VA+?
M '4IY"@03R$?)])^%.L^ZQ)OX%VFY>OT7T.W=:GMRWFD,OJ2X/ 0XVVE*F^O
M0\ ]>0" LU9L;C%3D=C=1DSTS+"F10R>TYPI7$0IQ:1Y//?N\\LN<]RIQ1).
M@F\7V^J,2N+>WB(==M;5$=J7,D+[N.ML(*&4D\#GJ%*\GDGL>2=!9M T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T%6W0W"K]JL"N,JLT.O1*YD+++(Y6Z
MM2DH;;3_ %4M24C_ #T&MV?41;HM30S,*EP\@G7;5/2*D%Z/!LPN*Y)<>2X\
MRAQ*66V7@X/;4>R4A/;N" \L>]3BK?,JK&G\<^GF2LNL</?>1.[MMR(M>9OO
M)_E@J;6$E/!ZJ'(/GXT$!C?J/1GEM@MPS13X4VTQ_)9D:)^,J$+O!E,L+0\A
M*.'"I004.%/* IP 'L=!G[>>IFSE8QL_89C20ZV-G>.N6WXQ$EK6PQ)1$3+^
MG*"T"%+9]U8^X@!A8Y4>"0W=B%S+R'%JFSGP/PJ9-BMR'8/N^Z8ZEI"NA5U3
MR1SP? \\Z#7&YN_$K;3,:RNEX\E=-+LJNL$Y<]"7W7)SY82MEA(42AI9;[J<
M*.>YZ]BG@A7XGJBENY;'KY&*H8JCG+V!OS$67=Y,L1R^T\AKV@%-*  5RI*D
MD^ L Z"L,[R7>X^[_I_O:Q,BIPS)W+MR.VW9+)GQD05J87(CA(0"2D.H^Y92
M" >#SH-R9WN98TN1'&L9I&\AR45#]U]'(F?2MEIM:6T-A?57\QQ:NJ>1U'51
M41X!"JW/J'L,;S;%Z>XQ%=7$O;.%4(]^Q:7,;?DQ%OA99;[)#2%MK94I2TDJ
M2LI"D@%0:PWG]2,C.O3GNO-QMV1CMUCB%,OMQYY8M*V2W-#8;>: 2MLN(2%I
M4"4*2L@$@$D-Z;<[J3<NS[.\0MJ5JIM<7<AK*XLPR69$>4TIQI7);04K'MN)
M4G@@< A1!\!H7<;(<JR2^]22Y5E-K&,%J ]2.T]W(C+86JG=>!4AM* YV4Y[
MA['[5(; [=0=!;JKU*S:#;*TMVZ5V_@8+25DG)Y;TWI*5[L%F4\IA'50=4VP
MZAT]U([%12#R"=!(9%ZLF\:N[:!*QYE"*[)JFE4\NQ*0N#8MA4>Q ]G\G8K2
MI'R/:<)4 G02V6>I6/B$R@9L:Z+!9OYUE!JI\R?[4.2[&6E#+)>+?5IV22OV
MTK/4AM7"B2 0E/5;F=[M]Z<MP\CQMQMBYKJ63(8D..%!8(;/\Q/"3RI/R >
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MK 5U4E2>1QUXY&@A]NO5?DKF%RJ>32N9MGM&JZ;?5"8=;3:M5\]41MU"6&7
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M/@$-8[\;ZY3>[#[C/L4%]AST&E@V]7D$1<J.A9=?2%L%Q3;1#J!QV2GLA27
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MK0M#B5I4%J!'G0;.Q;'4XS4(AF?,M7RHN/SI[@6](<)^Y:NH2D<_ZJ$I2
M !QH-=0?3#B#&T<+;>:N?;8U GMSH2);J0]&]N5]0VTE:$I)0#RCD\J4A2DJ
M4>=!GV'IRPBRQ?.J!V ZF!F5@;2R]I]2'$R?Y92XRH>6REQI+J>/ 65*_4Z"
M?P_;B+BUY:WTBPF7F0V;$>+)M)_MAQ3#'?VFDI;0E"4A3KJCPD<J<43^@ 5&
M7A\_/-^JR^M\354UV%MR$U5V[-:<5:+DM-A00TVHE+;?5?(= /=+:DCQSH,9
MCTO43$'+*9.1Y*,5R SW%8XF:VF)!=F!P2'(ZDMAU/8NN+"%.*0E2RI*0>.
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MDJ/"1PKDCG@,#-_5)-Q:Q./-XH3ET;)Z:CF5[LQ/LB-8J7[,MET)'=*O:=0
MH)*5I5R. .P6&L]2=9<YO"I(%-/L8$F?/JE64%"GA'E1 OW/=0$_:TI33C:'
M.Q[+2 4CLDD+'L]O#6;SXFQD=,VDU,AAIYJ2W(0Z 5 E;+@3Y;>:(ZN-J'*5
M>.3\Z"H[<;UO9%@6*Y4XV[.L-P)BU4-074-ML1^CKK84K@]0([)=<7PI791
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M+BN*4H_S4NKZ@@%*O!"N#R C:[U2XW=2;'+JI.33H+&WB,O%6LQVHQC!]X+
M0H]TRDEI:%<JZ<( ')\Z#PSCU1UKN$9S^)5N28T*NAK,B9E4TB,J8] FNJ;;
M=;*^4-N)6TX%(7S]OD<D\ +IF_J.K<,3EMA^$2K#&L.F,0LBM6'4?Z$IQMMU
M2D-?F=2TV^TMSRD@*^T+*2 $?(]442)F#E0[C%BW!C9@WA4NQ+[/#4QYEMV.
MM+845+;6'FP3X*>PY!^[@+YO3G\C:S:',\SB0$VC]!3RK1$-;OMI=]EI3G4J
MX/ ^W]M!HG(]_<MPW=&UM955,LZB#MFQE$S'8TQE#;"T2WO?=0M7RLLH\)Y(
M/4#E/DZ#8"?5'23LDK8%14V%S"D6D.HDR(C96[%=DQVWVW%-!)_DH#S0<7V'
M0K_*0"0&#OEEN3+WDVTP&J<F5]/DL:V<F3JV6F/*0IAEOH4+(/'MEWW.."%$
M)!! ((8N'>H6/&QC"X]?79'DDW*+V\IH3EU(BH?3+B.RU+;>6CA*6_\ 1G4H
M*0KA"$\\J^0\I/K(JXVVU7G*\4MVJ!R']7/D/K:0F,I,PPW8[1Y(?>0XE:^B
M>H+:>P/*DI(3&4>J"+C&6W]0[C%B[%QZ]JJ2TGA]D):_$?:3&>;1V*G$]WVP
MI/@I')\\<$++6;PR+VZBHK,5L[''94RPKD7<1QM2&WXGN)6IQ!(Z-+<9=:0X
M2>5I *4A25$-;5OJGK</V4P_+%U637&-/T$.V?O+IQA,E3+KJ&@DE "'I0"O
M<4V@)'4$@\E*2%PVUR>YG>HS>2AF6<B945;%&] B.D%$4OLR"Z$< 'A10D^>
M?C05W./5M&JMJ]P<KQRF3;R,4<DQ'XCTM+:V)+,L1BW);_.RH@^\A)'WM\$$
M$^ M&4>H(87F%)2W6,SX+%C9P*83ENHZJE2TJ*/93\O-H4$H<<''52QP% *(
M"L85ZJUWF'P+&WHV*NXN+NWJJJ 9O+;J(#[[;CCCH0HH # !/4\J6G@<>0'C
M8>L1AJF;F0\$OUR1ATC,WX4]34)V/'COAJ0RM+AY]U/W%/ ZJ''! /("5<]6
M%-76<N);TLVK]VMJK6I4XZVOZ]B?(^F8Y"2?:6'?S)/;A)[ G@@!Z1_4^AZ/
M2(.'VR;"UR63BK#94A##DIN,Y(;=;=<"2Y'<;;)#H1X(4"D$<$([%_5),S+*
MMNX%=BCK,+(H5X_8%Z0E;\)ZLDMQ7VD)1R'?YJU<*'Y@!P!R> V+LYN_6[T8
MK'R*F:2JJDLM/-2&Y"'AV6"5L+"?+;S1'5QM0Y2H\<GYT&O*GU:LSVJ2QD87
M;PJ"ZM+*AA3UR8ZU*L8BY*?96V%_8EWZ1X(<*N.P 5U!"B':B]6#=[C&/6Z\
M1F5!RF$+/'&;.:R/Q"*(C<AQU1:]PL]2ZAKA0Y*EI/Y>5 )S$_4Q2Y??45,Q
M5SJRVLZ:%>?A=QUAS6X[ZW4+(9<X+GL*:/O=3]G9!'8'00D7U=U$ZHL[F)CE
MK.HV<9DY3$GQ0%(?CL<%;3A4$I9>4@AQ"2I04GGR"DIT$1F'J^ET]);N5^'/
M?BD=K'I\-F;,;"),&VFB(T\2CGHM#@6"V?\ U3VX)X#Z0C...QVENM^RZI(*
MV^W;J>/(Y_7C]]!ZZ!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:"O;B8>WN
M%@618N]*<A1[JO?K79#*0I;;;S:FUJ2%>.W51XYY'/Z'0:GM?2337GUWUN0V
MG9ZAIJ2.['0TVY$562#)B2FU=3_-#RBH@@I(^WCCGD,S)O30QEKLJXGY%)&8
MOVU1;?C#$5"6T*KEJ7&:2P21[?+CY(*B2IY1Y "0 DL0V(E83D-TJMS:Y:Q.
MPG2K9K'0VRE$29(4IQY2'PGW"T7%K<#1\!1^2G[=!-[>;-U6WN2Y+?15ARRR
M!N(BP6VPEA$A;"7!]0XA'VJ?<]P^XYP.P2@< )T%(A>G-^/M]C>*U]W,QF;@
M]DN3B]_"#3ZFV"EU"&G6G!PM(9?6PM!X[!*5)4#^4+%*V0D)R:FRN#E<Z/F$
M.K?IY=J_':>$Z,ZZ'B%M<)2E3;H[M%/ 1R4E*TDC05A/I#H:^+:0:FYG5M=-
MPG^!DQTM-N%F(5N+6\%$<J>4IYPE1^WE7Y=!(8[Z;W\.RE%G0YS<5=?-A08E
MW6-,LE%@J(PEAEY+A3W8<+2$(66SPH)' 20#H,O%/3S_  O'O:-.76TG!YQF
MF'CBFV4)@?5EPO(2\E/N+;27G"VA?/3GY5U3U#G;[T]C!;O K1>2R[.3B6,.
M8JR'8K3:9$52F%=EA/D+'TK(Y!X\*\?=X#RG^EO%Y.'YK0Q)EC5_Q)=#($S8
MCB0]6S$O(D-*C=DE*4HD(4Z$$$%3KG(X4=![7&P]AEE+C3&29M8W%K47T*_7
M/^E992^[%5V::#*1T;;Y/*NOW*/^(>  Q]M,4&2;PY1N3(Q6VQ)YV(W1MQ;=
M3:7)BF7'.\SVFUK2 I!;;0LD+4A'D ==!89NR\"UW+R;*Y\YZ8QD&/-8W,J5
MMI#)C-K>6"%#[NQ,EX'SQP1X''.@J4'TU6']D-[MU;;B7EW23:9W'8;LF-'0
M]#@+;#9"BA(#SP; 2'5CD <\<E14&>_Z?9D;,8N14><6M!(DU,6FO6(D9A2+
M5F/W]EP=DDL/ .N)]Q!^%?'(20&#<>EN'<81G^,N9+/;BYAD*,CD/H8:+D9Y
M+C"_;;Y!!1S%:_/V/YO/GP$U;;&S'=S9V84N9VF._C<6/%R"MAL,J:L/8"DM
M.H6M)7'<ZK*"I!\I"? 4D* 5^7Z5F7;MPQ\NLHF-_P 7,YJS2HC,J]BP2[[S
MH0ZH%7LN.%2R@@D%:N% $ !<<YV3KLZS^IR69,=2U'IK''Y]:6TK9GP9A:4X
MVHG[D$*81]R?T*A^H(#!P'8:-A\_%9-A>2\A.)5;M-0JEM-H<CQW/;2I3JDC
M^:][;+3??A(ZI/V]E*40@K/TQ"?G+F1IS&T:4G+&LMCQUQV72R\(2H;C/N*'
M8M%M:B@?^;)/'.@M^ [,5>!9C>9/'=]VWNH<2'/?0RECZQ4?W.LE\(X#DA7N
MD*<X'(2D  #052#Z8HT"RK'VLEG?2U>;3,VA1C':X0])2^'F%*XY4V3*?(/A
M0[)'/V^0C*GTHO8I=Q;[&<^MJ._3+M')DQ$*,\B9&GS#,>86TM!2.CQ4IM8\
MI[*![@D:#?%="36P(T1+KKR6&TMAQ]PN.+X''*E'R2?U)^3H*9F>U:,PW&P7
M+3:OPG\3=E/1XK;2%-R#(8+"PX3YX"">.I'GR>?C04ZB],D2DK<,A)R.<^SB
M^4S<KC=X[0+TB291<;7P/[L&:_QQP?R\D]?(5J1Z+X3^.+I!FENF#(J<@J):
M51V%>XW;2%27G$ CAMQ+BU * \HX2?CG025MZ2XUY59;%F9;8J?R9FC:F26H
MK*"C\,4%M%M/! [J'W<\^/R\?.@M>&[)SL&O;A=?FEHK&9<R79Q,>=89]F'*
MDK6X]U<"0XMGW'7%I:4>$E7R0$@!KR7Z)8#^"0<2;S6Y;J8^&/X4I*F&5J7&
M6L+0\.1PAT<!*BD<+2$@@=0=!M;#-ICBNXM_F+]Y(L["ZJZ^LDM.,-MMA,3W
M2A:>OD%1D.E0/(\I XX\A5,\]*V/[B.Y'(M)\@6%UC]CCC]G'9;;EN1I;B5@
M/+ X>#'1(:"A]H*N>2HG01V4>EA_*[:?92\[LQ,F.T4Y9$-A243*QU+C:VTD
M'HTX4\J9'@*)4#Y((<3?2@&+B7=4&:V=!>-Y--R:KF-Q&'OI')C81,CK0L</
M,N>5<'A22$\*^T'06&]]/C>07T>XF9/92)S>,V.-..O-M*+K<UQMQYX^!PL*
M:1U2GA"0..O'' 5>V]'-1=5E'$?RBW9<IL5B8Q"EQD,MO,_2RF)4:6#U(]Y#
ML5D_'0@*!3]W@+38;$3\EBX@YDN:V-W;4%]'OS-,5EE$AUEMQM#092.C;?5U
M9/7[BH\]O &@C,4],,;$<GQ^\B918+F5EA?3'.\=KB0BV>1(DM^!]G5UI"D*
M'D $'GGG06W -F:O LQO,GCO%VXNH42'/?0RACZQ4?W.LE\(X2Y(5[I"G.!R
M$I   T'MN9@;^XMGB<%[JU2U=O'O):R05/.1E>Y'92/_ /-T<4K]FN!SVY 6
M"EH[2K@6C4G()-K(DS)$B,_+8:'TC:U%3;"4H2D*0V/M!5RH@?<2=!I_;WTF
M0MNHFW\>#E-C)3A,>VCUZI$=DJ<$\]G%.\  E"N"G@#]CSH)^-Z;:1OT_4FU
M+MI8+@4K$-N!;H]M$QAV*ZAV,^G[2CNA;:#^7@\$$<$C08&4>F=G+OK[>;D<
ME&:2;.JM$73$5 ;:<KEJ5%;$<D@M N/%22HDEY1"APD)#'QWTM1L>R"DN$Y7
M92Y=9EECEW\^.P [)FLK9>;4$I'#?1USCCR"H>>!QH+UGVUC6893BF4PK)VG
MR;&ER!"EI:#S3C,A"4/L/-DCNA71M7A25!3:"#X((:<&QM]B.^>&#%94^!4Q
ML;OF[#(W8C4CW)\^?&E.%:24@+6I#S@(3U24(204GJ0LO_9'H(46?"J;>=6U
MTK"#@@8#;;A1$*G%%_L1R7RIUPE1^TD_ET&-D_I"K,JJ[Z!)R:R;:M\6K,4<
M4VPSV;C0G5.MN)Y']XI3B^W/(X(X XT$[D'IKK\AF9DVY=2F:+-C&=R6H;91
M[<QUIMMI2VE?+/O--(;<'W<I2.O11*B&//\ 3%"L+2?-7D4Y*IF<1,Y<0&&N
M!)CM---L#QS[12PWS_BY!X4.=!97MK[#+=JLRPK+\AFW$?(F[*%]6M#*)$>'
M)"T(;!;0E!*$K/!*?V![<<D*Q:^F9-\JT?L<KG/3K3!C@TM]N(R@*8*EJ,A"
M>#U<_F+ 'E(!'@\<Z#WPGTZ2-O\ )'9%-G-Q'QZ<(K]G1!A@-R9;$=F.'TO!
M/N->XB.U[B$GA12>"GLH$+9E6U:,GW3PO-E6K\5_%V9K+$)#2%-/B4A"'"LG
M[O ;1UZD<'GGGG04[&?3'%QE>$EO(YLA.*W]ID45+D=H>\_.$GW4.<?X$F6]
MUZ\'\O)/'D*6]Z&*]>'S,;;SBX17RZ!^C>[QF%J_F6#D\/(\<(5[KJDJ '"T
M(;!X* =!;\B]+\?)I>7RI646"9.36U+;RW&XS(Z.UA:4RE X\)4IALJYY/R!
MQSX"=PS9*=@M[<*KLTM#C$N9+LXF/.L,EJ%)DK6X]U="0XMGW'7%I:4>$E7R
M0$@!KB7Z((#^#,XFUFUNU5MX@WB'"HS"U>TU(]]E\<CA+G/"7.H <2A'/!2#
MH-NX7M2,2W%R_,'+F193\F8@,R6G64-MM_2-K0A2.OG[O<65<\^2.. .-!2,
M[])=!N"C)7;&TE-VMW0O4+UM'8:1)=;6^V^VX^0.'U,J:0EOL!U05CSW)T'G
MD?I<>R;)YEY*S>R^KD7%+?=?HV5);EUZ0D!//D,N $^USPE2E*!/8@AT3Z4_
MPNKK4T.:V=+<4>0V5Y26:(C#IB(GN..2HCK:P4OM*+R_)ZJ'5L@@IY(2N2>F
MQC*;.RGS\HLY$NQQ&;B$EYUMI2ELRG?=>?'@ .=OR@#HD< )X&@A\C](U?DB
MX<AS*[:%8P,?K*2#.B-,I=C.0)0E1I:>R2"Z'1]R2.BDDIZCGG06B7L?.O7<
M(FY!F5A<VV-78O3*5&9:1)?$9V,E'M)'5IL-O.?:CR5$$J.@A,4]+D;#YN(S
M(.560DT#E]_-+#(5(;M7Q)D)/ X04/)0I"@/ '4@\\Z"Y;>[/5>W>39+D$18
M797[<1,];3"6$2'(Z7 )#B$>%/N>X>[G [=4#@!.@T[LAL'=VF"18^7R9M3^
M%9+?W%94.Q&A[#TJ5-]B0I?*O< 9E*<2GQU6Y]Q/4 !<CZ9368;ME6X]F5G1
M7VWT,UM5=HBL/*>AJ:0RXQ(94GHXE2&FB2.I"FTJ!'D$)W)-@*S+Y5 ]=V<J
MW733HEE&D36T+DLOLK[K4T\ "V'S]KJ0.JD<H2$@Z"OX_P"F-^CVVNMOW,]N
M[#$7JJ125,)]E@+K(CS:FR@K2D%\H0HI;+GA(XY"B.=!AY%Z2(-_&L$_Q381
MY#]'1TS#J8[*@Q^%2Q+BO=2/N47>>Z3X(/ Z\<Z#?D=M;3#:''"ZX$@*<( [
M']3P/C0>F@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@KNXF32,+P/(;Z+"
M58R:R _,;BI4D>XIMM2@.5*2./'GS\<\>>!H-%8AZAY>$;2U.;9LWDMK'M,?
MBY+.7]#%3%JF/98#RD.H*0H+6X7$,E2GNH7PD  :"T9+Z@Z7;S(=RY=M.N[*
M!C0I4R*V/7LE$7ZPJ0VMA8(6Z%J4GL%'[2D!(\G00[.^&1C>Y;,BIOH= C!I
M]XO%)$2,9XDQK%+ 4CHH]BXWR4I]T@A2?@G@!M# MW:7<A%*]2-2I$2VHV+]
MF7U06D,/*X:2LA1X<5PL]1R/Y:_/(XT&/OKFC6WVV=A=OVD^E:9DPVC.K(C4
MIYOW9330 ;=^TA16$$G\H42/(&@KV0^IK'\:R:ZIY=/=%-'<UU+:3D-,^Q$<
MG^V(CI_F]EMJ4\VD]$J4GGE20/.@ON;9F,-AP7$5-C=29TH1&(U<T%$+*%K*
MG%J*4--A+:N5K4$\]1SRH AIYG?&1G^Y&R$G%+>5'P_-ZBYE/Q78S0<[,-,%
MI1*DJ*5H4M8("B@\?J/)"T^E?.KS<7T\X;DV12S:7D^&IV3(2TVT7EAUQ(/5
M(2D<A(^ !H(3&/5M39FUCZJ;$<GEN9%3S+FF:4U%;5-;BNI:D-CM( ;6DN-G
M^84I4%#JHGQH)!7JGQ8T&-9"U77+F-7<>ID(MU14ML,"Q>]F,@]E N+[\!Q+
M066P05>"-!CU?JBJ77<M%M5/TZ*G*W<3@KD28Z4V$EMA+JB%%P!L=>Z^5\ )
M \E1*0'C!]6V.W$;&138QD]Y/R!B>]%KX$1A3J3"DMQY:%%3R4<H4ZD\A12I
M/E"E<I!#*QC?>*UMQ$NVFLBS%4JSN(X<_#F8[C28DB2'0ZH*2RTAL,EI"EJ!
M<ZH^5*.@P\.WCEYSO]C4>GM7)&"Y!MZ,GB1'8Z$$.*EL);<YZ]P2T[P4E1 /
MZ:"SYCO[4X;N'_!SM)=V%@W7L6\J3"8:,:)!<?4RJ2ZM;B>$-E"E+ !5U!*4
MJX.@K+7K'P(L6;[[LB+&B5\&T;DK6RIE^-+D(C-++B7"EHAUQL+2Z4*0E841
MQR0%DR/?AB@R"BQ]K$\AM;^ZAV$V'7Q&XX*T0W$(=Y<<>0@<^ZVI!*N%!:?/
MGC05:P]:6W<3%H&0L/RYU>] BV<EMI+:9,..^\XR"MA:PM:T+:="VVPM20VH
M\'QR%U3O3"DW[$&!07EK >L)52FWA1DKBB7';6IQM1*PI">6EMAU0#?N)ZE0
MY!T%0VZ]555FV)X)82:2=7W.74[UY!ITK:<=<C-%KN6SW <4 \@]!]_"5DI
M Y#>?/C0?+N4>I;(+A^@>I:N=2,1]T_X,EL$1GU6<=MN0EQ*>2?;)6VD\\IX
M''W'[N NH]6.*C'TRW84^-<B59PG**6Y&9DH>KUI1*1W4Z&5$*6WUZN$*]Q'
M'Z\!<9VZT6;LF_N)CL5ZUAN4BKF%'<1[+CJ/9+J0M*RGJ?\ 6!((X(^?&@U7
MM-NC=SW-J9.09!?N66;4CURU1J@03&<4W"C+="74?>A/=SW&TE7)]PA7 2
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M*YY!/VCX)^=!;LFPES%]SI6[<F7)L6JO%GZE5'552Y$EX%],E2V@E94M94V
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M=3W[!;84>>2G08&1^D6KR;"Y-%-LFGI$N?+NEVOT01*B6LB3[ZI\-Q*^S#B
M>B "1U">Q5]W8,B\],4JR?R.7'R=F/,L<Y@9S$+E:5MQWHR([?L.)#H+B%(C
MC[@4$*43Y' T'>?Z8WY5E>VK63ABWD9HQF]8^B#]D.4W$;AJ9<3[G\YIQA"D
MJX*%?S%$$<#@,ESTWN2LIJ,D?OV_QAK+QF%BI$'^7*>37JKVF&Q[G+:$,*'W
M'NHJ')^2-!;MG=J/[+MO',5EV*+QMV?8S7'Q&^G"OJY3TE:.G=7@%]20>?(
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MK_?L$.M/0^I!"N"CVI"_V[<)X\D)T%ZG>J/;V%"J+ 6YD5-@*T_B#2/Y4<6
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M*L1Y;:I4^8REA:&RKW'.&64 )2"I1\)!5QH+E.]1V)TZ;)NU19U4^LGP*^=
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MRJWTUY;BFXKF=4E_4.W/\36]I]%-CNB,Y L6HB'&%*22H.H5"96EP#@_<DI
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MGEL+")-O88Q7VE%D\3('XM+7N-0UI8;>;+:.3W[K]\J*U$A/5("3Y40WX!P
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MXY!X#(WWWR.TV6X!539\#&:/)'Y4>1D]LPIV)$?;0A3$=9"T);4\5+X6M02
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MQP>I_?0:C;]-6Z"[:;D:I^.M9(N#C4ILO3Y,EI^SJWI*G4/*+*3[+Z)2^%I
M+9">&R$Z#96083N=(R3$,XKF<7&0UR9\.?CKTQ]$)<24(Y/28&"M3R%Q6U=R
MR H*4GA/ .@CL@V1S#\=S>;72J6<UG&+QJ.S:E!QEN!*9;D-)?90$K[LEN20
M6B4GEM/W?>>H4N;Z4<PIGY]/CTRFD8\[D&*WC$RRE/(E)34L0F%L*;0TI)*T
MP4K#G;Y<*2D<=M!.CTWY8;E$DRJ<,G=4YXOB0Z5"']-[(9 ]K@N\^>.0G_UM
M!TVV]..887*VF1)?I7XF#7%_)<=:E.]YD:<7_94E!:X0XD/_ '(*B/M\*//@
M,.BV R? V,"M[3\,L(>'V>5WEA$@%Z4]*;L#*<;98:]H>XL!_J4DI[%/ Y[>
M C?1RF>Q*IU?A^/6]<S1-5<6SH[]^8[4Q6_YJ(CL=V,W[*>ZRD)+KCJ>B$GL
ME/8!BVN!VF[VZOJ9P2*:]FHR)RDA3I[[ZO>CL_0-I?+3000XKJ"D$K3U61SS
MQH+5D?IORV\VFWLQ5,JF:FYOD+]O7OF2\6V6G/IAU>_E<A0$<_E"@>WSX\AV
MWB].F7[D2MWGX4BEB',Z&EJ8B9$IX^PN(^^ZZISAG\I$@A/7DGIYXY\!=-N\
M&W PG(;NL>5CT[$'[R=?0IQ==_$$?5.N/KB*:+?0=7G7 'PX3[? ]L'R TCA
MV"Y1LIN1Z>\1Z4UO?4^+9+&=3]>XS'<"Y$%:"E99*@H\'[2CR$KX)XT&5*]$
M%Z:$4<6[K&HB<(D4(F*#A4;%VR18EPL]>/I_=24=._8H5QH+_/\ 3]-SS#?H
M\JQ#$:*4_+9EOL8?*>C/,R&6G S,CSDLM.)?2XL=>4<(1W22OL=!([P4T_'O
M2';4N8RVLNM44;-=83WXSA:??7T:,AP,@+0A*E!Q3B0"@(*^/MXT&K:S;K+M
MV,;=F18>(6E] R&#DS=P;IVUJKY;+"X9BR7/I&?;(C$<*;:<2%!*B.W/(;*8
MV/R-.?8!DS%9BM$Q1,W2Y-/4%;327IK32$)0I+*?<X4SRMU24%7<\(\ $*%M
MYZ4,OP"-CD*16X+EL1>)5F-VWXXEU[Z%^$7DHDQ4J94'FUH>/9E?M?<@'OY.
M@OCNT.XE/1[Q?P]8T\.XRO)6+NK?7(<X#"683+K+JO9/M+6W$< <0%]"Z"!R
M@$A6J[TU9G%MD*+E$B"WN@G.TE,Y];GTQB>TIC@L^7 HG[BKA0')X)X 1VX.
M"1L$V\W$ILJMH4+),WS%^_PQ-87)$E-FE+#D)*$J;3RZAV,A1 ^TI*@3QR=!
MOS^#+NHV>FX]1V<:+E*ZN0VQ:2&?<9%@XA:C(4V>>R2^LK*3SX/'G0:$_P"S
M1N0;K(,D:F4$:_DG&K6&A^PDRFESZT.)>9D++*5*:=2ZKAU([))'\L]?(;%R
M#"=SI&28AG%:SBXR&N3/AS\=>F/HA+B2A')Z2PP5J>0N*VKN60%!2D\)X!T$
M$=@\HC[HWMP]681D=3DK=>_+E6T11DU$R,RAE1BLEM:76E):;4A"G&RA8))5
MSH*3M#@EIN@K+:PFOCX]6;Q3LC<F!]2Y+GTLU,AIM+73JD+=0C^9W(Z!7CDZ
M#WQ#TLYM@]7MXH5^&9;(QNML<=FUEX^]]+*AORDOLRVE?3K]IY)0 ILH4"%*
M3W\ Z"2W%],V;V%3N?0XV]C:ZC/L9AU+JI"W80J94>.8X]AEMIQ*HZF^I".R
M2@@_F!\!MG>W;B\W(PS'*VL7 :GU^04]R_\ 5/+0TI$.6U(6A*DH4>5>WU'(
M'SR?CC0:ZM?3GEMA=V\Q$FF0U.W/KLW2E4EWLF)&CQFE-'^5_>J,?D#\O"_S
M>/(;&W"VXNK[>';',JI4%V/C7XG'FQ9;RVEK:E,MI"VRE"@5)4RG[3P"%$]A
MQP0T1(]&677&U> 89-MZ>&*'&LAHY4Z,\\Z2[.2D,.-H+:>R4EM)6E13R"0.
M?U#?FS>'7F/1Y<W(<;P_&;:4TTS(9Q%"E-R%([<NK=6TTH@E1ZME)Z G[U%7
M@*TSMIF^ ;Q[@97B4>BNZW-A"DR&+::]#=KYD>.F,%#HRZ'FE-H0HI^Q04D^
M2%<I".<]/=Y5WFW[]9,KY<3&,2MZ-UR4ZXRY)E3!&(<"$H4$MA<<\_<2 YX!
MZ^0UY)]'>8S-OI&..6=(TXYM)'V^$A+SRA]8R5J#W4MC^4HJ ^>P\G@Z"[SM
MBLJD[I6>2/4.$W5?D]?7HLV;WO*=II<9!05Q06.)+:DD'HHL\+3VY\D:"-C>
MGG/(<G'Z,2:.3C=!N([FD6T>EO":_&>=E/.1W&0R4^ZA<M8#@<ZJ2E/(2>=!
MMO<S%[_)I(@"IH,JPR77/1;/'[LEOWWBM!:6%^TXDHZ^X%)4G]4E)Y'!#4FW
MWICS#;6'M$U OJ^P?Q*DO::3(FJ=5].F<XR[']@*"B\B.6$,A"R@J0 >1QUT
M%5O?2KN7EE+D"[2;CWX[;XA25DA_\1D.I>LZZP5+4XHE@=6G^Q'VI'M>$A"@
M-!L6/L?DL3=_);Q=+AEO19+.A7*YMLA3]C32V6&6G$,!3)2\@_3MJ;45M%M9
M4KJKP-!.;1;)VFVN?W=O&F-5=!<15.SL=A/N.P56:WRM<R.VX/\ 1NZ20M"#
MU6I7;J"GE05C+?3??7T'<[$D3(#N(9Y>,7;LUYQ8F5QXC"2TEOJ4N=OI0IM?
M9/0N'D$('8+]L?MQ=[>3-Q';A4!:<BRF5?1?H7EN%MIUME 0YV0GA0]GGQR/
MN_IY"+R+8=O<MO<,9O&9F"_;76PVH5G(0@5P9*6FW  E(7[BWG#]JP"YXYXT
M%:Q79;<9$W9>SRBQI+2XPFGLJRSE,2GO_&"WV&66GD]FO!(9!7S^JCQSH->V
MWHSS2WVPVRQDVM"Q-Q#$I-&N0IQYYA^69,%]A9;+8[LDP$I<22#PZ0.>OD+_
M &>QF69"UA4\4&$XI85>5P<@L*^C<<#+J([+S2N'Q'0IUQ7O>.R$A"4!/)Y)
MT'&<>GK+[K--QLBI[*IAR[5_';&C,IQU2!)JG2Y[<I"4>&G>Q22A1*1YX)\:
M"P99A6Z&9LX\I]6.5D9UZ:+RFB2WRCVG(OM,%,GV4K?*' 5*04-!84 3PW]P
M3&P&&YMMQ@>&8C?IHE5E#C$&L6_7R'G7G)K(+2U#NVA/M%I#:AX[!2E#R "0
MVMH&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@
M:!H&@:!H&@:#@ )  ' 'Z:#G0- T#0- T#0- T#0-!QQQH 2 >>/.@YT#0-!
MP4@GGCSH.= T''SH'&@YT#0- T'!2#QR.>/C0<Z!H&@:#@) ^!QH.= T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
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M/4E/D _(\Z#3-%ZI9^XF-9WE> XDC(L3Q.5)A?52+'Z9^W=CI"I'TC?MJ'4
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MJLV23MXJM<D1DJL[8N\_RR'.A9;X*PZM20?=\>>W ?8GIZVOK-MMJ,;@MXQ
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M^Z?<([!'/DC]^- 2\A:U(2L%:>.R0?(Y^.?VT'"'VW HI6E002E7!YX(^0=
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M'@C0;=]3.*F^R#9BP70NW<&IS9I^<68*I9CL.09C(<4A*5$(]YQCD\<)\*/
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M#.OI6XDC"/K3#@1\@QN?:"7417I0H<F8$6.%K@O@%<-_APAA)"@EY+Z1V'W
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M>=!]#^GR?D-AAU]%R:JAP+B#:/0W)%.^XY66'#+1^HAI<^YMH]NI;Y(2XAP
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M80Y'D)=+H=;*04*"R25<@@]N3SSSSH,S0- T#0- T#0- T#0- T#0- T#0-
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M>$N*X2H^$DGQH,V@W.QG)\5L,D@68535ZY+4R0^TXQ].N.5!]+B'$I4DH*5
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MU=Q!#4@!4AM"T)[]D*Y3PXOD#CGGY\:"VI9;2E*4I2$H'"0!^4?'C]M!SU0
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MV'!2&!N1Z@KF'C^Z,\YJNBS;&KZIJJFD2M$?W83Q@=I7TC@*G/J!(D$*4%=
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M8>G(;4\7VK$-&2F*GD,^W'<6KZ=)/(93W2%]P0VED&YE;B:JR;7;L*N\"O\
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M*;G;>-B.:Q9UB,:JK9,;(JVO1W5)ARD*CH<2D)*RME];"P$\<@JYYT&JL:W
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M2D]O"E'@ #R3QXT$=C\O"<S[NTSE'<F$V8BS#]EY4="R%%I77DH!*02D\<\
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MAQY#". AMUI*DIX^. 1P/@:#+T#0- T#0- T#0- T#0- T#0- T#0- T#0-
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MP(&/0:RTOZ^TQV;"0ZVPB']2EM/VD/)=;2PB0L\GNA2P$@%!2&C]R-QLFR_
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M2G3]<F8%\K:0&N%-$*2/L<(*U)ZZ"TX;N5G&;[@RI<?(J6LIJ+,YF-6=--D
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MZI_4)E+>Y]/@UI!K%RTYE+Q:?/8:<0A]H4RK.-(925GVU=2A"T**QSV((Y'
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M =!K;;+<V[RRHVFIH$:IQ[#KK:NQNI6/PXBU-I6VJ(TEMM:G.4I2E\A/(/\
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M>3RD'J#QXT$MD7IYP'*E9 Y9TBY$F]EQ+";*$Z0A_P"IC)"8[S3J7 IAQM(
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MK;5[O!6GJH <*/(0VQWJ)N=SLJQNNMJ2#7Q<FPF+F=>J'(6XXPA:VVW&'NP
M4>74*2I/'CL"#P"0P][=Q,D;W,O\(BN16,;5MM;7;[B>Z)?U"7 RDH<2?MZ]
M@1QP?*CSR$\!1=O_ %.7NW.$X12Y!41[54[!:"SJY$22XN0Z](?BP/;?[)^Y
M1<DMN=D_IW3P2 HA]$[5Y7DV3Q+M&48\ND?@V*XT.1U]M%C%ZI4W(2TI2EM'
ME2D%"B>"V2"01H-7[,K==]6'J&C/2)#T2+^ "-&>?6ME@/0EK>]M"B4H[J 4
MKJ!R1YT$+M_N+>X51;98E108<V9F,R_:;L+>8^OZ=Z,M]U!6/*G$=$!/'8$
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MI\$@<_&@B<AVII<CW"Q_-7US6,@HHTB'"?BR5-H#3_7W4+0/M<"BA!X6#P4
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MR4]$\'Y)# G>D3 I-.S5,JN:ZN_AMO$9<>%:.-IGU;:5(98D?/<MI<6$K\+
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M4D%(/7LH<$+W@>ZKN>[<3<EC8W9QI\1<MA5-(1T=>>84I/#*U!*5H<Z@MN>
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M>1)<>=92RAPL@*<]QAQ!3\@\ ^5 :#T>]4N Q\<;N%S9X1_XQ+\/\-?^JB"
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MN< GKR0Q+;TE3'-NMR,:KKJ(C\4L?K,81+CE<>L9$M%A]*ZD>5-*F>]V _\
M-%"?/7C09=ML7E&3U&,.JHL+Q&QAY94W\^#0J665MPUE2S[PCH4ZXOGA(4A(
M0 !V/DZ"LM>F3-J3*6LG8A8?DT@9%D4UZANWGOI78-F]'>2I+OL+Z2&E1D#^
MZ4E25+'8>" N-QZ>+1[,,2R2E?KL7O:1,&&+"A[Q&7JYM:ER8#T0 MNL'DAH
M'[FRKL% CR$WL3LE.V@MKU,64FNQ:?'CN-8S&DN/PX4[LXJ6[$]P!3#+A6CA
MD'J"E1 3SQH*O@7IYR7':?:['+256S:K;6=(F5EBTZM,FR2(\B/%;=1TX9ZM
MR3[A"E]E-I('"B $SMYL1=X_Z2GMI[6;7HMW**=3&=#4MV."^EU*7/N2A7 ]
MT<CC]#YT%1E>G3.;6%9J?701I=AM2G!%-HG/K0W,!=_G=O8'+7#G// 5XXX_
M709&&>G3*,2S"4N1583?TUHBJE.V5FRMZ?4RXD*-%<$="F2EYM7TK:VR5M%M
M2E'JKP-!8=RMD[ZZWD?RNMI\0RBGN:-BEL8&6(6M4)3+SZVY$<!IQ+@(DN!;
M)]OMU0>X\Z"MYGZ:<NOYFXSD272!&27V,6<;W'G6_;9K%1E.A:4M$)4OZ;[4
MIY [^3]OD.SOIQS!$:;"9?IG(Z-TT9Y&?<E.H4[%+X?6PM(:/1P*Y0."I) "
MB1\:"+S;!Z[;?9'.</SFTAQEY/E5G/Q1^N4X[+?G293EA"2AKH.LAM[CA(4H
M*]OGD D -R';&1.V25B%O'K+Z?81.MRW8(5]+.>>7[DPD)Y*0M2W2GC\O*>/
MC05JJV2R.M]/N=;>F^<M%6L>R@T:KB6N0NOB/LEMEAV04EQT-E2CV(4KJ0GE
M74$A2<L],F99%59'':E4;+MEM6C 6RN4\4IE<N=GU<,_W7#AXX^XE/' YY >
M&4^EO,;:9F\F'*Q]3MI)QN[KT3UO.1U3:QMMM<62V&_NCN!K^\!*AW_N^4CD
M+>WLMDDG)-L[QNEQ+&?P'(95U95-*XM+02[7.PN$.!A'ON_S>Y6M#?A"4#X[
M:"+RCT[Y7=Y)F%@S(ITL76?X_E32')+P4B+7)AAQM7#7]XOZ/P!RD>YY5]OD
M(6/Z>]T9M\W<WD['K.U7BV08U+E_7/H]XS)#3L5]+88ZM)2EH)4TGPGDD*63
MH+Q:[,Y9'V/VQI*6=5(S'!55<AA,M;GT$UR*P8[K2UA'="'&UN<+""4JZGJ>
M.-!E3MN\Y=S[#MPT"D_'*Z'8UEC0-R'4Q51I:V'![4DM\J=;<C-DK4TD.!2_
M".!H*)3^E7),;$%$*?42$-8AD=.[W<=9'U]M.1,44)#:N&&UA20>>W!'V^/(
M0#_I$SAK;K-\5C3J%U628?CE();LIY CRZYLM.$I#)*FUIX4E7A7/(*?UT&V
MLLVMRP[BY+E-"JIDMY5C#-#85UD\X$1'V%2%,OMJ2@^ZWQ*=2MLA!/5)!\D
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MPVSQ';]]C&)5G48%48W<1K:XF5;>0,M+6KVXZDQ'C)0E39\(2A;9>6DE07P
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M' <Y'0_"^?MYT& [O+07$.#(QB_QRU0N]8I)1DVR6/;=4?O:1X45R.O"D-$
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M_P#'(\A2BM"B@-H)Z-J5]Q]UPE*?@A<,[V/R[+=RI><0Z-,3ZW*L7FKK7I3
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MW=?#L8M>_.C,SI046(KCR4NN@>3T23RKC]>!H.1<0"[);^MC^Y&!4^CW4\M
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M&:,H3D<.D4E,N/6R6BM)+B4*!)/ 4GN"4GSQ^F@V(/.@YT#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T&N_4/M>]O3L?F^$1I28,N\JGX<>0YST0Z4\ME7
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M2@-. E7!(^.>=!FRL,RO"=Q\LR.!@EC8XC'W"C71I:YED+EP_P #1$,F.R5
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M502[Z91V%F]8Q57<3Z-+?NI05HBQBVVIE@+"B$*0/N4LC[2-!H/+L9NZ//\
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M<FIGID/U[WT\R*XA;,B*X0%!+K2PE;9*2% * Y!!'(/.@G/'[_\ /0<\ _\
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M03S-7"C,(8:BL-LH)Z-I;2$IY/)X'' Y.@[(KHK4IR2B,RF0X0I;J6P%J('
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MU-2ZS%8<$@%')2M#JQP@H\^1Y X#9>W6Y649YN29G\85-=&J\MN,?LL8<?\
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M$"/!CL,NO!UM*9#J^.JD%27&OIVT 'N25)X1H-[;.RVYOJCWR>;<0M*Z[&E
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MD+DNK\!E:4N(2AKAPJ2I7/"=!@99OOEU-E.:0&+",EFIW+QK&XH<C(),*>B
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MMOBTY,M$C'ZY]J6T\R^RY'26W$/$%])1QQPYP._C[^/NYT':-MYC,,POIZ*
MP(89#"6V$I2@,\^R !X_E\GIS^3G[>-!D6V%T-[>55S8T\*=;52E*KYLAA*W
MHA4.%%I9'*"H>#QQR/!\:#!8VPQ.+<3K5G'JYNPFEU4A]$=(4XIP=75'] I8
M "E#RH <DZ"4QK%ZC#:2-3T-9$IJF*.K$&"REEEE///"$) "1S^@&@CZG;G&
M**[E7%?0P(=E)6XX[(982E14X075#CP"L@%9'!40"KGC00$7T[[80XC\5K ,
M<$=^.Y$<:-8T4J86OW%LD%/]V5 $H_+X'CQH+TQ718U>W!:8;1#;;#*6 G[
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M+4XAA)2!PVE:UJ"!X!42!YT%CT#0- T#0- T#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
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M@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@X^=
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M-J\<]00OT.4S/BLR6%!QEU <;7QQRDCD'S_0Z#VX'[:!P/V&@YT#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
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M<>? _301^W&9L[A[Q)R&PQ#,JJR1"?K*MNXQ^3#BU\,K"WG%O.)""Z^IID\
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1@:!H&@:!H&@:!H&@:!H/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>dyadiclogo.jpg
<TEXT>
begin 644 dyadiclogo.jpg
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M !U%9=*Y6(X>LZ$T'>J_SCF?UZ46M+.HK*IY;'UM&AR'95(&"41MK[KZO)V
MUXO[*M?I(CZ12=\19'4-Y?HZP<?=G$>J+<)\5:$R@!0!TH9A';B?.=8R-+_:
MO:B-)0WEJ,[!TS ]+VDQXH%N/_^RRGSX_I=F\J0Y9L*#T\Q==S]G[KSC:7/_
M?9/,Q(DOFQG_GFN6_+@,69(^;P,"YG>RO)T*Z <\,&&R$-,6B(RF37D3Y]BO
M $= JN^[[WQN]AAPENFUX7YFY-4/R#E;AYQR<.XW>D$Z!!M2[G(VP^NS/S)3
MGI]CIJ/ J9,[ALF3W_#[4R:] <PQ+_WK'2CZF9D__SNPZPHIR\,IENP[@^F6
M.HK#V8HG0]"$M*CW<\_.-E,+Z$U]7ICV%D0Z0G#E:*C*_<Z!]EQGOO[R.S/Y
MN=?%'M.F *Y\[EL]>!Y;@-MGGIYIOEWX8T96#D)'4OV#XWEPU$G/SS)34"[+
MD+*"-IDZ90ZV[ABV6(Z[G>05V5;W3L&WG]5GP?SOI9P77%V]'AW$I$FS41_;
MAK-FO&\^^6B^6?+3<D05S@92-F\&ZY)SWG^2#EH7*BO87['\9_/"U+=0GZ0]
M0[ =)Z%])STWV[SUQB?^9K].RG>ZJ,PJL#=8=XST-F_:IC-FS)/(A',[V^QQ
MDNG'"&6K0TSOS0\2]-H,X!;#J]Z_.\QL"A(YX. +S(47WV6F0T^QAT;MH4Y:
M3@VL6+K";+7GB8B8#C9OS?G$//7DJV;;W4\TF^\VS&RQRU"S^:XGF'T&#S=W
MW_L\DMOVWVJWH1)A_>>]+R$CJ!_U(-SQ;Z1#NX.D0UI%^Q]TOJW4EH>D <%V
M'UONUX*D81Z7WN59?YLCS(88DVZ%BNPQ\%PSY,@1YL33;L28]'$S=^[G5@?J
MY702W51Q=T[UM%MV4MQ5X(!WW_,<&@7CW)2NP;[7S9[O#3S]]QD0#SEJ('%>
MRK:VZ2R.&G:-Z;WI8"GOMRF==*OGL(4S_0Y.-O^+;W-EY2%Q8J<[SZ%M]QY\
MGNF]V8%6KI;IVB"T@0#I[KCS:<F?ZA2=@6\K>WS'GY]Q^J \U:$S4-VQWV?K
MWYM^VQTI<QN[[G>F&7CH1>9HV/V\"^\P3STU(]'#Z90>&=0#[9J0&7UESFMS
M36_5(6^KV/1 \6_K5[;,9/H@6TX6R.,[K(OTH<?7GW]K+KWB/C, )+,>"*<7
M?$OLNL7!4CY]NM=6."\ZZ!;@-:8A83E_W&W_,\T9P\>9CS]>D)3+<C1*K(&K
MKWO$]-YH?W/%51-PV&;^-.8QTWOC@>:4L\:845<]8,Z]X YID[[;'&X^_F2A
MY'GPH>FF]R:#S(FGWX1H+5\N88=U8B0W$:X7L2_DE'(D;%..'>Q7!?,$C15T
M$AI0#$4"),NC$5D>F?_P8T?BCO^ZZ$5=I+,X/>4XV[ARSC9B6^M:L_5>I]@&
MT#+#;0K0 8UT\)&7(:OKU.*$ZA"=QZ=H] VW/\I.#(H>&3MF;$1]1EZ-QO9S
M%76@1!K8AP[]SEN?2H>EPXJMMX2MM7PM4]N#YU'N*6>-3<O)*Z\=2-WP<'S[
MG?^P/I7UBXXBM*/6)>53Z( $SNTUX&QSVQW_D.%/J&,Q.'L0CF1F(6)A))+8
M4?70>KFMDI/S+[5KN\@10R0.N]:L7F.NN'*\V63'8VV]U)9J@UQ8<NH=DE2X
M[^RTV4['FNNN>PC%J5ZVS:J!!+WOD/--7_C8-U__@'.MYD]C'Q>=WGOO"R2Q
M<LXX9YSIM?$!&#5PR&?S;KOWJ8C@CD/TN=*?R^(W:F@+&L\IA ZZ'UC9=_ 4
MPDH61;4\>CZY3L(B43'T&P9V_?'[I5#/=D _C L[I#:Z.)"]ZX^XXG[KF%YV
M#9WA3.R\'&HD,NU0H-. K+/.OTWJ0R?BG5;NMJGR><Y>HR[K;_-[\^Z[GTG>
ME*RJ")TH:<^KKGM8.@9E2SGL2"Q'MK;L/FY+^S#:W!:DS@Y0O.PZ@!Q_(X&O
MW7[G,[8SB$XUVJ0P\F3P7.8\[-J'A(6.L_>@<\WT*6]!O]!N->#L*?#'+6;V
MS ],G]^!_#T9Y8#7T(<.QI!+\UI2:D?9+NUKK[UO]AYXCOBUO]%4L2&)2")T
M =I6ME;/5+3GKLLUU^\&'G*A^6#>?%]N+J#7FE6KS188HNVPS^EH6FN?L8Z<
MSKG@=C,:^Q=>^A>ST79'R5.[A=_\*&F8_[#CKH#M#C,+OOXNB P#X!S("7<1
M=FXF )*(I-7L-P3DQ :M8H#VH9H1PV-G)$U+ VXZR.RXSVD2?21A)G2ECH#7
M5R$5;15"XWA7HI6JSA/H!(,..8JA-^W!^J,<W78"\[_\UM[E>#?/V,"3A@><
M"(YWZMF(7E@/3[IUD-43QXS^!AQ\8?KF(G?VRG9(VL ZZ#^?G@DY.0[3$5 W
M0MJ%D1/(R>M4J4O[441&X%.T,=JZ'^[V5U__<*6^>= ZR'[2)K->FV<CTUS_
M"O1"A^=\D+>ILT4A&[MR__7"FV:C[8\66=ERDO9+VR(=*6417-.(3X";%\K8
M<I?C,7*9DZN+[J]<MMQLMLNQ9G=$I#(\P[DQ-UMR$ED,#C8ZP&R/&]Z33[Z*
M?*@O9< WCSGQ&KE)+IB_V)X/RQ&0G"I.)A!RRHV<BL!5/E7QX'QA(#TJR_43
M? J1-"R@CL*M&DXJ;_?Y>#.)GG+DAL=P,#;RR_]Z#UD#>?7@R- /.R6?/<<[
MY!\OO=LV$F0G44H(U0-;$.D&&/Y],(\3A3EE5450-LB5Y7X\[RNSODR,9LNK
M!JL'[77&N;= 9D>&/O5Q1XJ<*E%YLPJ/VXO\_%(&;Q:;#387C[@':FE[A[[%
MX[3N60@YU8N<"/BOCYRR<#=#/\?'?=YP]3J.7YS^#H9<Q[E (92=U,_:K49]
M4]=T/S^]U =E;0C_>7SBRZ(#=4E-K;CC'?N?!H(ZSJQ:N5K.CQG[A-3WX4=>
MD'5/&VY[I!#=FV]]:O,Z[#OD/-,7UWY8I-%48'OGSPTAIR0"J%+9>L80Y%W3
M<Y /-M\.#/S1AU]#M<"9E*QX[",K /M\FK+5'B?!T&ZNIZ(,'NN=!_LHX_?'
MC;*R%"JO&I F%;T%3SU^7+S$;(J&L5%36*Y"];';/IL,,F?]X=9$EI)O+6C:
M<!]UO^5FZR3I\JJ!Y;LVA*UV0*2Z9DWWD9/XCW3P0 ]OFR)P:5,W0LU?70Z'
M\GTP/!IWZU-0+;&AGR?3<U70$'(*RZ$OBS_C!N/\^M57YIJ-$7GWKNB'M>Q3
M>2U-^M60V$PFU#<_T&P*4IP__WOH0GT< KL<>^)UIM<F \VDR6_@-,AIG(V<
M7GSQ74E[PY\>,[TWV,_T1Q2OD]]??K[0]-OF]V:O@<--:XO6W];7PI;1 '*R
M%9(0,N5@H8&J[5>#ILG(0:6W0P3UYIN6A1,G4G)PG5G/PUAWWO5/]^3.=8+?
M6:?,#7EQGO-<SSX[RSE)I4UR@;+L9'S0<-#E D1-,C^0+2<$])%.!0+;:K=A
MLN0@D>&V=6'+]>M?@ ,.N<@^O<DK,P6U@]NR#:'+T_]XS<K*+:_CJ!XY)7HD
M;9/=9I&<9]O:R)0^4WD]'[B.NC+?+;?]'>I9V]DE!_2EV@3=$')R$%]F>?0C
MI\>_7_Z/V6+7$V0Y@*U;7GUXKMKY['[>.0??=X/K/ ?=]P</R+PO_"M\"X%Z
M<ST5_>R 0R_"M;5F+,EIHP&V#^'ZZE]6F5T'G&EZ;3S0/3%=;4X^:[0,]VZY
M%38/2(DW^3!J; @YA7,GPKB9ZWI'JQ9>ICJO3M8*F>B^-5QOG.L#0W#2=K&&
M@RFD#2? _@&'_E&,[,OPH'R%.X=T^QSTA[2,>E!B4D/C^+./%Y@-MCO*/HUT
M]2>22<H0*!_EWG+KDU:&DFP10$_KV#RV.KSSUG]-7]R9ZG::'(C-H<O04ZX7
MV;Y.#4(^.67:@/"3]IGSF;35.VV(=)XL>G->$NWT,(8A4F>U9W:;06,C)]A9
M.R:.O\!-:LM=AXFMZ/<JJ[(/N0<IN=!1@7L(0CFZK6NS!'SL?^S)UUD],3*P
M!&*)F_NGG#G&].K7']O1YOWWOS"W(A+]YBMWDP7HCZ/_]#=9$W;YJ/&F-\AK
M_T,82='7\VU+=,&<4U+IM-&RQ@C2>6-I(V?2>D=UV&2P.>:D:Z$B*V_O-LE[
M0+8SA6/XYY]['>$[9 =.I$^L*G1D&D1:3SS^BI=5$\&=3M*[[?#S;Q>G]+(K
M'%CKA"WNC#OU/\.TZE!*GA2JK$QY>0AT(%')JP0RSY6Q6U&@HVZQVXEFV9(5
M5C:15VX'4#URHGT"?6&O_#FZCJ*Z+<0'0%!<'S7_BT6)/57O*NW0F,B)95E2
MXNLH^C3ZL&-&5IDO93T.,;\-R=N35U)''2K+4SW1+]0QSQ;AN<QURH=///'X
MO[TO^/X%_9?^M-SL,^A<&;X==O3E9C&B++DF=K.V7/7+:G/*:3>97AL. .F>
M8#Y\?S[.)S?A,&+2_0:1$RJS!0S!X1,JH5N9ZW%W)3G/+0WEC9D&[]KB*#G&
M3M*X+>1RPLV_7P1]4W,%6G%W3.>P9%$M_->RL$6=]\,86>76A);%+8\1VB[X
M:K'9!&-UZLBRK,Y5AI($RI,5M$H"G#L+ZU /2"MU=[88<(A&BE7*RT4F+=IN
MXF/_JBRKD\@EIXJ;4X# ?RS2/B40G]*\83URY&40$B#)X#B-&&E+;=,J:.2P
MSK<WMG?]Y9^V_5)V">N%_: />:*B'NQS)#789?UMCY1'^%P$*=<HDY/JWEZA
MS#P$UY%OCP/.,6M6.]]4G;F%K19_MT36)O;9^ #3=^O#95W7'RZXPYSWQSO-
M$<=?:3;8X6C3>\/]S;Z#SS-SW_NORUN[?W6:G'1(QR7Q6^PV3%B1C_"W0$C*
M+9>Q;[;+4+/QCL?(6\I]]0D2G6K3 ^U$GS=4I<%LQ\:YK /#6#OO=Z:LR:E\
M'<!%(#HYC?V77WH/CHB\.8WB"2\X1_UDWL79HBH<(7AG!BX:<4]%Y**RT\,Z
MD#'JL1L:O;751H B2^OB=*\+Y-.70;GD8@,X)>M9E0P#I.JLQW1VZ'_2&:,A
MDCHEY?C]#B*/G%($$>C<#_6@3XD?[:)^9;?$)CL=*X_7V?EZ@R1X,Y!Y-@+M
MEZU;@M NP3YM!C_CZS"<&\GJGD5#AW6T+?R5BQ+3#W&(4%\M2V_D]EA>54&=
M=]O_+/$_/KK_8.X79N&"'\RGGRPPTZ:];6["T&KP[R^QP4-*?HBP+ MO1]3C
M@0<F>S^5"$=]5.K18NZ[?[*L.!>],!P4H"PN)Q@W[@G<=]WZ09?>[ZL]%#C7
M^<@)2G"M!Q<P+ENZPBQ=LER& \NQY3[?O5GRTU*S<.'WYLO/OS5SW_G,O/SB
M.^:!"=/,)9?=8_;G\ONM81 2E5]81J0;O,+12%9HC.E3[<)):RAG+(=D+@;
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M$=(OK Q\VK8#C^%/T(5+0.;_%\,KM$$R=.LDI$ZNSPC47K!5!]JWD2AOY$3
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M!?HEMH*=.!REX]> = QT0&EG/5^OLV7J_0A_<T4=?;L[G<M 3B%4/PRG=AW
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M*U&*R(D?E/,&$Z-:@TZ:] 9"WH/=W$"-#@(=^FU[N'QOW,OQ\O+++(IVD=.
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M1G0;4N24PS&U4)N<-')B07D-'Q$1$5$#74]..85&_$J@=[&\:Q$170Q+3B>
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3/&NTT4$]70    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>dyadicspecimen2018103111001.jpg
<TEXT>
begin 644 dyadicspecimen2018103111001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0  Q<# 2(  A$! Q$!_\0
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M,X"CC!!R 34]Y^V]XEL'F6X\,6*!+BUMG8S.$MM\<AGFD?E2D<B%0H.2,-N
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MQ]M9![T9KXY?]M;Q/8V=G)J7A*#39FCE:5I_.%N[(Q4E9,;D4@>:&9""@?\
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MOQ1XXU*3Q!J]Y?Z7XVC.EWEE(\9MK:&<NZF"(?ZIQ'NE4.&RF-Q+,!7$^*M
MUKPMJ#6,K7LC6T&+6YL[E[-)U7Y2Q94;9E5\P?*FR4N@ZL*;E%.Y<GRQ4VN9
M*^^^YV\4&H16[77A+P_X?O8G'S:A:2VVLSH^Y?+;,3+ H)1<B1(\;.I(.>V\
M1:+IEOX:N]8EL([>_DL?)&LV%G +J4;,K& B;F(P3L7Y?D !RHKP30+BXU;5
MK46%U/=W$L@E2ZDU^V:,1L1&MPVU1L3S]JR $%6QY>X,RG;\2:G8:?K4.LV>
MI*VL7ULVCR0F='@,J2 QQ%3,!+*5*#<&Q\ZMM4$XRE9RT)C57*Y):>?Z:'-'
MQ%-:6?B.6:^N+.2WFCAG2>YE,<,$CMN8Q&2XS\RQ(2!&3YQ'&<CFTG&F:NM[
M?23Z7-=1&);V[L9(F=#M&/L^]I;F(C=P9/+.?ND<5V_AW6/[5U.*YTMK:WA2
M=8[BX^TVT-O9PME3%<R02_NP^.2 <G[OEL,#4^&OPP\*&WN?$]W]ON'_ +3D
MAMK3[.(F@52)(VFD>9B[,LB%2CX..N,X+6U9QNE.K;DEL;OBWQ3X@U'PO;:-
M=I)ING6LENMC*D$\AF22.3>@*'.^-A)&K[=B?,'4;U(\QTM_^$8CMM1A@2UN
M$0R"X$44F'P05%SAK)4DY4E/)?C;GKGZ2\1K9^*?"D.G:KI<S11(\,-PIA#.
MQ55*I]Y&!^_Y;)(I!48!4,/(]0\'0>"/%NI1V=^;NYMK59].NA%<6:-(2K+
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MR[@Q,B1I&Q&S(5'51A2X"@G.>7\76E_H=[<C4;>2Q\A@\TA:"%(X2P'F%I(
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M$VK)-;1A9+*%[PS3S,T;2H%G,B*$:>-E+K@QG&WBO(=.AUB.YB8:7J#WVJ1
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M7  B$?6$$CTU(@U%.VJ?YG6^"-)T_P (6EO=ZA9VE]?HODZ=;LJ- KG<SS.
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MB:(Z-XMB@AEGMPC+=72+YMO&V2!Y5RBA6.1S#%SS7K7=>BJCW6YPU5*M2O\
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M&U:/4?$,VHWDL=OG7=$:5W^R-(H,$_F<"9)("0SY7<S==N[FNFT7PIH_Q&\
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MC_2X8EQY0)#,LDF WRX"YP,UM?#/2[^>?1TL9K>WB\VW60"X1H(HO)4S"5E
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M1&*@@:4_X;9S>@Z;,+K?!/#KM]&'8VT5LD/F/MR$4NF2I. "I&2U>8^--?\
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MN54G+,"-K$EL[2=7D\%1R67B:[L9/$+RRW2ZE #%"82%"[MBL6D2.-9N%!Q
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M'S$E)R<F1AQE@+]K\/[R]\/Z5:>(;P#6$LRC3V&U;6)VDDC4JV=Q:)UA^<X
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M5ENY[N*SGMXC'#;O',?LV0BNJB"-GS&'6)=LR^9)EOO!J)0<OB!KV5/;5O\
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M[/#0U"6-I"P"#;.5R" WW9 <J,'<%8<]XLGU#3M"\3+\&#XENM9?6+2/Q$#
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M3;M DR&D<;3O10V<;4E'2N]TZ*>PUUKF.*YN4D>+7%LTA+)';R-"(4%N@\R
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MF !W$9B*_.6!9@P&<"O)-:T^]TRXGBOP^GM=A[&Z$0+);7B1A9YBS@Y2**-
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MR/!O&WC>QU"2 6]AI\5FIBLXI8;0%+N%W#0R2)O8FPD8%?+(9BP)&Q@M>O\
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M(HW((8JKI\K YKS^73197$\AT+7&.E,[Q3BZ^>YO9AAYQFVR67!=9"0,11Y
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M*X)!93M-<?\ "S4U@\0:=X?G:9]#\52&PN[?38Y-L((+K<1[E#*(9@&61@6
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M&/E##H<-X]=_#3['XCU/0+7P[:O:W%P40M9WQAM;E"P1I9(97Q'M9_G&T%)
MV25VU[)XX^(/AWX=V?G6L=GJT]P8Q]EN(%;9+YBD121L'W.#'(IB49!&"4.U
MBG@C]FKXD_M -J.J^+K6S\"Z3K0A%Y--HULE]<P(H"PQP$,R1@ #-PS$&-&5
M%I4H.6YT*A[:T(ZM/^O(\*\4>)[#3;)-$M]-L=4U5Y!8:KIBVFJPW6IN(_)5
M(5E&9#&-ZK]X@JLO#/M7Z%^$_P"ROX\\7:/:6]U#)\,_#'D"*07+F;5[X*P9
M&>)6\N$J!L7>794"J5P#7U1\(_V=? GP6MD'AW1T.HK&L+ZK>GS[QT  "^8?
MNKQ]Q-JCLHKTRN^,(QV/9HY?&.L_N/,?A5^SAX"^#S&YT+14EUF0'S]:OV^T
M7LQ))),C?=!))*IM7GI7IU%%6>O&G&$4HJR"B@'KQ15I\KNB];!112$9'I4!
MZ"_I1129XS3W"S8M'?\ I2 YI?>AW6C"S"BBB@>H5S'Q"\>V_P .-!;6[[3-
M2O\ 2X"SWL^FPK,;*!49VG=-P9D7;@[ S<CY<9(Z>O ?V@O&=SXLCU'X;Z(F
MKB\U!UTR[&G16H:[CGM)Y98$DN&VQ;85#M)L;[P5 S9VW!<TK V>J>"/BCX4
M^(\<K>'-<M=3E@ ,]JK;+BWST$L+8DC/LZ@UG^,/BJGA?7SHEAX8UWQ9J<5M
M'>W<&B);_P"B6\CND<CF>:('<T4@"(6<[#\M<O\  3PEX<MCJ.KQZ1JT'C&R
MD;1]2NO$.HG4+R/ CE\I)M[((B'B<+%M7IE5(('GO[1,>DZK\73ITNM:+X6U
M(:! 9+S5_&-_HIOH'GG B2.UFC$@C96)9R3^^  '.;48\]B;GTEX:\0V'B[P
M]IFN:7,;C3=2M8KRVE*E2\4BAD.T@$9!'!&:\8\0?MR_!;PAK^K:'X@\8#1=
M9TN[FL[JSN+&Y=D:-RI.Z.-E*G 8$'H1G!R!Z-\(_!VG>"O ^FV>EW4MW:R0
M12JQU2XU"!1Y:@"WDF=R(< ;5!QCG'-> _$>?QQ\)_%VJVVF_ '3?BQH.HWL
MVH66LVMQ#%=1-/(TLD-PC0NV5D=]KCY=I7/(-)13DU8;;L>[_"/XU^$OCEH^
MI:OX,U%M6TFQO#8M>^2\222B*.1MH<!L 2J#D#D'ZUW5>5?L[:)K&F>%-2O?
M$6D:3X9U[5[\WUUX>T=T>'2QY$,<<#,@ :3RHXV9NA+G'&*]5K-^Z]!Q#& .
M<T4=Z*&VP:9@^+2?LD*KNW-)@;<')P<?+_$>X!^48R>!7/)M<,"?,#CD\L,$
M\Y'!8,1]9#Z(*Z'Q8K-;0!%W$R $$ @Y[$=6_P!T=<#) S7,(JB<N,E3EVSE
MMV>"<CKGH2!\WW$P 36$MS"3U+$N9P2S'82<L6Y.?E8EE]<8+#D_<3N:9(&C
MD9,E2A.,L$QM&"<C@;1@9'" @#+FFG+L7W,(XR<MN"XQD'YAP".A8<(/E7YB
M2)8XA&S#<&9>"54)@CD#!X7:.0IX0?,V6-0&KU)(C. RQ@H<  A I7'*@ \
MCJ%/"@EGR2!4(7"(I&4(V8P6SDYP,\D$\X/+GEL*,4'+A50XR<; F<Y^8#:<
M'GDA3U^^_'%-4AMY#+(Q4G))<8;OQRP..HYD(P,(* >P[>SG<)/,5E9FZMD$
MX)..3D\<<N?E7"@FB29@&9I C EF)8*1@;6)8<#'0L/NCY$RQS30X2-S(SJV
M<DL1E3R#EE'7^$LO ^XG/-(I5)-WW!'TSA-NWCIC VC\(QZN:J[)V' M!CDQ
M '"A?D*X!Q@'A=HY /"#YFRQJPK2(P1?N* !&/FSQN &>O0D \G[SG&!4:P\
M#Y"3P HX(XRN%;OGY@K?[[]A3$C8C.U6C88/!</NYX[D'T^](<$X4<E[[C5T
M6$ DB^[O7!R-S-D%N?0L&(^LAZ?*,TZ,[\G<Q4D[V8_,W0,21ZXP2/9%[FJZ
MLT^26/S;BQ#9Z\$DCKD\$CK]U.,FIX]T<:X'R@\G(4C;P>1PN!P2.%^ZN6.:
MDT'/)M<!79&4G+!@H^7@CC@8'!/1 0!EC3H?-0KR5Z;=BA>G( !]!R%/W?O,
M<X%,1N&C"!2I"XV@8P,C /"XZA3P@.YOF.*5F+2#8K _=QC<3GD  ]<\D \M
M]YL 4[V%=EK[4\;>7Y@9^.%)8<GCW.?S<Y/"BHI+@D.=P56S\[/N!R<'D=><
M GO]U>.:A>(,GW@RM\Q).X$-P23U(.<9'+GA<+FA-S2*#E #DG*AN, \CC(Z
M%APO"KELFB[*:N3+-+&=Q)WC+?,P'(&#DC@8'!(X4<#+&E$\GS$NP?<#Q\O(
M']TG P.0I^Z#N;FH5_=L> FW P,+C XQG@;>PZ(/F.6I)@\H /S@C!4)GKR!
M@\GU"GK]YN.*+L6RT'"5QT<N#C 3)&<Y''?)Y ZL?F.%I/M4DP.')3O^\)#
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MS  'J3R=IZ\NY P*+] >NI+&JR[54 @C ;EN"=V.>2#UP>7/+84"F-(@5MX
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M9 58G<69N0<;6)9>_12R]/N)SDU=9ZI,<MA7+("V1DEF+F0 @C@DL. 1]UF
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M[ GTP9#CH@I$K3<61@JG'S%L')8L,$X.<#)#$=1S(>!A1FHR3*&#[ER6)9W
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M_O6VYY(QQO(7<K ]D>\?LVW.OW7@.];Q-XPL/'.L)JMS'+K.EE1;N%V@(BH
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M&%)WI:1CM'3- "T444 )^-+110 4444 %%%% !1110 @&*"<4M%!+85P?QB
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MTTT+8+P.8RN48]1NZ\BO0K29VN8=J@L5P2O.>#QP:9%YTMXR/Q\A()^7^O\
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M%([ Y"9RV2:J>;G:JQMCA<;<Y#'( !ZYQD ]?O/@8%*S$,=JLAX5<+\P.,J
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MIA112?E2&+111038*X+XPEAI?AS:2,^(]+S@XX^TH3_*N]K@?B^P^P>&%/\
M'XCTX8_[; _TIIVU.>M>--L\JMD472K&[',:X"CZ'KWZ^WX58N%6.:)L@,,@
MEATQCK^5+;Y:4NP);8,1 YSP/PZYJ>^<1OMR,-\HVC'3V->&E8\DCO;>/=AC
M_",$Y S^O0@?A]*L!52$8 &&QN(XW'MC(-,F965/XE(ZJV,GZ<^GZFI3^\(5
MS\Y; "L3Q@XY[<5I>RL ^TFDDNMS#RT!P!Z  9Y^O'^>7VJ-+<@(X!"A@<[?
MPR#]:6-HX;PM'M)1L[2!@?AC'?\ 6I[=#)?22*-^\@$ 8&W\O7\_Y*>H'&/B
M0^)23M<Z_P"'><\8_M> @<_K7U%7S9(<Q>)8G.,>(/#[X(X.=5@((X]J^DAT
M%>CA[^R5SMP7P_UW8=:6BBMSTPJ2+H:CJ2'[IK:E\1,B2BBBNT@**** "BBB
M@ HHHH **** "BBB@".8X J.I)<8&:CKGJ>12L%%%%<J=B[!2"EHJG-O0$K!
MQ@^M(.E'>EJ[R2%9; >O!X]***0GFB\MA))@U+28S29-$4I*Q7H.HINZE!.:
M3BXZA84\TF10>E(!5**:N&VXN<]*!1C'(ZT"G)76@@.:\]^.=_9:1X NM0U.
MVU6YL+61)9CI&N1Z/-$H/^L-S)<VZJHSR#(,YZ&O0OQKDOB+X$/CNUT5$O$L
MY=+U2#4T\Z#SHI2@=2CIN&?ED8J<_*ZHW.W!B$K-)BD>:?LT:+%K1UGQG;ZA
MKD^D7USMTF#4?%S:R%@$4:R;C%=3V['S%<J=SN 3EAG:/>#TKS/X#_!V7X.^
M&KBQNM3M]4O+DV_FR65H;6 "&UAMDQ&7<EBL*EG+98GH  !Z;3E)-@KC1FG
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M*^%M,^$^D>)EN_B!J?[1%Q8?$VX9Y-.UF*Y5+'1+,L2;1+1BBE"F ^X+RH(
M(.2%KNX'TU^S1J]GK_PHMM2LM UKPS%<ZA?R/IWB.21]123[5*':X\QF8.S
MMMR0 P XQ7J><5YK^SD^DR?"'1VT;Q3+XWMO-NO-\1RC!U&X^T2>?,,9&UI?
M,VX)7;MP2,&O2B,UDY:V9:0M(12TF>:(/6P_0YKQ@C/+:!=PSGIM.2"".#]X
MCJ,_*OWFSM KSCXC^,1\/_ /B+Q,EF-0.EV,MTMJTA2.7J561VR5B+8+.>7P
M6.$ !]&\7P":6V!0,&!0CR@V[)'R\_>R1G9T.T%CM4YX_P 1+?7NC:C!I\5E
M->RPL$BU,.]K-GY<2;1N='^Z2!ND/RJ-@.<-'+4Y9;GGL7B+Q]X.\1>$X?&-
M_P"&M?TSQ5?-I\46B:=<6TUM.;>2<NC-/)]JAQ"59]L;8(Q\O%>JB1;>0G!5
MU8L,L!]W 8DC@;00"1P@.U<L37S=8?"3QYX$\1:)JGA/PA\,M,NX[B2WN;JT
MCNHVM[4V\N]4=\F*/S/)0_9^0V$&0&KW_P .7FH7>@:;=:SI_P#8^LS6L4EU
MIT<RRBTG"AGB\P?+B/+!2/E7[QR["KJ);Q!Z:&Y"D,#D X<!5)5=N" "  >%
MP,D*>$!W-EC2;(S"K/D[B%"8)!!.5 !Y()YP>6^\Q &*AB!PJ(HR<+\J]OO*
M I[G)8*W;YW["C>@4+N$D3 90LQRK-Z]6#$?64^B"N8J]T!*N6W?,IQNRQ8$
M$X)..6#$8XYD(V@!11O/F 9= "2XW<],,=PX!Y +KP!\B#.33C)ABJ_O"=V3
MG&3]TDE?IM+#I]Q.YI@9P 23$T9#'<0N N,^RX'4CA <#+FF1Z#T+*O("E.G
M(CQM&>G1=N>G(C'))<T?<78@QA@BH5Y]5 4]^-P5O=W]*;MV2)C>%P54!0I]
M5&TGC Y"G@<N_.*;&!A,ABCJ% R74@Y.!GE@3S@_-(>6P@%(JZ) !Y87<Q)7
M!(.\8;MGJP9L=]TI]$%-.752SX7/#.V1DY!)8#OD*67K]Q,#)H\TD%F8L.3N
M8DANHW9&"<G"D@?,?E0;<FI'+I*9<".-<L%+A=N!@G(Z$#AF&0@ 1 22:!-]
M$,4@3$%C'ALYW8VE>#ST4@8!/W4!VKEB:4.%=E4,"I5 $3E2!E5VG@8!)"GA
M/ON23BI ^&*AF4J1\N N".>F<# ((!X0'<V6.*:T0*J  0PVJ-NX'/(7:>3Z
MA3][[SX&!0-::C&F$@145 " %QE@VX[NA.6!YXZOU;"BD5]X/S#=][<3D'/&
M21R02,$C!<C:GRTUU9U.2K+C.>6W!L#)(^9@2.WS2$8&$!ICR,">#PQ<ECR,
M  DN. 1G!9>%'R1@G)IDRTU)?,*J78E&&[<'<*5QP<L!@8& 6&0@^5,L<TQ5
M .%^5E&P!552"HR!@\#:#E5/RQYW/ECBF[I!CY22F#GB,C:,C /"[<Y Z1@Y
M.7.*<X&WRN3(ZA %4$Y(W  -U/\ $%;W>3L*$[!S=3R/QE\'-8\5>/FO+;4M
M-A\,:K=Z3=:S9W%F\EW,+"1I8K>)B<&*5_+8J^#\LCGA\5UWPR\(W?@SPS]@
MO[RVU#4[N\O-2NYK*%HK0275P\SI#&6+"(,^U1DM*5[+FO/?BA\7Y_#OC>\T
M@_$+PEX.TU+:%H8=1\/7NK7%QO#-,TCQS1*H.$V@!C(.3A>*L?LZ_$NY\9VN
MLVVK_$70_'%^KSWD#:3I,]GY5L]S*$=I&9@X:-H$ 4!EP8PTG+UU2C.4+O8M
MIGM+H<MG]YC<VYG.X\;6.Y>XS@LHX'R1CJ:[ZU79:PJ !A ,!=HZ>AZ?2O/=
MRQ*2R'>&^\2%VE1@G<.%VC@D<1CY5RYKT*V_X]HNWR#IGT]^:PAN."):0"EH
MK>Z5T;ZA1114@%%)R![T YIVTN,6D_"EHJ1-V"BBB@FZ"D.32T52DT">HE+1
M12"X4444BKW"BBB@ KS_ .,) MO"0QDGQ)8XY]')/Z UZ!7!_%> W'_"(+D@
M+X@M7.WOA9#_ #Q0SDQ$OW4CS,&);J4RY&<EE#A ?3/H,58O3#%-N.Y&?H7;
M=@X[\<=>M-M;%5D1TD>1CB9O,08.<$#MZX_D:DNX!\VQD^5E!QR./<$]*\5*
M^QY$7<BN97/D;4Y*#<V#Q@D?XU9ARK(P5B<*<[CDD_Y&<57N%78A>1&0@@A!
MM  /;T__ %T^U">:WRR(67<74G>> ,\<'I6C38W?H2P%7NI00JN?48V^P'7I
MS^-21%C>HX9@6P.XZ=L#M[9[>M4E19&"JN%D)#L"I ]/]X<G^M68H+@W:!E+
MRG/S ;<\=3Z^^>M2U89B2HP/BC:60G7]!&"-O']JP]/8BOI0< #/..E?-6%;
M_A*0Y8,NN:&,L<DD:I"0>WMQ7TJ.@KTJ'\)';@G:']=V+1116QZ:=PJ2'[M1
MU)%T-;4OB%+8DHHHKM,PHHHH **** "BBB@ HHHH **** (Y>@J.I)>@J.N*
MK\1I'8****Q&%%%% !2$9H[TI.>V*OX=4P$(S0.*6BIN[6&(3BD([TZDP<^U
M:1=M4 @&:=2=!2TI2YA"8YS03BC-*<<<YK1)O?85Q <TM%)SFHY;O0=P Q7C
MG[4OB.+P[X#THSZE9:+!>:M':MJ>HZI<Z?!;$PS.I>2WG@<AF18\>8 #('((
M2O9#@#K7EWQ_$[:)X9C34'T^TGU^UM;QK6]CL[R2*59(@EM,Y&V3>\9.QE<Q
MK(%.2 ;BGSILANYY_P#LFV^B>+SK7C?1+W5_*N+A$\MO$EWJEE,LEE:2;6$[
MN/-A;,;$$D,KC('R)]($XKRC]G?56U;0O$C6NO\ _"1>'+?6I;;1;N35XM4F
M^S)%$K"2XC=RQ,HF91(QD",@?!X'JY.1CO3G&\KL<0'-+2#I03BN=[Z%BU\W
M_&/XH6.E_$C2)M.NKC2_'.GK>:/9:-JOAZ6^CU.&8P2-);D30(#F&,"0R@<N
MC#/3Z/S7GOQ6\:>"-)C@\/>,-,GUZ/4H9)QI4/A^YUCS(HV4,[PP0RX4,Z#+
M #)&*UINSV(D3_!K0;GPE\,M-MM0LKFTU!1/<7%M.D7F(\DTDK(JPNZ*H+X5
M%=PJA5W-C)^6?B=9>'OB[XLUC4?"UY#XMU/5I4N)+:RT&2[U315?3Q:F%Y<K
M';RQ.@FC2:2(I*\A(.!GZB^"7BOPKXI\$0CP;8WVGZ%932VD5O?Z?<6A0I(P
M8*LZJ2H;(&.!C;P5*CG/B5J'PDU7Q4;;Q$B-XGTYDB^W:7;72WUH64.J?:K9
M=\>5=6V;P"&!(P:UB[2:)/8$^6)<DL0.IZFOC'XMZ7\5OCQXK'A75/"WB3X>
M_!2T11+;Z$;>74M=4''E%HIBMO!@#Y3R0>0<X3[/.-G'0"O@;0?VA=8N/$\V
MB_LY>'O%_C6P@M+2!;74@1HEG<J91<+/<77SQD+Y "0NB9#$ ]U3OSNP,^QO
M@[I^DZ3\/-,T_0O#,_@_2+%YK2VTBZB\N2)8YG3>PR<[]IDW$DMOR2237:UC
M>$+G6[SPW83>(].L]*UMXP;JSL+MKJ&)_19&1"W_ 'SP>,G&3LUA-N]C1;!1
M114 <GXR53=6QVDDH5)VL05)'RG'8G'R#ES@<*&K 6X9-S-(Z$@N=[@X)X8E
ME[]%+#CI''ZUO>,@AN[?=L*K&=V7.Y ?ESP/E!SC(.YONKC)-87F>6Y+$KY?
MS$LX7!7@DGH-O<_=CR%7+GC*6YS2=F-AD8E5P0J,?F8!"NSZ<)M!Z_=C''+F
MFQ0A<*H8[2!L5,8/W@-C=/[P1NF?,DR<"I$7:V%P&4@ (H1E*@L,*QP"H.0A
MX0?.^6(%*D>Q0#F3G "C);/(49Y8,1G#',ARS$* *E6ZD$TLG'EA5EWC&[:7
M&&.0"."P/''60C)P@I&(8 [PV3N+LV[[WRD[AR<\*6'+?<3 R:A1FDP=X5MI
M8]7SNXW%ARP;&,C#2$87"@U*V(VRS$;6))=@&4@89MPP!@<,PX081,L2:15Q
MH)!;(8%3SC";"HP?F'"X!P6&0@^5<OFE8O'F-4"8PH 4*5V@D84\ @<JIX0?
M.^6(%,+&,J"I'.T 87:5Z'&2%VCD \1@[FRY H*R# $;.3C(5/\ @04*3SGD
MA6]WD.,"@EOJ*7+854&\@#:JE@=Q+ ;3@G)R0#@OC>^% J9&);((D&-VX$MN
M!.,DCDAL8R.9#PN%!IB@RQK@ Y7Y6;+J0S<\_>8$CZRD<82G/@2A2V[);YBY
MR.BDEA[9!8=,[$[FJTL6M  .0[;@BG.68#! *MDKT(^Z6'"\(@))-.8F' &1
MM'3(3&T?DNW/TC!R<N:1,"-]S&(H=V?ECV[>#[)M'7&0@]7-,,85@D0 8;1@
M)M*G&Y0 >,CJ%/"YWODD"C<+-$SME-CJ X8( 5#9_B "GZ;@&/'WW]*C$W[L
M$%2&X5ES)E6/;^)@3]&E([(*%C&3MQ)$^" !O#!N<>K!CSCK(1EL)BFMM\ML
M,"7.7.XG.XX+%@ 3D\97ER B84$TA>9(\KLF^0J1ECO+'C/RYW#U'!9?]Q.Y
MIK.&+ $1LF< $)MVCGGD+M!Y/(C!P,N:8/FERG!R69MP&-H(/S#[I ."PX0?
M*F6.0QT,<;!5.!@!=H0KCE<*W"E1R%/"#YWRW%(/,<Y7Y%4[ <* L>".K ;6
MXR.6"MPO+R<X%1M$9"0H$D+KM4;2P96.<8ZL&/.#\TIR6P@I[*65<;3D !4!
M8'.6 VG&<\G!Y<_,^%&*CWJ&>1F$@VY8DLP(8X)XY;.,9',I^5<(#3(:OH>0
M_$/XP>(- ^):^%]#\4^$;:1XHMD&L:=JES*LCHTFR2YMV$(DD$;%$R'8#:JD
M$9ZGX*0Q6?PUTF2TU^W\20W,EWJ'V^QC-M:[YIY)9%A0EC%'&9#'R28PA0#S
M"<>.?%IX-*^)?B".7XK>$?!R3W.CZH=(U33Y;ZZ%Y:F-H[B5TGC6)I!$L+*H
M(,:*%^9C7I/[./BWPIXA\#RP>&/$T7B:6SOKN[U&ZBMOLA\^:\N)7D\DDB)#
M)YQC7)"( Q+.PKKDK4U*)H[M'JG\!4Y1E PP01X*C(&#PNT9(4Y$8^9LL:]#
MM\"WBQTVC^(MV]3U^M>??9I#\BG(8!0L:Y/(W !6XS_$%;_?D)X%>AH-J*"2
M2!C)ZFN>.YK#8=2=:,XH&*W6FIJ &*",TM%',[W 3'% &*6BE=VL 4445(@H
MHHH):"BN,L/B_P"$KS5-<TZ76['3[W1KPV-W!?7443A_+20$*6SM*R*0?KZ5
MH#XD^$64,/%.BD'O_:$/_P 5569*1T=%<E8?%3PQK'C*U\,:9JUKJNIW%C/J
M.+&>.98H8I(HR7*L2I+3KMXYVMZ5UM*UBD%(.*6BD4%%%%!(5QWQ+T'6-:L]
M%GT.*RN;[3-2COA;W]T]M%*%212ID2.0C[X/W#G&*[&B@F<%./*SYN/P>\;J
MI":/9QIM\L)_PGEX1L'08.FGM_*GGX0>-D#E-/MR>H!\9S<G'3_D%U]&8!)]
M:7:*7+'L<KPL-SYQ;X0>-=BD:?'NYR/^$QDR,]?^892K\)?&\84I8C(&T_\
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MP6BMNG9 F]W=G<A!PJ[F.%'W1@=J^;_BW8)??%G6]5N-+5_%VG7=LOA[1_\
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M^XGS&D&V-P"&RIQRJKM*\@8Z+M!R,\1@Y;+FDM2O,?%F--N=O"@*D80@@;@
MIX7 Y"G[@^=\L0*:7 "*5#YPH506)S\P #<G)&0#][[[D* *5'959 AW' 4
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M6' / !<# ^XG.32-(L@+H!DDECOP<GY2=R]?0L/]Q.YI7C?S-JAT*D 8(0C
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M#S2T52>MRQ,\XI:3-&:UEKT)L'2@'-'6EK+96'9$=S.EK;RS29$<:EVVJ6.
M,G ')^@KC] ^+_ACQ-JT&FZ?<7[WDQ(19M)NX5R 2<O)$JC@'J174ZJ"=+O
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MI^8;: ,4#-%-\VP7 C-! 7IS1D44TVE9H ZB@#%%&14OF>@+R%HI,BEI7<=
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M->F^(K%M0TEECC2;<I#*T9D'EO\ ?4@X9U8KTX:4X^ZE<Y"T3:G>0Q;KBUN
MLDL#R;52,_*[APWS%3M4NHY \N,  FO1HR7*NK+.9E\/2686[2[61IT\[S6(
MR$'R,6*CY6X + ;>1''SDU<GU.]U"6#3H9W2VBC&;>/8F#'@D@]%*@?2(8QF
M1A5U)=)CLI5U*REEGM$9H?-/E C)VDX/!0EN>D8Z9<US_@RVM9-<_?1L8(L/
M;+Y0BRZ/OC7RF^Z0-Q$;_P"KYDD.\@#I<FD^=;%O?0]"\/6<%D9K&*$V_FVZ
MQ%=NW( 9OE1CPQ#;PIZ9+R$DXK9CC46B1Y9T"[0SEG+C./FS\SAB >3NE/)P
MG7-TV_MKG46:&/?.08]QC4EE?$BA1DDAN2 <,Y!9R% %:\$L\\4894C=@6<"
M0LH).,[@ 6!(QNP"Y^50%R:\JK)R=V*2MH2LK*#)R0"2T@;*G((+%AR<]"PZ
M\*G&340&PHIW AN,,%V[<@\CA=HX)'$8.%RYJ29F+<MLP=Q<D*P(7#?,,@$
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M(S2U7-%;$JXT&G445E)W+"IQT%05.O2MJ.[,Y"T445U$A1110 4444 %%%%
M!1110 4444 02D[L#I3".*?)PQIF<\5QV=]#6.P#-+UH Q28Q3>X73%I0.#F
MD'-!.*:LR-=@[T4FZE !QGBJL.W<![UX3\5OC#X;^'_QAT=/$/A^REMK6P,I
M\0N ]S9&1F4*B[2VTA#D@@\]#S7NV,U\N_'_ ,/^))OBP=:\*:+I&LZI9Z;&
MA87(N=0MHRS?O%LW(0#E@' 8]<5S5VXPO'NCZ+(:.'Q&,=/$_"XM?%RJ[T6O
M3[GZ,["']JSX/ZMDPZI]M9LY2+29Y68\=EC))_PJO\9/'?PLM?"6H+<Z?8:[
M=R6^PV=@$CNU1L9Q)@&)@&SR0:^9-=U_4=2OG.MW-S#?Q*4:&ZA^RR1@_P#3
M,*N,^PJ_8_##QGXTTN9=%\)W\\4T;*EU-LMX6Z<AG(R#UR <\UYDL34G>*C^
M'Z'Z;#A7+L(Z>)JXAPBM_?5GZ2M'\$?<_@"'3[?P/H$6DV\EII:V$ M8)6W/
M'%Y:[%8Y.2!@'D_6N@K.\.V!TK0=/LB<FVMXX<_[J@?TK1KTEIL?BU5J4Y2O
M>[8444A&:%:^IF SGFEI ,4AZUK92T0^HI.*\I^.WPZ\5>/5TC_A&=1@L3%#
M=VLK37DUL;<W"I&+R+RE;S)84\X(C;5S+G<I45ZL!N_"O&_V@-7U72;_ ,+#
MR_$DGA:7[4NICPM=1VUT)L1&WW2LZ,(\>>"(V#$E3T!JX*UNY$CM?A3X1U#P
M3X2_LS4KL74HO+J:%5GDG6W@>9VAA$DOSN$0JN6]#T&!77 YZUY/^SGXPUKQ
M-X/DM]:L==CFM;F?[/>ZXL)DGMFGD\A3)$[+)(D8178=^Y.37K  /UIV=W<:
M:L+P* ,@=Z78 .3S2?= QUI6TM<+KH&,$TAY/%+G=2@87I^-7L)NVXFW<"#T
M(KYA\6^%_&FBZW=6MAX2\7:SX,'B2+5UT>WETA8YISJ*7#2I,T_G"+SB9]C*
MIXVET7./I\\^U?+_ ,0/C_XST#5;NP74+/27&L_8;9)OA_XBNTDC%UM"K<QQ
MB.:1X@2/+&"QPK8P]-:W)>I[Z]AI/Q)\%6Z:_H ?3M2MDFGTC7+9&:+< VR5
M#N4,IX."<$<'O69X)\8> 8[R+P5X/U31&ETRW.-'T62-ELHE8+M9(\B/D\ X
M)YP#@UI:CJ-OK'PZN+^X^S):W>F-*_\ ;%I)#!M:+)\^"3:Z)@_,CX8#(/-?
M,'[-_C/0/!'CUM(U'QOI$*3V8AM-)\/^(HY-"1VE4((+2<_:(G).U0F8P,@\
M[<YJ-[MC3L?88!Q2$8![4N:#S[U-M= ;9\,^ -#N-"\1Z)\1[&"ZT_P-XG\4
MPQ"&V\9Z@=1GGENO(BENH2HBF!<#=!N.Q,C)V$5]RKD 5^>7PWUCPSJ_[4%C
M?Z-XJ\ 37AUMENK^[\.+I]Q>2LVUH[&+[3(S2MDJ;AD0')*F3)%?H:.@K2K9
M)6!'(^(G*ZK(0?+(0'+,$!'1CGJ.H!<\@?*HRQ-8V&W,C*N\<#)5""G(XY"[
M0<@=(P<G+G%:?BC='JK, R8VMN4!,X R<D\X&3O/" \ L1C-0OM0#. P&S;\
MP/W@-C'@_P 01NG^LD.<"N"3M*YC+<Y+Q'X1@O7\Y_9$98_WD9/*J 1RN?G$
M;G')ED;@"L:6"71-,26YEMIXHEW-)'YCLY>0!9$8?.PQD[@-TS=-L:\]Y?(&
MM]C@3(Z&.1&5I0RMG:"IY<,PZ<-*1DX05Q;RVDFM+;7$<(AF2;YG?S4\P[HV
M97X(!/[LN/O<11@*&-=<93G$U1?ETC4YKSS4NVENK=))8I5D9)26VYW%?E?(
M^5I$ .,1QC[S5M:.\T.FJ+_<EQ'*</.ZKDJQ*]MJ;1QCE8AC&7-<_I&H+;/:
M6=[M2_M,XF65 9HU&QF4J",KPK$<1@[4RQ)KK6G.(!*OGK$HDGD7"^40 T?R
M-T/\00Y"<.^6(J&V_=L:<MM$7PJ>8R(0'W;#M RI WJ-IZ$ [@K=!\[Y.!2+
MS^\90P8!5"Y8,&.< 'D@G!QUD(RV$ %9=G>E[ZZCV91Y?+153).?FQ@X)W9W
M -\SD%W.S K3WJR*X=-H.\L27)#'&<CYF5B,<<R' 7"BN:2Y78YI(5I@Y+1G
M+,=Q=F.U@3M))ZG/ W#EL!$PN37/:AHT4-Z^HVJFY$*R!H!+LQ*IVL0<;1@;
ME8\K&/E0%B:Z: A)P225!;<V_&"!@G('7& 6'"\(F3DUQ^JXDGFS=&PEAE8&
M,#8[  D$ <84,IYR(PV3E^*WH6UU-(^9BG^S9)3%>:<]Q:L1% L!,<B-P41@
MQ 3:"6QG$84LYW, +VC:';W7B>V2*+%I$_E>3*V[S@.5/7)5C\X#<OP[G&!6
M9?RRQ:L#9R(S%8_+$\!(;*;R@#?BP4\\;WXP*MZ7K=[?7(&G+&L@@+>1+#YN
MXLH+$$8+!F&<?>F;NL:UWR4N7F1;21V&C:&;.[O8F'G02%'CF9OX78[QN'S-
MGC+=9#P-J"M6*01HAX=U#.6:3+ ]"21QQT++P!\B#K5+1M3?4;5+I$(AV9>Y
M$I;S).CC('., %QU^XG&35F">*=2_F@LI?+,0C*4&&''"[<D$CA,X&6)->;4
M;;O(F5UL3O"J1D A67@*H"$;1[\ *#D#HF>[&FJH+!3Q\H5!&O.<9"[6[_Q!
M3[N_85'*ZJB! Q(V_(L/0\%0%/0C&0IX7[[\X%+$Q).5W%N$P=P /.,'!8$_
M\"D/)PH%9\I%Q6\N=&++OW\8.2"">>, L&(^LA'9!36R S2':OWF+'\"=P]>
M 6'H$3C)I%F8;GSO&<EBV<Y.TG<!D],9 ^8_(F ":XCQ;\;?#7@76#IVKSWJ
M742++)Y-A+(D:\C/F*I3(Q@X)"#Y1SS4-VW.FAAJV)G[.A!REV2NSN1Z;<8)
M&5(0C;Z=AM!/M&.!ES31'C!"DA2!M^Z00,K@'CCJ%;A?OOS@5Y[HO[0/@^^\
M-S:S:WMTMK%<&U""SDCE=PF<1QL/F&#P/NKRSG=4WA/XV^%/&&LQ:-:7$]MJ
M,RLL-M=VK()S\Q*H22K$X+;2V6(+-P *2G%/<ZWEF-C&4Y49)1WT>GJ>@6YW
MW$()7:NT$?,^<G(&?O$' /\ >?[S848KNNU<1;C9<PR;LX9<.TAYRPYW=2">
M_5SP,(*[8MQ7725SSXH!@T8/:@#O3JZ;%-VV$Y!YI:3/-!.*QDFW:Q6XM%)G
M H!S2<5:Z%J4];LI=1T:_M(93!-/;R1)*&==C,I ;*,K#!.<JRGT(/-?*/PR
MTU?"7[1$6CWCZ5>ZU;ZS):2Q?VEJDUXR-H_VC^TO*N;V8$?,MGYK(6P-H<#"
M#Z?\<OK4?@K7W\.*C^(%T^X.G+)C:;GRV\K.>,;]O7BO$?AX]LWQ \)OX1N/
M'%Y,XF7Q0WBO^T#$D'D2%=PNAY<=Q]I\C"6^T;#(<; M:4W:)#W/HD<>E%)M
MI0,5'N6+:/$/V0M/MO#?PQU'PTZ1Q:_HWB#5;?6(U&'-P]Y+*DC=SYD,D+J3
MU5E]*]O)"C).!7/1> M'MO'4_BZW@>VUNYLA874D,K(EU&K!HS*@.UV3Y@K$
M94.X!P:G\9>#]/\ '?AZZT35'O5T^Z 686%]-9RLH(.WS875P#C! 89!(/!J
M96<B4CS3P3X@TGQY^T=XOU309XKRT\/:/;Z!J%] =T<EX9Y)C!N'#-"F,CL;
M@CKFO9":\Y^$'[//@7X#1W\/@;2[K1;6^*M/:MJ=U<PLXX#A)I756P "P )
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M6A^/?%'A"S@TKPQK=YI%M-.2D%N8C$)'?GY7! )+?Y&:^DI/%O[.^KX673]
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MS8)8EDC&=BA:J,DVQ,]9O[K53X)GN9+86FM_8&D-M92).(I_+SMC:7RU?#<
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M+*RMC>1"5H[J.X^40LJAE0Q-R"=V]5?@#,DA)(!Z&GT+<4]3KV3RB8T4L!P
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M#+&B(H69QF)@3P7VXQP3N' QP"PR$Y5<DYIK&-70$;=FW"[ A&W##Y3P,#D
M\(/F;YL5IOJ4BA?Z4)KK[0F];ARL>^'Y)0.6&,]-N<A&X49=\D@5S^I2/:Z\
M/M443P7K#[(R_?;Y0SHHX+ E%81G/F'<SX08KH]2U..UW0*1+,VWY51G ))9
M1M)&2<%@"03C>Y"XJ.-8M5LQ/&$VR9*-(K.!N.#SPS*QSTYEX (09K>,I):H
MU5[:D=M8C59(;Z262-L?/$6WI*#D;LCJ3DKN !?&U0%&:NV4LD&D)<3-M6#=
MOWNH*[!M+%E& 0/O%>$QM4$\U&MO]G>-II3*8&\Q9)&"L#MVDEAQD9*EE^Z"
M$09R:EDN2MS%"K JAR\^T* R@Y5><*5'KQ&#W<U#=Q]+,;?W<<JN[6_E;5)$
M<A"X"#()SPA .0#Q'D,WS$"J<X'G1&W\W:'7>BYVC/W0%/+9)+!3U_UCG& 8
M+FUF2>66%%EA=56*W:/!8'Y]JJQ')QN$9Q_?D/05GV5S%=VC6EP'/V@YB<AI
M(B"<@$$AG#,">>9B"3B,5M!:$/N:=MKD=S/+%8Q(V<DR!6*/N;!;CDAB< \-
M*R\809J3Q5!*;2WDAE^Z[9E:3&01@Y(R "1M+#D?<3&2:+"W87,KH2DI#'RW
M)'5@"QVGYB=N"XZX"1X )K:N;*.^B*2ER$DW;T8+M9>"<_PD#(R.$Z#YJS=H
MRT+CW9PUII0MY\%\,YV G"&/8.F.B[1_P&$9ZR&K^G6'EIM2+."%$8C.3_$H
MVL>.[!&_ZZ2'/%;W]EV=CLCBM8DSMP&CQC;\RJ >A'4*>%R7?+&HO,#*T:>7
MAR<HD>5)8[L8/+!CDX/+GYF(7BE*KT1I>Y"EL)(V=8-R$'!VEU8,>2.A8,1U
M^]*>>$%>:^)_CSIG@KQOJ&B:SI=S):00I*+RS<2O)(RC*LH"X)5L%PQZ;5 '
M7TY[K<"WF!B1N^=BPY.,Y&"<G@XY<_(N%!-?,WQ$\*ZKX^^.&KZ/I][907#V
MD$ZQ:@608C10PW(& (W=!P "!D@US59R45R;W/I<@P6%QF(J1QVE.,6]VK6:
MUT3.J\2_&KX:^-+'[)K&@ZIJMJ,%('L8UV$#;E3Y@*-C@%>$'3YN:YO1?C'X
M/\%W^EV7@CP%-;/?7<-K=7%ZZPRX=U 8-NE9L%B0K$ 8R<\8\UU/2DT'Q'#I
M%SK>D^7YBP2W]HTDEM;,<8\QM@*X)YZA>K=#6AKW@J\\'>)_ PO-4TW5HM6U
M&TFMO[,#3I(GGQX?+;1@G!7KG&3P*XG5J:[77D?I4<FRJC35!3FXS3:BY2Y7
M97O9)+3<^R;*YB&J6Z H7C< ,#CY20P&?O88C.#\SD%F^4 5VT'R8)!Y[E>M
M<'HI1M:BEA4;@1B628N"&)R03T!/\?WI#TPBUW4-Q+& ?,+=\,.#7OP]W8_%
MDNQ+*P7/&TG@$55=67<  ":F,ZRX$G[ICW'2GR0N8"XPW<;>?Y5M=]BD^7<J
M'8(V9V&[L.].2UMI %:%"N> 1D?E5>5'9P2,8(XQ5NV)$9+':!VJ9&K2:N:5
ML$V?* #4XZ56C7Y0,<@<&E>>1$)6,S$= ,#-<TKVL<+U;.;^+;W2?"_Q6;'5
MK?0;P:7<F+5+NY^S16K>4V)'F_Y9J.I?^'KVKQ3X!^/_ (:>)/'MO9^&=,6V
MUH6LI\]?&FGZL&4;=W[N*_FE;/'S&/W)%>N_$;Q9JOASP3XBU6+[-I:V-A/<
M+<W,+78C*1D[C"A4N <':&!/3(S7B'P0N_$]E\28(_$T,LNNZI;S!=:UG0+F
M&[N-@#M%%(\AB@C&<^3&BJ<9P3DFZ:]UW(<==3ZJHJII\=U&C_:I$D8GY2B[
M<#WJX@#-BL4M= EIH4K,V&H6L=Q:_9[BVE&Z.6+:R./4$<$51\20ZA;:+<R:
M!I>G:AJRJ#!;ZC<&V@<Y&0TB12%>,]$/./K7YE>$/B%^U+::&;;P2GBM_#$-
MQ<I8-!X=M;B+RQ.^!')+ 69?0Y(QP#Q6W)\3?VSXFP+7Q@Z ')'A6PY/;'^C
M_6M&FI&=T?6G[.OC>_\ &7Q5^*D?B'X>0^ /%FEC3+*_^RZI]MBOX]MP\$JD
M11C 5V^;!)! .-N*]_)Q7R1^PUJ_Q#U_Q9\3;WXG0WL/B9HM)CQJ%A%9S&%5
MNMI*1HJGDO\ -CGIGCCZW(S5.*<[V*BUU$SFEVTM)FFFGH@UZ #FE)XZ4W!%
M&":+):C:N!.:4<]: ,"@\&INI=!OL@-)NI?>@'-2[); O,6FMUIU%2I).Z0+
M0**0<4=13LDA:W G%"C+4 8I:.91T*#.*0'-+12<DU:PEH)GFK"]*@J8'@5K
M2:(D.HHHKJ)"BBB@ HHHH **** $HI:* "DI:0C-)WZ 0O\ >--/ZTY_O&FX
MYS7$VN9FD=@'O2'&*4C-(1BKBT[6*0 #%*.E(!2@YIS;2T$+2'-+2$XK*+=P
ML5=2TRSUJQELM1M(+ZSE $EO<QB2-QG/*D8/(%<RGP<\!QW4=S'X-T*.XC8,
MLD>GQ*01T(POM78?>H'%$XWU9M"M4I75.37HVCS:X_9P^&UU=SW4OA2T:XGD
M:620,X)9CDGAO6L[X:_ :W^&WQ*UW7["[4:/=6J6UCIP5B]L"0TFZ1B2P+*,
M#MS7K=)NK.-.,FG;8[_[5Q[I2HNM)QDK--MJVCZ[;"TAX'%&Z@C-:KW'J>7Z
M@#1C- &*6E)ZZ,5D)C%(1S3J0G%5%WE<-4)R*\$^/OAK4-?\?Z!=?\(UI?B?
M1=-TV>:ZT_4H?+:Z+31KY=O<E@L<P4,RH_RO@@E/OCWS[U?-'[6'AFPU_P 0
MZ#]IL;+Q+>);>;!H5UI-SJ!00WMK/)*!#!/Y221Q/"[,F2'"KN^93LMT3)W/
M4O@-ID</P\TS4)-#_L"_NXBLMH]J;:6.))9/)1T/*E4;H?4^M>C5PGP,MK:S
M^$GAB&TU*+5K9;0>7<P1O'&%+$B-%?YU1,^6JO\ , @!Y!KNCQ6$[N5AK8.#
MS2XS2;LFE JHIK<'H'2BC'-%)IW(N)P!7R3\-1X^MOB'I<U_HVKPV]SJXNI;
M[6M/L(+?S':ZCNVB8A9T62%;-HU $FY2')4L*^M2<@CVKX4\#>$/#'B+XT:3
MIFJ^ /!%Y%<317[::N@N-5MW>74DE>XNI)F:8PM:Q^8TB!&,R[<$(&TA=)\P
MWN?9GQ \3CP7X'US73)#&=/M)+@-<*[)E1D J@+')P,*"3G KS?X:_%[Q)XX
M\4:AHEQ_84-Y8E&FBB@O8R5615N CR1A'>,ML8*QVOPU>G^,]/T35?"6KV?B
M)H8]!FMG2]>>;R$2+'S,9,C9@<[@1C&<C%>;_#/5/@]HWBJVTSPEXJT;4?$%
MQ:2QQ11ZZ+ZXFC,SSRD;I7+.TDCR.WWFP"V0@Q.D5JA=3V*J^H,BV%R96V1"
M-B[ $D+@Y.!5BL_Q!*D&@ZE+)]Q+:5FY[!#FL>I3V/@G]FGPOI-U\0/A]+:Z
MC976GVJV7V2YT_X?ZM9&ZBM+.XBMYOMDT8B4S"X,DA)P3'&%)W$U^@N*^/?V
M?/C=X[MS\,_"]SHOAFQ\)7-GI%A EE)=/=0PSZ7/=0#=)\K%4M0C$YY;-?8=
M:U6^8(G%:T1_:MPN0"67+*<G(7(Y;C*\D#[J9+')(J@1M^X1R @"Y;(/S8"G
MKG[V#RW+N0H K2UU$?5Y<Y9B43 &_)ZJN#QG@D)T'WWXQ66L0E)'[IM_0'YE
M;=T[@L&/?@RD=D%<6J;,G&[N#2O+$L)VN77+'/F*0V>3T+ACQQ@RG@80$TZ-
ML1+C]T,EW)<9R, G<.,CH67A<;$YR:>JD3"0N& !;<S^IV[B1W/0L/\ <08R
M:;)(D<3'RL"/IM98RI7C!(X7:#R>D8X&7-/X@Y;NXY[H6X;>RQ*@.$)$>W8N
M>3]U=HQQTCZG+FL>YO9[M)(8X76-3\J*@!<$;ERC$#)()",>GSR<<5+*?.FV
M%2JAL$*  @ RHVGCC.Y5;A1\\G.!45X(K+2F$<0DRNT;59\[CQ@'E@QYP>92
M-S$(*UA%)FT8&#>12-(TK#S5;)0H&<.&?L>KJ[8]&F([1KS>TO75TZ3,A,T$
MA+2$'>2?NL^\#+9^Z74<G$<8P":I222S(UP^UU^\79MQ(;Y"QVC)!(*DKRY^
M1,(":CAMWD8F56BD"F1F9Q&RX #'*Y VCAG7B,82/+DFNWW6K,Z.70Z6ZTX7
MMJMU!\DA!9%,HB=-JE2&9<JI0$KD#$0)"Y<YJ6-4LK&*&Y<QK$P(0H$ 8$.N
M%/ VCD*?N#YY"6INCV26SR2-'Y2\(D.Q48;2Q ]%"CE4/$8.Y\NU3WFE6NI/
M)$9%9E_=>40&P"-ZKM;KGA]C<L<._P N!7,^5:'/*(UYIM?TN*XMY1%PKQ.J
M,Q()X*@X+ XR <&0\MA.#D(+JWD2TO;59+<NX-Q*?,W;\ DL,;@Q(!Q@R'*(
M BDGI'4(TC.B7#;.3][Y&P.HY.X@#L9&&!A15:"\M+JX9L^5(%+ ,W3D*2".
MO0*6'3(CC[FAR2T)2N1Z5?37MW)*ZQ1Q6[NH99.@7Y3D@X!&/F<#" ^6F6R:
MVK;SE#;VWGS,9"],<@8Z+C/ /"#EB6-4X;>.V=3'&N&P"(P%*LHP.,$+MR>.
MD?NYJSY0P%6,(H(555,?[0PI_,*>GWW["LVS1*YG:A.T<_DHJ[R H1OF)SE@
M #US@L%/+?><@ 51V2NQ?:61\CYR65BQ ^K*3QG@R$8&$&:NZC-]HN&RB%3M
M0C!<,'[8ZL#Z<&0CG""HC+& Q8D':6+,W)Z*QRHY)P%+ ?[$?K6-M;&J5B&[
M<QEF;>1AG+L_ .,,=PXX'!8<*,1Q\G(\7^)WP@U+5_$E[XLB\76GAI;81^3*
MUN4>U9%"GY_-"CC)P>%# '+'%>RSSJC(#\AR<,R!-FQ<DEAD)M!Z](P<#+FO
MG?XK)XE\>_$:X\,:/IE[J,.D0QL((BMO!@J&WXD(7/SD $DC:2>>:*BBH>\K
M_P"9]-P_&L\6W3J*FE%\S=FN6ZOOIKH3Z0?@RMA;V^L7&C:]JV#]KU./29HX
MKE\DF3:%V#);@9P?O,<<5B^'?@6OB37--O=&\;P:GIUA<V\D;P6 = B2!A$H
M63"C*D8P"Q/W0 :Q%^$'CUE!_P"$5E9,!0PO;8C#'Y3CS><]0.I'/2HM$C\8
M_!WQ=HVL7NDW%G::C<):7,4>R9+B-Y!&P/E,>1NRO(W'(4XS7#/GFE=62/O:
ME#DC4>78_GG)/1RA*^^B26FG8^Q=*MI+>_M3,X:4G>6R&.3P6W=,G@%O<*G&
M:[ ,5.2 /=ORKC]$&[4(MD6XB;&Y%!R1@-D?=R ,%NB#Y%RQ)KK+F6%(SYLB
M1*6X+,!DU[%)^SAJ[GY''JB.:1)25W<\D@=>W:L^+4#;'8DA1@<94G\ZNM:]
M^.>1CGBL:_C6TF1V* $<[ADDUT0JJ>CT.E)6L:4'B&.XV),?)?)4.0 ,UIQG
MRV#$AL@X.>&'J*XB>999<A01D\D=\XZUJ:%K26TT<$RDVS\AFY"'CH>N*VE#
M2Z,Y0LO=.PBD(0'MC@"IEE8$Y4'!X/2JZC"CY0=PSQ4R;FP&^0 U@<<D<;\:
MK^TT_P"$/C&YOM/&JVR:1<F>P-PUL+A#&04\U59DSG&X D=0"17BWP:U7Q3)
M\8+&W\91W&ISVKZCI-C=S>(H[U;26%8GFVQ1Z=:;MZLH\URS\$<!CGZ#\?6U
MI<>#=7COYWMK-K9Q+-':K=,BXZB)TD5S_LE&!]#7A'P9US7-;^*=H+G4M:UF
MV235)G?5?#,5@L<.Z);><2BUB.^8%L@-\VPY4;>%!I)ZG,UK<^F:3%+1W ]3
M7,NPVC#\$SZ%/X2TF3PT8!H#VZ-9?9P5C\HC*X!Y'XTOB^ZUZTT.:3PQ9:=J
M.LY40V^JWCVMN<D!BTB12L,#) "')&,CK7YK>%/V7_CWXK\)V.N>%M:GT[1M
M0+W5I;IXKN[4"%W9@1$GRKG.[ /?G!Z0^$?V>?VA_%U[K/\ 97BN^N/[%U&7
M2KG?XXO0$G159@!D]/,7G@\&M.5IW2(OT/L_]G3PGXWT+XB?%'4_B)K'AW4/
M$VLSV%S]C\.R3-%8VRQRQPQGS8T(R%8]3D[B<9%>]U\K?L0^!/%/PZUOXG:1
MXTN)+SQ"+C3Y9KB74'O6=#;ML/FN=QX&,'I]*^J:4I2;N]"DKH*3%+14)V*L
M)UI<\8I/NT YK5IVNF%@HP*",T-TJ4K6L]P2\PQ0,=J!TI:4M-+CU"BBBI=N
M@E?J)12?>IU6U96;"S"BD)Q1NH4&U<>HM%)GC-)]ZDH]P%)XJ=1D<U7)[59'
M2MZ2LVF3(6BBBND@**** "BBB@ HHHH **2B@!:**0T 0O\ >-)0W)YI,\XK
MDY$W<M;"X.?04A'XT=*56P>E6E8=WN(, #UH Q2[>A-)FHDW>R!:BTA-%'6D
MI=6-*P$XZ4 T8%&,5IHR;H#GM2 >M*#FEZU$='8;=AIZTI-&!0>G2KLFQIK8
M3FCFE!H)Q6;;O:PQ<C'7FFD9H I<X/2KT3L*UMA!GM7F7Q3\,: =<T_Q%JGC
MZ]\!7BV[Z>EQ:WUK:K<HSA]C>?&X<@C(QR,MC[QKT_OFO"?C@MQHOCO3=?T^
MR.J7ITR6P>VO/"]]J]M&AD#;U>V4^4Y(PRG[X"?=V@EI\SLB&[GHOPO^']O\
M.?#L6EV.O:EK>G *UN=1:!S&O))5HHDW;B2Q9MQ)).>378#/>O*/V:O$NAZG
M\,-)TC1WU,MI%O%;S)JNDRZ;("06!6&0?+&>=H4L !MR=IKUBLG>+&GH!Y/3
M%+GC&*0?> H;@UJK]16 Y%-YI0<T9YI@KK0S=?N=4M-(N9M%L+;4]24#R;2[
MNC:Q2'(SNE$<A7C)^X>F.^1Y/X/^.?B/76\&7NI^#=.TG0?%%XUI;WT&O&XE
M1O*ED1C#]F3(?R3QNRN[Y@I! ]J 'I7RIX'M=$A^-V@:OHMUI-_+J>HW:2:A
M)X*?35NU,$S.UGJ!3RYGW)DA3^\0.P8A3D24F[@W=GO7QANM,LOAGXAEU:::
M"P%MAY+:SCNY02P"[(9$='8L5 #*1DC->9_ R_75?']S-+KMUKQ;2F,0UO0[
M>PO[26.[D@N8P\-M&KA7C"N QV,JG!$BD>G?%S18/$'PU\1:;<W-O9VUW:-#
M)-=W36L04D AY5^9 1QN7D9X(/->/_LW:?8Z#\1_$FEQ-HVI7/\ 9T=]_:6E
M>)+[6B!-<2F1)#<NWDEG&_"G]X<DYV\+6S%U/I #-4M<U2'0]$U#4KA'DM[.
MWDN)%C7<S*BEB .YP.E7:I:VQAT/4)/.DMMMO(WG0Q>:\>%/S*F#N(ZA<'/3
M!K.-FM!L\$\"?M1R>+/&_AC06\)65K::C]GMI+NUUA)VM+N:REO8X4C$0\Q5
MMHXR[A@%,R@!AEJ^ASP:^(_V;4L]-^-MOI=EXHUB72+9GGTVTE^&D6CPW<DU
MNQNBTZV,1@(,<1)WKOVJOS<"OMO.36CBKW*B<?KL8?49PP+,=J@/\P(/10!Q
M@]=O5R/F(515!I"[%F^8MELAR=P) /S+R<XP2.6(VIQDU;UH-_:DP*9 ZJ$(
M&UB >!S@XQ_>D/ PH)JJ_P!\L2 1ECO8*<@;2=R]".%9QPH^1/F)->?+1F+W
ML("L66&Z,+RS,X3&T<Y8# V@8+#A/NIELU4N9IIY5VJT0Z(-H4_*<C@G@@'<
M%.1&,N_S8%.N9,!HHT)"C9NC(C(*@8 [+M!S_=CZG<YHB@$8#8 <!4R!GK\R
MJ V#DG+!6Z_ZR3L*N.NIM%=2&&T\A5BPO V *,DG.X* >3G[P!Y;EWP,"LV\
MB>\<?*9"J,>59U<-QNR#DACE<\-*00F$!)UI02J%CN!&P;F:17#$XXSN<-[8
M:4CL@JG>WGE.P1AD9D<-*!A"0KLS#Z;2Z@GCRX^Y&L78U5RFMHEJZLQ)N 2=
MS/CD#:6+J, XPI8#"C]U'R2:U]-T-@JSW9>(8W!2H0C;T9AT38.@Z1@Y.7.1
M/8Z:+27[0ZF,)\T<3$1A-H(&X]%V@D8^[&#QESFKSC&5V_(V%(51E<#( 4CC
M&<A3PHR[G)Q3<[Z(SE/70J3;S Z1L^X* @CCY!^\H ;C)^\%;_?DXP*X\M"8
MH[A)!]ID<^;&"61@S\9'WG5V&>,-.5_AC%=%J4MZ&81$.)&5-DD?F+ACTV\%
ME."<?>D;EBL8K.:&*2YOI1'$UQR"'<C ?Y68E/F.XC:64?,1L3"C<;IQMN3N
M]#8TN<38F<@73(X8-)N!(.TL2HP<GY=R^@2,8R:H:KI\D5[$XC,"H=R+D1A"
MJE<Y&0NT$ M@B,':H+M4NG6\LLD,\K$&-VP 0"A7 ))7Y00,@L.(P=B98DUK
M.K,&MR^W?PG 0@  C"GA2HZ#HF-S98XK-R4)#:?0P]%GG0S6\N1(D@V(FT?,
M.0@4G@@?,J'.P'?(=QQ6ZAE=Y#+M,;8"C&0P;G;C.3G/0\N1DX7%9:V*0S6^
M] J J%*@GS0<LB@-DG^]MZL1OD( P=.)8[>!D>8EBY*LY+##-MZ]6#-@>LAX
M&$%34M+5%19A7VJ1I+,ZL&3/F!LEP>2"<J,G)P,CES\B8 )J W8@5G=A$1EW
M#N$8;0 26'RKMS@L.$'RIECFHM:DMK&ZDANHKM74&5;F()_ND[@>#@[2X P/
MD3G)K.L];TXC=+/<6;1D%FN(M@&WOU(7"C@?=C!).7/'%[6%[/0ZEJC;A8NB
MJOFQN7 7"[&'&5&P\+M&2%;A =SY?%>5^-M(U[X<_$6[\;>']'G\3:=?VZVF
MIZ/;@FX.,%9(U8DL/D!"D$MDEL*01Z5_:$<,<-Q:F"5-R*OE@D.,[MH!ZMU(
M1CUS)(>@KQ7QO\7?$6@?$?6K;2[^SGL1! (].OX3+#&60,[JR%7<LS')+8<#
ML*5>?N)IGO9+0Q&(Q$Z="*DG%\REHFKK2ZV?5/0]BOM=D_X1676DT"]O+@6O
MVM-*V;;MBRC]V>3R3\I/)<@A1M%?./B?4?%7Q(\>^%[K5?!/B"/1M,OXW_LZ
M&UE5@1("96F*J,Y5?F&  NU<'.=9_C]XVC#B:'0G8N0Q^R3 @XYR1,!T&,\8
M P,50TKXQ>+]8\5^%89=4@T^W.M6J3)8Q^2)D9PK)(2S94*6  ^[GCYL$<:K
M7:5SZ_+\CQF7.I4=*#=I6;E*\59[6_.USZ@TB"4:E'&Y.YI@BQLG *]BHX&!
MT'2,=<N:Z>1+#Q!:O$SI<-&Q4E1\R'W!YKF;6:/3[M9979(H659!'$PVD\J
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M8J\F3L'/3K\Q_2M*#PG91L&G!N9!SEN!GOQ47ET1SJI*?P+3NR\VJV*,%-Y
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M,+7-(>^]21YQ?7!9U C4$LSMGG[IY7OS@L/]Q.YJIJM^VE6#0VJYU&[;R+=
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M.:Z(V6BZ M#G_%'B]O!FF?VG;VT-W>K<6]I;PSS>5&TT\\<$9>3:=J!I5+$
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M:KI[ZA=2"-(E=S(6^0=58Y'<8V[A_N)WJK:B6\6">2 VYE8M' ,(RJ!\I..
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M@!3P,#)"GA.7<EB!5^*P@MCB(O&4XPI"%<<YP>%*YX'2,'+98XIPAB(4C)#
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MMM>GF?6VB?N]0*D[(6<"-RV#AE)VX/."<,%^\?OMV%:UY8K>7T3*S1NBE67
M(8=B?<'-9&B6YN=6A>.3>4; *D85#EN_.UCSG&Z0J&X5177C1?M,B,)S$XR
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M2I)I0-HS2#.WMBE&#CVH 3ES[4?+ZFE!RW- P>,&@ 8#J<TRGM[]*3(Y/8T
M, KC-0U74]=OWL=/D^S1$NF]#SM4[2Q/;D=J[;=D$<^U<1H$#Z/XE,=S(8F9
M9 NXG;("^1@]/_UUC):F-:3O%=&R['\.[&21)[F[O[BZ3($YNG! X.  < <#
MZX&:@U2Q\0Z0"^G7QO( ,"*9 S*/KU-=B6W $=*1@<Y.*IP70IP[.QP-O\1+
MR/"W6GJ\F[!6-RI'/H1Z?RK;M?'.FS*/-,ML>YD3C\Q5C6?"]KJJNZ#[-=''
M[Z(8)]CZBN9D\!ZG'",36TS@'IE<GUZ'%9QYDVCG<J\'M=%CQ1XG;5;5K32M
MTSDA<@%=S9X4>W<FK%K\,]/CAB:=I);T#+R[B%8DDGCTYZ5S9M;_ $:8BXAD
MM"V%$N?E)Z?>'TJ_8>,]4L=L9*7Z1\.'/[P_1N/US41^)\QE&K%S:JZ%[4=)
M@T:4[K*.->2DRC()]#7.:EH,MO<R:AI9,=P?]=;@A4G7.?3 ;WKL[#QQIFIH
M8;U&L'<[=ET!M;T^;I3-0\.21R>;8,'A;):(G)7W4]_I70X1FK&-;#2C[]+5
M,Y*PU&.91-!(\;JQ!5AAT?T/H<YKI1=C7[0+M7[? -Y&.'7H?ITKG;^Q::4W
M%OB.[7B6/!"R 'HWN,'!IMKJ#H5FC=HY8SN Z%2!DY_SS7EU:/+>G+9G/A\3
M/"U%./W%B]U"YTF\LM1@ (MI +I=OWK<G#X]QPW_  ''>O1;RTCU*Q>)QOBE
M0CZ@BN-N+VWU&S>^<QP.H(G1F&"#QD>H-7_!&HFWB;1II&=[5?\ 1WD))DA[
M<]RO3\!4X-\M\//Y>A];4JPQ,(UZ3.7FTB2RNKF.3 96V]>>IPW\J[_P]JC:
ME8_O<?:8OED [GU'L:RO$MJJZCO ^:6//_?)_P#KTWPQ,MMJ31MQ]H7  ]0,
M_P"-98:;H8ATGLS:JO:T5/J4/%4][K6C:A!#+'INHK!*+>XF7*PR[2%<@]0I
MPWX5\K?LX:G/IOQ9O;W3=<@FL##]KO8$\3/JGVZ-K.QB8HC,=P2ZCNG,XQ_K
M%4##X7ZN^*&A'4/#6JA();B.YLI[>>&!-[N&C*_*NY<GG&-PZCD=:^?-&\'^
M*+O4?#>I7'C@W#:-9&WAL]1\-PQ,J2"+S,A)OOE8U0X.!SA37KP2I<W,]&?-
MQ512:>_<]K^,_CU_#_AXV=A>:GI^LWLUM;:?-I:VOFR3RRA$C!N$DC4'G<SH
M<+DC+8%>9?L[>(M7\<#5]4,FM/XBU&VL)[V\UV:S;%F4E>U,7V6*)-IW3YR@
M?=G. %)O?%_Q'I0TH:KXGFMQHIEMU>-X//4R>8#"555+;A)M(XR" :K? 'XN
M_#+2YH?"?AIK2V>]E?:+:PGMS))&F&#M(@W,JKC!.0%QT%=$>6,?=5SM@W)M
M'H&MF)8_]#D:YNUD+F_E?ER.2%'H/\^M97Q$NU^('PA\7Z==ZRGAYY-&N;:Y
MU.8[([93$V97P00F.6Y!QG&#6[KNG+HM\(0P:RFS+$W\(YY!/?&?U]JX3QWI
MECJGP^\<VNH&Y;2[K2Y8G^Q20B4Y7(>,RLL8*\'YV"GO7<J<.2]]149RYFF<
M1\#K_P $^+/BQX?U#PE;>'/#5QI'AB2/4-.T;2;K3YM0DEDB!*":"'SK2+RP
M5<!FW2C.W^+Z?6;<N[') X'TKY5^ 'Q,U#XM_%N&YUW4]4\17>BZ5=Q6-[::
M':VNFQ+*]OYAEG@O;D/.X2/:@*J KG;TQ]1%P4QM)!&#6!Z=%^[<XJ_F-QX@
M:,/EC*SEU8%CL+9^;@ J#U(VQ \9D85K9=9QN^;)"A @YZ,H"MTQC*H3QS)(
M>@K-EC(U&[N<;I?," E$+C:2<==N1PRJ?ECYDD)8@5:#D8*H6VX( 1F+!FR!
MV+9()P>9#\S805YLM]#"5KA=2 09;_5A>%8M(K;CT_O,K-V/S2GDX05AM=9&
M]Y6,H+2<D%LDA6.>^3D$K_N)P":T+NZ<6IRRMYC,2VXL"K<%MXY()^7</F<K
MM0!152V#/?VV]=X!9MQ;;LVKW9>!C."PX3(5,L<UYN(5YHZJ2LKLFU:*2XBT
M[3$<G?+B0%E5]L>"WLNTD D96,?*N7/&E)K/D7R6\$9>0< #Y#M&< YX! .0
MASM!W/DD"J\B9E38H2>$-&LB@*<\' 4Y"D#& <A!\QRQQ4=QIJQV@OG#IMS'
MA$SNRV54*>3DG@'&?O/P,5@V^;0FR2]X=Y<&EV-_/:AU21GG*D;V>1SD=<9!
M/(4\L?F8A<"H+:U:VLK>R*K*LL+37#E3+YF\X;<1RV<=N9"-JA5&:?J\(N+2
MTTXNSK<R ,';<LB=6W'JP8\<8,AX&$!J"[D:?Q#:SETCBL89+N3=)]]V!A&2
MH[ ,"P_W(^YI7[B]"6!D;6+F8CRH=-@,(.0@5R,N20,#:H52PX0'8F3FH8(&
MBL[(.JLRJ;IB^(_F0%U&"<#:S @'Y8_O'+D8?' 'T_5?LTK3S2NY.=L15N ,
M9X78F/:,?WG-3:A;[YGMUC"00+"%01;CC=N QQZ9"YP.7<Y(%$7;<33V+=K9
MBWMXX1'\N1E0I8'G=C:><DDL 3D_?<XP*0JFURQ212A(7:75]QZ9ZL&/T,A'
M9!4GG%KADP"H1?NDOG=GUY8$CO\ -(>3A16?]H?4)Y'#?Z* 0KEPQ8XVL^Y?
M4_*6'+$;$  )I7NVQ+S'+IMI/+([$&1B22[]1PI)8=>NTLH_V$[FKA1HHX8H
MQY*Q@C*LJ!=HZ8'"E1W^[&",9<TS 0NOFLK*<O(Q"GY1@Y8<*5X!(&$'"Y8F
MI1$7Y4*@5P"FS!&/F'RG@$##!3P@.]\L<53DVRF5?(!P1A,A4^5#P "P&UN_
M.X*W3[\G85*T)NG$:;9!C*NI+JRMR <G+!C_ ,"E(R<(.9XD6Y8Q_*ZL@7:V
M2#DY P3DANNT\R?>;"@ OE@>99'P3"Q.9,E@V>#G'4'@''+_ '5PHS56>QGY
MLK.HMX9&=D:,YD,C.3R?E+%AUS]TL.N-B #)KR#Q)^SC8:YXAUC6I?$][:M>
MS/=2110PQI&1C@$@C"C&X\[<@ EC7LC-'Y$B[OW"AO,E:3;C'#88' *]"PX3
M[B98FJ,R/)+&54PQ(RB*-0%SM&5)4C"LHR54Y6,?.^6XJY148VEJ=N#QV)P$
MW4PL^5M6Z;?,\5O/V9K,3V8L/%>M:;);K^\G2.-;B:7J/F&W8 #]P8"CYG.:
MQM3_ &?-7T_Q5X2O[35[OQ6L>H0?:VUN7=) @E$FZ,L<LK!#\OWF(#'Y>GT!
M#'Y,7DH$=5VK% H)#,<L!@X+#^+#'+??? P*<D=O$VUOWN_<7D;]XLBL>2V.
M6WM\O&#(5  ""LW3BU:QZT>(,QC[TJG-NM4NOG:_XFQH"_\ $YB54#N5>17?
MYLDGYF!'KT+G[Q&% 4<]O#:XD#EBHQZUR/AZ(_VA"YBVNS.0K*'. ",[E. P
MX!;[HX1>YKLHXV;)/2NRE%K9'SCEH6,X.>!]:"Z[BJ\\=::[%8R ,TR+[Q.#
MGO7H.3BU%&5NI+M//M3<X-1W%P53:HRW3%-M7=T/F'!';L*U4KZ#2;5V2_,!
MP>1TSVJ!P(\DC&>N*L9]@*=& QY&,507L<M\2-.T:\\**^OZFFD:58WUCJDM
MY+*D21M;7<-Q&&9N K/$JGV8XP<5A>!/"'A?3O%EU=:'KPU*^TJ"XT^ZLUNH
MIFMVN+IKIO-51E&W$@ X^4=^M6_C?#I\O@9KF_\ $&G^%Q8WUI?0:IJT?FVL
M4\4Z/'YL?F1[U+ #&]3D@@@@&O,OV?O^$6'Q'O[?0O%=CXPNK/0T,]_I<<2P
M^;/=337#RE9'9I))B[@' 13@;B68O2QC?J?1!4CO5#Q#86FJZ#J5CJ#^787-
MM+#</OV;8V0ACN[<$\]JODUR'Q@('PE\:EL;1HEZ3GV@>I:N5JT=)I&GVVDZ
M59V-DH2SMH4AA0'(5%4!1^0%9/COQ+JOA;1&N]&\+:AXNOV)2/3].GMX6SM)
M!=YY8U5<@ D;CR/E-?FQX9^*_P"U]#H&G1V,'C"?3TMHUMYO^$1MV+1A!M.7
MM]Q.,<GDUT.G?%O]KV>X*S67BY$ X:3PA; $^V+;^=9M).[)N?8'[+-GXU7P
MSXLU'Q_HZ:!XFU?Q'<ZA+IL=U%<"WC:*%8DWQNP.U$4<D$XS@9KVD8'7.:^?
M/V)]4\0:U\,_$%_XL-X?$=QXDO&OOM]M]GG$@6-<-'M7;@* !@< 8KZ#&/0U
MIN(5@%[FD^7WHW'-!SN]Z  ;<=Z ><#]:4@L.HIG?% QX)+=LT;.*3C/0@4C
M$8X% @*\Y!XH/;D^] Q@4I/(STH'<80?6E'2G$C&!TH'(Q1<;=T(3WH!'6CZ
MT=#Q0+H+R030,8YS2=33B1C H$,(.:,XIWR^AIN,U$K=2TQT>=XYJ>JZ$[Q4
MXK>#TL*0M%%%:$A1110 4444 %%%% !1110 4AI:0T 1[L>_O3>IR1Q2YVD\
M<&D//0_A7. ORXSBC ],_2D)'3J:7!'3I0 I4#MFE' Z?A1TS_*C.1Z&@!#D
MD8XHR=OO0<XX/2G4 -8D'VINWKSTIQ(/>@ <XH 8"1TJAK&CQ:O H?Y)8SNC
M<=5-:0 .>*&PHR1@#DFD]A-*2LSC] UJ>ROVTZ^;/.Q"?X&[#/<$8Q[\5UIS
MGGK7D.N^*))-1FN7VMF0I&@X C4G;V[G)_\ K5Z5X9U)M3T:VFE=9)MN)-HQ
MAO<=CCG'O6--WN<U&;;<.QJ C-*<'H.:,9SQ2X(' YK<ZV1SVT5S T4J+*C#
M!5AG(KA6TNTTG6)+6^@#6LH BF;.5[#&.F,X/X5W^WN#BLKQ)I"ZK8NJC,ZC
M*'^8_&LYJ^MCGJPYES):HP+CP RL[6MV60 E89@6 ]L_XUDMIFNZ$%-JT]GA
MMS>6!-"V".HYQD<< ?I78>%]4^WV)21P;B$['7/) Z$^];3*& /2I44]8D1I
M1MS4W:YP!U^RUAF;4(1;3J#LNK?+@?4=?T]>E4-2T\*7N59)T*E5NXV#QG@<
M'TSFN^N_#UA>Y9[=0YY\Q/E;/U%8,G@:6TGDEL+UE+#'ER#*GC'(Z'\15M-I
MIJYSU,.ZGQK7NO\ (XMLRAHWC#@@*\;#C;C-2PQ3QV]M/:2".YL9 \0)+$KC
ME#SDCM^50:WINO:3=--=V+7%JK$F2U7'EK@X(')(YY!]*?I6J+/(DT,F9 ,%
M<8)/'!'YUY=6A*+YXG/0G5P4[O6+W.VNM1M]?TBVU&VPP1MK#=RA/!!Q[UER
MW'V1[:9#@BYA3[W!#2 ']":R)M0_X1^WO-0M("]G=KB2V4@!' X;I]?TJ;5[
MV-="CU-03;QR0W+*$+'8KAC@=2< ]*XJK4Z\*B6Y]90J1E2ERZKH>B:F]S#I
M]S):0+=7:1,T-O))Y:RN =JEL':"<#.#CT-?-WQ.\5?$Z'PN;K4_AMH_AJ'[
M7913:MIWB<7-Q"CW<*,%C^R)NR&*D;AUKZ#\3W]O;^%-6O+ED:SCLI9I&>Y^
MS*4"$G,V1Y8Q_'D;>N1BODOX;ZOX'\<?$:TN[/7],T>PTVR<O9I\2Y=5:>Z>
MXMTM7\J.Y("JY9#N.&,R+M;(Q]+RI[GFR1Z;^T5X=L]"\%6<UK<I%JT>IV<V
MEQ"Q>Z:XNXY0T<)2-E9@^UE)RNT9?(V5Y!\(]!O-1\2B?4]:E2_TJ_O=0FT"
M;1FM);:]O07;$AFD#PA9'\OC)W'+DJ0/4_CY.4\,6YO8D34+C4[:UM+RZOGL
M8]/N"3Y=PTR?,@7!4 ??+A#P]<?\(T,,OBBSN9H=4U>WOT6[UNWOGO([Z3R(
MV7#N/D9%95,0X3@_Q&GAZ/.N2&AQ4JSG-_TSTC2-676(M1\.S9AB92]J\H82
M)+D[@/0;><>QKC?B-X=E\._#WQ+'J!MKC2_L$@E>4VGE[3U#"[/D8]Y/EX^E
M=%!+';ZQ937"![GS@5FA^^,@@J1T(()^G7M5WXS:MINC_"+Q9>7C7:VPL65D
MLUA>=BQ"(B+,K1DLS!1O4K\W-;1C9\DU9GLP@N5RN>!_LG:Q=K\1IQ'/X^'A
M\Z6XA74VM?["+^9'M\D6_P"Z\P#=CR^-N[.>*^Q?-9USD%3@?6OC'X'_  XO
M_AK\2)+'6;37=#O]1TF>YL;%M:LKS394CG@$Q\JUM+=8YT,D6"58%7;!KZXM
M+Z2?0K:Y>-P2 [%.H YR#^%:RAL9T:JY'?IJ9VI'R)S!&K%MY79M&>26 "<@
MDXW"/OC?)A1BHEE)1)' D21/,)C#R ECC((P6#'C(^:8\+M136)JWB3[%<KO
M1+B-RXV[2"P9^1LZL&(SMX:9AR51:U+34[34P9$EW3L"SJTN&P?E9B5').-I
M=?3RX^YKRY4Y+=&4:D9ZICKGS%C$A4[E+R$R$G!Q@DLHX/\ "7' '[N,$Y-3
MV-M]E#22*(IF.2N%C/RCN.B[?3I&#DY<U/EX5B #*J'KD1XV@@D=EVYY/W8Q
M\JY?I$S+!PA\H@!00@!&!NP%8\8!+!3]W[\A)P*Y:L4U<Z(-VL1694ZE?6B(
M56U$<89(RQW-\VT*1CC((4^[R=JFU@QRWNEV*MOCDE:9X^3O4'UZL"W..LA'
M914=H$WN5C$8FD#LNUB)&;! YY;/)VG!<Y9L+@5%<O-+XGLG,@=18OAF;=EB
M<9)')SC&0,L?E7 R:X;)(U)#-YOB$C@I;6KNS2'):1AM)ROL-I8#G[J<9ING
M1L/$.KAU"I T$4;8 7"(3G.,+M)P2/E0<+EB:C6YLFNI;^WF)$\>QHN4964!
M2=PX0*"02/N_=4%C4]K((-0N959!!<1QLGR@-&Z'E<$X4!><8PG5LLU1'5-(
ME[F-'*\WA?[?/&TMW$K<2QE6#*Y(!0]"O4*>%SO?FM36;IM/MIKI8'GB9K>(
M1PJ7:0.Q&%4\D<YP>6/S-A1S&+&.\M=;TX(F':2-?W8.%<!U 1NN3DX/WL%G
MX %6F0ZMH2D@>5<P@M+N9AN8@[AC!()!' S(>!A!4Q6MBK]Q]W&LL+)ARMPI
M>61<MQD*<LH!;<>,CE_NH-HS52SO/M#[(X9HO+8DEDV88+@G<!@8&%+KPN0B
M9;)%34+S6D,+6-Q:.BLP8W#E2,?*6+ 8]59EZ?ZM.3FG2WVL0VS2^=;/L4F5
MH'".H1<'CHI7./2,>KGC903ZDV-:!%GQ*B^<A(:)D(&2OL>%*\X'1.IRYJU)
M:+&Y,A 9]JX0$@L03M"GZY"GKR[G  KGO#]W<WNGVT<,'V:&,,A1"H5-OS!0
M&ZGJP4^[N2<"GB&YEGD9K@3K)&-L<44DH!)SDEB-V<=.LIY.%%:.,$O>)=T:
MLEZEN'^SL+EF&5$CD+@G&<]6#$?60\#""H();VZD66=XX8R=[JC<'MPW;L&8
M#C[B#.35VWM[<.TI+W!9/]<[]/X6)*]2<8+#KPJ<9J.>-MVYMQ0/\Q&%/RY!
M!(X7:.">D8X&7.:U245H&ZL4I;]CN@BBEA="(XS&/+1< CYB.%V#ZK&"#\SG
M%20PH;&-;?.R,+&!MW%N<CAN2<\A6/\ MR>E-BNP$DB 1X_E0",$%"!D+AC]
M[G<%/"C+N<D"I$LY;&*.".W1H@I0^:#+D,0Q Z,VX]C\TA^9L*!GGE>3T!:$
M$MLXADF@C664H%0,2X*LPR.<$[R.O65L9P@JZEF?/81*JPE&X8Y +'!8D8YX
MP6'7[B=S5R(%;D2L51R0W+9 R<9W#DY/RDCEL;$PH)J22\MD$D\DF$3+.Q<#
M8RY#9(X!7H2.$^ZOS'-:TZ'-JQ-VT1<\-QB+4XHV^7#%0K+SE5QVXRN<<?*N
M0O+$UV3.L8!//L*Y+PZ\8NK=0/)XVB//EG 4X&WM@'_5_P .<DEC75O%N ZC
MTKNAS16AD[/<?O5AD56N+H0J<9R?:EES&@0#<6/%10V[,V9?GYSZ5HG)JS'&
M*M<+="<2-P<\ ]:L@%23ZT@&.>2.PIZQDDXYK6,>560W*XG?'Z9IP.T;<Y]:
ME6(+EL?,>]020NC%HUW9Z@G%6U8SO?0XGXS)<M\/-4%@-<;4RH%E_P (\S+=
M?:,_N^00NS=C=O\ DVYW<5Q'P'7QD?$=]_PL#[&WB1-'M/+9B/[0$)>7=]H\
MG_1<>8'V^5\V =W:NI^-=YI\OA6QTV]\)Z-XU_M34[:PBTCQ XCM&D=B5=R8
M9L;=I(Q&3GTKSS]F9-*D\9>(+W3OA]H7P^^V:)ITXM/#MPDEO-']HOD#.HM8
M"L@9'!^\"NWH0<OH3*Z>I]$_=JKJFFVFM:7>:??P)<V-W"]O<02C*R1NI5E/
ML02/QJZ5! ]:\X_:,OKG2O@1X^NK6Y:PFCT6Z_TM!EK=3&P:4>Z*2W_ :G<+
MIGRI\;/^"E=CX:UNXT+X:66DZA%:.8#K.L2L;>5E."((496D3@@.74'' *X)
MY;X;?\%0?$$>M6L'C;1-"U7399?+>;PZSVUU"N<%Q#+)() /0,I(Z9X!^W_A
M3\'_  )\*/"UAIW@G0=,T_3E@0)=6L*-)<KCAWE^](3UW$G.:WO%G@GP]XYT
MJ73?$6AZ?K=A*,/;W]LDR'WPP.#[CD5$M):"$\'7>@ZUHJ:YX=>WGT[6B-1%
MU:_=N"ZJ!(?<JJ@YYXP>16\"2>OXUXO^R[HNF>$_#?C#PSX?G:X\+Z'XGO+/
M2293*(XBL4LL0<Y)$=Q+<1\DGY,$Y%>SC)X%4(4<<YI1Q_4T!<#)&?:@-QTX
MH "!^'\Z;@^E.SN'3%.&>/04 -/3 !I-OR].:<1COSZTG_ J $(P >](X)P2
M:<>5&:0MT[XH&G8;UXHZ<4[H<XI0N3R*$DBKW&$9%.7@=.:.HQTQ2A2!UH)O
MT$[\B@'!I3D$$\TNT#DT"&G./:D(QCFG=5R33:!H$XD%3@YJ),;Q4U:1&W<*
M***T)"BBB@ HHHH **** "BBB@ HHHH C.!UI,K]*1AS@4A!48]:YP'%ACCF
ME8CN<5&!Q[T\GYOPH 5<=B32TS!*TH'R^YH 4D+1WZTAXQZTN.<T )@,*0D
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MA:?]VC84@_,.%P#@X&(QTRW-<$]+V.C5FIK6ZPL)I()&B\N5&D;_ %951\Q
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M)_>XKY0^',FH?$[7XM>\*>-]>UN#1I(8KJTGO/#-];RJT\182"Q"E,1QN0V
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MQ+N8,H&Z0LQ (( #,67C(& SKPHQ'&"Q)J6V80* K/$<A0%"H5*#ICE4V#D
MC;$#DY<\-JY7,EHB5(4AV[8_F3&-JB/:0N54 \+M W!#P@^=\L0*L $J/+48
M8*B[5W9SR  >N?O!3RWWWPN*2S2-LXW9. F$Z9R54*>O/S!6Y/WW["K4<:LI
MV[2C<G*EU<,<=.K!C_P*0^B#G-);L5VAC*;C.]5&1N8 $CDX)[%E)&,CF0\#
M"@DTK[3_ #VD9CL(8,V[ (P,'YAT(X4N,[1\B<Y-;&T3(QR0Y.YF+YW=F.X#
MZ L/]Q/6JDZ!03MP4RQYV8*C'T7;GD](^@RYS5<J2!2,TZ4BK(<X*#T5-K)T
MYZ# )XY$?4Y<U8BM4@8[$R1A?ECZYY"[3ZY+!3_ON>@HBO%$S1;'#<*6*CC'
MS !3T(Y(4].7<Y(%6)!&'3R4#ALAE W+\QS@#J0QYQP7/)(45SQY6]#9R=M0
M8!8PG!W+G*Y<$-R.ARV3_P "D([**AU'3(M86V$DQ4VX8AG?(.3@G(QC/0NO
M8^7&>2:MH0P)R1O);=UQGCJ.2">"1RV=J<9-2)#U9@5VGYG^5,%1@Y(&!@9!
M(X0?*N6R:VC)I^Z82=S'CTA]&O!=6Y$1+$2X(7*J,=N%V#T^6,$\,[9KH(D4
M_P"H."Q (4<?W@ IX!ZD*>@.]^>*C:-HT,*(5$9Q@8PN.@"G@<<A3PH^=\L0
M*FM;%9"RJ B$# Y8,2=W3K@GG'5SEFXP*UE[VY%RRZ%'P6 Q_"/G+9.<>^2/
MJYY.%%/6]6-3F,AL<NY)Z\$G'7L,CK]U> :=@"54!$A9 P+MNX/!)/?/KU;H
M, &D.4E<,"6.1D<'@ 9)''L2.!]U>3F@CF1>T4@WK.6W2,"&;=]XCKTZD>G1
M<X&3FN@SQ7.:(CB](VA4"!3M^7H!P1VQ_='"YY))KHE':NF&VA#U#-*,YYZ4
M$8I6Z5IL(:>^*CPX;/##VZT]CC%)V)J0#<0N2,4@89Y %+P1GFD (/:@#RG]
MHK[);^%-&U+5Y-3C\,:5J?V[7&TI[A95LTMK@%F^SL)"BNT3D+GA,X.*VOA%
M#X)6QU"3P7J3WZ,R"\CEU*XNI8' .U72=V>)L$_*0I/&1P*R/VDM(U;6_AC<
M6.EZ1=:['/*([_3[75H],$]HRLLJR3.I(3!Y5&1SV<<YYS]E#5=&U?3/$LVD
MSZ/),ES%%>QZ=IES#/',%;/VB[GED:\?G_6 X7!'-6E= >\<'-<W\1]'T'7O
M ^L:;XG>.+P_=P&&]:63RT,3<$,W8'.#]:Z4].*\D_:S2ZD_9L^(\=DDLEY+
MHEQ# L'^L,C+M4+C^+)&,=\5*U \X_:1\._#OP]\5/ NN^(KNU\"K-;ZB;GQ
M%I]W_9=VYCCA\I3-&5:4@GB-MX.2-IZ5XP?^"B)^'WBB*PL+K4?BGX/'[L:I
MJEA'I6HD\!?*8%5N<\\-! 2?XFSQG>!/^">WC[XE:FGB/XF>*+C1&G4;X3>-
MJFK%>Z-/(62(^P,HX[=OL+X3_LQ?#?X,%;CP]X>A?5PH5M9U$_:;Y_\ MJ^2
MH/\ =3:OM1S-Z =;\,O'T'Q.\&Z?XBM])U?0XKQ2RV.NV36EU'S_ !1M^A!(
M(Y!KJ@,'J33!C'/'TIX&!2 &.T4+R*!GOC%)UQCI0 O'Y4$X^M X))IC=<T
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MY7N<!2P_W$'4U%X)VQ+?E>'#)\V IRH(^]_"%!QZ(#A<L:A\9M>1ZO$99/\
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M@$J5R<%AQGVGP5^RE\)_ 6EQ6-AX%T6\D1</>ZI:)>W4I[L\LH9B2><# YX
M'%9_Q&_8V^$'Q)T2_LKSP1I6D7%Q"T8U+0[9+&ZB)! 8/$%W8Z[6W*>X-+6]
MKZ >L^&_#^G>%=$MM*TBU6ST^V!6&!"2J DD@9.>I-:=><_L]:AJ6J?!?PH^
MJWG]HZA#9BTFOCUNC"S1>=U/WQ&'Z_Q5Z+C(Q0 M&><4$9I#VH 4 DF@YS[4
M!N32$9/-,#AOCQ,+?X(_$&0AB$\/:@V%Z_\ 'M)TKFM:U!5\0:K#M?".GR^8
MI_Y91Y.,9' '4UT7QZ+1? _X@F,;G_X1^_P,]3]G>N:\0I*?$^H)""I,@)(P
M,_(H.3CVKS,=9P5^YQ5_\OU,N2YD9 &7"[NQ&W'8XR,?K55]XO$"QA@Z,"0V
M&/W?S]:L7,3+(A (9PJ@[3@<X'U]:CG3RKQ9")!&1@8)QGKDD>WX<UY:.75K
M0@U&-?+B(F\SD-N!)R<#V_KGCZ5!))Y2*$0DL1G R?R/?I4]^7CC0O''N8;<
MD;A@J!G]?:HC+(MSM0*S_(X;: #@GJ/PJF07+*1PD42Q2@C)SN )'RYZYYJR
MTK'XG>$E);!A;<!@$M@\D#_/6LRSN);O46'F Y9@ .,''UIT$9?XQ>%8P=KB
M%I&15R#\K<YZCH.O6LT_?2\T2]UZH] ^ *X^$OAX$8/E/QC'_+1^U>@O^M<%
M\!2)/@_X4<'(>QC<Y.>HS7H)  KZ:"]U'KTOX<?0C"'/-+L]*<:0' QZ51J*
M@P:?3%.33ZUAL 44458!1110 4444 %%%% !1110 4444 (!BC/-&:.*GT \
M"_:MO]-^R:'IFL:O#9Z==><[V5S>:)#%<E=F"R:G#*'V[C_J\8W'=G*UI_LF
MW6HR?">UM=2N6GDLS%''&6L7$*-;02!0]GB-E_>%@=JMAN=P =LW]I'7[31O
M$_AI-2N=4N=.FM+F/^RM&N]1MIFN))8(K:9GLD9MGFR+%AR.9MRJ[+MKU/X5
MRRW7PT\*3W.IQZW<R:5:O+J<6=EVQB4F49 .&/S<@'GH*;5T!U(Z4$9I:0G
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M,$'_ #Q52.%4O97;!RG)CP2>F<9SZ>]?'MQX@UO5]7 34M5?4L&?=9W$H=0
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M5Y /&5.5;&&5AQ7+)XH\7_#61H_%=K)XJ\.I]WQ%H]K_ *5 OK=6B EL#K)
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M:X0W,@W;D0J!A3A" 1E@2$S@98FJTWCF_P!7N-/DDMK>W2VD\Y(D.W>P!*J
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M!+PCX1\9S>)]!TXZ)J,\#6T\6GS/#:S(6+_-;@^5N#%F#!0V78Y^8Y[RBB@
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M!8DMNR.YR!SGID#G[J@#)I!'MP"<$$DN3M88&"<CA2.A(X0':N6)-)Q4MT=
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M+I;EH JA54RKPYP!R*\,_:6\!ZEJNJ:CXHLEU&72;?2D6\_LO4[&U9FMGN6
M/VFWE)8">11AD'SD'/;Z%\,6]M:>'=,@LXFAM(K:)(HV8L50( HR>3QB@#3H
MHHH **** $(R"#WKR'0)!\*OC)=^'"/*\-^,GFU32V)^6#4E :\MQV'FKFX4
M?WEN3Z5Z_7&?%OP++X_\&7%E8W"6.N6DB:AI%^XS]EOH3OAD/^SN&UA_$C.O
M1C0!V=%<K\,O',7Q$\&6&LK;M8W3;H+VQD.7L[J-C'/ WNDBLN>^ 1P1754
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MD#@GHO"KR:H".,B*X16D944\D8&".N.PP,9/1.@RQS5E)#G:W[P!AG QCC(
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M@;3[$D*>!]]^<"DD38%VDQA3TP%"D ] 3@8'(4\)RS9; IC%_-(())(4 +N
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MSUP>6Y9\**D."H&#*'S\W+KM;//!R=QXXY<\#"BD$C+&@W!BX#?+EUPWJ>K
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M&0;2SJTIWAU%;GAKQ5JGP]UF]N[N:&\DT@_:F2=&"W4>8VG1(<%<P)-"L*9
M261L9R16[2DTHF4'3=2.G]?TOP/I+]EZ\NM4^.4=W<QM'YGAB]D4.4<C.IA6
MPZ'#*61F!P/O$<D$G[$KY7^ SZ1+^T"[Z9<BX*^%KF-A BB*-1JC!4!50"5P
M5XSC:<\G)^J*]K!QY:5O,^LP2M2:O?5A1117<=X4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "'I7!?"?0]1\'Q^(/#=Q:M'
MH^GZC(^C3Y&U[.8"81@9X\J1Y8@,#")'ZUWU% !1110 4444 %%%% !1110
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M?4+?3-UO<>7<6EKY3+Y\KE-KJOD)\Q&. ) I7%>1BZCA-*-SPL;*7M-+V2/
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MQHGAK6M,\17>IOK%S$;.&6-$!C)!\T@#..,=.I&*^L+25C<R.4$<@8GYEY0
M\-T''UKYH\9>&?#VD7EEJ^KV7CE9-1OU2W<:MH]YYDC-N"KB[9@F 1G. .XK
MVR#QEJJ7LID\%ZKM<DAGU?1A@\\8^W\<'J/RJJ>'J1;]T\?.<7];HT&I.3][
M5JW5:+9.VQV2X6YBV,99&(8L !@ C<3_ /6["N)60VGQ#^)SK'L">$+M]VW!
M($$7?ICK5^/Q==F[5V\(:N45ADMJNB@$C_N(?_7^E9"LUQJWQ(U_481X?L;W
MPM=V<,5WJEC,9)/(0# @N9#GY&]B,<@\5O"G.,XMJRN?'2NG&Y\P^!;53:Q1
MW\5I+9Z<?/NS;EIX$2"2:3=&7)W"1UM5>)OFVAN#M^75U7Q!-HZ#4KZQT^[O
M=-@GOHH;=6LYDG=YD95>$KO;[+#,JEMPQ80?WAG2LO#^OZI=-87UQ+(UJWVM
MTP!G8!N9 6(!,D,6 <;U<AC]UQT1\/\ ]G:YHEE>!ELT@:__ +7B<M;)/%,X
MC!5L E95W!!\^, J4SG)5%?1GB0YDO=T. W:)X;FCA%MK$G]AB."[B2]@;[4
M9]@LP8WLPTA0#"JQ&SR.-V[G7\+6@M-5MM-B$=@MJ)]*>^$;75S-&PF>.4%Q
ML -TEW,D@5"3%; \$&O08?#%K:6MO!8>'HTTZ!9&+F-I9)HXY,R/N*F24Q,6
M$+C[Q6-NCG9@>&],_LG6OL&DZ?NTB#39I9-3CD=8+4PIY8@&U [L8L(N068(
MI4$@FFY7V-8QE&:YOP1['^RY/#=_'34)Q;PVVH2^'7EOHX0H5;@7,4$@CVC!
MB_T8,K9)8N['K7V#7R!^S%X;E\,?M#:Y;73+-J$GAM9+F<*JEV%R(4X50JIY
M<"%%!/5B0I; ^OZ]O"_PSZ3!*U+YL****[#O"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /G[]J_Q3>:+8Z9::2-0;54LM0UA4M=9.F1-#:1QM+N<0RL\G
M[Q-B*O\ ?)("FM3]F;1KV+0]2U6?Q-KNJ>;>W=E<Z=J]^M_%;W$-W,CM;W&Q
M6>/C R , 95&!4=K\4/AD/B58V]J^JG3X8A*LD9TVRO5F62,QLK+<PR  HSJ
M=N,K(P.0<5)\)?"VK^#/ ]KHNM7%I=7=I+<1Q36%O';Q-;^<Y@(BC1$C/E%,
MJHP"#R>I?0#R;XR>/?&.@>-_$MM:^*=8\,V<.EPRZ%;6/A?^U(]1N2)3)^\6
M)CD$(OE[E(^]G:37M'P\L]<L_"MF?$6J2ZKJLZB>1YH88VAW*#Y7[I55MIR-
MV.:\?\6?LMW,CP#1]>?7=!MXQ%'X.\7S7%UI*IG[B".1#@CC,ZW  X"@$@^^
MV$7D6-O%Y,=MLC5?)A^Y'@8VKP.!T' ^E("Q1110 5G:^<:1<'<5P 2P<)@
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MN%$,2EF:ZCE*V[,L4F2Z$MD?N -A9MLNH:)/X71]%T^*YCO(,L-6DTX7$R'
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M>QP^P*6QC)8Y53E1]P5[6%_A'T.!ES4;ON_S"BBBNP] **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KR'X\>+?$7AJ71D\.ZCJ%K/--
M$L\5KX<EU*/R#,@ED+JN%9(R[!,[F(& :]>KYR_:4TSPG#XOTC4?$6EOJ=S<
M0VL5LUW;6T=A"8+P3[9;RY98X_-;:A127902$;% '7>,/%=[9_L\:;J'BGPU
M8^(-7U6#2["\T+4 (K6:[O)8+?RY<K($C$LP)^5\ ' ->3ZE=_"71?$NGS^"
MO@GX3UZUTS6+"SU/Q-9:9:6MKIUS+>0VR+;3" FXGCDE4E4VJH4[G5L+7HGC
M&+PO\./V8O#FE^-K"TUCPS:PZ)H]VBSC[.H::VMTF\P!?DC=EDW#!PF1BLCQ
M!\9O@=)H/A+0-(OM UR*TUK2X-'T/2[B-!%,]S'!#)'&"%(B,HDQ@_<R!D @
M N_MFZ5;Z[\-M#TV[MYKJUO/$%G#+% 4$A4B3)4NK*".N2,#&>U?,=G\._"F
MHRVXD\6:);3W$X5K'4[:QG>?>^7'F6XF.2<9+*I9O+))<AQ]%_MVSI:_![39
M)"B*->LP9)+LVJ1CY]S-, 2@"[CD<]AR17QYX6N=;UW4-,@TRXU74Y)QYB)/
M>W4QF3>&B963RHB9&R&5'8)%G'RLY/AXK^+\CYK&-?66FKZ(E^,'Q(N/ 7@?
M0M+TW6M$^(VE7FIZAK,6M:A8+<6]E<8B(MH(GE:2)X02Q#A1^_'RD"N\U2PT
MSQYXGU>_\2_$6RTO4+JXCGGT+4K)KLZ#*$DW0--"_EX*J<?,A78W 8$K%XWN
MM0^'VD:%X/\ #NI1Z+<6B)KNIWNA6XE^W74^P^7E^0A5%&,8=8G=_NX-/QWH
M]SKUD?'EA%%)%K2Q7VI6=FF\PW(7RV=7>*<D$HDT6P#!7GJ,X2DKV>QRRWES
M:VMIVLNC6K^9K6WP@T/2XA=:7H4GC7R5*C^R;BTB&Y"8T"PQ&=Q@#Y>5"EG^
MX6.9K30-/\1:1J>CZIX)L%M()% T=()8Q-M#,F_;\RL",!0T@(&"H^6O&HW7
M[7Y;P6JF*2-&BMX;2;R%\L+'(Z(HDCC<;?O(K1,1@;"8SZ%-=:[J7@!['4=;
MO?"MQ):R7-HBZC#97Y:W<%HEC C"?\M<Y)3"[AM&%&<E?8E5%4V1D^*S=77B
M^'2ENWN+!I%BN'LWF94C*@?O5C5X$7:-XQ)'A0 0",#B=<G.JZO>AK59'_>J
M+>"(*R[2-L/FPXM65 G6Y:0@Y)7-=!JWB'3_ !1>1K]GAOWN UQ;*;VVN_M<
M98CY$6.4/*I!7R\*I9&V'@ ZT7@Z]\5:SHMGJ$UYI=WJ<<[S22Q7I,4<:Y4E
M8[6WV3E8W7RB\0.4.'W#=:4EL96<[\KZEWP#XNU?P[H=U;VL=SJ27%_;:?.L
MJ&1K:*8,YN'8!HW>,H/GC A990"7. GG^KW<UU=W5W>![B"7<9C+*R60*.$V
M2A#Y\S#"JPVSKG[I9>GT1I6EZ7X4T&^T[2-(DETYP\#PRV2G<27,D>S9\H==
MAV^6I.P;C( &/G?BOX>6C:1-XEMVGCO4:..2!$N5NYR0J!4GMTD=MK'<8F6;
M@'/0@91DG(<J4YVCS;'&0P/_ &&LRV.^YMIO*7[);K&SQG+E,K#+<[$P  UO
M&5$J#& "?6/AOX6TKQ-I&F:CJ*VNK:A:RRS6^H1SRJMN2VUDVNRL>'(83!/F
M!(3:<UPGBJ.STKSK>]@B_L:W8O'=WR"&.<DJS3,[6B*UUG VHP*\AC'MXT=!
M\;FZNWFAUN;11HT8$NF6VH6\\-Y<S'RXH+A%DW/(0LC!&PH([89A4XLN"C&?
MO:_UN2WGA&Q\5W(;_A#[Z<)</'+J.A 11J$;AG\Z!MI)1F&\H V6#@G(?I?P
MP\+O):F/QGHMM)\@32=2MK9I\$^8PW6HF.0^X[<(=\2L,$,6Y[Q]XGU/5M8^
MSZI<RM!'(?*/_"0VWD&-'9))%(7/EH4"'&&+)MPOS%L_PFNK:OJ5K!8/J$TC
MH)U6]N97!4Y:,ED2-"KD%Y-I95C0*N ,%)/J9.<7*RC=_P!=C1\7_$Z^^&R_
M#?1=,N=)^(]M879O-,UR2VCG:]GENLO#:$RLT6POY)$F"I"G V*:WO$6B^%]
M1_MF[UWXFZ9?O<7%S=>7<6<DKQN^R22T+J_D,ZN$4#S"&R@P%X;0\6^+)?AG
M>^'="T#58]'T;PFD<EY;V=E^XU&YE/G3M+N^=(_,9R$P,  K\V OH7ACP+H?
MPJ?_ (6;XQ\/2W?B35+N>Z\)^!H5$ES"\A,K.RDG]\,DDGY84 P-YQ73&#J-
MWV74ZXTN>;B]4K;[)6MI;?YG.>"?V6;77=&7Q/XQDF^'_A&W62:2XUEH$O[M
M68$RNKAUM5;@GS&DD)VY"%03T>F_''X<?"MIK/X-> K?5K^X'EMXBORT*7)9
M&DSYSJ]S<#:A?  5@#M;CCEO' \2_%+5!JOCRZ$_D_OK30(,BSL\<@A=PWL!
MD;VPQ)."@&4Z[1/!T?AN..YG0'5YP9Y9)!D0[QEE ;G "C).,[<E0V[.?UN-
M/2BOF:PJV;]A'E7?K_P#GM;\>?&'Q=(UUK'BG4M#T]HV=K+0K#[!%&/L_F &
M4"688/!;?U! !P<2>'_"6AW&H8UB]U/769TEE&JZW=7;;2H(0B24L0><C /T
MJ[J7Q1TJQ_=6>I/+<(N\FV@9@IW; ,\Y!/  SG!Q6YX1_L_7]:CGCGLKH(^U
MI<X9<-@@@\\ #'?&*XZF*J2T;=Q>T<I6<K_,K_'#X3> O#VI:?%;>'(=/N?)
M6XC^RJZOO(R&5@P*D;",J01^->?2:_XY\-W-S+X.\9^)X3"SGR);R34X3MA9
MPNRX$J %AC@@\'!SBOHWXWV%EXC%E,6MI4MH$/[PC !Y)'MM/TP:\=U/QAI^
MFMY+:TA0E>8HV9%WDJ"2 1CIGL/E!]AUZD:C:;-J[Y)M*5ET(KK]H9O$EO'X
M;^-7PPT_QEIP9T&HZ?8XECQ@;Q;RD\X93NBEW<\)E2!:A_9I\(>,A<^-?@WX
ME77LP?8[O0-9O9)%V AA 7?][ X ^[,&ZX^4$FGZ9!:>*M$FC=_[0M'WJS,!
ME"<AAT)!^\O/N".HKSV;P[K'PX\5G4-!O+K1=?A QJ=NOFM<QD_()><2J<;2
MK@Y(W<'A.M8M35JRN8RJWC^^7,N^S7S,:+P?87^L:GI>K>$/$>B:S8J5O85M
M8KSR?,RI>1#L41MDX8R.C[4RS;>-.U^$NE6<5[/#\0?!]E,8;@-+?21+-8,R
MB#S9"IE_A91DRC[T>]CCGV@SZ#^U;HL/A'QO:1>$_B?9V[RZ5JMK&#%< #YW
M@W_ZQ.GF6[Y('(/ <?/VE_#7Q9IOCN\\ :S81V5]\EO*UPPGM7AD=5-P/E1O
MLQ4%0P=I#+.0WS'C3V2BE*+O$SE04;2BN9/9[?)FAJWQUO=,_:,TG0VT.QU'
M5+/35TD>)3:H-5GA-@0;R-S/Y8A+9GSG=Y88;ADUI:)X"T2XTZV6Y^(6@>)+
MBVV,EVHFC^V!)I3&R&22&#*DR$CS#M9&.681F/6U;XC0:3\0(A:;/^$#L(_[
M"MM$&GIL:*.);;S?M18N9 AV <?-E &*MGSWQ+X7N_!FL_V7'%;WMC;?N;!U
MAC$%RD38$:M)$QC++MP[S96:(@ J23*E%RW,Y2LVV^:S?E;^K=3Z6_9;\*Z9
MX0^-GB;3M,L)["&'0K8$S/&1<$W$H\Y DDGWBAW$MN9MQ.3EC]:5\3_L$>7<
M>/\ QE<P?9I+=M"TL1SVL,$2RCS;O[R0DHKKC8VW )4E1M*U]L5[6'^ ^BP3
MYJ-[6U?YL****Z#N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *^>/VA5?_ (3+3EU#6?$.G:-.EC"D.C)JK1S$WC?:8W^QQ,A>2+:B
M!CNST"]3]#U\X?M'VVHZIXPT^SBMM5$"6T-Q:7-F=3:".=9W>6=ULYHQNABC
M)5&^:5Y8U0Y0@@'5Z38Q77[-_@I]1T2_^($UI8:+?BUT-UBFN[B#[/-'-'Y\
MD P)(UDP[+D+@K_#7-7_ ,?-(\>VD5EK?PL\:VVC6WB?3]+GO;F73EAM-12_
MMQ;[_*OC(56X,!.Q6!&>",BO:/AY ;7P'X<A;2QHC1:=;(VFJY<6A$2CR@QZ
M[/NY[XKAI_V;]#G\6RZQ_;WB)+";5X]=F\/I? :=+>I*DJ2E-F_B2)'P'VY7
MICB@#C/VX](_M[X:>'-/WRQF?Q): &'._B.8D+CG<0"!C&"1R.M>3> ]'L=%
MU2+2K0QR:MJKF76]=CGV20H"6"Q.<.R*J,"Q9CU0';FO9OVQ[ZUL?"G@B2\4
MM#_PE5JHQ@E7,%P(VP0V2'*$#:V2.AZ5Y#-XX6"339M+T^YO/MUW<Z;]MMDD
M>/3X9$B>1I,G:<2(X(!*X5FW%AM/S^,;]K9'@XF<85Y-OL>/^-+UO%'CC5;^
M6/R[C4+R7[,)82_EW;+Y-HO"D9A2"XC96SAV/'.1VGPO\3QCP+=2Z?'#G3KH
M7<%I>RYB:ROEWLDB@ 'RV;;C&<>6>,BL/6/"6F6A:.Y747,5IL=[29WQ$^_?
M.F8?]<T@G^8@[H\@!3+$ILKYG@:XGE2PEO#J<[6-YI]NTK"*.613)*&8#>,'
M 8#83$GS +@<;=V>2FX3<V0Z_P##[0M1UC2M3L%C?PE//' ]C>%4\BWE8O-$
MP:+!C& \9CV[@<ER%XM^*=0O=#TR:0Z9J=_K4UNQ%I#MB261BZRXV&;R0T0\
MQ$^1COVCYBP&C\0_$OA[6]&>TUB.._MX[@RK'-B)P(OG#[N&!2)9."PQ@D[E
M#.//_%7A2QO;F26.P,RW$WE*+6X,$[3^>6VPN^]#*K[F3A269EY\_"W&[T94
M]VH(R=)\.W$-GA[+5M0N;A7N-(DU'1UOI+*54RQD+JH5BP:-%<\RQJ_W2-U"
MP&J:1KEGXK.E:M'*]YNU!(?",43M+&R2&YD9'1QDOY@/S LL@Z?+4?BS2;2_
M\0W5E_8.J6:?:EMM.G^TP1>1/&A6VEAQ:X2.Y1$;<OR[SR/W>XV='\'P:Q?O
M%'X76&;7KFTO;>RU+)_TD&X5LQJL7E0+^^<LZLGE(<!FPHU2=^5'"E*4U3B_
MS_R/7?%&F6VD:Q:VMW<1:9;W&HM9IYBQ+'';.H$<2JSDGY0A)9>3)&,#^#C?
MBL=0>RT'0HPL%W>;Y9]UI:3FUC#21",H[@[5'FY8*?EW?WB*C\<>)!XDU&+4
M@([G1!*S&YODVVD-H;26<BW=",R,%O4\Y-BH2H ^56%7Q5&^K:);W%W9137-
MEI=Y:)]KM_,,+[7WJ[QC>8I \H6:#"!HF! ,GRY1I[';*\W*,#F=(OHM(N8F
MDTVY@\/02_9[6V2UL[61974;KN-$C_UBA%=@<JQ9(\8(*])X4U>;P;J-YI]S
M<W$@R5DO+KQ#%<M+=F-MD*HRKYL0\QB<ISN#@?,IKECX<N;>_@AL_"\4YL&.
MFZ=<:4\\]KYS;_M$[2!Y0H1V9@S$N/D_YYD#I1I1N=%T4?V.(0UK/811ZLTR
M2%(LA?W4+"<226ZQ%LJ2L*%?FWQ@:;K<Y8<ZT>Z_KL='XOTG_A(#I<%O.MS
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MQEO9]@HHHJSD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-=O\-)-:DCN--OQI<ET)BMWIVD/%/;Q6HA+>9/##OM[>19TM=@C5)"/-WH0
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M?;-*DW&#)0NA^62)QZ$9'/0X/:O>/$OBG3/%_P"T7\'=4TZ3S+34]+N;I0%
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MV("&(%,,JE\'+'<"<'I[']YW_P 7[R.W\"WLDD;LK7,4GG&/S5BVN)&=F:1
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M ^V1W-4M$^&WASPYKK:QI^GF#4&2=!(;B5U432))-M1F*J9'C1W*@%F7)R:
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MUU@;I'GGF#*HN%R7V&9#&[,J!651G!X]%1]BWRKWGOY>A=248U.5*TGOY?\
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M< 1J H\P\=*;)\#/"DEC-:^7JR+.09YH]=OTGG4*46.243AWC4,VV-F*KDD
M$UZ!10!Q.@_!SPKX:UVWU;3K&:VN;<N88EO;@VT3.NUW6W,AB5V&<L%R<GGD
MU&/@IX1&N?VK_9LC7*R&5(WO)V@B<W45VS1PE_+C)N+>&0[5&63G.3GNJ* .
M+T?X.^$/#]YHMUIVAVUI-HLE[+IQB# 6K7;E[G8,X =F/&,#) P*BN?@QX8O
M/%ESXCN(M1N-3N)+>243:O>/;DP2B6 "W,WE*$D&]0$P"6./F.>YHH \\;X"
M>#1?6UQ#97UE';WW]I)8V6KWEO9-<_:/M'FO:QS"&1O-PWSH>@'0 5(?@1X)
M>UU6VET=KJ#4H&M98KF[GF2*$N',4 =S]G0NJ-MBV#*(<95<=_10!R/B_P"'
M&B>,4T^TU"RNUBM4>.&?3+^>P>!&7:R;X)(WVL HV@D?*"1P,8[? +PFUX+H
M'7(IU@^RPF'Q'J2+;1?NP5@47&(<B*,'RPI(!!X9L^C44 >=)\ O!J000&RO
M9+:*,IY$NK7CQRDM(Q>5&E(EDW2N?,<,X)!SD BS<? [P1=?;3+X?M7-[/9W
M-P3N_>R6HQ S<\[0-I_O*2K9!(KO** //-3^ _A'5M1NKV:#4X9[AY97%EK5
M];1J\I!E=$CF58V?'S,@!;<V2=S9ZGP?X1T[P+X>M-$TG[4NGVB[(4N[R:Z=
M%[+YDSN^!T )P!@# K:HH BDE=9418F=6SEP1A>G7G/.3T';M4M%% !1110
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7HHHJS0**** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>dyadicspecimen2018103111002.jpg
<TEXT>
begin 644 dyadicspecimen2018103111002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0  Q<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT%+/R]?GM_*L=7::(M(;4;F;$;+M8,>"1R1S0!V-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54L])L=.N;
MVXM+*WM;B^E$]U+#$J/<2!%0/(0,LP1$7)R<*HZ 5;HH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6S1KM)CERK.65]W-<T?V3KZ?0=2TJY\5:9)'J-NL,\XT%WF5DDOI(RCRW4C
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M H!8<J5/F7C^RWJ=K-=F*U\,WVFBXD>WT&X$D5C(C7>L31M(J1DJ\?\ :D3
M+D;X6(*G8Z 'TQ17B?PD^ 5_\./$]IK5UJ5MJ-_MOHKZ]4.)[Q)?LOD^86SN
MV&W<X)P/,..2Q.$_[-^M:GXI,VHRZ/+HQU22[OBTDLL^NQ-?+<Q_;$V*FZ%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 2.$!$9F?RQY8Y9F 9V"[5VHO<4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7SI=_LT:MX@M[/0M:GT>;P
MKI4LL=I"#+)->6TNKV=\ZS@JJHPCM#&-I8%GW?+C%?1=% 'S9;_LK:W<ZA/)
MJOBMKJ)]2%P;FWEF@NY[=;VUFC$DJ,I$VRU7=(I&9/F 4' ]1\;^ =4N=/\
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M-&B\2><=;2#;<&Y>-I203M,AC)3?MV[MI8 YPS?>/34 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%P-CVOSA6E (S./O")6&<'$\>=IWA)4UZ\:8(WA[4T4N%\QFMRN"ZJ6XF)P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+GU\Q_[QRA\-:0UT+DZ59&X#^:)C;IO#YSNSC.<@'/K0!-%K%A-;/<1WMM)
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MP-N!@YYSWX_*G44 %1P*Z0QK*XDD"@,X7:&/<X[5)10 4444 %%%% !1110
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M)S_LGTJPEQ%)+)$DB-)'C>@8$KGID=LT 24444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #9(TFC:.15>-P596&00>H(K(LO!F@::JK:Z)I\&(HH<I
M;("4CQY:DXR0N!C/3'%;-% &1#X/T&WCMHXM$TZ*.U=)(%2TC A9"[(R#'RE
M3)(01T+MCJ:MZ/I%GX?TFSTS3K=+2PLX4M[>WC&%CC4!54>P %7** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4^$$=SHTVL^$OA+;6FCW>OQMX>L+:WLM6NPVP1,MPG(140R"/;(WFQX= /F
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MV?[2GA3[#83:@NH6):&Q;5)192O;:/)=K&T$=S,%VIN\U.?X%97DV(P8^L4
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M"VSQ3J:XQ_=Q<#;^&,U(GPNT9&0B]\193&,^)M2(^Z%YS<<\#OWR>I)KKJ*
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M_%I;Y?B'?!>>#I=F3[<^7]*[FB@#A/\ A"O&/_11;S_P56G_ ,14B^$/%P5
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MTVC#_P"APJ'!X7((/RE0"73?C+HFH:+J>LR6.M:?H]E;BZ%]=Z9,J7<1 VF
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M#\I4 W;?X[^"KO4A90:C>2L4M9%N$TJ\-L\=S+Y5M(EQY7E,DK\(X8JV#@D
MD7=9^,'A70]:N-'GO;JYU:!I5EL=.TVZO9U\J*WED.R&-S@)=VQSC&9D'4XK
MS[1?@OX:\0^')]!TSQ=:ZUI\&E:!HUR+<0R/C3KN6X+2>4P56G\QE*A5"8)
M(^44=<_92W>)(M5\/:UIVF1PS7;P6.H:?=7$4,<\>G*5!AO8')#Z<'RS$?O2
M HVC(!ZOHWQ2\,Z_X@?1;*_E:_$MQ @ELYXHII()&CG2*5T$<K1NCAE1F(VD
MGCFNKKROPK\"8?"GBG2M=M]<NI+BUU'6KZXMY&E>WF74+F2X*)$\K)"R,ZCS
M$&6"N, .0/5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#W[/^M_#WPKINE:GXA.H7$?@BP\,27>\,UI- CJQMRL<9,69"07RYV)TP:[
M_#[QF5X^*6KA]I_YA6G[=W';R,XZ\9[CGCE/^%?^-R /^%I:B#@Y(T>QZ\XQ
M^ZZ=..O7D9X //6^ OBO7='\*Z;?+H/AJ+P_IEAIJ/X>NY"9_)U&PN7=0UNG
MDA$L6\M/G&ZX8$@#<W7?&#X+:C\3_ VB^#$\0/#HJ3!M5O+V-9[JZC2)Q$,;
M0A<3&*7><8:%3ACFM0> ?'(_YJA>GK_S!K+_ .([4X>!/' !'_"S;PYSR=&L
M^.<_W/PH \QOO@EX\UW6)+C5+?P_<2W]H9-6>2_DFLKV[?16L9&%NUOYL#&7
M"[X)HB8,Y^8LC4;[]G?QIXB66ZO#HQ/V>XC%CJ<XFENP6TTI#=W,5LGFQNMA
M)$SLCR+&Z_,Y^5/7U\$>-UD#?\+(N&7'*G1K7G]*!X*\< #_ (N/*2!WT6VP
M?\_YS0!Y4WP$\<>)O&=QXCU"XTG0Y$O;C5](>&2.2\TZ\>"-%+M#:PK*H\OR
MF5V=FA9E,C;B*K_#7X"^//!%^XO!IDD%]9Z=%<1Z=J$36R7$&FQ02R%9K S8
M,T! ,<H)5XSL5@YKUT^"_'6&Q\1F!_ASHEOQUZ\\]OU_"-_!/Q ,C%?B4 G.
M%.@P$CTR=W/Y4 9O[/'P\UWX:>$8](UU8GN(;6TA%Q#+:N)#%%Y1'[BTMSC"
M*1O#G# 9&,5ZM7G/_"$_$+'_ "4M<X_Z $'7(_VO3/Y@]L$'@KXAJ01\2HF&
MT A_#\)^;N>)!Q[>G?O0!Z-17 1^%?B&G7Q]I\G)/S>'A_L\<3_[)_[[;_9Q
MN^ =6O\ 6?#8EU.6&>^AN[RREFMXC$DOD7,L(<(6;;N$8)&3R30!T5%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!P?P$F>X^!?PYEDDBED?PWIS-)"P9&)M8R2I  (/8@#Z"
MN\KSW]G:[%_^S]\,KH!0)_"^F2 (Y=>;2(\,>6'/4]:]"H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N4^&G_(NWG_ &&=6_\
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M_=UN^!Z8ZB:@#OZ*X-?@?X/4<6=_^.L7I_\ :U+_ ,*1\(?\^=__ .#>\_\
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MC QUWASPY8^$]'@TO34F2TA9V'VBYDN)69W9W9Y)&9W8LS$EF))- &G1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 C*&&#GJ#P<4M%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 43KFFK
M(\9U"U#H2K*9ERI'4$9XQ@Y^E']N::,?\3"UYQC]\O?IWJ3^RK+[:]Y]C@^U
MNH1KCRE\QE!R 6QG (!Q[5F#P)X:%N]N/#VE"!]N^+[%%M;:Q9<C;@X))'H2
M30!H?VUIV&/V^UPIP3YR\'\ZD74K1]FVZA;>"RXD'S 8R1S[C\ZI3^$="NI9
MI)M%T^629Q)([VL;%VV[06)')V@#)[#%4G^&WA&2-XV\+:*T;L69#I\)#'CD
MC;R>!^0H W!?6QCWBXB*;0VX.,8/(.?2I?,7!.X8!P3GH:Y?_A5'@C_H3M _
M\%<'_P 34;?"'P(Y);P5X=8DAB3I4!Y'0_<H ZP.K=&!YQP>]-:>-0"TB $X
M&6'7.,5R@^#W@)1@>"/#@&TI@:3;]#U'W.E(?@WX *[3X'\-E<YQ_9%OCO\
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M8/ _A#5]<M[WP%H<FK:1#,][IEC+:3:G 4TL7\CR0!>(=I\GS=QR[)\NUMP
M/I&BO&O&FL^#/"/CC3O#+>#_  RT^I&"=I;Z:SLO,DFE>-5B209GERCMM7G
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M)_AX4E3^T/&&\>''\4/'_;FJ;TM$9E9#_I'$P8,IBSNRI';@ ]RHKQGP1?\
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M,=?\,^&?#VC6>KW&N>*[.RNKRRM(V37-1D9I+J>.WA4H\C,H,D\8)(&W.20
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MT2VE[: ,1RQ\K4;D<GJ4;JHJ_-\'/"\M[K5VMG)%-K&IV&K7>R9MK7%G-'/
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M(J[J)"/LY(W, >$V][XI\$^);[Q#9^(/#NOZ=HFK'3CIUZM]ICWL,J[U='C
MFB*,A\W&2P8/AAP".]HH \U^$?P+TCX1+=?8;N[O7<I% \\\N([=((88XV0N
M4=PL"YDV@DD\"N0_X9CNK1=9N8/%8U#4-;C<ZHFLZ?\ :+2YE^WF\A*1K(CP
MK$9;M4V/N4S(X;,0#>\T4 >&:=^S[KMCJOAJ]/BJ.6XTV2-I[TK>?;7C6]DN
M3;>>;HF:#9(852X\W8,L.6(%/PY^S-J_A#0=%T32/&)M;*UDTB\O+A$O(9[B
MZL;2VM#CR;N,>1+%9Q PR>8H)<G>2,>_T4 ?-&M_L?WES::6-.\7"WFL],MK
M=XI+>=(I+V.\TRX>Z4Q7"21;UTJ)=J."&8N&W%MW2:?\!?$6F^,-*U^+Q%#O
MMK"UL9K8WNK[6$%U<S1MG[=^]!6Z*E9Q(/EP/E.P>YT4 <E\+O#M]X9\(BVU
M+<M[<ZAJ&I20M-YI@^U7DUR(=W0^6)A'QQ\G'&*ZVBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HKF-3^'6E:O?37<]WKL<LK;V6U\0W]O&#Q]V..=
M54<=  .OJ:KCX6Z,%8?;?$>&&#_Q4^I9_#_2./PH Z^BN._X57I 3:NH^)%Z
MY/\ PDNHDG(]YSCUXZ8].*<OPQTP.S?VGXC.['!\0WV!C/3][[_H* .OHKD1
M\,[ (R#5_$05BI(_MV[)X'J9,C/4X(J2+X?6\/F[-:U_YV1OFU:9]H7@ ;F/
M'KW;J230!U5%<DGPXM8DV1ZWXA5><YUB=R<IL/+,2.I/'1N1@@8<OP[MDNTG
M&M^(,I*)A&=6F*9   (W<KQG:>#SD&@#JZ*X]?AC8B%8VUGQ(^TY#'7;H-T
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M1X'UU H'Q#\0N .3):Z:2>OI: =_3L/>G_\ "&ZZ%P/'NM9V;<FTL/O?WO\
MCV_2@#KZ*Y!O!NO%% \>ZR&  +?9+#DY.3_Q[_3\JB_X0KQ'S_Q<+6?;_0;#
M_P"1Z .THKD8O"'B"-%#>.M4E(;<6>RLLD8QCB$<=_7WJ6/PMKR+"#XSU"0H
M<LS6=IF3E3AL1#T(XQ]X]\$ '4T5R\7AC78X=C>,;^5M^[S7L[7=C^[Q$!C\
M,^].?0?$3,0/%)1/+9!MT^+=N.<.23C@;>,8R#Z@  Z:BN:@T?Q/%(&?Q):S
M*=Q96TL#DA=H4B7@ ANN2=W7C)<-+\4^=DZ_I_E;\[?[*;=M],^?U]\?A0!T
M=%<H=(\9^4H'B;2!)SN8Z)(0>.,#[3QS]?PI!I/C42L?^$ET8Q[B0K:')D#/
M )%US]<4 =917*II?C12N[Q'HK * 1_8DHR<\G_CZJL=(\?[\CQ5X>VYZ'P[
M,?[O?[;[/_WTO]T[@#LZ*XXZ3X]#9'BCP]C X;P],><<G_C]%-;2OB&67;XH
M\,@87<#X;N#DX&2/]/XR<D>@('.,D [.BN*ETGXB$R>7XI\,*#]P-X:N6V\]
M_P#B8#/'';GGVJ(Z/\2]H_XJWPINR<G_ (1:YQCMQ_:/UH [JBN-72OB"'!;
MQ/X:*YY \.7 )&.F?M_7/.?3CWJ4:;XZ_=Y\1^'CC[^- G&[@=/]-XYW>O4>
MF2 =;17+1:=XU#L9/$&@,N#@+H4ZD'W/VPYIXL/&.X9UW0\>G]BS?_)= '34
M5RXT_P :;>=?T'=CK_8<^,_^!E":?XT&S=K^@G#?-C0YAD<<#_3.#UYY^GJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%1R2;'B7&=[;>_H3Z>W?% $E%%% !1110 4444
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M\>_0XY^IQCBF2^#M3D50OC37HB  62.QRWN<VQ_2@#J**Y0>"]5&/^*Y\0'
M(YBL.>O/_'KUY_2I(_"&IH"#XTUU\E3EHK'M]+;OW_3% '3T5RA\&:L68_\
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MRBN5C\(:TDH8^.-:D4,3L:VL<$>G%N#^M(/".N+&%7QQJ[-OW%I+2R.5[KQ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM80QC[1'(T4B#<H.[<C#W R,@@T >BT5R&H>#_!%A\LWAW0C<1Q/-';_ &*
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M6;R$C3AW,ID*@+M8$YXY[\T >B45R<_P]25LQ^(?$-N2[2'R]28C)W8'S \
MNV!TX4'(50"3P-?,5V>,O$,*J$&U6M3G:,'): GYNIYZ],4 =917&GP!J1 _
MXKSQ*,?]>7/_ )+4G_"O]3_Z'WQ-_P"27_R-0!V=%>?7?@IM"BN+R[^(NO6$
M4DB&6>XDL(U+MMC3)-MC).U1ZG ZU=?X?ZI)@K\0/$R 9'R"P.>H[VIZ?TH
M[2BN*/P_UC<Y7XB>)TW*%P(M-(4^HS9GG]/:ED\ ZT[$K\1O$\0^; 6#3"!D
M #K9GI@D9[L<YXP =I17#'X>:^<_\7/\5C@#_CVTG\_^/'_.:;_PKKQ!_P!%
M1\6?^ ND?_(% '=T5P,7P_UR>-9(OBKXJDC;HR6^D$'\?L%6/^%?Z[YBM_PL
MOQ3@8ROV;2L-\I'/^@YY)#<=P.V00#MJ*XX^!=:.S_BXGB4;8RA_T?3/F/\
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M]TN;4W^'.L:5K=LCVD1N]4DETV6UCF8MME8M#=%9&RJ-DETW9/VO10!\EO\
M!3Q->?%\:U/X9U'=<>)-.UBSU6)-)M5TW3XHK<&T:X4R7"F(1S0M#$#',LI
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M-MIM[;PW5PKM?75NB)<(\IV!FDC:==WR@E\X(^4^0:)^SGXY\-VXT-K.[O\
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M>'[SQ/>:K+IOB@>)M"O[:Y%M;V12Z>!HX6 6.0SO:>6T:EI4DF8[B"1^AM%
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M[H=R1%;*-2L>PC.05.0??/V>;F:;4?BC#<>([G7);?Q?>1?9KIX2;%=L;+&
MB*54A@0&SP 1U)/K+:;:/!)"UK"T,D0@>,QC:T8! 0C'*\GCIR?6I(K2""6:
M6*&..6=@TKHH!D(  +'N< #GL!0!+1110 4444 %%%% !1110 4444 %%%%
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M:>]PT\,A55O9Y+>U(*J=VZ2&4'&=@0L^U?FH ;_PNCP__P! _P 6?^$=J_\
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MCMGW;L;97!6,]'((7)H A;XK>"48JWC'0%8'!!U2#(_\>I/^%L>"/^AR\/\
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ML32O@EIVE_$)_%8U6_FF&HW6IPV3"(1127%O%!*,A S+B(,,G()ZX&*]'HH
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MY+3?V7O'-O'KDTVHZ.US?Z9H<$<5SJ^H7^VXTO43>(&GN0[B&?S)0RH%$6%
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M>+9I!HA^R[[ADT;4F#JMPR0LZ%=X#,HRH(((%>_TUHU=E9E#,ARI(Y!QC(_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKP2XTS7/$GB_XO:I#X\USP[)X>OX[;3HX98GL;=!I-E<$R02(5<>9
M+(6Y!(8@,O!%?2?VHKJ=?!KW6C:=)%JD.B1:HMK?2O=:?=:B(!&&B2%XXT$E
MS$ )IHV8,2H;"B0 ^@Z*^:] _:4\46^G:9I>I:+I5_XKNKS5Y)0MW>"UAL[?
M49+6'+PV,C>8Y78 4 Q&SD@D(=;Q%\=O$>NZ'%?^'?#QTW2X=5\/6&HW.HWG
MV74+.6^GL9)8OLLD#*?+M[V+=N=#EG  *Y(![]1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@))/!&#U/>EI
M H!)  ).3CO0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BN,\!_&+P?\3-8\1Z3X<U@7VJ>';K['JMC);RV\]K+
MEAADE16()1L, 5.TX)I;OXP>$++XI67PXDUA6\:WEB=2BTJ*WED86P+ RNZJ
M4C7*,!O89. ,EAD [*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEV3 $$9MT.".AZ5'+X1T*>-DDT73I$8 ,KVL9!'H1BM:B@#!_P"$ \,;=O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ8NOR5U?BCX(76LVOQ M[.]M+6+Q%!IMO;"2-I#"ML,$R%L[B1P#U& <Y&:
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MV.FFUMVM(3:VZQE(6?>R @="_P Q'=B3U)K+U7X1^#=:M[*"\\.6$L5DJK;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"ZL;:^$8N;>*X$;B1!*@;:X
MZ,,]",]:GHH **** "BBB@!C0QO(DC(K2)G:Q&2N>N#VI3&AD60JID4%0V.0
M#C(S[X'Y"G44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 PIF17W,, C /!SZ_E3Z** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **^;=6_:;U+3/%>L6*:GX/N9K+Q9#X<
M@\+FX>+5[I)&B3>F9"-^)1(,QA2JGY@/GKV30OBIX<\1S:=#87<TTU_>7UA%
M']ED#)/9R/'<K(-O[O:\;+E\ DK@G<N0#KJ*** "BBF-*J.B'.Y\@84GH,\^
MGXT /HHI%4*H50  , #M0 M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '@_\ PJZT\7Q>+_#NG_$33;SPWKVKRWVJ
M:=:6T4U[&TI#- DXE(BR(7PWE[UP65E*@A? WAR:V^,_Q \1V$MK-<SJO]AZ
M#?ZG$H$<HMS?7B&+S7CAG:&U(4K]Z(MA?.)K7UB/PI;:_>ZM?^*(;:%?$AU6
M18EDMV5DT\Z:T7F(P+X>-LOT!'ED9 -4/AEIVD_#'6-36\\6V%[:V>G013R7
M+S0W"O!;6=I(Q1G,;+N@3)105>4(>2=P!V][XO\ $FGW*6EQI_A6WO7$DHMY
MO$DB.854D2 &SR>GS<84 G)QBF0>+O%LU[<V0T;PL]];8\^VB\32L\6Y5,>Y
M?L8*[B6QD= ",YP.%^)>E:+XXCU?5+/QOHFEZ1>Z;>Z?>S>;O /V&Z5O-0R%
M-T8+2%@$D5('0DJ3MS'\.^']0US[,/&7AQ=,GOIY7MY;99)[O[3JJ7+Q2N6'
ME,'MYK=0.6;&1NC"D ]5?Q+XKMU=[C1O#L,2N0'/B"3&T$*Q.;08PQ QSSQ4
M<>O>++](;RVT#0KB)=X\Z'Q"Y3CAER+7!PPP?0K7C]MX1\.ZB/[6G^)GAS48
M=(:_+[Q!';-%//<SWK3[F9AN2XMG9D9%+VT;X52%7/\ %FA>'(M*;PY:?$/P
MAI^F)8V6@WP9@9H+NS6[#(JJ^ SNYW*V&3R9?O$G8 >TIXY\1/;13_V7X8*3
M2,D++XE8K*5;:VT_9>2&X('0\5:D\3>*HKR*S?1/#ZWLL9D2V;Q XD8#J0OV
M7)'O7DNE_#>SN_B?#=:!XPT;7KFW$UX]C-/%]H\BXBTH"4>7&5*JMFI&$ 99
MX\L"=Q6^\$2Z=KUGIU[?^';;6Y[&[C33FNQ%=:HQBO8E8HP95:9IS,98O+?F
M5&#@$@ ];EU[QI H:;PWH<2DA0SZ_( 6) 4?\>O4D@#W(I9/$'B^.,2'0-!$
M981[CK\@&\MMV_\ 'KUW87'J<5RWCE] \>_#"#3$\::0\EJ=,OCJYN5E0.ET
M/(FW(XY>>V<*P(^9"!R*XMO!VG^'M-DEE\:>%XK&YU"VOM4OQ+M;[19:P;J4
MH"[;F>YN!&Z;@$>4!0-P0 'JMWXVURV=/] \->7([K&TOB)D+ ,JCC[,>=SH
MI )P74=Q5F;7O&%N8UD\/:$C2OY<8?7I 7."0!_HO)P"<?7TKRGP#X#\+VI\
M(Z4/$/AJ]O$U&/7=.LK:5)3/;+8M;@PL0)64A=Z^8TS*L>WS'5!CH_VA_#VF
M>-;"STRX\3Z3HDVGPW5[<Q7]^ELZ6\UK/9"XR0Q54>X!!(VEE"DC- '7#Q/X
MMGDDBMO#^AW$\1"RQKK[9C; )!Q;$@\C\"#QG%6?[;\7B5$/AO2@6R<?VTV<
M @$@?9^>"?QP.^1P?PNTW3?ACXUUG1]0\4Z!+=ZQ=W%U96<=W!#<NTMS,[#[
M.(U8G<64GS'):-N!R!F_$;X1R^)/%/B6>;Q#HMG8SI<7U]+>QPR7%I:3Z7)8
MA&#)NCC#QR2B02(#^_0A@20 >H-J_C 7#A?#6F& $[7.LL&//&5^SX''/4X/
M'/6G1ZWXHD&Y?#VG.NXJ3'JY."#@_P#+'L<@_3\*\2B\$/XY\2:=XNB\>^&4
MN+_Q&=4T>TTZY%U;W%_#;VL#QI(2&=UL["^1@@#*MU-D8C.ZEIO[-BZSX973
M/#_CK3I+*^TC2)WGL((&R((KTVDT/E*JF+[1+!/%*VY\VI^=_EV 'O']N^*]
MJG_A%;;<S8Q_:J_*-P&6_=^F3@9Z8[U'_P )1XF_=Y\%7',FQ\:C;_*-R#>/
MFY7#,>Q^0C'()\9\6?"G1]3TG74UCQ;X82Q\5Z;K>C-;7LB-;-JMU<KAH3(Q
MR5,2(\8YWP(0 V[.1XL^'/A:ZO?B;?:=XJ\&Z?HVL2K8&8ZC911Z?<"SM;<6
MT@-LS(?]&)V><%PW^J/.0#Z'3Q'K9<!O"=ZH,FS/VNV.%P/F/[SIDG@9/'2J
MZ^+-?**3X(U,$D#:+RS. >Y_?=N_T.,\$^*:3X M[77=.BOM>\):?J]C'I$\
M@348);RQ@MM2N;C,6RUMU"W$=U'"6$<?$C@^82&?:_:5\.Z'\4DT;P^/%WA[
M3M0D:_T]+.^U*"&>662V$96(-'(QD0RQ$A K@2*0RDC(!Z>_B_7U2-AX%U9R
MP)*K>664]CF?'/MFFMXS\0*S > =98 <$7EAR?\ P(KG? L'A7PUXM\3ZB/%
M.D7DVHK'?V<"Z@KFSL'197*J7.V.2XDGFW#@B1!G"(!Q_BGX:77B;XCZ^-0\
M<:5 OB*6VC&CQ7+)>1VUG<VLD2Q$MU79=M\J*4>]8[VPFT ]1_X33Q!NQ_P@
M&M8SC/VRPZ>O_'Q3SXRUW!QX#UHGGC[78>^/^7CZ?G7.:)X-U?0?@SJ_A76]
M>T^X\2WT&L3-J 9H8F:>>:7S=I)9%7STW 9"]!QBO/O"W@35? 4ND6-N_A"P
MO+RRO=(GMSKD4+%I?LC1RQ1V^G6Z32!1RI1#AHL-AN #V$^-]=$ D_X5[KY8
MC/E"ZT[>#@<?\?6/;KVIK^.M<7&/AUXD?) ^6YTSCG!/-X.@Y^GOQ7B#_!?Q
M%X9CM[:\U'PIINI7L,FGGQ'<WS+?ZF7>.2"VY@#8C*"-?WC_ "1IA 68+0\#
M>$-=^'GB'3]:N==\%RVFF7D=M=VH\01VZ*_EZ@))&\NTC02D3QDJX:1A'(6E
M8J* /?HO'FMR,@;X<^)HPS;26N-+PH_O'%Z>/IS[4Q?'^NM&S'X:>*%(Z(;G
M2LMTZ?Z=COW]#[5QW[/_ (;M_A[I^NV=]-X>COUDB-W=Z=>VTDDSX.7F\NV@
M89+@CS6E<^8<MW;CM7^&6O\ B>\\2ZKX>O/#5Z+@:D&\2C6&\^Y5Y!<6MM(8
MX"8EA*Q1<R.JQH&"%G(4 ]D3Q[KC2JA^''B=%) ,C7.E[1DX).+W/'7I],GB
MGR>.=:1@!\._$K@C.5N-,P."<<WGMC\1[D>2W_PN\>WVHZE?KXAT;397AOR=
M*%[<LR&\-QYV^565,(KZ<REH6*FW<*5$I)J'X.^*O#ODV'AWQ9H]M#IM[%XE
MAC<+";OR;.U@$31PF-(XI72[+R[7 \U3L9@&4 ]FN/'.M0Q*Z?#SQ).Q )CC
MN-,!&0I(^:\ X+$'GJIQD8)E7QGJ[$ ^ _$"@KNR9].X/I_Q]]?TXZUX]??!
M/Q'+;:AHFM:WIFJ:9=^5+IMO>W<K2171NS+.H\S<2#&9&!7;CSVC"^6D85]U
M\$/$UU>7-C:_V=81'496N-6-X\O]H6372206DEH$5,0P )R>!"$7Y9I"H![(
M?%>J#=CP9K9P 1B:QY]A_I/6DE\6ZK&P"^"M=D&,Y6:PX]N;H5R_A'0+SPW\
M+]0\*7NN64FL2'538R+=8"V\ES<-:X'!18XFC7:HPGEE5)"BO/$^$'Q0MHT6
MY\0W.H6$IFN+RVMM;D6Y$OVB (L331O')&T$;$Q2;5#JR[@L[.@![4WB[50^
M!X)UUAD#<)K#'U_X^J:GC#5F.#X'UY/<SZ?_ $NJ\OL/A#XEBAAOI8[2WU>#
MP]JEE;W<5Y-&T%S+*!:OM+R"-A!@,4=E4@JGR*F'W_PQ\6^'Y]9OO#ZS>?J.
ML7CLL.IL)!:O9216[?O&VG9</YA&01DL-S  @'I[^+M3C0.W@S70N,MB2R8K
MT["Y)/4\#/0X[95?%VH%V5O!^N)@<$O9D,V,[1BX/YGY>V<UY/JOP=\>6NC:
M]#H7B*>+5[I;&&TOI]6N/+B,=N!/($._RP\P5BJC+<YZYJCK/PS^)5Q=2ZGX
M8O-3\.VMG;R/:Z!J7B*6Y^UW/D%&$LI,FR.3>RJ0S&-T2;;N+)0!Z\OCZZ*1
ML?!_B)2X)93#!E %!R?WV.^,#))!&/5T?Q!\QP/^$;\0JK(9%=K# *@J.F[(
M.6^Z0"=K'&!FHO$%EJFG^ ])M8);VZO[:XTM;B6WD9IY(TN8/M#$@Y8&,2%O
M4;A@YQ7@V@_#3XY6?@K1K2+5I(]7LH=/O+N34M8F)N;JUMG#P!A+,6CFG,3.
M[%0ZJX:->-P![M/\4;>W0,_AWQ.00I_=Z-,Y^90PX /8\^AR#@@BHW^+%G',
M8V\.^*@0<%ET*X9?S"G/X5XYKGPN^-SZK)#HGC*;3[.YOM7O(;^[N3<M8?:-
M4BD@C,)91+'':HQ16+;#(Z?="J>@T'2?'F@^,=&UBZT77/[,M[4+>V!UMM15
M0MIL*1LUROFN9\$&2 L1ES,A/DT >]T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBF2X\MCY?FX^8(,9)'(QGC.: %$B&1HPREU 8KGD YP<?@?R-.HHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *9)$DRA9$5U#!@&&1D'(/U! /X4^F2EQ&YC56D .U6;:">P
M)P<?D: 'T4@Z<]:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5'/N\B3:Y1MIPP7<0<=<=_I4E(V=IVXW8X
MSTS0!E:8FII:R+<1Q)*LJF,&=I 5(4N=V 3@LX4$#[J_6M:H(KV&=8VAFBE1
MV*!E<$$@'(&.IXZ?7TJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J.YW_9Y?+!:3:=H4@$G'')Z5)10!
MA:?92:;,)IK98UCC%M;QV88[81C'F<X8C:2./EW%06R29;"UTO4YK748=.@)
M6))[:ZDMMDJ[T*\;E!4[,#UP<$"IM2ADU33-0M6L@P<-"(YYO+692!D[DW%0
M<D=,\=*N1QAI%G,"QS-&%9CC>!UVY'49)[T +!;K;^9M:1@[E_WCEL$]AGH/
M;H.U2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1129.XC!QCKV- "T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444R.5)=VP[@K%
M2<<9'7Z_XY':@!]%,ED6&)Y&SM0%CM!)P/0#DT^@ HI&8*,D@#..:6@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M #UI(I/-4G:RX8KAA@\$C/TXH ?14<,7DH5SNRS-G'J2?ZU)0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !3514SM&,G)'O3J* "FN@D1E895A@@]Q
M3J* "BBB@!K*'&#GJ#P<4ZBB@ II0%P_.0".IQSCMT[?YS3J* (Y(4F^^NX8
M*E2>"#U!'0_C4G2BB@ J.6".8H9(TD,;;T+*#M;U'H>3S4E% #2BEU8J"RY
M8CD9ZTZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ex31imagea01.jpg
<TEXT>
begin 644 ex31imagea01.jpg
M_]C_X  02D9)1@ ! 0$ 7P!?  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" #[ I@# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            D*!P@$!08# @'_Q  4 0$
M        _]H # ,!  (0 Q    &?P
M
M                                       _AK4:?&C!BLSD9!.D/+GK
M3;,D(/=                                   U7(9B4LV\*TI$\71#;
M$'E2,LKKG>EE$D8    /R1BFGQHR;B%A\                          &
MIY6R+61DL%. TY+Z!VH (X"J >F+MYDD   $&1*6;!'3'4GKP
M               5)B5HE_!YXHPFTY<8  !4&- 2T&2Z   $.)B<GF
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M*<H  QX9# !CTR$
M                                                 ##)]CZ'W.8?
MHX1T9_3HCISISL3J#O#\'D3W9_3MS\':G2'X/T=(>C.:>#/3G5G&.*>S.>?<
M^)TQ]#B'Y..?D^9\C['3GE3SYZ0\:#SQ\STAZD_)V1W)V9W9V!Z4Y)C@_IPC
M@GMP=*< \&?@[PZDZ\YAO(  8Z.4?(_)V1Q#T9QCRYV!TYV9^#M3XGS.4<(Y
M9]#YG..B/L<@YQTYW)^SXG"/N?<X9R#\GZ/L?@_!]C\'X/L?@_!]C\ [HY(
M
M         /,GT/1                                      &&30X_1
M]38TV1/9  ^!K":SG--D#(1EX &,CTIZ@&$3"9^3(YLJ #78V)
M              /F:3FN1+*0_&<S:0Q>81)+ 15$B!%@2]$;ANH:0&1#*9QS
M6 VH-L 1"DO1C8BC)5C%!HH2_D.1*T:FG/-Z
M14DJQ!*;8&W9'2;;&YX.H([C5HEG([27@@_)P"/PR6:N$K8!H$:^$P!%T;9'
M@31HF,-"#G':&T9EP                       P0:IDD9HT<0S6:)F_)G@
M C!-TC-A&Z;:F*S;,TM,K&MQN*96 (>R3@T&-PS54[HV"-<#:TUC-WCV
M                         (<28X     UU-:3.IM6
M                #1\^!FPSV
M
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MW?\ ;=ABFXM<V'&?/B\)T@ 'N[?%L2UJ>=0%C>"J^Z[:U58O5"CF+[<(D2+
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M01;%$?I.1AS!L**C5P3L[56M6K%7B?.VE<3=[B";YX<OHYNN\0];5BKU8!]
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M_;L99<6@=!W]J(>Z/7Y$^7_P*V%JUBLZ(1[!&]->U\'KT-_M7__$ !01 0
M                 +#_V@ ( 0,! 3\!)@__Q  4$0$
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M+ZH@U9Y/I;O)=8J]1#7:T7M5E:"KKJA4SU5QYZ2"8 9B&<AX5:$"B"Q+Q/\
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MF2%XXJ*L5NOQW+$6)\0Q_P G='>6II.]6]_\0<?>\[K'W*LP*IB3HJY2QHI
M95KBKYR4149;/1-"B2M4I $48.:88K=18SF4QL[%$^B/'>.-A:?AK]]M/D3V
M?7.5NI<O3U_0Q=8M+K*^2K [^\[<9,Y47UH<CW#^#/SZ#[Y[P#L8[!QJIJC(
MV99096VS!6&5QI5(-BP9UM509F!H\=T<QSCN5BQ\X9*Q;%23P;:-I'I-(.@<
MSV^6Z.6RCDY5-#-G/%EN\@TX]Y7451SDL7%1!FY><"JZ:2U>T01QUF?\YFY"
M$O:Q3G+:YV#W(<Y"&)>]OPVQ%SUF_P K$XWBJ&@TBH5(&.YLE4<%6L/T-;9Y
M!HU*XBZE!4U%A*PJ\I74N*>(*;6;R/1T$P\=TT85%KYA]P.FL'/#0?PF"1/0
MS-6Z\FLIGW"HD+9RV,7*4<QF05\.<_RHR]@ZO(0)57)<-RP2N>IW=;#5",2@
M66*56+MF2#I:(88\0E_K$YWE+B7RN3N>AM*IYR*U5]D%4+^U\D=1M:/FLE$P
M?0*( 1%3TW>QX>QNB)Q4RF0U4?(N1'X:5UTYA'G/W_C@BR"S6S,:1,#6%BD!
M>P5[JK26=*25W<>G%?PY1IJM^GK%S&,OCUZ6Z,VY#JCLCD>I3QFDIPMFHWV^
M*U*!6,<\B5"<PP'LNGI"%89+J.1>ZC@"4BUU6?48"P+RAO(C63<6>3)-K*-J
MN!&<?V^=JU+DQQQ1$A[=W=Y\F;Y3 K3>(M:RQTB+3?\ 7OD7=%KQ,7M^'*_$
M<W'T4SJ<?KHE;HJ UN*"C0N8[;+59JE77" MD<RA?Y[93E,O1Y%3.2T=OEVB
M_.H;E&J=7&=_NJB+Q?#=T*)-+KO)(,J1L:[NWKF\BH2O^T#2='#[+/1O1T&
MIH(*G==;8O @*J*BL=E@Y+=*C" -+D)>WZ5I6;3^D?7'N&\9V/RECZKQ)5RR
M0)ME"F1G.:;>_P G*MG0179H@?TU.)K:N@LGL0@SIMXC \34UPX/&LU;-0'>
M3E@  !*Z[>@QGT'K $*IW3U$*MR]E:U$(*P*!5   OP33'L)S7"X4A:,>GBM
MH>UM[.O\D6#>./#46<ECW<6EJ="RC:I$\TN4SN:"7%(XOMV)RU1M5[B&?*P-
M,E]G'W\I ?4J_P EGK#1S1?F%@VQ/0''L"0OJTP5.-OZY]?88CD7W%W/,;DW
M*CF9<(4C1_8*CG'=B&?4\O:5MP]*/[#D6<>F@ZI(H?7.=)>]2 +R%A.A*&#;
MJ;*I&/H+E!Y/9683T,QBMAF#%BK'3>CM2=S6'^?:AW6V^W"XY5\I3I,4;T-=
MA_2A@Y!RRQ[=/&Y6\^Y!#L%?9V01IF@*97(77U]B%"/UQ_?](X\V#AS:ZA)A
M1V?7^:?RLVM)%6QK.$,.TA1=L%K[E_<%W:A'8&B17*:8T1ZO)57./@&[?>TV
M;CT[9!O<+GLI+>EG[TK'N%!/CGQ:95\_.45003#1=1)( E5%0#CM&!=8%:!
M$=?VT&.E:5C](B(^M;5S\]=30W90G69#$UN[\4G7/SO)'7LB%$J57#4=:5BD
M?Y3/Z_6A@Y".F;@?'7^MX2>"-?F9DS$##6Q3U3=,*-&^4?%#-V%[,>K\MGMN
M[F4/CMG=)),'+^0P-S<A6L6#C"M6MUN+YQY8>,9')F;>PX?0T&]G5N[K/:+Q
MF*%K]<9- 0E+3GJ J^4-"VD1N-\H\X1]9H3O-%*>/P%"?V* NN43(P%I]O\
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M.N?>Q@1QI!WXUT)5V'#V]H 'O Q+!^/EXV97EK?&--%?4V!V_.?*$D'>238
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MLDR]%BJ'V\X_K(ZC?'_/YW5,( -?.6'MK"=6OA\EY06-&HD++4Y#B(.-&U2
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MJ5TX$_(;C2LGK+:C&XRWS)@_#N.-R&N1EZ2]_1&*P7+L[&?QW--CZ>DT-Q;
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MM$_]R5=@0SKG'<)P&I4H3!+6:$$4=XFA!DI,TO2\36]9FMHF)^O_ &>\'_\
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MP>(:YPZ6%&A&@;'595NLPJCHUO\ !>O(KOU#;4%N4[IQV]#_ .V3%XH30]0
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M@"B6QS[05KJ/7T)M;"X?QZK"XC[6_ &%VCF+YZ4S<E0E&#V*)A@@ D3%HXO
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MIP[@Y-.("[RM?0=Y1L8ETRC^>G!J(0DT2RQ5_'R67<G;,VDE&J1+,:;!;A7
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MK'--56A1*]QA8LV.[$K>BV'=YYH)$<&J9=+BO'R/1QC*]P7KO%<(S81.4/M
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M 1D)Y\QAF%(1#%#3!?KE;B^]/(N5ZU'',F-N#*<8SGA(V%C92F2F<EL[#$S
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M)C%P=LXR7$0(MM%2QBV*0)+_ "6Z%AU?[&-4@5&$7NXROH[*@ZEPQ>NU?0T
M8;QYLE>]-9^49S'B#D#OYOGS%1-!>1%B 28*@&=C%WM:/J$AAJ<)6C%D9E=:
MPN-10^\I<-VD&5 B]&@IGO;C.T0!WAO?5'@O'O.>(L-\=6_X#HPSD\1^[BCL
MJ>%4?B@$@E<PF^U,>!.(\++%X6T'N)>%IFJ9V(%P.NC83+XI"3Z.9*V#/^0=
M4FD^F ['#Q!NJ%MAE'B>BY"M@+E[THG#V9G,>I,'@3G&(\D:0*XJ2J S/!9<
MF98]UQD >+D$J[?39Q^APF\ =E0ML,H\3T;2F_$6$]+"1]8X1^"@;U B?1)*
MFV<,8 N'Z-]8G3$C=.D=AWM)K@_* .,/95$ =ZD$<&0'8TU,G<I1N&'1Z=P;
M55&VSNMB(NF )2Y*X$$H*P3SOGX])A"^8L@VDW61CQ%N\6:I-E)9OL@JI%TK
MO8(64OE]^3-*]F\I55-N!T-QC8FU137 X,&0&I>@\[+.GH.F8/<TN^U#^'[A
M>CGJX\]*3C>NPN/&F-9MI,NN1]")+M9*-Z0HF3FQQ6DO8G12TV>5U'&LZ_8G
M!#:05COJ"_)_>N %JM,CO$Y-;S"F3%P%#N<N3PF$[G&/HPX3 U"*,L4W/S"C
M\FHZ6*3_ +[0/R2 R^L+,@0,PCRI-4:7$W9PF  )^RM#-XT>]I+JP,! _>1Q
M*[-N]S39,KH>U#@U0R<K% G@!%:!#'3PJ;_]'B,7:-=0KS;EC^(BV7CVRF&,
M[.O 6HR["X,K$G2G.G("*(H<9>@I/)DDC[,^+ZO#I^#"U-9H/<>>0FS%>AQN
M*)U&',H0Z%N1F%ILJ@/@'#*NUX[PB>C+O0[>@VI7H[%$?A2]:Z(/'61Q8N:<
MIP% ZEAU/.]UUF.HLTZW?:51US#&Z9,2&>$S*PFA[@VG+0:U&4Z>-W$#^@B%
M-]97/)G%WT_@+5P/RZ-(]3(TOR),F..N^1C$)[/[]?(%K1#ZVY21Z)2$^>!2
M<J9.#?0#R_5JXV"">?=4H]M6E*- JNW9FF#0DH)E,=@OD ;##("+4AOL^# J
MR@$46)F+%,4D<>BH[G') @3%6&9/D.]U'';?))Y'QEG0>UY;O>;Q3D64/:%\
M_M/G-)UF9]KDE8U8843P'41G$NG4(^EF6=!'C%K2AT)BR(B:K."0I.I1G/$^
M#%KK.HQB&0M)4S,(TG8=[Y,DP> <JB2.Z[(5?=!KMH^\5 7S^$C'&@$NLL8W
MS. \<X/F''*%'VB]ORT"X=HEKI;95$L? YHCN>*A8!U*07"=!*0W>I+ZD19,
M<7?2H1?#'W76/_IBLN 2(GE(W)H\!>"SF \\_D/P*6FM19"&=A0?62<-'V/H
MUSJ5#T"3M%_<4P ZP9DH-.L#MY[F<="$Z<W8.9-D@\KX\')Y5P#LL0:/LP76
M(*$)S(!U;!,OF]D+\L_.ZB1)Q@]D@':Z+ ?QK$W@@03\  3+!'.\MT7IPN"M
M51L4"4 NL@K3\TI_!^_$[XX>3>#9 =T(/;L4=I4B5O2:0^=MREA]BX]RN*I>
M&&+F!+8%=I8NH"TR=D1+3\N'GC_'VD$K10007R=0)23=]Q 2VQ\=QPQL6OBT
M?_445&.+3*"8MO"%X22F/(#I9KRTH%V-5 ?L<F64V'#S;P]/H],R[,DLQ:J+
MN+CUBWZFB/DJ,&QB!$#!X5A)0E]V-<;2"*$.L8\;$-AU#GGHQ?) *AG[6Q)*
M>XEAD0 628[OI=W$C5<%. L$]YIPIJ: U!$]"+>LPIR&>WS/!\4X/K@3QQNI
M R+@J@V9FS*;8[PX1>HQ[B4&R(0EV.WXO(IJ6K09.+-F?J<L<Y-0+C%'$"==
MA<!&\ZH.4,Z>!4.W#-?M\H;)0WS0JH.=E^6^(P:@E8VA=)>T@"G9-3,BSH+S
M!"0YQ)T1#"<\S@D73X0-9<2;T&Y[R"HQ,CKQE$$*V975I%=S W'>N2%<NBT_
M>GL/Z-U":FV 4X' :=-5AT=.E<8;EZ$SOI&CXMG+RMS^X1@.M6-IV6C$-?02
M3J!4PR-&4Y]]:KOAT4/#D49APF ?K&DP$H5#?F+67NSW /!;C# (8H !R?W<
M4IXBA\)():8A54/%G?)--] L0%ZP*_P$(0#TSQ!.S==N6"ERD8C\W\DO>]\#
MW6^(F7[6R4$W)SM7V""GYO9UE;&$:B3.GG^-2ISD 9@X$G!!*@Y<)+PY;LJF
ML".Y8P=J4'OH[NLV84\VV5KZ;LV?(W_KAD<F+I"+=W1OAO)JO]WX8%OT%ZK*
M+A294PJSX(S*AY-7@5Z.,%4AGN4=WZ;IT[*&@ F>EBZ+I-&DD&V\&3=E?#2T
M1SH_<595O"E!9T0,H#'2HDMRD"?-MSA39@^R;;!U OJK4)\FKUNYF=GSY!A(
M8)GPK(X"0C)-QP%[0.29)O=/1N6&%5;I\LM)HQ?MBK3^EPR&#OWI#/3%VM'.
M0J#W?SA$\+1&L>KMHU=SGHY@TI!;E5C]%2TM*0-X ,><8.'&<E.6,=0809+T
M]4ZI ,R>O!;KVF1J=8*,2T+38*(%C*>=#0.SISPFQ$).$AUH, "P*@EK'#TT
M=A1(4R@  !('(4Z D4R4)E? ]7RE+@62)H3G@EPL7N&%-""3C^GI9F\X^,*Q
MOL@IG&R+VJ>U[3TD0T73N.6% 6'H$YPFFZ/; ]6 MIV9I@8LL;/62F!YTE3Q
M6Q80E@I99.@'<X?7FZES*EU8C+=<!'^GTJ%&!%>M6W!CW)&<V%ILU* BSQ^F
M7A27OH>&@=O(LTVH<.[=);ARSE84,AYD3TT,9\SWILC_ '9UX9OGD6/NY-2.
M*#4#<6R@RXZ?_&;.9]>5B@$BW1#MQ9X%F^N>"EM2QH'S@"E^I:#(TJMNV'==
MG;V$C:\2ET:_(\+B![OR""V(+.60%,83_P ^V(K$><@<    & .@ Z .@/7R
M[PRF6K\#\0R4!(V&,>-!SKJ0W82LA-:H;JX^;ALX"I LJ@Q%4XPRS8BCA?M^
MK62K^97 <GJJR6_]D#O&5M"38PDN17YL&8=//6=(8#<KPX\/8!+GI+B]B-:>
M5%T'LB<#,O(\G0&.N0C&$:,%$'E362'3=+(R(<^%-. ,8UDJG^*;K&!:A5.Z
MB8$O4'T[1IE"<; TB>K.P^@[8D'F+<C<U '3K:DQI507P'S J^3S!Z$81)\T
M*!%[TU#BT^Z2*X?"@_P!)R1CY.*=<CTPG?&G"L7S//2WP5=X:9KNGM*W?\[%
M ?A- #-5AE'">CM3K>$KO^6Y:4"'BT#A]:GP.@!FJPRCA/1_R0J4K6E>:Q7A
M F !;&8=_P!A[N^9[]D1Y/@(W?8 R"Z(P_INV3;%VX<+J.:E;N%>P8X78@P&
M/ T!/U6&4,)Z/DNQ&TAKE2HS'B@;,NBX9&O0O5'F5E_0557GF&W%60:#RC"P
M3"$ !HATB=B=)XY)"!9QL7\MC->6?_P1 +L1:I5#@YE_?>_0NX/CEM(]//.-
MER9 P?4#M'0^]J/7ME)#S^Y/F@F[C'8H4Z3\3X^/8+7FCJLP8"T#5-BT@(<9
M4,8T ;%P#1Z.]]UD.+.T9!J :H&O:A=:@Z$APSI$RT!VY.B2'N@\T*\5C\.B
MH*NB8X^A@M43FBXF6#D$%TH(>B!B[@=A.V0GPH7+Q=XG.;28@H% "JN ':J]
M 'ML1FSJ(F4<:C0HHTW9[IN8/)Q,NZ>',P-I6*<".S]W+Y0Y :Z?-7LST"UW
MU_M.T>5#YX%/@&B"(&+\_CR.E=_.^A0GI2<QXQ4%323FYO&]N'[]&:)+T"(0
MW-BO3SNF[X=;I$<EGI 6.&4D*XI5NJ4L7F+@;O"]55[I2F4\$K$BVPF;J=DM
M(_P4?QI]-M"\/-FC+X2N^N'I(@.:M)@[-!"E9RI)UI6D3AEQ/?'_ ", F$H
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M\U/^!ZUL_ B*;>)=?^* R"M!"/[E]*9]E*D/_:UEQ'?_V@ , P$  @ #
M$
M
M            !)(!)(                                  !())  (
M    ! (                          !  !( ! (
M                 )   !                                  (( !
M   (    )                             (  (   )   (  !)   ! !
M   ) ) !(((          !!   (()!(( ))))    (!)) ( ()))
M   )    !  ))!   (! )(! ! !(!!!             ((  !( ()  )   !
M(!( ()    ) (            !(   (  )))   )  ()((!  )!  (()
M       )(   (( ( !(   ! !)(!  (() !)((          !(  !(   !()
M   !))  (! )!   ((          !)!  !(    )!( !! ) ! !!)(!   !!
M          )!) (( !()( ))! (  !( !)  )  !))           (     !
M)        ( (  (
M                                                    !!)!)( (
M !!  !()!)))()!()()(()!! (()  !   )( )!  (! ))!))!!!))))))(
M
M                                                   (  )!)  )
M                              ))!(( )! () !  )))(
M            !!(( !(((!( (  ()!                        (()  )
M!!     )!                               !     !(
M                      (
M
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M<^$)HGMQ^W&F.@HLKZ09&ACZ670MFT1/"4 6/*JL5W[MF77ZZB0*:-^2_$F
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M!QWUS&HOJ<FE=96=V!Q_NG@\>FJ=0HH8.Z(O<X3A/;5O*!\D6;,!%-HRNGM
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B#:3PW40D$L$E:H@3G+B8*N40)-#]KNEJ'/UX"D3*!W__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ex1012vttlogo.jpg
<TEXT>
begin 644 ex1012vttlogo.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" !< /@# 1$  A$! Q$!_\0
M'0   00# 0$               ,&!PD$!0@" ?_$ !0! 0
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M&N6VG2XH      :XH4-F;@;9(9:Z20?3Z5IG)1AE@AW,,8I.'F!=>9XN
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M<7!A*6(&YXA#T'1K40E[6>,??_*1(!20!.?_V@ , P$  @ #    $  !()
M           )!             )(             !( ((          !!(!
M)))))() (!) ((!))())!! !(()!))(  !! )!(!! !( !((!)(!)))( !(
M!!!!!!!!)((     ()) ))(()!(     !)   )!()(      !!  (!!)(( /
M_\0 %!$!                    @/_:  @! P$!/Q Z?__$ !01 0
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M#:CAWV]3@=( "0@%%D".D>G;_?5(5%I](]'6)FQ'"=NW$ FFO3:Z!"4PP("
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9*6S)FY(,EDVM1QD+6\2 3'76K>OU_3__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>exhibit1014schedule1.jpg
<TEXT>
begin 644 exhibit1014schedule1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" #A ^,# 1$  A$! Q$!_\0
M'@   @(# 0$! 0           P0  @$%!@<)" K_Q  4 0$
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M8(8!  0(V!4,*#P8=/?C^H(A"$*GP]/F,5%@)81*#(N:\<!#8F/B8^.%Q4A
MQDP +@2PH#,A#0FV+% I (P7+"H^+$&!0AKPX,,,BXF4## 4(6!!1HU@4R'
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MK(5DM9+5Q5Q5Q1=15Q?_ , R% WHL!60JXK(5>U7%9#]EQ5Q60_9>LUK(46
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MNFW+?8-"\<[3)!JD1H&D'T<1C@T6G 7;=(%7;=(BOHM++'#MFC6,:> !]*C
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M4W4D-041@W93*:_VIC7^Z7&EE\%;P[ +/94?$=ZR#(>\>CS1G!SCI%"KWNK
M4/D_>6[#QH6%2'%HSG2?)Q6LO#+RRRJX-=G9U[LY"^5=Z8NXRD#*!5[2,XH
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MVDU]'IPRI8V-6-6M6%!:M>K5:L#5B1:]6_\ V+__Q  4$0$
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MQQ938F3.)<8?,G,+7NL@0IR5W)W1URZ0F0=VPQ]R4E<NY2G$IIAX4%$YGVW
M\ZF@]MQ2CSJ8X]K-HP?'',0&OG-B,BMK=ICPYN'&<14:>Z9A/^RG:0(6%E!]
M-S_$$:Z3AIX9J5BVU.TFE1_=K$+^7ZW$M-#%<1:?9*RW-KGWM^F8<;6F;?9<
M"PI.=I12]<;Q-=X51,3#F-8NIR:+7;%*Q*:SS2F#5._670X^I";H#^;(/V4*
M::QW%$2Y>*TRR<0FDRX=5^T<+:7D-[QW]VM><(EE8QB3C*YB:"L.4],&3:[0
MI.=QL;U;6=U94'E)33>%.9532)&7=F)QY<L%(=+TZY,L.,M4;80TPZ5-LB6:
MW4G5OV99/=2H-H2M#K04ZZI"Y7=K*TIKWOF4@BLJ:(-#07H"5#E?A/V:F$(2
MVV79@MMM(:*<ZE*+:B$T7JG,@+%J9QK>*LY6RE2MY7+5&454%;P@T3[66P/.
M$8B)_#WIA1/]SFD3"WFAF/[7>(W:5D<5&U'AI>!ZFN]"+(;K0FVE*ZD#+3-X
M0A$Q*/2OK$J*WY=7 $<>;=$7M>_LWB;>EEA+J%(W>[465.=I66_U=O)11=":
M$J4@!MQ8XJTA"<NZ=F7$RF;?;I#+9#C*V3NR5AAIL+9*0/5L%'#0P[@4KVO*
MAZ=FIZ88W78%)9S*:;2X9;M)2',X2E1]:*9$B\,8I*8A*^GI1':GL&F&UH4N
M6*@WOVS,HI-SJG'T-2TDSP$5K6E8969+$YU/:VY=V7PV2Q .M./23+KSS#JF
M-RVK>J>D9A(N1*.I93N$-D[UMB?]'K+2&);#96?G9MZ7E<Y+J5AE.\8#_J\R
MLQ0I*A4!(CMDA+XLUB4W+S3'HW$\(<FZXH$J+4M+K0M;TTY9K>OW2T>^!EB;
ME\7V>5B\U-8!+-+0^C,, 9>EI'$&DRJYIF98F)EF54XW,,RS+[,JMYQ"LH;S
M1BF+3*=H5I$L_C,M.X*W*NRK2U+!8EU3#"PI;SP<=*C*,H# H"@PA.)XAC>S
M^&/8?-XE.)Q%#DVY,3F&)[6AJCS+0)=0@^N50!7#6&F9,NL2<\_@\QZ6>E69
M#&,)<=EC/2S$D[,SC+;8F4*W+CS8]>P TJE(>FVYCM^&2#F$IQ&=>Q*6[0Z]
M--!O=GLV^.:7=2M4PIA4P4HH5*-8Q/:;!E89BV&.X@W(8<N=Q.1G)N5#;;#@
MQ (W[24H>]8S*HF4ATH25;NU(F5XEBV&R,^SAC$TE[$9?"65/3<ZG?8AA?:<
M+,RMA"G$H:E7E,AQ259@I!$-SLKM)LXLR++KC+F<+<7F59A,O,R>1TBMENV]
MJ,#>Q?')''<'PUR<;D)'"L3DF9F0?EI=A:=\N798>[/4('$A8*4%/SC&!N2<
MWAR<0Q)7;&IV6Q1MU4H5'#L009IPH0J4<EQ/RX)N<[;Z1=N\KB,_C^)8SC[*
MI23Q[ULN94UFIE13(SRZ/S:$-*907RT0A.<^S&:9QD;]FF&RNZ67!N9=;CS<
MRK*R$&60R$2B7>^M;BEGN1B++$_A##@4ASB0]-.3:)A0(")C=#<K9;2I"CE]
M9GJ>[&"R;ZF9%*"$8C/N"9G6',QSI>4V A00TC@R,T'/6)4KQAUN2?=?;GG)
M*7F \Q+LNKW#FZ"D*(>0*-H!J$.$J-8:<F=H)T.YG%S$[,88Y,I"4-2<M*-!
MK/OEIW;>Z4K,,@:2J^>R>S8N].H2V]OW)23<E4LN+ID3^M%S?-*K5>2A12D3
MTNOLLRMQAC=/MK=1N5).=91E-RXDY5IIR\83-X?B]79&6EY=QA_"BP],;\N%
MUY 4I]IY3.;<)40'%H;!-!2&5YYLH6H)GV&)9MI_='.5AEU7J\]:440*9CTB
M<>FW-H)O#OU+L"&U[B<RJ<WDX'RK,WG0.',G]M2MHET2,OC"D/3I,W+NH;2.
MPI_9J,QO,K\QF&;*II*0.$JJ(49\8SE0XDRB9!&');W;=,B7TK 05'11HKQS
M0V)>2QEEBBG)A:7Y0OS;RW=5HRHEVTIE/U= 2GA7ZT1V3"QBTA,.RBY3$"W,
MH;E\0"W7U+=>0V:AU<NXW+9!5G@J12/5HG^RIE4LL;Y3(>6[G)6J9R%32TY*
M(:RI&0=-80^QAKDHP%L(,HU,$)$NVH!:0X0HJ=?:SU6H94ND+RFD'$E8*WBC
MK$VQ,X=VN;6TW+&6<.0S#;:%=LSH-PM2:&!->B<-$DDO*&%+S.RP7,W>XT!E
MW(%\3:%*4E-!PTM"6%H9H2 EMLN!IMKB): ))RFM+7I",^&X1(A*\P=P^4<;
M><4M(;5OEK?<S-9;I; 3E7Q4AA29:4>W <JE]*E-NY],Z H5IYZPZX93#YEQ
MV7=8")MI:FF-Y[3 0X@I(23EJ30Q)H_5SV-UUU"C+IXU+<0H(<YN-BALJL?T
M=4;S*IMI+:<RU9[@:CDA/LPX_)OM,.S+19<>7*,3)"=XV[5M,PAQ+;E6D@.H
M <2"JA )JI;K[CKKKJG'7'5 DN+U";#*D4LD6\(OYQ2PMJ+F)9QF8<94PMPM
M622WO@$NY*"G&D7S@\J<X9>?F7)A2$)902&PXEINN[0,J?9J;B&\SCJE)HGC
M=4LC+=*171.8\K0G.XO. 0"GO#-K1?2^D)9<<=W:"I64N$HS*U5N],QYJYP4
MZMH^=1-:]*0.'+T'+*17[8"RCVCXI\*0"0$DYC;^$$^S1=$_2^?[X1F44&E"
M4FA4.AZ0[2EN[>/.+'2$E(&9/,CFO6O.G6,"W[C3)[!BC<OGS9WW/1JY=IG-
MS<(5O"OVC1'Z>QV-*]9(.R$WAK;(]8L3C$UVEQ004T!4U,2P;*5%96E=DY4J
M4J4EFU3,R'IF;?EF"R^Q*2LJE"7L2=G9=:PANJ\KBG<BFZ+2\H4REUD3V%M.
MIRI#LP9]YA6=O.E_M$C*3;6Z01NRM2DC>\/C%#DFW$KW1W#*D9G+9=TE7K2"
M#4!QEMPB^2D%.Z&:H24&B5)42H9%E:$H2OA)R*4%4%::QE6VVE>50W:TA:J&
MV\2$C0'12<WPO#6;L^8O+92E"%%\J0E"LZSEW2MYFH@-N+4G(K>)0,I4HK2,
MCF4'*I65U(5FRJW9)&52 J@3O,R0$E-S"RRD,H6H.EMDNJ;9!H,H5,!U[B4,
MWK'312B $B"6V*-J!>;WJVZJ0BYIE4.+H*:\X"LHS+%Z*K1M?'D-C37K#"LH
M4MLD%E2:H6*4[^M1TI[XIDRUR\(JH)"ZT[H-/>!"=V;6=6I!*TM-$7=6$@\"
M34*RA1!!%(0AN::?WR$KJT'*543EKO&VZ:15>;2_[T-I:;>F'WE);9EVFUJ?
M></L--(!=<-?:"<IY$PXU,-.2TTVO(N6?"D/)76BD*30Y5(-4K2O*I)%"*P<
MU?C&_0P=P@.K,YP"6K+HS*H^5!JK8-%<>NE8>;+*'0E*)AUYD=H+;1[KAW!<
M%%<M3U @B8;G$*6TRZ$O)=2M35*MN(W@S%LI&EQ\VFL))1PYW$)HJJJMIS',
MD5*0>1/OI"R 02.<+JE>\)3D(4@#O"M06\VE=%B'Z*E@6-TD,OS 8<=+BTHJ
MT7,K/!FSJSO(.4'*%*HDTS5=42BF<+0/ZZ,[=/ZWE"E )"6D%;JLZ!PI6A*B
MVDJ"WE\5FF4N/*&926R$JHXE#Z)A+@;4RM"PY6H[JD(JXPL<VYA#2_HP%!^5
M)S*0ID[_ 'K64$YUI#!&4TRIR*6JOLC6'QZ8P-26I=F8;X<7<[3,N)S^CY=*
M,*)$\V",Z9@,,54,DPN]$M-.%\*9;?</9UL[F8<KO)=6>A*VJ#-2J4U%%&MI
MEQV>8E52R$*9E'$NF8G%+5E.XRM*;.[U7G<;X;BL;F8G$2R0%J_O>8=<) S(
MS96LH0XKN<1)Y@09GTP/2%2YZ'?PV<:F'$A>[<$NIM):*D-!#A0XXWPJ!!)-
M(HTZ'&LG O<E-CE-DJ4345(N1?E#B0XX49;++:4DFEP0%$4&@/2,IYH#8R"E
M!J<P_I*GJ4](==4I2 IAL-LR["4,B92 FZ"X<C90 205$K*CEC-4YCEK]%/M
M9?NA007<N]<""0/V>8[O-Q=[+3-K?F88[3ONRE2=^9(-IF,O/('@M"CYE,)=
MF43_ */1,.%4LB89EYQV7/<K,)E5M!74=F4!\XQ.@RTRZ\]N^Q/-SNX[*G^E
M2\G<*$UFY$[KRA1::F60IY1H],B9#32M,M6F[B&NT2"9]IN;WSZ3-/,=JD@/
M[PS-ISL!2N-4PV=Y>@ZPY4C,H^KS4=4!GJD!;H4MM2$4:S-92X!5=3#DR_@<
MO/OF72AA$TZ5R;,T$E&_<E0G), 5S!*R!FH2#2A0]Z)P=Q:6\I2_VY;6\HK,
MYV<3 82J^:@2&[ );1K#B=W(-2[RJM2J)1"V), <:91#E5,!Y?$[D<XKI-03
M!<#4NTKAX6642[9R\RAM-R?$P2RC"IB5W3B'97$\*DYUA16O>(7D<:NMEY+3
MB"5^R4\XDW$=F<[,II2VGY="FIE#;^_':E 9W59W'LO=*$%ME*LB(*5!EQL*
MF%)E\BDL(,R*+"$A>;=I/=!5YQA*U)PR8:P0TDY2:PYDRBQWOUQE  G2%T/K
MRK-D;J> 0A\XB%OHQ-&+A;DJP^$8@G>!+Z4NH-4MMKW:&EDC*&Q4;E-0]BF)
M]J?2H*WQDI=MU65)2E+JVZ;P95%-Q8&D/J;Q%^7[6F54L2GZN/U(YI565-4J
M7+N56P;%I9+B55,)GT8U.-3G:7Y[M0" ^F=?98EW)D.)&=;CK4LUO%+7F4O,
MHFIA;C&/XBRMZ85-.EIU31<FRG(9AP@DK5D*A3A[QK6&Y:4VEQ67E6G"XB7#
MRPVA:W,SJVSO<R"L%84"I:56S Q)M-[3XRD22Y5]C];<*69F30M,L\VUFR9T
M!Q::FJ E9RM!?$6RC&,1;(=<? ;FGD)W[U2^YP+11:U$U6BF;VA6',*:QS%/
M1ZGW7W9-$ZZ&=\ZC*7Z*SK*R;V<137B@?W0Q E.9&<SCV_"G4Y5JW]2K]B T
M0G(EP<D:1E8Q#$&4<VT3TR$WL11*T#)30!(5U6=8];-3CA:SI)=FGE+]8G=K
M"7%*58MVNG/].$EUQ3XX24N.O<)0-VC^D/<:X6O]QT3:"G=@55F]N@%*4[^1
M13\[=I4;W3K RLH5;NC-NJH2NBULE7K5)S94E3E@HGE'[%%=>).>IZJSE5:>
MQ\SE%=R@%%0,H"/CE'7QA)W0*N)*E$E50JH7D0O,4*(40HEQP%(IE'+-N44+
MA[J&^#,GB%TZ9Z ?1;1IR)6ANH^@"#30ZA23UHJD)HWN^I37*JO>JFO .B 2
M![X-;JJ4UNG@N$C+S KX7C><)HD-CU7(B^;UEP=(/=ZDI%RKK4G2E!3P@\A3
M*H"EQRY>$5! M<:BO,&PL8&7**7&6W]L(]I>;-:EK<_NBY//,HW)O!H[?6Z1
MH(J351]T9>2KCFH0"4G(K4U@TK3EY<H))S?-\(HLZ*&D$<-OH?9Q1U$"PIX:
MB%9E6!L/W16&U<[@_= K]4#-[J0L 5Y4\N<  WUR#[HN!F/%17(?QA!IIR,%
M2D\Z6\(N+5M6*HH**UY_9 )IUMS/C S)OF^J":<Z4]J+IM2M.D)4LGAY4^'U
M0!2HU2*FD9N[P\*?+6#W:K'"3JGYW(^Z *"J3SYQPHS4[QY?CW0"+9=:QG^K
MG&9([R-#UI[XV&4:?[8K";7'ZN*W_3V)E:M*93+XL^&G4;QO>.[F76O+;C#=
MVE>PX$+H<M(;W#>"-EJ0]'E3V 83-[Q#CH<=FGD3<F\B:Q)1 1Z1FM[.A'"B
M8;;]7%?1&RK[CCRUNK_-^0E'G4JU9[1AS4B[+M_2D%24U<CM/5,SV"4DF\S2
MA(2CDX9)(12J$]KFYB;"5:T[32NE.(EYA:6U;Y:5!0J'64!2SN6E'/ZKB!XL
MSF9(]92H,HZXZQ,KD4*:EDSLI+3#89(*<CC;C)0Y8ZJ2JX%*:PU-L/;B88<W
M@<;:8W>?+NA1E39"4*1=0"LH77(@:EA:)E>:5F.TLJ*&U)WRRXHN*3E36A4>
M"Z;^$3!3-3"4S:RJ:;;<<9:=7FSE9;9=0@DJT"DG**@0@K;0I3:M2*FA-5"Y
MO[XS) '*@2$^ L/#G!H5!*"I03E3WCK?6+/.H#F6J6G76J!)-:Y%C-6NE!YP
M<(1C$^C#\M%23+QEFGZJ+BDS!:]8^G>*4K]8+YO1.[1E0E"EOJ70)%-VE)&0
M94@',38#F?AI %#<UOT_C&[*11(*B"A!2KH"@VKU76I@D"@/LZCW$Z#P&D*'
MA *@<P-W M272-SNU<0_W8W=^^#O2**Y.%3N:NN>M#3HD&W(QZI R<%0G*E*
MLH4,Q4I*R-W6K9HI8I9Q)O!6A(]W"<QLHJ7_ $@IUI6+BM>E/XP"H @<OJBJ
MD(Y%)6E"_P#GI6GXI\J:PHD6%:!-$\6M:)"1]4#,VDGO FY2?G D52KZ2:*\
M=8* +"@2H9 I7,[QU"$K5I[06?IPK@]LVS>-:I<IF!]T*5NP"10WH5TLDN*2
M 2<M!FU'*$Y2$\-* '4Z\55%=/G*RD\Q )RKK0T--1SS"I%1:$K"4UH>_F7Y
M"M4V1[,<52:US7!(\1GL;4L>)( .D#A;XE<5$Y*VN<M5"]N?*$D9>AI *#_"
MUOMA7,\XO Y#4PFI(2.G2,^:HZ&.Z#^\2G_FQ?Z)L3TA6BD@<^$_5 M<=%&%
M6O6U28/$=:D6H??K":6Z5_E&EN<*;!HH4BFB<N7\?""+VL".@A5#SB\7IT@#
MG6E1TU@\1_K:_P!D>1TC7)TK_*L#/UR_SB@Y'E!5HI:@"1T_C * HW!J?*E[
MZP<O>U@Y]2JI$9<O>[W\HK:T5KE-P::7@YE$Y:::1X9C"2GDKGI>WWPY55*J
MJ*:"$)SGQ@"N85T^C_&+4IH*??&6O?*8-+7Y^$4\0#"T7I8U@T/$D?5!76IO
M;I H1X^<<[I,6KRORTC-TUZ>Z"E-SK0^,9%CPM\A/4U@$>^ 1S-853O9Q]L
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M[2WA!2#2T5UZQ2EBFW@J/*#;S@_4(]^D)/C6G2T%7=I?SN8S5&FG.+F]R.L
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M:_; &O+RBZSK\FIH!U@%7"!J.L4UBT9:5I \:F#Q& /C%N<5)H(51532!3P
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M#:X$:7-XJ#4\/VWC.OQT\=8&37F#"A7D(YJA(([QH*??'=K3G"5#O0:Y1;6
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MK:C\G<A(8SAV(*FY;?M2^UV-3;3K,U(/L/,S3:I1K<S'&IE3;*T7:2#^3AS
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MB;1)O&6*5K#P02WE:-'#GTH@V5TA,I);CM$QO""[-(E&TEEOM"UNO.60XE/
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MDD+(R*0FJA<9A45RD0FMO$YJ74>:@/A"12].=K'36!SRZF$94)JFNOM^U7W
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MGEJ<,596B23")>J'G_TZ?1UOVPQ)>3 3$!,#Q9P[WQ$2X[57XTB(^>S@VJF
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MX0"A1(G!<#NT:B;R1I4-$Q%1.0'"S>3I,=X 7B'HC?+XPE+HDT;HIZWBY22
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M=0/'CCZR>FR0AELIS+)L8FRPU$Q$1X;F;Q(D TD]&A\.+T@SC#UI]5@D6F(
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MTO."7[TBN/K-[6?E>:9_BQP]E_.,*+>O/GO$-CSSB6P,G@<&RV';M8)?/?\
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MA]8_;=<?&(*,1UG.!;U1QA!T@Y2Q&OC$I*C)E7TWA$=5/*T;R%0(6&!]_G'
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M7@#!9T0@WU_W48BI1)OA4XF:$UZY[0)C:V!P3G8W9NEU2;,S6),C%20$)!R
M4,DXQT;?>Q>J:4RF("HM4$G>B(T<)9LQD4Y69)(2527H"O/?2!!C]W(2#PQ\
M@^IXQ[>2@+)!];?E[<B6+* EXGR/YQ6"> (JF.8P:(V#T,O[(CH?T[C#+G2_
MD>N-0.PI^<16ODW\[_\ B8%2%(45+"NVLF_1_O.9I< 6U'TS7*CAX?WGJWX#
MBP& 2A@^,N !1Y9*P4VH$"-]9(22=-Q;'Y-?M'\X+456N'R\3A HW3'&"'88
M](K[RUG58Q);JAXO]X/.*YI>?N<)#FQ)/C#GD#5VX 5 (17.+)"CV5G6GUO(
MXKFJQ'9NR;O&*2Q*YEA]LDB8-2TNO.01H*0<P:P70(U1;3ZLG^<LQIKYK $W
M.??G)UYY7C.#:B',=][YR<CH_G(B!0DMIU^\O"4;=PO[RN4]/'; B$ZP=;AR
M0*ESF&QU"5AQ!(@\\(+/GC&;@B2GC63I:JMX<BIZK\8C!;>*YO+,14DG;,>F
M2*9CK7UG^Q]9-W?SFX)A&]S6(1@G!8YWDO9H_K:R[@B9!U _!K  :V]\L$*[
MH;(?7(@=PC;>S6:.T X.:ZUDI-[9Y]>\2<JT'@7&,@CB^YQ(@P(BQ]XU-N/V
M/P8JQASR)J>@UUA*'7GL%^OG(:U=%GYG!T^*:I_AD4EA+6_.\6[!*GF\@N!(
M;EN+WO(Y 0FN13E:\<]//IA&!)/.-?\ N;_,GOC&Y(4_^M"H%F/+WQ]XXMLU
MM[R6^%8K8[>>7Z8'L,KAS.*5OUQ.T]!W'[R+)"'3O)2!YC!$Q&X 3K]X7$LO
MKA@A*\>?SEKEE(-\_K#%!U7C)L2GYSR(+\T^HR4P5\T_]QD[,>"/)'^UK'B>
MK[K*+<N>\M\SEJ\$^;W]94G=?6<+_)JR->0Y*@2G:>7^\5QM_,/]9!3P@\8>
M<%'4_P"G)LB5#YP\6<Z_.3IN?J,5AT?!)/Y,%_T#(PEL?RR$@\=]']X0'62[
MY"*3]Y+=-HGJ-]T_&0*>'YR9Z_XP:-P5^' 1)"G[WD911^LXS5X^5@+' DET
M<OL83^I>(1:+=7D/OEZ:Q:+1]P,Z-XC;G\F+!_D9(>2)^<^0!PS SUX[^<0O
M=FU[P*7]R,FO)?(QFEMYRU2) 2/,>\OKD4,$='?.2"\[]Y>!%(\#%8_V9]-G
M/,MB9Q@8 L/G#!P5.*\9/ 2ZF"2"9$^WQA('<F_9D(/>4$?XR \R/WDIX(^D
M92QHON3B/O I;?H=?/WBCS<&\U_]48$JH;&2T?,![1D,L&:QI^,0,XP3,S9^
M<2PZT^1E%F'(A*$EYBQE1LI^;QVX<.=;3\'C#T;"9=E>Y$YL+ W>YS;?)TQ8
M:NJ.;,1-U'\X=-M6;P&7RC_/?/7L/9,(+:(?&('?^$:_>.MQ%OS^L]@#TP"+
MP3J(_G.MS<8G"K#762K@*;_SB6W4=(;^6\3H*>K!Q(9)_B%91*_G1A<)0  5
M_N<!#RZXRR:W_O;-.3@CAH7T<'7A/5_]R4+'O,^6+OA,8#10XYG=^3!8SI^9
MQPY!P*?!\8K.W\_\_>-(O7MDT]'*=P3WE?WGA;)/KSX<"';/RQ]1E@^?_E4[
M,8H?G$%0_!-F+<Q"(2>W1G:99!#T'S[9'W#[8CB9PC6*#:-'TO\ +(FZ9)^9
MX]\2+S/IA=B@/.)\TZ".>\@M;_CXP[9(HQ<3:?Q5LF6('DY!:@_;!)OP8B/K
M&P-?;[^,J$B$P8!!**GN*S<4YX,T/;O&T$%GYMQ"H$ L:UQEW.S-%=F+".\O
MPK3V/_@B?X%8H8A8^<A"98^\]6C\.-G<8^&_K A-(>S&E_F,8_)<-;E]8XD<
M!Z$G4?R4P(+L>O\ !DH=U_JP>R_@?WA+O#YX#%#<0],013X],HR\[K=Y,*1"
M!P:P--I^<;V?<!]9Y8@O7$YNL!MB9]A<[&.7@Q ATN#4:[XU>;4QFB+@LKTO
M\/C"A&KZLVG^P9]A^,>S'G(PG4F.BL]-/@4?G>)\+\)_D^^'HHC]8V#647J_
MG.<SA,S;_>:GD/G%,O#/Q>;RIYY.J$D2YRM./^/\N)!%_?@F*$;%],7,0/YR
M*BU#Z3_S*(X2<"KV?X?6%MU"/:<A#O\ +#4]!OE?W@0M<;Z\?OWPU-]WG':W
M'U-OWD X_N/WAX;'?[SR)7K&5&@'KYQ1?7>.,3[#SS_\!*=I7OD+2OVK$.R!
MZC?TO-'R/M7T_P#;Z7- 6-S7[R2]7R2!U,A-9'!"@ 5(.#Q.1_,6AZ;,!6$1
M5B, 4B3Y?\Q02/KOVG$$[_IG47@YDF6/C.>)4>>F$>>5T;R#.1BK1 ''IBB0
M=_;-8J>D![X"7"L)Z5'<>,X%/0N+NY<=GB.GV_6 (1*2<[Q4T?>WE0:5_6*
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M:-26MY=VGTFG3DAFPBH>&S;>LG<A]!%L[\8*44M#Q'YQ*E"ZU25]IOVPT06
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M^"IE%3N8!O!2N.+.-MSE#N2SEA=@6$=8K#\F)\2(G3GY0Z:48Q%1.))YF9*
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M*-[R(/><72)<@2 '<P*6P8#%#?62EI9\)R/C(LB,A071D5J<C)#[0"5L& J
MMQ"33.J_F#"RU5HY 2Z]P(+!(@NQC]^ )"2Q$ E;"!@BJ"D*0P"4A^3C $J4
M1*B?<HSEJDAQ?]O7.$M&=&( 520AA=S5"PXTECT!C$-$"(.B#:&R2;)K%@;!
MF9*@[16&);A1!RY.K^,403+R/- QW##0:7!!DIB"AG#/%E@*$6FQ2C(&?DFO
MXC)&0 E#6;W]=,I[-0N7O)VU:/)!KJL=SE> KR):9./*)Q_\K4U1'W3KA"O<
ME-;,[@^,3BW"@0PF_6'\)C=/E#H-_P#D2B)\?Z,Y0&S>CF.55D43?A4!GH1$
M)>N!.P:>808*-"XXM,*H(9>8>\X#=^W07,<*VC6\8YTH6!'7WQ\XB(O5\T'I
M.X89-#,D[5SB3@#%X;QU"<P'+>!02X<,KJ)[=9(9DR8\5RRTK!K)2.^F+QA2
M+?D!21X23-S0=D+Q6^JG'$3[>2R'B%]=Y)J29@\<*:)I6_2'$+HL9\(7#ZY9
MQ7(A;0B3H%9% JH^0":6F8X&<A9D6(N^HWCJHJ&1<4*KT$<F(43NIUJPVX"X
M:41%!*+9DKS.1I TJ]\U."4TL <@( :^![XRR6BQJ<4H8#29B'$ ?3" 9 EY
MW8+2+P6^("N"ZD0G,\&FB*(&@ *+$$("U$DYI7C591U,2$@5T.P9&6)\';)S
M&C<GJ4SH2,$@0P<\-D5 '48;KWR+"RPR$,B6(M\.2@N R(L(R,.II!"9'(R$
M4.,J3#$M84/D!G*["[',@D""*H02'"=N7)Q$2NMAAE#"4W!R9TI YD LE(.U
MH&-0!8\<1&#P@.3 T!4,ZQ  <.W1)R$TT@$V)JBB%F5P(2D<4(U3$K>;P0;0
M#5 $^OK&#2MS!D> 8)%PLZ&&%A "A*NP 66J9H!>4(E(+-R1MQFVZSUD"(@6
M I!1./C,0(\,&E!+:9+T&P;D!04"A&(!7E#Z@X  %X[L( *3A8L&$RA$  7"
MVC(!XDR"?2.::"1"(8M+RHZ^Y[/+U447)_FJ$+#'WT(JZ?>ZBFD 2Z4,A<!F
M*1<V"E@7@9KUY:S!D!5Y*1H,%,!')TB30(*5XG-(6P5QP7KSR*V.  EC>G[M
MR-QGU<P >2P8Y79%WD\S_GV-M0S@M3Q,W;D1(.8"+$H%.@DVA3Y:I@=L@*D0
MVB35C+D9GJ$D#"2$F&0K=8A*F.[.KQ;=G\RBEHT!E$Z+0#0T(WT&4L-<V75"
M<W6.$&,N+ NQY"=!U W<1\@?PR&1@<(]-D:6E\^$*2&#.%3=;^Y207$$M=89
M,*H/J)S"_4U!$>@3!TPP )%69.MPTD)@/$U^MSU$66 XVR8K$+%B;+$(0N5R
M75]6ZYT,,(2H5$'YZQ\B!,#'#%;*T"5E@#"N($M@:802S.& !:3XES!J D<M
MKG1 P%%X2X9R'(:EAH*MNX;FW8RV)+- )H8H !G<?*R<JW.A>0\9MKD3.)WR
M$\<['.>GX_G('Z\7I\D(0F D;QPR@RCWAPIB>!K#+/ ?KJ2EZ1E6\T2P92*0
M:%23FOI<B%*:NTJ!AU.QFUS&3I"^<F""+!6@P*9.IR!GG:I28+E"CXV/_L>*
MZS\!ZCL8/X(/.7B)20G*T)LVS/SD]I+-'BM]"J0Z,\[&@C#K-?4A/+'SG(3O
MAX @>0GPQH1!MF)24',154_@),1XZZI5*JJJL96$%W)=$3,]H/7"@)F#??G_
M /+-%9]&TE9S=*QSY:2+&;+ IJ66(V&*"*:P@YB,30]PKB?AD.E3B]XGBB!B
M"@2AE!DB$I=$!AGUF] Y(*8A,-!U2,.H9V8#X<_<5)4!^Q-"#]QI,B(8R3F,
M J-PS4DB")" =.,4W<8$ K4)@3/QE  #([?"LZ!3BYK*M\W3#:>2,<%:AYBB
MCK8N'P,(PJ+X/27JR#W%F#157.A#*02=,DG#"WK[Y;Z2*^$&IM.)R#]C[+"3
MEV: W@SBJ0T4!\RN%A>M8%!0[[$DUI63,\2_M%(D6K H#>)KR@#&X6'*S&<P
MQP5<)2RC*9GCT3W%N.P2A$@]("C*+T;/E!:1'= ?%4MHQ)0Q"\G\913$B%(8
M(#1$=H4:Q^MH4T@\EC$KBQ*:5#0E)0V_4,YQ07@83Y";(A-(@7ENEH1@HM3F
M1;K&%5G [)/<E1\X$SVT6SE4EEJZ#(%)$L=B2!2=*!&#J=-A:_?MN .)Z300
M\"(@0 VSMP7) 70ON@&P@*<*9@9D3LL)(!O!;(S0^F%@%HYEDDW9,JGZ5-#<
M"P'0(WV,(<YST#;824\T)G/"BK+<BLGX*F0JQ*.@CQ)D,#E(PK)2(S_\J5(U
MP+0T8;0'WP'*;K7 6)$4,%T(I+]@D"\(>"+S=] YJ/U1&2KMQKG&@FPHK@+H
M"8O4L5('4AQOTJW.>0(K.UT0GV36V'#<%7%$\I6I,Q-&".+-E F@;!.>2!!3
M"2"T'-""KM(R<BE00$[,.C V;0P.6[3((PB)!<>64C*P$X5@5*:6)P3SA,QC
MB*:R FXM0"A"%@#L@ZTC0K5[*9,V;*E7!;/"VV*ZR(/0P [C%)D$J]F5@R.P
M;S$(.A*<K> #NEID\E2.4AZQ#4D!HQ(L YO8\=3E U">XCK_ /<D6=>S&:F"
M#R6&.5+SFE6T2L@Y"5D7Y9!B; G X0X4 $>A*.UQSD&B[,AC(#G01O'C@'@Y
M6M7N0O#K\;"F9R+)C4I/<:R4V3TG$EUHAK$1AILE"H/@U;/+(:0'$K-V_:YR
MMM0-!SOG!RA2]\./!'@RBI5SN]=\C@P0)A=S9,SM/]QC= %NRFD(SU/;7M6L
MW:4^4_"D^\50V3JZL(E41KO(B80O)1BC9>H_..BP\,?6>94EM*FT_7_^Q?_:
M  P# 0 "  ,    0
M      $ $D@ D $D@                               $$$D$D$ D$ $
MD$@ @D@ D$ $$ D@D@ @      @ $@@@$$$ D$ D$$$@ DD@DD@$@$DD @ D
M@@$$@ @$@D$D$DD D $@D@   D $$$ $D $$ @@$$ DD@ D   D @D$@$$$
MDD   DDD @  $ $ D@@ @   @    @$@@D@ D@ @ @$@@ D@$$@$ DD@D DD
MD@$$@ $ $$$ D$DD$D$@$@$D@$    @  @ DD$@D   D$D $ @DD$$$$   $
M @  @D @@DDDD$@ DD$@D$@$@@@ D@  @D$ @$$ $$@@   $  $ @ @D$@$$
MD $@$    @@ $ D$$@ D@@D$DD@@DDD$   @@$@D$@@$ $$   D@DD@$@D@@
MDD$  $@D@D@ $@@@$$D$@ $$$$@D@D@D$@@  @$D @  @D@ D @$D$$@@D$@
M$$@@$ $D$$@@@ D$ $ D@@D  @$@DD $D $@@  $$D$$$@$D @D$ D@@DD@D
MD@$$   $   DD$$@$ $D@  @@D DD$@ $@D$   @  D$D@D@$ D $ @$$$@@
M @@$ $@$$D$ @D  $ D@D @@@ DDD$@ D@$@$$ D    $$@ @D @DD  @ $@
MD   @@DDD$$@   $$@@@ $$$D@ $@$ D$@$@@$$$$  @@  D@$$D$@$ $@ $
M$@$@@$@ DDD$ DD$   D  $$$$@$  @  @@$D$D @$$  DD   $@ D@ $ $
M$D$ @$D D@ $D$ @$@$@@D $DD $D DDD$$@@D D DD D@DD    @ $DDD$D
M$$D@$ D@$   @$@ @$ $@$@@DD$$@$D$D$$$@@$$@@$D@D@$D@D @  D @$$
M @$DD$ $D    D  @ DDD$@$D  D $ D  $@$@ $@$ @D@@D  @@$ D  @@$
M   @ @D  $$$@ @@$D@$$  $$  @ DD @$$ @$ D    $$$$ $ $$D@$D  $
M @@@$D D$ $DD$$D @$DDD $ @$ $@DD D$@@ @@D$D@@DDDD$$ $@@ @DD
M  $    D $$@D@D @D @@@@ @D @@$DD@D D$DD$@D @$$$ DD@DD @DD @@
MDD  $@$$@$DD$$D@@@ @@@@DD$ $$$$D@$$D$@$ $$@@  $   @@ $@$@D
MDD$$@  $DD DD   @D @@@D @  DD$DD @@D @D$ $$$  @@  D D@DD$$ @
M$@$@ D$@  D D   @$$@ $  $$@D D@D D@$$DD@$$D $@$D @@@ D $@@@
MD@D@@ D D@   $D@ D@@@$@D@ @$ $ @DD $D@@ $$@$DDD$@D @@DD@D@@$
MDD@$ $ D D @@  @DDD DD@D  D $$D @@ $$@$@D @@@ D $@D@DDD$@@ D
M@ DDD @$D  DD@   D$$ @@  D@ @ @DD@  $@$D @$D$@D   @$ $D@ $$D
M @@$@  $$D @$DD$@@   @D@@D$@  D@$D    $D$$D  D$$@$@$D@  @@@
MDD$ $D D@@D@@ D$      $$@$$DD$D  $$DD   @$ $D D DD @DD@
M                         DD@ @ DD $D
M
M                            '__$ !01 0                   +#_
MV@ ( 0,! 3\08I__Q  4$0$                   "P_]H " $" 0$_$&*?
M_\0 *Q ! 0$  P " @(!!0$!  ,! 1$A #%!46%Q@9&AL1 @P='P\>$P4&!P
M_]H " $!  $_$/\ _2BHOC=^?KB"?#K?DW?];!3I3^@%_KFJL N5'KIV_'!5
M"H[#'VZ7X'O,> J-'ICOXS3[ZY]W]/\ US[OZ?\ KGW?T_\ 7/L?_'UP5@[F
M1^0>>QXBHBF(@/PBB/TG$"I#TIC_ **PH(?@:-=4!3["3>N*C\#$*H"CJAXN
MA6 40*$A0C\6W@/+@I1$,C0!H$ CQ,3H9IK)P[?IG*__ . *"#=0B%BZ@@@]
M%2H#B* 2D 1H19.!J:!B/\HH)VD.(KQQX0I,;((I%7$$Q: 1D!%FL6B!!=:X
M 9H1"K7C$H@]V/>.(F]*@> ."6S"K(XG"$)W ]%%#X#L 'B8TG<)22L-4 VN
M:LICA/PEMYW6D[ JD*#=QH?''B"I@1?'\0IV&&@-X@TM :]'0"I E0!3IL6%
M"(2%WIB% %$B6" QU=#K/W.(Z@4*H5 %854 ]4#7GP(&J(:T0P Z&! ]B/3*
MM)1 D@B<WP"5 1") %@6,.D#9!FTP"SZ!1T%(6CKNS9(B"II$'&#0% DU1@,
M>C1FE@ED<C"0W )5T>(Z>BPC6"* *RT7+>*(C"N)0<%"(U@<6:0=T JB5B4)
M(+G E)*K ). @;U@ )4*!0BM%!(AV#[V9-0WP5*4 "RB" C&C$=X(" H"BL$
MX#6A!AA"$$*V B_,R^ :3T-"DD9EMR+@' P&I0&H!6(0&VNT9$,!7!CJ 1"[
MX8\4LG):Q4<!!/H0KXAHXG'P2D2,\>L;8@7.,B@XN590-<FIRYI#M+1B3G5/
M*3NEZ@9Z.BMP[7^EB'^HM -)R7&*!30@X:-B@.5P3'*?JMS^%,G"-^ Q:DHK
MB>DE20BY(VT#MMEO #=X))&?@@PCWEZN%^P/H@Q\D8Y[[07R64FA9%518<L(
M0 VN0QP6*4(WA7RPI\(*A14("FHIW@O]<$@I5R-8@?K=\O%@D9&$ RCW*B)1
M LHZ;E&?P?#(2.MLJD&FE@E*$W.,XIFD>D6_2SV<3D')[)0"$^:^7DG6Z?24
M^9;3A;P.O$(M%J*KT>6^NY,;%E& [&B8N->QAG6#4T?UPC6T!^'_ /FT%GBX
MN"]%\]?#UPX*0,"J@=8* I,&J#+_ *6\\Q*4 $7<$JE'.Q?(E0"P) FOSPHC
M&Q0H>E-'L>DTSGV'\\^S_//I<^[^G_KE&;C+'4O<F96RLX.H(BB#M,3^<Y(D
M7U_1_P"')BH 55!#5Z\]Y_\ .<4$4  *K@'.G#\\14-#LU0%ZT'_ !WQ8%HI
MJ*A71B>EY]Z_1_,GU^>(R@J+E50+[!SZYZFQ>E,8[U=ZY'S_ $_]<4(@2B'I
M*/+"D+7B(4*11)"#5$)ZKI?M:] J^$%?/Z<'!@0HCIH) 7PS'U$"C)C,J)!J
M<AJP6PJ/,"A46^ST((WH1>)(=%8P=P 1$I-.AYW!@BD4 0FA4B>G.Z!*E1!3
MHP4T](E$X@VWHZDX!5R2 PSE0!PGIX+U7PY3[_A_ZYM)OQ_[_'(EGX:?Q.("
MM@*ZZ-?."V67H01:,.27@23HWF4US*J*.85!*IT5EB-J <%#<T0LQD1Q#*TU
M0PE"B#1P\!%=DLTH925\%YLB:"FD%$BIG9ER\=C.B HG!(4:YG$]_@#Q+]^&
M."\L+11N!"PHC1;G$.Y\GSNA(RSJE[X-6E*%!M:,.:KAJEKVB?PX\D0TE+/"
M[![FEOD4:H&FR_5@V%I[;&\\JWWH/O,Z6I=6%DXH?^9,JKP4B['-:Y*_E1D"
MH&X<.2.U3D^'5'&[CD=8"GA6@4>![U<9W5\XF=W=X4BE$HA:<Q$RFMPP&N(5
M*;D##QSX-(D@UX]H\,=*0-.H$4N49T(OZO2 M B"Z#(O-JR>NSF&<!3F4I:_
M=/L/ -R&PQV,')/@?S9EWRS]&]Q*YY!O\H.2"(>!4:Q<,O*25:$%G_$A3#8A
M#R)!!(4_[I0PG"0DI:*NQ0H/$/XGNF'#Q:,B#'$_GSCKTY'SQ+Q!U/B("+)[
M\58<,LZ\ 62,E-"($SCHQX[_ *?M[%1H/;"2)^UF"&@Z7JV!--2!3. F].I$
MXER*"[QH$,H4_NU!JTL2Y'H7+L!O+%%MXY3ZH=S2:,,0A1\HN>/5%F8,>'1
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MP1 &J-JA]@)BX/!^&A!UA&^PR%!MW&I>XR-%<2M64^SA:2(_UDI02D*G@O2
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MG 7DRD+B @HA R+7A ,=,,@BH%!3&'B>EA#@$06>AD_?+E,Y"4H4%$,GS]O
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MB*%98 337_L"E50)%2"BY4#N\\!+'7T*/#L=><FG9F4JBD[$[!Y>/8<Q .B
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M;="(7S[[_7$J*4H5:'L[+E"\JJ=S=2VWT\_W5E28X;>E1(].=.;Q?VH;+M$
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M!LF@#/[]X& -6 (+^1$1-,ZY9*@U((%@8!IX7R:R-RWG0K.[L2YYWR,TX:H
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M 5E*CVJMPO55>9BE8B<Z1$/@%#P#C&RDE-)16AN;-_&R5N+G]MO^>_QPZP@
M11M0A+V=/XX6<JOW9($$$)YHG:0@H(!O 0I(.9]<J%5*P424DDM.GWA.HC&_
MF *V-_KSAK*DC;TTJ%F"4QIG%*D%2 ?82+]SWOGQIW(S4T9G3+Q,FZ*OPQ5
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MXJYVP4LK!%IT;A#B*BH"7#,W3N9IQXXQ! )I]V(L\G(ML".TD<8&MR[RQ3%
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M\SQ0!H&N]0^)]3F<7 =**5813#+.// $ %%ZBAW\7>91>(.FHSP"#V5XSR%
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M/-:@1KGRO94&<)Y@X'[3B4HKTQ#J#K\'!JBU'GIH#OGYA.-=W39Z^XU#)2]
M"&AT5HH"^>8# +%S^)M(P1$9(2(A!>X1YD_G(MR!^0.W ANC(W,6T@N'48\6
M$*./*14^ZT 2_#L5X"Q]YM\BZ;U5Q:&>H)QHJ&.$.&MQ6AXW5\_R4%)B6W<>
MMIKP.H"B(_F"QJ\ ]/S4PY)9\2A 2)ZHT&P#2P.(/8X(NP10#  8BI9)[&!I
M8$#H0P>JVM5X>%4O$"#N"F.MN\$V@:M/$^ G6&=!P"8S31%!=HU@55%WES+
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M?SP<-A/04"C]_)&=_'&4U! "G8;WQ51B)QWIT^K00]G!]>&PJ@06  $5>_.
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M4+]KW-R,GQ>$PFB$:L4?V_CCP0"I3L'R>OSR%BP$:L6KH3?.#8P_1@$^$?V
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M &DGL.B]Y9P,<BM!48;\%/\ [>.12FFGY?X_QQ@J@,EZ>0 H!XQ+K/R?^[.
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MM/M46>W\<MI[(B 8SP&?GS@&" E @2F1/L7C(Y1%#-2KH^&_(<:!, !W /\
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MQ<;7U#>!B 7(XE%)08:YP"I01-&T=%N(O"F5#)N/\IIE/B7!I0OW'X[LZO\
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M0<ZXQ*$2':)@H5I/WP@NB&U P*(N)I4Z44!9HP@3!1U:0?.ND.@!16'0=?\
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M&=*-["ZX<"W3P BB'1O#8"TJDP, :0J'#83-IGE2F[BHO%]>FQ5&,8 - ",
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1]SH.R!--07JZ-+?_ /L/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>stamp3.jpg
<TEXT>
begin 644 stamp3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X4DH17AI9@  24DJ  @    ( !H!!0 !
M    ;@   !L!!0 !    =@   "@! P !     @   #$! @ ,    ?@   #(!
M @ 4    B@   #L! @ *    G@   &F'!  !    Q!   !SJ @ ;$   J
M $HA  !X     0   '@    !    1TE-4" R+C$P+C( ,C Q.#HP.3HR-2 Q
M-3HR.#HT- !+<FES+E-T;W< ,C@@,C,T(# @," P(#@@," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M   %  .0 @ 4    !A$   20 @ 4    &A$  )&2 @ #    .#8  )*2 @ #
M    .#8  !SJ @ ;$   +A$        R,#$X.C Y.C(U(#$U.C(W.C T #(P
M,3@Z,#DZ,C4@,34Z,C<Z,#0 ,C@@,C,T(# @," P(#@@," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @
M," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P(# @," P
M   (   !!  !    N0    $!!  !      $   (! P #    L"$   ,! P !
M    !@    8! P !    !@   !4! P !     P    $"!  !    MB$   ("
M!  !    :B<        (  @ " #_V/_@ !!*1DE&  $!   !  $  /_; $,
M" 8&!P8%" <'!PD)" H,% T,"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH
M-RDL,#$T-#0?)SD].#(\+C,T,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_
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MDMK:S>"\^TI##\ZJOE["H.!C.2>!UJ"#PA!"$674977[0+IP,1DR['1B"N"
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M8E\KP[]?Z_06']BKJH4)T6*>2-'651_$O0T^$3RH50L5MQYVTG(!![#\:KJ
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M]'AFNUO8Y)(;L*$,R8)*@YP001Z]LU4UE]86ZA^RI_H 7]X;=U^T,V>  ^%
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M8=H?[N<<9]J2NGH#M*.IP]F+._T74M+L2$GDC-Q!Y=N8HE90NTHK<GG82?\
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MQ  >  $  00# 0$             " ,%!@<"! D!"O_$ !T! 0 !!0$! 0
M           & 0,$!0<"" G_V@ , P$  A #$    ??P
M
M                                                 *%5"H
M                           I3>?MNY]N6OJKSZ'%Z'WU3X#F
M                  #B<3F?#BIU[E,<\W(W9%C,?-C!<K$V[A9VYK?O#[E:
M%5]\7;B5/#M@                         6PIW+?RM/.[;:N6VMS]1Y.)
MY=R.-;FP\O?V-FZE86KMA8V+A7_7;23#R^W<1PG$S)-X,CPC::N6F%F;HP_7
M*ESZ                        !;%/)C?1O)/#0&?K/3S12?.Z^_+O9:2>
M6JVT*=SI)):S9Z3R[.R*4ZOFM\7]">:;M\[V'>VCTY]9FS;U6?S>U0
M                  "CS.W,?E/@YNC<S!Z'FOH+J=[:[K [V/D%N[A_NW;O
M/G7>38W?B9^7T\="B^5KTJW;%;9TJ                          HM_NU
M9?3&;V-J3UXAELM5?;5-$[#%GMJMGYS[>.R@QMSIB[JMX8&T[%WW>_'KKV_?
MI-JM_4I6J                          #B81ZL^$LO@V_;>5QP<O8?FNS
M,?,RCQ3&ZLIK<N^/E6B]B::R\.P6_.E<K']<]#+-JVKO(
M           '%XXKL&]K'\FM9D@L/,[/BN5^_7"UYX>+G.\IXWJHIRN>^5[%
MP6[BTO%[8UG+J5                         #BIQ>BG74ZOK'H*Z^LW,(
MR,&R;W&Q*_8H>/=FJZM+UXL^LMO>NU8L97@LWQ]ML'&S.Y[LU/+FIR5
M                 '6*YP"QP*"]J#U3 ]O&-*;V#]"31G#\GS7N9?.U?X/'
M:Q*4-UJJ%FMRP-QPM7;I3#O.JD63:?=[;CDPV'9SMD>55[Y*%>1Q.0
M             .)TCMU4JW.C[P].;.SI7?1?$=MI\$E,&KVK?4\8W?Q,2S;6
M_<;&PZOK3;6A'4>6ZT&"Y.-D.)D7BN'@][;V/=\VO.HF=UL8MUQ)GN6'2W:>
MJWNS+%_G<N5K'CA<<CD                    I:O==?9N-I"30G5$FC6%;
M/35+-W)-9ZM61E;PC$AU;G:G?>CE</NC\>O/BS+?G'3X>=7XIG<3ZOLS4;O&
M=-CY)GXVC>C\EVG!NWZVDW.K=LEUL8.:1>5Y3#>G2=PMMFMF_P!GR
M            '$Z]OUT;J&.XU4<9!"\CF<(9N/M*'2G5GA+2)SV/$XYM**%S
M& 76.'>A_)^^0 ZCS#.];=D9"NC:TVL7Z$2FF_<_#Q##V<6>Z_,>T83TB47/
MNNQ4D_.\:DD3K9NNP&YKO/RQU/T0CDIGA#9+NK67>7FE>[Z
M     %-2R>_7GG)8KYB].YQ(C%T\DK.LE=SWM>E/+!^B\:RF.]&D7H-KI[?1
M>R6,G:6!FP^Z=SO(];A2.@?7+-;W&";6$2RB70X@[WG5SFL(N^IW\C(1U6,6
M58UW/>%3@Y[WF+DHYKYH27(U1OM1)"%S3TOA<IF)H]]=_%X
M    #C3QAU^QYP2/0^6_7N1MGI_0CDG4=QRWE^Y(1T;+HQ+-$3_E=GW.JE]S
M'NWGY-.6;O\ -+!LM;A.UM7C1;+J/7>KL+'M(#D>)-KWJ[MSRM-:%C;.BDN
M[V]N*.[2EH.D:#Z-\\>7"5]C<:+6.^T6XH9U#V<YK+I0Z_>=M9Y^7)4
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M9^)=Z_3:D!Z'[?\ -NAR UV[JTM\E0              4M]6A-MJ?"_JG)\
MS]5.6 S6SYF31TN5J21:3UYBLBT3-^6V>SMNWI-7F$7E. ]7@_1R:]K"VS%N
MY!I<V7OY]_1?7T.^C%]I\GUE]%_,MUTT[N6I]]342J2''9UC\?UF.=GA."3F
M/X/*>>2LY#]*QEW6JT7B78%=8Y?7R-;=,;=\<O2S-YMT#V>Y_P!2SS"O/?H
M            <3@H-=VO'E!T&#1:Z-SW-+-98\^ENYH_.ME;F*=#6;*'72^4
M7SQ8S"'2C=O*I?LKBL[TM]$<LQ^;1O#I/=KWO-\T/J0OS?U#2<NU^38&UT#]
M-\(R?0S"M[PY(?,75,I^0>H?;-S7OV5RZ+WU3\VLG/IZF2<XS/\ SOSM'EFR
MN[-TFWESK=QX^=NXG==5;]7N5]I],8I([O3SQ7*B@            ZY36.O6
ML1]O$(_=.Y5D=?&T8-U&U9]O7=_09!FZ[7-S#N6;<8VEW?\ -W8-T_.G9>KS
M7(P3ZL@47OK_ (57\>J]RV\X?4N8_1QMK7M9G>S<;A>PNWJMS9;6DG1^<GT_
MUY%DQ1^JN86/M?+K;?T-NS[>I([TS"-?>A7M8K^B7E_9/SY=LYQW-E ^O<LY
M7&I?[N\GZE*/4["LO\GL         <3B"F!;<"V^KT=MK8C3T/C5JWT7D# 9
MUH';X,EM!)<*JTE/^;\F)7NKSK-GC^/XG=\D_1.#Z'U@G6H;'WZ#Y17+K?UO
M17ZEO&MN7A7+%WB_A6[*U'7P]IG\3SFFD&"2_ S'17,<ET?IW\ZW>-=A41ZA
MYU]8Y-Z#<UZ-T<7<^>O3.<>D/,^CX[EX,&>G\MG-QOM/LY"9GDE:U0
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M\^3*'??N<P![A';5,(5B$-Z/K;I?,K[OXW;?%+_>PY]\A[3[ \^G>16[P
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MN_,22:+&-UA4/55C!IL[=L0G6M-AH,>D>HN/NY(+FW1O>?G?0LYL9%6OOZ
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MR\@LYW5L6NAE9U?59$4-?(/6CX)[GHC;V(.?7O,HA=FYQZY\(ZUD5;]"SDP
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M^J>1O7^)WO WGN-Q/M'C;.XEMRY30LTYOE6@W'MIRGL4H=7M[QB7ZEVO*H
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MC,A4P)Q6-W!G<TMFYANHNC\N[US48Y&IE-: ]+]+(K()1:615J7>Q6H
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MN08>=F]W6RDCF]]+(1T_),'/X>E2[9B[91JN>.F>I:\5
M^%&OCC2M2OJV>[7F_P!5XMHJ[HIDP3J/1\WM*X6;(O W><['7[>T\@ZN1KKE
M=R(!2.#;)LW=+W<?4N_TFO/>!B/JF)[+%EM%9IJ#;QR0D=D,JM),M@VO,4Y'
MS/'[VJ[FRDNC9K"?6?BG:<EUV_\ -^]9D-9I6\^;494O2D5
M   ^*=7W:IV*6G)QO)GMWSMF>!G?-+*I$QB6QNC$V]([UKQ3SO/J'8\:MPK\
MW+];8I F0P;?&%NI3:C?4C$+U<P6<0]N#$Y>LF^8^1CF3@>2G2^,^T'*.Y:1
MW45\U9+';I@[/6'0.<3>Y9UB*,;EOK5?IYPK&VC.*7YI@
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MV=W+;MKE0  XUM^:\XY=VB>$,Z/YISZ 7V[K=WZR4S'A,V[(
M*-*<2/\ (8S 'H7,K[H]U-V'SO;F#LNC;]9;;RNZK4%&*7<7#+](];:,RBT,
MAV!XSU*]2[3'O5,!NZ^WW[.(Y6HS'7[;:GC*[6'GV*[[RBMG7%_ NMO.RJS>
M[:UV'OX50#X1JV\6\S^F\?V[I)!)6.3_ %7(M'JN31'UTXEW3L4
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M*5*^OJG5>_*_H/&-!;_1^N'+NR^6O0X'B4BBOK9Q_L.\=3(/OJH
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M6.3+GZ*.57$T_E:;S*Z=R;9VESY+Z&=1HD$8A[TGG?O[\]?2W<L>.7NH
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MG0/H,49#H(=S'EVTK&XG7#>@Z]SM)*Z*SKG[?%*#SIK9Z/S>Z!RO9>LW_I1
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M2JH%.*D7-Y%(;S6#^E7/NIX;=QH)RJ!QUZ1!/9[AO=MAZ/:UK]ZHJ
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MC;OHQ>Z79+164V:[9C1)-!H"<\_]".<=5EC"9GW_ %D<3D
M <?-"FEMSK(#],X'(2$=0D+I)'DF+E8G[O;7P,R"\[Y5G^ID&3XNRWQJ9)=*
M5^GRKZ H56P7 '%2W7+/3]VO.J8\YK9=K6>UT4P83T+.-5LH*3V#=/<1S9.!
MD>DG*.Y<USL7/(                *=+PC;*N:QKET+W)$NC;XTLDV=K-I'
M[;:+7N=K*-<61&LGD<MG$]OZW/WEJ]WPNV^=N]SN>2O'T450#B\\:5M[QY*]
M0XAH>2QKTUYCUREZO[4U^X@O-.>6![N65E>J'*NG=NBO2Y5K4
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MJK8VM Y4=N65K:6?BPDE6MV-8U'I;S;J>5:>0=^_8X%4Y
M      X4I\4ZOGSB6SUL:]]%>[:P\DP-]F=O8=?!W/&YK;;[LX)GXV?8&5MO
M%V/'SZ[Q3K;ZM,W76QU$/)WS..DBU.^HM(I[P?HNP,'9=JW3E5]K4
M               %.M7QPM>ENO4V&OT9L-9%^5\RRG7[G(K&?C^9JIF1+J>N
M]W!:E<S)M'(,&SH]LO DW.SL=,[6/Y%ZQ-U:>0]GQD_;5RM5\N.8
M               *5?'RW7[Z]</5>%BWQR?7/S:Z-WQ@&7K.TNZ\WG/E<R]Z
M:2Y/XR,RPMEW\?/^>J?6/5KD\JV:EJYR%QQ.0
M/E'VHI\"OT4*T^'U51\J^T!6BA6H
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M99$X(O;O57,KSUB"6!:?5VC1%B_FAHI+.E8V(D)6P33<9"-"K6=!N_AI..2
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MH@<$V[M>,>,M&1$DEI7@*+F<MC]HMY&:SKUH@=$3*H>:1GGU+]8/\)$C#Y"
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M"1@0B=_IA+[ (?#DP21G$HEK+5.$:U',X.ZV2LQD-=[5;VK?X>QM$99Z%<Z
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M_ CUP!]]9O7Y#J\5AJ-DJN;V-_G]W_HQ'KGF'7D'#K@ :-K:[-[3<UD;R?\
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M5WE-B)Z6O48S03;H '7SVBQ6&MMS7NTS?/RP,T>!*"4#E!E(+7M 6_+NLME
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MSLB;PDBT.N'S<+H-4SAWR3@8>7),T"/<H'J8,'FEWA>+FG%'<*6BILI65C[
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MOC\(WEC]\S4ZDJ_XJ^46Q4R34SDE_64XW_B\QX/X^,6VI*+K/&0%I4PSS!;
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MZWPZGE%UNET^W)E-+H%+0@'(J&&$E3MCZZ[Q4W47CAY:5$=H"I.G&H'6>3=
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M2D)+@G+Y!\"V&)&/$?:9K"LJ_C_&*^K73SD5<M^XQQX?TCA2Z_WMIQ2SDD%
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M%HR/..S"1"IG+V>^)4J=)7K#]8M_$-11@#O8\#'!E]G5R75J?&X,(GF:K25
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M^,5-.I2%;\_QBV4Y3,4_UO&MW$=F51V!^O;'9?VKS"T%X1(,3:<O%'*ZQ.I
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M-27Q@C$</+[6X$D\CS\#%Y1^L=BS_C$I+HQ$U)Y@^XQ+1]>^$)U\HF2E#8M
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M.!@]3$VX(MMLD'4-.A.5*&V.>,15V^W\12JBII E,_\ 5[%.=/@,[;'EZH<
MD"H5PS:*!<QW_P!/RP!R'/?\\F.(;%/X@T54I3]T'<<^\-O.)_!]WJT^C =W
MU<Z?;O'!G#51PY)O5,M6F5HEECL>ZHJ8^'XQPW32:;BKTR6G3-[:8"2,'4Z3
M[P3'$O#$R_\ %,Z1*+)K%2=1Y?JP"2_UB*^\T?#%+;^'IW>332A+8*"L,"EU
M,<,I6W/#)$6KB>SW^94\.2"_9H<E09.<]TG?)&X'-XI+17VBDK)]*0E$M*BD
M.D/ZS-Y;^+1:KY+OM--MM8?\R!.8G&0[9]KGP'F1P+VUMGWV@J^[)+%&K ^_
MCIN1D[1;IDZUVJHK!(2X4L@.@*(UGP)Z';(!Z1.XXN2PM?8-I5T'(^45E;)X
MBX<]/F)"9THH[I8*?M$@G20YPGESS@15T]+>+):I4U2 9:%[MR;JS''/?K%)
M.L]CMZY_9RUU*$E*5AB<N.3^P8+>L!SM5:JUW:HXAF$E%4HDI\,C(BHXBX>N
MV;C+'L?\H'&=ALJ3*MDKO+='JJQJQOS^#="^%2IJ[BJ>M^^2O/\ NS^,4B)T
M^XA(=G$2^'5ULL/T$<+V$V]6V?KK%^L1N4O2S8;R^4+X([!2CCF?QB\4 IM7
M@\25.3$N0(7(4=DJ/D"?D(]'4F7E)'L,6I!$[_J_&*!9.GR3^ A/JC]H.T[Z
M^Z8XX_\ H&:>>L9Y_P"H8D$J2/(1,DD[)@R.RRH^^ 7]7'E%+)0:=3G<1;+2
MFHJ%<]XNE@4;E+"7'?&SCY19^&1]EH+9[/IG:+G23:"<X2<*,&[GL=!2SAHN
MI_RR G"M;N,'UGY1Q/5&9P73R@H]KW4]T@'NJ&^=3^J=N>?6$</\03[352NT
M*P.Z[D\NL7CC*CK;?*U+3J"DI*2<[;I'1^?6+-QA:Z*1H6K<#<D_.)7$UJGJ
M7-"L@$CD[ D?(/GGCK%YXWJZKM)<M!2@DI<#)2-G('MBFNBDSTS5I9EI468*
MPI]VW]\2N("JO-0E+;Z3T=+?0=O9%[G3:RX&H4ZGW)+\FBA6JSU8J4$A6K5J
M!(/OB;QW55%.)*78C2INA#'ETB?7*IE:[2=,PEW&#J.^3XQ17&^SE%502-6Y
M! )?J1N/.)]QN79Z2>ZVV&]T3ZJ=J[VD9Z")$_TJ7K!TA(]483CP&(F7U8/8
M J9.V6$2;QK[JB_G^4+F">@]&./Y1+DG4?,_.#*&I)*1ZP.WC%?/U!+<@-O*
M+$0"%'=]XI+TB0I$O&6'*.'%(J4I6=REQC+8?W.(N$M*):E!MHOE]%&M:2>L
M7>M^TYA">O*%T4R0@$)/N@^DZAW#RBS5,Y*4H5+!&IV4@')8')#[>,7XI2@*
M"4I=+E@D9YX&WN'XQ2SGF#_D/G%JV3_Q$'U?V@[3OK[ICCC_ .@9O_,?_P#0
MQ124G1E.PYCI M[HU!)(;< M%SF3DJ(3*F;D>HK\HMLJ=.(U2IH=MT*'S$&U
MSY5,5:5C',$1PG0J7/.KGC,5O#BS<92@A1&H'"3%';.QMTL,W=$7'AF57DD@
M".(N&Y- "4S$..6I/+V_A%5^MGIEC*06QD154XGTJ9"BZ4Y8^&8K:274U"4R
MTZ3L^VT57#4]4B4I,QPZ20"^''C"J2B[27+U,62#ON!F)HHJ"0% DX\8I9U'
M5 GL\<U,6][-%QII:.\C Y=(2N7+H>T!"E] 75OTWBHJP*364$3#L"#JWZ,\
M2K?.JI6M4J9L_J*?Y1:*22F894V6>F4F%\(SJO-K=)WSC_R:/[K<148)FG6D
M9[A0K'_2\(DW.K5V;%)?3D-X0/T?W>H(4J8E(?<J2''P+-X1>$+L56BAR-3)
M/3+<]OSY0CA7M* 5PR5IU!@Y4.9QT^MH7;UR%'NJW/(]8IYI TGRA$D;Q,0
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MZE?=/C%SM]3:%:E!3 [L6WCAJJIZR0>V1ST:B"V1UVPV=SWHXAMTF@D6]<M
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M #B;.;GM")Y(.7P8E3YR5'?<\X74S3UBFIZF;*) 5MXPM$Z1-.L'VPNIF*P
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M2WPCB.UK"E+M8<$DCR)Q@QP[55E&XKI3O@.@8."^V0^W>#MG&#>T5E:5!$T
M*42,)!8G#MS:.&95;; LS)J0"A6X1_">IR_OBV4TFMUC6<E6Q*4YU/L?KGB.
M)K(BF7J3L5;\QMN>N[;$@.P$4\^IMZTFC"E%AZL76NNU5+2FHEJ04/@X2P&I
M]3L20.093)()*HX6O<NGHURYJ@"!S\'\_9RB\U@GUJYJ5.-14-^I\_Q\XH>+
ME4XTG+8SR;I]?@U?QFI6K2 D$,=/0[MSS_+:)U?3UJFE:BHGF5')\XH;'<:C
M,M/=.^VT4/"Z9:M00"KG@'SB1;9TD:9<H!FRS;=,!NN<XY;10T'9EUA_%6?Y
M#\^;0>Z&&/W9<+G+HY>I3)89)QMSBX<>H3,5*EJ"B72&+G.!@$Q46RZ7:L1J
M5,T*5JV+,<^43K2FR4DM<Q23L5!\MSC[5L%9+TTDK3./=(TJWYER.N.L7#AZ
MZ5BNTI'T.^&]7G\(KK44+ 8A0P<<Q$U%;(EC0I3#E O$XK 53*#'<S2KX18;
MZ)21J*$8SJ2#CSW]T5M[E3E?Y33G?SY[O%MN]N2D"X21J((U;Y.Q9L-]9BZ3
M[=*K!HG**5*=M)8/R#/CIT#14SK;Z"%)J%"84X "OB/K<?PD'A^OF25Y60AS
MGW^!W\N<7F8*[_WBB-+AM/K:>Z[JV!9\'#A+^M%JN%+;)H], 6/KSB^<5VRH
MDA$B6@' '="F\@H-YALQ.K%TA9!("LX/6$5*IHU%S"D@'I%-0(J&?() ]D4W
M"EOEZ52AWL'8[Q2T5;3@(D2SI+#U>44EM5*ROP)\^<:I2 S#W1J'*-_W-M&_
M]I4*8:IIQN'BZ\54]-K0E0*P"S'[V6\\^R*JZ<4\03_15R5BF6K3J# :3MG#
M8YQ;N!K-;4(JZR8\\LI25%18[GF?E%QO"V$NR2DKT]W !VP<^S<>PQ266KNW
M>O&I/0%_/81(X2HI+%#.-F^OQ$2K<JG&E(Y1=K6I<WU&STA?#:ERG*<-GRY_
M"%\(6Q??D^MOSW_J#%7P[5#NTY8#I MLRER*LN/]ABHK:V6=*:@GE_I_RB7.
MJE954$GJ93Q-GU>WI"B.G9Q0U-5*E$%)<Q+FUW:*44KTE^K1.F%"F)R3S/YQ
M0VWT_O>V$<-S:PMI.(3P],HAE./&*&PT%:_:K2D^[,7>@GVA0]!25@$'&<;Q
M9^(>W4GTQ+-I ? #;_RBDN,BHEI%.4J?HQA@8/=B5S^NL3/R^OKPCLR([1F'
M[DFX&,Q)[PSW?/\ LF3Y4D*4N9+3I!5WEI3MYF.,_P!(6G53TG>W1W _A]UX
MX:M=9Q+_ )B85(2._P!]T]3]YNA]T4=ZHK6/1%R4KF-I"F22.0REWQOD9Q'V
M>FX'MYJE)EK![N>;MS^'XXBUV63;E:I:=3YS_.*B?)TM-3I(#!L9;&1%#+J"
MLDDZ7<#PC4E  5E\?316TR#,!:#)E"G4Z0W9J?;^$Q9*>DJI4[0L":%S,*+?
M>/(_'\(3P_<)D]10M/9_[F]V7'MYQ5V$2P7H=?DMX5;*8:M5K7@.^3U\!"*6
M1_\ PR9S^Z6YLQ?/N'MB922Q_P#LJ8/$I7_^6%:$U E^C30 >\.R7W0X ?&-
MV\VR7B5;J15._8D**-E(8@MT@\%&HF:M)(*G88P_5BWN/E%MX9]!8-[Q%+;Y
M5/EAMO\ SBJI*>I"D@H<@C"AAXO%BN-NU3J8JTA3X&K_ '!TY^1'**'B673+
M[&Z2R75I=4L N<9PEQ[8J>'9-=1JJ:&8@%0U )6EP^>1]V/E%KX@K.':Y5/4
MIFJ3KTN4*89;I%MNB*H)(6DZ@"P4,/\ UA64O$OG]=8FQVFJ.S?]R(EF2=1R
M\3 9^06\HG7.CM=),G5<P)T@GO'//\8XHO:N**M=/;IB\*(!EK6"7V=E-AL,
M!XQPWP554:%5=S4GN.6F$3"6SN-7OVB7?*83?0J=#9$MY8*7?#G3YQ0\.RY4
MU$Q>265WB#OG8_6^\+I4IDI :!+=8^NO2+A0ZI85MS^O'K$B6 WE"RW]A#C2
M=C@^V+G:K?;*Q$^4M4OO.K0I>'.3@]#X..6\?;E*92)4IW[J7!(Y]>G7\H#%
M(?+@;QH3_"GW""F6WJ(_[1^7XPJ2@_<1_P!J8E2)9=Y:#_T ]?"*RG'(!O#G
M%O09DO\ TM'+O'??\C#29*VG(U/TSNX'N.?Y1>:M-LM\TH.="V))88?/-WQ@
M.=F+1P]7W2Y7=2B9IEIF:V*U: G5R2-GV 2.?2%*2-*9@!=(!< \HO\ P=2W
MB65L$J;&D:<^[\HLG#519E'4N84@EG4HAGQSBYTLNJ0I(DHUD$:M(?..C^U_
MCF-%9PQ.UJUD$J/>*B,_D^.D<,7>;?)8?# /O[S[O?&@;=(TPT,?W)J$W&S1
M6U:;>B8I2T@)2HY(&P)YQQ;Q'7<251M]"9NE2U(>6"H;MN(X1X-/#E-]HUTQ
M*IBT%0$P]YV(&YW&#[O**6LN=ZJ?0TNF2I92X'=9\;8B=8[/PI2>GUO9KF$%
M6H,3J;J'V.PA/'ZYU6$2POL];)P?5?'+'EEMG.YM%S-?3()Z1VFF9%QK6E8<
M^0BGK"2Q=_%QXC<?6(U:P#_;46^CK0\P!1\?/Q^CSBGM]OD]T(&[_>TO\OK;
MIC^P$DP "(3W ?KK^45U4J6ZDI*M.6 Y>X^[?F(G\57ZOURK10*0H:D'4R X
M+'4%(&' +.DN,JCA[^\I457I \,H?_TX9O:_MBOH/M*64+]HY;[;_7*+5;**
MRJ4KLTZE<V?Y9\'!?I%1,])6$H'3X;?EGXF.PFRT#O;;Y'NB>M,X:=.=MH]#
M2DZB-LM%YME/>F2$!QCZ]WY[18Z5'#X(TLXYAO#\?C'I 5D$9S';=<0P^C&G
M]Q[9Z1IEFG765![-,L*W+;>'CRCB.^'B2LF6ZB6LZ%!#)?OC5I5E.Q ;?!&L
MZ@=*56*Q4G#-,5>C#MBE*GF)*R2H:BQ(.0XQX]8NM'>K[4I$B<M$HK TC"=+
MYQ@-%OM]KX<H)<F;,1Z4H)&<+*_:>I\N>T7FTGB&A[-9.@G&>3_AM%9PK3VB
M4%A*7"1R^/41PKJF$A.P'YP4 D]8(#=8$D/M]?G"97]LSW1*Y_77_"M<(4#N
M![OY0R$^JA(\D@?(07Y$Q+!\8FI>)8"?.%N>9@S5(&WR@I5.BO[:URE54E)4
M$YV_E_+YQ0<2T_$$Q5+5-*4AP/NY]PBX7>;9I@4I](/7D^/A%@NM)Q!*#S$A
M0&1G!SX9<#D_L:.QT^S]R$A.58'CB/TD\83)$Q-FH5?ZS()EE]_+SC@KA@62
M1]MUV5305CM.N_/SB1<JJ^3^S7(TR=1 4P;2[/CP\3%7)M5FI5SEX4E!5W4E
M66'0?Q-CY13B\<8WP5*%S4TDA?-THTI.-V'+SW/6*2YR1-1:DS)9G2P'&I).
MWA[6VQL-)>.,YRY5.5'  ]F!'"G%\FDG3):E.3AL*=W'7\#A_;07 U!?+*+^
M_/2%9#^V N K^V;$O#_77_"M$(0P^OS@', 8,2Q]>^)@A6(EYWBYUZ) _K^+
MQ;[Q+F]UO="%29]*NFFH"BO8_'D"7Z-N?..)^&I]IK#74)4E)6%G1T=^7A%0
MN5Q);U:2.TER\Y#ND ;;NX^+1:[C6</7#LP5!)F!.<!BJ*:O$^7+4A6ITI)8
M@[A\MB$Y'3]Q2Y??"E;1QG>12R%)ED:M"O5PZM)'OZ1PE85\2UGVM6@Z9,PG
MOYV5X^4<3W,U\J79Z!SV92@Z,<QTY8BPVU5!:A*6/UA2#X]=]XJBLTYDK0%@
MX(4'P<?+QB522J6V3J2W)2B9-00Z $'47S@#/NSTCAC@V=:[M/N5RF3"5%2T
MZEDN2Y?<^?A@QQC4?:5',IY8^Z4!M_X1M]&."N!:CTTU$S5I*M2=3G[Q'S'/
MI%-1B0P8!OP@]/[=.MX[%OZP4:^]R$*"5C2#D0CZ^,3/KX0-8CM%]($#;^V7
MS^NL388PQBOH/2_Y116=%.74?I_.+MQ706F<F5VB2IP&&6]N&Z=>6T">B^49
M6ACKEGH6!!'U[XN4BJX3N#2@HRES%%1SI[Q<^S)$7:G3?:-$ZD [3NE02 %
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M53-A3E9Z!LN8D\5W*QJ[*5+7I4 %#3D)6!X."4GP,<.SN'0K[81W:XAU2#K
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MX;RZ9_#Q_P 'CRZP!$]90L(E$!1W&.?@86BI* 61,(RW=@3JPR)DQ<L!22D
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M.G[;+4W=C]*="5*$Y(.%!6!T(,<!W(UMA(6IRD)2SYQC;V1;"\I0\?Q@;_\
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MN#!<; E"@4.%/:;*>%[2E-:E-7^L5,8,D!:UZ@P #<LL22^PCBROKD)IJZ@
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M+\\#P$4=\K+"#37.2J9+1I0)Z3W=+@)+$ER0Q+/R("&>)%=3U:1/I)PF:QE
MW#X\_/GTB=3GT%<EV4I+XW!)?KN-_*+;1]A3JEDY+Y+/\S^.\5U!Z9/7;TS%
MHUOZKY<N>8_XEMP[X<1:[;*MT@4:63@.1A_$D>.?AR$7NPR9I%REG76RB#+2
M2&+*?()]^T6556NEU5P*5I<!)Z>S'DV//$+EJG<=%4M&A*2E] 9P4.5$;;'.
MSCUAJU1Q;95W2V=FCUDF6?<?Y]1ME^7#5":*B1*.#V8&^, ZMSY\])W2V(2&
MG*/^$RX[(;MMX0G5,#>KX#\HG?J1R(/7:*JZ4EN1^OTY?"6?W):*JY7"YJ:V
M!?9DY\G\879Y4A0KZE0)0-1"LLK!V) ^!'AD&+[Q9/N"4VZWHP")9,L-S;D(
ML?"G9%$V;EP%'5G*@_.*:1*IY80EDXY8V_M8?N?:-:=U#'.+W9**_2B)* %@
M,X#$GKLV_LB\V2]<.U&JFF3 @+"N[GN@YV\'Q%IXPH[C2^@UTH*4I EF:ONG
M9CNWS&T4%IJ+;5"JM-09TJ9,"C)*W0D*W+.1A//2#MB)MW6JY(I5!6DI'+NO
MI<\MOD1RCM?UN@,01ORV_GB%4'8S_3AE0.W@?KQ(VS@0IRGMGRVWG%4NJHZ]
M-PFZS0@Y0VH#&EV8[G=@<.S\Y%PIKM+"Z8Z4MD'N9Z,IORB@LJ)=\J:E02=C
MJ9SZIV4QQGO-G#YVB4$S539:_NX\(4I,DZ$[>$* (U?X>T\/A';@;D#SQ%PO
M4F@22X+<N?Y>^)_%:JLJ1+0KFD,#ORY=8H;34U+SKNHA![PU%L$N/+'6+GQ9
M;^&7E4*4K4Q26[WAAG>)%RJ^)DFG0F8CM#S21OYM'#'!--:%&IJPF:M6P/>8
ML6?V^YH,@)?2PZ;;09,PG?'[K.01X13I]&]L55%+N'^HE!!WU >V.-N#IJ)B
M5V-'>W4);[XV<#Q\>H$<&5"K53A%]"D*"3J[0^;,&<89W?,4]=9;@H^C*25N
M6Z[\B8J**M&:57CU][OG9FWZ0BKO""152F2.8 ./KF^/' A%TI=+3B <#2<9
M?I@?3P5B>EB 4GP#0+=3.[A'@.ZVQ?'X9Z1HI$-I7D[J#_DY]D=I)3ZJS_VF
M"$[P51W%\X[(>,:A_8N9.8C1Y164U1-/=<>7Y[PJRZQJKYP &[GE[XF7"P6?
M_3[-:T[8U'5[1UBJOE9?Y1E2Y92DX&D:>K;-%OX(FSI_;3]6^KO JV/B6]Y$
M6VVRZ8):6A.D 82!MSYOXM"E,EOW=Z\&9V<*FI2L:4ZR6=QU\XNMCE767WV1
M_P 2Q^$*X?38_P!93J6?O<S]>Z%<5W*2H(3+60DME)_*)?%/I "9Z42PV2ID
M; ^'N\8D_9=:-6N6HN_=4#W@_P#"3G?V9VB4$+2TMF Y'EM%;350+RU\\>/A
MT;=^75X-7<Y.3;=82-Q-];;;#^.>GE!XEJ);I5:EN[!EOGF3APWAO@&)=<N8
M0Z5#4'R&8,2WR&^X(A#J'L_"*>GF;ZNO.*@34^JZO+,(*CN#[H3@/TS%VXBI
MZ-!=G&_L]D5OZ19:%E"$$G8,%'.PA<[B&^J9)F(2OV8/NBU\#DA*[BI2B[ER
M8M]FHZ*7W4)QS;/A$KL]2F2PS&MH=_WAK?#9C23ES[XF +#$ _'YPN@EJR9:
M/^W^D7'AJVW>CF2T_JUE)8I)&<_C%#PG?K#6K5;U*G()4P6I3;%@IWWV[A4Q
MYC$6VZ<3V(ZKM0+E2P5**DS!/<$N"0-8'/ 9^8<9JOTF6O3IF4=3.*2':3,0
M$DO@ !ONDI2X=CXO2?I7IYE2*-=#-E:V )!5G_J2EG!WRW0OBGGTOHJ:Y<Q$
ML%!6=0#A@[,>N6Z1/_2)9Q/T8[JR';H6_#$3./;04) .?)B\4%RE7&3KEJW#
MCX^^*[BI=FG]FI)6DJ;8'FW-XMMX-<RM+%0V;KG.&,5,Y:!LW7V^45=BM]T?
MM'SNQ/.)/ MBD*UE(4H%QKSG?VQ(HT2<)0D 8#)&T*F!&/WH$-D1K($;1VG+
ME_6&E'$D:3X.(,U=,.\G6_UTA*94Q_\ +B4^74R_A$RCI3_JTLFH\Y<L,/:-
MXF\.V2KF">:*2@I+N$!)#?\ $ ^?RBIM-LK9'HHF*EITZ?OCE$W]&5#VVH*4
M05$XZ'VQ-_1U1"6-!4X\7_+/A%@L*[8C2I99N;#\3%=P[2W&853 ,9]WLBEH
MY5O;0-F^$&9+G#*8TTDKZ5"Z:7/[P40WG"2-NF/=$Q&7_?K#H/\ ^:?_Q !4
M$0 " 0(% @,$!P0'!@,& @L! A$#(0 $!1(Q(D$&$U$R87&!%"-"D:&Q\ <5
M4L$0($!08M'A%B0S<H+Q,)*B)28T0[+"4V!C<](U9("$D[/#\O_:  @! @$!
M/P'_ /E"W8)QL7'2N P."8QNQ/\ ?_R/W'"T]QX)^%_O_5^V%R^\$+U-' YG
MWCD8RV3>K4\N8-YG[/RD3\O^]32,P5DT_P"*0'4D!;CACNG@6%Q>!?%&@6.T
M"3?\!8_?'\L.D_''E&!;G@]O3]=K8\J?U_(X_EC\/[X5,%,#2ZH$DKMY[S':
MW'XB.Q.*U(*;$'U(X_,XTRF'SZA@&5K;2-P]DFXX_ WQ*4M2\E:5-:>R\*J_
M9C< +%>$X!G_  @3E*5%<]7IJ5*A6VW^U:1'%N/\/').-,>I0UBIT@@M46X_
MYO7X3\IQ13=J=6+?75>T"-QX_G[\9$41GG5*N\GS!W@QN($GVR.H[MS&I+5#
M(B,J*BYK,EEZAO)@2+R3M$2?\(N0L*;@8JLVSI%Y'_U#^6,PBC*T7) FG3/>
MY*3$P>?\0;=[/+3AK<7C\N_^F*BW^_\ /_/&0R7F]7/;C\IY'OX-O3&I97RJ
MD=^?O)_G,?#!L!_>HQDJ(9'8)N9 Q%I)(7<!'/>('/;G&:I5=JLX5.#MN"!W
MW"3QR!SZJ&&W#5Z3Y:D:LL JK,N>O;!G;R94W/O]3.8*ENA2!;U_G^CC(M&>
MI'TK4N;"S"?YG&HYMAG#L/;D7''S'X?=SC+5JM+4-SOTF"2?Q_G:,+F\M1SO
MGB\[B+6#,L$\!I-^?4GOBAGO_:#5#<23-N.0/E^/:<+G4HYIGHTP/:(4]//(
M^UL62>FRKZ+>,EJB_2LPU19W"\6O$0 QC\;Q DD##-E30J;5^L)Z/:_B]YVV
M_P 7;%7-;J5) 1T*@['V5V\7^4'_ *HY4J_+1ZWC\9&,WY8C85:W((;\9_48
MTK,HH 9E!/ ) )MV!N?6V-7K!ZTB#8#\3\OAWYQ4]D?WMI.9\HL";,.\^T/2
MT#IYGT$'MC-57>HVYR]_E]W8>X6[=L9'4A0HM3*AY8$!N%[^A]EAN&T<G=S)
MP=2/7TIUAE,]@P(,&U[\]H[\CKJ?X1^.!N7F6[3?O\1S@Y:J8=4<B)W*A/XQ
MZR /0>A!PRO[,$'B]OY"_P".&R+Y19=2N[B>3ZW!:.W,3VXQDLC4S;L5DL 3
MS[B1R1R1'('><?0ZBJ25XF8[1W]\^Z\#B6@4J!ER)( DW%@)D\P8_&.9PE-F
M,7-^WZ^/X^F'ILGJ#W$W_7_;G&PQR3\3.)*]_NP;\W^/][TR5%C?[L4E:J\"
MY)BY_$G]>@Q6RCT6&Y2A:XN/SXMQ^7.,YDC1%,GAH(:W,W'/81VO)Q4^CY+8
M#2%5V5=V_A0P(D2& W&>E1+ $M,7J^3505E14*[25 L>H6&V);LIX,F8F5R>
M?%7*9GI7?3IDHP'>'V])+<;9Y@S$6ELBRULVFXD["&,S,@3Z?Q<^J\W$XSCC
M,T:DH5\O='O"S<$K'4)XW=)]\8T9U1LQN)5?+C<#LV@J\L""=I'\4]@>V$IT
MZ=.LRU?, 5MM/<-JCJ;M]HG[4?+&57ZJN2(^K?UM]62+F\01M]P[DG&ETE8U
M'<':HY^$DV$F>+1_RCF=4I;6IN!9Z:\38\Q<(;AK2-QCV5@X>ELRX8CJ/<KL
MDDQ,0.1[)(NL%@+X<_WRAA@1ZC\\:FU*OE\NT7*]#P0)A>F1!!;D*8G8>X&-
M2H;M(RK"&:FR[W.T';W,FXW,$D*;V&-32GGWHU*-SY:#;N"FR\'JV@J9#"]_
MAC,T5RV2 <@57);;*L1&U>5,$$#=/(W0982=,S*4J597"Q4IWGOM)M$0VX,?
M?T\'G&3S"T*[.1-C^N2/G\>KDX7/U W4^X7D0!Z_+\0/2>Z9I5&8 7_BAA;:
MNT==A/QY$B#P(O0S7E,?0]O6./=_+CCN,R%I-3'),]QV$W!@P![@PL1R,4M4
M\M%ITTILNW:X=>EI%Y@VW=1:0PO<\G&:S0KTTLJD1T+P+;8 BPCA>.W4O.;I
M'-4J(I=0157D21M W3;@>G,SVQ4RYRYZA%S[_?[^??[_ .^FS@?((L]5,R1_
MA"LOYD K[1$VVWQ^\ZE3)&B2")'(O8D^OKMCIL =TR,4ZE5 6D_>1_EW_P!<
M-4J9HP6-K7))BY[DGDV[\>[ Z(4<8K':-R\G"J<!3BK*W$XIN3^6!39>,28.
M%S343TL5-O9[_$<-\_4^Z*M<YDR22?7] 7]?Y#^^GHK')OVG"4E''W89J]0P
MM/OV'^F*&1S)N5.*.DO8E2?CA]+/\(^X8_<[C[)_7XX_=38.AOZ8.B/Z872R
M+%1]V*NFL>%CX8;3W7M^&&ILGV?\\"FJX"J?2/C_ 'M!],!6)$ \^F$TNK4@
MP8/N)QE/#I8 M^-L4/#N67JVC@=S'W3 ^[#9#*TK!5_#"9- /9&*V64'C#4Z
M<=CAE4,+=Q^>!ED91"S;M?#99!R(^.*N73L)^&%RL^TA ]ZQBIIJ,)V_ABIH
MZDF!<_/W8U#P^]%9_(1^$G'T&LI/-O\ 7$$&X/\ >,8VX\EG-@3BADF8=6X2
M(BWXF"?QQDM$9D/3\_CC(Z!UW$QZCT^'\L)2ITQ$+Z<#%6CO]FWPQYGT8;:A
MC'TK)!VW5DW*-S+O$J/4B;"XN?7"5Z;BQ&*PFWK P=.\BD:I])QG-7G,>113
MS7W[" =L-, 25@R??:.>V!JVKZ/19JN7ILLC;UO(5H"R#1.X[CV(L0(Y.-.U
M*IK+2Z[&/*SP9(B8$_<,:AGET7.[:B51!L[*-C]"/T=1)]O;[(EE9>V,YXPR
MN:RZJ.AAR-AD?-05]]FQIFKI6Z)4S;L;X:A;S/GBN7S/21;"Z71/MQ)]V,_X
M<Z20.W8#%?1ZE)C*GX_KOBM1=.1A7/LX88(_NQ><4Z0?YGL+C\?7O]WKC):<
M'B%6X]HB;]I_BOSU#":4@ ;:)'NX]8^.*&RG2/NQ1U%4J,+?J<9[5Z=$F:J3
MSMW+NCW+,GW6N;8TO4#F*:U"I61,'W>A[J8E6%F6&X./$VK&IF!00[1]KM;B
M/@;_ '1$'">':V8TWZ320;A0+J"$5R0FX!C:&FQ/KC1-4K+F5H-48TY>GL<B
M%*P$V;NN(7:$W-S/K@'<@;YXU34ITC,[3M84:@!X(.U@#:]O=?'ANG])U*6N
M*9FXCV/]!'R&-0U#(:CEF0TU4(D-O$ !5ZID ;8%Y[<XT<)D33VU%J^KHP9"
M=QW;"/LJTJO<  &XQXYKG,9BF$-H/W]/X\V[_+&2R@.5WNX"@'<2;6L9^Z,9
M#*-0U2A ;:09/;:!!O,F&\L;3N7JD $3C6ZK9/2_.I;-ZT]TONVP+M.R_L3$
M?:C&E>(/I5;RG15F0&#$RPY$%!'<CK8P#BK29@'# #FY XQ3SJYA0MCV_EBO
MI].M?:#^OU&-0T9%4F/7%?([&X/-O?W_ %\,,I7G\H/QYYQ']U ;<"6XDXR&
MFO54G:<9'1V#R?Q]P)QIV6#\@6QG<S2R:F2+ S,1$7Q5\2Y/+KY=-/-+-#G=
M 59$D&"';J!""! :74@3D*N5SSU&@PP;U@R#C4LH<I4D [)(N2?A.Z?QQX5;
M]X4RI 4H=O\ S" 9$@?#Y<X\6TCE]6:X/UB&)G:-BC:?X9C?M_Q3]K'A<+F]
M&H4MUTHJG_E7:?RQJZ'(Z]4"P2F8+@1 OMJA8OZ[9D>MA84*OG>6.+#\L>(:
M*T].JHC02LV[P9*\B XE2>P/?'AFJE#/MN,;A*GM,Q]YD?C\]:S^IY/-&M3S
M4*?9A$ X]X(.*6M:O6U(5#FB4W"?JUO// C&N9D5:PV,'VHLQ<^83<'TX%NV
M*57-+2VC?Y9L1R-IM'%K'W?$<AM+RXR.5%."SJI)Y;@=^?F3CQ3G:OTBCH=.
M8-VB"2 I8"2#$-#38]/OQ24Y;.*#;;5%[CTGB.W/;U$6QK%5JN7R^QFW>8L;
M6B^UOY8T;)?1:1J5:I;<J&.R](G:8#&6GGL!;=N+#5\O3J.N^ZG:?CM!_)AA
M73.V]<5M%!]#/NQJGAW9N8$Q'LP+?\I$&_?<6OQM'-7)>3/)CL9_D&.*A(PG
MK_=&V2![_P"=L:7IGG[>DGCL?7UX[7_UOI^B)2H21]D22!),<F !)^ &'C+U
M2L>[&9S+Z?2:JE.HXB>A2Q^48U'6J^<K?6ETI\&G.VU@V\<L29[[/+]E?,DB
MJVEU"H521"SM/5VW&6L7 O#>T0 ><:?3TK*91*BH>I!$S(D6!YN.]^<:YE!7
MRKU L$=2V^/YBWP./"&IG):AL8@*Y\IIA>JY0W_ZD [EACQGD?.JIF4"GH/F
M'OM]H$?\IW>G/S'AO7&R"&B64*++U7@_Q#X]P3//O.<H#5-?@7\UU)(O V*M
MK6-A$R >J_LX?)?10D?P_P L/D'U$%&, SS_ *XUC1J^C5/,I$NO-O:!%[WB
M#QT@=AM/M8=]0UC)TR,B>DR:@J+-@5 V]Y[[A$6[AEI>'LSEM+.;;(FI47LA
MWU#+0.E06BX)@'8LDD@3C-4W6L341E&_AA'$2>._Q)]>P%#4,K1HB5!,6[WQ
MX+S5;-Y?4:N9J#;0;S%D0=S+>6/4\ (B[A]530+.Q1MTDC5M1U'6*X+#+!4I
M+ ^WO0\"Y$#O8/Z%3C6HH:C7[?6(8X-UG]?'%.H^:\M>5H^6T AB78GD"2 !
M:#')L;$50U/*27" 4P228@!;S."CYC.,58W;VANXM%S:2-I ]!CZ77TM4\P[
MA"C>$*]HZI=Y)]1%YMC1=57.)'/6Y_\ -48G\3C-9%LPEA/POC/>'6;<>#<\
M#WV/N^$'T(QG-.%/<+!QR#-X].+7C< ?3FP8;3']S!L*A?@8TK(M5;8R=)L?
M^J9'J/P]W>-)TQ5IJ2HM';&?SE+*TSLBPQK/B2O4=AEN P^N559/@K0RD\ S
MZD"_'AW5Z^>TBK0JJ&JT^A]RINO=6(]#<3"RRO"K&T>)]%J)1.:*G8Q"L%06
MDMU%P9 X7O!(CG&F90ZH@R^7(H,/XKM9H)OVP,R^AZ:^5S:+7>C41485$AU8
M(X!";ZE-J:N-RNG4-CH6#].6S5#6LC)44R5(*2#M8$J1(LPD&&M(@P)C&J9+
MZ#G3M-MVY"MNXW ^D&(,1\P<9;.T\WY08S*+S!^SQWQJ7ARC545*"A+>S2 0
M->1:57=Z$E>;GTR&F4-((JV:KM +F[&W:9@>X6X]!BKJ52O91,8U35FRID]/
MX8R-?]]TV"]?2WO['&C+]!5T:W4W/Q./I9WD2=I[=ONP^2RU8$.M-@3,,H83
MSW!Q6T++NP*J@ ] !;TMC.:8S9=*64J?1$$^93I+ JF% WE&1K09N=P-_9&/
M#E&KI=6IYP786L9LXCD@S_ZB3,B-H4MXXRE)\]1SJ_;W,(XZ-D__ %8\+Z?1
M3(?3:A4L=SF8@3,*/</3^(L>^-=U4UCY-,]/4'CYA1^<_+UQD:CY:KYC!B-P
M/X^^WXXS%+]]94(L+(IS:\*58CXD CN)]<:;DUTQF)M 8_=)QH7BBG7#H;%6
M*E7VSR8-F8$<B08D$=L=.=)([@_EC5M)8ABH]<9W*O0<C:?N_7ZX]Q/J/U]V
M.?[D\H$V_/\ '&F9 U"HVVX8E6D^D6B+\RW=;'&FZ0E#:=L0!VC#9M<LNT$"
MT8UW.U5I5NH^P\$&(L8(/;W&+83.4/+RZRJ[*E%JEO;0&:BV!,N;GN;AC!,M
MXSR.0R_E4,N4W-+,!3 <V&\A6+DE0L%E#0!,1AM2R^MZ*>A264@H?:W3;X$&
MX(X,,#P<4*QR&I*N81DVD^R+D#GUO$QU0UKP9QG*KZJWD9!7S(86)5T *#?=
MCMV-*].XB\38X>AGM,RM2F'>FSF2:1>5&Z>EUV'=82UN3(/>E0S>LUD1:=2I
M49@"^V%"_:9GV[5-IC9_RJ;#%+P\^4=(,1'/\_>>Y]<50:=)5W Q'<8S%.HX
MDM;XXRN:HT.EH/SG'[3M773LHU5>FTX_8KXM34LS4I5&5N1<CT;&L5*66S$+
M40 L3[:CD_'%"FE:D&1U<_X6#?EATKH?M?<<4/,)$SR,9RO]'JJA',?EBJJO
M1#@J#'J,)D/WNOT6JPZ3N4EH@W[R/>/GC-UJ^F!],H$M /L2P]?LXT_*OG,Z
MJ.&N][6_'MC5/#F4R^22IYE)#;VG5;D3 DB3\/S!QI'^[T"200!SV^_C&M:T
M=]2G2>&NNX00/47M)$CO'>X@Y%:],^<E5Z1$PP4$$&]]WM#@Q\8(8V\.ZSYK
M,C6J4S#K),>T%*D@;@T2+<<@82FN:4R.<:SH--]W2#\IQJ&0^CL\ B".0NUK
M'_AD=1("2RG@< B, 0?[B%/;WPH)[<XTS3?I%8(9W>U$BZS&X"9@&QM8D>LX
MT32J.7I M%A-_=AJZYA"M.+6M&-??5Z>:;93J+EZ;(=RLI:M<,UIW #V=IVR
M-_MAE44#3U'+@6854X,'D75N1(NK"\&1C5= ?*/O!.PNNV?L@D "9ZNHCF\6
MN>:/AU<PYJ%IA1V]W,$D<WX_#'AA=NM?1(W4BM17E@-L(2K1R_5TV_CW&8,U
M= /TUVS%1*H)Z-JE.68G<LMT@'8 7J;P3N[8R65RFFY?<0B0IBP'KZ8RAH:I
M0J;=C<]@>YQDJJZ5F6&U>\6&*E=LUS8'":;EV]NI?XG'BTYC2,C5:EN!VF".
MK_/&M?M9\0:+GJ@IU\SM5C ^C5&%NT[/EZ8\3?M6UWQ9DGH9D%21%X'\ACP5
MX^U_P9GFJ414*U&B?<9'\\:1XEUCQ>5FMF.H@GHJ<G'@?(YO3 #F*]4R!9T<
M_G.$S5!A?;]V*U6AR-OKVQGGK9VL-J\8\5:A7TJB))'SC'@;5-/UG*-]-R]X
MY%4@_ABG^[\CFZGT3)AYD2[[C!'^*</I>9S.XZ9&YI-H!!/H>01[L9WPUKW.
M;-0HLL=U1C87$>U/S.!K:Y;2FRJF:IMP>E2QN6[$@=')DJQ4I)PF2?-TJV8O
MLI=1/4>KVH$B"0/:&XQ*6$X7/U*N6:DB$D#;8>D^E[ ?R!DC'ABAFZ6>6J0X
M0;]Q(LTVV#<?6'WA3[ 4&"V,G4G&97<"/4?RQJ^B,58[9^UQ\\9S+M0J,OH;
M^Z;W^5XYN.QQL*7QS_<#'@?H8R.6%79:2S!5'ON9^X$\S M?&AZ!Y85CZ S8
M$GU,0+XU7,/D%*JT6/!]V*/B^KD'/074-<[O?U0(/'RGW6FIXYRF:!6IEV)X
MX63/I+#\8PVJT\KFS6RQW>81O]H;MOL^T+0L[2L(TF9Y&H9REJ>F"I1NY @*
M56HM12I ;<;08+>JW3=*SELYJ&7S7T5$WU&A0K@WW6665H@ B27:UV>9QD=
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M#U+89[_/%5TJB($QBK0KW\H[?AC+4,S30[F)QEC7%0FXB^'_ -]L?ABE17*
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MJB2)5A;GO<>\8R5?Z)F^JUXZK1!B/<?=VXQI>I!G54,3&/%?GC*NZN"#38L
M1==MQ\QCP6N7;(5FS-0 ;F959^W%E(3:"06"WL=TC=M4ZMX>RV=J+6:D")@L
MP%[QSCQ7XRHTLC5\MU-C$,..V*'[0S3U0S4"CSEY:/M8TKQSDL[D5ZZ>[RU^
MVO\ #C3=7.:S3!6Z9];8>H0)YQ3S6WG%1@U08SE.44XH9DV!P]:<>5CR<#G
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MFCV=QYCW7B3S$VG&I9-:V1?+TV&YZ3(LD[=Q4@3':>;8KZ*ZY:E0J&2$IJ[
M<[-L@6![0&(#<-[6-$RZT%5=H 0 *(["P%_08UO+#.'9M!!$&W;%3PXJK3A
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M]1C+?LHS>C5J6>>E4^KVL>ANW./V7ZW2;+ID:JB::QU"./C\,9NNM;(U-O\
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M\*5-/SCU=I66)M;&5ISDW2I:Q%\'(Z91SU5\P*=3>\GS%5U%@ME:0+"_<][
M )2\*UOJ:+Y#<\33049:.H':.8]H6MSC_9O1J@E*>6X)_P"'3_RQINFKE:];
MRR!3J5%9:2(B)2VTTIG;M$R^S<UXXA0=[/K?31^1QJ33VON;OZ3>W;C[Q-\
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MM93*[E8&-ZF5*Z;D4K^<6OUK DCDR;6)FUF'R]=4SU+2=+IY#+( <RCTS"R
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ME:97S]5@7=.DL MR-JK$Q=N(N95>PQX5H>3J8U%X\M*A:XD$LKT[;O0.2?>
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M1&,D%@+&9*JS>\*Q['%#/T7_ (3\\-GZ*^F#FJ%:B2  T8\3"MF*VP$[=P_
MC&@Z+E6SPWTU,@<@<[<>(_!E#,:AO2GM',[?08\.9.GI%15+*(@02!Q[L9G/
MT-BM*]NXP=8HC,*JE3QP1CQ=XB&5R>VDRI6JH5IR0"";;P-K;MFX&((F 8!G
M&5R^<S.3-8YC,W7>2*]23(F/:(',V XCB0= \19G3LYY-=GJJSK3ZCUTR2P9
MKK+KN83+2M.ZK (QEZPS"^NX _?C/Z12S 8,@.Y2"" 09%P1Z8SJ?N75_)]M
M4<E2;!EC=!VS'.V0H$B0@'3A?$%)Z8HT$%=GIQ3IH0"S,D@$GV(Y8M<">EGA
M3X;TO,:<CU:I(>IM8TP92G$^S:),]6T;8"J-VW>^7SA+0?Q]V-=USRZ9 /XX
MS>K5:U4G<8$P/?[[W]T1[\/5\PD]S,_?/_;#)>?[FR>=.2<&?6W8^[_7G[S.
M5U1:OLOMIB&VS"TP!'0 L;2 21/2>!U8T[4J;!#/*J1(*FX[@C<#Z@P1W$X3
M,4ZZ02#(C[\:]X/2J6JT3L=CN.T=+$G=N=.&:[7L>HR<>&]+;(TE\]/*J]6]
M9!B&,75F!E8/M'G&JZQELCEO+HGS*]64I4U]IVN3?A542S.3"CU)56\G4*SY
MC.O2J%0C/4J[=^U!R%5 S"FOM'D*-S.Q@N?"+C]](S*IC?$@2I,7'H8)4GTM
MP<5FWYL#M'';C'C)Z*ZLE!*,'UWS[?!Y[%28Q5T[*T?#]/,'*J:C945 ^\[@
MYI*=UH:Y"R+;@-IMCPKG:E>LR/4+0HVJ2-UBP8G[1'L7/N',D^),]7R;TWIU
M84&&I, 0UY#*;-N'==^T@3;:=^D^(L_G\Q3IU/*\N=K!4<-&VQ5MY'M]BOL]
MYQF] I9O+^<Y@A2_W"<:=K3+JJH644M[4J82#)4V9JGJP4[521U@-U#&;9<Q
MDT8 3M^>/$/TFCG-YJG:6.T*FQ:8%E!,L#,]18]3>R$6=F5HG.Y"F16S#5/+
M$M](JV8#C8'\N4/204,D?6;FDFCFZN0S\5&9A3?:=Y;=$\D0=QBZ[?:X(#FW
MB^O],H99UOM#+[^K8;?^0_HV\);,QE32M[(4CTMQ'Y>Z#QCQ-IIR><:H/8J,
M#Z01 M?N!(MS,M[*X\':@V<RU-:A!<#:2.^TLH-B1N*@;HMNF(%L9@;&,=QC
MQ)HM;,9E&5)!<[G^TO22#?F3 [Q/!N1X=T=,I1ED&XW+,!N-R1+1)VS F3',
MWQ4JTT4\8U'4TI$@'K(?:H,;MH_](X&XV!('+ '4=0\^9-_221(O:8[GVH$V
MD6L#))_NAJ/FWF,4-V7V[3_E\_\ +X'MBCJ;H05<J>D\B&BT-9MI/!CJC;<P
M(R&NM"RWWD?YG&2SAS\ L/O&*VF&.AA<=B,9GP[FLMG?.JUWK R.M1N",V\K
MN6)A[IT@(I* <%7\29'1,K6RXI*V;?+5/*5J=1D+LCK3+[1[.\=4,IV^ECCP
MMDZJZHE0TF58:Y1E-R-L3VVCO[L5&C-WMTF"?^7&=\'9G4\V^=^F[B:C/_PC
M[@H(#7VJH6;;@+WF<QHN=S.7I9)M3V)3394!H0:AM?<7&SBP M)DFT:'X:73
M06W^8[ ;G[$@?90':HDDQS?J8VQXCT\9ID&\)M<$\21<$"38W]K&AZ#1RK(=
MXJ/[1:(^Y9:! OU&6DV!@:_GWR.5;JA50S<"9L )(!+$PHFY(&*V1?+YI!O%
M,GJ\USY?>)$+TE97;<<PO?&3);)TQS8#'C3)[*:U1;:RM83[OE<@F.1*]\>#
M2:NZBUU#- ] UX/IU%B/\)&/&>47)Z@I4CJ'':Q'Y[OPPF6^G:<I]HJI@F3U
M)(]YB008-Q-[WT'47TW,E&E=[ &9 W 1',2WK ),"6Z<>**R9O+I4##<""HD
M=1]([].YH[;=W;'A-7R=!"RLA:^T\B6)%NUB#MN5F"202<M_O;7_ !_UQG,C
M09A.VWO&-5S:9)(0KQV(QF==JD5$2=T>VQ IJ3//)) O 4BXF)G&<U!ZD@.S
M<@LUB9,Q8+\+ 1VN,%2W)Q[/]U&H1S88RU5)ZC:T&>_R/_V\7)QH=7.5 ?HW
M4 !83(/-S/=8M'OF^,KG,S0?_>]R_' SF3S LRDXS&FKF#*JK?\ 2#C*9$T%
MG8H,?PC'B2MF:0FE0KU&8.%-%-^Q]LKO4$/M)[JI B"02N[PJ_BI\QU5*U.C
M3&YDJT$5:OF!O+4&I2W='M/LJ2IVJPN1CQ7D?$-7,I6%2HU/RPI6E66D ZL3
M+4_,IJ=P:-XW'I@B N/#SE,C3^D-]=Y-/S9(/UFSKXD>U/LV]+8\4_6U^AX(
M>;$^A%HX/R_&^/#]=E2D+Q31$_\ *NW^6/$&9^D"DJJSGSZ'"EHVU5?<T [0
M IZC8-$G&M4<[F ,S1I4]M(!O6HQ$<*4"#;<^TQ/($])\,>(6S2_1'4"HBR1
M:\$@E0>J!;=V!8*&;G&?R^4U"BPS16/1A(MQSZ&,:4N1R%=ZV19:B5]A#@F?
MM#9L(&P+/!.X,SHP44U&/%6D9G5,W2J4*351>895@].WVV61S(YQI>DMDLE2
M2HFURJ[E,-#'VA(L8/<"_(QJ/A2AFNH#8QN6IPI:T=5NJ+;9N(B=K,&R/A*F
M!3%5FJ^694U&F_8L!M5BOV25)!&[VNK"Z13RP!M;&8U*GE9$@1.-0\1J;>89
M)(%S<_D/F1>W.*^I>:27>5:1L)#6('M23N].FW5!W"&QF,V:IYXM [>OQ,2.
MT \3C=/S_NN<4:1SA"TT+$D*([G&F^ LQFU6HQ"]S>WKR8_(8R-;3_"E(^=Y
M3MP8*R3QVQFM>H^(,P]#+4JE,E3M=57;P;BY/2?XDB8YQI^F:GE*Y&8@T@I=
M:XJ 2=P IM2)W!R)<L/JXA1?%'55RP"M#'[\+KE)[6Q%#-]3 8R^6H((IU(^
M6-:T-\^K(U5BAO\ -3*V/2T$ [6#(?M*PMC3M*J9/*&EYU2H%$*:OE[E55"A
M91*<@1,L&<DF6-@-5T?/UZ]5DS (+@K3V; J\$>:I=B8ZO9(+"(53;0M+KT\
MFYS*T@R"S4W=B_/M*]--I$#AGW&3T\81,]5U;9Y:_1%(#,[07DKN9(4L&62%
M5AL8(P9EWHR:]5.3R[4,M26I58+M!'3<K,P5X63[0N,:>F8R++F/H^65V>&=
M7<MY9JR^U!2/MKU)NK>T5=U!W4QG=.SFIT#]%?RR1R02/?;<AX_Q<WOQC3?"
M];)UIS-2K$FU)WH[A  WM38,Q6Y!#+<DQ)8G)Y9(W,+CUQ65:ABPC"EFXO'I
M?&:U!LMNO$2?3C%3QF];<MS$B!WCL)@7XY ]^,_K'G]1K!22;(RO,3:ZGD1-
MA!L&]:U9GO>#/X]O\Q^8@D5.Q^6%3N<,VV/[H@X@XHELPIA3;_MC0_"M3/14
M):FAOP)98F1,[1\I^&*64R&AJU165F023"D],G[(O$V@8S?C#,LIIY:8(@$
M@7$ _9D?/C@XR6FC/DU,]7<%A<DQW+"QDVG@F/=WQ4US*:"?+RBBH8,E L"+
M7)//-A)L9QGO%.8SA.T[5^%YDW!#1QQTG^6$UXITUE2JLR ZA@#Z]>X2)L;8
MR_B!PTWO?&6\3,(%^UYY_7_;%#Q+%13/>#V(/H08(/Q%P0>#A_$(JTEXPV9H
M5>''R.*-#+F^X' &3-MZX^B9(WW+.&R.2J4C)4V[WQ0T_)"J9=3?OB*=,6(
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MQ,XJ9@9_)Y+(5J/DU,D'IH=P85%K.I+1M!5E\H* 3N 9@0 PQ7T++N ]*"P
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MTG.8(+^6DGZL*H,;69V"J Q_A7IF N!3TC6%>KFZRT<SG%J55/U:U?\ =SM
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M &CC7UC-93,%HZZ1GNQ4AD$\V(G[\>(,XN?\(TZ:P2*1EN;=[XJ^UA?[6,>
MC"U'@QU$%OA>_P#S3C4P<[XG51>'4DW/2C;CPP[P.#S>V/% C/(O\*BWR$_A
MC7W&FZ1I^7VH3'FU"HD;T39TKM$[GK;IMQU(RLPQ3JJRFURICOS\?7D]IF
M3+L"!$7'W?U6[8TND'CS*3':]+:>P+'VX+ =##J820IN-N[&JILSU6E]C<&Y
M-R5!)$F+W%K6VXTG)KF,\E$QM)E]T0!%YOR>!W!AHZ"#G-)RQHFEDVIUJU A
M:VW8');J8>@$L8%U7:4'73('^SF<JMNV$"22?,IV [D;I@B8 W7$& 9QM9*^
MTBZR+^H]<4,LK:348#C*U6OZ[&)O\<96H5J<D!:C<;HM*\"T<<P 8DL.G&2
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M@>4#?Q-%G@7,>N,U27_9'*!S \H'[BK<>\@8\"4Y\.J?=F/_ *FQKUL[F/\
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MQ*JX@L(*P>#R+\&P_"W<8;^@XI)TQW/N,XH[D<^_%/4LYE?_ )A*]KDQ\O\
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M;T^5N_,$S\8P[YH P9!Y@]NV[Y6N+B/08R6D9[/JYI*I*7==P#">^WL+=X,
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M$5(WD-QVB*P8B;J\:5X'@ \!4^BW/FQ( ,8V191R2(;1N%ZN4OA6O8[;U?\
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M>23)(><!I"L'+$7Q1?\ =/P3N^#5"I4ZJCE'<%KE$;7X0[2$MH?ET!"]ZO\
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MHVW&C-\./'7^^/\ G'__ "X@78;(C(,:UE'=K8Y_T70Z0>EX'>=KBM4\,8)
M589!.,KRWQ=U*+G]9ANM=:_DX.M*D+'W([!AZ1$N@_1'_P!XQH7EJPF6E>S[
MW&M7_P#1PBJG)V-L",0Y7-[(QXB@:S24)^JYSA,L^#A7H]N6D8OUF.:Y81$5
MN*#6WC<<=(K%+J3AM]MY.GAF6OV6)W&W O$=(FQ>(YDBMI"EME1Q][RF&V=1
M#Y3OFDSE+T#Q:8D2ZJ9YQ<L6)'!\YZHWTHY($IGUL.=)!BF'B<*<2TQ8M3IQ
M=[+I98&S[T'O0?*FVCGVUK<?[YCBT\,MT I4. 1VDC.^4ZEPZ=41=9$]6G1"
MQ_U/<U7SXX0@JCE87B*C-+I]Y'\J0MY^PQ/>SX56ZJ7TO>!GFB"_N?WHOVU^
MTF.&:JH];) Y%,/^NZ(O][Q,AIRMG(73^F+>_P ;$B"^1MS;$AX?A=XD!*'N
MMHWC="]_O?P; G2SQZ<(C=3AZ2'EM_3"\#_:<:I2S)[M.C(ID %.IXJ;/;GS
M_CD+_%@1!'I$*'+5]A\7;,!)L^+9VB=:Q[OQ8JL8C2ZF3IC44Z:3N9<Z1,^6
M>X!9D9Y>VQG[KL)JQFGFQVL9M\V,\:UQEC+"Z))@7.UTRZ->,EJ$IZ.[+FN.
M7M_M\9/9_P"KA-')&M[3<*Q$Y85<L9^[JPJ(F7Y6.;\=KT/E85C.2?*P_J<V
MX[:YX<X>;4&W,A$]DRX(75^9ZQ! _6X]/7_TL=CS^^QG[OOL,1//B9*+U7@%
MI$UWZG!ZF&/%6G.(,H"$<(! R-UUMF+VWL?5L,,]<^T/M$[!/"^:QFU<<E]'
M'$Y(17C_ '.4614AA##+.?4:AU_)U&#UHUD]2LE[QWGP?597P4@J:44^EGMW
M:-4W220QONWED4^T:/LYB]:.IXW=9=[OD23M8FTRE<%1S&U>E'KY8C/JC4F3
M_O.*E2:71X5!946OCNF".2=/%"+XH0E,D8%Z0#N_E!(WS^SVLO;2HRD=Z>(9
M)+=3*9#F5++^:=7_  L440G*NN&.435\<P>[+^W-^^,_M,GM3-])F0YK?U,H
M)C?W6$G_ /TM%CRV_I Q0AQ3YC"6E!+CN<345G3N]:[]!8O1Y>%I]/>(&01%
M=(M(8W5]XE[H<_QQW8KJS9Y"QYD&1"AMDC&P+YDH117;H/!!']T$>-[?W5CY
M8938A(E5E*.[]ZC;EC/&O"-GX)NE_N^*',DKUC0-N9OY4/JE_P!<M<>;/M>]
MPJ(S)/RL:-?OL(KU[#6]K3@-8;JOMZKFZO@_1_\ %QK7T,.1OFPN>+F3L,T)
MEJPP01D*5SNR,;=9'_JL2)$>.<L>(WKF:,N@7Z4N%J;H9O)]S3N;?0^9\3]/
MW?\ G6(Z!3-\HHQ"[6C60V)#B0-"@%=T7QO?)ZF=L5G<QT-] O+$><$T$8Y9
M2"C-,<K".(*]]!8\86WQ(I$F0RG%B0]Q)RLRR-\&STA2,O:BQ4*WO&$?3JML
MBB%U!N'=AANB+_6A2/YK@$%9!8K-B^5<&&]KM%"$HN?@^-X^"Q:FTXY37]U<
MHR,&9GS@3>VQ7C[:0:5$<+8N'(&UA;T<O2LV?@Z6I"+YI'0BQ-NFZW*TBKQS
MQW@I\ASHDHVDDN7T?!Z$8R=Q+N+(,Y"6=VLI<<<"D4N/*#1C'6.T\E["-8/R
MBB1]W=1 "[KZQGN>LJ2Y#ECIIH'$<" R"Z945C2 L>30]^9@KTR\N6P(B<D7
MJ^[Y\1ZA&%"8PT4>H?M'](.!! \85)V7--A7FFQ>SZ.EQ?\ (Q,Z@U>9OI-_
M4X%35F.@E"[4TC?U-[V$GYK!25?BN0D-HM$5P=JSJ?KH$7Z;$H'#U0E5:E#\
M TMM@ES]3MOH<<3<:\1UV-IXWX9K'#]$X<&,4J]-UJ*G2KOX;&FQ2=!,_)<9
M=U-E[Q%BQ:I3.'Z@^DI5Y4.1,FPNA4^Z19H=J&HA[Q8^^.X_-9002X>U[UNI
M$>M\  ^RD2$T8?*OD6<^O4X!KUB 6K</Q]QLO6SP]QWK=F/+W?=NZR:O#C5/
M@"H;FHM!PU7SCKT1WMH=JH@2FSX4'JK'SDQJG*BV32D27\*N5^EV(&\V@*G'
M/%E0)A.M:LE#W@*20Q#2+$B+&D[7UR)%PJM\Q!=K'$TT"JR76Y5&H4$B-UG]
M:F^41A+['N12]XQ^/3I_>V6.>&IECS8/&MZV&BS&.;^KZ.(YG"M%HY9$<K?3
MZ>Z-9_P<<N79]+$)*R>%3YT4'DR/,U#&=GD]0VK3+ZG.&R6-NH^:<C'3*-N,
M\-I,&OGJL%P]3Q"4H8;.K>M;6](!XW>/-C=09"QC6WBN(T1.P7F7Q_QXKDZL
M-J\B<"$3R6V8(JL?X,NY3@IWA#9Q @58_K-WX5CEVE]+#R+TM/8Q>>A%1OI.
M&+7KP)C&$>PSAZNS_A8CT\O,6VT.=\H=KPK6#C% J3X;CDTZ:=*MV[N'D2',
M$+3[8!0?WV"2:[3VH]U2V*SI+7GCN>09I8@_&%0V^\]V1$4@%5?<CQ0I"B2@
M&KKIS3J+6%P(HTVD&H"LY&O[F9YSKW4)LE3GM^$AE&)0R +%<$C1V- B](=M
M?/XW@>;%3*]6.>M)#( ,@2H]OJD-2!(0&W=E;5+P).?>UC9.5).W^R-!"U61
MX4_B 01>EH9M2B3J<S^$(7N\K7+$A@,BGCEL$&WWA/+P2Z/J"B/_ !%3$$)Q
MM]'<=3PW^#TL0,H  K5H!+HRE(XD61W2\-?5N01&47+TI*IGMDCY2Z*^H(CV
M/J6W!U+&DA9Y@W2]?K>VD?S7%1W%A-_ (P6G--4>W#(++K<S=T[SRR6R94Y9
M8XNX;F5"%#.2O5 H+A;$=[ [3:/"2RET-^*G0C9R5]W+<)@0WU!M-MT^8*)-
MMZ[,@ONE^A3J_P#'>L089I,&M5MY6Y2HS>W$9=O&+X'1S",4"Q)VNZN[KX/R
MK+)LN1'?(2.Z(,$:^_6(1NJ+HR 7_"]8[MZOAE6J1Y\K,!(\MR=<\MEJR$9K
MQ_H@R/U..():PI9HM9*][6W!,>T92F,:[];^$XIM'IE-VD6F'NB(XOB_/=(V
MY.'KF+_Y2DK\>>*2BP1H^* ;7.NZ]1+0?H/HL*=J-0[G:A.]FS$>'48[%*YP
MQ--J],GZ+#$:F:.;J]+ LD<_2[3IT^@,WBXF<-G ZF4JCU8D?:.:5Y#61&"&
M5=[MZS=_!?;8LF)K9JU-N>]QPU]CX-34M-2K$;3(YFBL4XE1+WN5^$'!XTC;
M[K\(V?K. UFI\/T2GQ1G'$!+FP9-9/N?'#:O)4I)9'="R-QSD]'SXD IL.O5
MI1*.S+##%!I\BY9NY$FGCSP;>Z2/WBF)WD7N1>]X$G"W#,(':ZAJX<LZ[]$*
M)"/3+/\ .-U*_FF-IQ!4A%I:5'RL"G1Z?!#'B$49A"$$H0^4# C!F&C]YDRL
MDY2]U+[UBVQ_5U#T_EC^=^O[OC@R(Z,J&TIQ7,&YI66F&C?>XEWVIM[ET,_9
M2%5,DYYY^^_?2<\E)_A8J=/>_,%7%= WZG"L7SM+IPD:*!\@SW:1L8W6]V#9
MA)3A 3M&F1RLZGA6QB]J;EYU]5\WGR3&\<^_+8]^F=*719&1;5L0L[ >CT+_
M *RZZ=,T1=O@0&*ZHJ_M$= +&.,3+F7B7DZWQ P_R7(CR(DJW*&V.43QQ]W\
M%Z/^R_FI@>?SX1?8:NTW#:>^*@GO:-FLC?3_ &^+@8 RW/:80@OY.G%V1:T-
M=IPM/B:+#6]K3B?1R!,LT\IAQ26NZ;6"RM1OVDL_Z]<!I,]Q)) S1R1S#$UO
MM[4H4C%Z'5RNF/N)$GG[OF3%"J#(D>.>E=832.OC*2Z$WS,:19Z/]57GAE12
M%%W"4T].<FLNAXRRMV(G]7Z7\ZZ_JNX[K4)$*4R*M3G2)\EHXT9X]P8GTP),
MC"TH<Y[(:KEM>EIM+D9?[3D)G_$F$OOYA;:;AF^F2I=I-(]P8AM.:A5;5[XU
M$)<"&IGJ +B6AN=TQ7O&LBPB^^PF?OL:T7EC\;<+R\WVM:)[W":GZ,)V\[>.
M;_1Q3*>SGM3CEN_*'=#_ )6-U+?E;;I:UN+;UVSS=*&YWMB&Q%XKI[H[(=0*
M,4QP_P (AQ;/S'YH7#-6!5>ARWP*G'W#02A^F'=Q30RV;_T!2XF/IO$=18E1
MF$FU )S;X$Z9+]<E2XDW<QYAY/PN1(C=[^&8VO$_V.$I-0<I'.K/ U02FZ+L
MJ]G#HDW<P ]#NW>MW[?9[7<]VJ#N%_LAQ)M"I6<^<T]*JD6NQ:8A.7=308P*
MF8 +T>7(CIRE('.)%\II%CS/)^Z2G-E$V8YKA/F,AW>D*84((T<Q['K>VQ2:
M"Q6H>8?4W4[I[</?#?W1L3YN@+((P1Z-1AC0S'L@4V3,N7QEY9WO539\V_B\
M_P"^>6,_D=K$>L0_'I1]QV?T1@X4X"78=2;N(;F_A%TW^4'$60QCTDQCW];'
M:-?5ZP?^SXIU29%DRP5%O2<&W;C]A%MF)GTC_0^?I2/P?#Q3IBO"\C"6FB$Q
MC+5VUS#\=Q,_XDPF0<W_ "L:\]/Y.,G+BR)<DU#=JQ.(<FM@RZ6M_58S<1K%
M=Z.IV)46-TCZKKG-]\/K?YN,F_HG?J<,1?.W'H:,*KGYXY8RQDJ9ZL,R'SU8
M[6.S\K"?%C-,9E]%V%47-/DX5'CPS+EV</5?>XS$!Q3M[3M+<:W<GM;Z.,W+
MEIP&I@#K>R&07[+"R)A.EJ[+?D8F1C11R4' F%;J\1A Q>C9Q^YM)Y/),69(
ME-@.N]@ETW_>S8I7#+9@*:VI&(+>2&ZV"LQ3&\)>1C=+;Q *J))E&!%543GC
M[T<2T20EWDD\$ZG9C^=Z :GUOS?_ &O'6X<G5$&Y( $FAL\LCDV?A5J'N:@$
M$CX+Y2BQ<*.K4>H0%ND$YLV'*B=0/C"ZP/'Q)/1I1Z3'KT&133%=%$]DZ'[8
M82S0?!OPB-WJ+A5RSU-]+$WC&=%W!H\CR30VN$4C'U28@O-8!)D>I%+ZO[F(
M<)BZVPXT>.URMT:K(D'K_P"DB?OKY6$RY8+'*QKPG;H<-WH/Q-HFL+I5#;J
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MTPC_ ,_$^I+IM&<2()Q&^CX/5Q58$N>..^FS"1W.E]C>62F#=#9_185AZ]#
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M5(L4Z\6L2Z/MT7:4W:U?G(DQ8M)#2$C56_)F1XG!\.G18-(?&J14,8-J%MI
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M[R!"KTVBOI(>%*,!6T^G57:&E"F0@1J@:=)#%-)^^$J3$25,.B1,MJD4G'?
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MREC%@"*]PA'X?IY'?.QXA097/UT41UPBK\G'$U9:O7J%>%3BM^CI, ,L/_\
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M<NF=3XTEFA!E&40C('RA#22$A8ZFITJ-(<G9<BM54P2MFI%*H\HXN^#I Y0
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M&*",67%25(TJT#I<=KG(LA$_@A41<9:N?HZEQLG)OZDYOJ@7>%^EQ$CT^GS
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MQ1"JQMS?/8$;N^Z_-/A.)%4MRQ38#-<VCAM$J 1W;-VS?\#PO=]MBN26#_\
MS9=2:<>CO,,@[T@HL^B5>AXV\WGG7I4_^/"NDB2*5'=IH^NQWUV(YYL;</A]
MH#7/+_=8. \:,\$@!(Y V!M[N85DHKB>Y9Q,'2N(N)*151%J%Z("HA&#OG2B
M2MH(*7@6;*2I'=9>[$?U7NV3'K6Z!5Q-?=<.M<*P"(]_S>?>9%G\4>3%RP*3
M/^QW1:JK"JZ2[A.HU".]F1;(OO=M]P;QLTVVZS0)UE[9,39I.!N/*<  KI&!
MCD.K1I=,?UV?3?-;3U;=>=/CP$M-X>^RD()Q"D1Y(.%]^ T<PKPBB)Y<ZH)
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ME&17+E@]+HO E=%6=M47QO*HD#$!+B1CN$D\IMM9"XUF.O> =Y+M6R4=VL5
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MI(L5,5=.+.-HU @\0%I53/P]2XLFIQVOB!-:@R@FD4P$+R;=$FVC2:I'ERP
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MD14J&47U5V^]9W*[5\&3H1=)&BD.%>>&[R(],_=5,>2:M,).X;KH&"%+,+:
MC2<H:!\8\@!O#-'Y9+@7&$)7GC$48C[8'J) RKPI190?P@YMO^JQ&=TTF4\;
M(4H.[&<F84LWE<GX0@E/S^/[7F_?_+!*>(S@5"JML13M;KLDYEN_L\2.,*@P
M=QS7EA_0QMKS_O38614(R)0.%SR'16N]K(#*"$/A?A(!&D8LU2KTZG2&BW&S
M-*$R7M\EZHHBY2# S";KI&]B;YA<J@ 3:;5:APW*=#EI(@7#TR0JE11B+-CI
M[:*7(T95 JBY+RQ5Y=%K,"9"/*CG;3^(B%@0*3#$IE,D24$RQPYM(,&6VC1F
ML$!?@VWDHF>29\^7I?D?TX,=,T:7T0HN@;?^K")\2?<#BTRG&U5()1>6RHNT
MA$)=MB#;YK44$,LAM]&LZ8,DE(LG;4T]5G/GR)#I)F2"3-\=8^Z+H865JD+>
M\3,"G<:+GM<HVWVL;G@=2BSHD=M9*IJ@E2JHF)$.0H0;D48RK.-$S+N,H\>3
MM+)^<>(D>-B@4^%4(1($L1XY9 U\FQ*0.)%[K=BG$ED,DUJ-$CKEM<5TU'XH
M9Q0+B><R(>3KN.B2!"+>O&#-DJ8\C="W4CEX0,T\V4JE5@D1X1TS53"2&]0Q
M)DJST[ .?BEP^//:854BT:.YK@$Z[MG!]M]#BGRZ;564JH4JCRV52$9DB'4Z
MO6!0;HQ"%.%)!G(FWEW$;=<B[1.<;**M0J,7;@IA[2[=LD\HJPQ!,4HA W*F
MS_!XV<GE\?GGI2DGV::=H'&DAL!D^,HR YYV>FOC)&EHEG=14P=LD(Q06^$Y
MOO\  Z33X9)PF/EAJU08TS(U+D11].,4B@LF.<O1TI(S;DOGQ(W%A8OL+?W5
M9IR4P+?+4F;*=,;'BCG0'RBH<(:<4,<"0X5/,(6T@)W;(2[M)3I$I3MI4_CC
MB"106%.0='CY1@L:IKP+83R*A!O .0QI)_)O>GF\T?+#RL%$H['(<X(XWOEU
M>J$10W@1=X=\Z8N>T8N<C;14L+)=&BLS2J33TCR6&%.VL9[)&X!(80=ZVA=,
M==Q'2UNTV_PJ/DGI+B9"&$?E 75ITC5H(PEHON_K<57A.H2==6AB)"+<<6YM
M]J':2NM^?7OJ<&HD]Y!@<<E..FD6@MJ4':%^H_OL-1.>7\ .>]>PUNK^3A]*
M@JZ0K3[2+9[=F/:#>_;X@T"G.TS*MKB:PRA1)$>/TKQ/ZP"['P&ACHLVF TC
M:2L29=\99AO&O%V,6.'KWL5"MQI,F!63P;36N+W"141"LPY,S,,D]E0C#'DI
M&RY!24B;O=;J@T(NWI#Z/33!XGJPZC(! JY"<*^4;DH<S:@%"IY[>VZ'>Y U
MJDSO>>VALE\4<05D#P71G#56+ .R9D4)HH,I(;".5),7O$EMY4(KY"+BL+33
MEVE3/'*&$YQGA@L -4MB(:08Y2G4I'/D:N:(%FGH)G]QFO+&B0$1Q>?08;",
M_P#-(F6!5J#1H4*H1PD  L,:16#&2[<RC TQ[KKI1J=8ZR>TK<]/+[7EB5#B
M<2NUL,TT:;&A@2SF*(S:2STZU8LBD[;O4?-><J4KI.?$,Z=1)=.="%>IE+@B
M&X!999(0F'$##W-WN0BY[?+==#O<2)BC5+B.CD8M(".<<.USGI,F24RNA-EU
MMP8?K/JWQIEBF\64.MQ:<YGJ,N1,%389;1#"^&[?K^*#]5A8)RT>KLCG&4Y
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M_$(IU#_JP:!*&M9#$,"^.O0()]:^Q(L;O$=?#+I-Y\\U3\52IU.I XT.K?\
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M]-A56!463;CH^O5D6ZOMXV&-EH)[D'I<4;=#'?JK^$Y9+]M[,\LVX>M5F!9
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MS([]^?Q8KDZ,K6R&QV-!<]"Y=3__ #B37BOR2DM)%$/3Z>[$8)L22(QB@X=
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M,"\BR(07H]UT<\17#*/]*-#Z?=Y;=W(J+YPY+"-4 A/(B:'L73J8R1\X+/\
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MPMV+$V7.&?NFWO\ >4E)VLE=(.D5R^40JUOI702F$^I*!#%_H3$>=&[8B-U
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M9^Z?3:*;3*%-'.VSSV!U%D49<H"D\',QB#-&W&49)00*^1&1$>T7!/&=&D0
MQ9#R,G"3,\0<LMZ[+"+-)L=3%-(W$>0LG;91DARG)GB)6(>RJ8%4CH4Y@1OT
MVBVU4!2MS$MX7N>?+#ZK4R(-K7:&Q]8V72=7_*Q4?LE\2KIU"(^,0GOND:]*
MZWT!?V.'@B$>\1IXX\.-JUC###T;O]9M!D8B4R,C6#C,[6ENC6_^ $7$VFHC
M4DN9JB.=Z#"?\%7!>'ZL($0$PNF8/J$VDSP1(*T9>LIK23/6OQ*F!RW5([/L
M?<4I($()7$=$H=<+:E!NBR7HGCQC1XLE$W&VY5=<J;O)7+_C/!94DC1@ -Y2
MD=[QB<\5B%!1KPQ1P'BF"/K21O!WO"RS#8M65YJN>?.-B Z7&C29<'6Z(<X1
M'-#>5!WMH4J+8SMIGM\O,G],4-3)*:V=!?,B2P122H$BWDB1QR0YW#+K1WFV
MS4*#<R8ZR8R/%(CD88)F#,(PE0C"#(B%&0947(@U1<T5.2IS\WW3Z;4VD?%>
M09,A$43VO%YE0B8HTHL)TB1P_$CPJ420>41D<44>0B)$O)!?(3\)VJR+S8[D
M7./'5GV@1ZO#;-!&D,E@&XA1HDD3"B:JV2AN)D5R*%W=US[2*J-RT1PC"/SZ
M!#8QG]@TRQ)(^1$6C/ W;14'HD"E)93-<@(A1+U?A&:=%$;Y\OM(257!SZ=;
M)G')3HP#Z\^EU09>9.:F_P"CM>UG&^[?L'N :JU"/2'2!DT/C@*&5+,HU^4<
M,-8WZ_\ %@E&X2J!N)CP:;Y8JU& "=Y,:^4.T:]20SLRGC \GFC&!E+E*:$G
MF[LM]R387% X(W2V1R%#/B1@RK2BN%!(H\T-XO*1MY$K;' B[7+;@'2Z>Q\>
MFQ6'=D624NE"JIBONG/F&^=2FZ/=M6I41F$H4%=?#U':1IR-[&N.&R&9XWM]
M\;_1<)PI"Z4B2"/M1M_!Q2KW^"7#N)Y0G,$@-$5SG>E>*$Q?[K"?B_@'X\1^
M,J6T:QXKHY93;'4WFZ];,7VWBB^IP*GU6+"67.HJ'B%(&X"#4"P?O=.%RS":
M/?SSC^;KQO-GG4/L?<3G0,^E22#X?OL+';.A@*8,L5.*:/&WH(YA;B(JYR9$
M67FB;6/W>FJ\[A,I]1CSW"TW!R+2KTBC7X_<-FNGJ\N>'I#B1HB/YO;' (&K
MZG+#AO1%:1KV._&PGGQ%ITRE--$AD(>,W<S6/CO-S+:DCD;E ES3./N-LMH/
M8[NS36*;2^+"S@4V-JF4IL2RR2=9!HIA%N&4+C45 T[5-BIYY>T[JB202?WK
MP]5:)4ZK3QQ9<L4Y*>:2".:[LRQMW:*@7<XI01A2>2[@^7NXDT?C*4+B&JPZ
MSY3!!J@TN#B)%  !0B7LS QY"RFR4YK'4_>TR/'63QW$2@1Y43BRLR!O;5(4
MV4";$F2JD:(.(:%.CQS;F%4#=V1=ROJG=Y<:3B.-[!^59_?:P=K-#W.]C&ZH
MK]FGAZ"!_"+\G)%DNP'@J@W2URM]"5M"ZSQH9BV;5D/>+\GJQ_S5>?><'KE3
MZDX\=DNJ'LV)=SV,%!KULT#EN_/NI05EJF'N"QYC:B-$-SBO' C&O>U^M_!<
M4JFYM<^'"CA*YH]&H@AI=_;9_P  \TSPG+$B%,;K$<!&E'_B8%3*G4)RTX@/
MO2[4/:>+#*(1?YL#N^*9Q-PV*'*XIX>D,D4YD@A'0YD=;K34\F4V* /,NYW*
MYNSB;5%CMD]FH0JC =2J_15&*JQE;:$XI2'#G'"8RS1+'+%4,N/(3NUT";E^
MKLSUHPQDJR1G[%A58@W2/>YJ3I?V\OCQ'G2V#CSVE/%J4-C5"Z%/BE($L8T4
MII$B.;PS;<[MPC3@5_GQ"D9!MFJ<2-)>95Z44JD4Q1-3Q#((?)O/W5RY98XD
MKE5@B%4)=8J*TV1N1F>M,DFO7$$%; =ROYO%D>,BQHR.R=2J'3*N]D79QX]2
M@O&98G2'+J\EEHN0=Z>#9V]0C_."BKRC2OM9_O'+W,1EIX8DNL3S: !EDZ,:
M,/F:26,(\<Y\\DC 1'1FJXFI9.8=M)A/XUX6; HT]ND<J/2ZG33IX.<H7E,\
M@$P(1%S<"/[I@+N]64:2S[)' -0=*DO  Y14TVLY=M&VJSJ3*";OE^",4;R=
M']:2_P"M[G:X+^["2>35Y54ERT9)E#FGB0R61"BW1&D1DZHB'LQI#HT=)&3=
M*)MTYNW%8E=B' %V]9/G3?,] 6)G'O%KLYS^O":3IL>0M]3%('V0<BBQ*H0C
MC+1X<P8A1XC>Q)F6OGO6/GL"4[/OI+ZLPWIZ26@]+'/^!"4XNEC]>L!K=QXB
M6BI_BX\@5;4*GFF$9I)<8-G=>B7Z\6WQ4_LF</2]!B"B%KE,(H]C5J8(D-Q4
MB=#N4Z2@A@W_ 'E$:<TC3N<1*E3I8"*4 B28K#B?(A%*-%+&E"154)8ZKI5'
M9<V_$O,[8:#@%*LHR&C@'V9DOQ92C5.J:]UUS]87SZO/AKZW.DUTK6Z&MF]F
M(+MIU11$Y(?W+^>>6%QQ9QQ*@5)L:APV1*<&74Q !4XFY-NAB$&E2%V/PZ+F
M?=1Y* 14D)*TQ:OQ3&@51T>CFB1S1I !1GF?,DQ I8,D@T(BIND5P-SNHV2;
MF*FXC7Y52?1STAH)BQA(\^[!+8C NNAE6(WHFNQY =NBL<Q.:YKA7B(,C6F(
M)7,<CV7 &4!F<L^J PB@7W4.)45$7E_RQ#&>C!A&0I'N]XP2*I7_ -F N <1
M6R!/*!6N\4;,D>4?Q\RB^LQ*X7X@JTL_#=<'+ETFHUBIZP")=EU%913'-8#+
MD'-*A57U7>5,D:7EWJ*F.&.+!1[S*9-VTW2T8WO'>%+AB-)M.,@%*&4'KWXD
M=9"KH:Z2Y))Z+&I%39/,2$8!YP(%B$4,D13$$04V5(0MF["SL1W;<\C/\&=1
M+XC"<59\H8S.+J< U0.011"*)+0C@RD1MOW:4TJ2T]:P6;,(Q93AOVL*[U#$
M_18?]D?C1NUAF:0\>#+;H[ 2;2'O+^7L _@R>PPE#X6.Y@7=WE31E]9NEL[7
MH_\ '6P+B6N(KCD!JC0"#] ESUK_ (^>_@;G@\B(C U0#;HB^A<LDO<_VO\
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M!_-I47P<1ZUQ5&21-"09:="N%9L/;=\]6WOL?6=UX.$:U$1$;EI3^"UP^/4
M7'.:]C2#4;)#/T13>;'E"B2C/BS[;'2 IK(+\UEV?'\+S]VQ$HW&<-E*J%7'
MLMMI+MY;##M%%=]CXOX3G\6*-,^QU4Y-7I;Y9 U.C5NJC2FH&4Q!>4[<+:@T
MQU"F9HT=:E%M 2+$EM65%5.$I--E"*>/N:?.0@GQY0]J>4:X%<C@$FU/'U(D
ME''%Y@=E<$/3)D><$!GQ2&C$N#;(&P9""N?B0HL\0N)%W+*E!B'A-49G,CF
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M$5"8B7$ DW/7_P#>QRO6M*<+Q%S0B),$-.R.RG/>]4BN7.688D;FB3!>Y4C
M<9'RO;"!(%P#NUSUSMM>EY_.S^7@V07T90.XWKI.-N8O9Y71B UH$KD@ =90
M2M@8!-R\^K/BE ;(5 0-T"K3.:098SETPBO-)/S>9&?FN_ZH+B?J#,Q-15U#
M$LS8!<-;B:NEE1U["8YGQ.TWRZ,$F0:G*&9V6,[S6ADO)S&TZM*:Q8U 8!#E
M4)!BD7K;B 90(K)7(0V])8M<^IWT2^A ,#X?^\E?RX'&952-&YPR?_ 8 &57
MFA_>UL1E_O9QJ,CR)9NPPN8E@:5M5$1!F#_<'*FDM&<P+3G?A;BU2%#!S!TM
MB9JDNGDK"T]F(++EEIE4"X>>W<TA"\-0)9&($;'XA0=C,C% 2/(GA311$O[
MTX.38S8@CG=31OBC-QJ+9WG,*")UX#T9KP09& G%H.*7("2)2?R[_?@12"(.
M4Q V0KCF+@M<L#AE, 2N I!40Q(S#O8198-ZG^1**Y&N%'T"2023X=>SX$$)
M<1*"Z8[K>:&9%T7)H8(Q D'\U D6^>H%.$B;?3R_??[S[Q%S*1WI.\X[_P">
M9?7%;A;$6*[#"*T$9Y^J&XGV9CF6&Q^>_A+%H?*[GWS<3VG/9Y2>LL>V=QS_
M $8:_C[R?)^D1AS)7)8?>PY_T4JA[)7ATB8T87X%"*/UL>]+"G!U5F=*1\WF
MK!P/J'?;"WU()8.(;4YQ]>XH:/5";L]U816>;)R?"?XE\69UGPE ^1A'?5^K
M-HTQ#SW]0H P5/8BVZHA9./-CF+[FT6B'7Z%/#[:5\B3\NX@<%79#OA8?;!(
MI&*8;%.ZSK<3O#6$U>]\>*S0,- 98N(%]C#*8[AWS\GZ=?4>KZMJ#=[+9!-J
M,TN$OTW/OAF'0R? _BHO'?E@Z:]<[_\ C>M/GQ]*VOGRZ[;7#TBG&/KKRDB$
M54J\F1%9&,/F2F; H<GZ*>V+Q(A=)<,&C_=?4LV08M@6??T-IV!NL%$7AJH(
ML67NUCR7QR,F!M1D<(DK\K(@O:)&3;0=UQ$$]4OV$^U 2I.,5Y![X]#T!<91
MW#,X0:*I4D%$;LB>)4,UEJ*'( G3OMK3K[.'%C,T;N1/M["6)^G'VGM X=@#
M?P_@  <7KAGG"1),5)]1U=<U^T'\3.5[,QG60V([S\[N01%T1D:E:?1GZ),W
MAR71G^P88'<H,B:<6!\$V4JM(-PB.!$$"6+]-N.VL^9Q,$E^I&1B-,<N#BZ;
M5EE'@(5ZEN,.(7>"2> $F*(?!M L<S-VR,$+)"L#.M]GG>9.( >L)G&A,0 2
MI<&,L5R Q/ODIHZ*%_LHGLA;B=YUAXBU\(YD:!<G@K.A@0E!\VSK*(UJ<@H>
M6!P=R!C2( J;O+.4>"1@D23H9<&3HGHQ[MZAK\(_8'/BPUB3-S%?\>D1O/Z&
M;'2TH;#HXS1N /XA3J%FXBVB0/\ U4CH,\3S8RO5XD0W*&:1-0C2:&&?!-!M
M>@;P4TI\@$K:SDB9QN-D#M%)<K!JC+;7&VBLJ]YE<C)U*ZIR-=70XC8(T[\V
M\7O6]!$L'%C$DY*)FE>CD94VG''*P+9D5A1'%RX.$BK"#2+Q1S@4* N/08P"
ML$HW$W)(B,Z*F-33U\29)K@G44Y \W >0)'S<24D\7MD91",R>;UJ_!MX,8^
M&8MB1AA!@DBRS&15I=;0VL* \<FX V;Y^RSBX6W*X\A12+27@-.J.L%'L=M*
MQPJ*PZU8"ECYBF=<T?0FDT[GB/ %H-T5G_069IC=*(4(&0-(S7G_  V\N0QT
MISN8(]70!(I[#LXOTGP\7*'(/"]&*-'.I%!TXT0C:(NK]DFB1I< YB1*&_3D
MT00)=T"5_KEQ$EV4W2G1&\>RD[\@-/O2<6;/#>W^TIT+*<0ABB-)M*"01!YO
M)Y%80P(]'H5",\R!C$MFN%X%&I=/R2H!]6H+G*5Q,^KRIV1=NE/^F/O\G:]:
M@6"S*HSIS>(=4Q=:K037-JPSFPU';M"\*G*-4?<-=N!J2LZJ]6<CWEGW78:+
MXOZY(33OW?CX,\LA>U[=6P),8&3LV$>'X(@0Q8&P_DVWB"@/)'.)7PW6*AP_
M@9\ =G)W?16_MCCOU:O)J U.*'@"0N,*))\72-]2- ZO,:Q(;T%6[9,NIV64
M';*%V$LF"1;!=%)<_(- [+EFY2@SH;$$!F JL,+/PM!X59"1JJ+90&>IC$(.
M2%FA7E#A@AKPE&9+IRM7ONU?JRE6U_4FH:23>!S@Z"0LQ:%FLYWBFY33JA!J
M00D%<-BJ4CAX4F&PEEPAJ@L1U-!#X&9A$< HR%.K11KB.FA8AEV^28 2?9PM
MHLT<I_6W 8ZR #PY6R&EG!J:G8"2C:ZE0^3)\?;^!H,1J2XEARATR )MH=CH
M*@'Q9\9$A\2?!,E0H;.=P,G_ $R:I=EWG/-YLNJJ6Z8H.D$.3*=YZ*2S)G/4
M%_'F4H:JNE@ZOW1>U,F%3+@#H6( = Z=M?5E9WZ&7DCQ_M-#-^'M68&_I%MI
M#&F**NFUN!*<0K.<YYT8(8*UR9=RST>,<Q7P9'8BZ5V8H50]+L30H:L(R&>+
M+' 0YJDC&QU(&JGB2II6A7QUB3T\B*:9TQF(BV&".33$*\C^!_D_)<=6?@/-
MEEV67.ZW_B\*.9#YJLH!(&R9F3YDN(!WAP 89+EY,ETN QH_.[6I=D,T(JR#
M7:DAO3&>DAQ[O:CA]+<VBD2?T8+5<+,H]D:\^(]?LRL_H:9>V/PUS@%AP*RF
MCB_T3/(5]'#M>'2ELB[;X&QAK2(J9+,R88GO98X,*3RYO0&==Y_J$:IY8A;Z
M<6LQ-X;@/EV;QC+("(?OA/@G!YY'GT.ATB-;9\8T@%2]&P)]1 DU5'BS]P?-
M#G:@QP;F*=+=/E$WN6S,F:OH(_JLW$MEV @X3%:JA '$&AX6A9# \@"_KUJD
M-",/%V@Y1N?=Z<=L-$?$7J$J.C=5%[]6'8_$Z\<?3*-/+F*W?J]-VZ/ZY5JP
M(/+/!O>+1%'9WRK<&+SEVC0]\GTB^2 L?U-,JN"9&LJ%(O.?;&TOCX^BDD'0
MEP9$*,L@4MEKA85>7U"IG)_>69\ <_,%-![>_C[2H"JG/RZ[MYDP*(G&F[$+
MGGA(T?U0F%Y>S*:P*2MKUP0AHF7BBNG"OIOEG$8YDQ?8=^2T0OZ[F<P,Z]:\
M)%+N+4MC*;)L^P94J012&/\ 3YVY\D*3%BK)9OJGD>61*;P=+#K'G\1.E,49
MEPXK.E@G$IE-B8$T<G,_NY'J@0!6I'"^38IKB54JON^C%7;?/-+H>IH$*T3&
MD>428*""FQDMA^U?T+5]G[9/XCXT(!A[:T.>%2SMIS@&7@K]OY&!]N,#=L1I
M0=>]D&74,M%!@,B%Z8 *%8[4)6$A_=.(2ON,%?S<4R=3*DX"RD'>A9-?X\*0
M0!+VL&9:S?VVC2"V[E,VM@TX>IZ>1_F-I$M:2\(/5E:\/#UC&%T<D,<WDFA
MTU@&@H GI&C;/ H%1Z>OMM>AYRR:Z\]LZN9IXO[4_-] Y>'H^D$:L(3 M[YO
MIZ'S=GT\WA1VR/??^)PC56K4"!#R ;<RN]368[2A:&/1B-8\K68-U$W00/WD
MVQ5E*66C%\<#% :$O>J$)M) :K=9/^\AE_C>%3/:*U,EV(:B&U2%5:JA(:FP
MW[P.VO(NN@/L?-\".SF>N._O[K9Z;UW'(J@)C5QYRPIR^/;C!3$"T2MDMJ*G
MI(:&&G[?E](/*?4KQ@\^BX%RR=?)\*(06*JA )N2&P0, (XU&\U$2)VBW *G
M*3.G+*.$'C(#)RG"ONG"Y59B.1P/!$V4?#?B3R_;W9E$,T* T7JXV1G?4B4?
M7T6&_P T_P"W9Y,VZ5/P>/GI-\3?7Q]G[>%+;ZSUOI!DK"+NQ U#-2N-HD%P
M8K^@9=M(WB=76'$86+EM WG@EA*8,9IE@*?D\NER0_N+^C/C[9\<_2]D&BD
MWL/_ .*%6-IDCSH0J$@9> ,#)_0 '7KFQ/ZJ%6\@2-Q'[Q)L<*539" )FXTN
MH\*00SU29?2/#6+,/M3+^_B;J'S?W_AV[ ';7_7KXE@]"JFA=V:> B:8,7(3
MDBG25T[?33RI]B0+"Q=,GN=@LH,Y_OV #=&  E(G'^\N_'I(8&S&V8DW<7XD
M@K0FZ;CAVO+B"G,"4B>:GQ,-5#2<?O/&#Y^0JKBM91D^*:G2ZYAYOA=&A?\
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M$C,JZ.6+Q9$/!(U/C$C9V\^T=<(FX9)#/2(JF":"R"<@%M=K0:^^_IX$TZ4
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M#=$+,$HBCZD$*J6]&/IFFX^4L+[NQ]7STJ-&*D44C_,"T;TW!O8>$5;=-L>
MVH<M*3]%, YUA5C$R.'B.]$7G4X!?J[%5<N(HXE,OJWR=$V.R4!7;1;W-RQ(
M0!#PF#'H\D41,0&=-:BR#ND[;:U1:IX93'TS[XA5=Q 1>"2(26'A:Z+(M"@>
MF>U* A(OPKIRAZ7"O +OAC.2QG(6P/KF&[7'D(NZ=A)^!$IFHG GPW?^)Y>)
M W9)G88_]@SW@\8/,P\%_G*/X6@^WW,(KXIF-(GT< S4EQ[E1:$%LN=?M1 !
M@P.*?)N3*VN/*]+S+<^ *]B% >L+\ "47%O7O#W.G1IYXNU7$E2^(.,HT;!,
M7HAN>+,RNV_@*9+4?*,1P+W$G!95(@!)OIF97)IK'YI,9:JHFCW8$"=H7C&M
M= :*EU;3@CV2_K I3)HX#$IW&&LUC5B,Q5V(X38E_";S7B@#A/G$:_\ -W^<
MF.KUC-9/D9Z/\W5>3W'*B#T)C$>L3B+ECG04N(]753FO+(W8-)WIN<R\2U#F
MF'X#4H8(L<A^^/G]4T$VL09%%F]+Q39JJ:'TZ\$V\&@S%-;!2!T*8?59\%,<
MZJLN0N+@B>H1*1A!&,]GW4<_JFZW@CQ&0-=;%IA]:]%NTU_ZD!?'UIVLQI,5
M[\-<9RFB_@X7B&6KYP_Z[:[X-G 32(OH+H:QJV'=I<<*"PR3DQWWCCZ0JK/@
M"-X+J8?-1(62,S-*:3.SE>"AJ&-A#[U<"(Y?5A$*9J>C<9E2&*1H%D3C_.;/
M-G$\$A_[K/-\1:H"E#JNUYI2NV2^6@=T GEQ>)!&G09%NNN\YQ1GJ%9/,"_D
MGP)_-@:['>(AFI(H$ .:(V3?48D8H"6DW=:W1UZL&W)=94GOXP+O)>OM4EH2
M AD/4,]+002= -,[ZU&J83NF+S!ENY1/>SJ8X !K [2IN0)&JQ;^04XIYR]L
M)MJS 9#+>\!1#O*E!JRO@S/8.'8F[)8E.A@7R)XSX2AO?-PS*3D(B=Z<ZR-F
M31EH+P=6#E)!QM5O%AD/DSEQSB3#+#%9HE;#QSEX9M6B)/X*!T+GQ*@9PQKD
MNJVPC<\5\IB%+H4'IMH,'$H:(CJG$0(5S>=B0FGYL33708& H.QSZ5)Q.0E2
M-S'$R#(U800:YN)/(-5;H80YDV4][>4T1( -E&?>%7,2([R-^'6)4>EV/\_.
MLU=+SSD>%:8ZEDJI5AL<YQ$E&"K%.#IA>;X66<G1,73BZ(=C_&(>AB?AW<A^
MZ:.6#TP-;J4/7=5'V<D/FSD$!EH)"2YP?SFI$]?I4(&>?L8 A.%I.)*3=^W*
M;#)L?; S=+PLEN?2-[T'<W$!(0IL_P"]-W:LF1C'MMA H#&:;ZS;KA5 4'&5
M^90(JB0>^%'!#>T)_NNL9XJ)HL0QA YJQ6RUIY%W(:X$P*1L9G\&8W<Z$M\^
M W&HL2G%V,,[-K7@K>:/&9\K^R]:/8Y9O!)#*C6W@P-"\"@<GX*_'@2:KT'(
MI,W[F8C-&!!/"I6Q8UG:>.V=J@$GFQ\:^O<6%9)2C/9 0".$-A$BDPW,<#[2
M&H*/#,[ U+6*\07D-BO,&NL3@+(M)&Z_4D\ !A+=W'T)')]?GR7N3Y3HI)FF
M:#Z3,S\L8/8;HI$,A0&])?++!$LI0%@'KAK)Q'_5O"N-G4W,&XH00DSY$GGI
M>*MD#)PP5 S1RV* H LU# 2WWC1#DC7+XHO\S*)YN8TL9D@EAF9,&X>(FE-$
M<;7":<R&.WL" !5KZ6+-<"S,LJUZY(\_;\<=<XJ^"/H@A:$^4I_ ^;PD6NK-
MH/[P&6OL3;LR"8G(<-DLX6&ZC)-]&2X:.>%E"IB'?)3T(MP88\T.&K=+&V,C
MB_V_L'K=X9EH*$5X]5NW%Y*3:3V52',?YQC)Y[)+_2"].6*1DE'5,)"I$PYV
M2P(@]3SA2E0:GJS-DI,Q+DLI0G,$4<G_ "R43(M@AH$2T,<,CPX52=K>\ 2V
M_"X,VYEZF=N,H2%HW24 !$-(1/& DIIV6$6&@;/;-U@BJDH,22'V6C*IA(V@
M"(Q/ MTM)N-S6R&12Z0F>OY[L(F+I$/8?:RJ9,.)+MV#G<,#9KT#Y-V3U8N2
M(T&=R-K6*YY10PC:N&_0!&Z2"MIP#S(Y(J'_ !=<.:DZ-,UXIJ&N9[&NTA6U
M>8AGC>J#=#GKTYTN'!(=>;&QLE,0H"H[VWP@?P3X^'@-ZIJ6YDI4[*!S-^.]
M(7SK.V;Z))61@QIV.<F,&I\W.B2)X[,:B.[CW2*O*D\E_ XWJUE^@^BA><SV
M)?0[_P!!,I$B]OJD,X%@L<J 2!&8]\K;>Q;/%?X;EV<"'$C(!FK(+ 9/=DP(
MO8=$[91]=*$=65TV% PK%(33KN\Y@$VPWG4 C$%':8T;<_K2:7[2;$OE9";9
M+3D>7<!.@>DA '>'^+)(U>.$/*%X==H;E-^W&@"%@)KVH4ET=V)O6),*&14]
M]!YP!QB#(Q#04" ,$MS 4?%F5YV1P76,!3::'J!0AR52<',IQRNVKI\NF*#0
M'ROV?+),=E'@31PNC;: B"XHTL1L$3LBX&\;2(A99CP(-E:T[ N-=\/N?P/P
M],C\1\]L%A1?%Z$27!V6I<I<P7]B<*L7A!UR%0@FA=X^@FWR;_3IN,W%"$4K
MVI)H$!,B?=N=OV(Q)>*R<.$-B1W@DL*F0=^")72BFD7K7&$4 "L #@T2+%$3
MX-OCTR::7EED G8AP(!KY>GD M!:M2C0ZH&RPH\&GBO%WQP'. Q03,N_3J8P
M!6>(M;&/_#]<Y%Y">_$"+5/^Y_\ 2.2<U<6".:!:9EL>2 /51*-")[/$"N5<
M[R#M?T,1S_\ ,?8LX)W&Q:C8\@JJT$5P*"H&=.-2HF!S-2! )P!ST&&%P245
M#4Q\_4FD<'FK9[#GTCR#TH<M@59%U7*]9W=^^:&C6]($CCD_K7UMB<*B3&)F
M>0+(+3S=@2:7YR,^F9!.ZA/6>9DRU0TIMD YTZ"CFIO*'_6U,K1&1DY1Z6^C
M?M_ [8^SMG\9M\Q"< _\9IQQ">K3EANTANF7RSHQ(G&8BO0%$Z$8#VC)G=KB
MUG!$  ,)-55Y8DMP$)EP,P]02W3%_P"]LYQHX:2,V;4ZDV9Z<G,JB?D\YU;H
M&34Y#(>"?%,:,J-$,B"<MM#W9!K@>,,MZ^V1A6+K6-C*@,&F>TS>EV)'SS5'
M'2T"3 ]I>V-C&=%M0YVY,_I@O12-3UO!@<_&@/NPU/&@3P#M%_-.HQ!2#B\Q
M(2(Y:2&C5)LJLQACYO@!( /6U69SC),K/SL_D8 2F\;HH.VLM:X<<$-,55D)
M5YU&,0I5X"@LY. *UEI1A4$#K$[3!SEU/(<,N ZEY7?K&Y?FH^D3(I#\ET-
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MDK'I'3R9R*['X]/><S(Z#$3/@F8\3_Y%_]H # ,!  (  P   !
M
M                                                        $(
M                               ',C>V:
M    02.ZJ-8H                           #$&D_O!$?V
M              !SX3F;.5N>(                         *-^L5LH,1
M                         !&0M[6^[,P
M  ,7&&'6\"                           (6!9)LV'X
M             7.MDPP/_K4                      "2%(9@J*;)UQ5'P
M0                   "1)P\O<Y^@8Y RS 0                    T$Y
M!I7>M"OOA?R                    3/"\=LV$=@4CHQ#:\
M       TFKVX(L"&F;,;1U4                  "[[AU0/;-6X3@/'L./F
M@               ;4?7,7:;2'U9^6L&(@L\               )AQ3RWZT
M/E:",^_4;U0P               G&%(L\9.UO35PK%7T&+P@
M 2'C6YP'PKW-KU;(IRH?SR>              755X7D\=E]>ZY5LKDHT+E"
M         0" -XZ0M3KSB[XX)PXE<<URLS@          " !Y1& \\/RO5VS
M\1MDM8KTKW           " (4@WBF4T<ZW.5D'&LZEOFT0           0"+
M>+UYA(OSR]&)Y+W;[+6VA(          2!X%U<JJ21. T!@BX'^^:FOADR
M        07C^ND@B)[X&%6BA@@:=)/K/.0          %^T%^NZ0W^&@-W68
M7!)6_AGN&        ""1"[TT5!%@<KDUD)I+#\+S78:A@        0249W7U
M4J)$P?YY.RJH\-A64&HR       0""3<5\ \N4& 4V6EYOZ-&E-,=#8T
M   00 *'I?R&.1O]UA/=?^C_  9G<340        $$F#C9XB0X%HLQ#1$93+
M&\.=IM*$          7N7ON%<A!1U1+41#VBU4LYIP[          &D)R1-B
MV)%WG8 '@6DB^OEPEY$        $ ""D&WMW+K>9/*9XZ\BRF0H"9S0
M  $@$)%-*R!J FN[R N31*?C5]>X-X         $  6V_9;^H$^/J;2YPQHE
MU[N'P          D$)^$HBCXZ%[*O+OZT!WA2X:.           @'0<G-;7#
M^47'_P!)(ZSAEQV3X          ))"4A=$BB>V5"D!I/=Y]]TQ;8
M !)(,^):C^20+.CWP I6J5!<VF&          (^=VSYH38W$S%H_:,Z!O+,T
M 1N          1BUI>!@_P T:]B(<J7T&M8V#IOP          (HPVDJ!8]X
M1FP,"LP84O:*6)4          2(@-)%"H4M S<DW:'\9P@>="$P
M     .=0(=:UNSFTC%=P4T+MZ                &_[\ONJ9PDF5*#;2M<:
M@               1S3L4N6CHHH0@,*V0LB<                 ;'Z4]6F
M[V4ZRPY7I0                   =$%%SK*/1Q&C H[8@
M    "F'K+Q#'%"N>QW+X@                   #[D74(/;>&%,WT9L
M             "T*IO4;&2=@VM1CRQ\\@               "1;0(EB%:]OD
M2GUIRYK$                7HA-]-D%5;\X/*(L^66
MQA&E:\Q.4SK?8U7U?0@                <4<O\5.#ZL17!/Y/-)X
M          "7752[HBHF MM,I!B_W                #NAC:R^QT7OD0%,
M!RA-)@              #^":+D<6XEG+C7G&]3\?"              !ZS3=
M7TD)PY.!\V@@E[2I5@             ,.#'J@"C+4]\8=HH45[E,P
M     ""1--PTP+>803<5,D ]_9@C@            #?DP*YC.(!3D<I[$  @
MU%HP            "!VK,B"\?@3/!5'>T  $ONJ@            0*T0H!"T
M7-ED 9-X" ".MJP            "&.^@02ZMMU5K)GD".<\T>V@
M   #7M*F *@8.-25OSD2. 9\,&             &@K@ #G!A 1[7X43BP+/Z
M!T             Y2G  %/D _,[Q%38_ ;'&"H            ?)^D 9/G#+
M1<3)>LO"> ]Z<            !X44@"=_87*X@>Y,8E0BOBO@
M *<;4 00, %A=9#DHGP(K3(4            3"CDD#HU0%II\)SR\9 F[7*H
M           #"!C,07RR5S?^(]ZW(83AQC4            DP\%0 &B$:U;E
M+>RG@55/3&             0<L   M?M86J)=,,$5B'E\     "        %
M9@&$"?<090;M9CZCRL+$              +F'+VT@1^6.Q>Q&\@5.3&,@
M          BG@*A=")*!9%O.&($^F$[$             !?O1*E<B+_6I%-P
M $7=GA @             #D_'"M6 L"$T1  &2?&*T0              .'?
M/@;N!    ( $7"WF80               5XKCOU"*@$  "B0C$$O
M         &\V\3!G$8$ !)$E!6U<                 <AK+T4J2=, ?Q#N
MVKB                 !'[378YP/1@1\33FF @                  )
M$+_<4H@%7LET$                    +>)IZYYA!@ ETXB
M         1V4(4R^K1AQ.=@                      %S-=3\#TQ)12
M                     90%8!\#2@FP"                        8&P
M(X*)%@                                               #__Q  L
M$0$!  (" @$# P4! 0$! 0 !$2$Q $%187&!D:&QP? 00-'A\5 @8#!P_]H
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MP)6!>?3\?7Z\S8&4H!.D^-WEI_(;A>T7_?"JP,D.L]GQDW'CLM9B#!.CU/\
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M5QO V[?-NZ9F%W?KO7\\<P.?#2X6FO.'Q+.+:0@*;@4EHDCV"(I&<(90<42
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M4;-N,.>OS.0W"#1(,1+\')V7OC+Y+*H# )B7 ,RAR:&1A12HRJ845EJ<,I;
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M-(51B$4^N?QYY@B,5!92F#U^W?,,CF$)]@?]^#@X&+[[!_U>!-8*[%A7KO\
MQQX $D0+$"+0BL0"3  +'7#G$%4;38K"<1.9< (@L <I3'L+5TX :!C!XS)_
M-.K75U[;@[WD\\))E(+"A6]DB.1IUS&L[%UO7QWR#JCDRYF!0N<!%QWE<ER'
M5-8=D[_YQX8O@\9?6?[LPCX3@(@(&<?#ZS>CXZX2I,E =:SZ/WSOA-$O")#U
M9UK[<&, A2#]4_GUY7SB(E"S&F-.Y%84=#3J/(Y$AAR3W.%@$ H= F(:'22J
M!."V<GG&K::DX8V@64ER(5&\*H<MA P..0T)E6>\W.=_XXI-0KEIF;R_[_1
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M# 1L%E/)?]^)QE3I10OTD[^6\TMN&3=9=UN]^/7#(%(H-,7 7YY,#WEZ>O\
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M"@!&4FH?TLXW\(5MHP3"7?7O \F1BG" HJU9*T<*3&$$6D<2D'_/ T:(&A?
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MKV!VAU_-<UZ@8D",O&3 $ICS-F80,"(<?7].',YF0*626,[$B2*::KC01$#
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M"J-%B+_/CA:25PS;=L;?E^DXQF+"(!2C0, 4BB%1@(O(25'2A4<&Y/?-R<Q
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M9]WQY"NP+NV\F\U % :F)J=S@7Z(+>;OCD""H[4<IG??MY%F " -2NO'!<M
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M@^C[\/%JQ-*4E\V7@ AATUR(* R&T<#;W,!8+$2A(#2.NXB#X,GJH=/HO"-
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M%4.1PVS]WG&\$CSP*>-7\_?Z<QH2* [&9!Z"P2^"U)KFXD*8CGN 6="X02'
M ,Q.PJ@1CYHT%K Q673=&,9]638U<U=)QRHAY'AGDF SK7C>^7*A1)O9XUPI
MB0OU.;_/GA##:5=:98F>SQ/'*]20L<6BP6NX>DMHC0!R+G#,N*9818K2CX'0
MQ8J=_.O-QKBJ*@H.]7_&/H<$5Q1/O&K[[Y@HK7)=K]>C^'$.@@#61UT97J>N
M1 \G4'!CM5TY&3-8.*OD .7;1+%PW+;$8]+K+;W$\SXXC (* %CW]#\GGF$
MA QC07!Q5X8F?3]=^^-"8 B;!_?^$X;I]IDOG+^G%$'H $%PA[QG\-.#9J*2
MK]8>/,RSG7?J&4+J^)/>,L.+9>AD )$Q17R!&',Y!(P1Z$&[&N% 9:3-,T50
MM1BJ6 (5S0.3#@M5E";)\W.7AP""J9XV<YBAPP"\"W#8CG:\WW]_GB()D+$K
M.AU^^L\, 1:&/ N ,W/@-W**)+A-?-<XRGT^.:'P?I_?I@ Q_CK_ !YX([IH
M6P6+&Y*'V7'&HA4"B3$Q0,#$;1#CC*"-9)L[#^?!QXB0E37FIY_/+4Y"JJ#
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MXX[-3$8.UN.RF=6]<78,J#- )G82_#KC[(Y*P*F:D)!/ T8-]B:,CH KCN@
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MAZ#CBCH(,SB:QZQ^_(>#['_DF=9^,\UO'S_N<7)F,(8/0Q3 .X,WR"M$5*H
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M)4VF[Y)5Z=];[-8UC/$E7.WM^]>^_P!^7F&*S)P#6/K_ (?_  U@O@O (Y*
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MIF="0*  \%OV"[2P*J98N$BGBF0(*MLF5<OSZA$RLB;00Q1VN'@H #PP>;.
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MI0!BQ30 VI4SP2/A0H4U%2P$QL%URID!0Y.CBQ,5FO"\M0,JL]_A.8'D?Z]
M^@_6<VCZ _H/_P 3!4]!X'Q\_P!!-"_ \W+7/7E9D?'\G$69\J?OG^=<N"A]
MCKZ_??O@88%%+N-^T]P^.(-9@6T!H/K/C/G#S)D2N!ZJ9C,R_C&0)!2JH8)A
M:&C[<56&+]<L3ZF,_#PUN]7X_P#ETSP\HR&#:+\;'P2&>O'#!]FD" JLDT0C
MD)A_>UQAA( IU <RXU,&J!5T""P&1"=;=9%1N*5;9C%5!8TC R,58(B_4#WP
M"[L85+0UEV^<R\8$V5U :Y3'2^76/[S'#&M?+QQ+*C.=7^WXXN<O1Z1]8!$.
MMW1S(Z0988#DP,$QO@*:E*I"$.F#I9GBH4EXJF+8 U@-Q8<B51&!U24]B!A0
M\/0A!Q(YJTA2 A> ,3K%,+,7'GCG>?G/]8 ?.%M\JYSO&?&/8 9LV^_B>?7C
M@3&,#@R%"92=#\G)PA8 JSCMNNF#BH/D'[G_ ,0J^OS_ *Q]]\T8L'88Q&&-
M9,8<[O"00:+-'2X2@=ZWK!HW-%9KX&7]_?(."PLRF#[=<L0L2[??N^/<OKCS
M;X?6=;^G%DO:9-&!L<[N=<&0)+1J"46!$4A#.:(:(BP.O>+7<?AD$BTY^*/5
M]^./7H_=_P#JN**2D)<GOB6P0)!@F(5I-I0(@LSQ,IP0(;H \X$YRH=X!(HE
M"@@.,U6:0:!42PIGLY'7A!4$:H"(XO9<<R")-&*#\2$[[,\R5DRX\9U_=T&9
MDU]_WX<*(A^I!G[]<,$#2A$!%3(G4PY@I'E$%\V.++GSQ3I%A,#-C$!EMVY7
MEAG+BD#H@*\V9,B)A/(I3* IA(H*],H1D#,5B#!R&031$.9 L*=L)7Y_^&&.
MNL_0H.8L&.&SC$$"N$(%WZ%<N\\Z4"!8A!H0F0 @FRTUR<K@2CDU%J+"H4LI
M?%+/C^E+*7Q<_;?"B(X .:#T9XYY! AA1@&=)D(P9QI2(H4:DD-8T5MA0X<O
MM()H1@4L*Z P(:%J&'9B,< '8RT;G 5B+I (_+]\\4#82QH1PXUBF<]N> 0C
M=29GFEIXR7UPD*::#B2=KW[Y, C"O@%(% Z,2"*\M\ 0)1:[0Z(9Q\[#0+ W
MFX]N_P#G%?3WCUY,_?F]9_K0VS^DN,EQ39<8]\-1*JHE )[LJ"O(YT,L4/E4
M 0-#^)PQC [!8#B5!4X:NBT8W+J"E,?;3.3P!XO3)&Z UV.^)'$ 0UT9MGO]
M>.5?/]XH'PC]GAD5LC,FFA!%/+YX*@%!X&T4AE,MB.'@P0@%H")G!4Z8>0 5
M8! @82!T$2O J BPR&$I4"P@FR1"V%*@U'$5]G7_ ,W883"(6QI=X?LWCTA'
M$G;&(Q-MINF.)PD]0&0..\#E025  PA&89-75^^?GB8D"FUHH;8B>04^AR*L
M:1C(!'4+ET_/&!X%XP+WFOGS/7&<XB1#)/,/3KS#@; $*44(7&Q 9R)0H$K*
MTJ(70(C#\6$ 1 BR@6I2I!Q@#\\X\%:$/1[-E.H#,B 9!;((1Y)PH"EQE!ZS
MAFCNZSPBZP-W& DK1A-CFDFZ3;F=U<9LZXAD*%(!I 10V,LDR4X5BR:H"J6L
M5,R%<G'>*I)E@SAKFBO'#2H#*X%.BPR,$M>XO.QL*7)C)R@T^9NPXH+MIBH+
M2!DH^[C"#5F3E@S4/]28[.(*SC<_'Z_:\, > X6DW<?/ A+,TE4VJ0Y2UVP<
M6^.&Y3$NN$6Y</GQX%5M541A0I51YP-@=#*1Q%4\Y.\<W;4'J#1='?Z8Q.1G
M3G10"'EIYSZXBII7W+^_]ZA(*05R$P5LFRG)-@BC$*R!M+M))V$,B)3 T%AN
MGZ'PRNP0B]% &5H5JJ14 2Z,5'$% P@1JHQ N#(S,S+]3?Z\,A\'_P 0A6$G
M3SYGM'STYX4@([62BXD)I($ T!0%@Z( 9"&(B;-0>)0$5+ 5!&TIM!>#NEEF
M599B8#7)<KMV0"9&<H@2[NVK!!8K"KD,3=9,'"(I06R,#03HM(6O)>,?A$P$
M4*8 JEJ\BDE -RE'8&F '"LXU4, M5(P%2@< #Y4GQ!5+D2P(0.<W"WT5"!P
M&,5\:BIA)("HD%<B=B3+B/15SG=<&:H7&P,'%X,:W7(8U\!B^./1HK)!24M,
M DI4SRDK)Q<8>5(L$IV>!((N%&C2'OI(>KYY1_64('!0<QW:*N 6([!.I-J4
M$8)@6SE"!,LA4N7*USI#<#/&8;@CA(ROLDO)QY/P?S^9SSXX%65.\$MIE,Z-
M)54IFH;S6F*;NT>$B5H(U<EA5=*??EF+6L0+;6.4J/F>5>5%"V)J8IAC^CXR
M8-(T(@>7'BL]>>$^R9$=TL]_WALF6D/.>**VL"[E0< Y=63&^#(&,PKD!Z7&
M6ZSP!%)EV4>7"N77%*AHG4 4Q$MA,IXB; Q N7#Y:_\ RX%\<N6K</EMNTN.
MKD;P$A$*:(VT8@%,XS'$5Y02"6 $ KGY58+PRYC" %$B#DYH$ $54^@!-JX"
M"&.@3C:<%D<VQBG2!!PEQD- &Z4R1T+A>!\*;(1AD<HJMOC/ !D1-0$!-'(=
M$469Y&+,/A41*0!0N$3G<:G;0"Z*<(%' ,!9#5?1:$1S$B$7)P&%W;5!IH M
M!J"1+42 3AH&*!VXR>5+Y:T:V6F*[[VZUG!#&XU"@B4UMER$F4O%TL5%513Y
M 7/5:C6"G3=<%6[L<(  W0!"] I@H*-0,W>7AL0T5@*U6,"[34Y!B@X.PZ)*
M'MLT9X8814Q,():%N69IOC(PRKUC?A^. 'V?]_YO]=J1" +J9-:@[C.(^-@
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M4N'7F5BQUCJ5T!L.PRWS#OOK@,QF6R@($6B&C'#_ !-RY8LLE53V4Y6# %2
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M+$L+6G#@!04*&32.,'5Q=O%!8H%MF>W-"8\N'7#N8G,&!D%'"*O19RN@6]J
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M#.%""UD-T3LY6U,I PI$#0C93N8+Z].MMZ4'*HY\3<BM;A<$O2[+C.HU 0)
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M89[]5Z>" I ,1:7$1^Y:QX#1*B3"TIN,9_!=C"[,@$,   !$!Q+'38SEIEV
MLPF87VR1X E'  JRL$$HA2;_ $(FK !P/2M(0(G),BU#/09P0$,AW00S 44
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M.5%"!DJ$.:814,CE#.+6&0=<>J:9DI8:/8RPR.)@># Q(#D""@L%#!5LX"9
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MHM(5 (A4)\SHY)4NP80+0@J I5\Q):1LTSEP101CFG P=T':DQ0<Y-S[\ 3
MI&#HHA)E_,XLA:3(7'TS_/HQ8X)&W!^9UQ@O&B [;0MSDLF</)4 JP0B ;M=
M03$49; D,.)DFC+F=KGAFB+0]^.CWX>N+_'>O+C[9Y/M])CY[^F?\51TW^AS
M([A,/?B3JF'UUS6; N L2U6'(<:9%ANKD+#4 @K)\;RHPD%1S1"%T04[A;Q(
M 8)C.E[/MK\G P]AR'_4[IKAR C*VF0J9 *$"\=5-OHI& #$!0 !Q"[:BMG9
M!()1S+2G!H"%BU($BJ"6XO)>)"T&(583W<0C9(&7D!Q?B?N8XMB&:A@' J(B
M$I&<5XF+,2$@X!J!< V7C?DJ$F3 "*H$J3E!MF&" 0+B(!BT3P=*(R!7<#-3
M*C''3ZAC.M2"#L&I"X.%9D7HP60!B BM4\6!(KSL+$^@.+!)V[#=([0"H1D%
MX4U).$5=I?$U]>/G #B-@5BGU]O+&1S$'-MF8T'V*<))-I-=2?9)XLO"4 19
M$L%ST34'+H%G#.Q!(DPJH[>KDMXA68#=WWF5^E2_THZ;_AW(GGCJ[-Y^WOR=
M=>." :/>3[)_-^.)1%U2RVSNY@M2L2MF%MIEX"-K!9.G&%XX ,30:_*4/SR7
M\J( )2N "M9 ^>(\.0G ?-61((.6(Q4; "(D1J(DZB<,B*Z 51@(:H9@,:J.
M2A4#,@"J#(.S/&*$ *.@<0D -RN81R5D;4P<S"A/)'(\54'R<: 3@F,F QP4
MQA)\:U_6_=YY9@0 7N *F2X$;$4M(!>YK3,1E2'&L/ <KZ8 4(K+-I%1"X"#
M0!.YCWOF9R#02-AIM98:&.3H!F#8 .! A 78<);UK U:U3NH7M<\>^Q7%!@&
M)!I-BN61V7M(S*) +O+D+F0-,QM<D4B)(M9Q%M!:+DJ HBWS3CF4QS<((7"+
M*8JFQA+1+FG>OT_G5Q#L8:?IO.?? "IC(!@%#VI1A8)Q2PHSL%IA1L$A!524
M20%E%SG6;9)YX5JQZWNGQ]=_XA1(M!BM'MD;UY:.;S*)U5L-0A D5 T[@.#U
M*0 "/!!9@$  XR#!483#CP?SOAVALXO4(N>T RR+QG#HI@8&1'1="*YM]H %
M9&HA**YVN'X*XIAV<IE+!K<F=L481J,I@14S0$M#<+QEDTPXQ#18X@GB0&A!
M%,J85(SQQ<-C 746(#3B$NAP8(B3VC%@D9)T06B;@A:'?\Q_.. N@1P1'I!'
MXSZF#_9*%$%@78FC0>5S4-!(;M$G#(!X!B(%J-8.#1H4+3J^UY!H!B1RR*<
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M$Y97 *^)QE*(A&%-=68O?,*H$''8R@S$[X8BJQ"IIEQ4OUF<\85H(PAXC/\
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M*V0?E]<?IQS0,5D-SX^#+S''C&O%G7Q^>-7Z]?/KX_/KB?JM^SQX'>;^>3)
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MR"%JG1G?_DX^D QBP\*.I,=^./FR@@ )N"'+IAX8Q0. *HH !5."N.!1[D+
MIPZ*.F)8Y3EI1$4$8X8L2.IPT@S5038A!G9B/!$YV!!30# %)4R-"IR$I/*4
MCA-[0TJ(<PP!62 1*,)//!5D\L6T5J$4\3),@"\(H<G53@+Q)%WHA,"-(>.A
MT!5M)D[?47/?+JT>DD8QZ>A"6###L0E-)<N?'UVU>:ZAA!J&BHHTPEX!B5>7
MAN%"<<"JA41N.1D--EUCB+Q@M$3=M78ES4SP*QM )"L)K8 0F3AL0056)R>P
M "&,=5D&J(%>FMF_Y,)593D#FNEOV.L<"GM1$8'RGGT:X3R$*5 [\#W^O,#2
MEN<F^J<+T/P%C'Q?KC\\R!4K!'&5D_F>-4 F,P/%UZK]GF19:,.@GQ_/U0[[
MWW;U_O;[VQ)> $X@D)T2";[YA0A]08BHV9>2CCF P8:9/Y8?F?W!:@.L8PN>
MF6??<YC0".D1-Z"G \4X'C@#L:QK=SX?MQICI\JS_KLX98734BJ+L 0#E9PW
MK -68&@)2H,1<?; ?;&?H0/&]\BDSD9=G;UWXXKF7L5PX_GQP>,$5SAAV/3G
M@!D%#TRR_;/YXT&!&?5^GU]KA'@#91M[,8C?4W^G*N",&:*[!T 08.!@H<$E
M-H(=8F=/#CJ-9514[,1"8'*9%!F%HZ+ F2C ])2Y/%,"R58Y,"+LWHMP'/J8
MA@ F)XD;22N3!O@3"B8141A@Y*'Z\<Y@F8 PAJ"7:.(#XE=!*&^#1,M85$".
M$)%'@X,ZBE*A8-8L+!)(B@(J.#"S+-O$$Q#X7B\.G-HV&8,J:01IP>"20 T[
MY!C; G@M@>VEG(2)$M(F<E3< P@L2+H(0DEQ$XC(HX84&&TQS,)H&%)AY ,*
MN!WKDV,0IF*\O'3]N K<6MZ(MLP%*]AQ'$EDLAE45<AT<'@G.J0<Z8QK_P [
MSQR(5!#6,#$^^?OS*CL44FVG;,OK5XJ(G""WL<]%^WCB!4JEH'U,W]OPHE K
M9VN+\^N ,8RR?6 '6_IZWE=1^+I_#PLBE+[\^;R0#VWKSX^/'US.+B([@]+Y
M\:Q].*43$E&X!&:H& =%%'S^[_Y]/[:AMG*2F?C/&0C$IG6;F>(8O>^&PO1\
M? Z]8QS'\#ZT9J>/_;PKIA,#T,\US\_?FI5&,TO2;Q_.WLB[!Y%V;?&?>]"K
M25\ ^O\ WC(T\E)D?";89]<3)2P)IEZ'5]^NN8SFI17J&U%^F/GD6_ E0&C7
MU'TYA5.8&N*Z%[_!XX&R,WF&8"G;K]7BV -9D<355JT,+A;E75P#-4@1*OG)
M 82#"FHR(GNLHP''K0"EBG;EDILT0Q$&G8"+?H/$?L>@P. #E0545@G<=I7;
M 4#0F#?'12V**=["S6DA0!?2--,@2ZP')$#P7]1#&-(2H@.H&:)21%B.14H
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M7O[?3B(CX"),9$'7=P^^&B!C$8WJ:M/''B+%OW?]<R Z:4W+KC +%68.\O\
MK7;WRJUC)NL/G/W\;Y/BPB"5&$='VUC@+8*(6H"*,%#P<K7[F5B?4OG!9R2+
M$QL%RTE??$X54@<DF&[NKKOZG+7\<Q%KJGW^GSQF;\).[C7Q];R IR7A+80;
MF  .-ZJ!<%A$FA;A&N2]M?<UW@]9. =+,)(K$@!6MRH- 9TSK?P_VV98YGXM
M^W!1]XXPD'8]V]D;BS]LSA=44X3LNCV[>(  AL:X.L,(+CBE\!"R!MH]8+SR
MLVV4'5]OQ]X,A 1AA$JL0SO7WC^'. ("B%!IPYG@EM4HJC@+")3WGF=)/EY:
M=-+C;^*X!Y!5*3KX>5M'E!!%5@?\-\/%I&NT1 +\4//,Y@H9R6GR\)3TF&<_
MLOGQP)L0J)AMO^^8?$+A6PZ_GSP3"DLBU?IHF;JG&PA%R(8NMD\S?"^1H&FJ
MD_4_8[M<:9* 4E#@#_S@012+@84S=4+GT<(HH50$%S4/K-;(<I(C+8QAS^%;
M>M\W[ H)%+DI\]>N^5[,05$4 &74FT%J.%[E.Z0R<*+)K&>*P*5MGI3K7F^N
M)D&[LV8J"N#L3.^'04H!IFJ @U (B()@09@@&A0CC8TH < ($L1L1G)W^/7
M,(@4B/G,/@ZX< Z?T>?6UKU. H%!EPOW^/Y> 2H1H+(;]S[?<^*HU9N,&*Y^
M?'-F&5H4XP#+C=PEX:CG$C RQY-DF=[X;@"]DIH"Y1K8_0E 2#X R?34]7SS
M.%BN$P%V  P4&(--BCVE,S,>,?3F&-\)>&Z\\O4'/)E3D)M)CPB(!"X,;O?_
M (9X\/'BVD]/9'H'3S=]/T?[:'#J!]W7\SS5>N1# *5T!F^H'SS(2A3?(I/?
M[\3!T@?'J?I\\&](@",@)] @9"V@K<0>!Y3)W7&?2F@O%&T6FTP@*"R*K*&"
M6?0&:$US8$BHL(S;E<?O>4_X,LR&/"LDS^1MEASS"BJ??O/*"5*53-2;UC'4
M>'1%0).905UVLNO+4\0PA$_ U->\\948MFM5_G>,&.+)C&.KX_GAUQX+!OO$
M<9Y$!H%+HN\'\QP!R%+)8^T<N*=@O\8@:B :AQF0S>N ,+,%ZE!:J5P10X\B
M#(](@_(<J+R*BN'I54.[U.($,R4U@#10HP+BC*VY4 ="#@S "@\N#AC1[HN7
MWA@5H$5!A^A2!-QQ1$X^,PIMW:B."A@!-.VY:A& 65HMZ4+PN$G(M]HMG *D
M%)! +"\4)@% H\9O1!0@0J0,97/E:\$B'R+D;<+[Q]-<=%\Y/J\>OF/N<!*!
M%,+@=!N<KJ $F,#?G0^,>GA)$V$+<D00<!N;5O$[HS72EVI;[WIY2=,0.+0E
M=;'_ %PG0!$X7$(?/\E<^<8A3>^MO(-0"2,"5BH*RGA,P0M"IL,9JE1BA7E)
MP  0N4P>_P"<\7@2RT&!+4BXYX1N?K>)URQ%9((LCV=HR)"%.41;''Q_)G^V
M$@]?OGF-N/G^/)]^+E.ZS,7'CU_WF@R##=SU/>H;.'!06MG;?S>_7%HHI(@
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MJC$<E+W);'YX^/#0@,.L7+Z/?!2@#7OR;+V_N\"!A=X9J> ^?]<NHQD QDH
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M*[BMHD#LB#.H\7$$!$,1"E=0"K@=-:$+&=GT"3.<1(R@(&9D1+96"QF\QXH
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M&[XQP1KH23.VXV_7-X?D[&27;UK>/UX,S^**9MFTB[,:\<3#% !&<ID;>_\
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MC/5,\&T'TE!09E&4\/OCY$(-8D6YUXN7@\<H@EB?+2^9\G'*#*2A(D;%)4D
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M[_7W)9:N0QO_ '_'C4$GLQ*^L=<)OVP_69N?SQ97YYD/6I])\\%N=F=(495
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MR Z2:."#G/&3[X_?]2_IWPP!X#_"0C &;UQGZJ4P$>UC8D(C&!Q$6QY'4$#
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M !40J0\]<!:(S+&R>9PYN*(JI%2&K5Z:@7D0.!:@*VW Y]$257$@B@4"I55
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MM"%-S4'NWC.HAX(V24K0(;@3^@(X5E[N#]@][XH@6$#-)3Z]ICL7C 0+JQ1
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MO3GJ?&#@QMWN;\[;B_?LY1W\?&]?#UCHT-_P=(4Q(I9T3$=3[\,(Z+SP1RV
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M!&KDG!U!+3#%!EU3.CYBJIX%[6(M5\BC@(:KK)5P$#W'Y2KH&[+D&Y)*@1>
M%!&QD309CZ]06&?71EC)A2+A<TX$ \$_P!LQ<Z\^N/>&B)J8P%=95ZUGD[V"
MR &RV$V@!X.#H-(882,B[H(%PF-E':[E&(64X >  9I(I!0.P=@KX+ "8A$4
M,E6JV E(/)5*B48 +NXV-C1(4.( #"0&!4LV8RZULY"$@@'"(CL.S#WQZU2[
M D-!@=29:Y>$RI/K?GQV_7@0&OY_OAG6?C/$0<."Z>,'1N$(SS'/C/B<9@0S
M*B$YZ@ICGX!4B>2,:,-%9H7:.0XQNG-$H%ZZ%*N*#*->>]8V9B]!7 8Q ! L
M$AF(4(IE2FPQ1;(LA D%@+"*BN(<&"8+ 1%1E!"TQ*BFLGG<')T@8>KDX!+?
M)]3K?#.3)Y,\$6"*;C9\R\C$FM=CW?Y\'-WX_P!?UZ5WRU@'%ZCUCDQ(F#=1
M1$ Q,$7&3XNHMP1RQ: #0PAG7AG$$ AR7PH$;8+)/A0087?;C@EB!":0@-BD
ML=@>"%(8 @@DA2F:( 5_M9*&+G$*4(J@R#Y!^^>.-X^<?WU2S'T[Y$&:K\S/
M[<9P9X"RL"C&$P@YB+AK PDH"+0D]TIQ: G(SE2494N"& 6+LSB@8.$ Y'(%
MB'QLK@5U(2*!!!>AH@:R,<#+5>5VULBG3*O4,F_5ZLR0>U*R./"S'WX[?E_7
M^KF^^^^"\5))(J>"<+%3ECM2-5:P; 3B"0C3J06@AU@N,8/55-F3O4.DD6(E
MKPE6$)*( CO9UB<L<YPK!@0GS!D0HD$2  4DA'-[!(C= X  0:.D F<9P1"@
MD$E$V%6Y$R=LI8#F!G$PPUN!90@'0%S\%@D@<;#I1C&OG!CKF:G  4Y@45()
M.YP%@5LMJFE$A=:Q]5J#M!KK.L>.#=K]O]8_IOA+U;Y\^_W^F^,=I \&JL22
MPSH1::@.(F D*1R7+!ZF9X:*F*.]B2H*@EK&5!X"! 1H%<!#9E@5E;* <@E(
MJ%106:A<Q$EH2 !V'+EG-PN. Q8$<WXC^++G''@>U,^7T^^&CX/[VDEH;,8^
M>%VS<0L"@4W7&L\%P&F4M^5^Y-<4I*Y+Y&#)T &,CC'.JJ)42X/9%4H2CD J
M:1L-P!9ASB0> /H>*?A <C*7\(R*D=C4 "5Y<"<[1%:C  *+HCB!.+D#^8O1
M?N=__+AQ-KH6@. H@@-'BM#F>8#C!*5(-W/#(\Q29T$K27'9WXXZSH'K-.C*
MRX%/#A<N!!%A:0 E<G#]Q8^9!*""\@1 $X O&F2:#4PVG%KHT@LD0X#'$N.G
MOK3HL,L& HX!J,LH/E'L2SCP2,EU 706&6&LW)KY56*= J$!H0(*3BR#PB9O
M6K/ #@$J;H(X8#6=E>&!A-C+B$!E05,!'#?%J@_3Q]3Z<,@^0_H#5TN''[>>
MN.A@=VDSZ9,T^]YM@!J$+#E&";DAR&WJ%U(S9K60!#B;"!2C1'2  C9-A7Q<
M(PI4B4=&3#"S"@:\ 4 5A!T00Q]6R$KV$-A%,*JV(5154!!!--"K A"*N!HS
M@F4AKXUW_>F4// 25@7"CUAQMF/GKD!:3P!'8M$Q R$>."%J=B$R)(VDBH %
M)= !:!II4%0@"1I0PJ%P*)"Q1.&XAB.'5,0$I$,2LIA)MB@.MD0S6'(#WIP
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MIS#')<@,"WH;=SUQZ.F>Y@_W^>&CX/[FX^+CBP7P7@&AY115.K!^3B<JTT:
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MCD/'^ <B>>'M*KX[QZ_WS$)CV>O>I^IQG:DA9'0!2)! G1"Y2V9H%L+L 8K
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MY#CK/(<"OJ/SYZZY#\WSG]N.-X^<<R[?7#]=XCWY]<J: JP78(BQ%;LSPN
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M]N J"QV#]-.[,XS\\WQ1^DQ_/]_Y6#L'Z?UWEWYY7SR&ICQR'@^Q_2OE^_\
M2'@^W]$'8/SR'@^W] - /C'Z?_T7_\0 +! !  $# @4$ P$! 0$! 0   1$
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M0FYRFM)0HD+7)%PX!?3$&:-X!Q#%N@4$=F,UW(R 7+;2P3-PB9)H!$6,YE$
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MA 0@HRNK8F"($1D<O9$71IWIUF!]"@** 1">W3 &J0!6(+I"LGHVHJ;9L=
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MSWE<U;;7GX]ZU /ZOX&^:R%U]MFN$ !WXOPIB?Y;9? B5@/14+?"O@7R7*4
MS 9-4J?!(D_634A>VS8H"J65:[J3](^LT%N O=4D!:MLM>:T"JO>\XVH5DV3
MD-HL$MBC ;/SOCG?TQ6+S^#_ "XG/X?S@\CW_.GV<OHOZ:U+>&FO$UG&=:*L
M@"A$RF4PQ:91KJJ 8WQL^E*B>6[<N?M19!LK(AR3HJP-&/MIFUZF\D=&H2W5
M.\VQ#$T>EH(E_B/AC3G$,8H.1DB0!I!#+HKL)6W^^'W1YG]C'SC.*V3]G^8G
MTH3/2:]VBSPFL2'BSBXOGUVM7E91'0QOG&)R/-?,$&)"F]MZFTFD_GVO4!O^
M.'I\09K1?GAG&+]-JXK_ ,C7SUZ"3S]17*EY_O9X0UVT^3;GQKZO^Y+&O&@\
MXN>EJZ )?:VO/E4\LKK#!F,,;=,-61+"]'7Z"]<T EG'?MPFA 9DY<K>:UJF
MXFFV9Z5'/]Z1X=JYZKEY\UQ #4(:3>$^MZL(?<^_#M31Z3;JR\GR"KD<KBL0
M%DT+QQJKF.=]A>_*8S<IN8N4Y0[25#7%SV6';73F1T28SZ'/ZQ>I(N^5A$<@
M8)5+$A1>F*H%D$(! YL@B872+'1W'OC_ ">4?K\R-DOU&W/3[GXOC\<_=^Z\
MG,I$L:6"%59+!.+WC6N,*:[.+^PJ('FY<_:D,.+$&N@AT"@DEZ=9K<X5(6<(
M-R^\T3 ,6E@B<GUM/B!?K/&($)$*8%\*=G $&CIE'JJ*[+ZBW(X>:D:U=-X8
M][%L<Y^$^KRX]MJWVSYQR?76L*JW2QYU:TD$3S\.-?6H''I;A>G+ X,])S<O
M' (@7++;ZY:]QM[_ #QAX5&JOF-^GS->&AWYW+L]XJ!8]_SCSQ6AN%_+WZZZ
M5R3Y;\U]#GFNF;<.+XZ]>T&Q^N';-7A)M[/>%VXU,NG8.7+8S[^;86W\Y5WT
MH_6<-^K;^0MWVOZ5X.K/>#;K-<.A.T].G6O B ;'2*T:B'96Z>A&*Z@ LVX3
MS;1"!%GBV_=!77!-6:<\5X13R(.W$:F?F;%?2)VL4<'*#U3/;'(#^)-@-'A7
M$@M/-OG[FLR &[37"U1)!L(&!V0</*7/S_S_ !?%/S^<N1F]3\9Z8^/6:\D_
M=;\W'\Z%GM++_;TS6["Y\T2=Y4LLE!80PILB&C<U V?1ZXM089:$*O*UDP$4
MHARL@$QS M1JU$?=*L/*0LCB(06?X@NF&P)3$0T88A &%0  $!B(+ @$^F?>
MVO2O?3;LMB8-T)F\5+\MTOJZ\K.*W=:=-O3[:-?0.,9QZUU!QOW^^MVM(H3S
M<&(FKZN?5W\TJ,:W1GS$-$JN;;^)?;2GJK&SW_NI6B7[1S],SX5[#Y\Q>]M*
M9T.7SIPK%7#3ZX\.%;(N,K&=O3I5D&O[T?>9S>W9Q^_+UY4.M7STS&.%6RG'
M\]/[%2O!^'WQM0[2\_FVY5]A'@SQO748+XM?9QB],<P4070627R@\FF<Q]&F
M;R<&JPJ7S22$(N"F20+W"&4F+20.39/W::T+Y9!O,@&J'!.10*$0^V;H<;S1
M@#-=6VLK&6E]")5YW3MYKB-CYO'6QK?A-ZU9_E7=K>^D0/@ @005FPAM+*HW
M"/(C(Y$G( 1@G;_-\WO7O?*M=/(?:KVBR;OUGR*]B;*</FVIT#,GGM^^(DL"
M7VG3%2#N7>)0$HC0E1ZU36<1[8-J&]#- 5F1U3%YEHC/B:!8['.DN/J$SMM#
M:/?,89(O*L\L4XI(T;\XMZ^]<>$0F\>9X5H&E\WG.HLM:/CVZ6KIM7;K(^1>
MM?/G2/DIQO@ZYV?&U&K.LQ:UHT^*\A?N<Z%LMZS=47GS;3C7FGW\Y5WQY_'
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MNQIHL6J0+$I13-BZI&L8QL7=!CE6OG I(Q7"1$\_.#\KTU]7C >#!T0Q;D%
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MA&^$*L;\ % <$UR4+ 3PT\"]J1A2DOPG@@()QXQ$U"@VEEP#Z8/ @H.M5K*
MGDR(S+%T>X&=4[G%)9.&'&.Q(V#46%=#Y!]>"^)  +S<)&_5&0O-H01.V"Z$
M@8$)8$;RC3?GQO6&2,HJ2:NB3(@;(]B->)Q()7 \-*\$8&_KZ5YC ^F.#G,4
M_N4H8? YTUD$27**;D.$P$4Q,"F@U;3+ZEC_ ,:S7OBDF.I?QKXO>NFK/;3G
M>OF2_3_0KKI]<\'CI7DA17/R*-MK6D4<)I8@00#.FYVF_I7HO\$=WT^OQY//
MVVF\]:^;Y_&>Y^YWSTS6M?1GY.F)I'>5C"23##HYXR;M;9JNK'#PKDQ3C?E;
M-<F<\MB/:\TMU;_7G*&KZX?6>?#X@J1#CO>W'XKW !KY'M,M<H//??F=]\H?
MJ2]-AGO7&49;Z)BOU*KOO.AFC 6?6;V\BLM\!W4I0X2BA)-6 BEA8B)(-I*!
MGIL#GX@1H3  !XKH5! ,MIN=#SAD(02(08',8138-I$UBR@G+WYE(U$I0UTT
M(0JR$<)M@!-)(')VM'K2B  !H8 T "BYM$#T 4" @HB6IZZ.;>W2$TE5TJTH
M9@0D@!$"R-G$7*Q7S%8&HD$0$20U&@@&%S^FWMXA7Y%N$7K]!IZ6\UK69+MU
MUOPX5*$C,=?2?UO6@V_MMKF_1S1X)/F-_2KR"WI?Z?::]0>7;=,7YYT"$GWQ
MWJ83 ;.).6^76].Q$*)4L%C,L3"BU""D"X3B.%SI&E)(NX0R#>$H%E1E#7N"
MZOB^DP3\5\PP V>/9MRZR#SEKSM5BLYLC^QR+ !HX02.JHIQ2K+?>$KGUD[T
M3,&2!$ @,%2!+ A_BAP[M?-\UYOSGZ[U#AW:[,B!C>_GS4+/QL6Z9MWK=;T6
M8UYT]+-9I%=;FNS;?H^O=-\EW?'2NH W+\(KGHX_>YZU>4,I+>%O2CA%8D0M
MR"\('.F&M0)X,<ICUX4'+D752(6R8P-\\"KZ$^(\MZP-5H")H)9QOAW)D@NC
M#3G0T,:X($6DVL/QUL_%XJX)X?YGV,5BNSA'3;AUI#\XMM/G.>ZW5GI''UJY
M9/SM$^6K56#GS_.]=%>?QQ(Z1KI7.$X>>O>O)2X^2U9?%YTU>$Q>A5HOFLQQ
MY4EB1']E2J.0Q(&.-V>R$$\-$.*<>!(@ZWVZZ&UQ/8E.^R  W%%75F8JP*!U
M<I""C<*=!TLE,\I+S)T^-YX5.+<^8G]=V--(9._F:_>/!/BW"A*]!ORZ7F.E
M:+HLTV\M/":E%$I\8_ZO2Z;Q>(BA(L+A(5*KOY[7Z)6,R0S)<!F/&!+. <PP
MC$X1K>Y(;-_U0W(VZ7@D(9ZUV95Y3-HDQC3[J<G\IN43[SRF&D"#M$W8G*6*
MM/[RHH>'W>@M!*7CA(B5J,8D)BL7G\'^6QH,=-/1GJZY.AN+K[Z^2E]3$WA9
M&W47T7>VN;/^.OMI4E^;M_+8B(J_:F:B1-Q3428=6F,+@8=%7US,F:=PK%$9
MQ!P00!T+?:@$)#(W= A#*2%?.")6N=_W69 K@PO#J;WO??F#*ZX\UX<L"H;^
MSV:@%9OCKKKPTUKJ+$]X^:ALLO.6E^9>O1!KUOU[N]=*L'N?LWK]B+S]^L9:
MM HK'CCDK,I:5":$"$P))5 F%]\8.8*V'2B\XZ[?1UH0@D(32*9%)5$4D(@@
MJ**VH1T/KL%H+AE8#;)9MS(7'R&%I>Z@)A ALT.+3HJ+5D# C(,Q+$8[\2;P
MM*@"E6:^<5XPZ"PA8;%@>^:/59X13)H)H#+2)=[. YC0%"[@N\0F9  7 1>=
MVS\9@O,5\X^3P\BOV';R+5YS%K;<N,TG!,\NS!QT.]7*]GLD[-(?%7W;]$79
M].EH")'GQYQUKT0!4"]/VE$ QFEOIU=MM*+ 4%(F.<8 VIHG8:WNEJ$M Q$4
MAH#:#V GMG-"\@L;+!EB"OU+(ISCT3Y]Z,#!>2-3N6+7X":E96UFW#]Q,_X_
MF^?R(1#;TC^\I:SV&=;>M6E-<%^<VGY7:K\?Q07K(*)0L,;:\,IF^_\ 4U(C
MT9>I7F)(27@!0M16=88B^-8U<Q2V@!$DO-XO&] D3&7R+J@%(E(HXD<R_7EZ
MY+5S&[,3$PZQ-ZG2A^WGI4ILKZ=B)5>5>R>E<?=OO]<3WOGU[]V?.//2M\6/
M'TEG@5\J3CQZ0;UX)-_;$=3>;P'F4J5%G!=&,BVC: 0K&,)2]&X'.18O"#.0
M>%4M+O*E+@+>R5E9!Q J=7)8P$V+1"3+$>%P<D*B$DH)0L3!LS""<G#H;5F<
M48T$16 TXSI+S6\OH"X933[Q=Z*0"P2[-JE85@P9FL0#<&J&[K<O2M4'Q@\9
M+ +0+@4C#P8T30!M "ZJOW"6Q\8VC,5[A,;^6^:)!['R\/3%<5[]_:V.'/SM
M(-+6G>^]>JTB!.MWE%"X5;MY\U:!\J?/>>DU]T@B?Y._+2K^@JX>E "JK8S$
M42(3+PEU\%1%HLJ@$0<1BR$"R@"CYGX=(4IYZ?H&0RCLSPVMK](16>PJ\/"B
M,*Q ZRMTJA(BM"$3JYXUZ+_#DF=';37KI7GG.IPW*\H_7X^<)Z_?EJ\AWY3C
MUXU=CG+^:2SI36\B9G%V>&_6L:W@\L?RHT%CF'\>6E,'\JK6.8L)2>=&HUQK
MNB[B?W0030U#J-I@"2F^!U=NT[5"@SQ\)Y#%>)?%9Q 8]\6VMQK]! 7XL\])
MH8 $_.S7ICKK,3'MMPK ?9_)OTG6H];V7G;VT^:Z1QT])C;:U<-$\T\TH+F3
M"96.3FE-.L]FT@P4"A<$+D03F>CKG\= ,*?EQ)JG%4:DA643FS;!(,H" 2DI
M%L_Q8.8XI(HJ6AP8-2IJ A(BI:J8<2=?HVBZG\VAJVA)-Y *H6L'DQ5#WD5&
M,&8  3ORD63@*O0(:K@Z9IE68-S6&4&];&7UQW[T[T%* #%$!N@PHZJ?S-^.
M-:Z7T\RZWJXE.EOZS\U8U$8?;&_'K750)-.'3^5P,$[=T=\:5C%*]/;E>+5
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MD<(J$Y=+(82NT0NF'?8BU $(X4[Z,30J8[L[VR(3A,X:L*?VD-C>_F:NJ(/
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M4*GJFB&"EZ,QZRFLR*0"K.L#B:N8(LHM,A!E,D!GEG_D_%\?C][;EC;S-'*
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MB^S#V2,5.0,-S#3$J*\<VT*E<F=SD0V:'_!</*@ H0DS,ZA=R^LS%3*#A9:
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MVQ5.\[<%#0IV!-"42A"I(P I&#)#:U,"),8Z%):IB8D&LD\8,-/O]%50J;)
M%;#$&0G95EXT)*X%%8D]NDP+ND!J7>O8;45F 6ZG,T5I=.K,A88E<@(?.KI!
M)K&1ZQA8P2-M S1)&*5NW&;%M;'7TC'X1JO"(\_>E<(J(03S9#;)K8BEO)83
M<)A%B5"6MSAC?MM@"0X#\2J,+PQFD&3< ^)IV\V;(B=3&2B9ETI+-!(&58AA
M2:-1!68(Y@,1@D7"ME/H$8B_0NR#%$6$A#.N-N=^M8O/X/\ 7 3;O:_*T]:0
M#G#M]U,&1$+O F2UIX&2]W"Z@V"9PPF8<7J<PRU@(L.LRV8C6I4.8"NP"D95
MFKK6E5(DJEVR%Q+%IN_O*(>G(D&J^C8<^+7!+87@!;M$(Y#VL<$MP--P9<U"
M6A %DR*R083[?A_!CC[5!=^)X,Y"T@!%[EL4*;/AF+YM>,1?6KHMP)%_3-L7
MF+5S/3ZK$TZ7T_O]:.)DB9+=>^E3J.FXLQ:>QIQO.*+WH6\'OBG4'8,B@7R@
M7S$-$ F;_$CP$D",PYD$(H!6MJV=MJ"8!0:81WHC0(1*8PJ>#+#P28/L7HS(
M*8>N&@2HO$@4DT1]J*M%)A1H YH.\IXJ&UE"$D4QD%'@ X20H$B J@,$?^,3
MG\-* !D13?=,7Q?-IIYU#DE5JXFW^((7M0*.'!)."1UER[ UTF2*(%)=>%G&
M&2PD& *:"%#DBXL:3KV"+(TBQ#64AT1-IDI1F0B')DO?.N;:25:2 8#A'/7_
M %_%\4X9V:V*^!#,9&T<)O+PJTBFV8(!&A@$20 \SR-$7B&228A":;N0;X$@
ME%[)@LU84FUM_G(VQ2]3N-[S$,C%DA5]EJV^'RP!AC>0IF0$;6?4!93!#]#
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M+]@L1%HN7ZVL:LW1:F0D"0 88BTQBN>['/4X=+]*9M!TN_PF*00:.4N@"\'
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M)S^&EO\ ?L;XMKF*(;&1K>S7 +Z08J<3XY]C)L#*F&(LM+X:9'K@3B;;%1'
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MI::+(B6WL$%F0)>01QW]9;)DF$:G+H^4<U90$JI*!J.5A,M=1)1 'RW1 WV
M!64I7(5@1<6FXGS^8-CL5?&X6&$AL,6IMD&\]F32SE!82BCZ9.5\RTE*  !!
M 5I8Z5//3W+LPWI$PJ$TF:9$I,@:(18"@M3SFP$FRJCJ-\WS1LSA_=)Y)HB2
M,19I5)^.P& .GX@,$?C%!@RP+EWSQ<8Q44*TR\L+%RPI<H7%(ER@39'0E3;"
M]'S*("2*AZ%X*"'NA-FEC6,\$%6 +D  %=,TA),"LY9=('GUFYA1&; &;CA>
M\%"8FY](CUC7?DLHO>6;^GW_ +XPOC")\VG29B@PF$LR,#$8-DC28BA:@T):
MU()W<6*-A7VN,43'A +H 4\WPTR*%*M7"Y08A"*"A"CLH+5]B>&$[$(E)-KR
M9JQ>M".Z2 DB+@LE.$RF83G9Y@-5EZ@HZ7%6E<NBU"\$2$GR7A/:*DW.]2;G
M?\B^?(QI>/&D04O,^9]'\.&<0S0"#*%XUN]@[Q' I!%H1=&SS.V/F.J^=/P,
MDQ'.F-2>D_\ F2)DC?2E(92(EOI28(4%JOR?W6JIL%85"-5#R7TX:1ZOD 09
M"CCKVT>KL*R J!E0A8XP-?2,.* N+TQ_PH!#S)!4R"2H9M-92(0!%AIB-*DD
MTN 138N,+2IE$!.EN'QY/XQ>?P?[C-OEMD\M5J&[:)T_6]1QQ[(C(F6UX#B2
M(543FTGPDD@%4""2**#QG(Y;/HK1.-1POBN[AW#SH497LD@<IK0+0E2/^Q"'
MYVX0:L8$K,"!YP#N $RWAGU9I*BK%D9(;GSE*IG9P+5B FZ3.%<MF.&8H0N,
M!$MIRB=M][XK Y'M_P"H# '_ (\NO_B?Z*G@<50<Z+%9(D ,LN97/# 048FZ
M6[-$B)%40O8"V8I.XPM5,;Q)%LN,:J2Z!J&XPCT$UU UTE6D2XRXS@NL)=/@
MI/+=\&%3#"2+=;N6<%C$6)@%@*+(GA[ F^"0@E5VH':(@W$U[1VOBBP&U8O/
MX/\ @0!#JZVC@XDTC.*,C*VT;=XU'CPM3ZQ*HR&8$D! (F62O@6!,6LB0VR)
M"(A:7E 5!WCDE-M4ZA(C.W#-Q*YS[@$G,&\)"(37('%\YL= ;H34B "1$B47
M$PQB<%"XNZT5BIZG1,J$QICA&%48(H;7\)Y! J![!2E(Q2A6I)""!H2;ELWQ
M4DQ).VM2;G?_ ,2.$?\ UB<_AJ93H:)00FL, PK0.Q: * -T(&X)03AZ\X^)
MDE3I<.]33B@6BD"=WQ8*=FPZ[3AI)*DJ@XI2A31K-4!:#+!119%"2I#[H.(B
M4)51,1@J(P4:0H)K$%B9..]*ZJC!D 0(BLE231:0,& 2(@C&UB8^Z*66B",]
MC7YHP:_\)8%V)J7"#3YX1?C&G"3_ )(*/C(LB$&9*UO;X:/0[,(8$N*%2A\I
MEQ+QVIH8N/>ILSE<H>X&U19 ,%S&)-HQKH/ KY:M![29MJR0[!IB(VS21,!@
MP6:-@JN)&!D8@^!1 V($!5-M[97<1AZ));4X-_D6F0!D6$54ZC'1>8+3;'.
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M<+A55T>(=DL!RWZ5[#$%"0\;6PO:] (//.GYQ>?P5;6]9SZ]X<TH_CS0M(D
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MHF4"&LEV("B-WKO!+5T6DQ$9%&Y>)8I28UA*[:#V*A0$)$&>V^"$*8>]<@4
MWE ,W8-$\_%:!@O',BXTH9Y4P2L^B_$"UOW4=WT^J,C1'85]?^BA"Q.ENL\<
M8WUIBJ[ ZY^O3!QLD1$N8S-Y]8ZZ4DL@/1^*! H+B8#CJXT.=,$ "7&["CQS
MC6+TX6]W:^I)ZB<K+0^;/ZV1F1$I-@(I^A.@"0-+-XQ,0%K7/,D(*SF$UF>[
M$=D"(.LF;EJ;)3BUHG$QU&J@Z9P 4M&8PAP9$2'DFC9 NE.Y(C=1PA4$U%=D
MM$Z1497-IU^H-GE>+5*7D-[DB[A)>.V+T +#$)/.>]MNU(9@YQ]5(1);MPTS
M-Y_M1U7SI^<7G\'_ $8'(/3\P;':H-CM^8-BH-CM4!@BH-J@V.U0.2?S!L7S
*QJ#;_P#0_P#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
